albuterol has been researched along with Asthma in 3866 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective, single center, open-label, two-arm, parallel-group, nonrandomized trial among children ages 5-17 years hospitalized within the PICU from April 2019 to December 2021 for critical asthma consented to receive methylprednisolone (standard care) or dexamethasone (intervention) at a 2:1 allocation ratio, respectively." | 9.69 | Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial. ( Darville, KK; Goldenberg, NA; Martin, M; McKinley, SD; Nakagawa, TA; Roddy, MR; Sellers, AR; Sochet, AA; Teppa-Sanchez, B, 2023) |
| "We conducted a multinational, phase 3, double-blind, randomized, event-driven trial to evaluate the efficacy and safety of albuterol-budesonide, as compared with albuterol alone, as rescue medication in patients with uncontrolled moderate-to-severe asthma who were receiving inhaled glucocorticoid-containing maintenance therapies, which were continued throughout the trial." | 9.51 | Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. ( Albers, FC; Beasley, R; Cappelletti, C; Chipps, BE; Cooper, M; Dunsire, L; Israel, E; Jeynes-Ellis, A; Johnsson, E; Panettieri, RA; Papi, A; Rees, R, 2022) |
| "To evaluate bronchodilator responses (BDR) to albuterol nebulized with 3%-HSS in asthmatic children, compared to albuterol nebulized with NSS." | 9.41 | Bronchodilator response to albuterol nebulized with hypertonic saline in asthmatic children. ( Alchundia Moreira, J; García Bournissen, F; Kofman, C; Köhler, T; Teper, A, 2021) |
| "The Phase 3 MANDALA study was designed to determine the efficacy of albuterol in combination with budesonide (albuterol/budesonide 180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg, respectively) versus albuterol (180 µg, two actuations of 90 µg) as rescue therapy in adult, adolescent and paediatric patients with moderate-to-severe asthma." | 9.41 | Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. ( Albers, FC; Cappelletti, C; Chipps, BE; Johnsson, E; Papi, A; Reilly, L, 2021) |
| " The participants were otherwise healthy children aged 2 to 17 years with moderate to severe asthma defined by a Pediatric Respiratory Assessment Measure (PRAM) score of 5 or greater (on a 12-point scale) after a 1-hour treatment with an oral corticosteroid and 3 inhaled albuterol and ipratropium treatments." | 9.34 | Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. ( Atenafu, EG; Beer, D; Black, K; Coates, AL; Curtis, S; Ducharme, FM; Finkelstein, Y; Freedman, SB; Gravel, J; Johnson, DW; Klassen, TP; Nicksy, D; Plint, AC; Rumantir, M; Schuh, S; Stephens, D; Sweeney, J; Thompson, G; Willan, AR; Zemek, R, 2020) |
| "Although the guidelines in most countries do not recommend continuous inhalation of l-isoproterenol to treat pediatric patients with acute severe exacerbation of asthma, lower dose of l-isoproterenol has been widely used in Japan." | 9.30 | Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial. ( Adachi, Y; Akashi, K; Fujisawa, T; Hashimoto, K; Imai, T; Katsunuma, T; Maekawa, T; Mizuno, M; Nakamura, H; Oba, MS; Ohashi, Y; Ohya, Y; Sako, M, 2019) |
| "The objective of this study was to determine if a rapid albuterol delivery pathway with a breath-enhanced nebulizer can reduce emergency department (ED) length of stay (LOS), while maintaining admission rates and side effects, when compared to a traditional asthma pathway with a standard jet nebulizer." | 9.27 | Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department. ( Allen, C; Higginbotham, E; Hovinga, C; Iyer, S; King, B; Wallace, A; Wilkinson, M, 2018) |
| "BACKGROUND The aim of this study was to evaluate the therapeutic effects of tiotropium bromide on asthma." | 9.27 | Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma. ( Han, S; Huang, G; Jin, L; Zhang, L, 2018) |
| "To evaluate the efficacy and safety of albuterol MDPI versus placebo MDPI after chronic dosing in children with asthma." | 9.24 | Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma. ( Iverson, H; LaForce, C; Shore, P; Taveras, H, 2017) |
| "Evaluate the safety of albuterol multidose dry powder inhaler (MDPI), a novel, inhalation-driven device that does not require coordination of actuation with inhalation, in patients with persistent asthma." | 9.22 | Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. ( Iverson, H; Miller, D; O'Brien, C; Raphael, G; Taveras, H, 2016) |
| "To compare the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of albuterol MDPI and albuterol HFA after a single inhaled dose in children with asthma." | 9.22 | Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma. ( Iverson, H; Ratnayake, A; Shore, P; Taveras, H, 2016) |
| "To demonstrate the comparability of albuterol MDPI and albuterol HFA in children with asthma." | 9.22 | Albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane versus placebo in children with persistent asthma. ( Iverson, H; Qaqundah, PY; Shore, P; Taveras, H, 2016) |
| "We have previously shown that in patients with asthma a single dose of an inhaled glucocorticosteroid (ICS) acutely potentiates inhaled albuterol-induced airway vascular smooth muscle relaxation through a nongenomic action." | 9.20 | Acute effect of an inhaled glucocorticosteroid on albuterol-induced bronchodilation in patients with moderately severe asthma. ( Arana, J; Cadet, L; Mendes, ES; Wanner, A, 2015) |
| "Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented." | 9.20 | Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. ( Brunetti, L; Dhanaliwala, F; Kang, H; Poiani, G; Poppiti, K; Suh, DC, 2015) |
| "Plasma albuterol was significantly correlated with serum lactate concentration after adjusting for asthma severity." | 9.19 | Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma. ( Aubuchon, K; Ferguson, I; House, SL; Johnson, K; Lewis, LM; Matsuda, K; Schneider, J, 2014) |
| "This study compares the effect of heliox-driven to that of air-driven bronchodilator therapy on the pulmonary function test (PFT) in patients with different levels of asthma severity." | 9.19 | Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma. ( Alawieh, M; Bou-Akl, I; Bou-Khalil, P; Chami, H; El-Khatib, MF; Husari, A; Jamaleddine, G; Kanj, N; Zeineddine, S, 2014) |
| "In subjects with either asthma or COPD, FEV(1) decline and bronchospasm can occur following inhaled loxapine, but more frequently in asthmatic subjects." | 9.19 | Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials. ( Cassella, JV; Fishman, RS; Greos, LS; Gross, N; Meltzer, EO; Spangenthal, S; Spyker, DA, 2014) |
| "To compare tulobuterol patch and oral salbutamol sulfate in terms of efficacy and safety in children with mild or moderate acute attack of bronchial asthma." | 9.17 | [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. ( Bao, YX; Lin, Q; Liu, QH, 2013) |
| "The combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting β2 agonist, is under development as a once-daily treatment of asthma and COPD." | 9.17 | Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. ( Bateman, ED; Bleecker, ER; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2013) |
| "Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma." | 9.17 | Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma. ( Aizawa, H; Fukuyama, S; Inoue, H; Komori, M; Koto, H; Matsumoto, K; Takata, S; Yoshida, M, 2013) |
| "To compare the efficacy of theophylline plus salmeterol/fluticasone propionate combination product (SFC) with SFC plus placebo in asthmatic patients." | 9.17 | Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma. ( Ding, X; Hu, S; Huang, Y; Liu, M; Nie, H; Zhang, G, 2013) |
| "Fourteen subjects with moderate asthma inhaled single doses of salmeterol (50 μg), fluticasone propionate (250 μg), salmeterol/fluticasone propionate (50/250 μg), or placebo; Qaw was measured before and serially for 240 min after drug administration." | 9.16 | Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma. ( Mendes, ES; Rebolledo, P; Wanner, A, 2012) |
| "Combination therapy with an inhaled corticosteroid (ICS) and a long-acting β(2)-agonist (LABA) in a single inhaler is the mainstay of asthma management and salmeterol/fluticasone combination (SFC) and fixed-dose formoterol/budesonide combination (FBC) are currently available in Japan; however, there is nothing to choose between the two." | 9.16 | Effect of switching from salmeterol/fluticasone to formoterol/ budesonide combinations in patients with uncontrolled asthma. ( Akamatsu, T; Chida, K; Hashimoto, D; Hayakawa, H; Ide, K; Inui, N; Kato, M; Kuroishi, S; Masuda, M; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yasui, H; Yokomura, K, 2012) |
| "Elderly patients (>60 years old) with diagnoses of severe asthma were observed over 24 months of therapy: the first 12 months using inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) and the second 12 months with oral montelukast added in two-thirds of the patients, with the remaining third representing the control group." | 9.16 | Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. ( Bozek, A; Filipowska-Gronska, A; Jarzab, J; Warkocka-Szoltysek, B, 2012) |
| "The pentosidine levels did not significantly differ between the two asthmatic subgroups with and without airway obstruction." | 9.16 | Association of airway pentosidine levels with bronchodilator response mediated by salbutamol administration in asthmatic patients. ( Hirata, K; Kanazawa, H; Tamagaki, G, 2012) |
| "In a randomized, two-period, two-sequence crossover clinical trial, we analyzed 31 stable asthmatic children (6-18 yrs of age) on two consecutive days, who were randomly assigned to receive 100 μg of albuterol MDI through either a locally produced valved spacer or a non-valved spacer." | 9.16 | Comparison of the bronchodilating effects of albuterol delivered by valved vs. non-valved spacers in pediatric asthma. ( Castro-Rodriguez, JA; Rodriguez-Martinez, CE; Sossa-Briceño, MP, 2012) |
| "To compare racemic albuterol (RAC) with levalbuterol (LEV) in continuous form for the treatment of acute pediatric asthma exacerbations in the emergency department." | 9.15 | Efficacy of racemic albuterol versus levalbuterol used as a continuous nebulization for the treatment of acute asthma exacerbations: a randomized, double-blind, clinical trial. ( Bulloch, B; Garcia-Filion, P; Keahey, L; Wilkinson, M, 2011) |
| "In a double-blind, crossover pilot study, we randomly assigned 46 patients with asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no intervention." | 9.15 | Active albuterol or placebo, sham acupuncture, or no intervention in asthma. ( Boyd, IO; Dutile, S; Israel, E; Kaptchuk, TJ; Kelley, JM; Kirsch, I; Marigowda, G; Wechsler, ME, 2011) |
| "In moderate acute asthma, nebulized procaterol and nebulized salbutamol were both effective in improving PEFR and decreasing asthma score." | 9.15 | The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: a randomized, double-blind, parallel group study. ( Louisa, M; Mangunnegoro, H; Novariska, F; Setiawati, A; Wiyono, WH, 2011) |
| "All patients between 6 and 17 years of age who presented to a pediatric emergency department in the winter months with acute exacerbation of bronchial asthma were given a combination of nebulized albuterol and ipratropium with warmed or room temperature humidified oxygen." | 9.14 | Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months. ( Hassen, GW; Nibhanipudi, K; Smith, A, 2009) |
| "We compared the systemic and clinical effects of ciclesonide (CIC) and fluticasone propionate (FP) administered, in addition to CIC 160 microg x day(-1) and salmeterol 50 microg twice daily, in 32 patients with persistent asthma using a randomised double-blind, placebo-controlled, double-dummy, five-period crossover design." | 9.14 | Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. ( Derom, E; Engelstätter, R; Joos, GF; Kaufman, JM; Louis, R; Tiesler, C, 2009) |
| "To evaluate the efficacy of add-on montelukast on asthma control and allergic rhinitis symptoms in asthmatic patients still symptomatic with chronic treatment with inhaled corticosteroid and long-acting beta(2) agonist (ICS/LABA), irrespective of the dose." | 9.14 | Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. ( Dramaix, M; Herbots, E; Korn, D; Peché, R; Potvin, E; Van den Brande, P, 2009) |
| " This double-blind, parallel group, non-inferiority study compared lung function and asthma control, based on Global Initiative for Asthma guidelines, in children receiving either salmeterol/fluticasone propionate (SFC) 50/100 microg bd (n = 160) or fluticasone propionate (FP) 200 microg bd (n = 161) for 12 wks." | 9.14 | Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. ( Anderton, S; Attali, V; Bennedbaek, O; de Blic, J; Desfougeres, JL; Hofman, J; Klink, R; Ogorodova, L; Poterre, M; Sidorenko, I; Valiulis, A, 2009) |
| "The modified adenosine infusion protocol with salbutamol premedication can be used in patients with asthma." | 9.14 | Pharmacological stress myocardial perfusion scintigraphy: use of a modified adenosine protocol in patients with asthma. ( Notghi, A; Smith, NB; Sundram, F, 2009) |
| "To assess asthma-related quality of life after treatment with combination fluticasone propionate and salmeterol delivered via hydrofluoroalkane 134a metered-dose inhaler compared with the individual components alone." | 9.14 | Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. ( Andersen, LB; Edin, HM; Ho, SY; Ortega, HG; Schoaf, L; Scott-Wilson, CA, 2009) |
| "Salmeterol and fluticasone propionate combination (SFC) provides better asthma control than fluticasone propionate (FP) alone, however, little is known on the effects of differential treatments on airway function and inflammation in patients with mild asthma." | 9.14 | Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma. ( Handa, H; Hoshino, M; Miyazawa, T, 2009) |
| "To assess the use of high-dose continuous levalbuterol (LEV), the single active (R)-enantiomer of racemic albuterol (RAC), in the treatment of status asthmaticus." | 9.14 | High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. ( Andrews, T; Chew, A; McGintee, E; Mittal, MK; Pawlowski, N; Tyler, L; Zhang, X; Zorc, JJ, 2009) |
| "In a non-randomized, non-placebo, single-blind, fixed sequence, pilot study, we evaluated 22 non-smoking, stable, moderate-severe adult asthmatics on maintenance inhaled fluticasone 250 microg/salmeterol 50 microg (F/S) via MDI bid> or =1 yr, with add-on oral zileuton 600 mg qid." | 9.14 | Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. ( Gelb, AF; Shinar, C; Simmons, M; Taylor, CF, 2009) |
| "To reduce symptoms and emergency department (ED) visits, the National Asthma Education and Prevention Program (NAEPP) guidelines recommend early treatment of acute asthma symptoms with albuterol and oral corticosteroids." | 9.14 | Home use of albuterol for asthma exacerbations. ( Freiner, D; Garbutt, JM; Highstein, GR; Nelson, KA; Smith, SR; Strunk, RC, 2009) |
| "Inhaled corticosteroids, such as fluticasone propionate (FP) and ciclesonide (CIC), are commonly used for the treatment of asthma." | 9.14 | Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ( Derendorf, H; Derom, E; Lahu, G; Nave, R; Xu, J, 2010) |
| "We investigated if a higher proportion of adults with previously uncontrolled asthma can achieve total control when given salmeterol/fluticasone propionate (50/250 microg) bid and compliance enhancement training (CET) compared to those given medication alone." | 9.14 | Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: a randomised controlled trial. ( Backer, V; Claudius, BK; Dahl, R; Harving, H; Hellquist, B; Høgholm, A; Jøhnk, IK; Siersted, HC; Tamm, M; Ulrik, CS, 2009) |
| "Indacaterol is a novel, inhaled once-daily ultra-long-acting beta-2 agonist under development as a fixed-dose combination with an inhaled corticosteroid (ICS) for asthma treatment." | 9.14 | 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. ( Adachi, M; Emery, C; Haida, M; Higgins, M; Hosoe, M; Ichinose, M; Kanada, S; Kramer, B; Sugihara, N, 2010) |
| "To evaluate whether salmeterol/fluticasone propionate (SFP), 50/100 μg twice a day, is noninferior regarding symptom control compared with fluticasone propionate (FP), 200 μg twice a day Diskus in children with symptomatic asthma." | 9.14 | Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. ( Brackel, HJ; Duiverman, EJ; Gerrits, GP; Hop, WC; Vaessen-Verberne, AA; van den Berg, NJ; van Nierop, JC, 2010) |
| "We were unable to demonstrate superiority of adding ipratropium to levalbuterol in alleviating obstruction as measured by FEV₁ or in decreasing the need for hospitalization among adult patients presenting to the ED with acute severe asthma exacerbation." | 9.14 | Levalbuterol versuss levalbuterol plus ipratropium in the treatment of severe acute asthma. ( Cydulka, RK; Emerman, CL; Muni, A, 2010) |
| "In a three-way, double-blind, triple-dummy crossover trial involving 210 patients with asthma, we evaluated the addition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease but not asthma) to an inhaled glucocorticoid, as compared with a doubling of the dose of the inhaled glucocorticoid (primary superiority comparison) or the addition of the LABA salmeterol (secondary noninferiority comparison)." | 9.14 | Tiotropium bromide step-up therapy for adults with uncontrolled asthma. ( Ameredes, BT; Bleecker, ER; Boushey, HA; Calhoun, WJ; Castro, M; Cherniack, RM; Chinchilli, VM; Craig, T; Denlinger, L; DiMango, EA; Engle, LL; Fahy, JV; Icitovic, N; Israel, E; Jarjour, N; Kazani, SD; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Lugogo, N; Martin, RJ; Meyers, DA; Moore, WC; Pascual, R; Peters, SP; Ramsdell, J; Sorkness, CA; Sutherland, ER; Szefler, SJ; Walter, MJ; Wasserman, SI; Wechsler, ME, 2010) |
| "The National Heart, Lung, and Blood Institute guideline recommends that dosing racemic albuterol be administered every 1 to 4 hours for treating patients with asthma or chronic obstructive pulmonary disease (COPD) in the hospital." | 9.13 | Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. ( Andrews, WT; Ciubotaru, RL; Claus, R; Donohue, JF; Hanania, NA; Noe, L; Pasta, DJ; Roach, J; Schaefer, K, 2008) |
| "This study compared the short-term safety and efficacy of cumulative doses of levalbuterol HFA MDI and racemic albuterol HFA MDI in asthmatic subjects." | 9.13 | A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. ( Baumgartner, RA; Corren, J; Goodwin, E; Hanrahan, JP; McVicar, WK; Nair, P; Pleskow, WW; Tripp, K, 2008) |
| "Based on these results, neither azithromycin nor montelukast is likely to be an effective inhaled corticosteroid-sparing alternative in children with moderate-to-severe persistent asthma." | 9.13 | Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. ( Bacharier, LB; Chinchilli, VM; Covar, R; Guilbert, T; Krawiec, M; Larsen, G; Lemanske, RF; Martinez, FD; Mauger, DT; Morgan, WJ; Paul, IM; Phillips, BR; Sorkness, CA; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2008) |
| "We analyzed the effects of time, albuterol, and budesonide on FEV(1), FEV(1)/forced vital capacity (FVC) ratio, forced expiratory flow from 25% to 75% of expired volume, and Mead's SR both early (between 75% and 50% of FVC, SR61) and late (between 75% and 50% of FVC, SR35) in exhalation in the Childhood Asthma Management Program cohort at baseline, 4 months, and the end of the study in participants who received either inhaled placebo or budesonide twice daily." | 9.13 | Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma. ( Patel, AC; Strunk, RC; Tonascia, J; Van Natta, ML; Wise, RA, 2008) |
| "The efficacy and safety of twice-daily inhaled salmeterol/fluticasone propionate combination (SFC) therapy have been well established in the treatment of adults and adolescents with asthma." | 9.13 | Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids. ( Chuchalin, A; Frith, L; Jacques, L, 2008) |
| "Albuterol reduces lower esophageal sphincter (LES) pressure in normal volunteers, although the effects of albuterol on esophageal function in asthmatic patients are not known." | 9.13 | The effects of nebulized albuterol on esophageal function in asthmatic patients. ( DesBiens, J; Lacy, BE; Liu, MC; Mathis, C, 2008) |
| "Although albuterol remains the standard treatment for asthma in the emergency department, formoterol fumarate may be more advantageous, with its rapid and long-lasting bronchodilation." | 9.13 | Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. ( Chou, V; Lee-Wong, M; Ogawa, Y, 2008) |
| "To compare the efficacy and safety of the salmeterol/fluticasone propionate combination product with concurrent sustained release theophylline plus fluticasone propionate in adult Japanese patients with persistent asthma." | 9.13 | Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients. ( Adachi, M; Aizawa, H; Ishihara, K; Nakashima, M; Ohta, K; Sano, Y; Taniguchi, H, 2008) |
| "An outpatient, randomized, double-blind, single-dose, crossover study in adult asthmatics with moderate-to-severe obstruction despite treatment with inhaled corticosteroids (ICS) was conducted comparing the fixed combination of ipratropium and albuterol (IB+ALB) to albuterol alone (ALB)." | 9.13 | Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ( Cassino, C; Conoscenti, CS; Gelb, AF; Johnson, P; Karpel, J; Wise, RA, 2008) |
| " Other measures of asthma control included peak expiratory flow, asthma symptoms, and albuterol use." | 9.13 | Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. ( Bailey, W; Castro, M; Dransfield, M; Matz, J; Ortega, H; White, M; Yancey, S, 2008) |
| "In this randomized controlled, double blind study, 30 asthmatics were challenged with histamine until forced expiratory volume in 1s (FEV(1)) fell with > or =20%." | 9.12 | Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchusobstruction. ( De Peuter, S; Lemaigre, V; Smets, A; Van den Bergh, O; Verleden, GM, 2006) |
| "The aim of this study was to assess asthma control using salmeterol plus fluticasone propionate (FP) in combination (SFC) versus salmeterol or FP as monotherapy in patients with mild to moderate asthma." | 9.12 | Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. ( James, M; Jonsson, AC; Larsson, LG; Lindberg, A; Lundbäck, B; Pétavy, F; Rönmark, E, 2006) |
| "Therefore, we compared the effects of beclomethasone dipropionate (BDP) on the degree of BHR to inhaled histamine and NKA in a double-blind, controlled, cross-over study of asthmatic patients." | 9.12 | Beclomethasone dipropionate attenuates airways hyperresponsiveness to neurokinin A and histamine in asthma. ( Arcidiacono, G; Ciamarra, I; Crimi, N; Polosa, R; Prosperini, G, 2006) |
| " Therefore, a 12-week randomized double-blind placebo-controlled clinical study was conducted to investigate the efficacy of a plant-based formulation (DCBT4567-Astha-15) in comparison with oral salbutamol, salbutamol + theophylline and a matching placebo in patients with reversible asthma." | 9.12 | Plant-based formulation for bronchial asthma: a controlled clinical trial to compare its efficacy with oral salbutamol and theophylline. ( Deivanayagam, CN; Krishnarajasekar, OR; Lakshmisubramanian, S; Murali, PM; Nalini, K; Perumal, T; Rajasekaran, S, 2006) |
| "A prospective blinded, randomized controlled trial was undertaken to compare the initial response of albuterol nebulized in heliox or control in the treatment of moderately severe asthma in children presenting to a pediatric ED." | 9.12 | Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial. ( Brown, L; Kim, TY; Minasyan, L; Rivera, ML; Stewart, GM, 2006) |
| "This study compared the efficacy and tolerability of the combination of fluticasone propionate (FP) and salmeterol (SAL) delivered via a single hydrofluoroalkane (HFA) 134a metered-dose inhaler (MDI) with those of its 2 components alone delivered via a chlorofluorocarbon (CFC) MDI and placebo (PLA) delivered via HFA MDI in adolescent and adult patients with persistent asthma that was not controlled by medium doses (equivalent to FP 440-660 microg/d) of inhaled corticosteroids (ICSs)." | 9.12 | Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. ( Dorinsky, P; Ellsworth, A; House, K; Nathan, RA; Rooklin, A; Schoaf, L; Scott, C, 2006) |
| "Although frequently used to treat status asthmaticus in children, intravenous (IV) terbutaline has not been shown to decrease hospital length of stay (LOS)." | 9.12 | Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus. ( Carroll, CL; Schramm, CM, 2006) |
| "Based on the assumption that bronchial asthma has not only inflammatory, but also certain neurogenic paroxysmal mechanism and pathophysiological links with other non-epileptic paroxysmal inflammatory diseases--migraine and trigeminal neuralgia, we decided to investigate efficacy of antiepileptic drug carbamazepine in patients with moderate persistent or severe asthma." | 9.12 | Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine. ( Lomia, M; Pruidze, M; Tchelidze, T, 2006) |
| " Additional endpoints included asthma symptom scores, daily albuterol use, and safety, including hypothalamic-pituitary-adrenal (HPA) axis function." | 9.12 | Once-daily ciclesonide in children: efficacy and safety in asthma. ( Gelfand, EW; Georgitis, JW; Noonan, M; Ruff, ME, 2006) |
| "This multicenter, randomized, double-blind trial compared nebulized levalbuterol (Lev) and racemic albuterol (Rac) in the treatment of acute asthma." | 9.12 | A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. ( Baumgartner, RA; Claus, R; Emerman, C; Hanania, NA; Hanrahan, JP; Nowak, R; Parsey, MV; Schaefer, K, 2006) |
| "To investigate the safety and effectiveness of a 4-mg tablet of oral montelukast in addition to short-acting beta2-agonist bronchodilator as the initial treatment in mild to moderate asthma exacerbations in children between 2 and 5 years old." | 9.12 | Oral montelukast treatment of preschool-aged children with acute asthma. ( Bakirtas, A; Degim, T; Harmanci, K; Turktas, I, 2006) |
| "Compared with placebo use, fluticasone propionate, 88 microg administered twice daily, significantly reduced asthma exacerbations, asthma symptoms, and rescue albuterol use and was well tolerated, with no clinically relevant systemic effects, as measured by growth velocity or 12-hour urinary cortisol excretion levels." | 9.12 | Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. ( Baker, JW; Blake, KV; Crim, C; Faris, MA; Kim, KT; Scott, CA; Wasserman, RL; Wu, W, 2006) |
| "In this study, levalbuterol administered via MDI significantly improved airway function in comparison with placebo in asthmatic children aged 4-11 years with a safety profile that was similar to placebo." | 9.12 | Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. ( Baumgartner, RA; Berger, WE; Milgrom, H; Parsey, MV; Skoner, DP; Tripp, K, 2006) |
| "To characterize the population pharmacokinetics (PK) of (R)- and (S)-albuterol in pediatric asthmatics using a model that supports a sparse blood sampling strategy." | 9.12 | Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. ( Baumgartner, RA; Grasela, T; Hsu, R; Maier, G; Rubino, C, 2007) |
| "To investigate the duration of bronchodilator action of a salmeterol/fluticasone combination (SFC) inhaler when administered in the evening to children with asthma." | 9.12 | Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma. ( Aldington, S; Beasley, R; Weatherall, M; Williams, M, 2006) |
| "Patients with inadequately controlled asthma on inhaled corticosteroid (400 to 1,600 microg/day chlorofluorocarbon beclomethasone equivalent) were treated with concomitant salmeterol (n = 18) or sustained-release tulobuterol (patch) (n = 18), or the inhaled corticosteroid dose was doubled (add-on) (n = 13) to compare clinical efficacy." | 9.12 | Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. ( Fujimoto, K; Komatsu, Y; Kubo, K; Urushihata, K; Yasuo, M, 2006) |
| "The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma." | 9.12 | Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. ( Aizawa, H; Fukuyama, S; Inoue, H; Kanaya, A; Komori, M; Matsumoto, K; Matsumoto, T; Matsumura, M; Moriwaki, A; Nakanishi, Y; Nakano, T; Tsuda, M; Yoshida, M, 2007) |
| "Multiple studies have examined adding nebulized ipratropium bromide to intermittent albuterol for the treatment of acute asthma." | 9.12 | A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. ( Lavery, RF; Lebowitz, J; Moore, T; Reischel, U; Salo, D; Tuel, M, 2006) |
| "To evaluate the efficacy and tolerability of fluticasone propionate (FP) hydrofluoroalkane (HFA) in children age 1 to < 4 years with asthma." | 9.12 | Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. ( Ceruti, E; Crim, C; Kleha, JF; Maspero, JF; Mehta, R; Qaqundah, PY; Scott, CA; Sugerman, RW; Wu, W, 2006) |
| " Thirty-six patients with persistent mild bronchial asthma were treated with the leukotriene receptor antagonist montelukast, administered once a day for 4 weeks." | 9.12 | Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma. ( Hajduch, M; Janostáková, A; Jarmila, S; Kopriva, F; Zápalka, M, 2006) |
| "To compare in a group of doctor-diagnosed patients with asthma or COPD, the effects of a lower dose of fluticasone in a combination product with salmeterol with conventional treatment (i." | 9.12 | Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD. ( Albers, JM; Costongs, RJ; Schermer, TR; Verblackt, HW; Westers, P, 2007) |
| "Sixty-four patients with persistent asthma receiving 200 to 800 microg of fluticasone propionate daily were enrolled in this switchover study." | 9.12 | Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. ( Kita, H; Kobayashi, Y; Kudou, M; Yasuba, H, 2007) |
| " After a 4-week run-in, patients with mild asthma were randomly assigned to receive one of four inhaled treatments: placebo twice daily plus 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler as needed (as-needed combination therapy); placebo twice daily plus 100 microg of albuterol as needed (as-needed albuterol therapy); 250 microg of beclomethasone twice daily and 100 microg of albuterol as needed (regular beclomethasone therapy); or 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler twice daily plus 100 microg of albuterol as needed (regular combination therapy)." | 9.12 | Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. ( Canonica, GW; Crimi, N; Fabbri, LM; Maestrelli, P; Morelli, P; Nicolini, G; Olivieri, D; Paggiaro, P; Papi, A; Pozzi, E; Vignola, AM, 2007) |
| "This study compared the effect of inhaled fluticasone propionate (FP) with the combination of salmeterol/fluticasone propionate (SFC) on lung function parameters in patients with mild asthma." | 9.12 | Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. ( Borrill, ZL; Houghton, CM; Langley, SJ; Lawson, N; Singh, D; Wixon, CL; Woodcock, A; Yoxall, S, 2007) |
| "To identify the asthma patients, on short-acting beta2-agonists alone, who would benefit from initial maintenance therapy (IMT) with salmeterol/fluticasone (SFC) propionate 50/100 microg bd compared with fluticasone propionate (FP) 100 microg bd alone." | 9.12 | Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 microg bd versus fluticasone propionate 100 microg bd alone in patients with persistent asthma: integrated analysis of four randomised trials. ( Barnes, NC; Bateman, ED; Goldfrad, C; Jacques, L, 2007) |
| " After a 2-week run-in period, 228 patients with moderate to severe asthma were randomized to a 12-week treatment with either beclomethasone 100 microg plus formoterol 6 microg or fluticasone 125 microg plus salmeterol 25 microg, both delivered two inhalations b." | 9.12 | Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. ( Fabbri, LM; Nicolini, G; Paggiaro, P; Papi, A; Vignola, AM, 2007) |
| "The effect of ethnicity on the efficacy of salmeterol (S)+fluticasone propionate (FP) has not been examined in Japanese and Caucasian asthmatics." | 9.12 | Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics. ( Hashimoto, K; Kawai, M; Kempsford, R; Lötvall, J; Pullerits, T; Takaori, S; Takemoto, Y, 2007) |
| "During the Gaining Optimal Asthma controL study, 3416 patients with uncontrolled asthma were randomized to receive salmeterol/fluticasone propionate combination (SFC) or fluticasone propionate (FP) for 1 year." | 9.12 | Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. ( Bateman, ED; Bousquet, J; Busse, WW; Clark, TJ; Pedersen, SE; Yoxall, S, 2007) |
| "This study compared the bronchodilator efficacy and safety of indacaterol with placebo, salbutamol and salmeterol, in patients with persistent asthma, at single therapeutic and supratherapeutic doses." | 9.12 | Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. ( Barbier, M; Brookman, LJ; Elharrar, B; Fuhr, R; Knowles, LJ; Pascoe, S, 2007) |
| "To examine the long-term safety of levalbuterol hydrofluoroalkane (HFA) vs racemic albuterol HFA administered via metered-dose inhaler (MDI) in patients with stable asthma." | 9.12 | Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. ( Baumgartner, RA; D'Urzo, A; Hamilos, DL; Levy, RJ; Marcus, M; McVicar, WK; Parsey, M; Tripp, K, 2007) |
| " 365 symptomatic patients with moderate asthma aged >18 years and receiving ICS in a dose equivalent to 1000 microg beclomethasone propionate per day were randomly assigned to receive either salmeterol xinafoate (50 microg) and fluticasone propionate (250 microg) in a single dry powder inhaler (Diskus) or 500 microg FP twice daily." | 9.11 | Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. ( Bergmann, KC; Braun, R; Lindemann, L; Steinkamp, G, 2004) |
| "Adjustable maintenance dosing with budesonide/formoterol provides more effective asthma control by reducing exacerbations and reliever medication usage compared with fixed-dose salmeterol/fluticasone." | 9.11 | Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. ( Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004) |
| "To determine whether a higher dose of albuterol is required to normalize lung function during nocturnal asthma." | 9.11 | Response to inhaled albuterol during nocturnal asthma. ( Ahrens, R; Beaty, R; Harman, EM; Hendeles, L; Stevens, G, 2004) |
| "A prospective, randomized, double blinded study was conducted to determine whether a combination of nebulized magnesium sulfate and albuterol as a single dose adds any benefit in management of children with mild to moderate asthma when compared to nebulized albuterol with saline." | 9.11 | Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma. ( Haritos, D; Mahajan, P; Rosenberg, N; Thomas, R, 2004) |
| " Montelukast significantly reduced blood eosinophil counts compared with salmeterol, whereas salmeterol significantly increased prealbuterol forced expiratory volume in 1 second, asthma-specific quality of life, morning peak expiratory flow rate, and decreased nocturnal awakenings compared with montelukast." | 9.11 | Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. ( Bird, SR; Edelman, JM; Friedman, B; Hustad, CM; Ilowite, J; Kerwin, E; Webb, R, 2004) |
| "The effects of high-dose fluticasone propionate therapy on dynamic cortisol stimulation in severe asthma are unknown." | 9.11 | Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. ( Bates, CE; Cowan, LM; Currie, GP; Lee, DK; Lipworth, BJ; McFarlane, LC, 2004) |
| "To determine whether initiation of maintenance treatment with the salmeterol (S)/fluticasone propionate (FP) combination (Seretide/Viani/Advair) is more effective than inhaled steroid alone in patients with asthma symptomatic on short-acting bronchodilator alone." | 9.11 | Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. ( Luckow, A; Strand, AM, 2004) |
| "We report a 4 yr follow up study of seven asthmatic children with chronic persistent asthma, high-residual volume and low-density areas at high-resolution computerized tomography after treatment with salmeterol and fluticasone." | 9.11 | Montelukast and airway remodeling in children with chronic persistent asthma: an open study. ( Boner, AL; Caramella, D; De Marco, E; Pietrobelli, A; Pifferi, M; Ragazzo, V, 2004) |
| "To compare the clinical efficacy and side effects of terbutaline and salbutamol administered by metered dose inhaler and holding chamber in the mild to moderate acute exacerbations of asthma in children." | 9.11 | Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma. ( Chandra, P; Kabra, SK; Lodha, R; Paliwal, L, 2004) |
| "The goal of this study was to evaluate the efficacy, tolerability, and effect on asthma-related quality of life (QOL) of a long-acting beta(2)-adrenoreceptor agonist, formoterol, delivered via multidose DPI, compared with albuterol delivered via pMDI or placebo in adolescents and adults with persistent asthma." | 9.11 | Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, p ( Andriano, K; Busse, W; Lavecchia, C; Levine, B; Yegen, U, 2004) |
| "The present study aimed to investigate whether a fixed combination of salmeterol and fluticasone (SFC) from a single inhaler provides sufficient asthma control comparable to that achieved with standard treatment (inhaled steroid in a dose of 1,000 mcg BDP- (beclomethasone dipropionate) equivalent plus a LABA and/or theophylline and/or montelukast)." | 9.11 | [Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment]. ( Liefring, E; Molitor, S; Trautmann, M, 2005) |
| "To evaluate the efficacy and the safety of low dose salmeterol/fluticasone (SM/FP) combination therapy as compared to morate dose of budesonide (BUD) in the management of adult asthma." | 9.11 | [Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma]. ( Cai, BQ; Chen, BY; Chen, XD; Feng, YL; Guo, XJ; Kang, J; Li, Q; Lin, YP; Qiu, C; Shen, HH; Sun, TY; Tao, JJ; Wang, DQ; Xiao, BR; Xie, CM; Xu, YP; Yin, KS; Zhang, DP; Zheng, JP; Zhong, NS; Zhou, JY; Zhou, X, 2005) |
| "Our study compared levalbuterol (LEV) to the combination of racemic albuterol (RAC) and ipratropium bromide (IB) in 140 patients aged 6-18 years presenting to a tertiary hospital Emergency Department with acute asthma and a peak expired flow rate (PEF)<80% predicted." | 9.11 | Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. ( Cline, SM; Coakley, TA; Euwema, MS; Knecht, KR; Ralston, ME; Ziolkowski, TJ, 2005) |
| "A randomised, open-label, multicentre study compared the efficacy and tolerability of salmeterol 25 microg/fluticasone propionate 125 microg (two puffs, twice daily) delivered via a hydrofluoroalkane metered-dose inhaler (HFA-MDI) and salmeterol 50microg/fluticasone propionate 250 microg (one puff, twice daily) delivered via a Diskus inhaler in Chinese patients with moderate asthma uncontrolled with inhaled corticosteroids (ICSs)." | 9.11 | Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. ( Du, X; Humphries, M; Jiang, J; Wang, L; You-Ning, L, 2005) |
| "An efficacy treatment study is conducted comparing levalbuterol to racemic albuterol for acute pediatric asthma in the emergency department (ED)." | 9.11 | Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. ( Burke, BL; Meadows, T; Qureshi, F; Welch, C; Zaritsky, A, 2005) |
| "To compare levalbuterol and racemic albuterol for the treatment of acute exacerbation of asthma in pediatric population." | 9.11 | Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. ( Bithoney, WG; DeBari, V; Gold, N; Hardasmalani, MD, 2005) |
| "To compare the safety of twice-daily treatment with inhaled fluticasone propionate plus the inhaled long-acting beta2-agonist salmeterol with that of fluticasone propionate used alone in children aged 4 to 11 years with persistent asthma." | 9.11 | The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. ( Dorinsky, P; Ellsworth, A; House, K; LaForce, C; Malone, R; Nimmagadda, S; Schoaf, L, 2005) |
| "To determine the relative cost-effectiveness of twice-daily treatment with inhaled fluticasone propionate-salmeterol via Diskus, 100/50 microg, with that of once-daily treatment with oral montelukast as initial maintenance therapy in patients with persistent asthma uncontrolled with a short-acting beta2-agonist alone." | 9.11 | Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. ( Borker, R; Dorinsky, P; Emmett, A; Jhingran, P; Rickard, K, 2005) |
| "To determine and define the beneficial effects of heliox-driven albuterol therapy on severe asthma exacerbation and clinical factors that affect greater response." | 9.11 | Beneficial effects of albuterol therapy driven by heliox versus by oxygen in severe asthma exacerbation. ( Chang, HW; Hsu, CW; Huang, YC; Lee, DL; Lee, H, 2005) |
| "In the management of asthma exacerbation, ad-lib administration of albuterol is therapeutically as effective as regular, scheduled administration." | 9.11 | Regular vs ad-lib albuterol for patients hospitalized with acute asthma. ( Chandra, A; Chung, V; Cohen, HW; Dhuper, S; Maggiore, D; Mani, K; Shim, C, 2005) |
| "Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo." | 9.11 | Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005) |
| "Continuously nebulized albuterol delivered by heliox was associated with a greater degree of clinical improvement compared with that delivered by oxygen among children with moderate to severe asthma exacerbations." | 9.11 | Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. ( Corcoran, T; Funt, N; Gracely, E; Kim, IK; Phrampus, E; Pitetti, R; Saville, A; Thompson, A; Venkataraman, S, 2005) |
| "To evaluate the efficacy and safety of mometasone furoate dry powder inhaler (MF-DPI) administered once daily in the evening or twice daily in patients with asthma previously maintained on twice-daily regimens of inhaled corticosteroids." | 9.11 | Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. ( Busse, WW; Karpel, JP; Lutsky, B; Monahan, ME; Noonan, MJ; Staudinger, H, 2005) |
| "Forty-two asthmatic patients sensitized to pollen allergens were randomly allocated to treatment with fluticasone propionate-salmeterol (n=21) or fluticasone propionate alone (n=21)." | 9.11 | Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma. ( Badiola, C; Bruno, L; Ferrer, A; Gutiérrez, V; Lanuza, A; Pérez-Francés, C; Prieto, L, 2005) |
| "To investigate whether, after 48 h of IV treatment with corticosteroids, the use of high-dose inhaled flunisolide is as effective as systemic corticosteroids in adults hospitalized for a severe asthma exacerbation." | 9.10 | Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. ( Acquah, S; Dayrit, FM; Kohli, AR; Lee-Wong, M; Mayo, PH, 2002) |
| "To compare the relative cost effectiveness of salmeterol (50 microg)/ fluticasone propionate (100 microg) with that of oral montelukast (10mg) as initial maintenance therapy in patients with persistent asthma uncontrolled on short-acting beta2-agonist therapy alone." | 9.10 | Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. ( Borker, R; Dorinsky, P; Emmett, A; Rickard, K; Sheth, K, 2002) |
| "We evaluated whether montelukast conferred additive effects in patients with asthma receiving fluticasone/salmeterol (FP/SM) combination and FP alone." | 9.10 | Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. ( Bates, CE; Currie, GP; Haggart, K; Lee, DK; Lipworth, BJ, 2003) |
| "The aim of this study was to compare the efficacy and safety of salmeterol/fluticasone propionate combination product (SFC) with fluticasone propionate (FP) plus oral montelukast (M) over 12 weeks in symptomatic asthma patients." | 9.10 | The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. ( Akveld, M; Bateman, ED; Eliraz, A; Mulder, PG; Pruzinec, R; Ringdal, N; Weber, HH, 2003) |
| "A prospective, randomized, double-blind study was conducted to determine whether there was any benefit to the addition of ipratropium to a single nebulized albuterol treatment in infants and children with mild to moderate acute asthma presenting to a pediatric office." | 9.10 | Addition of ipratropium to nebulized albuterol in children with acute asthma presenting to a pediatric office. ( Gunawardane, G; Kumaratne, M, 2003) |
| "The relative efficacies of aminophylline and salbutamol in severe acute childhood asthma are currently unclear." | 9.10 | Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. ( Begent, J; Buchdahl, R; Gomez, K; Habel, A; Lachman, P; Newsom, D; Raffles, A; Roberts, G; Saglani, S; Sloper, K, 2003) |
| "Safety and efficacy of desloratadine and montelukast each were assessed in a double-blind, placebo-controlled trial of patients with SAR and symptoms of asthma, who were assigned randomly to once-daily treatment with desloratadine 5 mg, montelukast 10 mg, or placebo for 4 weeks." | 9.10 | Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003) |
| "Fifteen mild-to-moderate asthmatics (mean FEV(1) 80% predicted) uncontrolled on inhaled corticosteroids (mean dose 470 microg) were randomised in a single-blind crossover fashion to receive 2 weeks each of fluticasone 250 microg plus salmeterol 50 microg in combination (FP+SM), 1 puff b." | 9.10 | Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. ( Bates, CE; Currie, GP; Jackson, CM; Lee, DK; Lipworth, BJ, 2003) |
| "The aim of this study was to test the hypothesis that the addition of the long-acting beta(2)-agonist salmeterol (SALM) to a low dose of the inhaled corticosteroid fluticasone propionate (FP) has a steroid-sparing effect and does not result in a worsening of bronchial inflammation compared to doubling the dose of inhaled corticosteroid." | 9.10 | Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. ( Bjermer, L; Djukanović, R; Holgate, S; Lindberg, A; Lundbäck, B; Sandström, T; Sue-Chu, M; Wallin, A; Ward, J; Wilson, S, 2003) |
| "The objective of this study was to evaluate parental preference for the treatment of asthmatic children with oral montelukast sodium or inhaled cromolyn sodium." | 9.10 | Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. ( Bird, SR; Bratton, DL; Bukstein, DA; Edelman, JM; Estojak, J; Firriolo, KM; Hustad, CM, 2003) |
| "To compare the efficacy and safety of twice-daily fluticasone propionate (FP) 88 microg and salmeterol 42 microg combined in a chlorofluorocarbon (CFC)-free (hydrofluoroalkane 134a) metered-dose inhaler (MDI) with the individual agents alone, each delivered through an MDI containing CFC propellants, in patient with persistent asthma previously uncontrolled with as-needed short-acting beta2-agonists alone." | 9.10 | Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. ( Baitinger, L; Dorinsky, P; Greos, LS; Gross, G; Nelson, HS; Scott, C; Wolfe, JD, 2003) |
| "To compare the control of FeNO provided by salmeterol or montelukast add-on therapy in asthmatic children undergoing regular maintenance treatment with a daily dose of 400 microg of budesonide." | 9.10 | Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. ( Bisgaard, H; Buchvald, F, 2003) |
| "To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone." | 9.10 | Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. ( Bisgaard, H; Bjermer, L; Bousquet, J; Dass, SB; Fabbri, LM; Greening, AP; Haahtela, T; Holgate, ST; Leff, JA; Menten, J; Picado, C; Polos, PG, 2003) |
| "To determine whether levalbuterol resulted in fewer hospital admissions than racemic albuterol when used for treatment of acute asthma." | 9.10 | Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. ( Carl, JC; Kercsmar, CM; Kirchner, HL; Myers, TR, 2003) |
| "Treatment of moderate-to-severe asthma with salmeterol/fluticasone propionate resulted in superior gains in HR-QOL relative to increasing the dose of inhaled corticosteroids." | 9.10 | Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. ( James, MH; Jenkins, C; Juniper, EF; Price, MJ, 2002) |
| "The goal of the present study was to evaluate the efficacy and safety of salmeterol/ fluticasone (50/250 microg twice daily) as initial treatment for symptomatic patients with mild to moderate bronchial asthma who had not previously received appropriate anti-asthma medication." | 9.10 | Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023). ( Baumgarten, C; Behre, U; Geldszus, R; Peslis, N; Trautmann, M, 2002) |
| "Initial maintenance therapy with FSC provides greater improvement in asthma control and patient satisfaction than montelukast." | 9.10 | Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. ( Bowers, B; Dorinsky, P; Emmett, A; Kalberg, C; Lieberman, AK; Pearlman, DS; Pepsin, PJ; Rickard, KA; White, MV, 2002) |
| " Patients kept records of peak flow meter (PFM) measurements, asthma attack rate and beta-2-agonist use (albuterol)." | 9.10 | Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial. ( Chervinsky, P; Goldstein, MF, 2002) |
| " We studied the spirometric effects of albuterol nebulized with heliox during emergency room visits for asthma exacerbations." | 9.10 | The utility of albuterol nebulized with heliox during acute asthma exacerbations. ( Barman, N; Gehlbach, BK; Hall, JB; Kress, JP; Miller, A; Morgan, S; Noth, I; Pohlman, AS, 2002) |
| "We sought to compare the efficacy and safety of nebulized magnesium sulfate (MgSO(4)) plus albuterol with that of albuterol alone in adult patients with mild-to-moderate acute asthma exacerbations." | 9.10 | A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. ( Becker, E; Bessmertny, O; Cohen, H; DiGregorio, RV; Golden, J; Johnson, T; Kohl, L; Looney, D, 2002) |
| " Sixty-three adolescent and adult asthmatic patients were randomized to receive at separate treatment visits single doses via a pressurized metered-dose inhaler of either placebo/hydrofluoroalkane (HFA) 134a; 100 microg, 200 microg, or 400 microg albuterol/HFA 134a; 100 microg or 200 microg albuterol/chlorofluorocarbon (CFC)." | 9.10 | A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. ( Batty, EP; Langley, SJ; Masterson, CM; Sykes, AP; Woodcock, A, 2002) |
| "We examined the partitioning of total lung resistance (RL) into airway resistance (Raw) and tissue resistance (Rti) in patients with mild to moderate asthma (baseline FEV1, 54 to 91% of predicted) before and after albuterol inhalation." | 9.09 | Airway and lung tissue mechanics in asthma. Effects of albuterol. ( Ingenito, EP; Israel, E; Kaczka, DW; Lutchen, KR, 1999) |
| "Thus in stable asthmatic subjects receiving regular salmeterol or formoterol, bronchoprotective subsensitivity was not overcome by administering a high dose of albuterol." | 9.09 | A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. ( Aziz, I; Lipworth, BJ, 1999) |
| "To compare the effectiveness of a helium-oxygen mixture with that of oxygen alone as an aerosolizing gas for beta-agonist therapy in patients with mild to moderate exacerbation of asthma." | 9.09 | Use of heliox-driven nebulizer therapy in the treatment of acute asthma. ( Acharya, P; Chan, LS; Henderson, SO; Kilaghbian, T; Korn, CS; Perez, J, 1999) |
| "The optimal dose of albuterol to use in the treatment of acute asthma has yet to be established." | 9.09 | Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma. ( Cydulka, RK; Emerman, CL; McFadden, ER, 1999) |
| "To compare the long-term efficacy and safety of albuterol administration using a Spiros Inhalation System (Dura Pharmaceuticals; San Diego, CA) dry powder inhaler (DPI) and albuterol (Ventolin; Glaxo Wellcome; Research Triangle Park, NC) administration using a metered-dose inhaler (MDI) in patients with asthma." | 9.09 | Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. ( Bieler, S; Hill, MR; Kemp, JP; Nelson, H; Vaughan, LM, 1999) |
| "To evaluate the 12-hour efficacy and safety of single doses of 25 micrograms and 50 micrograms of salmeterol powder administered via Diskus inhaler versus albuterol aerosol via pressurized metered-dose inhaler and placebo in preventing EIB in asthmatic children." | 9.09 | Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. ( Arledge, T; Blake, K; Pearlman, DS; Scott, C; Stahl, E; Wang, Y, 1999) |
| "To determine whether initiation of salmeterol and fluticasone propionate treatment together improves asthma control greater than initiation of monotherapy with the individual agents alone with no additional safety risk in patients with asthma who had not previously been treated with inhaled corticosteroids." | 9.09 | Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. ( Chervinsky, P; Gross, G; Pearlman, DS; Prillaman, B; Shah, T; Stricker, W; Weinstein, S; Woodring, A, 1999) |
| "Fluticasone propionate is a topically active glucocorticoid with potent antiinflammatory activity in the treatment of asthma." | 9.09 | Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. ( Brown, A; Finn, A; Galant, SP; Gross, G; Hamedani, AG; Harding, SM; Pleskow, W; van Bavel, J, 1999) |
| "The purpose of this study was to determine the safety and efficacy of increasing doses of nebulized levalbuterol (Xopenex; the pure R-isomer of racemic albuterol) and racemic albuterol compared with placebo in the treatment of asthma in pediatric patients." | 9.09 | The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. ( DeGraw, SS; Gawchik, SM; Noonan, M; Reasner, DS; Saccar, CL, 1999) |
| "In a randomized, double-blind, placebo-controlled trial, 56 adult asthmatic patients with peak expiratory flow rates (PEFRs) less than 50% predicted after an initial albuterol aerosol treatment were studied." | 9.09 | Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: A randomized controlled study. ( Bakalchuk, L; Curry, A; Dow, AM; Heyl, GT; Lin, RY; Pesola, GR; Tenenbaum, C; Westfal, RE, 1999) |
| "In patients with mild-to-moderate asthma in this study, the albuterol DPI was determined to be therapeutically comparable to albuterol MDI in the delivery of one and two actuations of albuterol." | 9.09 | Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma. ( Ahrens, R; Clarke, W; Geoffroy, P; Grossman, J; Hill, MR; Lalonde, RL; Vaughan, LM, 1999) |
| "Current treatment guidelines define inhaled corticosteroids such as fluticasone propionate (FP) as the cornerstone of anti-inflammatory therapy for asthma." | 9.09 | The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. ( Condemi, JJ; Emmett, A; Goldstein, S; Kalberg, C; Rickard, K; Yancey, S, 1999) |
| "The objective of this multicentre, randomised, double blind, parallel group study was to compare the efficacy and safety of the addition of salmeterol with that of doubling the dose of fluticasone propionate in asthmatic patients not controlled by a low or intermediate dose of inhaled corticosteroids." | 9.09 | Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. ( Mol, SJ; Mulder, PG; Schreurs, AJ; van Noord, JA, 1999) |
| "We sought to compare the efficacy and safety of 2 doses of fluticasone propionate (88 micrograms twice daily and 220 micrograms twice daily) with 2 doses of beclomethasone dipropionate (168 micrograms twice daily and 336 micrograms twice daily) in subjects with persistent asthma." | 9.09 | A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. ( Baker, J; Edwards, L; Lanier, RQ; Lincourt, WR; Raphael, GD; Rickard, K, 1999) |
| " We undertook a double-blind, randomized, placebo-controlled, cross-over study to investigate the effects of a single dose of formoterol inhaled via Turbuhaler (12 micrograms) and of albuterol inhaled via Turbuhaler (200 micrograms) on airway responsiveness to AMP and histamine in 16 subjects with mild atopic asthma." | 9.09 | Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. ( Barnes, PJ; Nightingale, JA; Rogers, DF, 1999) |
| "To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma." | 9.09 | Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. ( Mende, CN; Petrocella, VJ; Rickard, KA; Wiegand, L; Yancey, SW; Zaidel, G; Zwillich, CW, 1999) |
| "In children with mild acute asthma, to compare treatment with a single dose of albuterol delivered by a metered dose inhaler (MDI) with a spacer in either a weight-adjusted high dose or a standard low-dose regimen with delivery by a nebulizer." | 9.09 | Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. ( Callahan, S; Canny, GJ; Johnson, DW; Schuh, S; Stephens, D; Winders, P, 1999) |
| " In order to examine the usefulness of inhaled PDE3 inhibitors in the treatment of asthma, we investigated the bronchodilator effect of inhaled olprinone, a newly developed PDE3 inhibitor, in nine asthmatic patients." | 9.09 | Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. ( Fujimura, M; Hashimoto, T; Hirose, T; Ishiura, Y; Kamio, Y; Matsuda, T; Myou, S; Tachibana, H, 1999) |
| "To compare efficacy of an extended release oral beta-2 agonist, albuterol sulfate (Volmax), to a long-acting inhaled agent, salmeterol (Serevent) in the treatment of nocturnal asthma." | 9.09 | Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma. ( Beaucher, WN; Kiechel, F; Kraft, M; LaVallee, N; Martin, RJ; Shilstone, J; Sublett, JL, 1999) |
| "Outcome measures included FEV1, peak expiratory flow (PEF), supplemental albuterol use, nighttime awakenings, asthma symptoms, and physician global assessment." | 9.09 | Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. ( Baraniuk, J; Berger, WE; Edwards, LD; Johnson, M; Murray, JJ; Nathan, RA; Rickard, KA; Srebro, S, 1999) |
| "We investigated the bronchodilator dose-response to nebulized albuterol and the dose of albuterol which produces maximal bronchodilation in the acutely ill, hospitalized asthmatic." | 9.09 | Dose-response characteristics of nebulized albuterol in the treatment of acutely ill, hospitalized asthmatics. ( Brennan, K; Ciccolella, DE; Criner, GJ; Kelsen, SG, 1999) |
| "To evaluate the efficacy of nebulized budesonide compared to oral prednisolone early in the emergency room management of acute asthma, we conducted a double-blind, placebo-controlled trial." | 9.09 | Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. ( Jayshree, M; Kumar, L; Singhi, S, 1999) |
| "Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently introduced for the treatment of asthma." | 9.09 | The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. ( Bradding, P; Britten, KM; Gratziou, C; Holgate, ST; Howarth, PH; Roberts, JA; Walls, AF; Wilson, S, 1999) |
| "Twenty-four stable patients with asthma (forced expiratory volume in 1 second: 70% to 90% of predicted and a minimum of 10% reversibility after inhalation of albuterol sulfate) with no previous exposure to inhaled corticosteroids participated in this randomized, double-masked crossover trial." | 9.09 | Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. ( Everts, B; Hedner, J; Möller, CS, 1999) |
| "Fluticasone propionate 880 microg/day improved lung function and quality of life in adolescents with moderate-to-severe asthma when compared with flunisolide 1500 microg/day." | 9.09 | Comparison of the efficacy of inhaled fluticasone propionate, 880 microg/day, with flunisolide, 1500 microg/day, in moderate-to-severe persistent asthma. ( Eid, N; Goldsmith, LJ; Howell, L; Sheikh, S, 1999) |
| "All active treatment groups showed statistically significant improvement compared with placebo in pulmonary function (FEV1, FEF25-75%, morning and evening PEF), use of rescue albuterol, and asthma symptom scores." | 9.09 | Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. ( Banerji, D; Chervinsky, P; Jacobson, K; Kane, RE; Noonan, M; Uryniak, T, 1999) |
| " Efficacy was assessed by spirometry, and by daily recordings of albuterol use, peak expiratory flow (PEF), asthma symptom ratings, and nighttime awakenings throughout the study." | 9.09 | A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group. ( Banerji, D; Bernstein, D; Gross, G; Kane, RE; Welch, M, 1999) |
| "Three hundred forty-nine patients with asthma previously treated with medium doses of inhaled corticosteroids during a 2-wk, single-blind, run-in period were randomized to treatment with salmeterol 50 microg combined with fluticasone propionate (FP) 250 microg, salmeterol 50 microg, FP 250 microg, or placebo, each given twice daily through a Diskus device for 12 wk." | 9.09 | Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. ( Baitinger, L; Given, J; House, K; Lumry, W; Prillaman, B; Shah, T; Shapiro, G; White, MV; Wolfe, J; Woodring, A, 2000) |
| "Magnesium sulfate is thought to be an effective bronchodilator when administered intravenously to patients with acute severe asthma, and it can be safely administered via inhalation to patients with stable asthma." | 9.09 | Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma. ( Corna, RA; Mannarino, S; Nannini, LJ; Pendino, JC; Quispe, R, 2000) |
| "Twelve asthmatic patients were enrolled into a single-blind, placebo-controlled, crossover study, receiving additive therapy as either of the following: (1) montelukast alone, 10 mg (ML(10)); (2) inhaled salmeterol alone, 50 microg (SM(50)); (3) ML(10) and SM(50); (4) ML(10) and inhaled salmeterol, 100 microg (SM(100)); or (5) placebo inhaler and tablet." | 9.09 | Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. ( Dempsey, OJ; Lipworth, BJ; Mistry, C; Sims, EJ; Wilson, AM, 2000) |
| "Mometasone furoate (MF) is a new potent corticosteroid for use in treating asthma." | 9.09 | Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. ( Arshad, H; Harrison, JE; Holgate, ST; Stryszak, P, 2000) |
| "Our purpose was to evaluate the effectiveness of fluticasone propionate powder 200 microg/d administered as a once- or twice-daily dosage regimen in patients who were currently being treated with bronchodilators only (BD patients) and in patients who required inhaled corticosteroids for maintenance treatment of asthma (ICS patients)." | 9.09 | Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. ( Duke, S; Grady, J; Harding, S; Munk, ZM; Prillaman, B; Rooklin, A; Stevens, A; Wolfe, J, 2000) |
| "Three hundred and fifty-three asthmatic patients who remained symptomatic despite treatment with budesonide 800-1200 microg day(-1) (or equivalent) were randomized to a new combination therapy comprising salmeterol 50 microg and fluticasone propionate 250 microg (Seretide, Advair, Viani 50/250 microg) twice daily or budesonide 800 microg twice daily for 24 weeks." | 9.09 | Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma. ( James, MH; Jenkins, C; Lundback, B; Saarelainen, P; Woolcock, AJ, 2000) |
| "Once-daily treatment with fluticasone propionate resulted in an improvement in efficacy variables, such as FEV(1), morning and evening peak expiratory flow (PEF), asthma symptom scores, nighttime awakenings, albuterol use, and duration of study participation." | 9.09 | A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. ( Finn, A; Harding, SM; Jones, R; Li, JT; Nathan, RA; Payne, JE; Wolford, JP, 2000) |
| "To evaluate the efficacy and safety of fluticasone propionate administered as a once-daily or twice-daily regimen over a period of 1 year to patients with moderate asthma." | 9.09 | Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. ( Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000) |
| "Eighteen patients with mild-to-moderate persistent asthma receiving inhaled corticosteroid who expressed the homozygous glycine-16 genotype were randomized to completion (mean [SEM] age, 35." | 9.09 | Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. ( Aziz, I; Dempsey, OJ; Lipworth, BJ, 2000) |
| "This study was undertaken to compare the outcome of adults with acute severe asthma treated with 4 puffs of salbutamol (100 microg/actuation) every 20 minutes for 3 doses plus 4 puffs of oxitropium bromide (100 microg/actuation) with each of the 3 salbutamol doses versus salbutamol alone administered by means of a metered-dose inhaler with a spacer device." | 9.09 | Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. ( Chida, K; Enomoto, N; Hirai, R; Kawamoto, A; Nakano, Y, 2000) |
| "The safety and efficacy of two once daily dosing regimens (200 microg and 400 microg) of mometasone furoate (MF) administered in the morning by using a dry-powder inhaler (DPI) were compared with those of a twice daily dosing regimen (200 microg administered twice daily) in patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists." | 9.09 | Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. ( Berkowitz, RB; Harrison, JE; Kemp, JP; Miller, SD; Murray, JJ; Nolop, K, 2000) |
| "Intravenous magnesium sulfate (MgSO4), as an adjunctive medication to the standard treatment of acute asthma, improves admission rate or severity score in acute severe asthma patients." | 9.09 | Intravenous magnesium sulfate in acute severe asthma. ( Boonyavorakul, C; Charoenpan, P; Thakkinstian, A, 2000) |
| " The authors performed a prospective, randomized, double-blind, placebo-controlled trial to test the ability of intravenous lidocaine and inhaled albuterol to attenuate airway reactivity after tracheal intubation in asthmatic patients undergoing general anesthesia." | 9.09 | Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma. ( Boughton, R; Darvish, A; Israel, E; Loring, SH; Maslow, AD; Mehrez, M; Regan, MM, 2000) |
| "FP/Salm Combo treatment provided better overall asthma control than FP + montelukast with significantly greater improvements in morning peak expiratory flow (+24." | 9.09 | Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. ( Busse, WW; Church, N; Emmett, A; Kerwin, E; Knobil, K; Nelson, HS; Rickard, K, 2000) |
| "This was an open-label, parallel group, randomized, age-stratified, multicenter study designed to compare the safety and efficacy of regular use of albuterol formulated in hydrofluoroalkane-134a (HFA albuterol) and albuterol formulated in chlorofluorocarbons-11/12 (CFC albuterol) in children with asthma." | 9.09 | Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma. ( Colice, GL; Ekholm, BP; Klinger, NM; Shapiro, GS, 2000) |
| "This multi-centre, randomized, double-blind, double-dummy, parallel-group study was designed to investigate the hypothesis of equivalent efficacy and comparable safety of two inhaled presentations of salmeterol/fluticasone propionate combination product (SALM/FP) 50/100 microg administered twice daily to patients with mild-to-moderate asthma for 12 weeks." | 9.09 | Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. ( Bateman, ED; Bogolubov, M; Silins, V, 2001) |
| "Montelukast and salmeterol exhibited significant improvements in asthma control when given as second-line therapy." | 9.09 | Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. ( Dempsey, OJ; Lipworth, BJ; Sims, EJ; Wilson, AM, 2001) |
| "Comparison of inhaled salmeterol powder vs oral montelukast treatment in patients with persistent asthma who remained symptomatic while receiving inhaled corticosteroids." | 9.09 | Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. ( Boone, R; Emmett, A; Fish, JE; Israel, E; Murray, JJ; Rickard, KA; Yancey, SW, 2001) |
| "Asthmatic children having their tracheas intubated with sevoflurane often have an increase in respiratory system resistance (Rrs)." | 9.09 | Salbutamol prevents the increase of respiratory resistance caused by tracheal intubation during sevoflurane anesthesia in asthmatic children. ( Habre, W; Scalfaro, P; Sims, C; Sly, PD, 2001) |
| "To determine whether the addition of inhaled ipratropium bromide to inhaled albuterol and systemic corticosteroid therapy was more efficacious than inhaled albuterol and systemic corticosteroids alone in the inpatient treatment of acute asthma exacerbations in children." | 9.09 | Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. ( Goggin, N; Macarthur, C; Parkin, PC, 2001) |
| " In a patient subset with severe asthma, a dose-response relationship was observed for levalbuterol, indicating that higher doses were more effective." | 9.09 | Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. ( Baumgartner, RA; Bensch, G; Claus, R; Kim, KT; Milgrom, H; Skoner, DP, 2001) |
| "The aim of this study was to evaluate if continuous treatment with budesonide or salmeterol influences the bronchodilator response to terbutaline in children with asthma; 23 children, aged 7 to 16 years (mean = 11 years), with mild asthma were treated with inhaled budesonide 100 micrograms b." | 9.08 | Influence of budesonide on the response to inhaled terbutaline in children with mild asthma. ( Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1995) |
| "High-dose continuous nebulization of albuterol is as safe and as efficacious as intermittent nebulization of albuterol in the early treatment of asthma in an emergency department." | 9.08 | Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study. ( Dworkin, G; Kotch, A; Reisner, C, 1995) |
| "The aim of the study was to compare the efficacy, tolerability and patient acceptability of bambuterol (Bambec) against controlled release (CR) salbutamol (Volmax) in the treatment of nocturnal asthma." | 9.08 | Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group. ( Ayres, JG; Gunn, SD; McConchie, SM, 1995) |
| "We have recently demonstrated that a 2-week course of inhaled albuterol 200 micrograms four times daily caused a near doubling of the allergen-induced early asthmatic response." | 9.08 | Regular use of inhaled albuterol and the allergen-induced late asthmatic response. ( Bhagat, R; Cockcroft, DW; O'Byrne, PM; Swystun, VA, 1995) |
| "Many potential users of the H1 antihistamine cetirizine are asthmatic and may be using inhaled albuterol." | 9.08 | Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. ( Corren, J; Katz, RM; Nicodemus, CF; Rachelefsky, GS; Schanker, HM; Siegel, SC; Spector, SL, 1995) |
| "Salmeterol (42 micrograms twice daily) was compared with the short-acting beta 2-agonist albuterol (180 micrograms four times daily) in two double-blind, randomized studies involving 556 patients with mild-to-moderate asthma." | 9.08 | Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. ( Pearlman, DS, 1995) |
| "The objective of this trial was to determine the efficacy of frequent nebulized ipratropium added to high-dose albuterol therapy in children with severe asthma." | 9.08 | Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. ( Callahan, S; Canny, G; Johnson, DW; Levison, H; Schuh, S, 1995) |
| "This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma." | 9.08 | Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995) |
| "Adult, nonsmoking patients with mild to moderate asthma were randomized to receive 4 mg nedocromil sodium (n = 13), 200 micrograms albuterol (n = 13), or placebo (n = 12) four times daily for 16 wk in a double-blind, double-dummy protocol." | 9.08 | Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. ( Davies, RJ; Devalia, JL; Manolitsas, ND; McAulay, AE; Trigg, CJ; Wang, J, 1995) |
| "Asthmatics aged 18 to 65 years during acute exacerbation with FEV1 less than 75% predicted both before and after a single albuterol treatment." | 9.08 | Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. ( Bloch, H; Grant, S; Jagminas, L; Mancherje, N; Scharf, SM; Silverman, R, 1995) |
| "In a double-blind, double-dummy, multicenter study, 212 patients with asthma whose symptoms were not controlled by as-needed use of inhaled bronchodilators were randomized to receive either 4 mg of nedocromil sodium or 180 micrograms of albuterol four times daily for 12 weeks." | 9.08 | Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol. ( Findlay, SR; Furukawa, CT; Gross, GN; Henochowicz, SI; Hudson, LD; Marcoux, JP; Myers, DJ; Prenner, BM; Steinberg, P; Wasserman, SI, 1995) |
| "We performed a double-blind, two-phase study on protective and bronchodilator effects of prostaglandins E2 and E1 (PGE2, PGE1) and salbutamol in patients with aspirin-induced asthma (AIA)." | 9.08 | Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. ( Cmiel, A; Mastalerz, L; Nizankowska, E; Szczeklik, A, 1996) |
| "This was a 4-week, open-label, parallel-group study designed to compare the efficacy and safety of the long-acting inhaled bronchodilator, salmeterol, with the established inhaled bronchodilator, terbutaline, in the treatment of patients with mild to moderate asthma." | 9.08 | A 4-week comparison of salmeterol and terbutaline in adult asthma. ( Hermansson, BA; Jenkins, RJ, 1995) |
| "The effectiveness of maintenance albuterol aerosol therapy in cystic fibrosis (CF) was assessed by comparing spirometric measurements at the beginning and end of 1 year." | 9.08 | Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. ( Barbero, GJ; Gayer, D; König, P; Shaffer, J, 1995) |
| "To compare the magnitudes of the immediate effects of the nebulized beta-agonists isoetharine and albuterol in the treatment of acute severe asthma." | 9.08 | Isoetharine versus albuterol for acute asthma: greater immediate effect, but more side effects. ( Bidadi, K; Gourlay, S; Hayes, J; Robertson, S; Shrestha, M; Wainscott, M, 1996) |
| "Albuterol sulfate, in the syrup and tablet form for oral administration, has been an effective treatment for adults and children with bronchial asthma." | 9.08 | Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children. ( Boltansky, H; Harrison, JE; Kobayashi, RH; Lorber, RR; Pearlman, DS; Shapiro, G; Skoner, DP; Trochelmann, LM, 1996) |
| "Azelastine, an oral nonsteroidal, antiinflammatory drug with a good safety profile, has demonstrated relief of symptoms in patients with asthma." | 9.08 | An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. ( , 1996) |
| "Fluticasone propionate (FP) administered via metered-dose inhaler is a potent corticosteroid effective in the treatment of asthma." | 9.08 | A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. ( Gross, GN; Kellerman, DJ; Kral, KM; Munk, ZM; Schaberg, A; Schoenwetter, WF; Wasserman, SI, 1996) |
| "The purpose of this study was to evaluate the effect of albuterol dosing schedule on clinical outcome in subjects with moderate to severe stable asthma." | 9.08 | The effect of inhaled albuterol in moderate to severe asthma. ( Apter, AJ; Clive, J; McNally, D; Metersky, M; Reisine, ST; Wells, M; Willard, A; ZuWallack, RL, 1996) |
| "The inhaled corticosteroid, fluticasone propionate, was compared with the oral bronchodilator theophylline in the maintenance treatment of asthma." | 9.08 | Fluticasone propionate compared with theophylline for mild-to-moderate asthma. ( Baker, KA; Galant, SP; Kellerman, DJ; Lawrence, M; Meltzer, EO; Tomasko, M, 1996) |
| "In a multicenter, double-blind study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients)." | 9.08 | Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. ( Boushey, HA; Chinchilli, VM; Drazen, JM; Fahy, JV; Fish, JE; Israel, E; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, C; Szefler, SJ, 1996) |
| "To evaluate the role of inhaled ipratropium bromide in acute asthma, a double-blind study of 384 emergency department patients compared the effect of the combination of ipratropium and albuterol with that of albuterol alone." | 9.08 | A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. ( Aldrich, T; Fanta, C; Karpel, JP; Levey, D; Menjoge, SS; Schacter, EN; Spiro, P; Witek, TJ, 1996) |
| "The purpose of the study was to compare bronchodilator responses to albuterol between an ultrasonic and a jet nebulizer in moderate to severe asthma." | 9.08 | A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma. ( Leickly, FE; Pallares, DE; Pilarski, BR; Rodriguez, JL, 1996) |
| "To compare the efficacy and safety of continuous nebulized (CN) albuterol therapy with those of intermittent nebulized (IN) albuterol therapy in the ED treatment of children with moderate to severe asthma exacerbations." | 9.08 | Continuous vs intermittent nebulized albuterol for emergency management of asthma. ( Fuchs, SM; Khine, H; Saville, AL, 1996) |
| "Nedocromil sodium is recommended for daily treatment of mild persistent asthma but its effect on cellular changes in asthmatic airways is poorly understood." | 9.08 | Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma. ( Altraja, A; Laitinen, A; Laitinen, LA; Marran, S; Märtson, T; Meriste, S; Sillastu, H, 1996) |
| " The bronchodilator, cardiovascular, and tremorigenic responses following administration of salbutamol (SAL), terbutaline (TER) and fenoterol (FEN) by closed-port intermittent nebulization were compared for a period of 8 hr." | 9.08 | Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol. ( Naspitz, CK; Scalabrin, DM; Solé, D, 1996) |
| "These results confirm that there is activation of the RAS in asthmatic subjects by single doses of nebulized beta 2-agonists and that repeated dosing with nebulized albuterol has further, additive effects on plasma Ang II levels." | 9.08 | The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma. ( Connell, JM; Millar, EA; Thomson, NC, 1997) |
| "Nocturnal cough and wheeze are common in asthma and often treated with beta2 agonists or theophyllines." | 9.08 | Inhaled salmeterol or oral theophylline in nocturnal asthma? ( Douglas, NJ; Engleman, HM; Fitzpatrick, MF; Mackay, TW; Selby, C; Sime, PM, 1997) |
| " The present study was undertaken to compare the therapeutic effects of sustained release theophylline and a conventional low dose oral fenoterol in patients with asthma." | 9.08 | Oral fenoterol versus sustained release theophylline in adult asthmatics. ( Almagro, J; Andrade, RJ; Hidalgo Sanchez, R; Lucena, MI; Sanchez de la Cuesta, F, 1997) |
| "Twenty two asthmatic subjects were randomised to receive montelukast, 100 mg or 250 mg, or placebo in a double blind, three period, crossover trial." | 9.08 | Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. ( Botto, A; Busse, WW; Kundu, S; Reiss, TF; Sorkness, CA; Stricker, W; Zhang, J, 1997) |
| "To determine the efficacy of combination therapy using atropine sulfate and albuterol in the treatment for an acute exacerbation of asthma." | 9.08 | Efficacy of atropine sulfate in combination with albuterol in the treatment for acute asthma. ( Bradley, K; Díaz, JE; Dubin, R; Gaeta, TJ; Pelczar, P, 1997) |
| "The purpose of this study was to evaluate the feasibility of switching to once-daily (qd) administration of flunisolide in patients with asthma that was controlled by twice-daily (bid) dosing of this inhaled steroid." | 9.08 | The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. ( Bodenheimer, S; Bronsky, EA; Chervinsky, P; Cohen, L; Corren, J; Goldsobel, AB; Gong, H; Kaliner, MA; Lotner, GZ; Rachelefsky, GS; Rosen, JP; White, MV; ZuWallack, RL, 1997) |
| "Fluticasone propionate, an inhaled corticosteroid with negligible systemic bioavailability via the oral route, is efficacious in the treatment of asthma when administered via metered-dose inhaler." | 9.08 | Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. ( Goldstein, MF; Hamedani, AG; Kellerman, DJ; Noonan, MJ; Pearlman, DS; Schaberg, A; Tashkin, DP, 1997) |
| "Although theophylline is recommended by current guidelines for the management of asthma in patients with persistent symptoms, theophylline has a narrow therapeutic index, requiring individual dose titration and regular monitoring of serum theophylline concentrations to avoid adverse effects." | 9.08 | Salmeterol versus theophylline in the treatment of asthma. ( Cox, FM; Emmett, A; Pollard, SJ; Spector, SL; Yancey, SW, 1997) |
| "The aim of the present study was to compare the efficacy and the tolerability of salmeterol and theophylline in patients with nocturnal asthma." | 9.08 | [Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance]. ( Braun, H; Koper, I; Leutz, M; Schlimmer, P; Sybrecht, GW; Ukena, D, 1997) |
| " In a recent study in 17 adults with stable asthma, albuterol given using an ultrasonic nebulizer (UN) appeared to produce greater bronchodilatation than the same dose of albuterol given by a jet nebulizer (JN)." | 9.08 | Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children. ( Foster, C; Lamb, BM; Nakanishi, AK; Rubin, BK, 1997) |
| "To determine the optimal treatment interval for administering albuterol metered-dose inhaler (MDI) with a holding chamber to patients presenting to the emergency department (ED) with acute asthma." | 9.08 | Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered? ( Aldrich, TK; Gaitan-Salas, A; Guguchev, K; Karpel, JP; Pathiparti, R; Prezant, DJ, 1997) |
| " Efficacy was assessed by changes in FEV1, asthma symptom scores, albuterol use, and peak flow rates." | 9.08 | Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. ( Farrar, JR; Feiss, G; Levy, S; Smith, JA; Welch, MJ, 1997) |
| " A total of 291 male and female patients at least 12 years of age with asthma (FEV1 between 50% and 80% of predicted value), who had previously received maintenance therapy with beclomethasone dipropionate or triamcinolone acetonide, were switched to treatment with fluticasone propionate powder (250 microg twice daily), triamcinolone acetonide aerosol (200 microg four times daily), or placebo for 24 weeks." | 9.08 | Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. ( Ayars, GH; Berger, WE; Chervinsky, P; Condemi, JJ; Edwards, L; Ford, LB; Goldstein, MF; Pepsin, PJ; Rogenes, PR, 1997) |
| " We undertook two double-blind, randomized, crossover, placebo-controlled studies to investigate the effects of salmeterol and albuterol on airway responsiveness (AR) to AMP and histamine in patients with mild asthma." | 9.08 | Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. ( Aikman, SL; Barnes, PJ; Harris, JG; Jensen, MW; O'Connor, BJ; Taylor, DA, 1997) |
| "We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma." | 9.08 | Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997) |
| "To assess the effect of a long-acting inhaled beta 2-agonist, salmeterol (SM), compared to a short-acting inhaled beta 2-agonist, salbutamol (or albuterol, SB) on the occurrence of morning dip (MD) in patients recovering from an acute severe asthma attack (ASA)." | 9.08 | Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attack. ( Arnold-Ketterer, M; Chevrolet, JC; Ritz, M; Thorens, JB, 1997) |
| "In a randomized, double-blind, placebo-controlled trial, 55 adult asthmatic patients with peak expiratory flow rate (PEFR) less than 200 L/min were randomly assigned to nebulization treatment with albuterol alone (2." | 9.08 | Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial. ( Bakalchuk, L; Cataquet, D; Freyberg, CW; Heyl, GT; Lin, RY; Morgan, JP; Pesola, GR; Westfal, RE, 1998) |
| "We assessed the acute bronchodilator effect of nebulized furosemide when added to conventional therapy of acute emergency department (ED) asthma." | 9.08 | Effect of inhaled furosemide in acute asthma. ( Chapman, KR; Molfino, NA; Nannini, LJ; Pendino, JC; Slutsky, A, 1998) |
| "This randomized, double-blind trial was designed to determine the benefit of high and cumulative doses of flunisolide added to salbutamol in patients with acute asthma in the emergency room (ER)." | 9.08 | Inhaled flunisolide for acute severe asthma. ( Rodrigo, C; Rodrigo, G, 1998) |
| " We compared the safety and efficacy of fluticasone propionate (FP) and beclomethasone dipropionate (BDP) in 306 patients with moderate to severe asthma in a double-blind, multicenter, cross-over study of 12 mo duration." | 9.08 | Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. ( Demedts, MG; Geusens, P; Pauwels, RA; Yernault, JC, 1998) |
| "Although these preliminary results suggest that nebulized budesonide may be an effective adjunct to oral prednisone in the management of moderate to severe asthma exacerbations, a larger trial will be required before the widespread use of inhaled budesonide in acute asthma can be advocated." | 9.08 | Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. ( Klassen, TP; Osmond, MH; Sung, L, 1998) |
| " Efficacy was measured by weekly spirometry and daily diary recordings of peak flow rates, asthma symptom scores, and albuterol use." | 9.08 | A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma. ( Bernstein, DI; Cohen, R; Ginchansky, E; Pedinoff, AJ; Tinkelman, DG; Winder, JA, 1998) |
| "The aim of this study was to investigate whether regular treatment with inhaled salmeterol modifies the dose-response curve to the inhaled short-acting beta2-agonist terbutaline or affects the concentration of nitric oxide (NO) in exhaled air of children with asthma." | 9.08 | Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. ( Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1998) |
| "To evaluate the impact on asthma-specific quality of life, efficacy, and safety of salmeterol versus albuterol in adult patients with mild-to-moderate persistent asthma." | 9.08 | Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. ( Cox, F; Emmett, A; Kalberg, C; Lumry, W; Manning, M; Rickard, K; Wenzel, SE, 1998) |
| "The aim of the present multicentre, open, randomized, parallel group study was to evaluate the efficacy and safety of salmeterol versus theophylline in asthmatic patients." | 9.08 | Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline. ( Martini, T; Nutini, S; Righi, R, 1998) |
| "In an emergency department, 160 patients who presented with acute exacerbations of asthma received either standard (n = 80) or high-dose (n = 80) albuterol treatment." | 9.08 | Comparison of two dosage regimens of albuterol in acute asthma. ( Dixon, L; Galan, G; Hejal, R; McFadden, ER; Strauss, L, 1998) |
| " Overall reductions in supplemental albuterol use and mean asthma symptom scores were also significantly greater in children administered salmeterol compared with placebo (P=." | 9.08 | Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. ( Arledge, T; Bronsky, EA; Byrne, A; Liddle, R; Pearlman, DS; Stahl, E; Weinstein, SF, 1998) |
| "We determined the effect of a long acting beta2-agonist, salmeterol, on aspirin-induced asthma (AIA) attacks and urinary release of eicosanoids in a double-blind, placebo-controlled, crossover study in 10 asthmatics sensitive to aspirin." | 9.08 | Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. ( Cmiel, A; Dworski, R; Mastalerz, L; Nizankowska, E; Oates, JA; Prokop, A; Sheller, JR; Szczeklik, A, 1998) |
| "To determine whether children with severe acute asthma treated with large doses of inhaled salbutamol, inhaled ipratropium, and intravenous steroids are conferred any further benefits by the addition of aminophylline given intravenously." | 9.08 | Randomised controlled trial of aminophylline for severe acute asthma. ( South, M; Yung, M, 1998) |
| "To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta 2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled beta 2-agonist, in the treatment of asthma." | 9.07 | Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. ( D'Alonzo, GE; Henochowicz, S; Morris, RJ; Nathan, RA; Ratner, P; Rennard, SI, 1994) |
| "The aim of the multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial with a 2-week treatment period was to compare the efficacy and safety of salmeterol (50 micrograms twice daily) with slow-release (SR) terbutaline (5 mg orally, twice daily) in nocturnal asthma." | 9.07 | Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group. ( Bertin, L; Brambilla, C; Chastang, C; Georges, D, 1994) |
| "This study investigated the effects of an osmotic release oral drug delivery system of metoprolol on the changes induced by cumulative doses of inhaled salbutamol on bronchomotor tone, skeletal muscle, and the circulatory system after single (day 1) and multiple (day 7) dosing in 18 hypertensive asthmatic patients (forced expiratory volume in 1 second > 50% predicted; diastolic blood pressure > 90 mm Hg)." | 9.07 | Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors. ( Bauer, K; Kaik, B; Kaik, G, 1994) |
| "We investigated whether the beta 2-agonists fenoterol and salbutamol decreased plasma selenium and glutathione peroxidase activity in patients with asthma as this may partially explain the findings of reduced selenium status in asthmatic patients." | 9.07 | Nebulized beta 2-adrenoceptor agonists do not affect plasma selenium or glutathione peroxidase activity in patients with asthma. ( Beasley, R; Bremner, P; Burgess, CD; Crane, J; Siebers, RW; Thomson, CD, 1994) |
| "We conducted a randomized, double-blind, placebo-controlled study to determine if intravenous aminophylline adds any benefit to high doses of inhaled salbutamol in patients who presented for treatment of acute asthma." | 9.07 | Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer. ( Rodrigo, C; Rodrigo, G, 1994) |
| "A double-blind, randomized, crossover study was done to determine the efficacy of colchicine in 30 atopic children with moderately severe asthma." | 9.07 | A clinical study of colchicine in childhood asthma. ( Adalioglu, G; Saraçlar, Y; Tuncer, A; Türktas, I, 1994) |
| "Clinical studies of inhaled salmeterol xinafoate have been conducted mainly in moderately to severely affected asthmatic subjects in hospital settings." | 9.07 | Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group. ( Jones, KP, 1994) |
| "5 mg) albuterol (salbutamol) over 1 h in 47 patients admitted to hospital with severe acute asthma defined as a peak expiratory flow (PEF) below 150 L/min and hypercapnia (Pa(CO2) > or = 40 mm Hg)." | 9.07 | Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study. ( Brochard, L; Duroux, P; Henry-Amar, M; Mal, H; Renon, D; Salmeron, S; Simonneau, G; Tenaillon, A, 1994) |
| "In a double-blind, double-placebo, randomized crossover study, we compared the effects of 6 wk of treatment with the anti-inflammatory drug nedocromil sodium (16 mg/day) with 6 wk of treatment with the bronchodilator drug albuterol (800 micrograms/day) in 29 adults with allergic asthma." | 9.07 | Nedocromil sodium versus albuterol in the management of allergic asthma. ( de Jong, JW; de Monchy, JG; Koëter, GH; Postma, DS; Teengs, JP; van der Mark, TW, 1994) |
| "To evaluate the effects of aminophylline (Am) in children hospitalized with asthma." | 9.07 | Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. ( Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994) |
| "The use of oral prednisolone (2 mg/kg) to treat children admitted to hospital with acute asthma was assessed in a placebo controlled study." | 9.07 | Prednisolone and salbutamol in the hospital treatment of acute asthma. ( Connett, GJ; Lenney, W; Warde, C; Wooler, E, 1994) |
| "In an open randomised study 25 patients with severe acute asthma who presented to the emergency department were treated with either a combined nebulised salbutamol (5 mg/dose) and aminophylline infusion (0." | 9.07 | Effect of adding aminophylline infusion to nebulised salbutamol in severe acute asthma. ( Ismail, O; Yusoff, K; Zainudin, BM, 1994) |
| "Patients who presented to the ED with moderate to severe asthma and did not improve after one treatment with nebulized albuterol." | 9.07 | Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. ( Eberlein, RS; Mazur, JE; Rudnitsky, GS; Schoffstall, JM; Spivey, WH, 1993) |
| "To evaluate the effectiveness of inhibiting the formation of the 5-lipoxygenase products of arachidonic acid by the 5-lipoxygenase inhibitor zileuton in the treatment of mild-to-moderate asthma." | 9.07 | The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. ( Busse, W; Cohn, J; Drazen, JM; Fish, J; Grossman, J; Israel, E; Kaiser, HB; Karahalios, P; Kemp, JP; Lanni, C; Ledford, D; Murray, JJ; Pearlman, H; Pierson, W; Rosenthal, R; Rubin, P; Segal, AT; Siegel, SC; Tinkelman, D; Wenzel, S, 1993) |
| "To determine the effect of adding intravenous theophylline (administered as aminophylline) to nebulizations of albuterol and intravenous methylprednisolone in adults hospitalized for acute asthma." | 9.07 | Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma? ( Aull, L; Harman, E; Hendeles, L; Huang, D; O'Brien, RG; Reents, S; Shieh, G; Visser, J, 1993) |
| "The role of intravenous aminophylline in acute asthma is unclear despite meta-analysis of many studies comparing aminophylline with other bronchodilator therapies." | 9.07 | Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators. ( Cameron, P; Coleridge, J; Epstein, J; Teichtahl, H, 1993) |
| " The purpose of this study was to investigate whether the addition of a single aerosolized dose of glycopyrrolate to an albuterol regimen results in a greater improvement in pulmonary function than treatment with an albuterol regimen alone in patients with acute asthma." | 9.07 | Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma. ( Cydulka, RK; Emerman, CL, 1994) |
| "The aim of this study was to compare the response to inhaled albuterol after administration by nebulizer with the response after administration by a metered-dose inhaler and spacer device (MDI-spacer) to children with acute asthma." | 9.07 | Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. ( Bentur, L; Canny, GJ; Kerem, E; Levison, H; O'Brodovich, H; Reisman, J; Schuh, S, 1993) |
| " Patients with acute asthma received either albuterol, 0." | 9.07 | A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. ( Afilalo, M; Colacone, A; Kreisman, H; Wolkove, N, 1993) |
| "These data demonstrate that oral prednisone, within 4 hours of its administration, reduced the need for hospitalization among a subset of children treated in the emergency department for acute asthma." | 9.07 | Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. ( Fuchs, SM; Nager, AL; Scarfone, RJ; Shane, SA, 1993) |
| "To determine the efficacy of theophylline when given in addition to nebulized albuterol and intravenously administered corticosteroid to children hospitalized with mild to moderate asthma." | 9.07 | Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid. ( Alpert, SE; DiGiulio, GA; Kercsmar, CM; Krug, SE; Marx, CM, 1993) |
| "To determine whether intravenously administered theophylline, when added to frequently nebulized albuterol and intravenously administered methylprednisolone, benefits children hospitalized with severe asthma." | 9.07 | Efficacy of intravenously administered theophylline in children hospitalized with severe asthma. ( Carter, E; Chesrown, S; Cruz, M; Hendeles, L; Reilly, K; Shieh, G, 1993) |
| "The duration of the blocking effect of salmeterol (50 micrograms), albuterol (200 micrograms), and a placebo were compared in a double-blind study in 12 adult subjects with asthma who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days." | 9.07 | Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Malo, JL; Trudeau, C, 1992) |
| "Ninety-six patients with nocturnal asthma (FEV1 = 60-90% pred, reversibility greater than or equal to 15%, at least 2 awakenings in the week preceding the trial) were included in a double-blind, randomized, crossover, multicenter study which compared the efficacy and side effects of inhaled salmeterol (50 micrograms morning and evening) to the association theophylline-ketotifen (300 mg and 1 mg morning and evening, respectively)." | 9.07 | [Usefulness of salmeterol in nocturnal asthma: a comparative study with theophylline-ketotifen association. A French multicenter group]. ( Georges, D; Muir, JF, 1992) |
| "At four medical centers, 98 patients with stable asthma, histories of nighttime awakening at least three times weekly and nighttime declines of pulmonary function of at least 15%, who were not taking oral adrenergic agonists, were randomly treated with either oral repeat-action albuterol sulfate (Proventil Repetabs), 4 mg in the morning and 4-16 mg at bedtime, or a placebo for 2 weeks." | 9.07 | The effect of repeat action albuterol sulfate (Proventil Repetabs) in nocturnal symptoms of asthma. ( Bodman, SF; Greenstein, SM; Morris, RJ; Nathan, RA; Selner, JC; Storms, WW; Zwillich, CW, 1992) |
| "The aim of this investigation was to study whether certain patients benefit from adding theophylline to the beta 2-agonist treatment of acute asthma." | 9.07 | Which patients benefit from adding theophylline to beta 2-agonist treatment in severe acute asthma? ( Boe, J; Boman, G; Janson, C, 1992) |
| "For the management of mild-to-moderate asthma, salmeterol given twice daily is superior to albuterol given either four times daily or as needed." | 9.07 | A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. ( Chervinsky, P; Dockhorn, RJ; Grossman, J; Kemp, JP; LaForce, C; Liddle, RF; Pearlman, DS; Seltzer, JM; Southern, DL; Yancey, SW, 1992) |
| "The hypoxic effects of salbutamol 200 micrograms (CAS 18559-94-9) and bitolterol mesilate 740 micrograms (Biterol, CAS 30392-41-7), both administered by pressurized aerosol, were assessed by transcutaneous pO2 monitoring in 18 asthmatic subjects and in 12 normal volunteers." | 9.07 | Effects of salbutamol and bitolterol mesilate on pO2 levels in asthmatic patients and healthy volunteers. ( Allegra, L; Cogo, AL; Dal Negro, R; Pomari, C; Turati, C; Turco, P, 1992) |
| "In a placebo-controlled, double-blind, crossover study with a washout phase of 2 months between each treatment period, single daily doses of 10 and 30 mg of astemizole were given to 12 patients with extrinsic asthma during 28 consecutive days." | 9.07 | Effect of astemizole on allergic asthma. ( Abadías, M; Cisteró, A; Jané, F; Lafuente, V; Lleonart, R; Pintó, E; Torrent, J, 1992) |
| "The safety, tolerability and bronchodilator properties of inhaled verlukast (MK-0679), a new potent and selective LTD4-receptor antagonist, were studied in 12 asthmatic subjects with more than 15% increase in FEV1 after salbutamol inhalation." | 9.07 | Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast--MK-0679) in asthmatic patients. ( Buntinx, A; De Lepeleire, I; Decramer, M; Friedman, B; Lammers, JW; Van Daele, P; Van den Elshout, FM, 1992) |
| "Three combination regimens, (1) inhaled albuterol (ALB) with oral theophylline (THEO), (2) inhaled ALB with inhaled beclomethasone dipropionate (BDP), or (3) inhaled ALB, inhaled BDP, and oral THEO, were evaluated and compared as optimal pharmacotherapy for chronic asthma in 111 children." | 9.07 | Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma. ( Eigen, HN; Ellis, EF; Hemstreet, MP; Meltzer, EO; Orgel, HA, 1992) |
| " We compared the effect of 50 micrograms salmeterol administered by metered dose inhaler (MDI) and dry powder inhaler (DPI), with 200 micrograms albuterol (by MDI) on FEV1 and histamine-induced bronchoconstriction in 12 asthmatic subjects in a double-blind, placebo-controlled crossover study." | 9.07 | A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. ( Gongora, HC; Tattersfield, AE; Wisniewski, AF, 1991) |
| "In a controlled clinical crossover trial, the therapeutic effect of pirbuterol (CAS 38677-81-5) in the Autohaler was compared to that of salbutamol in a customary metered-dose aerosol in 17 children with asthma." | 9.07 | Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler. ( Kroll, VM; Schneider, B; Völkl, KP; Wiesemann, HG, 1991) |
| "This study compared the acute and chronic effects of albuterol syrup (2 mg) and metaproterenol syrup (10 mg) three times a day over 28 days in 65 children, aged 6 to 9 years, with mild to moderate asthma." | 9.07 | Comparison of albuterol and metaproterenol syrup in the treatment of childhood asthma. ( Ratner, PH; Shapiro, GG; Wolfe, JD, 1991) |
| "We compared the efficacy of inhaled formoterol, a long-acting beta 2-agonist, with inhaled albuterol in 145 stable adult asthmatics in a 12-wk multicenter trial." | 9.07 | A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. ( Broder, I; Cartier, A; Chapman, KR; Hyland, RH; Kesten, S; Knight, A; Malo, JL; Mazza, JA; Moote, DW; Small, P, 1991) |
| "To determine whether treatment of acute asthma with repeated doses of nebulized albuterol leads to greater bronchodilation and lower hospital admission rate than treatment with nebulized isoetharine." | 9.07 | A randomized, controlled comparison of isoetharine and albuterol in the treatment of acute asthma. ( Boehm, SP; Cydulka, RK; Effron, D; Emerman, CL; Gershman, H; Lukens, TW, 1991) |
| "In a multicentre, randomized, cross-over double-blind, double placebo trial the effectiveness and tolerability of slow-release oral salbutamol (SRS) were compared with those of long-acting (LA) theophylline (T) in the treatment of nocturnal asthma of adults." | 9.07 | [Slow-release salbutamol in the treatment of nocturnal asthma. Result of a comparative study vs. long-acting theophylline]. ( Arnaud, A; Desfougères, JL; Michel, FB; Pappo, M, 1991) |
| "The additional effect, if any, of subcutaneous, long-acting epinephrine (Sus-Phrine) to aerosolized albuterol for acute pediatric asthma was studied." | 9.07 | Effect of injected long-acting epinephrine in addition to aerosolized albuterol in the treatment of acute asthma in children. ( Aquino, N; Kornberg, AE; Mezzadri, F; Welliver, JR; Zuckerman, S, 1991) |
| "The protective efficacy of oral cetirizine, a selective and potent H1-receptor antagonist, against the immediate bronchoconstrictive response to allergen inhalation and exercise challenge was evaluated in 16 subjects with stable, predominantly mild asthma." | 9.06 | Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. ( Dauphinee, B; Djahed, B; Gong, H; Tashkin, DP; Wu, TC, 1990) |
| "The duration of effect of inhaled formoterol (24 micrograms) was compared with that of a placebo and that of inhaled albuterol (200 micrograms) in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days." | 9.06 | Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; Gontovnick, L; Malo, JL; Trudeau, C, 1990) |
| "The airway response and cardiovascular and hypokalaemic effects of fenoterol, salbutamol, and terbutaline given in multiples of standard doses from metered-dose inhalers were studied in ten patients with mild asthma." | 9.06 | Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. ( Britton, JR; Pavord, ID; Tattersfield, AE; Williams, J; Wong, CS, 1990) |
| "A double-blind, randomized, crossover chronic study was done to determine the efficacy of colchicine in 10 atopic patients with asthma." | 9.06 | A clinical and immunologic study of colchicine in asthma. ( Garty, MS; Greif, J; Ilfeld, DN; Kivity, S; Schlesinger, M; Schwarz, YA; Topilsky, M, 1990) |
| "We have investigated the ability of salbutamol to protect against bronchoconstriction induced by methacholine, histamine, and adenosine 5'-monophosphate (AMP) in nine subjects with asthma." | 9.06 | Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma. ( Finnerty, JP; Holgate, ST; Phillips, GD, 1990) |
| "The bronchodilator effect of nebulized AMN, albuterol and their combination was evaluated in 16 steroid-dependent asthmatic children." | 9.06 | Efficacy of atropine methylnitrate alone and in combination with albuterol in children with asthma. ( Hill, MR; Nelson, HS; Sladek, WA; Sur, S; Szefler, SJ; Vichyanond, P, 1990) |
| "Thirty-three children and adolescents from 5 to 17 years of age with moderate to severe acute asthma were given nebulized albuterol therapy in either a high (0." | 9.06 | Nebulized albuterol in acute childhood asthma: comparison of two doses. ( Bailey, D; Canny, G; Forbes, T; Levison, H; Pender, E; Reider, MJ; Schuh, S; Tan, YK, 1990) |
| "To determine the efficacy of intravenous aminophylline in the treatment of adult patients hospitalized for exacerbation of asthma." | 9.06 | Inhaled albuterol and oral prednisone therapy in hospitalized adult asthmatics. Does aminophylline add any benefit? ( Abou-Shala, N; Burns, R; Ellis, RF; Kellermann, AL; Self, TH; Stewart, CF; Tsiu, SJ, 1990) |
| "We studied the safety and efficacy of albuterol (salbutamol) delivered by continuous nebulization (CN) in the initial emergency department treatment of asthma." | 9.06 | Continuous nebulization of albuterol (salbutamol) in acute asthma. ( Afilalo, M; Colacone, A; Kreisman, H; Rosenthal, TM; Stern, E; Wolkove, N, 1990) |
| "A double-blind, crossover trial was conducted to examine the effect of albuterol aerosol on the fine-motor performance of children with chronic asthma." | 9.06 | The effect of albuterol aerosol on fine-motor performance in children with chronic asthma. ( Bender, B; Figueroa-Rosario, W; Mazer, B, 1990) |
| "Twenty asthmatic patients clinically free of heart disease were studied for the possible arrhythmogenic action of albuterol (salbutamol)." | 9.06 | Asthma, cardiac arrhythmias, and albuterol aerosol. ( Lazzari, JO; Martelli, NA; Raimondi, AC, 1986) |
| "The cardioselectivity and hypotensive properties of the beta 1-specific beta-blocker bisoprolol were investigated using a single-dose comparison of 10 and 20 mg bisoprolol, 100 mg atenolol, and placebo in 12 hypertensive asthmatic patients." | 9.06 | The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. ( Chatterjee, SS, 1986) |
| "Bronchodilator responses to both nebulized albuterol (salbutamol) and ipratropium bromide and aerosol delivery to the tracheobronchial tree have been assessed in eight patients with chronic stable asthma (mean baseline FEV1, 50 percent; reversibility greater than 20 percent)." | 9.06 | Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. ( Bloom, R; Clarke, SW; Johnson, MA; Newman, SP; Talaee, N, 1989) |
| "We studied the effects of salbutamol, ipratropium bromide and cromolyn sodium on PGF2 alpha-induced bronchospasm in ten patients with asthma." | 9.06 | Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F2 alpha-induced bronchospasm. ( Georgopoulos, D; Giulekas, D; Ilonidis, G; Sichletidis, L, 1989) |
| "Two double-blind, double-dummy, randomized, crossover studies were performed in 8 asthmatic patients to evaluate beta 2-adrenoceptor selectivity and potency of broxaterol compared to salbutamol." | 9.06 | Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment. ( Löfdahl, CG; Sigvaldasson, A; Skoogh, BE; Svedmyr, N, 1989) |
| "A study was carried out in 8 patients with chronic stable bronchial asthma to compare the bronchodilator response with terbutaline, administered by a recently developed powder inhalation system ('Turbuhaler') and equipotent doses of salbutamol administered by a widely used powder inhaler ('Rotahaler')." | 9.06 | Dose-effect relationship of terbutaline using a multi-dose powder inhalation system ('Turbuhaler') and salbutamol administered by powder inhalation ('Rotahaler') in asthmatics. ( Bogaard, JM; Slingerland, R; Verbraak, AF, 1989) |
| "A dose-ranging study and a 12-week treatment study were conducted in children with asthma, aged 4 to 12 years, to assess the efficacy and safety of albuterol inhaled as either an aerosol or as dry powder." | 9.06 | Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol. ( Bronsky, EA; Furukawa, CT; Grossman, J; Kemp, JP; Lemanske, RF; Mansfield, LE; Murphy, S; Ratner, PH; Reese, ME; Rogenes, PR, 1989) |
| "In order to examine a possible mechanism of action of ketotifen in asthma, a double-blind study was undertaken to determine whether ketotifen showed any effects on the beta-adrenergic system in asthmatic patients." | 9.06 | The effects of ketotifen on beta-adrenergic activity in asthmatics. ( Burge, PS; Gove, RI; Skinner, C; Stableforth, DE, 1988) |
| "Forty patients suffering from asthmatic conditions, often accompanied by emphysema, were treated either with an extempore combination of salbutamol syrup plus 30-mg oxatomide tablets or with 30-mg oxatomide tablets alone for purposes of comparison." | 9.06 | Treatment of asthma with an extempore combination of a bronchodilator, salbutamol, and a new antihistamine drug, oxatomide. ( Caprioglio, L; Scremin, S, 1986) |
| "The effect of long-term treatment with theophylline was studied in 20 chronic asthmatic patients receiving oral and inhaled beta 2-agonists." | 9.06 | Theophylline in maintenance treatment of chronic asthma: concentration-dependent additional effect to beta 2-agonist therapy. ( Billing, B; Dahlqvist, R; Hörnblad, Y; Leideman, T; Ripe, E; Skareke, L, 1987) |
| "140 children of 184 with acute asthma entered a randomised double-blind trial of oral prednisolone (n = 67) compared with placebo (n = 73) administered soon after admission." | 9.06 | Effect of a single oral dose of prednisolone in acute childhood asthma. ( Barrell, E; Barry, W; Hatcher, G; Lenney, W; Storr, J, 1987) |
| "4 mg azelastine administered orally on airway responsiveness, skin prick testing, daily peak expiratory flow rates and symptoms of asthma was compared with placebo in a 7 week double-blind, parallel group study of 24 patients with extrinsic asthma." | 9.06 | A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness. ( Aurich, R; Davies, RJ; Gould, CA; Ollier, S, 1988) |
| "The aim of the present study was to verify the effectiveness of procaterol, a recent and specific beta-2-adrenoceptor stimulant, in preventing exercise-induced asthma (EIA)." | 9.06 | A new bronchodilating agent, procaterol, in preventing exercise-induced asthma. ( Donner, CF; Fracchia, C; Ioli, F; Manini, G; Patessio, A; Spada, EL; Vecchio, C, 1986) |
| " The inadvertent administration of timolol to asthmatic patients continues to cause occasional severe and even fatal attacks of asthma." | 9.06 | Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects. ( Richards, R; Tattersfield, AE, 1987) |
| "The efficacy of procaterol, a new beta 2-selective sympathomimetic drug, was compared with that of salbutamol and placebo in a double-dummy crossover study in 20 asthmatic patients." | 9.06 | Comparison between oral procaterol and salbutamol in patients with bronchial asthma. ( Jaakkola, J; Terho, EO; Torkko, M; Tukiainen, H, 1988) |
| "Single-dose salbutamol (200 micrograms), beclomethasone dipropionate (200 micrograms), and sodium cromoglycate (SCG) (10 mg) administered by inhalation 10 minutes before allergen challenge were examined with regard to inhibition of allergen-induced early (EAR) and late (LAR) asthmatic responses and allergen-induced increase in bronchial responsiveness to inhaled histamine." | 9.06 | Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. ( Cockcroft, DW; Murdock, KY, 1987) |
| " Terfenadine, a histamine H1-receptor antagonist, was studied in 52 patients with stable mild perennial asthma with an allergic basis." | 9.06 | Treatment of bronchial asthma with terfenadine; a randomized controlled trial. ( Beaumont, D; Lewis, PJ; Pujet, JC; Sapene, M; Taytard, A, 1987) |
| "The objective of this open randomized cross-over study was to compare the clinical efficacy and safety of a recently introduced beta-2 mimetic, tulobuterol, with fenoterol in asthma patients." | 9.06 | Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients. ( Azanza, JR; Dal-Re, R; Rivero, A; Sanchez, J, 1988) |
| " Since inhalation of these drugs results in less systemic side effects, the present double-blind study was designed to investigate the influence of inhalation of the beta 2-adrenergic agonist albuterol (salbutamol) on esophageal motor function and gastroesophageal reflux in ten healthy volunteers." | 9.06 | Effects of albuterol (salbutamol) on esophageal motility and gastroesophageal reflux in healthy volunteers. ( Heinrich, C; Huber, RM; Müller-Lissner, SA; Schindlbeck, NE, 1988) |
| "Nifedipine, 30 mg/day for 4 weeks, was compared to placebo in a double-blind, randomized, crossover study, as an additional drug added to the usual treatment of 14 patients with bronchial asthma." | 9.06 | Nifedipine treatment of patients with bronchial asthma. ( Dascalopoulou, E; Maniki, E; Patakas, D; Tsara, V, 1987) |
| "Twelve patients with chronic severe asthma, having previously shown an FEV1 increase of less than 20% of the predicted value with prednisolone treatment (20-60 mg daily for 10 days), took part in a double blind crossover comparison of equipotent anti-inflammatory doses of betamethasone and prednisolone." | 9.06 | Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma. ( Belmatoug, N; De Lauture, D; Grandordy, B; Marsac, J; Morelle, A, 1987) |
| "Clenbuterol (C), a long-acting beta 2-selective bronchodilator was compared with salbutamol (S) in exercise-induced asthma (EIA) at two premedication time levels." | 9.06 | Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise-induced asthma in children. ( Boner, AL; Brighenti, C; Miglioranzi, P; Richelli, C; Schiassi, M; Vallone, G, 1988) |
| "In fifteen patients with asthma tulobuterol, a new beta 2-adrenoceptor agonist, given by inhalation in 100 micrograms increments up to a cumulative dose of 600 micrograms produced dose related increases in both the FEV1 and FVC." | 9.06 | Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. ( Patel, KR, 1986) |
| "The extrapulmonary effects of slow-release theophylline and an inhaled beta 2-agonist (albuterol) were examined separately and in combination among 18 adults and adolescents with asthma during a 3-month randomized, double-blind, crossover trial." | 9.06 | Extrapulmonary effects of maintenance therapy with theophylline and inhaled albuterol in patients with chronic asthma. ( Ahrens, RC; Joad, JP; Lindgren, SD; Weinberger, MM, 1986) |
| "In order to study the dose-related effect of nifedipine on expiratory flow rates, 15 asthmatic patients were given sublingually 10 mg and 20 mg of the drug on two different days and the FVC and FEV1 were measured during 90 minutes." | 9.06 | Nifedipine in asthma. Dose-related effect on resting bronchial tone. ( Chaniac, A; Gruzman, C; Katz, I; Lidgi, M; Molho, M, 1987) |
| "The bronchodilator effect of a combination of 200 micrograms salbutamol and 200 micrograms oxitropium bromide, given as pressurized aerosols, was compared to that of 200 and 400 micrograms of salbutamol in a controlled experiment on adult patients with asthma." | 9.06 | Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols. ( Laitinen, LA; Poppius, H, 1986) |
| "Sustained-release, 24-hour theophylline preparations have been formulated and may provide for convenient once-a-day dosing, although the use of such products in clinical asthma has yet to be fully established." | 9.06 | The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment. ( Bush, RK; Busse, WW; Smith, A, 1986) |
| "The relative benefit of maintenance therapy with theophylline, inhaled albuterol, and the combination was examined in 18 adolescents and adults with chronic asthma during a 3-month, randomized, double-blind, crossover trial." | 9.06 | Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. ( Ahrens, RC; Joad, JP; Lindgren, SD; Weinberger, MM, 1987) |
| "Three parenteral routes of albuterol sulfate were compared with placebo in their effects on serum potassium and glucose levels, heart rate, and pulmonary function in adult asthmatic subjects." | 9.06 | Efficacy of parenteral albuterol in the treatment of asthma. Comparison of its metabolic side effects with subcutaneous epinephrine. ( Katz, RM; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1986) |
| "The benefits of metered-dose inhalers with a spacer (MDI+S) have increasingly been recognized as an alternative method of albuterol administration for treating pediatric asthma exacerbations." | 9.05 | Metered-dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with meta-analysis. ( Barrios-Sanjuanelo, A; Contreras-Arrieta, S; Florez-García, V; Payares-Salamanca, L; Rodriguez-Martinez, CE; Stand-Niño, I, 2020) |
| "The efficacy and adverse effects of ketotifen 1 mg twice daily and 2 mg twice daily were compared with placebo in 50 patients with atopic asthma in a multicentre, double-blind study." | 9.05 | Ketotifen in adult asthma. ( Dyson, AJ; Mackay, AD, 1980) |
| "A double-blind crossover comparative study between carbuterol 3 mg thrice daily, carbuterol 2 mg thrice daily and salbutamol 4 mg thrice daily by the oral route was conducted in thirty patients suffering from bronchial asthma, selected at random, with more than 20% reduction in airway obstruction following isoprenaline inhalation." | 9.05 | Double-blind crossover study of carbuterol and salbutamol in bronchial asthma. ( Khemchandani, GT; Misra, NP; Tiwari, UC, 1981) |
| "Prazosin, a potent and selective alpha-adrenergic antagonist, was given by inhalation to nine asthmatic subjects aged 25-48 years (six with positive skin tests)." | 9.05 | Inhaled prazosin in asthma. ( Barnes, PJ; Dollery, CT; Ind, PW, 1981) |
| "A study to compare the bronchodilator effect of salbutamol powder (Ventolin, 200 micrograms) administered via a Rotahaler (SR), with that of terbutaline sulphate (Bricanyl, 500 micrograms) administered via a Misthaler (TM) was carried out in 25 children with stable moderate to severe asthma." | 9.05 | Bronchodilator effects of salbutamol powder administered via Rotahaler and of terbutaline aerosol administered via Misthaler. A comparison study in children with asthma. ( Mellis, CM; Sharota, E; Simpson, SJ; Towns, SJ, 1983) |
| " We evaluated 140 patients with bronchial asthma in a prospective double-blind controlled study of possible tachyphylaxis to albuterol aerosol as compared to isoproterenol aerosol." | 9.05 | Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. ( Anderson, JA; Bush, RK; Falliers, CJ; Kass, I; Kemp, JP; Reed, C; Repsher, LH; Siegel, S; Webb, DR, 1984) |
| "The bronchodilator activity in nebulised salbutamol, ipratropium bromide, clemastine, and a placebo was studied in 14 asthmatic children aged between 3 and 5 years." | 9.05 | Bronchodilator effects of clemastine, ipratropium, bromide, and salbutamol in preschool children with asthma. ( Groggins, RC; Milner, AD; Stokes, GM, 1981) |
| "The bronchodilator effect of 400 micrograms of salbutamol powder (2 capsules) administered by a rota-haler was compared with that of 500 micrograms of terbutaline (2 metered doses) administered as an aerosol via a tube-spacer in a group of ten stable asthmatic children (mean age 12 years)." | 9.05 | Comparison of salbutamol powder with terbutaline aerosol administered with a tube spacer in asthmatic children. ( Francis, PW; Kelly, CA; Zimmerman, PV, 1983) |
| "A double-blind randomised controlled trial was conducted to study the effects of oral theophylline alone compared with oral theophylline and salbutamol in a sample of asthmatic children." | 9.05 | Effects of oral theophylline and oral salbutamol in the treatment of asthma. ( Dawson, KP; Fergusson, DM, 1982) |
| "The effect of adding theophylline to treatment with a beta2-adrenoceptor stimulant was studied in 18 asthmatic children in a double-blind cross-over trial." | 9.05 | Combined treatment with sustained-release theophylline and beta2-adrenoceptor-stimulating agents in chronic childhood asthma. ( Foucard, T; Lindström, B; Lönnerholm, G, 1981) |
| "Sixty-four patients with mild of moderate extrinsic asthma were treated with placebo for 1 month and thereafter with ketotifen (1 mg twice daily, orally), disodium cromoglycate (inhalation of 20 mg, four times daily), or placebo for 2 subsequent months." | 9.05 | Comparison of ketotifen, disodium cromoglycate and placebo in the treatment of adult patients with mild extrinsic asthma. ( Ahonen, A; Haahtela, T; Hurme, R; Maasilta, P; Mattson, K; Muittari, A; Poppius, H; Venho, K, 1981) |
| "Lithium carbonate was evaluated in a double-blind, crossover study for prophylactic therapy in five patients with severe perennial asthma." | 9.05 | A double blind crossover trial of lithium carbonate in asthma. ( Bearman, J; Saltz, H; Spitz, E, 1982) |
| "The efficacy of nebulised sodium cromoglycate and an oral theophylline solution at currently recommended doses were compared in one to six-year-old children with chronic asthma." | 9.05 | Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study. ( Newth, CJ; Newth, CV; Turner, JA, 1982) |
| "In a double-blind trial we compared the efficacy and safety of inhaled salbutamol (albuterol), nebulized with oxygen by face mask, and subcutaneous epinephrine in 40 children with acute asthma." | 9.05 | Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children. ( Becker, AB; Nelson, NA; Simons, FE, 1983) |
| "Although albuterol aerosol is an effective bronchodilator in adult asthmatics its efficacy and safety are not fully established in asthmatic children." | 9.05 | Double-blind comparison of acute effects of inhaled albuterol, isoproterenol and placebo on cardiopulmonary function and gas exchange in asthmatic children. ( Katz, R; Littner, MR; Siegel, SC; Tashkin, DP, 1983) |
| "Inhalation histamine challenges were performed in groups of normal and asthmatic subjects." | 9.05 | Prostaglandins and the control of airways responses to histamine in normal and asthmatic subjects. ( Walters, EH, 1983) |
| "Oral administration of salbutamol and theophylline has been shown to be effective in relieving bronchoconstriction in asthmatic children aged between 3 and 5 years." | 9.05 | Efficacy of orally administered salbutamol and theophylline in pre-schoolchildren with asthma. ( Groggins, RC; Lenney, W; Milner, AD; Stokes, GM, 1980) |
| "In a double-blind controlled trial 14 chronic asthmatic patients with regular nocturnal exacerbations took 16 mg slow-release oral salbutamol (two Ventolin spandets), 450 mg slow-release aminophylline (two Phyllocontin Continus tablets), or placebo at midnight." | 9.05 | Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels. ( Davies, HJ; Fairfax, AJ; McNabb, WR; Spiro, SG, 1980) |
| "Twenty-one patients admitted to hospital with acute severe asthma were allocated in a random, single-blind manner to receive intravenous infusions for 24 hours or either aminophylline or salbutamol or a combination of the two drugs." | 9.05 | Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma. ( Crimmins, J; Evans, WV; Monie, RD; Seaton, A, 1980) |
| "The efficacy, safety, tolerance, and bio-equivalence of albuterol (a relatively selective beta 2-adrenergic drug) was evaluated in 20 asthmatic children (6 to 14 years of age)." | 9.05 | Oral albuterol in the treatment of childhood asthma. ( Katz, RM; Rachelefsky, GS; Siegel, SC, 1982) |
| "Albuterol (salbutamol) syrup was studied in 14 asthmatic children (three to six years of age) in a four-week, double-blind, crossover (with placebo) trial to determine efficacy, safety and tolerance." | 9.05 | Albuterol syrup in the treatment of the young asthmatic child. ( Katz, RM; Rachelefsky, GS; Siegel, SC, 1981) |
| "The bronchodilation produced by increasing intravenous doses of aminophylline, salbutamol, and a combination of aminophylline and salbutamol given in random order was determined in 10 stable asthmatics on three consecutive days." | 9.05 | Intravenous salbutamol and aminophylline in asthma: a search for synergy. ( Dart, AM; Davies, BH; Handslip, PD, 1981) |
| "The effect of slow-release aminophylline, salbutamol and a half dose combination of both was compared in children with chronic asthma." | 9.05 | A comparative trial of slow-release aminophylline, salbutamol and a half dose combination in the prevention of childhood asthma. ( Blumenthal, I, 1980) |
| " In this randomized, double-blind, crossover study, each of 20 male patients with moderate to severe asthma, ages 12 to 23 yr, received a single treatment with 100, 200, or 400 mcg of albuterol powder or placebo by Rotahaler on 4 study days separated by 2 to 10 days." | 9.05 | Inhaled albuterol powder for the treatment of asthma--a dose-response study. ( Kemp, JP; Meltzer, EO; Orgel, HA; Welch, MJ, 1985) |
| "1 mg/kg/6 hr) or placebo to 2- to 6-year old children whose extrinsic asthma was treated with maintenance theophylline in a prerandomized, double-blind crossover study design." | 9.05 | Albuterol syrup in the treatment of asthma. ( Bierman, CW; Furukawa, CT; Pierson, WE; Shapiro, GG, 1985) |
| "Our investigation supports the use of intravenous salbutamol as an alternative to aminophylline in the early stages of acute severe asthma." | 9.05 | Comparison of intravenous salbutamol (albuterol) and aminophylline in the treatment of acute asthmatic attacks. ( Greif, J; Markovitz, L; Topilsky, M, 1985) |
| "Calcium-channel blockers such as verapamil and nifedipine have been shown to inhibit exercise-induced asthma as well as acutely induced bronchoconstriction, but little is known of their chronic effects, if any, on bronchial asthma." | 9.05 | Nifedipine in chronic bronchial asthma: a randomized double-blind crossover trial against placebo. ( Boismare, F; Lemercier, JP; Leprevost, A; Moore, ND; Ozenne, G; Pasquis, P; Tardif, C, 1985) |
| "11 mg) and albuterol aerosol (two sprays, 180 mcg) were compared for efficacy of bronchodilation in 120 adolescent and young adult patients with moderate to severe asthma." | 9.05 | Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma. ( Kemp, JP; Orgel, HA; Tinkelman, DG; Webb, DR, 1985) |
| "The acute cardiopulmonary effects of oral albuterol, 4 mg, metaproterenol sulfate, 20 mg, and terbutaline sulfate, 5 mg, were compared over eight hours in 20 moderate to severe asthmatics." | 9.05 | Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics. ( Biedermann, AA; Chu, TJ; Wolfe, JD; Yamate, M, 1985) |
| "In 24 adult asthmatics the effects of clinically recommended doses of fenoterol (320 micrograms) and albuterol (180 micrograms) were compared to placebo in a double-blind, crossover trial." | 9.05 | A comparison of inhaled fenoterol and albuterol in asthma. ( Hordvik, NL; König, P; Sunderrajan, EV, 1985) |
| "The bronchodilator effects of 375 mg theophylline orally and 200 microg salbutamol by pressurized aerosol were compared in a randomized, cross-over, double-blind trial in fourteen asthmatic patients." | 9.04 | Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients. ( Hartnett, BJ; Marlin, GE, 1976) |
| "Eleven patients with bronchial asthma and 10 with chronic bronchitis were treated over four consecutive 3-day periods, firstly with aerosols either of ipratropium bromide (40 microgram four times a day) or of salbutamol (200 microgram four times daily) by random allocation, then the alternate drug, next by both drugs together, and finally with prednisolone (10 mg three times daily) in addition to both drugs." | 9.04 | Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis. ( Ingram, CG; Johnston, RN; Legge, JS; Lightbody, IM, 1978) |
| "The bronchodilating efficacy and the degree of beta2-selectivity of rimiterol, salbutamol and isoprenaline were determined in seven asthmatic patients." | 9.04 | The relative potencies and beta2-selectivities of intravenous rimiterol, salbutamol and isoprenaline in asthmatic patients. ( Marlin, GE; Turner, P, 1975) |
| "Albuterol, a new bronchodilator drug known to cause beta2-adrenergic receptor stimulation, was compared with isoproterenol sulphate for their pulmonary and cardiovascular effects in patients suffering from bronchial asthma." | 9.04 | Comparative study of acute effects of albuterol and isoproterenol sulphate aerosols in bronchial asthma. ( Huber, GL; Mahajan, VK; Tomashefski, JF, 1977) |
| "Albuterol and isoproterenol aerosols were compared with placebo in a double-blind manner in 18 patients with bronchial asthma." | 9.04 | Comparison of albuterol and isoproterenol aerosols in bronchial asthma. ( George, RB; Jenkinson, SG; Light, RW, 1977) |
| "The bronchodilator effects of aerosols of hexoprenaline (200 microgram and 400 microgram), and salbutamol (200 microgram) were compared in 15 patients with asthma, and nine patients with chronic bronchitis." | 9.04 | Bronchodilator effect of hexoprenaline aerosol in bronchial asthma and chronic bronchitis. ( Evers, R; Harris, M; Jenne, H; McMiken, D; Schonell, M, 1977) |
| "Dose-response curves to intravenous salbutamol were constructed after injection of saline or aminophylline in a group of ten asthmatic patients." | 9.04 | Additive interaction of aminophylline and salbutamol in asthma: an in vivo study using dose-response curves. ( Handslip, P; Leopold, D, 1979) |
| "A double-blind comparison between orally administered NAB 365 (clenbuterol) and salbutamol was conducted in 30 impatients with either asthma or chronic bronchitis with asthma who had at least 15% reversibility in airway obstruction following inhalation of 1,500 microgram of orciprenaline." | 9.04 | NAB 365 (clenbuterol) and salbutamol in asthmatics: a double-blind clinical trial. ( Capra, A; Pasotti, C; Vibelli, C, 1979) |
| "In a single blind crossover study 12 asthmatics received in randomised order single doses of pirbuterol (200 and 400 microgram), salbutamol (200 microgram) and placebo-aerosols, in order to determine the extent and duration of bronchodilator activity, the optimum dosage, the incidence, type and degree of side effects and the cardiovascular as well as hematologic, renal and hepatic functions after inhalative administration." | 9.04 | Comparative investigations on pirbuterol, salbutamol and placebo aerosols in bronchial asthma. ( Beumer, HM, 1979) |
| "A double-blind test to compare IV aminophylline with salbutamol in the treatment of acute, uncontrolled asthma showed that both drugs were equally effective during the first 24 hours." | 9.04 | Comparison of IV salbutamol with IV aminophylline in the treatment of severe, acute asthma in childhood. ( Hambleton, G; Stone, MJ, 1979) |
| "The effect of clenbuterol (NAB 365) in inhibiting exercise-induced asthma was compared with that of salbutamol in a single-blind, placebo-controlled, crossover study." | 9.04 | Aerosolized clenbuterol (NAB 365) and salbutamol in exercise-induced asthma. ( Del Bono, N; Quartieri, F; Vibelli, C, 1979) |
| "In a single blind cross-over study 12 patients with asthma received in randomised order aerosols of pirbuterol 400 micrograms, salbutamol 200 micrograms or placebo." | 9.04 | [Comparative studies on pirbuterol, salbutamol and a placebo administered as an aerosol in asthmatic patients]. ( Verstraeten, JM, 1978) |
| "A double-blind crossover trial was conducted in 10 asthmatic patients for comparison of fenoterol with salbutamol, in 12 other asthmatic patients for comparison of reproterol with salbutamol, and in 15 other asthmatic patients for comparison of terbutaline with salbutamol." | 9.04 | [The bronchospasmolytics salbutamol, fenoterol, terbutaline and reproterol. Their effects and side effects in asthmatics after inhalation with an electric nebulizer]. ( Budmiger, H; Kyd, K; Scherrer, M, 1978) |
| "In a randomized double-blind trial an intravenous injection of salbutamol (100mug) was compared with an intravenous injection of aminophylline (250mg) in 23 patients with acute exacerbations of asthma." | 9.04 | A controlled trial of intravenous salbutamol and aminophylline in acute asthma. ( Robinson, JS; Tribe, AE; Wong, RM, 1976) |
| "To evaluate the cost-utility of the treatment with a long acting beta-agonist (LABA) and inhaled corticosteroid (ICS) combination inhaler [salmeterol xinafoate (SAL)/fluticasone propionate (FP) combination inhaler (SFC) (Advair(®))] to continuing on current ICS dose (no ICS dose change) or increased ICS dose [fluticasone propionate (FP)] in patients with uncontrolled asthma in Canada." | 8.90 | COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada. ( Corriveau, D; FitzGerald, JM; Hawkins, N; Ismaila, AS; Li, C; Risebrough, N; Su, Z, 2014) |
| "To evaluate efficacy and safety of levalbuterol versus albuterol in acute asthma." | 8.89 | Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. ( Jat, KR; Khairwa, A, 2013) |
| "To assess the relative effects of fluticasone/salmeterol and budesonide/formoterol in people with asthma." | 8.87 | Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. ( Casali, L; Ferrara, G; Lasserson, TJ, 2011) |
| "To estimate the relative effects of fluticasone/salmeterol and budesonide/formoterol in terms of asthma control, safety and lung function." | 8.84 | Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. ( Casali, L; Cates, CJ; Ferrara, G; Lasserson, TJ, 2008) |
| "Theophylline and long acting beta-2 agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma." | 8.84 | Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. ( Gibson, PG; Irving, LB; Koh, MS; Lasserson, TJ; Tee, AK; Wilson, AJ, 2007) |
| "To systematically review the evidence for the medium to long term benefits and risks of montelukast as add-on therapy to inhaled corticosteroids (ICS) in comparison with placebo and active controls in mild to moderate asthma." | 8.84 | Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. ( Grouven, U; Joos, S; Kaiser, T; Miksch, A; Schneider, A; Szecsenyi, J; Wieseler, B, 2008) |
| "Our understanding of albuterol nebulization driven by helium-oxygen mixture (heliox) has matured with recent advances in clinical therapy, delivery systems, and understanding of dosing; this has led to substantial improvements in delivery as well as refinements of research protocols for asthma exacerbations." | 8.83 | Heliox-driven albuterol nebulization for asthma exacerbations: an overview. ( Corcoran, TE; Kim, IK; Saville, AL; Sikes, KL, 2006) |
| "To review the rationale supporting the use of levalbuterol [(R)-albuterol] for the treatment of pediatric and adult asthma." | 8.82 | Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. ( Berger, WE, 2003) |
| "Theophylline and long acting beta-2 agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma." | 8.82 | Long acting beta-agonists versus theophylline for maintenance treatment of asthma. ( Coughlan, J; Gibson, PG; Shah, L; Wilson, AJ, 2003) |
| "Pharmacoeconomic analyses indicate that salmeterol/fluticasone propionate administered via a single inhaler represents a cost-effective treatment option (relative to fluticasone propionate at the same nominal dosage, budesonide, formoterol plus budesonide and montelukast plus fluticasone propionate) in patients with asthma not controlled with inhaled corticosteroid therapy." | 8.82 | Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. ( Lyseng-Williamson, KA; Plosker, GL, 2003) |
| "A short cut review was carried out to establish whether intravenous salbutamol or intravenous aminophylline offers the quickest and least complicated treatment for patients with moderate to severe asthma not responding to inhaled therapy." | 8.82 | Best evidence topic reports. Is intravenous aminophylline better than intravenous salbutamol in the treatment of moderate to severe asthma? ( Jacobs, M; Munro, A, 2004) |
| "To evaluate the relative clinical superiority of increasing the dose of fluticasone propionate versus the addition of salmeterol to low-dose fluticasone propionate for long-term asthma control." | 8.81 | Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control. ( Arnold, AD; Crafts, R; Heyneman, CA; Holland, J, 2002) |
| "Theophylline and long acting beta2-agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma." | 8.80 | Long acting beta-agonists versus theophylline for maintenance treatment of asthma. ( Coughlan, J; Gibson, PG; Wilson, AJ, 2000) |
| "The long-acting beta2-agonist salmeterol and the corticosteroid fluticasone propionate are available as a combination inhalation device for the treatment of persistent asthma." | 8.80 | Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. ( Jarvis, B; Markham, A, 2000) |
| "Aminophylline is routinely recommended as a basic part of the emergency treatment of asthma." | 8.77 | Aminophylline treatment in severe, acute asthma. A meta-analysis. ( Littenberg, B, 1988) |
| "The effectiveness of a fix-dose salmeterol/fluticasone combination therapy in asthma was previously shown for the original product." | 8.31 | The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice. ( Almgren-Rachtan, A; Chudek, J; Doniec, Z; Hantulik, P; Olszanecka-Glinianowicz, M, 2023) |
| "Standardized acute asthma management with score-based, respiratory therapist (RT)-driven pathways and protocols improves outcomes including decreased length of stay (LOS) and time on continuous albuterol therapy." | 8.12 | Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation. ( Berlinski, A; Carper, NL; Danner, NP; Lloyd, TL; Willis, LD, 2022) |
| "Inability to access an albuterol inhaler at school increases risk to students of severe asthma attack." | 8.02 | Implementing the Asthma Scripts to School Programs to Facilitate Student Access to Albuterol. ( Fu, L; Gessner, L; Thompson, D; Torres, R, 2021) |
| "A decision-analysis model was developed to estimate the cost-effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations." | 7.96 | Metered-dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A cost-effectiveness analysis in a middle-income country. ( Castro-Rodriguez, JA; Rodriguez-Martinez, CE; Sossa-Briceño, MP, 2020) |
| "This study aimed to investigate whether airway obstruction could interfere with real FENO levels and if different FeNO changes after albuterol inhalation could assist in distinguishing asthma from chronic obstructive pulmonary disease (COPD)." | 7.85 | Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility. ( Cai, S; Dong, H; Li, R; Lv, Y; Wu, Y; Xiao, G; Yao, L; Zhao, H, 2017) |
| "The goal of this study was to examine the impact of a multidisciplinary intervention designed to improve appropriate albuterol inhaler utilization among patients with asthma." | 7.85 | Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma. ( Delate, T; Jenkins, DW; Lowe, R; Rader, N, 2017) |
| "Racemic albuterol and levalbuterol are used to treat acute episodes of asthma." | 7.85 | Clinical outcomes of levalbuterol versus racemic albuterol in pediatric patients with asthma: Propensity score matching approach in a medicaid population. ( Love, BL; Lu, ZK; Schulz, RM; Wu, J; Yuan, J; Zhang, Y, 2017) |
| "This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbumin allergic mouse models of the early (EAR) and late (LAR) asthmatic response." | 7.83 | Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma. ( Bauer, CM; Burns, L; Harris, P; Laine, D; Peng, R; Phillips, JE; Renteria, L; Stevenson, CS, 2016) |
| "Evaluation of the efficacy of nebulized magnesium sulfate (MgSO4) alone and in combination with salbutamol in acute asthma." | 7.83 | The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma. ( Ali, MA; El-Garhy, OH; Sarhan, HA; Youssef, NA, 2016) |
| " We present a case of a patient who was admitted with acute asthma exacerbation and was treated with β-2 agonist nebulisation and intravenous aminophylline." | 7.83 | Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation. ( Khwaja, YH; Tai, JM, 2016) |
| "Concerns have been raised regarding cardiac side effects of continuous high-dose albuterol nebulization in status asthmaticus management." | 7.81 | Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol. ( Eades, S; Hashmi, SS; Mosquera, RA; Samuels, C; Wisecup, S, 2015) |
| "Using private insurance data from January 1, 2004, to December 31, 2010, we investigated the effect of the CFC ban on out-of-pocket costs and utilization of albuterol inhalers among individuals with asthma (109,428 adults; 37,281 children), as well as asthma-related hospitalizations, emergency department visits, and outpatient visits." | 7.81 | The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma. ( Goldman, DP; Ho, O; Jena, AB; Karaca-Mandic, P, 2015) |
| "To determine if nitrites (nitric oxide metabolites) measured in induced sputum decrease and correlate with improvement of clinical asthma symptoms after treatment, we performed a prospective longitudinal study in a tertiary care hospital in Arequipa, Peru." | 7.80 | Correlation between nitrites in induced sputum and asthma symptoms in asthmatic schoolchildren. ( Cáceres, M; Castro-Rodriguez, JA; Molina, RO; Recabarren, A, 2014) |
| "To estimate the relative perinatal safety with the use of salmeterol and formoterol (LABAs) and that of fluticasone and budesonide (ICSs) during pregnancy." | 7.80 | Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. ( Beauchesne, MF; Blais, L; Cossette, B; Forget, A; Larivée, P; Lemière, C; Rey, E, 2014) |
| "This study aimed to assess the safety and efficacy of a high-dose continuous nebulized albuterol (CNA) protocol for treatment of asthma in the pediatric emergency department (ED)." | 7.79 | Evaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department. ( Flood, RG; Gerard, JM; Krebs, SE; Peter, JR, 2013) |
| "The concentration of exhaled carbon monoxide (eCO) in young children with stable asthma and during acute asthma attack is not known." | 7.78 | Exhaled carbon monoxide levels in preschool-age children with episodic asthma. ( Arai, H; Asamura, T; Morikawa, T; Ohara, T; Ohara, Y; Ohrui, T; Sasaki, H, 2012) |
| "The purpose of this study was to evaluate the use of xenon-enhanced dual-energy CT of the chest to assess ventilation changes after methacholine and salbutamol inhalation in subjects with asthma and healthy subjects." | 7.78 | Xenon-enhanced dual-energy CT of patients with asthma: dynamic ventilation changes after methacholine and salbutamol inhalation. ( Cho, SH; Goo, JM; Kim, JH; Kim, WW; Lee, CH; Park, EA; Park, SJ, 2012) |
| " Laboratory findings showed hypokalemia, hypophosphatemia, and lactic acidosis." | 7.78 | Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone. ( Hantson, P; Manara, A; Thys, F; Vanpee, D, 2012) |
| "To examine the proportion of children presenting to the emergency department (ED) with an acute asthma exacerbation with incorrect home use of their albuterol inhaler and to identify factors associated with improper treatment." | 7.78 | Inappropriate home albuterol use during an acute asthma exacerbation. ( Clayton, K; Harrington, K; King, W; Magruder, T; Monroe, K, 2012) |
| " We isolated caffeic acid and phenylpropanoid glycosides, 1-O-caffeoyl glycoside and acteoside [β-(3',4'-dihydroxyphenyl) ethyl-O-α-l-rhamnopyranosyl(1→3)-β-d-(4-O-caffeoyl)-glucopyranoside] from their ethylacetate fractions, respectively, and evaluated their anti-asthmatic effects on the aerosolized ovalbumin (OA) challenge in the OA-sensitized guinea-pigs measuring the specific airway resistance (sRaw) during the immediate-phase response (IAR) and late-phase response (LAR), and also measured recruitment of leukocytes and chemical mediators on the bronchoalveolar lavage fluids (BALF) in LAR, as well as histopathological survey." | 7.77 | Anti-asthmatic effects of phenylpropanoid glycosides from Clerodendron trichotomum leaves and Rumex gmelini herbes in conscious guinea-pigs challenged with aerosolized ovalbumin. ( Kim, CJ; Lee, JG; Lee, JY; Sim, SS; Whang, WK, 2011) |
| " albuterol, are used for quick reversal of bronchoconstriction in asthmatics." | 7.77 | Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma. ( Aimi, S; Barone, LM; Bates, JH; Irvin, CG; Lundblad, LK; Poynter, ME; Riesenfeld, EP; Rinaldi, LM; Wu, M, 2011) |
| "A retrospective observational cohort study compared the risk of asthma-related exacerbations [hospitalization, emergency department visit, and/or treatment with systemic corticosteroid] in patients receiving treatment with fluticasone propionate/salmeterol in a single inhaler (FSC) within 90 days following an initial asthma-related exacerbation (early treatment) versus patients receiving the treatment subsequently (late treatment)." | 7.77 | Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation. ( Delea, TE; Hagiwara, M; Stanford, RH, 2011) |
| "We commenced to estimate the economic impact of salmeterol/fluticasone combination (SFC) therapy compared to fluticasone propionate (FP) therapy for asthma control in Japanese patients." | 7.76 | [Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients]. ( Arakawa, I; Miyamoto, T; Nishima, S; Shiragami, M; Tohda, Y, 2010) |
| "The aim of this work was to compare rates of asthma-related health service utilization for Medicaid-eligible pediatric and adult patients with asthma treated with fixed-dose fluticasone propionate/salmeterol (FSC) or fluticasone propionate (FP) monotherapy." | 7.76 | Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy. ( Astry, CL; Johnson, JC; Riedel, AA; Stanford, RH, 2010) |
| " Asthma patients 16-65 years of age using budesonide/formoterol were matched according to age and markers of asthma severity to patients using fluticasone/salmeterol." | 7.75 | Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol. ( Beauchesne, MF; Blais, L; Forget, A, 2009) |
| "Six healthy and 5 experimentally asthmatic cats were randomized to receive inhaled R,S-albuterol, S-albuterol, R-albuterol, or placebo (saline) twice daily for 2 weeks, followed by a 6-week washout before crossover to the next treatment." | 7.75 | Enantiomer-specific effects of albuterol on airway inflammation in healthy and asthmatic cats. ( DeClue, AE; Delgado, C; Dhand, R; Reinero, CR; Spinka, C, 2009) |
| "The goal of this study was to examine whether the claims history for children in a US insured population indicate proper fluticasone propionate/ salmeterol (FPS) fixed-dose combination use in accordance with recommended asthma guidelines and a US Food and Drug Administration (FDA) advisory and black box warning regarding LABA use." | 7.75 | Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations. ( Crespi, S; Eid, NS; Friedman, HS; Reardon, G; Wilcox, TK, 2009) |
| "To investigate the effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of adult patients with asthma." | 7.75 | Effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of patients with asthma. ( de Melo, PL; Jansen, JM; Lopes, AJ; Veiga, J, 2009) |
| "We have now extended our previous population by 636 patients and explored the role of the Arg16 allele on asthma exacerbations in the context of the use of on-demand albuterol and regular salmeterol." | 7.75 | Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. ( Basu, K; Lipworth, BJ; Mukhopadhyay, S; Palmer, CN; Tavendale, R, 2009) |
| "To compare the rates of asthma-related emergency department (ED) visits and hospitalizations in the fall (September, October, November) between users and nonusers of fluticasone propionate plus salmeterol in a single inhaler (FSC) in the preceding summer." | 7.75 | Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall. ( Sheth, K; Spahn, J; Stanford, RH; Stempel, DA; Yeh, WS, 2009) |
| "Effects of quercetin inhalation on immediate (IAR), late-phase (LAR) and late late-phase (LLAR) asthmatic responses by exposure to aerosolized-ovalbumin (AOA) (2w/v% in saline, inhalation for 3 min) were studied in conscious guinea-pigs sensitized with AOA." | 7.74 | Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs. ( Choi, HH; Kim, CJ; Lee, JY; Moon, H; Moon, HJ; Sim, SS, 2008) |
| "Eighty-one patients with asthma (24% African American [AA]; 8 to 65 years old; baseline FEV1, 40 to 80% of predicted) received 180 microg of albuterol from a metered-dose inhaler (MDI), and then 90 microg every 15 min until maximum improvement or 540 microg was administered; all then received 2." | 7.74 | Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. ( Blake, K; Derendorf, H; Lima, J; Madabushi, R, 2008) |
| "To identify the relationship between resource utilization and treatment of asthma in subjects who were first time users of controller therapies, either fluticasone propionate (FP) and salmeterol delivered in a single Diskus device (FSC) or FP monotherapy." | 7.74 | An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes . ( Fuhlbrigge, A; Rey, GG; Riedel, A; Stanford, RH; Stempel, DA, 2008) |
| "Achievement of asthma control as defined by the global initiative on asthma guidelines (GINA) was examined in 1242 asthmatic patients not currently using ICS, enrolled in five clinical trials comparing fluticasone propionate and the combination of fluticasone and salmeterol." | 7.74 | Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. ( Boulet, LP; Franssen, E, 2007) |
| "This study evaluated the use and drug costs of inhaled corticosteroids (ICSs), long-acting beta2-agonists (LABAs), and fluticasone propionate and salmeterol in a fixed-dose combination (FSC) and their relationship to asthma exacerbations before and after the market introduction of FSC in April 2001." | 7.74 | The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. ( Brixner, DI; Lenhart, G; Samuelson, WM; Young, DC, 2007) |
| "To assess the frequency of beta2-AR polymorphisms in asthmatic children from Argentina, and to evaluate their influence on bronchodilator desensitization to albuterol over a 4-week treatment." | 7.74 | Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. ( Castaños, C; Chertkoff, L; Giubergia, V; Gravina, LP; Grenoville, M, 2008) |
| "This study was designed to expand on these earlier findings by comparing asthma-related health care resource utilization and costs, as well as adherence to ICSs, in children and adults with asthma receiving ICS monotherapy who either were switched to fluticasone propionate plus SAL from a single inhaler (FSC) or initiated add-on therapy with SAL from a separate inhaler or MON." | 7.74 | Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. ( Delea, TE; Hagiwara, M; Stanford, RH; Stempel, DA, 2008) |
| "Salmeterol/fluticasone propionate is a more cost-effective treatment option than fluticasone propionate plus montelukast for patients with symptomatic asthma uncontrolled by ICS." | 7.73 | Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. ( Pieters, WR; Smith, HC; Sondhi, S; Tamminga, JJ; Wilson, KK, 2005) |
| "To demonstrate that basic emergency medical technicians (EMT-Bs) are able to effectively administer nebulized albuterol to asthma patients in the out-of-hospital environment." | 7.73 | Out-of-hospital administration of albuterol for asthma by basic life support providers. ( Kusick, M; Matallana, L; Richmond, NJ; Silverman, R; Winokur, J, 2005) |
| "We conducted a prospective and descriptive study to assess levels of lactate and effects on bronchodilator response in adult patients with acute severe asthma treated with high doses of albuterol in the ED." | 7.73 | Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma. ( Rodrigo, C; Rodrigo, GJ, 2005) |
| "A disease-related, corticosteroid-insensitive increase in the expression of epidermal growth factor (EGF) receptor (EGFR) tyrosine kinase in asthmatic bronchial epithelium has been shown previously by the current authors." | 7.73 | Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium. ( Davies, DE; Dearman, RJ; Hamilton, LM; Holgate, ST; Howarth, PH; Kimber, I; Puddicombe, SM; Sandström, T; Wallin, A; Wilson, SJ, 2005) |
| "A post hoc resource use analysis of a 52-week, double-blind multicentre clinical trial (Investigation of Montelukast as a Partner Agent for Complementary Therapy) [corrected] including 1490 adults with chronic asthma, aged 15-72 years, with FEV(1) 50-90% of predicted and > or =12% increase in FEV(1) after salbutamol administration, treated with either montelukast 10 mg daily or salmeterol 50 microg twice daily in addition to fluticasone 200 microg, was undertaken." | 7.73 | Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. ( Bjermer, L; Bousquet, J; Gaugris, S; Kocevar, VS; Polos, PG; Yin, DD; Zhang, Q, 2005) |
| "(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma." | 7.73 | Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005) |
| "Acute asthma is often treated with racemic albuterol, a 1:1 mixture of (R)-albuterol and (S)-albuterol." | 7.73 | Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. ( Babin, S; Schreck, DM, 2005) |
| "British Thoracic Society guidelines recommend intravenous salbutamol or aminophylline for acute severe asthma in children." | 7.73 | A survey of consultant practice: intravenous salbutamol or aminophylline for acute severe childhood asthma and awareness of potential hypokalaemia. ( Parr, JR; Salama, A; Sebire, P, 2006) |
| "Carbon monoxide (CO) can be detected in exhaled air and is increased in adult and childhood persistent asthmatic patients." | 7.73 | Exhaled carbon monoxide levels in school-age children with episodic asthma. ( He, M; Morikawa, T; Ohara, Y; Ohrui, T; Sasaki, H; Yamaya, M; Yasuda, H, 2006) |
| "To determine resource utilization in controller naïve children diagnosed with asthma receiving initial therapy with fluticasone propionate (FP) and salmeterol (SAL) in a single inhaler (FSC), FP alone, montelukast (MON), inhaled corticosteroid (ICS) + SAL from separate inhalers, or ICS + MON." | 7.73 | Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. ( Carranza Rosenzweig, JR; Riedel, AA; Stempel, DA, 2006) |
| "We present 2 cases of Cushing syndrome with secondary adrenal insufficiency from concomitant use of ritonavir and inhaled corticosteroids in children with human immunodeficiency virus infection." | 7.73 | Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. ( Emmanuel, PJ; Johnson, SR; Lujan-Zilbermann, J; Marion, AA; Vrchoticky, T, 2006) |
| "The homozygous presence of the arginine-16 variant of the beta(2) adrenoceptor gene ADRB2 reverses the benefits from the regular use of short acting beta(2) agonists in asthmatic adults compared with the homozygous glycine-16 genotype." | 7.73 | Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. ( Ismail, T; Lee, S; Lipworth, BJ; Macgregor, DF; Mukhopadhyay, S; Palmer, CN, 2006) |
| "To compare asthma-related health care resource utilization among a matched cohort of asthma patients using inhaled corticosteroids (ICSs) plus either montelukast (MON) or salmeterol (SAL) as combination therapy for asthma, during a time prior to the availability of fixed-dose combinations of ICS/SAL." | 7.73 | Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. ( Allen-Ramey, FC; Bukstein, D; Luskin, A; Markson, LE; Sajjan, SG, 2006) |
| "Fifty children primarily with moderate-to-severe asthma were followed with measurements of urinary LTE(4), monitoring of FEV(1), and albuterol use." | 7.73 | Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. ( Gelfand, EW; Rabinovitch, N; Zhang, L, 2006) |
| " Theophylline possesses anti-inflammatory activities in asthma." | 7.72 | Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma. ( Chung, KF; Huang, KH; Kuo, HP; Lin, CH; Lin, HC; Liu, SL; Wang, CH; Yu, CT, 2003) |
| "This was a prospective, open-label, nonrandomized pilot study to evaluate efficacy and tolerability of levalbuterol (LEV) in acute asthma." | 7.72 | Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. ( Disantostefano, RL; Emerman, CL; Nowak, RM; Roach, JM; Schaefer, K; Vaickus, L, 2004) |
| "To determine the relative cost effectiveness when persistent asthma is treated with FP/salmeterol 100/50 microg twice daily administered via a single Diskus inhaler device versus treatment with FP 100 microg twice daily via a Diskus inhaler plus oral montelukast 10mg once daily." | 7.72 | Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. ( Borker, R; Dorinsky, P; Emmett, A; Jhingran, P; Nelson, H; O'Connor, RD; Rickard, K, 2004) |
| "Because the clinical efficacy of inhaled corticosteroids combined with long-acting beta 2 -agonists has been widely demonstrated in asthma, we studied, in vitro, the effect of fluticasone propionate (FP) and salmeterol alone and in combination on the activation and apoptosis of peripheral blood T cells (PBTs), on the expression of phosphorylated nuclear factor kappaB inhibitor (IkappaBalpha), and on the nuclear translocation of glucocorticoid receptor (GR) in PBTs from asthmatic subjects." | 7.72 | Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. ( Bonsignore, G; Bousquet, J; Ferraro, M; Gagliardo, R; Gjomarkaj, M; La Grutta, S; Melis, M; Pace, E; Siena, L; Vignola, AM, 2004) |
| "To compare the effectiveness of (1) fluticasone propionate, 100 microg, and salmeterol, 50 microg; (2) fluticasone propionate, 100 microg; and (3) montelukast, 10 mg, as first-line maintenance treatment for persistent asthma." | 7.72 | Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. ( Crim, C; Dorinsky, P; Edwards, L; O'Connor, RD; Rickard, KA; Stanford, R; Yancey, SW, 2004) |
| "Inhaled acetaldehyde and adenosine 5'-monophosphate (AMP) cause bronchoconstriction in asthmatics by a mechanism believed to involve histamine release from airway mast cells." | 7.71 | Airway obstruction induced by inhaled acetaldehyde in asthma: repeatability relationship to adenosine 5'-monophosphate responsiveness. ( Cervera, A; Gutiérrez, V; Liñana, J; Prieto, L, 2002) |
| "To determine whether NOs influence the bronchodilator activity of albuterol in asthmatic patients." | 7.71 | Nitrogen oxides reduce albuterol-induced bronchodilation in patients with bronchial asthma. ( Hirata, K; Kanazawa, H; Yoshikawa, J, 2002) |
| "The aim of this study was to assess changes in the costs of asthma drug therapy before and during the use of chronic montelukast treatment in the U." | 7.71 | Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. ( Ben-Joseph, RH; Price, DB; Zhang, Q, 2001) |
| "The purpose of this study was to observe the effectiveness of lidocaine in suppressing cough which is a logical extension of its established use in bronchoscopy." | 7.71 | Lidocaine inhalation for cough suppression. ( Udezue, E, 2001) |
| "To compare a combination of salmeterol and fluticasone with common asthma pharmacologic regimens used in real-world clinical practice, and to evaluate the associated costs and outcomes of care." | 7.71 | Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments. ( Bowers, BW; Legorreta, AP; Liu, X; Sennett, C; Wang, SW; Wiener, DJ, 2001) |
| "To investigate the mechanism of anti-inflammatory action of theophylline on asthma." | 7.71 | Effects of theophylline on CD4+ T lymphocyte, interleukin-5, and interferon gamma in induced sputum of asthmatic subjects. ( Hu, SP; Nie, HX; Wu, XJ; Yang, J, 2002) |
| "Albuterol administered by MDI/spacer is an efficacious and cost-effective alternative to nebulization in adults with acute asthma who present at a large urban ED." | 7.71 | A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. ( Hall, K; Hamilton, C; Milne, S; Newman, KB, 2002) |
| "A case of albuterol abuse by a pediatric patient with the development of hypokalemia with electrocardiographic changes is presented." | 7.70 | Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler. ( Farrar, HC; Kearns, GL; Rakhmanina, NY, 1998) |
| "Acutely ill asthmatic patients chronically taking salmeterol, and similar patients who were not taking salmeterol, were treated with albuterol, either as three aerosols of 2." | 7.70 | Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. ( Korosec, M; McFadden, ER; Myers, E; Novak, RD; Skowronski, M, 1999) |
| "This study was undertaken to assess drug-use patterns associated with albuterol delivery via a new propellant device compared with conventional chlorofluorocarbon (CFC) metered-dose inhalers (MDIs) in patients taking asthma medications in a population with pharmacy benefits." | 7.70 | Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. ( Boccuzzi, SJ; Roehm, JB; Wogen, J, 2000) |
| "To determine whether race and gender affect beta(2)receptor-stimulated bronchodilation, we quantified FEV(1)and plasma concentrations of albuterol at various times following the oral administration of a single 8-mg dose of albuterol in 15 black and 15 white male and female asthmatics." | 7.70 | Importance of beta(2)adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics. ( Eberle, LV; Johnson, JA; Lima, JJ; Mohamed, MH; Self, TH, 2000) |
| "The respiratory effects of nebivolol, a new selective ss(1)-adrenergic blocking agent, and celiprolol, a ss-blocker possessing strong ss(1)-adrenoceptor antagonist and mild ss(2)-agonist properties, were investigated in 12 patients with mild asthma." | 7.70 | Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. ( Cazzola, M; D'Amato, G; D'Amato, M; Noschese, P, 2000) |
| " Incubation of bronchial epithelial cells from patients with asymptomatic asthma with interleukin-1 or histamine, for 8 to 24 hours, resulted in increased expression of endothelin-1 messenger RNA and release of appreciable amounts of the peptide to the culture medium." | 7.69 | Constitutive expression of endothelin in bronchial epithelial cells of patients with symptomatic and asymptomatic asthma and modulation by histamine and interleukin-1. ( Ackerman, V; Bellini, A; Carpi, S; Marini, M; Mattoli, S; Vassalli, G, 1995) |
| "Forty-four adult patients with acute asthma were treated with albuterol at a rate of 15 mg/h over 2 h." | 7.69 | Association between reported use of inhaled triamcinolone and differential short-term responses to aerosolized albuterol in asthmatics in an emergency department setting. ( Fox, S; Lin, RY; Newman, TG; Sauter, D; Sirleaf, J; Tavakol, M; Walters, J, 1994) |
| "The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented." | 7.69 | Hypokalemia after normal doses of neubulized albuterol (salbutamol). ( D'Souza, L; Mahajan, M; Udezue, E, 1995) |
| "Hypomagnesaemia in a woman treated with theophylline and albuterol because of recurrent asthmatic attacks prompted us to explore the effects of these drugs on the metabolism of magnesium, calcium, sodium and phosphate in such patients." | 7.69 | Intravenous theophylline-induced excretion of calcium, magnesium and sodium in patients with recurrent asthmatic attacks. ( Bøhmer, T; Falch, J; Knutsen, R, 1994) |
| "Air-flow standardized breath sounds were recorded at the chest and at the trachea during histamine challenge test and after subsequent bronchodilation in 12 asthmatics and 6 healthy controls for spectral analysis, to be compared with simultaneous changes in spirometric variables." | 7.69 | Changes in frequency spectra of breath sounds during histamine challenge test in adult asthmatics and healthy control subjects. ( Haahtela, T; Katila, T; Malmberg, LP; Paajanen, E; Piirilä, P; Sovijärvi, AR, 1994) |
| "To determine the dose of albuterol required to terminate acute episodes of asthma, 92 acutely ill subjects received three doses of 2." | 7.69 | Observations on the effects of aerosolized albuterol in acute asthma. ( Dixon, L; Galan, G; Hejal, R; McFadden, ER; Strauss, L, 1997) |
| "We investigated platelet-activating factor (PAF)-induced migration in eosinophils obtained from asthmatic patients who were treated with or without intravenous prednisolone." | 7.69 | PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro. ( Fukumura, M; Koide, K; Shindo, K, 1997) |
| "A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported." | 7.69 | Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study. ( Baker, EK; Marinac, JS; Salzman, GA; Willsie, SK, 1997) |
| "The cases of two asthmatic adolescents who overdosed on albuterol are presented." | 7.68 | Propranolol treatment of albuterol poisoning in two asthmatic patients. ( Henretig, F; Joffe, M; Ramoska, EA; Spiller, HA, 1993) |
| " Throughout the study, the children received the standardized course of therapy for hospitalized asthmatics with corticosteroids and albuterol nebulizations." | 7.68 | Chronopharmacology of albuterol in hospitalized asthmatic children. ( Cloutier, M; Labrecque, G; Rivard, GB, 1993) |
| "To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm." | 7.68 | Safety of continuous nebulized albuterol for bronchospasm in infants and children. ( Crowley, MR; Grad, R; Katz, RW; Kelly, HW; McWilliams, BC; Murphy, SJ, 1993) |
| "To study the feasibility of using high-dose continuously aerosolized albuterol aerosol in adults, seven adult asthmatic patients were treated eight times with 0." | 7.68 | High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol. ( Hergenroeder, P; Lin, RY; Smith, AJ, 1993) |
| "We performed a prospective study over a 6-month period to test the efficacy and safety of a continuous nebulized albuterol protocol for the treatment of acute adult asthma attacks." | 7.68 | The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks. ( Barish, RA; Brandt, G; Hooper, F; Jerrard, D; Olshaker, J, 1993) |
| "Leukotriene B4 levels were measured after stimulation by calcium ionophore A23187: (i) in peripheral, neutrophils (PMN) from allergic asthmatics, rhinitis and healthy subjects; (ii) in macrophages collected by bronchoalveolar lavage." | 7.68 | Leukotriene B4 level in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapy. ( Chabannes, B; Gormand, F; Grosclaude, M; Hosni, R; Lagarde, M; Moliere, P; Pacheco, Y; Perrin-Fayolle, M; Piperno, D, 1992) |
| "Seven children from 3 to 14 years old with chronic steroid-dependent asthma were treated with methotrexate (MTX)." | 7.68 | Methotrexate treatment of severe asthma in children. ( Guss, S; Portnoy, J, 1992) |
| "The effect of a prior histamine challenge on the bronchodilator response to salbutamol after spontaneous recovery of FEV1 to 95% of the prechallenge level was studied in two groups of asthmatic children." | 7.68 | Assessment of bronchodilatation after spontaneous recovery from a histamine challenge in asthmatic children. ( Duiverman, EJ; Kerrebijn, KF; Merkus, PJ; Quanjer, PH; Rooda, HM; van Essen-Zandvliet, EE, 1992) |
| "The effects of prednisolone, salbutamol or theophylline treatment were studied in guinea pigs on bronchial hyperreactivity induced by chronic administration of PAF, (subsequently measuring respiratory flow after an intravenous injection of histamine) and the chemokinesis of leucocytes in vitro." | 7.68 | Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs. ( Berga, P; Fernández, AG; Gristwood, RW; Llupiá, J, 1991) |
| "Effects of flutropium bromide, a new bronchodilator with an anticholinergic action, alone or in combination with other antiasthma drugs were investigated in guinea pigs by using an index of inhibition of the acetylcholine (ACh)-induced bronchoconstriction." | 7.68 | [Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction]. ( Misawa, M; Mizuno, H; Ohno, H; Takahashi, Y, 1990) |
| "To examine the effects of serum theophylline concentration on the bronchodilating effect of beta 2-stimulant inhalated by patients with bronchial asthma, 200 micrograms-Salbutamol inhalation test was performed on 30 patients with bronchial asthma (from 17 to 71 years old, averaging 49." | 7.68 | [The influence of serum theophylline concentration on the bronchodilating effect of salbutamol inhalation for bronchial asthma]. ( Hashimoto, T; Kondo, A; Nakamata, M; Tsukioka, K, 1990) |
| "The purpose of this study is to evaluate the effect of disodium cromoglycate and albuterol on energy cost of running, gas exchange, and ventilation during maximal exercise in children with exercise-induced asthma (EIA)." | 7.68 | Effect of inhaled disodium cromoglycate and albuterol on energy cost of running in asthmatic children. ( Baraldi, E; Magagnin, G; Santuz, P; Zacchello, F; Zanconato, S, 1990) |
| "Albuterol used with a spacer device which induced atrial fibrillation is described." | 7.68 | Albuterol and spacer-induced atrial fibrillation. ( Breeden, CC; Safirstein, BH, 1990) |
| "Our study was designed to assess potential cardiovascular adverse effects in clinically stable asthmatic children due either to oral sustained-release theophylline or theophylline in combination with an inhaled beta-2 adrenergic agonist." | 7.68 | Lack of adverse cardiac effects of combined treatment with theophylline and albuterol in asthmatic children. ( Bastianon, V; Bernardini, L; Businco, L; Coletta, F; Colloridi, V; Di Fazio, A; Ferrucci, A; Marzano, MC; Pucci, S; Sorbara, N, 1990) |
| "Out of a group of 55 asthmatics, 16 fitted the strict definition of atropine resistance (less than 20% FEV1 response to inhaled anticholinergic drugs, with a 20% or more FEV1 response to subsequent inhalation of beta 2-adrenergic stimulants)." | 7.67 | Atropine resistance in asthma: definition and provisional hypothesis. ( Jolobe, OM, 1984) |
| "Fourteen patients with uncomplicated essential hypertension and mild asthma were treated with Atenolol 50-125 mg/day for up to 8 months." | 7.67 | Treatment of hypertension in mild asthmatic patients with atenolol. ( Clement, S; Grizotzki, B; Krauss, A; Krauss, S; Spitz, E, 1984) |
| "Twenty-seven asymptomatic asthmatic children with airway obstruction received a single oral dose of one out of three solutions, in a double-blind, randomized fashion, containing: etamiphylline, 6." | 7.67 | [Comparative study of the effect of a single oral dose of theophylline and etamiphyllin in children with asthma]. ( Labayru, MT; Vázquez, C, 1984) |
| "We report a case of respiratory arrest in a ten-year-old asthmatic girl under beta-2-agonists and theophylline." | 7.67 | [Respiratory arrest in an asthmatic girl treated with beta-2-mimetics and theophylline. Possible role of hypokalemia in sudden death in asthmatic patients]. ( Benhamou, PH; Devoldere, C; Epelbaum, S; Kremp, O; Pautard, JC; Piussan, C, 1989) |
| "4 mg salbutamol on the impedance of the respiratory system was studied in 25 asthmatic subjects after histamine-induced bronchoconstriction." | 7.67 | Response localization of the pharmacological agents histamine and salbutamol along the respiratory system by forced oscillations in asthmatic subjects. ( Polko, AH; Visser, BF; Wouters, EF, 1989) |
| "In 13 patients with bronchial asthma, who were on beta 2-adrenergic bronchodilator therapy, the effects of prednisolone and ketotifen on lymphocyte beta 2-adrenoceptor density and -responsiveness were investigated." | 7.67 | Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators. ( Brodde, OE; Egerszegi, S; Howe, U; Konietzko, N; Michel, MC, 1988) |
| "The effect of a fish oil enriched diet containing about 3 g of eicosapentaenoic acid was studied in 10 patients with aspirin intolerant asthma." | 7.67 | Effects of a fish oil enriched diet on aspirin intolerant asthmatic patients: a pilot study. ( Agusti-Vidal, A; Castillo, JA; Coronas, A; Ordinas, A; Picado, C; Pujades, M; Schinca, N, 1988) |
| "An albuterol (salbutamol) sulphate solution was successfully administered endotracheally to a 67-year-old woman suffering severe bronchospasm and impending ventilatory arrest secondary to asthma." | 7.67 | Treatment of asthma-related respiratory arrest with endotracheal albuterol (salbutamol). ( Gareau, AB; Rubes, CJ; Verbeek, PR, 1988) |
| "To explore the possibility that theophylline may act through adrenomedullary secretion of catecholamines, we examined the time courses of plasma norepinephrine (NE), epinephrine (E), and theophylline concentrations and peak expiratory flow (PEF) in nine children with an acute exacerbation of asthma receiving a 72-hour constant infusion of aminophylline." | 7.67 | Plasma catecholamine concentrations during a 72-hour aminophylline infusion in children with acute asthma. ( Ishizaki, T; Kanagawa, S; Minegishi, A; Morishita, M; Nagai, T; Odajima, Y; Yamaguchi, M, 1988) |
| "Single photon emission computed tomography, a rotating gamma camera, and continuous inhalation or infusion of krypton 81m (half life 13 seconds) were used to measure regional ventilation (V), perfusion (Q), and ventilation-perfusion (V/Q) ratios in five normal subjects in supine, prone, and lateral decubitus postures and in three asthmatic patients (supine posture only) before and after inhalation of 2." | 7.67 | Tomography of regional ventilation and perfusion using krypton 81m in normal subjects and asthmatic patients. ( Al-Suhali, AR; Henderson, B; Hughes, JM; Myers, MJ; Orphanidou, D, 1986) |
| "The concentrations of theophylline, terbutaline and salbutamol in post-mortem blood samples from 68 patients (17-85 years old) with asthma or chronic obstructive lung disease, 54 of whom had died of asthma, were analysed." | 7.67 | Post-mortem concentrations of salbutamol, terbutaline and theophylline in asthma patients. ( Boman, G; Lindsjö, M; Lindström, B; Strandberg, K; Wiholm, BE, 1987) |
| " On oral challenges, she developed an urticarial reaction after tartrazine; urticarial and bronchospastic reactions after salicylsalicylic acid; and urticarial and bronchospastic reactions after choline magnesium trisalicylate." | 7.67 | Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis. ( Chudwin, DS; Frey, C; Golden, HE; Luskin, AT; Richmond, GW; Strub, M, 1986) |
| "Asthma was provoked by histamine inhalation in five children in order to study the hypoxaemia that might ensue and the underlying ventilation-perfusion (VA/Q) mismatching." | 7.67 | Histamine-induced asthma in children: effects on the ventilation-perfusion relationship. ( Freyschuss, U; Hedenstierna, G; Hedlin, G, 1985) |
| "Studies using the guinea pig ileum bioassay technique have previously shown that patients with either asthma or chronic bronchitis have increased amounts of histamine in their sputum." | 7.66 | Histamine content of sputum from patients with asthma and chronic bronchitis. ( Bryant, DH; Pui, A, 1982) |
| "We have prospectively examined in 51 patients the relationship between the level of airway responsiveness to histamine and methacholine and the minimum medications required to control asthma." | 7.66 | Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. ( Frith, PA; Hargreave, FE; Juniper, EF, 1981) |
| "The efficacy and side effects of intravenous and intramuscular albuterol were determined in 13 adult asthmatic patients whose airway responsiveness had previously been evaluated with inhaled albuterol." | 7.66 | Intramuscular and intravenous albuterol in the treatment of asthma. ( Contreras, M; Rebuck, AS, 1982) |
| "We examined the effects of pharmacologic antagonists on the bronchial response to inhaled histamine in 11 normal and 11 asthmatic subjects." | 7.66 | Histamine dose-response relationships in normal and asthmatic subjects. The importance of starting airway caliber. ( Chung, KF; Keyes, SJ; Morgan, B; Snashall, PD, 1982) |
| "Plasma cholesterol, plasma and white blood cell ascorbic acid concentrations were estimated in 30 untreated, 32 salbutamol-treated patients with bronchial asthma and in 57 normal controls." | 7.66 | Plasma and white blood cell ascorbic acid concentrations in patients with bronchial asthma. ( Iboko, MI; Jessop, WJ; Ojutiku, OO; Olusi, SO, 1979) |
| "In a double-blind trial the effects on ventilatory function (FEV1), heart rate and blood pressure of oral pirbuterol and oral salbutamol in various single doses were studied in ten patients with chronic asthma." | 7.65 | Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics. ( Grant, IW; Pocock, SJ; Willey, RF, 1976) |
| "Controlled standardised histamine inhalation tests were carried out in 21 asthmatics to determine the degree of non-specific bronchial hyperreactivity with and without prior treatment with several anti-asthmatic drugs." | 7.65 | Protective effect of drugs on histamine-induced asthma. ( Cockcroft, DW; Hargreave, FE; Killian, DN; Mellon, JJ, 1977) |
| "Ten patients with exercise-induced asthma were premedicated with oral salbutamol and oral theophylline on separate occasions before performing a standardised exercise test." | 7.65 | A comparison of oral theophylline and oral salbutamol in exercise-induced asthma. ( Anderson, SD; Lindsay, DA; Seale, JP, 1977) |
| "Albuterol mDPI was comparable to ProAir HFA at 90 and 180 µg." | 6.82 | Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir(®) Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies. ( Iverson, H; Kerwin, EM; Lepore, MS; Miller, DS; Shah, T; Taveras, H; Wayne, D, 2016) |
| " Adverse events were comparable across groups." | 6.82 | Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. ( Bleecker, ER; Busse, WW; Donohue, JF; Garfinkel, S; Ghafouri, M; Manuel, RC; Schlenker-Herceg, R; Wise, R; Zubek, VB, 2016) |
| "Vilanterol (VI) is a novel long-acting beta2 agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (ICS)." | 6.79 | Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. ( Bateman, ED; Bleecker, ER; Busse, WW; Goldfrad, C; Jacques, L; Lötvall, J; O'Byrne, PM; Toler, WT; Woodcock, A, 2014) |
| "Fluticasone/formoterol was comparable to fluticasone/salmeterol for the primary efficacy endpoint, mean pre-dose FEV1 at week 12." | 6.76 | Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. ( Bodzenta-Lukaszyk, A; Dymek, A; Mansikka, H; McAulay, K, 2011) |
| " Pharmacokinetic results showed a greater initial absorption of salmeterol with DPI-C but greater continued absorption and a 40% greater AUC with DPI-A, which we attribute to slower but more extensive oral absorption because of the greater mass of swallowed large particles of salmeterol generated by DPI-A." | 6.76 | Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. ( Harrison, LI; Needham, MJ; Novak, CC; Ratner, P, 2011) |
| " The incidence of adverse events was low and similar between the two groups and events were of the type expected in this population." | 6.73 | Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. ( Chan, R; Jung, KS; Lee, YC; Park, SK; Shim, JJ; Uh, ST; Williams, AE, 2008) |
| "We conducted a double blind, randomised, placebo-controlled, crossover study evaluating the effects of halving inhaled steroid dosage plus salmeterol, or salmeterol and tiotropium." | 6.73 | A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. ( Fardon, T; Haggart, K; Lee, DK; Lipworth, BJ, 2007) |
| " Secondary outcomes included risk of hospitalization, pulmonary function, asthma control level, quality of life, and adverse events (AEs)." | 6.72 | Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis. ( Hong, JG; Lu, J; Qin, Z; Zhou, XJ, 2021) |
| " Significant benefit was gained from adding salmeterol in a group of patients who appeared to have been at the top of their steroid dose-response curve receiving FP250." | 6.71 | Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. ( Browning, D; Colman, NC; Dal Negro, R; Fletcher, CP; Ind, PW; James, MH, 2003) |
| " This randomized, placebo-controlled, multicenter, crossover study investigated the efficacy, dose-response and safety of HFA-albuterol delivered via a breath-actuated Autohaler inhalation device in comparison with the same medication delivered using a conventional P&B device." | 6.71 | Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. ( Cohen, RM; Gross, G; Guy, H, 2003) |
| " A bivariate dose-response model based on these principles was fitted simultaneously to all data." | 6.70 | Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients. ( Böcskei, C; Juhász, G; Larsson, P; Poczi, M; Rosenborg, J; Rott, Z, 2002) |
| "Histamine challenges were carried out by tidal breathing method at entry, and at Days 4, 8, 22, 36, and 40." | 6.69 | Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo. ( Cheung, D; de GOEIJ, JA; de GRAAFF, CS; Steen, H; Sterk, PJ; Wever, AM, 1998) |
| " Pulmonary function and safety measures were assessed after each dosing interval." | 6.69 | Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. ( Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1998) |
| " Safety was assessed by measuring changes in pulse rate, blood pressure, and electrocardiogram (ECG) intervals after dosing with study drug, monitoring adverse events, and performing prestudy and poststudy laboratory testing and physical examinations." | 6.69 | Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. ( Bronsky, E; Colice, GL; Ekholm, BP; Klinger, NM, 1999) |
| " On both assessment days for salmeterol, and during placebo administration periods, significant increases from predose FEV1 values were observed beginning with the lowest dose of albuterol and continuing throughout the dose-response assessment (p | 6.69 | Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. ( Berkowitz, RB; Emmett, AH; Nelson, HS; Rickard, KA; Tinkelman, DA; Yancey, SW, 1999) |
| "Albuterol treatment significantly reduced the median thickness of subepithelial Tn expression from 9." | 6.69 | Regular albuterol or nedocromil sodium--effects on airway subepithelial tenascin in asthma. ( Altraja, A; Laitinen, A; Laitinen, LA; Marran, S; Märtson, T; Meriste, S; Sillastu, H, 1999) |
| "Levalbuterol was found to provide significant bronchodilatory activity and was well tolerated." | 6.69 | Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. ( Caron, J; Handley, DA; Noonan, M; Rollins, TE; Snider, ME; Tinkelman, D, 2000) |
| " Safety assessments included monitoring of adverse events and morning serum cortisol concentrations." | 6.69 | Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. ( Anttila, H; Davies, PI; Hederos, CA; Ossip, MS; Ribeiro, BL; Van den Berg, NJ, 2000) |
| "Albuterol OR was added to their usual treatment." | 6.68 | Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients. ( Ariaansz, M; Nauta, JJ; Postmus, PE; Raaijmakers, JA; Van Keimpema, AR, 1996) |
| "Theophylline may produce a paradoxical increase in awareness of asthma in some individuals." | 6.68 | Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma. ( Higgs, CM; Laszlo, G, 1996) |
| " This study does not exclude the possibility that adverse cardiac events could occur with severe hypoxemia." | 6.68 | Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. ( Abboud, RT; Bowie, DM; Chapman, KR; Hodder, RV; McCallum, AL; Mesic-Fuchs, H; Molfino, NA; Newhouse, MT; Paré, PD, 1996) |
| "Albuterol treatment significantly increased the LAR compared to placebo treatment (p = 0." | 6.68 | Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. ( Cockroft, DW; Gauvreau, GM; Jordana, M; O'Byrne, PM; Watson, RM, 1997) |
| " 12 patients received during a month salbutamol combined with nedocromil (Tilade 8 mg per day)." | 6.67 | [Bronchial hyperreactivity in patients with bronchial asthma treated with salbutamol and salbutamol combined with beclocort or nedocromil]. ( Krasnowska, M; Liebhart, E; Małolepszy, J, 1994) |
| " A further 416 (57) micrograms reduction in inhaled corticosteroid dosage was possible during the treatment phase but this was almost identical in the WEB 2086 and placebo-treated groups, amounting to 353 (92) and 481 (65) micrograms/day respectively (not significant [NS])." | 6.67 | The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. ( Calverley, PM; Dhillon, P; Higgins, C; Holgate, ST; Johnston, SL; Ramhamadany, E; Spence, DP; Turner, S; Winning, A; Winter, J, 1994) |
| "Both procaterol and albuterol were highly effective in improving pulmonary function and controlling symptoms of asthma; both were well tolerated." | 6.67 | Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma. ( Mazza, JA; Reed, CE; Tashkin, DP, 1992) |
| "Procaterol is a new, potent, long-acting beta-2-adrenergic bronchodilator." | 6.67 | Inhaled procaterol versus salbutamol in bronchial asthma. ( Liippo, K; Silvasti, M; Tukiainen, H, 1991) |
| "treatment." | 6.67 | High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma. Swedish Society of Chest Medicine. ( , 1990) |
| "Theophylline was titrated for patients to receive, unblinded, theophylline serum concentrations of 10 to 20 micrograms/ml." | 6.67 | Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma. ( Bell, TD; LaForce, CF; MacCosbe, PE; Pierson, WE; Sykes, RS; Tinkelman, D, 1990) |
| " The slow-release tablets were preferred by 15 of 18 children and their families when the effects, side effects and dosage were evaluated." | 6.66 | Terbutaline slow-release tablets in children with asthma. A comparison with t.i.d. beta 2-agonist therapy. ( Croner, S; Gustafsson, M; Kjellman, NI; Säwedal, L, 1986) |
| "Pretreatment with albuterol abolished any significant bronchoconstriction, with mean maximal falls in SGaw and FEV1 after challenge of 7." | 6.66 | Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. ( Church, MK; Durham, SR; Holgate, ST; Howarth, PH; Kay, AB; Lee, TH, 1985) |
| "Pindolol was administered gradually by mouth (2." | 6.66 | Influence of pindolol on asthmatics and effect of bronchodilators. ( Antoniadou, H; Georgopoulos, D; Giulekas, D; Papakosta, D; Sotiropoulou, E; Vamvalis, C, 1986) |
| "Histamine PD20 FEV1 was assessed 4 h after the administration of salbutamol 200 micrograms, a combination of fenoterol 200 micrograms and ipratropium bromide 80 micrograms, and placebo." | 6.66 | Histamine-induced bronchial response after administration of placebo, salbutamol and a combination of a beta-2-adrenergic drug (fenoterol) with an anticholinergic agent (ipratropium bromide) in asymptomatic asthma patients. ( Cresci, F; Fontana, G; Mugnai, M; Panuccio, P, 1986) |
| " Airway responsiveness thus appears to be a useful tool for evaluating inhaled beta 2-agonists and designing beta 2-agonist dosing regimens." | 6.66 | Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. ( Ahrens, RC; Annis, L; Harris, JB; Milavetz, G; Ries, R, 1987) |
| "Tiaramide hydrochloride is a new non-steroidal anti-inflammatory agent previously shown to inhibit allergic responses both in vitro and in vivo." | 6.66 | A trial of tiaramide in asthma. ( Harvey, JE; Jones, P; Tanser, AR, 1985) |
| "Twenty-five patients with chronic bronchial asthma completed the trial." | 6.65 | A comparison of sustained-release terbutaline with ordinary salbutamol in bronchial asthma. ( Beskow, R; Ericsson, CH; Grönneberg, R; Sjögren, I; Skedinger, M, 1984) |
| "Clenbuterol is a beta 2-sympathomimetic bronchodilator." | 6.64 | A trial of clenbuterol in bronchial asthma. ( Anderson, G; Wilkins, E, 1977) |
| "The albuterol mDPI has an efficacy/tolerability profile consistent with other inhaled forms of albuterol, and is reliable, easy to use, and associated with a high level of patient satisfaction." | 6.53 | Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma. ( Welch, MJ, 2016) |
| "For patients with chronic obstructive pulmonary disease, quick-relief and long-acting bronchodilators are primarily used in the maintenance and treatment of associated symptoms, including shortness of breath." | 6.42 | Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease. ( Dalonzo, GE, 2004) |
| " Two recently completed trials have demonstrated that with respect to asthma control the combination of inhaled steroid (400 - 800 microg/d) plus theophylline is at least as effective as doubling the dose of inhaled steroid in patients who remain symptomatic on a dosage of 400 - 800 microg daily." | 6.40 | [Asthma therapy: combination of topical glucocorticosteroids and theophylline]. ( Ukena, D, 1997) |
| "Pulmonary function, asthma symptoms, supplemental albuterol use, asthma quality of life scores, and adverse events." | 6.19 | Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. ( Kalberg, C; Nathan, RA; Nelson, HS; Rickard, KA; Yancey, SW, 2001) |
| "We examined the effects of two year's treatment of three inhaled beta 2-agonists (beta 2), such as salbutamol (S), procaterol (P) and fenoterol (F) on acetylcholine induced bronchial hyperresponsiveness (BHR) in mild approximately moderate asthmatics." | 6.18 | [Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics]. ( Ogawa, C; Sano, Y, 1996) |
| "A prospective, single center, open-label, two-arm, parallel-group, nonrandomized trial among children ages 5-17 years hospitalized within the PICU from April 2019 to December 2021 for critical asthma consented to receive methylprednisolone (standard care) or dexamethasone (intervention) at a 2:1 allocation ratio, respectively." | 5.69 | Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial. ( Darville, KK; Goldenberg, NA; Martin, M; McKinley, SD; Nakagawa, TA; Roddy, MR; Sellers, AR; Sochet, AA; Teppa-Sanchez, B, 2023) |
| "In Colombia, compared with the use of albuterol alone, the use of beclomethasone dipropionate added to albuterol as needed for symptom relief is cost-effective in children 5 to 11 years old with mild intermittent (step 1) asthma, because it involves a higher probability of a lack of a requirement for prednisone for AE at lower total treatment costs." | 5.51 | As-Needed Use of Short-Acting β ( Buendia, JA; Rodríguez-Martínez, CE; Sossa-Briceño, MP, 2022) |
| "We conducted a multinational, phase 3, double-blind, randomized, event-driven trial to evaluate the efficacy and safety of albuterol-budesonide, as compared with albuterol alone, as rescue medication in patients with uncontrolled moderate-to-severe asthma who were receiving inhaled glucocorticoid-containing maintenance therapies, which were continued throughout the trial." | 5.51 | Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. ( Albers, FC; Beasley, R; Cappelletti, C; Chipps, BE; Cooper, M; Dunsire, L; Israel, E; Jeynes-Ellis, A; Johnsson, E; Panettieri, RA; Papi, A; Rees, R, 2022) |
| "In this 12-week study, participants aged 13 years or older with suboptimal asthma control (Asthma Control Test [ACT] score < 19) were randomized to use either RDS or standard of care albuterol reliever inhalers." | 5.51 | Effectiveness of a Digital Inhaler System for Patients With Asthma: A 12-Week, Open-Label, Randomized Study (CONNECT1). ( Brown, R; DePietro, M; Hill, TD; Hoyte, FCL; Li, T; Mosnaim, GS; Reich, M; Rogers, L; Safioti, G; Wechsler, ME, 2022) |
| "To evaluate bronchodilator responses (BDR) to albuterol nebulized with 3%-HSS in asthmatic children, compared to albuterol nebulized with NSS." | 5.41 | Bronchodilator response to albuterol nebulized with hypertonic saline in asthmatic children. ( Alchundia Moreira, J; García Bournissen, F; Kofman, C; Köhler, T; Teper, A, 2021) |
| "The Phase 3 MANDALA study was designed to determine the efficacy of albuterol in combination with budesonide (albuterol/budesonide 180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg, respectively) versus albuterol (180 µg, two actuations of 90 µg) as rescue therapy in adult, adolescent and paediatric patients with moderate-to-severe asthma." | 5.41 | Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. ( Albers, FC; Cappelletti, C; Chipps, BE; Johnsson, E; Papi, A; Reilly, L, 2021) |
| "The study suggests that LMWH in mild-moderate asthma attacks may be beneficial in the short term and could be prescribed in addition to standard albuterol therapy." | 5.41 | Evaluation of efficacy of nebulized low molecular weight heparin as an adjunctive extra treatment for acute mild-moderate asthma attack; a randomized clinical trial study. ( Hesam, S; Motamed, H; Nematollahi, AV; Verki, MM, 2021) |
| "Despite guidelines recommending administration of intravenous (IV) magnesium sulfate for refractory pediatric asthma, the number of asthma-related hospitalizations has remained stable, and IV magnesium therapy is independently associated with hospitalization." | 5.41 | Association Between Intravenous Magnesium Therapy in the Emergency Department and Subsequent Hospitalization Among Pediatric Patients With Refractory Acute Asthma: Secondary Analysis of a Randomized Clinical Trial. ( Beer, D; Black, KJ; Coates, AL; Curtis, S; Ducharme, F; Finkelstein, Y; Freedman, SB; Gravel, J; Johnson, DW; Plint, AC; Rumantir, M; Schuh, S; Stephens, D; Sweeney, J; Thompson, G; Zemek, R, 2021) |
| "006), while asthma symptoms and albuterol use was higher (p < 0." | 5.34 | Impact of sleep opportunity on asthma outcomes in adolescents. ( Beebe, DW; Flewelling, K; Jump, S; Meltzer, LJ; Strand, MJ; Sundström, D; White, M; Zeitlin, PL, 2020) |
| "Pilot, placebo-controlled, double-blinded, and randomized-controlled trial PATIENTS: Thirty children (15 per group) with critical asthma receiving high-intensity albuterol per a standardized pathway utilizing objective assessments to wean patients to less frequent albuterol administration." | 5.34 | Randomized pilot trial of ipratropium versus placebo in children with critical asthma. ( Craven, D; Gallagher, J; Mahmood, N; Murphy, K; Ross, K; Rotta, AT; Shein, SL; Speicher, R, 2020) |
| " The participants were otherwise healthy children aged 2 to 17 years with moderate to severe asthma defined by a Pediatric Respiratory Assessment Measure (PRAM) score of 5 or greater (on a 12-point scale) after a 1-hour treatment with an oral corticosteroid and 3 inhaled albuterol and ipratropium treatments." | 5.34 | Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. ( Atenafu, EG; Beer, D; Black, K; Coates, AL; Curtis, S; Ducharme, FM; Finkelstein, Y; Freedman, SB; Gravel, J; Johnson, DW; Klassen, TP; Nicksy, D; Plint, AC; Rumantir, M; Schuh, S; Stephens, D; Sweeney, J; Thompson, G; Willan, AR; Zemek, R, 2020) |
| " Drug use in the 6 months before and after step-up in treatment from inhaled corticosteroids [ICs; total daily dosage of < or =1000 microg beclomethasone dipropionate (BDP) or equivalent] to either salmeterol/fluticasone propionate combination (SFC) or concurrent BDP and long-acting beta(2)-agonists (LABAs) given in separate inhalers was compared." | 5.33 | Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. ( Angus, R; Cheesbrough, A; Reagon, R, 2005) |
| "Levalbuterol-treated patients required significantly fewer treatments with beta-agonists (mean [+/- SD] number of treatments, 19." | 5.32 | Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. ( Halpern, M; Truitt, T; Witko, J, 2003) |
| " The area under the plasma albuterol concentration versus time curve (AUC) was 72% greater for the HFA formulation, indicating a greater lung bioavailability (p = 0." | 5.32 | Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. ( Anderson, P; Breen, P; Compadre, C; Gann, L; Hiller, FC; Joguparthi, V; Zhou, X, 2003) |
| "Malondialdehyde levels of BAL were compared before and after treatment." | 5.31 | Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and beta2-agonist. ( Aydin, S; Besirli, K; Cetinkaya, A; Ozaras, R; Tahan, V; Talay, F; Turkmen, S; Uzun, H, 2000) |
| " Lung function, quality of life and adverse events were evaluated as primary outcome variables." | 5.31 | [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma]. ( Beeh, KM; Beier, J; Buhl, R; Kornmann, O; Wiewrodt, R, 2002) |
| "Baseline survey data, salivary cotinine levels, and allergen specific IgE serologic test results were obtained from children with uncontrolled asthma enrolled in a randomized clinical trial of a behavioral education environmental control intervention." | 5.30 | Characteristics of inner-city children with life-threatening asthma. ( Bollinger, ME; Butz, A; Lewis-Land, C; Morphew, T; Mudd, S; Tsoukleris, M, 2019) |
| "Although the guidelines in most countries do not recommend continuous inhalation of l-isoproterenol to treat pediatric patients with acute severe exacerbation of asthma, lower dose of l-isoproterenol has been widely used in Japan." | 5.30 | Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial. ( Adachi, Y; Akashi, K; Fujisawa, T; Hashimoto, K; Imai, T; Katsunuma, T; Maekawa, T; Mizuno, M; Nakamura, H; Oba, MS; Ohashi, Y; Ohya, Y; Sako, M, 2019) |
| "In an open-label trial involving adults with mild asthma, budesonide-formoterol used as needed was superior to albuterol used as needed for the prevention of asthma exacerbations." | 5.30 | Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. ( Beasley, R; Braithwaite, I; Ebmeier, S; Hancox, RJ; Harrison, T; Holliday, M; Houghton, C; Oldfield, K; Papi, A; Pavord, ID; Reddel, HK; Weatherall, M; Williams, M, 2019) |
| " Beta 2 adrenoceptor function was evaluated by measuring lymphocyte beta 2 adrenoceptor parameters and constructing dose-response curves to salbutamol (100-1600 micrograms)." | 5.30 | Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. ( Lipworth, BJ; McFarlane, LC; Tan, KS, 1997) |
| "Procaterol was administered per os (tabl." | 5.28 | [Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma]. ( Kruszewski, J; Płusa, T; Zaraś, E, 1992) |
| "Patients with bronchial asthma often develop acute attack in kitchen while burning honeycomb briquet which is widely used for cooking in southern China." | 5.28 | [Sulfur dioxide-induced bronchial constriction in asthmatics and its prophylaxis by salbutamol]. ( Luo, DF; Luo, ZY; Zheng, JP, 1990) |
| "The objective of this study was to determine if a rapid albuterol delivery pathway with a breath-enhanced nebulizer can reduce emergency department (ED) length of stay (LOS), while maintaining admission rates and side effects, when compared to a traditional asthma pathway with a standard jet nebulizer." | 5.27 | Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department. ( Allen, C; Higginbotham, E; Hovinga, C; Iyer, S; King, B; Wallace, A; Wilkinson, M, 2018) |
| "Magnesium sulfate has been shown to be an effective treatment in older children with asthma exacerbations, but it has not been investigated in acute severe virus-induced wheezing in young children." | 5.27 | Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial. ( Dunder, T; Kallio, M; Pokka, T; Pruikkonen, H; Renko, M; Tapiainen, T; Uhari, M, 2018) |
| "BACKGROUND The aim of this study was to evaluate the therapeutic effects of tiotropium bromide on asthma." | 5.27 | Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma. ( Han, S; Huang, G; Jin, L; Zhang, L, 2018) |
| " Subjects presenting with a Pediatric Asthma Score ranging from 5 to 11 received albuterol by BAN or MDI via standard weight-based and symptom severity dosing protocols." | 5.27 | A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers. ( Arnold, SR; Gilmore, B; Jacobs, J; Kink, R; Snider, MA; Wan, JY, 2018) |
| "To compare the efficacy of a long-term treatment with Fluticasone Propionate administered by an MDI through both type of spacers, with and without valves, in young children with recurrent wheezing and risk factors for asthma." | 5.27 | Usefulness of Nonvalved Spacers for Administration of Inhaled Steroids in Young Children with Recurrent Wheezing and Risk Factors for Asthma. ( Kofman, C; Teper, A, 2018) |
| " We conclude that procaterol and salbutamol are clinically similar with oral dosing and that the maximum effective dose of procaterol is not greater than 0." | 5.27 | A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma. ( Counihan, HE; Crowe, MJ; O'Malley, K, 1985) |
| "The long-acting muscarinic antagonist, umeclidinium (UMEC), combined with the inhaled corticosteroid, fluticasone furoate (FF), improves lung function in symptomatic patients with asthma." | 5.24 | The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study. ( Collison, K; Kerwin, E; Lee, L; Nelsen, L; Pascoe, S; Wu, W; Yang, S, 2017) |
| "To evaluate the efficacy and safety of albuterol MDPI versus placebo MDPI after chronic dosing in children with asthma." | 5.24 | Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma. ( Iverson, H; LaForce, C; Shore, P; Taveras, H, 2017) |
| "Evaluate the safety of albuterol multidose dry powder inhaler (MDPI), a novel, inhalation-driven device that does not require coordination of actuation with inhalation, in patients with persistent asthma." | 5.22 | Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma. ( Iverson, H; Miller, D; O'Brien, C; Raphael, G; Taveras, H, 2016) |
| "To compare the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of albuterol MDPI and albuterol HFA after a single inhaled dose in children with asthma." | 5.22 | Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma. ( Iverson, H; Ratnayake, A; Shore, P; Taveras, H, 2016) |
| "To demonstrate the comparability of albuterol MDPI and albuterol HFA in children with asthma." | 5.22 | Albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane versus placebo in children with persistent asthma. ( Iverson, H; Qaqundah, PY; Shore, P; Taveras, H, 2016) |
| "To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol." | 5.22 | Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β ( Chen, P; Dai, A; Kong, L; Shang, S; Wang, Y, 2016) |
| "To determine if the addition of ipratropium bromide (IB) by metered-dose inhaler in moderate acute asthma in children affects hospital admission rates when compared with inhaled salbutamol and oral prednisolone alone." | 5.20 | Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: A single-blinded randomised controlled trial. ( Borland, ML; Doyle, SK; Geelhoed, GC; Wyatt, EL, 2015) |
| "We have previously shown that in patients with asthma a single dose of an inhaled glucocorticosteroid (ICS) acutely potentiates inhaled albuterol-induced airway vascular smooth muscle relaxation through a nongenomic action." | 5.20 | Acute effect of an inhaled glucocorticosteroid on albuterol-induced bronchodilation in patients with moderately severe asthma. ( Arana, J; Cadet, L; Mendes, ES; Wanner, A, 2015) |
| "Patients aged 2 to 14 y with moderate and severe asthma (PRAM severity score ≥ 4) admitted to infirmary/observation unit care were randomized double-blind on admission to receive 800 mg nebulized magnesium or normal saline placebo after all received intensive therapy with combined nebulized albuterol-ipratropium and intravenous methylprednisolone." | 5.20 | Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial. ( Ahmed, W; Alamri, M; Alansari, K; Alrifaai, M; Davidson, BL; Zakaria, I, 2015) |
| "Results of a prospective study comparing clinical outcomes and costs of levalbuterol versus albuterol therapy for exacerbations of asthma or chronic obstructive pulmonary disease (COPD) are presented." | 5.20 | Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma. ( Brunetti, L; Dhanaliwala, F; Kang, H; Poiani, G; Poppiti, K; Suh, DC, 2015) |
| " Patients with mild to moderate asthma will be randomly allocated to either a verum acupuncture plus as-needed salbutamol aerosol and/or prednisone tablets group or a sham acupuncture plus as-needed salbutamol aerosol and/or prednisone tablets group." | 5.20 | Efficacy of acupuncture for chronic asthma: study protocol for a randomized controlled trial. ( Fan, L; Feng, JT; Hu, CP; Liu, YY; Shao, SJ; Wang, PY; Wang, WQ; Wang, Y; Xu, YD; Yang, YQ; Yin, LM; Zhang, TF, 2015) |
| "Plasma albuterol was significantly correlated with serum lactate concentration after adjusting for asthma severity." | 5.19 | Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma. ( Aubuchon, K; Ferguson, I; House, SL; Johnson, K; Lewis, LM; Matsuda, K; Schneider, J, 2014) |
| "Three hundred and thirty children of asthma with positive bronchial provocation test were randomly divided into three groups: magnesium sulfate, albuterol, and a combination of magnesium sulfate and albuterol." | 5.19 | Effect of inhaled MgSO4 on FEV1 and PEF in children with asthma induced by acetylcholine: a randomized controlled clinical trail of 330 cases. ( Dai, JH; Gong, CH; Liu, S; Shi, TT; Sun, YX; Yan, L; Yin, LJ; Yuan, XP, 2014) |
| "Post hoc descriptive analysis of data stratified by FAO category (screening post-albuterol FEV1/FVC | 5.19 | Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. ( Chipps, BE; Tashkin, DP; Trudo, F; Zangrilli, JG, 2014) |
| "This study compares the effect of heliox-driven to that of air-driven bronchodilator therapy on the pulmonary function test (PFT) in patients with different levels of asthma severity." | 5.19 | Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma. ( Alawieh, M; Bou-Akl, I; Bou-Khalil, P; Chami, H; El-Khatib, MF; Husari, A; Jamaleddine, G; Kanj, N; Zeineddine, S, 2014) |
| "In subjects with either asthma or COPD, FEV(1) decline and bronchospasm can occur following inhaled loxapine, but more frequently in asthmatic subjects." | 5.19 | Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials. ( Cassella, JV; Fishman, RS; Greos, LS; Gross, N; Meltzer, EO; Spangenthal, S; Spyker, DA, 2014) |
| "Subjects with acute exacerbation of asthma (FEV1 <50% predicted following 30 min of standardized treatment: 5 mg nebulized albuterol; 0." | 5.19 | Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation. ( Ferguson, I; House, SL; Johnson, K; Lewis, LM; Liu, J; Matsuda, K; Schneider, JE, 2014) |
| "To compare hyperpolarized helium-3 ((3) He) and xenon-129 ((129) Xe) MRI in asthmatics before and after salbutamol inhalation." | 5.17 | Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation. ( Kirby, M; Leary, D; Maksym, GN; McCormack, DG; Parraga, G; Starr, D; Svenningsen, S; Wheatley, A, 2013) |
| "To compare tulobuterol patch and oral salbutamol sulfate in terms of efficacy and safety in children with mild or moderate acute attack of bronchial asthma." | 5.17 | [Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study]. ( Bao, YX; Lin, Q; Liu, QH, 2013) |
| "The combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting β2 agonist, is under development as a once-daily treatment of asthma and COPD." | 5.17 | Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. ( Bateman, ED; Bleecker, ER; Busse, WW; Ellsworth, A; Jacques, L; Lötvall, J; Medley, H; O'Byrne, PM; Woodcock, A, 2013) |
| "Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma." | 5.17 | Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma. ( Aizawa, H; Fukuyama, S; Inoue, H; Komori, M; Koto, H; Matsumoto, K; Takata, S; Yoshida, M, 2013) |
| "To investigate the clinical benefits of 'add-on' therapy with GSK2190915 in combination with the inhaled corticosteroid (ICS) fluticasone propionate (FP) and the ICS/long-acting beta 2 agonist (LABA) combination FP/salmeterol in asthmatic subjects." | 5.17 | Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma. ( Clements, D; Follows, RM; Ho, SY; Snowise, NG, 2013) |
| "In a randomized, open-label, placebo-controlled, parallel group study, 66 patients with mild to moderate asthma received one of the following four treatments bid through an MDI for 42 days: mometasone furoate/formoterol (MF/F) 200 μg/10 μg, MF/F 400 μg/10 μg, fluticasone propionate/salmeterol (FP/S) 460 μg/42 μg, or placebo." | 5.17 | Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler. ( Cutler, DL; Hubbell, J; Johnson-Levonas, AO; Kantesaria, BS; Kim, K; Kosoglou, T; Miller, SD; Xu, D, 2013) |
| "Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials." | 5.17 | Predictors of response to tiotropium versus salmeterol in asthmatic adults. ( Ameredes, BT; Bleecker, ER; Boushey, HA; Calhoun, WJ; Castro, M; Cherniack, RM; Chinchilli, VM; Craig, T; Denlinger, LC; Dimango, EA; Engle, LL; Icitovic, N; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Lugogo, N; Martin, RJ; Meyers, DA; Moore, WC; Pascual, R; Peters, SP; Ramsdell, J; Sorkness, CA; Sutherland, ER; Szefler, SJ; Walter, MJ; Wasserman, SI; Wechsler, ME, 2013) |
| "Patients with asthma aged 18 to 65 years requiring high-dose inhaled corticosteroids (ICSs) (>750 μg/d of fluticasone propionate or equivalent) and long-acting β2-agonists (LABAs) (at least 100 μg/d of salmeterol or equivalent), with or without oral prednisone (≤30 mg/d), leukotriene modifiers, theophylline, or other asthma controller medications were enrolled in the Research in Severe Asthma (RISA) Trial." | 5.17 | Safety of bronchial thermoplasty in patients with severe refractory asthma. ( Armstrong, B; Chung, KF; Corris, PA; Cox, G; Laviolette, M; Niven, RM; Pavord, ID; Shargill, NS; Thomson, NC, 2013) |
| "To compare the efficacy of theophylline plus salmeterol/fluticasone propionate combination product (SFC) with SFC plus placebo in asthmatic patients." | 5.17 | Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma. ( Ding, X; Hu, S; Huang, Y; Liu, M; Nie, H; Zhang, G, 2013) |
| "To determine whether adding salmeterol or montelukast to low-dose inhaled corticosteroids (ICSs) can reduce the number of exacerbations requiring treatment with oral corticosteroids in children with uncontrolled asthma." | 5.17 | Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. ( James, M; Lenney, W; McKay, AJ; Price, D; Tudur Smith, C; Williamson, PR, 2013) |
| "The objective of this study was to investigate whether high-dose inhaled fluticasone propionate (FP), alone or in combination with salmeterol (SAL), is as effective as oral prednisolone in reducing airway inflammation and obstruction in cats with experimentally-induced acute asthma." | 5.16 | Effect of short-term oral and inhaled corticosteroids on airway inflammation and responsiveness in a feline acute asthma model. ( Clercx, C; Gustin, P; Kirschvink, N; Leemans, J; Snaps, F, 2012) |
| "Fourteen subjects with moderate asthma inhaled single doses of salmeterol (50 μg), fluticasone propionate (250 μg), salmeterol/fluticasone propionate (50/250 μg), or placebo; Qaw was measured before and serially for 240 min after drug administration." | 5.16 | Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma. ( Mendes, ES; Rebolledo, P; Wanner, A, 2012) |
| "Combination therapy with an inhaled corticosteroid (ICS) and a long-acting β(2)-agonist (LABA) in a single inhaler is the mainstay of asthma management and salmeterol/fluticasone combination (SFC) and fixed-dose formoterol/budesonide combination (FBC) are currently available in Japan; however, there is nothing to choose between the two." | 5.16 | Effect of switching from salmeterol/fluticasone to formoterol/ budesonide combinations in patients with uncontrolled asthma. ( Akamatsu, T; Chida, K; Hashimoto, D; Hayakawa, H; Ide, K; Inui, N; Kato, M; Kuroishi, S; Masuda, M; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yasui, H; Yokomura, K, 2012) |
| "Elderly patients (>60 years old) with diagnoses of severe asthma were observed over 24 months of therapy: the first 12 months using inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) and the second 12 months with oral montelukast added in two-thirds of the patients, with the remaining third representing the control group." | 5.16 | Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. ( Bozek, A; Filipowska-Gronska, A; Jarzab, J; Warkocka-Szoltysek, B, 2012) |
| "Forty steroid-naïve, symptomatic asthmatic patients, with sputum eosinophils <3%, were randomized to receive open-label salmeterol (50 µg twice a day, n = 30) or fluticasone (125 µg twice a day, n = 10) and were then assessed at 1, 3 and 6 months." | 5.16 | Transient sputum eosinophilia may occur over time in non-eosinophilic asthma and this is not prevented by salmeterol. ( Bacci, E; Bartoli, M; Cianchetti, S; Costa, F; Dente, FL; Di Franco, A; Latorre, M; Malagrinò, L; Novelli, F; Paggiaro, P; Vagaggini, B, 2012) |
| "The pentosidine levels did not significantly differ between the two asthmatic subgroups with and without airway obstruction." | 5.16 | Association of airway pentosidine levels with bronchodilator response mediated by salbutamol administration in asthmatic patients. ( Hirata, K; Kanazawa, H; Tamagaki, G, 2012) |
| "In a randomized, two-period, two-sequence crossover clinical trial, we analyzed 31 stable asthmatic children (6-18 yrs of age) on two consecutive days, who were randomly assigned to receive 100 μg of albuterol MDI through either a locally produced valved spacer or a non-valved spacer." | 5.16 | Comparison of the bronchodilating effects of albuterol delivered by valved vs. non-valved spacers in pediatric asthma. ( Castro-Rodriguez, JA; Rodriguez-Martinez, CE; Sossa-Briceño, MP, 2012) |
| "Adults with mild-to-moderate-severe persistent asthma were randomized to fluticasone/formoterol (100/10 or 250/10 μg twice daily [b." | 5.16 | Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. ( Aalbers, R; Bodzenta-Lukaszyk, A; Brusselle, G; Grothe, B; McIver, T, 2012) |
| " Patients with mild-to-moderate persistent stable asthma taking 1,000 μg/day or less beclomethasone dipropionate equivalent received 10 or 20 mg of oral propranolol followed by histamine challenge, with recovery to nebulized salbutamol (5 mg)." | 5.16 | Sensitivity of impulse oscillometry and spirometry in beta-blocker induced bronchoconstriction and beta-agonist bronchodilatation in asthma. ( Lipworth, BJ; Short, PM; Williamson, PA, 2012) |
| "Provision of a written action plan significantly increased patient adherence to inhaled and oral corticosteroids and asthma control and physicians' recommendation for maintenance fluticasone and medical follow-up, supporting its independent value in the acute-care setting." | 5.15 | Written action plan in pediatric emergency room improves asthma prescribing, adherence, and control. ( Chalut, D; Ducharme, FM; Khomenko, L; McGillivray, D; Noya, FJ; Resendes, S; Rouleau, R; Zemek, RL; Zhang, X, 2011) |
| "To compare racemic albuterol (RAC) with levalbuterol (LEV) in continuous form for the treatment of acute pediatric asthma exacerbations in the emergency department." | 5.15 | Efficacy of racemic albuterol versus levalbuterol used as a continuous nebulization for the treatment of acute asthma exacerbations: a randomized, double-blind, clinical trial. ( Bulloch, B; Garcia-Filion, P; Keahey, L; Wilkinson, M, 2011) |
| "Children with mild persistent asthma should not be treated with rescue albuterol alone and the most effective treatment to prevent exacerbations is daily inhaled corticosteroids." | 5.15 | Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. ( Bacharier, LB; Bade, E; Boehmer, SJ; Chinchilli, VM; Covar, RA; Friedman, NJ; Guilbert, TW; Heidarian-Raissy, H; Kelly, HW; Lemanske, RF; Malka-Rais, J; Martinez, FD; Mauger, DT; Mellon, MH; Morgan, WJ; Sorkness, CA; Strunk, RC; Szefler, SJ; Taussig, L; Zeiger, RS, 2011) |
| "We conducted a randomized study of one-time albuterol treatment with the AeroEclipse breath-actuated nebulizer versus standard therapy (single treatment via small-volume nebulizer or 1-hour of continuous nebulized albuterol) in pediatric asthma patients in the emergency department." | 5.15 | Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department. ( Asselin, JM; Gildengorin, V; Hawk, W; Sabato, K; Ward, P, 2011) |
| "To determine whether adiposity worsens the clinical and physiological manifestations of acute asthma and limits therapeutic effectiveness of standard treatment, we contrasted signs, symptoms, medication use, arterial oxygen saturation, peak expiratory flow rate, and the bronchodilator response to standard doses of albuterol in 90 non-obese and 90 obese asthmatics as they presented for urgent care." | 5.15 | Impact of obesity on the severity and therapeutic responsiveness of acute episodes of asthma. ( Coreno, AJ; Dickey-White, H; McFadden, ER; Seitz, RE; Skowronski, ME; Villalba, KD; Yeh, KH, 2011) |
| "In a double-blind, crossover pilot study, we randomly assigned 46 patients with asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no intervention." | 5.15 | Active albuterol or placebo, sham acupuncture, or no intervention in asthma. ( Boyd, IO; Dutile, S; Israel, E; Kaptchuk, TJ; Kelley, JM; Kirsch, I; Marigowda, G; Wechsler, ME, 2011) |
| " Patients 2 to 18 years of age with moderate to severe acute asthma were randomized to receive either a single 2-mg dose of budesonide inhalation suspension (BUD) or normal sterile saline (NSS) placebo, added to albuterol, ipratropium bromide (IB), and systemic corticosteroids (SCS)." | 5.15 | Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial. ( Chew, A; Mollen, CJ; Scarfone, RJ; Seiden, J; Upham, BD; Zorc, JJ, 2011) |
| "We sought to determine the clinical consequences of nocturnal asthma symptoms requiring albuterol (NASRAs) in children with mild-to-moderate persistent asthma outside of periods when oral corticosteroids were used for worsening asthma symptoms." | 5.15 | Most nocturnal asthma symptoms occur outside of exacerbations and associate with morbidity. ( Bacharier, LB; Graber, NJ; Horner, CC; Lemanske, RF; Mauger, D; Sorkness, CA; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2011) |
| "We analyzed baseline phenotypes and treatment failure rates (worsening asthma resulting in systemic corticosteroid use, hospitalization, emergency department visit, prolonged decrease in peak expiratory flow, increase in albuterol use, or safety concerns) in subjects participating in 10 ACRN trials (1993-2003)." | 5.15 | Impact of race on asthma treatment failures in the asthma clinical research network. ( Castro, M; Chinchilli, VM; Denlinger, L; Israel, E; Lazarus, SC; Lehman, E; Peters, SP; Sutherland, ER; Wechsler, ME, 2011) |
| "In moderate acute asthma, nebulized procaterol and nebulized salbutamol were both effective in improving PEFR and decreasing asthma score." | 5.15 | The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: a randomized, double-blind, parallel group study. ( Louisa, M; Mangunnegoro, H; Novariska, F; Setiawati, A; Wiyono, WH, 2011) |
| "Adults admitted to hospital with acute exacerbation of asthma were randomized to receive oral prednisolone 100 mg once daily or hydrocortisone 100 mg i." | 5.15 | Oral versus intravenous steroids in acute exacerbation of asthma--randomized controlled study. ( Dembla, G; Doifoide, DV; Mundle, RP; Salkar, HR, 2011) |
| "All patients between 6 and 17 years of age who presented to a pediatric emergency department in the winter months with acute exacerbation of bronchial asthma were given a combination of nebulized albuterol and ipratropium with warmed or room temperature humidified oxygen." | 5.14 | Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months. ( Hassen, GW; Nibhanipudi, K; Smith, A, 2009) |
| "We compared the systemic and clinical effects of ciclesonide (CIC) and fluticasone propionate (FP) administered, in addition to CIC 160 microg x day(-1) and salmeterol 50 microg twice daily, in 32 patients with persistent asthma using a randomised double-blind, placebo-controlled, double-dummy, five-period crossover design." | 5.14 | Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. ( Derom, E; Engelstätter, R; Joos, GF; Kaufman, JM; Louis, R; Tiesler, C, 2009) |
| "To evaluate the efficacy of add-on montelukast on asthma control and allergic rhinitis symptoms in asthmatic patients still symptomatic with chronic treatment with inhaled corticosteroid and long-acting beta(2) agonist (ICS/LABA), irrespective of the dose." | 5.14 | Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. ( Dramaix, M; Herbots, E; Korn, D; Peché, R; Potvin, E; Van den Brande, P, 2009) |
| "Eighteen patients with mild allergic asthma who did not use any regular antiasthmatic therapy inhaled the long-acting beta(2)-agonist salmeterol for 2 weeks followed by 2 weeks of combination therapy with salmeterol and the corticosteroid fluticasone." | 5.14 | Adverse effects of salmeterol in asthma: a neuronal perspective. ( Bratke, K; Edner, A; Kuepper, M; Lindner, Y; Lommatzsch, M; Virchow, JC, 2009) |
| " This double-blind, parallel group, non-inferiority study compared lung function and asthma control, based on Global Initiative for Asthma guidelines, in children receiving either salmeterol/fluticasone propionate (SFC) 50/100 microg bd (n = 160) or fluticasone propionate (FP) 200 microg bd (n = 161) for 12 wks." | 5.14 | Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. ( Anderton, S; Attali, V; Bennedbaek, O; de Blic, J; Desfougeres, JL; Hofman, J; Klink, R; Ogorodova, L; Poterre, M; Sidorenko, I; Valiulis, A, 2009) |
| "The modified adenosine infusion protocol with salbutamol premedication can be used in patients with asthma." | 5.14 | Pharmacological stress myocardial perfusion scintigraphy: use of a modified adenosine protocol in patients with asthma. ( Notghi, A; Smith, NB; Sundram, F, 2009) |
| "To assess asthma-related quality of life after treatment with combination fluticasone propionate and salmeterol delivered via hydrofluoroalkane 134a metered-dose inhaler compared with the individual components alone." | 5.14 | Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. ( Andersen, LB; Edin, HM; Ho, SY; Ortega, HG; Schoaf, L; Scott-Wilson, CA, 2009) |
| "Salmeterol and fluticasone propionate combination (SFC) provides better asthma control than fluticasone propionate (FP) alone, however, little is known on the effects of differential treatments on airway function and inflammation in patients with mild asthma." | 5.14 | Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma. ( Handa, H; Hoshino, M; Miyazawa, T, 2009) |
| "To assess the use of high-dose continuous levalbuterol (LEV), the single active (R)-enantiomer of racemic albuterol (RAC), in the treatment of status asthmaticus." | 5.14 | High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. ( Andrews, T; Chew, A; McGintee, E; Mittal, MK; Pawlowski, N; Tyler, L; Zhang, X; Zorc, JJ, 2009) |
| "In a non-randomized, non-placebo, single-blind, fixed sequence, pilot study, we evaluated 22 non-smoking, stable, moderate-severe adult asthmatics on maintenance inhaled fluticasone 250 microg/salmeterol 50 microg (F/S) via MDI bid> or =1 yr, with add-on oral zileuton 600 mg qid." | 5.14 | Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. ( Gelb, AF; Shinar, C; Simmons, M; Taylor, CF, 2009) |
| "To reduce symptoms and emergency department (ED) visits, the National Asthma Education and Prevention Program (NAEPP) guidelines recommend early treatment of acute asthma symptoms with albuterol and oral corticosteroids." | 5.14 | Home use of albuterol for asthma exacerbations. ( Freiner, D; Garbutt, JM; Highstein, GR; Nelson, KA; Smith, SR; Strunk, RC, 2009) |
| " Future exacerbations were somewhat predicted by asthma symptoms, albuterol use, previous exacerbations, and lung function, whereas maximum symptom days were predicted, also to a modest extent, by symptoms, albuterol use, and previous exacerbations, but not lung function." | 5.14 | Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence. ( Bloomberg, GR; Brown, M; Busse, WW; Calatroni, A; Chmiel, JF; David, G; Gergen, PJ; Gruchalla, RS; Kumar, R; Lamm, C; Liu, AH; Matsui, E; Sampson, HA; Smartt, E; Sorkness, CA; Steinbach, SF; Stone, KD; Szefler, SJ, 2009) |
| "Retrospective pharmacogenetic studies have questioned whether patients with asthma who are arginine homozygous at the beta(2-)adrenergic receptor (position 16) should use long-acting beta-agonists." | 5.14 | Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. ( Anderson, WH; Bleecker, ER; Corren, J; Emmett, AH; Kraft, M; Meyers, DA; Nelson, HS; Ortega, HG; Yancey, SW, 2010) |
| "Inhaled corticosteroids, such as fluticasone propionate (FP) and ciclesonide (CIC), are commonly used for the treatment of asthma." | 5.14 | Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ( Derendorf, H; Derom, E; Lahu, G; Nave, R; Xu, J, 2010) |
| "We randomly assigned 182 children (6 to 17 years of age), who had uncontrolled asthma while receiving 100 microg of fluticasone twice daily, to receive each of three blinded step-up therapies in random order for 16 weeks: 250 microg of fluticasone twice daily (ICS step-up), 100 microg of fluticasone plus 50 microg of a long-acting beta-agonist twice daily (LABA step-up), or 100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up)." | 5.14 | Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. ( Bacharier, LB; Boehmer, SJ; Covar, RA; Guilbert, TW; Jackson, DJ; Larsen, G; Lemanske, RF; Martinez, FD; Mauger, DT; Morgan, WJ; Moss, MH; Sorkness, CA; Spahn, JD; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2010) |
| "We investigated if a higher proportion of adults with previously uncontrolled asthma can achieve total control when given salmeterol/fluticasone propionate (50/250 microg) bid and compliance enhancement training (CET) compared to those given medication alone." | 5.14 | Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: a randomised controlled trial. ( Backer, V; Claudius, BK; Dahl, R; Harving, H; Hellquist, B; Høgholm, A; Jøhnk, IK; Siersted, HC; Tamm, M; Ulrik, CS, 2009) |
| "To evaluate the effect of montelukast, 5 mg, or inhaled salmeterol, 50 microg, added to inhaled fluticasone in reducing the maximum percentage decrease in forced expiratory volume in 1 second (FEV1) after a standardized exercise challenge and response to rescue bronchodilation with albuterol in children aged 6 to 14 years with persistent asthma and exercise-induced bronchoconstriction (EIB)." | 5.14 | Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. ( Aristizabal, G; Fogel, RB; Gaile, S; Loeys, T; Noonan, G; Polos, PG; Rosario, N; Smugar, SS, 2010) |
| "Indacaterol is a novel, inhaled once-daily ultra-long-acting beta-2 agonist under development as a fixed-dose combination with an inhaled corticosteroid (ICS) for asthma treatment." | 5.14 | 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. ( Adachi, M; Emery, C; Haida, M; Higgins, M; Hosoe, M; Ichinose, M; Kanada, S; Kramer, B; Sugihara, N, 2010) |
| "To evaluate whether salmeterol/fluticasone propionate (SFP), 50/100 μg twice a day, is noninferior regarding symptom control compared with fluticasone propionate (FP), 200 μg twice a day Diskus in children with symptomatic asthma." | 5.14 | Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. ( Brackel, HJ; Duiverman, EJ; Gerrits, GP; Hop, WC; Vaessen-Verberne, AA; van den Berg, NJ; van Nierop, JC, 2010) |
| "We were unable to demonstrate superiority of adding ipratropium to levalbuterol in alleviating obstruction as measured by FEV₁ or in decreasing the need for hospitalization among adult patients presenting to the ED with acute severe asthma exacerbation." | 5.14 | Levalbuterol versuss levalbuterol plus ipratropium in the treatment of severe acute asthma. ( Cydulka, RK; Emerman, CL; Muni, A, 2010) |
| "In a three-way, double-blind, triple-dummy crossover trial involving 210 patients with asthma, we evaluated the addition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease but not asthma) to an inhaled glucocorticoid, as compared with a doubling of the dose of the inhaled glucocorticoid (primary superiority comparison) or the addition of the LABA salmeterol (secondary noninferiority comparison)." | 5.14 | Tiotropium bromide step-up therapy for adults with uncontrolled asthma. ( Ameredes, BT; Bleecker, ER; Boushey, HA; Calhoun, WJ; Castro, M; Cherniack, RM; Chinchilli, VM; Craig, T; Denlinger, L; DiMango, EA; Engle, LL; Fahy, JV; Icitovic, N; Israel, E; Jarjour, N; Kazani, SD; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Lugogo, N; Martin, RJ; Meyers, DA; Moore, WC; Pascual, R; Peters, SP; Ramsdell, J; Sorkness, CA; Sutherland, ER; Szefler, SJ; Walter, MJ; Wasserman, SI; Wechsler, ME, 2010) |
| "To compare the cost-effectiveness of budesonide/formoterol in a single inhaler used as Maintenance and Reliever Therapy (SMART) versus fixed higher-dose budesonide/formoterol plus as-needed terbutaline reliever (FHDBF) or fixed dose fluticasone/salmeterol plus as-needed terbutaline reliever (FDFS) in controlling asthma in adults and adolescents." | 5.13 | Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation. ( FitzGerald, JM; Miller, E, 2008) |
| "GOAL was a 1-year, randomized, stratified, double-blind study of 3421 patients with uncontrolled asthma, which compared salmeterol/fluticasone propionate combination with fluticasone propionate in achieving two composite, guideline-based measures of control: totally controlled and well-controlled asthma." | 5.13 | Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. ( Bateman, ED; Bousquet, J; Busse, WW; Clark, TJ; Gibbs, M; Gul, N; Pedersen, S, 2008) |
| "The National Heart, Lung, and Blood Institute guideline recommends that dosing racemic albuterol be administered every 1 to 4 hours for treating patients with asthma or chronic obstructive pulmonary disease (COPD) in the hospital." | 5.13 | Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. ( Andrews, WT; Ciubotaru, RL; Claus, R; Donohue, JF; Hanania, NA; Noe, L; Pasta, DJ; Roach, J; Schaefer, K, 2008) |
| "This study compared the short-term safety and efficacy of cumulative doses of levalbuterol HFA MDI and racemic albuterol HFA MDI in asthmatic subjects." | 5.13 | A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. ( Baumgartner, RA; Corren, J; Goodwin, E; Hanrahan, JP; McVicar, WK; Nair, P; Pleskow, WW; Tripp, K, 2008) |
| "Based on these results, neither azithromycin nor montelukast is likely to be an effective inhaled corticosteroid-sparing alternative in children with moderate-to-severe persistent asthma." | 5.13 | Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. ( Bacharier, LB; Chinchilli, VM; Covar, R; Guilbert, T; Krawiec, M; Larsen, G; Lemanske, RF; Martinez, FD; Mauger, DT; Morgan, WJ; Paul, IM; Phillips, BR; Sorkness, CA; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2008) |
| "We analyzed the effects of time, albuterol, and budesonide on FEV(1), FEV(1)/forced vital capacity (FVC) ratio, forced expiratory flow from 25% to 75% of expired volume, and Mead's SR both early (between 75% and 50% of FVC, SR61) and late (between 75% and 50% of FVC, SR35) in exhalation in the Childhood Asthma Management Program cohort at baseline, 4 months, and the end of the study in participants who received either inhaled placebo or budesonide twice daily." | 5.13 | Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma. ( Patel, AC; Strunk, RC; Tonascia, J; Van Natta, ML; Wise, RA, 2008) |
| "Asthmatics treated adequately with ICS (750-1000 mcg ICS daily) were randomised to receive ICS (fluticasone propionate) + LABA (salmeterol) (500 mcg/50 mcg bd) or ICS alone (500 mcg bd)." | 5.13 | Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11. ( Dahl, R; Harving, H; Heinig, JH; Hoffmann, HJ; Nielsen, LP, 2008) |
| "In 10 asthmatic and 10 healthy subjects, airway blood flow and FEV(1) were measured before and 30 minutes after fluticasone or placebo inhalation and 15 minutes after the subsequent inhalation of racemic albuterol (0." | 5.13 | Rapid corticosteroid effect on beta(2)-adrenergic airway and airway vascular reactivity in patients with mild asthma. ( Campos, M; Horvath, G; Mendes, ES; Wanner, A, 2008) |
| "The efficacy and safety of twice-daily inhaled salmeterol/fluticasone propionate combination (SFC) therapy have been well established in the treatment of adults and adolescents with asthma." | 5.13 | Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids. ( Chuchalin, A; Frith, L; Jacques, L, 2008) |
| "Albuterol reduces lower esophageal sphincter (LES) pressure in normal volunteers, although the effects of albuterol on esophageal function in asthmatic patients are not known." | 5.13 | The effects of nebulized albuterol on esophageal function in asthmatic patients. ( DesBiens, J; Lacy, BE; Liu, MC; Mathis, C, 2008) |
| "Although albuterol remains the standard treatment for asthma in the emergency department, formoterol fumarate may be more advantageous, with its rapid and long-lasting bronchodilation." | 5.13 | Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. ( Chou, V; Lee-Wong, M; Ogawa, Y, 2008) |
| " Two groups followed a BHR treatment strategy (based on clinical parameters [lung function, asthma symptoms, and bronchodilator use] and BHR) and were treated with either fluticasone propionate/salmeterol (FSC(BHR) group) or fluticasone propionate (FP(BHR) group) (n=156 each)." | 5.13 | Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? ( Andersen, L; Dorinsky, P; Koenig, SM; Murray, JJ; Prillaman, B; Stauffer, J; Wolfe, J; Yancey, S, 2008) |
| "To compare the efficacy and safety of the salmeterol/fluticasone propionate combination product with concurrent sustained release theophylline plus fluticasone propionate in adult Japanese patients with persistent asthma." | 5.13 | Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients. ( Adachi, M; Aizawa, H; Ishihara, K; Nakashima, M; Ohta, K; Sano, Y; Taniguchi, H, 2008) |
| "An outpatient, randomized, double-blind, single-dose, crossover study in adult asthmatics with moderate-to-severe obstruction despite treatment with inhaled corticosteroids (ICS) was conducted comparing the fixed combination of ipratropium and albuterol (IB+ALB) to albuterol alone (ALB)." | 5.13 | Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. ( Cassino, C; Conoscenti, CS; Gelb, AF; Johnson, P; Karpel, J; Wise, RA, 2008) |
| "We investigated 28 single nucleotide polymorphisms in CRHR2 for associations with acute bronchodilator response to albuterol in 607 Caucasian asthmatic patients recruited as part of the Childhood Asthma Management Program." | 5.13 | Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. ( Hanrahan, JP; Irvin, CG; Lange, C; Lasky-Su, J; Lazarus, R; Lima, JJ; Litonjua, AA; Poon, AH; Tantisira, KG; Weiss, ST; Xu, J, 2008) |
| " Other measures of asthma control included peak expiratory flow, asthma symptoms, and albuterol use." | 5.13 | Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. ( Bailey, W; Castro, M; Dransfield, M; Matz, J; Ortega, H; White, M; Yancey, S, 2008) |
| "In this randomized controlled, double blind study, 30 asthmatics were challenged with histamine until forced expiratory volume in 1s (FEV(1)) fell with > or =20%." | 5.12 | Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchusobstruction. ( De Peuter, S; Lemaigre, V; Smets, A; Van den Bergh, O; Verleden, GM, 2006) |
| "The aim of this study was to assess asthma control using salmeterol plus fluticasone propionate (FP) in combination (SFC) versus salmeterol or FP as monotherapy in patients with mild to moderate asthma." | 5.12 | Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. ( James, M; Jonsson, AC; Larsson, LG; Lindberg, A; Lundbäck, B; Pétavy, F; Rönmark, E, 2006) |
| "Therefore, we compared the effects of beclomethasone dipropionate (BDP) on the degree of BHR to inhaled histamine and NKA in a double-blind, controlled, cross-over study of asthmatic patients." | 5.12 | Beclomethasone dipropionate attenuates airways hyperresponsiveness to neurokinin A and histamine in asthma. ( Arcidiacono, G; Ciamarra, I; Crimi, N; Polosa, R; Prosperini, G, 2006) |
| " Therefore, a 12-week randomized double-blind placebo-controlled clinical study was conducted to investigate the efficacy of a plant-based formulation (DCBT4567-Astha-15) in comparison with oral salbutamol, salbutamol + theophylline and a matching placebo in patients with reversible asthma." | 5.12 | Plant-based formulation for bronchial asthma: a controlled clinical trial to compare its efficacy with oral salbutamol and theophylline. ( Deivanayagam, CN; Krishnarajasekar, OR; Lakshmisubramanian, S; Murali, PM; Nalini, K; Perumal, T; Rajasekaran, S, 2006) |
| "Suppressing the release of pro-inflammatory mediators may play a role, at least in part, in the beneficial effects of aminophylline in the treatment of acute exacerbations in asthma." | 5.12 | Aminophilline suppress the release of chemical mediators in treatment of acute asthma. ( Nakano, J; Ohbayashi, O; Ohta, K; Yamamura, K; Yamashita, N; Yano, T; Yoshihara, H, 2006) |
| "A prospective blinded, randomized controlled trial was undertaken to compare the initial response of albuterol nebulized in heliox or control in the treatment of moderately severe asthma in children presenting to a pediatric ED." | 5.12 | Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial. ( Brown, L; Kim, TY; Minasyan, L; Rivera, ML; Stewart, GM, 2006) |
| "To compare the safety of salmeterol xinafoate or placebo added to usual asthma care." | 5.12 | The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. ( Bleecker, ER; Dorinsky, PM; Nelson, HS; Weiss, ST; Yancey, SW, 2006) |
| "After a 4 week fluticasone run-in period, 54 patients with allergic asthma were randomised to receive twice daily treatment with fluticasone 250 microg with or without salmeterol 50 microg for 1 year in a double blind, parallel group design (total daily dose of fluticasone 500 microg in both treatment groups)." | 5.12 | Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. ( Jansen, HM; Koopmans, JG; Lutter, R; van der Zee, JS, 2006) |
| "Bronchial epithelium was obtained from asthmatic and non-asthmatic normal subjects before and after segmental allergen challenge, and after regularly inhaled albuterol, in three separate protocols." | 5.12 | Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and beta2-agonist use. ( Batra, V; Cirelli, R; Foster, GC; Hastie, AT; Hawkins, GA; Peters, SP; Rybinski, KA; Wu, M; Zangrilli, JG, 2006) |
| "This study compared the efficacy and tolerability of the combination of fluticasone propionate (FP) and salmeterol (SAL) delivered via a single hydrofluoroalkane (HFA) 134a metered-dose inhaler (MDI) with those of its 2 components alone delivered via a chlorofluorocarbon (CFC) MDI and placebo (PLA) delivered via HFA MDI in adolescent and adult patients with persistent asthma that was not controlled by medium doses (equivalent to FP 440-660 microg/d) of inhaled corticosteroids (ICSs)." | 5.12 | Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. ( Dorinsky, P; Ellsworth, A; House, K; Nathan, RA; Rooklin, A; Schoaf, L; Scott, C, 2006) |
| "Although frequently used to treat status asthmaticus in children, intravenous (IV) terbutaline has not been shown to decrease hospital length of stay (LOS)." | 5.12 | Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus. ( Carroll, CL; Schramm, CM, 2006) |
| "To assess the effectiveness of distinct salbutamol and terbutaline doses delivered via an MDI with spacer for the treatment of acute asthma in the pediatric emergency department." | 5.12 | [Bronchodilators via metered-dose inhaler with spacer in the pediatric emergency department: what is the dosage?]. ( Benito Fernández, J; González Díaz, C; Landa Garriz, M; Mintegi Raso, S; Trebolazabala Quirante, N, 2006) |
| "2 mg of salbutamol on histamine-induced bronchoconstriction was assessed in 101 steroid-naïve asthmatic subjects." | 5.12 | Determinants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction. ( Kiviniemi, V; Koskela, HO; Purokivi, MK; Taivainen, AH; Tukiainen, HO, 2006) |
| "Based on the assumption that bronchial asthma has not only inflammatory, but also certain neurogenic paroxysmal mechanism and pathophysiological links with other non-epileptic paroxysmal inflammatory diseases--migraine and trigeminal neuralgia, we decided to investigate efficacy of antiepileptic drug carbamazepine in patients with moderate persistent or severe asthma." | 5.12 | Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine. ( Lomia, M; Pruidze, M; Tchelidze, T, 2006) |
| " Additional endpoints included asthma symptom scores, daily albuterol use, and safety, including hypothalamic-pituitary-adrenal (HPA) axis function." | 5.12 | Once-daily ciclesonide in children: efficacy and safety in asthma. ( Gelfand, EW; Georgitis, JW; Noonan, M; Ruff, ME, 2006) |
| "The Gaining Optimal Asthma ControL (GOAL) study has shown the superiority of a combination of salmeterol/fluticasone propionate (SFC) compared with fluticasone propionate alone (FP) in terms of improving guideline defined asthma control." | 5.12 | Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. ( Bateman, ED; Bousquet, J; Briggs, AH; Busse, WW; Clark, TJ; Pedersen, SE; Wallace, MV, 2006) |
| "This multicenter, randomized, double-blind trial compared nebulized levalbuterol (Lev) and racemic albuterol (Rac) in the treatment of acute asthma." | 5.12 | A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. ( Baumgartner, RA; Claus, R; Emerman, C; Hanania, NA; Hanrahan, JP; Nowak, R; Parsey, MV; Schaefer, K, 2006) |
| "To investigate the safety and effectiveness of a 4-mg tablet of oral montelukast in addition to short-acting beta2-agonist bronchodilator as the initial treatment in mild to moderate asthma exacerbations in children between 2 and 5 years old." | 5.12 | Oral montelukast treatment of preschool-aged children with acute asthma. ( Bakirtas, A; Degim, T; Harmanci, K; Turktas, I, 2006) |
| "Oral magnesium supplementation helped to reduce bronchial reactivity to methacholine, to diminish their allergen-induced skin responses and to provide better symptom control in pediatric patients with moderate persistent asthma treated with inhaled fluticasone." | 5.12 | Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial. ( Condino-Neto, A; Gontijo, LS; Gontijo-Amaral, C; Ribeiro, JD; Ribeiro, MA, 2007) |
| "Compared with placebo use, fluticasone propionate, 88 microg administered twice daily, significantly reduced asthma exacerbations, asthma symptoms, and rescue albuterol use and was well tolerated, with no clinically relevant systemic effects, as measured by growth velocity or 12-hour urinary cortisol excretion levels." | 5.12 | Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. ( Baker, JW; Blake, KV; Crim, C; Faris, MA; Kim, KT; Scott, CA; Wasserman, RL; Wu, W, 2006) |
| "This study investigated whether clinical asthma control and airway inflammation could be maintained after switching therapy from medium-dose fluticasone propionate (FP) to low-dose FP administered with the long-acting beta2-agonist (LABA) salmeterol." | 5.12 | Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. ( Davis, WB; Djukanovic, R; Doherty, DE; Dorinsky, PM; Edwards, LD; Hamid, Q; Israel, E; Jarjour, NN; Kavuru, MS; Koenig, SM; Laviolette, M; Moore, WC; Ramsdell, JW; Reilly, DS; Stauffer, JL; Tashkin, DP; Wilson, SJ; Yancey, SW, 2006) |
| "In this study, levalbuterol administered via MDI significantly improved airway function in comparison with placebo in asthmatic children aged 4-11 years with a safety profile that was similar to placebo." | 5.12 | Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. ( Baumgartner, RA; Berger, WE; Milgrom, H; Parsey, MV; Skoner, DP; Tripp, K, 2006) |
| "To characterize the population pharmacokinetics (PK) of (R)- and (S)-albuterol in pediatric asthmatics using a model that supports a sparse blood sampling strategy." | 5.12 | Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. ( Baumgartner, RA; Grasela, T; Hsu, R; Maier, G; Rubino, C, 2007) |
| "To investigate the duration of bronchodilator action of a salmeterol/fluticasone combination (SFC) inhaler when administered in the evening to children with asthma." | 5.12 | Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma. ( Aldington, S; Beasley, R; Weatherall, M; Williams, M, 2006) |
| "Patients with inadequately controlled asthma on inhaled corticosteroid (400 to 1,600 microg/day chlorofluorocarbon beclomethasone equivalent) were treated with concomitant salmeterol (n = 18) or sustained-release tulobuterol (patch) (n = 18), or the inhaled corticosteroid dose was doubled (add-on) (n = 13) to compare clinical efficacy." | 5.12 | Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids. ( Fujimoto, K; Komatsu, Y; Kubo, K; Urushihata, K; Yasuo, M, 2006) |
| "The purpose of this study was to investigate the efficacy and safety of salmeterol combined with high-dose ICSs plus theophylline in severe asthma." | 5.12 | Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline. ( Aizawa, H; Fukuyama, S; Inoue, H; Kanaya, A; Komori, M; Matsumoto, K; Matsumoto, T; Matsumura, M; Moriwaki, A; Nakanishi, Y; Nakano, T; Tsuda, M; Yoshida, M, 2007) |
| "We sought to determine whether the combination of the LTRA montelukast and the LABA salmeterol could provide an effective therapeutic strategy for asthma." | 5.12 | Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. ( Boushey, HA; Chinchilli, VM; Craig, TJ; Deykin, A; DiMango, E; Fahy, JV; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Leone, F; Martin, RJ; Pesola, GR; Peters, SP; Sorkness, CA; Szefler, SJ; Wechsler, ME, 2007) |
| " In an open-label study at 38 outpatient centres, patients > or =12 years old with asthma or chronic obstructive pulmonary disease (COPD) received two actuations of fluticasone propionate/salmeterol 125/25 microg (115/21 microg ex-actuator) hydrofluoroalkane (ADVAIR) HFA) via MDI with counter twice a day until all 120 actuations were completed." | 5.12 | Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfaction. ( Carranza-Rosenzweig, J; Crim, C; Lincourt, WR; Locantore, NW; Sheth, K; Wasserman, RL, 2006) |
| "Recent studies suggest that there might be an association between albuterol use and worsening asthma in patients homozygous for arginine (Arg/Arg) at codon 16 of the beta-receptor." | 5.12 | Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. ( Anderson, WH; Baitinger, LA; Bleecker, ER; Dorinsky, PM; Edwards, LD; Klotsman, M; Yancey, SW, 2006) |
| "Multiple studies have examined adding nebulized ipratropium bromide to intermittent albuterol for the treatment of acute asthma." | 5.12 | A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma. ( Lavery, RF; Lebowitz, J; Moore, T; Reischel, U; Salo, D; Tuel, M, 2006) |
| "Current guidelines recommend repeated doses of albuterol for the emergency treatment of acute asthma." | 5.12 | The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. ( Bag, R; Dickey, BF; Hanania, NA; Miller, CT; Moore, RH; Sharafkhaneh, A; Zimmerman, JL, 2007) |
| "To evaluate the efficacy and tolerability of fluticasone propionate (FP) hydrofluoroalkane (HFA) in children age 1 to < 4 years with asthma." | 5.12 | Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. ( Ceruti, E; Crim, C; Kleha, JF; Maspero, JF; Mehta, R; Qaqundah, PY; Scott, CA; Sugerman, RW; Wu, W, 2006) |
| "Both fluticasone monotherapy and PACT combination achieved greater improvements in asthma control days than montelukast." | 5.12 | Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. ( Bacharier, LB; Bloomberg, GR; Boehmer, SJ; Chinchilli, VM; Covar, RA; Guilbert, TW; Heldt, G; Larsen, G; Lemanske, RF; Martinez, FD; Mauger, DT; Mellon, MH; Morgan, WJ; Moss, MH; Sorkness, CA; Spahn, JD; Strunk, RC; Szefler, SJ; Taussig, LM; Zeiger, RS, 2007) |
| " Thirty-six patients with persistent mild bronchial asthma were treated with the leukotriene receptor antagonist montelukast, administered once a day for 4 weeks." | 5.12 | Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma. ( Hajduch, M; Janostáková, A; Jarmila, S; Kopriva, F; Zápalka, M, 2006) |
| "To compare in a group of doctor-diagnosed patients with asthma or COPD, the effects of a lower dose of fluticasone in a combination product with salmeterol with conventional treatment (i." | 5.12 | Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD. ( Albers, JM; Costongs, RJ; Schermer, TR; Verblackt, HW; Westers, P, 2007) |
| "Sixty-four patients with persistent asthma receiving 200 to 800 microg of fluticasone propionate daily were enrolled in this switchover study." | 5.12 | Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. ( Kita, H; Kobayashi, Y; Kudou, M; Yasuba, H, 2007) |
| "We randomly assigned 500 patients with asthma that was well controlled by inhaled fluticasone (100 microg twice daily) to receive continued fluticasone (100 microg twice daily) (169 patients), montelukast (5 or 10 mg each night) (166 patients), or fluticasone (100 microg) plus salmeterol (50 microg) each night (165 patients)." | 5.12 | Randomized comparison of strategies for reducing treatment in mild persistent asthma. ( Anthonisen, N; Castro, M; Holbrook, JT; Irvin, CG; Peters, SP; Smith, LJ; Wise, RA, 2007) |
| " After a 4-week run-in, patients with mild asthma were randomly assigned to receive one of four inhaled treatments: placebo twice daily plus 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler as needed (as-needed combination therapy); placebo twice daily plus 100 microg of albuterol as needed (as-needed albuterol therapy); 250 microg of beclomethasone twice daily and 100 microg of albuterol as needed (regular beclomethasone therapy); or 250 microg of beclomethasone and 100 microg of albuterol in a single inhaler twice daily plus 100 microg of albuterol as needed (regular combination therapy)." | 5.12 | Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. ( Canonica, GW; Crimi, N; Fabbri, LM; Maestrelli, P; Morelli, P; Nicolini, G; Olivieri, D; Paggiaro, P; Papi, A; Pozzi, E; Vignola, AM, 2007) |
| "This study compared the effect of inhaled fluticasone propionate (FP) with the combination of salmeterol/fluticasone propionate (SFC) on lung function parameters in patients with mild asthma." | 5.12 | Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. ( Borrill, ZL; Houghton, CM; Langley, SJ; Lawson, N; Singh, D; Wixon, CL; Woodcock, A; Yoxall, S, 2007) |
| "To identify the asthma patients, on short-acting beta2-agonists alone, who would benefit from initial maintenance therapy (IMT) with salmeterol/fluticasone (SFC) propionate 50/100 microg bd compared with fluticasone propionate (FP) 100 microg bd alone." | 5.12 | Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 microg bd versus fluticasone propionate 100 microg bd alone in patients with persistent asthma: integrated analysis of four randomised trials. ( Barnes, NC; Bateman, ED; Goldfrad, C; Jacques, L, 2007) |
| " After a 2-week run-in period, 228 patients with moderate to severe asthma were randomized to a 12-week treatment with either beclomethasone 100 microg plus formoterol 6 microg or fluticasone 125 microg plus salmeterol 25 microg, both delivered two inhalations b." | 5.12 | Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. ( Fabbri, LM; Nicolini, G; Paggiaro, P; Papi, A; Vignola, AM, 2007) |
| "The effect of ethnicity on the efficacy of salmeterol (S)+fluticasone propionate (FP) has not been examined in Japanese and Caucasian asthmatics." | 5.12 | Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics. ( Hashimoto, K; Kawai, M; Kempsford, R; Lötvall, J; Pullerits, T; Takaori, S; Takemoto, Y, 2007) |
| "During the Gaining Optimal Asthma controL study, 3416 patients with uncontrolled asthma were randomized to receive salmeterol/fluticasone propionate combination (SFC) or fluticasone propionate (FP) for 1 year." | 5.12 | Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. ( Bateman, ED; Bousquet, J; Busse, WW; Clark, TJ; Pedersen, SE; Yoxall, S, 2007) |
| "This study compared the bronchodilator efficacy and safety of indacaterol with placebo, salbutamol and salmeterol, in patients with persistent asthma, at single therapeutic and supratherapeutic doses." | 5.12 | Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. ( Barbier, M; Brookman, LJ; Elharrar, B; Fuhr, R; Knowles, LJ; Pascoe, S, 2007) |
| "To examine the long-term safety of levalbuterol hydrofluoroalkane (HFA) vs racemic albuterol HFA administered via metered-dose inhaler (MDI) in patients with stable asthma." | 5.12 | Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. ( Baumgartner, RA; D'Urzo, A; Hamilos, DL; Levy, RJ; Marcus, M; McVicar, WK; Parsey, M; Tripp, K, 2007) |
| "Our objective was to evaluate the efficacy and safety of two doses of fluticasone propionate (FP) in young children with recurrent wheezing and risk factors for asthma." | 5.11 | Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. ( Bergadá, I; Colom, AJ; Kofman, CD; Maffey, AF; Teper, AM; Vidaurreta, SM, 2004) |
| " 365 symptomatic patients with moderate asthma aged >18 years and receiving ICS in a dose equivalent to 1000 microg beclomethasone propionate per day were randomly assigned to receive either salmeterol xinafoate (50 microg) and fluticasone propionate (250 microg) in a single dry powder inhaler (Diskus) or 500 microg FP twice daily." | 5.11 | Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. ( Bergmann, KC; Braun, R; Lindemann, L; Steinkamp, G, 2004) |
| "Adjustable maintenance dosing with budesonide/formoterol provides more effective asthma control by reducing exacerbations and reliever medication usage compared with fixed-dose salmeterol/fluticasone." | 5.11 | Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. ( Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004) |
| "To determine whether a higher dose of albuterol is required to normalize lung function during nocturnal asthma." | 5.11 | Response to inhaled albuterol during nocturnal asthma. ( Ahrens, R; Beaty, R; Harman, EM; Hendeles, L; Stevens, G, 2004) |
| "A prospective, randomized, double blinded study was conducted to determine whether a combination of nebulized magnesium sulfate and albuterol as a single dose adds any benefit in management of children with mild to moderate asthma when compared to nebulized albuterol with saline." | 5.11 | Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma. ( Haritos, D; Mahajan, P; Rosenberg, N; Thomas, R, 2004) |
| " Montelukast significantly reduced blood eosinophil counts compared with salmeterol, whereas salmeterol significantly increased prealbuterol forced expiratory volume in 1 second, asthma-specific quality of life, morning peak expiratory flow rate, and decreased nocturnal awakenings compared with montelukast." | 5.11 | Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. ( Bird, SR; Edelman, JM; Friedman, B; Hustad, CM; Ilowite, J; Kerwin, E; Webb, R, 2004) |
| "The variability of asthma rescue-free days, asthma symptoms, albuterol use, medical resource use, and exercise Limitations among patients with documented mild persistent asthma was compared between the month before study enrollment and the last 2 weeks of the run-in period." | 5.11 | Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study. ( Baker, JW; Bird, S; Edelman, J; Hustad, C; Kaplan, MS; Pearlman, DS; Schatz, M; Zeiger, RS, 2004) |
| "The effects of high-dose fluticasone propionate therapy on dynamic cortisol stimulation in severe asthma are unknown." | 5.11 | Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. ( Bates, CE; Cowan, LM; Currie, GP; Lee, DK; Lipworth, BJ; McFarlane, LC, 2004) |
| "To determine whether initiation of maintenance treatment with the salmeterol (S)/fluticasone propionate (FP) combination (Seretide/Viani/Advair) is more effective than inhaled steroid alone in patients with asthma symptomatic on short-acting bronchodilator alone." | 5.11 | Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. ( Luckow, A; Strand, AM, 2004) |
| "We report a 4 yr follow up study of seven asthmatic children with chronic persistent asthma, high-residual volume and low-density areas at high-resolution computerized tomography after treatment with salmeterol and fluticasone." | 5.11 | Montelukast and airway remodeling in children with chronic persistent asthma: an open study. ( Boner, AL; Caramella, D; De Marco, E; Pietrobelli, A; Pifferi, M; Ragazzo, V, 2004) |
| "In patients symptomatic while taking short-acting beta2-agonists alone, initial maintenance treatment of the 2 main components of asthma, inflammation and smooth muscle dysfunction, with fluticasone propionate and salmeterol, 100 and 50 microg, administered via the Diskus results in greater improvements in overall asthma control compared with treatment of either component alone." | 5.11 | Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. ( Baitinger, L; Blake, K; Dorinsky, P; House, K; Murray, J; Rosenthal, R; Somerville, L; VanderMeer, A, 2004) |
| "To compare the clinical efficacy and side effects of terbutaline and salbutamol administered by metered dose inhaler and holding chamber in the mild to moderate acute exacerbations of asthma in children." | 5.11 | Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma. ( Chandra, P; Kabra, SK; Lodha, R; Paliwal, L, 2004) |
| "The goal of this study was to evaluate the efficacy, tolerability, and effect on asthma-related quality of life (QOL) of a long-acting beta(2)-adrenoreceptor agonist, formoterol, delivered via multidose DPI, compared with albuterol delivered via pMDI or placebo in adolescents and adults with persistent asthma." | 5.11 | Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, p ( Andriano, K; Busse, W; Lavecchia, C; Levine, B; Yegen, U, 2004) |
| "The present study aimed to investigate whether a fixed combination of salmeterol and fluticasone (SFC) from a single inhaler provides sufficient asthma control comparable to that achieved with standard treatment (inhaled steroid in a dose of 1,000 mcg BDP- (beclomethasone dipropionate) equivalent plus a LABA and/or theophylline and/or montelukast)." | 5.11 | [Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment]. ( Liefring, E; Molitor, S; Trautmann, M, 2005) |
| "The pharmacokinetics and pharmacodynamics of albuterol were studied following inhalation of three different in-house dry powder formulations in healthy volunteers and in asthmatics." | 5.11 | The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. ( Muanpanarai, D; Srichana, T; Suedee, R; Tanmanee, N, 2005) |
| "To evaluate the efficacy and the safety of low dose salmeterol/fluticasone (SM/FP) combination therapy as compared to morate dose of budesonide (BUD) in the management of adult asthma." | 5.11 | [Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma]. ( Cai, BQ; Chen, BY; Chen, XD; Feng, YL; Guo, XJ; Kang, J; Li, Q; Lin, YP; Qiu, C; Shen, HH; Sun, TY; Tao, JJ; Wang, DQ; Xiao, BR; Xie, CM; Xu, YP; Yin, KS; Zhang, DP; Zheng, JP; Zhong, NS; Zhou, JY; Zhou, X, 2005) |
| "Our objective was to compare the efficacy and safety of formoterol (Foradil) delivered via a novel multidose dry powder inhaler (Certihaler) with placebo and albuterol [pressurized metered-dose inhaler (pMDI)], in patients with persistent asthma." | 5.11 | Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma. ( Andriano, K; LaForce, C; Lavecchia, C; Prenner, BM; Yegen, U, 2005) |
| "Our study compared levalbuterol (LEV) to the combination of racemic albuterol (RAC) and ipratropium bromide (IB) in 140 patients aged 6-18 years presenting to a tertiary hospital Emergency Department with acute asthma and a peak expired flow rate (PEF)<80% predicted." | 5.11 | Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. ( Cline, SM; Coakley, TA; Euwema, MS; Knecht, KR; Ralston, ME; Ziolkowski, TJ, 2005) |
| "A randomised, open-label, multicentre study compared the efficacy and tolerability of salmeterol 25 microg/fluticasone propionate 125 microg (two puffs, twice daily) delivered via a hydrofluoroalkane metered-dose inhaler (HFA-MDI) and salmeterol 50microg/fluticasone propionate 250 microg (one puff, twice daily) delivered via a Diskus inhaler in Chinese patients with moderate asthma uncontrolled with inhaled corticosteroids (ICSs)." | 5.11 | Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. ( Du, X; Humphries, M; Jiang, J; Wang, L; You-Ning, L, 2005) |
| "An efficacy treatment study is conducted comparing levalbuterol to racemic albuterol for acute pediatric asthma in the emergency department (ED)." | 5.11 | Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. ( Burke, BL; Meadows, T; Qureshi, F; Welch, C; Zaritsky, A, 2005) |
| "To compare levalbuterol and racemic albuterol for the treatment of acute exacerbation of asthma in pediatric population." | 5.11 | Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. ( Bithoney, WG; DeBari, V; Gold, N; Hardasmalani, MD, 2005) |
| "To compare the safety of twice-daily treatment with inhaled fluticasone propionate plus the inhaled long-acting beta2-agonist salmeterol with that of fluticasone propionate used alone in children aged 4 to 11 years with persistent asthma." | 5.11 | The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. ( Dorinsky, P; Ellsworth, A; House, K; LaForce, C; Malone, R; Nimmagadda, S; Schoaf, L, 2005) |
| "To determine the relative cost-effectiveness of twice-daily treatment with inhaled fluticasone propionate-salmeterol via Diskus, 100/50 microg, with that of once-daily treatment with oral montelukast as initial maintenance therapy in patients with persistent asthma uncontrolled with a short-acting beta2-agonist alone." | 5.11 | Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. ( Borker, R; Dorinsky, P; Emmett, A; Jhingran, P; Rickard, K, 2005) |
| "To determine and define the beneficial effects of heliox-driven albuterol therapy on severe asthma exacerbation and clinical factors that affect greater response." | 5.11 | Beneficial effects of albuterol therapy driven by heliox versus by oxygen in severe asthma exacerbation. ( Chang, HW; Hsu, CW; Huang, YC; Lee, DL; Lee, H, 2005) |
| "In the management of asthma exacerbation, ad-lib administration of albuterol is therapeutically as effective as regular, scheduled administration." | 5.11 | Regular vs ad-lib albuterol for patients hospitalized with acute asthma. ( Chandra, A; Chung, V; Cohen, HW; Dhuper, S; Maggiore, D; Mani, K; Shim, C, 2005) |
| "Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo." | 5.11 | Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. ( Fardon, TC; Hodge, MR; Lee, DK; Lipworth, BJ, 2005) |
| "Continuously nebulized albuterol delivered by heliox was associated with a greater degree of clinical improvement compared with that delivered by oxygen among children with moderate to severe asthma exacerbations." | 5.11 | Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. ( Corcoran, T; Funt, N; Gracely, E; Kim, IK; Phrampus, E; Pitetti, R; Saville, A; Thompson, A; Venkataraman, S, 2005) |
| "To evaluate the efficacy and safety of mometasone furoate dry powder inhaler (MF-DPI) administered once daily in the evening or twice daily in patients with asthma previously maintained on twice-daily regimens of inhaled corticosteroids." | 5.11 | Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. ( Busse, WW; Karpel, JP; Lutsky, B; Monahan, ME; Noonan, MJ; Staudinger, H, 2005) |
| "Investigating whether adding the long-acting beta(2)-agonist salmeterol to the inhaled corticosteroid fluticasone propionate has an effect on allergen-induced allergic inflammation in asthma." | 5.11 | Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. ( Jansen, HM; Koopmans, JG; Lutter, R; van der Zee, JS, 2005) |
| "Forty-two asthmatic patients sensitized to pollen allergens were randomly allocated to treatment with fluticasone propionate-salmeterol (n=21) or fluticasone propionate alone (n=21)." | 5.11 | Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma. ( Badiola, C; Bruno, L; Ferrer, A; Gutiérrez, V; Lanuza, A; Pérez-Francés, C; Prieto, L, 2005) |
| "To investigate whether, after 48 h of IV treatment with corticosteroids, the use of high-dose inhaled flunisolide is as effective as systemic corticosteroids in adults hospitalized for a severe asthma exacerbation." | 5.10 | Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. ( Acquah, S; Dayrit, FM; Kohli, AR; Lee-Wong, M; Mayo, PH, 2002) |
| "To compare the relative cost effectiveness of salmeterol (50 microg)/ fluticasone propionate (100 microg) with that of oral montelukast (10mg) as initial maintenance therapy in patients with persistent asthma uncontrolled on short-acting beta2-agonist therapy alone." | 5.10 | Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. ( Borker, R; Dorinsky, P; Emmett, A; Rickard, K; Sheth, K, 2002) |
| "On separate study days, 15 nonsmokers with mild asthma received randomized nominal albuterol doses of 0 to 576 microg by using specially manufactured MDI canisters." | 5.10 | A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers. ( Adams, WP; Creticos, PS; Khattignavong, AP; Lewis, LD; Lietman, PS; Martinez, MN; Molzon, JA; Petty, BG; Singh, GJ; Williams, RL, 2002) |
| "In a prospective, pragmatic, randomised, parallel group study, 170 patients of mean (SD) age 37 (12) years with acute asthma (peak expiratory flow (PEF) 212 (80) l/min) presenting to hospital received treatment with either high dose prednisolone and continuous nebulised salbutamol as recommended in the US or lower dose prednisolone and bolus nebulised salbutamol as recommended in the UK by the BTS." | 5.10 | Randomised pragmatic comparison of UK and US treatment of acute asthma presenting to hospital. ( Daynes, TJ; Harrison, BD; Innes, NJ; Stocking, JA, 2002) |
| "We evaluated whether montelukast conferred additive effects in patients with asthma receiving fluticasone/salmeterol (FP/SM) combination and FP alone." | 5.10 | Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. ( Bates, CE; Currie, GP; Haggart, K; Lee, DK; Lipworth, BJ, 2003) |
| "In asthmatics, awake fiberoptic intubation evokes a more than 50% decrease in FEV1 following dyclonine inhalation." | 5.10 | Both local anesthetics and salbutamol pretreatment affect reflex bronchoconstriction in volunteers with asthma undergoing awake fiberoptic intubation. ( Groeben, H; Pavlakovic, G; Peters, J; Schlicht, M; Stieglitz, S, 2002) |
| "The aim of this study was to compare the efficacy and safety of salmeterol/fluticasone propionate combination product (SFC) with fluticasone propionate (FP) plus oral montelukast (M) over 12 weeks in symptomatic asthma patients." | 5.10 | The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. ( Akveld, M; Bateman, ED; Eliraz, A; Mulder, PG; Pruzinec, R; Ringdal, N; Weber, HH, 2003) |
| "A prospective, randomized, double-blind study was conducted to determine whether there was any benefit to the addition of ipratropium to a single nebulized albuterol treatment in infants and children with mild to moderate acute asthma presenting to a pediatric office." | 5.10 | Addition of ipratropium to nebulized albuterol in children with acute asthma presenting to a pediatric office. ( Gunawardane, G; Kumaratne, M, 2003) |
| "The relative efficacies of aminophylline and salbutamol in severe acute childhood asthma are currently unclear." | 5.10 | Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. ( Begent, J; Buchdahl, R; Gomez, K; Habel, A; Lachman, P; Newsom, D; Raffles, A; Roberts, G; Saglani, S; Sloper, K, 2003) |
| "We examined whether a combination of glucocorticoids and beta-agonists inhaled by asthmatics had an influence on the metabolism of L-arginine, an amino acid involved in the production of urea, creatinine, and NO that is known to play a significant role in asthma." | 5.10 | Creatininuria in asthmatic children treated with a combination of glucocorticoid and beta-agonist. ( Ferrières, J; Giroux, M, 2003) |
| "1) Mean weekly inhaled steroid adherence [(number of actuations/prescribed number of actuations) x 100]; 2) number of days with overuse of inhaled steroids; 3) 24-hour and nighttime albuterol use; 4) included forced expiratory volume in 1 second; and 5) Asthma Quality of Life Questionnaire total score." | 5.10 | Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence. ( Apter, A; Connors, M; Litt, M; McCusker, C; Onyirimba, F; Reisine, S; ZuWallack, R, 2003) |
| "Safety and efficacy of desloratadine and montelukast each were assessed in a double-blind, placebo-controlled trial of patients with SAR and symptoms of asthma, who were assigned randomly to once-daily treatment with desloratadine 5 mg, montelukast 10 mg, or placebo for 4 weeks." | 5.10 | Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. ( Baena-Cagnani, CE; Berger, WE; Danzig, M; DuBuske, LM; Gurné, SE; Lorber, R; Stryszak, P, 2003) |
| "Fifteen mild-to-moderate asthmatics (mean FEV(1) 80% predicted) uncontrolled on inhaled corticosteroids (mean dose 470 microg) were randomised in a single-blind crossover fashion to receive 2 weeks each of fluticasone 250 microg plus salmeterol 50 microg in combination (FP+SM), 1 puff b." | 5.10 | Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. ( Bates, CE; Currie, GP; Jackson, CM; Lee, DK; Lipworth, BJ, 2003) |
| "This study tests the hypothesis that the administration of multiple doses of inhaled albuterol (A), ipratropium bromide (IB), and flunisolide (F) provides an additional benefit to adults with acute severe asthma compared with the administration of A plus IB (A/IB) or A plus F (A/F)." | 5.10 | Triple inhaled drug protocol for the treatment of acute severe asthma. ( Rodrigo, C; Rodrigo, GJ, 2003) |
| "The aim of this study was to test the hypothesis that the addition of the long-acting beta(2)-agonist salmeterol (SALM) to a low dose of the inhaled corticosteroid fluticasone propionate (FP) has a steroid-sparing effect and does not result in a worsening of bronchial inflammation compared to doubling the dose of inhaled corticosteroid." | 5.10 | Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. ( Bjermer, L; Djukanović, R; Holgate, S; Lindberg, A; Lundbäck, B; Sandström, T; Sue-Chu, M; Wallin, A; Ward, J; Wilson, S, 2003) |
| "The goal of this study was to examine the efficacy of formoterol in patients with moderate to severe persistent asthma that was suboptimally controlled with an inhaled corticosteroid (ICS) combined with on-demand salbutamol (albuterol in the United States) with or without salmeterol." | 5.10 | Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study. ( Bourdeix, I; Brambilla, C; Le Gros, V, 2003) |
| "The objective of this study was to evaluate parental preference for the treatment of asthmatic children with oral montelukast sodium or inhaled cromolyn sodium." | 5.10 | Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. ( Bird, SR; Bratton, DL; Bukstein, DA; Edelman, JM; Estojak, J; Firriolo, KM; Hustad, CM, 2003) |
| "To compare the efficacy and safety of twice-daily fluticasone propionate (FP) 88 microg and salmeterol 42 microg combined in a chlorofluorocarbon (CFC)-free (hydrofluoroalkane 134a) metered-dose inhaler (MDI) with the individual agents alone, each delivered through an MDI containing CFC propellants, in patient with persistent asthma previously uncontrolled with as-needed short-acting beta2-agonists alone." | 5.10 | Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. ( Baitinger, L; Dorinsky, P; Greos, LS; Gross, G; Nelson, HS; Scott, C; Wolfe, JD, 2003) |
| "To compare the control of FeNO provided by salmeterol or montelukast add-on therapy in asthmatic children undergoing regular maintenance treatment with a daily dose of 400 microg of budesonide." | 5.10 | Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. ( Bisgaard, H; Buchvald, F, 2003) |
| "To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone." | 5.10 | Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. ( Bisgaard, H; Bjermer, L; Bousquet, J; Dass, SB; Fabbri, LM; Greening, AP; Haahtela, T; Holgate, ST; Leff, JA; Menten, J; Picado, C; Polos, PG, 2003) |
| "To determine whether levalbuterol resulted in fewer hospital admissions than racemic albuterol when used for treatment of acute asthma." | 5.10 | Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. ( Carl, JC; Kercsmar, CM; Kirchner, HL; Myers, TR, 2003) |
| "Treatment of moderate-to-severe asthma with salmeterol/fluticasone propionate resulted in superior gains in HR-QOL relative to increasing the dose of inhaled corticosteroids." | 5.10 | Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. ( James, MH; Jenkins, C; Juniper, EF; Price, MJ, 2002) |
| "The goal of the present study was to evaluate the efficacy and safety of salmeterol/ fluticasone (50/250 microg twice daily) as initial treatment for symptomatic patients with mild to moderate bronchial asthma who had not previously received appropriate anti-asthma medication." | 5.10 | Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023). ( Baumgarten, C; Behre, U; Geldszus, R; Peslis, N; Trautmann, M, 2002) |
| "Initial maintenance therapy with FSC provides greater improvement in asthma control and patient satisfaction than montelukast." | 5.10 | Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. ( Bowers, B; Dorinsky, P; Emmett, A; Kalberg, C; Lieberman, AK; Pearlman, DS; Pepsin, PJ; Rickard, KA; White, MV, 2002) |
| " Patients kept records of peak flow meter (PFM) measurements, asthma attack rate and beta-2-agonist use (albuterol)." | 5.10 | Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial. ( Chervinsky, P; Goldstein, MF, 2002) |
| " We studied the spirometric effects of albuterol nebulized with heliox during emergency room visits for asthma exacerbations." | 5.10 | The utility of albuterol nebulized with heliox during acute asthma exacerbations. ( Barman, N; Gehlbach, BK; Hall, JB; Kress, JP; Miller, A; Morgan, S; Noth, I; Pohlman, AS, 2002) |
| "We sought to compare the efficacy and safety of nebulized magnesium sulfate (MgSO(4)) plus albuterol with that of albuterol alone in adult patients with mild-to-moderate acute asthma exacerbations." | 5.10 | A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. ( Becker, E; Bessmertny, O; Cohen, H; DiGregorio, RV; Golden, J; Johnson, T; Kohl, L; Looney, D, 2002) |
| " Sixty-three adolescent and adult asthmatic patients were randomized to receive at separate treatment visits single doses via a pressurized metered-dose inhaler of either placebo/hydrofluoroalkane (HFA) 134a; 100 microg, 200 microg, or 400 microg albuterol/HFA 134a; 100 microg or 200 microg albuterol/chlorofluorocarbon (CFC)." | 5.10 | A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. ( Batty, EP; Langley, SJ; Masterson, CM; Sykes, AP; Woodcock, A, 2002) |
| "We compared the bronchodilator response to salbutamol (albuterol) delivered by a compressed air nebulizer through a mouthpiece and via a facemask in 18 asthmatic children, to determine the most appropriate delivery method." | 5.10 | Mouthpiece versus facemask for delivery of nebulized salbutamol in exacerbated childhood asthma. ( Aoki, T; Izawa, M; Kabayama, H; Kishida, M; Koshibu, T; Kurita, F; Okada, M; Shinomiya, N; Suzuki, I; Takeshita, Y, 2002) |
| "To compare albuterol with isoproterenol as a bronchodilator in pulmonary function test and their value in the diagnosis and differential diagnosis of asthma." | 5.09 | [A comparison between the effects of albuterol and isoproterenol in bronchodilation test]. ( He, T; Luo, Y; Wang, L; Yuan, Y; Zeng, J, 2001) |
| "We examined the partitioning of total lung resistance (RL) into airway resistance (Raw) and tissue resistance (Rti) in patients with mild to moderate asthma (baseline FEV1, 54 to 91% of predicted) before and after albuterol inhalation." | 5.09 | Airway and lung tissue mechanics in asthma. Effects of albuterol. ( Ingenito, EP; Israel, E; Kaczka, DW; Lutchen, KR, 1999) |
| "Thus in stable asthmatic subjects receiving regular salmeterol or formoterol, bronchoprotective subsensitivity was not overcome by administering a high dose of albuterol." | 5.09 | A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. ( Aziz, I; Lipworth, BJ, 1999) |
| "To compare the effectiveness of a helium-oxygen mixture with that of oxygen alone as an aerosolizing gas for beta-agonist therapy in patients with mild to moderate exacerbation of asthma." | 5.09 | Use of heliox-driven nebulizer therapy in the treatment of acute asthma. ( Acharya, P; Chan, LS; Henderson, SO; Kilaghbian, T; Korn, CS; Perez, J, 1999) |
| "The optimal dose of albuterol to use in the treatment of acute asthma has yet to be established." | 5.09 | Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma. ( Cydulka, RK; Emerman, CL; McFadden, ER, 1999) |
| "Patients with mild-to-moderate asthma (12 to 76 years old) who were treated with albuterol alone were randomized (nZ = 879; nP = 605) and included in subset analyses." | 5.09 | An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. ( Bonuccelli, CM; Howland, WC; Minkwitz, MC; Nathan, RA; Simonson, SG; Tashkin, DP, 1999) |
| "To compare the long-term efficacy and safety of albuterol administration using a Spiros Inhalation System (Dura Pharmaceuticals; San Diego, CA) dry powder inhaler (DPI) and albuterol (Ventolin; Glaxo Wellcome; Research Triangle Park, NC) administration using a metered-dose inhaler (MDI) in patients with asthma." | 5.09 | Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. ( Bieler, S; Hill, MR; Kemp, JP; Nelson, H; Vaughan, LM, 1999) |
| "The Childhood Asthma Management Program (CAMP) is a multicenter, randomized, double-masked clinical trial designed to determine the long-term effects of three inhaled treatments for mild to moderate childhood asthma: budesonide (a glucocorticoid used daily) and albuterol (a short-acting beta-agonist bronchodilator used as needed); nedocromil (a nonsteroid anti-inflammatory agent used daily) and albuterol; and placebo and albuterol." | 5.09 | The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group. ( , 1999) |
| "These data demonstrate that asthma duration is associated with lower lung function, greater methacholine responsiveness, more asthma symptomatology, and greater use of as-needed albuterol, which are all measures of asthma severity." | 5.09 | Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP) ( Dawson, C; Weiss, S; Zeiger, RS, 1999) |
| "The objective of this study was to compare the effect of twice daily formoterol (Foradil), 4 times daily albuterol, and on-demand albuterol on bronchial hyperresponsiveness (BHR), lung function measurements, symptoms, and other indicators of disease control over 6 months inpatients with asthma of moderate or greater severity receiving concomitant inhaled corticosteroids." | 5.09 | Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. ( Brambilla, R; Chapman, KR; Della Cioppa, G; Fairbarn, MS; FitzGerald, JM; Stubbing, D; Till, MD, 1999) |
| "To evaluate the 12-hour efficacy and safety of single doses of 25 micrograms and 50 micrograms of salmeterol powder administered via Diskus inhaler versus albuterol aerosol via pressurized metered-dose inhaler and placebo in preventing EIB in asthmatic children." | 5.09 | Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. ( Arledge, T; Blake, K; Pearlman, DS; Scott, C; Stahl, E; Wang, Y, 1999) |
| " Backup albuterol was available to control asthma symptoms." | 5.09 | Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial. ( Arledge, T; Chervinsky, P; Galant, S; Goldberg, P; Stahl, E; Wang, Y; Welch, MB, 1999) |
| "Outcome measures included Asthma Quality of Life Questionnaire (AQLQ) global and individual domain scores, FEV1, PEF, nighttime awakenings, asthma symptoms, and supplemental albuterol use." | 5.09 | Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. ( Cox, F; DuBuske, LM; Friedman, B; Lockey, RF; Petrocella, V; Rickard, K, 1999) |
| "To determine whether initiation of salmeterol and fluticasone propionate treatment together improves asthma control greater than initiation of monotherapy with the individual agents alone with no additional safety risk in patients with asthma who had not previously been treated with inhaled corticosteroids." | 5.09 | Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. ( Chervinsky, P; Gross, G; Pearlman, DS; Prillaman, B; Shah, T; Stricker, W; Weinstein, S; Woodring, A, 1999) |
| "Fluticasone propionate is a topically active glucocorticoid with potent antiinflammatory activity in the treatment of asthma." | 5.09 | Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. ( Brown, A; Finn, A; Galant, SP; Gross, G; Hamedani, AG; Harding, SM; Pleskow, W; van Bavel, J, 1999) |
| "Patients >12 months of age were eligible if they were to be treated according to a standardized ED protocol for acute asthma with nebulized albuterol (2." | 5.09 | Ipratropium bromide added to asthma treatment in the pediatric emergency department. ( Duggan, AK; Lebet, R; Ogborn, CJ; Pusic, MV; Zorc, JJ, 1999) |
| "The purpose of this study was to determine the safety and efficacy of increasing doses of nebulized levalbuterol (Xopenex; the pure R-isomer of racemic albuterol) and racemic albuterol compared with placebo in the treatment of asthma in pediatric patients." | 5.09 | The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. ( DeGraw, SS; Gawchik, SM; Noonan, M; Reasner, DS; Saccar, CL, 1999) |
| "The primary objective was to compare the safety of HFA albuterol to an albuterol product formulated in chlorofluorocarbon propellants (CFC albuterol) during 1 year of treatment in asthmatics." | 5.09 | Safety of long-term treatment with HFA albuterol. ( Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1999) |
| "Randomized, double-blind, placebo-controlled comparison of the bronchodilator response to albuterol DPI (200 microg) at inspiratory flow rates of approximately 15, 30, and 60 L/min in patients with stable asthma with demonstrated reversibility to albuterol." | 5.09 | Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. ( Chambers, CB; Nantel, NP; Newhouse, MT; Parry-Billings, M; Pratt, B, 1999) |
| "In a randomized, double-blind, placebo-controlled trial, 56 adult asthmatic patients with peak expiratory flow rates (PEFRs) less than 50% predicted after an initial albuterol aerosol treatment were studied." | 5.09 | Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: A randomized controlled study. ( Bakalchuk, L; Curry, A; Dow, AM; Heyl, GT; Lin, RY; Pesola, GR; Tenenbaum, C; Westfal, RE, 1999) |
| "In patients with mild-to-moderate asthma in this study, the albuterol DPI was determined to be therapeutically comparable to albuterol MDI in the delivery of one and two actuations of albuterol." | 5.09 | Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma. ( Ahrens, R; Clarke, W; Geoffroy, P; Grossman, J; Hill, MR; Lalonde, RL; Vaughan, LM, 1999) |
| "Current treatment guidelines define inhaled corticosteroids such as fluticasone propionate (FP) as the cornerstone of anti-inflammatory therapy for asthma." | 5.09 | The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. ( Condemi, JJ; Emmett, A; Goldstein, S; Kalberg, C; Rickard, K; Yancey, S, 1999) |
| "The objective of this multicentre, randomised, double blind, parallel group study was to compare the efficacy and safety of the addition of salmeterol with that of doubling the dose of fluticasone propionate in asthmatic patients not controlled by a low or intermediate dose of inhaled corticosteroids." | 5.09 | Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. ( Mol, SJ; Mulder, PG; Schreurs, AJ; van Noord, JA, 1999) |
| "We sought to compare the efficacy and safety of 2 doses of fluticasone propionate (88 micrograms twice daily and 220 micrograms twice daily) with 2 doses of beclomethasone dipropionate (168 micrograms twice daily and 336 micrograms twice daily) in subjects with persistent asthma." | 5.09 | A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. ( Baker, J; Edwards, L; Lanier, RQ; Lincourt, WR; Raphael, GD; Rickard, K, 1999) |
| " We undertook a double-blind, randomized, placebo-controlled, cross-over study to investigate the effects of a single dose of formoterol inhaled via Turbuhaler (12 micrograms) and of albuterol inhaled via Turbuhaler (200 micrograms) on airway responsiveness to AMP and histamine in 16 subjects with mild atopic asthma." | 5.09 | Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. ( Barnes, PJ; Nightingale, JA; Rogers, DF, 1999) |
| " The primary efficacy measure was morning peak expiratory flow (PEF); secondary efficacy measures included evening PEF, asthma symptom scores, supplemental albuterol use, nighttime awakenings, sleep symptoms, asthma exacerbations, and FEV1." | 5.09 | Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. ( Busse, W; Kalberg, C; Nelson, H; Rickard, KA; Wolfe, J; Yancey, SW, 1999) |
| "To compare the efficacy, safety, and effects on sleep quality of salmeterol and extended-release theophylline in patients with nocturnal asthma." | 5.09 | Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. ( Mende, CN; Petrocella, VJ; Rickard, KA; Wiegand, L; Yancey, SW; Zaidel, G; Zwillich, CW, 1999) |
| "In children with mild acute asthma, to compare treatment with a single dose of albuterol delivered by a metered dose inhaler (MDI) with a spacer in either a weight-adjusted high dose or a standard low-dose regimen with delivery by a nebulizer." | 5.09 | Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. ( Callahan, S; Canny, GJ; Johnson, DW; Schuh, S; Stephens, D; Winders, P, 1999) |
| "To compare the safety and efficacy of salmeterol xinafoate, beclomethasone dipropionate (BDP), and placebo over a 6-month treatment period in patients with persistent asthma." | 5.09 | A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. ( Emmett, AH; Grossman, J; Nathan, RA; Pinnas, JL; Rickard, KA; Schwartz, HJ; Yancey, SW, 1999) |
| " In order to examine the usefulness of inhaled PDE3 inhibitors in the treatment of asthma, we investigated the bronchodilator effect of inhaled olprinone, a newly developed PDE3 inhibitor, in nine asthmatic patients." | 5.09 | Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. ( Fujimura, M; Hashimoto, T; Hirose, T; Ishiura, Y; Kamio, Y; Matsuda, T; Myou, S; Tachibana, H, 1999) |
| "To compare efficacy of an extended release oral beta-2 agonist, albuterol sulfate (Volmax), to a long-acting inhaled agent, salmeterol (Serevent) in the treatment of nocturnal asthma." | 5.09 | Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma. ( Beaucher, WN; Kiechel, F; Kraft, M; LaVallee, N; Martin, RJ; Shilstone, J; Sublett, JL, 1999) |
| " Subjects recorded asthma-related symptoms, morning and evening peak expiratory flow (PEF) levels, and use of supplemental albuterol daily on diary cards." | 5.09 | Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. ( Baker, JW; Busse, WW; Emmett, A; Kalberg, C; Kemp, JP; Rickard, KA; Rosenthal, RR, 1999) |
| "Outcome measures included FEV1, peak expiratory flow (PEF), supplemental albuterol use, nighttime awakenings, asthma symptoms, and physician global assessment." | 5.09 | Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. ( Baraniuk, J; Berger, WE; Edwards, LD; Johnson, M; Murray, JJ; Nathan, RA; Rickard, KA; Srebro, S, 1999) |
| "We investigated the bronchodilator dose-response to nebulized albuterol and the dose of albuterol which produces maximal bronchodilation in the acutely ill, hospitalized asthmatic." | 5.09 | Dose-response characteristics of nebulized albuterol in the treatment of acutely ill, hospitalized asthmatics. ( Brennan, K; Ciccolella, DE; Criner, GJ; Kelsen, SG, 1999) |
| "To evaluate the efficacy of nebulized budesonide compared to oral prednisolone early in the emergency room management of acute asthma, we conducted a double-blind, placebo-controlled trial." | 5.09 | Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. ( Jayshree, M; Kumar, L; Singhi, S, 1999) |
| "Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently introduced for the treatment of asthma." | 5.09 | The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. ( Bradding, P; Britten, KM; Gratziou, C; Holgate, ST; Howarth, PH; Roberts, JA; Walls, AF; Wilson, S, 1999) |
| "Twenty-four stable patients with asthma (forced expiratory volume in 1 second: 70% to 90% of predicted and a minimum of 10% reversibility after inhalation of albuterol sulfate) with no previous exposure to inhaled corticosteroids participated in this randomized, double-masked crossover trial." | 5.09 | Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. ( Everts, B; Hedner, J; Möller, CS, 1999) |
| "Fluticasone propionate 880 microg/day improved lung function and quality of life in adolescents with moderate-to-severe asthma when compared with flunisolide 1500 microg/day." | 5.09 | Comparison of the efficacy of inhaled fluticasone propionate, 880 microg/day, with flunisolide, 1500 microg/day, in moderate-to-severe persistent asthma. ( Eid, N; Goldsmith, LJ; Howell, L; Sheikh, S, 1999) |
| "All active treatment groups showed statistically significant improvement compared with placebo in pulmonary function (FEV1, FEF25-75%, morning and evening PEF), use of rescue albuterol, and asthma symptom scores." | 5.09 | Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. ( Banerji, D; Chervinsky, P; Jacobson, K; Kane, RE; Noonan, M; Uryniak, T, 1999) |
| " Efficacy was assessed by spirometry, and by daily recordings of albuterol use, peak expiratory flow (PEF), asthma symptom ratings, and nighttime awakenings throughout the study." | 5.09 | A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group. ( Banerji, D; Bernstein, D; Gross, G; Kane, RE; Welch, M, 1999) |
| "05) to doubling the dose of beclomethasone in improving peak expiratory flow (PEF) and forced expiratory volume in 1 sec (FEV1), and in reducing symptoms of asthma, sleep loss, nighttime awakenings, and use of albuterol." | 5.09 | Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. ( Anderson, WH; Church, NL; Emmett, AH; Gillman, SA; Kelsen, SG; Lanier, BQ; Rickard, KA, 1999) |
| "Three hundred forty-nine patients with asthma previously treated with medium doses of inhaled corticosteroids during a 2-wk, single-blind, run-in period were randomized to treatment with salmeterol 50 microg combined with fluticasone propionate (FP) 250 microg, salmeterol 50 microg, FP 250 microg, or placebo, each given twice daily through a Diskus device for 12 wk." | 5.09 | Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. ( Baitinger, L; Given, J; House, K; Lumry, W; Prillaman, B; Shah, T; Shapiro, G; White, MV; Wolfe, J; Woodring, A, 2000) |
| "Magnesium sulfate is thought to be an effective bronchodilator when administered intravenously to patients with acute severe asthma, and it can be safely administered via inhalation to patients with stable asthma." | 5.09 | Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma. ( Corna, RA; Mannarino, S; Nannini, LJ; Pendino, JC; Quispe, R, 2000) |
| "In order to compare the efficacy of different asthma treatment in subjects with mild-to-moderate asthma, three groups of 11 patients were treated with nedocromil sodium (NS), beclomethasone dipropionate (BDP) and beclomethasone dipropionate plus salmeterol (BDP + S) in an open, randomized study." | 5.09 | Comparison of different long-term asthma treatments in subjects with mild-to-moderate asthma. ( Bacci, E; Dente, FL; Di Franco, A; Giannini, D; Paggiaro, PL; Vagaggini, B, 1999) |
| " Efficacy was assessed by serial measurements of forced expiratory volume in one second (FEV1) over 12 hours, daily peak expiratory flow (PEF), self-rated asthma symptom scores, nighttime awakenings, and supplemental albuterol use." | 5.09 | Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma. ( Chervinsky, P; Davis, S; Kreitzer, S; Lawrence, M; Reilly, D; Stahl, E; Wang, Y; Wolfe, J, 2000) |
| "To compare the costs and effectiveness of albuterol by metered dose inhaler (MDI) and spacer versus nebulizer in young children with moderate and severe acute asthma." | 5.09 | Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. ( Aickin, RP; Asher, MI; Campanella, SG; Leversha, AM, 2000) |
| "Twelve asthmatic patients were enrolled into a single-blind, placebo-controlled, crossover study, receiving additive therapy as either of the following: (1) montelukast alone, 10 mg (ML(10)); (2) inhaled salmeterol alone, 50 microg (SM(50)); (3) ML(10) and SM(50); (4) ML(10) and inhaled salmeterol, 100 microg (SM(100)); or (5) placebo inhaler and tablet." | 5.09 | Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. ( Dempsey, OJ; Lipworth, BJ; Mistry, C; Sims, EJ; Wilson, AM, 2000) |
| "Undiluted albuterol short treatments seem to be as effective as standard diluted albuterol in severe asthmatics, while offering the ease and efficiency of shorter treatment administration time." | 5.09 | Undiluted albuterol aerosols in the pediatric emergency department. ( Gutglass, DJ; Hampers, L; Krug, SE; Nimmagadda, SR; Roosevelt, G; Teoh, D, 2000) |
| "Mometasone furoate (MF) is a new potent corticosteroid for use in treating asthma." | 5.09 | Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. ( Arshad, H; Harrison, JE; Holgate, ST; Stryszak, P, 2000) |
| "Our purpose was to evaluate the effectiveness of fluticasone propionate powder 200 microg/d administered as a once- or twice-daily dosage regimen in patients who were currently being treated with bronchodilators only (BD patients) and in patients who required inhaled corticosteroids for maintenance treatment of asthma (ICS patients)." | 5.09 | Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. ( Duke, S; Grady, J; Harding, S; Munk, ZM; Prillaman, B; Rooklin, A; Stevens, A; Wolfe, J, 2000) |
| "Three hundred and fifty-three asthmatic patients who remained symptomatic despite treatment with budesonide 800-1200 microg day(-1) (or equivalent) were randomized to a new combination therapy comprising salmeterol 50 microg and fluticasone propionate 250 microg (Seretide, Advair, Viani 50/250 microg) twice daily or budesonide 800 microg twice daily for 24 weeks." | 5.09 | Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma. ( James, MH; Jenkins, C; Lundback, B; Saarelainen, P; Woolcock, AJ, 2000) |
| "Once-daily treatment with fluticasone propionate resulted in an improvement in efficacy variables, such as FEV(1), morning and evening peak expiratory flow (PEF), asthma symptom scores, nighttime awakenings, albuterol use, and duration of study participation." | 5.09 | A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. ( Finn, A; Harding, SM; Jones, R; Li, JT; Nathan, RA; Payne, JE; Wolford, JP, 2000) |
| "To evaluate the efficacy and safety of fluticasone propionate administered as a once-daily or twice-daily regimen over a period of 1 year to patients with moderate asthma." | 5.09 | Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. ( Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000) |
| "To assess the safety and efficacy of salmeterol xinafoate as an adjunct to conventional therapy for the in-hospital management of acute asthma." | 5.09 | A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma. ( Davis, CP; Jones, AP; Lawson, RW; LeGrand, TS; Peters, JI; Shelledy, DC, 2000) |
| "Eighteen patients with mild-to-moderate persistent asthma receiving inhaled corticosteroid who expressed the homozygous glycine-16 genotype were randomized to completion (mean [SEM] age, 35." | 5.09 | Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. ( Aziz, I; Dempsey, OJ; Lipworth, BJ, 2000) |
| "This study was undertaken to compare the outcome of adults with acute severe asthma treated with 4 puffs of salbutamol (100 microg/actuation) every 20 minutes for 3 doses plus 4 puffs of oxitropium bromide (100 microg/actuation) with each of the 3 salbutamol doses versus salbutamol alone administered by means of a metered-dose inhaler with a spacer device." | 5.09 | Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. ( Chida, K; Enomoto, N; Hirai, R; Kawamoto, A; Nakano, Y, 2000) |
| "The safety and efficacy of two once daily dosing regimens (200 microg and 400 microg) of mometasone furoate (MF) administered in the morning by using a dry-powder inhaler (DPI) were compared with those of a twice daily dosing regimen (200 microg administered twice daily) in patients with mild-to-moderate persistent asthma previously taking only inhaled beta(2)-adrenergic agonists." | 5.09 | Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. ( Berkowitz, RB; Harrison, JE; Kemp, JP; Miller, SD; Murray, JJ; Nolop, K, 2000) |
| "Intravenous magnesium sulfate (MgSO4), as an adjunctive medication to the standard treatment of acute asthma, improves admission rate or severity score in acute severe asthma patients." | 5.09 | Intravenous magnesium sulfate in acute severe asthma. ( Boonyavorakul, C; Charoenpan, P; Thakkinstian, A, 2000) |
| " The authors performed a prospective, randomized, double-blind, placebo-controlled trial to test the ability of intravenous lidocaine and inhaled albuterol to attenuate airway reactivity after tracheal intubation in asthmatic patients undergoing general anesthesia." | 5.09 | Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma. ( Boughton, R; Darvish, A; Israel, E; Loring, SH; Maslow, AD; Mehrez, M; Regan, MM, 2000) |
| "FP/Salm Combo treatment provided better overall asthma control than FP + montelukast with significantly greater improvements in morning peak expiratory flow (+24." | 5.09 | Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. ( Busse, WW; Church, N; Emmett, A; Kerwin, E; Knobil, K; Nelson, HS; Rickard, K, 2000) |
| "To evaluate the clinical comparability of albuterol sulfate formulated in a new hydrofluoroalkane-134a (HFA) propellant (Ventolin HFA Inhalation Aerosol), and conventional CFC-containing albuterol (Ventolin Inhalation Aerosol) in children with asthma." | 5.09 | Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma. ( Barnhart, F; Bronsky, E; Murray, A; Reisner, C; Shapiro, G; VanderMeer, A, 2000) |
| "Mometasone furoate (MF) administered by dry powder inhaler (DPI) was composed with budesonide (BUD) Turbuhaler in the treatment of moderate persistent asthma." | 5.09 | Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. ( Barraza, CH; Boulet, LP; Bousquet, J; D'Urzo, A; Harnest, U; Hebert, J; Lundbäck, B; Lutsky, BN; Martinez Morales, G; Nieminen, MM; Nolop, KB; Suárez-Chacón, R; Visser, S, 2000) |
| "This was an open-label, parallel group, randomized, age-stratified, multicenter study designed to compare the safety and efficacy of regular use of albuterol formulated in hydrofluoroalkane-134a (HFA albuterol) and albuterol formulated in chlorofluorocarbons-11/12 (CFC albuterol) in children with asthma." | 5.09 | Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma. ( Colice, GL; Ekholm, BP; Klinger, NM; Shapiro, GS, 2000) |
| "The aim of this study was to compare the efficacy, safety, and tolerability of formoterol powder for inhalation delivered via the Aerolizer device with placebo and with albuterol delivered via metered-dose inhaler in patients with mild to moderate persistent asthma." | 5.09 | A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. ( Bensch, G; Della Cioppa, G; Kiselev, P; Lapidus, RJ; Levine, BE; Lumry, W; Yegen, U, 2001) |
| "This multi-centre, randomized, double-blind, double-dummy, parallel-group study was designed to investigate the hypothesis of equivalent efficacy and comparable safety of two inhaled presentations of salmeterol/fluticasone propionate combination product (SALM/FP) 50/100 microg administered twice daily to patients with mild-to-moderate asthma for 12 weeks." | 5.09 | Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. ( Bateman, ED; Bogolubov, M; Silins, V, 2001) |
| " We therefore studied the effects of therapeutic doses of inhaled albuterol in five asthmatic subjects (mean age 23." | 5.09 | Effects of therapeutic doses of albuterol on beta2-adrenergic receptor density and metabolic changes. ( Anstead, MI; Burki, NK; Hunt, TA; McConnell, JW, 2001) |
| "Montelukast and salmeterol exhibited significant improvements in asthma control when given as second-line therapy." | 5.09 | Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. ( Dempsey, OJ; Lipworth, BJ; Sims, EJ; Wilson, AM, 2001) |
| " The efficacy, safety and tolerability of the Novolizer has been compared with those of established inhalational devices for the delivery of salbutamol (Sultanol) in patients with chronic obstructive pulmonary disease and for the administration of budesonide (Pulmicort Turbuhaler) to patients with asthma." | 5.09 | Therapeutic equivalence of the Sofotec Novolizer to established standard devices in COPD and asthma. ( Chuchalin, AG; Kunkel, G, 2001) |
| "Comparison of inhaled salmeterol powder vs oral montelukast treatment in patients with persistent asthma who remained symptomatic while receiving inhaled corticosteroids." | 5.09 | Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. ( Boone, R; Emmett, A; Fish, JE; Israel, E; Murray, JJ; Rickard, KA; Yancey, SW, 2001) |
| "The objective of this study was to determine whether initial maintenance therapy for the treatment of inflammation and bronchoconstriction associated with persistent asthma is more effective with a combination product (100 microg of fluticasone propionate and 50 microg of salmeterol [FSC]) administered twice daily through the Diskus device (GlaxoWellcome, Research Triangle Park, NC) or with montelukast at 10 mg once daily." | 5.09 | Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone. ( Calhoun, WJ; Dorinsky, P; Emmett, A; Kalberg, C; Nathan, RA; Nelson, HS; Pepsin, PJ; Rickard, KA, 2001) |
| "Asthmatic children having their tracheas intubated with sevoflurane often have an increase in respiratory system resistance (Rrs)." | 5.09 | Salbutamol prevents the increase of respiratory resistance caused by tracheal intubation during sevoflurane anesthesia in asthmatic children. ( Habre, W; Scalfaro, P; Sims, C; Sly, PD, 2001) |
| "To determine whether the addition of inhaled ipratropium bromide to inhaled albuterol and systemic corticosteroid therapy was more efficacious than inhaled albuterol and systemic corticosteroids alone in the inpatient treatment of acute asthma exacerbations in children." | 5.09 | Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. ( Goggin, N; Macarthur, C; Parkin, PC, 2001) |
| " In a patient subset with severe asthma, a dose-response relationship was observed for levalbuterol, indicating that higher doses were more effective." | 5.09 | Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. ( Baumgartner, RA; Bensch, G; Claus, R; Kim, KT; Milgrom, H; Skoner, DP, 2001) |
| "Two identically designed, prospective, randomized, double-blind, parallel studies were conducted comparing salmeterol 42 micrograms twice daily, albuterol 180 micrograms four times daily, and placebo over 12 weeks in 556 patients (12 to 73 years old) with mild-to-moderate chronic asthma." | 5.08 | Safety of salmeterol in the maintenance treatment of asthma. ( Alexander, WJ; Chervinsky, P; Kemp, JP; Liddle, R; Mills, R; Nathan, RA; Seltzer, JM, 1995) |
| "The aim of this study was to evaluate if continuous treatment with budesonide or salmeterol influences the bronchodilator response to terbutaline in children with asthma; 23 children, aged 7 to 16 years (mean = 11 years), with mild asthma were treated with inhaled budesonide 100 micrograms b." | 5.08 | Influence of budesonide on the response to inhaled terbutaline in children with mild asthma. ( Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1995) |
| "The purpose of this study was to assess the efficacy and safety of inhaled salmeterol xinafoate 50 micrograms bid via the Diskhaler when added to the existing treatment of children with moderate to severe asthma." | 5.08 | Salmeterol xinafoate in children on high dose inhaled steroids. ( Price, JF; Russell, G; Weller, P; Williams, DA, 1995) |
| "High-dose continuous nebulization of albuterol is as safe and as efficacious as intermittent nebulization of albuterol in the early treatment of asthma in an emergency department." | 5.08 | Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study. ( Dworkin, G; Kotch, A; Reisner, C, 1995) |
| "The aim of the study was to compare the efficacy, tolerability and patient acceptability of bambuterol (Bambec) against controlled release (CR) salbutamol (Volmax) in the treatment of nocturnal asthma." | 5.08 | Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group. ( Ayres, JG; Gunn, SD; McConchie, SM, 1995) |
| "We have recently demonstrated that a 2-week course of inhaled albuterol 200 micrograms four times daily caused a near doubling of the allergen-induced early asthmatic response." | 5.08 | Regular use of inhaled albuterol and the allergen-induced late asthmatic response. ( Bhagat, R; Cockcroft, DW; O'Byrne, PM; Swystun, VA, 1995) |
| "Many potential users of the H1 antihistamine cetirizine are asthmatic and may be using inhaled albuterol." | 5.08 | Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. ( Corren, J; Katz, RM; Nicodemus, CF; Rachelefsky, GS; Schanker, HM; Siegel, SC; Spector, SL, 1995) |
| "Salmeterol (42 micrograms twice daily) was compared with the short-acting beta 2-agonist albuterol (180 micrograms four times daily) in two double-blind, randomized studies involving 556 patients with mild-to-moderate asthma." | 5.08 | Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. ( Pearlman, DS, 1995) |
| "The objective of this trial was to determine the efficacy of frequent nebulized ipratropium added to high-dose albuterol therapy in children with severe asthma." | 5.08 | Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. ( Callahan, S; Canny, G; Johnson, DW; Levison, H; Schuh, S, 1995) |
| "This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma." | 5.08 | Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995) |
| "Adult, nonsmoking patients with mild to moderate asthma were randomized to receive 4 mg nedocromil sodium (n = 13), 200 micrograms albuterol (n = 13), or placebo (n = 12) four times daily for 16 wk in a double-blind, double-dummy protocol." | 5.08 | Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. ( Davies, RJ; Devalia, JL; Manolitsas, ND; McAulay, AE; Trigg, CJ; Wang, J, 1995) |
| "Asthmatics aged 18 to 65 years during acute exacerbation with FEV1 less than 75% predicted both before and after a single albuterol treatment." | 5.08 | Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. ( Bloch, H; Grant, S; Jagminas, L; Mancherje, N; Scharf, SM; Silverman, R, 1995) |
| "These data suggest that the addition of theophylline to albuterol and corticosteroids does not enhance improvement of children admitted to the hospital with asthma." | 5.08 | Theophylline does not shorten hospital stay for children admitted for asthma. ( Gladstein, J; Kaifer, MC; Needleman, JP; Nold, JT; Redding, MM; Shuster, PE, 1995) |
| "In a double-blind, double-dummy, multicenter study, 212 patients with asthma whose symptoms were not controlled by as-needed use of inhaled bronchodilators were randomized to receive either 4 mg of nedocromil sodium or 180 micrograms of albuterol four times daily for 12 weeks." | 5.08 | Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol. ( Findlay, SR; Furukawa, CT; Gross, GN; Henochowicz, SI; Hudson, LD; Marcoux, JP; Myers, DJ; Prenner, BM; Steinberg, P; Wasserman, SI, 1995) |
| "We performed a double-blind, two-phase study on protective and bronchodilator effects of prostaglandins E2 and E1 (PGE2, PGE1) and salbutamol in patients with aspirin-induced asthma (AIA)." | 5.08 | Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. ( Cmiel, A; Mastalerz, L; Nizankowska, E; Szczeklik, A, 1996) |
| "This was a 4-week, open-label, parallel-group study designed to compare the efficacy and safety of the long-acting inhaled bronchodilator, salmeterol, with the established inhaled bronchodilator, terbutaline, in the treatment of patients with mild to moderate asthma." | 5.08 | A 4-week comparison of salmeterol and terbutaline in adult asthma. ( Hermansson, BA; Jenkins, RJ, 1995) |
| "The effectiveness of maintenance albuterol aerosol therapy in cystic fibrosis (CF) was assessed by comparing spirometric measurements at the beginning and end of 1 year." | 5.08 | Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. ( Barbero, GJ; Gayer, D; König, P; Shaffer, J, 1995) |
| "To compare the magnitudes of the immediate effects of the nebulized beta-agonists isoetharine and albuterol in the treatment of acute severe asthma." | 5.08 | Isoetharine versus albuterol for acute asthma: greater immediate effect, but more side effects. ( Bidadi, K; Gourlay, S; Hayes, J; Robertson, S; Shrestha, M; Wainscott, M, 1996) |
| "Albuterol sulfate, in the syrup and tablet form for oral administration, has been an effective treatment for adults and children with bronchial asthma." | 5.08 | Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children. ( Boltansky, H; Harrison, JE; Kobayashi, RH; Lorber, RR; Pearlman, DS; Shapiro, G; Skoner, DP; Trochelmann, LM, 1996) |
| "These findings suggest that albuterol behaves as a partial agonist at beta-receptors when compared with fenoterol, and that when inhaled in doses currently recommended for severe asthma, albuterol will result in lesser maximum cardiac and metabolic effects than fenoterol." | 5.08 | Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol. ( Beasley, R; Bremner, P; Burgess, C; Crane, J; Siebers, R, 1996) |
| "Azelastine, an oral nonsteroidal, antiinflammatory drug with a good safety profile, has demonstrated relief of symptoms in patients with asthma." | 5.08 | An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. ( , 1996) |
| "Fluticasone propionate (FP) administered via metered-dose inhaler is a potent corticosteroid effective in the treatment of asthma." | 5.08 | A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. ( Gross, GN; Kellerman, DJ; Kral, KM; Munk, ZM; Schaberg, A; Schoenwetter, WF; Wasserman, SI, 1996) |
| "The purpose of this study was to evaluate the effect of albuterol dosing schedule on clinical outcome in subjects with moderate to severe stable asthma." | 5.08 | The effect of inhaled albuterol in moderate to severe asthma. ( Apter, AJ; Clive, J; McNally, D; Metersky, M; Reisine, ST; Wells, M; Willard, A; ZuWallack, RL, 1996) |
| "The inhaled corticosteroid, fluticasone propionate, was compared with the oral bronchodilator theophylline in the maintenance treatment of asthma." | 5.08 | Fluticasone propionate compared with theophylline for mild-to-moderate asthma. ( Baker, KA; Galant, SP; Kellerman, DJ; Lawrence, M; Meltzer, EO; Tomasko, M, 1996) |
| "In a multicenter, double-blind study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients)." | 5.08 | Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. ( Boushey, HA; Chinchilli, VM; Drazen, JM; Fahy, JV; Fish, JE; Israel, E; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, C; Szefler, SJ, 1996) |
| "To evaluate the role of inhaled ipratropium bromide in acute asthma, a double-blind study of 384 emergency department patients compared the effect of the combination of ipratropium and albuterol with that of albuterol alone." | 5.08 | A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. ( Aldrich, T; Fanta, C; Karpel, JP; Levey, D; Menjoge, SS; Schacter, EN; Spiro, P; Witek, TJ, 1996) |
| "In a pediatric emergency department setting, aerosolized albuterol delivered by MDI-spacer was equal in effectiveness to nebulization in the acute asthma management of children > or = six years of age." | 5.08 | Delivery of albuterol in a pediatric emergency department. ( Bothner, JP; Swanton, RD; Williams, JR, 1996) |
| "The aim of this study was to compare the clinical efficacy of salmeterol versus theophylline in the treatment of moderate-to-severe asthma." | 5.08 | Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. ( Di Franco, A; Giannini, D; Paggiaro, PL; Testi, R, 1996) |
| "The purpose of the study was to compare bronchodilator responses to albuterol between an ultrasonic and a jet nebulizer in moderate to severe asthma." | 5.08 | A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma. ( Leickly, FE; Pallares, DE; Pilarski, BR; Rodriguez, JL, 1996) |
| "To compare the efficacy and safety of continuous nebulized (CN) albuterol therapy with those of intermittent nebulized (IN) albuterol therapy in the ED treatment of children with moderate to severe asthma exacerbations." | 5.08 | Continuous vs intermittent nebulized albuterol for emergency management of asthma. ( Fuchs, SM; Khine, H; Saville, AL, 1996) |
| "Bronchodilator effect and toxicity of theophylline 300 mg twice a day (E1), Salbutamol 4 mg tid (E2), their combination in higher (200/4 mg, E3), and lower doses (100/2 mg E4), and placebo calcium lactate (300 mg) tid (E5) were compared in 30 patients with bronchial asthma in a randomized cross over trial." | 5.08 | [Sympathomimetics and theophylline: combined use?]. ( Alvarez Castro, MR; Alvarez Sintes, R, 1995) |
| "Nedocromil sodium is recommended for daily treatment of mild persistent asthma but its effect on cellular changes in asthmatic airways is poorly understood." | 5.08 | Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma. ( Altraja, A; Laitinen, A; Laitinen, LA; Marran, S; Märtson, T; Meriste, S; Sillastu, H, 1996) |
| " The bronchodilator, cardiovascular, and tremorigenic responses following administration of salbutamol (SAL), terbutaline (TER) and fenoterol (FEN) by closed-port intermittent nebulization were compared for a period of 8 hr." | 5.08 | Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol. ( Naspitz, CK; Scalabrin, DM; Solé, D, 1996) |
| " In a double-blind placebo-controlled crossover study in 12 patients with mild asthma, we investigated the effect of inhaled budesonide or identical placebo on the protection conferred by albuterol (200 micrograms) against methacholine-induced bronchoconstriction before and after treatment with the long-acting beta 2-agonist salmeterol." | 5.08 | An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. ( Barnes, PJ; Kharitonov, SA; Yates, DH, 1996) |
| "These results confirm that there is activation of the RAS in asthmatic subjects by single doses of nebulized beta 2-agonists and that repeated dosing with nebulized albuterol has further, additive effects on plasma Ang II levels." | 5.08 | The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma. ( Connell, JM; Millar, EA; Thomson, NC, 1997) |
| "Nocturnal cough and wheeze are common in asthma and often treated with beta2 agonists or theophyllines." | 5.08 | Inhaled salmeterol or oral theophylline in nocturnal asthma? ( Douglas, NJ; Engleman, HM; Fitzpatrick, MF; Mackay, TW; Selby, C; Sime, PM, 1997) |
| "We detected significant improvement in pulmonary function studies over 120 minutes in children with severe asthma who were given nebulized ipratropium combined with albuterol and oral steroids, compared with children who received the standard therapy." | 5.08 | Efficacy of nebulized ipratropium in severely asthmatic children. ( Lakkis, H; Qureshi, F; Zaritsky, A, 1997) |
| "These data suggest that for children with moderate to severe asthma exacerbation, hospital admission rates are similar in children given oral methylprednisolone and those given i." | 5.08 | Intravenous versus oral corticosteroids in the management of acute asthma in children. ( Barnett, PL; Baskin, M; Caputo, GL; Kuppermann, N, 1997) |
| " The present study was undertaken to compare the therapeutic effects of sustained release theophylline and a conventional low dose oral fenoterol in patients with asthma." | 5.08 | Oral fenoterol versus sustained release theophylline in adult asthmatics. ( Almagro, J; Andrade, RJ; Hidalgo Sanchez, R; Lucena, MI; Sanchez de la Cuesta, F, 1997) |
| "Twenty two asthmatic subjects were randomised to receive montelukast, 100 mg or 250 mg, or placebo in a double blind, three period, crossover trial." | 5.08 | Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. ( Botto, A; Busse, WW; Kundu, S; Reiss, TF; Sorkness, CA; Stricker, W; Zhang, J, 1997) |
| "To determine the efficacy of combination therapy using atropine sulfate and albuterol in the treatment for an acute exacerbation of asthma." | 5.08 | Efficacy of atropine sulfate in combination with albuterol in the treatment for acute asthma. ( Bradley, K; Díaz, JE; Dubin, R; Gaeta, TJ; Pelczar, P, 1997) |
| "The purpose of this study was to evaluate the feasibility of switching to once-daily (qd) administration of flunisolide in patients with asthma that was controlled by twice-daily (bid) dosing of this inhaled steroid." | 5.08 | The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. ( Bodenheimer, S; Bronsky, EA; Chervinsky, P; Cohen, L; Corren, J; Goldsobel, AB; Gong, H; Kaliner, MA; Lotner, GZ; Rachelefsky, GS; Rosen, JP; White, MV; ZuWallack, RL, 1997) |
| "Fluticasone propionate, an inhaled corticosteroid with negligible systemic bioavailability via the oral route, is efficacious in the treatment of asthma when administered via metered-dose inhaler." | 5.08 | Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. ( Goldstein, MF; Hamedani, AG; Kellerman, DJ; Noonan, MJ; Pearlman, DS; Schaberg, A; Tashkin, DP, 1997) |
| "Although theophylline is recommended by current guidelines for the management of asthma in patients with persistent symptoms, theophylline has a narrow therapeutic index, requiring individual dose titration and regular monitoring of serum theophylline concentrations to avoid adverse effects." | 5.08 | Salmeterol versus theophylline in the treatment of asthma. ( Cox, FM; Emmett, A; Pollard, SJ; Spector, SL; Yancey, SW, 1997) |
| "The aim of the present study was to compare the efficacy and the tolerability of salmeterol and theophylline in patients with nocturnal asthma." | 5.08 | [Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance]. ( Braun, H; Koper, I; Leutz, M; Schlimmer, P; Sybrecht, GW; Ukena, D, 1997) |
| " In a recent study in 17 adults with stable asthma, albuterol given using an ultrasonic nebulizer (UN) appeared to produce greater bronchodilatation than the same dose of albuterol given by a jet nebulizer (JN)." | 5.08 | Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children. ( Foster, C; Lamb, BM; Nakanishi, AK; Rubin, BK, 1997) |
| "To determine the optimal treatment interval for administering albuterol metered-dose inhaler (MDI) with a holding chamber to patients presenting to the emergency department (ED) with acute asthma." | 5.08 | Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered? ( Aldrich, TK; Gaitan-Salas, A; Guguchev, K; Karpel, JP; Pathiparti, R; Prezant, DJ, 1997) |
| "To determine what proportion of asthmatic patients attending a tertiary University-based respiratory clinic meet typical drug study spirometric criteria of a baseline FEV1 of 50% to 80% predicted and > or = 15% delta FEV1 improvement following 200 micrograms inhaled albuterol." | 5.08 | The current dilemma with spirometric inclusion criteria for asthma drug trials. ( Cockcroft, DW; Fitzpatrick, MF; Jokic, R; Marciniuk, DD, 1997) |
| " Efficacy was assessed by changes in FEV1, asthma symptom scores, albuterol use, and peak flow rates." | 5.08 | Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. ( Farrar, JR; Feiss, G; Levy, S; Smith, JA; Welch, MJ, 1997) |
| " A total of 291 male and female patients at least 12 years of age with asthma (FEV1 between 50% and 80% of predicted value), who had previously received maintenance therapy with beclomethasone dipropionate or triamcinolone acetonide, were switched to treatment with fluticasone propionate powder (250 microg twice daily), triamcinolone acetonide aerosol (200 microg four times daily), or placebo for 24 weeks." | 5.08 | Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. ( Ayars, GH; Berger, WE; Chervinsky, P; Condemi, JJ; Edwards, L; Ford, LB; Goldstein, MF; Pepsin, PJ; Rogenes, PR, 1997) |
| " We undertook two double-blind, randomized, crossover, placebo-controlled studies to investigate the effects of salmeterol and albuterol on airway responsiveness (AR) to AMP and histamine in patients with mild asthma." | 5.08 | Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. ( Aikman, SL; Barnes, PJ; Harris, JG; Jensen, MW; O'Connor, BJ; Taylor, DA, 1997) |
| "We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma." | 5.08 | Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. ( Aaronson, D; Beaucher, W; Berkowitz, R; Bronsky, E; Chen, R; Chervinsky, P; Cohen, R; Corren, J; Fourre, J; Grossman, J; Harris, AG; Meltzer, E; Pedinoff, A; Stricker, W; Wanderer, A, 1997) |
| "To assess the effect of a long-acting inhaled beta 2-agonist, salmeterol (SM), compared to a short-acting inhaled beta 2-agonist, salbutamol (or albuterol, SB) on the occurrence of morning dip (MD) in patients recovering from an acute severe asthma attack (ASA)." | 5.08 | Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attack. ( Arnold-Ketterer, M; Chevrolet, JC; Ritz, M; Thorens, JB, 1997) |
| "In a randomized, double-blind, placebo-controlled trial, 55 adult asthmatic patients with peak expiratory flow rate (PEFR) less than 200 L/min were randomly assigned to nebulization treatment with albuterol alone (2." | 5.08 | Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial. ( Bakalchuk, L; Cataquet, D; Freyberg, CW; Heyl, GT; Lin, RY; Morgan, JP; Pesola, GR; Westfal, RE, 1998) |
| "We assessed the acute bronchodilator effect of nebulized furosemide when added to conventional therapy of acute emergency department (ED) asthma." | 5.08 | Effect of inhaled furosemide in acute asthma. ( Chapman, KR; Molfino, NA; Nannini, LJ; Pendino, JC; Slutsky, A, 1998) |
| "This randomized, double-blind trial was designed to determine the benefit of high and cumulative doses of flunisolide added to salbutamol in patients with acute asthma in the emergency room (ER)." | 5.08 | Inhaled flunisolide for acute severe asthma. ( Rodrigo, C; Rodrigo, G, 1998) |
| " We compared the safety and efficacy of fluticasone propionate (FP) and beclomethasone dipropionate (BDP) in 306 patients with moderate to severe asthma in a double-blind, multicenter, cross-over study of 12 mo duration." | 5.08 | Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. ( Demedts, MG; Geusens, P; Pauwels, RA; Yernault, JC, 1998) |
| "Although these preliminary results suggest that nebulized budesonide may be an effective adjunct to oral prednisone in the management of moderate to severe asthma exacerbations, a larger trial will be required before the widespread use of inhaled budesonide in acute asthma can be advocated." | 5.08 | Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. ( Klassen, TP; Osmond, MH; Sung, L, 1998) |
| " Efficacy was measured by weekly spirometry and daily diary recordings of peak flow rates, asthma symptom scores, and albuterol use." | 5.08 | A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma. ( Bernstein, DI; Cohen, R; Ginchansky, E; Pedinoff, AJ; Tinkelman, DG; Winder, JA, 1998) |
| "The aim of this study was to investigate whether regular treatment with inhaled salmeterol modifies the dose-response curve to the inhaled short-acting beta2-agonist terbutaline or affects the concentration of nitric oxide (NO) in exhaled air of children with asthma." | 5.08 | Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma. ( Agertoft, L; Fuglsang, G; Pedersen, S; Vikre-Jørgensen, J, 1998) |
| "To evaluate the impact on asthma-specific quality of life, efficacy, and safety of salmeterol versus albuterol in adult patients with mild-to-moderate persistent asthma." | 5.08 | Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. ( Cox, F; Emmett, A; Kalberg, C; Lumry, W; Manning, M; Rickard, K; Wenzel, SE, 1998) |
| "The aim of the present multicentre, open, randomized, parallel group study was to evaluate the efficacy and safety of salmeterol versus theophylline in asthmatic patients." | 5.08 | Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline. ( Martini, T; Nutini, S; Righi, R, 1998) |
| " The aim of the study was to determine the carbachol and albuterol responsiveness in treated and untreated asthmatic and allergic children exposed to environmental tobacco smoke assessed by urinary cotinine measurements." | 5.08 | Possible interaction between exposure to environmental tobacco smoke and therapy in children with asthma. ( Badier, M; Bruguerolle, B; Dubus, JC; Guillot, C; Oddoze, C, 1998) |
| "In an emergency department, 160 patients who presented with acute exacerbations of asthma received either standard (n = 80) or high-dose (n = 80) albuterol treatment." | 5.08 | Comparison of two dosage regimens of albuterol in acute asthma. ( Dixon, L; Galan, G; Hejal, R; McFadden, ER; Strauss, L, 1998) |
| " Overall reductions in supplemental albuterol use and mean asthma symptom scores were also significantly greater in children administered salmeterol compared with placebo (P=." | 5.08 | Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. ( Arledge, T; Bronsky, EA; Byrne, A; Liddle, R; Pearlman, DS; Stahl, E; Weinstein, SF, 1998) |
| "Among children with a severe exacerbation of asthma, the addition of ipratropium bromide to albuterol and corticosteroid therapy significantly decreases the hospitalization rate." | 5.08 | Effect of nebulized ipratropium on the hospitalization rates of children with asthma. ( Davis, P; Pestian, J; Qureshi, F; Zaritsky, A, 1998) |
| "We determined the effect of a long acting beta2-agonist, salmeterol, on aspirin-induced asthma (AIA) attacks and urinary release of eicosanoids in a double-blind, placebo-controlled, crossover study in 10 asthmatics sensitive to aspirin." | 5.08 | Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. ( Cmiel, A; Dworski, R; Mastalerz, L; Nizankowska, E; Oates, JA; Prokop, A; Sheller, JR; Szczeklik, A, 1998) |
| " Four asthma medications, salbutamol, salmeterol, fluticasone propionate (FP) and beclomethasone dipropionate (BDP), currently containing standard CFC propellants, were formulated with HFA134a for investigation." | 5.08 | Clinical evaluation of CFC-free metered dose inhalers. ( Jenkins, M, 1995) |
| "To determine whether children with severe acute asthma treated with large doses of inhaled salbutamol, inhaled ipratropium, and intravenous steroids are conferred any further benefits by the addition of aminophylline given intravenously." | 5.08 | Randomised controlled trial of aminophylline for severe acute asthma. ( South, M; Yung, M, 1998) |
| " Patients treated with salmeterol also had significant improvements in mean PEF rates, supplemental albuterol use, asthma symptom scores, and forced expiratory volume in 1 second compared with those given placebo." | 5.08 | Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma. ( Busse, WW; Casale, TB; Cox, F; Murray, JJ; Petrocella, V; Rickard, K, 1998) |
| " When tested for the spirometric response to albuterol, patients with a history of asthma had a slightly greater increase in FEV1 and FEF25-75% than those who had never had asthma." | 5.07 | The effect of transfusion on pulmonary function in patients with thalassemia major. ( Barreto, M; Cutrera, R; Ronchetti, R; Santamaria, F; Villa, MP; Werner, B, 1994) |
| " Their airway smooth muscle relaxant potencies and effect on histamine contraction in human bronchi in vitro were compared with their effects on airway calibre and histamine reactivity in asthmatic subjects in vivo." | 5.07 | Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo. ( Baldwin, DR; Knox, AJ; Pavord, ID; Sivardeen, Z, 1994) |
| "To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta 2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled beta 2-agonist, in the treatment of asthma." | 5.07 | Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. ( D'Alonzo, GE; Henochowicz, S; Morris, RJ; Nathan, RA; Ratner, P; Rennard, SI, 1994) |
| "The aim of the multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial with a 2-week treatment period was to compare the efficacy and safety of salmeterol (50 micrograms twice daily) with slow-release (SR) terbutaline (5 mg orally, twice daily) in nocturnal asthma." | 5.07 | Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group. ( Bertin, L; Brambilla, C; Chastang, C; Georges, D, 1994) |
| "This study investigated the effects of an osmotic release oral drug delivery system of metoprolol on the changes induced by cumulative doses of inhaled salbutamol on bronchomotor tone, skeletal muscle, and the circulatory system after single (day 1) and multiple (day 7) dosing in 18 hypertensive asthmatic patients (forced expiratory volume in 1 second > 50% predicted; diastolic blood pressure > 90 mm Hg)." | 5.07 | Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors. ( Bauer, K; Kaik, B; Kaik, G, 1994) |
| "We investigated whether the beta 2-agonists fenoterol and salbutamol decreased plasma selenium and glutathione peroxidase activity in patients with asthma as this may partially explain the findings of reduced selenium status in asthmatic patients." | 5.07 | Nebulized beta 2-adrenoceptor agonists do not affect plasma selenium or glutathione peroxidase activity in patients with asthma. ( Beasley, R; Bremner, P; Burgess, CD; Crane, J; Siebers, RW; Thomson, CD, 1994) |
| "We conducted a randomized, double-blind, placebo-controlled study to determine if intravenous aminophylline adds any benefit to high doses of inhaled salbutamol in patients who presented for treatment of acute asthma." | 5.07 | Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer. ( Rodrigo, C; Rodrigo, G, 1994) |
| "A double-blind, randomized, crossover study was done to determine the efficacy of colchicine in 30 atopic children with moderately severe asthma." | 5.07 | A clinical study of colchicine in childhood asthma. ( Adalioglu, G; Saraçlar, Y; Tuncer, A; Türktas, I, 1994) |
| "In atopic asthmatics we have found, that 2 weeks of regular inhalative salbutamol monotherapy (200 mcg/qid) enhances BHR to histamine." | 5.07 | [Inhalation corticosteroid therapy and nonspecific bronchial responsiveness enhanced with salbutamol]. ( Brzostek, D; Droszcz, W; Piotrowska, B, 1994) |
| "Clinical studies of inhaled salmeterol xinafoate have been conducted mainly in moderately to severely affected asthmatic subjects in hospital settings." | 5.07 | Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group. ( Jones, KP, 1994) |
| "To determine the effect of the institution of out-of-hospital albuterol treatments for acute asthma on out-of-hospital time intervals emergency department (ED) morbidity." | 5.07 | Effect of out-of-hospital albuterol inhalation treatments on patient comfort and morbidity. ( Anand, P; Ernst, AA; May, WL; Orgeron, D; Weiss, SJ, 1994) |
| "5 mg) albuterol (salbutamol) over 1 h in 47 patients admitted to hospital with severe acute asthma defined as a peak expiratory flow (PEF) below 150 L/min and hypercapnia (Pa(CO2) > or = 40 mm Hg)." | 5.07 | Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study. ( Brochard, L; Duroux, P; Henry-Amar, M; Mal, H; Renon, D; Salmeron, S; Simonneau, G; Tenaillon, A, 1994) |
| "Nine young asthmatic children aged 2-5 years underwent methacholine challenge after placebo or albuterol administered by metered dose inhaler through a spacer device (Babyhaler) with a face mask in a double-blind, cross-over, randomized study." | 5.07 | Protective effect of albuterol delivered via a spacer device (Babyhaler) against methacholine induced bronchoconstriction in young wheezy children. ( Avital, A; Godfrey, S; Schachter, J; Springer, C, 1994) |
| "In a double-blind, double-placebo, randomized crossover study, we compared the effects of 6 wk of treatment with the anti-inflammatory drug nedocromil sodium (16 mg/day) with 6 wk of treatment with the bronchodilator drug albuterol (800 micrograms/day) in 29 adults with allergic asthma." | 5.07 | Nedocromil sodium versus albuterol in the management of allergic asthma. ( de Jong, JW; de Monchy, JG; Koëter, GH; Postma, DS; Teengs, JP; van der Mark, TW, 1994) |
| "To evaluate the effects of aminophylline (Am) in children hospitalized with asthma." | 5.07 | Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. ( Bonagura, VR; Strauss, RE; Valacer, DJ; Wertheim, DL, 1994) |
| "The use of oral prednisolone (2 mg/kg) to treat children admitted to hospital with acute asthma was assessed in a placebo controlled study." | 5.07 | Prednisolone and salbutamol in the hospital treatment of acute asthma. ( Connett, GJ; Lenney, W; Warde, C; Wooler, E, 1994) |
| "Twenty seven adults and 20 children with previously diagnosed stable asthma, using a salbutamol pressurized metered dose inhaler (P-MDI) and living in Cairns, Townsville and Southport, Queensland, Australia participated in a randomized, open-label cross-over comparison of terbutaline administered via Turbuhaler and salbutamol administered via P-MDI." | 5.07 | A multicentre comparison of the efficacy of terbutaline Turbuhaler and salbutamol pressurized metered dose inhaler in hot, humid regions. ( Buchanan, PR; Lindsay, DA; Russell, NL; Shellshear, ID; Thompson, JE; Warnock, TH, 1994) |
| "In an open randomised study 25 patients with severe acute asthma who presented to the emergency department were treated with either a combined nebulised salbutamol (5 mg/dose) and aminophylline infusion (0." | 5.07 | Effect of adding aminophylline infusion to nebulised salbutamol in severe acute asthma. ( Ismail, O; Yusoff, K; Zainudin, BM, 1994) |
| "Patients who presented to the ED with moderate to severe asthma and did not improve after one treatment with nebulized albuterol." | 5.07 | Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. ( Eberlein, RS; Mazur, JE; Rudnitsky, GS; Schoffstall, JM; Spivey, WH, 1993) |
| "To evaluate the effectiveness of inhibiting the formation of the 5-lipoxygenase products of arachidonic acid by the 5-lipoxygenase inhibitor zileuton in the treatment of mild-to-moderate asthma." | 5.07 | The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. ( Busse, W; Cohn, J; Drazen, JM; Fish, J; Grossman, J; Israel, E; Kaiser, HB; Karahalios, P; Kemp, JP; Lanni, C; Ledford, D; Murray, JJ; Pearlman, H; Pierson, W; Rosenthal, R; Rubin, P; Segal, AT; Siegel, SC; Tinkelman, D; Wenzel, S, 1993) |
| "To determine the effect of adding intravenous theophylline (administered as aminophylline) to nebulizations of albuterol and intravenous methylprednisolone in adults hospitalized for acute asthma." | 5.07 | Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma? ( Aull, L; Harman, E; Hendeles, L; Huang, D; O'Brien, RG; Reents, S; Shieh, G; Visser, J, 1993) |
| "The role of intravenous aminophylline in acute asthma is unclear despite meta-analysis of many studies comparing aminophylline with other bronchodilator therapies." | 5.07 | Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators. ( Cameron, P; Coleridge, J; Epstein, J; Teichtahl, H, 1993) |
| " The purpose of this study was to investigate whether the addition of a single aerosolized dose of glycopyrrolate to an albuterol regimen results in a greater improvement in pulmonary function than treatment with an albuterol regimen alone in patients with acute asthma." | 5.07 | Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma. ( Cydulka, RK; Emerman, CL, 1994) |
| "The aim of this study was to compare the response to inhaled albuterol after administration by nebulizer with the response after administration by a metered-dose inhaler and spacer device (MDI-spacer) to children with acute asthma." | 5.07 | Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. ( Bentur, L; Canny, GJ; Kerem, E; Levison, H; O'Brodovich, H; Reisman, J; Schuh, S, 1993) |
| " Patients with acute asthma received either albuterol, 0." | 5.07 | A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. ( Afilalo, M; Colacone, A; Kreisman, H; Wolkove, N, 1993) |
| "We investigated the effects of inhaled nedocromil sodium and albuterol administered prior to allergen challenge in the late asthmatic response (LAR) and circulating cells in a double-blind placebo-controlled study." | 5.07 | Albuterol and nedocromil sodium affect airway and leukocyte responses to allergen. ( Holgate, ST; Sams, VR; Twentyman, OP, 1993) |
| "These data demonstrate that oral prednisone, within 4 hours of its administration, reduced the need for hospitalization among a subset of children treated in the emergency department for acute asthma." | 5.07 | Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. ( Fuchs, SM; Nager, AL; Scarfone, RJ; Shane, SA, 1993) |
| "Bronchodilator effect and toxicity of theophylline 300 mg twice a day (R1), salbutamol 4 mg tid (R2), their combination in higher (200/4mg, R3), and lower doses (100/2mg R4), and placebo (calcium lactate 300 mg) tid (R5) were compared in 25 patients with bronchial asthma in a randomized crossover trial." | 5.07 | Is combined therapy of sympathomimetics and theophylline indicated? ( Devpura, K; Garg, VK; Jain, NK; Sharma, SD; Sharma, TN, 1993) |
| "To determine the efficacy of theophylline when given in addition to nebulized albuterol and intravenously administered corticosteroid to children hospitalized with mild to moderate asthma." | 5.07 | Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid. ( Alpert, SE; DiGiulio, GA; Kercsmar, CM; Krug, SE; Marx, CM, 1993) |
| "To determine whether intravenously administered theophylline, when added to frequently nebulized albuterol and intravenously administered methylprednisolone, benefits children hospitalized with severe asthma." | 5.07 | Efficacy of intravenously administered theophylline in children hospitalized with severe asthma. ( Carter, E; Chesrown, S; Cruz, M; Hendeles, L; Reilly, K; Shieh, G, 1993) |
| "5, 25, 50, 100 micrograms) were compared with albuterol aerosol 200 micrograms and placebo in 24 patients with moderate asthma with 24-hour pulmonary function testing and Holter monitoring." | 5.07 | Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. ( Bierman, CW; Cocchetto, DM; Kemp, JP, 1993) |
| "Nine patients with asthma with a mean(SE) age of 65(5) years and percentage predicted forced expiratory volume in one second (FEV1 of 61(9)% participated in a double blind, placebo controlled, within subject crossover study to assess the effect of two weeks of treatment with salbutamol (Volmax; 8 mg twice daily) or theophylline (Phyllocontin; 350 mg twice daily) on lung mucociliary clearance during sleep." | 5.07 | Effect of oral bronchodilators on lung mucociliary clearance during sleep in patients with asthma. ( Agnew, JE; Clarke, SW; Hasani, A; Pavia, D; Vora, H, 1993) |
| "We treated 30 asthmatic patients in 2 sessions with the beta-agonist albuterol using the above-mentioned devices." | 5.07 | Clinical comparison of Gentle-Haler Actuator and Aerochamber Spacer for Metered Dose Inhaler (MDI) use by asthmatics. ( Chipps, BE; Naumann, PF; Raabe, OG; Wong, GA, 1992) |
| "The duration of the blocking effect of salmeterol (50 micrograms), albuterol (200 micrograms), and a placebo were compared in a double-blind study in 12 adult subjects with asthma who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days." | 5.07 | Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Malo, JL; Trudeau, C, 1992) |
| "The duration of the blocking effect of salmeterol (50 micrograms), albuterol (200 micrograms) and placebo was compared in a double-blind study carried out in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air on 4 study days." | 5.07 | [Duration of bronchial protective effect of salmeterol in asthma induced by hyperventilation with dry cold air]. ( Cartier, A; Ghezzo, H; L'Archevêque, J; Malo, JL; Trudeau, C, 1992) |
| "Ninety-six patients with nocturnal asthma (FEV1 = 60-90% pred, reversibility greater than or equal to 15%, at least 2 awakenings in the week preceding the trial) were included in a double-blind, randomized, crossover, multicenter study which compared the efficacy and side effects of inhaled salmeterol (50 micrograms morning and evening) to the association theophylline-ketotifen (300 mg and 1 mg morning and evening, respectively)." | 5.07 | [Usefulness of salmeterol in nocturnal asthma: a comparative study with theophylline-ketotifen association. A French multicenter group]. ( Georges, D; Muir, JF, 1992) |
| "At four medical centers, 98 patients with stable asthma, histories of nighttime awakening at least three times weekly and nighttime declines of pulmonary function of at least 15%, who were not taking oral adrenergic agonists, were randomly treated with either oral repeat-action albuterol sulfate (Proventil Repetabs), 4 mg in the morning and 4-16 mg at bedtime, or a placebo for 2 weeks." | 5.07 | The effect of repeat action albuterol sulfate (Proventil Repetabs) in nocturnal symptoms of asthma. ( Bodman, SF; Greenstein, SM; Morris, RJ; Nathan, RA; Selner, JC; Storms, WW; Zwillich, CW, 1992) |
| "The aim of this investigation was to study whether certain patients benefit from adding theophylline to the beta 2-agonist treatment of acute asthma." | 5.07 | Which patients benefit from adding theophylline to beta 2-agonist treatment in severe acute asthma? ( Boe, J; Boman, G; Janson, C, 1992) |
| "For the management of mild-to-moderate asthma, salmeterol given twice daily is superior to albuterol given either four times daily or as needed." | 5.07 | A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. ( Chervinsky, P; Dockhorn, RJ; Grossman, J; Kemp, JP; LaForce, C; Liddle, RF; Pearlman, DS; Seltzer, JM; Southern, DL; Yancey, SW, 1992) |
| " Thirty six adults with chronic asthma requiring beta-agonists four times daily were treated with terbutaline 500 micrograms via T and salbutamol 400 micrograms via D four times daily, each period lasting four weeks." | 5.07 | Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists. ( Armstrong, S; Brown, PH; Crompton, GK; Lenney, J; Ning, AC, 1992) |
| "The hypoxic effects of salbutamol 200 micrograms (CAS 18559-94-9) and bitolterol mesilate 740 micrograms (Biterol, CAS 30392-41-7), both administered by pressurized aerosol, were assessed by transcutaneous pO2 monitoring in 18 asthmatic subjects and in 12 normal volunteers." | 5.07 | Effects of salbutamol and bitolterol mesilate on pO2 levels in asthmatic patients and healthy volunteers. ( Allegra, L; Cogo, AL; Dal Negro, R; Pomari, C; Turati, C; Turco, P, 1992) |
| "Twenty-five patients with acute severe asthma were treated with oxygen, corticosteroids and either salbutamol or aminophylline by intravenous infusion." | 5.07 | Mechanisms of abnormal glucose metabolism during the treatment of acute severe asthma. ( Banks, J; Buchanan, K; Cheong, B; Gunawardena, KA; Smith, AP, 1992) |
| "In a placebo-controlled, double-blind, crossover study with a washout phase of 2 months between each treatment period, single daily doses of 10 and 30 mg of astemizole were given to 12 patients with extrinsic asthma during 28 consecutive days." | 5.07 | Effect of astemizole on allergic asthma. ( Abadías, M; Cisteró, A; Jané, F; Lafuente, V; Lleonart, R; Pintó, E; Torrent, J, 1992) |
| "Both drugs are effective bronchodilators in young and old asthmatic subjects, but albuterol results in a greater magnitude of response in both age groups." | 5.07 | Effect of age on bronchodilator response. ( Abuan, TH; Driesner, NK; Emmick, G; Kradjan, WA; Schoene, RB, 1992) |
| "One hundred twenty consecutive patients aged 18 to 65 years with acute asthma unresponsive to a single albuterol treatment." | 5.07 | Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. ( Green, SM; Rothrock, SG, 1992) |
| "We have measured the plasma levels of salbutamol, terbutaline and theophylline in 140 patients (70 men, mean age 57 yrs) arriving for emergency treatment with severe acute asthma." | 5.07 | Bronchodilator intake and plasma levels on admission for severe acute asthma. ( Boe, J; Boman, G; Janson, C; Mossberg, B; Svedmyr, N, 1992) |
| "The safety, tolerability and bronchodilator properties of inhaled verlukast (MK-0679), a new potent and selective LTD4-receptor antagonist, were studied in 12 asthmatic subjects with more than 15% increase in FEV1 after salbutamol inhalation." | 5.07 | Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast--MK-0679) in asthmatic patients. ( Buntinx, A; De Lepeleire, I; Decramer, M; Friedman, B; Lammers, JW; Van Daele, P; Van den Elshout, FM, 1992) |
| "Three combination regimens, (1) inhaled albuterol (ALB) with oral theophylline (THEO), (2) inhaled ALB with inhaled beclomethasone dipropionate (BDP), or (3) inhaled ALB, inhaled BDP, and oral THEO, were evaluated and compared as optimal pharmacotherapy for chronic asthma in 111 children." | 5.07 | Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma. ( Eigen, HN; Ellis, EF; Hemstreet, MP; Meltzer, EO; Orgel, HA, 1992) |
| "In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart." | 5.07 | Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. ( Barnes, NC; Hui, KP, 1991) |
| " We compared the effect of 50 micrograms salmeterol administered by metered dose inhaler (MDI) and dry powder inhaler (DPI), with 200 micrograms albuterol (by MDI) on FEV1 and histamine-induced bronchoconstriction in 12 asthmatic subjects in a double-blind, placebo-controlled crossover study." | 5.07 | A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. ( Gongora, HC; Tattersfield, AE; Wisniewski, AF, 1991) |
| "In a controlled clinical crossover trial, the therapeutic effect of pirbuterol (CAS 38677-81-5) in the Autohaler was compared to that of salbutamol in a customary metered-dose aerosol in 17 children with asthma." | 5.07 | Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler. ( Kroll, VM; Schneider, B; Völkl, KP; Wiesemann, HG, 1991) |
| "Salbutamol controlled-release (CR), a new salbutamol formulation, was compared in asthmatic patients to another long-acting bronchodilator, theophylline L." | 5.07 | [Delayed-release salbutamol, a new beta-mimetic with prolonged action. Results of a comparative study against theophylline L.A]. ( Brune, J; Desfougères, JL, 1991) |
| "This study compared the acute and chronic effects of albuterol syrup (2 mg) and metaproterenol syrup (10 mg) three times a day over 28 days in 65 children, aged 6 to 9 years, with mild to moderate asthma." | 5.07 | Comparison of albuterol and metaproterenol syrup in the treatment of childhood asthma. ( Ratner, PH; Shapiro, GG; Wolfe, JD, 1991) |
| "We compared the efficacy of inhaled formoterol, a long-acting beta 2-agonist, with inhaled albuterol in 145 stable adult asthmatics in a 12-wk multicenter trial." | 5.07 | A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. ( Broder, I; Cartier, A; Chapman, KR; Hyland, RH; Kesten, S; Knight, A; Malo, JL; Mazza, JA; Moote, DW; Small, P, 1991) |
| "To determine whether treatment of acute asthma with repeated doses of nebulized albuterol leads to greater bronchodilation and lower hospital admission rate than treatment with nebulized isoetharine." | 5.07 | A randomized, controlled comparison of isoetharine and albuterol in the treatment of acute asthma. ( Boehm, SP; Cydulka, RK; Effron, D; Emerman, CL; Gershman, H; Lukens, TW, 1991) |
| "In a multicentre, randomized, cross-over double-blind, double placebo trial the effectiveness and tolerability of slow-release oral salbutamol (SRS) were compared with those of long-acting (LA) theophylline (T) in the treatment of nocturnal asthma of adults." | 5.07 | [Slow-release salbutamol in the treatment of nocturnal asthma. Result of a comparative study vs. long-acting theophylline]. ( Arnaud, A; Desfougères, JL; Michel, FB; Pappo, M, 1991) |
| "The additional effect, if any, of subcutaneous, long-acting epinephrine (Sus-Phrine) to aerosolized albuterol for acute pediatric asthma was studied." | 5.07 | Effect of injected long-acting epinephrine in addition to aerosolized albuterol in the treatment of acute asthma in children. ( Aquino, N; Kornberg, AE; Mezzadri, F; Welliver, JR; Zuckerman, S, 1991) |
| "The protective efficacy of oral cetirizine, a selective and potent H1-receptor antagonist, against the immediate bronchoconstrictive response to allergen inhalation and exercise challenge was evaluated in 16 subjects with stable, predominantly mild asthma." | 5.06 | Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. ( Dauphinee, B; Djahed, B; Gong, H; Tashkin, DP; Wu, TC, 1990) |
| "The cardiovascular, respiratory, and hypokalemic effects of repeated inhalation of fenoterol, albuterol, and isoproterenol were compared in 12 subjects with stable asthma according to a double-blind, crossover design." | 5.06 | The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma. ( Beasley, R; Burgess, CD; Crane, J; Pearce, N; Purdie, G; Siebers, RW; Windom, HH, 1990) |
| "The duration of effect of inhaled formoterol (24 micrograms) was compared with that of a placebo and that of inhaled albuterol (200 micrograms) in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air (-20 degrees C) on 4 study days." | 5.06 | Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. ( Cartier, A; Ghezzo, H; Gontovnick, L; Malo, JL; Trudeau, C, 1990) |
| "The airway response and cardiovascular and hypokalaemic effects of fenoterol, salbutamol, and terbutaline given in multiples of standard doses from metered-dose inhalers were studied in ten patients with mild asthma." | 5.06 | Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. ( Britton, JR; Pavord, ID; Tattersfield, AE; Williams, J; Wong, CS, 1990) |
| "To determine the effect of pharmacologic modulation of alterations of peripheral blood T-cell subsets caused by antigen-induced bronchoconstriction, we administered albuterol immediately after antigen-induced bronchoconstriction in a double-blind to protocol to 12 atopic asthmatic subjects." | 5.06 | Antigen-induced T-cell changes: modulation by pharmacologic agents. ( Gerblich, A; Salik, H; Schuyler, M; Varghese, J, 1990) |
| "A double-blind, randomized, crossover chronic study was done to determine the efficacy of colchicine in 10 atopic patients with asthma." | 5.06 | A clinical and immunologic study of colchicine in asthma. ( Garty, MS; Greif, J; Ilfeld, DN; Kivity, S; Schlesinger, M; Schwarz, YA; Topilsky, M, 1990) |
| "We have investigated the ability of salbutamol to protect against bronchoconstriction induced by methacholine, histamine, and adenosine 5'-monophosphate (AMP) in nine subjects with asthma." | 5.06 | Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma. ( Finnerty, JP; Holgate, ST; Phillips, GD, 1990) |
| "The bronchodilator effect of nebulized AMN, albuterol and their combination was evaluated in 16 steroid-dependent asthmatic children." | 5.06 | Efficacy of atropine methylnitrate alone and in combination with albuterol in children with asthma. ( Hill, MR; Nelson, HS; Sladek, WA; Sur, S; Szefler, SJ; Vichyanond, P, 1990) |
| "Thirty-three children and adolescents from 5 to 17 years of age with moderate to severe acute asthma were given nebulized albuterol therapy in either a high (0." | 5.06 | Nebulized albuterol in acute childhood asthma: comparison of two doses. ( Bailey, D; Canny, G; Forbes, T; Levison, H; Pender, E; Reider, MJ; Schuh, S; Tan, YK, 1990) |
| "To determine the efficacy of intravenous aminophylline in the treatment of adult patients hospitalized for exacerbation of asthma." | 5.06 | Inhaled albuterol and oral prednisone therapy in hospitalized adult asthmatics. Does aminophylline add any benefit? ( Abou-Shala, N; Burns, R; Ellis, RF; Kellermann, AL; Self, TH; Stewart, CF; Tsiu, SJ, 1990) |
| "In a randomised controlled trial 38 asthmatic children aged 2-11 yr who had not received regular oral or inhaled steroids during the previous year, were treated with a standard regime of nebulised salbutamol and intravenous aminophylline plus either hydrocortisone and oral prednisolone for 5 days, or placebo." | 5.06 | Placebo controlled trial of systemic corticosteroids in acute childhood asthma. ( Gleeson, JG; Loftus, BG; Price, JF, 1990) |
| "We studied the safety and efficacy of albuterol (salbutamol) delivered by continuous nebulization (CN) in the initial emergency department treatment of asthma." | 5.06 | Continuous nebulization of albuterol (salbutamol) in acute asthma. ( Afilalo, M; Colacone, A; Kreisman, H; Rosenthal, TM; Stern, E; Wolkove, N, 1990) |
| "A double-blind, crossover trial was conducted to examine the effect of albuterol aerosol on the fine-motor performance of children with chronic asthma." | 5.06 | The effect of albuterol aerosol on fine-motor performance in children with chronic asthma. ( Bender, B; Figueroa-Rosario, W; Mazer, B, 1990) |
| "Twenty asthmatic patients clinically free of heart disease were studied for the possible arrhythmogenic action of albuterol (salbutamol)." | 5.06 | Asthma, cardiac arrhythmias, and albuterol aerosol. ( Lazzari, JO; Martelli, NA; Raimondi, AC, 1986) |
| "The cardioselectivity and hypotensive properties of the beta 1-specific beta-blocker bisoprolol were investigated using a single-dose comparison of 10 and 20 mg bisoprolol, 100 mg atenolol, and placebo in 12 hypertensive asthmatic patients." | 5.06 | The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. ( Chatterjee, SS, 1986) |
| "Bronchodilator responses to both nebulized albuterol (salbutamol) and ipratropium bromide and aerosol delivery to the tracheobronchial tree have been assessed in eight patients with chronic stable asthma (mean baseline FEV1, 50 percent; reversibility greater than 20 percent)." | 5.06 | Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. ( Bloom, R; Clarke, SW; Johnson, MA; Newman, SP; Talaee, N, 1989) |
| "We studied the effects of salbutamol, ipratropium bromide and cromolyn sodium on PGF2 alpha-induced bronchospasm in ten patients with asthma." | 5.06 | Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F2 alpha-induced bronchospasm. ( Georgopoulos, D; Giulekas, D; Ilonidis, G; Sichletidis, L, 1989) |
| "Two double-blind, double-dummy, randomized, crossover studies were performed in 8 asthmatic patients to evaluate beta 2-adrenoceptor selectivity and potency of broxaterol compared to salbutamol." | 5.06 | Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment. ( Löfdahl, CG; Sigvaldasson, A; Skoogh, BE; Svedmyr, N, 1989) |
| "A study was carried out in 8 patients with chronic stable bronchial asthma to compare the bronchodilator response with terbutaline, administered by a recently developed powder inhalation system ('Turbuhaler') and equipotent doses of salbutamol administered by a widely used powder inhaler ('Rotahaler')." | 5.06 | Dose-effect relationship of terbutaline using a multi-dose powder inhalation system ('Turbuhaler') and salbutamol administered by powder inhalation ('Rotahaler') in asthmatics. ( Bogaard, JM; Slingerland, R; Verbraak, AF, 1989) |
| "A dose-ranging study and a 12-week treatment study were conducted in children with asthma, aged 4 to 12 years, to assess the efficacy and safety of albuterol inhaled as either an aerosol or as dry powder." | 5.06 | Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol. ( Bronsky, EA; Furukawa, CT; Grossman, J; Kemp, JP; Lemanske, RF; Mansfield, LE; Murphy, S; Ratner, PH; Reese, ME; Rogenes, PR, 1989) |
| "Fifteen otherwise healthy asthmatics with reversible airway obstruction were treated with salbutamol (8 mg slow release twice daily) and theophylline (300 mg twice daily)." | 5.06 | Effect of theophylline and salbutamol on hepatic drug metabolism. ( Christensen, HR; Døssing, M; Evald, T; Lange, P, 1989) |
| "In order to examine a possible mechanism of action of ketotifen in asthma, a double-blind study was undertaken to determine whether ketotifen showed any effects on the beta-adrenergic system in asthmatic patients." | 5.06 | The effects of ketotifen on beta-adrenergic activity in asthmatics. ( Burge, PS; Gove, RI; Skinner, C; Stableforth, DE, 1988) |
| "Forty patients suffering from asthmatic conditions, often accompanied by emphysema, were treated either with an extempore combination of salbutamol syrup plus 30-mg oxatomide tablets or with 30-mg oxatomide tablets alone for purposes of comparison." | 5.06 | Treatment of asthma with an extempore combination of a bronchodilator, salbutamol, and a new antihistamine drug, oxatomide. ( Caprioglio, L; Scremin, S, 1986) |
| "The effect of long-term treatment with theophylline was studied in 20 chronic asthmatic patients receiving oral and inhaled beta 2-agonists." | 5.06 | Theophylline in maintenance treatment of chronic asthma: concentration-dependent additional effect to beta 2-agonist therapy. ( Billing, B; Dahlqvist, R; Hörnblad, Y; Leideman, T; Ripe, E; Skareke, L, 1987) |
| "140 children of 184 with acute asthma entered a randomised double-blind trial of oral prednisolone (n = 67) compared with placebo (n = 73) administered soon after admission." | 5.06 | Effect of a single oral dose of prednisolone in acute childhood asthma. ( Barrell, E; Barry, W; Hatcher, G; Lenney, W; Storr, J, 1987) |
| "In 12 adult patients with reversible bronchospasm (7 bronchial asthma and 5 chronic obstructive bronchitis) the bronchodilator activity and tolerability of 200 and 400 mcg of broxaterol hydrochloride (Z 1170) were compared to those of 200 mcg of salbutamol administered by metered-dose inhaler." | 5.06 | A comparison of the bronchodilator effects of broxaterol and salbutamol. ( Casali, L; Colombo, ML; Manazza, P; Rossi, A; Zoia, MC, 1988) |
| "4 mg azelastine administered orally on airway responsiveness, skin prick testing, daily peak expiratory flow rates and symptoms of asthma was compared with placebo in a 7 week double-blind, parallel group study of 24 patients with extrinsic asthma." | 5.06 | A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness. ( Aurich, R; Davies, RJ; Gould, CA; Ollier, S, 1988) |
| "The aim of the present study was to verify the effectiveness of procaterol, a recent and specific beta-2-adrenoceptor stimulant, in preventing exercise-induced asthma (EIA)." | 5.06 | A new bronchodilating agent, procaterol, in preventing exercise-induced asthma. ( Donner, CF; Fracchia, C; Ioli, F; Manini, G; Patessio, A; Spada, EL; Vecchio, C, 1986) |
| " The inadvertent administration of timolol to asthmatic patients continues to cause occasional severe and even fatal attacks of asthma." | 5.06 | Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects. ( Richards, R; Tattersfield, AE, 1987) |
| "The efficacy and safety of orally administered procaterol hydrochloride, a potent beta 2-adrenergic bronchodilator, was compared with that of albuterol in an eight-center, double-blind study conducted in 223 patients with mild to moderate, reversible bronchial airway obstruction." | 5.06 | A comparison of oral procaterol and albuterol in reversible airflow obstruction. ( Beaupre, A; Boulet, LP; Brandon, ML; Busse, WW; Chervinsky, P; Mazza, J; Petty, TL; Schoenweter, W, 1988) |
| "The efficacy of procaterol, a new beta 2-selective sympathomimetic drug, was compared with that of salbutamol and placebo in a double-dummy crossover study in 20 asthmatic patients." | 5.06 | Comparison between oral procaterol and salbutamol in patients with bronchial asthma. ( Jaakkola, J; Terho, EO; Torkko, M; Tukiainen, H, 1988) |
| "Single-dose salbutamol (200 micrograms), beclomethasone dipropionate (200 micrograms), and sodium cromoglycate (SCG) (10 mg) administered by inhalation 10 minutes before allergen challenge were examined with regard to inhibition of allergen-induced early (EAR) and late (LAR) asthmatic responses and allergen-induced increase in bronchial responsiveness to inhaled histamine." | 5.06 | Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. ( Cockcroft, DW; Murdock, KY, 1987) |
| " Terfenadine, a histamine H1-receptor antagonist, was studied in 52 patients with stable mild perennial asthma with an allergic basis." | 5.06 | Treatment of bronchial asthma with terfenadine; a randomized controlled trial. ( Beaumont, D; Lewis, PJ; Pujet, JC; Sapene, M; Taytard, A, 1987) |
| "The objective of this open randomized cross-over study was to compare the clinical efficacy and safety of a recently introduced beta-2 mimetic, tulobuterol, with fenoterol in asthma patients." | 5.06 | Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients. ( Azanza, JR; Dal-Re, R; Rivero, A; Sanchez, J, 1988) |
| " Since inhalation of these drugs results in less systemic side effects, the present double-blind study was designed to investigate the influence of inhalation of the beta 2-adrenergic agonist albuterol (salbutamol) on esophageal motor function and gastroesophageal reflux in ten healthy volunteers." | 5.06 | Effects of albuterol (salbutamol) on esophageal motility and gastroesophageal reflux in healthy volunteers. ( Heinrich, C; Huber, RM; Müller-Lissner, SA; Schindlbeck, NE, 1988) |
| "Twelve subjects with stable asthma each inhaled two puffs (200 micrograms) of salbutamol on 2 separate days 3 h after double-blind oral administration of ketotifen (two 1-mg capsules) or identical placebo." | 5.06 | Effect of ketotifen on the bronchodilation induced by salbutamol. ( Baldanza, C; Bonanno, CT; Carpentiere, G; Castello, F; Marino, S, 1988) |
| "Nifedipine, 30 mg/day for 4 weeks, was compared to placebo in a double-blind, randomized, crossover study, as an additional drug added to the usual treatment of 14 patients with bronchial asthma." | 5.06 | Nifedipine treatment of patients with bronchial asthma. ( Dascalopoulou, E; Maniki, E; Patakas, D; Tsara, V, 1987) |
| "Twelve patients with chronic severe asthma, having previously shown an FEV1 increase of less than 20% of the predicted value with prednisolone treatment (20-60 mg daily for 10 days), took part in a double blind crossover comparison of equipotent anti-inflammatory doses of betamethasone and prednisolone." | 5.06 | Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma. ( Belmatoug, N; De Lauture, D; Grandordy, B; Marsac, J; Morelle, A, 1987) |
| "Inhalation of albuterol aerosol, 200 micrograms, delivered from metered dose inhalers via Aerochamber, elicited a highly significant improvement in peak expiratory flow rate from 70% to 84% and 91% predicted normal 5 and 20 minutes after treatment, respectively, in 30 asthmatic children 3 to 6 years of age." | 5.06 | Delivery of albuterol aerosol by aerochamber to young children. ( Barbera, JM; Eby, DM; Middleton, HB; Sly, RM, 1988) |
| "Clenbuterol (C), a long-acting beta 2-selective bronchodilator was compared with salbutamol (S) in exercise-induced asthma (EIA) at two premedication time levels." | 5.06 | Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise-induced asthma in children. ( Boner, AL; Brighenti, C; Miglioranzi, P; Richelli, C; Schiassi, M; Vallone, G, 1988) |
| "The bronchodilator efficacy of two brands of salbutamol (USAN albuterol) metered-dose inhalers (MDIs) was compared in a double-blind protocol involving 31 asthmatics." | 5.06 | Differing bioavailability of salbutamol metered-dose inhalers. ( Chhabra, SK, 1987) |
| "In fifteen patients with asthma tulobuterol, a new beta 2-adrenoceptor agonist, given by inhalation in 100 micrograms increments up to a cumulative dose of 600 micrograms produced dose related increases in both the FEV1 and FVC." | 5.06 | Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. ( Patel, KR, 1986) |
| "The extrapulmonary effects of slow-release theophylline and an inhaled beta 2-agonist (albuterol) were examined separately and in combination among 18 adults and adolescents with asthma during a 3-month randomized, double-blind, crossover trial." | 5.06 | Extrapulmonary effects of maintenance therapy with theophylline and inhaled albuterol in patients with chronic asthma. ( Ahrens, RC; Joad, JP; Lindgren, SD; Weinberger, MM, 1986) |
| "Four regimens of bronchodilatation therapy administered on 2 consecutive days were tested in 4 randomly selected groups of 6 asthmatic patients: 1) intravenous atropine + inhaled oxitropium bromide; 2) intravenous atropine alone; 3) intravenous salbutamol + inhaled salbutamol; 4) intravenous salbutamol alone." | 5.06 | [Comparative study of anticholinergic and betamimetic agents in the treatment of asthma attacks]. ( Arnaud, A; Herkert, A; Philip-Joet, F; Vervloet, D, 1986) |
| "In order to study the dose-related effect of nifedipine on expiratory flow rates, 15 asthmatic patients were given sublingually 10 mg and 20 mg of the drug on two different days and the FVC and FEV1 were measured during 90 minutes." | 5.06 | Nifedipine in asthma. Dose-related effect on resting bronchial tone. ( Chaniac, A; Gruzman, C; Katz, I; Lidgi, M; Molho, M, 1987) |
| "The bronchodilator effect of a combination of 200 micrograms salbutamol and 200 micrograms oxitropium bromide, given as pressurized aerosols, was compared to that of 200 and 400 micrograms of salbutamol in a controlled experiment on adult patients with asthma." | 5.06 | Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols. ( Laitinen, LA; Poppius, H, 1986) |
| "Sustained-release, 24-hour theophylline preparations have been formulated and may provide for convenient once-a-day dosing, although the use of such products in clinical asthma has yet to be fully established." | 5.06 | The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment. ( Bush, RK; Busse, WW; Smith, A, 1986) |
| "The relative benefit of maintenance therapy with theophylline, inhaled albuterol, and the combination was examined in 18 adolescents and adults with chronic asthma during a 3-month, randomized, double-blind, crossover trial." | 5.06 | Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. ( Ahrens, RC; Joad, JP; Lindgren, SD; Weinberger, MM, 1987) |
| "Three parenteral routes of albuterol sulfate were compared with placebo in their effects on serum potassium and glucose levels, heart rate, and pulmonary function in adult asthmatic subjects." | 5.06 | Efficacy of parenteral albuterol in the treatment of asthma. Comparison of its metabolic side effects with subcutaneous epinephrine. ( Katz, RM; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1986) |
| "The benefits of metered-dose inhalers with a spacer (MDI+S) have increasingly been recognized as an alternative method of albuterol administration for treating pediatric asthma exacerbations." | 5.05 | Metered-dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with meta-analysis. ( Barrios-Sanjuanelo, A; Contreras-Arrieta, S; Florez-García, V; Payares-Salamanca, L; Rodriguez-Martinez, CE; Stand-Niño, I, 2020) |
| "The efficacy and adverse effects of ketotifen 1 mg twice daily and 2 mg twice daily were compared with placebo in 50 patients with atopic asthma in a multicentre, double-blind study." | 5.05 | Ketotifen in adult asthma. ( Dyson, AJ; Mackay, AD, 1980) |
| "A double-blind crossover comparative study between carbuterol 3 mg thrice daily, carbuterol 2 mg thrice daily and salbutamol 4 mg thrice daily by the oral route was conducted in thirty patients suffering from bronchial asthma, selected at random, with more than 20% reduction in airway obstruction following isoprenaline inhalation." | 5.05 | Double-blind crossover study of carbuterol and salbutamol in bronchial asthma. ( Khemchandani, GT; Misra, NP; Tiwari, UC, 1981) |
| "Prazosin, a potent and selective alpha-adrenergic antagonist, was given by inhalation to nine asthmatic subjects aged 25-48 years (six with positive skin tests)." | 5.05 | Inhaled prazosin in asthma. ( Barnes, PJ; Dollery, CT; Ind, PW, 1981) |
| "A study to compare the bronchodilator effect of salbutamol powder (Ventolin, 200 micrograms) administered via a Rotahaler (SR), with that of terbutaline sulphate (Bricanyl, 500 micrograms) administered via a Misthaler (TM) was carried out in 25 children with stable moderate to severe asthma." | 5.05 | Bronchodilator effects of salbutamol powder administered via Rotahaler and of terbutaline aerosol administered via Misthaler. A comparison study in children with asthma. ( Mellis, CM; Sharota, E; Simpson, SJ; Towns, SJ, 1983) |
| "Chlorpheniramine, clemastine and a placebo have been compared for their ability to relieve bronchoconstriction in 14 childhood asthmatics between the ages of 6 and 14 years." | 5.05 | Bronchodilator effect of two inhaled H1-receptor antagonists, clemastine and chlorpheniramine, in wheezy school-children. ( Hodges, IG; Milner, AD; Stokes, GM, 1983) |
| "Forty-four asthmatic patients were treated on separate days with increasing doses of albuterol in four double-blind studies that included placebo controls." | 5.05 | The bronchodilator response to inhalation of increasing doses of aerosolized albuterol. ( Dwek, JH; George, RB; Nelson, HS; Spector, SL; Whitsett, TL, 1983) |
| " We evaluated 140 patients with bronchial asthma in a prospective double-blind controlled study of possible tachyphylaxis to albuterol aerosol as compared to isoproterenol aerosol." | 5.05 | Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. ( Anderson, JA; Bush, RK; Falliers, CJ; Kass, I; Kemp, JP; Reed, C; Repsher, LH; Siegel, S; Webb, DR, 1984) |
| "Dose-response curves for atropine and ipratropium bromide were made in nine asthmatics unresponsive to salbutamol." | 5.05 | Comparison of atropine with ipratropium bromide in patients with reversible airways obstruction unresponsive to salbutamol. ( Burge, PS; Harries, MG; l'Anson, E, 1980) |
| "The bronchodilator activity in nebulised salbutamol, ipratropium bromide, clemastine, and a placebo was studied in 14 asthmatic children aged between 3 and 5 years." | 5.05 | Bronchodilator effects of clemastine, ipratropium, bromide, and salbutamol in preschool children with asthma. ( Groggins, RC; Milner, AD; Stokes, GM, 1981) |
| "The bronchodilator effect of 400 micrograms of salbutamol powder (2 capsules) administered by a rota-haler was compared with that of 500 micrograms of terbutaline (2 metered doses) administered as an aerosol via a tube-spacer in a group of ten stable asthmatic children (mean age 12 years)." | 5.05 | Comparison of salbutamol powder with terbutaline aerosol administered with a tube spacer in asthmatic children. ( Francis, PW; Kelly, CA; Zimmerman, PV, 1983) |
| "A double-blind randomised controlled trial was conducted to study the effects of oral theophylline alone compared with oral theophylline and salbutamol in a sample of asthmatic children." | 5.05 | Effects of oral theophylline and oral salbutamol in the treatment of asthma. ( Dawson, KP; Fergusson, DM, 1982) |
| "Double-blind cross-over studies of oral and inhaled terbutaline and salbutamol have been performed in two groups of asthmatic patients." | 5.05 | A comparison of the effects of different methods of administration of beta-2-sympathomimetics in patients with asthma. ( Clark, TJ; Rees, J; Webb, J, 1982) |
| "The effect of adding theophylline to treatment with a beta2-adrenoceptor stimulant was studied in 18 asthmatic children in a double-blind cross-over trial." | 5.05 | Combined treatment with sustained-release theophylline and beta2-adrenoceptor-stimulating agents in chronic childhood asthma. ( Foucard, T; Lindström, B; Lönnerholm, G, 1981) |
| "Sixty-four patients with mild of moderate extrinsic asthma were treated with placebo for 1 month and thereafter with ketotifen (1 mg twice daily, orally), disodium cromoglycate (inhalation of 20 mg, four times daily), or placebo for 2 subsequent months." | 5.05 | Comparison of ketotifen, disodium cromoglycate and placebo in the treatment of adult patients with mild extrinsic asthma. ( Ahonen, A; Haahtela, T; Hurme, R; Maasilta, P; Mattson, K; Muittari, A; Poppius, H; Venho, K, 1981) |
| "Lithium carbonate was evaluated in a double-blind, crossover study for prophylactic therapy in five patients with severe perennial asthma." | 5.05 | A double blind crossover trial of lithium carbonate in asthma. ( Bearman, J; Saltz, H; Spitz, E, 1982) |
| "The efficacy of nebulised sodium cromoglycate and an oral theophylline solution at currently recommended doses were compared in one to six-year-old children with chronic asthma." | 5.05 | Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study. ( Newth, CJ; Newth, CV; Turner, JA, 1982) |
| "In a double-blind trial we compared the efficacy and safety of inhaled salbutamol (albuterol), nebulized with oxygen by face mask, and subcutaneous epinephrine in 40 children with acute asthma." | 5.05 | Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children. ( Becker, AB; Nelson, NA; Simons, FE, 1983) |
| "Fifteen patients suffering from asthma received inhalations of phentolamine, albuterol (salbutamol), a combination of phentolamine and albuterol, and placebo, in a single-blind fashion; the changes in the pulmonary function tests were recorded over a three-hour period." | 5.05 | Comparison between an alpha-adrenergic antagonist and a beta 2-adrenergic agonist in bronchial asthma. ( Molho, MI; Shiner, RJ, 1983) |
| "Although albuterol aerosol is an effective bronchodilator in adult asthmatics its efficacy and safety are not fully established in asthmatic children." | 5.05 | Double-blind comparison of acute effects of inhaled albuterol, isoproterenol and placebo on cardiopulmonary function and gas exchange in asthmatic children. ( Katz, R; Littner, MR; Siegel, SC; Tashkin, DP, 1983) |
| "Inhalation histamine challenges were performed in groups of normal and asthmatic subjects." | 5.05 | Prostaglandins and the control of airways responses to histamine in normal and asthmatic subjects. ( Walters, EH, 1983) |
| "Oral administration of salbutamol and theophylline has been shown to be effective in relieving bronchoconstriction in asthmatic children aged between 3 and 5 years." | 5.05 | Efficacy of orally administered salbutamol and theophylline in pre-schoolchildren with asthma. ( Groggins, RC; Lenney, W; Milner, AD; Stokes, GM, 1980) |
| "In a double-blind controlled trial 14 chronic asthmatic patients with regular nocturnal exacerbations took 16 mg slow-release oral salbutamol (two Ventolin spandets), 450 mg slow-release aminophylline (two Phyllocontin Continus tablets), or placebo at midnight." | 5.05 | Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels. ( Davies, HJ; Fairfax, AJ; McNabb, WR; Spiro, SG, 1980) |
| "Twenty-one patients admitted to hospital with acute severe asthma were allocated in a random, single-blind manner to receive intravenous infusions for 24 hours or either aminophylline or salbutamol or a combination of the two drugs." | 5.05 | Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma. ( Crimmins, J; Evans, WV; Monie, RD; Seaton, A, 1980) |
| "Salbutamol increased significantly the bronchodilating effect of proxyphylline both in experimental animals and in asthmatic patients." | 5.05 | Interaction between proxyphylline and salbutamol. ( Allonen, H; Kanto, J; Kulmala, T; Mäntylä, R; Tala, E, 1981) |
| "The efficacy, safety, tolerance, and bio-equivalence of albuterol (a relatively selective beta 2-adrenergic drug) was evaluated in 20 asthmatic children (6 to 14 years of age)." | 5.05 | Oral albuterol in the treatment of childhood asthma. ( Katz, RM; Rachelefsky, GS; Siegel, SC, 1982) |
| "Albuterol (salbutamol) syrup was studied in 14 asthmatic children (three to six years of age) in a four-week, double-blind, crossover (with placebo) trial to determine efficacy, safety and tolerance." | 5.05 | Albuterol syrup in the treatment of the young asthmatic child. ( Katz, RM; Rachelefsky, GS; Siegel, SC, 1981) |
| "The bronchodilation produced by increasing intravenous doses of aminophylline, salbutamol, and a combination of aminophylline and salbutamol given in random order was determined in 10 stable asthmatics on three consecutive days." | 5.05 | Intravenous salbutamol and aminophylline in asthma: a search for synergy. ( Dart, AM; Davies, BH; Handslip, PD, 1981) |
| "The effect of slow-release aminophylline, salbutamol and a half dose combination of both was compared in children with chronic asthma." | 5.05 | A comparative trial of slow-release aminophylline, salbutamol and a half dose combination in the prevention of childhood asthma. ( Blumenthal, I, 1980) |
| "Forty asthmatic children were treated either with a combination of salbutamol plus oxatomide (20 cases) or with salbutamol alone (20 cases) for purposes of comparison." | 5.05 | Treatment of asthma syndromes in pediatric patients using a combination of a beta 2-stimulant drug and a histamine antagonist. ( Bianchi, G, 1985) |
| " In this randomized, double-blind, crossover study, each of 20 male patients with moderate to severe asthma, ages 12 to 23 yr, received a single treatment with 100, 200, or 400 mcg of albuterol powder or placebo by Rotahaler on 4 study days separated by 2 to 10 days." | 5.05 | Inhaled albuterol powder for the treatment of asthma--a dose-response study. ( Kemp, JP; Meltzer, EO; Orgel, HA; Welch, MJ, 1985) |
| "1 mg/kg/6 hr) or placebo to 2- to 6-year old children whose extrinsic asthma was treated with maintenance theophylline in a prerandomized, double-blind crossover study design." | 5.05 | Albuterol syrup in the treatment of asthma. ( Bierman, CW; Furukawa, CT; Pierson, WE; Shapiro, GG, 1985) |
| "Our investigation supports the use of intravenous salbutamol as an alternative to aminophylline in the early stages of acute severe asthma." | 5.05 | Comparison of intravenous salbutamol (albuterol) and aminophylline in the treatment of acute asthmatic attacks. ( Greif, J; Markovitz, L; Topilsky, M, 1985) |
| "Calcium-channel blockers such as verapamil and nifedipine have been shown to inhibit exercise-induced asthma as well as acutely induced bronchoconstriction, but little is known of their chronic effects, if any, on bronchial asthma." | 5.05 | Nifedipine in chronic bronchial asthma: a randomized double-blind crossover trial against placebo. ( Boismare, F; Lemercier, JP; Leprevost, A; Moore, ND; Ozenne, G; Pasquis, P; Tardif, C, 1985) |
| "11 mg) and albuterol aerosol (two sprays, 180 mcg) were compared for efficacy of bronchodilation in 120 adolescent and young adult patients with moderate to severe asthma." | 5.05 | Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma. ( Kemp, JP; Orgel, HA; Tinkelman, DG; Webb, DR, 1985) |
| "The acute cardiopulmonary effects of oral albuterol, 4 mg, metaproterenol sulfate, 20 mg, and terbutaline sulfate, 5 mg, were compared over eight hours in 20 moderate to severe asthmatics." | 5.05 | Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics. ( Biedermann, AA; Chu, TJ; Wolfe, JD; Yamate, M, 1985) |
| "In 24 adult asthmatics the effects of clinically recommended doses of fenoterol (320 micrograms) and albuterol (180 micrograms) were compared to placebo in a double-blind, crossover trial." | 5.05 | A comparison of inhaled fenoterol and albuterol in asthma. ( Hordvik, NL; König, P; Sunderrajan, EV, 1985) |
| "The bronchodilator effects of 375 mg theophylline orally and 200 microg salbutamol by pressurized aerosol were compared in a randomized, cross-over, double-blind trial in fourteen asthmatic patients." | 5.04 | Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients. ( Hartnett, BJ; Marlin, GE, 1976) |
| "Eleven patients with bronchial asthma and 10 with chronic bronchitis were treated over four consecutive 3-day periods, firstly with aerosols either of ipratropium bromide (40 microgram four times a day) or of salbutamol (200 microgram four times daily) by random allocation, then the alternate drug, next by both drugs together, and finally with prednisolone (10 mg three times daily) in addition to both drugs." | 5.04 | Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis. ( Ingram, CG; Johnston, RN; Legge, JS; Lightbody, IM, 1978) |
| "The bronchodilating efficacy and the degree of beta2-selectivity of rimiterol, salbutamol and isoprenaline were determined in seven asthmatic patients." | 5.04 | The relative potencies and beta2-selectivities of intravenous rimiterol, salbutamol and isoprenaline in asthmatic patients. ( Marlin, GE; Turner, P, 1975) |
| "Ninety-nine patients with severe bronchial asthma were tested with two inhalations of Terbutaline." | 5.04 | Terbutaline: an effective bronchodilator by inhalation. ( Goldgraber, MB, 1977) |
| "The bronchodilator effects of terbutaline, 500 microng, and salbutamol, 200 microng, by pressurised aerosol were compared in 16 patients (eight asthma, eight chronic bronchitis with asthma)." | 5.04 | Comparison of terbutaline and salbutamol aerosols. ( Hartnett, BJ; Marlin, GE, 1977) |
| "Albuterol, a new bronchodilator drug known to cause beta2-adrenergic receptor stimulation, was compared with isoproterenol sulphate for their pulmonary and cardiovascular effects in patients suffering from bronchial asthma." | 5.04 | Comparative study of acute effects of albuterol and isoproterenol sulphate aerosols in bronchial asthma. ( Huber, GL; Mahajan, VK; Tomashefski, JF, 1977) |
| "Albuterol and isoproterenol aerosols were compared with placebo in a double-blind manner in 18 patients with bronchial asthma." | 5.04 | Comparison of albuterol and isoproterenol aerosols in bronchial asthma. ( George, RB; Jenkinson, SG; Light, RW, 1977) |
| "2 mg of albuterol (salbutamol), or placebo were compared in a double-blind three-way crossover study in a group of 12 asthmatic patients." | 5.04 | Clinical comparison of fenoterol and albuterol administered by inhalation. A double-blind study. ( Huhti, E; Poukkula, A, 1978) |
| "The bronchodilator effects of aerosols of hexoprenaline (200 microgram and 400 microgram), and salbutamol (200 microgram) were compared in 15 patients with asthma, and nine patients with chronic bronchitis." | 5.04 | Bronchodilator effect of hexoprenaline aerosol in bronchial asthma and chronic bronchitis. ( Evers, R; Harris, M; Jenne, H; McMiken, D; Schonell, M, 1977) |
| "Dose-response curves to intravenous salbutamol were constructed after injection of saline or aminophylline in a group of ten asthmatic patients." | 5.04 | Additive interaction of aminophylline and salbutamol in asthma: an in vivo study using dose-response curves. ( Handslip, P; Leopold, D, 1979) |
| "A double-blind comparison between orally administered NAB 365 (clenbuterol) and salbutamol was conducted in 30 impatients with either asthma or chronic bronchitis with asthma who had at least 15% reversibility in airway obstruction following inhalation of 1,500 microgram of orciprenaline." | 5.04 | NAB 365 (clenbuterol) and salbutamol in asthmatics: a double-blind clinical trial. ( Capra, A; Pasotti, C; Vibelli, C, 1979) |
| "In a single blind crossover study 12 asthmatics received in randomised order single doses of pirbuterol (200 and 400 microgram), salbutamol (200 microgram) and placebo-aerosols, in order to determine the extent and duration of bronchodilator activity, the optimum dosage, the incidence, type and degree of side effects and the cardiovascular as well as hematologic, renal and hepatic functions after inhalative administration." | 5.04 | Comparative investigations on pirbuterol, salbutamol and placebo aerosols in bronchial asthma. ( Beumer, HM, 1979) |
| "A double-blind test to compare IV aminophylline with salbutamol in the treatment of acute, uncontrolled asthma showed that both drugs were equally effective during the first 24 hours." | 5.04 | Comparison of IV salbutamol with IV aminophylline in the treatment of severe, acute asthma in childhood. ( Hambleton, G; Stone, MJ, 1979) |
| "The effect of clenbuterol (NAB 365) in inhibiting exercise-induced asthma was compared with that of salbutamol in a single-blind, placebo-controlled, crossover study." | 5.04 | Aerosolized clenbuterol (NAB 365) and salbutamol in exercise-induced asthma. ( Del Bono, N; Quartieri, F; Vibelli, C, 1979) |
| "In a single blind cross-over study 12 patients with asthma received in randomised order aerosols of pirbuterol 400 micrograms, salbutamol 200 micrograms or placebo." | 5.04 | [Comparative studies on pirbuterol, salbutamol and a placebo administered as an aerosol in asthmatic patients]. ( Verstraeten, JM, 1978) |
| "Out of 62 asthmatic patients admitted to hospital with an acute exacerbation of their disease, those whose symptoms had not sufficiently improved 15 minutes after an initial intensive regimen were randomly allocated to receive an intravenous infusion of either salbutamol 10 microgram/min (20 patients) or aminophylline 1 mg/min (19 patients)." | 5.04 | Intravenous infusion of salbutamol in severe acute asthma. ( Bateman, S; Clarke, SW; Johnson, AJ; Pidgeon, J; Spiro, SG, 1978) |
| "A double-blind crossover trial was conducted in 10 asthmatic patients for comparison of fenoterol with salbutamol, in 12 other asthmatic patients for comparison of reproterol with salbutamol, and in 15 other asthmatic patients for comparison of terbutaline with salbutamol." | 5.04 | [The bronchospasmolytics salbutamol, fenoterol, terbutaline and reproterol. Their effects and side effects in asthmatics after inhalation with an electric nebulizer]. ( Budmiger, H; Kyd, K; Scherrer, M, 1978) |
| "In a randomized double-blind trial an intravenous injection of salbutamol (100mug) was compared with an intravenous injection of aminophylline (250mg) in 23 patients with acute exacerbations of asthma." | 5.04 | A controlled trial of intravenous salbutamol and aminophylline in acute asthma. ( Robinson, JS; Tribe, AE; Wong, RM, 1976) |
| " Other findings indicate that there is no robust evidence to support the use of intravenous or nebulized magnesium sulphate in adults with severe acute asthma, and that levalbuterol was not superior to albuterol regarding efficacy and safety in individuals with acute asthma." | 4.91 | Advances in acute asthma. ( Rodrigo, GJ, 2015) |
| "To evaluate the cost-utility of the treatment with a long acting beta-agonist (LABA) and inhaled corticosteroid (ICS) combination inhaler [salmeterol xinafoate (SAL)/fluticasone propionate (FP) combination inhaler (SFC) (Advair(®))] to continuing on current ICS dose (no ICS dose change) or increased ICS dose [fluticasone propionate (FP)] in patients with uncontrolled asthma in Canada." | 4.90 | COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada. ( Corriveau, D; FitzGerald, JM; Hawkins, N; Ismaila, AS; Li, C; Risebrough, N; Su, Z, 2014) |
| "To evaluate efficacy and safety of levalbuterol versus albuterol in acute asthma." | 4.89 | Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. ( Jat, KR; Khairwa, A, 2013) |
| " Bogie 2007 investigated the addition of intravenous terbutaline to high dose nebulised albuterol in children with acute severe asthma, requiring intensive care unit (ICU) admission." | 4.88 | Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. ( Camargo, CA; Jones, AP; Milan, SJ; Rowe, BH; Travers, AH, 2012) |
| "To assess the relative effects of fluticasone/salmeterol and budesonide/formoterol in people with asthma." | 4.87 | Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. ( Casali, L; Ferrara, G; Lasserson, TJ, 2011) |
| "To estimate the relative effects of fluticasone/salmeterol and budesonide/formoterol in terms of asthma control, safety and lung function." | 4.84 | Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. ( Casali, L; Cates, CJ; Ferrara, G; Lasserson, TJ, 2008) |
| "Theophylline and long acting beta-2 agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma." | 4.84 | Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. ( Gibson, PG; Irving, LB; Koh, MS; Lasserson, TJ; Tee, AK; Wilson, AJ, 2007) |
| "To systematically review the evidence for the medium to long term benefits and risks of montelukast as add-on therapy to inhaled corticosteroids (ICS) in comparison with placebo and active controls in mild to moderate asthma." | 4.84 | Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. ( Grouven, U; Joos, S; Kaiser, T; Miksch, A; Schneider, A; Szecsenyi, J; Wieseler, B, 2008) |
| "Levalbuterol is an alternative to racemic albuterol with the potential to improve patient outcomes and reduce costs in the treatment of acute asthma exacerbations." | 4.83 | Asthma pathophysiology and evidence-based treatment of severe exacerbations. ( Schreck, DM, 2006) |
| "Our understanding of albuterol nebulization driven by helium-oxygen mixture (heliox) has matured with recent advances in clinical therapy, delivery systems, and understanding of dosing; this has led to substantial improvements in delivery as well as refinements of research protocols for asthma exacerbations." | 4.83 | Heliox-driven albuterol nebulization for asthma exacerbations: an overview. ( Corcoran, TE; Kim, IK; Saville, AL; Sikes, KL, 2006) |
| "Compared with saline,the use of isotonic magnesium sulfate as an adjuvant to nebulize salbutamol is a beneficial therapy with improving spirometric airway function in the severe asthma exacerbation." | 4.83 | [Comparison of different vehicles for nebulized salbutamol in treatment of bronchial asthma exacerbations: a Meta-analysis]. ( Lu, XY; Zhou, JY, 2006) |
| "Levalbuterol, the pure (R)-isomer of racemic albuterol, is a new therapeutic option for patients with asthma." | 4.82 | Single-isomer levalbuterol: a review of the acute data. ( Nowak, R, 2003) |
| "To review the rationale supporting the use of levalbuterol [(R)-albuterol] for the treatment of pediatric and adult asthma." | 4.82 | Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. ( Berger, WE, 2003) |
| "Theophylline and long acting beta-2 agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma." | 4.82 | Long acting beta-agonists versus theophylline for maintenance treatment of asthma. ( Coughlan, J; Gibson, PG; Shah, L; Wilson, AJ, 2003) |
| "Pharmacoeconomic analyses indicate that salmeterol/fluticasone propionate administered via a single inhaler represents a cost-effective treatment option (relative to fluticasone propionate at the same nominal dosage, budesonide, formoterol plus budesonide and montelukast plus fluticasone propionate) in patients with asthma not controlled with inhaled corticosteroid therapy." | 4.82 | Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. ( Lyseng-Williamson, KA; Plosker, GL, 2003) |
| "A short cut review was carried out to establish whether intravenous salbutamol or intravenous aminophylline offers the quickest and least complicated treatment for patients with moderate to severe asthma not responding to inhaled therapy." | 4.82 | Best evidence topic reports. Is intravenous aminophylline better than intravenous salbutamol in the treatment of moderate to severe asthma? ( Jacobs, M; Munro, A, 2004) |
| "The studies fell into 3 primary categories with some overlap: those assessing toxicity of the S-enantiomer of albuterol, those evaluating the risk of specific genotypes regarding worsening asthma, and those assessing asthma outcomes with LABA therapy." | 4.82 | What is new with the beta2-agonists: issues in the management of asthma. ( Kelly, HW, 2005) |
| "A meta-analysis was carried out of randomised, double blind clinical trials that compared the efficacy of adding salmeterol to moderate doses of ICS (fluticasone propionate 200 mug/day or equivalent) with increasing the ICS dose by at least twofold in symptomatic adult patients with asthma." | 4.82 | Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. ( Beasley, R; Holt, S; Masoli, M; Weatherall, M, 2005) |
| "Overall, this review supports the equivalence of continuous and intermittent albuterol nebulization in the treatment of acute adult asthma." | 4.81 | Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. ( Rodrigo, C; Rodrigo, GJ, 2002) |
| "To evaluate the relative clinical superiority of increasing the dose of fluticasone propionate versus the addition of salmeterol to low-dose fluticasone propionate for long-term asthma control." | 4.81 | Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control. ( Arnold, AD; Crafts, R; Heyneman, CA; Holland, J, 2002) |
| "Salbutamol (albuterol) is a beta2-adrenoceptor agonist used as a bronchodilator for the treatment of asthma and as a uterine relaxant for the suspension of premature labour." | 4.81 | The pharmacokinetics of levosalbutamol: what are the clinical implications? ( Boulton, DW; Fawcett, JP, 2001) |
| "The aim of this study was to compare the efficacy and safety of salmeterol vs theophylline in asthma management using meta-analysis of clinical trials." | 4.80 | The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. ( Brooks, G; Davies, B; Devoy, M, 1998) |
| "Salmeterol xinafoate is a highly selective beta2-adrenoceptor for the maintenance treatment of asthma in adults and children." | 4.80 | Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy. ( Buchwald, A; Hochhaus, G, 1998) |
| "Theophylline and long acting beta2-agonists are bronchodilators used for the management of persistent asthma symptoms, especially nocturnal asthma." | 4.80 | Long acting beta-agonists versus theophylline for maintenance treatment of asthma. ( Coughlan, J; Gibson, PG; Wilson, AJ, 2000) |
| "The long-acting beta2-agonist salmeterol and the corticosteroid fluticasone propionate are available as a combination inhalation device for the treatment of persistent asthma." | 4.80 | Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. ( Jarvis, B; Markham, A, 2000) |
| "Albuterol has been proven to be a vital component in the management of severe, acute asthma in children and adults." | 4.79 | Administration of albuterol by continuous nebulization. ( Buck, ML, 1995) |
| "This report describes a precocious eight-year-old child who presented with hallucinations from excessive use of albuterol inhalers." | 4.79 | Beta-agonist inhaler causing hallucinations. ( Santeiro, ML; Schnapf, BM, 1994) |
| "Salmeterol xinafoate is a selective beta 2-adrenoceptor agonist indicated for the maintenance treatment of adults and children with asthma." | 4.79 | Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma. ( Adkins, JC; McTavish, D, 1997) |
| " It is, further, necessary to apply these agents systemically together with theophylline, the best approach to pre-status and status asthmaticus being continuous i." | 4.77 | [Treatment of the severe asthma attack and status asthmaticus]. ( Baur, X, 1989) |
| "Aminophylline is routinely recommended as a basic part of the emergency treatment of asthma." | 4.77 | Aminophylline treatment in severe, acute asthma. A meta-analysis. ( Littenberg, B, 1988) |
| "The acute bronchodilator effect of the beta 2-adrenoceptor agonist terbutaline was tested single-blind cross-over in out-patients with chronic obstructive airways disease (intrinsic asthma)." | 4.76 | [Pulmonary function tests with the bronchodilator Terbutaline]. ( Bonelli, J; Hitzenberger, G; Kaik, G; Laggner, A; Magometschnigg, D, 1979) |
| "To compare hospital costs and resource utilization for pediatric asthma admissions based on the hospitals' availability of continuous albuterol aerosolization administration (CAA) in non-intensive care unit (ICU) settings." | 4.31 | Cost analysis of hospitals performing continuous albuterol in non-intensive care settings. ( Andoh, AA; Bode, RS; Gee, SW; Leonard, JC; Lo, CB; Shi, J, 2023) |
| "The effectiveness of a fix-dose salmeterol/fluticasone combination therapy in asthma was previously shown for the original product." | 4.31 | The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice. ( Almgren-Rachtan, A; Chudek, J; Doniec, Z; Hantulik, P; Olszanecka-Glinianowicz, M, 2023) |
| "A new asthma drug, Airsupra, combines the short-acting β2-adrenergic agonist albuterol with the corticosteroid budesonide to treat acute asthma attacks." | 4.31 | New Combination Asthma Drug. ( Aschenbrenner, DS, 2023) |
| "We examined the baseline change in FEV1 and FVC in response to albuterol among 931 participants with poorly controlled asthma pooled from three clinical trials conducted by the American Lung Association - Airways Clinical Research Centers." | 4.31 | Bronchodilator response does not associate with asthma control or symptom burden among patients with poorly controlled asthma. ( Dixon, AE; He, J; Henderson, R; Holbrook, JT; Irvin, CG; Kaminsky, DA; Mastronarde, J; Smith, LJ; Sugar, EA; Wise, RA, 2023) |
| "Outcomes of interest were utilization of asthma medications on the PDL (controllers and albuterol), asthma exacerbations (oral steroid bursts and asthma-related emergency department use), and out-of-pocket spending (all and asthma-specific)." | 4.31 | Utilization and Spending With Preventive Drug Lists for Asthma Medications in High-Deductible Health Plans. ( Galbraith, AA; LeCates, RF; Ross-Degnan, D; Sinaiko, AD; Wharam, JF; Wu, AC; Zhang, F, 2023) |
| " There was high agreement in albuterol use for bronchospasm and epinephrine use in anaphylaxis." | 4.12 | Variation in Prehospital Protocols for Pediatric Respiratory Distress Management in the United States. ( Martin-Gill, C; McCans, K; Owusu-Ansah, S; Ramgopal, S; Varma, S, 2022) |
| "Ensuring students with asthma residing in disadvantaged communities have access to rescue medication (albuterol) is important." | 4.12 | School-based Stock Inhaler Programs and Neighborhood Disadvantage. ( Clemens, C; Gerald, JK; Gerald, LB; Lowe, AA, 2022) |
| "Standardized acute asthma management with score-based, respiratory therapist (RT)-driven pathways and protocols improves outcomes including decreased length of stay (LOS) and time on continuous albuterol therapy." | 4.12 | Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation. ( Berlinski, A; Carper, NL; Danner, NP; Lloyd, TL; Willis, LD, 2022) |
| "Albuterol has been a cornerstone of asthma treatment for several decades, but evidence suggests that it may be overused at the expense of more efficacious treatment." | 4.12 | Albuterol: Still first-line in rescue therapy? ( Pitonzo, DG, 2022) |
| "Between January and December, 2015, asthmatic children aged between 5 and 17 years old performed impulse oscillometry (IOS) and spirometry during the same visit before and after albuterol administration." | 4.02 | A comparative analysis of the bronchodilatador response measured by impulse oscillometry and spirometry in asthmatic children living at high altitude. ( Alvarez, I; Aristizabal-Duque, R; Ramirez, O; Rodriguez-Martinez, CE; Sossa-Briceño, MP; Villamil, M, 2021) |
| " Using the continuous albuterol metric, predictability of the asthma scale had an area under the curve of 0." | 4.02 | Comparison of Two Assessment Tools for Hospitalized Subjects With Asthma. ( Kolaitis, IN; Nevin, MA; Palac, H; Samady, W; Schroeder, SK; Shreffler, L; Smith, CM, 2021) |
| "Implementation of an asthma protocol in the pediatric ICU did not result in significant improvements in time on continuous albuterol or hospital and pediatric ICU LOS, likely due to low adherence to the protocol." | 4.02 | Implementation of a Critical Asthma Protocol in a Pediatric ICU. ( Davey, CS; Fischer, GA; Gupta, S; Kucher, NM; S Dhaliwal, D, 2021) |
| "A total of 15 states allow schools to manage respiratory emergencies among multiple students by using a single albuterol inhaler (stock inhaler) paired with a disposable holding chamber." | 4.02 | Managing respiratory emergencies at school: A county-wide stock inhaler program. ( Clemens, CJ; Gerald, JK; Gerald, LB; Lowe, AA; Stern, DA, 2021) |
| "Inability to access an albuterol inhaler at school increases risk to students of severe asthma attack." | 4.02 | Implementing the Asthma Scripts to School Programs to Facilitate Student Access to Albuterol. ( Fu, L; Gessner, L; Thompson, D; Torres, R, 2021) |
| "Higher neighbourhood-level social deprivation was associated with more albuterol and inhaled steroid prescriptions among children with asthma, while problem list documentation of asthma and asthma severity varied little across neighbourhoods with differing deprivation scores." | 4.02 | Role of social deprivation on asthma care quality among a cohort of children in US community health centres. ( Bazemore, A; Cowburn, S; Ezekiel-Herrera, D; Fankhauser, K; Giebultowicz, S; Heintzman, J; Kaufmann, J; Lucas, JA; Marino, M, 2021) |
| "Children (6-11 years, N = 299) and adolescents (12-21 years, N = 331) with confirmed asthma underwent clinical phenotyping procedures and a test of maximal bronchodilation with escalating doses of albuterol sulfate up to 720 mcg." | 3.96 | Bronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations. ( Bruce, AC; Fitzpatrick, AM; Grunwell, JR; Nguyen, KM, 2020) |
| "A decision-analysis model was developed to estimate the cost-effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations." | 3.96 | Metered-dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A cost-effectiveness analysis in a middle-income country. ( Castro-Rodriguez, JA; Rodriguez-Martinez, CE; Sossa-Briceño, MP, 2020) |
| " Stock asthma rescue medication policies authorize school districts to maintain unassigned albuterol and enable trained staff members to administer the medication in response to asthma symptoms, exercise premedication, and asthma emergencies." | 3.96 | Preventing Asthma Emergencies in Schools. ( O'Rourke, A; Pappalardo, AA; Platt, H; Zimmerman, A, 2020) |
| " Effectiveness of switch was assessed as the proportion without severe asthma exacerbation and the proportion achieving risk domain asthma control (RDAC; no asthma-related hospitalization, antibiotics without upper respiratory diagnosis or acute course of oral corticosteroids) and overall asthma control (OAC; RDAC and ≤ 200 μg salbutamol/≤500 μg terbutaline average daily dose) comparing 1 year after and before the switch." | 3.91 | Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA. ( Ban, GY; Carter, V; Hardjojo, A; Jie, JLZ; Lee, HY; Park, HS; Price, DB; Van Boven, JFM; Wan Yau Ming, S; Yoon, D, 2019) |
| "The implementation of an asthma pathway was associated with decreased hospital LOS, PICU LOS, and time on continuous albuterol." | 3.91 | A Respiratory Therapist-Driven Asthma Pathway Reduced Hospital Length of Stay in the Pediatric Intensive Care Unit. ( Bartlett, KW; Gates, RM; Haynes, KE; Heath, TS; McLean, HS; Miller, AG; Rehder, KJ; Zimmerman, KO, 2019) |
| "Phenylephrine and salbutamol are drugs that are used widely to treat diseases/disorders, such as nasal congestion, hypotension, and asthma, in individuals of different age groups." | 3.91 | Impact of SULT1A3/SULT1A4 genetic polymorphisms on the sulfation of phenylephrine and salbutamol by human SULT1A3 allozymes. ( Abunnaja, MS; Alatwi, ES; Alherz, FA; Bairam, AF; El Daibani, AA; Gohal, SA; Kurogi, K; Liu, MC; Rasool, MI, 2019) |
| " For asthma, albuterol was reported most frequently (77." | 3.88 | Agreement Between Maternal Report and Medical Records During Pregnancy: Medications for Rheumatoid Arthritis and Asthma. ( Ansari, S; Bandoli, G; Chambers, CD; Hulugalle, A; Kuo, GM; Palmsten, K; Xu, R, 2018) |
| "Albuterol, a bronchodilator medication, is the first-line therapy for asthma worldwide." | 3.88 | Whole-Genome Sequencing of Pharmacogenetic Drug Response in Racially Diverse Children with Asthma. ( Ahituv, N; Avila, PC; Brigino-Buenaventura, E; Bunting, KL; Burchard, EG; Celedón, JC; Dahlin, A; Darnell, RB; Eckalbar, WL; Eng, C; Farber, HJ; Forno, E; Galanter, J; Germer, S; Goddard, P; Hakonarson, H; Hernandez, RD; Himes, BE; Hu, D; Huntsman, S; Keys, KL; Kumar, R; Kwok, PY; Lenoir, MA; Levin, AM; Liberto, J; Mak, ACY; Meade, K; Moreno-Estrada, A; Nguyen, TA; Nuckton, TJ; Oh, SS; Pino-Yanes, M; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Salazar, S; Sandoval, K; Seibold, MA; Sen, S; Serebrisky, D; Sleiman, PM; Szpiech, ZA; Tantisira, KG; Thyne, SM; Torgerson, DG; Vogel, JM; Weiss, ST; White, MJ; Williams, LK; Winkler, CA; Wu, AC; Zaitlen, N; Ziv, E, 2018) |
| " We analyze microparticles (1-5 μm diameter) composed of polystyrene latex and from three real-world pressurized metered dose inhalers (pMDIs) used in the treatment of asthma: salmeterol xinafoate (Serevent), salbutamol sulfate (Salamol), and ciclesonide (Alvesco)." | 3.88 | 1064 nm Dispersive Raman Microspectroscopy and Optical Trapping of Pharmaceutical Aerosols. ( Davidson, NM; Gallimore, PJ; Kalberer, M; Pope, FD; Ward, AD, 2018) |
| "The objective of this study was to evaluate ordering of albuterol via metered-dose inhaler with spacer (MDI-spacer), length of stay (LOS), and 72-hour return rates before and after publication of an internally developed pediatric asthma clinical practice guideline (CPG)." | 3.88 | Effect of an Asthma Guideline in 2 Pediatric Emergency Departments and an Urgent Care Center. ( Allen, NH; Dilts, JJ; Humiston, SG; Lee, BR; Michael, JG, 2018) |
| "This study aimed to investigate whether airway obstruction could interfere with real FENO levels and if different FeNO changes after albuterol inhalation could assist in distinguishing asthma from chronic obstructive pulmonary disease (COPD)." | 3.85 | Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility. ( Cai, S; Dong, H; Li, R; Lv, Y; Wu, Y; Xiao, G; Yao, L; Zhao, H, 2017) |
| "The goal of this study was to examine the impact of a multidisciplinary intervention designed to improve appropriate albuterol inhaler utilization among patients with asthma." | 3.85 | Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma. ( Delate, T; Jenkins, DW; Lowe, R; Rader, N, 2017) |
| "Racemic albuterol and levalbuterol are used to treat acute episodes of asthma." | 3.85 | Clinical outcomes of levalbuterol versus racemic albuterol in pediatric patients with asthma: Propensity score matching approach in a medicaid population. ( Love, BL; Lu, ZK; Schulz, RM; Wu, J; Yuan, J; Zhang, Y, 2017) |
| "This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbumin allergic mouse models of the early (EAR) and late (LAR) asthmatic response." | 3.83 | Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma. ( Bauer, CM; Burns, L; Harris, P; Laine, D; Peng, R; Phillips, JE; Renteria, L; Stevenson, CS, 2016) |
| "The objective was to determine the occurrence of, and the factors associated with, diastolic hypotension and troponin elevation or electrocardiogram (ECG) ST-segment changes in a convenience sample of children with moderate to severe asthma receiving continuous albuterol nebulization." | 3.83 | Diastolic Hypotension, Troponin Elevation, and Electrocardiographic Changes Associated With the Management of Moderate to Severe Asthma in Children. ( Fagbuyi, DB; Jeong, K; Lin, Y; Manole, MD; Pitetti, RD; Ralphe, JC; Saladino, RA; Venkataraman, S; Zuckerbraun, NS, 2016) |
| "The ideal dosing of albuterol via metered-dose inhalers for acute childhood asthma is not well established." | 3.83 | Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe. ( da Silva Filho, LV; De Lalibera, IB; de Souza, AV; Muchão, FP; Rodrigues, JC; Schvartsman, C; Souza, JM; Torres, HC, 2016) |
| "Evaluation of the efficacy of nebulized magnesium sulfate (MgSO4) alone and in combination with salbutamol in acute asthma." | 3.83 | The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma. ( Ali, MA; El-Garhy, OH; Sarhan, HA; Youssef, NA, 2016) |
| " We present a case of a patient who was admitted with acute asthma exacerbation and was treated with β-2 agonist nebulisation and intravenous aminophylline." | 3.83 | Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation. ( Khwaja, YH; Tai, JM, 2016) |
| "Concerns have been raised regarding cardiac side effects of continuous high-dose albuterol nebulization in status asthmaticus management." | 3.81 | Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol. ( Eades, S; Hashmi, SS; Mosquera, RA; Samuels, C; Wisecup, S, 2015) |
| "Using private insurance data from January 1, 2004, to December 31, 2010, we investigated the effect of the CFC ban on out-of-pocket costs and utilization of albuterol inhalers among individuals with asthma (109,428 adults; 37,281 children), as well as asthma-related hospitalizations, emergency department visits, and outpatient visits." | 3.81 | The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma. ( Goldman, DP; Ho, O; Jena, AB; Karaca-Mandic, P, 2015) |
| "To determine if nitrites (nitric oxide metabolites) measured in induced sputum decrease and correlate with improvement of clinical asthma symptoms after treatment, we performed a prospective longitudinal study in a tertiary care hospital in Arequipa, Peru." | 3.80 | Correlation between nitrites in induced sputum and asthma symptoms in asthmatic schoolchildren. ( Cáceres, M; Castro-Rodriguez, JA; Molina, RO; Recabarren, A, 2014) |
| "To estimate the relative perinatal safety with the use of salmeterol and formoterol (LABAs) and that of fluticasone and budesonide (ICSs) during pregnancy." | 3.80 | Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. ( Beauchesne, MF; Blais, L; Cossette, B; Forget, A; Larivée, P; Lemière, C; Rey, E, 2014) |
| " The majority of asthmatics were admitted to PICUs based on clinical asthma examination/score or because the patient was receiving continuous albuterol." | 3.79 | Corticosteroid therapy in critically ill pediatric asthmatic patients. ( Canarie, MF; Carroll, CL; Faustino, EV; Giuliano, JS; Li, S; Pinto, MG, 2013) |
| " Among different strategies conducted to identify this 'missing heritability', here we illustrate the importance of complex gene-environment interactions using findings regarding the role of leukotrienes on the bronchodilator response to albuterol in Latino asthmatics." | 3.79 | Role of interactions in pharmacogenetic studies: leukotrienes in asthma. ( González Burchard, E; Tcheurekdjian, H; Via, M, 2013) |
| "This study aimed to assess the safety and efficacy of a high-dose continuous nebulized albuterol (CNA) protocol for treatment of asthma in the pediatric emergency department (ED)." | 3.79 | Evaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department. ( Flood, RG; Gerard, JM; Krebs, SE; Peter, JR, 2013) |
| "The concentration of exhaled carbon monoxide (eCO) in young children with stable asthma and during acute asthma attack is not known." | 3.78 | Exhaled carbon monoxide levels in preschool-age children with episodic asthma. ( Arai, H; Asamura, T; Morikawa, T; Ohara, T; Ohara, Y; Ohrui, T; Sasaki, H, 2012) |
| "Responsiveness to corticosteroids dexamethasone (Dex), budesonide (Bud) and fluticasone propionate (FP) was determined, as IC(50) values on TNF-α-induced interleukin 8 release, in U937 monocytic cell line treated with hydrogen peroxide (H(2) O(2) ) or peripheral blood mononuclear cells (PBMCs) from patients with COPD or severe asthma." | 3.78 | Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition. ( Barnes, PJ; Ito, K; Ito, M; Osoata, G; Rossios, C; To, Y, 2012) |
| "In mild asthma exacerbations, administering albuterol via MDI+S decreases ED treatment time when compared to administering nebulized albuterol." | 3.78 | Evaluating the length of stay and value of time in a pediatric emergency department with two models by comparing two different albuterol delivery systems. ( Baxendale, S; Cross, KP; Gracely, E; Kim, IK; Peek, M; Southard, G; Staggs, L, 2012) |
| "To examine the use of intravenous magnesium in Canadian pediatric emergency departments (EDs) in children requiring hospitalization for acute asthma and association of administration of frequent albuterol/ipratropium and timely corticosteroids with hospitalization." | 3.78 | Magnesium use in asthma pharmacotherapy: a Pediatric Emergency Research Canada study. ( Black, KJ; Freedman, S; Gouin, S; Hernandez, A; Johnson, DW; Plint, A; Porter, R; Schuh, S; Zemek, R, 2012) |
| "To investigate the dynamic changes in airways in response to methacholine and salbutamol inhalation and to correlate the xenon ventilation index on xenon-enhanced chest CTs in asthmatics." | 3.78 | Quantitative analysis of dynamic airway changes after methacholine and salbutamol inhalation on xenon-enhanced chest CT. ( Cho, SH; Goo, JM; Jung, JW; Kim, JH; Lee, CH; Park, EA; Park, HW; Park, SJ, 2012) |
| "The overwhelming majority of children discharged from Canadian pediatric EDs with acute asthma are prescribed inhaled albuterol via MDIs." | 3.78 | Practice patterns in asthma discharge pharmacotherapy in pediatric emergency departments: a pediatric emergency research Canada study. ( Black, KJ; Freedman, S; Gouin, S; Johnson, DW; Plint, A; Porter, R; Schuh, S; Zemek, R, 2012) |
| "The purpose of this study was to evaluate the use of xenon-enhanced dual-energy CT of the chest to assess ventilation changes after methacholine and salbutamol inhalation in subjects with asthma and healthy subjects." | 3.78 | Xenon-enhanced dual-energy CT of patients with asthma: dynamic ventilation changes after methacholine and salbutamol inhalation. ( Cho, SH; Goo, JM; Kim, JH; Kim, WW; Lee, CH; Park, EA; Park, SJ, 2012) |
| " Laboratory findings showed hypokalemia, hypophosphatemia, and lactic acidosis." | 3.78 | Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone. ( Hantson, P; Manara, A; Thys, F; Vanpee, D, 2012) |
| "To examine the proportion of children presenting to the emergency department (ED) with an acute asthma exacerbation with incorrect home use of their albuterol inhaler and to identify factors associated with improper treatment." | 3.78 | Inappropriate home albuterol use during an acute asthma exacerbation. ( Clayton, K; Harrington, K; King, W; Magruder, T; Monroe, K, 2012) |
| " Both studies were continued for a further 9 months during which time exacerbation rates, lung function at the clinic and adverse events were monitored." | 3.78 | Efficacy and safety of salmeterol in childhood asthma. ( Boner, AL; Ebbutt, A; Jenkins, MM; Lenney, W; Pedersen, S, 1995) |
| " We isolated caffeic acid and phenylpropanoid glycosides, 1-O-caffeoyl glycoside and acteoside [β-(3',4'-dihydroxyphenyl) ethyl-O-α-l-rhamnopyranosyl(1→3)-β-d-(4-O-caffeoyl)-glucopyranoside] from their ethylacetate fractions, respectively, and evaluated their anti-asthmatic effects on the aerosolized ovalbumin (OA) challenge in the OA-sensitized guinea-pigs measuring the specific airway resistance (sRaw) during the immediate-phase response (IAR) and late-phase response (LAR), and also measured recruitment of leukocytes and chemical mediators on the bronchoalveolar lavage fluids (BALF) in LAR, as well as histopathological survey." | 3.77 | Anti-asthmatic effects of phenylpropanoid glycosides from Clerodendron trichotomum leaves and Rumex gmelini herbes in conscious guinea-pigs challenged with aerosolized ovalbumin. ( Kim, CJ; Lee, JG; Lee, JY; Sim, SS; Whang, WK, 2011) |
| " albuterol, are used for quick reversal of bronchoconstriction in asthmatics." | 3.77 | Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma. ( Aimi, S; Barone, LM; Bates, JH; Irvin, CG; Lundblad, LK; Poynter, ME; Riesenfeld, EP; Rinaldi, LM; Wu, M, 2011) |
| "We measured the incremental cost-effectiveness from the perspective of the hospital, by creating a model using outcome characteristics from a Cochrane systematic review comparing the efficacy of using MDIs versus nebulizers for the delivery of albuterol to children presenting to the ED with asthma." | 3.77 | Cost-effectiveness of metered-dose inhalers for asthma exacerbations in the pediatric emergency department. ( Doan, Q; Johnson, D; Shefrin, A, 2011) |
| " We describe asthma prescription patterns in a cohort of patients (n =17,745) in the General Practice Research Database who initiated treatment with salmeterol-containing prescriptions between 2003 and 2006, including salmeterol and salmeterol/fluticasone propionate in a single device." | 3.77 | Prescription patterns in asthma patients initiating salmeterol in UK general practice: a retrospective cohort study using the General Practice Research Database (GPRD). ( Davis, KJ; DiSantostefano, RL, 2011) |
| "A retrospective observational cohort study compared the risk of asthma-related exacerbations [hospitalization, emergency department visit, and/or treatment with systemic corticosteroid] in patients receiving treatment with fluticasone propionate/salmeterol in a single inhaler (FSC) within 90 days following an initial asthma-related exacerbation (early treatment) versus patients receiving the treatment subsequently (late treatment)." | 3.77 | Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation. ( Delea, TE; Hagiwara, M; Stanford, RH, 2011) |
| " Asthmatic patients with the Arg19/Arg19 genotype showed decreased responsiveness to albuterol." | 3.77 | Relationship between polymorphisms in the 5' leader cistron, positions 16 and 27 of the adrenergic β2 receptor gene and asthma in a Han population from southwest China. ( Dai, LM; Fang, LZ; Fu, WP; Liu, L; Shu, JK; Sun, C; Wang, L; Wang, XM; Zhang, JQ; Zhao, ZH; Zhong, L, 2011) |
| "Ambient particulate matter concentrations have been positively associated with urinary leukotriene E(4) (LTE(4)) levels and albuterol usage in children with asthma but interactions with environmental tobacco smoke (ETS) exposure have not been demonstrated despite obvious exposure to both pollutants in an urban setting." | 3.77 | The response of children with asthma to ambient particulate is modified by tobacco smoke exposure. ( Gelfand, EW; Rabinovitch, N; Silveira, L; Strand, M, 2011) |
| "04), but not to asthma symptoms or albuterol use." | 3.76 | Adherence to pediatric asthma treatment in economically disadvantaged African-American children and adolescents: an application of growth curve analysis. ( Drotar, D; Kercsmar, C; McNally, K; Redline, S; Riekert, K; Rohan, J; Schluchter, M; Schmidt, A; Vavrek, P, 2010) |
| "We present a 19-month-old boy with a history of asthma who presented to the pediatric emergency department with noisy breathing and tachypnea partially responsive to albuterol." | 3.76 | A 19-month-old boy with recurrent respiratory distress. ( Cross, KP; Herr, SM; Randell, KA, 2010) |
| "Two large datasets comparing treatment with fluticasone propionate and fluticasone propionate plus salmeterol were analyzed, including the number of clinically reported upper respiratory tract infections, asthma-related exacerbations, and the presence of an exacerbation and concurrent report of an upper respiratory tract infection." | 3.76 | Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections. ( Gul, N; Kral, KM; Prazma, CM; Stempel, DA; Yancey, SW, 2010) |
| "Short-acting inhaled beta2-agonists such as albuterol are used for bronchodilation and are the mainstay of asthma treatment worldwide." | 3.76 | GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. ( Avila, PC; Burchard, EG; Chapela, R; Choudhry, S; Eng, C; Kim, SO; Kumar, G; Liu, L; Que, LG; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Stamler, JS; Thyne, S; Yang, Z, 2010) |
| "We commenced to estimate the economic impact of salmeterol/fluticasone combination (SFC) therapy compared to fluticasone propionate (FP) therapy for asthma control in Japanese patients." | 3.76 | [Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients]. ( Arakawa, I; Miyamoto, T; Nishima, S; Shiragami, M; Tohda, Y, 2010) |
| "Epithelial cells from bronchial brushings of normal (n = 8), asthma (n = 8) and COPD (n = 8) subjects were grown in air-liquid interface cultures, and treated with cigarette smoke extract (CSE) and/or Th2 cytokine IL-13, followed by Mp infection and treatment with beta2-agonists albuterol and formoterol for up to seven days." | 3.76 | beta2-agonists promote host defense against bacterial infection in primary human bronchial epithelial cells. ( Bowler, RP; Chu, HW; Green, RM; Gross, CA; Schnell, C; Weinberger, AR, 2010) |
| " Fifteen (8 males), non-smoking, patients with moderate-to-severe treated (inhaled corticosteroid (ICS) and inhaled long-acting beta(2)-agonist (LABA)) asthma, age 57+/-13 years (mean+/-SD), were studied at baseline, during exacerbation prior to oral corticosteroid, and during recovery after an 8 day tapering prednisone course." | 3.76 | Central and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma. ( Fraser, C; Gelb, AF; George, SC; Krishnan, A; Maginot, T; Shinar, CM; Silkoff, PE; Taylor, CF, 2010) |
| "In a cross-sectional study of 293 Mexicans and 356 Puerto Ricans with asthma, ALOX5AP and LTA4H genes were sequenced, and interactions between gene polymorphisms and bronchodilator responsiveness to albuterol were compared between leukotriene modifier users and nonusers." | 3.76 | ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos. ( Avila, PC; Burchard, EG; Chapela, R; Corvol, H; De Giacomo, A; Eng, C; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Tcheurekdjian, H; Thyne, S; Via, M, 2010) |
| "We present the case of an 83-year-old woman who was diagnosed with bronchial asthma in 1929 and had been treated in her childhood with "Dr Nathan Tucker Asthma Specific", a cocaine-based aerosolised asthma treatment." | 3.76 | Dr Nathan Tucker's Asthma Specific--a treatment for asthma preceding inhaled steroids and beta-agonists. ( Beckert, L; Hamilton, N, 2010) |
| "The aim of this work was to compare rates of asthma-related health service utilization for Medicaid-eligible pediatric and adult patients with asthma treated with fixed-dose fluticasone propionate/salmeterol (FSC) or fluticasone propionate (FP) monotherapy." | 3.76 | Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy. ( Astry, CL; Johnson, JC; Riedel, AA; Stanford, RH, 2010) |
| " With currently used dosing regimens, theophylline appears to produce relatively constant levels of effect on airway responsiveness and clinical efficacy around the clock, while inhaled beta 2 agonists appear to have insufficient effects at the end of longer dosing intervals." | 3.76 | The effect of theophylline and beta 2 agonists on airway reactivity. ( Ahrens, RC; Joad, J; Milavetz, G, 1987) |
| " The suggestion is made that failure to recognize the nonlinearity of the dose-response curves for bronchodilators has resulted in underestimating their combined action." | 3.76 | Theophylline as a bronchodilator in COPD and its combination with inhaled beta-adrenergic drugs. ( Jenne, JW, 1987) |
| " Asthma patients 16-65 years of age using budesonide/formoterol were matched according to age and markers of asthma severity to patients using fluticasone/salmeterol." | 3.75 | Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol. ( Beauchesne, MF; Blais, L; Forget, A, 2009) |
| " Despite similar clinical asthma scores on hospital admission, the children with the Gly/Gly genotype had significantly shorter hospital ICU length of stay and duration of continuously nebulized albuterol therapy and were significantly less likely to require IV beta(2)-AR therapy than those with Arg/Arg or Arg/Gly genotypes." | 3.75 | Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. ( Carroll, CL; Schramm, CM; Stoltz, P; Zucker, AR, 2009) |
| "Six healthy and 5 experimentally asthmatic cats were randomized to receive inhaled R,S-albuterol, S-albuterol, R-albuterol, or placebo (saline) twice daily for 2 weeks, followed by a 6-week washout before crossover to the next treatment." | 3.75 | Enantiomer-specific effects of albuterol on airway inflammation in healthy and asthmatic cats. ( DeClue, AE; Delgado, C; Dhand, R; Reinero, CR; Spinka, C, 2009) |
| "Quantitative and qualitative methods were used to collect data from a convenience sample of adolescents with asthma previously prescribed fluticasone/salmeterol (F/S)." | 3.75 | Adolescents and asthma: why bother with our meds? ( Apter, AJ; Bogen, D; Freedman, TG; Ginsburg, KR; Naimi, DR; Rand, CS, 2009) |
| "The goal of this study was to examine whether the claims history for children in a US insured population indicate proper fluticasone propionate/ salmeterol (FPS) fixed-dose combination use in accordance with recommended asthma guidelines and a US Food and Drug Administration (FDA) advisory and black box warning regarding LABA use." | 3.75 | Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations. ( Crespi, S; Eid, NS; Friedman, HS; Reardon, G; Wilcox, TK, 2009) |
| "Among children with persistent asthma, use of leukotriene modifiers is associated with augmented bronchodilator responsiveness to albuterol in Puerto Ricans, but not Mexican Americans." | 3.75 | Augmentation of bronchodilator responsiveness by leukotriene modifiers in Puerto Rican and Mexican children. ( Avila, PC; Burchard, EG; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Tcheurekdjian, H; Thyne, SM; Via, M; Williams, LK, 2009) |
| "To investigate the effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of adult patients with asthma." | 3.75 | Effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of patients with asthma. ( de Melo, PL; Jansen, JM; Lopes, AJ; Veiga, J, 2009) |
| "Albuterol has been used for more than 40 years to treat acute asthma exacerbations as a racemic mixture of isomers: the active form, (R)-albuterol, or levalbuterol, and (S)-albuterol, classically considered inert." | 3.75 | Levalbuterol versus albuterol. ( Ameredes, BT; Calhoun, WJ, 2009) |
| " During the visit, the simulated patient enacted a standardized scenario of someone with moderately controlled asthma who wished to purchase a salbutamol (albuterol) inhaler without prescription." | 3.75 | Measuring the assessment and counseling provided with the supply of nonprescription asthma reliever medication: a simulated patient study. ( Clifford, RM; Everett, AW; Geelhoed, E; Kendall, PA; Schneider, CR, 2009) |
| "We have now extended our previous population by 636 patients and explored the role of the Arg16 allele on asthma exacerbations in the context of the use of on-demand albuterol and regular salmeterol." | 3.75 | Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. ( Basu, K; Lipworth, BJ; Mukhopadhyay, S; Palmer, CN; Tavendale, R, 2009) |
| "To compare the rates of asthma-related emergency department (ED) visits and hospitalizations in the fall (September, October, November) between users and nonusers of fluticasone propionate plus salmeterol in a single inhaler (FSC) in the preceding summer." | 3.75 | Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall. ( Sheth, K; Spahn, J; Stanford, RH; Stempel, DA; Yeh, WS, 2009) |
| "Effects of quercetin inhalation on immediate (IAR), late-phase (LAR) and late late-phase (LLAR) asthmatic responses by exposure to aerosolized-ovalbumin (AOA) (2w/v% in saline, inhalation for 3 min) were studied in conscious guinea-pigs sensitized with AOA." | 3.74 | Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs. ( Choi, HH; Kim, CJ; Lee, JY; Moon, H; Moon, HJ; Sim, SS, 2008) |
| "Eighty-one patients with asthma (24% African American [AA]; 8 to 65 years old; baseline FEV1, 40 to 80% of predicted) received 180 microg of albuterol from a metered-dose inhaler (MDI), and then 90 microg every 15 min until maximum improvement or 540 microg was administered; all then received 2." | 3.74 | Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. ( Blake, K; Derendorf, H; Lima, J; Madabushi, R, 2008) |
| "National asthma guidelines recommend that patients with persistent asthma regularly use an inhaled corticosteroid (ICS) in addition to as-needed albuterol, yet recent debates question whether this combination is equally efficacious in all ethnicities." | 3.74 | Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients. ( Avila, PC; Burchard, EG; Castro, RA; Chapela, R; Choudhry, S; DeBoard, JA; LeNoir, M; Meade, K; Naqvi, M; Navarro, D; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Tcheurekdjian, H; Thyne, SM; Watson, HG; Williams, LK, 2008) |
| " We describe an unusual case of a 47-year-old woman whose increased use of inhaled albuterol led to a non-ST-segment elevation myocardial infarction and unmasking of hemodynamically significant myocardial bridging." | 3.74 | Increased use of beta-agonists leading to non-ST-segment elevation myocardial infarction in a patient with hemodynamically significant myocardial bridging. ( Gold, DR; Makaryus, AN; Zolli, JR, 2008) |
| "The aim of the present study was to assess the response of high-dose salmeterol/fluticasone combination (SFC) and low-dose SFC compared with regimens without inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA) in a large cohort with severe or difficult-to-treat asthma." | 3.74 | The response to combination therapy treatment regimens in severe/difficult-to-treat asthma. ( Borish, L; Campbell, JD; Haselkorn, T; Lee, JH; Rasouliyan, L; Sullivan, SD; Wenzel, SE, 2008) |
| "Data on German asthma patients initiating treatment with budesonide/formoterol or salmeterol/fluticasone between June 2001 and June 2005 were obtained from the IMS Disease Analyzer database." | 3.74 | A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany. ( Aballéa, S; Cure, S; Vogelmeier, C; Wirén, A, 2008) |
| "To identify the relationship between resource utilization and treatment of asthma in subjects who were first time users of controller therapies, either fluticasone propionate (FP) and salmeterol delivered in a single Diskus device (FSC) or FP monotherapy." | 3.74 | An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes . ( Fuhlbrigge, A; Rey, GG; Riedel, A; Stanford, RH; Stempel, DA, 2008) |
| "We evaluated the response to albuterol inhalation in 10 healthy subjects, 9 subjects with asthma, and 15 subjects with chronic obstructive pulmonary disease (COPD) with mean (SD) age in years of 38 (SD, 11), 45 (SD, 11), and 64 (SD, 8), respectively." | 3.74 | The confounding effects of thoracic gas compression on measurement of acute bronchodilator response. ( Babb, TG; Boriek, AM; Hanania, NA; Officer, TM; Sharafkhaneh, A; Sharafkhaneh, H, 2007) |
| "Achievement of asthma control as defined by the global initiative on asthma guidelines (GINA) was examined in 1242 asthmatic patients not currently using ICS, enrolled in five clinical trials comparing fluticasone propionate and the combination of fluticasone and salmeterol." | 3.74 | Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. ( Boulet, LP; Franssen, E, 2007) |
| "This study evaluated the use and drug costs of inhaled corticosteroids (ICSs), long-acting beta2-agonists (LABAs), and fluticasone propionate and salmeterol in a fixed-dose combination (FSC) and their relationship to asthma exacerbations before and after the market introduction of FSC in April 2001." | 3.74 | The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. ( Brixner, DI; Lenhart, G; Samuelson, WM; Young, DC, 2007) |
| "Peripheral blood lymphocytes from asthmatic subjects were cultured 6 days ex vivo with IL-2 and various concentrations of albuterol, formoterol, and budesonide." | 3.74 | Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells. ( Foster, S; Loza, MJ; Penn, RB; Peters, SP, 2008) |
| "There are theoretical benefits of delivering drug aerosols to patients with asthma and chronic obstructive pulmonary disease (COPD) using Heliox as a carrier gas." | 3.74 | The effects of Heliox on the output and particle-size distribution of salbutamol using jet and vibrating mesh nebulizers. ( Bland, H; Crosby, D; Dougill, B; Jackson, J; O'Callaghan, C; White, J, 2007) |
| "MDI-VHC utilization increased from 25% to 77% among all non-intensive-care patients receiving albuterol, and from 10% to 79% among patients with asthma (p < 0." | 3.74 | The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience. ( Carter, ER; Cowan, CA; Crotwell, DN; DiBlasi, RM; Salyer, JW, 2008) |
| "CPGs for mild to moderate asthma were similar across sites and based on salbutamol delivery by metered dose inhaler with spacer and oral prednisolone." | 3.74 | Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines. ( Acworth, J; Babl, FE; Borland, M; Cotterell, E; Francis, P; Jamison, S; Krieser, D; Neutze, J; Ngo, P; Schutz, J; Sheriff, N; Thomson, F, 2008) |
| "Our data show that S-albuterol stimulates cell proliferation by activating expression and phosphorylation of several intracellular mitogenic proteins and may exacerbate asthma by stimulating the release of IL-6." | 3.74 | Mechanisms by which S-albuterol induces human bronchial smooth muscle cell proliferation. ( Abdallah, MF; Ibe, BO; Raj, JU, 2008) |
| "To assess the frequency of beta2-AR polymorphisms in asthmatic children from Argentina, and to evaluate their influence on bronchodilator desensitization to albuterol over a 4-week treatment." | 3.74 | Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. ( Castaños, C; Chertkoff, L; Giubergia, V; Gravina, LP; Grenoville, M, 2008) |
| "This study was designed to expand on these earlier findings by comparing asthma-related health care resource utilization and costs, as well as adherence to ICSs, in children and adults with asthma receiving ICS monotherapy who either were switched to fluticasone propionate plus SAL from a single inhaler (FSC) or initiated add-on therapy with SAL from a separate inhaler or MON." | 3.74 | Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. ( Delea, TE; Hagiwara, M; Stanford, RH; Stempel, DA, 2008) |
| "To determine whether there are differences in health care use and costs of asthma treatment in asthma patients treated with montelukast compared with fluticasone proponiate 44 microg." | 3.73 | Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis. ( Balkrishnan, R; Kulkarni, AS; Nelsen, LM; Pleasants, RA; Schechter, MS; Whitmire, JT, 2005) |
| "Salmeterol/fluticasone propionate is a more cost-effective treatment option than fluticasone propionate plus montelukast for patients with symptomatic asthma uncontrolled by ICS." | 3.73 | Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma. ( Pieters, WR; Smith, HC; Sondhi, S; Tamminga, JJ; Wilson, KK, 2005) |
| "To demonstrate that basic emergency medical technicians (EMT-Bs) are able to effectively administer nebulized albuterol to asthma patients in the out-of-hospital environment." | 3.73 | Out-of-hospital administration of albuterol for asthma by basic life support providers. ( Kusick, M; Matallana, L; Richmond, NJ; Silverman, R; Winokur, J, 2005) |
| "We conducted a prospective and descriptive study to assess levels of lactate and effects on bronchodilator response in adult patients with acute severe asthma treated with high doses of albuterol in the ED." | 3.73 | Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma. ( Rodrigo, C; Rodrigo, GJ, 2005) |
| "A disease-related, corticosteroid-insensitive increase in the expression of epidermal growth factor (EGF) receptor (EGFR) tyrosine kinase in asthmatic bronchial epithelium has been shown previously by the current authors." | 3.73 | Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium. ( Davies, DE; Dearman, RJ; Hamilton, LM; Holgate, ST; Howarth, PH; Kimber, I; Puddicombe, SM; Sandström, T; Wallin, A; Wilson, SJ, 2005) |
| "A post hoc resource use analysis of a 52-week, double-blind multicentre clinical trial (Investigation of Montelukast as a Partner Agent for Complementary Therapy) [corrected] including 1490 adults with chronic asthma, aged 15-72 years, with FEV(1) 50-90% of predicted and > or =12% increase in FEV(1) after salbutamol administration, treated with either montelukast 10 mg daily or salmeterol 50 microg twice daily in addition to fluticasone 200 microg, was undertaken." | 3.73 | Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. ( Bjermer, L; Bousquet, J; Gaugris, S; Kocevar, VS; Polos, PG; Yin, DD; Zhang, Q, 2005) |
| "(R)- and (S)-Enantiomers of albuterol likely exert differential effects in patients with asthma." | 3.73 | Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. ( Banerjee, ER; Chi, EY; Henderson, WR, 2005) |
| "Airway responsiveness to histamine, diurnal peak-flow variability, and bronchodilator reversibility cannot be used interchangeably as objective markers of asthma in epidemiologic studies." | 3.73 | Recognition of asthma in adolescents and young adults: which objective measure is best? ( Backer, V; Postma, DS; Ulrik, CS, 2005) |
| "Acute asthma is often treated with racemic albuterol, a 1:1 mixture of (R)-albuterol and (S)-albuterol." | 3.73 | Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. ( Babin, S; Schreck, DM, 2005) |
| "After a 4-week steroid-run-in period (fluticasone 250 microg twice daily) 48 allergic patients with persistent asthma underwent a bronchial challenge with a single dose of allergen, after inhalation of salbutamol (400 microg, nebulized dose)." | 3.73 | Clinically masked increases in bronchial inflammation in guideline-treated persistent asthma. ( Jansen, HM; Koopmans, JG; Lutter, R; van der Zee, JS, 2006) |
| "To compare asthma exacerbations, medication switch, and use of SABAs among 3 treatment cohorts: fluticasone propionate and salmeterol as a single inhaler (FSC), fluticasone and salmeterol as separate inhalers (FP + SAL), and fluticasone propionate alone (FP)." | 3.73 | Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. ( Gilmore, AS; Legorreta, AP; O'Connor, RD; Rosenzweig, JR; Ryskina, KL; Stanford, RH; Stempel, DA, 2005) |
| "British Thoracic Society guidelines recommend intravenous salbutamol or aminophylline for acute severe asthma in children." | 3.73 | A survey of consultant practice: intravenous salbutamol or aminophylline for acute severe childhood asthma and awareness of potential hypokalaemia. ( Parr, JR; Salama, A; Sebire, P, 2006) |
| "Carbon monoxide (CO) can be detected in exhaled air and is increased in adult and childhood persistent asthmatic patients." | 3.73 | Exhaled carbon monoxide levels in school-age children with episodic asthma. ( He, M; Morikawa, T; Ohara, Y; Ohrui, T; Sasaki, H; Yamaya, M; Yasuda, H, 2006) |
| "To determine resource utilization in controller naïve children diagnosed with asthma receiving initial therapy with fluticasone propionate (FP) and salmeterol (SAL) in a single inhaler (FSC), FP alone, montelukast (MON), inhaled corticosteroid (ICS) + SAL from separate inhalers, or ICS + MON." | 3.73 | Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. ( Carranza Rosenzweig, JR; Riedel, AA; Stempel, DA, 2006) |
| "We present 2 cases of Cushing syndrome with secondary adrenal insufficiency from concomitant use of ritonavir and inhaled corticosteroids in children with human immunodeficiency virus infection." | 3.73 | Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. ( Emmanuel, PJ; Johnson, SR; Lujan-Zilbermann, J; Marion, AA; Vrchoticky, T, 2006) |
| "Asthma severity was categorized individually for symptoms, albuterol use, and morning peak expiratory flow and then overall taking into account all three parameters." | 3.73 | Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting beta2-agonists. ( Baitinger, L; Chipps, BE; Dorinsky, PM; Emmett, AH; Sorkness, CA; Spahn, JD; Sutton, LB, 2006) |
| "We contrasted clinical features, airflow limitation, and albuterol responsiveness in adults acutely ill with asthma, 155 of whom where African American and 140 white, as they presented to eight emergency departments." | 3.73 | Impact of race on the severity of acute episodes of asthma and adrenergic responsiveness. ( Brianas, L; Coreno, AJ; Dickey-White, H; El-Ekiaby, A; Galan, G; Kaeberlein, FJ; McFadden, ER; Seitz, RE; Skowronski, ME; Villaba, KD, 2006) |
| "The homozygous presence of the arginine-16 variant of the beta(2) adrenoceptor gene ADRB2 reverses the benefits from the regular use of short acting beta(2) agonists in asthmatic adults compared with the homozygous glycine-16 genotype." | 3.73 | Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. ( Ismail, T; Lee, S; Lipworth, BJ; Macgregor, DF; Mukhopadhyay, S; Palmer, CN, 2006) |
| "To compare asthma-related health care resource utilization among a matched cohort of asthma patients using inhaled corticosteroids (ICSs) plus either montelukast (MON) or salmeterol (SAL) as combination therapy for asthma, during a time prior to the availability of fixed-dose combinations of ICS/SAL." | 3.73 | Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. ( Allen-Ramey, FC; Bukstein, D; Luskin, A; Markson, LE; Sajjan, SG, 2006) |
| " In multivariable regression analyses, hospitalists were significantly more likely to report often or almost always using the following evidence-based therapies for asthma: albuterol and ipratropium in the first 24 hours of hospitalization." | 3.73 | Variations in management of common inpatient pediatric illnesses: hospitalists and community pediatricians. ( Chiang, VW; Conway, PH; Edwards, S; Landrigan, CP; Ottolini, MC; Stucky, ER, 2006) |
| "Fifty children primarily with moderate-to-severe asthma were followed with measurements of urinary LTE(4), monitoring of FEV(1), and albuterol use." | 3.73 | Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. ( Gelfand, EW; Rabinovitch, N; Zhang, L, 2006) |
| "Studies of the efficacy of heliox in patients with severe asthma have shown mixed results." | 3.73 | Room air entrainment during beta-agonist delivery with heliox. ( Ahmed, A; Babbar, H; Chandra, A; Choksi, S; Chung, V; Dhuper, S; Jha, G; Selvaraj, S; Shim, C; Walia, B, 2006) |
| "A retrospective, observational study using an integrated managed care database of children aged 4-17 years with an initial medical claim for asthma and an initial pharmacy claim for fluticasone propionate (FP) and salmeterol in a single inhaler (FSC), FP alone, montelukast (MON), or combination FP + MON." | 3.73 | The use of rhinitis medications in children receiving initial controller therapy for asthma. ( Carranza Rosenzweig, JR; McLaughlin, TP; Stanford, RH; Stempel, DA, 2006) |
| "To evaluate the relationship between inflammatory markers and severity of asthma in children, the amount of interleukin-8 (IL-8) and granulocyte/macrophage colony-stimulating factor (GM-CSF) released by peripheral blood mononuclear cells, exhaled nitric oxide (FE NO) levels, p65 nuclear factor-kappaB subunit, and phosphorylated IkBalpha expression by peripheral blood mononuclear cells were assessed in six control subjects, 12 steroid-naives subjects with intermittent asthma, and 17 children with moderate asthma." | 3.72 | Clinical and biological heterogeneity in children with moderate asthma. ( Bellia, V; Bonsignore, G; Bousquet, J; Gagliardo, R; La Grutta, S; Mirabella, F; Pajno, GB; Vignola, AM, 2003) |
| " Theophylline possesses anti-inflammatory activities in asthma." | 3.72 | Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma. ( Chung, KF; Huang, KH; Kuo, HP; Lin, CH; Lin, HC; Liu, SL; Wang, CH; Yu, CT, 2003) |
| " The most dangerous potential herbal and prescription medication combination reported was ephedra and albuterol in an adolescent with asthma." | 3.72 | Herbal therapy use in a pediatric emergency department population: expect the unexpected. ( Greenwald, M; Lanski, SL; Perkins, A; Simon, HK, 2003) |
| "At baseline, all patients met the criteria for moderate or severe persistent asthma (mean FEV(1) of 64% of predicted value or albuterol use and symptoms on 4." | 3.72 | Asthma variability in patients previously treated with beta2-agonists alone. ( Calhoun, WJ; Dorinsky, PM; Emmett, A; Sutton, LB, 2003) |
| "This was a prospective, open-label, nonrandomized pilot study to evaluate efficacy and tolerability of levalbuterol (LEV) in acute asthma." | 3.72 | Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. ( Disantostefano, RL; Emerman, CL; Nowak, RM; Roach, JM; Schaefer, K; Vaickus, L, 2004) |
| "PBMCs from control subjects and allergic asthmatic patients were stimulated with PHA in the presence of low doses of fluticasone propionate (FP) with or without salmeterol for 72 hours." | 3.72 | Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists. ( Dunlap, A; Goleva, E; Leung, DY, 2004) |
| "To determine the relative cost effectiveness when persistent asthma is treated with FP/salmeterol 100/50 microg twice daily administered via a single Diskus inhaler device versus treatment with FP 100 microg twice daily via a Diskus inhaler plus oral montelukast 10mg once daily." | 3.72 | Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. ( Borker, R; Dorinsky, P; Emmett, A; Jhingran, P; Nelson, H; O'Connor, RD; Rickard, K, 2004) |
| "Because the clinical efficacy of inhaled corticosteroids combined with long-acting beta 2 -agonists has been widely demonstrated in asthma, we studied, in vitro, the effect of fluticasone propionate (FP) and salmeterol alone and in combination on the activation and apoptosis of peripheral blood T cells (PBTs), on the expression of phosphorylated nuclear factor kappaB inhibitor (IkappaBalpha), and on the nuclear translocation of glucocorticoid receptor (GR) in PBTs from asthmatic subjects." | 3.72 | Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. ( Bonsignore, G; Bousquet, J; Ferraro, M; Gagliardo, R; Gjomarkaj, M; La Grutta, S; Melis, M; Pace, E; Siena, L; Vignola, AM, 2004) |
| "To compare the effectiveness of (1) fluticasone propionate, 100 microg, and salmeterol, 50 microg; (2) fluticasone propionate, 100 microg; and (3) montelukast, 10 mg, as first-line maintenance treatment for persistent asthma." | 3.72 | Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs. ( Crim, C; Dorinsky, P; Edwards, L; O'Connor, RD; Rickard, KA; Stanford, R; Yancey, SW, 2004) |
| "While 127 (77%) of subjects used albuterol as the first treatment for their last asthma attack, 18 (11%) used rubbing ointments." | 3.72 | Rubbing ointments and asthma morbidity in adolescents. ( Ozuah, PO; Reznik, M; Sharif, I, 2004) |
| "2 years; range, 12-18 years; healthy controls (n = 6); asthmatics on inhaled steroids (n = 5); and asthmatics on no steroids (n = 5)] had exhaled nitric oxide (FE(NO)) measurements on 4 consecutive days as follows: pre- and postspirometry (day 1); pre- and postalbuterol metered dose inhaler (MDI) therapy (day 2); pre- and postspirometry and albuterol MDI therapy (day 3); and pre- and postspirometry and placebo MDI (day 4)." | 3.71 | Effect of beta2-agonist treatment and spirometry on exhaled nitric oxide in healthy children and children with asthma. ( Blake, KV; Duckworth, LJ; Kissoon, N; Lima, JJ; Murphy, SP, 2002) |
| "Inhaled acetaldehyde and adenosine 5'-monophosphate (AMP) cause bronchoconstriction in asthmatics by a mechanism believed to involve histamine release from airway mast cells." | 3.71 | Airway obstruction induced by inhaled acetaldehyde in asthma: repeatability relationship to adenosine 5'-monophosphate responsiveness. ( Cervera, A; Gutiérrez, V; Liñana, J; Prieto, L, 2002) |
| "To determine whether NOs influence the bronchodilator activity of albuterol in asthmatic patients." | 3.71 | Nitrogen oxides reduce albuterol-induced bronchodilation in patients with bronchial asthma. ( Hirata, K; Kanazawa, H; Yoshikawa, J, 2002) |
| "Beta2-adrenoceptor agonists (beta2-agonists) such as albuterol (salbutamol) and terbutaline and their long-acting analogs salmeterol and formoterol are widely used as bronchodilators in the treatment of asthma." | 3.71 | Beta2-agonist eutomers: a rational option for the treatment of asthma? ( Boulton, DW; Fawcett, JP, 2002) |
| "The aim of this study was to assess changes in the costs of asthma drug therapy before and during the use of chronic montelukast treatment in the U." | 3.71 | Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. ( Ben-Joseph, RH; Price, DB; Zhang, Q, 2001) |
| "The purpose of this study was to observe the effectiveness of lidocaine in suppressing cough which is a logical extension of its established use in bronchoscopy." | 3.71 | Lidocaine inhalation for cough suppression. ( Udezue, E, 2001) |
| " This paper presents age- and gender-specific asthma death rates in patients prescribed the long-acting beta2-agonists salmeterol and bambuterol." | 3.71 | Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies. ( Martin, RM; Shakir, S, 2001) |
| "In 9 healthy and 14 asthmatic subjects before and after a standard bronchial challenge and a modified [deep inspiration (DI), inhibited] bronchial challenge and after albuterol, we tracked airway caliber by synthesizing a method to measure airway resistance (Raw; i." | 3.71 | Selected contribution: airway caliber in healthy and asthmatic subjects: effects of bronchial challenge and deep inspirations. ( Atileh, H; Ingenito, EP; Jensen, A; Lutchen, KR; Suki, B, 2001) |
| "To compare a combination of salmeterol and fluticasone with common asthma pharmacologic regimens used in real-world clinical practice, and to evaluate the associated costs and outcomes of care." | 3.71 | Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments. ( Bowers, BW; Legorreta, AP; Liu, X; Sennett, C; Wang, SW; Wiener, DJ, 2001) |
| "In comparison with the use of montelukast and ICS, the use of salmeterol and ICS was associated with a significant reduction in SABA use, decreased hospital event rates, and significantly lower total asthma care costs." | 3.71 | Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. ( Meyer, JW; O'Donnell, JC; Stempel, DA, 2002) |
| "To investigate the mechanism of anti-inflammatory action of theophylline on asthma." | 3.71 | Effects of theophylline on CD4+ T lymphocyte, interleukin-5, and interferon gamma in induced sputum of asthmatic subjects. ( Hu, SP; Nie, HX; Wu, XJ; Yang, J, 2002) |
| "To compare asthma-related health-care utilization and expenditures for patients prescribed one of three dual-controller therapies: fluticasone plus salmeterol, inhaled corticosteroids (ICS) [excluding fluticasone] plus salmeterol, and ICS plus a leukotriene modifier (LTM)." | 3.71 | Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. ( Legorreta, AP; O'Connor, RD; O'Donnell, JC; Pinto, LA; Wiener, DJ, 2002) |
| "Albuterol administered by MDI/spacer is an efficacious and cost-effective alternative to nebulization in adults with acute asthma who present at a large urban ED." | 3.71 | A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. ( Hall, K; Hamilton, C; Milne, S; Newman, KB, 2002) |
| "The state of inducible NO-synthase (iNOs) in the rat lung with experimental model of bronchial asthma (BA) was studied after administrating short-acting beta 2-agonist fenoterol, long-acting beta 2-agonist salmeterol, and adrenoblocker propranolol." | 3.71 | [Inducible nitric oxide synthase in rat lungs in experimental bronchial asthma and its status in administering drugs with adrenergic action]. ( Eliseeva, EV, 2002) |
| "High levels of histamine can be found in the airways of asthma patients." | 3.70 | Histamine affects interleukin-4, interleukin-5, and interferon-gamma production by human T cell clones from the airways and blood. ( Bast, A; Bruinier, B; Hol, BE; Jansen, HM; Krouwels, FH; Lutter, R; Out, TA, 1998) |
| "A case of albuterol abuse by a pediatric patient with the development of hypokalemia with electrocardiographic changes is presented." | 3.70 | Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler. ( Farrar, HC; Kearns, GL; Rakhmanina, NY, 1998) |
| "This paper reviews the impact of the use of technologically dissimilar beta-agonist aerosols--the Maxair Autohaler (pirbuterol acetate) breath-actuated aerosol and the traditional albuterol press-and-breathe inhaler-on the treatment costs of asthma." | 3.70 | The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers. ( Langley, PC, 1999) |
| "To determine whether genetic polymorphisms of the beta2-adrenergic receptor gene affect the relationship between albuterol (INN, salbutamol) plasma concentrations and the forced expiratory volume in 1 second (FEV1) in subjects with moderate asthma." | 3.70 | Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. ( Eberle, LV; Johnson, JA; Lima, JJ; Mohamed, MH; Self, TH; Thomason, DB, 1999) |
| "Acutely ill asthmatic patients chronically taking salmeterol, and similar patients who were not taking salmeterol, were treated with albuterol, either as three aerosols of 2." | 3.70 | Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. ( Korosec, M; McFadden, ER; Myers, E; Novak, RD; Skowronski, M, 1999) |
| "We determined airway mucosal blood flow (Qaw) and FEV (1) before and after inhaled albuterol in 19 glucocorticosteroid (GS)-naive patients with mild intermittent asthma, and assessed the effects of a 2-wk course of fluticasone propionate (FP; 440 microg daily) on these parameters." | 3.70 | Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. ( Brieva, JL; Danta, I; Wanner, A, 2000) |
| "A 22-year-old woman with mild intermittent asthma, who had no previous history of an adverse reaction to an albuterol metered-dose inhaler, developed paradoxical bronchoconstriction after inhalation of the fourth dose of an albuterol nebulizer solution." | 3.70 | Laryngospasm and paradoxical bronchoconstriction after repeated doses of beta 2-agonists containing edetate disodium. ( Chan, L; Moonjelly, E; Mutlu, GM; Olopade, CO, 2000) |
| "This study was undertaken to assess drug-use patterns associated with albuterol delivery via a new propellant device compared with conventional chlorofluorocarbon (CFC) metered-dose inhalers (MDIs) in patients taking asthma medications in a population with pharmacy benefits." | 3.70 | Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. ( Boccuzzi, SJ; Roehm, JB; Wogen, J, 2000) |
| "To determine whether race and gender affect beta(2)receptor-stimulated bronchodilation, we quantified FEV(1)and plasma concentrations of albuterol at various times following the oral administration of a single 8-mg dose of albuterol in 15 black and 15 white male and female asthmatics." | 3.70 | Importance of beta(2)adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics. ( Eberle, LV; Johnson, JA; Lima, JJ; Mohamed, MH; Self, TH, 2000) |
| "In a 75-year-old woman with asthma, acute angle-closure glaucoma in the right eye was probably caused by local absorption of albuterol after nebulizer administration." | 3.70 | Acute angle-closure glaucoma after albuterol nebulizer treatment. ( Rho, DS, 2000) |
| "The respiratory effects of nebivolol, a new selective ss(1)-adrenergic blocking agent, and celiprolol, a ss-blocker possessing strong ss(1)-adrenoceptor antagonist and mild ss(2)-agonist properties, were investigated in 12 patients with mild asthma." | 3.70 | Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. ( Cazzola, M; D'Amato, G; D'Amato, M; Noschese, P, 2000) |
| " Incubation of bronchial epithelial cells from patients with asymptomatic asthma with interleukin-1 or histamine, for 8 to 24 hours, resulted in increased expression of endothelin-1 messenger RNA and release of appreciable amounts of the peptide to the culture medium." | 3.69 | Constitutive expression of endothelin in bronchial epithelial cells of patients with symptomatic and asymptomatic asthma and modulation by histamine and interleukin-1. ( Ackerman, V; Bellini, A; Carpi, S; Marini, M; Mattoli, S; Vassalli, G, 1995) |
| "To determine the relationship between changes in room air oxygen saturation (SaO2) and changes in the clinical signs of pediatric asthma patients after treatment with nebulized albuterol, a 9-month prospective observational study was conducted." | 3.69 | Pediatric asthma--a correlation of clinical treatment and oxygen saturation. ( Cook, T; Stone, G, 1995) |
| "Forty-four adult patients with acute asthma were treated with albuterol at a rate of 15 mg/h over 2 h." | 3.69 | Association between reported use of inhaled triamcinolone and differential short-term responses to aerosolized albuterol in asthmatics in an emergency department setting. ( Fox, S; Lin, RY; Newman, TG; Sauter, D; Sirleaf, J; Tavakol, M; Walters, J, 1994) |
| " A case of albuterol-induced inhibition of hypoxic pulmonary vasoconstriction is described in a patient with steroid-dependent asthma." | 3.69 | Scintigraphic appearance of albuterol-induced inhibition of hypoxic pulmonary vasoconstriction. ( Alavi, A; Kim, E; Palevsky, HI; Worsley, DF, 1994) |
| "The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented." | 3.69 | Hypokalemia after normal doses of neubulized albuterol (salbutamol). ( D'Souza, L; Mahajan, M; Udezue, E, 1995) |
| " We measured EPBF with the argon freon-22 rebreathing technique in children with acute severe asthma to assess their response to nebulized salbutamol and to determine whether induced changes in the EPBF could be predicted from baseline measurements." | 3.69 | Effective pulmonary blood flow in children with acute asthma attack requiring hospitalization. ( Milner, AD; Yiallouros, PK, 1994) |
| "Short-term circulatory effects with the maximum recommended dose of inhaled albuterol (Proventil) were studied on 12 asthmatic patients between 33 and 39 weeks' gestation." | 3.69 | Short-term effects of inhaled albuterol on maternal and fetal circulations. ( Atkinson, BD; Gilbert, K; Rayburn, WF; Turnbull, GL, 1994) |
| "Hypomagnesaemia in a woman treated with theophylline and albuterol because of recurrent asthmatic attacks prompted us to explore the effects of these drugs on the metabolism of magnesium, calcium, sodium and phosphate in such patients." | 3.69 | Intravenous theophylline-induced excretion of calcium, magnesium and sodium in patients with recurrent asthmatic attacks. ( Bøhmer, T; Falch, J; Knutsen, R, 1994) |
| "Air-flow standardized breath sounds were recorded at the chest and at the trachea during histamine challenge test and after subsequent bronchodilation in 12 asthmatics and 6 healthy controls for spectral analysis, to be compared with simultaneous changes in spirometric variables." | 3.69 | Changes in frequency spectra of breath sounds during histamine challenge test in adult asthmatics and healthy control subjects. ( Haahtela, T; Katila, T; Malmberg, LP; Paajanen, E; Piirilä, P; Sovijärvi, AR, 1994) |
| "The following study was performed to further characterize a primate model of asthma using classes of drugs that target allergy (pyrilamine, cetirizine), are bronchodilators for the treatment of asthma (salbutamol, salmeterol) or are anti-inflammatory (dexamethasone)." | 3.69 | Characterization of a primate model of asthma using anti-allergy/anti-asthma agents. ( Andresen, CJ; Smith, WB; Turner, CR; Watson, JW, 1996) |
| "There was no relationship between the bronchial responsiveness to histamine and acetic acid cough threshold in these patients." | 3.69 | Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma. ( Mochizuki, H; Morikawa, A; Shimizu, T; Tokuyama, K, 1996) |
| "We performed pulmonary function tests and HRCT on eight asthmatic adults and two nonasthmatic control adults under three conditions: baseline, after methacholine inhalation, and after albuterol inhalation." | 3.69 | High-resolution computed tomography of airway changes after induced bronchoconstriction and bronchodilation in asthmatic volunteers. ( Chen, DR; Fahy, JV; Gamsu, G; Kee, ST, 1996) |
| " A careful review of his medical history and the mechanisms of drug-induced asthma revealed that the etiology of his death was more likely due to heroin abuse and noncardiogenic pulmonary edema." | 3.69 | The role of pharmacology and forensics in the death of an asthmatic. ( Blaho, K; Merigian, K, 1995) |
| "To determine the dose of albuterol required to terminate acute episodes of asthma, 92 acutely ill subjects received three doses of 2." | 3.69 | Observations on the effects of aerosolized albuterol in acute asthma. ( Dixon, L; Galan, G; Hejal, R; McFadden, ER; Strauss, L, 1997) |
| " Bronchial challenge tests were carried out with cumulative doses of inhaled carbachol in 10 healthy children (aged 7-14 yrs) and 50 asthmatic children (aged 5-15 yrs)." | 3.69 | Oscillatory pressure transients after flow interruption during bronchial challenge test in children. ( Frey, U; Kraemer, R, 1997) |
| "We compared mood variables, symptom severity, albuterol use, and peak expiratory flow rate (PEFR) measured three times daily over a 21-day period in 21 adults with moderate to severe asthma." | 3.69 | Perception of airway obstruction in asthma: sequential daily analyses of symptoms, peak expiratory flow rate, and mood. ( Affleck, G; Apter, AJ; Barrows, E; Reisine, ST; Tennen, HA; Wells, M; Willard, A; ZuWallack, RL, 1997) |
| "In the UK population studied, salmeterol, ipratropium bromide and theophylline are regularly used to treat patients with asthma of increasing severity." | 3.69 | Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. ( Jick, H; Meier, CR, 1997) |
| "We investigated platelet-activating factor (PAF)-induced migration in eosinophils obtained from asthmatic patients who were treated with or without intravenous prednisolone." | 3.69 | PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro. ( Fukumura, M; Koide, K; Shindo, K, 1997) |
| "A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported." | 3.69 | Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study. ( Baker, EK; Marinac, JS; Salzman, GA; Willsie, SK, 1997) |
| "The bronchodilating effects of 5 different beta-adrenergic stimulants, isoproterenol, salbutamol, trimetoquinol, orciprenaline and procaterol were examined in 28 same patients who were in a free period from asthmatic attack." | 3.68 | [Comparison of the bronchodilating effects of five beta-adrenergic stimulants administered by inhalation to patients with bronchial asthma]. ( Kokubu, H, 1993) |
| " Allergic bronchial eosinophilia in guinea pigs was inhibited by orally administered dexamethasone and methylprednisolone." | 3.68 | Allergic bronchial eosinophilia: a therapeutic approach for the selection of potential bronchial anti-inflammatory drugs. ( Chand, N; De Vine, CL; Diamantis, W; Harrison, JE; Jakubicki, RG; Nolan, KW; Pillar, J; Rooney, SM; Sofia, RD, 1993) |
| "A 40-yr-old woman with severe chronic asthma complained that her regular nebulized albuterol was exacerbating her symptoms." | 3.68 | Paradoxical bronchoconstriction with nebulized albuterol but not with terbutaline. ( Finnerty, JP; Howarth, PH, 1993) |
| "The cases of two asthmatic adolescents who overdosed on albuterol are presented." | 3.68 | Propranolol treatment of albuterol poisoning in two asthmatic patients. ( Henretig, F; Joffe, M; Ramoska, EA; Spiller, HA, 1993) |
| " Throughout the study, the children received the standardized course of therapy for hospitalized asthmatics with corticosteroids and albuterol nebulizations." | 3.68 | Chronopharmacology of albuterol in hospitalized asthmatic children. ( Cloutier, M; Labrecque, G; Rivard, GB, 1993) |
| "To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm." | 3.68 | Safety of continuous nebulized albuterol for bronchospasm in infants and children. ( Crowley, MR; Grad, R; Katz, RW; Kelly, HW; McWilliams, BC; Murphy, SJ, 1993) |
| "To study the feasibility of using high-dose continuously aerosolized albuterol aerosol in adults, seven adult asthmatic patients were treated eight times with 0." | 3.68 | High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol. ( Hergenroeder, P; Lin, RY; Smith, AJ, 1993) |
| "We performed a prospective study over a 6-month period to test the efficacy and safety of a continuous nebulized albuterol protocol for the treatment of acute adult asthma attacks." | 3.68 | The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks. ( Barish, RA; Brandt, G; Hooper, F; Jerrard, D; Olshaker, J, 1993) |
| "We have compared radioaerosol deposition pattern and bronchodilator response following inhalation of 100 micrograms of albuterol from a correctly used conventional metered dose inhaler (MDI) to those from Gentlehaler, a new compact low-velocity pressurized aerosol device (Schering Corporation), in a group of ten asthmatic patients (mean baseline FEV1 52 percent; reversibility > 15 percent)." | 3.68 | Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. ( Clarke, SW; Newman, SP, 1993) |
| "Leukotriene B4 levels were measured after stimulation by calcium ionophore A23187: (i) in peripheral, neutrophils (PMN) from allergic asthmatics, rhinitis and healthy subjects; (ii) in macrophages collected by bronchoalveolar lavage." | 3.68 | Leukotriene B4 level in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapy. ( Chabannes, B; Gormand, F; Grosclaude, M; Hosni, R; Lagarde, M; Moliere, P; Pacheco, Y; Perrin-Fayolle, M; Piperno, D, 1992) |
| "The effect of inhaled corticosteroid therapy on airway mucosal inflammation was investigated in 10 symptomatic atopic asthmatic patients treated with inhaled albuterol and whose disease severity required preventative antiinflammatory treatment." | 3.68 | Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. ( Britten, KM; Djukanović, R; Holgate, ST; Howarth, PH; Roche, WR; Walls, AF; Wilson, JW; Wilson, SJ, 1992) |
| "Seven children from 3 to 14 years old with chronic steroid-dependent asthma were treated with methotrexate (MTX)." | 3.68 | Methotrexate treatment of severe asthma in children. ( Guss, S; Portnoy, J, 1992) |
| "The effect of a prior histamine challenge on the bronchodilator response to salbutamol after spontaneous recovery of FEV1 to 95% of the prechallenge level was studied in two groups of asthmatic children." | 3.68 | Assessment of bronchodilatation after spontaneous recovery from a histamine challenge in asthmatic children. ( Duiverman, EJ; Kerrebijn, KF; Merkus, PJ; Quanjer, PH; Rooda, HM; van Essen-Zandvliet, EE, 1992) |
| "The effects of prednisolone, salbutamol or theophylline treatment were studied in guinea pigs on bronchial hyperreactivity induced by chronic administration of PAF, (subsequently measuring respiratory flow after an intravenous injection of histamine) and the chemokinesis of leucocytes in vitro." | 3.68 | Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs. ( Berga, P; Fernández, AG; Gristwood, RW; Llupiá, J, 1991) |
| "Effects of flutropium bromide, a new bronchodilator with an anticholinergic action, alone or in combination with other antiasthma drugs were investigated in guinea pigs by using an index of inhibition of the acetylcholine (ACh)-induced bronchoconstriction." | 3.68 | [Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction]. ( Misawa, M; Mizuno, H; Ohno, H; Takahashi, Y, 1990) |
| "To examine the effects of serum theophylline concentration on the bronchodilating effect of beta 2-stimulant inhalated by patients with bronchial asthma, 200 micrograms-Salbutamol inhalation test was performed on 30 patients with bronchial asthma (from 17 to 71 years old, averaging 49." | 3.68 | [The influence of serum theophylline concentration on the bronchodilating effect of salbutamol inhalation for bronchial asthma]. ( Hashimoto, T; Kondo, A; Nakamata, M; Tsukioka, K, 1990) |
| " Inhaled beta-agonists were the most commonly prescribed antiasthmatic agents in 1986, followed by sustained-release theophylline and inhaled corticosteroids." | 3.68 | Use of antiasthmatic drugs in Australia. ( Bowes, G; Hurley, SF; Jenkins, MA; McNeil, JJ, 1990) |
| "The purpose of this study is to evaluate the effect of disodium cromoglycate and albuterol on energy cost of running, gas exchange, and ventilation during maximal exercise in children with exercise-induced asthma (EIA)." | 3.68 | Effect of inhaled disodium cromoglycate and albuterol on energy cost of running in asthmatic children. ( Baraldi, E; Magagnin, G; Santuz, P; Zacchello, F; Zanconato, S, 1990) |
| " We discuss a case report of albuterol used with a spacer device that induced atrial fibrillation." | 3.68 | Spacer-induced atrial fibrillation. ( Breeden, CC; Safirstein, BH, 1990) |
| "Albuterol used with a spacer device which induced atrial fibrillation is described." | 3.68 | Albuterol and spacer-induced atrial fibrillation. ( Breeden, CC; Safirstein, BH, 1990) |
| "Our study was designed to assess potential cardiovascular adverse effects in clinically stable asthmatic children due either to oral sustained-release theophylline or theophylline in combination with an inhaled beta-2 adrenergic agonist." | 3.68 | Lack of adverse cardiac effects of combined treatment with theophylline and albuterol in asthmatic children. ( Bastianon, V; Bernardini, L; Businco, L; Coletta, F; Colloridi, V; Di Fazio, A; Ferrucci, A; Marzano, MC; Pucci, S; Sorbara, N, 1990) |
| "Concomitant intradermal injection of salbutamol inhibits histamine-induced weal volume in the skin of atopic asthmatic subjects and the degree of this inhibition (index of beta-adrenergic effect in the skin) correlates with the bronchodilator effect of inhaled salbutamol in the same subjects (index of beta-adrenergic effect in the lung)." | 3.67 | Beta-adrenoceptor agonist responses in the skin and lungs of asthmatic subjects. ( Basran, GS; Morley, J; Paul, W, 1984) |
| "Drug intake and plasma concentrations of theophylline and beta-agonists were recorded in 19 patients with acute asthma (peak expiratory flow rate less than 50% of predicted normal value and heart rate greater than 100 beats/min)." | 3.67 | Drug intake and plasma concentrations in acute asthma. ( Boe, J; Ljungholm, K, 1984) |
| "Ten male asthmatic volunteers each inhaled two puffs (200 micrograms) of salbutamol on two separate days 30 minutes after double blind oral administration of either 20 mg nifedipine or identical placebo." | 3.67 | Nifedipine enhances the bronchodilator effect of salbutamol. ( Corris, PA; Gibson, GJ; Lever, AM, 1984) |
| "Out of a group of 55 asthmatics, 16 fitted the strict definition of atropine resistance (less than 20% FEV1 response to inhaled anticholinergic drugs, with a 20% or more FEV1 response to subsequent inhalation of beta 2-adrenergic stimulants)." | 3.67 | Atropine resistance in asthma: definition and provisional hypothesis. ( Jolobe, OM, 1984) |
| "Fourteen patients with uncomplicated essential hypertension and mild asthma were treated with Atenolol 50-125 mg/day for up to 8 months." | 3.67 | Treatment of hypertension in mild asthmatic patients with atenolol. ( Clement, S; Grizotzki, B; Krauss, A; Krauss, S; Spitz, E, 1984) |
| "Twenty-seven asymptomatic asthmatic children with airway obstruction received a single oral dose of one out of three solutions, in a double-blind, randomized fashion, containing: etamiphylline, 6." | 3.67 | [Comparative study of the effect of a single oral dose of theophylline and etamiphyllin in children with asthma]. ( Labayru, MT; Vázquez, C, 1984) |
| "To determine whether asthma alone can cause irreversible airflow obstruction 42 men and 47 women with chronic asthma (mean duration 22 (SD 13) years) without evidence of other disease likely to cause irreversible airflow obstruction were treated with theophylline orally and a beta agonist both orally and by inhalation for four weeks." | 3.67 | Asthma and irreversible airflow obstruction. ( Brown, PJ; Finucane, KE; Greville, HW, 1984) |
| "We report a case of respiratory arrest in a ten-year-old asthmatic girl under beta-2-agonists and theophylline." | 3.67 | [Respiratory arrest in an asthmatic girl treated with beta-2-mimetics and theophylline. Possible role of hypokalemia in sudden death in asthmatic patients]. ( Benhamou, PH; Devoldere, C; Epelbaum, S; Kremp, O; Pautard, JC; Piussan, C, 1989) |
| "The plasma potassium level was studied in 15 patients with acute severe asthma before and six to 14 hours (mean = seven) after treatment with a nebulised beta 2-agonist, salbutamol, intravenous aminophylline and hydrocortisone in recommended doses." | 3.67 | Plasma potassium in acute severe asthma before and after treatment. ( Khan, MA, 1989) |
| "4 mg salbutamol on the impedance of the respiratory system was studied in 25 asthmatic subjects after histamine-induced bronchoconstriction." | 3.67 | Response localization of the pharmacological agents histamine and salbutamol along the respiratory system by forced oscillations in asthmatic subjects. ( Polko, AH; Visser, BF; Wouters, EF, 1989) |
| "Beta-adrenoceptor binding in lymphocytes of asthmatic and non-asthmatic children and healthy adult volunteers was investigated with the radioligand 125-iodocyanopindolol (ICYP)." | 3.67 | Beta-adrenoceptor density and resolution of high and low affinity state on B- and T-cells in asthmatic and non-asthmatic children. ( Griese, M; Körholz, D; Reifenhäuser, A; Reinhardt, D; Seeger, K; Wahn, V, 1988) |
| "In 13 patients with bronchial asthma, who were on beta 2-adrenergic bronchodilator therapy, the effects of prednisolone and ketotifen on lymphocyte beta 2-adrenoceptor density and -responsiveness were investigated." | 3.67 | Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators. ( Brodde, OE; Egerszegi, S; Howe, U; Konietzko, N; Michel, MC, 1988) |
| " Inhalation of ovalbumin by sensitized guinea pigs induced three phases of airways obstruction: an early asthmatic response (EAR) peaking at 2 h, a late response (LAR) peaking at 17 h, and a further late response (LLAR) being observed at 72 h." | 3.67 | The effect of cromolyn sodium and albuterol on early and late phase bronchoconstriction and airway leukocyte infiltration after allergen challenge of nonanesthetized guinea pigs. ( Church, MK; Holgate, ST; Hutson, PA, 1988) |
| "The effect of a fish oil enriched diet containing about 3 g of eicosapentaenoic acid was studied in 10 patients with aspirin intolerant asthma." | 3.67 | Effects of a fish oil enriched diet on aspirin intolerant asthmatic patients: a pilot study. ( Agusti-Vidal, A; Castillo, JA; Coronas, A; Ordinas, A; Picado, C; Pujades, M; Schinca, N, 1988) |
| "An albuterol (salbutamol) sulphate solution was successfully administered endotracheally to a 67-year-old woman suffering severe bronchospasm and impending ventilatory arrest secondary to asthma." | 3.67 | Treatment of asthma-related respiratory arrest with endotracheal albuterol (salbutamol). ( Gareau, AB; Rubes, CJ; Verbeek, PR, 1988) |
| "A study of patients with a stable course of bronchial asthma (BA) has confirmed the absence of a significant bronchodilating effect of nifedipine during an acute drug test (a single sublingual administration of the drug at a dose of 20 mg)." | 3.67 | [The possibilities and prospects in using the calcium antagonist korinfar in patients with bronchial asthma]. ( Alekseev, VG; Efimov, AV; Sinopal'nikov, AI, 1988) |
| "Co-administration of intravenous albuterol and theophylline resulted in increased theophylline clearance in a child with severe asthma." | 3.67 | Enhancement of theophylline clearance by intravenous albuterol. ( Amirav, I; Amitai, Y; Avital, A; Godfrey, S, 1988) |
| "To explore the possibility that theophylline may act through adrenomedullary secretion of catecholamines, we examined the time courses of plasma norepinephrine (NE), epinephrine (E), and theophylline concentrations and peak expiratory flow (PEF) in nine children with an acute exacerbation of asthma receiving a 72-hour constant infusion of aminophylline." | 3.67 | Plasma catecholamine concentrations during a 72-hour aminophylline infusion in children with acute asthma. ( Ishizaki, T; Kanagawa, S; Minegishi, A; Morishita, M; Nagai, T; Odajima, Y; Yamaguchi, M, 1988) |
| "Single photon emission computed tomography, a rotating gamma camera, and continuous inhalation or infusion of krypton 81m (half life 13 seconds) were used to measure regional ventilation (V), perfusion (Q), and ventilation-perfusion (V/Q) ratios in five normal subjects in supine, prone, and lateral decubitus postures and in three asthmatic patients (supine posture only) before and after inhalation of 2." | 3.67 | Tomography of regional ventilation and perfusion using krypton 81m in normal subjects and asthmatic patients. ( Al-Suhali, AR; Henderson, B; Hughes, JM; Myers, MJ; Orphanidou, D, 1986) |
| "The concentrations of theophylline, terbutaline and salbutamol in post-mortem blood samples from 68 patients (17-85 years old) with asthma or chronic obstructive lung disease, 54 of whom had died of asthma, were analysed." | 3.67 | Post-mortem concentrations of salbutamol, terbutaline and theophylline in asthma patients. ( Boman, G; Lindsjö, M; Lindström, B; Strandberg, K; Wiholm, BE, 1987) |
| " On oral challenges, she developed an urticarial reaction after tartrazine; urticarial and bronchospastic reactions after salicylsalicylic acid; and urticarial and bronchospastic reactions after choline magnesium trisalicylate." | 3.67 | Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis. ( Chudwin, DS; Frey, C; Golden, HE; Luskin, AT; Richmond, GW; Strub, M, 1986) |
| "Asthma was provoked by histamine inhalation in five children in order to study the hypoxaemia that might ensue and the underlying ventilation-perfusion (VA/Q) mismatching." | 3.67 | Histamine-induced asthma in children: effects on the ventilation-perfusion relationship. ( Freyschuss, U; Hedenstierna, G; Hedlin, G, 1985) |
| "Studies using the guinea pig ileum bioassay technique have previously shown that patients with either asthma or chronic bronchitis have increased amounts of histamine in their sputum." | 3.66 | Histamine content of sputum from patients with asthma and chronic bronchitis. ( Bryant, DH; Pui, A, 1982) |
| "The anti-asthmatic activity, pulmonary mechanics and cardiovascular effects of BB-1502 (9-cyclohexyl-2-n-propoxy-9H-adenine) administered by aerosol were evaluated in guinea pigs and dogs and compared with the effects of salbutamol." | 3.66 | Anti-asthmatic activity of BB-1502 by inhalation. ( Hirano, M; Imanishi, H; Kamei, H; Kawaguchi, H; Kawano, K, 1982) |
| "In five subjects with mild asthma and in five normal subjects, we determined the effect of a 4 wk course of inhaled salbutamol (albuterol), 200 micrograms q." | 3.66 | Selective subsensitization of beta-adrenergic receptors in central airways of asthmatics and normal subjects during long-term therapy with inhaled salbutamol. ( Conolly, ME; Hui, KK; Littner, MR; Tashkin, DP; Wolfe, RN, 1982) |
| "We have prospectively examined in 51 patients the relationship between the level of airway responsiveness to histamine and methacholine and the minimum medications required to control asthma." | 3.66 | Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma. ( Frith, PA; Hargreave, FE; Juniper, EF, 1981) |
| " The added observation that theophylline and salbutamol were effective suggests that the condition is a manifestation of asthma." | 3.66 | Persistent cough a forme-fruste of asthma. ( Benzaray, S; Katznelson, D; Yahav, Y, 1982) |
| "Bronchial responsiveness to histamine was measured in 35 adult asthmatics whose symptoms were controlled on a minimum of medication." | 3.66 | Long-term stability of bronchial responsiveness to histamine. ( Frith, PA; Hargreave, FE; Juniper, EF, 1982) |
| "The efficacy and side effects of intravenous and intramuscular albuterol were determined in 13 adult asthmatic patients whose airway responsiveness had previously been evaluated with inhaled albuterol." | 3.66 | Intramuscular and intravenous albuterol in the treatment of asthma. ( Contreras, M; Rebuck, AS, 1982) |
| "We examined the effects of pharmacologic antagonists on the bronchial response to inhaled histamine in 11 normal and 11 asthmatic subjects." | 3.66 | Histamine dose-response relationships in normal and asthmatic subjects. The importance of starting airway caliber. ( Chung, KF; Keyes, SJ; Morgan, B; Snashall, PD, 1982) |
| "In the management of severe chronic asthma, extensive avoidance of known precipitating factors and optimum betastimulation supported by theophylline have pride of place." | 3.66 | [Problems of indication and execution of long-term steroid therapy in advanced disabling bronchial asthma]. ( Imhof, K; Scherrer, M, 1980) |
| "Plasma cholesterol, plasma and white blood cell ascorbic acid concentrations were estimated in 30 untreated, 32 salbutamol-treated patients with bronchial asthma and in 57 normal controls." | 3.66 | Plasma and white blood cell ascorbic acid concentrations in patients with bronchial asthma. ( Iboko, MI; Jessop, WJ; Ojutiku, OO; Olusi, SO, 1979) |
| "There are many sympathomimetic products available in treatment of asthma, such as ephedrin, isoproterenol, orciprenalin, salbutamol, terbutalin." | 3.66 | [Use of sympathomimetics in the treatment of asthma]. ( Hugues, FC; Julien, D, 1978) |
| "In a double-blind trial the effects on ventilatory function (FEV1), heart rate and blood pressure of oral pirbuterol and oral salbutamol in various single doses were studied in ten patients with chronic asthma." | 3.65 | Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics. ( Grant, IW; Pocock, SJ; Willey, RF, 1976) |
| "Controlled standardised histamine inhalation tests were carried out in 21 asthmatics to determine the degree of non-specific bronchial hyperreactivity with and without prior treatment with several anti-asthmatic drugs." | 3.65 | Protective effect of drugs on histamine-induced asthma. ( Cockcroft, DW; Hargreave, FE; Killian, DN; Mellon, JJ, 1977) |
| "Twenty asthmatics and 14 non-atopic controls were given long-acting theophylline tablets, 400 mg twice daily, and were then challenged, after a control period, with 0." | 3.65 | Effect of salbutamol inhalations of plasma and urinary cyclic adenosine monophosphate levels in asthmatics and non-atopic controls. ( Härkönen, M; Muittari, A; Raij K-Alanko, K, 1976) |
| "Ten patients with exercise-induced asthma were premedicated with oral salbutamol and oral theophylline on separate occasions before performing a standardised exercise test." | 3.65 | A comparison of oral theophylline and oral salbutamol in exercise-induced asthma. ( Anderson, SD; Lindsay, DA; Seale, JP, 1977) |
| "The therapeutic efficacy of atropine and salbutamol sprays alone or in association was experimented in patients with atopic bronchial asthma as part of an investigation of the bronchodilatatory drugs and the pathogenesis of bronchospasm." | 3.65 | [The neurovegetative system in the pathogenesis of bronchial spasm]. ( Giammarruto, R; Mannino, F; Mariotta, S; Pasqua, F, 1977) |
| "Six asthmatic patients whose airway obstruction improved significantly during a trial of prednisone have been studied in detail." | 3.65 | Patterns of response to isoprenaline in asthmatic patients. ( Clarke, SW; Hodson, ME; Paterson, JW; Shenfield, GM, 1975) |
| " Pharmacokinetic-pharmacodynamic (PKPD) models to guide paediatric dosing are lacking." | 3.30 | Optimising intravenous salbutamol in children: a phase 2 study. ( Anderson, BJ; Kloprogge, F; Pan, S; Ramnarayan, P; Sheng, Y; Standing, JF; Walsh, S, 2023) |
| "This study aimed to investigate the dose-response and pharmacology of a range of single doses of nebulised ensifentrine (RPL554), an inhaled dual phosphodiesterase (PDE) 3/4 inhibitor in patients with asthma." | 2.90 | Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. ( Abbott-Banner, K; Bjermer, L; Newman, K, 2019) |
| "A total of 180 patients with pediatric bronchial asthma were randomized into the oxygen-driven aerosol group (Group A, n=90) and the air compressor-driven aerosol group (Group B, n=90)." | 2.87 | Analysis of the advantages and disadvantages in application of oxygen-driven aerosol and aerosol inhalation by air compressor for the pediatric asthma. ( Wang, J; Wang, X, 2018) |
| "Salbutamol sulphate (SS) is a model short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm having poor bioavailability (50%) due to its extensive first-pass effect." | 2.84 | Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy. ( Kharshoom, RM; Sallam, NM; Sanad, RA; Zeneldin, MA, 2017) |
| " Although systemic intake is banned, inhalation for asthma is permitted but with dosage restrictions." | 2.82 | Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control. ( Biollaz, J; Buclin, T; Courlet, P; Guidi, M; Mazzoni, I; Rabin, O, 2022) |
| "Albuterol mDPI was comparable to ProAir HFA at 90 and 180 µg." | 2.82 | Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir(®) Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies. ( Iverson, H; Kerwin, EM; Lepore, MS; Miller, DS; Shah, T; Taveras, H; Wayne, D, 2016) |
| "The albuterol MDPI was generally well tolerated." | 2.82 | Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter. ( Given, J; Iverson, H; Taveras, H, 2016) |
| "To compare the efficacy of nebulised salbutamol alone and in combination with ipratropium bromide in acute severe asthma in children." | 2.82 | Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. ( Ahmed Khan, KM; Bai, C; Gowa, MA; Memon, BN; Parkash, A, 2016) |
| " Adverse events were comparable across groups." | 2.82 | Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. ( Bleecker, ER; Busse, WW; Donohue, JF; Garfinkel, S; Ghafouri, M; Manuel, RC; Schlenker-Herceg, R; Wise, R; Zubek, VB, 2016) |
| "After discontinuation of the treatment, cough scores increased, pulmonary function and eosinophilic airway inflammation were aggravated and returned to the baseline levels." | 2.80 | Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma. ( Kawagoe, M; Kirishi, S; Kondo, M; Kubota, N; Tagaya, E; Tamaoki, J, 2015) |
| "Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment." | 2.80 | Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. ( Beasley, R; Bowles, D; Charles, T; Fingleton, J; Shirtcliffe, P; Strik, R; Travers, J; Weatherall, M; Williams, M, 2015) |
| " For the combined asthma and COPD subjects, the plasma AUC and Cmax for FP and salmeterol were higher for Rotahaler:Rotahaler/Diskus geometric mean ratios (90% confidence intervals) for FP AUC0-τ of 1." | 2.79 | Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. ( Chan, RH; Daley-Yates, PT; Despa, SX; Louey, MD; Mehta, R, 2014) |
| "Vilanterol (VI) is a novel long-acting beta2 agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (ICS)." | 2.79 | Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. ( Bateman, ED; Bleecker, ER; Busse, WW; Goldfrad, C; Jacques, L; Lötvall, J; O'Byrne, PM; Toler, WT; Woodcock, A, 2014) |
| " The profile of treatment-emergent adverse events judged as related to abediterol was consistent with that seen after adrenergic stimulation and occurred exclusively in patients who received abediterol 10 μg or 25 μg." | 2.79 | Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma. ( Beier, J; de Miquel, G; Fuhr, R; Jiménez, E; Massana, E; Ruiz, S; Seoane, B, 2014) |
| "Patients with asthma or chronic obstructive pulmonary disease (COPD) (n = 1016)." | 2.78 | Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD. ( Gálffy, G; Mezei, G; Müller, V; Németh, G; Orosz, M; Selroos, O; Tamási, L, 2013) |
| "We found no significant difference in pharmacokinetic profile of inhaled and oral salbutamol between elite athletes with asthma and nonasthmatic subjects." | 2.77 | The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects. ( Backer, V; Dalhoff, K; Elers, J; Hemmersbach, P; Henninge, J; Pedersen, L, 2012) |
| " Other endpoints included adverse events and pulmonary function." | 2.76 | A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma. ( Curry, L; Goodwin, E; Hanrahan, JP; Hinkle, J; Hinson, J; Kerwin, E; Sciarappa, K, 2011) |
| "Fluticasone/formoterol was comparable to fluticasone/salmeterol for the primary efficacy endpoint, mean pre-dose FEV1 at week 12." | 2.76 | Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. ( Bodzenta-Lukaszyk, A; Dymek, A; Mansikka, H; McAulay, K, 2011) |
| " Pharmacokinetic results showed a greater initial absorption of salmeterol with DPI-C but greater continued absorption and a 40% greater AUC with DPI-A, which we attribute to slower but more extensive oral absorption because of the greater mass of swallowed large particles of salmeterol generated by DPI-A." | 2.76 | Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. ( Harrison, LI; Needham, MJ; Novak, CC; Ratner, P, 2011) |
| "We hypothesised that airway remodelling contributes to airway hyper-responsiveness in asthma, independent of steroid-responsive airway inflammation." | 2.76 | The effect of airway remodelling on airway hyper-responsiveness in asthma. ( Berend, N; Brown, NJ; Farah, CS; Hardaker, KM; Kermode, JA; King, GG; Salome, CM, 2011) |
| "To compare the clinical diagnosis of chronic obstructive pulmonary disease (COPD) with results of post-bronchodilator spirometry in general practice, and examine practitioner, practice and patient characteristics associated with agreement between clinical and spirometric diagnoses." | 2.76 | Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice. ( Comino, EJ; Hasan, I; Hermiz, O; Marks, GB; Middleton, S; Vagholkar, S; Wilson, SF; Zwar, NA, 2011) |
| "For chronic persistent bronchial asthma, heat-sensitive moxibustion can improve the clinical symptoms and the pulmonary ventilation function, and it is better than Seretide inhalant." | 2.75 | [Comparative observation on therapeutic effect of chronic persistent bronchial asthma treated with heat-sensitive moxibustion and medication]. ( Liang, C; Yang, K; Zhang, TF, 2010) |
| " During the 40-day period, subjects performed resistance exercise (REX) with their unloaded leg on an inertial resistance ergometer and, as part of a double-blind design, consumed the maximal oral therapeutic dosage of albuterol (i." | 2.73 | Temporal strength changes from resistance exercise and albuterol on unloaded muscle. ( Caruso, JF; Cook, TD; Hamill, JL; Mercado, DR; Saito, K; Yamauchi, M, 2008) |
| " The incidence of adverse events was low and similar between the two groups and events were of the type expected in this population." | 2.73 | Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. ( Chan, R; Jung, KS; Lee, YC; Park, SK; Shim, JJ; Uh, ST; Williams, AE, 2008) |
| "We conducted a double blind, randomised, placebo-controlled, crossover study evaluating the effects of halving inhaled steroid dosage plus salmeterol, or salmeterol and tiotropium." | 2.73 | A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. ( Fardon, T; Haggart, K; Lee, DK; Lipworth, BJ, 2007) |
| "For similar systemic exposure, dosing should be adjusted to age or size but not on a fixed microg kg(-1) basis, which may lead to unnecessary suboptimal dosing." | 2.73 | Age dependent systemic exposure to inhaled salbutamol. ( Bisgaard, H; Bønnelykke, K; Jespersen, JJ, 2007) |
| "The relative lung bioavailability of salbutamol sulfate particles produced using supercritical fluids (SEDS) and delivered by dry powder inhaler (DPI) was compared with the performance of a conventional micronized drug DPI using the same device design (Clickhaler, Innovata Biomed)." | 2.73 | Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. ( Chrystyn, H; de Matas, M; Hosker, H; Mukherjee, R; Richardson, CH; Wong, I, 2007) |
| " The aims of this study were to evaluate the long-term efficacy (including symptom-free days and exacerbations) and impact on HRQoL of a stable-dose regimen of salmeterol/fluticasone propionate (SAL/FP) and an adjustable maintenance dosing (AMD) regimen of formoterol/budesonide (FOR/BUD) where treatment is adjusted based on symptoms [SAM40056]." | 2.73 | Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. ( Price, DB; Williams, AE; Yoxall, S, 2007) |
| " At the baseline visit 2-6 days later, the provocative concentration of methacholine to induce a 30% decrease in forced expiratory volume in 1 second (FEV(1) PC(30)) was determined, followed by a nebulized racemic albuterol dose-response study with three doses of albuterol, to familiarize patients with the procedures." | 2.73 | Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction. ( Esparham, A; Harkins, M; Kelly, HW; Raissy, HH, 2007) |
| " For patients in group A, a fixed dosage was maintained for 18 months, while those in group B received tailored dosage or withdrawal of therapy according to the clinical control level (well or total control)." | 2.73 | [A clinical study on the significance of airway hyperresponsiveness monitoring in the adjustment of combined therapy for asthmatic patients]. ( Liu, CT; Pang, YM; Tan, CW; Wang, G; Wang, YM, 2007) |
| "The aim of these experiments was to investigate the use of artificial neural networks (ANNs) for generating models able to predict the relative lung bioavailability and clinical effect of salbutamol when delivered to healthy volunteers and asthmatic patients from dry powder inhalers (DPIs)." | 2.73 | Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks. ( Chrystyn, H; de Matas, M; Richardson, CH; Shao, Q, 2008) |
| "This study evaluated pharmacokinetic and glucodynamic responses to AIR inhaled insulin relative to subcutaneous insulin lispro, safety, pulmonary function, and effects of salbutamol coadministration." | 2.73 | AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ( Berclaz, PY; de la Peña, A; Gates, JR; Muchmore, DB; Tibaldi, FS; Wolzt, M, 2008) |
| " The two FSC treatments were similar except that QD dosing did not maintain improvements in lung function for 24h compared with twice daily dosing." | 2.73 | Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. ( Dorinsky, PM; Kerwin, EM; Meltzer, EO; Nathan, RA; Ortega, HG; Schoaf, L; Yancey, SW, 2008) |
| " Secondary outcomes included risk of hospitalization, pulmonary function, asthma control level, quality of life, and adverse events (AEs)." | 2.72 | Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis. ( Hong, JG; Lu, J; Qin, Z; Zhou, XJ, 2021) |
| " FEV(1) 90 min after dosing (primary variable) increased compared with pre-dose FEV(1) by an average of 30% and 32% for budesonide/formoterol and salbutamol, respectively (P = 0." | 2.72 | Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. ( Balanag, VM; Jorup, C; Yang, PC; Yunus, F, 2006) |
| " The results highlight a more significant effect of inspiratory flow on variable dosage emission when using the Symbicort Turbuhaler compared with the Seretide Diskus." | 2.72 | Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. ( Assi, KH; Chrystyn, H; Pearson, SB; Tarsin, WY, 2006) |
| "Bronchial asthma is defined as "a chronic inflammatory disease of the airways involving many cells" and inhaled corticosteroids have therefore become the fundamental drugs for the long-term management of the disease." | 2.72 | The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma. ( Dal Negro, RW; Guerriero, M; Micheletto, C; Tognella, S; Trevisan, F, 2006) |
| "The effect of treatment on FEV1 and breathlessness (using the Borg scale) was measured at 1, 3, 5, 10, 15, 20, 25 and 30 minutes after test treatment." | 2.72 | Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study. ( Aalbers, R; Bantje, TA; Jonkers, RE, 2006) |
| "Non-cortisone-treated asthmatic patients displayed higher levels of both R- and S-salbutamol in plasma than did healthy volunteers after one single ingestion of racemic salbutamol (CMAX both comparisons P<0." | 2.71 | Metabolism of salbutamol differs between asthmatic patients and healthy volunteers. ( Ahlner, J; Andersson, RG; Josefsson, M; Naidu Sjöswärd, K; Schmekel, B, 2003) |
| " Significant benefit was gained from adding salmeterol in a group of patients who appeared to have been at the top of their steroid dose-response curve receiving FP250." | 2.71 | Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. ( Browning, D; Colman, NC; Dal Negro, R; Fletcher, CP; Ind, PW; James, MH, 2003) |
| "Chronic obstructive pulmonary disease (COPD) is characterised by limited bronchial reversibility and chronic neutrophilic inflammation." | 2.71 | Reversibility to a beta2-agonist in COPD: relationship to atopy and neutrophil activation. ( Lötvall, J; Malakauskas, K; Sakalauskas, R; Sitkauskiene, B, 2003) |
| "However, in the severe COPD group, 7-19% of the patients were not able to generate the optimum flows through the DPIs." | 2.71 | Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. ( Broeders, ME; Folgering, HT; Hop, WC; Molema, J, 2003) |
| "The cumulative dose-response study compared the biological effects (pulmonary function, respiratory muscle function, systemic effects) of an equal dose of salbutamol delivered via four different devices in 23 patients with asthma and 21 patients with moderate or severe chronic obstructive pulmonary disease (COPD)." | 2.71 | Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients? ( Broeders, ME; Folgering, HT; Hop, WC; Molema, J; Vermue, NA, 2003) |
| " This randomized, placebo-controlled, multicenter, crossover study investigated the efficacy, dose-response and safety of HFA-albuterol delivered via a breath-actuated Autohaler inhalation device in comparison with the same medication delivered using a conventional P&B device." | 2.71 | Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma. ( Cohen, RM; Gross, G; Guy, H, 2003) |
| "Patients with bronchial asthma were chosen on clinical grounds." | 2.71 | Effect of inhalation of salbutamol, beclomethasone dipropionate & ipratropium bromide on mucociliary clearance in some patients with chronic stable bronchial asthma. ( Guleria, R; Gupta, K; Padhy, AK; Pande, JN; Singh, TR; Sinha, S, 2003) |
| " Primary safety variables were asthma-related and nonasthma-related serious adverse events (SAE)s and adverse events (AE)s resulting in discontinuation (DAE)s." | 2.71 | Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. ( Aubier, M; Bengtsson, T; Campbell, M; Huang, S; Lindh, A; Pauwels, RA; Petermann, W; Schwabe, G; Sears, MR; Villasante, C, 2003) |
| " Forced expiratory volume in 1 s (FEV1), pulse, blood pressure, electrocardiogram, adverse events and urine formoterol were assessed." | 2.71 | Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. ( Honomichlová, H; Kopriva, F; Matulka, M; Pohunek, P; Rybnícek, O; Svobodová, T, 2004) |
| " Our aim was to establish whether adverse effects of SABAs are greater at higher than normal doses and after withdrawing inhaled corticosteroid (ICS) therapy." | 2.71 | Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate. ( Cowan, JO; Flannery, EM; Herbison, GP; Smith, AD; Taylor, DR; Wraight, JM, 2004) |
| "The earlier described faster onset-of-action of formoterol as compared to a equipotent dosage of salmeterol was confirmed in this study." | 2.71 | Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma. ( Creemers, JP; Greefhorst, AP; Hoff, WJ; Schermer, TR; Sips, AP; van Herwaarden, CL; Westbroek, J, 2004) |
| " The lack of differences in FEV(1) increases observed after 200 and 400 microg salbutamol may reflect attainment of the flat portion of the dose-response curve using either device." | 2.71 | Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction. ( Fontana, GA; Geri, P; Lavorini, F; Luperini, M; Maluccio, NM; Mariani, L; Marmai, C; Pistolesi, M, 2004) |
| " This study compared the dose-response of salbutamol delivered by the Aerodose Inhaler (Aerogen Inc." | 2.71 | Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics. ( Cockburn, W; Fishman, R; Lipworth, BJ; Sims, EJ; Taylor, K, 2005) |
| " No patients discontinued due to treatment-related adverse events." | 2.71 | Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma. ( Ayre, G; Dobson, C; Horowitz, A; Kruse, M; Rosenkranz, B, 2005) |
| "This was a randomised, double-blind, placebo-controlled, cross-over study comparing the systemic pharmacodynamic effects (heart rate and serum potassium) and pharmacokinetics of salmeterol delivered by the non-CFC hydrofluoralkane (HFA) propellant 134a and the CFC propellant (propellant 11/12) metered dose inhalers (MDI) in healthy subjects." | 2.71 | Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. ( Daley-Yates, P; De Silva, M; Handel, M; Kempsford, R; Mehta, R, 2005) |
| "A patient-driven, adjustable maintenance dosing (AMD) approach to asthma therapy, in which the dose is adjusted by patients according to the severity of their symptoms, has recently been compared with fixed-dose therapy in open-label studies." | 2.71 | The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast ( Boulet, LP; FitzGerald, JM; Follows, RM, 2005) |
| "Optimum treatment of bronchial asthma requires accurate diagnosis and severity classification." | 2.71 | Evaluation of severity of bronchial asthma through an exercise bronchial challenge. ( Cruz, HM; Lazo-Velásquez, JC; Lozada, AR, 2005) |
| " A bivariate dose-response model based on these principles was fitted simultaneously to all data." | 2.70 | Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. ( Böcskei, C; Juhász, G; Larsson, R; Poczi, M; Rosenborg, J; Rott, Z, 2002) |
| " A bivariate dose-response model based on these principles was fitted simultaneously to all data." | 2.70 | Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients. ( Böcskei, C; Juhász, G; Larsson, P; Poczi, M; Rosenborg, J; Rott, Z, 2002) |
| " Cumulative dose-response curves (200, 400, 800 and 1600 microg) were constructed." | 2.70 | Metal versus plastic spacers: an in vitro and in vivo comparison. ( Ekkelenkamp, MB; Janssen, R; Lammers, JW; Weda, M; Zanen, P, 2002) |
| " Blood samples were taken for plasma salbutamol at 5, 10, 15 and 20 min after inhalation to measure lung bioavailability as a surrogate for relative lung dose." | 2.70 | Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children. ( Anhøj, J; Bisgaard, H; Lee, DK; Lipworth, BJ, 2002) |
| "Airway inflammation was assessed 24 h after the AC by bronchoalveolar lavage (BAL) (n = 16) and bronchial biopsies (n = 13)." | 2.70 | Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. ( Boulet, LP; Boutet, M; Chakir, J; Laviolette, M; Milot, J, 2001) |
| " Dose-response curves for change in FEV1 with salbutamol were compared using analysis of covariance to take account of methacholine-induced changes in spirometry." | 2.70 | Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. ( Cowan, JO; Flannery, EM; Hancox, RJ; Herbison, GP; Jones, SL; Taylor, DR, 2001) |
| " This study investigated the influence of the chronic use of short-acting and long-acting beta(2)-agonists, compared with the additional use of inhaled corticosteroids on the perception of histamine-induced bronchoconstriction." | 2.70 | Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma. ( Bijl-Hofland, ID; Cloosterman, SG; Folgering, HT; van den Elshout, FJ; van Schayck, CP; van Weel, C, 2001) |
| "In both asthmatic and COPD patients, the overall effect of salmeterol and zafirlukast on the forced expiratory volume in 1 s (FEV1) was considered extremely significant (p < 0." | 2.70 | Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. ( Allegra, L; Boveri, B; Cazzola, M; Centanni, S; Di Marco, F; Matera, MG; Santus, P, 2001) |
| " The difference in percent change in FEV1 between the Taifun and the other devices was statistically significant at the two first dose levels, but diminished towards the higher doses when the plateau of the dose-response curve was reached." | 2.70 | The efficacy of a new salbutamol metered-dose powder inhaler in comparison with two other inhaler devices. ( Aalto, E; Hakonen, T; Jouhikainen, T; Liipp, K; Lukkari-Lax, E; Nieminen, MM; Seppälä, OR, 2001) |
| " This study showed that chronic use of short- or long-acting beta2-agonists in asthmatics for a period of 12 weeks, did not significantly change the perception of histamine-induced bronchoconstriction compared with placebo." | 2.70 | Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma. ( Bijl-Hofland, ID; Cloosterman, SG; Folgering, HT; van der Elshout, FJ; van Schayck, CP; Van Weel, C, 2002) |
| "Fifteen patients of bronchial asthma were included in the study." | 2.70 | Comparative evaluation of market spacer and home made spacer in the management of bronchial asthma. ( Gaur, SN; Vatsa, HK, 2002) |
| " Vital signs were recorded over 6 h after dosing with study drug at weeks 0, 4, 8, and 12." | 2.69 | Proventil HFA and ventolin have similar safety profiles during regular use. ( Bleecker, ER; Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, J; Slade, HB; Tinkelman, DG, 1998) |
| "At weeks 0, 4, 8, and 12, spirometry was performed predose and serially over 6 h after dosing with study drug." | 2.69 | Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics. ( Bleecker, ER; Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, J; Slade, HB; Tinkelman, DG, 1998) |
| " Lymphocyte beta2-adrenoceptor parameters and a dose-response curve to inhaled albuterol (200 to 1600 microg) were evaluated at 36 hours after the last dose of each treatment period." | 2.69 | Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. ( Aziz, I; Hall, IP; Lipworth, BJ; McFarlane, LC, 1998) |
| " Peak inspiratory flow (PIF) through Turbuhaler was measured on each dosing occasion." | 2.69 | Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma. ( Boe, J; Löfdahl, CG; Maranetra, N; Nana, A; Selroos, O; Ståhl, E; Youngchaiyud, P, 1998) |
| " No adverse events of clinical relevance were reported." | 2.69 | Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma. ( Bondesson, E; Friberg, K; Löfdahl, CG; Soliman, S, 1998) |
| "Albuterol was administered at the maximum recommended dosages of two puffs for MDI." | 2.69 | Albuterol delivered by metered-dose inhaler (MDI), MDI with spacer, and Rotahaler device--a comparison of efficacy and safety. ( Beck, G; Curtis-McCarthy, P; Eng, P; Golish, J; Kavuru, M; McCarthy, K; Wagner, W, 1998) |
| "Histamine challenges were carried out by tidal breathing method at entry, and at Days 4, 8, 22, 36, and 40." | 2.69 | Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo. ( Cheung, D; de GOEIJ, JA; de GRAAFF, CS; Steen, H; Sterk, PJ; Wever, AM, 1998) |
| "Although beta2-adrenoceptor agonists are widely used in the treatment of asthma, a number of studies have suggested that their long-term use may exacerbate the condition." | 2.69 | Effect of systemic beta-agonist therapy on IgE production in allergic subjects in vivo. ( Beasely, R; Church, M; Corne, JM; Howarth, PH; Lau, LC; Linaker, CH; Merrett, T, 1998) |
| " Pulmonary function and safety measures were assessed after each dosing interval." | 2.69 | Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. ( Colice, GL; Ekholm, BP; Klinger, NM; Ramsdell, JW, 1998) |
| "Hypokalemia is a common side effect in adult asthmatic patients on beta 2 adrenergic therapy." | 2.69 | Hypokalemia and salbutamol therapy in asthma. ( Chu, DM; Hung, CH; Wang, CL; Yang, KD, 1999) |
| " Safety was assessed by measuring changes in pulse rate, blood pressure, and electrocardiogram (ECG) intervals after dosing with study drug, monitoring adverse events, and performing prestudy and poststudy laboratory testing and physical examinations." | 2.69 | Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. ( Bronsky, E; Colice, GL; Ekholm, BP; Klinger, NM, 1999) |
| "As no cardiac side effects were detected, it could be concluded that salmeterol is quite a safe drug for use in childhood asthma treatment." | 2.69 | Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children. ( Demirsoy, S; Olguntürk, R; Tunaoğlu, FS; Türktaş, I, 1999) |
| " On both assessment days for salmeterol, and during placebo administration periods, significant increases from predose FEV1 values were observed beginning with the lowest dose of albuterol and continuing throughout the dose-response assessment (p | 2.69 | Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. ( Berkowitz, RB; Emmett, AH; Nelson, HS; Rickard, KA; Tinkelman, DA; Yancey, SW, 1999) |
| " Salmeterol, however, showed a flatter dose-response curve, and a significantly weaker maximal protective effect (2." | 2.69 | Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. ( Ibsen, T; Lötvall, J; Mellén, A; Palmqvist, M, 1999) |
| "Albuterol treatment significantly reduced the median thickness of subepithelial Tn expression from 9." | 2.69 | Regular albuterol or nedocromil sodium--effects on airway subepithelial tenascin in asthma. ( Altraja, A; Laitinen, A; Laitinen, LA; Marran, S; Märtson, T; Meriste, S; Sillastu, H, 1999) |
| ", a significant dose-response relationship was present (p = 0." | 2.69 | Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine. ( Ahrens, RC; Clarke, WR; Dockhorn, RJ; Han, SH; Hendeles, L; Hill, MR; Lux, C; Vaughan, LM, 1999) |
| " Dose-response curves were compared using an analysis of covariance." | 2.69 | Tolerance to beta-agonists during acute bronchoconstriction. ( Aldridge, RE; Cowan, JO; Flannery, EM; Hancox, RJ; Herbison, GP; McLachlan, CR; Taylor, DR; Town, GI, 1999) |
| "Different mixed-effects models were compared to evaluate the population dose-response and relative potency of two albuterol inhalers." | 2.69 | Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability. ( Hill, MR; Kimanani, EK; Lalonde, RL; Ouellet, D; Potvin, D; Vaughan, LM, 1999) |
| " The pharmacokinetic parameters were determined by noncompartmental analysis and model-fitting." | 2.69 | Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. ( DeGraw, S; Gumbhir-Shah, K; Jusko, WJ; Kellerman, DJ; Koch, P, 1999) |
| " Patients received treatments each for 2 weeks followed by a bolus (IV/inhaled) of corticosteroid or placebo: (1) placebo inhaler bid + bolus placebo; (2) formoterol Turbuhaler 24 microg metered dosage bid (delivered dosage 18 microg bid) + placebo; (3) formoterol 24 microg bid + bolus IV hydrocortisone, 200 mg; or (4) formoterol 24 microg bid + bolus inhaled budesonide, 1,600 microg." | 2.69 | Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. ( Aziz, I; Lipworth, BJ, 2000) |
| " Deviation from parallelism of the generic and Ventolin dose-response curves (p = 0." | 2.69 | Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. ( Ahrens, RC; Carrier, S; Frosolono, M; Han, SH; Lux, C; Milavetz, G; Stewart, BA, 2000) |
| " As opposed to data from an adult population, no plateau was reached in the dose-response curve using the above doses over time." | 2.69 | Is nebulized aerosol treatment necessary in the pediatric emergency department? ( Gilad, E; Houri, S; Mandelberg, A; Morag, B; Priel, IE; Tsehori, S, 2000) |
| "Levalbuterol was found to provide significant bronchodilatory activity and was well tolerated." | 2.69 | Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. ( Caron, J; Handley, DA; Noonan, M; Rollins, TE; Snider, ME; Tinkelman, D, 2000) |
| " Safety assessments included monitoring of adverse events and morning serum cortisol concentrations." | 2.69 | Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. ( Anttila, H; Davies, PI; Hederos, CA; Ossip, MS; Ribeiro, BL; Van den Berg, NJ, 2000) |
| "Homozygous Arg-16 patients are susceptible to clinically important increases in asthma exacerbations during chronic dosing with the short acting beta(2) agonist salbutamol." | 2.69 | Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. ( Drazen, JM; Hancox, RJ; Herbison, GP; Taylor, DR; Town, GI; Yandava, CN, 2000) |
| " Urine was also obtained from subjects who had received the maximum dosage of inhaled salbutamol advisable for competing athletes to provide protection from exercise-induced asthma and treatment of asthma (1600 microgram in 24 h, 800 microgram being in the last 4 h)." | 2.69 | Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. ( Bergés, R; de La Torre, X; Farré, M; Fitch, KD; Mas, M; Morton, AR; Segura, J; Ventura, R, 2000) |
| " A histamine challenge test was done 12 h after the last dose of each treatment period, and dose-response curves to inhaled salbutamol (200-3200 micrograms) were constructed 36 h after the last dose." | 2.68 | Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. ( Grove, A; Lipworth, BJ, 1995) |
| " Bronchodilator dose-response studies were performed by administering increasing doses of isuprel intravenously before and after treatment with salbutamol." | 2.68 | [Bronchial reactivity after regular inhalation of salbutamol]. ( Krasnowska, M; Małlolepszy, J; Passowicz-Muszyńska, E, 1995) |
| " Part 3, the effect of cessation of long-term administration of inhaled corticosteroid on FEV1 PD20 histamine and symptoms was investigated for 6 months in 28 steroid group children." | 2.68 | Long-term intervention in childhood asthma: the Dutch study results. Dutch Chronic Nonspecific Lung Disease Study Group. ( van Essen-Zandvliet, EE, 1995) |
| " Dosing intervals and the use of other medications were determined by the treating physician." | 2.68 | Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. ( Chou, KJ; Crain, EF; Cunningham, SJ, 1995) |
| " Dose-response curves were constructed using cumulative doses of 100 micrograms, 200 micrograms, 400 micrograms, 1000 micrograms, 2000 micrograms, and 4000 micrograms, and airways and systemic responses were measured 20 minutes after each dose with 40 minute increments." | 2.68 | Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. ( Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Newnham, DM; Winter, JH, 1995) |
| "We studied three doses of inhaled salbutamol, 200, 400, and 800 micrograms/day, to determine dose-response curves for these two adverse effects." | 2.68 | Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. ( Bhagat, R; Cockcroft, DW; Swystun, VA, 1996) |
| "Albuterol OR was added to their usual treatment." | 2.68 | Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients. ( Ariaansz, M; Nauta, JJ; Postmus, PE; Raaijmakers, JA; Van Keimpema, AR, 1996) |
| "This study compares the safety and efficacy of HFA 134a salbutamol sulfate (Airomir in the 3M CFC-free system [3M Pharmaceuticals]) and CFC 11/12 salbutamol (Ventolin [Allen & Hanburys]) in a cumulative dose-response (1, 1, 2, 4, 8 inhalations at 30-min intervals) study in asthmatic patients." | 2.68 | Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. ( Cline, AC; Ekholm, BP; Kleerup, EC; Tashkin, DP, 1996) |
| " Hypothetically, twice daily dosing of salmeterol may result in continuous protection." | 2.68 | Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. ( Creyghton, FB; de Jongste, JC; Hop, WC; Kerrebijn, KF; van den Berg, M; van Rooij, RW; Verberne, AA, 1996) |
| " One hour after inhaling single doses of placebo, salmeterol 25 micrograms, or formoterol 12 micrograms, dose-response curves to repeated doses of inhaled fenoterol were constructed (cumulative doses of 100-3200 micrograms)." | 2.68 | Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol. ( Grove, A; Lipworth, BJ, 1996) |
| "Theophylline may produce a paradoxical increase in awareness of asthma in some individuals." | 2.68 | Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma. ( Higgs, CM; Laszlo, G, 1996) |
| " We wanted to assess whether the combination of a beta 2-bronchodilator with an anti-inflammatory treatment in the same metered-dose inhaler (MDI) with a regular dosing schedule might improve compliance." | 2.68 | Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group. ( Braunstein, GL; Harper, AE; Trinquet, G, 1996) |
| " This study does not exclude the possibility that adverse cardiac events could occur with severe hypoxemia." | 2.68 | Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. ( Abboud, RT; Bowie, DM; Chapman, KR; Hodder, RV; McCallum, AL; Mesic-Fuchs, H; Molfino, NA; Newhouse, MT; Paré, PD, 1996) |
| " Additionally, during dosing with TBH, fewer patients experienced adverse events than during dosing with RH or DH." | 2.68 | Relative efficacy of three different inhalers containing salbutamol in patients with asthma. ( Hamersma, WB; Mahadewsingh, JV; Schreurs, AJ, 1996) |
| "This was a 1-week study evaluating the safety and efficacy of two dosage regimens of salmeterol in children with asthma." | 2.68 | A one-week dose-ranging study of inhaled salmeterol in children with asthma. ( Bronsky, EA; Chervinsky, P; Howland, WC; Liddle, R; Nathan, RA; Pollard, SJ; Prenner, B; Stahl, E; Weinstein, S, 1997) |
| " The aim of this study was to determine the effects of regular treatment with the long-acting beta-agonist, salmeterol, on the methacholine dose-response curve (DRC) in mild-to-moderate asthmatics." | 2.68 | Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. ( O'Shaughnessy, AD; Sears, MR; Walker, CM; Wong, AG, 1997) |
| " The shape of the dose-response curves and the magnitude of the total increase in the forced expiratory volume in one second (FEV1) was identical for CPAP and control conditions." | 2.68 | Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask. ( Bersten, AD; Parkes, SN, 1997) |
| " For secondary end points salmeterol treatment was associated with higher morning and evening peak expiratory flow and forced expiratory volume in one second; a reduction in symptoms, bronchodilator use and airway responsiveness to methacholine; and no effect on serum potassium concentration, 24 hour heart rate, or the final forced expiratory volume in one second achieved during a salbutamol dose-response study." | 2.68 | Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. ( Bennett, J; Clark, M; Cooper, S; Lewis, S; Oborne, J; Rushton, L; Tattersfield, AE; Thompson Coon, J; Wilding, P, 1997) |
| "Patients treated for severe bronchial asthma often suffer from attacks of bronchoconstriction despite appropriate anti-inflammatory treatment." | 2.68 | [Better control of asthma symptoms with salmeterol]. ( Barliński, J; Kurzawa, R, 1997) |
| "Albuterol treatment significantly increased the LAR compared to placebo treatment (p = 0." | 2.68 | Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. ( Cockroft, DW; Gauvreau, GM; Jordana, M; O'Byrne, PM; Watson, RM, 1997) |
| "01), but significant differences between salmeterol doses were no longer evident, despite an apparent dose-response effect." | 2.67 | A 1-week dose-ranging study of inhaled salmeterol in patients with asthma. ( Bierman, CW; Bronsky, EA; Kemp, JP; Liddle, RF; Orgel, HA; Tinkelman, DG; van As, A, 1994) |
| " Cough, headache and itchy throat were adverse events possibly related to the use of Salmeterol." | 2.67 | Efficacy and safety of inhaled Salmeterol (Serevent) as maintenance therapy for asthma in Nairobi. ( Gikonyo, BM; Nganga, LW; Odhiambo, JA, 1994) |
| " 12 patients received during a month salbutamol combined with nedocromil (Tilade 8 mg per day)." | 2.67 | [Bronchial hyperreactivity in patients with bronchial asthma treated with salbutamol and salbutamol combined with beclocort or nedocromil]. ( Krasnowska, M; Liebhart, E; Małolepszy, J, 1994) |
| "As a result, it was concluded that in bronchial asthmatic patients, the bronchodilator effects of the combination of a beta-2 agonist with anticholinergic drugs was as effective and lasted as long as salbutamol." | 2.67 | Comparison of a single dose of aerosol salbutamol and fenoterol/ipratropium on bronchial asthmatic patients. ( Bulgur, D; Dikensoy, O; Ekinci, E; Filiz, A; Oz, M, 1994) |
| " We studied the effect of a mild increase in serum magnesium level on the bronchial dose-response curve to salbutamol in six patients with asthma (age 54 +/- 3." | 2.67 | Effect of intravenous magnesium infusion on salbutamol-induced bronchodilatation in patients with asthma. ( Brussino, L; Bucca, C; Colagrande, P; Rolla, G, 1994) |
| " The PD20 (dose of histamine causing a 20% fall in FEV1) was measured before and 11, 35, and 59 h after cessation of treatment and a bronchodilator dose-response study before and 83 h after cessation of treatment." | 2.67 | Asthma control during and after cessation of regular beta 2-agonist treatment. ( Pavord, ID; Tattersfield, AE; Wahedna, I; Wisniewski, AF; Wong, CS, 1993) |
| " The lung function parameters after cumulative dosing of salbutamol were equal during each study day." | 2.67 | A novel multiple dose powder inhaler. Salbutamol powder and aerosol give equal bronchodilatation with equal doses. ( Haahtela, T; Korhonen, P; Laurikainen, K; Nyberg, A; Silvasti, M; Vidgren, M, 1994) |
| " A further 416 (57) micrograms reduction in inhaled corticosteroid dosage was possible during the treatment phase but this was almost identical in the WEB 2086 and placebo-treated groups, amounting to 353 (92) and 481 (65) micrograms/day respectively (not significant [NS])." | 2.67 | The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. ( Calverley, PM; Dhillon, P; Higgins, C; Holgate, ST; Johnston, SL; Ramhamadany, E; Spence, DP; Turner, S; Winning, A; Winter, J, 1994) |
| "The relative bronchodilator (delta FEV1, V25, V50) potency and side effect profile (delta tremor, heart rate, breathlessness, BP) of nebulized salbutamol and fenoterol were evaluated by means of a randomized, double-blind, crossover, cumulative (50 to 2,500 micrograms) dose-response study." | 2.67 | Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma. ( Dolovich, MB; Kazim, F; Newhouse, MT, 1994) |
| " The slopes of the dose-response curves of FEV1 and plasma cAMP to intravenous S were unaffected by the two treatment courses." | 2.67 | Effects of therapeutic doses of salbutamol alone and combined with beclomethasone dipropionate on airway responsiveness and cyclic AMP plasma levels in asthmatic patients. ( Adami, S; Ferrari, M; Lo Cascio, V; Olivieri, M; Prior, M; Romito, D; Squassante, L; Testi, R, 1993) |
| "Tremor was objectively measured, as well as heart rate (HR), respiratory rate (RR), and blood pressure (BP)." | 2.67 | Efficacy and side effects of salbutamol in acute asthma in children: comparison of oral route and two different nebulizer systems. ( Naspitz, CK; Scalabrin, DM, 1993) |
| "Twelve patients with mild bronchial asthma participated in a double-blind, randomized, placebo-controlled clinical trial." | 2.67 | Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. ( Behr, N; Jörres, R; Magnussen, H; Nowak, D; Rabe, KF, 1993) |
| " The dose-response curves for change in PC20 indicated that the higher doses of the nebulizer solution delivered more drug to beta 2 receptors in the lung than the lower doses from the MDI." | 2.67 | Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation. ( Blake, KV; Harman, E; Hendeles, L; Hoppe, M, 1992) |
| " Of 25 subjects whose control differed significantly between treatments with baseline vs increased corticosteroid, 22 (88 percent) favored the increased dosage (p < 0." | 2.67 | Increased inhaled bronchodilator vs increased inhaled corticosteroid in the control of moderate asthma. ( Flannery, EM; Herbison, GP; Lake, DC; Print, CG; Sears, MR; Taylor, DR, 1992) |
| " Thirty-two patients requested home nebulizer treatment for long-term use (nine salbutamol, five IB, 18 mixture)." | 2.67 | A long-term prospective assessment of home nebulizer treatment. ( Bernstein, A; Chetty, MC; Kay, EA; O'Driscoll, BR; Taylor, RJ; Weatherby, H, 1992) |
| "Finally, baseline airway obstruction correlated with the degree of bronchodilation achieved with MK-571 (r = -0." | 2.67 | Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. ( Bush, RK; Busse, WW; Gaddy, JN; Margolskee, DJ; Williams, VC, 1992) |
| "To study the dose-response relationship of salmeterol for protection against a naturally occurring stimulus, isocapnic hyperventilation tests of cold air were done in 16 asthmatic patients." | 2.67 | Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. ( Jörres, R; Lüthke, M; Magnussen, H; Nowak, D; Rabe, KF; Wiessmann, J, 1992) |
| " After each period, dose-response curves were measured on 4 study days with doubling doses of salbutamol, ipratropium, a combination of salbutamol and ipratropium, and placebo until a plateau in FEV1 was reached." | 2.67 | Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma. ( Alting-Hebing, D; Breederveld, N; Koëter, GH; Postma, DS; van der Mark, TW; Wempe, JB, 1992) |
| "Both procaterol and albuterol were highly effective in improving pulmonary function and controlling symptoms of asthma; both were well tolerated." | 2.67 | Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma. ( Mazza, JA; Reed, CE; Tashkin, DP, 1992) |
| " Forced expiratory volume in one second (FEV1) dose-response curves for inhaled salbutamol were repeatedly recorded during the study, and no tachyphylaxis was found." | 2.67 | Inhaled formoterol during one year in asthma: a comparison with salbutamol. ( Arvidsson, P; Larsson, S; Löfdahl, CG; Melander, B; Svedmyr, N; Wåhlander, L, 1991) |
| "For most patients with mild to moderate bronchial asthma higher doses will not add much to the bronchodilating effect." | 2.67 | A study with cumulative doses of formoterol and salbutamol in children with asthma. ( Foucard, T; Lönnerholm, G, 1991) |
| "tremor) were more frequent after treatment with 100 micrograms b." | 2.67 | Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. ( Dahl, R; Earnshaw, JS; Palmer, JB, 1991) |
| "Pretreatment with albuterol, cromolyn, and a combination of albuterol and cromolyn 30 minutes before ETS exposure significantly diminished airway reactivity to ETS." | 2.67 | Asthmatic responses to passive cigarette smoke: persistence of reactivity and effect of medications. ( Lehrer, SB; Menon, PK; Rando, RJ; Salvaggio, JE; Stankus, RP, 1991) |
| " In 8 patients the single dose mean Cmax was 4." | 2.67 | Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma. ( Lee, HS; Tan, WC, 1991) |
| "Procaterol is a new, potent, long-acting beta-2-adrenergic bronchodilator." | 2.67 | Inhaled procaterol versus salbutamol in bronchial asthma. ( Liippo, K; Silvasti, M; Tukiainen, H, 1991) |
| " To determine whether these drugs also protect against excessive airway narrowing, the effect of inhaled salbutamol on the position and shape of the dose-response curves for histamine or methacholine was investigated in 12 patients with asthma and 11 with chronic obstructive lung disease." | 2.67 | The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. ( Bel, EH; Dijkman, JH; Sterk, PJ; Timmers, MC; Zwinderman, AH, 1991) |
| "Tulobuterol is a synthetic beta-adrenergic agonist which, when administered orally, is a potent, long-acting bronchodilator." | 2.67 | Can a new beta 2-agonist reduce the mortality of asthma? ( Aldons, PM, 1990) |
| " Dose-response curves to inhaled SB were obtained the day before and the day after each treatment period." | 2.67 | Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. ( Hedner, J; Svedmyr, N; Ullman, A, 1990) |
| " The study which is the first report in Africa to assess this novel formulation of salbutamol in a group of African patients, demonstrates that controlled release salbutamol 8 mg administered twice daily is safe and effective, offering benefits over current therapies in the treatment of asthma." | 2.67 | The efficacy and safety of a controlled release formulation of salbutamol in the management of patients with asthma in Nairobi, Kenya. ( Aluoch, JA; Gathua, SN, 1990) |
| "treatment." | 2.67 | High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma. Swedish Society of Chest Medicine. ( , 1990) |
| "Theophylline was titrated for patients to receive, unblinded, theophylline serum concentrations of 10 to 20 micrograms/ml." | 2.67 | Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma. ( Bell, TD; LaForce, CF; MacCosbe, PE; Pierson, WE; Sykes, RS; Tinkelman, D, 1990) |
| " The drug dosage was controlled by limiting the inspired volumes of gas (single and cumulative) to the pretested inspiratory capacity." | 2.67 | Single breath versus panting technique in salbutamol delivery through a 750 mL spacing device. ( James, RW; Masters, IB, 1990) |
| "The purpose of the present study was to compare the efficacy and systemic effects of 4 mg and 8 mg doses of salbutamol controlled release (SCR) after single dosing and at steady state in patients with asthma." | 2.67 | Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma. ( Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Palmer, JB, 1990) |
| "In a randomized, double-blind, double-dummy, crossover study consisting of two 1-month periods with a 2-week 'run-in' we compared the effects of a combination of fenoterol with ipratropium bromide (Duovent, Boehringer Ingelheim) and salbutamol administered by standard metered dose inhalers in conventional dosage in young adults with nocturnal asthma." | 2.66 | Comparison of a combination of fenoterol with ipratropium bromide (Duovent) and salbutamol in young adults with nocturnal asthma. ( Shettar, SP; Wolstenholme, RJ, 1989) |
| " It is concluded that IPB alone is less effective than beta-adrenoceptor agonist, but its combination with SAS would be an effective and safe treatment in acute asthmatic attack." | 2.66 | [Effects of ipratropium bromide (IPB) and its combination with salbutamol sulfate (SAS) in acute asthmatic attack]. ( Chen, L; Deng, K; Ye, YQ, 1989) |
| " At steady-state the geometric mean values for Cmax were 8." | 2.66 | Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. ( Charter, MK; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Palmer, JB, 1989) |
| " The purpose of the present study was to assess the pharmacokinetics, efficacy and adverse effects of standard salbutamol tablets given by this route to patients with asthma." | 2.66 | Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. ( Clark, GA; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG; Moreland, TA; Struthers, AD, 1989) |
| " At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms)." | 2.66 | Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. ( Lipworth, BJ; McDevitt, DG; Struthers, AD, 1989) |
| "Sixteen patients suffering from bronchial asthma, with or without chronic bronchitis, sufficiently severe to be treated with inhaled corticosteroids, were studied in a single-blind trial (blind observer) of beclomethasone dipropionate (BDP) given in three randomized dosage regimens: 500, 1000 and 2000 micrograms per day, each for 4 weeks." | 2.66 | Effects of inhaled beclomethasone dipropionate on beta 2-receptor function in the airways and adrenal responsiveness in bronchial asthma. ( Folgering, HT; Lammers, JW; Molema, J; van Herwaarden, CL, 1988) |
| " The slow-release tablets were preferred by 15 of 18 children and their families when the effects, side effects and dosage were evaluated." | 2.66 | Terbutaline slow-release tablets in children with asthma. A comparison with t.i.d. beta 2-agonist therapy. ( Croner, S; Gustafsson, M; Kjellman, NI; Säwedal, L, 1986) |
| "Pretreatment with albuterol abolished any significant bronchoconstriction, with mean maximal falls in SGaw and FEV1 after challenge of 7." | 2.66 | Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. ( Church, MK; Durham, SR; Holgate, ST; Howarth, PH; Kay, AB; Lee, TH, 1985) |
| " Dose-response effects were clearly seen with salbutamol but not with ipratropium bromide." | 2.66 | Nebulized salbutamol and ipratropium bromide in asthmatic children. ( Evans, NA; Lenney, W, 1986) |
| "Pindolol was administered gradually by mouth (2." | 2.66 | Influence of pindolol on asthmatics and effect of bronchodilators. ( Antoniadou, H; Georgopoulos, D; Giulekas, D; Papakosta, D; Sotiropoulou, E; Vamvalis, C, 1986) |
| "Histamine PD20 FEV1 was assessed 4 h after the administration of salbutamol 200 micrograms, a combination of fenoterol 200 micrograms and ipratropium bromide 80 micrograms, and placebo." | 2.66 | Histamine-induced bronchial response after administration of placebo, salbutamol and a combination of a beta-2-adrenergic drug (fenoterol) with an anticholinergic agent (ipratropium bromide) in asymptomatic asthma patients. ( Cresci, F; Fontana, G; Mugnai, M; Panuccio, P, 1986) |
| "Nine patients with clinically stable bronchial asthma who had received no drug treatment in the preceding 48 hours were examined." | 2.66 | [Ultrasonic spray protection against bronchospasm. Comparison of fenoterol and a combination of salbutamol and ipratropium bromide]. ( Ardizzi, A; Galietti, F; Giorgis, GE; Gribaldo, E; Miravalle, C; Oliaro, A, 1987) |
| " In fifteen selected chronic asthmatics, individual cumulative dose-response curves to S and IB were performed on two separate days (linear regression of bronchodilator response (delta FEV1) between 20 and 80% of maximal response, versus log dose), and the dose of S equipotent to the IB dose giving the maximal bronchodilator effect (IBopt) was calculated by interpolation of each S curve." | 2.66 | Cumulative dose-response curves for assessing combined effects of salbutamol and ipratropium bromide in chronic asthma. ( de Lauture, D; Grandordy, BM; Marsac, J; Thomas, V, 1988) |
| "The albuterol group was also studied at 2 and 4 weeks, but they only used their inhaler as needed between study visits." | 2.66 | A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm. ( Katz, RM; Lanier, R; Rachelefsky, GS; Rohr, AS; Siegel, SC; Spector, SL, 1987) |
| " Airway responsiveness thus appears to be a useful tool for evaluating inhaled beta 2-agonists and designing beta 2-agonist dosing regimens." | 2.66 | Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma. ( Ahrens, RC; Annis, L; Harris, JB; Milavetz, G; Ries, R, 1987) |
| "It is likely that arrhythmias may be precipitated in patients with hypoxaemia, acidosis or those with preexisting cardiovascular disease." | 2.66 | Hypokalaemic and electrocardiographic effects of aminophylline and salbutamol in obstructive airways disease. ( Burgess, CD; Crane, J; Graham, AN; Maling, TJ, 1987) |
| "Pretreatment with albuterol attenuated both the cough and the drop in FEV1." | 2.66 | Cough and wheezing from beclomethasone aerosol. ( Shim, C; Williams, MH, 1987) |
| "Tiaramide hydrochloride is a new non-steroidal anti-inflammatory agent previously shown to inhibit allergic responses both in vitro and in vivo." | 2.66 | A trial of tiaramide in asthma. ( Harvey, JE; Jones, P; Tanser, AR, 1985) |
| " No significant differences were observed between the three dosage groups." | 2.66 | Nebulised salbutamol without oxygen in severe acute asthma: how effective and how safe? ( Crompton, GK; Douglas, JG; Fergusson, RJ; Grant, IW; Prescott, RJ; Rafferty, P, 1985) |
| " Ipratropium bromide in adequate dosage appears to be effective in reducing morning dipping in asthma." | 2.65 | Ipratropium bromide in patients with nocturnal asthma. ( Cox, ID; Hughes, DT; McDonnell, KA, 1984) |
| " This provides a simple, rapid and reproducible way of obtaining linear dose-response curves by plotting times of exposures against absolute or percent increases in sRaw." | 2.65 | Drug effect on bronchial response to PGF2 alpha and water inhalation. ( Bianco, S; Damonte, C; Robuschi, M, 1983) |
| " Cumulative log dose-response curves were constructed." | 2.65 | Methacholine dose-response curves in normal and asthmatic man: effect of starting conductance and pharmacological antagonism. ( Chung, KF; Snashall, PD, 1984) |
| "Twenty-five patients with chronic bronchial asthma completed the trial." | 2.65 | A comparison of sustained-release terbutaline with ordinary salbutamol in bronchial asthma. ( Beskow, R; Ericsson, CH; Grönneberg, R; Sjögren, I; Skedinger, M, 1984) |
| " The FEV1 dose-response curves were almost identical indicating bronchodilating equipotency between the two modes of administration." | 2.65 | The effect of powder aerosol compared to pressurized aerosol. ( Löfdahl, CG; Svedmyr, K; Svedmyr, N, 1982) |
| "Histamine challenge is a satisfactory method of assessing the proective effect of a drug in asthmatic children." | 2.65 | Protective effect of inhaled salbutamol powder in children assessed by histamine challenge. ( Martin, AJ; Pullan, CR, 1980) |
| " The highest dose used in the dose-response trials (=0." | 2.65 | Inhalation of racemic epinephrine in children with asthma. Dose-response relation and comparison with salbutamol. ( Kjellman, B; Tollig, H; Wettrell, G, 1980) |
| " Increase of dosage did not lead to improved effectiveness." | 2.65 | [Parasympathicolytic drugs in treatment of obstructive lung diseases (author's transl)]. ( Gonsior, E; Meier-Sydow, J; Schultze-Werninghaus, G, 1979) |
| " Salbutamol powder in a dose of 200 micrograms per capsule was able to control asthma as well as the aerosol, but some patients needed to increase the frequency of dosage when using the powder." | 2.65 | Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients. ( Hartley, JP; Nogrady, SG; Seaton, A, 1979) |
| "Albuterol aerosol was an effective bronchodilator as reflected by indices of pulmonary function obtained from spirometry and flow volume curves; Compared with isoproterenol, there were minimal side effects even at the highest doses, and bronchodilation lasted significantly longer." | 2.64 | Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: response to albuterol, isoproterenol, and placebo aerosols. ( Garza Gomez, M; Spector, SL, 1977) |
| "Clenbuterol is a beta 2-sympathomimetic bronchodilator." | 2.64 | A trial of clenbuterol in bronchial asthma. ( Anderson, G; Wilkins, E, 1977) |
| "Salbutamol in a powder aerosol from the Rotahaler insufflator was compared, with equal doses of the conventional pressurized aerosol by dose-response curves and in a 1 month open trial, in the treatment of asthma patients with good inhalation technique." | 2.64 | Comparison of salbutamol Rotahaler with conventional pressurized aerosol. ( Clark, TJ; Hetzel, MR, 1977) |
| " Drug dosage was one 4-mg tablet, of two inhalations of 100 mug of salbutamol aerosol or a combination of both, four times daily." | 2.64 | The efficacy, as modified by the circadian rhythm of salbutamol administered by different routes. ( Alanko, K; Lahdensuo, A, 1976) |
| "Rimiterol is an acceptable alternative to the short-acting isoprenaline but lacks the cardiovascular effects of isoprenaline and is an alternative to salbutamol where very prolonged action is unnecessary." | 2.64 | Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol. ( Bianco, S; Kamburoff, PL; Prime, FJ, 1975) |
| "1 In a double-blind placebo controlled dose-response experiment in six asthmatic patients with reversible airways obstruction the effect of i." | 2.64 | The effect of intramuscular salbutamol in asthmatics. ( Gaddie, J; Ingram, J; Palmer, KN; Skinner, C, 1975) |
| " There are also concerns with regard to the effects of LABAs on bronchial hyperresponsiveness (BHR), where long-term use is associated with increased BHR and loss of bronchoprotection." | 2.58 | Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed. ( Calzetta, L; Farber, MO; Hostrup, M; Jacobson, GA; Page, CP; Raidal, S; Walters, EH; Wood-Baker, R, 2018) |
| " OBJECTIVES: To assess risks of mortality and non-fatal serious adverse events (SAEs) in trials that randomised participants with chronic asthma to regular salmeterol and ICS versus the same dose of ICS." | 2.58 | Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. ( Cates, CJ; Ferrer, M; Sayer, B; Schmidt, S; Waterson, S, 2018) |
| "The albuterol mDPI has an efficacy/tolerability profile consistent with other inhaled forms of albuterol, and is reliable, easy to use, and associated with a high level of patient satisfaction." | 2.53 | Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma. ( Welch, MJ, 2016) |
| " Clinical trials record these safety outcomes as non-fatal and fatal serious adverse events (SAEs), respectively." | 2.50 | Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews. ( Cates, CJ; Kew, KM; Oleszczuk, M; Wieland, LS, 2014) |
| " Although their usefulness in reversing acute bronchospasm remains undiminished, there is increasing evidence that chronic use may lead to development of tolerance and thus, potentially increasing morbidity and even mortality." | 2.49 | Tolerance & resistance to β₂-agonist bronchodilators. ( Koumbourlis, AC; Yim, RP, 2013) |
| "To assess the risk of mortality and non-fatal serious adverse events in trials which randomised patients with chronic asthma to regular salmeterol and inhaled corticosteroids in comparison to the same dose of inhaled corticosteroids." | 2.49 | Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. ( Cates, CJ; Ferrer, M; Jaeschke, R; Schmidt, S, 2013) |
| "Pregnancy is also associated with a physiological suppression of the immune system." | 2.49 | Management of asthma during pregnancy. ( Adams, SG; Levine, SM; Maselli, DJ; Peters, JI, 2013) |
| "An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews." | 2.48 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. ( Cates, CJ; Lasserson, TJ, 2012) |
| "The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular formoterol versus placebo or regular short-acting beta(2)-agonists." | 2.48 | Regular treatment with formoterol for chronic asthma: serious adverse events. ( Cates, CJ; Cates, MJ, 2012) |
| " As a result, asthma exacerbation can be treated with pMDIs used through holding chambers in emergency room successfully when applied with dosing scheme appropriate for the patient's age, weight and severity of exacerbation (usually 1/4th of nebule dosing) on the contrary to ordinary method of nebulizers." | 2.48 | [Salbutamol in asthma treatment: with nebulizer or inhaler?]. ( Cavkaytar, O; Sekerel, BE, 2012) |
| "Adrenal insufficiency was diagnosed in a 7-year-old boy on 460 µg ICS for 16 months, with a diagnosis of chronic persistent asthma." | 2.48 | Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature. ( Alpan, O; Ascher, DP; Neacsu, O; Schwartz, RH, 2012) |
| " We extracted the data relating to children from each review and from new trials found in the updated searches (including risks of bias, study characteristics, serious adverse event outcomes, and control arm event rates)." | 2.48 | Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. ( Cates, CJ; Oleszczuk, M; Stovold, E; Wieland, LS, 2012) |
| "Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory disorders that have an increasing prevalence and associated morbidity and mortality." | 2.47 | (R)-salbutamol in the treatment of asthma and chronic obstructive airways disease. ( Patel, M; Thomson, NC, 2011) |
| " However, several studies have indicated an increased risk of asthma mortality and asthma-related serious adverse events and the FDA recently mandated restrictions to the use of LABAs in asthma." | 2.47 | Safe use of long-acting β-agonists: what have we learnt? ( Sears, MR, 2011) |
| "An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews." | 2.46 | Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. ( Cates, CJ; Lasserson, TJ, 2010) |
| "an increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews." | 2.46 | Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. ( Cates, CJ; Lasserson, TJ, 2010) |
| " Subgroup analysis suggests that children, patients receiving salmeterol, and a duration of treatment>12 weeks are associated with a higher risk of serious adverse effects; also there was a protective effect of concomitant use of ICS." | 2.45 | Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. ( Castro-Rodriguez, JA; Marcos, LG; Moral, VP; Rodrigo, GJ, 2009) |
| "For the acute COPD studies, one was double-blind and randomised, one was single-blind and randomised, and one was open-label." | 2.45 | Use of dry powder inhalers in acute exacerbations of asthma and COPD. ( Borgström, L; Ingelf, J; Selroos, O, 2009) |
| " Using the same stratified data to calculate the sample size required to prove or disprove an association between the use of LABA with mandatory ICS therapy and adverse outcomes, assuming the RD is exactly 0." | 2.45 | Safety of long-acting beta-agonists: are new data really required? ( Sears, MR, 2009) |
| "The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular salmeterol with inhaled corticosteroids versus the same dose of inhaled corticosteroids alone." | 2.45 | Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. ( Cates, CJ; Jaeschke, R; Lasserson, TJ, 2009) |
| "An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews." | 2.45 | Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. ( Cates, CJ; Lasserson, TJ, 2009) |
| "For many years, chronic obstructive pulmonary disease (COPD) was considered a disease of fixed airflow obstruction for which there was no good treatment." | 2.45 | Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm. ( Gordon, E; Lazarus, SC, 2009) |
| "The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular salmeterol versus placebo or regular short-acting beta(2)-agonists." | 2.44 | Regular treatment with salmeterol for chronic asthma: serious adverse events. ( Cates, CJ; Cates, MJ, 2008) |
| "The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic asthma to regular formoterol versus placebo or regular short-acting beta(2)-agonists." | 2.44 | Regular treatment with formoterol for chronic asthma: serious adverse events. ( Cates, CJ; Cates, MJ; Lasserson, TJ, 2008) |
| " Whether this association represents adverse effects of beta -agonist use or is entirely due to disease severity is a matter of ongoing debate." | 2.44 | Safety of long-acting beta2-agonists in the treatment of asthma. ( Cazzola, M; Matera, MG, 2007) |
| "The costs of asthma and chronic obstructive pulmonary disease (COPD), the two most common chronic respiratory illnesses, are substantial and rising." | 2.44 | Seretide: a pharmacoeconomic analysis. ( Chapman, KR; Fritscher, L, 2008) |
| " There has been concern that chronic use of racemic salbutamol may lead to loss of effectiveness and clinical deterioration." | 2.44 | Evidence based review on levosalbutamol. ( Gupta, MK; Singh, M, 2007) |
| " Traditional press-and-breathe Metered Dose Inhalers (pMDIs) have recently improved their ecological appeal, can be used in every clinical and environmental situation, their dosing is convenient and highly reproducible, but their efficient delivery remains highly technique dependent." | 2.44 | Inhalatory therapy training: a priority challenge for the physician. ( Melani, AS, 2007) |
| "Although large surveys have documented the favourable safety profile of beta(2)-adrenoceptor agonists (beta(2)-agonists) and, above all, that of the long-acting agents, the presence in the literature of reports of adverse cardiovascular events in patients with obstructive airway disease must induce physicians to consider this eventuality." | 2.43 | Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. ( Cazzola, M; Donner, CF; Matera, MG, 2005) |
| "Levalbuterol was evaluated in several recent trials for treatment of asthma in the emergency department, for its effect in improving pulmonary function and on hospitalization rate." | 2.43 | Review of guidelines and the literature in the treatment of acute bronchospasm in asthma. ( Blake, K, 2006) |
| " There is much to suggest that the adverse outcomes associated with LABA monotherapy have been due to "masking of inflammation" rather than a toxic effect of the drugs." | 2.43 | Long-acting beta-agonists in adult asthma: Evidence that these drugs are safe. ( Nelson, HS, 2006) |
| "Airway inflammation is a key factor in the mechanisms of asthma." | 2.42 | Mechanisms of asthma. ( Busse, WW; Rosenwasser, LJ, 2003) |
| "To determine the magnitude of residual bronchoprotection after chronic dosing with long-acting beta(2)-agonists." | 2.42 | Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids. ( Currie, GP; Jackson, CM; Lipworth, BJ; Ogston, SA, 2003) |
| "Despite concerns in the 1970s and 1980s about the safety of short-acting beta2-agonists, it is now generally accepted that these agents, used at appropriate doses, provide safe and effective treatment for asthma symptoms." | 2.42 | State of the art in beta2-agonist therapy: a safety review of long-acting agents. ( Rabe, KF, 2003) |
| "Chronic-obstructive pulmonary disease (COPD) is a global public health problem and its impact is increasing." | 2.42 | Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. ( Bailey, WC; Dransfield, MT, 2004) |
| "For patients with chronic obstructive pulmonary disease, quick-relief and long-acting bronchodilators are primarily used in the maintenance and treatment of associated symptoms, including shortness of breath." | 2.42 | Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease. ( Dalonzo, GE, 2004) |
| "Albuterol is a selective beta2-agonist that is widely used in the prevention and treatment of reactive airway disease." | 2.42 | The cost effectiveness of levalbuterol versus racemic albuterol. ( Quinn, C, 2004) |
| " Fixed dosing with budesonide/formoterol or salmeterol/fluticasone provides effective asthma control in line with guideline goals." | 2.42 | Combination therapy in asthma--fixed or variable dosing in different patients? ( Lötvall, J, 2004) |
| "Indeed, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy emphasises the role of bronchodilators in symptomatic management of all stages of COPD." | 2.41 | Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. ( Barnes, PJ; Hansel, TT, 2002) |
| " Long-term use of long-acting beta(2)-agonists can induce tolerance, which can be partially reversed with corticosteroids." | 2.41 | Long-acting beta2-agonists: comparative pharmacology and clinical outcomes. ( Aalbers, R; van der Woude, HJ, 2002) |
| "The goal of management of patients with respiratory failure is to restore them to a state of quiet breathing, without complication." | 2.41 | Management of respiratory failure in patients with asthma. ( Corbridge, T; Gluckman, TJ, 2000) |
| "Albuterol is a 50:50 mixture of R-albuterol, the active enantiomer, and S-albuterol, which appears to be inactive in humans." | 2.41 | Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? ( Asmus, MJ; Hendeles, L, 2000) |
| " This dosage is also as effective when added to low-dosage inhaled corticosteroid therapy as doubling of corticosteroid dosages." | 2.41 | Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. ( Dunn, CJ; Goa, KL, 2001) |
| "R-albuterol has greater bronchodilatory effects than the racemate and may have anti-inflammatory properties." | 2.41 | Levalbuterol hydrochloride. ( Colin, AA; Slattery, D; Wong, SW, 2002) |
| " Two recently completed trials have demonstrated that with respect to asthma control the combination of inhaled steroid (400 - 800 microg/d) plus theophylline is at least as effective as doubling the dose of inhaled steroid in patients who remain symptomatic on a dosage of 400 - 800 microg daily." | 2.40 | [Asthma therapy: combination of topical glucocorticosteroids and theophylline]. ( Ukena, D, 1997) |
| "These drugs are particularly useful in bronchial asthma and meet the requirements of several treatment guidelines to combine long-acting bronchodilator therapy with inhaled corticosteroids in patients with persistent asthma." | 2.40 | [Long-acting beta(2)-adrenoceptor agonists for asthma and COPD]. ( Magnussen, H; Rabe, KF; Ukena, D, 1997) |
| "Current evidence suggests that addition of the long-acting beta2-agonist salmeterol to an inhaled corticosteroid in patients with persistent asthma symptoms provides greater clinical benefit than doubling the dosage of the inhaled corticosteroid." | 2.40 | Salmeterol/fluticasone propionate combination. ( Jarvis, B; Spencer, CM, 1999) |
| "(S)-albuterol does not activate beta(2 )-adrenoceptors and does not modify activation of beta(2 )-adrenoceptors by (R)-albuterol so that for many years it was presumed to be biologically inert." | 2.40 | Contrasting properties of albuterol stereoisomers. ( Morley, J; Page, CP, 1999) |
| " We sought to determine how many children required escalation of care once placed on every 4-h dosing of albuterol." | 1.91 | Inpatient albuterol spacing as an indicator of discharge readiness. ( Aoyama, B; Lee, B; Shen, BH, 2023) |
| "Patients admitted for asthma or COPD exacerbations, doctors, and nurses in a university-affiliated hospital were surveyed from 1 April 2021 to 30 September 2021 regarding their views on the effectiveness, ease of use, preparation and administration, side effects, and infection risk of the two administration methods." | 1.91 | Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease exacerbation: attitudes of patients and healthcare providers in the COVID-19 era. ( Alsuwaigh, R; Binte Mohd Noor, N; Cao, Y; Chen, H; Li, XL; Liew, J; Mohamed Noor, SB; Puan, Y; Tay, TR; Ye, H; Yii, A, 2023) |
| "Bronchial asthma is one of the much known long-term respiratory conditions." | 1.91 | Use of Drugs Considering Route of Administration on Drug Prescription Pattern for Bronchial Asthma in a Tertiary Level Hospital. ( Akter, S; Khatun, S; Nishi, MK; Shams, N; Tania, IJ, 2023) |
| " The primary safety outcome was a composite of serious adverse events (SAEs) and/or adverse events leading to discontinuation (DAEs); the primary effectiveness outcome was time-to-first exacerbation." | 1.91 | Safety and Effectiveness of As-Needed Formoterol in Asthma Patients Taking Inhaled Corticosteroid (ICS)-Formoterol or ICS-Salmeterol Maintenance Therapy. ( Anderson, GP; Brusselle, G; Gustafson, P; Jorup, C; Lamarca, R; Reddel, HK, 2023) |
| "Amitriptyline is a drug of high potential, which inhibits acute bronchoconstriction and induces bronchodilatation in pre-contracted airways." | 1.91 | Amitriptyline inhibits bronchoconstriction and directly promotes dilatation of the airways. ( Böll, S; Braunschweig, T; Hempel, P; Klein, V; Martin, C; Michely, A; Rieg, AD; Spillner, J; Tenbrock, K; Verjans, E; von Stillfried, S; Wagner, N, 2023) |
| "Although studies on epileptic seizures occurring during acute asthma attacks are limited, there is widespread belief among families and physicians that salbutamol causes seizures." | 1.72 | Is Seizure an Adverse Effect of Salbutamol in the Pediatric Population? ( Özünal, ZG; Uysalol, M; Yıldız, R, 2022) |
| "Asthma airway remodeling is closely related to the abnormal migration of human airway smooth muscle cells (ASMCs), and vascular endothelial growth factor (VEGF) is involved in the pathophysiological process of asthma." | 1.72 | Effects of Different Intervention Factors on Vascular Endothelial Growth Factor-Induced Human Airway Smooth Muscle Cell Migration. ( Gao, Y; Li, J; Liao, G; Lv, C; Wu, L, 2022) |
| "Obesity was defined as BMI ≥95%." | 1.72 | Association of obesity with severity outcomes in hospitalized pediatric asthma exacerbations. ( Arca, M; Delgado, Y; Isbell, T; Parlar-Chun, R; Truong, G, 2022) |
| "The aim of this study was to investigate and discuss the salbutamol combined with budesonide in treatment of pediatric bronchial asthma (BA) and its effect on eosinophils (EOS)." | 1.62 | Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils. ( Fan, C; Huang, X; Li, S; Mei, Q; Qian, D; Quan, J, 2021) |
| "Lactic acidosis is a common complication of status asthmaticus in adults." | 1.62 | Prevalence and risk factors of lactic acidosis in children with acute moderate and severe asthma, a prospective observational study. ( Di Paolo, ER; Gehri, M; Pauchard, JY; Rochat Guignard, I; Ruman-Colombier, M, 2021) |
| "Our aim was to survey treatment practices used for preschool children with wheezing in emergency rooms (ER) focussing on inhalation device choice and handling, face mask use, salbutamol dosing and written instructions." | 1.62 | Heterogeneity of emergency treatment practices in wheezing preschool children. ( Csonka, P; Lehtimäki, L; Mäkelä, MJ; Tapiainen, T, 2021) |
| "Albuterol was prescribed for 19 (86%) of the patients with two patients who had both albuterol and QVAR® prescribed." | 1.56 | Prevalence of asthma at a school-based health clinic in Nicaragua. ( Banasiak, NC; Meadows-Oliver, M, 2020) |
| " This study evaluated the relative lung and systemic bioavailability and oropharyngeal deposition of salbutamol post-inhalation from Ventolin® Evohaler® (GlaxoSmithKline) either alone following verbal inhaler technique counselling (VC) or connected to a newly improved Able Spacer® (AS)." | 1.56 | Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design. ( Ammari, WG; Oriquat, GA; Sanders, M, 2020) |
| "The risk of dental caries was evaluated with the dietary record, oral hygiene index and number of carious lesions." | 1.51 | ]Risk of dental caries in pediatric asthmatic patients undergoing treatment with salbutamol and budesonide inhalation therapy, Peru.] ( Bustos de la Cruz, J; Carhuamaca-Salvador, M; Chávez-Rimache, L; Chumpitaz-Cerrate, V, 2019) |
| " Conventional dosage schemes used in public health to cure various diseases generally lead to undesirable side effects and renders the overall treatment ineffective." | 1.51 | An Efficient, Lung-Targeted, Drug-Delivery System To Treat Asthma Via Microparticles. ( Al-Dhubiab, BE; Attimarad, M; Handral, M; Haroun, M; Hiremath, JG; Nair, AB; Ramnarayanan, C; Roopashree, TS; Shinu, P; SreeHarsha, N; Tratrat, C; Venugopala, KN, 2019) |
| "The motive behind present work was to discover a solution for overcoming the problems allied with a deprived oral bioavailability of salbutamol sulfate (SS) due to its first pass hepatic metabolism, shorter half-life, and systemic toxicity at high doses." | 1.51 | Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy. ( Hajare, A; Honmane, S; More, H; Osmani, RAM; Salunkhe, S, 2019) |
| " The assay was successfully applied to the quantification of blood salbutamol concentrations in three healthy volunteers dosed with 1 mg salbutamol by inhalation." | 1.48 | Quantitation of salbutamol using micro-volume blood sampling - applications to exacerbations of pediatric asthma. ( Cordell, RL; Hawcutt, DB; Monks, PS; Pandya, HC; Semple, MG; Valkenburg, TSE, 2018) |
| "Dyspnea has been reported to be a main contributor to exercise avoidance in asthma." | 1.48 | Exertional dyspnea and operating lung volumes in asthma. ( Bhutani, M; Brotto, AR; Moore, LE; Phillips, DB; Stickland, MK, 2018) |
| "Oxymetazoline or Salbutamol were prescribed according to best clinical practice guidelines." | 1.46 | Efficacy and usability of a novel nebulizer targeting both upper and lower airways. ( Hofmaier, S; Lau, S; Matricardi, PM; Perna, S; Pizzulli, A; Posa, D; Wagner, P, 2017) |
| "Airway obstruction was more severe in COPD patients as compared with controls (mean FEV1 and FEV1% predicted both P<0." | 1.43 | Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data. ( Gálffy, G; Kováts, Z; Müller, V; Odler, B; Orosz, M; Selroos, O; Tamási, L, 2016) |
| " For salbutamol and formoterol, urine thresholds have been adopted to limit supratherapeutic dosing and to discriminate between inhaled (permitted) and oral (prohibited) use." | 1.43 | Beta2-Agonist Doping Control and Optical Isomer Challenges. ( Fawcett, JP; Jacobson, GA, 2016) |
| "The sensitivity of detecting airway obstruction in these children by FEV1 was 15." | 1.43 | Assessment of Airway Bronchodilation by Spirometry Compared to Airway Obstruction in Young Children with Asthma. ( Bar-Yoseph, R; Bentur, L; Hakim, F; Livnat, G; Ofek, M; Vilozni, D, 2016) |
| "Although lactic acidosis is a rare side effect to β ² agonist treatment, it is important to recog-nize it when present." | 1.43 | [Lactic acidosis in a 24-year-old woman with status asthmaticus]. ( Albertsen, S; Bergmann, TK; Madsen, PH; Ramazan-Yousif, L; Steen, NP, 2016) |
| " Twenty-five subjects with asthma were recruited and underwent SULT1A3 genotyping, from which four SNP homozygote (GG) subjects and nine wild-type (AA) subjects were selected to participated in the pharmacokinetic investigation." | 1.42 | SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? ( Jacobson, GA; Walters, EH; Wood-Baker, R; Yee, KC, 2015) |
| "The effectiveness of inhaled salbutamol in routine care depends particularly on prescribed dosage and applied inhalation technique." | 1.42 | How to improve prescription of inhaled salbutamol by providing standardised feedback on administration: a controlled intervention pilot study with follow-up. ( Bertsche, A; Bertsche, T; Frontini, R; Kaune, A; Kiess, W; Musiol, J; Neininger, MP; Prenzel, F; Rink, J, 2015) |
| "Obesity is associated with poor asthma control, increased asthma morbidity, and decreased response to inhaled corticosteroids." | 1.42 | Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma. ( Avila, PC; Bibbins-Domingo, K; Borrell, LN; Brigino-Buenaventura, E; Burchard, EG; Castellanos, E; Davis, A; Eng, C; Farber, HJ; Kumar, R; LeNoir, MA; McGarry, ME; Meade, K; Oh, SS; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Sen, S; Serebrisky, D; Thakur, N; Thyne, SM, 2015) |
| " Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone." | 1.42 | HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma? ( Madlon-Kay, DJ; Townsend, L, 2015) |
| "Asthma and chronic obstructive pulmonary disease (COPD) are common lung diseases characterized by chronic airway inflammation and airway obstruction." | 1.42 | [Asthma-COPD overlap syndrome]. ( Bavbek, S; Çelik, G; Demir, T; Gemicioğlu, B; Günen, H; Kıyan, E; Mungan, D; Oğuzülgen, K; Polatlı, M; Saryal, S; Sayıner, A; Şen, E; Türktaş, H; Yıldırım, N; Yıldız, F; Yorgancıoğlu, A, 2015) |
| "We report the case of a severe acute pulmonary edema secondary to the administration of salbutamol to a patient admitted for severe asthma." | 1.42 | [Cardiogenic pulmonary edema following β2 agonist infusion for acute, severe asthma]. ( Abid, L; Bahloul, M; Bouaziz, M; Chaari, A; Chelly, H; Chtourou, K; Dammak, H; Kallel, H; Medhioub, F; Rekik, N, 2015) |
| "Hypokalemic periodic paralysis is the most common form of periodic paralysis and is characterized by attacks of muscle paralysis associated with a low serum potassium (K+) level due to an acute intracellular shifting." | 1.40 | Thyrotoxic periodic paralysis triggered by β2-adrenergic bronchodilators. ( Chiang, WF; Lin, SH; Wang, CC; Yeh, FC, 2014) |
| " Using SBS as the model drug in this study, we developed SBS-loaded liposomes for oral administration and explored the relationship between their bioavailability and anti-asthmatic efficacy." | 1.39 | Effect of liposomes on the absorption of water-soluble active pharmaceutical ingredients via oral administration. ( Bian, Z; Chen, H; Chen, X; Huang, W; Lu, A; Wong, BC; Xu, M; Yang, Z; Zhang, G; Zhao, Z, 2013) |
| " Patients remaining on FP-SAL (n=1,146) were compared with those switched to efBDP-FOR at an equivalent or lower inhaled corticosteroid (ICS) dosage (n=382)." | 1.39 | Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. ( Brockman, J; Burden, A; Gruffydd-Jones, K; Harris, T; Haughney, J; King, C; Lavorini, F; Papi, A; Price, D; Ryan, D; Small, I, 2013) |
| "Although lactic acidosis is a rare complication to inhalation of beta-agonists, it is important for the clinicians to recognize this." | 1.39 | [Lactic acidosis in a patient with exercabation of asthma receiving inhalation therapy]. ( Ekelund, K; Følsgaard, S, 2013) |
| "The main objective of this study was to develop a novel aerosolized liposome formulation for pulmonary delivery of anti-asthmatic medication and to explore the relationship between the bioavailability and anti-asthmatic efficacy of such a formulation." | 1.38 | Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. ( Chen, X; Huang, W; Wong, BC; Wong, YF; Xu, M; Yang, Z; Yin, L, 2012) |
| " In conclusion, our results suggest that abediterol has a preclinical profile for once-daily dosing in humans together with a fast onset of action and a favorable cardiovascular safety profile." | 1.38 | Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. ( Aparici, M; Beleta, J; Carcasona, C; Cortijo, J; De Alba, J; Gavaldà, A; Gómez-Angelats, M; Gras, J; Miralpeix, M; Morcillo, E; Otal, R; Puig, C; Ramos, I; Ryder, H; Vilella, D; Viñals, M, 2012) |
| "Chronic obstructive pulmonary disease (COPD) management was investigated in two sub-studies of the BEACH (Bettering the Evaluation and Care of Health) program at 5711 general practitioner-patient encounters in February to March 2010 and April to May 2011." | 1.38 | Management of COPD in general practice. ( Harrison, C; Henderson, J; Miller, G, 2012) |
| "Treatment with rosiglitazone preserved salbutamol relaxant activity, mitigated carbachol hyperresponsiveness and partially restored β₂-adrenoceptor binding sites in tracheal tissues from homologously desensitized animals." | 1.37 | Rosiglitazone reverses salbutamol-induced β(2) -adrenoceptor tolerance in airway smooth muscle. ( Adinolfi, B; Bardelli, C; Betti, L; Breschi, MC; Brunelleschi, S; Fabbrini, L; Fogli, S; Giannaccini, G; Lucacchini, A; Mariotti, V; Melissari, E; Pellegrini, S; Stefanelli, F, 2011) |
| "One of them, obesity, has been reported to exert a harmful influence on asthma control." | 1.37 | Influence of obesity on control in asthmatic Japanese patients defined by the Japanese definition of obesity. ( Arakawa, M; Gejyo, F; Hasegawa, T; Koya, T; Narita, I; Sakagami, T; Suzuki, E; Suzuki, K; Toyabe, S; Youkou, A, 2011) |
| " The films were designed to release the drug for a prolonged period of time so as to reduce the frequency of administration of the available conventional dosage forms of SS." | 1.36 | In vitro and in vivo evaluation of buccal bioadhesive films containing salbutamol sulphate. ( Deshpande, SB; Jain, A; Muthu, MS; Rawat, MK; Singh, S; Singh, SK; Soni, R, 2010) |
| "Wheezing is common in preschool children, but objective evidence for airway obstruction and its reversibility are rarely available in clinical practice." | 1.36 | Lung function in preschool children with a history of wheezing measured by forced oscillation and plethysmographic specific airway resistance. ( Gibson, AM; Harrison, J; Johnson, K; Ranganathan, S; Singh, G; Skoric, B, 2010) |
| "5, 3 and 6 μm mass median aerodynamic diameter in a cumulative dosing schedule of 10, 20, 40 and 100 μg." | 1.36 | Predicting the clinical effect of a short acting bronchodilator in individual patients using artificial neural networks. ( Biddiscombe, MF; Chrystyn, H; de Matas, M; Meah, S; Shao, Q; Usmani, OS, 2010) |
| "COPD was likely the predominant diagnosis but patients with asthma may have been included." | 1.36 | Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. ( Deesomchok, A; Forkert, L; Jensen, D; Lam, YM; O'Donnell, DE; Ofir, D; Webb, KA, 2010) |
| "Wheezing was the most common mentioned symptoms in taking asthma into consideration." | 1.35 | A survey of pediatricians' knowledge on asthma management in children. ( Abdollahpour, H; Bemanian, MH; Gharagozlou, M; Moinfar, Z; Sedaghat, M, 2008) |
| "Subjects with bronchial asthmatic symptoms, forced expiratory volume in 1 second (FEV(1)) and FEV(1)/forced vital capacity [FVC] > 80% could show a positive reversibility test with salbutamol in about 25% of the cases." | 1.35 | When should a reversibility test be performed on patients with early stages of asthma and normal spirometry? ( Mariotta, S; Ricci, A; Sposato, B, 2008) |
| "We report a case of dilated cardiomyopathy that we believe is secondary to excessive use of inhaled beta agonists." | 1.35 | Can beta agonists cause dilated cardiomyopathy? ( Choudhary, AS; Robinson, GM, 2009) |
| "Prevalence of wheezing is increasing, bronchodilators are sub-optimally utilized and antibiotics are over-prescribed." | 1.35 | Are we adequately managing children with wheeze using the standard case management guidelines? ( Bunnag, T; Jatanachai, P; Lochindarat, S; Nisar, YB; Qazi, SA, 2008) |
| "In subjects with persistent asthma, the ADRB2 Arg16Gly polymorphism does not alter lung function responses to SAL or FSC over the 12 hour dosing interval following acute and chronic dosing." | 1.35 | Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms. ( Anderson, WH; Edwards, LD; Klotsman, M; Ortega, HG; Yancey, SW, 2009) |
| " Adverse events, clinical laboratory test results, and vital signs were recorded throughout the 2 clinical studies." | 1.35 | Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propiona ( Daley-Yates, PT; Gillett, B; House, KW; Ortega, HG; Parkins, DA; Thomas, MJ, 2009) |
| "COPD is a debilitating disease that is primarily caused by smoking and is therefore largely preventable." | 1.35 | An analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma. ( Barry, M; Bennett, K; McGowan, B; O'Connor, M; Owens, M, 2009) |
| " Studies have shown that a large volume spacer attached to a metered dose inhaler provides similar bronchodilator effects to nebulized dosing during the management of patients following an acute exacerbation." | 1.35 | Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation. ( Chrystyn, H; Ismail, NE; Mazhar, SH; Newton, DA, 2008) |
| "Cough is one of the most common symptoms of asthma." | 1.35 | Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. ( Kontra, KM; Koskela, HO; Purokivi, MK; Taivainen, AH; Tukiainen, HO, 2008) |
| " Lactic acidosis improved within 24 h after discontinuation or decrease in the dosage of beta2-agonists." | 1.34 | Lactic acidosis in children with acute exacerbation of severe asthma. ( Koul, PB; Minarik, M; Totapally, BR, 2007) |
| " An increased frequency of dosing with these drugs seems preferable for cases of severe or uncontrolled asthma." | 1.34 | Optimization of dosing schedule of daily inhalant dexamethasone to minimize phase shifting of clock gene expression rhythm in the lungs of the asthma mouse model. ( Hayasaka, N; Honma, K; Honma, S; Kudo, T; Kuwaki, T; Shibata, S; Yaita, T, 2007) |
| "Albuterol (180 microg) was given, by spacer, at 15 min intervals until the FEV1 increased < 5%." | 1.34 | Adrenergic responsiveness: FEV1 and symptom differences in Whites and African Americans with mild asthma. ( Brown, JK; Gold, WM; Hardie, GE, 2007) |
| "Thirty subjects with bronchial asthma and 10 normal controls inhaled up to three 600 microg nebulized doses of BAC using a jet nebulizer." | 1.34 | Benzalkonium chloride induced bronchoconstriction in patients with stable bronchial asthma. ( Kim, SH; Lee, BH, 2007) |
| "Both asthma and chronic obstructive pulmonary disease (COPD) are often underdiagnosed and undertreated among the elderly." | 1.33 | Treatment of acute bronchospasm in elderly patients. ( Berger, WE, 2005) |
| "Bronchodilator tolerance, assessed by a reduction of the area under the salbutamol dose-response curve, occurred after 1 dose of formoterol (28% reduction, 95% CI 12, 45%), increased up to 1 week and plateaued between 1 and 2 weeks (58% reduction, 95% CI 38, 78%)." | 1.33 | Rapid onset of tolerance to beta-agonist bronchodilation. ( Hancox, RJ; Haney, S, 2005) |
| " Drug use in the 6 months before and after step-up in treatment from inhaled corticosteroids [ICs; total daily dosage of < or =1000 microg beclomethasone dipropionate (BDP) or equivalent] to either salmeterol/fluticasone propionate combination (SFC) or concurrent BDP and long-acting beta(2)-agonists (LABAs) given in separate inhalers was compared." | 1.33 | Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. ( Angus, R; Cheesbrough, A; Reagon, R, 2005) |
| " Seventy-two hours after the last OVA challenge, guinea pigs were anesthetized and tracheostomized, respiratory system resistance and elastance were measured and a dose-response curve to inhaled methacholine chloride was obtained." | 1.33 | Effect of salbutamol on pulmonary responsiveness in chronic pulmonary allergic inflammation in guinea pigs. ( Arantes-Costa, FM; Kasahara, DI; Lopes, FD; Martins, MA; Nunes, MP; Perini, A, 2005) |
| "Six patients with bronchial asthma and 12 patients with mild COPD." | 1.33 | Acute electrophysiologic effects of inhaled salbutamol in humans. ( Kallergis, EM; Kanoupakis, EM; Klapsinos, NK; Manios, EG; Mavrakis, HE; Schiza, SE; Vardas, PE, 2005) |
| "Based on time from onset of symptoms to death, cases fell into two distinct groups: short course <3 (1." | 1.33 | Time to death, airway wall inflammation and remodelling in fatal asthma. ( Abramson, MJ; Elliot, JG; James, AL; Walters, EH, 2005) |
| "The prevalence of bronchial asthma is 4-8% among pregnant women." | 1.33 | [The management of bronchial asthma during pregnancy--Hungarian experiences]. ( Bohács, A; Losonczy, G; Magyar, P; Pállinger, E; Rigó, J; Tamási, L, 2005) |
| " Effective maintenance therapywith the correct dosage ofinhalational corticosteroids administered correctly can probably stop the potentially fatal asthma type II from developing." | 1.33 | [Fatal asthma in childhod preventable by recognizing risk factors and presenting features]. ( Corel, LJ; de Hoog, M; Joosten, KF; Tiddens, HA; Verbruggen, SC, 2006) |
| "He also had subcutaneous emphysema on the left side of the chest anteriorly." | 1.33 | Spontaneous pneumopericardium, pneumomediastinum and subcutaneous emphysema: unusual complications of asthma in a 2-year-old boy. ( Ameh, V; Bradbury, A; Jenner, R; Jilani, N, 2006) |
| " According to the dose-response curve to methacholine, they were categorized as having either unlimited airway narrowing (UAN group) (n = 20) or response plateau (RP group) (n = 18)." | 1.33 | Dyspnea perception and reversibility of methacholine-induced unlimited airway narrowing in asthmatics. ( Malakauskas, K; Sakalauskas, R; Sitkauskiene, B; Stravinskaite, K, 2006) |
| " The strategy of adjustable maintenance dosing (AMD) involves adjustment of the maintenance dose, (using a single combination [budesonide/formoterol] inhaler, Symbicort((R))) in response to variability of asthma control over time." | 1.33 | Inhaled Glucocorticosteroid and Long-Acting beta(2)-Adrenoceptor Agonist Single-Inhaler Combination for Both Maintenance and Rescue Therapy : A Paradigm Shift in Asthma Management. ( D'Urzo, AD, 2006) |
| "Sixty-five patients with bronchial asthma were treated for pre- and post-bronchodilation of 400 microg salbutamol." | 1.33 | [Expiratory flow limitation detected by negative expiratory pressure in patients with bronchial asthma]. ( Chen, AH; Chen, RC; Li, JM; Liu, Q; Zhang, NF; Zhong, NS, 2006) |
| "Levalbuterol-treated patients required significantly fewer treatments with beta-agonists (mean [+/- SD] number of treatments, 19." | 1.32 | Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. ( Halpern, M; Truitt, T; Witko, J, 2003) |
| " The main outcome measures were: indication for use of Ventolin MDI, assessment of disease severity, event rates during each period of observation; deaths, pregnancies, reported adverse drug reactions and reasons for discontinuation of MDI." | 1.32 | Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England. ( Craig-McFeely, PM; Maier, WC; Shakir, SA; Soriano, JB; Wilton, LV, 2003) |
| " The area under the plasma albuterol concentration versus time curve (AUC) was 72% greater for the HFA formulation, indicating a greater lung bioavailability (p = 0." | 1.32 | Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. ( Anderson, P; Breen, P; Compadre, C; Gann, L; Hiller, FC; Joguparthi, V; Zhou, X, 2003) |
| " These findings suggest that ways need to be found: (i) to increase the use of current asthma management guidelines by practitioners; (ii) to improve documentation of prescribed medications and their dosage and; (iii) to improve education of parents in home management measures." | 1.32 | Prescribing for asthmatic children in primary care. Are we following guidelines? ( Dashash, NA; Mukhtar, SH, 2003) |
| "Recently, dry powder inhaler (DPI) was more available than pressure metered dosed inhaler (pMDI) for the inhalation therapy of the respiratory disease." | 1.32 | [Comparison of the bronchodilator effect of salbutamol between pressure metered dosed inhaler and dry powder inhaler in patients with stable bronchial asthma]. ( Fujimura, M; Kasahara, K; Nakao, S; Yasui, M; Yoshimi, Y, 2004) |
| "Pulmonary function methods which are able to detect small pharmacological effects may be useful for assessing the full dose-response curve of bronchodilatators." | 1.32 | A comparison of lung function methods for assessing dose-response effects of salbutamol. ( Houghton, CM; Singh, D; Woodcock, AA, 2004) |
| "Tremor was measured using a laser pointer technique." | 1.32 | Tremor side effects of salbutamol, quantified by a laser pointer technique. ( Broeders, ME; Folgering, HT; Nizet, TA, 2004) |
| " Combination therapy is highly efficacious and safe for asthmatics under the age of 5." | 1.32 | Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5. ( Alam, M; Parekh, M; Sait, T; Sekhsaria, S; Starr, B, 2004) |
| " However, in view of the steep bronchodilator dose-response curve for salbutamol, further studies are needed to determine whether such device care is clinically necessary." | 1.32 | Effect of mouthpiece washing on aerosol performance of CFC-free Ventolin. ( Bosnic-Anticevich, SZ; Chan, HK; Chew, NY; Reddel, HK, 2004) |
| "Albuterol delivery was estimated by measuring the amount of the albuterol collected on a filter placed at the inlet of the lung model." | 1.31 | In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position. ( Chatmongkolchart, S; Dillman, C; Hess, DR; Kacmarek, RM; Schettino, GP, 2002) |
| " Depending on the intensity of allergen exposure, complaints now occur in February/March only, requiring updating of the therapy in respect of dosage and number of drugs used." | 1.31 | [Two out-of-the-ordinary (?) case reports an asthmatic disease]. ( Hausen, T, 2000) |
| "Lung sounds were measured in nine patients with asthma and five control subjects, alongside air flow measurements of forced expiratory volume (FEV1) and forced vital capacity (FVC)." | 1.31 | Limitations in the use of median frequency for lung sound analysis. ( Anderson, K; Carter, R; Lucas, M; Whittaker, AR, 2000) |
| "Malondialdehyde levels of BAL were compared before and after treatment." | 1.31 | Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and beta2-agonist. ( Aydin, S; Besirli, K; Cetinkaya, A; Ozaras, R; Tahan, V; Talay, F; Turkmen, S; Uzun, H, 2000) |
| "0), and hourly albuterol dosing interval (OR 4." | 1.31 | Predictors of hospitalization in children with acute asthma. ( Arseneault, R; Bacal, L; Keogh, KA; Macarthur, C; Parkin, PC; Schuh, S; Stephens, D; Tennis, O, 2001) |
| " Outcomes assessed were completion of the test protocol, adequacy of sputum samples, decrease in FEV1, and adverse effects during the procedure." | 1.31 | The tolerability, safety, and success of sputum induction and combined hypertonic saline challenge in children. ( Gibson, PG; Hankin, R; Henry, RL; Jones, PD; Simpson, J, 2001) |
| "Sputum induction is a safe and effective technique to study airway inflammation in stable asthma." | 1.31 | Safety of sputum induction with isotonic saline in adults with acute severe asthma. ( Gibson, PG; Hensley, MJ; Simpson, JL; Wark, PA, 2001) |
| " These results indicate that the difference in FPM does not warrant a change in the recommended dosage of salmeterol administered when using the VHCs tested." | 1.31 | Evaluation of particle size distribution of salmeterol administered via metered-dose inhaler with and without valved holding chambers. ( Ahrens, RC; Garris, T; Holmes, M; Kelly, HW; Reisner, C; Stevens, AL; Vandermeer, AK, 2001) |
| " Lung function, quality of life and adverse events were evaluated as primary outcome variables." | 1.31 | [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma]. ( Beeh, KM; Beier, J; Buhl, R; Kornmann, O; Wiewrodt, R, 2002) |
| "Latent forms of long QT syndrome have been already reported." | 1.30 | [Latent long QT syndrome: discription of a clinical case]. ( Bianconi, L; Castro, A; Pandozi, C; Santini, M; Toscano, S, 1997) |
| " Beta 2 adrenoceptor function was evaluated by measuring lymphocyte beta 2 adrenoceptor parameters and constructing dose-response curves to salbutamol (100-1600 micrograms)." | 1.30 | Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. ( Lipworth, BJ; McFarlane, LC; Tan, KS, 1997) |
| " Even when controlling for dosage in the preceding 24 h, there was a 262-fold and 810-fold variation in the urinary concentrations for unchanged and total salbutamol, respectively, among the community patients." | 1.30 | Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy. ( Jacobson, GA; McLean, S; Peterson, GM, 1997) |
| "albuterol, Airomir, 3M) has been approved for marketing in over 35 countries." | 1.30 | The change to non-CFC metered dose inhalers. ( Rubinfeld, A, 1997) |
| "Childhood pneumonia is associated with reduced ventilatory function in adults." | 1.30 | Effect of pneumonia and whooping cough in childhood on adult lung function. ( Anderson, HR; Johnston, ID; Strachan, DP, 1998) |
| "Serum sex hormones, lymphocyte beta2-adrenoceptor parameters, and bronchodilator and systemic dose-response curves (DRCs) to albuterol (Salbutamol) (100 to 1,600 microg) were measured at both on and off periods." | 1.30 | Beta2-adrenoceptor regulation and function in female asthmatic patients receiving the oral combined contraceptive pill. ( Lipworth, BJ; McFarlane, LC; Tan, KS, 1998) |
| "A dose-response increase in pulmonary function was found, but only 70% improved sufficiently to be discharged." | 1.30 | Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma. ( Rodrigo, C; Rodrigo, G, 1998) |
| "A study was undertaken to test the hypothesis that airway calibre may alter lung deposition and therefore lung bioavailability of inhaled drugs as a result of narrowed airways reducing peripheral drug delivery." | 1.30 | Effects of airway calibre on lung delivery of nebulised salbutamol. ( Clark, DJ; Lipworth, BJ, 1997) |
| " One theory for this paradox is that chronic use of beta2-adrenoceptor agonists compromises the anti-inflammatory action of glucocorticosteroids." | 1.30 | Albuterol does not antagonize the inhibitory effect of dexamethasone on monocyte cytokine release. ( Adcock, IM; Barnes, PJ; Giembycz, MA; O'Connor, BJ; Seldon, PM; Stevens, DA, 1998) |
| " The accuracy of dosing and the technically perfect use of devices are extremely important, especially when drugs with potential systemic side effects are administered." | 1.30 | Inhalation devices in childhood asthma. ( Gács, E; Göndöcs, R; Jákly, A; Uhereczky, G, 1998) |
| "We suggest that children with bronchial asthma treated with inhaler drugs should receive special preventive attention." | 1.30 | Inhaler medicament effects on saliva and plaque pH in asthmatic children. ( Dagli, E; Ergeneli, S; Karakoc, F; Kargul, B; Tanboga, I, 1998) |
| " Intratracheal administration of IL-1beta or chronic administration of albuterol significantly decreased (p < 0." | 1.30 | An in vivo model of beta-adrenoceptor desensitization. ( Agrawal, DK; Chong, BT; Romero, FA; Townley, RG, 1998) |
| " Metered dosing (metered-dosing inhaler or premixed solution) were chosen by 22 caregivers (54%), calibrated measuring tools (droppers, syringes) by 15 (37%), and noncalibrated delivery devices (teaspoon) by 4 (10%)." | 1.30 | Caregiver knowledge and delivery of a commonly prescribed medication (albuterol) for children. ( Simon, HK, 1999) |
| "Salbutamol is widely used in the treatment of bronchial asthma, and is usually administered either by inhalation, orally, or parenterally." | 1.30 | Intranasal salbutamol instillation in asthma attack. ( Brill, S; Gurman, GM; Tarnapolski, A; Weksler, N, 1999) |
| " A dose-response curve for nebulized ipratropium was determined." | 1.29 | [Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience]. ( Beck, R, 1995) |
| " The dose-response curve for each subject was measured by a log transformation and linear regression analysis as well as a formula fitted to the data points to obtain values for a (slope) and b (position)." | 1.29 | Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction. ( Huang, TJ; Kuo, HP; Lin, HC; Shieh, WB; Wang, CH; Yang, CT; Yu, CT, 1995) |
| "04), a relative oral bioavailability of 104%, indicating equivalent total salbutamol output, was also obtained in the human subjects." | 1.29 | Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs. ( Chang, C; Simon, OR, 1994) |
| " In the 11 patients with complete dose-response curves, the geometric mean of diurnal PFV variation (% mean range) was 5." | 1.29 | [Relations between nonspecific bronchial hyperreactivity, diurnal variation of peak expiratory flow and medication requirements in patients with mild asthma]. ( Bertó, JM; Camps, B; Gutiérrez, V; Pérez, MJ; Prieto, L, 1994) |
| " The main finding was that older children had higher concentrations than younger children, despite similar dosage regimens." | 1.29 | Systemic absorption of salbutamol following nebulizer delivery in acute asthma. ( Dawson, KP; Manglick, P; Penna, AC; Tam, J, 1993) |
| " Change-point dose-response curves showed that the risk of asthma death began to escalate drastically at about 1." | 1.29 | A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. ( Blais, L; Boivin, JF; Buist, AS; Cockroft, D; Ernst, P; Habbick, B; Horwitz, RI; McNutt, M; Spitzer, WO; Suissa, S, 1994) |
| "The authors compared the effectiveness and advantages of the powdered inhalation variety of the preparation Ventodisc (Glaxo) with the "classical" dosed inhalation form of Salbutamol (Polfa) in 21 patients with bronchial asthma." | 1.29 | [The bronchodilator agent, Ventodisk, in the powdered inhalation form without freon is better]. ( Malý, M; Reisová, M; Vondra, V, 1993) |
| " These aerosolized medications are not without the potential for adverse effects." | 1.29 | Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants. ( Oenbrink, RJ, 1993) |
| "Fourteen patients with moderate bronchial asthma were selected for the study." | 1.29 | [Effect of corticosteroids on tachyphylaxis induced by beta-2- receptor agonists in patients with bronchial asthma]. ( Małolepszy, J; Passowicz-Muszyńska, E, 1993) |
| " The aim of this study was to seek such a relationship in young asthmatic children using dose-response curves (DRC)." | 1.29 | The effect of age on bronchodilator responsiveness. ( Landau, LI; LeSouëf, PN; Turner, DJ, 1993) |
| "Taking into account that in bronchial asthma an alteration in the beta-adrenergic neural control of airways has been hypothesized, we aimed to verify whether, in asthmatic children, beta-adrenergic activation inhibits or not GH secretion." | 1.29 | Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children. ( Bellone, J; Camanni, F; Castello, D; Gaggero, L; Ghigo, E; Valente, F; Valetto, MR; Visca, A, 1993) |
| "Albuterol delivery was significantly (p < or = ." | 1.29 | Albuterol delivery by metered-dose inhaler in a mechanically ventilated pediatric lung model. ( Bradley, JW; Garner, SS; Habib, DM; Lesher, BA; Wiest, DB, 1996) |
| "Nimesulide is a nonsteroidal anti-inflammatory drug, supposed to act by inhibition of phosphodiesterase type IV." | 1.29 | The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils. ( Knol, EF; Mul, FP; Roos, D; Tool, AT; Verhoeven, AJ, 1996) |
| " Given orally, RP 58802B (5 mg/kg, 60 min before challenge) produced a greater than three-fold shift to the right of the dose-response curve and depressed the maximum response to histamine by 39 +/- 11%." | 1.28 | RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. ( Lewis, SA; Raeburn, D; Underwood, SL, 1992) |
| "Procaterol was administered per os (tabl." | 1.28 | [Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma]. ( Kruszewski, J; Płusa, T; Zaraś, E, 1992) |
| " Bronchial lability was characterized by (1) variability in mean daily peak expiratory flow rate and (2) bronchial responsiveness to either carbachol (as assessed by the threshold dose and the slope of the dose-response curve) or salbutamol (as assessed by the threshold dose and maximal response)." | 1.28 | Relationship between spontaneous dyspnoea and lability of airway obstruction in asthma. ( Lockhart, A; Marsac, J; Peiffer, C; Razzouk, H; Toumi, M, 1992) |
| " Before salmeterol treatment was initiated and after 3, 6, 9 and 12 months of salmeterol treatment, a cumulative dose-response curve to inhaled salbutamol (100, 300 and 900 micrograms) was performed, and FEV1 measured." | 1.28 | Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells. ( Lötvall, J; Lunde, H; Svedmyr, N; Törnqvist, H; Ullman, A, 1992) |
| "Albuterol was effective in increasing the PEFR in patients with asthma, COPD and NANC." | 1.28 | The prehospital use of nebulized albuterol on patients with wheezing whose chief complaint is shortness of breath. ( Dickinson, ET; Megargel, R; O'Connor, RE, 1992) |
| " During the high dosing the secretion rate of parotid saliva decreased and the concentrations of its total protein, amylase, hexosamine and the ratio of hexosamine/total protein were lowered." | 1.28 | Saliva composition in asthmatic patients after treatment with two dose levels of a beta 2-adrenoceptor agonist. ( Ericson, T; Möller, C; Ryberg, M, 1990) |
| "Albuterol was administered from each of the delivery systems in the following manner: MDI, two actuations (180 micrograms); JN, 0." | 1.28 | Assessment of bronchodilator response to a beta-adrenergic delivered from an ultrasonic nebulizer. ( Ballard, RD; Bogin, RM; Pak, J, 1991) |
| "Recently, it was suggested that long-term administration of an inhaled beta 2-agonist might increase bronchial hyperresponsiveness (BHR) to histamine, possibly as a consequence of subsensitization to the inhaled beta 2-agonist." | 1.28 | Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. ( Dompeling, E; Graafsma, SJ; van Herwaarden, CL; van Schayck, CP; van Weel, C; Visch, MB, 1990) |
| "Patients with bronchial asthma often develop acute attack in kitchen while burning honeycomb briquet which is widely used for cooking in southern China." | 1.28 | [Sulfur dioxide-induced bronchial constriction in asthmatics and its prophylaxis by salbutamol]. ( Luo, DF; Luo, ZY; Zheng, JP, 1990) |
| "Aminophylline is a potent antagonist at purinoceptor level." | 1.28 | Role of purinergic system in tracheobronchial reactivity of healthy and bronchopathic subjects. ( Carapella, N; Filippelli, A; Loffreda, A; Marmo, E; Matera, MG; Montanaro, C; Santagata, A; Servodio, R; Susanna, V, 1990) |
| " Plasma glucose, potassium, and magnesium were measured at each step of the dose-response curve." | 1.28 | The biochemical effects of high-dose inhaled salbutamol in patients with asthma. ( Clark, RA; Fraser, CG; Lipworth, BJ; McDevitt, DG, 1989) |
| "We have compared bronchodilator dose-response curves to inhaled salbutamol in seven normal and eight asthmatic subjects." | 1.27 | Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. ( Barnes, PJ; Pride, NB, 1983) |
| " Although it is safe to use oxygen as the driving gas for nebulisers in patients with obstructive airways disease with normal Pco2, caution should be exercised in those who already have carbon dioxide retention." | 1.27 | Oxygen as a driving gas for nebulisers: safe or dangerous? ( Campbell, IA; Gunawardena, KA; MacDonald, JB; Patel, B; Smith, AP, 1984) |
| " There was a linear log dose-response relationship for each airways parameter (FEV1, VC, sGaw, FEF 50%)." | 1.27 | Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. ( Brown, RA; Clark, RA; Dhillon, DP; Lipworth, BJ; McDevitt, DG, 1988) |
| " We conclude that procaterol and salbutamol are clinically similar with oral dosing and that the maximum effective dose of procaterol is not greater than 0." | 1.27 | A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma. ( Counihan, HE; Crowe, MJ; O'Malley, K, 1985) |
| " Dose-response curves were plotted upon the inhalation of salbutamol in two-week intervals in patients treated with betamimetics." | 1.27 | Development of drug tachyphylaxis in asthmatic patients treated with beta-adrenergic drugs. ( Böszörményi-Nagy, G; Debreczeni, LA; Herjavecz, I; Szeitz, A, 1987) |
| "Twenty patients with mild chronic bronchial asthma (females and males between 45-69 years old) treated with single dose of 0." | 1.27 | Pharmacodynamics of salbutamol in humans. ( Chazan, R; Droszcz, W; Maruchin, JE, 1988) |
| " This reduction in severity appears to require the long-term use of medications, including aerosol corticosteroids, with daily home monitoring to allow adjustment of the amount of treatment required." | 1.27 | Effect of therapy on bronchial hyperresponsiveness in the long-term management of asthma. ( Salome, CM; Woolcock, AJ; Yan, K, 1988) |
| " The bronchodilator effect of the two aerosols was determined from cumulative dose-response studies." | 1.27 | Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma. ( Mitchell, DM; Short, M; Solomon, MA; Spiro, SG; Tolfree, SE, 1987) |
| " This study was undertaken to compare the clinical effectiveness and toxicity of these two drugs and to try to establish dosage schedules of inhaled salbutamol with spacer in the treatment of acute asthma." | 1.27 | [Subcutaneous adrenaline versus inhaled salbutamol in the treatment of childhood asthmatic crisis]. ( Bonal de Falgas, J; Farré Riba, R; Ferrés Mataró, J; Juliá Brugues, A; Mangues Bafalluy, MA, 1987) |
| "Thirteen patients with bronchial asthma were treated with 2 mg salbutamol three times daily (one patient with 4 mg three times daily)." | 1.26 | Effect of beta 2-adrenergic stimulation on serum lipids. ( Elo, J; Lehtonen, A; Sallinen, VP; Viikari, J, 1982) |
| " The development of resistance was assessed from salbutamol dose-response studies in which the airway response was measured as specific airway conductance (sGaw)." | 1.26 | Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. ( Harvey, JE; Tattersfield, AE, 1982) |
| "A review of childhood bronchial asthma in Zaria, northern Nigeria is presented." | 1.26 | Childhood bronchial asthma in northern Nigeria. ( Abdurrahman, MB; Taqi, AM, 1982) |
| "Cumulative inhalation dose-response curves for the response to prostaglandin E2 (PGE2) have been constructed in normal subjects and patients with mild, stable asthma." | 1.26 | Interactions between response to inhaled prostaglandin E2 and chronic beta-adrenergic agonist treatment. ( Bevan, M; Davies, BH; Walters, EH, 1982) |
| " The dose-response curve for non-esterified fatty acids and insulin, though displaced downwards, did not indicate an impaired response to salbutamol since the shape was unchanged." | 1.26 | Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol. ( Alberti, KG; Baldwin, CJ; Harvey, JE; Tattersfield, AE; Wood, PJ, 1981) |
| "1 Cumulative dose-response curves (FEV1) to pressurized aerosol salbutamol were established in 17 patients admitted to hospital with acute severe asthma." | 1.26 | Comparative efficacy of salbutamol by pressurized aerosol and wet nebulizer in acute asthma. ( Madsen, BW; Paterson, JW; Tarala, RA, 1980) |
| " Adequate theophylline dosage is an effective bronchodilator." | 1.26 | Treatment of asthma in children. ( Hobday, JD, 1978) |
| " Tremor was found to be the dose-limiting side effect with both modes of administration." | 1.26 | Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics. ( Larsson, S; Svedmyr, N, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 843 (21.81) | 18.7374 |
| 1990's | 1107 (28.63) | 18.2507 |
| 2000's | 1167 (30.19) | 29.6817 |
| 2010's | 606 (15.68) | 24.3611 |
| 2020's | 143 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Sohda, S | 1 |
| Fujimoto, M | 1 |
| Tamegai, T | 1 |
| Hirose, N | 1 |
| Jacobsen, JR | 1 |
| Choi, SK | 1 |
| Combs, J | 1 |
| Fournier, EJ | 1 |
| Klein, U | 1 |
| Pfeiffer, JW | 1 |
| Thomas, GR | 1 |
| Yu, C | 1 |
| Moran, EJ | 1 |
| Xing, G | 1 |
| Woo, AY | 1 |
| Pan, L | 1 |
| Lin, B | 1 |
| Cheng, MS | 1 |
| Teper, A | 2 |
| Kofman, C | 2 |
| Alchundia Moreira, J | 1 |
| Köhler, T | 1 |
| García Bournissen, F | 1 |
| Wilkinson, A | 1 |
| Woodcock, A | 11 |
| Zhou, XJ | 1 |
| Qin, Z | 1 |
| Lu, J | 1 |
| Hong, JG | 1 |
| Chipps, BE | 6 |
| Albers, FC | 2 |
| Reilly, L | 1 |
| Johnsson, E | 2 |
| Cappelletti, C | 3 |
| Papi, A | 14 |
| Arnold, DH | 3 |
| Gong, W | 1 |
| Antoon, JW | 1 |
| Bacharier, LB | 13 |
| Stewart, TG | 1 |
| Johnson, DP | 1 |
| Akers, WS | 1 |
| Hartert, TV | 2 |
| Shen, BH | 1 |
| Aoyama, B | 1 |
| Lee, B | 3 |
| Busse, WW | 28 |
| Panettieri, RA | 6 |
| Corren, J | 8 |
| Morgenstern-Kaplan, D | 1 |
| Gonzalez-Estrada, A | 1 |
| Amir Najim Abood, HA | 1 |
| Al-Musawi, ZM | 1 |
| Hussein, AM | 1 |
| Hameed, RM | 1 |
| Ramey, OL | 1 |
| Silva Almodóvar, A | 1 |
| Nahata, MC | 1 |
| Andoh, AA | 1 |
| Lo, CB | 1 |
| Shi, J | 1 |
| Bode, RS | 1 |
| Gee, SW | 1 |
| Leonard, JC | 1 |
| Lucas, JA | 3 |
| Kaufmann, J | 2 |
| Jones, M | 1 |
| Garg, A | 2 |
| Ezekiel-Herrera, D | 2 |
| Puro, J | 1 |
| Marino, M | 3 |
| Heintzman, J | 3 |
| Rodríguez-Martínez, CE | 6 |
| Sossa-Briceño, MP | 5 |
| Buendia, JA | 2 |
| McCans, K | 1 |
| Varma, S | 1 |
| Ramgopal, S | 2 |
| Martin-Gill, C | 2 |
| Owusu-Ansah, S | 2 |
| Courlet, P | 1 |
| Buclin, T | 1 |
| Biollaz, J | 1 |
| Mazzoni, I | 1 |
| Rabin, O | 1 |
| Guidi, M | 1 |
| Vega-Briceño, L | 1 |
| Muchão, FP | 2 |
| Souza, AV | 1 |
| Souza, JME | 1 |
| Silva Filho, LVRFD | 1 |
| Zhang, H | 1 |
| Cui, Y | 1 |
| Zhang, X | 8 |
| Yuan, X | 2 |
| Xu, D | 2 |
| Zhang, L | 4 |
| Colombo, M | 1 |
| Plebani, A | 1 |
| Bosco, A | 1 |
| Agosti, M | 1 |
| Lajunen, K | 1 |
| Kataja, J | 1 |
| Jartti, T | 1 |
| Peltoniemi, O | 1 |
| Tervonen, M | 1 |
| Elenius, V | 1 |
| Nash, JL | 1 |
| Southcott, AM | 1 |
| Jayaram, L | 1 |
| Beasley, R | 30 |
| Israel, E | 32 |
| Cooper, M | 1 |
| Dunsire, L | 1 |
| Jeynes-Ellis, A | 1 |
| Rees, R | 1 |
| Lowe, AA | 2 |
| Gerald, JK | 4 |
| Clemens, C | 1 |
| Gerald, LB | 6 |
| Koldeweij, C | 1 |
| Appelbaum, N | 1 |
| Rodriguez Gonzalvez, C | 1 |
| Nijman, J | 1 |
| Nijman, R | 1 |
| Sinha, R | 1 |
| Maconochie, I | 2 |
| Clarke, J | 1 |
| Alsuwaigh, R | 1 |
| Cao, Y | 1 |
| Puan, Y | 1 |
| Yii, A | 1 |
| Mohamed Noor, SB | 1 |
| Ye, H | 1 |
| Chen, H | 3 |
| Li, XL | 1 |
| Binte Mohd Noor, N | 1 |
| Liew, J | 1 |
| Tay, TR | 1 |
| Hsiao, YH | 1 |
| Lin, YJ | 1 |
| Jeng, TH | 1 |
| Su, KC | 1 |
| Ko, HK | 1 |
| Yang, SN | 1 |
| Perng, DW | 1 |
| Kou, YR | 1 |
| Ball, J | 2 |
| Doniec, Z | 1 |
| Olszanecka-Glinianowicz, M | 1 |
| Hantulik, P | 1 |
| Almgren-Rachtan, A | 1 |
| Chudek, J | 1 |
| Uysalol, M | 1 |
| Yıldız, R | 1 |
| Özünal, ZG | 1 |
| Boeschoten, SA | 2 |
| Buysse, CMP | 2 |
| de Winter, BCM | 2 |
| van Rosmalen, J | 2 |
| de Jongste, JC | 8 |
| de Jonge, RC | 1 |
| Heisterkamp, SGJ | 2 |
| van Woensel, JB | 1 |
| Kneyber, MCJ | 1 |
| van Zwol, A | 1 |
| Boehmer, ALM | 2 |
| de Hoog, M | 5 |
| Willis, LD | 1 |
| Danner, NP | 1 |
| Lloyd, TL | 1 |
| Carper, NL | 1 |
| Berlinski, A | 1 |
| Siddiqui, H | 1 |
| Siddiqui, SA | 1 |
| Yadav, RK | 1 |
| Singh, MV | 1 |
| Kumar, D | 2 |
| Singh, DK | 1 |
| Hoyte, FCL | 1 |
| Mosnaim, GS | 1 |
| Rogers, L | 1 |
| Safioti, G | 1 |
| Brown, R | 1 |
| Li, T | 1 |
| DePietro, M | 1 |
| Reich, M | 1 |
| Hill, TD | 1 |
| Wechsler, ME | 13 |
| Confalonieri, M | 1 |
| Lipworth, BJ | 72 |
| Chan, R | 4 |
| Stewart, KE | 1 |
| Pitonzo, DG | 1 |
| Lv, C | 1 |
| Liao, G | 1 |
| Wu, L | 1 |
| Li, J | 1 |
| Gao, Y | 1 |
| Zyryanov, SK | 1 |
| Dyakov, IN | 1 |
| Aisanov, ZR | 1 |
| Kosoko, AA | 1 |
| Khoei, AA | 1 |
| Khose, S | 1 |
| Genisca, AE | 1 |
| Mackey, JM | 1 |
| Marques, L | 4 |
| Vale, N | 3 |
| Crossingham, I | 3 |
| AlKhalidi, L | 3 |
| Zhao, W | 2 |
| Hogan, MB | 2 |
| Alizadeh Bahmani, AH | 2 |
| Slob, EMA | 2 |
| Bloemsma, LD | 2 |
| Brandstetter, S | 2 |
| Corcuera-Elosegui, P | 2 |
| Gorenjak, M | 2 |
| Harner, S | 2 |
| Hashimoto, S | 2 |
| Hedman, AM | 2 |
| Kabesch, M | 3 |
| Koppelman, GH | 2 |
| Korta-Murua, J | 2 |
| Kraneveld, AD | 2 |
| Neerincx, AH | 2 |
| Pijnenburg, MW | 2 |
| Pino-Yanes, M | 4 |
| Potočnik, U | 2 |
| Sardón-Prado, O | 2 |
| Vijverberg, SJH | 2 |
| Wolff, C | 2 |
| Abdel-Aziz, MI | 2 |
| Maitland-van der Zee, AH | 2 |
| Walsh, S | 1 |
| Pan, S | 2 |
| Sheng, Y | 1 |
| Kloprogge, F | 1 |
| Standing, JF | 1 |
| Anderson, BJ | 2 |
| Ramnarayan, P | 2 |
| Rabbany, MA | 1 |
| Saha, BK | 1 |
| Subha, N | 1 |
| Sultana, I | 1 |
| Islam, MS | 1 |
| Hossain, AJ | 1 |
| Seraj, S | 1 |
| Farzana, S | 1 |
| Sharmin, M | 1 |
| Ali, MM | 1 |
| Nahar, A | 1 |
| Siddiqui, KA | 1 |
| Nishi, MK | 1 |
| Akter, S | 1 |
| Tania, IJ | 1 |
| Shams, N | 1 |
| Khatun, S | 1 |
| Douros, K | 1 |
| Moriki, D | 1 |
| Sardeli, O | 1 |
| Boutopoulou, B | 1 |
| Galani, A | 1 |
| Papaevangelou, V | 1 |
| Priftis, KN | 1 |
| Roddy, MR | 1 |
| Sellers, AR | 1 |
| Darville, KK | 1 |
| Teppa-Sanchez, B | 1 |
| McKinley, SD | 1 |
| Martin, M | 1 |
| Goldenberg, NA | 1 |
| Nakagawa, TA | 1 |
| Sochet, AA | 1 |
| Rajashekar, C | 1 |
| Shankar, NCG | 1 |
| S, A | 1 |
| Sharada, RC | 1 |
| Nedunchelian, K | 1 |
| Reddel, HK | 8 |
| Brusselle, G | 2 |
| Lamarca, R | 1 |
| Gustafson, P | 1 |
| Anderson, GP | 2 |
| Jorup, C | 3 |
| Bilak, VM | 1 |
| Ignatko, LV | 1 |
| Sochka, NV | 1 |
| Debretseni, OV | 1 |
| Kossey, GB | 1 |
| Mashika, VY | 1 |
| Griadil, TI | 1 |
| Steward, M | 1 |
| Sheth, S | 1 |
| Ouédraogo, AR | 1 |
| Boncoungou, K | 1 |
| Ouédraogo, JCRP | 1 |
| Ouédraogo, GA | 1 |
| Kiendrebeogo, JA | 1 |
| Sourabie, A | 1 |
| Maiga, S | 1 |
| Kafando, S | 1 |
| Ouédraogo, G | 1 |
| Badoum, G | 1 |
| Ouédraogo, M | 1 |
| Aschenbrenner, DS | 1 |
| Diao, J | 1 |
| Lam, M | 1 |
| Gregory, KJ | 1 |
| Leach, K | 1 |
| Bourke, JE | 2 |
| Anderson, K | 2 |
| Hall-Lipsy, E | 1 |
| McCulley, K | 1 |
| Vuong, E | 1 |
| Phan, H | 1 |
| Bailey, SR | 1 |
| Hsu, A | 2 |
| Datta, R | 1 |
| Cottrell, E | 1 |
| Kim, YJ | 1 |
| Suglia, SF | 1 |
| Bazemore, A | 2 |
| Meredith, E | 1 |
| Thomas, J | 1 |
| Kaminsky, DA | 3 |
| He, J | 1 |
| Henderson, R | 1 |
| Dixon, AE | 2 |
| Irvin, CG | 9 |
| Mastronarde, J | 1 |
| Smith, LJ | 3 |
| Sugar, EA | 1 |
| Wise, RA | 6 |
| Holbrook, JT | 2 |
| Jayasooriya, S | 1 |
| Stolbrink, M | 1 |
| Khoo, EM | 1 |
| Sunte, IT | 1 |
| Awuru, JI | 1 |
| Cohen, M | 1 |
| Lam, DC | 1 |
| Spanevello, A | 1 |
| Visca, D | 1 |
| Centis, R | 1 |
| Migliori, GB | 1 |
| Ayuk, AC | 1 |
| Awokola, BI | 1 |
| Del-Rio-Navarro, BE | 2 |
| Muteti-Fana, S | 1 |
| Lao-Araya, M | 1 |
| Chiarella, P | 1 |
| Badellino, H | 1 |
| Somwe, SW | 1 |
| Anand, MP | 1 |
| Garcí-Corzo, JR | 1 |
| Bekele, A | 1 |
| Soto-Martinez, ME | 1 |
| Ngahane, BHM | 1 |
| Florin, M | 1 |
| Voyi, K | 1 |
| Tabbah, K | 1 |
| Bakki, B | 1 |
| Alexander, A | 1 |
| Garba, BL | 1 |
| Salvador, EM | 1 |
| Fischer, GB | 1 |
| Falade, AG | 1 |
| ŽivkoviĆ, Z | 1 |
| Romero-Tapia, SJ | 1 |
| Erhabor, GE | 1 |
| Zar, H | 1 |
| Gemicioglu, B | 2 |
| Brandão, HV | 1 |
| Kurhasani, X | 1 |
| El-Sharif, N | 1 |
| Singh, V | 1 |
| Ranasinghe, JC | 1 |
| Kudagammana, ST | 1 |
| Masjedi, MR | 1 |
| Velásquez, JN | 1 |
| Jain, A | 2 |
| Cherrez-Ojeda, I | 1 |
| Valdeavellano, LFM | 1 |
| Gómez, RM | 1 |
| Mesonjesi, E | 1 |
| Morfin-Maciel, BM | 1 |
| Ndikum, AE | 1 |
| Mukiibi, GB | 1 |
| Reddy, BK | 1 |
| Yusuf, O | 1 |
| Taright-Mahi, S | 1 |
| Mérida-Palacio, JV | 1 |
| Kabra, SK | 10 |
| Nkhama, E | 1 |
| Filho, NR | 1 |
| Zhjegi, VB | 1 |
| Mortimer, K | 1 |
| Rylance, S | 1 |
| Masekela, RR | 1 |
| Sinaiko, AD | 1 |
| Ross-Degnan, D | 1 |
| Wharam, JF | 1 |
| LeCates, RF | 1 |
| Wu, AC | 3 |
| Zhang, F | 1 |
| Galbraith, AA | 2 |
| Barchilon, M | 1 |
| Reinero, CR | 2 |
| Emel, E | 1 |
| Ayhan, O | 1 |
| Recep, B | 1 |
| Ulku, S | 1 |
| Hempel, P | 1 |
| Klein, V | 1 |
| Michely, A | 1 |
| Böll, S | 1 |
| Rieg, AD | 1 |
| Spillner, J | 1 |
| Braunschweig, T | 1 |
| von Stillfried, S | 1 |
| Wagner, N | 1 |
| Martin, C | 1 |
| Tenbrock, K | 1 |
| Verjans, E | 1 |
| Knox, SK | 1 |
| Mahr, TA | 1 |
| Wongwaree, S | 1 |
| Daengsuwan, T | 1 |
| Coverstone, AM | 1 |
| Wilson, BS | 1 |
| Fitzpatrick, AM | 6 |
| Teague, WG | 3 |
| Phipatanakul, W | 5 |
| Wenzel, SE | 8 |
| Gaston, BM | 2 |
| Bleecker, ER | 17 |
| Moore, WC | 7 |
| Ramratnam, S | 2 |
| Jarjour, NN | 5 |
| Ly, NP | 1 |
| Fahy, JV | 16 |
| Mauger, DT | 13 |
| Schechtman, KB | 1 |
| Yin-DeClue, H | 1 |
| Boomer, JS | 1 |
| Castro, M | 11 |
| Saeed, H | 2 |
| Abdelrahim, ME | 2 |
| Rabea, H | 1 |
| Salem, HF | 1 |
| Louis, R | 3 |
| Bougard, N | 1 |
| Guissard, F | 1 |
| Paulus, V | 1 |
| Henket, M | 2 |
| Schleich, F | 1 |
| Graden, A | 1 |
| Gandhi, S | 1 |
| Joshi, AY | 1 |
| Lipworth, B | 8 |
| Kuo, CR | 2 |
| Grunwell, JR | 1 |
| Nguyen, KM | 1 |
| Bruce, AC | 1 |
| Mazzarini, A | 1 |
| Winter, BK | 1 |
| Carlton, E | 1 |
| Meltzer, LJ | 1 |
| Beebe, DW | 1 |
| Jump, S | 1 |
| Flewelling, K | 1 |
| Sundström, D | 1 |
| White, M | 3 |
| Zeitlin, PL | 1 |
| Strand, MJ | 1 |
| Carhuamaca-Salvador, M | 1 |
| Bustos de la Cruz, J | 1 |
| Chávez-Rimache, L | 1 |
| Chumpitaz-Cerrate, V | 1 |
| Calzetta, L | 3 |
| Matera, MG | 7 |
| Goldstein, MF | 5 |
| Fairweather, WR | 2 |
| Howard, WW | 2 |
| Cazzola, M | 9 |
| Rogliani, P | 1 |
| Woodward, S | 1 |
| Mundorff, M | 1 |
| Weng, C | 1 |
| Gamboa, DG | 1 |
| Johnson, MD | 1 |
| Lin, NY | 1 |
| Ramsey, RR | 1 |
| Miller, JL | 1 |
| McDowell, KM | 2 |
| Zhang, N | 1 |
| Hommel, K | 1 |
| Guilbert, TW | 6 |
| Dickman, CTD | 1 |
| Russo, V | 1 |
| Thain, K | 1 |
| Beyer, ST | 1 |
| Walus, K | 1 |
| Getsios, S | 1 |
| Mohamed, T | 1 |
| Wadsworth, SJ | 1 |
| SreeHarsha, N | 1 |
| Venugopala, KN | 1 |
| Nair, AB | 1 |
| Roopashree, TS | 1 |
| Attimarad, M | 1 |
| Hiremath, JG | 1 |
| Al-Dhubiab, BE | 1 |
| Ramnarayanan, C | 1 |
| Shinu, P | 1 |
| Handral, M | 1 |
| Haroun, M | 1 |
| Tratrat, C | 1 |
| Pearmain, L | 1 |
| Gupta, R | 2 |
| Bright-Thomas, RJ | 1 |
| Castro-Rodriguez, JA | 6 |
| Elgendy, MO | 1 |
| Hassan, AH | 1 |
| Eldin, RS | 1 |
| Vempilly, JJ | 1 |
| Abejie, BA | 1 |
| Rashidian, A | 1 |
| Jain, VV | 1 |
| Bhakta, N | 1 |
| Banasiak, NC | 1 |
| Meadows-Oliver, M | 1 |
| Vet, NJ | 1 |
| Dunk-Craaijo, JH | 1 |
| Koch, BCP | 1 |
| de Wildt, SN | 1 |
| Zhao, T | 1 |
| Liu, Z | 2 |
| Niu, J | 1 |
| Lv, B | 1 |
| Xiao, Y | 1 |
| Li, Y | 2 |
| Andrews, AL | 1 |
| Williams, DC | 1 |
| Hogan, AH | 1 |
| Smith, NMJ | 1 |
| Couper, J | 1 |
| Fullerton, CJ | 1 |
| Richmond, G | 1 |
| Talbot, NP | 1 |
| Hancock, G | 1 |
| Pavord, I | 2 |
| Ritchie, GAD | 1 |
| Robbins, PA | 1 |
| Petousi, N | 1 |
| Ammari, WG | 1 |
| Oriquat, GA | 1 |
| Sanders, M | 1 |
| Woolf, AD | 1 |
| Manzi, SF | 1 |
| Pertzborn, MC | 1 |
| Prabhakaran, S | 1 |
| Abu-Hasan, M | 2 |
| Baker, D | 1 |
| Wu, S | 2 |
| Wu, Y | 2 |
| Hendeles, L | 14 |
| O'Rourke, A | 1 |
| Zimmerman, A | 1 |
| Platt, H | 1 |
| Pappalardo, AA | 2 |
| Moody, GB | 1 |
| Luckett, PM | 1 |
| Shockley, CM | 1 |
| Huang, R | 1 |
| Ari, A | 2 |
| Cockcroft, DW | 24 |
| Davis, BE | 6 |
| Tollefson, G | 1 |
| Yurach Pikaluk, M | 1 |
| Suárez-Medina, R | 1 |
| Venero-Fernández, S | 1 |
| Alvarez-Valdés, V | 1 |
| Sardiñas-Baez, N | 1 |
| Cristina, C | 1 |
| Loinaz-Gonzalez, M | 1 |
| Verdecia-Pérez, Z | 1 |
| Corona-Tamayo, B | 1 |
| Betancourt-López, M | 1 |
| Britton, J | 2 |
| Fogarty, AW | 1 |
| Guezguez, F | 1 |
| Ben Saad, H | 1 |
| Taytard, J | 1 |
| Aupiais, C | 1 |
| Jovien, S | 1 |
| Assouline Kabla, J | 1 |
| Haziot, N | 1 |
| Fuger, M | 1 |
| Alberti, C | 1 |
| Beydon, N | 3 |
| Codispoti, CD | 1 |
| Bandi, S | 1 |
| Patel, P | 1 |
| Mahdavinia, M | 1 |
| Amirav, I | 5 |
| Newhouse, MT | 7 |
| Harding, AM | 1 |
| Taylor, SE | 1 |
| O'Keefe, C | 1 |
| Stone, RG | 1 |
| McDonald, M | 1 |
| Elnazir, B | 1 |
| Tommola, M | 1 |
| Won, HK | 1 |
| Ilmarinen, P | 1 |
| Jung, H | 1 |
| Tuomisto, LE | 1 |
| Lehtimäki, L | 2 |
| Niemelä, O | 1 |
| Kim, TB | 1 |
| Kankaanranta, H | 2 |
| Traynor, K | 1 |
| Gillette, C | 1 |
| Cooney, JW | 1 |
| Sisson, CB | 1 |
| Rockich-Winston, N | 1 |
| Perry, CJ | 1 |
| Ramirez, O | 1 |
| Alvarez, I | 1 |
| Aristizabal-Duque, R | 1 |
| Villamil, M | 1 |
| Hodroge, SS | 1 |
| Glenn, M | 1 |
| Breyre, A | 1 |
| Aldridge, NR | 1 |
| Sporer, KA | 1 |
| Koenig, KL | 1 |
| Gausche-Hill, M | 1 |
| Salvucci, AA | 1 |
| Rudnick, EM | 1 |
| Brown, JF | 1 |
| Gilbert, GH | 1 |
| Higaki, N | 1 |
| Iwamoto, H | 1 |
| Yamaguchi, K | 2 |
| Sakamoto, S | 1 |
| Horimasu, Y | 1 |
| Masuda, T | 1 |
| Miyamoto, S | 1 |
| Nakashima, T | 1 |
| Ohshimo, S | 1 |
| Fujitaka, K | 1 |
| Hamada, H | 1 |
| Hattori, N | 1 |
| Alhammad, AM | 1 |
| Alajmi, G | 1 |
| Alenizi, A | 1 |
| Alrashidi, E | 1 |
| Alghannam, G | 1 |
| Alaki, E | 1 |
| Alsaadi, MM | 1 |
| Mayet, AY | 1 |
| Payares-Salamanca, L | 1 |
| Contreras-Arrieta, S | 1 |
| Florez-García, V | 1 |
| Barrios-Sanjuanelo, A | 1 |
| Stand-Niño, I | 1 |
| Li, S | 2 |
| Mei, Q | 1 |
| Qian, D | 1 |
| Huang, X | 1 |
| Fan, C | 1 |
| Quan, J | 1 |
| Parlar-Chun, R | 1 |
| Truong, G | 1 |
| Isbell, T | 1 |
| Delgado, Y | 1 |
| Arca, M | 1 |
| Schroeder, SK | 1 |
| Samady, W | 1 |
| Kolaitis, IN | 1 |
| Smith, CM | 2 |
| Palac, H | 1 |
| Shreffler, L | 1 |
| Nevin, MA | 1 |
| Hikino, K | 1 |
| Kobayashi, S | 1 |
| Ota, E | 1 |
| Mushiroda, T | 1 |
| Urayama, KY | 1 |
| Kobayashi, T | 1 |
| Bennett, MR | 1 |
| Chang, CL | 2 |
| Tuffery, C | 1 |
| Hopping, S | 1 |
| Hancox, RJ | 11 |
| Murphy, K | 1 |
| Mahmood, N | 1 |
| Craven, D | 1 |
| Gallagher, J | 1 |
| Ross, K | 4 |
| Speicher, R | 1 |
| Rotta, AT | 3 |
| Shein, SL | 1 |
| Ruman-Colombier, M | 1 |
| Rochat Guignard, I | 1 |
| Di Paolo, ER | 1 |
| Gehri, M | 1 |
| Pauchard, JY | 1 |
| Chen, KYH | 1 |
| Lawrence, J | 1 |
| Berry, A | 1 |
| Hiscock, H | 1 |
| Robertson, C | 4 |
| Boddy, CE | 1 |
| Naveed, S | 1 |
| Craner, M | 1 |
| Murphy, AC | 1 |
| Siddiqui, S | 2 |
| Bradding, P | 7 |
| Kan, K | 1 |
| Shaunfield, S | 1 |
| Kanaley, M | 1 |
| Chadha, A | 1 |
| Boon, K | 1 |
| Morales, L | 1 |
| Davis, MM | 1 |
| Vojta, D | 1 |
| Gupta, RS | 1 |
| Schuh, S | 15 |
| Sweeney, J | 2 |
| Rumantir, M | 2 |
| Coates, AL | 3 |
| Willan, AR | 2 |
| Stephens, D | 5 |
| Atenafu, EG | 1 |
| Finkelstein, Y | 2 |
| Thompson, G | 2 |
| Zemek, R | 5 |
| Plint, AC | 3 |
| Gravel, J | 2 |
| Ducharme, FM | 7 |
| Johnson, DW | 6 |
| Black, K | 1 |
| Curtis, S | 2 |
| Beer, D | 2 |
| Klassen, TP | 3 |
| Nicksy, D | 1 |
| Freedman, SB | 2 |
| Cloutier, MM | 2 |
| Krishnan, JA | 2 |
| Lemanske, RF | 27 |
| Pace, W | 1 |
| Schatz, M | 3 |
| Monteverde-Fernandez, N | 1 |
| Diaz-Rubio, F | 1 |
| Vásquez-Hoyos, P | 1 |
| González-Dambrauskas, S | 1 |
| Moore, A | 1 |
| Preece, A | 1 |
| Sharma, R | 4 |
| Heaney, LG | 1 |
| Costello, RW | 1 |
| Ludwig-Sengpiel, A | 1 |
| Mosnaim, G | 1 |
| Rees, J | 3 |
| Tomlinson, R | 1 |
| Tal-Singer, R | 1 |
| Stempel, DA | 17 |
| Barnes, N | 3 |
| Motamed, H | 2 |
| Forouzan, A | 2 |
| Heybar, H | 1 |
| Khorasani, MJ | 1 |
| Hesam, S | 2 |
| Kucher, NM | 1 |
| S Dhaliwal, D | 1 |
| Fischer, GA | 1 |
| Davey, CS | 1 |
| Gupta, S | 3 |
| Clemens, CJ | 1 |
| Stern, DA | 1 |
| Xu, H | 1 |
| Tong, L | 1 |
| Gao, P | 1 |
| Hu, Y | 1 |
| Wang, H | 2 |
| Chen, Z | 1 |
| Fang, L | 1 |
| Saad, HB | 1 |
| Chenuel, B | 1 |
| Guijon, OL | 2 |
| Morphew, T | 4 |
| Ehwerhemuepha, L | 1 |
| Galant, SP | 6 |
| Gates, RM | 2 |
| Haynes, KE | 2 |
| Rehder, KJ | 2 |
| Zimmerman, KO | 2 |
| Miller, AG | 2 |
| Csonka, P | 2 |
| Tapiainen, T | 2 |
| Mäkelä, MJ | 3 |
| Verki, MM | 1 |
| Nematollahi, AV | 1 |
| Nino, G | 2 |
| Hopp, RJ | 2 |
| Wilson, M | 1 |
| Pasha, MA | 2 |
| Gessner, L | 1 |
| Thompson, D | 1 |
| Torres, R | 1 |
| Fu, L | 2 |
| Fankhauser, K | 1 |
| Giebultowicz, S | 1 |
| Cowburn, S | 1 |
| Ducharme, F | 1 |
| Black, KJ | 3 |
| Napolitano, N | 1 |
| Nanda, A | 1 |
| Russell, AF | 1 |
| Bingemann, TA | 1 |
| Pound, CM | 1 |
| Gelt, V | 1 |
| Akiki, S | 1 |
| Eady, K | 1 |
| Moreau, K | 1 |
| Momoli, F | 1 |
| Murchison, B | 1 |
| Mulholland, B | 1 |
| Kovesi, T | 2 |
| Koh, MS | 2 |
| Yii, AC | 1 |
| Ong, YY | 1 |
| Sofianopoulou, E | 2 |
| Pless-Mulloli, T | 2 |
| Rushton, S | 1 |
| Diggle, PJ | 2 |
| Horn, FC | 1 |
| Marshall, H | 1 |
| Collier, GJ | 1 |
| Kay, R | 1 |
| Brightling, CE | 2 |
| Parra-Robles, J | 1 |
| Wild, JM | 1 |
| Steinbacher, M | 1 |
| Pfleger, A | 1 |
| Schwantzer, G | 1 |
| Jauk, S | 1 |
| Weinhandl, E | 1 |
| Eber, E | 2 |
| Pilcher, J | 4 |
| Patel, M | 6 |
| Pritchard, A | 4 |
| Thayabaran, D | 1 |
| Ebmeier, S | 2 |
| Shaw, D | 4 |
| Black, P | 4 |
| Braithwaite, I | 2 |
| Weatherall, M | 14 |
| Wilkinson, M | 2 |
| King, B | 1 |
| Iyer, S | 1 |
| Higginbotham, E | 1 |
| Wallace, A | 1 |
| Hovinga, C | 1 |
| Allen, C | 1 |
| Mukherjee, M | 1 |
| Cingolani, E | 1 |
| Pritchard, DI | 2 |
| Bosquillon, C | 1 |
| Capaldi, DPI | 1 |
| Sheikh, K | 1 |
| Eddy, RL | 1 |
| Guo, F | 1 |
| Svenningsen, S | 3 |
| Nair, P | 2 |
| McCormack, DG | 4 |
| Parraga, G | 4 |
| Helm, ME | 1 |
| Carlson, S | 1 |
| Borrell, LN | 3 |
| Eng, C | 6 |
| Nguyen, M | 1 |
| Thyne, S | 5 |
| LeNoir, MA | 4 |
| Burke-Harris, N | 1 |
| Burchard, EG | 13 |
| Thakur, N | 2 |
| Fischer, J | 1 |
| Ohmer, M | 1 |
| Petersen, M | 1 |
| Liu, Q | 2 |
| Li, Q | 3 |
| Han, T | 1 |
| Hu, T | 1 |
| Hu, J | 1 |
| Hu, H | 1 |
| Tan, W | 2 |
| Cogen, JD | 1 |
| DiBlasi, RM | 2 |
| Gibson, RL | 1 |
| Debley, JS | 1 |
| Zhao, C | 1 |
| Liu, J | 3 |
| Yang, H | 1 |
| Xiang, L | 1 |
| Zhao, S | 1 |
| Knihtilä, H | 1 |
| Kotaniemi-Syrjänen, A | 2 |
| Pelkonen, AS | 2 |
| Kalliola, S | 1 |
| Malmberg, LP | 3 |
| Zook, HG | 1 |
| Payne, NR | 1 |
| Puumala, SE | 1 |
| Ziegler, KM | 1 |
| Kharbanda, AB | 1 |
| Lee, L | 1 |
| Kerwin, E | 4 |
| Collison, K | 1 |
| Nelsen, L | 1 |
| Wu, W | 3 |
| Yang, S | 1 |
| Pascoe, S | 3 |
| Shariff, A | 1 |
| Hillerson, D | 1 |
| Ross, J | 1 |
| Ayala-Pena, E | 1 |
| Posa, D | 1 |
| Pizzulli, A | 1 |
| Wagner, P | 1 |
| Perna, S | 1 |
| Hofmaier, S | 1 |
| Matricardi, PM | 1 |
| Lau, S | 1 |
| Palmsten, K | 1 |
| Hulugalle, A | 1 |
| Bandoli, G | 1 |
| Kuo, GM | 1 |
| Ansari, S | 1 |
| Xu, R | 1 |
| Chambers, CD | 1 |
| Ko, FW | 1 |
| Hui, DS | 1 |
| Tehrany, R | 1 |
| DeVos, R | 1 |
| Bruton, A | 1 |
| Masoumi, K | 1 |
| Delirrooyfard, A | 1 |
| Asgari Darian, A | 1 |
| Mokhtar Gandomani, L | 1 |
| Koskela, HO | 3 |
| Lätti, AM | 1 |
| Purokivi, MK | 3 |
| Gelb, AF | 5 |
| Yamamoto, A | 1 |
| Verbeken, EK | 1 |
| Schein, MJ | 2 |
| Moridzadeh, R | 1 |
| Tran, D | 1 |
| Fraser, C | 2 |
| Barbers, R | 1 |
| Elatre, W | 1 |
| Koss, MN | 1 |
| Glassy, EF | 1 |
| Nadel, JA | 1 |
| Cordell, RL | 1 |
| Valkenburg, TSE | 1 |
| Pandya, HC | 2 |
| Hawcutt, DB | 1 |
| Semple, MG | 1 |
| Monks, PS | 1 |
| Kibirige, D | 1 |
| Kampiire, L | 1 |
| Atuhe, D | 1 |
| Mwebaze, R | 1 |
| Katagira, W | 1 |
| Muttamba, W | 1 |
| Nantanda, R | 1 |
| Worodria, W | 1 |
| Kirenga, B | 1 |
| Morjaria, JB | 1 |
| Rigby, AS | 1 |
| Morice, AH | 2 |
| Strother, J | 1 |
| Burkholder, B | 1 |
| Ozer, M | 1 |
| Buyuktiryaki, B | 2 |
| Sahiner, UM | 3 |
| Teksam, O | 1 |
| Karaatmaca, B | 2 |
| Soyer, O | 2 |
| Sekerel, BE | 3 |
| Jacobson, GA | 5 |
| Raidal, S | 1 |
| Hostrup, M | 1 |
| Wood-Baker, R | 3 |
| Farber, MO | 1 |
| Page, CP | 3 |
| Walters, EH | 23 |
| Suissa, S | 5 |
| Donohue, J | 1 |
| Evans, S | 1 |
| Kemp, J | 2 |
| Pruikkonen, H | 1 |
| Kallio, M | 1 |
| Dunder, T | 1 |
| Pokka, T | 1 |
| Uhari, M | 1 |
| Renko, M | 1 |
| Huang, G | 1 |
| Jin, L | 1 |
| Han, S | 1 |
| Keeley, D | 1 |
| Jackson, DJ | 4 |
| Boehmer, S | 1 |
| Beigelman, A | 2 |
| Chmiel, JF | 4 |
| Gaffin, JM | 2 |
| Morgan, WJ | 8 |
| Peters, SP | 25 |
| Sheehan, WJ | 2 |
| Cabana, MD | 2 |
| Holguin, F | 4 |
| Martinez, FD | 10 |
| Pongracic, JA | 3 |
| Baxi, SN | 2 |
| Benson, M | 2 |
| Blake, K | 6 |
| Covar, R | 5 |
| Gentile, DA | 2 |
| Kumar, HV | 2 |
| Lang, JE | 2 |
| Lazarus, SC | 18 |
| Lima, JJ | 9 |
| Long, D | 1 |
| Ly, N | 3 |
| Marbin, J | 2 |
| Moy, JN | 3 |
| Myers, RE | 2 |
| Olin, JT | 2 |
| Raissy, HH | 3 |
| Robison, RG | 2 |
| Sorkness, CA | 23 |
| Mak, ACY | 1 |
| White, MJ | 1 |
| Eckalbar, WL | 1 |
| Szpiech, ZA | 1 |
| Oh, SS | 3 |
| Hu, D | 2 |
| Goddard, P | 1 |
| Huntsman, S | 2 |
| Galanter, J | 1 |
| Himes, BE | 3 |
| Germer, S | 1 |
| Vogel, JM | 1 |
| Bunting, KL | 1 |
| Salazar, S | 1 |
| Keys, KL | 1 |
| Liberto, J | 1 |
| Nuckton, TJ | 1 |
| Nguyen, TA | 1 |
| Torgerson, DG | 2 |
| Kwok, PY | 1 |
| Levin, AM | 2 |
| Celedón, JC | 2 |
| Forno, E | 2 |
| Hakonarson, H | 1 |
| Sleiman, PM | 1 |
| Dahlin, A | 1 |
| Tantisira, KG | 6 |
| Weiss, ST | 14 |
| Serebrisky, D | 3 |
| Brigino-Buenaventura, E | 3 |
| Farber, HJ | 4 |
| Meade, K | 5 |
| Avila, PC | 9 |
| Sen, S | 3 |
| Thyne, SM | 5 |
| Rodriguez-Cintron, W | 9 |
| Winkler, CA | 1 |
| Moreno-Estrada, A | 2 |
| Sandoval, K | 2 |
| Rodriguez-Santana, JR | 9 |
| Kumar, R | 4 |
| Williams, LK | 4 |
| Ahituv, N | 1 |
| Ziv, E | 2 |
| Seibold, MA | 2 |
| Darnell, RB | 1 |
| Zaitlen, N | 1 |
| Hernandez, RD | 2 |
| Langton, D | 2 |
| Wang, W | 1 |
| Thien, F | 5 |
| Plummer, V | 2 |
| Merkus, PJFM | 1 |
| van Wijngaarden, JMC | 1 |
| Cochius-den Otter, SCM | 1 |
| Barakat, D | 1 |
| Rockers, PC | 1 |
| Vian, T | 1 |
| Onyango, MA | 1 |
| Laing, RO | 1 |
| Wirtz, VJ | 1 |
| Lui, KJ | 2 |
| Snider, MA | 1 |
| Wan, JY | 1 |
| Jacobs, J | 1 |
| Kink, R | 1 |
| Gilmore, B | 1 |
| Arnold, SR | 1 |
| Murayama, N | 2 |
| Murayama, K | 1 |
| Dufetelle, E | 1 |
| Bokov, P | 1 |
| Delclaux, C | 1 |
| Moore, LE | 2 |
| Brotto, AR | 2 |
| Phillips, DB | 1 |
| Bhutani, M | 1 |
| Stickland, MK | 2 |
| Sharif, Z | 1 |
| Al-Alawi, M | 1 |
| Leelathipkul, L | 1 |
| Tanticharoenwiwat, P | 1 |
| Ithiawatchakul, J | 1 |
| Prommin, D | 1 |
| Sirisalee, P | 1 |
| Junhunee, P | 1 |
| Poachanukoon, O | 1 |
| Gallimore, PJ | 1 |
| Davidson, NM | 1 |
| Kalberer, M | 1 |
| Pope, FD | 1 |
| Ward, AD | 1 |
| Zhang, HP | 1 |
| Wang, L | 5 |
| Wang, Z | 1 |
| Xu, XR | 1 |
| Zhou, XM | 1 |
| Liu, G | 1 |
| He, LY | 1 |
| Wang, J | 6 |
| Li, WM | 1 |
| Wang, G | 2 |
| Schissler, AJ | 1 |
| Celli, BR | 1 |
| Nilsen, K | 1 |
| Gove, K | 1 |
| Wilkinson, T | 1 |
| Thompson, BR | 1 |
| Chachi, L | 3 |
| Alzahrani, A | 1 |
| Koziol-White, C | 1 |
| Biddle, M | 1 |
| Bagadood, R | 1 |
| Amrani, Y | 3 |
| Kane, JM | 1 |
| Phillips, M | 1 |
| Sanchez, J | 2 |
| Sánchez, A | 1 |
| Cardona, R | 1 |
| Starczewska-Dymek, L | 1 |
| Bozek, A | 3 |
| Jakalski, M | 1 |
| Szefler, SJ | 29 |
| Hoch, HE | 1 |
| Tuffli, M | 1 |
| Gondalia, R | 1 |
| Barrett, MA | 1 |
| Van Sickle, D | 1 |
| Hanania, NA | 7 |
| Dini, FL | 1 |
| Honmane, S | 1 |
| Hajare, A | 1 |
| More, H | 1 |
| Osmani, RAM | 1 |
| Salunkhe, S | 1 |
| Magee, JS | 1 |
| Pittman, LM | 1 |
| Jette-Kelly, LA | 1 |
| Valenzuela, PL | 1 |
| Santos-Lozano, A | 1 |
| Morales, JS | 1 |
| Drobnic, F | 1 |
| Lucia, A | 1 |
| Ing, A | 1 |
| Sha, J | 1 |
| Bennetts, K | 1 |
| Hersch, N | 1 |
| Kwok, M | 1 |
| Farah, C | 1 |
| Cates, CJ | 15 |
| Schmidt, S | 2 |
| Ferrer, M | 2 |
| Sayer, B | 1 |
| Waterson, S | 1 |
| Kozian, A | 1 |
| Schilling, T | 1 |
| Wang, X | 1 |
| Gonem, S | 1 |
| Cumella, A | 1 |
| Richardson, M | 1 |
| Ibrahim, WH | 1 |
| Rasul, F | 1 |
| Ahmad, M | 1 |
| Bajwa, AS | 1 |
| Alamlih, LI | 1 |
| El Arabi, AM | 1 |
| Al-Mohannadi, D | 1 |
| Siddiqui, MY | 1 |
| Al-Sheikh, IS | 1 |
| Ibrahim, AA | 1 |
| Iramain, R | 2 |
| Jara, A | 1 |
| Cardozo, L | 1 |
| Bogado, N | 2 |
| Morinigo, R | 1 |
| De Jesús, R | 1 |
| Fu, M | 1 |
| Zou, B | 1 |
| An, K | 1 |
| Yu, Y | 1 |
| Tang, D | 1 |
| Wu, J | 2 |
| Xu, Y | 1 |
| Ti, H | 1 |
| Varegg, MS | 1 |
| Kløverød, KM | 1 |
| Austnes, MK | 1 |
| Siwinska, N | 1 |
| Slowikowska, M | 1 |
| Zak, A | 1 |
| Niedzwiedz, A | 1 |
| D'Vaz, N | 1 |
| Okitika, TA | 1 |
| Shackleton, C | 2 |
| Devadason, SG | 8 |
| Hall, GL | 3 |
| Bollinger, ME | 4 |
| Butz, A | 2 |
| Tsoukleris, M | 1 |
| Lewis-Land, C | 2 |
| Mudd, S | 1 |
| Fishe, JN | 1 |
| Palmer, E | 1 |
| Finlay, E | 1 |
| Smotherman, C | 1 |
| Gautam, S | 1 |
| Hendry, P | 1 |
| Rowe, BH | 5 |
| Villa-Roel, C | 1 |
| Krebs, L | 1 |
| Charlier, P | 1 |
| Deo, S | 2 |
| Kluger, N | 1 |
| Katsunuma, T | 1 |
| Fujisawa, T | 2 |
| Maekawa, T | 1 |
| Akashi, K | 1 |
| Ohya, Y | 1 |
| Adachi, Y | 1 |
| Hashimoto, K | 2 |
| Mizuno, M | 1 |
| Imai, T | 1 |
| Oba, MS | 1 |
| Sako, M | 1 |
| Ohashi, Y | 1 |
| Nakamura, H | 5 |
| Giubergia, V | 4 |
| Ramírez Farías, MJ | 1 |
| Pérez, V | 1 |
| Crespi, N | 1 |
| Castaños, C | 3 |
| Allen, H | 1 |
| Backhouse, SH | 1 |
| Hull, JH | 1 |
| Price, OJ | 1 |
| Park, HS | 1 |
| Yoon, D | 1 |
| Lee, HY | 1 |
| Ban, GY | 1 |
| Wan Yau Ming, S | 1 |
| Jie, JLZ | 1 |
| Carter, V | 1 |
| Hardjojo, A | 1 |
| Van Boven, JFM | 1 |
| Price, DB | 4 |
| Heath, TS | 1 |
| Bartlett, KW | 1 |
| McLean, HS | 1 |
| Ravi, A | 1 |
| Chowdhury, S | 1 |
| Dijkhuis, A | 1 |
| Bonta, PI | 1 |
| Sterk, PJ | 12 |
| Lutter, R | 5 |
| Holliday, M | 1 |
| Harrison, T | 1 |
| Houghton, C | 1 |
| Oldfield, K | 1 |
| Pavord, ID | 9 |
| Williams, M | 5 |
| Geier, ET | 1 |
| Theilmann, RJ | 1 |
| Prisk, GK | 1 |
| Sá, RC | 1 |
| Bairam, AF | 1 |
| Rasool, MI | 1 |
| Alherz, FA | 1 |
| Abunnaja, MS | 1 |
| El Daibani, AA | 1 |
| Gohal, SA | 1 |
| Alatwi, ES | 1 |
| Kurogi, K | 1 |
| Liu, MC | 3 |
| Bjermer, L | 7 |
| Abbott-Banner, K | 1 |
| Newman, K | 1 |
| Janson, C | 5 |
| Malinovschi, A | 1 |
| Amaral, AFS | 1 |
| Accordini, S | 1 |
| Bousquet, J | 27 |
| Buist, AS | 3 |
| Canonica, GW | 4 |
| Dahlén, B | 2 |
| Garcia-Aymerich, J | 1 |
| Gnatiuc, L | 1 |
| Kowalski, ML | 1 |
| Patel, J | 1 |
| Torén, K | 1 |
| Zuberbier, T | 1 |
| Burney, P | 1 |
| Jarvis, D | 1 |
| Kahveci, M | 1 |
| Arık Yılmaz, E | 1 |
| Esenboğa, S | 1 |
| Gür Çetinkaya, P | 1 |
| Jabbal, S | 3 |
| Kapoor, K | 1 |
| Byers, BW | 1 |
| Ghods-Esfahani, D | 1 |
| Henry, SL | 1 |
| St James, RB | 1 |
| Ming, M | 1 |
| Li, C | 2 |
| Luo, Z | 1 |
| Lv, S | 1 |
| Domingo, C | 1 |
| Ahmed, S | 1 |
| Sutradhar, SR | 2 |
| Miah, AH | 1 |
| Bari, MA | 1 |
| Hasan, MJ | 1 |
| Alam, MK | 1 |
| Tariquzzaman, M | 1 |
| Sarker, CN | 1 |
| Liu, D | 1 |
| Yi, HL | 1 |
| Guo, C | 1 |
| Chen, M | 2 |
| Li, WK | 1 |
| Char, DS | 1 |
| Ibsen, LM | 1 |
| Ramamoorthy, C | 1 |
| Bratton, SL | 1 |
| Hill-Taylor, BJ | 1 |
| Hurley, KF | 2 |
| Sketris, I | 2 |
| O'Connell, C | 1 |
| Sinclair, D | 1 |
| Wing, A | 1 |
| Yim, RP | 1 |
| Koumbourlis, AC | 1 |
| van Noord, JA | 5 |
| Brindicci, C | 2 |
| Lindemann, L | 3 |
| Varoli, G | 1 |
| Perpiña, M | 1 |
| Guastalla, D | 1 |
| Casula, D | 1 |
| Patel, S | 2 |
| Chanez, P | 10 |
| Jaeschke, R | 2 |
| Eeftinck Schattenkerk, JK | 1 |
| Lager, PS | 1 |
| Gravina, L | 1 |
| Chertkoff, L | 2 |
| Serra, HA | 1 |
| Klapouszko, FP | 1 |
| De Salvo, MC | 1 |
| Bavasso, EC | 1 |
| Rey, L | 1 |
| Downey, D | 1 |
| Lopez, D | 1 |
| Roganovich, JM | 1 |
| Rizzo, LF | 1 |
| Akamatsu, T | 2 |
| Shirai, T | 2 |
| Kato, M | 2 |
| Yasui, H | 2 |
| Hashimoto, D | 2 |
| Tsuchiya, T | 1 |
| Inui, N | 2 |
| Suda, T | 3 |
| Chida, K | 4 |
| Kirby, M | 2 |
| Starr, D | 1 |
| Leary, D | 1 |
| Wheatley, A | 1 |
| Maksym, GN | 2 |
| Yang, Z | 3 |
| Lu, A | 1 |
| Wong, BC | 2 |
| Chen, X | 2 |
| Bian, Z | 1 |
| Zhao, Z | 1 |
| Huang, W | 2 |
| Zhang, G | 4 |
| Xu, M | 3 |
| Giuliano, JS | 1 |
| Faustino, EV | 1 |
| Pinto, MG | 1 |
| Canarie, MF | 1 |
| Carroll, CL | 4 |
| Coleman, M | 1 |
| DiSantostefano, RL | 4 |
| Yeakey, AM | 2 |
| Raphiou, I | 1 |
| Nuijsink, M | 2 |
| Hop, WC | 9 |
| Jongste, JC | 1 |
| Duiverman, AE | 1 |
| Barker, D | 1 |
| Chin, H | 1 |
| Hossain, AS | 1 |
| Barua, UK | 1 |
| Roy, GC | 1 |
| Rahman, I | 1 |
| Rahman, G | 1 |
| Via, M | 3 |
| Tcheurekdjian, H | 4 |
| González Burchard, E | 1 |
| Popov, TA | 2 |
| Petrova, D | 1 |
| Kralimarkova, TZ | 1 |
| Ivanov, Y | 1 |
| Popova, T | 1 |
| Peneva, M | 1 |
| Odzhakova, T | 1 |
| Ilieva, Y | 1 |
| Yakovliev, P | 1 |
| Lazarova, T | 1 |
| Georgiev, O | 1 |
| Hodzhev, V | 1 |
| Hodzheva, E | 1 |
| Staevska, MT | 1 |
| Dimitrov, VD | 1 |
| Lin, Q | 1 |
| Liu, QH | 1 |
| Bao, YX | 1 |
| Anderson, WJ | 2 |
| Short, PM | 3 |
| Williamson, PA | 5 |
| Morrison, AE | 1 |
| Palmer, C | 2 |
| Tavendale, R | 3 |
| Molina, RO | 1 |
| Cáceres, M | 1 |
| Recabarren, A | 1 |
| Lötvall, J | 19 |
| O'Byrne, PM | 15 |
| Bateman, ED | 18 |
| Medley, H | 1 |
| Ellsworth, A | 3 |
| Jacques, L | 7 |
| Gedeit, RG | 1 |
| Paggiaro, P | 11 |
| Nicolini, G | 8 |
| Pradelli, L | 1 |
| Zaniolo, O | 1 |
| Currie, GP | 16 |
| Small, I | 2 |
| Douglas, G | 1 |
| Bel, EH | 3 |
| Pencharz, D | 1 |
| Quigley, AM | 1 |
| Hall, M | 1 |
| Wagner, TL | 1 |
| García-Falcón, D | 1 |
| Lawrence, KK | 1 |
| Prendes-Columbié, MC | 1 |
| Lewis, LM | 3 |
| Ferguson, I | 3 |
| House, SL | 3 |
| Aubuchon, K | 2 |
| Schneider, J | 2 |
| Johnson, K | 4 |
| Matsuda, K | 3 |
| Matsumoto, K | 3 |
| Aizawa, H | 3 |
| Fukuyama, S | 2 |
| Yoshida, M | 2 |
| Komori, M | 2 |
| Takata, S | 1 |
| Koto, H | 1 |
| Inoue, H | 2 |
| Drake, KA | 1 |
| Gignoux, CR | 1 |
| Galanter, JM | 1 |
| Roth, LA | 1 |
| Yee, SW | 1 |
| Lin, L | 1 |
| Bustamante, CD | 1 |
| Davis, A | 2 |
| Chapela, R | 6 |
| Ford, JG | 4 |
| Lurmann, F | 1 |
| Giacomini, KM | 1 |
| Snowise, NG | 1 |
| Clements, D | 1 |
| Ho, SY | 3 |
| Follows, RM | 2 |
| Schauer, SG | 1 |
| Cuenca, PJ | 1 |
| Johnson, JJ | 1 |
| Ramirez, S | 1 |
| Levy, ML | 1 |
| Hardwell, A | 1 |
| McKnight, E | 1 |
| Holmes, J | 1 |
| Gálffy, G | 2 |
| Mezei, G | 1 |
| Németh, G | 1 |
| Tamási, L | 3 |
| Müller, V | 2 |
| Selroos, O | 8 |
| Orosz, M | 2 |
| Vichyanond, P | 4 |
| Veskitkul, J | 1 |
| Rienmanee, N | 1 |
| Pacharn, P | 1 |
| Jirapongsananuruk, O | 1 |
| Visitsunthorn, N | 1 |
| Daley-Yates, PT | 2 |
| Mehta, R | 3 |
| Chan, RH | 1 |
| Despa, SX | 1 |
| Louey, MD | 1 |
| Corin, A | 1 |
| Helm, C | 1 |
| Tofield, C | 1 |
| Kosoglou, T | 1 |
| Hubbell, J | 1 |
| Cutler, DL | 1 |
| Johnson-Levonas, AO | 1 |
| Kantesaria, BS | 1 |
| Kim, K | 1 |
| Miller, SD | 2 |
| Wu, XH | 1 |
| Cai, C | 1 |
| Xu, JP | 1 |
| Ru, CH | 1 |
| He, F | 1 |
| Rabinovitch, N | 6 |
| Reisdorph, N | 1 |
| Malka, J | 2 |
| Zeiger, RS | 12 |
| Kunselman, SJ | 6 |
| Icitovic, N | 3 |
| Pascual, R | 2 |
| Ameredes, BT | 6 |
| Boushey, HA | 14 |
| Calhoun, WJ | 10 |
| Cherniack, RM | 4 |
| Craig, T | 2 |
| Denlinger, LC | 4 |
| Engle, LL | 2 |
| Dimango, EA | 2 |
| Kraft, M | 14 |
| Lugogo, N | 2 |
| Martin, RJ | 14 |
| Meyers, DA | 8 |
| Ramsdell, J | 5 |
| Sutherland, ER | 6 |
| Wasserman, SI | 5 |
| Walter, MJ | 3 |
| Chinchilli, VM | 18 |
| Koch, S | 2 |
| MacInnis, MJ | 1 |
| Sporer, BC | 1 |
| Rupert, JL | 1 |
| Koehle, MS | 2 |
| Thomson, NC | 13 |
| Niven, RM | 1 |
| Corris, PA | 3 |
| Chung, KF | 9 |
| Cox, G | 2 |
| Armstrong, B | 1 |
| Shargill, NS | 1 |
| Laviolette, M | 6 |
| Babar, ZU | 1 |
| Lessing, C | 1 |
| Mace, C | 1 |
| Bissell, K | 1 |
| Chang, TS | 1 |
| Gangnon, RE | 1 |
| Page, CD | 1 |
| Price, D | 5 |
| Haughney, J | 1 |
| Ryan, D | 1 |
| Gruffydd-Jones, K | 1 |
| Lavorini, F | 4 |
| Harris, T | 2 |
| Burden, A | 2 |
| Brockman, J | 1 |
| King, C | 1 |
| FitzPatrick, M | 1 |
| Donovan, C | 1 |
| Rushton, SP | 1 |
| Corradi, M | 2 |
| Pigeon-Francisco, C | 1 |
| Baronio, R | 2 |
| Siergiejko, Z | 4 |
| Petruzzelli, S | 2 |
| Fabbri, LM | 9 |
| Rabe, KF | 8 |
| Sun, YX | 1 |
| Gong, CH | 1 |
| Liu, S | 1 |
| Yuan, XP | 1 |
| Yin, LJ | 1 |
| Yan, L | 1 |
| Shi, TT | 1 |
| Dai, JH | 1 |
| Morales, DR | 2 |
| Petreschi, F | 1 |
| Ullmann, N | 1 |
| Bottero, S | 1 |
| Tomà, P | 1 |
| Inserra, A | 1 |
| Francalanci, P | 1 |
| Zicari, AM | 1 |
| Cutrera, R | 4 |
| Moustafa, F | 1 |
| Garrouste, C | 1 |
| Bertrand, PM | 1 |
| Kauffmann, S | 1 |
| Schmidt, J | 1 |
| Grzelewski, T | 2 |
| Majak, P | 1 |
| Jerzyńska, J | 2 |
| Stelmach, W | 2 |
| Stelmach, R | 2 |
| Janas, A | 1 |
| Grzelewska, A | 1 |
| Witkowski, K | 1 |
| Makandjou-Ola, E | 1 |
| Stelmach, I | 2 |
| Hozawa, S | 2 |
| Terada, M | 2 |
| Hozawa, M | 2 |
| Rodrigo, GJ | 10 |
| Senthilkumaran, S | 1 |
| Shah, S | 1 |
| Menezes, RG | 1 |
| Thirumalaikolundusubramanian, P | 1 |
| Powell, C | 1 |
| Kolamunnage-Dona, R | 1 |
| Lowe, J | 1 |
| Boland, A | 1 |
| Petrou, S | 1 |
| Doull, I | 2 |
| Hood, K | 1 |
| Williamson, P | 1 |
| Chang, KC | 1 |
| Wieland, LS | 2 |
| Oleszczuk, M | 2 |
| Kew, KM | 1 |
| Tashkin, DP | 9 |
| Trudo, F | 1 |
| Zangrilli, JG | 2 |
| Hojo, M | 1 |
| Iikura, M | 1 |
| Hirashima, J | 1 |
| Suzuki, M | 1 |
| Sugiyama, H | 2 |
| Coro, M | 1 |
| Cowl, A | 1 |
| Sala, KA | 1 |
| Schramm, CM | 3 |
| Ioan, I | 2 |
| Coutier, L | 2 |
| Bonabel, C | 2 |
| Demoulin, B | 4 |
| Marchal, F | 5 |
| Schweitzer, C | 4 |
| Varechova, S | 2 |
| El-Khatib, MF | 1 |
| Jamaleddine, G | 1 |
| Kanj, N | 1 |
| Zeineddine, S | 1 |
| Chami, H | 1 |
| Bou-Akl, I | 1 |
| Husari, A | 1 |
| Alawieh, M | 1 |
| Bou-Khalil, P | 1 |
| Yatera, K | 1 |
| Yamasaki, K | 1 |
| Nishida, C | 1 |
| Noguchi, S | 1 |
| Oda, K | 1 |
| Akata, K | 1 |
| Nagata, S | 1 |
| Kawanami, Y | 1 |
| Kawanami, T | 1 |
| Ishimoto, H | 1 |
| Mukae, H | 1 |
| Cossette, B | 1 |
| Beauchesne, MF | 2 |
| Forget, A | 2 |
| Lemière, C | 2 |
| Larivée, P | 1 |
| Rey, E | 1 |
| Blais, L | 4 |
| Ismaila, A | 1 |
| Corriveau, D | 2 |
| Vaillancourt, J | 1 |
| Parsons, D | 1 |
| Stanford, R | 3 |
| Su, Z | 2 |
| Sampalis, JS | 1 |
| Itoga, NK | 1 |
| Kinoshita, CK | 1 |
| Masutani, SM | 1 |
| Yamamoto, LG | 3 |
| Konno, S | 1 |
| Hizawa, N | 3 |
| Makita, H | 1 |
| Shimizu, K | 1 |
| Sakamoto, T | 2 |
| Kokubu, F | 3 |
| Saito, T | 1 |
| Endo, T | 1 |
| Ninomiya, H | 1 |
| Iijima, H | 1 |
| Kaneko, N | 1 |
| Ito, YM | 1 |
| Nishimura, M | 3 |
| Yee, KC | 1 |
| Tsuchida, T | 1 |
| Matsuse, H | 3 |
| Gross, N | 1 |
| Greos, LS | 3 |
| Meltzer, EO | 8 |
| Spangenthal, S | 1 |
| Fishman, RS | 1 |
| Spyker, DA | 1 |
| Cassella, JV | 1 |
| Maneechotesuwan, K | 2 |
| Assawabhumi, J | 1 |
| Rattanasaengloet, K | 1 |
| Suthamsmai, T | 1 |
| Pipopsuthipaiboon, S | 1 |
| Udompunturak, S | 1 |
| Sliwiński, P | 1 |
| Chazan, R | 9 |
| Dąbrowiecki, P | 1 |
| Jahnz-Różyk, K | 1 |
| Mróz, R | 1 |
| Pirożyński, M | 1 |
| Spahn, JD | 5 |
| Strunk, RC | 11 |
| Yeh, FC | 1 |
| Chiang, WF | 1 |
| Wang, CC | 1 |
| Lin, SH | 1 |
| Pelham, A | 1 |
| Claret, PG | 1 |
| Bobbia, X | 1 |
| de La Coussaye, JE | 1 |
| Smith, A | 4 |
| Davies, C | 1 |
| Travers, J | 2 |
| Harwood, M | 3 |
| Toler, WT | 1 |
| Goldfrad, C | 3 |
| Wang, Y | 8 |
| Wells, KE | 1 |
| Padhukasahasram, B | 1 |
| Yang, JJ | 1 |
| Starkey, ES | 1 |
| Mulla, H | 1 |
| Sammons, HM | 1 |
| Hallberg, CJ | 1 |
| Lysaught, MT | 1 |
| Najarro, RA | 1 |
| Cea Gil, F | 1 |
| Villatoro, C | 1 |
| Diaz de Uriarte, AC | 1 |
| Olson, LE | 1 |
| Radhakrishna, N | 1 |
| Hew, M | 1 |
| Wyatt, EL | 1 |
| Borland, ML | 1 |
| Doyle, SK | 1 |
| Geelhoed, GC | 4 |
| Pellegrino, R | 4 |
| Antonelli, A | 1 |
| Crimi, E | 4 |
| Gulotta, C | 1 |
| Torchio, R | 1 |
| Dutto, L | 1 |
| Pedersen, OF | 5 |
| Brusasco, V | 8 |
| Ditcham, W | 1 |
| Murdzoska, J | 1 |
| Roller, C | 1 |
| von Hollen, D | 1 |
| Nikander, K | 1 |
| Foster, JM | 2 |
| Usherwood, T | 2 |
| Smith, L | 2 |
| Sawyer, SM | 2 |
| Xuan, W | 1 |
| Rand, CS | 3 |
| Mehra, R | 1 |
| Schneider, JE | 1 |
| Zwitserloot, A | 1 |
| Fuchs, SI | 1 |
| Müller, C | 1 |
| Bisdorf, K | 1 |
| Gappa, M | 2 |
| Kamps, AW | 2 |
| Veeger, NJ | 1 |
| Heijsman, SM | 1 |
| Ismaila, AS | 1 |
| Risebrough, N | 1 |
| Hawkins, N | 2 |
| FitzGerald, JM | 6 |
| Rodriguez, E | 1 |
| Barthold, JS | 1 |
| Kreiger, PA | 1 |
| Armani, MH | 1 |
| Michelini, KA | 1 |
| Wolfson, MR | 1 |
| Boyce, R | 1 |
| Barone, CA | 1 |
| Zhu, Y | 1 |
| Waldman, SA | 1 |
| Shaffer, TH | 1 |
| Beier, J | 3 |
| Fuhr, R | 2 |
| Massana, E | 1 |
| Jiménez, E | 1 |
| Seoane, B | 1 |
| de Miquel, G | 1 |
| Ruiz, S | 1 |
| Morris, I | 1 |
| Lyttle, MD | 1 |
| O'Sullivan, R | 1 |
| Sargant, N | 1 |
| Doull, IJ | 2 |
| Powell, CV | 2 |
| Tagaya, E | 1 |
| Kondo, M | 1 |
| Kirishi, S | 1 |
| Kawagoe, M | 1 |
| Kubota, N | 1 |
| Tamaoki, J | 1 |
| Albrecht, J | 1 |
| Devillier, P | 2 |
| Salvator, H | 1 |
| Grassin-Delyle, S | 1 |
| Naline, E | 1 |
| Advenier, C | 1 |
| Roche, N | 2 |
| Mehta, N | 1 |
| Aggarwal, B | 1 |
| Gogtay, J | 2 |
| Abdool-Gaffar, S | 1 |
| Desai, AG | 1 |
| Togias, A | 5 |
| Schechter, C | 1 |
| Fisher, B | 1 |
| Parow, A | 1 |
| Skloot, G | 1 |
| Shahane, G | 1 |
| Parsania, C | 1 |
| Sengupta, D | 1 |
| Joshi, M | 1 |
| Erokhina, IL | 1 |
| Voronchikhin, PA | 1 |
| Okovityĭ, SV | 1 |
| Emel'ianova, OI | 1 |
| Golden, C | 1 |
| Estrada, CM | 1 |
| Bandaru, S | 3 |
| Tiwari, G | 1 |
| Akka, J | 3 |
| Marri, VK | 3 |
| Alvala, M | 2 |
| Gutlapalli, VR | 1 |
| Nayarisseri, A | 2 |
| Mundluru, HP | 3 |
| Neame, M | 1 |
| Aragon, O | 1 |
| Fernandes, RM | 1 |
| Sinha, I | 1 |
| Mendes, ES | 3 |
| Cadet, L | 1 |
| Arana, J | 1 |
| Wanner, A | 7 |
| Neininger, MP | 1 |
| Kaune, A | 1 |
| Bertsche, A | 1 |
| Rink, J | 1 |
| Musiol, J | 1 |
| Frontini, R | 1 |
| Prenzel, F | 1 |
| Kiess, W | 1 |
| Bertsche, T | 1 |
| Alansari, K | 1 |
| Ahmed, W | 1 |
| Davidson, BL | 1 |
| Alamri, M | 1 |
| Zakaria, I | 1 |
| Alrifaai, M | 1 |
| Dissanayake, SB | 1 |
| Visser, R | 2 |
| van der Palen, J | 2 |
| de Jongh, FH | 2 |
| Thio, BJ | 2 |
| Wisecup, S | 1 |
| Eades, S | 1 |
| Hashmi, SS | 1 |
| Samuels, C | 1 |
| Mosquera, RA | 1 |
| McGarry, ME | 1 |
| Castellanos, E | 1 |
| Bibbins-Domingo, K | 1 |
| Fingleton, J | 1 |
| Charles, T | 1 |
| Bowles, D | 1 |
| Strik, R | 1 |
| Shirtcliffe, P | 1 |
| Ahn, JR | 1 |
| Blake, LK | 1 |
| Silverstone, E | 1 |
| Yates, DH | 5 |
| Redberg, RF | 2 |
| Ross, JS | 1 |
| Jena, AB | 1 |
| Ho, O | 1 |
| Goldman, DP | 1 |
| Karaca-Mandic, P | 1 |
| Maggini, V | 1 |
| Lombardi, N | 1 |
| Lenti, MC | 1 |
| Masi, S | 1 |
| Trapani, S | 1 |
| Pugi, A | 1 |
| Mugelli, A | 1 |
| Vannacci, A | 1 |
| Cochius-den Otter, SC | 1 |
| Joosten, KF | 2 |
| Buysse, CM | 1 |
| Shah, NJ | 1 |
| Vinod Kumar, S | 1 |
| Gurusamy, U | 1 |
| Annan Sudarsan, AK | 1 |
| Shewade, DG | 1 |
| Quirce, S | 1 |
| Domínguez-Ortega, J | 1 |
| Barranco, P | 1 |
| Brunetti, L | 2 |
| Poiani, G | 1 |
| Dhanaliwala, F | 1 |
| Poppiti, K | 1 |
| Kang, H | 1 |
| Suh, DC | 1 |
| Hartman, S | 1 |
| Merkus, P | 1 |
| Maseland, M | 1 |
| Roovers, L | 1 |
| van Setten, P | 1 |
| Anwar, MM | 1 |
| El-Haggar, RS | 1 |
| Zaghary, WA | 1 |
| Ponnala, D | 1 |
| Zhao, H | 1 |
| Li, R | 1 |
| Lv, Y | 1 |
| Dong, H | 1 |
| Yao, L | 1 |
| Xiao, G | 1 |
| Cai, S | 1 |
| Stephen, D | 1 |
| Vatsa, M | 1 |
| Lodha, R | 9 |
| Townsend, L | 1 |
| Madlon-Kay, DJ | 1 |
| O'Reilly, DA | 1 |
| Awale, A | 1 |
| Cartledge, P | 1 |
| de Boer, AH | 2 |
| Gjaltema, D | 1 |
| Hagedoorn, P | 2 |
| Frijlink, HW | 2 |
| Brehm, JM | 1 |
| Man Tse, S | 1 |
| Croteau-Chonka, DC | 1 |
| Litonjua, AA | 4 |
| Raby, BA | 2 |
| Chen, W | 1 |
| Yan, Q | 1 |
| Boutaoui, N | 1 |
| Acosta-Pérez, E | 1 |
| Avila, L | 1 |
| Soto-Quiros, M | 1 |
| Spear, ML | 1 |
| Kolls, JK | 1 |
| Canino, G | 1 |
| Kelderman, S | 1 |
| Füeßl, HS | 1 |
| Breuer, O | 1 |
| Shoseyov, D | 1 |
| Kerem, E | 4 |
| Brooks, R | 2 |
| Eke Gungor, H | 1 |
| Altuner Torun, Y | 1 |
| Batmaz, SB | 1 |
| Kuyucu, S | 1 |
| Arıkoglu, T | 1 |
| Tezol, O | 1 |
| Aydogdu, A | 1 |
| Raphael, G | 1 |
| Taveras, H | 6 |
| Iverson, H | 6 |
| O'Brien, C | 1 |
| Miller, D | 1 |
| Ledochowski, S | 1 |
| Mohkam, K | 1 |
| Rague, P | 1 |
| Glehen, O | 1 |
| Friggeri, A | 1 |
| Yin, LM | 1 |
| Fan, L | 1 |
| Xu, YD | 1 |
| Wang, WQ | 1 |
| Liu, YY | 1 |
| Feng, JT | 1 |
| Hu, CP | 1 |
| Wang, PY | 1 |
| Zhang, TF | 2 |
| Shao, SJ | 1 |
| Yang, YQ | 1 |
| Perez, T | 1 |
| Dusser, D | 1 |
| Yawn, BP | 3 |
| Fuhlbrigge, AL | 3 |
| Pace, WD | 1 |
| Pencina, MJ | 1 |
| Doros, G | 1 |
| Kazani, S | 2 |
| Lanzillotti, J | 1 |
| Madison, S | 1 |
| Swenson, ER | 2 |
| Kerwin, EM | 2 |
| Wayne, D | 1 |
| Shah, T | 5 |
| Lepore, MS | 1 |
| Miller, DS | 1 |
| Chauhan, BF | 1 |
| Chartrand, C | 1 |
| Ni Chroinin, M | 3 |
| Milan, SJ | 2 |
| Zha, N | 1 |
| Pike, D | 1 |
| Capaldi, DP | 1 |
| Knight, JM | 1 |
| Mak, G | 1 |
| Shaw, J | 1 |
| Porter, P | 1 |
| McDermott, C | 1 |
| Roberts, L | 1 |
| You, R | 1 |
| Millien, VO | 1 |
| Qian, Y | 1 |
| Song, LZ | 1 |
| Frazier, V | 1 |
| Kim, C | 1 |
| Kim, JJ | 1 |
| Bond, RA | 2 |
| Milner, JD | 1 |
| Zhang, Y | 4 |
| Mandal, PK | 1 |
| Luong, A | 1 |
| Kheradmand, F | 1 |
| McMurray, JS | 1 |
| Corry, DB | 1 |
| Lewis, RJ | 1 |
| Newby, C | 1 |
| Pillard, F | 1 |
| Lavit, M | 1 |
| Cances, VL | 1 |
| Rami, J | 1 |
| Houin, G | 1 |
| Didier, A | 2 |
| Rivière, D | 1 |
| Cheng, QJ | 1 |
| Huang, SG | 1 |
| Chen, YZ | 1 |
| Lin, JT | 1 |
| Zhou, X | 3 |
| Chen, BY | 2 |
| Feng, YL | 2 |
| Ling, X | 1 |
| Sears, MR | 18 |
| Heffler, E | 2 |
| Crimi, C | 1 |
| Campisi, R | 1 |
| Sichili, S | 1 |
| Nicolosi, G | 1 |
| Porto, M | 1 |
| Intravaia, R | 1 |
| Sberna, ME | 1 |
| Liuzzo, MT | 1 |
| Crimi, N | 6 |
| Given, J | 2 |
| Kováts, Z | 1 |
| Odler, B | 1 |
| Snyder, A | 1 |
| Disney, J | 1 |
| Thomas, A | 1 |
| Wilcox, G | 1 |
| Brown, MA | 1 |
| Manoharan, A | 2 |
| Lipworth, J | 2 |
| Anderson, W | 1 |
| Short, P | 1 |
| Holt, S | 4 |
| Şen, E | 1 |
| Oğuzülgen, K | 1 |
| Bavbek, S | 1 |
| Günen, H | 2 |
| Kıyan, E | 1 |
| Türktaş, H | 2 |
| Yorgancıoğlu, A | 1 |
| Polatlı, M | 1 |
| Yıldız, F | 1 |
| Çelik, G | 1 |
| Demir, T | 1 |
| Mungan, D | 2 |
| Saryal, S | 1 |
| Sayıner, A | 1 |
| Yıldırım, N | 1 |
| Memon, BN | 1 |
| Parkash, A | 1 |
| Ahmed Khan, KM | 1 |
| Gowa, MA | 1 |
| Bai, C | 2 |
| Yu, H | 1 |
| Tan, X | 1 |
| Zhang, P | 1 |
| Fang, Z | 2 |
| Wang, C | 1 |
| He, X | 1 |
| Ricciardolo, FL | 1 |
| Rindone, E | 1 |
| Schiavetti, I | 1 |
| Ciprandi, G | 3 |
| Sahi, PK | 1 |
| Shastri, S | 1 |
| Gupta, N | 1 |
| Pandey, RM | 3 |
| Kabra, M | 1 |
| Craig, S | 1 |
| Tuszynski, M | 1 |
| Armstrong, D | 1 |
| Andrzejowski, P | 1 |
| Carroll, W | 1 |
| Brown, RH | 2 |
| Eisenstein, EM | 1 |
| Phillips, JE | 1 |
| Renteria, L | 1 |
| Burns, L | 1 |
| Harris, P | 1 |
| Peng, R | 1 |
| Bauer, CM | 1 |
| Laine, D | 1 |
| Stevenson, CS | 1 |
| Virchow, JC | 4 |
| Backer, V | 7 |
| Kuna, P | 3 |
| Prieto, L | 5 |
| Nolte, H | 1 |
| Villesen, HH | 1 |
| Ljørring, C | 1 |
| Riis, B | 1 |
| de Blay, F | 1 |
| Singanayagam, A | 1 |
| Johnston, SL | 3 |
| Fagbuyi, DB | 1 |
| Venkataraman, S | 2 |
| Ralphe, JC | 1 |
| Zuckerbraun, NS | 1 |
| Pitetti, RD | 1 |
| Lin, Y | 1 |
| Jeong, K | 1 |
| Saladino, RA | 1 |
| Manole, MD | 1 |
| Donohue, JF | 4 |
| Wise, R | 1 |
| Garfinkel, S | 1 |
| Zubek, VB | 1 |
| Ghafouri, M | 1 |
| Manuel, RC | 1 |
| Schlenker-Herceg, R | 1 |
| Fawcett, JP | 4 |
| Isaac, BT | 1 |
| McLellan, T | 1 |
| Samuel, J | 1 |
| Yung, B | 1 |
| Souza, JM | 1 |
| Torres, HC | 1 |
| De Lalibera, IB | 1 |
| de Souza, AV | 1 |
| Rodrigues, JC | 2 |
| Schvartsman, C | 1 |
| da Silva Filho, LV | 1 |
| Czövek, D | 1 |
| Hantos, Z | 1 |
| Taylor, K | 2 |
| Kumar, A | 1 |
| Chacko, A | 1 |
| Ware, RS | 1 |
| Makan, G | 1 |
| Radics, B | 1 |
| Gingl, Z | 1 |
| Sly, PD | 6 |
| Rajaure, Y | 1 |
| Kumar, B | 1 |
| Sahoo, K | 1 |
| T, V | 1 |
| Shaw, N | 1 |
| Le Souëf, P | 1 |
| Turkovic, L | 1 |
| McCahon, L | 1 |
| Kicic, A | 1 |
| Devadason, S | 1 |
| Schultz, A | 2 |
| Fattore, E | 1 |
| Davoli, E | 1 |
| Castiglioni, S | 1 |
| Bosetti, C | 1 |
| Re Depaolini, A | 1 |
| Marzona, I | 1 |
| Zuccato, E | 1 |
| Fanelli, R | 1 |
| Sarhan, HA | 1 |
| El-Garhy, OH | 1 |
| Ali, MA | 1 |
| Youssef, NA | 1 |
| Du, H | 1 |
| Shi, Y | 1 |
| Yu, J | 1 |
| Sun, W | 1 |
| Delate, T | 1 |
| Rader, N | 1 |
| Jenkins, DW | 1 |
| Lowe, R | 1 |
| Welch, MJ | 5 |
| Vilozni, D | 1 |
| Hakim, F | 1 |
| Livnat, G | 1 |
| Ofek, M | 1 |
| Bar-Yoseph, R | 1 |
| Bentur, L | 4 |
| Tarigopula, P | 1 |
| Kattamuri, RK | 1 |
| Mangalarapu, M | 1 |
| Vinukonda, S | 1 |
| Sagurthi, SR | 1 |
| Spin, P | 1 |
| Hill-Taylor, B | 1 |
| Ward, C | 7 |
| Ratnayake, A | 1 |
| Shore, P | 3 |
| Phillips, BR | 2 |
| Bhakta, NR | 1 |
| Cardet, JC | 1 |
| Aujla, S | 1 |
| Comhair, SA | 1 |
| Coverstone, A | 1 |
| DeBoer, M | 1 |
| Erzurum, SC | 2 |
| Fain, SB | 1 |
| Fajt, M | 1 |
| Gaffin, J | 1 |
| Gaston, B | 1 |
| Hastie, AT | 3 |
| Hawkins, GA | 4 |
| Irani, AM | 1 |
| Levy, BD | 1 |
| Myers, R | 1 |
| Opina, MT | 1 |
| Peters, MC | 1 |
| Schiebler, ML | 1 |
| Sorkness, RL | 3 |
| Woodruff, PG | 1 |
| Bush, A | 3 |
| Frey, U | 4 |
| He, M | 2 |
| Driehuys, B | 1 |
| Que, LG | 2 |
| Huang, YT | 1 |
| Pascoe, SJ | 2 |
| Wilsdon, T | 1 |
| Kichenadasse, G | 1 |
| Rowland, A | 1 |
| Hasegawa, T | 2 |
| Uno, H | 1 |
| Wei, LJ | 1 |
| Weinberger, M | 8 |
| Qaqundah, PY | 2 |
| Yuan, J | 1 |
| Lu, ZK | 1 |
| Love, BL | 1 |
| Schulz, RM | 1 |
| Hall, AB | 1 |
| Novotny, A | 1 |
| Bhisitkul, DM | 2 |
| Melton, J | 1 |
| Regan, T | 1 |
| Leckie, M | 1 |
| Adams, CD | 1 |
| Strand, M | 3 |
| Koehler, K | 1 |
| Volckens, J | 1 |
| Quan-Jun, Y | 1 |
| Jian-Ping, Z | 1 |
| Jian-Hua, Z | 1 |
| Yong-Long, H | 1 |
| Bo, X | 1 |
| Jing-Xian, Z | 1 |
| Bona, D | 1 |
| Yuan, Z | 1 |
| Cheng, G | 1 |
| Parsa, SA | 1 |
| Khaheshi, I | 1 |
| Memaryan, M | 1 |
| Naderian, M | 1 |
| Boehmer, SJ | 6 |
| Paul, IM | 2 |
| Daines, CL | 1 |
| Daines, MO | 1 |
| Gower, WA | 1 |
| Morgan, W | 2 |
| Sallam, NM | 1 |
| Sanad, RA | 1 |
| Kharshoom, RM | 1 |
| Zeneldin, MA | 1 |
| Mudd, SS | 1 |
| Ogborn, CJ | 2 |
| Kub, J | 1 |
| Bellin, MH | 1 |
| Khwaja, YH | 1 |
| Tai, JM | 1 |
| Fung, V | 1 |
| Li, L | 1 |
| Butler, MG | 1 |
| Nordin, JD | 1 |
| Hsu, J | 1 |
| Smith, D | 1 |
| Vollmer, WM | 2 |
| Lieu, TA | 2 |
| Soumerai, SB | 1 |
| Comaru, T | 1 |
| Pitrez, PM | 1 |
| Friedrich, FO | 1 |
| Silveira, VD | 1 |
| Pinto, LA | 2 |
| Chen, P | 1 |
| Dai, A | 1 |
| Shang, S | 1 |
| Kong, L | 2 |
| Nieto, A | 1 |
| Mazón, Á | 1 |
| Nieto, M | 1 |
| Ramazan-Yousif, L | 1 |
| Albertsen, S | 1 |
| Bergmann, TK | 1 |
| Madsen, PH | 1 |
| Steen, NP | 1 |
| Chauhan, B | 1 |
| LaForce, C | 5 |
| Delstanche, S | 1 |
| Servais, L | 1 |
| Gidaro, T | 1 |
| Kirkland, SW | 1 |
| Vandenberghe, C | 1 |
| Voaklander, B | 1 |
| Nikel, T | 1 |
| Campbell, S | 1 |
| Biswas, R | 1 |
| Sabharwal, A | 1 |
| Kola, M | 1 |
| Hacıoğlu, D | 1 |
| Erdöl, H | 1 |
| Türk, A | 1 |
| Dilts, JJ | 1 |
| Humiston, SG | 1 |
| Lee, BR | 1 |
| Allen, NH | 1 |
| Michael, JG | 1 |
| Navanandan, N | 1 |
| Federico, M | 1 |
| Mistry, RD | 1 |
| Mathew, JL | 2 |
| Walia, M | 1 |
| O' Kane, R | 1 |
| Green, RH | 1 |
| Miller, E | 1 |
| Weiss, KB | 1 |
| Bateman, E | 1 |
| Nelson, H | 4 |
| Kral, K | 2 |
| Sutton, L | 1 |
| Ortega, H | 2 |
| Yancey, S | 6 |
| Dachs, R | 1 |
| Darby-Stewart, A | 1 |
| Graber, MA | 1 |
| Caruso, JF | 1 |
| Hamill, JL | 1 |
| Yamauchi, M | 1 |
| Saito, K | 1 |
| Cook, TD | 1 |
| Mercado, DR | 1 |
| Gharagozlou, M | 1 |
| Abdollahpour, H | 1 |
| Moinfar, Z | 1 |
| Bemanian, MH | 1 |
| Sedaghat, M | 1 |
| Fujimura, M | 4 |
| Moon, H | 1 |
| Choi, HH | 1 |
| Lee, JY | 3 |
| Moon, HJ | 1 |
| Sim, SS | 2 |
| Kim, CJ | 3 |
| Al Obaidi, AH | 1 |
| Al Samarai, AM | 1 |
| Madabushi, R | 1 |
| Derendorf, H | 2 |
| Lima, J | 1 |
| Clark, TJ | 18 |
| Gul, N | 3 |
| Gibbs, M | 1 |
| Pedersen, S | 9 |
| Naqvi, M | 2 |
| DeBoard, JA | 1 |
| Navarro, D | 2 |
| Castro, RA | 3 |
| Watson, HG | 2 |
| LeNoir, M | 2 |
| Choudhry, S | 4 |
| Davis, KJ | 2 |
| Crim, C | 6 |
| Godard, P | 7 |
| Greillier, P | 1 |
| Pigearias, B | 1 |
| Nachbaur, G | 2 |
| Desfougeres, JL | 9 |
| Attali, V | 3 |
| Sposato, B | 1 |
| Mariotta, S | 2 |
| Ricci, A | 1 |
| Ciubotaru, RL | 1 |
| Noe, L | 1 |
| Pasta, DJ | 1 |
| Schaefer, K | 3 |
| Claus, R | 3 |
| Andrews, WT | 1 |
| Roach, J | 1 |
| Lasserson, TJ | 12 |
| Ferrara, G | 2 |
| Casali, L | 6 |
| Cates, MJ | 3 |
| Gold, DR | 1 |
| Zolli, JR | 1 |
| Makaryus, AN | 1 |
| Macleod, KA | 1 |
| Horsley, AR | 1 |
| Bell, NJ | 1 |
| Greening, AP | 3 |
| Innes, JA | 1 |
| Cunningham, S | 1 |
| Campbell, JD | 1 |
| Borish, L | 1 |
| Haselkorn, T | 1 |
| Rasouliyan, L | 2 |
| Lee, JH | 2 |
| Sullivan, SD | 1 |
| Tripp, K | 3 |
| McVicar, WK | 2 |
| Pleskow, WW | 2 |
| Goodwin, E | 2 |
| Baumgartner, RA | 7 |
| Hanrahan, JP | 5 |
| Duplessis, CA | 1 |
| Gumpert, B | 1 |
| Cooper, PR | 1 |
| Chang, C | 2 |
| Wang, XH | 1 |
| Yao, WZ | 1 |
| Liu, XF | 1 |
| Hang, YJ | 1 |
| Boonsarngsuk, V | 2 |
| Pipopchaiyasit, N | 1 |
| Kiatboonsri, S | 2 |
| Aballéa, S | 1 |
| Cure, S | 1 |
| Vogelmeier, C | 7 |
| Wirén, A | 1 |
| Maspero, J | 2 |
| Guerra, F | 1 |
| Cuevas, F | 1 |
| Gutierrez, JP | 1 |
| Soto-Ramos, M | 1 |
| Anderton, S | 2 |
| Mechali, D | 1 |
| Stanford, RH | 13 |
| Fuhlbrigge, A | 1 |
| Riedel, A | 1 |
| Rey, GG | 1 |
| Lowe, DO | 1 |
| Lummis, H | 1 |
| Sketris, IS | 1 |
| Wijesinghe, M | 3 |
| Perrin, K | 4 |
| Koenig, SM | 3 |
| Ostrom, N | 1 |
| Pearlman, D | 2 |
| Waitkus-Edwards, K | 1 |
| Prillaman, BA | 1 |
| Dorinsky, P | 16 |
| Taussig, LM | 6 |
| Guilbert, T | 1 |
| Krawiec, M | 1 |
| Larsen, G | 3 |
| Huchon, G | 1 |
| Magnussen, H | 13 |
| Chuchalin, A | 4 |
| Dymek, L | 1 |
| Gonod, FB | 1 |
| Qian, Z | 2 |
| Lin, HM | 2 |
| Lehman, EB | 2 |
| Stewart, WF | 1 |
| Shah, N | 1 |
| Duan, Y | 2 |
| Craig, TJ | 7 |
| Wilson, WE | 2 |
| Liao, D | 2 |
| Bascom, R | 2 |
| Covar, RA | 4 |
| Moss, M | 1 |
| Patel, AC | 1 |
| Van Natta, ML | 1 |
| Tonascia, J | 1 |
| Friedman, H | 1 |
| Wilcox, T | 1 |
| Reardon, G | 2 |
| Crespi, S | 2 |
| Butt, AT | 1 |
| Kamat, D | 1 |
| Pansare, M | 1 |
| Moral, VP | 1 |
| Marcos, LG | 1 |
| Stoltz, P | 1 |
| Zucker, AR | 1 |
| Jung, KS | 1 |
| Uh, ST | 1 |
| Lee, YC | 1 |
| Shim, JJ | 1 |
| Park, SK | 1 |
| Williams, AE | 2 |
| Uspal, NG | 1 |
| Agrawal, D | 1 |
| Lundbäck, B | 10 |
| Rönmark, E | 3 |
| Lindberg, A | 3 |
| Jonsson, AC | 2 |
| Larsson, LG | 2 |
| James, M | 3 |
| Miyagawa, T | 3 |
| Nibhanipudi, K | 1 |
| Hassen, GW | 1 |
| Dell'Aniello, S | 1 |
| Ernst, P | 7 |
| Larsen, GL | 2 |
| Heldt, GP | 1 |
| Martinez, F | 1 |
| Radford, S | 1 |
| Pillmann, F | 1 |
| Choudhary, AS | 1 |
| Robinson, GM | 1 |
| Dhuper, S | 3 |
| Chandra, A | 3 |
| Ahmed, A | 2 |
| Bista, S | 1 |
| Moghekar, A | 1 |
| Verma, R | 1 |
| Chong, C | 1 |
| Shim, C | 4 |
| Cohen, H | 2 |
| Choksi, S | 2 |
| Foliaki, S | 1 |
| Fakakovikaetau, T | 1 |
| D'Souza, W | 1 |
| Latu, S | 1 |
| Tutone, V | 1 |
| Cheng, S | 1 |
| Pearce, N | 9 |
| Hackshaw, A | 1 |
| Djukanovic, R | 8 |
| Lindmark, B | 1 |
| Clearie, K | 1 |
| Chhabra, R | 1 |
| Maheshwari, P | 1 |
| Kardos, P | 4 |
| Awab, A | 1 |
| Alilou, M | 1 |
| El Moussaoui, R | 1 |
| El Hijri, A | 1 |
| Azzouzi, A | 1 |
| Derom, E | 2 |
| Tiesler, C | 1 |
| Engelstätter, R | 1 |
| Kaufman, JM | 1 |
| Joos, GF | 1 |
| Watanabe, N | 1 |
| Makino, S | 4 |
| Kihara, N | 1 |
| Fukuda, T | 4 |
| Stavreska, V | 1 |
| Verheggen, M | 1 |
| Oostryck, J | 1 |
| Stick, SM | 1 |
| Korn, D | 1 |
| Van den Brande, P | 1 |
| Potvin, E | 1 |
| Dramaix, M | 1 |
| Herbots, E | 1 |
| Peché, R | 1 |
| Shi, L | 2 |
| Guadarrama, A | 1 |
| Schell, K | 1 |
| Green, D | 1 |
| Morrin, A | 1 |
| Hogan, K | 1 |
| Gern, JE | 1 |
| Peters, M | 1 |
| Lommatzsch, M | 1 |
| Lindner, Y | 1 |
| Edner, A | 1 |
| Bratke, K | 1 |
| Kuepper, M | 1 |
| de Blic, J | 5 |
| Ogorodova, L | 1 |
| Klink, R | 1 |
| Sidorenko, I | 1 |
| Valiulis, A | 1 |
| Hofman, J | 2 |
| Bennedbaek, O | 1 |
| Poterre, M | 1 |
| Miller, DP | 1 |
| Tom, G | 1 |
| Chipps, B | 3 |
| Yilmaz, O | 1 |
| Sogut, A | 1 |
| Kose, U | 1 |
| Sakinci, O | 1 |
| Yuksel, H | 3 |
| Lochindarat, S | 1 |
| Qazi, SA | 1 |
| Bunnag, T | 1 |
| Nisar, YB | 1 |
| Jatanachai, P | 1 |
| Vangveeravong, M | 2 |
| Bloomberg, GR | 4 |
| Banister, C | 1 |
| Sterkel, R | 1 |
| Epstein, J | 2 |
| Bruns, J | 1 |
| Swerczek, L | 1 |
| Wells, S | 1 |
| Yan, Y | 1 |
| Garbutt, JM | 2 |
| Sundram, F | 1 |
| Notghi, A | 1 |
| Smith, NB | 1 |
| Yancey, SW | 21 |
| Klotsman, M | 2 |
| Ortega, HG | 7 |
| Edwards, LD | 5 |
| Anderson, WH | 5 |
| Richter, DC | 1 |
| Joubert, JR | 4 |
| Nell, H | 1 |
| Schuurmans, MM | 1 |
| Irusen, EM | 1 |
| Parkins, DA | 1 |
| Thomas, MJ | 1 |
| Gillett, B | 1 |
| House, KW | 2 |
| Hernández-Cadena, L | 1 |
| Barraza-Villarreal, A | 1 |
| Del Río-Navarro, BE | 2 |
| Sienra-Monge, JJ | 2 |
| Romieu, I | 1 |
| Ferrua, S | 1 |
| Varbella, F | 1 |
| Conte, MR | 1 |
| Delgado, C | 1 |
| Spinka, C | 1 |
| DeClue, AE | 1 |
| Dhand, R | 2 |
| Naimi, DR | 1 |
| Freedman, TG | 1 |
| Ginsburg, KR | 1 |
| Bogen, D | 1 |
| Apter, AJ | 5 |
| Munnik, P | 1 |
| Wissink, J | 1 |
| Heskamp, I | 1 |
| de Kruijf, W | 1 |
| van Rijn, CJ | 1 |
| Zanen, P | 4 |
| Edin, HM | 1 |
| Andersen, LB | 1 |
| Schoaf, L | 4 |
| Scott-Wilson, CA | 2 |
| Borgström, L | 2 |
| Ingelf, J | 1 |
| Fritscher, L | 1 |
| Chapman, KR | 16 |
| Hoshino, M | 1 |
| Handa, H | 1 |
| Miyazawa, T | 1 |
| Andrews, T | 1 |
| McGintee, E | 1 |
| Mittal, MK | 1 |
| Tyler, L | 1 |
| Chew, A | 2 |
| Pawlowski, N | 1 |
| Zorc, JJ | 3 |
| Taylor, CF | 3 |
| Simmons, M | 1 |
| Shinar, C | 1 |
| Ukena, D | 4 |
| González Jiménez, D | 1 |
| Concha Torre, A | 1 |
| Menéndez Cuervo, S | 1 |
| García Hernández, I | 1 |
| McGowan, B | 1 |
| Bennett, K | 1 |
| Barry, M | 1 |
| Owens, M | 1 |
| O'Connor, M | 1 |
| Moore, PE | 3 |
| Ryckman, KK | 1 |
| Williams, SM | 1 |
| Patel, N | 2 |
| Summar, ML | 1 |
| Sheller, JR | 2 |
| Cayley, WE | 1 |
| El-Gendy, NA | 1 |
| Sabry, NA | 1 |
| El-Attar, M | 1 |
| Omar, E | 1 |
| Mahmoud, M | 1 |
| Friedman, HS | 3 |
| Eid, NS | 1 |
| Wilcox, TK | 1 |
| Milanese, M | 3 |
| Saporiti, R | 1 |
| Bartolini, S | 1 |
| Baroffio, M | 2 |
| Freiner, D | 1 |
| Highstein, GR | 1 |
| Nelson, KA | 2 |
| Smith, SR | 2 |
| Greenstone, I | 2 |
| Gruchalla, RS | 1 |
| Sampson, HA | 2 |
| Matsui, E | 1 |
| David, G | 1 |
| Gergen, PJ | 2 |
| Calatroni, A | 2 |
| Brown, M | 1 |
| Liu, AH | 3 |
| Lamm, C | 1 |
| Smartt, E | 1 |
| Steinbach, SF | 1 |
| Stone, KD | 2 |
| Kercsmar, CM | 3 |
| Di Corcia, D | 1 |
| Morra, V | 1 |
| Pazzi, M | 1 |
| Vincenti, M | 1 |
| Berger, WE | 9 |
| Veiga, J | 1 |
| Lopes, AJ | 1 |
| Jansen, JM | 1 |
| de Melo, PL | 1 |
| Holley, AD | 1 |
| Boots, RJ | 1 |
| Schneider, CR | 1 |
| Everett, AW | 1 |
| Geelhoed, E | 1 |
| Kendall, PA | 1 |
| Clifford, RM | 1 |
| Erickson, E | 1 |
| Sivasankar, M | 1 |
| Kurosaka, F | 1 |
| Nishio, H | 1 |
| Rohan, J | 2 |
| Drotar, D | 2 |
| McNally, K | 1 |
| Schluchter, M | 2 |
| Riekert, K | 1 |
| Vavrek, P | 2 |
| Schmidt, A | 3 |
| Redline, S | 2 |
| Kercsmar, C | 2 |
| Page, C | 1 |
| McKeage, K | 1 |
| Keam, SJ | 1 |
| Carroll, WD | 1 |
| Jones, PW | 1 |
| Boit, P | 1 |
| Clayton, S | 1 |
| Cliff, I | 1 |
| Lenney, W | 16 |
| Aumiller, J | 1 |
| Baraldi, E | 3 |
| Boner, AL | 9 |
| Rossi, GA | 3 |
| Basu, K | 2 |
| Palmer, CN | 3 |
| Mukhopadhyay, S | 4 |
| Tilemann, L | 1 |
| Gindner, L | 1 |
| Meyer, FJ | 1 |
| Laux, G | 1 |
| Szecsenyi, J | 2 |
| Schneider, A | 2 |
| Navaratnam, P | 1 |
| Urdaneta, E | 1 |
| Zachgo, W | 1 |
| von Berg, A | 5 |
| Kamin, W | 2 |
| Stern-Sträter, C | 1 |
| Steinkamp, G | 3 |
| Ridley-Smith, RM | 1 |
| Hussain-Rizvi, A | 1 |
| Kunkov, S | 1 |
| Crain, EF | 2 |
| Cruse, G | 1 |
| Yang, W | 1 |
| Duffy, SM | 1 |
| Leyland, M | 1 |
| Vandeleur, M | 1 |
| Chróinín, MN | 1 |
| Gordon, E | 1 |
| Fernández, A | 2 |
| Guardia, S | 2 |
| González, A | 2 |
| Serrano, R | 1 |
| Rodenstein, D | 3 |
| Sala, H | 2 |
| McNally, KA | 1 |
| Riekert, KA | 1 |
| Spahn, J | 1 |
| Sheth, K | 3 |
| Yeh, WS | 1 |
| Nelson, HS | 20 |
| Emmett, AH | 8 |
| Papiris, SA | 1 |
| Manali, ED | 1 |
| Kolilekas, L | 1 |
| Triantafillidou, C | 1 |
| Tsangaris, I | 1 |
| Elers, J | 3 |
| Pedersen, L | 3 |
| Henninge, J | 3 |
| Lund, TK | 1 |
| Hemmersbach, P | 3 |
| Dalhoff, K | 3 |
| Bleecker, E | 2 |
| Denlinger, L | 3 |
| Jarjour, N | 2 |
| Kim, S | 1 |
| Markezich, A | 1 |
| Permaul, P | 1 |
| Spier, S | 4 |
| Bérubé, D | 2 |
| Carr, S | 1 |
| Watson, W | 1 |
| McIvor, RA | 3 |
| Virchow, C | 1 |
| Renzi, PM | 1 |
| Howard, LA | 1 |
| Ahmad, FF | 1 |
| Pérez-de-Llano, LA | 1 |
| Carballada, F | 1 |
| Castro Añón, O | 1 |
| Pizarro, M | 1 |
| Golpe, R | 1 |
| Baloira, A | 1 |
| Vázquez Caruncho, M | 1 |
| Boquete, M | 1 |
| Punj, A | 1 |
| Prakash, A | 1 |
| Bhasin, A | 1 |
| Pinto Pereira, LM | 3 |
| Boodoo, S | 1 |
| Dindial, KA | 1 |
| Hosein, A | 1 |
| Seemungal, TA | 1 |
| Bekele, I | 1 |
| Park, HY | 1 |
| Lim, SY | 1 |
| Park, HK | 1 |
| Park, SY | 1 |
| Kim, TS | 1 |
| Suh, GY | 1 |
| Puckett, JL | 1 |
| Taylor, RW | 2 |
| Leu, SY | 1 |
| Aledia, AS | 1 |
| George, SC | 2 |
| Camargo, CA | 5 |
| Boulet, LP | 19 |
| Ferro, TJ | 1 |
| Menzella, F | 1 |
| Facciolongo, N | 1 |
| Castagnetti, C | 1 |
| Simonazzi, A | 1 |
| Zucchi, L | 1 |
| Frois, C | 1 |
| Wu, EQ | 1 |
| Ray, S | 1 |
| Colice, GL | 9 |
| Scichilone, N | 2 |
| Battaglia, S | 1 |
| Sorino, C | 1 |
| Paglino, G | 1 |
| Martino, L | 1 |
| Paternò, A | 1 |
| Santagata, R | 1 |
| Spatafora, M | 1 |
| Bellia, V | 3 |
| Di Berardino, F | 1 |
| Forti, S | 1 |
| Piatti, G | 1 |
| Fasano, V | 1 |
| Cross, KP | 2 |
| Randell, KA | 1 |
| Herr, SM | 1 |
| VanHaitsma, TA | 1 |
| Mickleborough, T | 1 |
| Stager, JM | 1 |
| Koceja, DM | 1 |
| Lindley, MR | 2 |
| Chapman, R | 1 |
| Xu, J | 2 |
| Nave, R | 1 |
| Lahu, G | 1 |
| Burgess, SW | 1 |
| O'Connor, RD | 6 |
| Patrick, DL | 1 |
| Parasuraman, B | 2 |
| Martin, P | 3 |
| Goldman, M | 4 |
| Wiwanitkit, V | 1 |
| Riesenfeld, EP | 3 |
| Sullivan, MJ | 2 |
| Thompson-Figueroa, JA | 1 |
| Haverkamp, HC | 1 |
| Lundblad, LK | 3 |
| Bates, JH | 3 |
| Singh, S | 1 |
| Soni, R | 1 |
| Rawat, MK | 1 |
| Deshpande, SB | 2 |
| Singh, SK | 2 |
| Muthu, MS | 1 |
| Rotta, ET | 1 |
| Amantéa, SL | 1 |
| Froehlich, PE | 1 |
| Becker, A | 2 |
| von Mutius, E | 1 |
| Drazen, JM | 14 |
| Moss, MH | 2 |
| Prazma, CM | 1 |
| Kral, KM | 2 |
| Yang, Y | 2 |
| Shi, Q | 1 |
| Li, RJ | 1 |
| Pan, PW | 1 |
| Hou, YY | 1 |
| Lu, WG | 1 |
| Bai, G | 1 |
| Hoffmann, HJ | 1 |
| Nielsen, LP | 2 |
| Harving, H | 2 |
| Heinig, JH | 1 |
| Dahl, R | 10 |
| Ulrik, CS | 3 |
| Claudius, BK | 1 |
| Tamm, M | 2 |
| Siersted, HC | 1 |
| Hellquist, B | 1 |
| Høgholm, A | 1 |
| Jøhnk, IK | 1 |
| Vu, LT | 1 |
| Nguyen, MT | 1 |
| Nguyen, YT | 2 |
| Ortega, HA | 1 |
| Liu, L | 2 |
| Kim, SO | 1 |
| Kumar, G | 1 |
| Stamler, JS | 1 |
| Tohda, Y | 1 |
| Nishima, S | 2 |
| Arakawa, I | 2 |
| Shiragami, M | 2 |
| Miyamoto, T | 1 |
| Hu, A | 1 |
| Grunstein, JS | 1 |
| Grunstein, MM | 1 |
| Ahmad, Z | 1 |
| Kumar, P | 1 |
| Parashette, KR | 1 |
| Noronha, P | 1 |
| Holden, NS | 1 |
| Rider, CF | 1 |
| Bell, MJ | 1 |
| Velayudhan, J | 1 |
| King, EM | 1 |
| Kaur, M | 1 |
| Salmon, M | 1 |
| Giembycz, MA | 3 |
| Newton, R | 1 |
| Gibson, PG | 8 |
| Peters, MJ | 3 |
| Wark, PA | 2 |
| Sand, IB | 1 |
| Hoyos, CM | 1 |
| Jenkins, CR | 2 |
| Kovacevic, A | 1 |
| Schwahn, B | 1 |
| Schuster, A | 2 |
| Stallaert, R | 1 |
| Reznikova, E | 1 |
| Bloemen, P | 1 |
| Adamek, L | 1 |
| Joos, G | 1 |
| Gross, CA | 1 |
| Bowler, RP | 1 |
| Green, RM | 1 |
| Weinberger, AR | 1 |
| Schnell, C | 1 |
| Chu, HW | 1 |
| Aalbers, R | 14 |
| Boorsma, M | 3 |
| van der Woude, HJ | 7 |
| Jonkers, RE | 3 |
| Yamaguchi, T | 1 |
| Soma, T | 1 |
| Takaku, Y | 1 |
| Nakagome, K | 1 |
| Hagiwara, K | 1 |
| Kanazawa, M | 2 |
| Nagata, M | 2 |
| Hirst, C | 1 |
| Calingaert, B | 1 |
| Castellsague, J | 3 |
| Bianchi, M | 1 |
| Clavenna, A | 1 |
| Bonati, M | 1 |
| Berdel, D | 4 |
| Buhl, R | 6 |
| Criée, CP | 1 |
| Freihorst, J | 1 |
| Gillissen, A | 3 |
| Karg, O | 1 |
| Pfeifer, M | 1 |
| Teschler, H | 1 |
| Welte, T | 3 |
| Wettengel, R | 4 |
| Worth, H | 2 |
| Andrade, WC | 1 |
| Camargos, P | 3 |
| Lasmar, L | 1 |
| Liao, MM | 1 |
| Ginde, AA | 1 |
| Clark, S | 2 |
| Fogel, RB | 1 |
| Rosario, N | 1 |
| Aristizabal, G | 1 |
| Loeys, T | 1 |
| Noonan, G | 1 |
| Gaile, S | 1 |
| Smugar, SS | 1 |
| Polos, PG | 3 |
| Mele, L | 1 |
| Calogero, C | 1 |
| Bernardini, R | 1 |
| Novembre, E | 1 |
| Azzari, C | 1 |
| de Martino, M | 1 |
| Lombardi, E | 1 |
| Sugihara, N | 1 |
| Kanada, S | 1 |
| Haida, M | 1 |
| Ichinose, M | 2 |
| Adachi, M | 7 |
| Hosoe, M | 1 |
| Emery, C | 1 |
| Higgins, M | 1 |
| Kramer, B | 1 |
| Vaessen-Verberne, AA | 1 |
| van den Berg, NJ | 2 |
| van Nierop, JC | 1 |
| Brackel, HJ | 2 |
| Gerrits, GP | 1 |
| Duiverman, EJ | 12 |
| Silkoff, PE | 2 |
| Krishnan, A | 1 |
| Shinar, CM | 2 |
| Maginot, T | 1 |
| Turner, DL | 1 |
| Ferrari, N | 1 |
| Ford, WR | 1 |
| Kidd, EJ | 1 |
| Paquet, L | 1 |
| Renzi, P | 1 |
| Broadley, KJ | 2 |
| Harada, M | 1 |
| Hirota, T | 1 |
| Jodo, AI | 1 |
| Hitomi, Y | 1 |
| Sakashita, M | 1 |
| Tsunoda, T | 1 |
| Doi, S | 2 |
| Kameda, M | 2 |
| Fujita, K | 1 |
| Miyatake, A | 2 |
| Enomoto, T | 1 |
| Noguchi, E | 2 |
| Masuko, H | 1 |
| Suzuki, Y | 2 |
| Yoshihara, S | 1 |
| Ebisawa, M | 1 |
| Saito, H | 2 |
| Nakajima, T | 1 |
| Mathias, RA | 1 |
| Rafaels, N | 1 |
| Barnes, KC | 1 |
| Duan, QL | 2 |
| Nakamura, Y | 1 |
| Ziegler, SF | 1 |
| Tamari, M | 1 |
| Krakowiak, J | 1 |
| Crompton, GK | 22 |
| Pisarik, P | 1 |
| Kim, TD | 1 |
| Lee, JG | 1 |
| Whang, WK | 1 |
| Zemek, RL | 1 |
| Chalut, D | 2 |
| McGillivray, D | 2 |
| Noya, FJ | 1 |
| Resendes, S | 1 |
| Khomenko, L | 1 |
| Rouleau, R | 2 |
| De Giacomo, A | 1 |
| Corvol, H | 2 |
| Welsh, EJ | 1 |
| Qazi, K | 1 |
| Altamimi, SA | 1 |
| Tamim, H | 1 |
| Serrano, K | 1 |
| Fogli, S | 1 |
| Pellegrini, S | 1 |
| Adinolfi, B | 1 |
| Mariotti, V | 1 |
| Melissari, E | 1 |
| Betti, L | 1 |
| Fabbrini, L | 1 |
| Giannaccini, G | 1 |
| Lucacchini, A | 1 |
| Bardelli, C | 1 |
| Stefanelli, F | 2 |
| Brunelleschi, S | 1 |
| Breschi, MC | 1 |
| Harrison, J | 1 |
| Gibson, AM | 1 |
| Singh, G | 1 |
| Skoric, B | 1 |
| Ranganathan, S | 1 |
| Jayakrishnan, B | 1 |
| Al-Rawas, OA | 1 |
| Gaume, BR | 1 |
| Klanderman, B | 1 |
| Liggett, SB | 3 |
| Mannava, B | 1 |
| Franklin, AE | 1 |
| Garner, WJ | 1 |
| Dickey, BF | 3 |
| Knobil, K | 2 |
| Cydulka, RK | 8 |
| Emerman, CL | 8 |
| Muni, A | 1 |
| Hamilton, N | 1 |
| Beckert, L | 3 |
| de Matas, M | 3 |
| Shao, Q | 2 |
| Biddiscombe, MF | 6 |
| Meah, S | 1 |
| Chrystyn, H | 6 |
| Usmani, OS | 6 |
| Reszka, KJ | 1 |
| Sallans, L | 1 |
| Macha, S | 1 |
| Brown, K | 1 |
| McGraw, DW | 1 |
| Kovacic, MB | 1 |
| Britigan, BE | 1 |
| Kazani, SD | 1 |
| Curfman, GD | 1 |
| Morrissey, S | 1 |
| Krajewska, J | 1 |
| Jarzab, J | 2 |
| Mishra, RK | 1 |
| Radhi, S | 1 |
| Nugent, KM | 1 |
| Brillet, PY | 1 |
| Capderou, A | 1 |
| Becquemin, MH | 1 |
| Beigelman-Aubry, C | 1 |
| Fetita, CI | 1 |
| Similowski, T | 1 |
| Zelter, M | 1 |
| Grenier, PA | 1 |
| Le Souëf, TJ | 1 |
| Venter, A | 1 |
| Le Souëf, PN | 2 |
| Sellers, WF | 3 |
| Ahmad, I | 1 |
| Bathke, PS | 1 |
| Brown, CJ | 1 |
| Fernandez, T | 1 |
| Barker, A | 1 |
| Postma, DS | 12 |
| Asamoto, H | 1 |
| Boucher, A | 1 |
| Payen, C | 1 |
| Garayt, C | 1 |
| Ibanez, H | 1 |
| Dieny, A | 1 |
| Doche, C | 1 |
| Chuniaud, C | 1 |
| Descotes, J | 1 |
| Chen, R | 3 |
| Xiong, J | 1 |
| Yi, F | 1 |
| Chi, Z | 1 |
| Zhang, B | 1 |
| Vora, C | 1 |
| Renvall, MJ | 1 |
| Chao, P | 1 |
| Ferguson, P | 1 |
| Ramsdell, JW | 4 |
| Deesomchok, A | 1 |
| Webb, KA | 1 |
| Forkert, L | 2 |
| Lam, YM | 1 |
| Ofir, D | 1 |
| Jensen, D | 1 |
| O'Donnell, DE | 2 |
| Riedel, AA | 2 |
| Johnson, JC | 1 |
| Astry, CL | 1 |
| Zedan, M | 1 |
| Settin, A | 1 |
| El-Chennawi, F | 1 |
| El-Desouky, T | 1 |
| Nasef, N | 1 |
| Fouda, A | 1 |
| Liang, C | 1 |
| Yang, K | 1 |
| Bulloch, B | 1 |
| Garcia-Filion, P | 1 |
| Keahey, L | 1 |
| Abramo, TJ | 1 |
| Ozier, A | 1 |
| Girodet, PO | 1 |
| Bara, I | 1 |
| Tunon de Lara, JM | 1 |
| Marthan, R | 2 |
| Berger, P | 1 |
| Miller, DR | 1 |
| Chetty, M | 1 |
| Matsuda, S | 1 |
| Shikada, M | 1 |
| Sakai, T | 1 |
| Nakano, T | 2 |
| Oh, Y | 1 |
| Lam, KP | 1 |
| Chu, YT | 1 |
| Lee, MS | 1 |
| Chen, HN | 1 |
| Wang, WL | 1 |
| Tok, TS | 1 |
| Chin, YY | 1 |
| Chen, SC | 1 |
| Kuo, CH | 1 |
| Hung, CH | 2 |
| Checkley, W | 1 |
| Bade, E | 1 |
| Friedman, NJ | 1 |
| Heidarian-Raissy, H | 1 |
| Kelly, HW | 7 |
| Malka-Rais, J | 1 |
| Mellon, MH | 2 |
| Taussig, L | 1 |
| López-Herce, J | 1 |
| Coronel, J | 1 |
| Spitters, C | 1 |
| Guggiari, J | 1 |
| Sabato, K | 1 |
| Ward, P | 1 |
| Hawk, W | 1 |
| Gildengorin, V | 1 |
| Asselin, JM | 1 |
| Guo, JJ | 1 |
| Tsai, K | 1 |
| Kelton, CM | 1 |
| Bian, B | 1 |
| Wigle, PR | 1 |
| Leemans, J | 2 |
| Kirschvink, N | 2 |
| Clercx, C | 2 |
| Snaps, F | 2 |
| Gustin, P | 2 |
| Casarosa, P | 1 |
| Kollak, I | 1 |
| Kiechle, T | 1 |
| Ostermann, A | 1 |
| Schnapp, A | 1 |
| Kiesling, R | 1 |
| Pieper, M | 1 |
| Sieger, P | 1 |
| Gantner, F | 1 |
| Kurashima, K | 1 |
| Kagiyama, N | 1 |
| Takayanagi, N | 1 |
| Sugita, Y | 1 |
| Halterman, JS | 1 |
| Szilagyi, PG | 1 |
| Fisher, SG | 1 |
| Fagnano, M | 1 |
| Tremblay, P | 1 |
| Conn, KM | 1 |
| Borrelli, B | 1 |
| Rinaldi, LM | 1 |
| Poynter, ME | 1 |
| Wu, M | 2 |
| Aimi, S | 1 |
| Barone, LM | 1 |
| Bar-Yishay, E | 1 |
| Avital, A | 3 |
| Springer, C | 2 |
| Meah, SN | 1 |
| Underwood, SR | 3 |
| Doan, Q | 1 |
| Shefrin, A | 1 |
| Johnson, D | 3 |
| Polat, TB | 1 |
| Saz, EU | 1 |
| Nursoy, MA | 1 |
| Araújo, L | 1 |
| Moreira, A | 1 |
| Palmares, C | 1 |
| Beltrão, M | 1 |
| Fonseca, J | 1 |
| Delgado, L | 2 |
| Direkwatanachai, C | 1 |
| Teeratakulpisarn, J | 1 |
| Suntornlohanakul, S | 1 |
| Trakultivakorn, M | 1 |
| Ngamphaiboon, J | 1 |
| Wongpitoon, N | 1 |
| Hinkle, J | 1 |
| Hinson, J | 1 |
| Sciarappa, K | 1 |
| Curry, L | 1 |
| Panontin, E | 2 |
| Longo, G | 3 |
| Thamrin, C | 1 |
| Nydegger, R | 1 |
| Stern, G | 1 |
| Watt, RA | 1 |
| FitzPatrick, S | 1 |
| Taylor, DR | 21 |
| Yeh, KH | 1 |
| Skowronski, ME | 2 |
| Coreno, AJ | 2 |
| Seitz, RE | 2 |
| Villalba, KD | 1 |
| Dickey-White, H | 2 |
| McFadden, ER | 11 |
| Bodzenta-Lukaszyk, A | 2 |
| Dymek, A | 1 |
| McAulay, K | 1 |
| Mansikka, H | 1 |
| Grainge, CL | 1 |
| Lau, LC | 2 |
| Ward, JA | 1 |
| Dulay, V | 1 |
| Lahiff, G | 1 |
| Wilson, S | 3 |
| Holgate, S | 3 |
| Davies, DE | 2 |
| Howarth, PH | 11 |
| Christian Virchow, J | 1 |
| Ali, M | 1 |
| Chisholm, A | 1 |
| Lee, AJ | 1 |
| Hillyer, EV | 1 |
| von Ziegenweidt, J | 1 |
| Signori, A | 1 |
| Cirillo, I | 1 |
| Clearie, KL | 1 |
| McKinlay, L | 1 |
| Radice, S | 2 |
| Milanesi, A | 1 |
| Antoniazzi, S | 2 |
| Perrone, V | 2 |
| Carnovale, C | 2 |
| Clementi, E | 2 |
| Khianey, R | 1 |
| Oppenheimer, J | 2 |
| Harrison, LI | 1 |
| Novak, CC | 1 |
| Needham, MJ | 1 |
| Ratner, P | 2 |
| Fink, JB | 1 |
| Armstrong, L | 1 |
| Wan, Y | 1 |
| Alagappan, VK | 1 |
| Ohlssen, D | 1 |
| Kelley, JM | 1 |
| Boyd, IO | 1 |
| Dutile, S | 1 |
| Marigowda, G | 1 |
| Kirsch, I | 1 |
| Kaptchuk, TJ | 1 |
| Moerman, DE | 1 |
| Upham, BD | 1 |
| Mollen, CJ | 1 |
| Scarfone, RJ | 3 |
| Seiden, J | 1 |
| Mendonça, NT | 1 |
| Kenyon, J | 1 |
| LaPrad, AS | 1 |
| Syeda, SN | 1 |
| O'Connor, GT | 3 |
| Lutchen, KR | 4 |
| Hagiwara, M | 3 |
| Delea, TE | 3 |
| Fu, WP | 1 |
| Zhao, ZH | 1 |
| Zhong, L | 1 |
| Sun, C | 1 |
| Fang, LZ | 1 |
| Zhang, JQ | 1 |
| Shu, JK | 1 |
| Wang, XM | 1 |
| Dai, LM | 1 |
| Kornmann, O | 3 |
| Schmidt, P | 1 |
| Pivovarova, A | 1 |
| Engel, M | 1 |
| Kermode, JA | 1 |
| Brown, NJ | 1 |
| Hardaker, KM | 1 |
| Farah, CS | 1 |
| Berend, N | 1 |
| King, GG | 2 |
| Salome, CM | 3 |
| Garriga, T | 1 |
| Labrador-Horrillo, M | 1 |
| Guillén, M | 1 |
| Luengo, O | 1 |
| Eseverri, JL | 1 |
| Guilarte, M | 1 |
| Marin, AM | 1 |
| Cardona, V | 1 |
| Tovey, D | 1 |
| Zwar, NA | 1 |
| Marks, GB | 1 |
| Hermiz, O | 1 |
| Middleton, S | 1 |
| Comino, EJ | 1 |
| Hasan, I | 1 |
| Vagholkar, S | 1 |
| Wilson, SF | 1 |
| Matos, AC | 1 |
| Srirangalingam, U | 1 |
| Barry, T | 1 |
| Grossman, AB | 1 |
| Horner, CC | 1 |
| Mauger, D | 1 |
| Graber, NJ | 1 |
| Kupczyk, M | 2 |
| Dahlén, SE | 2 |
| Silveira, L | 1 |
| Gelfand, EW | 4 |
| Lehman, E | 3 |
| Korn, S | 2 |
| Flor-Escriche, X | 1 |
| Rodríguez-Mas, M | 1 |
| Espiau, M | 1 |
| Castán-Enseñat, X | 1 |
| Vigatà-Reig, JM | 1 |
| Poblet-Cortés, R | 1 |
| Miravitlles, M | 1 |
| Youkou, A | 1 |
| Suzuki, K | 2 |
| Koya, T | 1 |
| Sakagami, T | 1 |
| Toyabe, S | 1 |
| Arakawa, M | 1 |
| Gejyo, F | 1 |
| Narita, I | 1 |
| Suzuki, E | 1 |
| Ogorodova, LM | 2 |
| Kulikov, ES | 1 |
| Deev, IA | 2 |
| Cherniak, BA | 1 |
| Fassakhov, RS | 1 |
| Mangunnegoro, H | 1 |
| Novariska, F | 1 |
| Wiyono, WH | 1 |
| Setiawati, A | 1 |
| Louisa, M | 1 |
| Nair, A | 1 |
| Ward, J | 3 |
| Rebolledo, P | 1 |
| Kroegel, C | 2 |
| Rolla, G | 4 |
| Bucca, C | 4 |
| Bibalo, C | 1 |
| Straumann, A | 1 |
| Safroneeva, E | 1 |
| Schoepfer, AM | 1 |
| Debley, J | 1 |
| Stanojevic, S | 2 |
| Filbrun, AG | 1 |
| Subbarao, P | 1 |
| Mysore, S | 1 |
| Ruffin, RE | 4 |
| Ohara, Y | 2 |
| Ohara, T | 1 |
| Ohrui, T | 2 |
| Morikawa, T | 2 |
| Asamura, T | 1 |
| Sasaki, H | 2 |
| Arai, H | 1 |
| Bernaerts, F | 1 |
| Billen, F | 1 |
| McCabe, JC | 1 |
| Koppenhagen, F | 1 |
| Blair, J | 1 |
| Zeng, XM | 1 |
| Hartnett, BJ | 2 |
| Marlin, GE | 5 |
| Willey, RF | 4 |
| Grant, IW | 11 |
| Pocock, SJ | 2 |
| Sanchez, AM | 1 |
| Collomp, K | 1 |
| Carra, J | 1 |
| Borrani, F | 1 |
| Coste, O | 1 |
| Préfaut, C | 3 |
| Candau, R | 1 |
| Hu, Z | 1 |
| Cai, Z | 1 |
| Yu, L | 1 |
| Fei, Y | 1 |
| Weng, L | 1 |
| Ge, X | 1 |
| Zhu, T | 1 |
| Wildfire, JJ | 1 |
| Mitchell, HE | 1 |
| Kattan, M | 4 |
| Teach, SJ | 1 |
| Wood, RA | 1 |
| Conroy, K | 1 |
| Rivera-Sanchez, Y | 1 |
| Lin, S | 1 |
| Munsie, JP | 1 |
| Herdt-Losavio, ML | 1 |
| Druschel, CM | 1 |
| Campbell, K | 1 |
| Browne, ML | 1 |
| Romitti, PA | 1 |
| Olney, RS | 1 |
| Bell, EM | 1 |
| Rossios, C | 1 |
| To, Y | 1 |
| Osoata, G | 1 |
| Ito, M | 2 |
| Barnes, PJ | 24 |
| Ito, K | 3 |
| Bledsoe, B | 1 |
| Buchannan, K | 1 |
| Hodnick, R | 1 |
| Yasmin, S | 1 |
| Mollah, AH | 1 |
| Basak, R | 1 |
| Islam, KT | 1 |
| Chowdhury, YS | 1 |
| Spears, M | 1 |
| Janssens, T | 1 |
| Verleden, G | 1 |
| De Peuter, S | 2 |
| Petersen, S | 1 |
| Van den Bergh, O | 2 |
| Gerzeli, S | 1 |
| Rognoni, C | 1 |
| Quaglini, S | 1 |
| Cavallo, MC | 1 |
| Cremonesi, G | 1 |
| Mougey, EB | 1 |
| Chen, C | 2 |
| Blake, KV | 5 |
| Leach, CL | 1 |
| Kuehl, PJ | 1 |
| Chand, R | 1 |
| Ketai, L | 1 |
| Norenberg, JP | 1 |
| McDonald, JD | 1 |
| Doan, ML | 1 |
| Roy, D | 1 |
| Pinsker, JE | 1 |
| Arun, JJ | 1 |
| Staggs, L | 1 |
| Peek, M | 1 |
| Southard, G | 1 |
| Gracely, E | 2 |
| Baxendale, S | 1 |
| Kim, IK | 3 |
| Melosini, L | 1 |
| Dente, FL | 16 |
| Bacci, E | 15 |
| Bartoli, ML | 6 |
| Cianchetti, S | 6 |
| Costa, F | 2 |
| Di Franco, A | 15 |
| Malagrinò, L | 2 |
| Novelli, F | 2 |
| Vagaggini, B | 15 |
| Yin, L | 1 |
| Wong, YF | 1 |
| Vasudevan, VP | 1 |
| Suryanarayanan, M | 1 |
| Shahzad, S | 1 |
| Megjhani, M | 1 |
| Bahloul, M | 1 |
| Chaari, A | 1 |
| Dammak, H | 1 |
| Medhioub, F | 1 |
| Abid, L | 1 |
| Chtourou, K | 1 |
| Rekik, N | 1 |
| Chelly, H | 1 |
| Kallel, H | 1 |
| Bouaziz, M | 1 |
| Yokomura, K | 1 |
| Hayakawa, H | 1 |
| Ide, K | 1 |
| Toyoshima, M | 1 |
| Kuroishi, S | 1 |
| Yasuda, K | 1 |
| Suganuma, H | 1 |
| Yamada, T | 2 |
| Masuda, M | 1 |
| Gómez, FP | 2 |
| Casas, A | 1 |
| Rodriguez-Roisin, R | 8 |
| Dembla, G | 1 |
| Mundle, RP | 1 |
| Salkar, HR | 1 |
| Doifoide, DV | 1 |
| Plint, A | 2 |
| Freedman, S | 2 |
| Porter, R | 2 |
| Gouin, S | 2 |
| Hernandez, A | 1 |
| Teoh, L | 1 |
| Hurwitz, M | 1 |
| Acworth, JP | 1 |
| van Asperen, P | 2 |
| Chang, AB | 1 |
| Machado, D | 1 |
| Pereira, C | 1 |
| Tavares, B | 1 |
| Loureiro, G | 1 |
| Segorbe-Luís, A | 1 |
| Jenkins, C | 4 |
| Seccombe, L | 1 |
| Tomlins, R | 1 |
| Jacobs, TS | 1 |
| Jones, BL | 1 |
| MacGinnitie, AJ | 1 |
| Warkocka-Szoltysek, B | 1 |
| Filipowska-Gronska, A | 1 |
| Trifilieff, A | 1 |
| Fozard, JR | 1 |
| Sturney, S | 1 |
| Suntharalingam, J | 1 |
| Aparici, M | 1 |
| Gómez-Angelats, M | 1 |
| Vilella, D | 1 |
| Otal, R | 1 |
| Carcasona, C | 1 |
| Viñals, M | 1 |
| Ramos, I | 1 |
| Gavaldà, A | 1 |
| De Alba, J | 1 |
| Gras, J | 1 |
| Cortijo, J | 1 |
| Morcillo, E | 1 |
| Puig, C | 1 |
| Ryder, H | 1 |
| Beleta, J | 1 |
| Miralpeix, M | 1 |
| Naya, I | 2 |
| Ekelund, J | 1 |
| Chiang, WC | 1 |
| Chen, YM | 1 |
| Tan, HK | 1 |
| Balakrishnan, A | 1 |
| Liew, WK | 1 |
| Lim, HH | 1 |
| Goh, SH | 1 |
| Loh, WY | 1 |
| Wong, P | 1 |
| Teoh, OH | 1 |
| Goh, A | 1 |
| Chay, OM | 1 |
| Nicholls, DJ | 1 |
| Jordan, S | 1 |
| Cadogan, E | 1 |
| Lawson, M | 1 |
| Austin, RP | 1 |
| Paine, SW | 1 |
| Gardiner, P | 1 |
| Bonnert, R | 1 |
| Connolly, S | 1 |
| Young, A | 1 |
| Klemola, T | 1 |
| Kajosaari, M | 1 |
| Fabbri, L | 2 |
| Olivieri, D | 3 |
| Rossi, A | 5 |
| Park, SJ | 2 |
| Lee, CH | 2 |
| Goo, JM | 2 |
| Kim, JH | 2 |
| Park, EA | 2 |
| Jung, JW | 1 |
| Park, HW | 1 |
| Cho, SH | 3 |
| Zuccotti, G | 1 |
| Piazza, A | 1 |
| Cavkaytar, O | 1 |
| Kalo, Z | 1 |
| Abonyi-Toth, Z | 1 |
| Bartfai, Z | 1 |
| Voko, Z | 1 |
| Singh, D | 3 |
| Bindi, E | 1 |
| Haran, M | 1 |
| Schattner, A | 1 |
| Mate, A | 1 |
| Starobin, D | 1 |
| Haran, G | 1 |
| Shtalrid, M | 1 |
| Molise, MC | 1 |
| Maffey, AF | 2 |
| Ramos, P | 1 |
| Rubinstein, F | 1 |
| Latorre, M | 1 |
| Bartoli, M | 1 |
| Matsunaga, K | 1 |
| Akamatsu, K | 1 |
| Hirano, T | 2 |
| Costella, S | 1 |
| Paterson, NA | 1 |
| Mecklin, M | 1 |
| Paassilta, M | 1 |
| Korppi, M | 2 |
| Zajda, E | 1 |
| Durmišević, S | 1 |
| Durmišević-Serdarević, J | 1 |
| Ahmetović, N | 1 |
| Sivic, S | 1 |
| Lelić, M | 1 |
| Titus, MO | 1 |
| Eady, M | 1 |
| King, L | 1 |
| Bowman, CM | 1 |
| Jackson, C | 4 |
| Fielding, S | 1 |
| Guthrie, B | 1 |
| Tamagaki, G | 1 |
| Kanazawa, H | 5 |
| Hirata, K | 3 |
| Song, NC | 1 |
| He, JB | 1 |
| Xu, HB | 1 |
| Wu, JF | 1 |
| Schwartz, RH | 1 |
| Neacsu, O | 1 |
| Ascher, DP | 1 |
| Alpan, O | 1 |
| Golden, LR | 1 |
| DeSimone, HA | 1 |
| Yeroshalmi, F | 1 |
| Pranevicius, M | 1 |
| Saraghi, M | 1 |
| Stovold, E | 1 |
| McIver, T | 1 |
| Grothe, B | 1 |
| Blanchette, CM | 1 |
| Roberts, MH | 1 |
| Petersen, H | 1 |
| Kanemitsu, Y | 1 |
| Kita, H | 2 |
| Niimi, A | 1 |
| Fuseya, Y | 1 |
| Tanimura, K | 1 |
| Katayama, Y | 1 |
| Takahashi, T | 2 |
| Hatachi, Y | 1 |
| Nishihara, Y | 1 |
| Sado, T | 1 |
| Kim, WW | 1 |
| Smith, TC | 1 |
| Feustel, PJ | 1 |
| Jourd'heuil, D | 1 |
| Donald, HP | 1 |
| Macgregor, DF | 2 |
| Ogston, SA | 2 |
| Maselli, DJ | 1 |
| Adams, SG | 1 |
| Peters, JI | 2 |
| Levine, SM | 1 |
| Manara, A | 1 |
| Hantson, P | 1 |
| Vanpee, D | 1 |
| Thys, F | 1 |
| McMillan, SS | 1 |
| Hattingh, HL | 1 |
| King, MA | 1 |
| Manthei, DM | 1 |
| Ahn, K | 1 |
| Chinchili, VM | 1 |
| King, T | 1 |
| Sheerar, D | 1 |
| Henderson, J | 1 |
| Harrison, C | 1 |
| Miller, G | 1 |
| Tosca, MA | 1 |
| Capasso, M | 1 |
| Liu, ZW | 1 |
| Yue, F | 1 |
| Gao, FY | 1 |
| Qian, YB | 1 |
| Wang, RL | 1 |
| Clayton, K | 1 |
| Monroe, K | 1 |
| Magruder, T | 1 |
| King, W | 1 |
| Harrington, K | 1 |
| Stewart, SL | 1 |
| Martin, AL | 1 |
| Labuda, M | 1 |
| Laberge, S | 1 |
| Brière, J | 1 |
| Krajinovic, M | 1 |
| Jat, KR | 1 |
| Khairwa, A | 1 |
| Travers, AH | 1 |
| Jones, AP | 2 |
| Richards, DH | 2 |
| Beghé, B | 1 |
| Nie, H | 1 |
| Liu, M | 1 |
| Ding, X | 1 |
| Huang, Y | 1 |
| Hu, S | 1 |
| Borrego, LM | 1 |
| Stocks, J | 1 |
| Almeida, I | 1 |
| Antunes, J | 1 |
| Leiria-Pinto, P | 1 |
| Rosado-Pinto, JE | 1 |
| Hoo, AF | 1 |
| Lauritsen, L | 1 |
| Sahl, C | 1 |
| Thorsen, S | 1 |
| Ekelund, K | 1 |
| Følsgaard, S | 1 |
| Krebs, SE | 1 |
| Flood, RG | 1 |
| Peter, JR | 1 |
| Gerard, JM | 1 |
| McKay, AJ | 1 |
| Tudur Smith, C | 1 |
| Williamson, PR | 1 |
| Werfel, PA | 1 |
| Moreau-Colson, C | 1 |
| Rodrigo, C | 15 |
| Stratakos, G | 1 |
| Kalomenidis, J | 1 |
| Routsi, C | 1 |
| Papiris, S | 1 |
| Roussos, C | 1 |
| Rosenborg, J | 4 |
| Larsson, R | 1 |
| Rott, Z | 2 |
| Böcskei, C | 2 |
| Poczi, M | 2 |
| Juhász, G | 2 |
| Furusho, K | 1 |
| Nishikawa, K | 2 |
| Sasaki, S | 1 |
| Akasaka, T | 1 |
| Arita, M | 1 |
| Edwards, A | 2 |
| Carnevali, S | 3 |
| Giannini, D | 14 |
| Ruocco, L | 2 |
| Paggiaro, PL | 10 |
| Chowdhury, BA | 2 |
| Asmus, MJ | 2 |
| Ahrens, RC | 8 |
| Bisgaard, H | 7 |
| Chhabra, SK | 5 |
| Vijayan, VK | 1 |
| De, S | 1 |
| Bensch, G | 4 |
| Blokhin, BM | 1 |
| Socolovsky, AL | 1 |
| Thomson, MH | 1 |
| Till, MD | 3 |
| Della Cioppa, G | 6 |
| Kissoon, N | 1 |
| Duckworth, LJ | 1 |
| Murphy, SP | 1 |
| Sternberg, AL | 1 |
| Larsson, P | 3 |
| Pandey, KK | 1 |
| Gutiérrez, V | 4 |
| Torres, V | 1 |
| Uixera, S | 1 |
| Marín, J | 1 |
| Janssen, R | 1 |
| Weda, M | 1 |
| Ekkelenkamp, MB | 1 |
| Lammers, JW | 5 |
| Frith, LF | 1 |
| Braunstein, GL | 3 |
| Asano, K | 1 |
| Shiomi, T | 1 |
| Hasegawa, N | 1 |
| Kudo, H | 1 |
| Matsuzaki, T | 1 |
| Hakuno, H | 1 |
| Fukunaga, K | 1 |
| Pizzichini, E | 3 |
| Pizzichini, MM | 3 |
| Leigh, R | 1 |
| Cervera, A | 1 |
| Liñana, J | 1 |
| Ortiz, G | 1 |
| Menendez, R | 2 |
| Lee-Wong, M | 2 |
| Dayrit, FM | 1 |
| Kohli, AR | 1 |
| Acquah, S | 1 |
| Mayo, PH | 1 |
| Borker, R | 3 |
| Emmett, A | 14 |
| Rickard, K | 11 |
| Wolf, BL | 1 |
| Bowie, D | 1 |
| Cartier, A | 19 |
| Cockroft, D | 2 |
| Cowie, R | 2 |
| Fitzgerald, M | 2 |
| Sears, M | 1 |
| Terzano, C | 2 |
| Allegra, L | 4 |
| Grembiale, RD | 2 |
| Pelaia, G | 3 |
| Naty, S | 2 |
| Vatrella, A | 3 |
| Tranfa, CM | 2 |
| Marsico, SA | 3 |
| Fraser, J | 1 |
| Duarte, M | 1 |
| Abbott, MB | 3 |
| Levin, RH | 3 |
| Miller, JA | 2 |
| Creticos, PS | 1 |
| Adams, WP | 1 |
| Petty, BG | 1 |
| Lewis, LD | 3 |
| Singh, GJ | 1 |
| Khattignavong, AP | 1 |
| Molzon, JA | 1 |
| Martinez, MN | 1 |
| Lietman, PS | 1 |
| Williams, RL | 1 |
| Ringdal, N | 3 |
| Chovan, L | 1 |
| Tudoric, N | 1 |
| Maggi, E | 1 |
| Whitehead, PJ | 2 |
| Gustafsson, P | 1 |
| Källman, S | 1 |
| Goedhart, DM | 1 |
| Chatmongkolchart, S | 1 |
| Schettino, GP | 1 |
| Dillman, C | 1 |
| Kacmarek, RM | 1 |
| Hess, DR | 1 |
| Lee, DK | 14 |
| Anhøj, J | 1 |
| Kanniess, F | 1 |
| Richter, K | 3 |
| Janicki, S | 1 |
| Schleiss, MB | 1 |
| Jörres, RA | 3 |
| Robert, J | 1 |
| Heyneman, CA | 1 |
| Crafts, R | 1 |
| Holland, J | 1 |
| Arnold, AD | 1 |
| Innes, NJ | 1 |
| Stocking, JA | 1 |
| Daynes, TJ | 1 |
| Harrison, BD | 1 |
| Smithline, HA | 1 |
| Malice, MP | 1 |
| Green, SA | 1 |
| Reiss, TF | 2 |
| Haggart, K | 2 |
| Bates, CE | 5 |
| Yoshikawa, J | 4 |
| Braunstein, G | 2 |
| Groeben, H | 1 |
| Schlicht, M | 1 |
| Stieglitz, S | 1 |
| Pavlakovic, G | 1 |
| Peters, J | 1 |
| Brito, FF | 1 |
| Mur, P | 1 |
| Barber, D | 1 |
| Lombardero, M | 1 |
| Galindo, PA | 1 |
| Gómez, E | 1 |
| Borja, J | 1 |
| Verbanck, S | 2 |
| Schuermans, D | 2 |
| Paiva, M | 2 |
| Vincken, W | 3 |
| Sarver, JH | 1 |
| Friedlaender, EY | 1 |
| Zeggwagh, AA | 1 |
| Abouqal, R | 1 |
| Madani, N | 1 |
| Abidi, K | 1 |
| Moussaoui, R | 1 |
| Zekraoui, A | 1 |
| Kerkeb, O | 1 |
| Jeffery, PK | 1 |
| Venge, P | 3 |
| Gizycki, MJ | 1 |
| Egerod, I | 1 |
| Faurschou, P | 5 |
| Arets, HG | 1 |
| Mulder, PG | 7 |
| Vermue, NA | 3 |
| van der Ent, CK | 1 |
| Habib, GS | 1 |
| Saliba, WR | 1 |
| Cohen, L | 2 |
| Campbell, LM | 3 |
| Walters, JA | 3 |
| Gibson, PW | 1 |
| Truitt, T | 1 |
| Witko, J | 1 |
| Halpern, M | 1 |
| Yuan, Y | 1 |
| He, T | 1 |
| Zeng, J | 1 |
| Luo, Y | 1 |
| Bowes, D | 1 |
| Sjöswärd, KN | 1 |
| Josefsson, M | 2 |
| Ahlner, J | 2 |
| Schmekel, B | 2 |
| Nowak, R | 2 |
| La Grutta, S | 2 |
| Gagliardo, R | 4 |
| Mirabella, F | 1 |
| Pajno, GB | 2 |
| Bonsignore, G | 2 |
| Vignola, AM | 7 |
| Mamoto, T | 1 |
| Molimard, M | 3 |
| Moore, N | 1 |
| Nagel, MW | 1 |
| Wiersema, KJ | 1 |
| Bates, SL | 1 |
| Mitchell, JP | 1 |
| Hansel, TT | 1 |
| Schultze-Werninghaus, G | 2 |
| Craig-McFeely, PM | 1 |
| Wilton, LV | 2 |
| Soriano, JB | 1 |
| Maier, WC | 1 |
| Shakir, SA | 2 |
| Rosenwasser, LJ | 2 |
| Rickard, KA | 15 |
| Stiegler, KA | 1 |
| Yunker, NS | 1 |
| Crouch, MA | 1 |
| Wooltorton, E | 2 |
| Eliraz, A | 1 |
| Pruzinec, R | 1 |
| Weber, HH | 2 |
| Akveld, M | 1 |
| Shann, F | 1 |
| Kumaratne, M | 1 |
| Gunawardane, G | 1 |
| Sharma, S | 1 |
| Godatwar, P | 1 |
| Kulkarni, LR | 1 |
| South, M | 2 |
| Roberts, G | 1 |
| Newsom, D | 1 |
| Gomez, K | 1 |
| Raffles, A | 1 |
| Saglani, S | 1 |
| Begent, J | 1 |
| Lachman, P | 1 |
| Sloper, K | 1 |
| Buchdahl, R | 1 |
| Habel, A | 1 |
| Nakano, Y | 2 |
| Morita, S | 1 |
| Kawamoto, A | 2 |
| Naito, T | 1 |
| Enomoto, N | 2 |
| Wang, CH | 2 |
| Lin, HC | 2 |
| Lin, CH | 1 |
| Yu, CT | 2 |
| Liu, SL | 1 |
| Huang, KH | 1 |
| Kuo, HP | 2 |
| Soroksky, A | 1 |
| Stav, D | 1 |
| Shpirer, I | 1 |
| Silvestri, M | 1 |
| Sabatini, F | 1 |
| Sale, R | 1 |
| Defilippi, AC | 1 |
| Fregonese, L | 1 |
| Battistini, E | 1 |
| Biraghi, MG | 1 |
| Pershad, J | 1 |
| Chin, T | 2 |
| Giroux, M | 1 |
| Ferrières, J | 1 |
| Naidu Sjöswärd, K | 1 |
| Andersson, RG | 1 |
| Onyirimba, F | 1 |
| Apter, A | 1 |
| Reisine, S | 1 |
| Litt, M | 1 |
| McCusker, C | 1 |
| Connors, M | 1 |
| ZuWallack, R | 2 |
| Lanski, SL | 1 |
| Greenwald, M | 1 |
| Perkins, A | 1 |
| Simon, HK | 2 |
| Ind, PW | 7 |
| Dal Negro, R | 2 |
| Colman, NC | 1 |
| Fletcher, CP | 1 |
| Browning, D | 1 |
| James, MH | 3 |
| Joguparthi, V | 1 |
| Breen, P | 1 |
| Compadre, C | 1 |
| Gann, L | 1 |
| Hiller, FC | 1 |
| Anderson, P | 1 |
| Baena-Cagnani, CE | 1 |
| DuBuske, LM | 2 |
| Gurné, SE | 1 |
| Stryszak, P | 2 |
| Lorber, R | 1 |
| Danzig, M | 1 |
| Jackson, CM | 9 |
| van Veen, A | 1 |
| Weller, FR | 3 |
| Wierenga, EA | 1 |
| Jansen, HM | 7 |
| Wraight, JM | 2 |
| Herbison, GP | 10 |
| Cowan, JO | 6 |
| Flannery, EM | 8 |
| Messahel, B | 1 |
| Chong, FV | 1 |
| Reid, DW | 3 |
| Wang, N | 1 |
| Zheng, L | 1 |
| Bish, R | 4 |
| Orsida, B | 1 |
| Weiner, P | 2 |
| Magadle, R | 2 |
| Beckerman, M | 1 |
| Berar-Yanay, N | 2 |
| Kizkin, O | 1 |
| Turker, G | 1 |
| Hacievliyagil, SS | 1 |
| Sitkauskiene, B | 2 |
| Sakalauskas, R | 2 |
| Malakauskas, K | 2 |
| Hasani, A | 2 |
| Toms, N | 1 |
| O'Connor, J | 2 |
| Dilworth, JP | 1 |
| Agnew, JE | 2 |
| Coleman, CI | 1 |
| Reddy, P | 1 |
| Laster-Bradley, NM | 1 |
| Dorval, S | 1 |
| Munagala, B | 1 |
| White, CM | 1 |
| Watt, PM | 1 |
| Clements, B | 1 |
| Chaney, GM | 1 |
| Syme-Grant, NJ | 1 |
| McFarlane, LC | 5 |
| Carey, FA | 1 |
| Broeders, ME | 5 |
| Molema, J | 6 |
| Folgering, HT | 11 |
| Hughes, R | 1 |
| Goldkorn, A | 1 |
| Masoli, M | 5 |
| Burgess, C | 9 |
| Clement, YN | 1 |
| Pinto Pereira, SM | 1 |
| Lindqvist, A | 2 |
| Karjalainen, EM | 1 |
| Laitinen, LA | 5 |
| Kava, T | 1 |
| Altraja, A | 3 |
| Pulkkinen, M | 1 |
| Halme, M | 1 |
| Laitinen, A | 3 |
| Pyke, SD | 1 |
| Johnson, M | 7 |
| Pritchard, JN | 1 |
| Wallin, A | 4 |
| Sue-Chu, M | 1 |
| Sandström, T | 7 |
| Dashash, NA | 1 |
| Mukhtar, SH | 1 |
| Stenback, S | 1 |
| Khan, SR | 1 |
| Henry, RL | 4 |
| Hurst, T | 1 |
| Li, SL | 1 |
| Browne, GJ | 4 |
| Wilkins, BH | 1 |
| Balanov, I | 1 |
| Gorenberg, M | 1 |
| Groshar, D | 1 |
| Luder, AS | 2 |
| Dubus, JC | 3 |
| Guillot, C | 2 |
| Badier, M | 2 |
| Gordon, JR | 2 |
| Swystun, VA | 11 |
| Li, F | 1 |
| Hull, P | 1 |
| Nightingale, JA | 3 |
| Marotta, A | 1 |
| Klinnert, MD | 1 |
| Price, MR | 1 |
| Shah, L | 1 |
| Wilson, AJ | 3 |
| Coughlan, J | 2 |
| Miesen, WM | 1 |
| van der Heide, S | 1 |
| Kerstjens, HA | 5 |
| Dubois, AE | 1 |
| de Monchy, JG | 3 |
| Oguri, K | 1 |
| Brambilla, C | 3 |
| Le Gros, V | 3 |
| Bourdeix, I | 2 |
| Meyts, I | 1 |
| Proesmans, M | 1 |
| De Boeck, K | 2 |
| Lyseng-Williamson, KA | 2 |
| Plosker, GL | 2 |
| Meyer, MF | 1 |
| Hopkins, WE | 1 |
| Crater, GD | 1 |
| Hartzema, A | 1 |
| Habashy, D | 1 |
| Lam, LT | 1 |
| Martinat, Y | 2 |
| SJOGREN, I | 2 |
| Boonsawat, W | 3 |
| Charoenratanakul, S | 1 |
| Pothirat, C | 1 |
| Sawanyawisuth, K | 1 |
| Seearamroongruang, T | 1 |
| Bengtsson, T | 4 |
| Brander, R | 1 |
| Paul, N | 1 |
| John, G | 1 |
| Kurtaran, H | 1 |
| Karadag, A | 1 |
| Catal, F | 1 |
| Isik, B | 1 |
| Uras, N | 1 |
| Bukstein, DA | 2 |
| Bratton, DL | 1 |
| Firriolo, KM | 1 |
| Estojak, J | 1 |
| Bird, SR | 2 |
| Hustad, CM | 2 |
| Edelman, JM | 2 |
| Gross, G | 6 |
| Cohen, RM | 1 |
| Guy, H | 1 |
| Pleskow, W | 2 |
| LaForce, CF | 2 |
| Yegen, U | 4 |
| Matos, D | 1 |
| Wolfe, JD | 3 |
| Baitinger, L | 6 |
| Scott, C | 4 |
| Buchvald, F | 1 |
| Haahtela, T | 8 |
| Holgate, ST | 21 |
| Picado, C | 7 |
| Menten, J | 1 |
| Dass, SB | 1 |
| Leff, JA | 2 |
| Ellis, C | 1 |
| Taccola, M | 3 |
| Tonelli, M | 2 |
| Zingoni, M | 2 |
| Slaughter, JC | 1 |
| Lumley, T | 1 |
| Sheppard, L | 1 |
| Koenig, JQ | 1 |
| Shapiro, GG | 4 |
| Gibson, MD | 1 |
| Guleria, R | 2 |
| Singh, TR | 1 |
| Sinha, S | 1 |
| Padhy, AK | 1 |
| Gupta, K | 1 |
| Pande, JN | 4 |
| Fenton, C | 1 |
| Keating, GM | 1 |
| MaCartney, NJ | 1 |
| Hadjikoumi, I | 2 |
| Hassan, A | 1 |
| Milner, AD | 13 |
| Pauwels, RA | 6 |
| Campbell, M | 3 |
| Villasante, C | 2 |
| Huang, S | 2 |
| Lindh, A | 2 |
| Petermann, W | 3 |
| Aubier, M | 2 |
| Schwabe, G | 1 |
| Nathan, RA | 15 |
| Rosenzweig, JR | 2 |
| Edin, H | 1 |
| Prillaman, B | 6 |
| Barbato, A | 2 |
| Panizzolo, C | 1 |
| Landi, L | 1 |
| Semenzato, R | 1 |
| Rugge, M | 1 |
| Al-Mobeireek, A | 1 |
| Cockburn, WJ | 1 |
| Carl, JC | 1 |
| Myers, TR | 1 |
| Kirchner, HL | 1 |
| Sutton, LB | 2 |
| Dorinsky, PM | 9 |
| Marabini, A | 2 |
| Siracusa, A | 2 |
| Stopponi, R | 1 |
| Tacconi, C | 1 |
| Abbritti, G | 1 |
| Sims, EJ | 4 |
| Hall, IP | 2 |
| Pereira, A | 1 |
| Mendes, E | 1 |
| Ferreira, T | 1 |
| Magnan, A | 1 |
| Fardon, TC | 3 |
| Grosclaude, M | 3 |
| Cerruti, JL | 1 |
| Delannay, B | 1 |
| Hérent, M | 1 |
| Spilthooren, F | 1 |
| Kapoor, U | 1 |
| Tayal, G | 1 |
| Mittal, SK | 1 |
| Sharma, VK | 1 |
| Tekur, U | 1 |
| Juniper, EF | 8 |
| Price, MJ | 3 |
| Boulton, DW | 2 |
| Nowak, RM | 1 |
| Vaickus, L | 1 |
| Roach, JM | 2 |
| Girgis, M | 1 |
| Milner, Q | 1 |
| Teper, AM | 1 |
| Colom, AJ | 1 |
| Kofman, CD | 1 |
| Vidaurreta, SM | 1 |
| Bergadá, I | 1 |
| Munro, A | 2 |
| Jacobs, M | 1 |
| Mutschler, E | 1 |
| Perera, BJ | 4 |
| Boskabady, MH | 1 |
| Saadatinejad, M | 1 |
| Bergmann, KC | 1 |
| Braun, R | 1 |
| Botting, C | 1 |
| Sutherland, M | 1 |
| Wells, E | 2 |
| Town, I | 1 |
| Sainsbury, R | 1 |
| Toop, L | 1 |
| Delvaux, M | 1 |
| Lau, L | 1 |
| Kange, P | 1 |
| Bartsch, P | 1 |
| Wilkinson, TS | 1 |
| Potter-Perigo, S | 1 |
| Tsoi, C | 1 |
| Altman, LC | 1 |
| Wight, TN | 1 |
| Gupta, G | 1 |
| Baruah, BP | 1 |
| Nagpal, R | 1 |
| Martinez-Moragón, E | 1 |
| Plaza, V | 2 |
| Serrano, J | 1 |
| Galdiz, JB | 1 |
| López-Viña, A | 1 |
| Sanchis, J | 1 |
| Stoloff, SW | 2 |
| Meyer, J | 1 |
| Carranza Rosenzweig, JR | 5 |
| Rissmiller, RW | 2 |
| Larj, MJ | 2 |
| Wisniewski, ME | 1 |
| Cox, FM | 3 |
| Nielsen, KE | 1 |
| Pohunek, P | 1 |
| Matulka, M | 1 |
| Rybnícek, O | 1 |
| Kopriva, F | 2 |
| Honomichlová, H | 1 |
| Svobodová, T | 1 |
| Everden, P | 2 |
| Harnden, C | 1 |
| McGoldrick, H | 1 |
| Bodalia, B | 1 |
| Manion, V | 1 |
| Reynia, S | 1 |
| Kava, TT | 1 |
| Omenaas, ER | 1 |
| Nowak-Wegrzyn, A | 1 |
| Beyer, K | 1 |
| Bardina, L | 1 |
| Metcalfe, S | 2 |
| Moodie, P | 2 |
| Clement, Y | 1 |
| Rouse, J | 1 |
| Matthew, J | 1 |
| Asgarali, Z | 1 |
| Ramoutar, D | 1 |
| Teelucksingh, S | 1 |
| Koninck, JC | 1 |
| Magro, P | 1 |
| Khanjari, F | 1 |
| Lemarié, E | 2 |
| Diot, P | 2 |
| Tomari, S | 2 |
| Machida, I | 2 |
| Kondo, Y | 2 |
| Kawano, T | 2 |
| Obase, Y | 2 |
| Fukushima, C | 2 |
| Shimoda, T | 2 |
| Kohno, S | 3 |
| Fukkuda, T | 1 |
| Sharma, A | 2 |
| Madaan, A | 1 |
| Wolf, B | 1 |
| Schwindt, C | 1 |
| Hamilton, RG | 1 |
| Lee, E | 2 |
| McNally, DL | 1 |
| Zuckerman, IH | 1 |
| Bergqvist, PB | 1 |
| Winter, TH | 3 |
| Makolkin, VI | 1 |
| Ovcharenko, SI | 1 |
| Peredel'skaia, OA | 1 |
| Axel'rod, AS | 1 |
| Du-Thanh, A | 1 |
| Groleron, S | 1 |
| Le Quellec, A | 1 |
| Smith, AD | 2 |
| Weir, RE | 1 |
| Whitehead, DE | 1 |
| Zaidi, FH | 1 |
| Greaves, BB | 1 |
| Sobolev, I | 1 |
| Mazzeo, AT | 1 |
| Spada, A | 1 |
| Praticò, C | 1 |
| Lucanto, T | 1 |
| Santamaria, LB | 1 |
| van Helden, HP | 1 |
| Kuijpers, WC | 1 |
| Diemel, RV | 1 |
| Beaty, R | 1 |
| Ahrens, R | 3 |
| Stevens, G | 1 |
| Harman, EM | 1 |
| Merkus, PJ | 5 |
| van Pelt, W | 1 |
| van Houwelingen, JC | 1 |
| van Essen-Zandvliet, LE | 1 |
| Kerrebijn, KF | 14 |
| Quanjer, PH | 5 |
| Schermer, TR | 2 |
| Hoff, WJ | 1 |
| Greefhorst, AP | 1 |
| Creemers, JP | 1 |
| Sips, AP | 1 |
| Westbroek, J | 1 |
| van Herwaarden, CL | 10 |
| Mahajan, P | 1 |
| Haritos, D | 1 |
| Rosenberg, N | 1 |
| Thomas, R | 1 |
| Nussbaum, E | 2 |
| Gutierrez, C | 2 |
| Schein, A | 1 |
| Epstein, JD | 1 |
| Zamel, N | 4 |
| Ilowite, J | 1 |
| Webb, R | 1 |
| Friedman, B | 3 |
| Goleva, E | 1 |
| Dunlap, A | 1 |
| Leung, DY | 2 |
| Yoshimi, Y | 1 |
| Yasui, M | 1 |
| Kasahara, K | 1 |
| Nakao, S | 1 |
| Beeh, KM | 2 |
| Rodrigues, RG | 1 |
| Houghton, CM | 2 |
| Woodcock, AA | 2 |
| Pedersen, SE | 6 |
| Dransfield, MT | 1 |
| Bailey, WC | 1 |
| Raftos, J | 1 |
| Kerr, D | 1 |
| Rosengarten, P | 1 |
| Kelly, AM | 2 |
| Puxeddu, I | 1 |
| Lack, G | 1 |
| Smith, SJ | 1 |
| Levi-Schaffer, F | 1 |
| Dalonzo, GE | 1 |
| Jhingran, P | 2 |
| El-Kassimi, FA | 2 |
| Politiek, MJ | 2 |
| Nizet, TA | 1 |
| Baker, JW | 3 |
| Kaplan, MS | 1 |
| Pearlman, DS | 11 |
| Bird, S | 1 |
| Hustad, C | 1 |
| Edelman, J | 1 |
| Quinn, C | 1 |
| Sekhsaria, S | 1 |
| Alam, M | 1 |
| Sait, T | 1 |
| Starr, B | 1 |
| Parekh, M | 1 |
| Bye, MR | 1 |
| Schweizer, C | 1 |
| Saugy, M | 1 |
| Kamber, M | 1 |
| Haddad, S | 1 |
| Arabi, Y | 1 |
| Shimemeri, AA | 1 |
| Benito-Fernández, J | 1 |
| González-Balenciaga, M | 1 |
| Capapé-Zache, S | 1 |
| Vázquez-Ronco, MA | 1 |
| Mintegi-Raso, S | 1 |
| Guill, MF | 1 |
| Barnes, NC | 3 |
| Mirza, N | 1 |
| Kasper Schwartz, S | 1 |
| Antin-Ozerkis, D | 1 |
| Cowan, LM | 1 |
| Saini, B | 1 |
| Krass, I | 1 |
| Armour, C | 1 |
| Strand, AM | 1 |
| Luckow, A | 1 |
| Pifferi, M | 1 |
| Caramella, D | 1 |
| Ragazzo, V | 1 |
| De Marco, E | 1 |
| Pietrobelli, A | 1 |
| Halvorsen, T | 1 |
| Skadberg, BT | 1 |
| Eide, GE | 1 |
| Røksund, OD | 1 |
| Carlsen, KH | 4 |
| Bakke, P | 1 |
| Murray, J | 1 |
| Rosenthal, R | 2 |
| Somerville, L | 2 |
| House, K | 6 |
| VanderMeer, A | 3 |
| Geri, P | 3 |
| Luperini, M | 1 |
| Maluccio, NM | 2 |
| Mariani, L | 2 |
| Marmai, C | 2 |
| Pistolesi, M | 3 |
| Fontana, GA | 3 |
| Pace, E | 1 |
| Melis, M | 1 |
| Ferraro, M | 1 |
| Siena, L | 1 |
| Gjomarkaj, M | 2 |
| Tonnel, AB | 1 |
| Patel, R | 1 |
| Potter, SJ | 1 |
| Ung, N | 1 |
| Nazario, S | 2 |
| Casal, J | 2 |
| Torres, A | 2 |
| Gorman, JD | 1 |
| Salari, K | 1 |
| Toscano, M | 1 |
| Sylvia, JS | 1 |
| Alioto, M | 1 |
| Salazar, M | 1 |
| Gomez, I | 1 |
| Fagan, JK | 1 |
| Salas, J | 1 |
| Lilly, C | 1 |
| Matallana, H | 1 |
| Selman, M | 1 |
| Sheppard, D | 1 |
| Silverman, EK | 2 |
| Marogna, M | 1 |
| Falagiani, P | 1 |
| Bruno, M | 1 |
| Massolo, A | 1 |
| Riva, G | 1 |
| Asero, R | 1 |
| Chandra, P | 1 |
| Paliwal, L | 1 |
| Parker, AL | 1 |
| Chew, NY | 1 |
| Bosnic-Anticevich, SZ | 1 |
| Chan, HK | 1 |
| Edwards, L | 4 |
| Lincourt, W | 2 |
| ZuWallack, RL | 6 |
| Busse, W | 3 |
| Levine, B | 1 |
| Andriano, K | 2 |
| Lavecchia, C | 2 |
| Cockburn, W | 1 |
| Fishman, R | 1 |
| Feltis, BN | 1 |
| Dundas, I | 1 |
| Chan, EY | 1 |
| Bridge, PD | 5 |
| McKenzie, SA | 5 |
| Peden, D | 1 |
| Condemi, JJ | 3 |
| Weinstein, S | 4 |
| Lau, BH | 1 |
| Riesen, SK | 1 |
| Truong, KP | 1 |
| Lau, EW | 1 |
| Rohdewald, P | 1 |
| Barreta, RA | 1 |
| Ponticiello, A | 2 |
| Parrella, R | 2 |
| Reznik, M | 1 |
| Sharif, I | 1 |
| Ozuah, PO | 1 |
| Profita, M | 1 |
| Di Giorgi, R | 1 |
| Pompeo, F | 1 |
| Holt, A | 1 |
| Weiner, AL | 1 |
| Holmes, M | 2 |
| Cavanaugh, R | 1 |
| Bussamra, MH | 1 |
| Cukier, A | 1 |
| Lindgren, B | 1 |
| Svensson, K | 1 |
| Berggren, F | 1 |
| Kruse, M | 1 |
| Rosenkranz, B | 1 |
| Dobson, C | 1 |
| Ayre, G | 1 |
| Horowitz, A | 1 |
| Ploin, D | 1 |
| Rousson, A | 1 |
| Vitoux-Brot, C | 1 |
| Nouyrigat, V | 1 |
| Foucaud, P | 1 |
| Lemaire, JP | 1 |
| Chevallier, B | 1 |
| Bergeron, S | 1 |
| Martinot, A | 1 |
| Chéron, G | 2 |
| Floret, D | 1 |
| Tobin, A | 1 |
| Santamaria, J | 1 |
| Burnell, PK | 1 |
| Molitor, S | 1 |
| Liefring, E | 1 |
| Trautmann, M | 3 |
| Srichana, T | 2 |
| Suedee, R | 2 |
| Muanpanarai, D | 2 |
| Tanmanee, N | 2 |
| Chopra, N | 1 |
| Rimmer, M | 1 |
| Kahl, L | 1 |
| Jenkins, M | 2 |
| Kempsford, R | 2 |
| Handel, M | 1 |
| De Silva, M | 1 |
| Daley-Yates, P | 1 |
| Dennis, SM | 2 |
| Altmann, DR | 1 |
| Lee, TH | 3 |
| Waring, WS | 1 |
| Leigh, RB | 1 |
| Butz, AM | 1 |
| Donithan, M | 1 |
| Rand, C | 1 |
| Thompson, RE | 1 |
| Carnathan, B | 1 |
| Sung, J | 1 |
| Paramore, LC | 1 |
| Balkrishnan, R | 1 |
| Nelsen, LM | 1 |
| Kulkarni, AS | 1 |
| Pleasants, RA | 1 |
| Whitmire, JT | 1 |
| Schechter, MS | 1 |
| Deykin, A | 5 |
| Dimango, E | 3 |
| Leone, F | 3 |
| Pesola, GR | 5 |
| Pieters, WR | 2 |
| Wilson, KK | 1 |
| Smith, HC | 1 |
| Tamminga, JJ | 1 |
| Sondhi, S | 1 |
| Ayling, J | 1 |
| Haney, S | 3 |
| Tamura, G | 2 |
| Suda, Y | 1 |
| Ohshima, Y | 1 |
| Hata, I | 1 |
| Tsukahara, H | 1 |
| Omata, N | 1 |
| Yasutomi, M | 1 |
| Yamada, A | 1 |
| Mayumi, M | 1 |
| Angus, R | 1 |
| Reagon, R | 1 |
| Cheesbrough, A | 1 |
| Zhong, NS | 2 |
| Zheng, JP | 2 |
| Cai, BQ | 1 |
| Xie, CM | 1 |
| Sun, TY | 1 |
| Wang, DQ | 1 |
| Lin, YP | 1 |
| Tao, JJ | 1 |
| Kang, J | 1 |
| Xu, YP | 1 |
| Guo, XJ | 1 |
| Chen, XD | 1 |
| Yin, KS | 2 |
| Zhang, DP | 1 |
| Zhou, JY | 2 |
| Shen, HH | 1 |
| Qiu, C | 1 |
| Xiao, BR | 1 |
| Nabe, T | 1 |
| Yamauchi, K | 1 |
| Shinjo, Y | 1 |
| Niwa, T | 1 |
| Imoto, K | 1 |
| Koda, A | 2 |
| Richmond, NJ | 1 |
| Silverman, R | 3 |
| Kusick, M | 1 |
| Matallana, L | 1 |
| Winokur, J | 1 |
| Adcock, IM | 2 |
| Westerhof, FJ | 1 |
| Zuidhof, AB | 1 |
| Kok, L | 1 |
| Meurs, H | 1 |
| Zaagsma, J | 1 |
| Prenner, BM | 3 |
| van den Toorn, LM | 1 |
| Prins, JB | 1 |
| Leman, K | 1 |
| Hoogsteden, HC | 2 |
| Overbeek, SE | 1 |
| Rogeaux, Y | 1 |
| Moyse, D | 1 |
| Pello, JY | 1 |
| Giraud, V | 1 |
| Boot, JD | 1 |
| Tarasevych, S | 1 |
| Schoemaker, RC | 2 |
| Amin, D | 1 |
| Cohen, AF | 2 |
| Diamant, Z | 1 |
| Small, KM | 1 |
| Reti, S | 2 |
| Kasahara, DI | 1 |
| Perini, A | 1 |
| Lopes, FD | 1 |
| Arantes-Costa, FM | 1 |
| Martins, MA | 2 |
| Nunes, MP | 1 |
| Hamilton, LM | 1 |
| Puddicombe, SM | 1 |
| Dearman, RJ | 1 |
| Kimber, I | 1 |
| Wilson, SJ | 3 |
| Kallergis, EM | 1 |
| Manios, EG | 1 |
| Kanoupakis, EM | 1 |
| Schiza, SE | 1 |
| Mavrakis, HE | 1 |
| Klapsinos, NK | 1 |
| Vardas, PE | 1 |
| Kokturk, N | 1 |
| Kara, P | 1 |
| Mullaoglu, S | 1 |
| Yilmaz, F | 1 |
| Karamercan, A | 1 |
| Ralston, ME | 1 |
| Euwema, MS | 1 |
| Knecht, KR | 1 |
| Ziolkowski, TJ | 1 |
| Coakley, TA | 1 |
| Cline, SM | 1 |
| Jögi, R | 1 |
| Haugen, T | 1 |
| Meren, M | 1 |
| Loit, HM | 1 |
| Sairanen, U | 2 |
| Sandahl, A | 1 |
| You-Ning, L | 1 |
| Humphries, M | 1 |
| Du, X | 1 |
| Jiang, J | 1 |
| Gaugris, S | 1 |
| Kocevar, VS | 1 |
| Zhang, Q | 3 |
| Yin, DD | 1 |
| Epton, MJ | 1 |
| Kennedy, MA | 1 |
| Iles, S | 1 |
| Miller, AL | 1 |
| Littlejohn, MD | 1 |
| Hewitt, T | 1 |
| Swanney, MP | 1 |
| Brassett, KP | 1 |
| Qureshi, F | 3 |
| Zaritsky, A | 3 |
| Welch, C | 1 |
| Meadows, T | 1 |
| Burke, BL | 1 |
| Lemaigre, V | 1 |
| Smets, A | 1 |
| Verleden, GM | 1 |
| Kukreti, R | 1 |
| Bhatnagar, P | 1 |
| B-Rao, C | 1 |
| Madan, B | 1 |
| Das, C | 1 |
| Athavale, AU | 1 |
| Brahmachari, SK | 1 |
| Ghosh, B | 1 |
| Saeki, S | 1 |
| Balanag, VM | 1 |
| Yunus, F | 1 |
| Yang, PC | 1 |
| McLaughlin, TP | 2 |
| Hardasmalani, MD | 1 |
| DeBari, V | 1 |
| Bithoney, WG | 1 |
| Gold, N | 1 |
| Anthracopoulos, MB | 1 |
| Karatza, AA | 1 |
| Davlouros, PA | 1 |
| Chiladakis, JA | 1 |
| Manolis, AS | 1 |
| Beratis, NG | 1 |
| Olaguíbel, JM | 1 |
| Alvarez-Puebla, MJ | 1 |
| Anda, M | 1 |
| Gómez, B | 1 |
| García, BE | 1 |
| Tabar, AI | 1 |
| Arroabarren, E | 1 |
| Berti, I | 1 |
| Visintin, S | 1 |
| Donner, CF | 2 |
| Reynolds, NA | 1 |
| Wiseman, LR | 1 |
| Henderson, WR | 1 |
| Banerjee, ER | 1 |
| Chi, EY | 1 |
| Malone, R | 1 |
| Nimmagadda, S | 1 |
| Hellerud, BC | 1 |
| Kittang, OB | 1 |
| Vesterhus, P | 1 |
| Gillies, J | 1 |
| Brown, J | 1 |
| Byrnes, C | 2 |
| Farrell, A | 1 |
| Graham, D | 1 |
| James, AL | 1 |
| Elliot, JG | 1 |
| Abramson, MJ | 2 |
| Davies, A | 1 |
| McNee, W | 1 |
| Dougherty, S | 1 |
| Ryskina, KL | 2 |
| Legorreta, AP | 5 |
| Lee, DL | 1 |
| Hsu, CW | 1 |
| Lee, H | 6 |
| Chang, HW | 1 |
| Huang, YC | 1 |
| Wertheim, D | 1 |
| Jackson, AC | 1 |
| Langley, SJ | 4 |
| Allen, D | 1 |
| McDonnell, B | 1 |
| Wheeler, N | 1 |
| Sharma, RK | 1 |
| Sykes, A | 1 |
| Foroughi, S | 1 |
| Thyagarajan, A | 1 |
| Cohen, HW | 1 |
| Chung, V | 2 |
| Maggiore, D | 1 |
| Mani, K | 1 |
| Eryonucu, B | 2 |
| Uzun, K | 2 |
| Güler, N | 2 |
| Tuncer, M | 1 |
| Sezgi, C | 1 |
| Oh, SY | 1 |
| Bahn, JW | 1 |
| Choi, JY | 1 |
| Chang, YS | 1 |
| Kim, YK | 1 |
| Min, KU | 1 |
| Kim, YY | 1 |
| Adler, A | 1 |
| Uziel, Y | 1 |
| Mei-Zahav, M | 1 |
| Horowitz, I | 1 |
| Brugnami, G | 1 |
| Curradi, F | 1 |
| Bandi, V | 1 |
| Velamuri, S | 1 |
| Sirgi, C | 1 |
| Wendt, J | 1 |
| Wendt, R | 1 |
| Guntupalli, K | 1 |
| Lazo-Velásquez, JC | 1 |
| Lozada, AR | 1 |
| Cruz, HM | 1 |
| Moreno-Ancillo, A | 1 |
| Gil-Adrados, AC | 1 |
| Domínguez-Noche, C | 1 |
| Cosmes, PM | 1 |
| Skoner, DP | 4 |
| Kim, KT | 3 |
| Parsey, M | 2 |
| Hodge, MR | 1 |
| Baouz, S | 1 |
| Giron-Michel, J | 1 |
| Azzarone, B | 1 |
| Giuliani, M | 1 |
| Cagnoni, F | 1 |
| Olsson, S | 1 |
| Testi, R | 8 |
| Gabbiani, G | 1 |
| Lurie, P | 1 |
| Wolfe, SM | 1 |
| Nardi, AE | 1 |
| Jones, D | 1 |
| Estrada-Reyes, E | 1 |
| Rosas-Vargas, MA | 1 |
| Nava-Ocampo, AA | 1 |
| Pétavy, F | 1 |
| Phrampus, E | 1 |
| Pitetti, R | 1 |
| Saville, A | 1 |
| Corcoran, T | 1 |
| Funt, N | 1 |
| Thompson, A | 1 |
| D'Urzo, A | 3 |
| Pauwels, R | 2 |
| Merino, JM | 1 |
| Jaspal, M | 1 |
| Boutet, S | 1 |
| Karpel, JP | 4 |
| Noonan, MJ | 2 |
| Monahan, ME | 1 |
| Lutsky, B | 1 |
| Staudinger, H | 1 |
| Koopmans, JG | 3 |
| van der Zee, JS | 5 |
| Prosperini, G | 2 |
| Arcidiacono, G | 1 |
| Ciamarra, I | 2 |
| Polosa, R | 2 |
| Schreck, DM | 2 |
| Babin, S | 1 |
| Bohács, A | 1 |
| Pállinger, E | 1 |
| Rigó, J | 1 |
| Magyar, P | 1 |
| Losonczy, G | 1 |
| Tomlinson, HS | 1 |
| Corlett, SA | 1 |
| Allen, MB | 1 |
| Murali, PM | 1 |
| Rajasekaran, S | 1 |
| Krishnarajasekar, OR | 1 |
| Perumal, T | 1 |
| Nalini, K | 1 |
| Lakshmisubramanian, S | 1 |
| Deivanayagam, CN | 1 |
| Pérez-Francés, C | 1 |
| Badiola, C | 1 |
| Lanuza, A | 1 |
| Bruno, L | 1 |
| Ferrer, A | 2 |
| Ankerst, J | 2 |
| Brodbeck, T | 1 |
| Majumdar, A | 1 |
| Town, GI | 5 |
| Silverman, M | 7 |
| Suki, B | 2 |
| Liu, W | 1 |
| Marriott, C | 1 |
| Snooks, H | 1 |
| Halter, M | 1 |
| Palmer, Y | 1 |
| Booth, H | 5 |
| Moore, F | 1 |
| Nakano, J | 1 |
| Yano, T | 1 |
| Yamamura, K | 1 |
| Yoshihara, H | 1 |
| Ohbayashi, O | 1 |
| Yamashita, N | 1 |
| Ohta, K | 2 |
| Rivera, ML | 1 |
| Kim, TY | 1 |
| Stewart, GM | 1 |
| Minasyan, L | 1 |
| Brown, L | 1 |
| Bourdin, A | 1 |
| Paganin, F | 2 |
| Kieseler, D | 1 |
| Yun, AJ | 1 |
| Lee, PY | 1 |
| Doux, JD | 1 |
| Mathison, DA | 2 |
| Koziol, JA | 2 |
| Nishimura, S | 1 |
| Silva, CS | 1 |
| Torres, LA | 1 |
| Rahal, A | 1 |
| Terra Filho, J | 1 |
| Vianna, EO | 1 |
| Gilmore, AS | 2 |
| Agarwal, R | 1 |
| Gupta, D | 1 |
| Parr, JR | 1 |
| Salama, A | 1 |
| Sebire, P | 1 |
| Sannier, N | 1 |
| Timsit, S | 1 |
| Cojocaru, B | 1 |
| Leis, A | 1 |
| Wille, C | 1 |
| Garel, D | 1 |
| Bocquet, N | 1 |
| Adelroth, E | 1 |
| Fairall, L | 1 |
| Lombardi, DM | 2 |
| English, R | 1 |
| Ibe, BO | 2 |
| Portugal, AM | 1 |
| Raj, JU | 2 |
| Rubinfeld, AR | 1 |
| Scicchitano, R | 1 |
| Hunt, A | 1 |
| Thompson, PJ | 2 |
| Van Nooten, A | 1 |
| Sin, DD | 1 |
| Man, SF | 1 |
| Pearse, DB | 1 |
| Pyrgos, G | 1 |
| Permutt, S | 2 |
| Bahnmiller, N | 1 |
| Li, AM | 1 |
| Tsang, T | 1 |
| Wong, E | 2 |
| Chan, D | 1 |
| Sung, R | 1 |
| Ng, PC | 1 |
| Foster, GC | 1 |
| Batra, V | 2 |
| Rybinski, KA | 1 |
| Cirelli, R | 2 |
| Tsuruta, D | 1 |
| Sowa, J | 1 |
| Kobayashi, H | 2 |
| Ishii, M | 1 |
| Rooklin, A | 2 |
| Verbruggen, SC | 1 |
| Corel, LJ | 1 |
| Tiddens, HA | 1 |
| Carter, K | 1 |
| Cheung, D | 3 |
| van Klink, HC | 1 |
| Atienza, T | 1 |
| Mihaescu, T | 1 |
| Duggan, M | 1 |
| Benito Fernández, J | 1 |
| Trebolazabala Quirante, N | 1 |
| Landa Garriz, M | 1 |
| Mintegi Raso, S | 1 |
| González Díaz, C | 1 |
| Mintz, ML | 1 |
| Hyvärinen, MK | 1 |
| Reijonen, TM | 1 |
| Korhonen, K | 1 |
| Kiviniemi, V | 2 |
| Yasuda, H | 1 |
| Yamaya, M | 1 |
| Taivainen, AH | 2 |
| Tukiainen, HO | 2 |
| Manjunath, R | 1 |
| Jhingran, PM | 1 |
| Tarsin, WY | 1 |
| Pearson, SB | 1 |
| Assi, KH | 1 |
| Lomia, M | 1 |
| Tchelidze, T | 1 |
| Pruidze, M | 1 |
| Capriles, E | 1 |
| Do Campo, A | 1 |
| Verde, O | 1 |
| Pluchino, S | 1 |
| Capriles Hulett, A | 1 |
| Kobiakova, OS | 1 |
| Nikitina, LIu | 1 |
| Smetanenko, TV | 1 |
| Petrovskiĭ, FI | 1 |
| Georgitis, JW | 1 |
| Noonan, M | 4 |
| Ruff, ME | 1 |
| Johnson, SR | 1 |
| Marion, AA | 1 |
| Vrchoticky, T | 1 |
| Emmanuel, PJ | 1 |
| Lujan-Zilbermann, J | 1 |
| Aggarwal, P | 1 |
| Sharad, S | 1 |
| Handa, R | 1 |
| Dwiwedi, SN | 1 |
| Irshad, M | 1 |
| Briggs, AH | 2 |
| Wallace, MV | 1 |
| Emerman, C | 1 |
| Parsey, MV | 2 |
| Gor, D | 1 |
| Yoxall, S | 4 |
| Mosen, D | 1 |
| Stibolt, TB | 1 |
| Leong, A | 1 |
| Johnson, MS | 1 |
| Mendoza, G | 1 |
| Cook, EF | 1 |
| Schwabe, A | 1 |
| Krämer, I | 1 |
| Aït-Khaled, N | 4 |
| Enarson, DA | 3 |
| Rutkowski, R | 1 |
| Stasiak-Barmuta, A | 1 |
| Moniuszko, T | 1 |
| Rutkowska-Rogacz, D | 1 |
| Woińska, M | 1 |
| Rutkowski, K | 1 |
| Sidorczuk, M | 1 |
| Ameh, V | 1 |
| Jenner, R | 1 |
| Jilani, N | 1 |
| Bradbury, A | 1 |
| Fromer, L | 1 |
| McHugh, P | 1 |
| Duncan, B | 1 |
| Houghton, F | 1 |
| Singam, R | 1 |
| Jena, PK | 1 |
| Behera, S | 1 |
| Hellermann, GR | 1 |
| Lockey, RF | 2 |
| Ledford, D | 2 |
| Mohapatra, SS | 1 |
| Saville, AL | 2 |
| Sikes, KL | 1 |
| Corcoran, TE | 1 |
| Watanasomsiri, A | 1 |
| Harmanci, K | 1 |
| Bakirtas, A | 1 |
| Turktas, I | 3 |
| Degim, T | 1 |
| Salpeter, SR | 1 |
| Buckley, NS | 1 |
| Ormiston, TM | 1 |
| Salpeter, EE | 1 |
| Zagdańska, R | 2 |
| Grzelewska-Rzymowska, I | 3 |
| El-Ekiaby, A | 1 |
| Brianas, L | 1 |
| Galan, G | 4 |
| Kaeberlein, FJ | 1 |
| Villaba, KD | 1 |
| Lu, XY | 1 |
| Pines, JM | 1 |
| Lee, S | 1 |
| Ismail, T | 1 |
| Gontijo-Amaral, C | 1 |
| Ribeiro, MA | 1 |
| Gontijo, LS | 1 |
| Condino-Neto, A | 1 |
| Ribeiro, JD | 1 |
| Allen-Ramey, FC | 1 |
| Bukstein, D | 4 |
| Luskin, A | 1 |
| Sajjan, SG | 1 |
| Markson, LE | 1 |
| Crownover, BK | 1 |
| Wasserman, RL | 2 |
| Scott, CA | 2 |
| Faris, MA | 1 |
| Johansson, G | 1 |
| Andreasson, EB | 1 |
| Larsson, PE | 1 |
| Vogelmeier, CF | 1 |
| Davis, WB | 1 |
| Doherty, DE | 1 |
| Hamid, Q | 1 |
| Kavuru, MS | 1 |
| Reilly, DS | 1 |
| Stauffer, JL | 1 |
| Caramori, G | 1 |
| Egbagbe, EE | 1 |
| Elusoji, SO | 1 |
| Akerman, MJ | 1 |
| Yaegashi, M | 1 |
| Khiangte, Z | 1 |
| Murugan, AT | 1 |
| Abe, O | 1 |
| Marmur, JD | 1 |
| Milgrom, H | 3 |
| Crane, J | 17 |
| Aslan, S | 1 |
| Kandiş, H | 1 |
| Akgun, M | 1 |
| Cakir, Z | 1 |
| Inandi, T | 1 |
| Görgüner, M | 1 |
| Kuntz, KM | 1 |
| Paltiel, AD | 1 |
| Rovati, GE | 1 |
| Citro, S | 1 |
| Brichetto, L | 1 |
| Ravasi, S | 1 |
| Bell, A | 1 |
| Conway, PH | 1 |
| Edwards, S | 1 |
| Stucky, ER | 1 |
| Chiang, VW | 1 |
| Ottolini, MC | 1 |
| Landrigan, CP | 1 |
| Sagara, H | 1 |
| Maier, G | 1 |
| Rubino, C | 1 |
| Hsu, R | 1 |
| Grasela, T | 1 |
| Fedor, ME | 1 |
| Rubinstein, A | 1 |
| Vassiliou, V | 1 |
| Zipitis, CS | 1 |
| Spurling, G | 1 |
| Doust, J | 1 |
| Bencharif, N | 2 |
| Boulahdib, F | 1 |
| Camara, LM | 2 |
| Dagli, E | 3 |
| Karadag, B | 1 |
| Koadag, B | 1 |
| Ottmani, SE | 1 |
| Pham, DL | 2 |
| Sow, O | 2 |
| Yousser, M | 2 |
| Zidouni, N | 2 |
| Aldington, S | 1 |
| Langley, S | 1 |
| Jiang, WH | 1 |
| Deng, L | 1 |
| Wen, HH | 1 |
| Yu, JL | 1 |
| Zeng, Q | 1 |
| Francavilla, R | 1 |
| Tesse, R | 1 |
| Strippoli, A | 1 |
| Polimeno, L | 1 |
| Loforese, A | 1 |
| Miniello, VL | 1 |
| Armenio, L | 1 |
| Stănescu, DC | 2 |
| Pasaoglu, G | 1 |
| Gok, H | 1 |
| Sonel, B | 1 |
| Yalcin, P | 1 |
| Misirligil, Z | 1 |
| Holt, EW | 1 |
| Tan, J | 1 |
| Hosgood, HD | 1 |
| Fujimoto, K | 1 |
| Komatsu, Y | 1 |
| Yasuo, M | 1 |
| Urushihata, K | 1 |
| Kubo, K | 1 |
| Hartmann, U | 1 |
| Metzenauer, P | 1 |
| Stravinskaite, K | 1 |
| Matsumoto, T | 1 |
| Matsumura, M | 1 |
| Tsuda, M | 1 |
| Kanaya, A | 1 |
| Moriwaki, A | 1 |
| Nakanishi, Y | 1 |
| Williams, C | 2 |
| Seymour, SM | 1 |
| Sullivan, EJ | 1 |
| Meyer, RJ | 2 |
| Davi, RC | 1 |
| Fitzgerald, MA | 1 |
| Lincourt, WR | 2 |
| Locantore, NW | 1 |
| Carranza-Rosenzweig, J | 1 |
| Li, HT | 1 |
| Zhang, TT | 1 |
| Zhou, H | 1 |
| Qu, XJ | 1 |
| Wu, WM | 1 |
| Huang, J | 1 |
| Lavaud, J | 1 |
| Baitinger, LA | 1 |
| Bender, BG | 1 |
| Pedan, A | 1 |
| Varasteh, LT | 1 |
| Haidl, P | 1 |
| Schmidt, F | 1 |
| Wiese, C | 1 |
| Koehler, D | 1 |
| Selvaraj, S | 1 |
| Jha, G | 1 |
| Babbar, H | 1 |
| Walia, B | 1 |
| Nishiyama, O | 1 |
| Taniguchi, H | 2 |
| Kondoh, Y | 1 |
| Kimura, T | 2 |
| Kato, K | 1 |
| Kume, H | 1 |
| Shimokata, K | 1 |
| Ohm, R | 1 |
| Aaronson, LS | 1 |
| Salo, D | 1 |
| Tuel, M | 1 |
| Lavery, RF | 1 |
| Reischel, U | 1 |
| Lebowitz, J | 1 |
| Moore, T | 1 |
| Marchese, R | 1 |
| Soresi, S | 1 |
| Interrante, A | 1 |
| Keech, ML | 1 |
| Moore, RH | 2 |
| Zimmerman, JL | 1 |
| Miller, CT | 1 |
| Bag, R | 1 |
| Sharafkhaneh, A | 2 |
| Dal Negro, RW | 2 |
| Micheletto, C | 1 |
| Tognella, S | 1 |
| Trevisan, F | 2 |
| Guerriero, M | 1 |
| Asher, I | 1 |
| O'Connell, O | 1 |
| Hasford, J | 1 |
| Sugerman, RW | 1 |
| Ceruti, E | 1 |
| Maspero, JF | 1 |
| Kleha, JF | 1 |
| Lawyer, MC | 1 |
| Antoniu, SA | 1 |
| Babb, TG | 1 |
| Officer, TM | 1 |
| Sharafkhaneh, H | 1 |
| Boriek, AM | 1 |
| Mickleborough, TD | 1 |
| Turner, LA | 1 |
| Chakraborti, A | 1 |
| Lang, DM | 1 |
| Heldt, G | 1 |
| Bantje, TA | 1 |
| Kolbe, J | 1 |
| D'Urzo, AD | 4 |
| Janostáková, A | 1 |
| Jarmila, S | 1 |
| Zápalka, M | 1 |
| Hajduch, M | 1 |
| Naya, IP | 2 |
| Andersson, TL | 1 |
| Fardon, T | 1 |
| Koul, PB | 1 |
| Minarik, M | 1 |
| Totapally, BR | 1 |
| Subramanian, S | 1 |
| Kumaravel, A | 1 |
| D'Urzo, TD | 1 |
| Axelrod, S | 1 |
| Bielory, L | 1 |
| Casuso, M | 1 |
| Rodriguez, JC | 1 |
| Castro, P | 1 |
| Varela, NM | 1 |
| Morero, JL | 1 |
| Rizzo, OE | 1 |
| Bertolot, G | 1 |
| Schiavi, EA | 2 |
| Albers, JM | 1 |
| Verblackt, HW | 1 |
| Costongs, RJ | 1 |
| Westers, P | 1 |
| Jantikar, A | 1 |
| Brashier, B | 1 |
| Maganji, M | 1 |
| Raghupathy, A | 1 |
| Mahadik, P | 1 |
| Gokhale, P | 1 |
| Salvi, S | 1 |
| Jamalvi, SW | 1 |
| Raza, SJ | 1 |
| Naz, F | 1 |
| Shamim, S | 1 |
| Jamalvi, SM | 1 |
| Zhang, NF | 1 |
| Chen, AH | 1 |
| Chen, RC | 1 |
| Li, JM | 1 |
| Bønnelykke, K | 1 |
| Jespersen, JJ | 1 |
| Gupta, MK | 1 |
| Singh, M | 2 |
| Chaulier, K | 1 |
| Chalumeau, S | 1 |
| Ber, CE | 1 |
| Bret, M | 1 |
| Rimmelé, T | 1 |
| Tomcsányi, J | 1 |
| Somlói, M | 1 |
| Frész, T | 1 |
| Arabadzisz, H | 1 |
| Zsoldos, A | 1 |
| Vecsey, T | 1 |
| Simon, LJ | 1 |
| Yacobov, R | 1 |
| Edwards, MR | 1 |
| Haas, J | 1 |
| Ribeiro de Andrade, C | 1 |
| Duarte, MC | 1 |
| Hayasaka, N | 1 |
| Yaita, T | 1 |
| Kuwaki, T | 1 |
| Honma, S | 1 |
| Honma, K | 1 |
| Kudo, T | 1 |
| Shibata, S | 1 |
| Kemeny, ME | 1 |
| Rose, RM | 1 |
| Berg-Smith, SM | 1 |
| Kline, JN | 1 |
| Najafizadeh, K | 1 |
| Sohrab Pour, H | 1 |
| Ghadyanee, M | 1 |
| Shiehmorteza, M | 1 |
| Jamali, M | 1 |
| Majdzadeh, S | 1 |
| Kobayashi, Y | 1 |
| Yasuba, H | 1 |
| Kudou, M | 1 |
| Kharitonov, SA | 3 |
| Trachsel, D | 1 |
| Newth, CJ | 3 |
| Hammer, J | 1 |
| Anthonisen, N | 1 |
| Maestrelli, P | 1 |
| Pozzi, E | 1 |
| Morelli, P | 1 |
| Shepard, JA | 1 |
| Mark, EJ | 1 |
| Richardson, CH | 2 |
| Hosker, H | 1 |
| Mukherjee, R | 1 |
| Wong, I | 1 |
| Thomas, M | 1 |
| Stamuli, E | 1 |
| Tabberer, M | 1 |
| Gosden, T | 1 |
| Rudge, H | 1 |
| Kolpakova, AF | 1 |
| Alzoghaibi, MA | 1 |
| Bahammam, AS | 1 |
| Bagdonas, A | 1 |
| Gibbs, MR | 1 |
| Jee, R | 1 |
| Brownlow, H | 1 |
| Fredenburgh, LE | 1 |
| Campion, EW | 1 |
| Lovén, J | 1 |
| Svitacheva, N | 1 |
| Jerre, A | 1 |
| Miller-Larsson, A | 1 |
| Korn, SH | 1 |
| Gross, NJ | 1 |
| Karkoulias, K | 1 |
| Charokopos, N | 1 |
| Kaparianos, A | 1 |
| Sampsonas, F | 1 |
| Tsiamita, M | 1 |
| Spiropoulos, K | 1 |
| Stanković, I | 2 |
| Pejcić, T | 1 |
| Milenković, B | 1 |
| Jovanović, D | 1 |
| Rancić, M | 1 |
| Bonabel-Chone, C | 1 |
| Lawson, N | 1 |
| Borrill, ZL | 1 |
| Wixon, CL | 1 |
| Tee, AK | 1 |
| Irving, LB | 1 |
| Banik, N | 1 |
| Tews, JT | 1 |
| Nowak, D | 3 |
| Black, PN | 2 |
| Zitt, MJ | 1 |
| Rachelefsky, GS | 7 |
| Terracciano, L | 1 |
| Fiocchi, A | 2 |
| Bouygue, GR | 1 |
| Franssen, E | 2 |
| Perrio, MJ | 1 |
| Dahiya, B | 1 |
| Arandelović, M | 1 |
| Nikolić, M | 1 |
| M'buila, C | 1 |
| Bados, A | 1 |
| Peiffer, C | 2 |
| Bernard, A | 1 |
| Zaccaria, I | 1 |
| Denjean, A | 1 |
| Harkins, M | 1 |
| Esparham, A | 1 |
| Cowie, RL | 1 |
| Keith, PK | 1 |
| Bonniaud, P | 1 |
| Favrolt, N | 1 |
| Collet, E | 1 |
| Dumas, JP | 1 |
| Guilloux, L | 1 |
| Pauli, G | 1 |
| Camus, P | 1 |
| Hulme, J | 1 |
| Bogacka, E | 1 |
| Bocheńska-Marciniak, M | 1 |
| Sterchaluk-Grzyb, E | 1 |
| Tworek, D | 1 |
| Parker, D | 1 |
| Rice, L | 1 |
| Brown, AD | 1 |
| Bunnage, ME | 1 |
| Glossop, PA | 1 |
| Holbrook, M | 1 |
| Jones, RD | 1 |
| Lane, CA | 1 |
| Lewthwaite, RA | 1 |
| Mantell, S | 1 |
| Perros-Huguet, C | 1 |
| Price, DA | 1 |
| Webster, R | 1 |
| Blitz, S | 1 |
| Diner, B | 1 |
| Mackey, D | 1 |
| Ross, S | 1 |
| Senthilselvan, A | 1 |
| Kawai, M | 1 |
| Pullerits, T | 1 |
| Takaori, S | 1 |
| Takemoto, Y | 1 |
| Chan, CK | 1 |
| Okell, M | 1 |
| O'Byrne, P | 1 |
| Bai, T | 1 |
| Quiralte, J | 1 |
| Martinez-Aguilar, NE | 1 |
| Carlsheimer, A | 1 |
| Macklem, P | 1 |
| Mitchell, H | 1 |
| Noble, P | 1 |
| McFawn, P | 1 |
| Mazhar, SH | 1 |
| Ismail, NE | 1 |
| Newton, DA | 1 |
| Brixner, DI | 1 |
| Lenhart, G | 1 |
| Young, DC | 1 |
| Samuelson, WM | 1 |
| Benninger, C | 1 |
| Mastronarde, JG | 1 |
| Exline, MC | 1 |
| Huang, DD | 1 |
| Zheng, JY | 1 |
| Hardie, GE | 1 |
| Brown, JK | 1 |
| Gold, WM | 1 |
| Stern, T | 1 |
| Dawson, N | 1 |
| Tsai, HJ | 1 |
| Frith, L | 3 |
| Thompson-Figueroa, J | 1 |
| Klein, J | 1 |
| Flynn, F | 1 |
| Lang, S | 1 |
| Bourassa, L | 1 |
| Burns, S | 1 |
| Liu, CT | 1 |
| Wang, YM | 1 |
| Tan, CW | 1 |
| Pang, YM | 1 |
| Eigen, H | 2 |
| Montgomery, GS | 1 |
| Amaro, S | 1 |
| Liao, O | 1 |
| Bohn, D | 2 |
| Curran-Everett, D | 1 |
| Camiciottoli, G | 1 |
| Brookman, LJ | 1 |
| Knowles, LJ | 1 |
| Barbier, M | 1 |
| Elharrar, B | 1 |
| Seed, MJ | 1 |
| Agius, RM | 2 |
| Wangsuppasawad, N | 1 |
| Kiatboonsri, C | 1 |
| Choothakan, S | 1 |
| Sag, C | 1 |
| Ozden, FO | 1 |
| Acikgoz, G | 1 |
| Anlar, FY | 1 |
| Horvath, G | 1 |
| Campos, M | 1 |
| Loza, MJ | 1 |
| Foster, S | 1 |
| Penn, RB | 1 |
| Lawrance, RM | 1 |
| Ambrose, HJ | 1 |
| Cooray, M | 1 |
| Mills, G | 1 |
| O'Callaghan, C | 5 |
| White, J | 1 |
| Jackson, J | 1 |
| Crosby, D | 1 |
| Dougill, B | 1 |
| Bland, H | 1 |
| Soltani, A | 1 |
| Wolzt, M | 1 |
| de la Peña, A | 1 |
| Berclaz, PY | 1 |
| Tibaldi, FS | 1 |
| Gates, JR | 1 |
| Muchmore, DB | 1 |
| Goryachkina, L | 1 |
| Hamilos, DL | 1 |
| Levy, RJ | 1 |
| Marcus, M | 1 |
| Hooimeijer, HL | 1 |
| van der Deure, J | 1 |
| de Langen, JJ | 1 |
| Wepner, U | 1 |
| Reddy, PJ | 1 |
| Aksoy, MO | 1 |
| Li, XX | 1 |
| Ji, R | 1 |
| Kelsen, SG | 3 |
| Kaplan, A | 1 |
| Wang, MT | 1 |
| Skrepnek, GH | 1 |
| Armstrong, E | 1 |
| Sherrill, DL | 1 |
| Harris, RB | 1 |
| Tsai, CL | 1 |
| Malone, DC | 1 |
| Lacy, BE | 1 |
| Mathis, C | 1 |
| DesBiens, J | 1 |
| Manrique, HA | 1 |
| Muñoz, PA | 1 |
| Peña, AM | 1 |
| Barberà, JA | 3 |
| Roca, J | 6 |
| Salyer, JW | 1 |
| Crotwell, DN | 1 |
| Cowan, CA | 1 |
| Carter, ER | 2 |
| Liu, H | 1 |
| Zhou, LF | 1 |
| Qian, FH | 1 |
| Huang, M | 1 |
| Zhang, XL | 1 |
| Lee, BH | 1 |
| Kim, SH | 1 |
| Chou, V | 1 |
| Ogawa, Y | 1 |
| Murray, JJ | 6 |
| Wolfe, J | 5 |
| Andersen, L | 1 |
| Stauffer, J | 1 |
| Leo, HL | 1 |
| Dombkowski, KJ | 1 |
| Clark, NM | 1 |
| Melani, AS | 1 |
| Song, TW | 1 |
| Kim, KW | 1 |
| Kim, ES | 1 |
| Park, JW | 1 |
| Sohn, MH | 1 |
| Kim, KE | 1 |
| Plotnick, L | 1 |
| Savdie, C | 1 |
| Kudirka, D | 1 |
| Meng, L | 1 |
| Ward, JE | 1 |
| Bamford, T | 2 |
| Mast, A | 1 |
| Pain, MC | 1 |
| Smallwood, D | 1 |
| Tran, T | 1 |
| Wilson, J | 1 |
| Stewart, AG | 1 |
| Babl, FE | 1 |
| Sheriff, N | 1 |
| Borland, M | 1 |
| Acworth, J | 1 |
| Neutze, J | 1 |
| Krieser, D | 1 |
| Ngo, P | 1 |
| Schutz, J | 1 |
| Thomson, F | 1 |
| Cotterell, E | 1 |
| Jamison, S | 1 |
| Francis, P | 1 |
| Chen, ZG | 1 |
| Li, M | 1 |
| Chen, YF | 1 |
| Chen, FH | 1 |
| Ji, JZ | 1 |
| Abdallah, MF | 1 |
| Singhania, N | 1 |
| Dhamija, R | 1 |
| Gravina, LP | 1 |
| Grenoville, M | 1 |
| Luigi, DB | 1 |
| Emanuel, DT | 1 |
| Federica, DB | 1 |
| Fabrizio, DT | 1 |
| Ishihara, K | 1 |
| Sano, Y | 2 |
| Nakashima, M | 1 |
| Karpel, J | 1 |
| Cassino, C | 1 |
| Johnson, P | 1 |
| Conoscenti, CS | 1 |
| Poon, AH | 1 |
| Lazarus, R | 1 |
| Lasky-Su, J | 1 |
| Lange, C | 1 |
| Creagh-Brown, BC | 1 |
| Stuhlman, K | 1 |
| Broski, SE | 1 |
| Amundson, DE | 1 |
| Joos, S | 1 |
| Miksch, A | 1 |
| Wieseler, B | 1 |
| Grouven, U | 1 |
| Kaiser, T | 1 |
| Hampel, FC | 1 |
| Mezzanotte, WS | 1 |
| Shah, SR | 1 |
| Kontra, KM | 1 |
| Bailey, W | 1 |
| Matz, J | 2 |
| Dransfield, M | 1 |
| ten Hacken, NH | 1 |
| Zhao, HJ | 1 |
| Cai, SX | 1 |
| Tong, WC | 1 |
| Li, WJ | 1 |
| Reinhardt, D | 5 |
| Zehmisch, T | 2 |
| Becker, B | 2 |
| Nagel-Hiemke, M | 2 |
| Dyson, AJ | 2 |
| Mackay, AD | 3 |
| Howarth, NJ | 1 |
| Gadsby, R | 1 |
| Guerrin, F | 1 |
| Robin, H | 1 |
| Lahoutte, C | 1 |
| Voisin, C | 1 |
| Falliers, CJ | 2 |
| Morell Brotad, F | 1 |
| Anto Boque, JM | 1 |
| Oriol Sabater, J | 1 |
| Orriols Martínez, R | 1 |
| Ingemann-Hansen, T | 1 |
| Bundgaard, A | 4 |
| Halkjaer-Kristensen, J | 1 |
| Siggaard-Andersen, J | 1 |
| Weeke, B | 1 |
| Misra, NP | 1 |
| Tiwari, UC | 1 |
| Khemchandani, GT | 1 |
| Dollery, CT | 3 |
| Svedmyr, K | 4 |
| Youngchaiyud, P | 2 |
| Liebhart, E | 5 |
| Suchnicka, R | 2 |
| Krasnowska, M | 8 |
| Löfdahl, CG | 13 |
| Bengtsson, B | 2 |
| Svedmyr, N | 21 |
| Lehtonen, A | 1 |
| Viikari, J | 1 |
| Sallinen, VP | 1 |
| Elo, J | 2 |
| Pride, NB | 2 |
| Lillington, AW | 1 |
| Campbell, AN | 1 |
| Poulier, RA | 1 |
| Bierman, CW | 5 |
| Sly, RM | 4 |
| Horn, CR | 4 |
| Cochrane, GM | 9 |
| Oosterhuis, B | 1 |
| Braat, MC | 1 |
| van Boxtel, CJ | 1 |
| Basran, GS | 1 |
| Paul, W | 1 |
| Morley, J | 10 |
| Manresa, F | 2 |
| Rodriguez, B | 1 |
| Sabaté, I | 1 |
| Romero, P | 2 |
| Tschopp, JM | 1 |
| Turner-Warwick, M | 1 |
| Jones, G | 1 |
| Tarlo, SM | 2 |
| Dolovich, J | 6 |
| Hargreave, FE | 14 |
| Tomioka, K | 1 |
| Ida, H | 1 |
| Bryant, DH | 2 |
| Pui, A | 1 |
| Brown, MJ | 1 |
| Tomita, Y | 1 |
| Masaki, T | 1 |
| Sugimoto, H | 1 |
| Matsunaga, M | 1 |
| Yamada, S | 1 |
| Arai, Y | 3 |
| Mishima, T | 1 |
| Shioda, H | 2 |
| Posner, V | 1 |
| Posner, B | 1 |
| Miraglia Del Giudice, M | 6 |
| Capristo, A | 4 |
| Maiello, N | 1 |
| Thiessen, B | 4 |
| Bell, R | 1 |
| Sahay, JN | 3 |
| Barber, PV | 1 |
| Chatterjee, SS | 4 |
| Jolobe, OM | 4 |
| Leahy, BC | 1 |
| Gomm, SA | 1 |
| Allen, SC | 1 |
| Stokes, GM | 4 |
| Hodges, IG | 2 |
| Flint, K | 1 |
| Hockley, B | 4 |
| Johnson, NM | 6 |
| Flint, KC | 1 |
| Scheinmann, P | 3 |
| Benoist, MR | 1 |
| Meyer, B | 1 |
| Paupe, J | 2 |
| Baños Hidalgo, P | 1 |
| Ramos Martos, A | 1 |
| Cabrera Moreno, R | 1 |
| Luque Leal, J | 1 |
| Palacios Giner, A | 1 |
| Naeraa, N | 1 |
| Lyager, S | 1 |
| Hilberg, C | 1 |
| Fischbacher, CM | 1 |
| Milroy, R | 1 |
| Monie, RD | 4 |
| Cox, ID | 1 |
| Hughes, DT | 1 |
| McDonnell, KA | 1 |
| Vázquez, C | 3 |
| Fidalgo, I | 1 |
| Virto, MC | 1 |
| Labayru, MT | 2 |
| Casas, C | 1 |
| Yamada, Y | 1 |
| Kawai, T | 1 |
| Onaka, A | 1 |
| Kamo, T | 1 |
| Ajisawa, A | 1 |
| Conolly, ME | 4 |
| Yamato, T | 1 |
| Yamagishi, M | 1 |
| Mizuki, M | 1 |
| Morita, M | 1 |
| Kitamura, S | 1 |
| Ishihara, Y | 1 |
| Hartley, JP | 7 |
| Davies, CJ | 1 |
| Charles, TJ | 1 |
| Nogrady, SG | 4 |
| Winson, MD | 1 |
| Kamei, H | 1 |
| Hirano, M | 1 |
| Kawano, K | 1 |
| Imanishi, H | 1 |
| Kawaguchi, H | 1 |
| Hui, KK | 1 |
| Littner, MR | 2 |
| Wolfe, RN | 1 |
| Ikemori, R | 2 |
| Motojima, S | 2 |
| Tattersfield, AE | 16 |
| Harvey, JE | 4 |
| Gribbin, HR | 1 |
| Titinchi, S | 1 |
| Al Shamma, M | 1 |
| Patel, KR | 6 |
| Kerr, JW | 4 |
| Clark, B | 1 |
| Andersson, P | 2 |
| Olsson, OA | 1 |
| Waldeck, B | 1 |
| Schiffer, R | 1 |
| Grimwood, K | 2 |
| Fergusson, DM | 5 |
| Dawson, KP | 10 |
| Towns, SJ | 1 |
| Sharota, E | 1 |
| Simpson, SJ | 1 |
| Mellis, CM | 3 |
| Alanko, K | 5 |
| Sahlström, K | 2 |
| Muers, M | 1 |
| Dawkins, K | 1 |
| Bolle, R | 3 |
| Holt, J | 2 |
| Stiell, IG | 1 |
| Rivington, RN | 2 |
| Williams, RI | 1 |
| Fergusson, RJ | 3 |
| Carmichael, J | 4 |
| Rafferty, P | 2 |
| Higgs, CM | 2 |
| Laszlo, G | 3 |
| Bianco, S | 4 |
| Robuschi, M | 1 |
| Damonte, C | 1 |
| Sturani, C | 1 |
| Schiavina, M | 1 |
| Tosi, I | 1 |
| Gunella, G | 1 |
| Pounsford, JC | 2 |
| Fuller, RW | 7 |
| Saunders, KB | 3 |
| Spector, SL | 7 |
| Whitsett, TL | 1 |
| George, RB | 4 |
| Dwek, JH | 1 |
| Izquierdo, R | 1 |
| Evans, HE | 5 |
| Nakhosteen, JA | 2 |
| Hirche, H | 1 |
| Lahdensuo, A | 6 |
| Repsher, LH | 2 |
| Anderson, JA | 1 |
| Bush, RK | 4 |
| Kass, I | 1 |
| Kemp, JP | 16 |
| Reed, C | 1 |
| Siegel, S | 1 |
| Webb, DR | 2 |
| Sil'vestrov, VP | 2 |
| Surovov, IuA | 2 |
| Pakulin, IA | 2 |
| Larin, NV | 1 |
| Plit, M | 1 |
| Pover, GM | 4 |
| Snashall, PD | 4 |
| Maesen, FP | 9 |
| Smeets, JJ | 9 |
| Bernsen, R | 1 |
| Cornelissen, PJ | 2 |
| Beskow, R | 1 |
| Ericsson, CH | 1 |
| Grönneberg, R | 1 |
| Skedinger, M | 1 |
| Brenner, BE | 1 |
| Svenonius, E | 4 |
| Kautto, R | 2 |
| Arborelius, M | 9 |
| Tullett, WM | 1 |
| Davies, JG | 1 |
| Dhillon, P | 2 |
| Cole, P | 1 |
| Levison, H | 14 |
| Isles, A | 1 |
| Gregg, I | 2 |
| Gunawardena, KA | 3 |
| Patel, B | 1 |
| Campbell, IA | 2 |
| MacDonald, JB | 1 |
| Smith, AP | 3 |
| Al-Hillawi, AH | 1 |
| Hayward, R | 1 |
| Boe, J | 5 |
| Inui, H | 1 |
| Nagakura, T | 1 |
| Iikura, Y | 2 |
| Kalloghlian, A | 1 |
| Jenkins, J | 1 |
| Edmonds, J | 1 |
| Barker, G | 1 |
| Srivastava, N | 1 |
| Gupta, SP | 2 |
| Srivastava, LM | 1 |
| Burge, PS | 2 |
| Harries, MG | 1 |
| l'Anson, E | 1 |
| Kaik, G | 3 |
| Kaik, B | 2 |
| Laggner, A | 2 |
| Ward, MJ | 4 |
| Fentem, PH | 1 |
| Smith, WH | 1 |
| Davies, D | 2 |
| Baur, X | 4 |
| Rasmussen, FV | 2 |
| Madsen, L | 1 |
| Firstater, E | 1 |
| Mizrachi, E | 1 |
| Topilsky, M | 3 |
| Groggins, RC | 2 |
| Ullah, MI | 1 |
| Newman, GB | 1 |
| Gayrard, P | 5 |
| Orehek, J | 9 |
| Hedlin, G | 2 |
| Freyschuss, U | 2 |
| Turpeinen, M | 1 |
| Kuokkanen, J | 1 |
| Backman, A | 1 |
| Ljungholm, K | 1 |
| Lever, AM | 1 |
| Gibson, GJ | 5 |
| Giulekas, D | 3 |
| Tsakalos, N | 1 |
| Christaki-Kukuriku, P | 1 |
| Kotsopoulos, T | 1 |
| Antoniou, D | 1 |
| Tal, A | 2 |
| Pasterkamp, H | 2 |
| Leahy, F | 1 |
| Pomari, C | 2 |
| Turco, P | 2 |
| Zoccatelli, D | 1 |
| Gupta, SC | 1 |
| Mathur, RN | 1 |
| Swaroop, AK | 1 |
| Goyal, RK | 1 |
| Krauss, S | 1 |
| Spitz, E | 2 |
| Krauss, A | 1 |
| Grizotzki, B | 1 |
| Clement, S | 1 |
| Kraemer, R | 4 |
| Geubelle, F | 1 |
| Aebischer, JC | 1 |
| Benoit, RC | 1 |
| Scherrer, M | 6 |
| Mann, DW | 1 |
| Sadler, WA | 1 |
| Yukawa, T | 1 |
| Numao, T | 1 |
| Shimizu, T | 3 |
| Hayashi, T | 1 |
| Nitta, K | 2 |
| Shida, T | 2 |
| Andersson, L | 2 |
| Boëthius, G | 1 |
| Benfield, GF | 2 |
| Charpin, D | 4 |
| Beaupre, A | 2 |
| Louridas, G | 1 |
| Kakoura, M | 1 |
| Galanis, N | 1 |
| Patakas, D | 3 |
| Kastritsi, K | 1 |
| Richards, IM | 1 |
| Eady, RP | 1 |
| Jackson, DM | 1 |
| Orr, TS | 1 |
| Vendy, K | 1 |
| Masters, NJ | 1 |
| Francis, PW | 3 |
| Kelly, CA | 1 |
| Zimmerman, PV | 1 |
| Brown, PJ | 1 |
| Greville, HW | 1 |
| Finucane, KE | 1 |
| Lamarre, A | 4 |
| Lapierre, JG | 1 |
| Rousseau, E | 2 |
| Gauthier, M | 2 |
| van Doesburg, N | 1 |
| Anderson, PB | 3 |
| Goude, A | 1 |
| Peake, MD | 1 |
| Webb, J | 1 |
| Johnson-Barrett, JJ | 1 |
| Taylor, B | 1 |
| Lönnerholm, G | 2 |
| Foucard, T | 2 |
| Lindström, B | 2 |
| Paterson, IC | 2 |
| Diaz, P | 1 |
| Kay, AB | 3 |
| Clark, CJ | 2 |
| Boyd, G | 4 |
| Moran, F | 1 |
| Mattson, K | 1 |
| Poppius, H | 6 |
| Ahonen, A | 2 |
| Hurme, R | 1 |
| Maasilta, P | 1 |
| Muittari, A | 7 |
| Venho, K | 1 |
| Jones, RS | 2 |
| Hasham, F | 1 |
| Kennedy, JD | 1 |
| Gale, AE | 1 |
| Hughes, D | 1 |
| Mindorff, C | 1 |
| Saltz, H | 1 |
| Bearman, J | 1 |
| Newth, CV | 1 |
| Turner, JA | 1 |
| Becker, AB | 5 |
| Nelson, NA | 1 |
| Simons, FE | 6 |
| Blumenthal, I | 3 |
| Shiner, RJ | 1 |
| Molho, MI | 1 |
| Rochat, T | 3 |
| Vonwil, A | 1 |
| Bachofen, H | 3 |
| Dalén, G | 1 |
| Kjellman, B | 3 |
| Siegel, SC | 7 |
| Katz, R | 1 |
| Zychowicz, C | 1 |
| Ryan, G | 2 |
| Latimer, KM | 3 |
| Grassi, C | 2 |
| Rampulla, C | 4 |
| Zanon, P | 1 |
| Cerveri, I | 1 |
| Mastroberardino, M | 1 |
| Mustchin, CP | 1 |
| Sterling, GM | 1 |
| Kyd, K | 2 |
| Swinburn, PD | 1 |
| Sexton, M | 1 |
| Pullan, CR | 1 |
| Martin, AJ | 1 |
| Sinclair, V | 1 |
| Fairfax, AJ | 1 |
| McNabb, WR | 1 |
| Davies, HJ | 3 |
| Spiro, SG | 10 |
| Croner, S | 2 |
| Hedenskog, S | 1 |
| Kjellman, NI | 3 |
| Odelram, H | 1 |
| Bakran, I | 2 |
| Vrhovac, B | 2 |
| Plavsić, F | 1 |
| Evans, WV | 2 |
| Crimmins, J | 1 |
| Seaton, A | 6 |
| Lawford, P | 3 |
| Dowd, DE | 1 |
| Palmer, KN | 7 |
| Kabiraj, MU | 1 |
| Rolf, C | 1 |
| Simonsson, BG | 1 |
| Shepherd, GL | 3 |
| Hetzel, MR | 4 |
| Latimer, K | 1 |
| Jenkinson, SG | 2 |
| Light, RW | 3 |
| Spector, S | 1 |
| Kanto, J | 2 |
| Allonen, H | 1 |
| Kulmala, T | 1 |
| Mäntylä, R | 1 |
| Tala, E | 1 |
| Frith, PA | 3 |
| Cockroft, A | 1 |
| Griffiths, T | 1 |
| Rocchiccioli, K | 1 |
| Davies, BH | 4 |
| Jagodziński, J | 3 |
| Woźniakowska, U | 3 |
| Webber, BA | 2 |
| Collins, JV | 1 |
| Branthwaite, MA | 1 |
| Yates, T | 1 |
| Dubin, B | 1 |
| Bell-Jesion, C | 1 |
| Yahav, Y | 1 |
| Katznelson, D | 1 |
| Benzaray, S | 2 |
| Katz, RM | 5 |
| Pratt, HF | 1 |
| O'Doherty, K | 1 |
| Cauberghs, M | 1 |
| Van de Woestijne, KP | 1 |
| Forsell, P | 1 |
| Holroyde, MC | 1 |
| Smith, SY | 1 |
| Holme, G | 1 |
| Abdurrahman, MB | 1 |
| Taqi, AM | 1 |
| Berg, IM | 1 |
| Berg, T | 2 |
| Ringqvist, I | 1 |
| LEE, HS | 2 |
| Chryssidis, E | 1 |
| Frewin, DB | 1 |
| Rebuck, AS | 6 |
| Contreras, M | 1 |
| Bevan, M | 1 |
| Roberts, R | 1 |
| Anderson, SD | 5 |
| Schoeffel, RE | 1 |
| Liubchenko, LN | 1 |
| Strongina, EI | 1 |
| Ardashnikova, SN | 1 |
| Baskakova, NV | 1 |
| Heinzen, P | 1 |
| Roelli, HJ | 1 |
| Meister, B | 1 |
| Rossi, E | 1 |
| Morgan, B | 1 |
| Keyes, SJ | 1 |
| Weissen, A | 1 |
| Smith, SC | 1 |
| Connolly, CK | 2 |
| Muller, N | 1 |
| Bryan, AC | 2 |
| Christensson, P | 3 |
| Lilja, B | 5 |
| Bangham, CR | 1 |
| Hope, RA | 1 |
| Baldwin, CJ | 1 |
| Wood, PJ | 1 |
| Alberti, KG | 1 |
| Madsen, BW | 2 |
| Murphy, BP | 1 |
| Tarala, RA | 3 |
| Jankowska, R | 1 |
| Racineux, JL | 2 |
| Troussier, J | 1 |
| Turcant, A | 1 |
| Tuchais, E | 1 |
| Allain, P | 1 |
| Miller, TD | 1 |
| Smith, S | 1 |
| Tomashefski, JF | 2 |
| König, P | 10 |
| Godfrey, S | 10 |
| Edmunds, AT | 2 |
| Handslip, PD | 3 |
| Dart, AM | 1 |
| Iaia, E | 2 |
| Cagnazzo, R | 1 |
| Digilio, VS | 1 |
| Scoditti, A | 1 |
| Sevieri, GP | 1 |
| Quartieri, F | 2 |
| Del Bono, N | 3 |
| Tandon, MK | 1 |
| Gurwitz, D | 1 |
| Stemmann, EA | 2 |
| Wolff, GE | 1 |
| Velardocchio, JM | 2 |
| Grimaud, C | 3 |
| Collier, JG | 1 |
| Dobbs, RJ | 1 |
| Williams, I | 1 |
| Imhof, K | 1 |
| Krastins, IR | 1 |
| Santo, M | 1 |
| Sidi, Y | 1 |
| Pinkhas, Y | 1 |
| Peel, ET | 1 |
| Pincus, R | 1 |
| Bannister, OM | 1 |
| Paterson, JW | 7 |
| Beck, PD | 1 |
| Ormerod, LP | 1 |
| Thomson, RA | 1 |
| Anderson, CM | 1 |
| Stableforth, DE | 2 |
| Tollig, H | 1 |
| Wettrell, G | 1 |
| Robichaud, A | 1 |
| Michoud, MC | 2 |
| Hamet, P | 1 |
| du Souich, P | 2 |
| Skorodin, MS | 1 |
| Ackerman, V | 1 |
| Carpi, S | 1 |
| Bellini, A | 1 |
| Vassalli, G | 1 |
| Marini, M | 1 |
| Mattoli, S | 1 |
| Nehmiz, G | 1 |
| Wald, FD | 1 |
| Seltzer, JM | 2 |
| Chervinsky, P | 14 |
| Alexander, WJ | 1 |
| Liddle, R | 4 |
| Mills, R | 1 |
| Cook, T | 1 |
| Stone, G | 1 |
| Abroug, F | 2 |
| Nouira, S | 3 |
| Bchir, A | 1 |
| Boujdaria, R | 2 |
| Elatrous, S | 3 |
| Bouchoucha, S | 2 |
| Wheatley, G | 1 |
| Walden, S | 1 |
| Ng, HW | 1 |
| Perrin-Fayolle, M | 3 |
| Hyland, ME | 5 |
| Crocker, GR | 1 |
| Barry, PW | 2 |
| Cracco, A | 1 |
| Tormena, F | 1 |
| Novello, A | 1 |
| Fuglsang, G | 2 |
| Agertoft, L | 2 |
| Vikre-Jørgensen, J | 2 |
| Bhagat, R | 7 |
| Subratty, AH | 2 |
| Russell, G | 1 |
| Williams, DA | 1 |
| Weller, P | 2 |
| Price, JF | 6 |
| Habbick, B | 3 |
| Baker, MJ | 1 |
| McNutt, M | 3 |
| Kalra, S | 3 |
| Rutten-van Mölken, MP | 2 |
| Custers, F | 1 |
| van Doorslaer, EK | 2 |
| Jansen, CC | 1 |
| Heurman, L | 1 |
| Bommer, AM | 2 |
| Raaijmakers, JA | 3 |
| Lødrup Carlsen, KC | 2 |
| Halvorsen, R | 1 |
| Ahlstedt, S | 1 |
| Wellman, JJ | 1 |
| Johnston, P | 1 |
| Krakovsky, D | 1 |
| Mark, S | 1 |
| Keller, KA | 1 |
| Newman, SP | 4 |
| Watson, JP | 1 |
| Lewis, RA | 1 |
| Kostianev, S | 1 |
| Onadeko, BO | 1 |
| Bamidele, EO | 1 |
| Ekweani, CN | 1 |
| Erabor, GE | 1 |
| Zerah, F | 2 |
| Lorino, AM | 2 |
| Lorino, H | 2 |
| Harf, A | 2 |
| Macquin-Mavier, I | 1 |
| Lai, CK | 3 |
| Chan, CH | 1 |
| Ho, SS | 1 |
| Hui, AC | 1 |
| Lai, KN | 2 |
| Grove, A | 3 |
| Salmeron, S | 2 |
| Ellrodt, A | 1 |
| Taravella, O | 1 |
| Wong, C | 2 |
| Ayson, M | 1 |
| Rajasingham, S | 1 |
| Scheen, AJ | 1 |
| van Schayck, CP | 12 |
| Dompeling, E | 6 |
| Folgering, H | 6 |
| Akkermans, RP | 2 |
| van den Broek, PJ | 1 |
| van Weel, C | 11 |
| Williams, AJ | 2 |
| Weiner, C | 1 |
| Reiff, D | 1 |
| Hughes, JM | 2 |
| Reisner, C | 4 |
| Kotch, A | 1 |
| Dworkin, G | 1 |
| Gunn, SD | 1 |
| Ayres, JG | 6 |
| McConchie, SM | 1 |
| Dockhorn, R | 1 |
| Vanden Burgt, JA | 1 |
| Ekholm, BP | 9 |
| Donnell, D | 1 |
| Cullen, MT | 1 |
| Beck, R | 3 |
| Huang, D | 2 |
| Nicodemus, CF | 2 |
| Schanker, HM | 1 |
| Langton Hewer, S | 1 |
| Hobbs, J | 1 |
| French, D | 1 |
| Małlolepszy, J | 1 |
| Passowicz-Muszyńska, E | 2 |
| van Essen-Zandvliet, EE | 9 |
| Kolendowicz, R | 1 |
| Punthakee, Z | 1 |
| Harris, TA | 1 |
| Yiallouros, PK | 2 |
| Saeed, SA | 1 |
| Ali, N | 1 |
| Saleem, S | 1 |
| Callahan, S | 3 |
| Canny, G | 6 |
| Tjørnum, TE | 1 |
| Devoy, MA | 1 |
| Palmer, JB | 12 |
| Hesse, IF | 1 |
| Yang, CT | 1 |
| Huang, TJ | 1 |
| Shieh, WB | 1 |
| Engel, AM | 1 |
| Haanaes, OC | 1 |
| Shaheen, MZ | 1 |
| Benincasa, C | 1 |
| Quadrelli, S | 1 |
| Roncoroni, AJ | 1 |
| Montiel, GC | 1 |
| Gawlik, R | 1 |
| Sachs, K | 1 |
| Oldaeus, G | 1 |
| Kubista, J | 1 |
| Ståhl, E | 8 |
| Parkin, PC | 3 |
| Saunders, NR | 1 |
| Diamond, SA | 1 |
| Winders, PM | 1 |
| Macarthur, C | 3 |
| Buck, ML | 1 |
| Robertson, CF | 3 |
| Mellis, C | 2 |
| Staugas, R | 1 |
| Isles, AF | 1 |
| Landau, LI | 4 |
| Chand, N | 2 |
| Achterrath-Tuckermann, U | 1 |
| Szelenyi, I | 1 |
| Sofia, RD | 2 |
| Rutten, MP | 1 |
| van den Boom, G | 1 |
| Malo, JL | 15 |
| L'Archevêque, J | 6 |
| Ghezzo, H | 8 |
| Grant, JA | 1 |
| Findlay, SR | 2 |
| Glovsky, MM | 1 |
| Grossman, J | 8 |
| Kaiser, H | 1 |
| Mitchell, DQ | 1 |
| Selner, J | 1 |
| Bartfield, JM | 2 |
| Boenau, IB | 1 |
| Lozon, J | 1 |
| Raccio-Robak, N | 2 |
| Manolitsas, ND | 1 |
| Devalia, JL | 1 |
| Trigg, CJ | 2 |
| McAulay, AE | 1 |
| Davies, RJ | 4 |
| Fedoseev, GB | 1 |
| Emel'ianov, AV | 1 |
| Sinitsina, TM | 1 |
| Goncharova, VA | 1 |
| Lin, RY | 7 |
| Newman, TG | 1 |
| Sauter, D | 2 |
| Sirleaf, J | 2 |
| Walters, J | 3 |
| Fox, S | 1 |
| Tavakol, M | 2 |
| Willenbrock, U | 1 |
| Jörres, R | 4 |
| Nolte, D | 2 |
| Penna, AC | 4 |
| Manglick, P | 3 |
| Bloch, H | 1 |
| Mancherje, N | 1 |
| Grant, S | 1 |
| Jagminas, L | 1 |
| Scharf, SM | 1 |
| Ohe, M | 1 |
| Munakata, M | 2 |
| Itoh, A | 1 |
| Doi, I | 1 |
| Yamaguchi, E | 1 |
| Homma, Y | 2 |
| Kawakami, Y | 2 |
| Taggart, SC | 1 |
| Custovic, A | 1 |
| Santamaria, F | 1 |
| Villa, MP | 1 |
| Werner, B | 1 |
| Barreto, M | 1 |
| Ronchetti, R | 1 |
| Kamada, AK | 2 |
| Worsley, DF | 1 |
| Alavi, A | 1 |
| Kim, E | 1 |
| Palevsky, HI | 1 |
| Jones, K | 2 |
| Johnston, PR | 2 |
| Borkhoff, CM | 2 |
| Guyatt, GH | 1 |
| Haukioja, A | 1 |
| Brussino, L | 2 |
| Ohnishi, H | 1 |
| Maeda, H | 2 |
| Nishimura, Y | 2 |
| Takenaka, K | 1 |
| Yahata, T | 1 |
| Takatsuki, K | 1 |
| Yokoyama, M | 2 |
| Perrin, B | 1 |
| Curran, MA | 2 |
| Pellicer Ciscar, C | 1 |
| Perpiña Tordera, M | 1 |
| de Diego Damia, A | 1 |
| Macián Gisbert, V | 1 |
| Baldwin, DR | 1 |
| Sivardeen, Z | 1 |
| Knox, AJ | 2 |
| Rodrigo, G | 10 |
| Staehr, P | 1 |
| Vestbo, I | 1 |
| Côté, J | 3 |
| Kreisman, H | 5 |
| Small, DI | 1 |
| Alexander, M | 2 |
| Day, A | 1 |
| Harsanyi, Z | 1 |
| Darke, AC | 1 |
| Aldrey, OE | 1 |
| Añez, H | 1 |
| Deibis, L | 1 |
| Tassinari, P | 1 |
| Isturiz, G | 1 |
| Bianco, NE | 1 |
| Chou, KJ | 1 |
| Cunningham, SJ | 1 |
| Needleman, JP | 1 |
| Kaifer, MC | 1 |
| Nold, JT | 1 |
| Shuster, PE | 1 |
| Redding, MM | 1 |
| Gladstein, J | 1 |
| Furukawa, CT | 4 |
| Henochowicz, SI | 1 |
| Marcoux, JP | 1 |
| Gross, GN | 2 |
| Hudson, LD | 2 |
| Myers, DJ | 1 |
| Steinberg, P | 1 |
| Jakubowska-Najnigier, M | 1 |
| Liszewska-Pfejfer, D | 1 |
| Jaworski, A | 3 |
| Tadeusiak, W | 3 |
| Droszcz, W | 11 |
| Rubin, ID | 1 |
| Lanes, R | 1 |
| Duran, Z | 1 |
| Aguirre, J | 1 |
| Espina, L | 1 |
| Alvarez, W | 1 |
| Villaroel, O | 1 |
| Zdanowicz, M | 1 |
| Visitsuntorn, N | 1 |
| Wichienwattanachai, V | 1 |
| Kerdsomnuk, S | 1 |
| Tuchinda, M | 1 |
| Yan, MY | 1 |
| Shun, LH | 1 |
| Hebe, A | 1 |
| Soomaree, V | 1 |
| Taylor, IK | 2 |
| Sorooshian, M | 1 |
| Wangoo, A | 1 |
| Haynes, AR | 1 |
| Kotecha, S | 1 |
| Mitchell, DM | 2 |
| Shaw, RJ | 1 |
| Solèr, M | 1 |
| Joos, L | 1 |
| Bolliger, CT | 1 |
| Elsasser, S | 1 |
| Perruchoud, AP | 1 |
| Robertson, W | 1 |
| Simkins, J | 1 |
| O'Hickey, SP | 1 |
| Freeman, S | 1 |
| Cayton, RM | 4 |
| López-Guillen, A | 1 |
| López-Llorente, MT | 1 |
| Pastor, E | 1 |
| Figueras, A | 1 |
| Löfroos, AB | 1 |
| Pietinalho, A | 1 |
| Riska, H | 2 |
| Newnham, DM | 2 |
| Clark, RA | 8 |
| Dhillon, DP | 7 |
| Winter, JH | 1 |
| McDevitt, DG | 8 |
| Stewart, CM | 1 |
| Wathen, CG | 2 |
| Moffat, R | 1 |
| Senn, S | 2 |
| Vidgren, M | 5 |
| Silvasti, M | 10 |
| Korhonen, P | 2 |
| Kinkelin, A | 1 |
| Frischer, B | 1 |
| Stern, K | 1 |
| Udezue, E | 2 |
| D'Souza, L | 1 |
| Mahajan, M | 1 |
| Meyer, JM | 1 |
| Wenzel, CL | 1 |
| Kradjan, WA | 2 |
| Lebecque, P | 1 |
| Vliers, S | 1 |
| De Saint-Moulin, T | 1 |
| Godding, V | 1 |
| Hughes, MD | 3 |
| Waalkens, HJ | 5 |
| Bronsky, EA | 5 |
| Orgel, HA | 5 |
| Tinkelman, DG | 5 |
| van As, A | 2 |
| Liddle, RF | 2 |
| D'Alonzo, GE | 3 |
| Henochowicz, S | 1 |
| Morris, RJ | 4 |
| Rennard, SI | 1 |
| Bone, RC | 1 |
| Kesten, S | 6 |
| Szalai, JP | 1 |
| Northfield, M | 1 |
| Shaw, G | 1 |
| Shale, DJ | 1 |
| Kenyon, CA | 1 |
| Jacobs, PA | 1 |
| Kok-Jensen, A | 3 |
| Alessandro, F | 1 |
| Zuccotti, GV | 1 |
| Vincenzo, ZG | 1 |
| Sala, M | 1 |
| Marco, S | 1 |
| Giovannini, M | 1 |
| Marcello, G | 1 |
| Riva, E | 1 |
| Enrica, R | 1 |
| Chastang, C | 1 |
| Georges, D | 3 |
| Bertin, L | 2 |
| Bauer, K | 1 |
| Ramage, L | 1 |
| Cree, IA | 1 |
| Gardiner, PV | 2 |
| Allison, A | 1 |
| Hendrick, DJ | 7 |
| Burgess, CD | 3 |
| Bremner, P | 3 |
| Thomson, CD | 1 |
| Siebers, RW | 2 |
| Odhiambo, JA | 1 |
| Nganga, LW | 1 |
| Gikonyo, BM | 1 |
| Adalioglu, G | 2 |
| Saraçlar, Y | 2 |
| Tuncer, A | 2 |
| Clive, J | 2 |
| O'Donnell, M | 1 |
| Garippa, RJ | 1 |
| Rinaldi, N | 1 |
| Selig, WM | 1 |
| Tocker, JE | 1 |
| Tannu, SA | 1 |
| Wasserman, MA | 1 |
| Welton, A | 1 |
| Bolin, DR | 1 |
| Finkelstein, FN | 1 |
| Simon, OR | 1 |
| Mann, RD | 2 |
| Brzostek, D | 2 |
| Piotrowska, B | 2 |
| Małolepszy, J | 6 |
| Goodman, DE | 1 |
| Rosenberg, M | 1 |
| Johnston, R | 1 |
| Weersink, EJ | 3 |
| Koëter, GH | 6 |
| Kauffman, HF | 1 |
| Woodman, K | 3 |
| Pacor, ML | 2 |
| Biasi, D | 1 |
| Cortina, P | 1 |
| Maleknia, T | 1 |
| Lunardi, C | 1 |
| Gautrin, D | 1 |
| D'Aquino, LC | 1 |
| Gagnon, G | 1 |
| Benbow, AG | 1 |
| Filiz, A | 1 |
| Ekinci, E | 1 |
| Dikensoy, O | 1 |
| Bulgur, D | 1 |
| Oz, M | 1 |
| Franchi, L | 1 |
| Jones, KP | 3 |
| Weiss, SJ | 1 |
| Anand, P | 1 |
| Ernst, AA | 1 |
| Orgeron, D | 1 |
| May, WL | 1 |
| Wang, CR | 1 |
| Yeh, TS | 1 |
| Chuang, CY | 1 |
| Chen, CY | 1 |
| Fjellbirkeland, L | 1 |
| Gulsvik, A | 1 |
| Hulks, G | 2 |
| Colagrande, P | 1 |
| Bertó, JM | 1 |
| Camps, B | 1 |
| Pérez, MJ | 1 |
| Brochard, L | 1 |
| Mal, H | 1 |
| Tenaillon, A | 1 |
| Henry-Amar, M | 1 |
| Renon, D | 2 |
| Duroux, P | 2 |
| Simonneau, G | 1 |
| Poriadin, GV | 1 |
| Salmasi, ZhM | 1 |
| Busarova, EA | 1 |
| Zhuravleva, NE | 1 |
| Twentyman, OP | 5 |
| Taylor, MR | 2 |
| Clarke, JR | 1 |
| Aston, H | 1 |
| Schnapf, BM | 1 |
| Santeiro, ML | 1 |
| Davison, AG | 1 |
| Hawkins, ER | 1 |
| Newman Taylor, AJ | 1 |
| Schachter, J | 1 |
| Kuwahara, B | 1 |
| Goresky, GV | 1 |
| Dor, A | 1 |
| Azzabi, M | 1 |
| Holmgren, D | 3 |
| Sixt, R | 3 |
| Bennett, JA | 1 |
| Smyth, ET | 2 |
| Wilding, PJ | 1 |
| Rayburn, WF | 1 |
| Atkinson, BD | 1 |
| Gilbert, K | 1 |
| Turnbull, GL | 1 |
| Verberne, AA | 6 |
| Bos, AB | 1 |
| Wong, CS | 3 |
| Wisniewski, AF | 3 |
| Williams, J | 2 |
| Castle, W | 1 |
| Fuller, R | 2 |
| Hall, J | 1 |
| Palmer, J | 2 |
| Inman, WH | 1 |
| Bunney, R | 1 |
| Flaten, O | 1 |
| Kokubu, H | 1 |
| Beach, JR | 2 |
| Young, CL | 1 |
| Harkawat, R | 2 |
| Avery, AJ | 2 |
| Coward, GA | 1 |
| Pedersen, B | 3 |
| Larsen, BB | 1 |
| Wahedna, I | 1 |
| McParland, CP | 1 |
| Britto, SA | 1 |
| Rutherford, BC | 1 |
| Nyberg, A | 2 |
| Laurikainen, K | 4 |
| Tam, J | 1 |
| de Jong, JW | 1 |
| Teengs, JP | 1 |
| van der Mark, TW | 2 |
| Harrison, JE | 4 |
| Rooney, SM | 1 |
| Nolan, KW | 1 |
| De Vine, CL | 1 |
| Jakubicki, RG | 1 |
| Pillar, J | 1 |
| Diamantis, W | 1 |
| Boivin, JF | 2 |
| Horwitz, RI | 2 |
| Spitzer, WO | 2 |
| Desmond, KJ | 1 |
| Demizio, DL | 1 |
| Allen, PD | 1 |
| MacDonald, ND | 1 |
| Strauss, RE | 1 |
| Wertheim, DL | 1 |
| Bonagura, VR | 1 |
| Valacer, DJ | 1 |
| Connett, GJ | 3 |
| Warde, C | 1 |
| Wooler, E | 1 |
| Veale, D | 2 |
| Cooper, BG | 1 |
| Griffiths, CJ | 1 |
| Anantharaman, V | 1 |
| Brand, PL | 3 |
| van der Bruggen-Bogaarts, BA | 1 |
| Hall, SK | 1 |
| Elias, M | 1 |
| Lindsay, DA | 3 |
| Russell, NL | 1 |
| Thompson, JE | 1 |
| Warnock, TH | 1 |
| Shellshear, ID | 1 |
| Buchanan, PR | 1 |
| Imagawa, J | 1 |
| Kamei, K | 1 |
| Yoshida, S | 1 |
| Sugo, I | 1 |
| Koga, T | 1 |
| Nabata, H | 1 |
| Spence, DP | 1 |
| Calverley, PM | 1 |
| Higgins, C | 1 |
| Ramhamadany, E | 1 |
| Turner, S | 1 |
| Winning, A | 1 |
| Winter, J | 1 |
| Osundwa, VM | 1 |
| Dawod, ST | 1 |
| Ehlayel, MS | 1 |
| Nieminen, MM | 4 |
| Järvinen, M | 1 |
| Liippo, K | 2 |
| Tammivaara, R | 1 |
| Vetto, TA | 1 |
| Moore, GP | 1 |
| Watson, WT | 2 |
| Shuckett, EP | 1 |
| Galoppin, L | 1 |
| Azevedo, I | 1 |
| Vargaftig, BB | 3 |
| Bachelet, M | 3 |
| Ginko, T | 1 |
| Fischer, M | 1 |
| Voss, W | 1 |
| Knutsen, R | 1 |
| Bøhmer, T | 1 |
| Falch, J | 1 |
| Zainudin, BM | 4 |
| Ismail, O | 1 |
| Yusoff, K | 1 |
| Dolovich, MB | 2 |
| Kazim, F | 2 |
| Madl, ML | 1 |
| Rudnitsky, GS | 1 |
| Eberlein, RS | 1 |
| Schoffstall, JM | 1 |
| Mazur, JE | 1 |
| Spivey, WH | 1 |
| Newman, T | 1 |
| Gerritsen, J | 2 |
| Knol, K | 1 |
| Rubin, P | 1 |
| Pierson, W | 1 |
| Tinkelman, D | 3 |
| Segal, AT | 1 |
| Fish, J | 1 |
| Kaiser, HB | 2 |
| Wenzel, S | 1 |
| Cohn, J | 1 |
| Lanni, C | 1 |
| Pearlman, H | 1 |
| Karahalios, P | 1 |
| O'Brien, RG | 1 |
| Harman, E | 2 |
| Aull, L | 1 |
| Reents, S | 1 |
| Visser, J | 1 |
| Shieh, G | 2 |
| Coleridge, J | 1 |
| Cameron, P | 1 |
| Teichtahl, H | 1 |
| Essex, E | 3 |
| Volans, GN | 1 |
| Eda, R | 1 |
| Okada, C | 1 |
| Bewtra, AK | 1 |
| Townley, RG | 2 |
| Arvidsson, P | 5 |
| Larsson, S | 8 |
| Vondra, V | 1 |
| Reisová, M | 1 |
| Malý, M | 1 |
| Sovijärvi, AR | 2 |
| Paajanen, E | 1 |
| Piirilä, P | 1 |
| Katila, T | 1 |
| Coppola, M | 1 |
| Westfall, M | 1 |
| Nelson, MS | 1 |
| Staudinger, HW | 1 |
| Haas, JF | 1 |
| Munro, NC | 1 |
| Castle, WM | 1 |
| Hall, JR | 1 |
| Fishwick, K | 2 |
| Devereux, G | 1 |
| Taskar, VS | 1 |
| Mahashur, AA | 2 |
| John, PJ | 1 |
| Kolhatkar, VP | 1 |
| Menon, L | 1 |
| Bijur, S | 1 |
| Packe, GE | 2 |
| Freeman, W | 2 |
| Melchor, R | 1 |
| Mak, VH | 1 |
| Short, MD | 1 |
| Connett, G | 1 |
| Tang, CB | 1 |
| Quan, BW | 1 |
| Wang, XF | 1 |
| Xiong, YX | 1 |
| Wu, GH | 1 |
| Oberklaid, F | 1 |
| Souëf, PN | 1 |
| Maccarrone, AL | 1 |
| Finnerty, JP | 5 |
| O'Brodovich, H | 1 |
| Reisman, J | 3 |
| Canny, GJ | 3 |
| Rosenhall, L | 3 |
| Melander, B | 5 |
| Oenbrink, RJ | 1 |
| Trudeau, C | 5 |
| Chinet, TC | 1 |
| Ramoska, EA | 1 |
| Henretig, F | 1 |
| Joffe, M | 1 |
| Spiller, HA | 1 |
| Sakamoto, K | 1 |
| Houya, I | 1 |
| Inoue, K | 1 |
| Kiuchi, H | 1 |
| Sakamoto, Y | 2 |
| Yamamoto, K | 1 |
| Dohi, Y | 1 |
| Colacone, A | 3 |
| Afilalo, M | 3 |
| Wolkove, N | 3 |
| Malerba, M | 3 |
| Politi, A | 2 |
| Filippi, B | 2 |
| Boni, E | 1 |
| Grassi, V | 4 |
| Kaliner, MA | 2 |
| Schlegel, J | 1 |
| Turk, B | 1 |
| Kienast, K | 1 |
| Ferlinz, R | 1 |
| Angus, RM | 2 |
| McCallum, MJ | 1 |
| Sams, VR | 1 |
| Church, MK | 3 |
| Hutson, PA | 2 |
| Ferrari, M | 1 |
| Romito, D | 1 |
| Adami, S | 1 |
| Olivieri, M | 1 |
| Squassante, L | 1 |
| Prior, M | 1 |
| Lo Cascio, V | 1 |
| Smolik, K | 1 |
| Cloutier, M | 1 |
| Labrecque, G | 1 |
| Rivard, GB | 1 |
| Bonnin, AJ | 1 |
| Richmond, GW | 2 |
| Musto, PK | 1 |
| Volgman, AS | 1 |
| Fuchs, SM | 2 |
| Nager, AL | 1 |
| Shane, SA | 1 |
| Katz, RW | 1 |
| Crowley, MR | 1 |
| Grad, R | 1 |
| McWilliams, BC | 1 |
| Murphy, SJ | 2 |
| Smith, AJ | 1 |
| Hergenroeder, P | 1 |
| Fink, G | 1 |
| Kaye, C | 1 |
| Blau, H | 1 |
| Spitzer, SA | 1 |
| Jain, NK | 1 |
| Sharma, SD | 1 |
| Garg, VK | 1 |
| Sharma, TN | 1 |
| Devpura, K | 1 |
| Scalabrin, DM | 2 |
| Naspitz, CK | 3 |
| Herdman, MJ | 1 |
| Ferguson, H | 1 |
| Thomas, K | 1 |
| DiGiulio, GA | 1 |
| Krug, SE | 2 |
| Alpert, SE | 1 |
| Marx, CM | 1 |
| Carter, E | 1 |
| Cruz, M | 1 |
| Chesrown, S | 1 |
| Reilly, K | 1 |
| Campbell, AM | 2 |
| Couret, I | 1 |
| Michel, FB | 5 |
| Stenius-Aarniala, B | 2 |
| Kiviranta, K | 1 |
| Cocchetto, DM | 2 |
| Turner, DJ | 1 |
| LeSouëf, PN | 5 |
| Olshaker, J | 1 |
| Jerrard, D | 1 |
| Barish, RA | 1 |
| Brandt, G | 1 |
| Hooper, F | 1 |
| Clarke, SW | 8 |
| Patel, SR | 1 |
| Print, CG | 2 |
| Lake, DC | 2 |
| Yates, DM | 1 |
| Lucas, MK | 1 |
| Rawlinson, DW | 1 |
| Lyttle, BD | 1 |
| Hollestelle, AM | 1 |
| Bancalari, L | 2 |
| Carrara, M | 1 |
| Giuntini, C | 2 |
| Clark, CE | 1 |
| Ferguson, AD | 1 |
| Siddorn, JA | 1 |
| Pavia, D | 1 |
| Vora, H | 1 |
| Behr, N | 1 |
| Morley, TE | 1 |
| Ghigo, E | 1 |
| Valetto, MR | 1 |
| Gaggero, L | 1 |
| Visca, A | 1 |
| Valente, F | 1 |
| Bellone, J | 1 |
| Castello, D | 2 |
| Camanni, F | 1 |
| Gibson, P | 1 |
| Henry, D | 1 |
| Francis, L | 2 |
| Cruickshank, D | 1 |
| Dupen, F | 1 |
| Higginbotham, N | 1 |
| Henry, R | 1 |
| Sutherland, D | 2 |
| Knol, KK | 1 |
| Meijer, GG | 1 |
| van Aalderen, WM | 1 |
| Fisher, JD | 1 |
| Vinci, RJ | 1 |
| Shaughnessy, AF | 2 |
| Slawson, DC | 1 |
| Wlodarczyk, JH | 1 |
| Borgas, T | 1 |
| Inman, MD | 3 |
| Koller, DY | 1 |
| Herouy, Y | 1 |
| Götz, M | 1 |
| Hagel, E | 1 |
| Urbanek, R | 1 |
| Eichler, I | 1 |
| Di Lorenzo, G | 2 |
| Morici, G | 2 |
| Norrito, F | 1 |
| Mansueto, P | 1 |
| Melluso, M | 1 |
| Purello D'Ambrosio, F | 2 |
| Barbagallo Sangiorgi, G | 1 |
| Flüge, T | 3 |
| Fabel, H | 2 |
| Wagner, TO | 2 |
| Schneider, B | 4 |
| Forssmann, WG | 3 |
| Szczeklik, A | 4 |
| Mastalerz, L | 2 |
| Nizankowska, E | 3 |
| Cmiel, A | 2 |
| Targhetta, R | 1 |
| Chavagneux, R | 1 |
| Ayoub, J | 1 |
| Lemerre, C | 1 |
| Bourgeois, JM | 1 |
| Balmes, P | 1 |
| Hermansson, BA | 1 |
| Jenkins, RJ | 2 |
| Aubert, B | 1 |
| Bons, J | 2 |
| Hall, CM | 1 |
| Louw, SJ | 1 |
| Joubert, G | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Kubota, K | 1 |
| Pearce, G | 1 |
| Wilton, L | 1 |
| Gayer, D | 1 |
| Barbero, GJ | 1 |
| Shaffer, J | 1 |
| Van Keimpema, AR | 1 |
| Ariaansz, M | 1 |
| Nauta, JJ | 1 |
| Postmus, PE | 1 |
| Kleerup, EC | 2 |
| Cline, AC | 1 |
| Keatings, V | 1 |
| Thomas, PS | 1 |
| Ahmad, HR | 2 |
| Khan, MA | 3 |
| Memon, M | 1 |
| Khan, MN | 1 |
| Shrestha, M | 2 |
| Gourlay, S | 2 |
| Robertson, S | 1 |
| Bidadi, K | 2 |
| Wainscott, M | 1 |
| Hayes, J | 2 |
| Woolcock, A | 2 |
| Jacques, LA | 1 |
| Leatherman, JW | 1 |
| Fluegel, WL | 1 |
| David, WS | 1 |
| Davies, SF | 1 |
| Iber, C | 1 |
| Boltansky, H | 1 |
| Kobayashi, RH | 1 |
| Shapiro, G | 3 |
| Trochelmann, LM | 1 |
| Lorber, RR | 1 |
| Siebers, R | 1 |
| Sitenga, GL | 1 |
| Ing, EB | 1 |
| Van Dellen, RG | 1 |
| Younge, BR | 1 |
| Leavitt, JA | 1 |
| Creyghton, FB | 1 |
| van Rooij, RW | 1 |
| van den Berg, M | 1 |
| Millar, EA | 2 |
| Chalmers, GW | 4 |
| Kelso, TM | 1 |
| Abou-Shala, N | 2 |
| Heilker, GM | 1 |
| Arheart, KL | 1 |
| Portner, TS | 1 |
| Self, TH | 4 |
| Desager, KN | 2 |
| van Bever, HP | 3 |
| Vermeire, PA | 1 |
| Wendel, PJ | 1 |
| Ramin, SM | 1 |
| Barnett-Hamm, C | 1 |
| Rowe, TF | 1 |
| Cunningham, FG | 1 |
| Swystun, UA | 1 |
| Ringbaek, TJ | 1 |
| Søes-Petersen, U | 1 |
| Christensen, M | 1 |
| Iversen, ET | 2 |
| Garner, SS | 1 |
| Wiest, DB | 1 |
| Bradley, JW | 1 |
| Lesher, BA | 1 |
| Habib, DM | 1 |
| Schoenwetter, WF | 1 |
| Munk, ZM | 2 |
| Schaberg, A | 2 |
| Kellerman, DJ | 4 |
| de Benedictis, FM | 2 |
| Martinati, LC | 1 |
| Solinas, LF | 1 |
| Tuteri, G | 2 |
| Kidney, JC | 1 |
| Wong, BJ | 1 |
| Morris, MM | 2 |
| Efthimiadis, A | 1 |
| Anderson, R | 1 |
| Feldman, C | 1 |
| Theron, AJ | 1 |
| Ramafi, G | 1 |
| Cole, PJ | 2 |
| Wilson, R | 1 |
| Gioulekas, D | 1 |
| Papakosta, D | 2 |
| Vordoyianni, P | 1 |
| Baloti, H | 1 |
| Vamvalis, C | 2 |
| Turner, CR | 1 |
| Andresen, CJ | 1 |
| Smith, WB | 1 |
| Watson, JW | 1 |
| Kakhnovskiĭ, IM | 2 |
| Marinin, VF | 2 |
| Sorokina, LA | 2 |
| Markova, ZS | 1 |
| Leblanc, P | 1 |
| Knight, A | 4 |
| Reisine, ST | 2 |
| Willard, A | 2 |
| Wells, M | 2 |
| Metersky, M | 1 |
| McNally, D | 1 |
| Lawrence, M | 2 |
| Tomasko, M | 1 |
| Baker, KA | 1 |
| Facchini, G | 1 |
| Antonicelli, L | 1 |
| Cinti, B | 1 |
| Bonifazi, F | 1 |
| Massei, V | 1 |
| Mannino, F | 4 |
| Kishida, M | 2 |
| Suzuki, I | 2 |
| Koshibu, T | 2 |
| Matsumoto, H | 1 |
| Uchiyama, Y | 1 |
| Kabayama, H | 2 |
| Nagayama, T | 1 |
| Sasamoto, A | 2 |
| Aoki, T | 3 |
| Gustafson, T | 1 |
| Boman, K | 1 |
| Wester, PO | 1 |
| Giustina, A | 1 |
| Bresciani, E | 1 |
| Desenzani, P | 1 |
| Licini, M | 1 |
| Zaltieri, G | 1 |
| Fish, JE | 8 |
| Sorkness, C | 2 |
| Mochizuki, H | 1 |
| Tokuyama, K | 1 |
| Morikawa, A | 1 |
| Costa, JC | 1 |
| Plácido, JL | 1 |
| Silva, JP | 1 |
| Vaz, M | 1 |
| Trinquet, G | 1 |
| Harper, AE | 1 |
| Dagg, KD | 2 |
| Thomson, LJ | 2 |
| Ramsay, SG | 1 |
| Kee, ST | 1 |
| Chen, DR | 1 |
| Gamsu, G | 1 |
| McCallum, AL | 1 |
| Abboud, RT | 2 |
| Bowie, DM | 1 |
| Hodder, RV | 1 |
| Paré, PD | 2 |
| Mesic-Fuchs, H | 1 |
| Molfino, NA | 3 |
| Schacter, EN | 1 |
| Fanta, C | 1 |
| Levey, D | 1 |
| Spiro, P | 1 |
| Aldrich, T | 1 |
| Menjoge, SS | 1 |
| Witek, TJ | 2 |
| Ebbutt, A | 1 |
| Jenkins, MM | 2 |
| Garnier, P | 1 |
| Fajac, I | 1 |
| Dessanges, JF | 1 |
| Dall'Ava-Santucci, J | 1 |
| Lockhart, A | 3 |
| Dinh-Xuan, AT | 1 |
| Wolstenholme, RJ | 2 |
| Kane, GC | 1 |
| Tolino, M | 1 |
| Pollice, M | 1 |
| Hand, CH | 1 |
| Bradley, C | 1 |
| Matsumoto, I | 1 |
| Walker, S | 1 |
| Phagoo, SB | 1 |
| Wilson, NM | 1 |
| Lebel, B | 1 |
| Arnoux, B | 1 |
| Bougeard, YH | 1 |
| Daures, JP | 2 |
| Takamatsu, I | 1 |
| Inoue, T | 1 |
| Toyoshima, K | 1 |
| Mahadewsingh, JV | 1 |
| Hamersma, WB | 1 |
| Schreurs, AJ | 2 |
| Williams, JR | 1 |
| Bothner, JP | 1 |
| Swanton, RD | 1 |
| Blum, PS | 1 |
| Chambe, MT | 1 |
| Tool, AT | 1 |
| Mul, FP | 1 |
| Knol, EF | 1 |
| Verhoeven, AJ | 1 |
| Roos, D | 1 |
| Forsch, R | 1 |
| Romano, L | 1 |
| Zofra, S | 1 |
| DiLeva, A | 1 |
| Bariffi, F | 2 |
| Steffensen, I | 1 |
| Humbert, M | 1 |
| Robinson, DS | 1 |
| Assoufi, B | 1 |
| Durham, SR | 3 |
| Rayani, HH | 1 |
| Vellani, CW | 1 |
| Zaidi, SR | 1 |
| Pallares, DE | 1 |
| Pilarski, BR | 1 |
| Rodriguez, JL | 1 |
| Leickly, FE | 1 |
| Dottorini, ML | 1 |
| Tantucci, C | 1 |
| Peccini, F | 1 |
| Sorbini, CA | 3 |
| Pazzelli, P | 1 |
| Niccoli, A | 1 |
| Mezzetti, D | 1 |
| Vaccaro, R | 1 |
| Bagnato, GF | 1 |
| Mileto, A | 1 |
| Gulli, S | 1 |
| Oriti, S | 1 |
| Di Cesare, E | 1 |
| Cinquegrani, M | 1 |
| Bonaiuto, M | 1 |
| Saitta, A | 1 |
| D'Angelo, E | 1 |
| Milic-Emili, J | 2 |
| Marazzini, L | 3 |
| Gong, H | 3 |
| Linn, WS | 1 |
| Shamoo, DA | 1 |
| Anderson, KR | 1 |
| Nugent, CA | 1 |
| Clark, KW | 1 |
| Lin, AE | 1 |
| Khine, H | 1 |
| Alvarez Sintes, R | 2 |
| Alvarez Castro, MR | 1 |
| Merigian, K | 1 |
| Blaho, K | 1 |
| Meriste, S | 2 |
| Marran, S | 2 |
| Märtson, T | 2 |
| Sillastu, H | 2 |
| Tomaç, N | 1 |
| Horikoshi, S | 1 |
| Ogawa, C | 1 |
| Couper, FJ | 3 |
| Drummer, OH | 3 |
| Whitehead, F | 1 |
| Solé, D | 2 |
| Strachan, DP | 2 |
| Griffiths, JM | 1 |
| Johnston, ID | 2 |
| Anderson, HR | 3 |
| Arledge, TE | 2 |
| Rossing, TH | 2 |
| Whitehead, J | 1 |
| Carletti, A | 1 |
| Connell, JM | 1 |
| Dimond, JP | 1 |
| Palazzo, MG | 1 |
| Selby, C | 1 |
| Engleman, HM | 1 |
| Fitzpatrick, MF | 3 |
| Sime, PM | 1 |
| Mackay, TW | 1 |
| Douglas, NJ | 2 |
| Boucher, S | 1 |
| Hébert, J | 2 |
| Singhi, SC | 1 |
| Jayashree, K | 1 |
| Sarkar, B | 1 |
| Friberg, K | 3 |
| Balter, MS | 1 |
| Hyland, RH | 3 |
| Peters, S | 1 |
| Jennings, BH | 1 |
| Lakkis, H | 1 |
| Barnett, PL | 1 |
| Caputo, GL | 1 |
| Baskin, M | 1 |
| Kuppermann, N | 1 |
| Lucena, MI | 1 |
| Almagro, J | 1 |
| Andrade, RJ | 1 |
| Hidalgo Sanchez, R | 1 |
| Sanchez de la Cuesta, F | 1 |
| Penna, AS | 1 |
| Phung, X | 1 |
| Soo, M | 1 |
| Spiers, R | 1 |
| Strauss, L | 3 |
| Hejal, R | 2 |
| Dixon, L | 3 |
| Mariette, C | 1 |
| Pollard, SJ | 2 |
| Prenner, B | 1 |
| Howland, WC | 2 |
| Calderon, P | 1 |
| Lins, R | 1 |
| Rosillon, D | 1 |
| Stricker, W | 3 |
| Botto, A | 1 |
| Kundu, S | 1 |
| Zhang, J | 1 |
| Quebe-Fehling, E | 2 |
| Brambilla, R | 2 |
| Bromly, CL | 2 |
| Grunfeld, A | 1 |
| Levy, RD | 1 |
| Hodder, R | 1 |
| Wong, AG | 1 |
| O'Shaughnessy, AD | 1 |
| Walker, CM | 1 |
| Díaz, JE | 1 |
| Dubin, R | 1 |
| Gaeta, TJ | 1 |
| Pelczar, P | 1 |
| Bradley, K | 1 |
| Zahger, D | 1 |
| Rosen, JP | 2 |
| Goldsobel, AB | 1 |
| White, MV | 4 |
| Lotner, GZ | 1 |
| Bodenheimer, S | 1 |
| Parkes, SN | 1 |
| Bersten, AD | 1 |
| Wildhaber, JH | 4 |
| Hayden, MJ | 1 |
| Summers, QA | 3 |
| Song, P | 1 |
| Rehder, K | 1 |
| Douma, RR | 1 |
| Hamedani, AG | 2 |
| Eggleston, PA | 1 |
| Williamson, IJ | 1 |
| Reid, A | 1 |
| Fennerty, AG | 1 |
| Rimmer, EM | 1 |
| Bettinger, CM | 1 |
| Margo, K | 1 |
| Hedner, J | 4 |
| Lunde, H | 2 |
| Mandahl, A | 1 |
| Affleck, G | 1 |
| Tennen, HA | 1 |
| Barrows, E | 1 |
| Reid, RW | 1 |
| Wilding, P | 1 |
| Clark, M | 1 |
| Thompson Coon, J | 1 |
| Lewis, S | 1 |
| Rushton, L | 1 |
| Bennett, J | 3 |
| Oborne, J | 1 |
| Cooper, S | 2 |
| Plaut, TF | 1 |
| Westby, L | 1 |
| Koper, I | 1 |
| Braun, H | 1 |
| Leutz, M | 1 |
| Schlimmer, P | 1 |
| Sybrecht, GW | 1 |
| Sohal, T | 1 |
| Jones, JI | 1 |
| Upchurch, FC | 1 |
| Nakanishi, AK | 1 |
| Lamb, BM | 1 |
| Foster, C | 1 |
| Rubin, BK | 1 |
| Maury, E | 1 |
| Ioos, V | 1 |
| Lepecq, B | 1 |
| Guidet, B | 1 |
| Offenstadt, G | 1 |
| elSanadi, N | 1 |
| McFadden, CB | 1 |
| Shoemaker, L | 1 |
| Gilbert, L | 1 |
| Warren, E | 1 |
| Hammonds, T | 1 |
| Finkelstein, F | 1 |
| Rihmer, Z | 1 |
| Raimondi, AC | 2 |
| Schottlender, J | 1 |
| Lombardi, D | 1 |
| Díaz, O | 1 |
| Marrades, R | 1 |
| Wong, HH | 2 |
| Castro, A | 2 |
| Pandozi, C | 1 |
| Bianconi, L | 1 |
| Toscano, S | 1 |
| Santini, M | 1 |
| Meier, CR | 1 |
| Jick, H | 1 |
| Tan, KS | 2 |
| Jack, D | 1 |
| Adkins, JC | 2 |
| McTavish, D | 1 |
| Tolep, KA | 1 |
| Shindo, K | 1 |
| Koide, K | 1 |
| Fukumura, M | 1 |
| Aldrich, TK | 1 |
| Prezant, DJ | 1 |
| Guguchev, K | 1 |
| Gaitan-Salas, A | 1 |
| Pathiparti, R | 1 |
| Everts, KB | 1 |
| Shaver, JR | 1 |
| Zangrilli, J | 1 |
| Pollice, MB | 1 |
| Garrett, JE | 3 |
| Rodwell, P | 1 |
| Marrades, RM | 1 |
| de Jover, L | 1 |
| MacNee, W | 1 |
| Jokic, R | 2 |
| Marciniuk, DD | 1 |
| Vir, R | 1 |
| Shah, A | 1 |
| Frost, C | 2 |
| Roorda, RJ | 1 |
| van der Laag, H | 1 |
| Boczkowski, J | 1 |
| Murciano, D | 2 |
| Pichot, MH | 1 |
| Ferretti, A | 1 |
| Pariente, R | 1 |
| Worsdell, M | 1 |
| Graf Bigler, U | 1 |
| Casaulta Aebischer, C | 1 |
| Weder, M | 1 |
| Birrer, P | 1 |
| Levy, S | 1 |
| Smith, JA | 1 |
| Feiss, G | 1 |
| Farrar, JR | 1 |
| Haimovici, R | 1 |
| Gragoudas, ES | 1 |
| Duker, JS | 1 |
| Sjaarda, RN | 1 |
| Eliott, D | 1 |
| Ford, LB | 1 |
| Ayars, GH | 1 |
| Rogenes, PR | 2 |
| Pepsin, PJ | 3 |
| Klig, JE | 1 |
| Hodge, D | 2 |
| Rutherford, MW | 1 |
| van Zomeren, EH | 1 |
| Sethi, GR | 3 |
| Sachdev, HP | 1 |
| Hill, MR | 7 |
| Vaughan, LM | 5 |
| Ostrom, NK | 1 |
| Crowther, SD | 3 |
| Costello, JF | 3 |
| Peterson, GM | 1 |
| McLean, S | 1 |
| Westfal, RE | 3 |
| Bakalchuk, L | 3 |
| Freyberg, CW | 2 |
| Cataquet, D | 2 |
| Heyl, GT | 3 |
| Kurzawa, R | 1 |
| Barliński, J | 1 |
| Bootsma, GP | 1 |
| Dekhuijzen, PN | 2 |
| Festen, J | 1 |
| Amemiya, M | 1 |
| Myou, S | 2 |
| Mizuguchi, M | 1 |
| Matsuda, T | 2 |
| Salome, C | 1 |
| Li, Z | 1 |
| Yu, R | 1 |
| Jartti, TT | 2 |
| Kaila, TJ | 2 |
| Tahvanainen, KU | 2 |
| Kuusela, TA | 2 |
| Vanto, TT | 2 |
| Välimäki, IA | 2 |
| Graves, PE | 1 |
| Baldini, M | 1 |
| Solomon, S | 1 |
| Erickson, R | 1 |
| Mandelberg, A | 2 |
| Chen, E | 1 |
| Noviski, N | 1 |
| Priel, IE | 2 |
| Słomka, A | 1 |
| Stremler, N | 1 |
| Mely, L | 1 |
| Bruguerolle, B | 2 |
| Taylor, DA | 1 |
| Jensen, MW | 1 |
| Aikman, SL | 1 |
| Harris, JG | 1 |
| O'Connor, BJ | 3 |
| Gauvreau, GM | 1 |
| Jordana, M | 1 |
| Watson, RM | 2 |
| Cockroft, DW | 1 |
| Reynolds, PL | 1 |
| Bondesson, E | 3 |
| Carlsson, LG | 1 |
| Hörnblad, Y | 2 |
| Jemsby, P | 1 |
| Källén, A | 1 |
| Ullman, A | 4 |
| Werner, S | 1 |
| Palmqvist, M | 6 |
| Persson, G | 3 |
| Lazer, L | 1 |
| Dzyngel, B | 1 |
| Tarlo, S | 1 |
| Slutsky, AS | 2 |
| Baker, EK | 1 |
| Willsie, SK | 1 |
| Marinac, JS | 1 |
| Salzman, GA | 1 |
| Kozlik-Feldmann, R | 1 |
| Harris, AG | 1 |
| Aaronson, D | 1 |
| Beaucher, W | 1 |
| Berkowitz, R | 2 |
| Bronsky, E | 4 |
| Cohen, R | 2 |
| Fourre, J | 1 |
| Meltzer, E | 1 |
| Pedinoff, A | 1 |
| Wanderer, A | 1 |
| Ushkow, BS | 1 |
| Reicho, PR | 1 |
| Slawson, JG | 1 |
| Flynn, CA | 1 |
| Chyrek-Borowska, S | 2 |
| Kowal, K | 1 |
| Swiebocka, E | 1 |
| Grubek-Jaworska, H | 2 |
| Hermanowicz-Salomon, J | 1 |
| Ritz, M | 1 |
| Thorens, JB | 1 |
| Arnold-Ketterer, M | 1 |
| Chevrolet, JC | 1 |
| Rubinfeld, A | 1 |
| Morgan, JP | 1 |
| Drotar, DE | 1 |
| Davis, EE | 1 |
| Higham, MA | 1 |
| Sharara, AM | 1 |
| Wilson, P | 1 |
| Glendenning, GA | 1 |
| Larsson, L | 1 |
| Dickinson, J | 1 |
| Hutton, S | 1 |
| Atkin, A | 1 |
| Breitigan, JM | 1 |
| Klinger, NM | 6 |
| Slade, HB | 2 |
| Handley, DA | 4 |
| McCullough, JR | 1 |
| Wilcke, JT | 2 |
| Cook, DA | 1 |
| Incaudo, GA | 1 |
| Kalberg, C | 9 |
| Pendino, JC | 2 |
| Nannini, LJ | 2 |
| Slutsky, A | 1 |
| Clark, DJ | 3 |
| Seldon, PM | 1 |
| Stevens, DA | 1 |
| Yernault, JC | 1 |
| Demedts, MG | 1 |
| Geusens, P | 1 |
| Sung, L | 1 |
| Osmond, MH | 2 |
| Aziz, I | 4 |
| Hamilton, AL | 1 |
| Khan, A | 1 |
| Strayhorn, V | 1 |
| Leeper, K | 1 |
| Tolley, E | 1 |
| Self, T | 1 |
| Montoya, C | 1 |
| Weissburg, A | 1 |
| Zuckerman, LH | 1 |
| Edell, D | 2 |
| Bruce, E | 1 |
| Hale, K | 1 |
| Khoshoo, V | 1 |
| Bernstein, DI | 1 |
| Ginchansky, E | 1 |
| Pedinoff, AJ | 1 |
| Winder, JA | 1 |
| Krouwels, FH | 1 |
| Hol, BE | 1 |
| Bruinier, B | 1 |
| Bast, A | 1 |
| Out, TA | 3 |
| Smirnova, ZV | 1 |
| Arkhipova, SV | 1 |
| Crossland, L | 1 |
| Finnerty, J | 1 |
| Baki, A | 2 |
| Karagüzel, G | 2 |
| Pirie, J | 1 |
| Cox, P | 1 |
| Rakhmanina, NY | 1 |
| Kearns, GL | 1 |
| Farrar, HC | 1 |
| Norden, MA | 1 |
| Fitzgerald, DA | 1 |
| Connor, FL | 1 |
| Van Asperen, PP | 3 |
| Cooper, PJ | 1 |
| Allen, HD | 1 |
| Tolep, K | 1 |
| Uhereczky, G | 1 |
| Gács, E | 1 |
| Jákly, A | 1 |
| Göndöcs, R | 1 |
| Durante, S | 1 |
| Borrello, G | 1 |
| Dykewicz, MS | 1 |
| Ledford, DK | 1 |
| Nana, A | 1 |
| Maranetra, N | 1 |
| Davies, B | 1 |
| Brooks, G | 1 |
| Devoy, M | 1 |
| la Rosa, M | 1 |
| Kaad, PH | 1 |
| Moorat, A | 1 |
| Soliman, S | 1 |
| Elidrissi, H | 1 |
| Trabelsi, H | 1 |
| Boussarsar, M | 2 |
| Ouannes, L | 1 |
| Bouzouita, K | 1 |
| Abroug, MF | 1 |
| Hewer, SL | 2 |
| Kargul, B | 1 |
| Tanboga, I | 1 |
| Ergeneli, S | 1 |
| Karakoc, F | 1 |
| Lumry, W | 4 |
| Manning, M | 1 |
| Cox, F | 3 |
| Masterson, CM | 2 |
| Batty, EP | 2 |
| Magrì, S | 1 |
| Pagano, C | 1 |
| Paolino, G | 1 |
| Santonocito, G | 1 |
| Milot, J | 4 |
| Rossinen, J | 1 |
| Partanen, J | 1 |
| Nieminen, MS | 1 |
| Kumar, SD | 1 |
| Emery, MJ | 1 |
| Atkins, ND | 1 |
| Danta, I | 2 |
| Grol, MH | 1 |
| Nutini, S | 1 |
| Martini, T | 1 |
| Righi, R | 1 |
| Weinstein, AG | 1 |
| Golish, J | 1 |
| Curtis-McCarthy, P | 1 |
| McCarthy, K | 1 |
| Kavuru, M | 2 |
| Wagner, W | 2 |
| Beck, G | 1 |
| Eng, P | 1 |
| Oddoze, C | 1 |
| Weinstein, SF | 1 |
| Byrne, A | 1 |
| Arledge, T | 3 |
| Brophy, C | 1 |
| Ahmed, B | 1 |
| Bayston, S | 1 |
| Arnold, A | 1 |
| McGivern, D | 1 |
| Greenstone, M | 1 |
| Proud, D | 1 |
| Reynolds, CJ | 1 |
| Lichtenstein, LM | 1 |
| Kagey-Sobotka, A | 1 |
| Lanes, SF | 2 |
| Wentworth, CE | 2 |
| Turcotte, H | 3 |
| Mangat, HS | 1 |
| D'Souza, GA | 1 |
| Jacob, MS | 1 |
| Hellinckx, J | 1 |
| Bande-Knops, J | 1 |
| van der Poel, M | 1 |
| Demedts, M | 1 |
| Malozowski, S | 1 |
| Stadel, BV | 1 |
| Pian, LP | 1 |
| Moy, ML | 2 |
| Lantin, ML | 1 |
| Harver, A | 1 |
| Schwartzstein, RM | 1 |
| Wever, AM | 1 |
| de GOEIJ, JA | 1 |
| de GRAAFF, CS | 1 |
| Steen, H | 1 |
| Lanza, LL | 1 |
| Turner, MO | 1 |
| Hussack, P | 1 |
| Vachier, I | 2 |
| Chiappara, G | 1 |
| Altieri, E | 1 |
| Térouanne, B | 1 |
| Vic, P | 1 |
| Sellers, J | 1 |
| Greene, S | 1 |
| Flaster, E | 1 |
| Colice, G | 1 |
| Kou, M | 1 |
| Phil, M | 1 |
| Kumana, CR | 1 |
| Ip, MS | 1 |
| Lauder, IJ | 1 |
| Lam, WK | 1 |
| Chan, JC | 1 |
| Mincewicz, G | 1 |
| Sopel, R | 1 |
| Kozłowki, M | 1 |
| Kurowski, W | 1 |
| Pestian, J | 1 |
| Davis, P | 1 |
| Dworski, R | 2 |
| Prokop, A | 1 |
| Oates, JA | 1 |
| Garrett, J | 1 |
| Williams, S | 2 |
| Holdaway, D | 1 |
| Zou, JP | 1 |
| Gu, FQ | 1 |
| Liao, WJ | 1 |
| Johnson, C | 1 |
| Beckerman, RC | 1 |
| Davis, GM | 1 |
| Adinoff, AD | 1 |
| Schwartz, HJ | 2 |
| Swearingen, BE | 1 |
| Seppälä, OP | 1 |
| Kari, E | 1 |
| Löyttyniemi, E | 1 |
| Kunkel, G | 3 |
| Jenne, JW | 2 |
| Kerac, M | 1 |
| Montgomery, H | 1 |
| Johnson, N | 1 |
| Crago, S | 1 |
| Coors, L | 1 |
| Lapidus, JA | 1 |
| Sapien, R | 1 |
| Samaranayake, SW | 1 |
| Dalphin, JC | 1 |
| Dubiez, A | 1 |
| Monnet, E | 1 |
| Gora, D | 1 |
| Westeel, V | 1 |
| Pernet, D | 1 |
| Polio, JC | 1 |
| Gibey, R | 1 |
| Laplante, JJ | 1 |
| Depierre, A | 1 |
| Corne, JM | 1 |
| Linaker, CH | 1 |
| Merrett, T | 1 |
| Beasely, R | 1 |
| Church, M | 1 |
| Caussade, D | 1 |
| Sanchez, P | 1 |
| Berjaud, J | 1 |
| Ducassé, JL | 1 |
| DiSantostefano, R | 1 |
| DeGraw, S | 2 |
| Reasner, DS | 2 |
| Rollins, TE | 2 |
| Rubin, PD | 1 |
| Vervloet, D | 2 |
| Ekström, T | 2 |
| Pela, R | 1 |
| Duce Gracia, F | 1 |
| Kopp, C | 1 |
| Silvert, BD | 1 |
| Di Benedetto, G | 2 |
| Wrońska, J | 1 |
| Mazurek, J | 1 |
| Dawson, KL | 1 |
| Kaczka, DW | 1 |
| Ingenito, EP | 4 |
| Kim, JT | 1 |
| Kim, CK | 1 |
| Koh, YY | 1 |
| Buchwald, A | 1 |
| Hochhaus, G | 1 |
| Henderson, SO | 1 |
| Acharya, P | 1 |
| Kilaghbian, T | 1 |
| Perez, J | 1 |
| Korn, CS | 1 |
| Chan, LS | 1 |
| Goh, SY | 1 |
| Arulanandam, S | 1 |
| Ho, CL | 1 |
| Goh, DY | 1 |
| Chew, FT | 1 |
| Lee, BW | 1 |
| Cargill, K | 1 |
| Wolfe, S | 1 |
| Darby, H | 1 |
| Hamid, S | 1 |
| Kumaradevan, J | 1 |
| Minkwitz, MC | 1 |
| Simonson, SG | 1 |
| Bonuccelli, CM | 1 |
| Chu, DM | 1 |
| Wang, CL | 1 |
| Yang, KD | 1 |
| Bieler, S | 1 |
| Guttman, A | 1 |
| Dankoff, J | 1 |
| Tselios, C | 1 |
| Stern, E | 2 |
| Basran, G | 1 |
| Schiraldi, G | 1 |
| Eivindson, A | 1 |
| Jamieson, AH | 1 |
| Olsson, H | 1 |
| Wakita, S | 1 |
| Chatkin, J | 1 |
| Ansarin, K | 1 |
| Caramori, M | 1 |
| McClean, P | 1 |
| Rushby, I | 1 |
| Scullion, J | 1 |
| Morgan, MD | 1 |
| Dawson, C | 1 |
| Weiss, S | 1 |
| Stubbing, D | 1 |
| Fairbarn, MS | 1 |
| Vermetten, FA | 1 |
| Boermans, AJ | 1 |
| Luiten, WD | 1 |
| Schleufe, P | 1 |
| Reiffen, HP | 1 |
| Piepenbrock, S | 1 |
| Goldberg, P | 1 |
| Galant, S | 1 |
| Welch, MB | 2 |
| Petrocella, V | 2 |
| Langley, PC | 1 |
| Sill, V | 1 |
| Bartuschka, B | 1 |
| Villiger, B | 1 |
| Ortland, C | 1 |
| Domej, W | 1 |
| Li, JT | 2 |
| Woodring, A | 3 |
| van Bavel, J | 1 |
| Finn, A | 2 |
| Brown, A | 1 |
| Harding, SM | 3 |
| Chong, BT | 1 |
| Agrawal, DK | 1 |
| Romero, FA | 1 |
| Pusic, MV | 1 |
| Lebet, R | 1 |
| Duggan, AK | 1 |
| Naumann, PF | 1 |
| Wong, GA | 1 |
| Raabe, OG | 1 |
| Sculpher, MJ | 1 |
| Buxton, MJ | 1 |
| Stãlhammar, NO | 1 |
| Peters, DH | 1 |
| Faulds, D | 2 |
| Laursen, LC | 1 |
| Mackowiak, J | 1 |
| Yung, M | 1 |
| Harrison, TW | 1 |
| Gawchik, SM | 1 |
| Saccar, CL | 1 |
| DeGraw, SS | 1 |
| Tunaoğlu, FS | 1 |
| Olguntürk, R | 1 |
| Demirsoy, S | 1 |
| Löwhagen, O | 2 |
| Ekström, L | 1 |
| Holmberg, S | 1 |
| Wennerblom, B | 1 |
| Rosenfeldt, M | 1 |
| Nantel, NP | 1 |
| Chambers, CB | 1 |
| Pratt, B | 1 |
| Parry-Billings, M | 1 |
| Dewar, AL | 1 |
| Stewart, A | 1 |
| Cogswell, JJ | 1 |
| Dow, AM | 1 |
| Tenenbaum, C | 1 |
| Curry, A | 1 |
| Geoffroy, P | 1 |
| Lalonde, RL | 2 |
| Clarke, W | 1 |
| Goldstein, S | 1 |
| Nocker, RE | 2 |
| de Riemer, MJ | 2 |
| Noppen, M | 3 |
| Van Muylem, A | 1 |
| Berkowitz, RB | 2 |
| Tinkelman, DA | 1 |
| Scuotri, L | 1 |
| Grootendorst, DC | 1 |
| van den Bos, JW | 1 |
| Romeijn, JJ | 1 |
| Veselic-Charvat, M | 1 |
| Vrijlandt, EJ | 1 |
| Roldaan, AC | 1 |
| Boothman-Burrell, D | 1 |
| Hancox, B | 1 |
| Harré, E | 1 |
| Laubscher, K | 1 |
| Linscott, V | 1 |
| Ramsay, CM | 2 |
| Richards, G | 1 |
| Mol, SJ | 1 |
| Raphael, GD | 1 |
| Lanier, RQ | 1 |
| Baker, J | 1 |
| Casale, TB | 1 |
| Norhaya, MR | 1 |
| Yap, TM | 1 |
| Thomason, DB | 1 |
| Mohamed, MH | 2 |
| Eberle, LV | 2 |
| Johnson, JA | 2 |
| Rogers, DF | 2 |
| Zietkowski, Z | 2 |
| Rogalewska, A | 1 |
| Razzouk, H | 2 |
| dos Santos, L | 1 |
| Giudicelli, J | 1 |
| Queirós, M | 1 |
| de Lurdes Chieira, M | 1 |
| Ramos, C | 1 |
| Lindbladh, C | 2 |
| Wiegand, L | 1 |
| Mende, CN | 1 |
| Zaidel, G | 1 |
| Zwillich, CW | 2 |
| Petrocella, VJ | 1 |
| Massasso, DH | 1 |
| Seale, JP | 3 |
| Woolcock, AJ | 3 |
| Bryan, S | 1 |
| Ibsen, T | 1 |
| Mellén, A | 2 |
| Parameswaran, KN | 1 |
| Summers, E | 1 |
| Tymińska, K | 2 |
| Kroczyńska-Bednarek, J | 2 |
| Kwiatkowska, S | 2 |
| Winders, P | 1 |
| Dore, ND | 1 |
| Wilson, JM | 1 |
| Spencer, CM | 1 |
| Jarvis, B | 2 |
| Pinnas, JL | 1 |
| Müller, HH | 1 |
| Schäfer, H | 1 |
| Matthys, H | 2 |
| Sauer, R | 1 |
| Schauer, P | 1 |
| Menz, G | 1 |
| Malmström, K | 2 |
| Sorva, R | 1 |
| Gordon, S | 1 |
| Vizel', AA | 1 |
| Khabibullin, KA | 1 |
| Sander, N | 1 |
| Costello, J | 1 |
| Handley, D | 1 |
| Cowan, J | 1 |
| Flannery, E | 1 |
| McLachlan, C | 1 |
| Anderson, TJ | 2 |
| Parashchak, MR | 2 |
| Burke, CM | 2 |
| Watson, SA | 2 |
| Turbitt, ML | 2 |
| Wallaert, B | 1 |
| Brun, P | 1 |
| Ostinelli, J | 1 |
| Champel, F | 1 |
| Blaive, B | 1 |
| Montané, F | 1 |
| Kamio, Y | 1 |
| Ishiura, Y | 1 |
| Tachibana, H | 1 |
| Hirose, T | 1 |
| Hashimoto, T | 2 |
| Beaucher, WN | 1 |
| Kiechel, F | 1 |
| Sublett, JL | 1 |
| LaVallee, N | 1 |
| Shilstone, J | 1 |
| Stormon, MO | 1 |
| Kilham, HA | 1 |
| Rosenthal, RR | 1 |
| Baraniuk, J | 1 |
| Srebro, S | 1 |
| Korosec, M | 1 |
| Novak, RD | 1 |
| Myers, E | 1 |
| Skowronski, M | 1 |
| Ciccolella, DE | 1 |
| Brennan, K | 1 |
| Criner, GJ | 1 |
| Singhi, S | 1 |
| Kumar, L | 1 |
| Jayshree, M | 1 |
| Clarke, WR | 1 |
| Dockhorn, RJ | 2 |
| Lux, C | 2 |
| Han, SH | 2 |
| Durham, S | 1 |
| Roberts, JA | 2 |
| Britten, KM | 2 |
| Walls, AF | 2 |
| Gratziou, C | 1 |
| Aldridge, RE | 1 |
| McLachlan, CR | 2 |
| Kotani, Y | 1 |
| Burschtin, O | 1 |
| Mentz, P | 1 |
| Forssmann, K | 1 |
| Meyer, M | 1 |
| Smith, P | 1 |
| Jackson, L | 1 |
| Begishvilli, B | 1 |
| Jamieson, A | 1 |
| Everts, B | 1 |
| Möller, CS | 1 |
| Ouellet, D | 1 |
| Kimanani, EK | 1 |
| Potvin, D | 1 |
| Sheikh, S | 1 |
| Goldsmith, LJ | 1 |
| Howell, L | 1 |
| Eid, N | 1 |
| Jacobson, K | 1 |
| Kane, RE | 2 |
| Banerji, D | 2 |
| Uryniak, T | 1 |
| Bouros, D | 1 |
| Bachlitzanakis, N | 1 |
| Kottakis, J | 2 |
| Pfister, P | 1 |
| Polychronopoulos, V | 1 |
| Papadakis, E | 1 |
| Constantopoulos, S | 1 |
| Froudarakis, M | 1 |
| Sichletidis, L | 2 |
| Siafakas, N | 1 |
| Holz, O | 1 |
| Mücke, M | 1 |
| Schneider, LC | 1 |
| Lester, MR | 1 |
| Li, X | 2 |
| Bao, X | 1 |
| Bailey, M | 1 |
| Wilson, JW | 4 |
| Haydn Walters, E | 2 |
| Welch, M | 1 |
| Bernstein, D | 1 |
| Hughes, DA | 1 |
| Walley, T | 1 |
| Grutters, JC | 1 |
| Brinkman, L | 1 |
| Aslander, MM | 1 |
| van den Bosch, JM | 1 |
| Koenderman, L | 1 |
| Garcia-Rodríguez, LA | 1 |
| Pérez-Gutthann, S | 1 |
| Agostinis, L | 1 |
| Cattaruzi, C | 1 |
| Troncon, MG | 1 |
| Gumbhir-Shah, K | 1 |
| Koch, P | 1 |
| Jusko, WJ | 1 |
| DeGraff, AC | 2 |
| O'Riordan, TG | 1 |
| Herrle, MR | 1 |
| Stahl, EG | 1 |
| Choy, DK | 1 |
| Ko, F | 1 |
| Li, ST | 1 |
| lp, LS | 1 |
| Leung, R | 1 |
| Hui, D | 1 |
| Weksler, N | 1 |
| Brill, S | 1 |
| Tarnapolski, A | 1 |
| Gurman, GM | 1 |
| Anderson, AJ | 1 |
| Koester, J | 1 |
| Snider, ME | 2 |
| Gluckman, TJ | 1 |
| Corbridge, T | 1 |
| Church, NL | 1 |
| Gillman, SA | 1 |
| Lanier, BQ | 2 |
| Brieva, JL | 1 |
| Redington, AE | 1 |
| Rees, PJ | 4 |
| Rogalewska, AM | 1 |
| Madsen, F | 1 |
| Schlösser, NJ | 1 |
| Steinmetz, KO | 1 |
| Jones, SL | 2 |
| Gershman, NH | 1 |
| Liu, JT | 1 |
| Little, SA | 2 |
| MacLeod, KJ | 2 |
| McSharry, C | 2 |
| Rosi, E | 1 |
| Scano, G | 1 |
| Hamzaoui, A | 1 |
| Hamzaoui, K | 1 |
| Salah, H | 1 |
| Chabbou, A | 1 |
| Hidi, R | 1 |
| Timmermans, S | 1 |
| Liu, E | 1 |
| Schudt, C | 1 |
| Dent, G | 1 |
| Stewart, BA | 1 |
| Carrier, S | 1 |
| Frosolono, M | 1 |
| Milavetz, G | 3 |
| Corna, RA | 1 |
| Mannarino, S | 1 |
| Quispe, R | 1 |
| Mutlu, GM | 1 |
| Moonjelly, E | 1 |
| Chan, L | 1 |
| Olopade, CO | 1 |
| Boccuzzi, SJ | 1 |
| Wogen, J | 1 |
| Roehm, JB | 1 |
| Okamura, D | 1 |
| Nagamine, J | 1 |
| Boychuk, RB | 1 |
| Halm, B | 1 |
| Yee, LL | 1 |
| Dellamary, LA | 1 |
| Tarara, TE | 1 |
| Smith, DJ | 1 |
| Woelk, CH | 1 |
| Adractas, A | 1 |
| Costello, ML | 1 |
| Gill, H | 1 |
| Weers, JG | 1 |
| Auregan, G | 1 |
| Djankine, K | 1 |
| Keita, B | 1 |
| Ky, C | 1 |
| Mahi, S | 1 |
| Ngoran, K | 1 |
| Kreitzer, S | 1 |
| Reilly, D | 1 |
| Davis, S | 2 |
| Leversha, AM | 1 |
| Campanella, SG | 1 |
| Aickin, RP | 1 |
| Asher, MI | 2 |
| Hernández, M | 1 |
| Salmen, S | 1 |
| Berrueta, L | 1 |
| Navas, M | 1 |
| Sánchez, B | 1 |
| Muñoz, J | 1 |
| Delgado, R | 1 |
| Romano, E | 1 |
| Rangel, A | 1 |
| Fowler, SJ | 4 |
| Dempsey, OJ | 3 |
| Wilson, AM | 2 |
| Mistry, C | 1 |
| Jang, AS | 1 |
| Choi, IS | 1 |
| Park, CS | 1 |
| Horner, SD | 1 |
| Small, RC | 1 |
| Chiu, P | 1 |
| Cook, SJ | 1 |
| Foster, RW | 1 |
| Isaac, L | 1 |
| Hausen, T | 1 |
| Sato, R | 1 |
| Gutglass, DJ | 1 |
| Hampers, L | 1 |
| Roosevelt, G | 1 |
| Teoh, D | 1 |
| Nimmagadda, SR | 1 |
| Karras, DJ | 1 |
| Sammon, ME | 1 |
| Terregino, CA | 1 |
| Lopez, BL | 1 |
| Griswold, SK | 1 |
| Arnold, GK | 1 |
| Callahan, CW | 2 |
| Tsehori, S | 1 |
| Houri, S | 1 |
| Gilad, E | 1 |
| Morag, B | 1 |
| Arshad, H | 1 |
| Fink, J | 1 |
| Shrewsbury, S | 4 |
| Pyke, S | 2 |
| Britton, M | 1 |
| Mícheli, F | 1 |
| Cersósimo, MG | 1 |
| Scorticati, MC | 1 |
| Velez, M | 1 |
| Gonzalez, S | 2 |
| Ventura, R | 2 |
| Segura, J | 2 |
| Bergés, R | 2 |
| Fitch, KD | 3 |
| Morton, AR | 2 |
| Berruezo, S | 1 |
| Jiménez, C | 1 |
| Healy, MJ | 1 |
| Melamed, J | 1 |
| Grady, J | 1 |
| Stevens, A | 1 |
| Duke, S | 1 |
| Harding, S | 1 |
| Milano, M | 1 |
| Reining, U | 1 |
| Mattes, J | 1 |
| Storm van's Gravesande, K | 1 |
| Ihorst, G | 1 |
| Kühr, J | 1 |
| Peterson, D | 1 |
| Pang, L | 1 |
| Caron, J | 1 |
| Hilliard, TN | 1 |
| Witten, H | 1 |
| Male, IA | 1 |
| Seddon, PC | 1 |
| Richter, B | 1 |
| Bender, R | 1 |
| Berger, M | 1 |
| Davis, EB | 1 |
| Lindsay, MA | 1 |
| Moilanen, E | 1 |
| Rosenberg, NM | 2 |
| Posner, JC | 1 |
| Waltzman, ML | 1 |
| Bhende, M | 1 |
| Whittaker, AR | 1 |
| Lucas, M | 1 |
| Carter, R | 1 |
| Cooper, DM | 1 |
| Kunselman, S | 1 |
| McLean, DE | 1 |
| Yandava, CN | 2 |
| Sharp, SJ | 1 |
| Vickers, MR | 1 |
| Frost, CD | 1 |
| Horiuchi, T | 1 |
| Baumgarten, CR | 1 |
| Dorow, P | 1 |
| Gebhardt, R | 1 |
| Kettner, J | 1 |
| Sykes, AP | 4 |
| Salat, D | 1 |
| Popov, D | 1 |
| Joshi, A | 1 |
| Sah, SP | 1 |
| Agrawal, S | 1 |
| Agarwalla, A | 1 |
| Jacob, M | 1 |
| Seberová, E | 1 |
| Andersson, A | 1 |
| Greening, A | 1 |
| Ossip, MS | 1 |
| Hederos, CA | 1 |
| Anttila, H | 1 |
| Ribeiro, BL | 1 |
| Davies, PI | 1 |
| Saarelainen, P | 1 |
| Thwaites, RM | 1 |
| Jones, R | 1 |
| Payne, JE | 1 |
| Wolford, JP | 1 |
| Adelglass, J | 1 |
| Clifford, DP | 1 |
| Duke, SP | 1 |
| Wire, PD | 1 |
| Faris, M | 1 |
| Shelledy, DC | 1 |
| Lawson, RW | 1 |
| Davis, CP | 1 |
| LeGrand, TS | 1 |
| Stephens, MB | 1 |
| Balzano, G | 1 |
| Battiloro, R | 1 |
| Biraghi, M | 1 |
| Fuschillo, S | 1 |
| Gaudiosi, C | 1 |
| De Angelis, E | 1 |
| Besbes-Ouanes, L | 1 |
| Knani, J | 1 |
| Waterer, GW | 1 |
| Hills, BA | 1 |
| Chen, Y | 1 |
| Farré, M | 1 |
| Mas, M | 1 |
| de La Torre, X | 1 |
| Wade, D | 1 |
| Hirai, R | 1 |
| Nolop, K | 1 |
| Laurent, F | 1 |
| Latrabe, V | 1 |
| Raherison, C | 1 |
| Tunon-de-Lara, JM | 1 |
| Rho, DS | 1 |
| Blomgren, A | 1 |
| Boonyavorakul, C | 1 |
| Thakkinstian, A | 1 |
| Charoenpan, P | 1 |
| Ozaras, R | 1 |
| Tahan, V | 1 |
| Turkmen, S | 1 |
| Talay, F | 1 |
| Besirli, K | 1 |
| Aydin, S | 1 |
| Uzun, H | 1 |
| Cetinkaya, A | 1 |
| Lee, T | 1 |
| Dennis, S | 1 |
| Jébrak, G | 1 |
| Maslow, AD | 1 |
| Regan, MM | 1 |
| Darvish, A | 1 |
| Mehrez, M | 1 |
| Boughton, R | 1 |
| Loring, SH | 1 |
| Beckett, P | 1 |
| Niu, T | 1 |
| Rogus, JJ | 1 |
| Wang, B | 1 |
| Yang, J | 2 |
| Xu, X | 1 |
| Frei, SP | 1 |
| Noschese, P | 1 |
| D'Amato, M | 1 |
| D'Amato, G | 2 |
| Karch, AM | 1 |
| Karch, FE | 1 |
| Duane, M | 1 |
| Chandran, L | 1 |
| Morelli, PJ | 1 |
| Church, N | 1 |
| Murray, A | 3 |
| Barnhart, F | 2 |
| Kamachi, A | 1 |
| Nasuhara, Y | 1 |
| Ohtsuka, Y | 1 |
| Amishima, M | 1 |
| Zetterström, O | 1 |
| Lähelmä, S | 1 |
| Keski-karhu, J | 2 |
| Ostling-kulling, E | 1 |
| Markham, A | 2 |
| Sherman, J | 1 |
| Becker, JM | 1 |
| Iskandrian, S | 1 |
| Conkling, J | 1 |
| Barraza, CH | 1 |
| Suárez-Chacón, R | 1 |
| Harnest, U | 1 |
| Martinez Morales, G | 1 |
| Nolop, KB | 1 |
| Visser, S | 1 |
| Lutsky, BN | 1 |
| Oudesluys-Murphy, AM | 1 |
| Janssens, HM | 1 |
| Hop, W | 1 |
| Brinkman, JG | 1 |
| Sukhai, RN | 1 |
| Brieva, J | 1 |
| Beckman, O | 1 |
| Peterson, S | 1 |
| Fishwick, D | 1 |
| Bradshaw, L | 1 |
| Macdonald, C | 1 |
| Gash, D | 1 |
| Shapiro, GS | 1 |
| McRae, W | 1 |
| Koskela, T | 1 |
| Peltola, S | 1 |
| Ojima, F | 1 |
| Ebihara, M | 1 |
| Shoji, T | 1 |
| Tomike, H | 1 |
| Nakagawa, Y | 1 |
| Chuffart, AA | 1 |
| Sennhauser, FH | 1 |
| Lapidus, RJ | 1 |
| Levine, BE | 1 |
| Kiselev, P | 1 |
| Bourcereau, J | 1 |
| Leynadier, F | 1 |
| Ben-Joseph, RH | 1 |
| Bailey, MJ | 1 |
| Driver, JS | 1 |
| Forbes, AB | 1 |
| McNeil, JJ | 2 |
| Sanguinetti, CM | 1 |
| Silins, V | 1 |
| Bogolubov, M | 1 |
| Singhal, T | 1 |
| Garg, H | 1 |
| Arora, HS | 1 |
| Tesarowski, D | 1 |
| Huang, MT | 1 |
| Yang, YH | 1 |
| Lin, YT | 1 |
| Lu, MY | 1 |
| Wang, LH | 1 |
| Tsai, MJ | 1 |
| Chiang, BL | 1 |
| Anstead, MI | 1 |
| Hunt, TA | 1 |
| McConnell, JW | 1 |
| Burki, NK | 1 |
| Chakir, J | 1 |
| Boutet, M | 1 |
| Liam, CK | 1 |
| Lim, KH | 1 |
| Wong, CM | 1 |
| Dunn, CJ | 1 |
| Goa, KL | 1 |
| Clayton, RA | 1 |
| McGrath, JC | 1 |
| Hinton, KL | 1 |
| Kratzenberg, JJ | 1 |
| Dubé, L | 1 |
| Noveck, R | 1 |
| Linder, JA | 1 |
| Stafford, RS | 1 |
| Leone, FT | 1 |
| Mauger, EA | 1 |
| Ford, J | 1 |
| McGeady, SJ | 1 |
| Romano, F | 1 |
| Recchia, G | 1 |
| Staniscia, T | 1 |
| Bonitatibus, A | 1 |
| Villa, M | 1 |
| Nicolosi, A | 1 |
| De Carli, G | 1 |
| Mannino, S | 1 |
| Panicker, J | 1 |
| Sehgal, V | 1 |
| Eisner, MD | 1 |
| Chi, F | 1 |
| Capra, AM | 1 |
| Mendoza, GR | 1 |
| Selby, JV | 1 |
| Blanc, PD | 1 |
| Chavis, C | 1 |
| Majori, M | 1 |
| Farce, M | 1 |
| Cloosterman, SG | 4 |
| Bijl-Hofland, ID | 4 |
| van Den Elshout, FJ | 2 |
| Blais, R | 1 |
| Grégoire, JP | 1 |
| Bouchard, J | 1 |
| Martin, RM | 1 |
| Shakir, S | 1 |
| Chuchalin, AG | 1 |
| O'Brien, K | 1 |
| Mitsufuji, H | 1 |
| Imasaki, T | 1 |
| Ichikawa, T | 1 |
| Kawakami, T | 1 |
| Tomita, T | 1 |
| Jensen, A | 1 |
| Atileh, H | 1 |
| Burggraaf, J | 1 |
| Westendorp, RG | 1 |
| in't Veen, JC | 1 |
| Blauw, GJ | 1 |
| Rebrov, AP | 1 |
| Karoli, NA | 1 |
| Orsida, BE | 1 |
| Stone, BD | 1 |
| Elias-Todd, T | 1 |
| Parrino, J | 1 |
| Zieba, M | 1 |
| Keogh, KA | 1 |
| Arseneault, R | 1 |
| Tennis, O | 1 |
| Bacal, L | 1 |
| Bilge, M | 1 |
| Boone, R | 1 |
| Goraya, JS | 1 |
| Virdi, VS | 1 |
| Wang, SW | 1 |
| Liu, X | 1 |
| Wiener, DJ | 2 |
| Sennett, C | 1 |
| Bowers, BW | 1 |
| Scalfaro, P | 1 |
| Sims, C | 1 |
| Habre, W | 1 |
| Naedele-Risha, R | 1 |
| Mircetić, RN | 1 |
| Dodig, S | 1 |
| Raos, M | 1 |
| Petres, B | 1 |
| Cepelak, I | 1 |
| Kips, JC | 1 |
| Wood, R | 1 |
| Jones, PD | 1 |
| Hankin, R | 1 |
| Simpson, J | 1 |
| Cash, R | 1 |
| Blonski, J | 1 |
| Cates, C | 1 |
| Eliseeva, EV | 2 |
| Romanova, NA | 1 |
| Maistrovskaya, YV | 1 |
| Maloney, A | 1 |
| Ventresca, GP | 1 |
| Morris, A | 1 |
| Centanni, S | 1 |
| Boveri, B | 1 |
| Di Marco, F | 1 |
| Santus, P | 1 |
| Simpson, JL | 1 |
| Hensley, MJ | 1 |
| Abisheganaden, J | 1 |
| Chee, CB | 1 |
| Goh, SK | 1 |
| Yeo, LS | 1 |
| Prabhakaran, L | 1 |
| Earnest, A | 1 |
| Wang, YT | 2 |
| Armstrong, TJ | 2 |
| Britton, TB | 2 |
| Forand, PE | 2 |
| Pillari, A | 1 |
| Corona-Hernández, L | 1 |
| Fragoso-Ríos, R | 1 |
| Berber, A | 1 |
| Torres-Alcántara, S | 1 |
| Cuairán-Ruidíaz, V | 1 |
| Goggin, N | 1 |
| McDonald, DM | 1 |
| Coskun, S | 2 |
| Tikiz, H | 1 |
| Danahaliloğlu, S | 1 |
| Mallmann, F | 1 |
| Fernandes, AK | 1 |
| Avila, EM | 1 |
| Nogueira, FL | 1 |
| Steinhorst, AM | 1 |
| Saucedo, DZ | 1 |
| Machado, FJ | 1 |
| Raymundi, MG | 1 |
| Dalcin, PT | 1 |
| Menna Barreto, SS | 1 |
| Mallol, J | 1 |
| Aguirre, V | 1 |
| Rhem, R | 1 |
| Rodriguez, J | 1 |
| Dolovich, M | 1 |
| Botkin, JR | 1 |
| Clayton, E | 1 |
| Nelson, R | 1 |
| Wilfond, B | 1 |
| Munger, MA | 1 |
| Miller, FG | 1 |
| Shorr, AF | 1 |
| Friedman Ross, L | 1 |
| Polat, M | 1 |
| Onag, A | 1 |
| Marosi, A | 1 |
| Stiesmeyer, J | 1 |
| Hallett, C | 1 |
| Stevens, AL | 1 |
| Vandermeer, AK | 1 |
| Garris, T | 1 |
| Seppälä, OR | 1 |
| Aalto, E | 1 |
| Hakonen, T | 1 |
| Lukkari-Lax, E | 1 |
| Jouhikainen, T | 1 |
| Liipp, K | 1 |
| Walter, SD | 1 |
| Cohn, JR | 1 |
| Sataloff, RT | 1 |
| Branton, C | 1 |
| Hellier, JP | 1 |
| Baudrimont, M | 1 |
| Dussaule, JC | 1 |
| Berenbaum, F | 1 |
| Slattery, D | 1 |
| Wong, SW | 1 |
| Colin, AA | 1 |
| Dyer, CA | 1 |
| Singh, SJ | 1 |
| Stockley, RA | 1 |
| Sinclair, AJ | 1 |
| Hill, SL | 1 |
| Baty, JD | 1 |
| Baumgarten, C | 1 |
| Geldszus, R | 1 |
| Behre, U | 1 |
| Peslis, N | 1 |
| Mylonopoulou, M | 1 |
| Everard, ML | 1 |
| Hiller, EJ | 4 |
| Ross-Russell, R | 1 |
| O'Keefe, P | 1 |
| Stoloff, S | 1 |
| Poinsett-Holmes, K | 1 |
| Madan, A | 1 |
| Wiewrodt, R | 1 |
| Punin, AA | 1 |
| Bogachev, RS | 1 |
| Zubkov, SK | 1 |
| Kozyrev, OA | 1 |
| Khokhlova, IuA | 1 |
| Loader, P | 1 |
| Bracken, M | 1 |
| Lieberman, AK | 1 |
| Bowers, B | 1 |
| van der Elshout, FJ | 1 |
| Trieu, L | 1 |
| O'Donnell, JC | 2 |
| Meyer, JW | 1 |
| van den Hoogen, H | 1 |
| Nie, HX | 1 |
| Hu, SP | 1 |
| Wu, XJ | 1 |
| Vatsa, HK | 1 |
| Gaur, SN | 1 |
| Delaisi, B | 1 |
| Newman, KB | 1 |
| Milne, S | 1 |
| Hamilton, C | 1 |
| Hall, K | 1 |
| Newton, MF | 1 |
| Hunter, CJ | 1 |
| Woltmann, G | 1 |
| Wardlaw, AJ | 1 |
| Love, JG | 1 |
| Hayday, K | 1 |
| Stevermer, JJ | 1 |
| Tsoĭ, AN | 1 |
| Apkhipov, VV | 1 |
| Medvedeva, IV | 1 |
| Lapik, SV | 1 |
| Gur'eva, SA | 1 |
| Savina, IA | 1 |
| Kress, JP | 1 |
| Noth, I | 1 |
| Gehlbach, BK | 1 |
| Barman, N | 1 |
| Pohlman, AS | 1 |
| Miller, A | 1 |
| Morgan, S | 1 |
| Hall, JB | 1 |
| Lloyd, A | 1 |
| Hutchinson, J | 1 |
| Plumb, J | 1 |
| Drago, A | 1 |
| Esposito-Pellitteri, M | 1 |
| Candore, G | 1 |
| Lo Bianco, C | 1 |
| Caruso, C | 1 |
| Bessmertny, O | 1 |
| DiGregorio, RV | 1 |
| Becker, E | 1 |
| Looney, D | 1 |
| Golden, J | 1 |
| Kohl, L | 1 |
| Johnson, T | 1 |
| Phillips, B | 1 |
| Schmitt, BD | 1 |
| Grella, E | 1 |
| Mazzarella, G | 1 |
| Izawa, M | 1 |
| Takeshita, Y | 1 |
| Kurita, F | 1 |
| Okada, M | 1 |
| Shinomiya, N | 1 |
| Perneger, TV | 1 |
| Sudre, P | 1 |
| Muntner, P | 1 |
| Uldry, C | 1 |
| Courteheuse, C | 1 |
| Naef, AF | 1 |
| Jacquemet, S | 1 |
| Nicod, L | 1 |
| Assal, JP | 1 |
| Vialatte, J | 1 |
| Mancini, G | 1 |
| Tellini, M | 1 |
| D'Ambrosio, R | 1 |
| Blasi, A | 1 |
| Marzo, C | 1 |
| Hills, EA | 1 |
| Davies, S | 1 |
| Geary, M | 1 |
| Salorinne, Y | 2 |
| Stenius, B | 1 |
| Tukiainen, P | 2 |
| Pinder, RM | 1 |
| Brogden, RN | 3 |
| Speight, TM | 2 |
| Avery, GS | 2 |
| Panico, D | 1 |
| Shotter, MV | 1 |
| Morris, HG | 1 |
| Rusnak, SA | 1 |
| Selner, JC | 2 |
| Barnes, J | 1 |
| Von Graffenried, B | 1 |
| Lindsay, D | 1 |
| Milledge, JS | 4 |
| Morris, J | 2 |
| Gonsior, E | 1 |
| Meier-Sydow, J | 1 |
| Cooper, W | 1 |
| Nizankowski, R | 1 |
| Mruk, J | 1 |
| Connellan, SJ | 1 |
| Wilson, RS | 1 |
| Bacon, CJ | 1 |
| Green, C | 1 |
| Uffholtz, H | 1 |
| Sadoul, P | 1 |
| Lempereur, L | 1 |
| Sentissi, M | 1 |
| Fitzgerald, JD | 1 |
| Killian, DN | 1 |
| Mellon, JJ | 1 |
| Lightbody, IM | 1 |
| Ingram, CG | 1 |
| Legge, JS | 3 |
| Johnston, RN | 1 |
| Nascimbene, T | 1 |
| Marcus, HI | 1 |
| Charpin, J | 5 |
| Bonelli, J | 1 |
| Hitzenberger, G | 1 |
| Magometschnigg, D | 1 |
| Griffiths, AD | 1 |
| Germouty, J | 1 |
| Bonnaud, F | 2 |
| Gay, G | 1 |
| Greenacre, JK | 2 |
| Raij K-Alanko, K | 1 |
| Härkönen, M | 1 |
| Ikemori, K | 1 |
| Kashima, T | 1 |
| Reinert, M | 1 |
| Biro, G | 1 |
| Retiene, K | 1 |
| Kallenbach, J | 1 |
| Joffe, BI | 2 |
| Zwi, S | 2 |
| Seftel, HC | 2 |
| Leifer, KN | 1 |
| Wittig, HJ | 1 |
| Turner, P | 3 |
| Bülow, K | 3 |
| Cristensson, P | 1 |
| Schindl, R | 3 |
| Safirstein, BH | 3 |
| Dhakhwa, RB | 1 |
| Gelb, B | 1 |
| Fontunato, FD | 1 |
| Boye, NP | 1 |
| Vale, JR | 1 |
| Neville, A | 1 |
| Gaddie, J | 3 |
| May, CS | 2 |
| Murchison, LE | 1 |
| Femi-Pearse, D | 3 |
| George, WO | 1 |
| Ilechukwu, ST | 1 |
| Elegbeleye, OO | 3 |
| Afonja, AO | 2 |
| Goldgraber, MB | 1 |
| Kamburoff, PL | 3 |
| Prime, FJ | 3 |
| Schmidt, OP | 1 |
| Garza Gomez, M | 1 |
| Picchioni, P | 1 |
| Minelli, P | 1 |
| Thompson, P | 1 |
| Friedman, M | 2 |
| Mahajan, VK | 1 |
| Huber, GL | 1 |
| Raine, D | 1 |
| Doner, HC | 1 |
| Posey, WC | 1 |
| Jones, BJ | 1 |
| Anderson, G | 1 |
| Wilkins, E | 1 |
| Cimbritz, H | 1 |
| Jungquist, G | 1 |
| Bennis, J | 1 |
| Huhti, E | 1 |
| Poukkula, A | 1 |
| Cummiskey, J | 1 |
| Keelan, P | 1 |
| Gray, P | 1 |
| Cox, GA | 1 |
| Beumer, HM | 2 |
| Mills, JG | 1 |
| Sharpe, PC | 1 |
| Hill, A | 1 |
| Middleton, H | 1 |
| Momen, M | 1 |
| Prescott, RJ | 2 |
| Schonell, M | 1 |
| Harris, M | 1 |
| McMiken, D | 1 |
| Jenne, H | 1 |
| Evers, R | 2 |
| Capecchi, V | 1 |
| Cavalli, F | 1 |
| Falcoone, F | 1 |
| Fasano, E | 1 |
| Jonderko, G | 1 |
| Kwiatek, R | 1 |
| Bierowiec, J | 1 |
| Górnisiewicz, J | 1 |
| Kapela-Lachowicz, B | 1 |
| Olak, Z | 1 |
| Webber, B | 1 |
| Poddar, SP | 1 |
| Nath, S | 1 |
| Wood, DO | 1 |
| Chandler, D | 1 |
| Dugdale, AE | 1 |
| Obminski, G | 1 |
| Bloomfield, P | 1 |
| Petrie, GR | 2 |
| Jewell, NP | 1 |
| Leopold, D | 2 |
| Handslip, P | 1 |
| Pierce, RJ | 1 |
| Allen, CJ | 1 |
| Campbell, AH | 2 |
| Pasotti, C | 1 |
| Capra, A | 1 |
| Vibelli, C | 2 |
| Honeybourne, D | 1 |
| Guleria, JS | 3 |
| Vasu, KV | 1 |
| Hambleton, G | 2 |
| Stone, MJ | 1 |
| Hanna, CJ | 1 |
| Eyre, P | 1 |
| Harris, MR | 2 |
| Schonell, ME | 1 |
| McMiken, DF | 1 |
| Tormey, WP | 1 |
| Duncan, D | 1 |
| Kingsley, PJ | 1 |
| Hobday, JD | 1 |
| Bateson, M | 1 |
| Leméshkina, VS | 1 |
| Shiriaéva, IS | 1 |
| Monie, R | 1 |
| Liang, A | 1 |
| Macfie, AE | 1 |
| Harris, EA | 1 |
| Whitlock, RM | 1 |
| Olusi, SO | 1 |
| Ojutiku, OO | 1 |
| Jessop, WJ | 1 |
| Iboko, MI | 1 |
| Wemeau, J | 1 |
| Bonniere, B | 1 |
| Pihlajamäki, K | 1 |
| Bhalla, JS | 1 |
| Klumpp, JA | 1 |
| Rutland, J | 1 |
| Verstraeten, JM | 1 |
| Houston, K | 1 |
| McEvoy, A | 1 |
| Pavicic, F | 1 |
| Duraković, Z | 1 |
| Razon, S | 1 |
| Knoop, U | 1 |
| Lin, MT | 1 |
| Collins-Williams, C | 2 |
| Johnson, AJ | 5 |
| Pidgeon, J | 2 |
| Bateman, S | 1 |
| Brørs, O | 1 |
| Williams, KO | 1 |
| Hugues, FC | 1 |
| Julien, D | 1 |
| Budmiger, H | 1 |
| Holmes, PW | 1 |
| Barter, CE | 1 |
| Hurst, NP | 1 |
| Lecerof, H | 1 |
| Fruhmann, G | 1 |
| Wildbolz, U | 1 |
| Février, D | 1 |
| Sillett, RW | 1 |
| Dash, CH | 2 |
| McNicol, MW | 2 |
| Coady, TJ | 2 |
| Stewart, CJ | 1 |
| Davis, HJ | 1 |
| Blackhall, MI | 1 |
| Dauth, M | 1 |
| Mahoney, M | 1 |
| O'Donnell, SR | 1 |
| Tribe, AE | 2 |
| Wong, RM | 1 |
| Robinson, JS | 1 |
| Williams, SJ | 2 |
| Graham, JD | 1 |
| Graff-Lonnevig, V | 2 |
| Donevan, RE | 1 |
| Copland, GM | 1 |
| Pasqua, F | 1 |
| Giammarruto, R | 1 |
| Ancetti, A | 1 |
| Caputo, G | 1 |
| Spiro, S | 1 |
| Rubin, AH | 1 |
| Mansur, A | 1 |
| Schey, G | 1 |
| Shahor, Y | 1 |
| Bruderman, I | 1 |
| Tuttle, CB | 1 |
| Sidorov, J | 1 |
| Gemelli, M | 8 |
| De Lucia, F | 1 |
| Barberio, G | 8 |
| Franchina, A | 7 |
| Tickner, TR | 1 |
| Cramp, DG | 1 |
| Foo, AY | 1 |
| Bateman, SM | 1 |
| Wills, MR | 1 |
| Ruggerini, R | 1 |
| Romitti, M | 1 |
| Sprocato, S | 1 |
| Bianco, F | 1 |
| Hawkins, R | 1 |
| Pepys, J | 2 |
| Bell, GM | 1 |
| Rawlins, MD | 1 |
| Komarov, FI | 1 |
| Daniliak, IG | 1 |
| Da Costa, JL | 1 |
| Goh, BK | 1 |
| Teoh, PC | 1 |
| Fawcett, IW | 1 |
| Erooga, MA | 1 |
| Semple, PD | 2 |
| Habeshaw, T | 1 |
| Del Torre, L | 1 |
| Fiore, G | 1 |
| Macluso, S | 1 |
| Pesce, L | 1 |
| De Luca, F | 5 |
| Petraglia, A | 1 |
| De Cataldis, G | 1 |
| Tarantino, O | 1 |
| Materazzi, F | 1 |
| Choo-Kang, YF | 3 |
| Renovanz, HD | 1 |
| Nonhoff, R | 1 |
| Avner, SE | 1 |
| Taeger, D | 1 |
| Arnaud, A | 4 |
| Autran, P | 1 |
| Tricard, P | 1 |
| Goldman, HI | 1 |
| Haynes, DR | 1 |
| Parrish, RW | 1 |
| Fitchett, DH | 1 |
| Riordan, JF | 1 |
| D'Arcangelo, GV | 1 |
| Arca, S | 1 |
| Miletto, A | 1 |
| Kennedy, MC | 1 |
| Posner, E | 1 |
| Tomasi, L | 3 |
| Todisco, T | 2 |
| Ansidei, V | 1 |
| Miele, N | 1 |
| Porcellati, C | 1 |
| Shenfield, GM | 3 |
| Hodson, ME | 1 |
| Lewis, HE | 1 |
| Bhatia, SP | 1 |
| Ingram, J | 1 |
| Skinner, C | 4 |
| Barnes, P | 1 |
| Kieselstein-Gross, E | 1 |
| Abrahamov, A | 1 |
| Sarsfield, JK | 1 |
| Liberti, R | 1 |
| Cicconetti, CA | 1 |
| Gentili, G | 1 |
| Ingrao, F | 1 |
| Ingianna, O | 1 |
| Spadoni, M | 1 |
| Melillo, G | 1 |
| Cocco, G | 1 |
| Brancaccio, L | 1 |
| Murano, G | 1 |
| Paroli, M | 1 |
| Zanotelli, F | 1 |
| Serembe, M | 1 |
| Camerota, G | 1 |
| Pontiggia, P | 1 |
| Curti, PC | 1 |
| Fantera, A | 1 |
| Brettoni, B | 1 |
| De Paola, E | 1 |
| Baccini, A | 1 |
| Bruscoli, G | 1 |
| Orlandi, O | 1 |
| Banaudi, C | 1 |
| Bruna, S | 1 |
| Dolcetti, A | 1 |
| Perino, B | 1 |
| Boschetti, E | 1 |
| Valenti, S | 1 |
| Mirabelli, S | 1 |
| DeLuca, F | 2 |
| Guideri, A | 1 |
| Dotti, A | 1 |
| Grasso Caprioli, G | 1 |
| Quadri, A | 1 |
| Rovetta, A | 1 |
| Spedini, C | 1 |
| Carnimeo, N | 1 |
| Maiorano, V | 1 |
| Cesco, G | 1 |
| Tansini, GC | 1 |
| Gandola, L | 1 |
| Soccini, F | 1 |
| MacKenzie, AM | 1 |
| Zieliński, J | 2 |
| Koziorowski, A | 2 |
| Maszczyk, Z | 2 |
| Underwood, SL | 1 |
| Lewis, SA | 1 |
| Raeburn, D | 1 |
| Płusa, T | 1 |
| Zaraś, E | 1 |
| Kruszewski, J | 1 |
| Hoppe, M | 1 |
| Toumi, M | 1 |
| Marsac, J | 3 |
| O'Brien, J | 1 |
| Sparrow, D | 1 |
| Fanta, CH | 2 |
| Murphy, S | 2 |
| Pacheco, Y | 1 |
| Hosni, R | 1 |
| Chabannes, B | 1 |
| Gormand, F | 1 |
| Moliere, P | 1 |
| Piperno, D | 1 |
| Lagarde, M | 1 |
| Geddes, DM | 1 |
| Cockcroft, D | 1 |
| Hilton, CJ | 2 |
| O'Shaughnessy, KM | 1 |
| Choudry, NB | 1 |
| Midgren, B | 1 |
| Balder, B | 1 |
| Wåhlander, L | 3 |
| Brémont, F | 1 |
| Moisan, V | 1 |
| Dutau, G | 1 |
| Pappo, M | 2 |
| Muir, JF | 2 |
| Storms, WW | 2 |
| Bodman, SF | 1 |
| Greenstein, SM | 1 |
| Jackson, R | 2 |
| Haffner, CA | 1 |
| Kendall, MJ | 1 |
| Meyer, CR | 1 |
| Boman, G | 4 |
| Takahashi, S | 1 |
| Beusenberg, FD | 1 |
| Van Amsterdam, JG | 1 |
| Hekking, PR | 2 |
| Brouwers, JW | 1 |
| Schermers, HP | 1 |
| Bonta, IL | 1 |
| Timmers, MC | 2 |
| Zwinderman, AH | 2 |
| Dijkman, JH | 2 |
| Southern, DL | 1 |
| Brown, PH | 1 |
| Lenney, J | 1 |
| Armstrong, S | 1 |
| Ning, AC | 1 |
| Soni, NR | 1 |
| Cifelli, AT | 1 |
| Broder, I | 3 |
| Mazza, JA | 3 |
| Moote, DW | 2 |
| Small, P | 2 |
| Wilkinson, JR | 1 |
| Sprogøe-Jakobsen, U | 1 |
| Viktrup, L | 1 |
| Davidsen, O | 1 |
| Viskum, K | 1 |
| Törnqvist, H | 1 |
| Douglass, JA | 1 |
| Tuxen, DV | 1 |
| Horne, M | 1 |
| Scheinkestel, CD | 1 |
| Weinmann, M | 1 |
| Czarny, D | 1 |
| Bowes, G | 2 |
| Frazier, CA | 1 |
| Rogers, P | 1 |
| Wiebe, RA | 1 |
| Anaya, C | 1 |
| Chang, RK | 1 |
| Chang, MA | 1 |
| Terada, AM | 1 |
| Bray, ML | 1 |
| Ching, CY | 1 |
| Kim, MY | 1 |
| Shinsato, ET | 1 |
| Morice, A | 1 |
| Gleason, MC | 1 |
| Gromova, OA | 1 |
| Gusel', VA | 1 |
| Yamada, N | 1 |
| Kadowaki, S | 1 |
| Umezu, K | 1 |
| Tan, WC | 2 |
| Chan, TB | 2 |
| Ang, SM | 2 |
| Bodenhamer, J | 1 |
| Bergstrom, R | 1 |
| Brown, D | 1 |
| Gabow, P | 1 |
| Marx, JA | 1 |
| Lowenstein, SR | 1 |
| Trussard, V | 1 |
| Seneterre, E | 1 |
| Giron, J | 1 |
| Sénac, JP | 1 |
| Cogo, AL | 1 |
| Turati, C | 1 |
| Waler, JA | 1 |
| Mann, MC | 1 |
| Eliasson, O | 1 |
| Patel, K | 1 |
| Akkermans, R | 1 |
| van Grunsven, PM | 1 |
| Britton, MG | 1 |
| Earnshaw, JS | 2 |
| Drblik, SP | 1 |
| Lapierre, G | 2 |
| Marcotte, JE | 1 |
| Bourgeois, M | 1 |
| Mueller, GA | 1 |
| Bjure, J | 1 |
| Engström, I | 1 |
| Sten, G | 1 |
| Wennergren, G | 1 |
| Banks, J | 1 |
| Buchanan, K | 1 |
| Cheong, B | 2 |
| Waterhouse, JC | 1 |
| Simmons, JL | 1 |
| Wray, H | 1 |
| Howard, P | 1 |
| O'Driscoll, BR | 4 |
| Kay, EA | 2 |
| Taylor, RJ | 3 |
| Weatherby, H | 1 |
| Chetty, MC | 1 |
| Bernstein, A | 3 |
| Dickinson, ET | 1 |
| O'Connor, RE | 1 |
| Megargel, R | 1 |
| Iakovlev, VN | 1 |
| Nechaev, DF | 1 |
| Mironov, MB | 1 |
| Semenova, TA | 1 |
| Marshall, S | 1 |
| Lowenthal, D | 1 |
| Khilnani, G | 1 |
| Parchani, H | 1 |
| Toshniwal, G | 1 |
| Bronstein, M | 1 |
| Deutsch, M | 1 |
| Reinikainen, K | 1 |
| Freudenthal, Y | 1 |
| Gaddy, JN | 1 |
| Margolskee, DJ | 1 |
| Williams, VC | 1 |
| Lüthke, M | 1 |
| Wiessmann, J | 1 |
| Zambruni, U | 1 |
| Verver, S | 1 |
| Cisteró, A | 1 |
| Abadías, M | 1 |
| Lleonart, R | 1 |
| Lafuente, V | 1 |
| Pintó, E | 1 |
| Torrent, J | 1 |
| Jané, F | 1 |
| Cohen, BM | 1 |
| Mathieu, M | 1 |
| Lellouche, N | 1 |
| Sartene, R | 1 |
| De Stefano, G | 2 |
| Piacentini, GL | 2 |
| Bonizzato, C | 1 |
| Sette, L | 2 |
| Banfi, F | 1 |
| Hindi-Alexander, MC | 1 |
| Wempe, JB | 1 |
| Breederveld, N | 1 |
| Alting-Hebing, D | 1 |
| Reed, CE | 1 |
| Driesner, NK | 1 |
| Abuan, TH | 1 |
| Emmick, G | 1 |
| Schoene, RB | 1 |
| Green, SM | 1 |
| Rothrock, SG | 1 |
| Speelberg, B | 1 |
| Roche, WR | 1 |
| Wassermann, K | 1 |
| Pothoff, G | 1 |
| Bahra, J | 1 |
| Hilger, HH | 1 |
| Guss, S | 1 |
| Portnoy, J | 1 |
| Lødrup, KC | 1 |
| Svindland, A | 1 |
| Refvem, OK | 1 |
| Derom, EY | 1 |
| Van der Straeten, ME | 1 |
| Raper, R | 1 |
| Fisher, M | 1 |
| Bihari, D | 1 |
| Mossberg, B | 2 |
| Suda, H | 1 |
| Nagai, H | 1 |
| Iwama, T | 1 |
| Rooda, HM | 1 |
| Van Daele, P | 1 |
| Van den Elshout, FM | 1 |
| Decramer, M | 1 |
| Buntinx, A | 1 |
| De Lepeleire, I | 1 |
| Fleisher, GR | 1 |
| Surpure, JS | 1 |
| Kulick, R | 1 |
| Vázquez Cordero, C | 1 |
| Corera Sánchez, M | 1 |
| Molinuevo Alvaro, J | 1 |
| Seto, W | 1 |
| Wong, M | 1 |
| Mitchell, EA | 1 |
| Ward, AJ | 1 |
| Kassem, N | 1 |
| Evans, JM | 1 |
| Moxham, J | 1 |
| Ganderton, D | 1 |
| Ellis, EF | 1 |
| Eigen, HN | 1 |
| Hemstreet, MP | 1 |
| Bogin, RM | 2 |
| Ballard, RD | 2 |
| Kozlik, R | 1 |
| Sarin, S | 1 |
| Shami, S | 1 |
| Cheatle, T | 1 |
| de Kock, JC | 1 |
| Hui, KP | 1 |
| Ramsdale, EH | 1 |
| Otis, J | 1 |
| Kline, PA | 1 |
| Gontovnick, LS | 1 |
| Jenkins, WJ | 1 |
| Alexander, J | 1 |
| Coward, G | 1 |
| Upchurch, F | 1 |
| Okiyama, M | 1 |
| Fujiwara, H | 1 |
| Kudo, M | 1 |
| Simizu, M | 1 |
| Maeda, M | 1 |
| Yamada, M | 1 |
| Toshimitsu, Y | 1 |
| Gongora, HC | 1 |
| Völkl, KP | 1 |
| Kroll, VM | 1 |
| Wiesemann, HG | 1 |
| Weaving, PG | 1 |
| Henderson, A | 1 |
| Ryberg, M | 2 |
| Möller, C | 2 |
| Ericson, T | 2 |
| Walajtys-Rode, E | 1 |
| Madalinska, M | 1 |
| Vincent, D | 1 |
| Havet, N | 1 |
| Marrash-Chahla, R | 1 |
| Pradalier, A | 2 |
| Dry, J | 1 |
| Shields, MD | 1 |
| Reisman, JJ | 1 |
| Fakhoury, K | 1 |
| Pedder, L | 1 |
| Menon, PK | 1 |
| Stankus, RP | 1 |
| Rando, RJ | 1 |
| Salvaggio, JE | 1 |
| Lehrer, SB | 1 |
| Le Roux, AM | 1 |
| Kotze, D | 1 |
| Wium, CA | 1 |
| Van Jaarsveld, PP | 1 |
| Weisz, AW | 1 |
| Talaee, N | 2 |
| Eiser, N | 2 |
| Talini, D | 1 |
| Mapp, CE | 1 |
| Frans, A | 1 |
| Garin, P | 1 |
| Van den Eeckhaudt, J | 1 |
| Brune, J | 1 |
| Jobanputra, P | 1 |
| Ford, A | 1 |
| Gomm, PJ | 1 |
| Osselton, MD | 1 |
| Broster, CG | 1 |
| Upton, K | 1 |
| Llupiá, J | 1 |
| Fernández, AG | 1 |
| Berga, P | 1 |
| Gristwood, RW | 1 |
| Tukiainen, H | 4 |
| Harbers, H | 1 |
| Maas, KL | 1 |
| Higgins, BG | 1 |
| Powell, RM | 1 |
| Schauer, U | 1 |
| Dippel, E | 1 |
| Gieler, U | 1 |
| Bräuer, J | 1 |
| Jung, T | 1 |
| Heymanns, J | 1 |
| Rieger, CH | 1 |
| Verbeek, AL | 1 |
| van der Hoogen, HJ | 1 |
| Vidgren, P | 1 |
| Paronen, P | 1 |
| Lehti, H | 1 |
| Ratner, PH | 2 |
| Pak, J | 1 |
| Solopov, VN | 1 |
| Lunichkina, IV | 1 |
| Li, ZG | 1 |
| Narang, NK | 1 |
| Meratwal, S | 1 |
| Toshniwal, GL | 1 |
| Richardson, WN | 1 |
| Shaw, M | 1 |
| Bibi, H | 1 |
| Montgomery, M | 1 |
| Chernick, V | 1 |
| Domagala, B | 1 |
| Pinis, G | 1 |
| Basomba, A | 1 |
| Burches, E | 1 |
| Almodovar, A | 1 |
| de Rojas, DH | 1 |
| Amsler, B | 1 |
| Tarayre, JP | 1 |
| Aliaga, M | 1 |
| Barbara, M | 1 |
| Tisseyre, N | 1 |
| Vieu, S | 1 |
| Tisne-Versailles, J | 1 |
| Effron, D | 1 |
| Lukens, TW | 1 |
| Gershman, H | 1 |
| Boehm, SP | 1 |
| Charlton, I | 2 |
| Charlton, G | 2 |
| Broomfield, J | 2 |
| Mullee, MA | 2 |
| Quessy, SN | 1 |
| Larsen, JS | 1 |
| Weisberg, SC | 1 |
| Halverson, PC | 1 |
| Green, CP | 1 |
| Hoskyns, EW | 1 |
| Thomson, A | 1 |
| Decker, E | 1 |
| Hutchins, A | 1 |
| Simpson, H | 1 |
| Clearihan, L | 1 |
| Mizuno, H | 1 |
| Takahashi, Y | 1 |
| Ohno, H | 1 |
| Misawa, M | 1 |
| Gubbelmans, HL | 2 |
| Zweers, PG | 3 |
| Dauphinee, B | 1 |
| Djahed, B | 1 |
| Wu, TC | 1 |
| Pelucchi, A | 2 |
| Sher, E | 1 |
| Mastropasqua, B | 2 |
| Diedenhofen, A | 1 |
| Mazza, P | 1 |
| Cavigioli, G | 1 |
| Browaldh, L | 1 |
| Stein, R | 1 |
| Brittain, RT | 1 |
| Aldons, PM | 1 |
| Maesen, F | 1 |
| Greefhorst, A | 1 |
| Prins, J | 1 |
| Tan, Y | 1 |
| Zweers, P | 1 |
| Windom, HH | 1 |
| Purdie, G | 1 |
| Graafsma, SJ | 1 |
| Visch, MB | 1 |
| Tsukioka, K | 1 |
| Nakamata, M | 1 |
| Kondo, A | 1 |
| Shovlin, CL | 1 |
| Tam, FW | 1 |
| Harris, A | 1 |
| Jenkins, MA | 1 |
| Hurley, SF | 1 |
| Gontovnick, L | 1 |
| Britton, JR | 1 |
| Halpern, GM | 1 |
| Mackay, T | 1 |
| Driver, H | 1 |
| Gay, PC | 1 |
| Patel, HG | 1 |
| Nelson, SB | 1 |
| Gilles, B | 1 |
| Hubmayr, RD | 1 |
| Leduc, T | 1 |
| Proulx, F | 1 |
| Perreault, S | 1 |
| Duranceau, A | 1 |
| Amyot, R | 1 |
| Joliat, TL | 1 |
| Weber, RW | 1 |
| White, KD | 1 |
| Fitzsimons, T | 1 |
| Patterson, R | 1 |
| Patterson, DR | 1 |
| Plaut, T | 1 |
| Cammell, JS | 1 |
| Holdaway, MD | 1 |
| Smith, NA | 1 |
| Kornberg, AE | 1 |
| Zuckerman, S | 1 |
| Welliver, JR | 1 |
| Mezzadri, F | 1 |
| Aquino, N | 1 |
| Costongs, R | 1 |
| Brombacher, PJ | 1 |
| Bendefy, IM | 1 |
| Pennington, WT | 1 |
| Bardin, PG | 1 |
| Bishop, J | 1 |
| Nolan, T | 1 |
| Navajas, D | 1 |
| Agusti, AG | 1 |
| Wagner, PD | 3 |
| Hayes, JP | 1 |
| Lambourn, L | 1 |
| Hopkirk, JA | 1 |
| Taylor, AJ | 1 |
| Gathua, SN | 1 |
| Aluoch, JA | 1 |
| Varghese, J | 1 |
| Gerblich, A | 1 |
| Salik, H | 1 |
| Schuyler, M | 1 |
| Zanconato, S | 1 |
| Santuz, P | 1 |
| Magagnin, G | 1 |
| Zacchello, F | 1 |
| Jones, A | 1 |
| Moncrieff, CS | 1 |
| Brown, HM | 1 |
| Schwarz, YA | 1 |
| Kivity, S | 1 |
| Ilfeld, DN | 1 |
| Schlesinger, M | 1 |
| Greif, J | 2 |
| Garty, MS | 1 |
| Hussein, A | 3 |
| Harrie, K | 1 |
| Kussau, D | 1 |
| Patrick, DM | 1 |
| Dales, RE | 1 |
| Stark, RM | 1 |
| Laliberte, G | 1 |
| Dickinson, G | 1 |
| Suzuki, S | 1 |
| Miyashita, A | 1 |
| Matsumoto, Y | 1 |
| Okubo, T | 1 |
| Barros, MJ | 1 |
| Stevens, WJ | 2 |
| Philip-Joet, F | 2 |
| Reynaud-Gaubert, M | 1 |
| Jirou-Najou, JL | 1 |
| Kallenbach, JM | 1 |
| Panz, VR | 1 |
| Jankelow, D | 1 |
| Soares, FJ | 1 |
| Cluzel, M | 1 |
| Clauzel, AM | 1 |
| Godard, PH | 1 |
| Pierson, WE | 2 |
| Bell, TD | 1 |
| MacCosbe, PE | 1 |
| Sykes, RS | 1 |
| Phillips, GD | 1 |
| James, RW | 1 |
| Masters, IB | 1 |
| Levy, N | 1 |
| Bearman, JE | 1 |
| Sladek, WA | 1 |
| Sur, S | 2 |
| Kwong, T | 2 |
| Flatt, A | 2 |
| Reider, MJ | 1 |
| Pender, E | 1 |
| Forbes, T | 1 |
| Tan, YK | 2 |
| Bailey, D | 1 |
| Mohs, E | 2 |
| Chavarría, F | 2 |
| Luo, ZY | 1 |
| Luo, DF | 1 |
| Richards, JG | 1 |
| Mauger, P | 1 |
| Le Dune, P | 1 |
| Mohiuddin, AA | 1 |
| Burns, R | 1 |
| Stewart, CF | 1 |
| Ellis, RF | 1 |
| Tsiu, SJ | 1 |
| Kellermann, AL | 1 |
| Guarnaccia, S | 1 |
| Pasquali, M | 1 |
| Acerbis, F | 1 |
| Pedrali, M | 1 |
| Duse, M | 1 |
| Ugazio, AG | 1 |
| Wiebicke, W | 1 |
| Carrington, D | 1 |
| Hollingworth, J | 1 |
| Gleeson, JG | 2 |
| Loftus, BG | 3 |
| Schuddinck, L | 1 |
| Wojciechowski, M | 1 |
| Prasher, VP | 1 |
| Corbett, JA | 1 |
| Vanmaele, L | 1 |
| Impens, N | 1 |
| Schandevyl, W | 1 |
| Rosenthal, TM | 1 |
| Voss, KR | 1 |
| Willsie-Ediger, SK | 1 |
| Pyszczynski, DR | 1 |
| Breeden, CC | 2 |
| Ballester, E | 2 |
| Ramis, L | 1 |
| Thompson, LM | 1 |
| Ingram, RH | 2 |
| Kelkel, E | 1 |
| Pison, C | 1 |
| Pin, I | 2 |
| Paramelle, B | 1 |
| Connolly, MJ | 2 |
| Jarvis, EH | 1 |
| Habib, RH | 1 |
| Dorkin, HL | 1 |
| Wall, MA | 1 |
| Meyer, A | 1 |
| Jacobsen, P | 1 |
| McLaren, M | 1 |
| Susanna, V | 1 |
| Loffreda, A | 1 |
| Servodio, R | 1 |
| Filippelli, A | 1 |
| Santagata, A | 1 |
| Montanaro, C | 1 |
| Carapella, N | 1 |
| Marmo, E | 1 |
| Mazer, B | 1 |
| Figueroa-Rosario, W | 1 |
| Bender, B | 1 |
| Mihatsch, W | 1 |
| Biddiscombe, M | 1 |
| Tolfree, SE | 3 |
| Short, M | 3 |
| Bastianon, V | 1 |
| Di Fazio, A | 1 |
| Colloridi, V | 1 |
| Marzano, MC | 1 |
| Ferrucci, A | 1 |
| Pucci, S | 1 |
| Bernardini, L | 1 |
| Coletta, F | 1 |
| Sorbara, N | 1 |
| Businco, L | 1 |
| Martelli, NA | 1 |
| Lazzari, JO | 1 |
| Valdés Cuadrado, L | 1 |
| Salgueiro Rodriguez, M | 1 |
| Alvarez-Calderón Prat, P | 1 |
| Arias Castells, MR | 1 |
| Berdugo Oviedo, M | 1 |
| Rabuñal Rey, R | 1 |
| Ventosa Rial, J | 1 |
| Rodríguez Suarez, JR | 1 |
| Pelikan, Z | 1 |
| Pelikan-Filipek, M | 1 |
| Karnik, AM | 1 |
| Medhat, M | 1 |
| Farah, S | 1 |
| Tennina, S | 1 |
| Johnson, MA | 1 |
| Bloom, R | 1 |
| Crespo Notario, JA | 1 |
| Sobradillo Peña, V | 1 |
| Garnacho López, E | 1 |
| Ansola Zubiaurre, PM | 1 |
| Mazo Echániz, J | 1 |
| Georgopoulos, D | 2 |
| Ilonidis, G | 1 |
| Shettar, SP | 1 |
| Jindal, SK | 1 |
| Kaur, SJ | 1 |
| Chaieb, J | 1 |
| Belcher, N | 1 |
| Chen, L | 1 |
| Deng, K | 1 |
| Ye, YQ | 1 |
| Masliah, J | 1 |
| Malanchère, E | 1 |
| Lefort, J | 1 |
| Bereziat, G | 1 |
| Neijens, HJ | 1 |
| Raatgeep, HC | 1 |
| Degenhart, HJ | 1 |
| Recaldin, S | 1 |
| Smith, F | 2 |
| White, PT | 1 |
| Pharoah, CA | 1 |
| Freeling, P | 1 |
| Ball, M | 1 |
| Martelli, A | 1 |
| Otero, C | 1 |
| Gil, B | 1 |
| Horsley, MG | 1 |
| Chambers, DK | 1 |
| Summers, Q | 1 |
| Tarala, R | 1 |
| Sigvaldasson, A | 1 |
| Skoogh, BE | 1 |
| Epelbaum, S | 1 |
| Benhamou, PH | 1 |
| Pautard, JC | 1 |
| Devoldere, C | 1 |
| Kremp, O | 1 |
| Piussan, C | 1 |
| Hill, P | 1 |
| Bogaard, JM | 1 |
| Slingerland, R | 1 |
| Verbraak, AF | 1 |
| Lim, R | 1 |
| Walshaw, MJ | 1 |
| Saltissi, S | 1 |
| Hind, CR | 1 |
| Phanichyakarn, P | 1 |
| Mansfield, LE | 1 |
| Reese, ME | 2 |
| Tierce, JC | 1 |
| Meller, W | 1 |
| Berlow, B | 1 |
| Gerth, WC | 1 |
| Charter, MK | 1 |
| Moreland, TA | 1 |
| Struthers, AD | 2 |
| Clark, GA | 1 |
| Wouters, EF | 1 |
| Polko, AH | 1 |
| Visser, BF | 1 |
| Bâ, M | 1 |
| Bennati, D | 1 |
| Peroni, DG | 1 |
| DaCruz, D | 1 |
| Holburn, C | 1 |
| Crockett, AJ | 1 |
| Blight, MM | 1 |
| Henry, DA | 1 |
| Benton, G | 1 |
| Thomas, RC | 1 |
| Nickerson, BG | 1 |
| McQuitty, JC | 1 |
| Okikawa, J | 1 |
| Croft, RD | 1 |
| Fraser, CG | 1 |
| Meslier, N | 1 |
| Six, P | 1 |
| Døssing, M | 1 |
| Evald, T | 1 |
| Lange, P | 1 |
| Christensen, HR | 1 |
| Sheehan, GJ | 1 |
| Kutzner, MR | 1 |
| Chin, WD | 1 |
| Lowe, RS | 1 |
| Kersey, J | 1 |
| Reyes, A | 1 |
| Guitart, R | 1 |
| Lim, TK | 1 |
| Anani, A | 1 |
| Higgins, AJ | 1 |
| Osborne, J | 1 |
| Valentine, J | 1 |
| Cocksedge, S | 1 |
| Milner, A | 1 |
| Kinnear, G | 1 |
| Körholz, D | 1 |
| Seeger, K | 1 |
| Griese, M | 1 |
| Wahn, V | 1 |
| Reifenhäuser, A | 1 |
| Gove, RI | 1 |
| Brown, RA | 1 |
| Verini, M | 1 |
| Ansaloni, A | 1 |
| Di Vincenzo, MG | 1 |
| Napoleone, M | 1 |
| Morgese, G | 1 |
| Bianchi, G | 1 |
| DiPalma, JR | 1 |
| Corsico, R | 1 |
| Majani, U | 1 |
| Lodola, E | 1 |
| Crowe, MJ | 1 |
| Counihan, HE | 1 |
| O'Malley, K | 1 |
| Scremin, S | 1 |
| Caprioglio, L | 1 |
| Gustafsson, M | 1 |
| Säwedal, L | 1 |
| De Candussio, G | 1 |
| Franchi, D | 1 |
| Manini, G | 2 |
| Arossa, W | 1 |
| Billing, B | 1 |
| Dahlqvist, R | 1 |
| Leideman, T | 1 |
| Skareke, L | 1 |
| Ripe, E | 1 |
| Storr, J | 3 |
| Barrell, E | 2 |
| Barry, W | 1 |
| Hatcher, G | 1 |
| Fleming, DM | 1 |
| Whittington, RM | 1 |
| Joad, J | 1 |
| Morin, D | 1 |
| Cookson, WO | 1 |
| Herjavecz, I | 1 |
| Böszörményi-Nagy, G | 1 |
| Szeitz, A | 1 |
| Debreczeni, LA | 1 |
| Brodde, OE | 1 |
| Howe, U | 1 |
| Egerszegi, S | 1 |
| Konietzko, N | 1 |
| Michel, MC | 1 |
| Manazza, P | 1 |
| Colombo, ML | 1 |
| Zoia, MC | 1 |
| Gould, CA | 1 |
| Ollier, S | 1 |
| Aurich, R | 1 |
| Williams, WR | 1 |
| Kagamimori, S | 1 |
| Kakiuchi, H | 1 |
| Naruse, Y | 1 |
| Diamant, B | 1 |
| Madsen, PL | 1 |
| Vilkka, V | 1 |
| Parkin, P | 1 |
| Rajan, A | 1 |
| Healy, R | 1 |
| Rieder, M | 1 |
| Soldin, SJ | 1 |
| Galdès-Sebaldt, M | 1 |
| Delnitz, D | 1 |
| Rozniecki, J | 1 |
| Macfarlane, JT | 1 |
| Birch, MJ | 1 |
| Evans, NA | 1 |
| Gamble, S | 1 |
| Bidat, E | 1 |
| Johnson, CE | 1 |
| Belfield, PW | 1 |
| Cooke, NJ | 2 |
| Spencer, A | 1 |
| Davies, JA | 1 |
| Ioli, F | 1 |
| Fracchia, C | 1 |
| Patessio, A | 1 |
| Spada, EL | 1 |
| Vecchio, C | 1 |
| Antoniadou, H | 1 |
| Sotiropoulou, E | 1 |
| Niero, E | 1 |
| Vallone, G | 2 |
| Gaburro, D | 1 |
| Del Bono, L | 1 |
| Fontana, G | 1 |
| Mugnai, M | 1 |
| Cresci, F | 1 |
| Panuccio, P | 1 |
| Mazzei, JA | 1 |
| Torres, J | 1 |
| Ebden, P | 2 |
| Farrow, PR | 1 |
| Cookson, JB | 2 |
| Moneret-Vautrin, DA | 1 |
| Trechot, P | 1 |
| Maria, Y | 1 |
| Rayner, RJ | 1 |
| Cartlidge, PH | 1 |
| Upton, CJ | 1 |
| Gribaldo, E | 1 |
| Ardizzi, A | 1 |
| Oliaro, A | 1 |
| Galietti, F | 1 |
| Giorgis, GE | 1 |
| Miravalle, C | 1 |
| Richards, R | 1 |
| Galdes-Sebalt, M | 1 |
| Stewart, DE | 1 |
| Gillies, AJ | 2 |
| Wiberg, R | 1 |
| Ekberg, P | 1 |
| Hanley, SP | 1 |
| Garrett, HV | 1 |
| Hadfield, JW | 2 |
| Ryan, CA | 1 |
| Wherrett, BA | 1 |
| Higgins, RM | 1 |
| Stradling, JR | 1 |
| Lane, DJ | 1 |
| Larsson, K | 1 |
| Bevegård, S | 1 |
| Grandordy, BM | 1 |
| Thomas, V | 1 |
| de Lauture, D | 2 |
| Petty, TL | 1 |
| Brandon, ML | 1 |
| Schoenweter, W | 1 |
| Mazza, J | 1 |
| Jaakkola, J | 1 |
| Torkko, M | 1 |
| Terho, EO | 2 |
| Steedman, DJ | 1 |
| Robertson, CE | 1 |
| Green, S | 1 |
| Jeyasingh, K | 1 |
| Teo, J | 1 |
| Kwang, LW | 1 |
| Yip, WC | 1 |
| Osman, J | 1 |
| Blainey, AD | 1 |
| Mazzoni, L | 1 |
| Sanjar, S | 1 |
| von der Hardt, H | 1 |
| Müller, W | 1 |
| Schell, SM | 1 |
| Voy, RO | 1 |
| Murdock, KY | 1 |
| Rohr, AS | 2 |
| Lanier, R | 1 |
| Thorne, KJ | 1 |
| Richardson, BA | 1 |
| Butterworth, AE | 1 |
| Hay, I | 1 |
| Higenbottam, TW | 1 |
| Taytard, A | 1 |
| Beaumont, D | 1 |
| Pujet, JC | 1 |
| Sapene, M | 1 |
| Lewis, PJ | 1 |
| Reynolds, SR | 1 |
| Rajan, G | 1 |
| Forderer, A | 1 |
| Abelitis, M | 1 |
| Koch, I | 1 |
| Wesołowski, S | 1 |
| Carey, OJ | 1 |
| Quinton, D | 1 |
| Rivero, A | 1 |
| Dal-Re, R | 1 |
| Azanza, JR | 1 |
| Montserrat, JM | 1 |
| Lloberas, P | 1 |
| Serra, J | 1 |
| Luengo, M | 1 |
| Agusti-Vidal, A | 3 |
| Schindlbeck, NE | 1 |
| Heinrich, C | 1 |
| Huber, RM | 1 |
| Müller-Lissner, SA | 1 |
| Schöni, MH | 1 |
| Bruderer, K | 1 |
| Morley, TF | 1 |
| Marozsan, E | 1 |
| Zappasodi, SJ | 1 |
| Gordon, R | 1 |
| Griesback, R | 1 |
| Giudice, JC | 1 |
| Kaneshige, H | 1 |
| Suzuki, H | 1 |
| Takagi, H | 1 |
| Akisawa, T | 1 |
| Narushima, M | 1 |
| Tonozuka, H | 1 |
| Tanaka, K | 1 |
| Nakagami, K | 1 |
| McDonald, C | 1 |
| Maruchin, JE | 1 |
| Beauvoir, C | 1 |
| Sissman, J | 1 |
| Mussell, MJ | 1 |
| Maniki, E | 2 |
| Tsara, V | 2 |
| Daskalopoulou, E | 1 |
| Carpentiere, G | 1 |
| Marino, S | 1 |
| Castello, F | 1 |
| Bonanno, CT | 1 |
| Baldanza, C | 1 |
| Littenberg, B | 1 |
| Kelly, C | 1 |
| Harris, JB | 1 |
| Annis, L | 1 |
| Ries, R | 1 |
| Dascalopoulou, E | 1 |
| Grandordy, B | 1 |
| Belmatoug, N | 1 |
| Morelle, A | 1 |
| Román, L | 1 |
| Azcarate, MJ | 1 |
| Rodriguez Soriano, J | 1 |
| Graham, AN | 1 |
| Maling, TJ | 1 |
| Castillo, JA | 1 |
| Schinca, N | 1 |
| Pujades, M | 1 |
| Ordinas, A | 1 |
| Coronas, A | 1 |
| Verbeek, PR | 1 |
| Gareau, AB | 1 |
| Rubes, CJ | 1 |
| Brunette, MG | 1 |
| Lands, L | 1 |
| Thibodeau, LP | 1 |
| Yan, K | 1 |
| Barbera, JM | 1 |
| Middleton, HB | 1 |
| Eby, DM | 1 |
| Shellshear, I | 1 |
| Sinopal'nikov, AI | 1 |
| Efimov, AV | 1 |
| Alekseev, VG | 1 |
| Brighenti, C | 1 |
| Schiassi, M | 1 |
| Miglioranzi, P | 1 |
| Richelli, C | 1 |
| Pincemaille, O | 1 |
| Jouk, PS | 1 |
| Bost, M | 1 |
| Amitai, Y | 1 |
| Ishizaki, T | 1 |
| Minegishi, A | 1 |
| Morishita, M | 1 |
| Odajima, Y | 1 |
| Kanagawa, S | 1 |
| Nagai, T | 1 |
| Yamaguchi, M | 1 |
| Montserrat, J | 1 |
| Bellamy, D | 1 |
| Penketh, A | 1 |
| Asai, S | 1 |
| Watanabe, T | 1 |
| Hayashida, M | 1 |
| Miura, N | 1 |
| Yamasaki, H | 1 |
| Inuyama, M | 1 |
| Kiya, T | 1 |
| Izumikawa, K | 1 |
| Orphanidou, D | 1 |
| Myers, MJ | 1 |
| Al-Suhali, AR | 1 |
| Henderson, B | 1 |
| Renard, RL | 1 |
| Mendelson, LM | 2 |
| Selcow, JE | 1 |
| Noyes, JH | 1 |
| Dubey, GR | 1 |
| Dabholkar, SV | 1 |
| Kamat, SR | 2 |
| Shah, SP | 1 |
| Sonaje, AG | 1 |
| Athawale, SS | 1 |
| Zellweger, JP | 1 |
| Clottu, R | 1 |
| Crittin, A | 1 |
| Dottrens, A | 1 |
| Heinzer, F | 1 |
| Stinghe, R | 1 |
| Vodoz, JM | 1 |
| Unter, CE | 2 |
| Allan, J | 2 |
| Greenough, A | 1 |
| Pool, J | 1 |
| Joad, JP | 2 |
| Lindgren, SD | 2 |
| Weinberger, MM | 2 |
| Kirby, JG | 1 |
| Herkert, A | 1 |
| Molho, M | 2 |
| Gruzman, C | 1 |
| Katz, I | 1 |
| Lidgi, M | 1 |
| Chaniac, A | 1 |
| Bucholtz, GA | 1 |
| Condemi, J | 1 |
| Ghafouri, MA | 1 |
| Hudson, L | 1 |
| Lakshminarayan, S | 1 |
| Lockey, R | 1 |
| Lidji, M | 1 |
| Karasik, A | 1 |
| Steir, S | 1 |
| Baum, GL | 1 |
| Mikhail, JR | 1 |
| Daly, S | 3 |
| Gupta, SK | 3 |
| Mitra, K | 1 |
| Faucon, B | 1 |
| Francomme, P | 1 |
| Parise, M | 1 |
| Lindsjö, M | 1 |
| Strandberg, K | 1 |
| Wiholm, BE | 1 |
| Solomon, MA | 1 |
| Ferrés Mataró, J | 1 |
| Mangues Bafalluy, MA | 1 |
| Farré Riba, R | 1 |
| Juliá Brugues, A | 1 |
| Bonal de Falgas, J | 1 |
| Banerjee, DK | 1 |
| Lee, GS | 1 |
| Malik, SK | 1 |
| Mackenzie, HM | 1 |
| Lewis, H | 1 |
| Holli, H | 1 |
| Karvonen, J | 1 |
| Isawa, T | 1 |
| Teshima, T | 1 |
| Ebina, A | 1 |
| Anazawa, Y | 1 |
| Konno, K | 1 |
| Sinclair, BL | 1 |
| Clark, DW | 1 |
| Coupe, MO | 1 |
| Guly, U | 1 |
| Brown, E | 1 |
| Church, SE | 1 |
| Gupta, A | 1 |
| Bhatnagar, OP | 1 |
| Jain, AK | 1 |
| Djurhuus, S | 1 |
| Rohold, A | 1 |
| Medici, R | 1 |
| Vadstrup, S | 1 |
| Couriel, JM | 1 |
| Demis, T | 1 |
| Olinsky, A | 1 |
| Rodríguez Sanchón, B | 1 |
| Cardona, MJ | 1 |
| Gilmartin, JJ | 1 |
| Adams, PC | 1 |
| Chudwin, DS | 1 |
| Strub, M | 1 |
| Golden, HE | 1 |
| Frey, C | 1 |
| Luskin, AT | 1 |
| Schwartzstein, RS | 1 |
| Greger, G | 1 |
| Kaspar, P | 1 |
| Beswick, KB | 1 |
| Sampson, S | 1 |
| Giner, MT | 1 |
| Nevot, S | 1 |
| Sierra, JI | 1 |
| Plaza, A | 1 |
| Coma, G | 1 |
| Youssef, W | 1 |
| Williams, MH | 1 |
| Küng, M | 1 |
| Croley, SW | 1 |
| Phillips, BA | 1 |
| Blot, P | 1 |
| Carson, JW | 2 |
| Hey, AA | 1 |
| Jones, P | 1 |
| Tanser, AR | 1 |
| Burger, G | 1 |
| Shephard, E | 1 |
| Markovitz, L | 1 |
| Dunn, C | 1 |
| Greenstein, S | 1 |
| Ozenne, G | 1 |
| Moore, ND | 1 |
| Leprevost, A | 1 |
| Tardif, C | 1 |
| Boismare, F | 1 |
| Pasquis, P | 1 |
| Lemercier, JP | 1 |
| Pearce, JL | 1 |
| Wesley, HM | 1 |
| Hedenstierna, G | 1 |
| Mackay, M | 1 |
| Currie, DC | 1 |
| Cobos Barroso, N | 1 |
| Schwartz, E | 1 |
| Grunstein, M | 1 |
| Chai, H | 1 |
| Windebank, WJ | 1 |
| Bateman, JR | 1 |
| Douglas, JG | 2 |
| Leslie, MJ | 1 |
| Yamate, M | 1 |
| Biedermann, AA | 1 |
| Chu, TJ | 1 |
| Bouslama, A | 1 |
| Grandory, B | 1 |
| Bozzoni, M | 1 |
| Longhini, E | 1 |
| Claybo, R | 1 |
| Lacroix, J | 1 |
| Shelton, D | 1 |
| Maisey, MN | 1 |
| Monego, A | 1 |
| Cambria, S | 1 |
| Cocksedge, SH | 1 |
| Jackson, MB | 1 |
| Williamson, L | 1 |
| Cain, AR | 1 |
| Osborne, JP | 1 |
| Hordvik, NL | 1 |
| Sunderrajan, EV | 1 |
| Luu, M | 1 |
| Maillard, D | 1 |
| Boureau, F | 1 |
| Franklin, W | 1 |
| Ulmer, WT | 1 |
| Krieger, E | 1 |
| Mutina, ES | 1 |
| Benatar, SR | 1 |
| Hönig, P | 1 |
| Cameron, SJ | 1 |
| Cooper, EJ | 1 |
| Hoare, MV | 2 |
| Reilly, BJ | 1 |
| Orange, RP | 1 |
| Thiruvengadam, KV | 1 |
| Subramanian, N | 1 |
| Narasimhan, SV | 1 |
| Nalini, S | 1 |
| Murray, AB | 1 |
| Hardwick, DF | 1 |
| Pirie, GE | 1 |
| Fraser, BM | 1 |
| Cornia, G | 1 |
| Gramiccioni, E | 1 |
| Tekeres, M | 1 |
| Mezey, B | 1 |
| Kellényi, L | 1 |
| Dirksen, H | 1 |
| dos Santos, ML | 1 |
| Romaldini, H | 1 |
| Nery, LE | 1 |
| Bogossian, M | 1 |
| Ratto, OR | 1 |
| Evans, ME | 1 |
| Walker, SR | 2 |
| Epstein, SW | 1 |
| Barnard, JA | 1 |
| Zsotér, TT | 1 |
| Hanan, ME | 1 |
| Kerr, JA | 1 |
| Cromptom, GK | 1 |
| Holst, PE | 1 |
| O'Donnell, TV | 1 |
| Martin, PD | 1 |
| Gebbie, T | 1 |
| Salmond, CE | 1 |
| Das, S | 1 |
| Dübi, B | 1 |
| Studer, A | 1 |
| Ferrara, M | 1 |
| Srivastava, BN | 1 |
| Shrivastava, VK | 1 |
| Rao, VS | 1 |
| Vas, GP | 1 |
| Mehta, GS | 1 |
| Kochar, AS | 2 |
| Store, SD | 1 |
| Warrier, NV | 1 |
| Sanghavi, B | 1 |
| Kulkarni, PS | 1 |
| Sheth, UK | 1 |
| Veneskoski, T | 1 |
| Batra, GK | 1 |
| Mattila, MJ | 1 |
| Singh, A | 1 |
| Singh, P | 1 |
| Hodgson, SV | 1 |
| McPherson, A | 1 |
| Jorde, W | 1 |
| MacDonald, HL | 1 |
| Horne, NW | 1 |
| Williams, FM | 1 |
| Draffan, GH | 1 |
| Wise, G | 1 |
| Sahyoun, H | 1 |
| Phelan, PD | 1 |
| Stocks, JG | 1 |
| Kersten, W | 1 |
| Koivikko, A | 1 |
| Leinonen, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older Wit[NCT03769090] | Phase 3 | 3,132 participants (Actual) | Interventional | 2018-12-13 | Completed | ||
| Efficacy and Safety of Increasing Doses of Inhaled Albuterol Administered by Metered Dose Inhalers in Children With Acute Wheezing Episodes[NCT01323010] | 119 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| Comparison of Vibrating Mesh Nebulizer Versus Jet Nebulizer in the Pediatric Asthma Patient a Randomized Controlled Trial[NCT02774941] | 220 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| Seinäjoki Adult Asthma Study: A 12-year Real-life Follow-up Study of New-onset Asthma Diagnosed at Adult Age and Treated in Primary and Specialized Care. Finnish Title: Diagnoosista Hoitotasapainoon: Voidaanko Aikuisen Astman Hoitotasapainoa Ennustaa Diag[NCT02733016] | 259 participants (Actual) | Observational [Patient Registry] | 1999-10-31 | Completed | |||
| Magnesium Nebulization Utilization in Management of Pediatric Asthma[NCT01429415] | Phase 2 | 818 participants (Actual) | Interventional | 2011-09-26 | Completed | ||
| An Open Label, Randomised, Parallel Group Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Relvar/Breo ELLIPTA Therapy, in Asthmatic Subjects With Poor Control[NCT03380429] | Phase 4 | 437 participants (Actual) | Interventional | 2018-01-31 | Completed | ||
| FUNLUM: Functional Lung MRI for Early Treatment Response Assessment and Outcome Prediction for Patients With Severe Eosinophilic Asthma on Anti IL 5 Antibody Therapy[NCT04512521] | 40 participants (Anticipated) | Observational | 2020-05-04 | Recruiting | |||
| 200699: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component[NCT02164539] | Phase 2 | 338 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap[NCT03263130] | 60 participants (Anticipated) | Observational [Patient Registry] | 2017-01-01 | Recruiting | |||
| Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers[NCT01225913] | Phase 4 | 50 participants (Anticipated) | Interventional | 2007-10-31 | Recruiting | ||
| Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers[NCT00576069] | 60 participants (Anticipated) | Observational | 2007-10-25 | Recruiting | |||
| The Efficacy of Intravenous Magnesium in Acute Wheezy Bronchitis in Small Children - a Randomized, Controlled Study[NCT01383655] | 61 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations[NCT02066129] | Phase 3 | 254 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Effect of Forward-leaning Position on Vital Signs, Pain and Anxiety of Children With Acute Asthma Attacks: A Randomized Controlled Study[NCT05318885] | 86 participants (Actual) | Interventional | 2019-10-15 | Completed | |||
| Asthma Express Intervention to Bridge Emergency to Primary Care for High Risk Children With Asthma[NCT01981564] | 222 participants (Actual) | Interventional | 2013-04-15 | Completed | |||
| A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma[NCT02427165] | Phase 2 | 29 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER®)[NCT00901368] | Phase 4 | 431 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| "A Two-arm, Placebo-controlled Randomized Clinical Trial to Evaluate the Effect of Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma With a T2 Immune Signature"[NCT03884842] | Phase 3 | 24 participants (Actual) | Interventional | 2019-07-01 | Completed | ||
| Single-centre Study Exploring the Utility of Hyperpolarized 129Xe Magnetic Resonance Imaging in Healthy Volunteers and Patients With Lung Disease[NCT03455686] | 60 participants (Anticipated) | Interventional | 2018-04-19 | Recruiting | |||
| A Proof of Concept Study to Evaluate the Trough Bronchoprotection Conferred by Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics[NCT00831376] | Phase 4 | 30 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Assess Efficacy and Safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adu[NCT01147848] | Phase 3 | 810 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Phase II, Randomized, Modified Single-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma[NCT00683449] | Phase 2 | 29 participants (Actual) | Interventional | 2008-06-30 | Terminated (stopped due to Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more appropriate dosing scheme for MN-221 in subjects with asthma.) | ||
| A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone[NCT01248975] | Phase 2 | 145 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100mg, GSK2190915 300mg, Montelukast 10mg or Placebo Tablets Once Daily or Salmeter[NCT01156792] | Phase 2 | 162 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Video-based Teach-to-goal Intervention on Inhaler Technique on Adults With Asthma and COPD: a Randomized Controlled Trial[NCT05664347] | 154 participants (Actual) | Interventional | 2020-03-09 | Completed | |||
| A Comparative Bioavailability Study to Compare the Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of Fluticasone Propionate and Salmeterol Delivered by Fluticasone Propionate/ Salmeterol Combination in a Capsule-based Inhaler and a Multi-dose Dry P[NCT01494610] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2010-10-25 | Completed | ||
| Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)[NCT00565266] | Phase 3 | 210 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Safety and Effectiveness of the Alair® System for the Treatment of Asthma: A Multicenter Randomized Clinical Trial(Asthma Intervention Research (AIR2) Trial)[NCT00231114] | 297 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| Long Term Safety Evaluation of Bronchial Thermoplasty With the Alair® System in Patients With Severe Asthma[NCT00401986] | 14 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| 48-week,Multinational,Randomized,Double-blind,2-parallel Groups,Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics >=18 Years of Age[NCT00861926] | Phase 3 | 2,079 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| FeNO Result Prediction Factors in Children With Allergic Diseases[NCT00815984] | 800 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| Comparasion of Efficacy of Nebulized Magnesium Sulphate With Intravenous Magnesium Sulphate in Children With Acute Asthma[NCT04497766] | Phase 4 | 148 participants (Actual) | Interventional | 2019-10-01 | Completed | ||
| A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5[NCT00652002] | Phase 3 | 450 participants (Anticipated) | Interventional | 2002-07-31 | Completed | ||
| Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease[NCT00889837] | Phase 1 | 53 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma[NCT00890175] | Phase 1 | 52 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in [NCT01181895] | Phase 3 | 348 participants (Actual) | Interventional | 2010-09-01 | Completed | ||
| Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer in the Treatment of Mild to Moderate Asthma in El Salvador[NCT01795742] | Phase 2 | 110 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers[NCT02777125] | 980 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| Therapeutic Drug Monitoring of Corticosteroids/β2-agonists in Hair in Asthmatic Patients: an Open-label Feasibility Study[NCT03691961] | 24 participants (Actual) | Interventional | 2018-09-20 | Active, not recruiting | |||
| Asthma Mobile Health Application 2.0[NCT03248869] | 7,752 participants (Actual) | Interventional | 2015-03-15 | Completed | |||
| MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma[NCT00838591] | Phase 2 | 176 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Acute Effect of Mometasone Furoate DPI on Beta-adrenergic Airway and Airway Vascular Relaxation in Moderately Severe Asthma[NCT01210170] | 22 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial[NCT02584738] | Phase 4 | 152 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)[NCT01584726] | 400 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | |||
| Comparison of Doses of Nebulized Magnesium Sulphate as an Adjuvant Treatment With Salbutamol in Children With Status Asthmaticus[NCT04929626] | Phase 1 | 126 participants (Actual) | Interventional | 2022-01-01 | Completed | ||
| The Effect of Beclomethasone/Formoterol in Extra-fine Formulation on Quality of Life and Dyspnea is Associated to the Improvement in Small Airway Dysfunction in COPD Patients. A Pilot Study (IOSCOPD20161102)[NCT04421742] | 43 participants (Actual) | Observational | 2017-05-31 | Completed | |||
| Measurement of Breathing Parameters of Asthma and COPD Patients With Different Degrees of Disease Severity for the Computer Simulation of Lung Deposition of Aerosol Drugs[NCT05445349] | 200 participants (Anticipated) | Observational | 2022-09-01 | Recruiting | |||
| A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma[NCT01424813] | Phase 3 | 158 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A 12-week Comparison of the Efficacy and Safety and Steady-State Pharmacokinetics of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma[NCT01747629] | Phase 3 | 160 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma[NCT01698320] | Phase 3 | 364 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Clinical Assessment of Acupuncture for the Treatment of Asthma: A Randomized, Multicenter, Double-blind, Parallel-group Controlled Trial[NCT01931696] | 200 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Evaluation of the Prevalence and the Reversibility of the Lung Hyperinflation in Uncontrolled Persistent Asthmatic Patients With Dyspnea[NCT01573364] | 450 participants (Actual) | Observational | 2011-02-28 | Completed | |||
| Blacks and Exacerbations on LABA vs. Tiotropium (BELT)[NCT01290874] | Phase 3 | 1,070 participants (Actual) | Interventional | 2011-03-30 | Completed | ||
| A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter[NCT01857323] | Phase 3 | 317 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Multicenter Randomized Study Starting With a 4 Week 2 Way Crossover Double Blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI Followed by a 4 Week Open Label Combivent Respimat Treatment Phase When All Stud[NCT00818454] | Phase 2 | 226 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Single-Dose, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Period Crossover, Dose-Ranging Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® HFA in Pediatric Patients With Persistent Asthma[NCT01899144] | Phase 2 | 61 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler (MDPI) Relative to Placebo in Pediatric Asthmatics[NCT02126839] | Phase 3 | 186 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Severe Asthma Research Program (SARP) - University of Wisconsin[NCT01760915] | 107 participants (Actual) | Observational | 2012-11-28 | Completed | |||
| Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease[NCT01280994] | Phase 2 | 445 participants (Anticipated) | Interventional | 2011-01-31 | Recruiting | ||
| Individualized Therapy For Asthma in Toddlers[NCT01606306] | Phase 3 | 300 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And Chronic Obstructive Pulmonary Disease (COPD) Patients[NCT02447575] | 23 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations in Children: A Randomized Controlled Trial[NCT02494076] | Phase 4 | 52 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Exclusion of Asthmatics From Clinical Trials Due to the 15 Percent Rule[NCT00940927] | Phase 4 | 81 participants (Actual) | Interventional | 1993-07-31 | Completed | ||
| Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia[NCT02447250] | Phase 4 | 14 participants (Actual) | Interventional | 2013-10-24 | Completed | ||
| Changes in the Lung Clearance Index as Measured by Multiple-breath Washout, in Pediatric Patients With Asthma After Challenge With Inhaled Steroids and Short-acting Bronchodilator[NCT02678949] | 105 participants (Anticipated) | Interventional | 2016-03-31 | Not yet recruiting | |||
| Randomised, Double-blind, Double-dummy, Parallel-group, Comparative Study of Salmeterol/FP 50/100mcg bd Inhalation Powder Via Diskus With Oral Montelukast (5mg QD) Chewable Tablets in Children 6-14 Years[NCT00328718] | Phase 3 | 526 participants | Interventional | 2005-10-31 | Completed | ||
| Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)[NCT00471809] | Phase 4 | 210 participants | Interventional | 2006-03-31 | Terminated (stopped due to The CARE Network DSMB recommended to the NHLBI that the MARS trial be terminated, based on a futility analysis with 55 randomized children.) | ||
| A 24-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Moderate to Severe Persistent Asthma[NCT00476268] | Phase 3 | 824 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| SUccessful Control and Clinical Effectiveness of SERETIDE Study in aSthma, a Randomised Controlled Study to Investigate the Clinical Effectiveness and Health Outcome of SERETIDE in Patients With Moderate and Severe Persistent Asthma in Korea[NCT00480649] | Phase 4 | 424 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma[NCT00736801] | 35 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children[NCT02409277] | 926 participants (Actual) | Interventional | 2013-08-31 | Completed | |||
| Changes of Pulmonary Function, Voice and Swallowing Symptoms After Total Parathyroidectomy for Secondary Hyperparathyroidism in the Presence of Intact Recurrent Laryngeal Nerve[NCT04267965] | 48 participants (Actual) | Observational [Patient Registry] | 2017-08-01 | Completed | |||
| Implementing a Guidelines-Based M-Health Intervention for High Risk Asthma Patients[NCT03842033] | 370 participants (Actual) | Interventional | 2019-03-04 | Active, not recruiting | |||
| Individualized Interventions to Improve Asthma Adherence[NCT00115323] | 397 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics[NCT00575861] | Phase 4 | 19 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Methods to Identify and Treat Severe Asthma Patients Project 1: GSNOR Phenotyping and GSNO Challenge[NCT03926741] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2019-04-30 | Recruiting | ||
| Double Blind, Multinational, Multicentre, Parallel-group, Placebo-controlled Design Trial of the Efficacy and Safety of Nebulised Beclometahsone Dipropionate (400 μg b.i.d.) Plus as Needed Salbutamol Versus as Needed Salbutamol or as Needed Salbutamol/Bec[NCT00497523] | Phase 3 | 283 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma[NCT02758873] | 241 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Steroid-sparing Management of the Salmeterol/Fluticasone 50/100µg b.i.d. Combination Compared to Fluticasone 200µg b.i.d. in Children and Adolescents With Moderate Asthma[NCT00315744] | Phase 4 | 285 participants (Actual) | Interventional | 2004-11-04 | Completed | ||
| Randomized, Double-Blind Comparison of Advair 100/50 BID vs Salmeterol BID vs Albuterol QID in Subjects With ARG/ARG Genotype 12 Years of Age and Older With Presistent Asthma on Short-Acting Beta2-Agonists Alone[NCT00102882] | Phase 4 | 547 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Prospective Open Randomized Clinical Trial Comparing Bilevel Positive Airway Pressure (BiPAP) Therapy Against Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma Unresponsive to Inhaled Bronchodilators.[NCT02347462] | 0 participants (Actual) | Interventional | 2015-04-30 | Withdrawn (stopped due to we were not able to work through the logistics of the study to support enrolment in ER) | |||
| A Prospective Open Randomized Clinical Trial of Non-invasive Ventilation Versus Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma.[NCT03296579] | 100 participants (Anticipated) | Interventional | 2018-06-30 | Not yet recruiting | |||
| Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)[NCT00200967] | Phase 3 | 87 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Tel-Me-Box: Validating and Testing a Novel, Low-cost, Real-time Monitoring Device With Hair Level Analysis Among Adherence-challenged Patients[NCT03086655] | 131 participants (Actual) | Interventional | 2021-08-13 | Completed | |||
| A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age [NCT00646594] | Phase 3 | 1,200 participants (Anticipated) | Interventional | 2003-11-30 | Completed | ||
| PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study[NCT04129931] | Phase 2 | 600 participants (Anticipated) | Interventional | 2019-12-19 | Recruiting | ||
| Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)[NCT00395304] | Phase 3 | 182 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized, Open Label Comparative Study to Determine the Proportion of Asthma Patients on SERETIDE Diskus 50/250 mcg b.i.d. Achieving Total Control When Given Medication and Compliance Enhancement Training Compared to Those Receiving Medication Only[NCT00351143] | Phase 4 | 274 participants (Actual) | Interventional | 2005-07-26 | Completed | ||
| A Randomized Double Blind Comparison Between Single Doses of Symbicort Turbuhaler (Budesonide/Formoterol Combination), Formoterol, Salbutamol and Placebo in Repeated AMP-challenges in Patients With Mild - to Moderate Asthma. Investigating the Supplementar[NCT00272753] | Phase 4 | 20 participants | Interventional | 2004-04-30 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Crossover Design Study to Evaluate the Effect of Montelukast Vs. Salmeterol on the Inhibition of Exercise-Induced Bronchoconstriction in Asthmatic Patients Aged 6-14 Years[NCT00127166] | Phase 3 | 154 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Multicentre, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Product (Seretide®) 50/100 mcg With Fluticasone Propionate (Flixotide® ) 200 mcg, Both Delivered Twice Daily [NCT00197106] | Phase 4 | 176 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Does the Use of a New Written Action Plan Increase Short-term Adherence to Prescribed Medication and Asthma Control in Children Treated for an Asthma Attack in the Emergency Department: A Randomized Controlled Trial.[NCT00381355] | Phase 4 | 218 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma[NCT00073840] | Phase 3 | 386 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| [NCT00046644] | 0 participants | Observational | 2002-06-30 | Completed | |||
| The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial[NCT00156819] | Phase 4 | 500 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Autonomic Nervous System Role in Uncontrolled ASTHMA and the Paucigranulocitic Phenotype[NCT02836691] | 40 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| An 8-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CHF 718 pMDI (HFA Beclomethasone Dipropionate Via Pressured Metered Dose Inhaler) in Asth[NCT03084718] | Phase 2 | 610 participants (Actual) | Interventional | 2017-07-28 | Completed | ||
| Efficacy of Ciclesonide and of a Fixed Combination With Fluticasone Propionate and Salmeterol Versus Placebo on Long-term Asthma Control[NCT00163358] | Phase 3 | 630 participants | Interventional | 2003-09-30 | Completed | ||
| Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients[NCT03611699] | Phase 4 | 15 participants (Actual) | Interventional | 2019-01-24 | Completed | ||
| Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma[NCT02566902] | 118 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)[NCT00394329] | Phase 3 | 288 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| School-Based Asthma Therapy: Stage 2 Effectiveness Study[NCT01175369] | 530 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| A Cumulative Dose Safety and Tolerability Crossover Study of Arformoterol Tartrate Inhalation Solution and Levalbuterol Hydrochloride Inhalation Solution in Pediatric Subjects (Aged 2 to 11 Years of Age) With Asthma[NCT00583947] | Phase 2 | 53 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [NCT00476073] | Phase 3 | 228 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol on Peripheral Airway Function in Asthma Patients[NCT02415179] | 52 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| A Randomized, Double-Blind, Cross-Over Study to Demonstrate Superiority of Fluticasone/Salmeterol Over Double the Dose of Fluticasone on Methacholine Hyper-Reactivity in Patients With Persistent, Mild to Moderate Asthma[NCT00830505] | Phase 4 | 38 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A 16-week Randomised, Placebo-controlled, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol F[NCT00350207] | Phase 2 | 388 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway[NCT01231230] | 14 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| Reversal of Acute β-Blocker Induced Bronchoconstriction[NCT01070225] | Phase 4 | 14 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)[NCT02148796] | Phase 2 | 822 participants (Actual) | Interventional | 2017-01-03 | Active, not recruiting | ||
| Is Adenosine Monophosphate Superior to Histamine for Bronchial Provocation Test in Evaluation of Asthma?[NCT02318043] | 84 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PARALLEL-GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND TOLERABILITY OF CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®)[NCT00394368] | Phase 3 | 180 participants | Interventional | 2004-11-30 | Completed | ||
| Comparing Rapid Bronchodilatory Effect of Formoterol and Salbutamol in Children Between 5-15 Years With Mild to Moderate Acute Exacerbation of Asthma- A Double Blind Randomized Controlled Trial[NCT00900874] | Phase 4 | 78 participants (Anticipated) | Interventional | 2009-01-31 | Recruiting | ||
| Assessing the Use of Digital Therapeutic in Adult Asthma Patients: A Remote Observational Study[NCT03103880] | 104 participants (Actual) | Interventional | 2017-04-21 | Completed | |||
| Prospective, Randomised, Open-label, Multicentre, Active Drug Controlled, Parallel Group Design Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate 400 mcg + Formoterol 24 mcg pMDI Via HFA-134a (Foster™) vs. Fluticasone Propionate 500[NCT00497237] | Phase 3 | 382 participants (Anticipated) | Interventional | 2007-04-30 | Completed | ||
| Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma[NCT04651777] | Phase 3 | 30 participants (Anticipated) | Interventional | 2022-08-08 | Recruiting | ||
| A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype[NCT00655616] | 64 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| Salbutamol: Tolerance to Bronchoprotection vs. Methacholine: Time Course of Onset[NCT01338311] | Phase 4 | 15 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Childhood Asthma Management Program[NCT00000575] | Phase 3 | 1,041 participants (Actual) | Interventional | 1991-09-30 | Completed | ||
| A Pilot Study to Evaluate the Dose-response of Inhaled Formoterol to Inhibit Airway Responsiveness to Methacholine in Patients With Mild Asthma[NCT00643578] | 37 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| Analysing the Effects of Coupling Nebulization to Noninvasive Ventilation Through Pulmonary Scintigraphy on the Radioaerosol Deposition During Asthma Exacerbation[NCT01012050] | 39 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| The Effect of Bi-PAP at Individualized Pressures on the Postoperative Pulmonary Recovery of Morbidly Obese Patients (MOP) Undergoing Open Bariatric Surgery (OBS) and Possible Placebo Device-related Effects (Sham-Bi-PAP)[NCT03438383] | 48 participants (Actual) | Interventional | 2011-05-23 | Completed | |||
| Quantifying Delivery Of Radio Labeled Aerosol During Noninvasive Ventilation To Stable Moderate And Severe Asthmatics: A Randomized, Cross-Over Clinical Trial[NCT01823926] | 13 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| IN VIVO ASSESSMENT OF RADIOLABELED AEROSOL DURING NONINVASIVE VENTILATION IN STABLE COPD: A RANDOMIZED CROSSOVER CLINICAL TRIAL[NCT02247856] | 9 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Is the Exhaled Nitric Oxide in Infants a Predictive Marker of Asthma?[NCT01239199] | 86 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Adherence Feedback for Improving Respiratory Medication Use[NCT00459368] | 2,698 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| A Pilot Study of the Mechanism of Synergism Between Fluticasone (FP) and Salmeterol in Preventing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations[NCT00116402] | Phase 1 | 15 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Assessment of Bronchial Asthma Among Patients Attending Sohag University Hospital[NCT06141161] | 200 participants (Anticipated) | Observational | 2023-11-01 | Recruiting | |||
| Asthma Clinical Research Network (ACRN)[NCT00000577] | Phase 3 | 0 participants (Actual) | Interventional | 1993-09-30 | Withdrawn (stopped due to Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.) | ||
| The Pharmacokinetics of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols[NCT00692978] | Phase 4 | 30 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| The Clinical Effect in Asthma of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols[NCT01662778] | Phase 4 | 21 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| [NCT00575445] | 100 participants (Anticipated) | Observational | 2007-11-30 | Terminated (stopped due to Nitric Oxide analyzer not functioning properly) | |||
| A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI (Formoterol Fumarate) in Asthmatic Subjects[NCT03086460] | Phase 2 | 67 participants (Actual) | Interventional | 2017-09-08 | Completed | ||
| A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)[NCT01457261] | Phase 1 | 10 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Effect of Anti-IL5 and Anti-IgE on Alternative Functions of Eosinophils in Severe Asthma[NCT04520165] | 50 participants (Anticipated) | Observational | 2020-09-01 | Recruiting | |||
| A Comparative, Multicenter and Randomized Study Evaluating the Safety and Efficacy of RESPIMER® Netiflow® Versus Saline Solutions During Nasal Irrigation Following Bilateral Ethmoidectomy in the Treatment of Nasal Polyposis.[NCT02559284] | 189 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| A Retrospective Evaluation of the Effectiveness of Fixed-dose Combination Inhaled Corticosteroid /. Long-acting Beta Agonist (ICS/LABA) Therapy in the Management of Asthma in a Representative UK Primary Care Population[NCT01141465] | 815,377 participants (Actual) | Observational | 2001-01-31 | Completed | |||
| Small Airways Involvement in Smoker Asthmatic Patients: a Pilot Study[NCT01620099] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-11-30 | Completed | ||
| A 12 Week, Randomized, Double-blind, Multicenter, Active Controlled, 2-Arm Parallel Group Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate) Compar[NCT05292586] | Phase 3 | 580 participants (Anticipated) | Interventional | 2022-10-05 | Recruiting | ||
| A Prospective Observational Study in a Tertiary Pediatric Hospital in Beijing to Understand the Accuracy of Bronchodilator Response (BDR) in Chinese Controller Naive Asthmatic Children Between the Age of 4~12 Years Old[NCT01500525] | 587 participants (Actual) | Observational | 2011-12-31 | Completed | |||
| Nebulizer Intervention for Minority Children With Asthma[NCT00218816] | Phase 3 | 221 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils[NCT02140541] | 130,248 participants (Actual) | Observational | 2013-02-28 | Active, not recruiting | |||
| Evaluation of the Usefulness of Induced Sputum Eosinophilia, eNO and Bronchial Hyperresponsiveness in Predicting the Failure of Inhaled Corticosteroids Dose Reduction in Children and Adolescents With Stable Asthma[NCT03788057] | 50 participants (Anticipated) | Interventional | 2016-02-01 | Recruiting | |||
| The Various Effects of Gaseous Albuterol on Serum Lactate[NCT02073747] | 28 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| Randomised, Double-blind, Double-dummy, 52-week, Parallel Group Study of a Standard Dosing Regimen With Salmeterol/Fluticasone propionate50/250 Twice Daily Diskus Versus a Symptom-driven, Variable Dosing Regimen With Formoterol/Budesonide Combination 4.5/[NCT00479739] | Phase 4 | 700 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Effectiveness of a Mobile Health Intervention in Improving the Technique of Inhaled Medications Among Children With Asthma: A Pilot Study[NCT03615248] | Early Phase 1 | 30 participants (Actual) | Interventional | 2021-01-01 | Completed | ||
| Novel Nano-vesicles of Salbutamol Sulphate in Metered Dose Inhalers: Formulation, Characterization, In Vitro and In Vivo Evaluation[NCT03059017] | Phase 1 | 20 participants (Actual) | Interventional | 2017-02-05 | Completed | ||
| A Prospective, Randomized, Controlled, Single Center Trial of the Use of Heliox in Children Admitted to the Hospital With Status Asthmaticus[NCT00410150] | Phase 2 | 42 participants (Actual) | Interventional | 2006-04-30 | Terminated (stopped due to Study was stopped after interim analysis and slow enrollment.) | ||
| Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD)[NCT01721291] | Phase 4 | 65 participants (Actual) | Interventional | 2012-10-01 | Completed | ||
| Evaluation of Exercise Induced Bronchoconstriction by Field Test Using Lung Function and a Novel Automated Digital Clinical Decision System[NCT04275648] | 60 participants (Anticipated) | Interventional | 2020-12-01 | Recruiting | |||
| Fluctuation of Airway Function in Children With Asthma Phenotype as a Predictor of Outcome[NCT02252289] | 120 participants (Actual) | Observational | 2014-09-30 | Completed | |||
| The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma[NCT00595361] | 30 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| Functional Evaluation of Distal Airways by Forced Oscillations: Diagnosis Help in Bronchiolitis Obliterans Syndrome in Post Bone Marrow Transplantation[NCT02902471] | 110 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)[NCT03137303] | Phase 3 | 402 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma Managed in the Emergency Department: A Randomized Controlled Trial[NCT04016220] | Phase 1 | 60 participants (Anticipated) | Interventional | 2019-05-20 | Recruiting | ||
| Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Carbamazepine Efficacy in Moderate Persistent and Severe Asthma Therapy[NCT00153296] | Phase 4 | 68 participants | Interventional | 2004-08-31 | Completed | ||
| Identification of Biomarkers in Exhaled Breath Condensates From Asthmatic Patients[NCT00635271] | 19 participants (Actual) | Observational | 2008-02-29 | Terminated | |||
| Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy: A Pilot Study[NCT02982824] | 60 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| Daily Supplementation of Magnesium Citrate in Moderate-severe Chronic Obstructive Pulmonary Disease: a Randomized, Controlled, Double-blind Trial[NCT02680769] | 76 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | |||
| Metacholine-provocation of Mablet-treated Asthmatics[NCT01118923] | 12 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| Daily Magnesium-supplement With Mablet for Steroid-resistant, Severe Asthmatics[NCT01113151] | 5 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Daily Mablet-treatment of Patients With COPD[NCT01118936] | 11 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| Pharmacokinetic Study of Mablet as Oral Supplement and Magnesium Sulfate as Infusion[NCT01113138] | 10 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| Feasibility and Safety of Immunoglobulin (Ig) Prophylactic Treatment in COPD Patients With Frequent Exacerbations: A Pilot Study[NCT02690038] | Phase 2 | 48 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Efficacy of an Education Protocol in the Correction of Inhalation Techniques in Patients With Chronic Obstructive Pulmonary Disease[NCT03144557] | 61 participants (Actual) | Interventional | 2017-01-02 | Completed | |||
| Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma.[NCT00382889] | Phase 3 | 480 participants | Interventional | 2002-08-31 | Completed | ||
| Adjustment of Asthma Treatment in Children Based on an Indirect Hyperresponsiveness Test - a Randomized Trial[NCT04509921] | 108 participants (Actual) | Interventional | 2018-07-02 | Completed | |||
| A Prospective, Open Label, Single-center Study of the Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children.[NCT01144910] | 0 participants (Actual) | Observational | 2011-05-31 | Withdrawn (stopped due to Due to few capacities 2011 to 2016 the study was withdrawn.) | |||
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered[NCT00268216] | Phase 3 | 6,228 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS® Inhaler 50/100 mcg Twice Daily vs FLIXOTIDE® Inhaler 200 mcg Twice Daily[NCT00370591] | Phase 4 | 48 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-[NCT00242775] | Phase 3 | 2,100 participants | Interventional | 2005-05-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DI[NCT00920543] | Phase 4 | 464 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Single Dose, Randomized, Double-blind Crossover Comparison of Combivent CFC MDI and Albuterol HFA MDI in Patients With Moderate to Severe Persistent Asthma and Persistent Symptoms Despite Treatment With Inhaled Corticosteroids[NCT00096616] | Phase 2 | 113 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 10[NCT00102765] | Phase 4 | 479 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Effects of Bronchodilation on CT Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent: Comparisons Between CT Scans Obtained Before and After Bronchodilation and Relationships With Pulmonary Function Tests.[NCT01142531] | 20 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| Ideal Steroids for Asthma Treatment in the PICU (iSTAT PICU): A Prospective, Comparative, Single-arm Study Assessing Dexamethasone Versus Methylprednisolone in Severe Status Asthmaticus Admitted to the Pediatric Intensive Care Unit[NCT03900624] | Phase 4 | 92 participants (Actual) | Interventional | 2019-04-21 | Completed | ||
| Diagnostic Accuracy Of Forced Oscillation Technique To Detect Lung Function Anomalies[NCT04006964] | 579 participants (Actual) | Observational | 2018-10-18 | Completed | |||
| Effectiveness and Costs of Albuterol Delivered by MDI With Spacer Versus Nebulizer in Children Hospitalized With Moderate and Severe Asthma Exacerbations[NCT00623688] | 11 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| "Are Steroids Efficacious in Hospitalized Patients With Bronchiolitis Who Show an Objective Clinical Improvement After Albuterol (Albuterol Responders)?"[NCT00798616] | 0 participants (Actual) | Interventional | Withdrawn (stopped due to We were unable to enroll a sufficient number of patients due to manpower.) | ||||
| A Multi-centre Randomised Trial of Lay-led Individualised Self-management Education for Adults With Asthma[NCT00129987] | 567 participants (Actual) | Interventional | 2003-11-30 | Completed | |||
| Single Dose Dexamethasone is as Effective as Two Doses in Mild to Moderate Pediatric Asthma Exacerbations in the Emergency Department[NCT02192827] | Phase 3 | 318 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation[NCT03513458] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2020-09-30 | Withdrawn (stopped due to [The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.) | ||
| Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation[NCT03513471] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2019-08-09 | Withdrawn (stopped due to The risk of inhaled allergen challenge and anakinra treatment outweigh benefits to participants with allergic asthma due to the COVID-19 pandemic.) | ||
| Oral Dexamethasone Versus Oral Prednisone in Children Hospitalized With Asthma: A Randomized Control Study[NCT02780479] | Phase 4 | 6 participants (Actual) | Interventional | 2017-03-20 | Terminated (stopped due to insufficient number of participants met the enrollment criteria.) | ||
| [NCT00005475] | 0 participants | Observational | 1996-08-31 | Completed | |||
| Budesonide Inhalation Suspension for Acute Asthma in Children[NCT00393367] | Phase 4 | 179 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Initiating Inhaled Corticosteroid Therapy at Discharge From the Pediatric Emergency Department to Prevent Asthma Relapse: A Randomized Control Trial[NCT03369847] | Phase 4 | 43 participants (Actual) | Interventional | 2017-09-10 | Completed | ||
| Epinephrine Inhalation Aerosol USP, an HFA-MDI CLINICAL STUDY-B2 FOR ASSESSMENT OF PHARMACOKINETICS (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)[NCT01188577] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS, A Randomized, Evaluator-Blind, Single-Dose, Three Arm, Crossover,PK Study in Healthy Volunteers[NCT01255709] | Phase 2 | 24 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Effects of Herbal Lollipops on Streptococcus Mutans Levels and the Dental Caries Experience of Children With Asthma Taking beta2-adrenergic Agonist Drugs[NCT01147835] | 39 participants (Actual) | Interventional | 2009-09-23 | Terminated (stopped due to Study was stopped and not completed) | |||
| A Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Crossover Dose-ranging Study of A006 in Adult Asthma Patients[NCT01581177] | Phase 2 | 23 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Efficacy, Dose-ranging and Safety Evaluation (A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Single Dose, Five-arm, Crossover, and Dose-ranging Study of A006 in Adult Asthma Patients)[NCT02210806] | Phase 2 | 22 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers (A Randomized, Double- or Evaluator-blinded, Single-dose, Four-arm, Crossover Pharmacokinetics (PK) Study in Healthy Adults)[NCT02271334] | Phase 2 | 22 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Phase I, Single Center, Placebo-Controlled, Blinded Pilot Study of Ipratropium Bromide in Children Admitted to the Intensive Care Unit With Status Asthmaticus[NCT02872597] | Phase 1 | 30 participants (Actual) | Interventional | 2016-09-05 | Completed | ||
| Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide[NCT01219738] | 20 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| Double-blind, Crossover, Placebo-controlled Evaluation of the Effect of Levalbuterol (R-albuterol) on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma[NCT00320034] | Phase 2 | 15 participants (Anticipated) | Interventional | 2006-04-30 | Completed | ||
| Prophylactic Racemic Epinephrine for the Prevention of Dysphagia in Patients Undergoing Anterior Cervical Discectomy and Fusion: A Randomized Control Trial[NCT02724761] | 90 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | |||
| [NCT00005537] | 0 participants | Observational | 1997-07-31 | Completed | |||
| Assessment of the Severity of Acute Asthma Exacerbation in Children Attending the Emergency Departments to Predict Outcomes by Modified Pulmonary Index Score[NCT03190759] | 1 participants (Anticipated) | Observational | 2017-11-11 | Not yet recruiting | |||
| Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism[NCT00116324] | Phase 3 | 150 participants | Interventional | 2003-04-30 | Completed | ||
| Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone in Paediatric Patients - a Retrospective, Real-life Observational Study in a uk Primary Care Asthma Population[NCT01877954] | 2,654 participants (Actual) | Observational | 2011-02-28 | Completed | |||
| Inflammatory Cellular Trafficking in Asthma in Response to Segmental Allergen Challenge[NCT00595491] | Phase 1 | 313 participants (Anticipated) | Interventional | 2008-01-31 | Recruiting | ||
| A Randomized, Double Blind, Placebo-controlled Three-way Crossover Study in Mild Asthmatics to Evaluate the Effect of Smoking Status on the Attenuation by Inhaled Corticosteroids of the Allergen-induced Asthmatic Response.[NCT01400906] | Phase 2 | 36 participants (Actual) | Interventional | 2011-07-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The annualized severe exacerbation rate (severe exacerbations per year) is estimated from a negative binomial model with treatment, age group, region, and number of severe exacerbations in the last 12 months prior to randomization as categorical covariates. The logarithm of the time at risk is included as an offset variable. (NCT03769090)
Timeframe: From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.
| Intervention | Severe exacerbations per year (Least Squares Mean) |
|---|---|
| BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | 0.45 |
| AS MDI 180 μg (Full Analysis Set; >=12 Years) | 0.59 |
| BDA MDI 80/180 μg (Full Analysis Set) | 0.49 |
| AS MDI 180 μg (Full Analysis Set) | 0.61 |
The ACQ-5 consists of 5 questions on symptom control, with each scored on a 7-point scale (0 = excellent asthma control; 6 = extremely poor control). The overall score (0 = excellent asthma control; 6 = extremely poor control, so a lower score is the better outcome) is the mean of the 5 symptom items. A responder is defined as a participant with a decrease from baseline to Week 24 overall ACQ-5 score of 0.5 or more. ACQ-5 is not validated for children less than 6 years old, data for participants who were 4 or 5 years old was excluded from the analysis of ACQ-5. (NCT03769090)
Timeframe: From baseline to Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | 677 |
| AS MDI 180 μg (Full Analysis Set; >=12 Years) | 630 |
| BDA MDI 80/180 μg (Full Analysis Set) | 681 |
| AS MDI 180 μg (Full Analysis Set) | 650 |
The AQLQ+12 consists of 32 questions in 4 domains and is assessed on separate 7-point Likert scales from 1 to 7, with higher values indicating better health-related quality of life. The overall score is the mean of all responses. A responder is defined as a participant with an increase from baseline to week 24 AQLQ-12 score of at least 0.5. (NCT03769090)
Timeframe: From baseline to 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | 508 |
| BDA MDI 80/180 μg (Full Analysis Set; >=12 Years) | 489 |
| AS MDI 180 μg (Full Analysis Set; >=12 Years) | 461 |
Time to first severe asthma exacerbation will be calculated as the time from randomization until the start date of the first severe asthma exacerbation. An asthma exacerbation will be considered severe if it results in at least one of the following: a temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening (a single depo-injectable dose of corticosteroids will be considered equivalent), an emergency room or urgent care visit (<24 hours in the facility for evaluation and treatment) due to asthma that required systemic corticosteroids, or an in-patient hospitalization (admission to an in-patient facility and/or ≥ 24 hours in a healthcare facility) due to asthma. The descriptive summary shows the number of participants with a severe exacerbation event, occurring between the date of randomization up to the date of randomized treatment discontinuation or a change in maintenance therapy. (NCT03769090)
Timeframe: From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | 207 |
| AS MDI 180 μg (Full Analysis Set; >=12 Years) | 266 |
| BDA MDI 80/180 μg (Full Analysis Set) | 241 |
| AS MDI 180 μg (Full Analysis Set) | 276 |
This endpoint includes all systemic corticosteroids (SCS) taken in response to a severe exacerbation event from randomization up to randomized treatment discontinuation or a change in maintenance therapy. All SCS are standardized to equipotent doses of prednisone before deriving the total dose. The total annualized dose is calculated as the total dose of SCS divided by the duration of the randomized treatment period. (NCT03769090)
Timeframe: From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.
| Intervention | Milligram(s) (Mean) |
|---|---|
| BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | 86.2 |
| AS MDI 180 μg (Full Analysis Set; >=12 Years) | 129.3 |
| BDA MDI 80/180 μg (Full Analysis Set) | 95.5 |
| AS MDI 180 μg (Full Analysis Set) | 127.1 |
Admission rates in patients with and without any of the following viruses detected by PCR in nasal lavage samples: Adenovirus; Bocavirus; Coronavirus; Enterovirus (Echovirus); Influenza (A H3N2, A H1N1/2009, B and C); Metapneumovirus (subtypes A and B); Parainfluenza 1, 2, 3 and 4 (subtypes A and B); Rhinovirus; Respiratory Syncytial Virus type A and Respiratory Syncytial Virus type B. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| Virus Detected | 12.3 |
| No Virus Detected | 22.7 |
Admission rates in patients with and without rhinovirus detected by PCR in nasal lavage samples. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| Rhinovirus Detected | 10.2 |
| No Rhinovirus Detected | 20.6 |
Admission rates in patients with the Arg16Gly polymorphisms of the beta-2 adrenergic receptor (Arg16Gly, Arg16Arg and Gly16Gly genotypes). (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | participants (Number) |
|---|---|
| Arg16Gly Patients | 1 |
| Gly16Gly Patients | 1 |
| Arg16Arg Patients | 7 |
Albuterol determination in the plasma was carried out at at discharge or hospital admission (up to 4 hours post treatment), dosage was accomplished by High Performance Liquid Chromatography. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | ng/ml (Median) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 2.57 |
| Albuterol - Lower Dose (Control) | 1.08 |
"Change in the Pediatric Respiratory Assessment Measure (PRAM) score one hour post-treatment in comparison with baseline.~The PRAM score is used to assess the severity of asthma attacks, it ranges from 0 to 15, and the higher the score, the greater the severity of the attack.~We calculated the difference between the PRAM score measured one hour post treatment and the PRAM score at baseline (PRAM score 1 hour - PRAM score baseline).~The larger the absolute value of the difference, the better the outcome (e.g., a difference of -4 indicates a better outcome that a difference of -2).~minimum value of the difference (Albuterol - Higher Dose, experimental group): -8 maximum value of the difference (Albuterol - Higher Dose, experimental group): 0~minimum value of the difference (Albuterol - Lower Dose, control group): -8 maximum value of the difference (Albuterol - Lower Dose, control group): 0" (NCT01323010)
Timeframe: One hour post-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -3 |
| Albuterol - Lower Dose (Control) | -4 |
Change in pulse oximetry one hour post-treatment in comparison with baseline (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline
| Intervention | percentage of oxygen saturation (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 1.54 |
| Albuterol - Lower Dose (Control) | 1.39 |
Changes in bicarbonate serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | mmol/L (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -1.75 |
| Albuterol - Lower Dose (Control) | -1.44 |
Changes in glucose serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | mg/dL (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 34.73 |
| Albuterol - Lower Dose (Control) | 22.90 |
Change in heart rate one hour post-treatment in comparison with baseline. (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline
| Intervention | beats per minute (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 1.75 |
| Albuterol - Lower Dose (Control) | -1.47 |
Changes in heart rate at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | beats per minute (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -0.263 |
| Albuterol - Lower Dose (Control) | -0.65 |
Changes in potassium serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | mEq/L (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -0.38 |
| Albuterol - Lower Dose (Control) | -0.59 |
"Change in the Pediatric Respiratory Assessment Measure (PRAM) score at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline.~The PRAM score is used to assess the severity of asthma attacks, it ranges from 0 to 15, and the higher the score, the greater the severity of the attack.~We calculated the difference between the PRAM score measured at discharge or admission and the PRAM score at baseline (PRAM score discharge or admission - PRAM score baseline).~The larger the absolute value of the difference, the better the outcome (e.g., a difference of -4 indicates a better outcome that a difference of -2).~minimum value of the difference (Albuterol - Higher Dose, experimental group): -9 maximum value of the difference (Albuterol - Higher Dose, experimental group): 0~minimum value of the difference (Albuterol - Lower Dose, control group): -9 maximum value of the difference (Albuterol - Lower Dose, control group): 1" (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | units on a scale (Median) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -4.5 |
| Albuterol - Lower Dose (Control) | -5 |
Changes in pulse oximetry at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | percentage of oxygen saturation (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 2.14 |
| Albuterol - Lower Dose (Control) | 1.59 |
Change in respiratory rate one hour post-treatment in comparison with baseline. (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline
| Intervention | breaths per minute (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -2.08 |
| Albuterol - Lower Dose (Control) | -4.31 |
Changes in respiratory rate at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.
| Intervention | breaths per minute (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | -2.92 |
| Albuterol - Lower Dose (Control) | -5.76 |
Electrocardiogram performed at baseline (NCT01323010)
Timeframe: at baseline
| Intervention | participants with ECG abnormalities (Number) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 0 |
| Albuterol - Lower Dose (Control) | 0 |
Electrocardiogram at discharge or hospital admission to identify possible rhythm disturbances. (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | participants with ECG abnormalities (Number) |
|---|---|
| Experimental Group | 0 |
| Control Group | 0 |
Electrocardiogram one hour post-treatment to identify possible rhythm disturbances. (NCT01323010)
Timeframe: One hour post-treatment
| Intervention | participants with ECG abnormalities (Number) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 0 |
| Albuterol - Lower Dose (Control) | 0 |
Change in FEV1 one hour post-treatment in comparison with baseline. Spirometry was performed only in subjects older than 6 years and who could perform the maneuver properly. (NCT01323010)
Timeframe: One hour post-treatment in comparison with baseline
| Intervention | percentage of predicted (Mean) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 14.67 |
| Albuterol - Lower Dose (Control) | 11.3 |
Hospital admission was defined as the need to stay in the emergency room for more than 4 hours, due to the failure to meet the discharge criteria (PRAM score ≤ 3 and pulse oximetry, ≥ 92%) (NCT01323010)
Timeframe: Starting at 4 hours post-treatment
| Intervention | participants (Number) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 11 |
| Albuterol - Lower Dose (Control) | 8 |
lengths of stay in the emergency room for discharged patients (NCT01323010)
Timeframe: one to four hours
| Intervention | hours (Median) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 1.50 |
| Albuterol - Lower Dose (Control) | 1.40 |
The need for additional therapies such as magnesium sulphate or intravenous albuterol were recorded (NCT01323010)
Timeframe: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)
| Intervention | participants (Number) |
|---|---|
| Albuterol - Higher Dose (Experimental) | 0 |
| Albuterol - Lower Dose (Control) | 0 |
The primary outcome measure is rate of hospitalization between the two treatment groups overall (NCT02774941)
Timeframe: Within emergency department visit time frame (no more than 12 hours)
| Intervention | Participants (Count of Participants) |
|---|---|
| Control - Jet Nebulizer | 22 |
| Study - Vibrating Mesh Nebulizer | 15 |
(NCT02774941)
Timeframe: Within emergency department visit time frame (no more than 12 hours)
| Intervention | number of treatments (Median) |
|---|---|
| Control - Jet Nebulizer | 3.0 |
| Study - Vibrating Mesh Nebulizer | 2 |
Daily adherence is defined as the participant taking one dose of Relvar/Breo ELLIPTA, within a 24-hour period, starting at 12.00 anti-meridiem (a.m.) each day of the treatment period. The percentage of ELLIPTA doses taken were determined by the clip-on sensor attached to ELLIPTA, which records the time and date when the ELLIPTA cover was opened and closed. Analysis was carried out by Analysis of Covariance (ANCOVA) model. Least Square mean percentage of ELLIPTA doses taken (daily adherence) between Months 4 and 6 was determined by the maintenance sensor daily adherence over the last three months of the study period (between months 4 to 6). The daily adherence to ELLIPTA maintenance therapy when both the participant and the HCP were supplied with data from the maintenance sensor (Cohort 1) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 4 to Month 6
| Intervention | Percentage of ELLIPTA doses (Least Squares Mean) |
|---|---|
| Cohort 1: Data on Maintenance Use Supplied to Par and HCP | 80.9 |
| Cohort 5: No Data Supplied to Par or HCP | 69.0 |
The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled). Total score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the latest assessment prior to randomization (Day 1, pre-dose). Change from Baseline was calculated as post-dose visit value minus the Baseline value. (NCT03380429)
Timeframe: Baseline and Month 6
| Intervention | Scores on a Scale (Least Squares Mean) |
|---|---|
| Cohort 1: Data on Maintenance Use Supplied to Par and HCP | 3.4 |
| Cohort 2: Data on Maintenance Use Supplied to Par | 4.3 |
| Cohort 3: Data on Maintenance and Rescue Use to Par and HCP | 4.7 |
| Cohort 4: Data on Maintenance and Rescue Use Supplied to Par | 4.2 |
| Cohort 5: No Data Supplied to Par or HCP | 3.9 |
Data for rescue medication use was collected by the clip-on sensor for salbutamol MDI which records time and date when the MDI was actuated. Total rescue use was determined by the rescue sensor records of date, time and number of inhaler actuations. The mean number of doses of rescue medicines between Months 4 and 6 when maintenance data was supplied to both the participant and the HCP (Cohort 1); maintenance data was only supplied to participants (Cohort 2); rescue and maintenance data were supplied to participant and HCP (Cohort 3) and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 4 to Month 6
| Intervention | Doses of rescue medication (Mean) |
|---|---|
| Cohort 1: Data on Maintenance Use Supplied to Par and HCP | 55.3 |
| Cohort 2: Data on Maintenance Use Supplied to Par | 40.6 |
| Cohort 3: Data on Maintenance and Rescue Use to Par and HCP | 29.5 |
| Cohort 4: Data on Maintenance and Rescue Use Supplied to Par | 27.0 |
| Cohort 5: No Data Supplied to Par or HCP | 55.8 |
Daily adherence is defined as the participant taking one dose of Relvar/Breo ELLIPTA, within a 24-hour period, starting at 12.00 a.m. each day of the treatment period. The percentage of ELLIPTA doses taken were determined by the clip-on sensor attached to ELLIPTA, which records the time and date when the ELLIPTA cover was opened and closed. Least Square mean percentage of ELLIPTA doses taken (daily adherence) between Months 1 and 3 was determined by the maintenance sensor daily adherence. The effect on daily adherence to maintenance therapy when maintenance data was supplied to both the participant and the HCP (Cohort 1), maintenance data was only supplied to participants (Cohort 2), rescue and maintenance data were supplied to participant and HCP (Cohort 3), and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 1 to Month 3
| Intervention | Percentage of ELLIPTA doses (Least Squares Mean) |
|---|---|
| Cohort 1: Data on Maintenance Use Supplied to Par and HCP | 85.7 |
| Cohort 2: Data on Maintenance Use Supplied to Par | 84.2 |
| Cohort 3: Data on Maintenance and Rescue Use to Par and HCP | 82.0 |
| Cohort 4: Data on Maintenance and Rescue Use Supplied to Par | 79.2 |
| Cohort 5: No Data Supplied to Par or HCP | 76.4 |
Daily adherence is defined as the participant taking one dose of Relvar/Breo ELLIPTA, within a 24-hour period, starting at 12.00 a.m. each day of the treatment period. The percentage of ELLIPTA doses taken were determined by the clip-on sensor attached to ELLIPTA, which records the time and date when the ELLIPTA cover was opened and closed. Least Square mean percentage of ELLIPTA doses taken (daily adherence) between Months 1 and 6 was determined by the maintenance sensor daily adherence. The effect on daily adherence to maintenance therapy when maintenance data was supplied to both the participant and the HCP (Cohort 1), maintenance data was only supplied to participants (Cohort 2), rescue and maintenance data were supplied to participant and HCP (Cohort 3), and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 1 to Month 6
| Intervention | Percentage of ELLIPTA doses (Least Squares Mean) |
|---|---|
| Cohort 1: Data on Maintenance Use Supplied to Par and HCP | 81.5 |
| Cohort 2: Data on Maintenance Use Supplied to Par | 78.8 |
| Cohort 3: Data on Maintenance and Rescue Use to Par and HCP | 77.7 |
| Cohort 4: Data on Maintenance and Rescue Use Supplied to Par | 75.2 |
| Cohort 5: No Data Supplied to Par or HCP | 71.8 |
Daily adherence is defined as the participant taking one dose of Relvar/Breo ELLIPTA, within a 24-hour period, starting at 12.00 a.m. each day of the treatment period. The percentage of ELLIPTA doses taken were determined by the clip-on sensor attached to ELLIPTA, which records the time and date when the ELLIPTA cover was opened and closed. Least Square mean percentage of ELLIPTA doses taken (daily adherence) between Months 4 and 6 was determined by the maintenance sensor daily adherence over the last three months of the study period (between months 4 to 6). The effect on daily adherence to maintenance therapy when maintenance data was only supplied to participants (Cohort 2), rescue and maintenance data were supplied to participant and HCP (Cohort 3), and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 4 to Month 6
| Intervention | Percentage of ELLIPTA doses (Least Squares Mean) |
|---|---|
| Cohort 2: Data on Maintenance Use Supplied to Par | 77.2 |
| Cohort 3: Data on Maintenance and Rescue Use to Par and HCP | 78.3 |
| Cohort 4: Data on Maintenance and Rescue Use Supplied to Par | 77.1 |
| Cohort 5: No Data Supplied to Par or HCP | 69.0 |
Percentage of participants attaining asthma control was defined as participants with an ACT total score >=20 at Month 6. The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled). Total score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Percentage of participants who attained asthma control at Month 6 is presented. (NCT03380429)
Timeframe: Month 6
| Intervention | Percentage of participants (Number) |
|---|---|
| Cohort 1: Data on Maintenance Use Supplied to Par and HCP | 52 |
| Cohort 2: Data on Maintenance Use Supplied to Par | 66 |
| Cohort 3: Data on Maintenance and Rescue Use to Par and HCP | 55 |
| Cohort 4: Data on Maintenance and Rescue Use Supplied to Par | 53 |
| Cohort 5: No Data Supplied to Par or HCP | 62 |
The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled). Total score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. Baseline value was the latest assessment prior to randomization (Day 1, pre-dose). Percentage of participants who had either an ACT total score of >=20 and/or an increase from Baseline >=3 in ACT total score at Month 6 is presented. (NCT03380429)
Timeframe: Baseline and Month 6
| Intervention | Percentage of participants (Number) |
|---|---|
| Cohort 1: Data on Maintenance Use Supplied to Par and HCP | 66 |
| Cohort 2: Data on Maintenance Use Supplied to Par | 75 |
| Cohort 3: Data on Maintenance and Rescue Use to Par and HCP | 65 |
| Cohort 4: Data on Maintenance and Rescue Use Supplied to Par | 67 |
| Cohort 5: No Data Supplied to Par or HCP | 70 |
The ACT is a validated self-completed questionnaire utilizing 5 questions to assess asthma control on a 5-point categorical scale ranging from 1 (not controlled at all) to 5 (completely controlled). Total score is calculated as the sum of the scores from the 5 questions and can range from 5 to 25, with higher scores indicating better control. An ACT total score of 5 to 19 suggests that the participant's asthma is unlikely to be well controlled, whilst a score of 20 to 25 suggests that the participant's asthma is likely to be well controlled. Baseline value was the latest assessment prior to randomization (Day 1, pre-dose). Percentage of participants with an increase from Baseline >=3 in ACT total score at Month 6 is presented. (NCT03380429)
Timeframe: Baseline and Month 6
| Intervention | Percentage of participants (Number) |
|---|---|
| Cohort 1: Data on Maintenance Use Supplied to Par and HCP | 61 |
| Cohort 2: Data on Maintenance Use Supplied to Par | 69 |
| Cohort 3: Data on Maintenance and Rescue Use to Par and HCP | 65 |
| Cohort 4: Data on Maintenance and Rescue Use Supplied to Par | 63 |
| Cohort 5: No Data Supplied to Par or HCP | 64 |
Data for rescue medication use was collected by the clip-on sensor for salbutamol MDI which records time and date when the MDI was actuated. Percentage of rescue free days were determined by the rescue sensor records of date, time and number of inhaler actuations. Least Square mean percentage of rescue free days between Months 4 and 6 when maintenance data was supplied to both the participant and the HCP (Cohort 1); maintenance data was only supplied to participants (Cohort 2); rescue and maintenance data were supplied to participant and HCP (Cohort 3) and rescue and maintenance data only supplied to participant (Cohort 4) versus no data supplied to the participant or HCP (Cohort 5) is summarized. (NCT03380429)
Timeframe: Month 4 to Month 6
| Intervention | Percentage of rescue free days (Least Squares Mean) |
|---|---|
| Cohort 1: Data on Maintenance Use Supplied to Par and HCP | 81.1 |
| Cohort 2: Data on Maintenance Use Supplied to Par | 81.2 |
| Cohort 3: Data on Maintenance and Rescue Use to Par and HCP | 85.6 |
| Cohort 4: Data on Maintenance and Rescue Use Supplied to Par | 83.7 |
| Cohort 5: No Data Supplied to Par or HCP | 76.4 |
FEV1 is defined as forced expiratory volume in one second and measured in the morning at Visits 1 through 8 between 6:00 and 11:00 electronically by spirometry. Change from Baseline in trough FEV1 is defined as the difference in the value obtained at Visit 6 (24 hours post-dose on Visit 5) and the last acceptable/borderline acceptable value obtained prior to randomization (from Visit 2 pre-bronchodilator or Visit 3 pre-dose). Trough FEV1 is defined as the acceptable/borderline acceptable FEV1 value obtained at Visit 6, approximately 24 hours after morning dosing on Visit 5. ITT population is comprised of all participants randomized to treatment who received at least one dose of randomized study medication in the treatment period. All comparisons for statistical purposes are with the FF 100 µg arm. (NCT02164539)
Timeframe: Baseline and Day 29
| Intervention | Liters (Mean) |
|---|---|
| FF 100 µg | 0.047 |
| FF/UMEC 100/15.6 µg | 0.146 |
| FF/UMEC 100/62.5 µg | 0.193 |
| FF/UMEC 100/125 µg | 0.175 |
| FF/UMEC 100/250 µg | 0.143 |
| FF/VI 100/25 µg | 0.121 |
Peak expiratory flow (PEF) stability limit was calculated from AM PEF measurements on the 7 days preceding Visit 3 as mean AM PEF from the available 7 days preceding Visit 3 x 80%. PEF stability limit serves as a benchmark of the participants run-in COPD status and used for comparison during the treatment phase to assess subject safety. Change from Baseline over the last 21 days of Treatment Phase A is the difference between the last 21 days of Treatment Phase A and the appropriate Baseline week. The last 21 days of Treatment Phase A include the AM assessments on the date of Visit 6. AM assessments include the date of Visit 6 and the 20 consecutive days preceding the date of Visit. Analysis performed using analysis of covariance with covariates of treatment, age, sex, Baseline AM PEF, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. Baseline is the last 7 days of the run-in period prior to randomization (NCT02164539)
Timeframe: Baseline and from Day 8 through Day 29
| Intervention | Liters per minute (L/min) (Least Squares Mean) |
|---|---|
| FF 100 µg | -14.2 |
| FF/UMEC 100/15.6 µg | 3.9 |
| FF/UMEC 100/62.5 µg | 7.6 |
| FF/UMEC 100/125 µg | 5.5 |
| FF/UMEC 100/250 µg | 10.5 |
| FF/VI 100/25 µg | 4.3 |
FEV1 was measured in the morning by spirometry. At Visit 5, after trough FEV1 is measured, subject received investigational product. 3 hours post-dose, spirometry was repeated and subject then received 2 puffs of albuterol/salbutamol. After 30 minutes,spirometry was repeated.. Change from Baseline in clinic trough (pre-dose) FEV1 is the difference in the trough value at 3 hours post-dose peak FEV1 and the Baseline value. If the trough value or the Baseline was missing, then change from Baseline was considered as missing. Baseline value of clinic FEV1 is the last acceptable/borderline acceptable (pre-dose) FEV1 value obtained prior to randomization (from Visit 3 pre-dose or from Visit 2 pre-bronchodilator). Analysis done using analysis of covariance with covariates of treatment, age, sex, baseline clinic trough FEV1, pre-dose trough FEV1 at Visit 5, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. (NCT02164539)
Timeframe: Baseline and Day 28
| Intervention | Liters (L) (Least Squares Mean) |
|---|---|
| FF 100 µg | 0.048 |
| FF/UMEC 100/15.6 µg | 0.093 |
| FF/UMEC 100/62.5 µg | 0.088 |
| FF/UMEC 100/125 µg | 0.072 |
| FF/UMEC 100/250 µg | 0.052 |
| FF/VI 100/25 µg | 0.124 |
FEV1 is defined as forced expiratory volume in one second and measured in the morning at Visits 1 through 8 between 6:00 and 11:00 electronically by spirometry. Reversibility was measured at Visit 1 and Visit 2 for study eligibility by change in clinic FEV1 within 20 to 60 minutes following 4 inhalations of albuterol/salbutamol and again measured 3 hours after dosing at Visit 5 by change in clinic FEV1 30 minutes following 2 inhalations of albuterol/salbutamol. Baseline value of clinic FEV1 is the last acceptable/borderline acceptable (pre-dose) FEV1 value obtained prior to randomization (either from Visit 3 pre-dose or from Visit 2 pre-bronchodilator). Analysis performed using analysis of covariance with covariates of treatment, age, sex, baseline clinic trough FEV1, pre-albuterol/salbutamol FEV1 at Visit 5, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. (NCT02164539)
Timeframe: Baseline and Day 28
| Intervention | Liters (L) (Least Squares Mean) |
|---|---|
| FF 100 µg | 0.249 |
| FF/UMEC 100/15.6 µg | 0.161 |
| FF/UMEC 100/62.5 µg | 0.159 |
| FF/UMEC 100/125 µg | 0.160 |
| FF/UMEC 100/250 µg | 0.189 |
| FF/VI 100/25 µg | 0.087 |
A daily symptoms score for exacerbations of chronic pulmonary disease tool - Respiratory Symptoms (E-RS) is derived by summing the 11 item-level E-RS scores and has a theoretical range of 0-40, with higher values indicating more severe respiratory symptoms. The Baseline E-RS score is defined as the mean within-subject daily score over the 7 days prior to randomization, with data present for a minimum of 4 of the 7 days. Change from Baseline at the end of Treatment Phase is the difference between the end of Treatment Phase value and the appropriate Baseline week. Analysis performed using analysis of covariance with covariates of treatment, age, sex, baseline score, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. Baseline is the last 7 days of the run-in period prior to randomization. All comparisons for statistical purposes are with the FF 100 µg arm. (NCT02164539)
Timeframe: Baseline and End of Treatment Phase A (The end of Treatment Phase A was defined as the last 7 days of Treatment Phase A, including the AM assessments on the date of Visit 6)
| Intervention | Score on scale (Least Squares Mean) |
|---|---|
| FF 100 µg | 0.5 |
| FF/UMEC 100/15.6 µg | -2.6 |
| FF/UMEC 100/62.5 µg | -2.5 |
| FF/UMEC 100/125 µg | -1.5 |
| FF/UMEC 100/250 µg | -1.5 |
| FF/VI 100/25 µg | -1.1 |
All participants received the albuterol/salbutamol via MDI as a rescue medication on an as-needed basis. Total daily rescue medication use for a given day is the sum of daytime albuterol/salbutamol use recorded in PM and nighttime albuterol/salbutamol use recorded in AM the next day. The number of puffs of albuterol (salbutamol) MDI used in the last 12 hours for relief of symptoms were recorded morning and evening in the eDiary by the participants. End of Treatment Phase A is the last 7 days of Treatment Phase A. Change from Baseline at the end of Treatment Phase is the difference between the end of Treatment Phase value and the appropriate baseline week. Analysis performed using analysis of covariance with covariates of treatment, age, sex, baseline rescue medication use, pack years smoked per randomization stratification and age when first treated with an inhaler per randomization stratification. Baseline is the last 7 days of the run-in period prior to randomization (NCT02164539)
Timeframe: Baseline and End of Treatment Phase A (The end of Treatment Phase A was defined as the last 7 days of Treatment Phase A, including the AM assessments on the date of Visit 6)
| Intervention | Puffs (Least Squares Mean) |
|---|---|
| FF 100 µg | 0.6 |
| FF/UMEC 100/15.6 µg | -0.4 |
| FF/UMEC 100/62.5 µg | -0.5 |
| FF/UMEC 100/125 µg | 0.0 |
| FF/UMEC 100/250 µg | -0.2 |
| FF/VI 100/25 µg | -0.1 |
The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period. (NCT02066129)
Timeframe: end of 48 week treatment period
| Intervention | exacerbations per year (Least Squares Mean) |
|---|---|
| Fluticasone 44 mcg | 0.37 |
| Fluticasone 220 mcg | 0.48 |
Number of participants hospitalized for asthma during the 48 week treatment period. (NCT02066129)
Timeframe: end of 48 week treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| Fluticasone 44 mcg | 0 |
| Fluticasone 220 mcg | 4 |
Rate of emergency department (ED) or urgent care visits for asthma during the 48 week treatment period. (NCT02066129)
Timeframe: end of 48 week treatment period
| Intervention | visits per year (Least Squares Mean) |
|---|---|
| Fluticasone 44 mcg | 0.47 |
| Fluticasone 220 mcg | 0.64 |
Use of albuterol rescue medication during 7-day yellow zone episodes. (NCT02066129)
Timeframe: end of 48 week treatment period
| Intervention | number of albuterol puffs (Least Squares Mean) |
|---|---|
| Fluticasone 44 mcg | 13 |
| Fluticasone 220 mcg | 15 |
Study participants completed a daily symptom diary. They scored the following diary elements on a scale from 0-3 (none-severe): Cough, Wheeze, Trouble Breathing, Interference With Activities. A combined score was calculated as the sum of the 4 elements and ranged from 0 to 12. The study intervention was based on yellow-zones as noted in the Study Description. This outcome was based on diary data including 21 days, beginning 7 days prior to the onset of the yellow-zone intervention and ending 14 days after the onset of the intervention. The total symptom burden outcome was defined as the sum of the combined score on each diary day and ranged from 0 to 252 (max combined score of 12 per day multiplied by 21 days). A score of zero would indicate no symptoms over the entire 21 days. A score of 252 would indicate severe cough, wheeze, shortness of breath, and interference with activities on all of the 21 days. (NCT02066129)
Timeframe: end of 48 week treatment period
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Fluticasone 44 mcg | 20 |
| Fluticasone 220 mcg | 23 |
Number of emergency department visits for asthma in the past 3 months (NCT01981564)
Timeframe: 3 months
| Intervention | visits (Mean) |
|---|---|
| Asthma Express Intervention | 0.64 |
| Standard Asthma Education Control Group | 0.62 |
Symptom days for asthma during past 14 days (NCT01981564)
Timeframe: 3 months
| Intervention | symptom days over past 14 days (Mean) |
|---|---|
| Asthma Express Intervention | 6.24 |
| Standard ASthma Education Control Group | 4.82 |
"The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, How much of the time did your asthma keep you from getting as much done at work, school or at home?, How often have you had shortness of breath?, How often did your asthma symptoms wake you up at night or earlier than usual in the morning?, How often have you used your rescue inhaler or nebulizer medication (such as albuterol)? and How would you rate your asthma control? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the Day 168 value minus the Baseline value." (NCT01147848)
Timeframe: Baseline and Day 168
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 2.3 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 2.0 |
"The AQLQ is a disease-specific, self-administered quality of life (QOL) questionnaire developed to evaluate the impact of asthma treatments on the QOL of asthma sufferers. The AQLQ contains 32 items in four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The response format consists of a 7-point scale: a value of 1 indicates total impairment; a value of 7 indicates no impairment. The AQLQ total score is defined as the average of the scores from all 32 questions, provided at least 90% of the questions have been answered; thus, the total score ranges from 1 (indicates total impairment) to 7 (indicates no impairment). Change from Baseline was calculated as the Day 168 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline total AQLQ score, country, sex, age, and treatment." (NCT01147848)
Timeframe: Baseline and Day 168
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 0.46 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 0.37 |
"The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). The second part is a 20 centimeter VAS that has endpoints labelled best imaginable health state and worst imaginable health state anchored at 100 and 0, respectively. Participants were asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS that best represents their own health on that day. Analysis was performed using ANCOVA with covariates of Baseline VAS score, country, sex, age, and treatment." (NCT01147848)
Timeframe: Baseline and Day 168
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 5.5 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 4.1 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Trough FEV1 is defined as the pre-dose measurement on Day 168/Week 24. Any missing data at Day 168/Week 24 was imputed using the last observation carried forward (LOCF). Baseline was the pre-dose measurement on Day 1. Change from Baseline was calculated as the pre-dose measurement on Day 168/Week 24 minus the Baseline value. (NCT01147848)
Timeframe: Baseline and Day 168
| Intervention | Liters (Least Squares Mean) |
|---|---|
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 0.281 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 0.300 |
The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline and Day 168 was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. (NCT01147848)
Timeframe: Baseline and Day 168
| Intervention | Liters (Mean) |
|---|---|
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 0.360 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 0.394 |
The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 1 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. (NCT01147848)
Timeframe: Baseline and Randomization
| Intervention | Liters (Least Squares Mean) |
|---|---|
| FFluticasone Furoate/Vilanterol 100/25 µg OD | 0.316 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 0.346 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, on Day 168/Week 24. Change from Baseline was calculated as the weighted mean of the 24-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment. (NCT01147848)
Timeframe: Baseline and Day 168/Week 24
| Intervention | Liters (Least Squares Mean) |
|---|---|
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 0.341 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 0.377 |
"The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a three-point Likert scale (1=no problems, 2=some problems and 3=severe problems). Respondents are asked to choose one level that reflects their own health state today for each of the five dimensions." (NCT01147848)
Timeframe: Day 168/Week 24
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Mobility | Self care | Usual activities | Pain/Discomfort | Anxiety/Depression | |
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 86 | 98 | 86 | 70 | 78 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 84 | 98 | 82 | 66 | 81 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. (NCT01147848)
Timeframe: Baseline
| Intervention | Liters (Mean) | ||
|---|---|---|---|
| All Participants, n=401, 401 | Completers, n=359, 355 | Withdrawals, n=42, 46 | |
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 2.011 | 2.013 | 1.996 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 2.048 | 2.043 | 2.091 |
All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (to the general ward [GW] or the intensive care unit [ICU]) that were associated with asthma exacerbations were recorded. (NCT01147848)
Timeframe: Baseline to Day 168
| Intervention | visits per participant (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Number of Home Visits during the Day | Number of Home Visits during the Night | Number of Physician Office/Practice Visits | Number of Urgent Care/Outpatient Clinic Visits | Number of Emergency Room Visits | Number of Inpatient Hospitalization (ICU) Days | Number of Inpatient Hospitalization (GW) Days | |
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The number of participants obtaining a >=12% and >=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated at 12-hours post-dose and at 24-hours post-dose on Day 168. (NCT01147848)
Timeframe: Baseline and Day 168
| Intervention | participants (Number) | |
|---|---|---|
| 12 hours post-dose, n=356,354 | 24 hours post-dose, n=354, 354 | |
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 199 | 181 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 178 | 176 |
Time to onset of bronchodilator effect at Day 1 is defined as the actual time during the 4-hour serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) measurements that the participant first meets or exceeds a 12% and 200 mL increase over Baseline and was derived at Day 1 only. Time to onset was calculated over 0 to 4 hours (5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 4 hours) post-dose. Participants who never exceeded a 12% and 200 mL increase over Baseline were censored at the actual time of their last FEV1 measurement. (NCT01147848)
Timeframe: Baseline to Day 1
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| 5 minutes | 15 minutes | 30 minutes | 1 hour | 2 hours | 3 hours | 4 hours | Censored | |
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 100 | 41 | 40 | 32 | 19 | 17 | 11 | 140 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 85 | 51 | 55 | 39 | 29 | 12 | 12 | 118 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . The pre-dose FEV1 assessment and the individual serial FEV1 assessments at Day 168/Week 24 at the indicated time points (pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 11 hours, 12 hours, 12.5 hours, 13 hours, 14 hours, 16 hours, 20 hours, 23 hours, and 24 hour s) were summarized. (NCT01147848)
Timeframe: Day 168
| Intervention | Liters (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-dose, n=359,353 | 5 minutes, n=356, 344 | 15 minutes, n=355, 347 | 30 minutes, n=357, 351 | 1 hour, n=358, 353 | 2 hours, n=359, 353 | 3 hours, n=357, 353 | 4 hours, n=357, 354 | 11 hours, n=359, 347 | 12 hours, n=356, 354 | 12.5 hours, n=357, 352 | 13 hours, n=354, 354 | 14 hours, n=356, 353 | 16 hours, n=354, 350 | 20 hours, n=355, 352 | 23 hours, n=354, 353 | 24 hours, n=354, 354 | |
| Fluticasone Furoate/Vilanterol 100/25 µg OD | 0.304 | 0.320 | 0.323 | 0.339 | 0.344 | 0.362 | 0.373 | 0.356 | 0.305 | 0.330 | 0.330 | 0.343 | 0.357 | 0.351 | 0.321 | 0.310 | 0.304 |
| Fluticasone Propionate/Salmeterol 250/50 µg BID | 0.323 | 0.339 | 0.354 | 0.366 | 0.390 | 0.409 | 0.419 | 0.417 | 0.319 | 0.338 | 0.380 | 0.396 | 0.426 | 0.419 | 0.376 | 0.344 | 0.340 |
The primary efficacy summary was change from Baseline in FEV1 (percent predicted), at Hour 2. Baseline was defined as FEV1 (percent predicted) after two doses of albuterol (5 mg each) and ipratropium (0.5 mg each) and FEV1 (percent predicted) FEV1 at Hour 2 was defined as the FEV1 (percent predicted) at 2 hours after the start of the infusion of MN-221 or placebo. Change from Baseline in FEV1 (percent predicted), was summarized by treatment group at Hour 2. (NCT00683449)
Timeframe: Baseline and Hour 2
| Intervention | FEV1 (percent of predicted) (Mean) |
|---|---|
| 240 μg MN-221 i.v. (Intravenous) Infusion for 15 Minutes | 16.57 |
| MN-221 Placebo i.v. Infusion | 3.88 |
| 1,000-1,080 μg MN-221 i.v. | 3.03 |
| 450 μg MN-221 i.v. for 15 Minutes | 4.27 |
| 1,995 μg MN-221 i.v. Over 15 Minutes and 25 Minutes | -0.82 |
FEV1 (L) was determined over time using a spirometer. Measure the mean change in FEV1 (L) from Baseline. (NCT00683449)
Timeframe: Baseline to Hour 2
| Intervention | liters per second (Mean) |
|---|---|
| MN-221 at 16.0 μg/Min for 15 Min (Total 240 μg) | 0.60 |
| Placebo Administered Intravenously | 0.10 |
| 450 μg MN-221 Given i.v. | 0.12 |
| 1,000-1,080 μg MN-221 Given i.v. for 15 Minutes | 0.10 |
| 1,995 MN-221 Administered i.v. for 15 Minutes and 25 Minutes | -0.02 |
After a patient in the emergency department (ED) presents with an acute exacerbation of asthma, the hospital proceeds with SOC procedures for this condition. Despite treatment in the ED, it is sometimes necessary to admit the patient into the hospital. In the study described here, the rate of hospital admissions was recorded. (NCT00683449)
Timeframe: Hour -1.5 through Hour 5
| Intervention | participants (Number) |
|---|---|
| 240 μg MN-221 i.v. (Intravenous) Infusion for 15 Minutes | 0 |
| MN-221 Placebo i.v. Infusion | 7 |
| 1,000-1,080 μg MN-221 i.v. | 0 |
| 450 μg MN-221 i.v. for 15 Minutes | 3 |
| 1,995 μg MN-221 i.v. Over 15 Minutes and 25 Minutes | 1 |
The PEF is a measure of lung function and measures how fast a person can breathe out. PEF was measured every morning and evening prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily eDiary. Daily average of morning and evening PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. This outcome measure explored the efficacy between GSK2190915 and montelukast due to the dosing time difference. (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | L/min (Least Squares Mean) |
|---|---|
| FP + GSK2190915 100 mg | 352.37 |
| FP + GSK2190915 300 mg | 356.16 |
| FP + Montelukast | 356.52 |
Daytime and night time asthma symptoms were recorded every evening at bedtime and every morning upon rising, respectively, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on scales ranging from '0' (implying no symptoms) to either 5 (for daytime symptoms) or 4 (for night time symptoms) (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. 24-hour period asthma symptom scores were averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| FP + Placebo | 2.26 |
| FP + GSK2190915 100 mg | 2.26 |
| FP + GSK2190915 300 mg | 2.15 |
| FP + Montelukast | 2.22 |
| FP / Salmeterol | 2.25 |
The PEF is a measure of lung function and measures how fast a person can breathe out. PEF was measured every evening prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily eDiary. Daily evening PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | L/min (Least Squares Mean) |
|---|---|
| FP + Placebo | 354.06 |
| FP + GSK2190915 100 mg | 355.71 |
| FP + GSK2190915 300 mg | 359.16 |
| FP + Montelukast | 358.88 |
| FP / Salmeterol | 364.35 |
A SABA (albuterol) was provided to participants as a rescue medication, to use as needed for symptomatic relief of asthma symptoms. Participants were required to record their albuterol use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The daily rescue SABA use was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | Number of inhalations (Least Squares Mean) |
|---|---|
| FP + Placebo | 2.17 |
| FP + GSK2190915 100 mg | 2.14 |
| FP + GSK2190915 300 mg | 2.03 |
| FP + Montelukast | 2.09 |
| FP / Salmeterol | 2.08 |
The PEF is a measure of lung function and measures how fast a person can breathe out. Trough PEF was measured every morning prior to study medication dose and any rescue albuterol (bronchodilator) use. Participants recorded PEF in a daily electronic diary (eDiary). Daily trough morning PEF was averaged over the last 3 weeks of the 6-week treatment period, and analyzed using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | Liters/minute (L/min) (Least Squares Mean) |
|---|---|
| FP + Placebo | 349.19 |
| FP + GSK2190915 100 mg | 350.14 |
| FP + GSK2190915 300 mg | 354.96 |
| FP + Montelukast | 354.17 |
| FP / Salmeterol | 361.33 |
Participants were withdrawn if they met any of the following three criteria for 'lack of efficacy': 1) Clinic FEV1 below the FEV1 'Stability Limit' value, 2) During any consecutive 7-day period, the participant experienced PEF fallen below the PEF 'Stability Limit' for more than 3 days, or if >= 12 inhalations per day of albuterol were used for more than 2 days, and 3) Ashtma exacerbation. The number of withdrawals due to lack of efficacy were summarized for each treatment and Fisher's Exact test was used for comparison with placebo add-on. Withdrawals occurring during active washout periods are not included. (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | Number of participants (Number) |
|---|---|
| FP + Placebo | 9 |
| FP + GSK2190915 100 mg | 5 |
| FP + GSK2190915 300 mg | 3 |
| FP + Montelukast | 7 |
| FP / Salmeterol | 5 |
Night time asthma symptoms were recorded every morning upon rising, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 5-point scale: 0 = no symptoms during the night, 1 = symptoms causing to wake once, 2 = symptoms causing to wake twice or more, 3 = symptoms causing to be awake most of the night, 4 = could not sleep due to severe symptoms. Participants recorded the symptoms in a daily eDiary. The number of nights with no awakenings due to asthma during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant. (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | Percentage of nights (Least Squares Mean) |
|---|---|
| FP + Placebo | 37.21 |
| FP + GSK2190915 100 mg | 38.22 |
| FP + GSK2190915 300 mg | 40.55 |
| FP + Montelukast | 37.70 |
| FP / Salmeterol | 38.47 |
"Albuterol was provided as a rescue medication, and participants were required to record rescue medication use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The number of days when rescue medication was not used (rescue-free days) during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant." (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | Percentage of days (Least Squares Mean) |
|---|---|
| FP + Placebo | 40.44 |
| FP + GSK2190915 100 mg | 42.43 |
| FP + GSK2190915 300 mg | 42.59 |
| FP + Montelukast | 42.77 |
| FP / Salmeterol | 41.96 |
"Albuterol was provided as a rescue medication, and participants were required to record rescue medication use in the morning and in the evening. Participants recorded the number of inhalations of rescue medication in a daily eDiary. The number of nights when rescue medication was not used (rescue-free nights) during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant." (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | Percentage of nights (Least Squares Mean) |
|---|---|
| FP + Placebo | 45.12 |
| FP + GSK2190915 100 mg | 45.69 |
| FP + GSK2190915 300 mg | 48.79 |
| FP + Montelukast | 45.32 |
| FP / Salmeterol | 43.98 |
"Daytime asthma symptoms were recorded every evening at bedtime, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 6-point scale ranging from '0' (implying no symptoms) to 5 (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. The number of days when symptoms were not experienced (symptom-free days) during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant." (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | Percentage of days (Least Squares Mean) |
|---|---|
| FP + Placebo | 30.84 |
| FP + GSK2190915 100 mg | 33.51 |
| FP + GSK2190915 300 mg | 36.14 |
| FP + Montelukast | 34.88 |
| FP / Salmeterol | 35.45 |
"Night time asthma symptoms were recorded every morning upon rising, before taking any rescue or study medication and before assessing the PEF. Symptoms were recorded on a 5-point scale ranging from '0' (implying no symptoms) to 4 (implying severe symptoms). Participants recorded the symptoms in a daily eDiary. The number of nights when symptoms were not experienced (symptom-free nights) during the last 3 weeks of the 6-week treatment period were counted, and percentage calculated by dividing by 21 and multiplying by 100. Analysis was done using mixed effect ANCOVA model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effects of participant." (NCT01156792)
Timeframe: Week 4 to Week 6
| Intervention | Percentage of nights (Least Squares Mean) |
|---|---|
| FP + Placebo | 37.21 |
| FP + GSK2190915 100 mg | 38.22 |
| FP + GSK2190915 300 mg | 40.55 |
| FP + Montelukast | 37.70 |
| FP / Salmeterol | 38.47 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured electronically using spirometry, prior to study medication and any rescue albuterol (bronchodilator) use. At the end of the 6-week treatment period, FEV1 was measured approximately 24 hours after the participant's last morning dose of study medication and approximately 12 hours after the evening dose of study medication. Trough FEV1 was analyzed using mixed effect analysis of covariance (ANCOVA) model for treatment effects, incorporating fixed effects of baseline, period, age, center, smoking status, and random effect of participant. Intent-to-Treat Population is defined as all participants who were randomized and received at least one dose of study drug. (NCT01156792)
Timeframe: End of Week 6
| Intervention | Liters (L) (Least Squares Mean) |
|---|---|
| FP + Placebo | 2.36 |
| FP + GSK2190915 100 mg | 2.39 |
| FP + GSK2190915 300 mg | 2.40 |
| FP + Montelukast | 2.42 |
| FP / Salmeterol | 2.43 |
The electrocardiogram (ECG) of the participants was taken, and the maximum and weighted mean of QTc(B) and QTc(F) was measured. Weighted mean was calculated by using all values of QTc(B) and QTc(F) at the indicated timepoint contributing to the calculation of the mean but with different weightage. The ECG helps in the assessment of the condition of the heart. The QT interval gives the measure of the heart rate, and the cQT interval gives the corrected value. (NCT01494610)
Timeframe: At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 3 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Milliseconds (msec) (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Max, QTc(B) interval, Asthma + COPD; n=57, 57 | Max, QTc(B) interval, Asthma; n=33, 33 | Max, QTc(B) interval, COPD; n=24, 24 | Weighted mean QTc(B), Asthma + COPD; n=57, 57 | Weighted mean QTc(B), Asthma; n=33, 33 | Weighted mean QTc(B), COPD; n=24, 24 | Max QTc(F), Asthma + COPD; n=57, 57 | Max QTc(F), Asthma; n=33, 33 | Max QTc(F), COPD; n=24, 24 | Weighted mean QTc(F), Asthma + COPD; n=57, 57 | Weighted mean QTc(F), Asthma; n=33, 33 | Weighted mean QTc(F), COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 434.4 | 424.7 | 447.6 | 416.8 | 406.3 | 431.3 | 422.6 | 413.7 | 434.9 | 410.1 | 401.3 | 422.3 |
| FP/Salmeterol From MDPI | 434.0 | 423.7 | 448.1 | 416.8 | 405.7 | 431.9 | 422.5 | 413.5 | 434.9 | 410.3 | 401.2 | 422.9 |
"The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | g/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Albumin, 1st admin, Asthma; n=33, 33 | Albumin, 2nd admin, Asthma; n=31, 33 | Albumin, 1st admin, COPD; n=25, 25 | Albumin, 2nd admin, COPD; n=25, 25 | Total protein, 1st admin, Asthma; n=33, 33 | Total protein, 2nd admin, Asthma; n=31, 33 | Total protein, 1st admin, COPD; n=25, 25 | Total protein, 2nd admin, COPD; n=25, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 42.3 | 41.8 | 41.4 | 40.0 | 66.0 | 64.8 | 64.9 | 63.5 |
| FP/Salmeterol From MDPI | 43.0 | 42.0 | 40.9 | 40.8 | 66.8 | 65.4 | 64.7 | 64.6 |
"Blood samples of participants were collected for the evaluation of AP, ALT, AST, and GGT. All of these parameters are measured to help assess the condition of the liver. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | International units per liter (IU/L) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AP, 1st admin, Asthma; n=33, 33 | AP, 2nd admin, Asthma; n=31, 33 | AP, 1st admin, COP ; n=25, 25 | AP, 2nd admin, COPD; n=25, 25 | ALT, 1st admin, Asthma; n=33, 33 | ALT, 2nd admin, Asthma; n=31, 33 | ALT, 1st admin, COPD; n=25, 25 | ALT, 2nd admin, COPD; n=25, 25 | AST, 1st admin, Asthma; n=33, 33 | AST, 2nd admin, Asthma; n=31, 33 | AST, 1st admin, COPD; n=25, 25 | AST, 2nd admin, COPD; n=25, 25 | GGT, 1st admin, Asthma; n=33, 33 | GGT, 2nd admin, Asthma; n=31, 33 | GGT, 1st admin, COPD; n=25, 25 | GGT, 2nd admin, COPD; n=25, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 63.4 | 63.9 | 69.9 | 68.4 | 20.4 | 19.1 | 23.4 | 21.2 | 21.6 | 20.1 | 24.7 | 21.1 | 21.0 | 21.0 | 44.0 | 29.6 |
| FP/Salmeterol From MDPI | 64.6 | 65.0 | 69.6 | 69.8 | 20.1 | 21.5 | 21.2 | 20.9 | 21.2 | 20.7 | 22.7 | 22.5 | 21.3 | 22.7 | 36.9 | 31.8 |
Blood samples of participants (par.) with asthma and chronic obstructive pulmonary disease (COPD) were collected and analyzed for AUC(0-tau), a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). Asthma is a disorder that causes the airways of the lungs to swell and narrow, leading to difficulty in breathing. COPD is a chronic lung disease with structural changes in lungs, leading to difficulty in breathing. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Picogram hours per milliliter (pg*h/mL) (Geometric Mean) | ||
|---|---|---|---|
| Asthma + COPD; n=57, 57 | Asthma; n=33, 33 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 573.1 | 559.1 | 593.0 |
| FP/Salmeterol From MDPI | 376.9 | 350.5 | 416.4 |
Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tlast). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | pg*h/mL (Geometric Mean) | ||
|---|---|---|---|
| Asthma + COPD; n=57, 57 | Asthma; n=33, 33 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 580.9 | 558.4 | 613.2 |
| FP/Salmeterol From MDPI | 380.1 | 355.7 | 416.5 |
"Blood samples of participants were collected for the evaluation of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, and WBC count. Data are reported for the first (1st) and second (2nd) administration (admin) of FP/salmeterol via MDPI or capsule-based inhaler. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Giga (10^9) cells/L (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils, 1st admin, Asthma; n=33, 33 | Basophils, 2nd admin, Asthma; n=31, 33 | Basophils, 1st admin, COPD; n=25, 25 | Basophils, 2nd admin, COPD; n=24, 25 | Eosinophils, 1st admin, Asthma; n=33, 33 | Eosinophils, 2nd admin, Asthma; n=31, 33 | Eosinophils, 1st admin, COPD; n=25, 25 | Eosinophils, 2nd admin, COPD; n=24, 25 | Lymphocytes, 1st admin, Asthma; n=33, 33 | Lymphocytes, 2nd admin, Asthma; n=31,33 | Lymphocytes, 1st admin, COPD; n=25, 25 | Lymphocytes, 2nd admin, COPD; n=24, 25 | Monocytes, 1st admin, Asthma; n=33, 33 | Monocytes, 2nd admin, Asthma; n=31, 33 | Monocytes, 1st admin, COPD; n=25, 25 | Monocytes, 2nd admin, COPD; n=24, 25 | TN, 1st admin, Asthma; n=33, 33 | TN, 2nd admin, Asthma; n=31, 33 | TN, 1st admin, COPD; n=25, 25 | TN, 2nd admin, COPD; n=24, 25 | Platelet count, 1st admin, Asthma; n=33, 33 | Platelet count, 2nd admin, Asthma; n=31, 33 | Platelet count, 1st admin, COPD; n=24, 24 | Platelet count, 2nd admin, COPD; n=23, 24 | WBC count, 1st admin, Asthma; n=33, 33 | WBC count, 2nd admin, Asthma; n=31, 33 | WBC count, 1st admin, COPD; n=25, 25 | WBC count, 2nd admin, COPD; n=24, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 0.06 | 0.04 | 0.04 | 0.04 | 0.33 | 0.31 | 0.23 | 0.26 | 1.92 | 1.86 | 1.72 | 1.68 | 0.55 | 0.52 | 0.60 | 0.63 | 3.37 | 3.28 | 3.48 | 3.75 | 223.9 | 230.8 | 226.6 | 240.1 | 6.182 | 5.976 | 6.036 | 6.312 |
| FP/Salmeterol From MDPI | 0.05 | 0.04 | 0.07 | 0.04 | 0.37 | 0.31 | 0.25 | 0.25 | 1.96 | 1.90 | 1.70 | 1.75 | 0.54 | 0.54 | 0.64 | 0.63 | 3.28 | 3.30 | 3.70 | 3.45 | 225.1 | 230.7 | 230.6 | 235.1 | 6.145 | 6.071 | 6.340 | 6.092 |
"Blood samples of participants were collected for the evaluation of calcium, chloride, glucose, potassium, sodium, carbon dioxide (CO2) content/bicarbonate, and urea/BUN. All of these parameters are measured to help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | µmol/L (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calcium, 1st admin, Asthma; n=33, 32 | Calcium, 2nd admin, Asthma; n=31, 33 | Calcium, 1st admin, COPD; n=25, 25 | Calcium, 2nd admin, COPD; n=25, 25 | Chloride, 1st admin, Asthma; n=33, 33 | Chloride, 2nd admin, Asthma; n=31, 33 | Chloride, 1st admin, COP; n=25, 25 | Chloride, 2nd admin, COPD n=25, 25 | Glucose, 1st admin, Asthma; n=33, 33 | Glucose, 2nd admin, Asthma; n=31, 33 | Glucose, 1st admin, COPD; n=25, 25 | Glucose, 2nd admin, COPD; n=25, 25 | Potassium, 1st admin, Asthma; n=32, 33 | Potassium, 2nd admin, Asthma; n=31, 33 | Potassium, 1st admin, COPD n=25, 25 | Potassium, 2nd admin, COPD; n=25, 25 | Sodium, 1st admin, Asthma; n=33, 33 | Sodium, 2nd admin, Asthma; n=31, 33 | Sodium, 1st admin, COPD n=25, 25 | Sodium, 2nd admin, COPD n=25, 25 | CO2 content/bicar, 1st admin, Asthma; n=33, 33 | CO2 content/bicar, 2nd admin, Asthma; n=31, 33 | CO2 content/bicar, 1st admin, COPD; n=25, 25 | CO2 content/bicar, 2nd admin, COPD; n=25, 25 | Urea/BUN, 1st admin, Asthma; n=33, 33 | Urea/BUN, 2nd admin, Asthma; n=31, 33 | Urea/BUN, 1st admin, COPD; n=25, 25 | Urea/BUN, 2nd admin, COPD; n=25, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 2.178 | 2.170 | 2.189 | 2.190 | 104.8 | 105.3 | 104.0 | 104.4 | 5.06 | 5.15 | 5.37 | 5.45 | 4.05 | 4.02 | 4.08 | 4.11 | 140.5 | 140.4 | 140.5 | 140.2 | 25.6 | 26.0 | 27.3 | 27.2 | 5.41 | 5.43 | 6.09 | 6.12 |
| FP/Salmeterol From MDPI | 2.191 | 2.190 | 2.205 | 2.206 | 104.7 | 104.5 | 104.4 | 104.1 | 5.06 | 5.06 | 5.36 | 5.63 | 4.15 | 4.06 | 4.16 | 4.10 | 140.5 | 140.1 | 140.5 | 140.1 | 26.1 | 26.2 | 27.2 | 27.3 | 5.34 | 5.31 | 5.98 | 5.90 |
"Blood samples of participants were collected for the evaluation of MCV. MCV is a measure of the average red blood cell size that is reported as part of a standard complete blood count. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Femtoliters (fL; 10^-15 L)/cell (Mean) | |||
|---|---|---|---|---|
| 1st admin, Asthma; n=33, 33 | 2nd admin, Asthma; n=31, 33 | 1st admin, COPD; n=25, 25 | 2nd admin, COPD; n=24, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 89.41 | 89.77 | 90.37 | 90.64 |
| FP/Salmeterol From MDPI | 89.65 | 89.52 | 90.21 | 90.76 |
"Blood samples of participants were collected for the evaluation of MCH. MCH is the average mass or amount of hemoglobin per red blood cell in a sample of blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | picograms (pg)/cell (Mean) | |||
|---|---|---|---|---|
| 1st admin, Asthma; n=33, 33 | 2nd admin, Asthma; n=31, 33 | 1st admin, COPD; n=25, 25 | 2nd admin, COPD; n=24, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 29.86 | 29.92 | 29.72 | 29.83 |
| FP/Salmeterol From MDPI | 29.99 | 29.80 | 29.72 | 29.73 |
"Blood samples of participants were collected for the evaluation of DP, TB, creatinine, and uric acid. DB and TB are measures that help assess the condition of the liver, and creatinine and uric acid are measures that help assess the condition of the kidneys. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Micromoles per liter (µmol/L) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DB, 1st admin, Asthma; n=33, 33 | DB, 2nd admin, Asthma; n=31, 33 | DB, 1st admin, COPD; n=25, 25 | DB, 2nd admin, COPD; n=25, 25 | TB, 1st admin, Asthma; n=33, 33 | TB, 2nd admin, Asthma; n=31, 33 | TB, 1st admin, COPD; n=25, 25 | TB, 2nd admin, COPD; n=25, 25 | Creatinine, 1st admin, Asthma; n=33, 33 | Creatinine, 2nd admin, Asthma; n=31, 33 | Creatinine, 1st admin, COPD; n=25, 25 | Creatinine, 2nd admin, COPD; n=25, 25 | Uric acid, 1st admin, Asthma n=33, 33 | Uric acid, 2nd admin, Asthma; n=31, 33 | Uric acid, 1st admin, COPD; n=25, 25 | Uric acid, 2nd admin, COPD; n=25, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 2.7 | 2.6 | 2.8 | 2.9 | 9.9 | 8.6 | 9.4 | 8.4 | 75.8 | 75.2 | 77.7 | 79.4 | 331.5 | 325.6 | 348.3 | 352.0 |
| FP/Salmeterol From MDPI | 3.2 | 3.0 | 2.9 | 2.7 | 9.5 | 9.9 | 8.7 | 8.5 | 77.2 | 76.9 | 79.4 | 79.6 | 328.9 | 338.4 | 354.2 | 361.7 |
"Blood samples of participants were collected for the evaluation of hematocrit. The hematocrit is the percentage of the RBCs in the blood. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | percentage of RBCs (Mean) | |||
|---|---|---|---|---|
| 1st admin, Asthma; n=33, 33 | 2nd admin, Asthma; n=31, 33 | 1st admin, COPD; n=25, 25 | 2nd admin, COPD; n=24, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 0.405 | 0.396 | 0.405 | 0.391 |
| FP/Salmeterol From MDPI | 0.413 | 0.399 | 0.405 | 0.400 |
"Blood samples of participants were collected for the evaluation of mean hemoglobin (mean level of hemoglobin in the whole blood sample) and MCH concentration. The MCH concentration is the average concentration of hemoglobin in a red blood cell. Hemoglobin is the red pigment in the blood, and it is reponsible for carrying oxygen. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Grams per liter (g/L) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Hemoglobin, 1st admin, Asthma; n=33, 33 | Hemoglobin, 2nd admin, Asthma; n=31, 33 | Hemoglobin, 1st admin, COPD; n=25, 25 | Hemoglobin, 2nd admin, COPD; n=24, 25 | MCH concentration, 1st admin, Asthma; n=33, 33 | MCH concentration, 2nd admin, Asthma; n=31, 33 | MCH concentration, 1st admin, COPD; n=,25, 25 | MCH concentration, 1st admin, COPD; n=24, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 135.4 | 132.3 | 133.1 | 128.5 | 334.0 | 333.2 | 328.5 | 328.8 |
| FP/Salmeterol From MDPI | 138.2 | 133.0 | 133.3 | 130.6 | 334.7 | 333.0 | 329.0 | 327.4 |
Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of Salmeterol in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | pg/mL (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| Cmax, Asthma + COPD; n=57, 57 | Cmax, Asthma; n=33, 33 | Cmax, COPD; n=24, 24 | Cmin, Asthma + COPD; n=57, 57 | Cmin, Asthma; n=33, 33 | Cmin, COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 92.27 | 110.21 | 72.27 | 14.354 | 14.634 | 13.978 |
| FP/Salmeterol From MDPI | 59.28 | 64.97 | 52.26 | 12.752 | 12.676 | 12.857 |
Blood samples of participants with asthma and COPD were collected and analyzed for Cmax and Cmin of FP in the blood. Cmax and Cmin are used to estimate the time at which the activity of the drug will be at its maximum and minimum, respectively. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Picograms per milliliter (pg/mL) (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| Cmax, Asthma + COPD; n= 57, 57 | Cmax, Asthma; n=33, 33 | Cmax, COPD; n=24, 24 | Cmin, Asthma + COPD; n=57, 57 | Cmin, Asthma; n=33, 33 | Cmin, COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 105.79 | 109.98 | 100.29 | 21.547 | 18.866 | 25.866 |
| FP/Salmeterol From MDPI | 54.64 | 53.66 | 56.02 | 15.904 | 13.635 | 19.654 |
The maximum observed value of heart rate was measured from the time of the morning dose on Day 10 to 4 hours post dose. (NCT01494610)
Timeframe: At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | bpm (Mean) | ||
|---|---|---|---|
| Asthma + COPD; n=57, 57 | Asthma; n=33, 33 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 74.3 | 73.5 | 75.4 |
| FP/Salmeterol From MDPI | 73.0 | 72.3 | 74.0 |
Blood samples of participants with asthma and COPD were collected and analyzed for AUC(0-tau) and AUC(0-tlast). AUC(0-tau) is a measure of the amount of drug available at target tissue (in plasma) for a fixed dosing interval (12 hours). AUC(0-tlast) is a measure of the plasma drug concentration from pre-dose to the last measurable concentration. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | pg*h/mL (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| AUC(0-tau), asthma + COPD; n=57, 57 | AUC(0-tau), asthma; n=33, 33 | AUC(0-tau), COPD; n=24, 24 | AUC(0-t), asthma + COPD; n=57, 57 | AUC(0-t), asthma; n=33, 33 | AUC(0-t), COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 345.1 | 356.4 | 330.1 | 345.0 | 356.4 | 330.0 |
| FP/Salmeterol From MDPI | 300.2 | 305.8 | 292.7 | 303.5 | 305.2 | 301.2 |
Blood samples of participants were collected for evaluating t1/2. The t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | hours (Geometric Mean) | ||
|---|---|---|---|
| Asthma + COPD; n=54, 55 | Asthma; n=30, 32 | COPD; n=24, 23 | |
| FP/Salmeterol From Capsule-based Inhaler | 5.844 | 5.238 | 6.806 |
| FP/Salmeterol From MDPI | 6.660 | 5.906 | 7.740 |
Blood samples of participants were collected for evaluating t1/2. t1/2 is the time required for the plasma/blood concentration of the drug to decrease by 50% after the false equilibrium of distribution has been reached. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | hours (Geometric Mean) | ||
|---|---|---|---|
| Asthma + COPD; n=56, 56 | Asthma; n=32, 32 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 7.260 | 7.538 | 6.905 |
| FP/Salmeterol From MDPI | 6.576 | 6.429 | 6.776 |
Urine samples of participants were collected to evaluate urine cortisol excretion over 0-24 hours post treatment dose. A 24-hour urine cortisol sample was used to measure the total amount of cortisol excreted in urine in 24 hours. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in the amount of cortisol excreted in the urine. (NCT01494610)
Timeframe: 0-24 hours post dose on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | nmol (Geometric Mean) | ||
|---|---|---|---|
| Asthma + COPD; n=57, 57 | Asthma; n=33, 33 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 59.66 | 66.28 | 51.62 |
| FP/Salmeterol From MDPI | 63.53 | 72.86 | 52.62 |
The diastolic and systolic blood pressure of the participants was measured. The maximum and minimum observed values from the time of the morning dose on Day 10 to 4 hours post dose were measured for SBP and DBP. The weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. Weighted mean was calculated by using all values of DBP and SBP at the indicated timepoint contributing to the calculation of the mean but with different weightage. (NCT01494610)
Timeframe: At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | millimeters of mercury (mmHg) (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DBP, Asthma + COPD; n=57, 57 | DBP, Asthma; n=33, 33 | DBP, COPD; n=24, 24 | Weighted mean DBP, Asthma + COPD; n=57, 57 | Weighted mean DBP, Asthma; n=33, 33 | Weighted mean DBP, COPD; n=24, 24 | SBP, Asthma + COPD; n=57, 57 | SBP, Asthma; n=33, 33 | SBP, COPD; n=24, 24 | Weighted mean SBP, Asthma + COPD; n=57, 57 | Weighted mean SBP, Asthma; n=33, 33 | Weighted mean SBP, COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 66.2 | 62.6 | 71.2 | 72.2 | 68.8 | 77.0 | 129.3 | 122.1 | 139.1 | 120.3 | 114.6 | 128.2 |
| FP/Salmeterol From MDPI | 64.7 | 61.6 | 69.1 | 71.1 | 68.0 | 75.4 | 128.0 | 119.9 | 139.1 | 118.8 | 112.9 | 126.9 |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. (NCT01494610)
Timeframe: Randomization (Day 1) up to Follow-up (Days 47-50)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| 1st admin, Asthma; n=33, 34 | 2nd admin, Asthma; n=31, 33 | 1st admin, COPD; n=26, 25 | 2nd admin, COPD; n=25, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 13 | 15 | 11 | 11 |
| FP/Salmeterol From MDPI | 13 | 12 | 14 | 9 |
"Blood samples of participants were collected for the evaluation of RBC and reticulocytes count. Reticulocytes are immature red blood cells. Normally, about 1% to 2% of the red blood cells in the blood are reticulocytes. The timing of the first and second administrations depended on the randomization schedule. If the treatment sequence received was ABBA, then Days 10 and 40, respectively, correspond to the first and second administrations for treatment A." (NCT01494610)
Timeframe: Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Trillion (10^12) cells/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| RBC, 1st admin, Asthma; n=33, 33 | RBC, 2nd admin, Asthma; n=31, 33 | RBC, 1st admin, Asthma, COPD; n=25, 25 | RBC, 2nd admin, COPD; n=24, 25 | Reticulocytes, 1st admin, Asthma ; n=33, 32 | Reticulocytes, 2nd admin, Asthma; n=31, 33 | Reticulocytes, 1st admin, COPD; n=25, 25 | Reticulocytes, 2nd admin, COPD; n=24, 25 | |
| FP/Salmeterol From Capsule-based Inhaler | 4.542 | 4.424 | 4.530 | 4.358 | 0.050 | 0.050 | 0.054 | 0.061 |
| FP/Salmeterol From MDPI | 4.608 | 4.460 | 4.523 | 4.438 | 0.049 | 0.051 | 0.054 | 0.059 |
Blood samples of participants were collected for the evaluation of minimum serum cortisol. Any differences in systemic exposure as a result of the absorbed steroid component of the two differing inhaled devices should also result in differences in serum cortisol concentrations. (NCT01494610)
Timeframe: Day 10 of each study period (Periods 1-4); Study Day 10 (+/-1) (reference day is Study Day 1 or Randomization day), Period 1; Study Day 20 (+/-1), Period 2; Study Day 30 (+/-1), Period 3; Study Day 40 (+/-1), Period 4
| Intervention | nmol/L (Geometric Mean) | ||
|---|---|---|---|
| Asthma + COPD; n=57, 57 | Asthma; n=33, 33 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 79.6 | 70.0 | 94.9 |
| FP/Salmeterol From MDPI | 88.6 | 79.8 | 102.4 |
Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | hours (Median) | ||
|---|---|---|---|
| Asthma + COPD; n=57, 57 | Asthma; n=33, 33 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 0.530 | 0.335 | 0.673 |
| FP/Salmeterol From MDPI | 1.045 | 1.000 | 1.173 |
Blood samples of participants were collected for evaluating Tmax. Tmax is a measure of the time required to reach the maximum concentration of the drug. (NCT01494610)
Timeframe: At pre-morning dose; 5, 10, 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | hours (Median) | ||
|---|---|---|---|
| Asthma + COPD; n=57, 57 | Asthma; n=33, 33 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 0.080 | 0.080 | 0.080 |
| FP/Salmeterol From MDPI | 0.750 | 0.335 | 1.000 |
Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the maximum plasma glucose level. Weighted mean was calculated by using all values of plasma glucose at the indicated timepoint contributing to the calculation of the mean but with different weightage. (NCT01494610)
Timeframe: At pre-morning dose; 30, 60 minutes post-dose (PD); and 2 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | mmol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Weighted mean, Asthma + COPD; n=57, 57 | Weighted mean, Asthma; n=33, 33 | Weighted mean, COPD; n=24, 24 | Max, Asthma + COPD; n=57, 57 | Max, Asthma; n=33, 33 | Max, COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 5.95 | 5.80 | 6.16 | 7.19 | 6.96 | 7.50 |
| FP/Salmeterol From MDPI | 5.85 | 5.67 | 6.11 | 6.94 | 6.64 | 7.36 |
The heart rate (number of heartbeats per unit of time, typically expressed as beats per minute [bpm]) of the participants was monitored for evaluating the weighted mean over the course of 0 to 4 hours post dose. The Capsule-MDPI difference for heart rate was calculated for each participant, and the weighted mean value from the time of the morning dose on Day 10 to 4 hours post dose was calculated. The weighted mean was calculated by using all values at the indicated timepoint contributing to the calculation of the mean but with different weightage. (NCT01494610)
Timeframe: At pre-morning dose; 15, 30, 60, 90 minutes post-dose (PD); and 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | bpm (Mean) | ||
|---|---|---|---|
| Asthma + COPD; n=57, 57 | Asthma; n=33, 33 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 66.7 | 65.7 | 68.1 |
| FP/Salmeterol From MDPI | 66.2 | 64.8 | 68.2 |
Blood samples of participants were collected for the evaluation of weighted mean over 0 to 4 hours post dose and the minimum plasma potassium level. Weighted mean was calculated by using all values of plasma potassium at the indicated timepoint contributing to the calculation of the mean but with different weightage. (NCT01494610)
Timeframe: At pre-morning dose; 30, 60 minutes post-dose (PD); and 2 and 4 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Millimoles per liter (mmol/L) (Mean) | |||||
|---|---|---|---|---|---|---|
| Weighted mean, Asthma + COPD; n=56, 57 | Weighted mean, Asthma; n=32, 33 | Weighted mean, COPD; n=24, 24 | Min, Asthma + COPD; n=57, 57 | Min, Asthma; n=33, 33 | Min, COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 4.11 | 4.10 | 4.13 | 3.90 | 3.89 | 3.92 |
| FP/Salmeterol From MDPI | 4.11 | 4.11 | 4.11 | 3.91 | 3.92 | 3.89 |
Participants' blood samples were collected and analyzed for SC levels. Weighted mean SC levels are evaluted as a measure of the degree of cortisol suppression, allowing for the determination of whether differences in systemic exposure to the inhaled steroid component of two devices can be significant enough to result in the differences in the body's ability to release cortisol. Weighted means were derived by calculating the AUC over the 0-12 hour period, using the linear trapezoidal rule (statistical technique used for numerical analysis) and then dividing it by the actual time interval. (NCT01494610)
Timeframe: At pre-morning dose; 30 minutes post-dose (PD); and 1, 2, 4, 8, 10, and 12 hours PD on Day 10 of each study period (P): Study Day (SD) 10 (reference day is SD 1 or Randomization day), 20, 30, and 40 (+/-1) for P 1, 2, 3, and 4, respectively
| Intervention | Nanomoles per liter (nmol/L) (Geometric Mean) | ||
|---|---|---|---|
| Asthma + COPD;n=57, 57 | Asthma; n=33, 33 | COPD; n=24, 24 | |
| FP/Salmeterol From Capsule-based Inhaler | 178.3 | 166.6 | 195.6 |
| FP/Salmeterol From MDPI | 193.5 | 187.3 | 202.4 |
"Asthma symptoms were recorded as 0 (absent = no symptom )~(mild = symptom was minimally troublesome, i.e. not sufficient to interfere with normal daily activity or sleep)~(moderate = symptom was sufficiently troublesome to interfere with normal daily activity or sleep)~(severe = symptom was so severe as to prevent normal activity and/or sleep )" (NCT00565266)
Timeframe: Asthma symptoms were measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Tio + 1xICS | -0.09 |
| LABA + 1xICS | -0.04 |
| 2xICS | 0.03 |
Total number of puffs from the albuterol (rescue) inhaler during the previous 24 hours (excluding those puffs for preventive use). (NCT00565266)
Timeframe: Albuterol rescue puffs were measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.
| Intervention | puffs per day (Least Squares Mean) |
|---|---|
| Tio + 1xICS | -0.11 |
| LABA + 1xICS | -0.16 |
| 2xICS | -0.07 |
Scores on the Asthma Control Questionnaire range from 0 to 6, with a higher score indicating worse asthma control. (NCT00565266)
Timeframe: The asthma control questionnaire score was measured on four occasions during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Tio + 1xICS | -0.22 |
| LABA + 1xICS | -0.31 |
| 2xICS | -0.03 |
Scores on the Asthma Quality-of-Life Questionnaire range from 1 to 7, with a higher score indicating a better quality of life. (NCT00565266)
Timeframe: The asthma quality-of-life questionnaire score was measured on four occasions during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Tio + 1xICS | 0.15 |
| LABA + 1xICS | 0.28 |
| 2xICS | 0.05 |
(NCT00565266)
Timeframe: FEV1 was measured on four occasions during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.
| Intervention | liters (Least Squares Mean) |
|---|---|
| Tio + 1xICS | 0.12 |
| LABA + 1xICS | 0.01 |
| 2xICS | 0.02 |
(NCT00565266)
Timeframe: AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.
| Intervention | Liters per minute (Least Squares Mean) |
|---|---|
| Tio + 1xICS | 24.4 |
| LABA + 1xICS | 18.0 |
| 2xICS | -1.4 |
An asthma control day was defined as a day in which there were no symptoms and no albuterol (rescue) puffs. (NCT00565266)
Timeframe: An asthma control day was determined daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.
| Intervention | proportion of asthma control days (Least Squares Mean) |
|---|---|
| Tio + 1xICS | 0.13 |
| LABA + 1xICS | 0.14 |
| 2xICS | 0.05 |
Change between Baseline and 12-month Follow-Up Visit. The ACQ is a self-administered patient questionnaire that also includes the patient's FEV1 value (% Predicted) that assesses individual subject asthma control. The ACQ comprises 6 questions that relate to the patient's asthma symptoms, activity limitations, and daily rescue bronchodilator use, and FEV1. Each question is scored from 0 (Better) to 6 (Worse). A decrease in the ACQ score indicates better asthma control. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Units on a scale (Mean) |
|---|---|
| Alair | -0.82 |
| Sham | -0.77 |
(NCT00231114)
Timeframe: 12 Months
| Intervention | Days/Subject/Year (Mean) |
|---|---|
| Alair | 1.32 |
| Sham | 3.9 |
(NCT00231114)
Timeframe: 12 Months
| Intervention | Events/Subject/Year (Mean) |
|---|---|
| Alair | 0.07 |
| Sham | 0.43 |
(NCT00231114)
Timeframe: 12 Months
| Intervention | Events/Subject/Year (Number) |
|---|---|
| Alair | 0.04 |
| Sham | 0.13 |
"Change between Baseline and the average of 6-, 9-, and 12-month Follow-Up Visits. The AQLQ consists of 32 questions (scale from 1 to 7, where 7 reflects a higher quality of life). An increase in the AQLQ score indicates a better quality of life. The average of the 6-, 9-, and 12-month differences in the AQLQ Score are referred to as the Integrated AQLQ Score." (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Units on a scale (Mean) |
|---|---|
| Alair | 1.35 |
| Sham | 1.16 |
Change between Baseline and 12-month Follow-Up Visit. The peak expiratory flow rate measures the maximal rate at which a person can exhale air. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | L/Min (Mean) |
|---|---|
| Alair | 27.8 |
| Sham | 22.3 |
Change between Baseline and 12-Month Follow-up Visit. Average number of puffs per week. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Puffs/7 Days (Mean) |
|---|---|
| Alair | -6.0 |
| Sham | -4.3 |
Change between Baseline and 12-Month Follow-up Visit. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Percent Change (Mean) |
|---|---|
| Alair | -24.0 |
| Sham | -22.0 |
Change between Baseline and 12-month Follow-Up Visit. Symptom-Free Days were defined as days when Subject reported no cough, wheeze, breathlessness, or sputum during the daytime, and no wheeze, cough, or awakenings due to asthma symptoms during nighttime. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Percent Change (Mean) |
|---|---|
| Alair | 24.4 |
| Sham | 21.0 |
Percent of subjects experiencing worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Percent of Subjects (Number) |
|---|---|
| Alair | 26.3 |
| Sham | 39.8 |
Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Percent Change (Mean) |
|---|---|
| Alair | -2.8 |
| Sham | -2.4 |
Change between Baseline and 12-month Follow-Up Visit. The FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Percent Change (Mean) |
|---|---|
| Alair | -1.4 |
| Sham | -0.1 |
Rate of occurrence of worsening of asthma requiring treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a Subject taking maintenance oral corticosteroids at Study entry. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Events/Subject/Year (Mean) |
|---|---|
| Alair | 0.48 |
| Sham | 0.70 |
Change from Baseline and 12-month Follow-Up Visit. Total Symptom Score comprises the sum of these six asthma symptom measurements: wheeze during the night, cough during the night, wheeze during the day, cough during the day, breathlessness during the day, and sputum production during the day. Each of these symptoms is scored on a scale of 0 to 3 each day by the subject. The sum of the scores for these 6 symptoms comprises the Total Symptom Score, which measures overall asthma symptoms. The maximum score possible is 18. A lower Total Symptom score represents better asthma control. (NCT00231114)
Timeframe: Baseline, 12 Months
| Intervention | Units on a scale (Mean) |
|---|---|
| Alair | -1.7 |
| Sham | -1.6 |
(NCT00231114)
Timeframe: 12 Months
| Intervention | Events/Subject/Year (Mean) |
|---|---|
| Alair | 0.28 |
| Sham | 0.36 |
Pull down menu does not have a rate unit. Rate of Emergency Room Visits for Respiratory Symptoms (number of Events/number of Subjects/year) (NCT00401986)
Timeframe: 2-year, 3-year, 4-year and 5-year follow up post procedure
| Intervention | Number of events/number of subject/Year (Number) | |||
|---|---|---|---|---|
| Year 2, n=14 | Year 3, n=14 | Year 4, n=12 | Year 5, n=12 | |
| Alair Group | 0.3 | 0 | 0 | 0.1 |
Pull down menu does not have a rate unit. Rate of Hospitalizations for Respiratory Symptoms (number of Events/number of Subject/year) (NCT00401986)
Timeframe: 2-year, 3-year, 4-year and 5-year follow up post procedure
| Intervention | Number of events/number of subject/Year (Number) | |||
|---|---|---|---|---|
| Year 2, n=14 | Year 3, n=14 | Year 4, n=12 | Year 5, n=12 | |
| Alair Group | 0.4 | 0.2 | 0.1 | 0.1 |
The respiratory-related adverse event profile for the Alair group was analyzed on an annual basis in order to highlight trends in adverse occurrence. (NCT00401986)
Timeframe: 2-year, 3-year, 4-year and 5-year follow up post procedure
| Intervention | percentage subjects with respiratory AEs (Number) | |||
|---|---|---|---|---|
| Year 2, n=14 | Year 3, n=14 | Year 4, n=12 | Year 5, n=12 | |
| Alair Group | 78.6 | 85.7 | 83.3 | 100 |
Pull down menu does not have a rate unit. Numbers reported represents Rate of Respiratory Adverse (number of Events/number of Subject/year). (NCT00401986)
Timeframe: 2-year, 3-year, 4-year and 5-year follow up post procedure
| Intervention | Number of events/number of subject/Year (Number) | |||
|---|---|---|---|---|
| Year 2, n=14 | Year 3, n=14 | Year 4, n=12 | Year 5, n=12 | |
| Alair Group | 1.4 | 2.4 | 1.7 | 2.4 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization. Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Weeks 1-12
| Intervention | Liters per minute (L/min) (Least Squares Mean) |
|---|---|
| Placebo | 14.2 |
| Vilanteral 25 µg OD | 28.0 |
| Salmeterol 50 µg BID | 23.6 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization. Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Weeks 1-12
| Intervention | Liters per minute (L/min) (Least Squares Mean) |
|---|---|
| Placebo | 11.0 |
| Vilanteral 25 µg OD | 24.9 |
| Salmeterol 50 µg BID | 18.8 |
The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Weeks 1-12
| Intervention | Percentage of rescue-free 24-hr periods (Least Squares Mean) |
|---|---|
| Placebo | 14.6 |
| Vilanteral 25 µg OD | 21.7 |
| Salmeterol 50 µg BID | 22.9 |
Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Weeks 1-12
| Intervention | Percentage of symptom-free 24-hr periods (Least Squares Mean) |
|---|---|
| Placebo | 12.7 |
| Vilanteral 25 µg OD | 19.4 |
| Salmeterol 50 µg BID | 19.5 |
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12. The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment. (NCT01181895)
Timeframe: Baseline and Week 12
| Intervention | Liters (Least Squares Mean) |
|---|---|
| Placebo | 0.289 |
| Vilanteral 25 µg OD | 0.359 |
| Salmeterol 50 µg BID | 0.283 |
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12). The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. Analysis was performed separately for each planned time point. (NCT01181895)
Timeframe: Baseline and Week 12
| Intervention | Liters (Least Squares Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Predose, n=97,104,101 | 5 min, n=95,100,98 | 15 min, n=96, 101, 99 | 30 min, n=,96,101,100 | 60 min, n=96, 101, 100 | 2 hours, n=96, 100, 99 | 3 hours, n=96, 101, 100 | 4 hours, n=96, 101, 100 | 5 hours, n=96, 100, 100 | 11 hours, n=94, 99, 96 | 12 hours, n=93,98,95 | 12.5 hours, n=96, 97, 98 | 13 hours, 96, 98, 100 | 14 hours, n=95, 99, 99 | 16 hours, n=95, 98, 97 | 20 hours, n= 94, 101, 99 | 23 hours, 94, 101, 99 | 24 hours, n= 95, 101, 100 | |
| Placebo | 0.302 | 0.313 | 0.308 | 0.322 | 0.336 | 0.313 | 0.304 | 0.311 | 0.292 | 0.195 | 0.250 | 0.270 | 0.312 | 0.341 | 0.364 | 0.318 | 0.310 | 0.301 |
| Salmeterol 50 µg BID | 0.233 | 0.214 | 0.257 | 0.272 | 0.296 | 0.335 | 0.316 | 0.293 | 0.279 | 0.179 | 0.217 | 0.282 | 0.304 | 0.359 | 0.357 | 0.296 | 0.271 | 0.275 |
| Vilanteral 25 µg OD | 0.272 | 0.301 | 0.324 | 0.344 | 0.352 | 0.369 | 0.374 | 0.359 | 0.368 | 0.312 | 0.341 | 0.337 | 0.341 | 0.401 | 0.371 | 0.371 | 0.345 | 0.330 |
At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often. (NCT01181895)
Timeframe: Week 4 and Week 12
| Intervention | Participants (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4, AS: Much better, n=110, 109, 110 | Week 4, AS: Somewhat better, n=110, 109, 110 | Week 4, AS: A little better, n=110, 109, 110 | Week 4, AS: The same, n=110, 109, 110 | Week 4, AS: A little worse, n=110, 109, 110 | Week 4, AS: Somewhat worse, n=110, 109, 110 | Week 4, AS: Much worse, n=110, 109, 110 | Week 4, RMU: Much less often, n=110, 109, 110 | Week 4, RMU: Somewhat less often, n=110, 109, 110 | Week 4, RMU: A little less often, n=110, 109, 110 | Week 4, RMU: The same, n=110, 109, 110 | Week 4, RMU: A little more often, n=110, 109, 110 | Week 4, RMU: Somewhat more often, n=110, 109, 110 | Week 4, RMU: Much more often, n=110, 109, 110 | Week 12, AS: Much better, n=100, 105, 101 | Week 12, AS: Somewhat better, n=100, 105, 101 | Week 12, AS: A little better, n=100, 105, 101 | Week 12, AS: The same, n=100, 105, 101 | Week 12, AS: A little worse, n=100, 105, 101 | Week 12, AS: Somewhat worse, n=100, 105, 101 | Week 12, AS: Much worse, n=100, 105, 101 | Week 12, RMU: Much less often, n=100, 105, 101 | Week 12, RMU: Somewhat less often, n=100, 105, 101 | Week 12, RMU: A little less often, n=100, 105, 101 | Week 12, RMU: The same, n=100, 105, 101 | Week 12, RMU: A little more often, n=100, 105, 101 | Week 12, RMU: Somewhat more often, n=100, 105, 101 | Week 12, RMU: Much more often, n=100, 105, 101 | |
| Placebo | 25 | 35 | 24 | 17 | 6 | 2 | 1 | 18 | 40 | 18 | 26 | 4 | 2 | 2 | 31 | 35 | 13 | 12 | 4 | 4 | 1 | 25 | 31 | 13 | 23 | 2 | 4 | 2 |
| Salmeterol 50 µg BID | 34 | 34 | 21 | 16 | 3 | 2 | 0 | 28 | 36 | 20 | 17 | 7 | 2 | 0 | 35 | 34 | 16 | 11 | 4 | 1 | 0 | 32 | 29 | 13 | 21 | 4 | 2 | 0 |
| Vilanteral 25 µg OD | 37 | 43 | 14 | 13 | 1 | 0 | 1 | 33 | 31 | 23 | 18 | 3 | 0 | 1 | 52 | 31 | 9 | 9 | 2 | 1 | 1 | 40 | 32 | 16 | 11 | 5 | 0 | 1 |
The number of participants with a >=12% and >=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a >=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points. Participants who did not achieve a >=12% and >=200 mL increase from Baseline in FEV1 over this time period were considered censored. (NCT01181895)
Timeframe: Day 1 and Week 12
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, 5 min, n=113, 115, 116 | Day 1, 15 min, n=113, 115, 116 | Day 1, 30 min, n=113, 115, 1116 | Day 1, 1 hr, n=113, 115, 116 | Day 1, 2 hr, n=113, 115, 116 | Day 1, Censored, n=113, 115, 116 | Week 12, 5 min, n=96, 101, 100 | Week 12, 15 min, n=96, 101, 100 | Week 12, 30 min, n=96, 101, 100 | Week 12, 1 hr, n=96, 101, 100 | Week 12, 2 hr, n=96, 101, 100 | Week 12, Censored, n=96, 101, 100 | |
| Placebo | 23 | 2 | 3 | 3 | 5 | 77 | 39 | 6 | 2 | 1 | 3 | 45 |
| Salmeterol 50 µg BID | 18 | 11 | 13 | 6 | 11 | 57 | 30 | 7 | 8 | 5 | 4 | 46 |
| Vilanteral 25 µg OD | 33 | 11 | 8 | 7 | 6 | 50 | 42 | 2 | 2 | 4 | 7 | 44 |
Patient disposition is measured as subjects requiring further treatment and being admitted to hospital. We record the number of patients in each cohort that required admission to the hospital after being evaluated and treated in the Emergency Department. (NCT02777125)
Timeframe: 6 hours
| Intervention | Participants admitted to the Hospital (Number) |
|---|---|
| Albuterol by Metered Dose Inhaler | 53 |
| Albuterol Breath Actuated Nebulizer | 57 |
Defined as a repeat visit to the Emergency Department for a complaint related to their wheezing, within 7 days of initial enrollment in the study. (NCT02777125)
Timeframe: Within 7 days of initial presentation
| Intervention | Participants (Count of Participants) |
|---|---|
| Albuterol by Metered Dose Inhaler | 5 |
| Albuterol Breath Actuated Nebulizer | 4 |
Defined as a patient needing ondansetron for symptomatic relief of their nausea after initiating therapy in the Emergency Department. (NCT02777125)
Timeframe: 6 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Albuterol by Metered Dose Inhaler | 14 |
| Albuterol Breath Actuated Nebulizer | 18 |
Defined as anytime after initiation of therapy when the patient's heart rate exceeded age adjusted normal sinus rhythm heart rates for their age. Not uncommonly, patient's experience tachycardia as an unintended side effect of receiving albuterol. Tachycardia can result in a patient requiring further observation in the Emergency department and therefore increasing Emergency Department length of stay. We want to determine if indeed tachycardia is unavoidable, or if its presence suggests that patients are receiving too much albuterol or if albuterol is being given by the wrong appliance. (NCT02777125)
Timeframe: 6 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Albuterol by Metered Dose Inhaler | 101 |
| Albuterol Breath Actuated Nebulizer | 141 |
Emergency department length of stay is defined as the point of time when the patient checked into the Emergency Department to the time of final disposition. (NCT02777125)
Timeframe: 6 hours
| Intervention | minutes (Mean) | |
|---|---|---|
| Mild severity | Moderate severity | |
| Albuterol Breath Actuated Nebulizer | 197 | 245 |
| Albuterol by Metered Dose Inhaler | 192 | 232 |
Qaw will be measured before and 15 min after albuterol inhalation (NCT01210170)
Timeframe: change in Qaw 15 minutes after albuterol inhalation
| Intervention | percent change in Qaw (Mean) |
|---|---|
| 400 mcg Mometasone 30 Minutes Before Albuterol | 18 |
| Mometasone Placebo 30 Minutes Before Albuterol | 0 |
| 400 mcg Mometasone and Albuterol Simultaneously | 30 |
| Mometasone Placebo and Albuterol Simultaneously | -2 |
| 400 mcg Mometasone 60 Minutes Before Albuterol | NA |
| Mometasone Placebo 60 Minutes Before Albuterol | NA |
| 200 mcg Mometasone and Albuterol Simultaneously | NA |
| 200 mcg Mometasone 60 Minutes Before Albuterol | NA |
| 200 mcg Mometasone 30 Minutes Before Albuterol | NA |
FEV1 will be measured before and after inhalation of 180 mcg albuterol. (NCT01210170)
Timeframe: 15 minutes after albuterol inhalation
| Intervention | liters (Mean) |
|---|---|
| All Participants Received 400 mcg Mometasone-30 Min | 0.27 |
| All Participants Received Placebo 30 Minutes Before Albuterol | 0.18 |
| All Participants Received 400 mcg Mometasone Simultaneous | 0.32 |
| All Participants Received Placebo Simultaneously With Albutero | 0.20 |
| All Participants Received 200 mcg Mometasone-30 Min | 0.23 |
| All Participants Received 400 mcg -60 Min | NA |
| All Participants Received Placebo -60 Min | NA |
| All Participants Received 200 mcg Mometasone Simultaneous | NA |
| All Participants Received 200 mcg -60 Min | NA |
"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 1.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01424813)
Timeframe: Day 1
| Intervention | L*hr (Mean) |
|---|---|
| Placebo MDPI | 0.52 |
| Albuterol MDPI | 1.58 |
"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 8.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01424813)
Timeframe: Day 8
| Intervention | L*hr (Mean) |
|---|---|
| Placebo MDPI | 0.26 |
| Albuterol MDPI | 0.99 |
"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day. The baseline-adjustment refers to change from baseline at each post dose timepoint recorded on Day 85.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01424813)
Timeframe: Day 85
| Intervention | L*hr (Mean) |
|---|---|
| Placebo MDPI | 0.06 |
| Albuterol MDPI | 0.74 |
"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average (by the trapezoidal rule) of FEV1 AUC 0-6 measures adjusted for the baseline measure (i.e., change from baseline at each timepoint) recorded on days 1, 8 and 85 of the treatment period. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01424813)
Timeframe: Day 1, Day 8 and Day 85
| Intervention | L*hr (Mean) |
|---|---|
| Placebo MDPI | 0.28 |
| Albuterol MDPI | 1.11 |
Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01424813)
Timeframe: Day 1 to Day 92
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Severe adverse events | Treatment-related AE | Deaths | Other serious AEs | Withdrawn from study due to AEs | |
| Albuterol MDPI | 22 | 1 | 1 | 0 | 0 | 0 |
| Placebo MDPI | 25 | 1 | 1 | 0 | 0 | 0 |
"For both standard and serial vital signs, participants were seated for at least 5 minutes before vital signs were assessed. Heart rate was obtained prior to the blood pressure measurement. Serial heart rate and blood pressure were conducted in the sitting position prior to the spirometry assessment; baseline measures were taken pre-dose at -30 ± 5 and -5 minutes on Day 1. Day 85 serial vital sign measures were taken in the sitting position prior to spirometry assessments pre-dose at -30 ± 5 and -5 minutes, then post-dose at 30 (±5) minutes, 1hr (± 10 min), 2hr (± 10 min), 3hr (± 10 min), 4hr (± 10 min), 5hr (± 10 min) and 6 hr (± 10 min).~Serial heart rate and blood pressure measurements that were elevated to the following criteria were considered clinically significant:~Systolic blood pressure: > 160 beats/minute Diastolic blood pressure: >100 beats/minute Heart rate: >120 beats/minute" (NCT01424813)
Timeframe: Day 8, Day 85
| Intervention | participants (Number) | ||
|---|---|---|---|
| Systolic blood pressure - high | Diastolic blood pressure - high | Heart rate - high | |
| Albuterol MDPI | 0 | 1 | 1 |
| Placebo MDPI | 3 | 3 | 0 |
Physical exam was recorded as normal or abnormal based on physician assessment. Format for results is: Test Baseline/Endpoint HEENT = head, eyes, ears, nose, throat (NCT01424813)
Timeframe: Day 1 (Baseline), Day 85
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General appearance Normal/Normal | General appearance Normal/Abnormal | General appearance Abnormal/Normal | General appearance Abnormal/Abnormal | HEENT Normal/Normal | HEENT Normal/Abnormal | HEENT Abnormal/Normal | HEENT Abnormal/Abnormal | Chest and Lungs Normal/Normal | Chest and Lungs Normal/Abnormal | Chest and Lungs Abnormal/Normal | Chest and Lungs Abnormal/abnormal | Heart Normal/Normal | Heart Normal/Abnormal | Heart Abnormal/Normal | Heart Abnormal/Abnormal | Abdomen Normal/Normal | Abdomen Normal/Abnormal | Abdomen Abnormal/Normal | Abdomen Abnormal/Abnormal | Musculoskeletal Normal/Normal | Musculoskeletal Normal/Abnormal | Musculoskeletal Abnormal/Normal | Musculoskeletal Abnormal/Abnormal | Skin Normal/Normal | Skin Normal/Abnormal | Skin Abnormal/Normal | Skin Abnormal/Abnormal | Lymph nodes Normal/Normal | Lymph nodes Normal/Abnormal | Lymph nodes Abnormal/Normal | Lymph nodes Abnormal/Abnormal | Neurological Normal/Normal | Neurological Normal/Abnormal | Neurological Abnormal/Normal | Neurological Abnormal/Abnormal | |
| Albuterol MDPI | 76 | 0 | 1 | 1 | 50 | 5 | 12 | 11 | 67 | 4 | 7 | 0 | 77 | 0 | 1 | 0 | 77 | 0 | 1 | 0 | 76 | 1 | 1 | 0 | 73 | 1 | 4 | 0 | 78 | 0 | 0 | 0 | 78 | 0 | 0 | 0 |
| Placebo MDPI | 76 | 0 | 1 | 0 | 46 | 12 | 11 | 8 | 66 | 8 | 2 | 1 | 76 | 0 | 1 | 0 | 75 | 1 | 0 | 1 | 74 | 0 | 3 | 0 | 75 | 0 | 2 | 0 | 77 | 0 | 0 | 0 | 76 | 1 | 0 | 0 |
Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Day 8
| Intervention | pg*hr/mL (Mean) |
|---|---|
| Albuterol MDPI | 3605 |
Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Day 1
| Intervention | pg*hr/mL (Mean) |
|---|---|
| Albuterol MDPI | 2278 |
"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01747629)
Timeframe: Day 1
| Intervention | L*hr (Mean) |
|---|---|
| Placebo MDPI | 0.58 |
| Albuterol MDPI | 1.63 |
"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01747629)
Timeframe: Day 8
| Intervention | L*hr (Mean) |
|---|---|
| Placebo MDPI | 0.37 |
| Albuterol MDPI | 1.15 |
"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure. The baseline was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01747629)
Timeframe: Day 85
| Intervention | L*hr (Mean) |
|---|---|
| Placebo MDPI | 0.20 |
| Albuterol MDPI | 1.12 |
"FEV1 AUC 0-6 is the area under the effect-time curve from time 0 (pre-dose) up to 6 hours post-dose. It represents the weighted average (by the trapezoidal rule) over six hours of the FEV1 AUC 0-6 measures adjusted for the baseline measure (i.e., change from baseline at each timepoint) recorded on days 1, 8 and 85 of the treatment period. The baseline for each study day was the average of the 2 pre-dose FEV1 measurements on that study day.~FEV1 was measured using spirometry. Spirometry assessments were obtained predose at -30 ± 5, and - 5 minutes, then post dose at 5 ± 2, 15 ± 5, 30 ± 5, 45 ± 5 minutes, and at 1hr ± 5 min, 2hr ± 5 min, 3hr ± 5 min, 4hr ± 5 min, 5hr ± 5 min, and 6hr ± 5 min." (NCT01747629)
Timeframe: Day 1, Day 8 and Day 85
| Intervention | L*hr (Mean) |
|---|---|
| Placebo MDPI | 0.38 |
| Albuterol MDPI | 1.30 |
"Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min).~AUC0-t on Day 8 is not from pre-dose but at steady state." (NCT01747629)
Timeframe: Days 1 and 8
| Intervention | pg*hr/mL (Mean) | |
|---|---|---|
| Day 1 | Day 8 | |
| Albuterol MDPI | 1747 | 2165 |
"Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min).~AUC0-6 on Day 8 is not from pre-dose but at steady state." (NCT01747629)
Timeframe: Days 1 and 8
| Intervention | pg*hr/mL (Mean) | |
|---|---|---|
| Day 1 | Day 8 | |
| Albuterol MDPI | 1325 | 2163 |
Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Days 1 and 8
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Day 1 | Day 8 | |
| Albuterol MDPI | 347.2 | 499.1 |
Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01747629)
Timeframe: Day 1 to Day 93
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Severe adverse event | Treatment-related adverse event | Deaths | Other serious adverse event | Withdrawn from study due to adverse event | |
| Albuterol MDPI | 22 | 1 | 1 | 0 | 2 | 2 |
| Placebo MDPI | 36 | 3 | 2 | 0 | 0 | 1 |
"For both standard and serial vital signs, participants were seated for at least 5 minutes before vital signs were assessed. Heart rate was obtained prior to the blood pressure measurement. Serial heart rate and blood pressure were conducted in the sitting position prior to the spirometry assessment; baseline measures were taken pre-dose at -30 ± 5 and -5 minutes on Day 1. Day 85 serial vital sign measures were taken in the sitting position prior to spirometry assessments pre-dose at -30 ± 5 and -5 minutes, then post-dose at 30 (±5) minutes, 1hr (± 10 min), 2hr (± 10 min), 3hr (± 10 min), 4hr (± 10 min), 5hr (± 10 min) and 6 hr (± 10 min).~Serial heart rate and blood pressure measurements that were elevated to the following criteria were considered clinically significant:~Systolic blood pressure: > 160 beats/minute Diastolic blood pressure: >100 beats/minute Heart rate: >120 beats/minute" (NCT01747629)
Timeframe: Days 8 and 85
| Intervention | participants (Number) | ||
|---|---|---|---|
| Systolic blood pressure - high | Diastolic blood pressure - high | Heart rate - high | |
| Albuterol MDPI | 3 | 2 | 0 |
| Placebo MDPI | 2 | 2 | 0 |
Physical exam was recorded as normal or abnormal based on physician assessment. Format for results is: Test Baseline/Endpoint. HEENT = head, eyes, ears, nose, throat. (NCT01747629)
Timeframe: Day 1 (Baseline), Day 85
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General appearance Normal/Normal | General appearance Normal/Abnormal | General appearance Abnormal/Normal | General appearance Abnormal/Abnormal | HEENT Normal/Normal | HEENT Normal/Abnormal | HEENT Abnormal/Normal | HEENT Abnormal/Abnormal | Chest and Lungs Normal/Normal | Chest and Lungs Normal/Abnormal | Chest and Lungs Abnormal/Normal | Chest and Lungs Abnormal/Abnormal | Heart Normal/Normal | Heart Normal/Abnormal | Heart Abnormal/Normal | Heart Abnormal/Abnormal | Abdomen Normal/Normal | Abdomen Normal/Abnormal | Abdomen Abnormal/Normal | Abdomen Abnormal/Abnormal | Musculoskeletal Normal/Normal | Musculoskeletal Normal/Abnormal | Musculoskeletal Abnormal/Normal | Musculoskeletal Abnormal/Abnormal | Skin Normal/Normal | Skin Normal/Abnormal | Skin Abnormal/Normal | Skin Abnormal/Abnormal | Lymph nodes Normal/Normal | Lymph nodes Normal/Abnormal | Lymph nodes Abnormal/Normal | Lymph nodes Abnormal/Abnormal | Neurological Normal/Normal | Neurological Normal/Abnormal | Neurological Abnormal/Normal | Neurological Abnormal/Abnormal | |
| Albuterol MDPI | 72 | 1 | 0 | 1 | 52 | 2 | 5 | 15 | 64 | 3 | 7 | 0 | 70 | 1 | 0 | 3 | 71 | 1 | 0 | 2 | 72 | 1 | 0 | 1 | 63 | 1 | 4 | 6 | 74 | 0 | 0 | 0 | 74 | 0 | 0 | 0 |
| Placebo MDPI | 81 | 0 | 0 | 2 | 59 | 1 | 7 | 16 | 76 | 2 | 3 | 2 | 82 | 0 | 0 | 1 | 82 | 0 | 0 | 1 | 81 | 1 | 0 | 1 | 69 | 5 | 2 | 7 | 83 | 0 | 0 | 0 | 83 | 0 | 0 | 0 |
Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Days 1 and 8
| Intervention | hour (Mean) | |
|---|---|---|
| Day 1 | Day 8 | |
| Albuterol MDPI | 4.7 | 5.7 |
Pharmacokinetic parameters of albuterol were determined on Day 1 after the first dose administration and at steady-state on Day 8. Day 1 serial (10-hr) blood samples for pharmacokinetics pre-dose (within 30 minutes prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5, 6, 8 and 10 hours (±10 minutes). Day 8 serial (6-hr) blood samples for pharmacokinetics pre-dose (within 30 min prior to dosing), and post-dose at the following times: 15 (±5) min, 30 (±5) min, and 1, 2, 3, 4, 5 and 6 hr (±10 min). (NCT01747629)
Timeframe: Days 1 and 8
| Intervention | hour (Median) | |
|---|---|---|
| Day 1 | Day 8 | |
| Albuterol MDPI | 0.48 | 0.44 |
"Participants were seated at least 2 minutes before blood pressure measurements were obtained by either an electronic or manual sphygmomanometer.~Week 12 values represent change from Week 0. Week 52 values represent change from Week 12." (NCT01698320)
Timeframe: Week 0, Week 12 and Week 52
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Systolic BP Week 12 (n=166, 155) | Systolic BP Week 52 (n=159, 155) | Diastolic BP Week 12 (n=166, 155) | Diastolic BP Week 52 (n=159, 155) | |
| Albuterol MDPI-Albuterol MDPI | 0.2 | 0.7 | 0.3 | 1.0 |
| Placebo MDPI-Albuterol MDPI | 1.0 | -0.4 | 0.0 | 0.2 |
"Participants were seated at least 2 minutes before pulse measurements were obtained by radial pulse.~Week 12 values represent change from Week 0. Week 52 values represent change from Week 12." (NCT01698320)
Timeframe: Week 0, Week 12 and Week 52
| Intervention | beats/minute (Mean) | |
|---|---|---|
| Pulse Week 12 (n=166, 155) | Pulse Week 52 (n=159, 155) | |
| Albuterol MDPI-Albuterol MDPI | 0.9 | -0.3 |
| Placebo MDPI-Albuterol MDPI | -0.1 | -0.4 |
A standard 12-lead ECG was performed at screening, week 12, and week 52 or early termination/discontinuation. The ECG recording methods were centralized and standardized across all study participants. A centralized cardiologist was responsible for providing all ECG interpretations. (NCT01698320)
Timeframe: Weeks 0 (screening visit), 12, and 52
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 0: Normal | Week 0: Abnormal, not clinically relevant | Week 0: Abnormal, clinically relevant | Week 12: Normal (n=166, 155) | Week 12: Abnormal, not clinically relevant | Week 12: Abnormal, clinically relevant | Week 52: Normal (n=152, 161) | Week 52: Abnormal, not clinically relevant | Week 52: Abnormal, clinically relevant | |
| Albuterol MDPI-Albuterol MDPI | 154 | 14 | 0 | 140 | 15 | 0 | 148 | 13 | 0 |
| Placebo MDPI-Albuterol MDPI | 151 | 19 | 0 | 143 | 23 | 0 | 138 | 23 | 1 |
"The physical exam was performed by a qualified healthcare professional, and when possible, the same qualified healthcare professional that performed the physical examination at study screening performed all the scheduled physical examinations. Abnormalities and clinical relevance were determined by the qualified healthcare professional.~HEENT = head, eyes, ears, nose, throat" (NCT01698320)
Timeframe: Weeks 0, 12 and 52
| Intervention | participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General appearance - Week 0 (n=170, 167) | General appearance - Week 12 (n=166, 155) | General appearance - Week 52 (n=162, 161) | HEENT - Week 0 (n=170, 167) | HEENT - Week 12 (n=166, 155) | HEENT - Week 52 (n=162, 161) | Chest and lungs - Week 0 (n=170, 167) | Chest and lungs - Week 12 (n=166, 155) | Chest and lungs - Week 52 (n=162, 161) | Heart - Week 0 (n=170, 167) | Heart - Week 12 (n=166, 155) | Heart - Week 52 (n=162, 161) | Abdomen - Week 0 (n=168, 167) | Abdomen - Week 12 (n=166, 155) | Abdomen - Week 52 (n=162, 161) | Musculoskeletal - Week 0 (n=169, 167) | Musculoskeletal - Week 12 (n=166, 155) | Musculoskeletal - Week 52 (n=162, 161) | Skin - Week 0 (n=169, 167) | Skin - Week 12 (n=167, 155) | Skin - Week 52 (n=162, 161) | Lymph Nodes - Week 0 (n=169, 167) | Lymph Nodes - Week 120 (n=166, 155) | Lymph Nodes - Week 52 (n=162, 161) | Neurological - Week 0 (n=169, 167) | Neurological - Week 12 (n=166, 155) | Neurological - Week 52 (n=162, 161) | Extremities/back - Week 0 (n=169, 167) | Extremities/back - Week 12 (n=166, 155) | Extremities/back - Week 52 (n=162, 160) | |
| Albuterol MDPI-Albuterol MDPI | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo MDPI-Albuterol MDPI | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01698320)
Timeframe: Day 1 to Week 12
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Severe adverse event | Treatment-related adverse event | Deaths | Other serious adverse events | Withdrawn from treatment due to adverse events | |
| Albuterol MDPI-Albuterol MDPI | 84 | 3 | 5 | 0 | 0 | 1 |
| Placebo MDPI-Albuterol MDPI | 105 | 6 | 1 | 0 | 1 | 1 |
Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01698320)
Timeframe: Weeks 13-52
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Severe adverse event | Treatment-related adverse event | Deaths | Other serious adverse events | Withdrawn from treatment due to adverse events | |
| Albuterol MDPI-Albuterol MDPI | 94 | 13 | 1 | 0 | 4 | 2 |
| Placebo MDPI-Albuterol MDPI | 106 | 12 | 2 | 0 | 3 | 2 |
"Average Change in Asthma Control Score Per Participant Over 12 Months Using the Asthma Control Questionnaire (ACQ).~The ACQ has six questions regarding symptoms, rescue short-acting β-agonist use and one about FEV1 % predicted. A 7-point scale (0 = no impairment, 6 = maximum impairment) is used for each question and the ACQ score is the mean value of these questions - hence between 0 (totally controlled) and 6 (severely uncontrolled)." (NCT01290874)
Timeframe: from baseline to 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Tiotropium | -0.70 |
| Salmeterol or Formoterol | -0.66 |
"Average Change in Asthma Quality of Life Score Per Participant Over 12 Months Using the Asthma Quality of Life Questionnaire (AQLQ).~The AQLQ has 32 questions in four domains (symptoms, activity limitation, emotional function, and environmental stimuli) and measures the functional problems that are troublesome to individuals with asthma. Symptoms (11 items), Activity Limitation (12 items, 5 of which are individualized), Emotional Function (5 items), and Environmental Exposure (4 items); 7-point Likert scale (7 = not impaired at all - 1 = severely impaired); scores range 1-7, with higher scores indicating better quality of life." (NCT01290874)
Timeframe: from baseline to 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Tiotropium | 1.00 |
| Salmeterol or Formoterol | 1.02 |
"Average Change in Asthma Symptom Utility Score Per Participant Over 12 Months Using the Asthma Symptom Utility Index (ASUI).~The ASUI is an 11-item preference-based outcome measure used in clinical trials and cost-effectiveness studies for asthma and is designed to assess the frequency and severity of cough, wheeze, dyspnea, nighttime awakenings, and side effects, weighted according to patient preferences.~4-point Likert scale to assess frequency (not at all, 1 to 3 days, 4 to 7 days, and 8 to 14 days) and severity (not applicable, mild, moderate and severe); scores range from 0 (worst possible symptoms) to 1 (no symptoms)." (NCT01290874)
Timeframe: from baseline to 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Tiotropium | 0.11 |
| Salmeterol or Formoterol | 0.10 |
Average change in lung function (FEV1) evaluated by spirometry per participant over 12 months (NCT01290874)
Timeframe: from baseline to 12 months
| Intervention | liters (Mean) |
|---|---|
| Tiotropium | -0.018 |
| Salmeterol or Formoterol | 0.003 |
Average Change in Rescue Medication Use Per Participant Over 12 Months. Monthly questionnaires will evaluate the amount of rescue medication subjects have used on average, measured in puffs per day. (NCT01290874)
Timeframe: from baseline to 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Tiotropium | -0.92 |
| Salmeterol or Formoterol | -0.97 |
We summarize the survival experience using mean number of exacerbations/person-year and compare it using the log-rank test comparing kaplan-meier survival curve. (NCT01290874)
Timeframe: evaluated monthly (on average) via questionnaire for 12 months
| Intervention | event per person-year (Mean) |
|---|---|
| Tiotropium | 0.37 |
| Salmeterol or Formoterol | 0.42 |
"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome is calculated for each inhaler as beginning counter reading minus end counter reading minus patient-recorded number of dose cycles. The total inhaler discrepancy size is an important measure because it provides the most relevant means of ensuring that the inhaler does not exhaust its supply of albuterol before the counter has recorded the labeled 200 doses." (NCT01857323)
Timeframe: Day 1 - Day 50
| Intervention | discrepancies/inhaler (Mean) |
|---|---|
| Albuterol Spiromax® | 2.0 |
"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures when the inhaler counter advances (decreases, e.g., 50 to 48) between dosing sessions but the participant has not knowingly executed the dose cycle (i.e., the counter number at the beginning of the dosing session is less than the counter number at the end of the previous dosing session). The discrepancy rate was calculated as number of discrepancies/total number of dose cycles *200." (NCT01857323)
Timeframe: Day 1 - Day 50
| Intervention | discrepancies/200 dose cycles (Number) |
|---|---|
| Albuterol Spiromax® | 0.43 |
"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures when the inhaler counter counts upwards (number increases, e.g. 50 to 52) rather than downward between dosing sessions but the participant has not knowingly executed the dose cycle (i.e., the counter number at the beginning of the dosing session is greater than the counter number at the end of the previous dosing session). The discrepancy rate was calculated as number of discrepancies/total number of dose cycles *200." (NCT01857323)
Timeframe: Day 1 - Day 50
| Intervention | discrepancies/200 dose cycles (Number) |
|---|---|
| Albuterol Spiromax® | 0.17 |
"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures when the inhaler counter reading increases, instead of decreases, after the participant has executed the dose cycle (i.e., the ending counter reading is greater than the beginning counter reading within a dosing session). The discrepancy rate was calculated as number of discrepancies/total number of dose cycles *200." (NCT01857323)
Timeframe: Day 1 - Day 50
| Intervention | discrepancies/200 dose cycles (Number) |
|---|---|
| Albuterol Spiromax® | 2.46 |
"The purpose of the study is to determine if the dose counter on Albuterol Spiromax is counting accurately; accuracy is determined by concordance/agreement between patient-reported Albuterol Spiromax counter readings and patient-reported dose cycles recorded in patient diaries. This outcome measures how often the dose cycle was not counted: the participant completes a full dose cycle (opens the mouthpiece cap, inhales the medication, and closes the mouthpiece cap) but the counter display does not advance (i.e., does not count down) within a dosing session. The discrepancy rate was calculated as number of discrepancies/total number of dose cycles *200." (NCT01857323)
Timeframe: Day 1 - Day 50
| Intervention | discrepancies/200 dose cycles (Number) |
|---|---|
| Albuterol Spiromax® | 2.05 |
Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01857323)
Timeframe: Day 1 to Day 50
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Severe adverse event | Treatment-related adverse event | Deaths | Other serious adverse events | Withdrawn from study due to adverse event | |
| Albuterol Spiromax® | 85 | 2 | 7 | 0 | 2 | 1 |
Change from baseline after 4 weeks in ACQ score. Worst score - 6(most severe), best score - 0 (no symptoms) (NCT00818454)
Timeframe: Baseline, 4 weeks
| Intervention | Scores on scale (Least Squares Mean) |
|---|---|
| Albuterol HFA | -0.25 |
| Combivent CFC | -0.25 |
Change from baseline after 4 weeks in Forced Expiratory Volume Area Under (FEV1 AUC) the Curve from 0 to 6 hours. (NCT00818454)
Timeframe: Test day baseline and test day FEV1 AUC 0-6, after 4 weeks
| Intervention | liters (Least Squares Mean) |
|---|---|
| Albuterol HFA | 0.167 |
| Combivent CFC | 0.252 |
Change from baseline after 4 weeks in Forced Expiratory Volume Area Under the Curve from 0 to 6 hours (NCT00818454)
Timeframe: Test day baseline and test day FEV1 AUC 0-6, after 4 weeks
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo Respimat | 0.041 |
| Combivent Respimat | 0.236 |
Change from baseline after 4 weeks in Mini-AQLQ score. Worst score - 1 (most severe), best score - 7 (less severe) (NCT00818454)
Timeframe: Baseline, 4 weeks
| Intervention | Scores on scale (Least Squares Mean) |
|---|---|
| Albuterol HFA | 0.150 |
| Combivent CFC | 0.220 |
Change from baseline after 4 weeks in peak Forced Expiratory Volume response (NCT00818454)
Timeframe: Test day baseline and test day peak FEV1, after 4 weeks
| Intervention | liters (Least Squares Mean) |
|---|---|
| Placebo Respimat | 0.199 |
| Combivent Respimat | 0.412 |
Change from baseline after 4 weeks in peak Forced Expiratory Volume response (NCT00818454)
Timeframe: Test day baseline and test day peak FEV1, after 4 weeks
| Intervention | liters (Least Squares Mean) |
|---|---|
| Albuterol HFA | 0.357 |
| Combivent CFC | 0.434 |
Change from baseline in weekly mean of puffs of open-label albuterol used during day (NCT00818454)
Timeframe: Baseline, 4 weeks
| Intervention | Puffs (Least Squares Mean) |
|---|---|
| Albuterol HFA | -2.24 |
| Combivent CFC | -2.28 |
Change from baseline in weekly mean of puffs of open-label albuterol used during night (NCT00818454)
Timeframe: Baseline, 4 weeks
| Intervention | Puffs (Least Squares Mean) |
|---|---|
| Albuterol HFA | -0.92 |
| Combivent CFC | -0.93 |
Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during day (NCT00818454)
Timeframe: Baseline, 4 weeks
| Intervention | Puffs (Least Squares Mean) |
|---|---|
| Albuterol HFA | -0.49 |
| Combivent CFC | -0.53 |
Change from baseline in weekly mean of puffs of blinded study medication (albuterol HFA or combivent CFC) used during night (NCT00818454)
Timeframe: Baseline, 4 weeks
| Intervention | Puffs (Least Squares Mean) |
|---|---|
| Albuterol HFA | -0.10 |
| Combivent CFC | -0.12 |
FEV1 AUC0-6 was calculated using the linear trapezoidal rule, and baseline adjustment was made by subtracting the average of the 2 pre-dose FEV1 values from each post-dose FEV1 determination. (NCT01899144)
Timeframe: Treatment visits 1-5 (approximately days 1, 6, 11, 16, and 21); -35 and -5 minutes prior to dosing and 5 (±2), 15 (±5), 30 (±5), 45 (±5), 60 (±5), 120 (±5), 180 (±5), 240 (±5), 300 (±5), and 360 (±5) minutes after the completion of study drug administrati
| Intervention | L*hour (Mean) |
|---|---|
| Albuterol Spiromax 90 mcg | 0.88 |
| Albuterol Spiromax 180 mcg | 0.93 |
| ProAir HFA 90 mcg | 0.74 |
| ProAir HFA 180 mcg | 0.93 |
| Placebo | 0.48 |
"Percent predicted FEV1: measured FEV1 as a percent of the predicted values for the patients of similar characteristics. Predicted FEV1 values were computed and adjusted for age, height, and gender for patients aged 4-5 years (Eigen et al 2001) and for patients aged 6-11 years (Quanjer et al 1995) using ATS/European Thoracic Society (ERS) criteria applicable to pediatric patients (ATS/ERS 2007).~The percent predicted FEV1 (PPFEV1) area under the curve (AUC)0-6 was calculated using the linear trapezoidal rule, and baseline adjustment was made by subtracting the average of the 2 pre-dose PPFEV1 values from each post-dose PPFEV1 determination." (NCT01899144)
Timeframe: Treatment visits 1-5 (approximately days 1, 6, 11, 16, and 21); -35 and -5 minutes prior to dosing and 5 (±2), 15 (±5), 30 (±5), 45 (±5), 60 (±5), 120 (±5), 180 (±5), 240 (±5), 300 (±5), and 360 (±5) minutes after the completion of study drug administrati
| Intervention | %predicted FEV1*hour (Mean) |
|---|---|
| Albuterol Spiromax 90 mcg | 46.6 |
| Albuterol Spiromax 180 mcg | 48.0 |
| ProAir HFA 90 mcg | 37.9 |
| ProAir HFA 180 mcg | 49.1 |
| Placebo | 25.4 |
"Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator as mild (no limitation of usual activities), moderate, or severe (inability to carry out usual activities).~Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes." (NCT01899144)
Timeframe: Day 1 up to Day 35
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Treatment-related AE | Severe TEAE | Related TEAE | Death | Serious AE | TEAE leading to withdrawal | |
| Albuterol Spiromax 180 mcg | 2 | 0 | 0 | 0 | 0 | 0 |
| Albuterol Spiromax 90 mcg | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo | 1 | 0 | 0 | 0 | 0 | 0 |
| ProAir HFA 180 mcg | 1 | 0 | 0 | 0 | 0 | 0 |
| ProAir HFA 90 mcg | 5 | 0 | 0 | 0 | 0 | 0 |
Serial PEF measurements were obtained via spirometry. PEF measures for purpose of serial PEF assessment (pre and postdose) were collected from the spirometer assessed PEF, utilizing the values from the efforts selected based on the highest of 3 acceptable FEV1 maneuvers. (NCT02126839)
Timeframe: 30 ±5 and 5 ±2 minutes prior to dosing, and at 5 ±2, 15 ±5, 30 ±5, 45 ±5, 60 ±10, 120 ±10, 240 ±10, and 360 ±10 minutes after completion of dosing on Days 1 and 22
| Intervention | Liters/min*hour (Least Squares Mean) |
|---|---|
| Placebo MDPI QID | 71.52 |
| Albuterol MDPI 180 mcg QID | 147.85 |
Following measurement of the baseline FEV1 and dose administration on Days 1 and 22, FEV1 values (highest of 3 acceptable maneuvers) will be obtained at 5 (±2), 15 (±5), 30 (±5), 45 (±5), 60 (±10), 120 (±10), 240 (±10), and 360 (±10) minutes after the completion of dosing. Predicted FEV1 values were computed and adjusted for age, height, and gender according to Eigen et al (Eigen et al 2001) for participants 4 to 5 years of age and to Quanjer et al (Quanjer et al 1995) for participants aged 6 to 11 years using ATS criteria (American Thoracic Society/European Respiratory Society Statement 2007). (NCT02126839)
Timeframe: 30 ±5 and 5 ±2 minutes prior to dosing, and at 5 ±2, 15 ±5, 30 ±5, 45 ±5, 60 ±10, 120 ±10, 240 ±10, and 360 ±10 minutes after completion of dosing on Days 1 and 22
| Intervention | % predicted FEV1/hour (Least Squares Mean) |
|---|---|
| Placebo MDPI QID | 18.71 |
| Albuterol MDPI 180 mcg QID | 43.73 |
"Adverse events (AEs) summarized in this table are those that began or worsened after treatment with study drug (treatment-emergent AEs). An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator as mild (no limitation of usual activities), moderate, or severe (inability to carry out usual activities).~Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes." (NCT02126839)
Timeframe: 6 Months
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Severe adverse event | Treatment-related adverse event | Deaths | Other serious AE | Withdrawn from study due to AE | |
| Albuterol MDPI 180 mcg QID | 21 | 0 | 0 | 0 | 0 | 0 |
| Placebo MDPI QID | 21 | 0 | 0 | 0 | 0 | 0 |
The primary outcome was differential response to the three therapies on the basis of fixed threshold criteria for the following asthma control measures, which encompassed domains of risk and impairment: the time from the start of the treatment period to an asthma exacerbation treated with systemic corticosteroids, and the annualized number of asthma control days (ACDs) from within that period. ACDs were defined as full calendar days without symptoms, rescue medication use, or unscheduled healthcare visits. Children were defined as differential responders if, first, the time to an asthma exacerbation was at least four weeks longer, or second, if the number of annualized ACDs was at least 31 days more for one treatment than another, in that order. If neither threshold was met, the participant was considered a non differential responder. Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period. (NCT01606306)
Timeframe: The last 14 weeks of each 16-week treatment period
| Intervention | probability (Number) | |||
|---|---|---|---|---|
| Non-differential responders | Responded best to daily ICS | Responded best to daily LTRA | Responded best to as-needed ICS | |
| All Evaluable Participants | .26 | .40 | .18 | .16 |
"This is an observational study, the aim is to record a variety of MDI usage techniques performed by patients. The technique is scored out of 7 for the following 7 steps:~Shaking (0 = not shaken, 1 = shaken)~Coordination (0 = MDI actuated before inhalation start, 1 = MDI actuated after inhalation start)~Flow rate (0 = mean inspiratory flow rate <30L/min or greater than 60L/min, 1 = mean inspiratory flow rate between 30-60L/min)~Duration of inhalation (0 = duration of inhalation <3 sec, 1 = duration of inhalation >=3sec)~Orientation of inhaler (0 = inhaler not upright = > 30° from the vertical position, 1 = inhaler upright = within 30° from the vertical position)~Number of exhalation (0 = exhalation during inhaler use, 1 = no exhalations)~Single Actuation (0 = less than 0 or more than 1 inhaler actuation, 1 = exactly 1 inhaler actuation)~The total score is a minimum of 0 correct steps if all the steps are incorrect to a maximum of 7 correct steps." (NCT02447575)
Timeframe: Single event- Outcome measured per inhaler puff, during the single clinic visit.
| Intervention | correct steps (Mean) |
|---|---|
| MDI Use Evaluation | 3.52 |
The primary outcome was the change in asthma severity as determined by change in Pulmonary Asthma Score (PAS) before and after administration of intervention (or control). The same trained, blinded physician assessor, who was not involved in the care of the patient, assessed PAS scores for study subjects before intervention (or control), and 15 minutes after completion of administration. The PAS is a pediatric asthma severity scoring system adapted from previously validated scores, and includes measures of respiratory rate, oxygen saturation, auscultory findings, retractions, and dyspnea. Values from each category are summed producing a total score between 5 and 15. Total scores < 7 correspond with mild asthma exacerbations, while scores ≥ 7 and < 12 indicate moderate asthma, and scores ≥12 to 15 indicate severe asthma. The primary outcome was determined by subtracting the post-intervention score from the pre-intervention score. (NCT02494076)
Timeframe: 0-30 minutes
| Intervention | mean PAS score (Mean) |
|---|---|
| EzPAP | 0.9 |
| Standard Care | 0.4 |
Number of patients in each group requiring hospital admission (NCT02494076)
Timeframe: After intervention or control and until follow-up phone call 72 hours after disposition
| Intervention | Participants (Count of Participants) |
|---|---|
| EzPAP | 10 |
| Standard Care | 13 |
Second line therapies include: continuous albuterol, intravenous magnesium sulfate, subcutaneous or intravenous terbutaline, non-invasive ventilation (BiPAP or CPAP), and supplemental oxygen. The need for these second line therapies will be assessed by the child's treating team in the Emergency Department. (NCT02494076)
Timeframe: participants will be followed for the duration of ED stay, an expected average of 6-8 hours
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Continuous albuterol | Subcutaneous or intravenous terbutaline | Intravenous magnesium | Supplemental oxygen | |
| EzPAP | 11 | 0 | 1 | 2 |
| Standard Care | 15 | 1 | 3 | 7 |
Maximum percentage of predicted FEV1 effect (NCT00940927)
Timeframe: 15 minutes after each dose
| Intervention | percentage of predicted (Number) |
|---|---|
| Albuterol | 24.0 |
ED50 is the cumulative dose of albuterol required to bring about 50% of maximum effect of albuterol (NCT00940927)
Timeframe: 15 minutes after each dose
| Intervention | ug (Number) |
|---|---|
| Albuterol | 141 |
Mothers who smoked cigarettes during pregnancy and the rate of albuterol response of their infants (NCT02447250)
Timeframe: Smoking and second hand smoke exposure history will be obtained at enrollment. Albuterol response will be obtained within one week.
| Intervention | participants (Number) | |
|---|---|---|
| albuterol responders of mothers who smoked | albuterol responders of non-smoker mothers % | |
| Single Arm: Varied Albuterol Dose Response | 4 | 6 |
birth weight in grams of each subject was recorded at time of enrollment (NCT02447250)
Timeframe: within one week of entering study
| Intervention | grams (Mean) | |
|---|---|---|
| albuterol responders | albuterol non responders | |
| Single Arm: Varied Albuterol Dose Response | 847.2 | 1147.7 |
The primary outcome is the percentage of subjects who show a positive response to each dose of albuterol. A positive response is defined as a greater than or equal to 10% decrease in respiratory resistance (Rrs). The change in RRs was measured at baseline and again after each dose of albuterol. All measurements were taken within a 7 day time frame for each subject such that each subject would have up to 3 results measured during a 7 day period, if he/she were able to complete three sets of PFTs according to study protocol. The change in Rrs was calculated by subtracting the baseline Rrs from the post-albuterol Rrs. (NCT02447250)
Timeframe: Within one week of performing pulmonary function tests
| Intervention | cm h2o/mL/sec (Mean) | ||
|---|---|---|---|
| dose 1 | dose 2 | dose 3 | |
| Single Arm: Varied Albuterol Dose Response | 0.011 | 0.006 | 0.014 |
Reason for each subject's preterm delivery was classified as either preterm labor or delivery for maternal indications (eg pre-eclampsia). (NCT02447250)
Timeframe: within one week of entering study
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| preterm labor, responsive to albuterol | maternal indicated delivery, responsive to albuter | |
| Single Arm: Varied Albuterol Dose Response | 4 | 6 |
Family history was obtained from verbal history by subject's mother at time of enrollment in study. A positive family history was noted if a first degree relative of the subject (infant) had a diagnosis of asthma. (NCT02447250)
Timeframe: History collected at enrollment, albuterol response assessed within one week
| Intervention | participants (Number) | |
|---|---|---|
| family hx of asthma, respond to albuterol | no fam hx asthma, respond to albuterol | |
| Single Arm: Varied Albuterol Dose Response | 1 | 9 |
Average gestational age (GA) in weeks at birth for subjects who responded to albuterol versus subjects without a positive response (NCT02447250)
Timeframe: within one week of entering study
| Intervention | weeks (Mean) | |
|---|---|---|
| birth GA albuterol responders, weeks | birth GA albuterol non responders | |
| Single Arm: Varied Albuterol Dose Response | 26.7 | 28.5 |
Maternal BMI will be obtained from her medial record, and she will be asked about weight gain during pregnancy at time of enrollment. Results will be compared for infants born to women with a normal BMI vs. those with obese BMI (>30). (NCT02447250)
Timeframe: Maternal information collected at enrollment; albuterol response assessed within one week
| Intervention | kg/m^2 (Mean) | |
|---|---|---|
| mean BMI mothers of albuterol-responders , any dos | mean BMI mothers of albuterol non-responders | |
| Single Arm: Varied Albuterol Dose Response | 27.4 | 27.3 |
Compare number of subjects who have a positive response (greater than or equal to 10% decrease in respiratory resistance) to each dose of albuterol (NCT02447250)
Timeframe: Data collected 15 minutes after dose in each session. Study includes 3 sessions within a 7 day period.
| Intervention | participants (Number) | ||
|---|---|---|---|
| positive Rrs response at 180 mcg albuterol | positive Rrs response at 270 mcg albuterol | positive Rrs response at 360 mcg albuterol | |
| Single Arm: Varied Albuterol Dose Response | 6 | 4 | 4 |
ED and hospital admission evaluated using data collected through Intermountain Healthcare claims data and ED visits and hospital encounters. Statistical analysis was not conducted since the numbers of ED/Hospital admissions was very small (2 and 0) in both group (during the 3 months study window). Here we used intent-to-treat analysis and included the overall 325 (rather than 318 used in analysis of other outcomes) participants. (NCT02409277)
Timeframe: 3-month period prior to the late clinics starting the e-AT
| Intervention | number of ED/Hospital admission (Number) |
|---|---|
| Early Starting Clinics | 2 |
| Late Starting Clinics | 0 |
ED and hospital admission was evaluated using data collected through Intermountain Healthcare claims data and ED visits and hospital encounters. Analyses (at the patient level) comparing the rates of ED/hospital admissions between a 1 year period following initiation of the e-AT for those in both standard and intensive e-AT groups who were enrolled early during the study period (patients with enrollment dates between January 2014 and December 2014) to rates of ED/hospital admissions for patients who started the e-AT later (patients with enrollment dates between January 2015 and December 2015), during a 1-year period prior to the late patient starting the e-AT. (NCT02409277)
Timeframe: 1 year following e-AT use for early and late starting patients
| Intervention | number of ED/Hospital admission (Mean) |
|---|---|
| Early Starting Patients | 0.10 |
| Late Starting Patients | 0.18 |
ED/hospital re-admission data were compared between prior and post 12 month period (for both intensive and standard interventions overall) when e-AT was administered. (NCT02409277)
Timeframe: 1 year
| Intervention | number of ED/hospital admission (Mean) |
|---|---|
| Prior e-AT Use | 0.22 |
| Post e-AT Use | 0.09 |
Use of oral steroid was evaluated using data collected through Intermountain Healthcare claims data and oral steroids prescribed. Statistical analysis was not conducted since the numbers of ED/Hospital admissions was very small (2 and 0) in both group (during the 3 months study window). Here we used intent-to-treat analysis and included the overall 325 (rather than 318 used in analysis of other outcomes) participants (NCT02409277)
Timeframe: 3 month period prior to the late clinics starting the e-AT
| Intervention | number of oral steroid use (Number) |
|---|---|
| Early Patients | 4 |
| Late Patients | 0 |
"Oral steroid use data was collected through Intermountain Healthcare claims data and clinics prescribing oral steroid.~Oral steroid use was evaluated using data collected through Intermountain Healthcare claims data and oral steroids prescribed. Analyses (at the patient level) comparing the rates oral steroid use between a 1 year period following initiation of the e-AT for those in both standard and intensive e-AT groups who were enrolled early during the study period (patients with enrollment dates between January 2014 and December 2014) to rates of oral steroid use for patients who started the e-AT later (patients with enrollment dates between January 2015 and December 2015), during a 1-year period prior to the late patient starting the e-AT." (NCT02409277)
Timeframe: 1 year
| Intervention | number of oral steroid use (Mean) |
|---|---|
| Early Starting Patients | 0.53 |
| Late Starting Patients | 0.53 |
Use of oral steroid was evaluated using data collected through Intermountain Healthcare claims data and oral steroids prescribed. Comparison was made between prior and post e-AT (both interventions) overall. (NCT02409277)
Timeframe: 1 year
| Intervention | number of oral steroid use (Mean) |
|---|---|
| Prior e-AT Use | 0.74 |
| Post e-AT Use | 0.51 |
Asthma control information was collected weekly through the e-AT for 1 year. Asthma control was measured using the Asthma Control Test (ACT), which had a score ranging from 5 to 25, with 5 being poor control and 25 being optimal control. The analysis compared the mean change in scores from baseline to quarters 1, 2, 3, and 4. (NCT02409277)
Timeframe: Average baseline ACT scores compared to average ACT scores at quarter 1, 2, 3 and 4, and between Standard vs. Intensive
| Intervention | mean score (points) change (Mean) | |||
|---|---|---|---|---|
| Qtr 1 vs baseline | Qtr 2 vs baseline | Qtr 3 vs baseline | Qtr 4 vs baseline | |
| Intensive e-AT Intervention | 1.78 | 2.18 | 2.18 | 3.30 |
| Standard e-AT Intervention | 2.55 | 3.09 | 3.26 | 3.33 |
"Asthma control information was collected through the e-AT, comparing change of asthma control from baseline to quarter 1, quarter 2, quarter 3 and quarter 4.~Asthma control was measured using the Asthma Control Test (ACT), which scale ranged from 5-25, with 5=poorly controlled and 25=well controlled.~Each patient submitted an ACT score weekly for 12 months." (NCT02409277)
Timeframe: baseline ACT scores were compared to quarters 1, 2, 3, 4.
| Intervention | Score (points) ranging from 5-25 (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 | |
| All e-AT Users | 18.85 | 22.28 | 22.82 | 22.81 | 22.97 |
Number of child interrupted/missed school days were collected longitudinally (information includes mean at baseline, 3, 6, and 12 months in the study). (NCT02409277)
Timeframe: 1 year
| Intervention | Number of days (interrupted or missed) (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 Months Follow-up | 6 Months Follow-up | 12 Months Follow-up | |
| All e-AT Users | 1.91 | 0.80 | 0.52 | 0.79 |
"Number of child interrupted/missed school days were collected longitudinally at the same time as collecting the QOL scores: baseline, 3, 6, and 12 months in the study.~Number of child interrupted/missed school days during the 3 months prior to baseline, 3, 6, and 12 months follow-up surveys were counted." (NCT02409277)
Timeframe: Interrupted/missed school days were collected at baseline, 3, 6, and 12 month follow-ups
| Intervention | Number of interrupted/missed school days (Number) | |||
|---|---|---|---|---|
| Baseline | 3 Months Follow-up | 6 Months Follow-up | 12 Months Follow-up | |
| Intensive e-AT Intervention | 129 | 60 | 30 | 37 |
| Standard e-AT Intervention | 435 | 114 | 87 | 129 |
Non randomized comparison of ED and hospital admissions between e-AT interventions (both intensive and standard) compared usual care (matched control patients drawn from non-participating clinics) in the prior vs. post e-AT intervention time periods. (NCT02409277)
Timeframe: 1 year
| Intervention | Rate per 1000-days (Mean) | |
|---|---|---|
| Prior | Post | |
| e-AT Intervention | 0.59 | 0.24 |
| Usual Care (Non-randomized Cohort) | 0.23 | 0.24 |
"ED and hospital admissions were evaluated using data collected through Intermountain Healthcare claims data and ED visits and hospital encounters.~We evaluated number ED and hospital admissions 12 months prior to intervention and 12 months post intervention" (NCT02409277)
Timeframe: Change in 1 year ED/hospital admission between 12-month prior and 12 month post e-AT use
| Intervention | Number of ED/hospital admissions (Number) | |
|---|---|---|
| Prior | Post | |
| Intensive e-AT Intervention | 18 | 8 |
| Standard e-AT Intervention | 53 | 21 |
Non randomized comparison of use of oral steroid between e-AT interventions (both intensive and standard) compared usual care (matched control patients drawn from non-participating clinics) in the prior vs. post e-AT intervention time periods. (NCT02409277)
Timeframe: 1 year
| Intervention | Rate per 1000-days (Mean) | |
|---|---|---|
| Prior | Post | |
| e-AT Intervention | 2.02 | 1.41 |
| Usual Care (Non-randomized Cohort) | 1.87 | 1.99 |
Number of parent interrupted/missed work days were collected longitudinally at the same time as collecting the QOL scores: Information includes mean at baseline, 3, 6, and 12 months in the study. (NCT02409277)
Timeframe: 1 year
| Intervention | Number of days (interrupted or missed) (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 Months Follow-up | 6 Months Follow-Up | 12 Months Follow-up | |
| All e-AT Users | 0.72 | 0.27 | 0.25 | 0.20 |
"Number of parent interrupted/missed work days were collected longitudinally at the same time as collecting the QOL scores: baseline, 3, 6, and 12 months in the study.~Number of parent interrupted/missed work days during the 3 months prior to baseline, 3, 6, and 12 months follow-up surveys were counted." (NCT02409277)
Timeframe: Interrupted/missed work days were measured baseline 3, 6, and 12 months
| Intervention | Number of interrupted/missed work days (Number) | |||
|---|---|---|---|---|
| Baseline | 3 Months Follow-up | 6 Months Follow-up | 12 Months Follow-up | |
| Intensive e-AT Intervention | 56 | 14 | 15 | 18 |
| Standard e-AT Intervention | 176 | 44 | 42 | 23 |
"Parent satisfaction data was collected using a modified version of patient satisfaction survey developed and validated by Varni et al. at baseline and at 12 months in the study.~The scale ranged from 1-5, with 1=Very Dissatisfied and 5=Very Satisfied." (NCT02409277)
Timeframe: Satisfaction at 1 year following e-AT use was compared to baseline satisfaction scores
| Intervention | units (points) on a scale (from 1-5) (Mean) | |
|---|---|---|
| Baseline | 12 months Follow-up | |
| All e-AT Users | 4.66 | 4.46 |
"Parent satisfaction data was collected at baseline and at 12 months in the study.~The scale ranges from 1-5, with 1 being Very Dissatisfied and 5 Very Satisfied." (NCT02409277)
Timeframe: Changes in satisfaction was compared between 12 month follow-up and baseline satisfaction across Standard and Intensive interventions
| Intervention | units (points) on a scale (from 1-5) (Mean) | |
|---|---|---|
| Baseline | 12 months Follow-up | |
| Intensive e-AT Intervention | 4.63 | 4.54 |
| Standard e-AT Intervention | 4.63 | 4.38 |
"Patient QOL and missed school days was collected longitudinally through surveys of the study population defined above. The QOL questionnaire included the Integrated Therapeutics Group Child Asthma Short Form (ITG-CASF) and was used at baseline (at first assessment), 3, 6, and 12 months in the study.~Items within QOL scales are summed and linearly transformed from 0 to 100, with higher scores indicating better functioning." (NCT02409277)
Timeframe: Quality of Life assessed at baseline, then compared to 3 months, 6 months, and 12 months after intervention.
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| 3 Months Follow-up vs Baseline | 6 Months Follow-up compared vs Baseline | 12 Months Follow-up vs Baseline | |
| Intensive e-AT Intervention | 7.64 | 5.78 | 9.29 |
| Standard e-AT Intervention | 8.55 | 8.37 | 9.39 |
Patient QOL and missed school days was collected longitudinally through surveys of the study population defined above. The QOL questionnaire included the Integrated Therapeutics Group Child Asthma Short Form - ITG-CASF and was used at baseline (at first assessment), 3, 6, and 12 months in the study. Items within scales are summed and linearly transformed from 0 to 100, with higher scores indicating better functioning. (NCT02409277)
Timeframe: Average Baseline QOL was compared to QOL scores at 3, 6 and 12 month follow-up QOL
| Intervention | units (points) on a scale, range 0-100 (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 Months | 6 Months | 12 Months | |
| All e-AT Users | 79.07 | 90.98 | 90.04 | 90.64 |
Change between placebo salmeterol and active salmeterol for ACQ, where ACQ ranges from 0 (best asthma control) to 6 (worst asthma control). (NCT00200967)
Timeframe: Clinic visits at weeks 0 and 18 of each treatment period
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| B16 Arg/Arg | 0.13 |
| B16 Gly/Gly | 0.11 |
Change between placebo salmeterol and active salmeterol for asthma symptoms (0=absent, 1=mild, 2=moderate, 3=severe). (NCT00200967)
Timeframe: Recorded daily on a diary card, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| B16 Arg/Arg | 0.04 |
| B16 Gly/Gly | 0.00 |
Change between placebo salmeterol and active salmeterol for PM PEF rate (NCT00200967)
Timeframe: Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period
| Intervention | liters per minute (Least Squares Mean) |
|---|---|
| B16 Arg/Arg | -25 |
| B16 Gly/Gly | -24 |
Change between placebo salmeterol and active salmeterol for EBC (NCT00200967)
Timeframe: Clinic visits at weeks 0, 10, and 18 of each treatment period
| Intervention | pH (Least Squares Mean) |
|---|---|
| B16 Arg/Arg | -0.10 |
| B16 Gly/Gly | -0.03 |
Change between placebo salmeterol and active salmeterol for eNO (NCT00200967)
Timeframe: Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period
| Intervention | parts per billion (Geometric Mean) |
|---|---|
| B16 Arg/Arg | 0.12 |
| B16 Gly/Gly | -0.02 |
Change between placebo salmeterol and active salmeterol for methacholine PC20 (NCT00200967)
Timeframe: Clinic visits at weeks 0 and 18 of each treatment period
| Intervention | milligrams per milliliter (Geometric Mean) |
|---|---|
| B16 Arg/Arg | 0.06 |
| B16 Gly/Gly | -1.27 |
Change between placebo salmeterol and active salmeterol for AM PEF rate (NCT00200967)
Timeframe: Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period
| Intervention | liters per minute (Least Squares Mean) |
|---|---|
| B16 Arg/Arg | -21 |
| B16 Gly/Gly | -22 |
Change between placebo salmeterol and active salmeterol for PEF variability, where PEF variability is defined as 100% x (PM PEF - AM PEF)/(PM PEF) (NCT00200967)
Timeframe: Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period
| Intervention | percentage (Least Squares Mean) |
|---|---|
| B16 Arg/Arg | 0.2 |
| B16 Gly/Gly | 0.7 |
Change between placebo salmeterol and active salmeterol for rescue medication use (NCT00200967)
Timeframe: Recorded daily on a diary card, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period
| Intervention | puffs per day (Mean) |
|---|---|
| B16 Arg/Arg | 0.2 |
| B16 Gly/Gly | 0.0 |
Change between placebo salmeterol and active salmeterol for Spirometry FEV1, pre-bronchodilator (NCT00200967)
Timeframe: Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period
| Intervention | liters (Least Squares Mean) |
|---|---|
| B16 Arg/Arg | -0.08 |
| B16 Gly/Gly | -0.04 |
Change between placebo salmeterol and active salmeterol for Spirometry FVC, pre-bronchodilator (NCT00200967)
Timeframe: Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period
| Intervention | liters (Least Squares Mean) |
|---|---|
| B16 Arg/Arg | -0.04 |
| B16 Gly/Gly | -0.03 |
Change between placebo salmeterol and active salmeterol for Spirometry PEF rate, pre-bronchodilator (NCT00200967)
Timeframe: Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period
| Intervention | liters per minute (Least Squares Mean) |
|---|---|
| B16 Arg/Arg | -17 |
| B16 Gly/Gly | -17 |
Asthma quality of life is measured as the average of 23 questions, each of which is scored from 1 (worse) to 7 (best) (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| 2xICS | 0.2 |
| 1xICS + LABA | 0.3 |
| 1xICS + LTRA | 0.3 |
The ACT consists of five items, each scored as 1 (worst) to 5 (best). The five items are averaged. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| 2xICS | 1.49 |
| 1xICS + LABA | 1.87 |
| 1xICS + LTRA | 1.69 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | percentage points (Mean) |
|---|---|
| 2xICS | 2.84 |
| 1xICS + LABA | 4.87 |
| 1xICS + LTRA | 2.29 |
Change from baseline in the impulse oscillometry resistance at 5 Hertz, measured in kiloPascals per liters per second (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | kiloPascals per liters per second (Mean) |
|---|---|
| 2xICS | -0.08 |
| 1xICS + LABA | -0.09 |
| 1xICS + LTRA | -0.06 |
The methacholine PC20 is the concentration of methacholine that causes a 20% decrease in the pre-bronchodilator FEV1. The logarithm base 2 transformation converts the PC20 into doubling dilutions. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | doubling dilutions (Mean) |
|---|---|
| 2xICS | 1.11 |
| 1xICS + LABA | 1.20 |
| 1xICS + LTRA | 1.00 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | percentage points (Mean) |
|---|---|
| 2xICS | 4.44 |
| 1xICS + LABA | 6.26 |
| 1xICS + LTRA | 4.04 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | natural logarithm of parts per billion (Mean) |
|---|---|
| 2xICS | -0.04 |
| 1xICS + LABA | -0.05 |
| 1xICS + LTRA | -0.02 |
PEFR variability is calculated as 100% times the difference between the evening and morning PEFR values, divided by the average of the evening and morning PEFR values, i.e., PEFR variability = 100% x (morning PEFR - evening PEFR)/((morning PEFR + evening PEFR)/2) (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | percentage points (Mean) |
|---|---|
| 2xICS | 2.09 |
| 1xICS + LABA | 1.61 |
| 1xICS + LTRA | 1.72 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | percentage points (Mean) |
|---|---|
| 2xICS | -0.2 |
| 1xICS + LABA | -1.2 |
| 1xICS + LTRA | -0.8 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | ratio (Mean) |
|---|---|
| 2xICS | 0.98 |
| 1xICS + LABA | 2.13 |
| 1xICS + LTRA | 0.55 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | percentage points (Mean) |
|---|---|
| 2xICS | 0.26 |
| 1xICS + LABA | 1.07 |
| 1xICS + LTRA | -0.84 |
(NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | percentage points (Mean) |
|---|---|
| 2xICS | -1.00 |
| 1xICS + LABA | -1.58 |
| 1xICS + LTRA | -1.56 |
An asthma exacerbation was defined as the administration of a course of oral/systemic prednisone for the treatment of asthma. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| 2xICS | 49 |
| 1xICS + LABA | 35 |
| 1xICS + LTRA | 37 |
One treatment period was ranked as better than another if the total amount of prednisone received during the period was at least 180 mg less, if the number of annualized asthma-control days during the final 12 weeks of the period was increased by at least 31 days, or if the FEV1 at the end of the period was at least 5% higher. If the prednisone threshold was met, then we ignored the number of asthmacontrol days and the FEV1. If the threshold for asthma-control days was met, then we ignored the FEV1. Otherwise, the order of response was determined by the FEV1. (NCT00395304)
Timeframe: Measured during the last 12 weeks of each 16-week treatment period
| Intervention | Participants (Number) |
|---|---|
| All Participants | 161 |
The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on the extent and severity of EIB as measured by the area under the curve from 0 to 20 minutes (AUC0-20) for FEV1 percent change from pre-exercise baseline. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)
| Intervention | Percent times Minutes (Least Squares Mean) |
|---|---|
| Montelukast | 116.04 |
| Salmeterol | 168.75 |
The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on the extent and severity of EIB as measured by the average percent change in FEV1 after first β-agonist intake and prior to second β-agonist use. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)
| Intervention | Percent change from baseline (Least Squares Mean) |
|---|---|
| Montelukast | 6.51 |
| Salmeterol | 2.72 |
The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on short-acting β-agonist bronchodilation as measured by the maximum FEV1 percent predicted following first β-agonist use. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)
| Intervention | Percent of predicted value (Least Squares Mean) |
|---|---|
| Montelukast | 104.03 |
| Salmeterol | 99.92 |
The effect of four weeks of treatment with oral montelukast plus inhaled fluticasone, and inhaled salmeterol plus inhaled fluticasone on EIB as measured by the maximum post-exercise percent fall (relative to pre-exercise baseline) in FEV1. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)
| Intervention | Percent change from baseline (Least Squares Mean) |
|---|---|
| Montelukast | 10.57 |
| Salmeterol | 13.82 |
The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on the extent and severity of EIB as measured by the time to recovery (to within 5 percent of the pre-exercise baseline FEV1) following a standardized exercise challenge. (NCT00127166)
Timeframe: 4 weeks (Weeks 0 to 4 or Weeks 6 to 10)
| Intervention | minutes (Median) |
|---|---|
| Montelukast | 5.9 |
| Salmeterol | 11.1 |
Geometric mean values of NO at week 26 were compared using ANCOVA with adjustment for baseline value of NO, age, gender and center. Analysis of covariance (ANCOVA) is a general linear model with one continuous outcome variable (quantitative) and one or more factor variables. (NCT00197106)
Timeframe: Baseline and Week 26
| Intervention | parts per billion (Geometric Mean) |
|---|---|
| Salmeterol/FP 50/100 mcg Plus Placebo | 8.6 |
| FP 200 mcg | 10.0 |
Change from Baseline was calculated as the Week 26 value minus the Baseline value. Forced vital capacity is defined as the maximum volume of air that can be forcibly expired from the lungs and is calculated by use of spirometry. The spirometry test is performed by using a device called a spirometer, which measures the amount of air one can blow out maximally. Generally, the participant is asked to take the deepest breath they can, and then exhale into the sensor as hard as possible, for as long as possible. The test is normally repeated three times to ensure reproducibility. (NCT00197106)
Timeframe: Baseline and Week 26
| Intervention | liters (Mean) |
|---|---|
| Salmeterol/FP 50/100 mcg Plus Placebo | 2.28 |
| FP 200 mcg | 2.28 |
Change from Baseline was calculated as the Week 26 value minus the Baseline value. MEF 50 is defined as maximum expiratory flow rate at 50% of vital capacity. Vital capacity is the maximum amount of air that a person can expel from the lungs after first filling the lungs to their maximum extent. Midexpiratory flow was calculated by use of spirometry. The test is normally repeated at least three times in order to ensure reproducibility. (NCT00197106)
Timeframe: Baseline and Week 26
| Intervention | liters/second (Mean) |
|---|---|
| Salmeterol/FP 50/100 mcg Plus Placebo | 2.28 |
| FP 200 mcg | 2.19 |
Change from Baseline was calculated as the Week 26 value minus the Baseline value. The percentage predicted FEV1 is defined as the volume of air that can be forced out in one second after taking a deep breath and is corrected for the FEV1 value corresponding with the same age. (NCT00197106)
Timeframe: Baseline and Week 26
| Intervention | percent predicted change (Mean) |
|---|---|
| Salmeterol/FP 50/100 mcg Plus Placebo | 102.5 |
| FP 200 mcg | 103.0 |
PD20 was calculated by using increasing dosages of methacholine. The dosage that caused a 20% fall in FEV1 was used for analysis. The presented data are ratios (month 6/Baseline) of geometric mean PD20 values. (NCT00197106)
Timeframe: Baseline and Week 26
| Intervention | ratio (Log Mean) |
|---|---|
| Salmeterol/FP 50/100 mcg Plus Placebo | 2.7 |
| FP 200 mcg | 1.5 |
An exacerbation is defined as a worsening of the asthma complaints (commonly referred to as an asthma attack) and is reported by the participant experiencing the event. An exacerbation was verified by the use of asthma rescue medication. (NCT00197106)
Timeframe: Week 26
| Intervention | number of exacerbations (Number) |
|---|---|
| Salmeterol/FP 50/100 mcg Plus Placebo | 10 |
| FP 200 mcg | 7 |
Change from Baseline was calculated as the Week 26 value minus the Baseline value. Interrupter respiratory resistance (RINT) measurements were calculated by a combined analysis for relation between change from baseline and occurrence of the endpoint. RINT is a technique that is used for evaluating lung function in poorly collaborating patients (e.g., small children). The measurement is performed during tidal breathing (normal breathing) instead of during maximal expiration, as is done by a spirometry test. (NCT00197106)
Timeframe: Baseline and Week 26
| Intervention | percent (Number) |
|---|---|
| Salmeterol/FP 50/100 mcg Plus Placebo | -9.1 |
| FP 200 mcg | -9.9 |
Asthma symptom-free days are defined as days (24 hour period) with no symptoms, as recorded in the participant's diary. (NCT00197106)
Timeframe: Last 10 weeks of the treatment period (Weeks 16-26)
| Intervention | percentage of days (Mean) |
|---|---|
| Salmeterol/FP 50/100 mcg Plus Placebo | 50.45 |
| FP 200 mcg | 49.75 |
Asthma symptom-free days are defined as days (24 hour period) with no symptoms, as recorded in the participant's diary (NCT00197106)
Timeframe: Baseline to Week 26
| Intervention | percentage of days (Mean) | |||
|---|---|---|---|---|
| Baseline | 0-6 weeks | 6-16 weeks | 16-26 weeks | |
| FP 200 mcg | 23.06 | 31.50 | 45.24 | 49.75 |
| Salmeterol/FP 50/100 mcg Plus Placebo | 22.78 | 31.58 | 44.60 | 50.45 |
The primary outcome measure was treatment failure, defined as the occurrence of any one of the following events: hospitalization or an urgent medical visit for asthma initiated by the patient or physician; use of systemic corticosteroids for asthma or need for open-label use of inhaled corticosteroids for asthma, as determined by the study physician or an asthma care provider; a decrease in prebronchodilator forced expiratory volume in 1 second (FEV1) to more than 20% below the baseline value measured at randomization; a decrease in the morning peak expiratory flow rate to more than 35% below the baseline value (the mean over the final 2 weeks of the run-in period) on 2 consecutive days; use of 10 puffs or more per day of rescue beta-agonist for 2 consecutive days (except as medication before exercise); refusal of the patient to continue because of lack of satisfaction with treatment; or judgment by a physician that the patient should stop treatment for reasons of safety. (NCT00156819)
Timeframe: 16 weeks
| Intervention | participants (Number) |
|---|---|
| Fluticasone | 34 |
| Montelukast | 50 |
| Fluticasone Plus Salmeterol | 33 |
"12-lead electrocardiogram (12-lead ECG) parameter - heart rate (HR) was measured at baseline (Day 1) and Week 8.~Change from baseline.~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose;~bpm=Beats per minute;" (NCT03084718)
Timeframe: Baseline, Week 8
| Intervention | bpm (Mean) |
|---|---|
| Treatment A (CHF 718 pMDI 100 µg TDD) | 0.6 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 0.2 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 0.4 |
| Treatment D (Placebo) | 1.2 |
| Treatment E (QVAR^®, 320 µg TDD) | -0.4 |
"24-hr Creatinine - Change From Baseline.~For the evaluation of the 24-hr creatinine excretion, 24-hour urine sample were collected. Creatinine was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS).~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose;" (NCT03084718)
Timeframe: Baseline, Week 8
| Intervention | umol/mol (Median) |
|---|---|
| Treatment A (CHF 718 pMDI 100 µg TDD) | 0.00 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 0.00 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 0.00 |
| Treatment D (Placebo) | 0.00 |
| Treatment E (QVAR^®, 320 µg TDD) | 0.00 |
"24-hr Urinary Free Cortisol - Change From Baseline.~For the evaluation of the 24-hr Urine-Free cortisol excretion, 24-hour urine samples were collected. Urine-free cortisol was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS).~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose;" (NCT03084718)
Timeframe: Baseline, Week 8
| Intervention | nmol/day (Median) |
|---|---|
| Treatment A (CHF 718 pMDI 100 µg TDD) | -3.60 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | -5.35 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | -4.10 |
| Treatment D (Placebo) | 1.40 |
| Treatment E (QVAR^®, 320 µg TDD) | -3.50 |
"Change from baseline in pre-dose morning FEV1 at Week 4.~Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Definitions:~Baseline=Baseline values for pre-dose FEV1 were the average of measurements taken at V2 (Week 0) at 45 minutes and 15 minutes pre-dose; FEV1=Forced expiratory volume in the 1st second;" (NCT03084718)
Timeframe: Baseline, Week 4
| Intervention | Litres (Least Squares Mean) |
|---|---|
| Treatment A (CHF 718 pMDI 100 µg TDD) | 0.021 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 0.120 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 0.073 |
| Treatment D (Placebo) | 0.003 |
| Treatment E (QVAR^®, 320 µg TDD) | 0.077 |
"Change from baseline in pre-dose morning FEV1 (average of pre-dose FEV1 measurements) at Week 8.~Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Definitions:~Baseline=Baseline values for pre-dose FEV1 were the average of measurements taken at V2 (Week 0) at 45 minutes and 15 minutes pre-dose; FEV1=Forced expiratory volume in the 1st second;" (NCT03084718)
Timeframe: Baseline, Week 8
| Intervention | Litres (Least Squares Mean) |
|---|---|
| Treatment A (CHF 718 pMDI 100 µg TDD) | 0.021 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 0.090 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 0.070 |
| Treatment D (Placebo) | -0.023 |
| Treatment E (QVAR^®, 320 µg TDD) | 0.078 |
"12-lead electrocardiogram (12-lead ECG) parameters - PR, QRS, QTcF intervals - were measured at baseline (Day 1) and Week 8.~Changes from baseline.~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0); QTcF=Fridericia-corrected QT interval; msec=Millisecond;" (NCT03084718)
Timeframe: Baseline, Week 8
| Intervention | msec (Mean) | ||
|---|---|---|---|
| PR | QRS | QTcF | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | -2.6 | 0.1 | 1.6 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 1.5 | -1.3 | 0.7 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | -1.9 | 0.9 | 0.7 |
| Treatment D (Placebo) | -1.3 | -0.5 | 4.6 |
| Treatment E (QVAR^®, 320 µg TDD) | 1.0 | -0.3 | 1.2 |
"Number of participants with prolonged QTcF. Change from baseline.~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose; QTcF=Fridericia-corrected QT interval;" (NCT03084718)
Timeframe: Baseline, Week 8
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| QTcF > 30 msec | QTcF > 60 msec | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | 6 | 1 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 4 | 1 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 4 | 0 |
| Treatment D (Placebo) | 9 | 2 |
| Treatment E (QVAR^®, 320 µg TDD) | 3 | 1 |
"The ACQ consists of 7 items: 6 simple self-administered questions referring to asthma control and rescue treatment usage with 1 week recall, and a 7th item consisting of the percent (%) predicted FEV1 completed by clinic staff. Scoring uses a 7-point scale: 0 = totally controlled and 6 = severely uncontrolled. The ACQ score was calculated as the average of all 7 items.~Definitions:~ACQ-7 score=Asthma Control Questionnaire-7©; Information regarding the American Thoracic Society ACQ questionnaire is also available at: https://member.thoracic.org/members/assemblies/assemblies/srn/questionaires/acq.php; Baseline ACQ-7 score = ACQ score recorded at V2 (Week 0) Day 1, before randomization; FEV1=Forced expiratory volume in the 1st second;" (NCT03084718)
Timeframe: Baseline, Week 4, Week 8
| Intervention | score on a scale (Least Squares Mean) | |
|---|---|---|
| Week 4 | Week 8 | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | -0.43 | -0.53 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | -0.53 | -0.58 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | -0.49 | -0.66 |
| Treatment D (Placebo) | -0.27 | -0.43 |
| Treatment E (QVAR^®, 320 µg TDD) | -0.47 | -0.64 |
"Change from baseline in average use of rescue medication, during Inter-visit period 1, Inter-visit period 2, Entire treatment period.~Definitions:~Baseline=For the efficacy variable -- average use of rescue medication -- derived from the electronic diary (eDiary), baseline values were the averages recorded during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)
| Intervention | puffs/day (Least Squares Mean) | ||
|---|---|---|---|
| Inter-visit period 1 | Inter-visit period 2 | Entire treatment period | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | -0.11 | -0.12 | -0.11 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | -0.27 | -0.35 | -0.31 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | -0.14 | -0.25 | -0.20 |
| Treatment D (Placebo) | 0.07 | 0.01 | 0.04 |
| Treatment E (QVAR^®, 320 µg TDD) | -0.13 | -0.18 | -0.15 |
"Overall daily asthma symptoms scores - Change From Baseline (am and pm).~Subjects had to record asthma symptom score (overall symptoms, cough, wheeze, chest tightness and breathlessness) in the am (night-time asthma symptom score) and in the pm (daytime asthma symptom score). These data were collected in the subject's diary. Daily asthma symptoms score were performed separately for am score and pm score and also as a total, where the total equals the sum of the am and pm scores. Degree of asthma symptoms by score: 0=None, 1=Mild, 2=Moderate, and 3=Severe.~Baseline=Averages values during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)
| Intervention | score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Inter-visit period 1 | Inter-visit period 2 | Entire treatment period | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | -0.1 | -0.1 | -0.1 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | -0.1 | -0.1 | -0.1 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | -0.1 | -0.1 | -0.1 |
| Treatment D (Placebo) | 0.0 | -0.0 | 0.0 |
| Treatment E (QVAR^®, 320 µg TDD) | -0.1 | -0.1 | -0.1 |
"Change from baseline in percentage (%) of asthma control days, during Inter-visit period 1, Inter-visit period 2, Entire treatment period.~This outcome measure was calculated according to the following definition: Days with a total daily morning + evening asthma score = 0 AND No rescue medication use.~Definitions:~Baseline=For the efficacy variable -- asthma control days -- derived from the eDiary, baseline values were the averages/percentages recorded during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)
| Intervention | % of asthma control days (Least Squares Mean) | ||
|---|---|---|---|
| Inter-visit period 1 | Inter-visit period 2 | Entire treatment period | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | 7.3 | 14.3 | 10.8 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 10.6 | 16.3 | 13.4 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 10.4 | 17.5 | 13.9 |
| Treatment D (Placebo) | 5.0 | 10.5 | 7.7 |
| Treatment E (QVAR^®, 320 µg TDD) | 12.8 | 20.63 | 16.7 |
"Change from baseline in Percentage (%) of asthma symptoms-free days.~Asthma symptoms-free days is the number of days with a total asthma score=0 (daily morning plus evening asthma score).~Subjects recorded asthma symptom score as described in the Outcome measure #7.~Definitions:~Baseline=For the efficacy variables -- daytime and night-time asthma symptom scores -- derived from the eDiary, baseline values were the averages/percentages recorded during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)
| Intervention | % of of asthma symptom-free days (Least Squares Mean) | ||
|---|---|---|---|
| Inter-visit period 1 | Inter-visit period 2 | Entire treatment period | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | 8.6 | 16.4 | 12.5 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 10.5 | 17.0 | 13.8 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 10.1 | 17.2 | 13.6 |
| Treatment D (Placebo) | 5.7 | 11.7 | 8.7 |
| Treatment E (QVAR^®, 320 µg TDD) | 12.8 | 21.2 | 17.0 |
"Change from baseline in percentage (%) of rescue medication-free days. An increased value indicates improvement from baseline.~Definitions:~Baseline=For the efficacy variable -- percentage (%) of rescue medication-free days -- derived from the electronic diary (eDiary), baseline values were the averages/percentages recorded during the run-in period.~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)
| Intervention | % of rescue medication-free days (Least Squares Mean) | ||
|---|---|---|---|
| Inter-visit period 1 | Inter-visit period 2 | Entire treatment period | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | 5.9 | 8.9 | 7.4 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 9.0 | 13.1 | 11.1 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 6.1 | 10.0 | 8.1 |
| Treatment D (Placebo) | 1.5 | 4.1 | 2.8 |
| Treatment E (QVAR^®, 320 µg TDD) | 7.7 | 11.2 | 9.5 |
"Change from baseline in pre-dose morning FVC at Week 4 and 8.~Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Definitions:~Baseline=Baseline values for pre-dose FVC were the average of measurements taken at V2 (Week 0) at 45 minutes and 15 minutes pre-dose; FVC=Forced vital capacity;" (NCT03084718)
Timeframe: Baseline, Week 4, Week 8
| Intervention | Litres (Least Squares Mean) | |
|---|---|---|
| Week 4 | Week 8 | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | 0.036 | 0.014 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 0.099 | 0.089 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 0.066 | 0.036 |
| Treatment D (Placebo) | 0.023 | -0.016 |
| Treatment E (QVAR^®, 320 µg TDD) | 0.056 | 0.063 |
"Change from baseline in pre-dose Peak Expiratory Flow (PEF) (Liters/min), morning and evening measurements.~Definitions:~Baseline=For the efficacy variable -- morning and evening PEF -- derived from the eDiary, the baseline values were the averages/percentages recorded during the run-in period; PEF=evening peak expiratory flow;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)
| Intervention | Liters/min (Least Squares Mean) | ||
|---|---|---|---|
| Inter-visit period 1 | Inter-visit period 2 | Entire treatment period | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | -2 | -4 | -3 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | -3 | 3 | 0.3 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | -4 | -5 | -4 |
| Treatment D (Placebo) | -6 | -4 | -4.9 |
| Treatment E (QVAR^®, 320 µg TDD) | 0 | 2 | 1 |
"Vital signs (systolic and diastolic blood pressure) at baseline, week 4, and week 8.~Change from baseline.~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose; DBP=Diastolic blood pressure; SBP=Systolic blood pressure;" (NCT03084718)
Timeframe: Baseline, Week 4, Week 8
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| SBP, Week 4 | SBP, Week 8 | DBP, Week 4 | DBP, Week 8 | |
| Treatment A (CHF 718 pMDI 100 µg TDD) | -0.4 | 1.0 | -0.1 | 0.8 |
| Treatment B (CHF 718 pMDI 400 µg TDD) | 1.0 | 2.5 | 0.2 | 1.0 |
| Treatment C (CHF 718 pMDI 800 µg TDD) | 0.5 | 0.8 | -0.8 | 0.3 |
| Treatment D (Placebo) | 0.6 | 0.2 | 0.1 | -0.5 |
| Treatment E (QVAR^®, 320 µg TDD) | 0.0 | -0.9 | 0.8 | 1.2 |
Pre-treatment spirometry measurement assessed at the time of study enrollment. Post-treatment spirometry measurement assessed following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in FEV1 calculated as post-treatment FEV1 minus pre-treatment FEV1 (NCT02566902)
Timeframe: 10 minutes
| Intervention | %predicted (Mean) |
|---|---|
| T-piece Nebulizer | 13.8 |
| Breath-Enhanced Nebulizer | 9.1 |
"Blinded research personnel will assess subject's heart rate by auscultation and/or pulse palpation prior to and immediately following albuterol administration.~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in heart rate calculated as post-treatment heart rate minus pre-treatment heart rate." (NCT02566902)
Timeframe: 10 minutes
| Intervention | beats per minute (Mean) |
|---|---|
| T-piece Nebulizer | 4.34 |
| Breath-Enhanced Nebulizer | 15.05 |
"Based on examination and auscultation of lungs prior to and immediately following albuterol administration.~PAS score is on a scale of 0-10 which is a sum of five separate sub-scores each on a scale of 0-2. The five sub-scores are:~Respiratory rate (6-12yr/>12yr): <=26/23 (0), 27-30/24-27 (1), >31/28 (2)~Oxygenation: >95% (0), 90-95 (1), <90 (2)~Auscultation: clear/end expiratory wheeze (0), expiratory wheeze (1), biphasic wheeze/diminished (2)~Work of Breathing (accessory muscles): <= 1 (0), 2 (1), >=3 (2)~Dyspnea: Full sentences (0), Partial sentences (1), Single words (2)~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in PAS calculated as post-treatment PAS minus pre-treatment PAS." (NCT02566902)
Timeframe: 10 minutes
| Intervention | score on a scale (Median) |
|---|---|
| T-piece Nebulizer | -1 |
| Breath-Enhanced Nebulizer | -2 |
"Determined by examination and auscultation of lungs to prior to and immediately following albuterol administration.~PASS is a total score on a scale of 0-6 which is calculated as a sum of three sub-scores, each on a scale of 0-2. The sub-scores are:~Wheezing: None or Mild (0), Moderate (1), Severe wheezing or absent wheezing due to poor air exchange (2)~Work of breathing (accessory muscle use or retractions): None or mild (0), Moderate (1), Severe (2)~Prolonged expiration: Normal or mildly prolonged (0), moderately prolonged (1), severely prolonged (2)~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in PASS calculated as post-treatment PASS minus pre-treatment PASS." (NCT02566902)
Timeframe: 10 minutes
| Intervention | score on a scale (Median) |
|---|---|
| T-piece Nebulizer | -1 |
| Breath-Enhanced Nebulizer | -1 |
"Respiratory rate will be measured by observation and auscultation over 30 seconds prior to and immediately following albuterol administration~Pre-treatment assessment at the time of study enrollment. Post-treatment assessment following the administration of one time 5mg nebulized albuterol sulfate treatment. Assessments taken at baseline (prior to albuterol therapy) and 10 min post-treatment. Change in respiratory rate calculated as post-treatment respiratory rate minus pre-treatment respiratory rate." (NCT02566902)
Timeframe: 10 minutes
| Intervention | breaths/min (Mean) |
|---|---|
| T-piece Nebulizer | -3.1 |
| Breath-Enhanced Nebulizer | -3.2 |
Total length of stay will be assessed at the time of Emergency Department disposition which will be approximately 3 hours, but will be assessed up to 24 hours depending on duration of ED stay. (NCT02566902)
Timeframe: Up to 24 hours
| Intervention | minutes (Mean) |
|---|---|
| T-piece Nebulizer | 246.3 |
| Breath-Enhanced Nebulizer | 246.2 |
"Subjects and parents/guardians will be asked whether subjects experienced nausea, vomiting, palpitations, headache, dizziness either during (assessed by non-blinded personnel) or following treatment (assessed by blinded personnel during post-treatment assessment). Subject and parent/guardian will also be asked if any other side effects were experienced." (NCT02566902)
Timeframe: 10 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| T-piece Nebulizer | 5 |
| Breath-Enhanced Nebulizer | 5 |
Admission rate to inpatient hospital will be assessed at the time of Emergency Department disposition which will be approximately 3 hours, but will be assessed up to 24 hours depending on duration of ED stay. (NCT02566902)
Timeframe: Up to 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| T-piece Nebulizer | 11 |
| Breath-Enhanced Nebulizer | 11 |
Cumulative dose of albuterol in mg will be assessed at the time of Emergency Department disposition which will be approximately 3 hours, but will be assessed up to 24 hours depending on duration of ED stay. (NCT02566902)
Timeframe: up to 24 hours
| Intervention | mg (Mean) |
|---|---|
| T-piece Nebulizer | 18.2 |
| Breath-Enhanced Nebulizer | 18.7 |
(NCT00394329)
Timeframe: Rescue albuterol puffs were measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | count of the number of puffs per day (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.26 |
| B: Daily ICS | 0.24 |
| C: Rescue ICS | 0.26 |
| D: Placebo | 0.18 |
(NCT00394329)
Timeframe: An asthma control day was determined daily during each of the 44-week treatment periods. The primary analysis constructed the change between week 14 and week 0.
| Intervention | proportion of asthma control days (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | -0.006 |
| B: Daily ICS | -0.021 |
| C: Rescue ICS | -0.064 |
| D: Placebo | -0.034 |
The ACT consisted of five questions, each ranging from 1 (worst) to 5 (best). The five questions were summed to yield an overall score that ranged from 5 (worst) to 25 (best). (NCT00394329)
Timeframe: The ACT was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.17 |
| B: Daily ICS | -0.15 |
| C: Rescue ICS | -0.57 |
| D: Placebo | -0.76 |
The asthma-specific quality of life scale ranged from 1 (worst) to 7 (best) (NCT00394329)
Timeframe: The asthma-specific quality of life assessment was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.15 |
| B: Daily ICS | 0.07 |
| C: Rescue ICS | 0.05 |
| D: Placebo | -0.03 |
(NCT00394329)
Timeframe: Evening PEFR was measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | liters per minute (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 16.2 |
| B: Daily ICS | 14.9 |
| C: Rescue ICS | 12.9 |
| D: Placebo | 20.6 |
(NCT00394329)
Timeframe: eNO was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | parts per billion (Least Squares Mean) |
|---|---|
| Daily ICS + Rescue ICS | -0.08 |
| Daily ICS | 0.07 |
| Rescue ICS | 0.58 |
| Placebo | 0.34 |
(NCT00394329)
Timeframe: Morning PEFR was measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | liters per minute (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 17.7 |
| B: Daily ICS | 16.3 |
| C: Rescue ICS | 16.5 |
| D: Placebo | 21.1 |
(NCT00394329)
Timeframe: Pre-bronchodilator FEV1 was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | liters (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.104 |
| B: Daily ICS | 0.113 |
| C: Rescue ICS | 0.097 |
| D: Placebo | 0.063 |
PEFR variability represents the relative change between the evening and morning PEFR measurements, so it could be a positive or negative number. It was measured daily during the 44-week treatment period. Specifically, the PEFR variability on a specific day is defined as 100% x (evening PEFR - morning PEFR)/{0.5*(evening PEFR + morning PEFR)} (NCT00394329)
Timeframe: PEFR variability was measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | relative change (AM and PM peak flow) (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.836 |
| B: Daily ICS | -0.043 |
| C: Rescue ICS | 0.098 |
| D: Placebo | 0.894 |
(NCT00394329)
Timeframe: Measured during the 44-week treatment period
| Intervention | participants (Number) |
|---|---|
| A: Daily ICS + Rescue ICS | 22 |
| B: Daily ICS | 20 |
| C: Rescue ICS | 25 |
| D: Placebo | 36 |
The primary outcome variable is the average number of symptom free days over 2 weeks assessed during peak asthma season (data collected during November, December, January and February during the school year). (NCT01175369)
Timeframe: Average Symptom Free Days, over 2 weeks, during peak asthma season (November-February)
| Intervention | Days (Mean) |
|---|---|
| Usual Care | 10.7 |
| School-based Care | 11.6 |
Mean diastolic blood pressure measured at various timepoints minus the predose diastolic blood pressure (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose
| Intervention | mmHg (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 min post dose 1 (n=51,52,40) | 30 min post dose 1 (n=51,52,40) | 60 min post dose 1 (n=51,51,40) | 15 min post dose 2 (n=50,51,40) | 30 min post dose 2 (n=47,50,40) | 60 min post dose 2 (n=46,50,37) | 30 min post last dose (n=49,52,40) | 60 min post last dose (n=49,52,40) | 1.5 hours post last dose (n=48,52,40) | 2 hours post last dose (n=50,52,40) | 2.5 hours post last dose (n=49,52,40) | 3 hours post last dose (n=50,52,40) | 3.5 hours post last dose (n=50,52,40) | 4 hours post last dose (n=50,52,40) | 4.5 hours post last dose (n=50,52,40) | 5 hours post last dose (n=50,52,40) | |
| Arformoterol 15 Mcg | -1.0 | -1.9 | -1.3 | -2.8 | -1.9 | -1.8 | -1.9 | -1.1 | -1.1 | -1.5 | -1.3 | -1.1 | -1.0 | -3.7 | -1.7 | -3.6 |
| Arformoterol 7.5 Mcg | -1.1 | -0.6 | -0.7 | 0.1 | -1.1 | -1.3 | -1.2 | -1.1 | -0.9 | -0.9 | -3.5 | -1.8 | -2.6 | -0.0 | -1.0 | -0.1 |
| Levalbuterol 0.63 mg | -1.1 | -1.7 | 0.8 | -1.1 | 0.8 | 0.0 | 0.8 | 0.8 | 0.1 | 1.4 | -1.9 | 0.8 | -0.4 | 0.5 | 0.2 | -0.1 |
Heart rate measured at various timepoints minus the heart rate at predose. (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose
| Intervention | beats per minute (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 min post dose 1 (n=51,52,40) | 30 min post dose 1 (n=51,52,40) | 60 min post dose 1 (n=51,51,40) | 15 min post dose 2 (n=50,51,40) | 30 min post dose 2 (n=47,50,40) | 60 min post dose 2 (n=46,50,37) | 30 min post last dose (n=49,52,40) | 60 min post last dose (n=49,52,40) | 1.5 hours post last dose (n=48,52,40) | 2 hours post last dose (n=50,52,40) | 2.5 hours post last dose (n=49,52,40) | 3 hours post last dose (n=50,52,40) | 3.5 hours post last dose (n=50,52,40) | 4 hours post last dose (n=50,52,40) | 4.5 hours post last dose (n=50,52,40) | 5 hours post last dose (n=50,51,40) | |
| Arformoterol 15 Mcg | 2.3 | 2.5 | 6.5 | 5.5 | 6.3 | 9.5 | 9.0 | 10.0 | 8.3 | 8.9 | 7.8 | 6.4 | 7.9 | 7.4 | 6.9 | 5.8 |
| Arformoterol 7.5 Mcg | 0.5 | 2.0 | 4.4 | 2.8 | 4.5 | 4.7 | 5.6 | 8.6 | 7.1 | 6.6 | 5.5 | 5.9 | 5.1 | 4.6 | 4.9 | 5.3 |
| Levalbuterol 0.63 mg | 1.6 | 3.2 | 8.7 | 7.8 | 10.0 | 13.2 | 11.9 | 8.7 | 8.9 | 5.6 | 6.8 | 6.7 | 5.9 | 6.6 | 5.9 | 5.0 |
PEFR is the fastest rate at which air can move through the airways during a forced expiration starting with fully inflated lungs as measured by peak flow meters. Change in PEFR was calculated as postdose value minus the predose value at each visit. (NCT00583947)
Timeframe: predose, various postdose times
| Intervention | liters/second (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 10 minutes post dose 1 (n=37,38,27) | 25 minutes post dose 1 (n=37,37,27) | 10 minutes post dose 2 (n=36,38,27) | 25 minutes post dose 2 (n=36,38,27) | 10 minutes post dose 3 (n=34,38,27) | 25 minutes post dose 3 (n=35,38,26) | 2 hours post dose 1 (n=36,37,27) | 4 hours post dose 1 (n=36,38,27) | 6 hours post dose 1 (n=36,38,27) | |
| Arformoterol 15 Mcg | 0.259 | 0.279 | 0.360 | 0.424 | 0.513 | 0.449 | 0.501 | 0.474 | 0.451 |
| Arformoterol 7.5 Mcg | 0.242 | 0.320 | 0.344 | 0.419 | 0.457 | 0.462 | 0.596 | 0.484 | 0.513 |
| Levalbuterol 0.63 mg | 0.322 | 0.399 | 0.458 | 0.452 | 0.524 | 0.539 | 0.575 | 0.509 | 0.324 |
Change in mean serum glucose at the specified timepoint minus the predose value. (NCT00583947)
Timeframe: predose, 2 and 6 hours post dose
| Intervention | mg/dl (Mean) | |
|---|---|---|
| 2 hours post dose 1 (n=48,47,39) | 6 hours post dose 1 (n=49,48,38) | |
| Arformoterol 15 Mcg | 32.9 | 18.6 |
| Arformoterol 7.5 Mcg | 22.4 | 12.1 |
| Levalbuterol 0.63 mg | 27.1 | 20.3 |
Change in mean serum potassium at the specified timepoint minus the predose value. (NCT00583947)
Timeframe: predose, 2 and 6 hours post dose
| Intervention | mEq/L (Mean) | |
|---|---|---|
| 2 hours post dose 1 (n=48,47,38) | 6 hours post dose 1 (n=48,49,38) | |
| Arformoterol 15 Mcg | -0.62 | -0.39 |
| Arformoterol 7.5 Mcg | -0.42 | -0.31 |
| Levalbuterol 0.63 mg | -0.58 | -0.23 |
Mean systolic blood pressure measured at various timepoints minus the mean systolic blood pressure at predose (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose
| Intervention | mmHg (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 min post dose 1 (n=51,52,40) | 30 min post dose 1 (n=51,52,40) | 60 min post dose 1 (n=51,51,40) | 15 min post dose 2 (n=50,51,40) | 30 min post dose 2 (n=47,50,40) | 60 min post dose 2 (n=46,50,37) | 30 min post last dose (n=49,52,40) | 60 min post last dose (n=49,52,40) | 1.5 hours post last dose (n=48,52,40) | 2 hours post last dose (n=50,52,40) | 2.5 hours post last dose (n=49,52,40) | 3 hours post last dose (n=50,52,40) | 3.5 hours post last dose (n=50,52,40) | 4 hours post last dose (n=50,52,40) | 4.5 hours post last dose (n=50,52,40) | 5 hours post last dose (n=50,52,40) | |
| Arformoterol 15 Mcg | 2.0 | -0.3 | 2.6 | 1.6 | 1.4 | 1.8 | 1.1 | 4.4 | 2.4 | 1.3 | 0.7 | 1.3 | 0.9 | -0.0 | 0.9 | 1.6 |
| Arformoterol 7.5 Mcg | -0.4 | 0.9 | 1.1 | -0.3 | 0.8 | -0.3 | -0.4 | 1.5 | 0.3 | 1.8 | -0.0 | 0.6 | 1.7 | 0.6 | 1.7 | 2.5 |
| Levalbuterol 0.63 mg | 0.8 | 2.6 | 3.7 | 2.6 | 3.3 | 4.0 | 2.4 | 3.5 | 1.8 | 2.3 | 0.4 | 3.9 | 1.2 | 1.3 | 2.2 | 4.5 |
Forced Expiratory Volume in one second (FEV1) is the volume of air forcibly exhaled in one second as measured by a spirometer. Change in FEV1 was calculated as postdose value minus the predose value at each visit. (NCT00583947)
Timeframe: predose, various postdose timepoints
| Intervention | liters (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 10 minutes post dose 1 (n=37,38,27) | 25 minutes post dose 1 (n=37,37,27) | 10 minutes post dose 2 (n=36,38,27) | 25 minutes post dose 2 (n=36,38,27) | 10 minutes post dose 3 (n=34,38,27) | 25 minutes post dose 3 (n=35,38,26) | 2 hours post dose 1 (n=36,37,27) | 4 hours post dose 1 (n=36,38,27) | 6 hours post dose 1 (n=36,38,27) | |
| Arformoterol 15 Mcg | 0.133 | 0.158 | 0.175 | 0.183 | 0.203 | 0.205 | 0.218 | 0.198 | 0.174 |
| Arformoterol 7.5 Mcg | 0.117 | 0.142 | 0.169 | 0.162 | 0.179 | 0.188 | 0.194 | 0.170 | 0.173 |
| Levalbuterol 0.63 mg | 0.160 | 0.159 | 0.199 | 0.194 | 0.226 | 0.226 | 0.216 | 0.163 | 0.098 |
Diastolic blood pressure measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes). (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose
| Intervention | mmHg (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Predose (n=51,52,40) | 15 min post dose 1 (n=51,52,40) | 30 min post dose 1 (n=51,52,40) | 60 min post dose 1 (n=51,51,40) | 15 min post dose 2 (n=50,51,40) | 30 min post dose 2 (n=47,50,40) | 60 min post dose 2 (n=46,50,37) | 30 min post last dose (n=49,52,40) | 60 min post last dose (n=49,52,40) | 1.5 hours post last dose (n=48,52,40) | 2 hours post last dose (n=50,52,40) | 2.5 hours post last dose (n=49,52,40) | 3 hours post last dose (n=50,52,40) | 3.5 hours post last dose (n=50,52,40) | 4 hours post last dose (n=50,52,40) | 4.5 hours post last dose (n=50,52,40) | 5 hours post last dose (n=50,52,40) | |
| Arformoterol 15 Mcg | 63.6 | 62.5 | 61.6 | 62.3 | 60.8 | 61.7 | 62.3 | 61.6 | 62.5 | 62.5 | 62.1 | 62.3 | 62.5 | 62.6 | 59.9 | 61.9 | 60.0 |
| Arformoterol 7.5 Mcg | 63.2 | 62.0 | 62.5 | 62.5 | 63.3 | 62.2 | 62.0 | 62.0 | 62.1 | 62.3 | 62.3 | 59.7 | 61.4 | 60.5 | 63.1 | 62.2 | 63.0 |
| Levalbuterol 0.63 mg | 62.5 | 61.4 | 60.8 | 63.4 | 61.7 | 63.1 | 62.8 | 63.4 | 63.5 | 63.1 | 63.8 | 60.7 | 63.2 | 62.0 | 62.9 | 62.6 | 62.3 |
Forced Expiratory Volume in one second (FEV1) is the volume of air forcibly exhaled in one second as measured by a spirometer. (NCT00583947)
Timeframe: predose, various postdose times
| Intervention | liters (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| predose (n=37,38,27) | 10 minutes post dose 1 (n=37,38,27) | 25 minutes post dose 1 (n=37,37,27) | 10 minutes post dose 2 (n=36,38,27) | 25 minutes post dose 2 (n=36,38,27) | 10 minutes post dose 3 (n=34,38,27) | 25 minutes post dose 3 (n=35,38,26) | 2 hours post dose 1 (n=36,37,27) | 4 hours post dose 1 (n=36,38,27) | 6 hours post dose 1 (n=36,38,27) | |
| Arformoterol 15 Mcg | 1.486 | 1.620 | 1.644 | 1.661 | 1.669 | 1.689 | 1.700 | 1.704 | 1.684 | 1.660 |
| Arformoterol 7.5 Mcg | 1.552 | 1.668 | 1.695 | 1.721 | 1.714 | 1.731 | 1.740 | 1.754 | 1.722 | 1.725 |
| Levalbuterol 0.63 mg | 1.554 | 1.714 | 1.712 | 1.741 | 1.735 | 1.775 | 1.782 | 1.784 | 1.732 | 1.667 |
Heart rate measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes). (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose
| Intervention | beats per minute (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Predose (n=51,52,40) | 15 min post dose 1 (n=51,52,40) | 30 min post dose 1 (n=51,52,40) | 60 min post dose 1 (n=51,51,40) | 15 min post dose 2 (n=50,51,40) | 30 min post dose 2 (n=47,50,40) | 60 min post dose 2 (n=46,50,37) | 30 min post last dose (n=49,52,40) | 60 min post last dose (n=49,52,40) | 1.5 hours post last dose (n=48,52,40) | 2 hours post last dose (n=50,52,40) | 2.5 hours post last dose (n=49,52,40) | 3 hours post last dose (n=50,52,40) | 3.5 hours post last dose (n=50,52,40) | 4 hours post last dose (n=50,52,40) | 4.5 hours post last dose (n=50,52,40) | 5 hours post last dose (n=50,51,40) | |
| Arformoterol 15 Mcg | 87.0 | 89.4 | 89.5 | 93.5 | 92.5 | 93.3 | 96.1 | 96.1 | 97.1 | 95.3 | 95.9 | 94.8 | 93.4 | 95.0 | 94.5 | 93.9 | 92.9 |
| Arformoterol 7.5 Mcg | 84.7 | 85.2 | 86.6 | 89.0 | 87.5 | 88.9 | 89.3 | 90.3 | 93.3 | 91.8 | 91.2 | 90.2 | 90.6 | 89.8 | 89.3 | 89.6 | 89.8 |
| Levalbuterol 0.63 mg | 87.6 | 89.3 | 90.9 | 96.4 | 95.4 | 97.1 | 100.4 | 99.2 | 96.0 | 96.2 | 93.0 | 94.1 | 94.1 | 93.3 | 94.0 | 93.3 | 92.4 |
PEFR is the fastest rate at which air can move through the airways during a forced expiration starting with fully inflated lungs as measured by peak flow meters. (NCT00583947)
Timeframe: predose, various postdose times
| Intervention | liters/second (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| predose (n=37,38,27) | 10 minutes post dose 1 (n=37,38,27) | 25 minutes post dose 1 (n=37,37,27) | 10 minutes post dose 2 (n=36,38,27) | 25 minutes post dose 2 (n=36,38,27) | 10 minutes post dose 3 (n=34,38,27) | 25 minutes post dose 3 (n=35,38,26) | 2 hours post dose 1 (n=36,37,27) | 4 hours post dose 1 (n=36,38,27) | 6 hours post dose 1 (n=36,38,27) | |
| Arformoterol 15 Mcg | 3.565 | 3.824 | 3.844 | 3.925 | 3.989 | 4.077 | 4.017 | 4.066 | 4.039 | 4.016 |
| Arformoterol 7.5 Mcg | 3.546 | 3.788 | 3.877 | 3.890 | 3.964 | 4.003 | 4.007 | 4.178 | 4.029 | 4.058 |
| Levalbuterol 0.63 mg | 3.604 | 3.926 | 4.003 | 4.053 | 4.047 | 4.156 | 4.176 | 4.221 | 4.155 | 3.970 |
(NCT00583947)
Timeframe: Predose, 2 and 6 hours post dose 1
| Intervention | mg/dl (Mean) | ||
|---|---|---|---|
| Predose (n=51,52,40) | 2 hours post dose 1 (n=48,47,39) | 6 hours post dose 1 (n=49,48,38) | |
| Arformoterol 15 Mcg | 87.6 | 120.6 | 106.3 |
| Arformoterol 7.5 Mcg | 87.5 | 108.6 | 99.0 |
| Levalbuterol 0.63 mg | 86.4 | 114.5 | 107.6 |
(NCT00583947)
Timeframe: Predose, 2 hours and 6 hours postdose 1
| Intervention | mEq/L (Mean) | ||
|---|---|---|---|
| Predose (n=51,52,39) | 2 hours post dose 1 (n=48,47,38) | 6 hours post dose 1 (n=48,49,38) | |
| Arformoterol 15 Mcg | 4.31 | 3.71 | 3.87 |
| Arformoterol 7.5 Mcg | 4.27 | 3.83 | 3.95 |
| Levalbuterol 0.63 mg | 4.25 | 3.67 | 3.99 |
Systolic blood pressure measured at various timepoints: predose and timepoints after each of the three dosings. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes). (NCT00583947)
Timeframe: predose, various timeframes up to 5 hours post last dose
| Intervention | mmHg (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Predose (n=51,52,40) | 15 min post dose 1 (n=51,52,40) | 30 min post dose 1 (n=51,52,40) | 60 min post dose 1 (n=51,51,40) | 15 min post dose 2 (n=50,51,40) | 30 min post dose 2 (n=47,50,40) | 60 min post dose 2 (n=46,50,37) | 30 min post last dose (n=49,52,40) | 60 min post last dose (n=49,52,40) | 1.5 hours post last dose (n=48,52,40) | 2 hours post last dose (n=50,52,40) | 2.5 hours post last dose (n=49,52,40) | 3 hours post last dose (n=50,52,40) | 3.5 hours post last dose (n=50,52,40) | 4 hours post last dose (n=50,52,40) | 4.5 hours post last dose (n=50,52,40) | 5 hours post last dose (n=50,52,40) | |
| Arformoterol 15 Mcg | 100.6 | 102.6 | 100.3 | 103.2 | 102.1 | 101.9 | 102.9 | 101.6 | 104.9 | 103.0 | 101.8 | 101.3 | 101.9 | 101.4 | 100.5 | 101.5 | 102.1 |
| Arformoterol 7.5 Mcg | 101.5 | 101.2 | 102.5 | 102.7 | 101.7 | 102.8 | 101.9 | 101.2 | 103.0 | 101.9 | 103.4 | 101.5 | 102.1 | 103.2 | 102.1 | 103.2 | 104.1 |
| Levalbuterol 0.63 mg | 102.1 | 102.9 | 104.6 | 105.8 | 105.0 | 106.4 | 107.2 | 105.0 | 106.1 | 104.8 | 104.6 | 103.0 | 106.1 | 103.4 | 103.6 | 104.5 | 106.7 |
If the mean plasma concentration was 'below the limit of quantification' (BLQ) which was set as <=0.5 picograms/milliliter, the value is displayed as a zero. (NCT00583947)
Timeframe: predose, various postdose times
| Intervention | picogram/milliliter (Mean) | ||||
|---|---|---|---|---|---|
| predose (n=51,52,39) | 25 minutes post dose 1 (n=50,46,36) | 25 minutes post dose 2 (n=48,47,36) | 2 hours post dose 1 (n=50,51,38) | 6 hours post dose 1 (n=50,50,37) | |
| Arformoterol 15 Mcg | 0.737 | 1.659 | 3.325 | 4.189 | 2.818 |
| Arformoterol 7.5 Mcg | 0 | 2.236 | 1.845 | 1.885 | 0.874 |
| Levalbuterol 0.63 mg | 0.646 | 2.402 | 0 | 0 | 0 |
Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.539 |
| Salmeterol | 1.505 |
| Placebo | 1.572 |
Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.528 |
| Salmeterol | 1.515 |
| Placebo | 1.669 |
Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.679 |
| Salmeterol | 1.605 |
| Placebo | 1.652 |
Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.519 |
| Salmeterol | 1.56 |
| Placebo | 1.575 |
Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.203 |
| Salmeterol | 1.194 |
| Placebo | 1.224 |
Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.196 |
| Salmeterol | 1.135 |
| Placebo | 1.185 |
Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.267 |
| Salmeterol | 1.22 |
| Placebo | 1.232 |
Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.182 |
| Salmeterol | 1.176 |
| Placebo | 1.21 |
Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.458 |
| Salmeterol | 1.436 |
| Placebo | 1.52 |
Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.446 |
| Salmeterol | 1.415 |
| Placebo | 1.593 |
Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.549 |
| Salmeterol | 1.514 |
| Placebo | 1.583 |
Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.475 |
| Salmeterol | 1.478 |
| Placebo | 1.545 |
Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.57 |
| Salmeterol | 1.482 |
| Placebo | 1.62 |
Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.623 |
| Salmeterol | 1.482 |
| Placebo | 1.691 |
Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.699 |
| Salmeterol | 1.627 |
| Placebo | 1.735 |
Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.557 |
| Salmeterol | 1.571 |
| Placebo | 1.643 |
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.572 |
| Salmeterol | 1.495 |
| Placebo | 1.682 |
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.609 |
| Salmeterol | 1.476 |
| Placebo | 1.711 |
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.735 |
| Salmeterol | 1.637 |
| Placebo | 1.744 |
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.603 |
| Salmeterol | 1.569 |
| Placebo | 1.699 |
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.612 |
| Salmeterol | 1.486 |
| Placebo | 1.615 |
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.519 |
| Salmeterol | 1.436 |
| Placebo | 1.542 |
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.536 |
| Salmeterol | 1.461 |
| Placebo | 1.647 |
Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 1.504 |
| Salmeterol | 1.481 |
| Placebo | 1.613 |
Change from baseline in mean weekly morning peak expiratory flow at 16 weeks. Baseline is defined as the last week prior to the randomisation visit (NCT00350207)
Timeframe: baseline and after 16 weeks of treatment
| Intervention | L/min (Least Squares Mean) |
|---|---|
| Tiotropium | -3.93 |
| Salmeterol | -3.15 |
| Placebo | -24.63 |
Diastolic blood pressure collected in conjunction with spirometry at 6 weeks (NCT00350207)
Timeframe: After 6 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Tiotropium | 78.62 |
| Salmeterol | 77.62 |
| Placebo | 79.34 |
Diastolic blood pressure collected in conjunction with spirometry at 12 weeks (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Tiotropium | 77.88 |
| Salmeterol | 77.22 |
| Placebo | 78.29 |
Diastolic blood pressure collected in conjunction with spirometry at 16 weeks (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Tiotropium | 79.23 |
| Salmeterol | 77.61 |
| Placebo | 78.38 |
PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100% (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | ratio expressed in percent (Least Squares Mean) |
|---|---|
| Tiotropium | 11.735 |
| Salmeterol | 11.320 |
| Placebo | 11.257 |
PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100% (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | ratio expressed in percent (Least Squares Mean) |
|---|---|
| Tiotropium | 11.742 |
| Salmeterol | 10.793 |
| Placebo | 12.305 |
PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100% (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | ratio expressed in percent (Least Squares Mean) |
|---|---|
| Tiotropium | 12.043 |
| Salmeterol | 10.547 |
| Placebo | 12.085 |
PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100% (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | ratio expressed in percent (Least Squares Mean) |
|---|---|
| Tiotropium | 13.377 |
| Salmeterol | 11.252 |
| Placebo | 12.964 |
Mean weekly evening forced expiratory volume in 1 second at week 12, pre-dose (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.31 |
| Salmeterol | 2.299 |
| Placebo | 2.231 |
Mean weekly evening forced expiratory volume in 1 second at week 16, pre-dose (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.343 |
| Salmeterol | 2.291 |
| Placebo | 2.215 |
Mean weekly evening forced expiratory volume in 1 second at week 4, pre-dose (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.369 |
| Salmeterol | 2.318 |
| Placebo | 2.25 |
Mean weekly evening forced expiratory volume in 1 second at week 8, pre-dose (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.32 |
| Salmeterol | 2.301 |
| Placebo | 2.239 |
Mean weekly evening peak expiratory flow at week 12, pre-dose (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | L/min (Least Squares Mean) |
|---|---|
| Tiotropium | 366.282 |
| Salmeterol | 362.01 |
| Placebo | 344.291 |
Mean weekly evening peak expiratory flow at week 16, pre-dose (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | L/min (Least Squares Mean) |
|---|---|
| Tiotropium | 363.657 |
| Salmeterol | 360.304 |
| Placebo | 340.099 |
Mean weekly evening peak expiratory flow at week 4, pre-dose (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | L/min (Least Squares Mean) |
|---|---|
| Tiotropium | 374.496 |
| Salmeterol | 366.219 |
| Placebo | 348.344 |
Mean weekly evening peak expiratory flow at week 8, pre-dose (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | L/min (Least Squares Mean) |
|---|---|
| Tiotropium | 368.758 |
| Salmeterol | 359.586 |
| Placebo | 345.299 |
Mean weekly morning forced expiratory volume in 1 second at week 12, pre-dose (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.256 |
| Salmeterol | 2.254 |
| Placebo | 2.156 |
Mean weekly morning forced expiratory volume in 1 second at week 16, pre-dose (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.3 |
| Salmeterol | 2.278 |
| Placebo | 2.188 |
Mean weekly morning forced expiratory volume in 1 second at week 4, pre-dose (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.301 |
| Salmeterol | 2.316 |
| Placebo | 2.161 |
Mean weekly morning forced expiratory volume in 1 second at week 8, pre-dose (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.254 |
| Salmeterol | 2.287 |
| Placebo | 2.164 |
Mean weekly morning peak expiratory flow at week 12, pre-dose (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | L/min (Least Squares Mean) |
|---|---|
| Tiotropium | 359.05 |
| Salmeterol | 351.3 |
| Placebo | 332.808 |
Mean weekly morning peak expiratory flow at week 16, pre-dose (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | L/min (Least Squares Mean) |
|---|---|
| Tiotropium | 355.619 |
| Salmeterol | 355.799 |
| Placebo | 334.525 |
Mean weekly morning peak expiratory flow at week 4, pre-dose (NCT00350207)
Timeframe: After 4 weeks of treatment
| Intervention | L/min (Least Squares Mean) |
|---|---|
| Tiotropium | 360.695 |
| Salmeterol | 359.762 |
| Placebo | 335.515 |
Mean weekly morning peak expiratory flow at week 8, pre-dose (NCT00350207)
Timeframe: After 8 weeks of treatment
| Intervention | L/min (Least Squares Mean) |
|---|---|
| Tiotropium | 355.42 |
| Salmeterol | 350.53 |
| Placebo | 330.193 |
Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 5.233 |
| Salmeterol | 5.399 |
| Placebo | 5.078 |
Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 5.305 |
| Salmeterol | 5.454 |
| Placebo | 5.214 |
Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value (NCT00350207)
Timeframe: After 6 weeks of treatment
| Intervention | Unit on a scale (Least Squares Mean) |
|---|---|
| Tiotropium | 5.050 |
| Salmeterol | 5.259 |
| Placebo | 5.097 |
Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 6 weeks of treatment (NCT00350207)
Timeframe: After 6 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.471 |
| Salmeterol | 2.401 |
| Placebo | 2.299 |
Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 12 weeks of treatment (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.467 |
| Salmeterol | 2.442 |
| Placebo | 2.266 |
Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 16 weeks od treatment (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 2.439 |
| Salmeterol | 2.457 |
| Placebo | 2.29 |
Morning pre-dose forced vital capacity as measured by spirometry after 6 weeks of treatment (NCT00350207)
Timeframe: After 6 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 3.531 |
| Salmeterol | 3.441 |
| Placebo | 3.367 |
Morning pre-dose forced vital capacity as measured by spirometry after 12 weeks of treatment (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 3.509 |
| Salmeterol | 3.495 |
| Placebo | 3.307 |
Morning pre-dose forced vital capacity as measured by spirometry after 16 weeks of treatment (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | L (Least Squares Mean) |
|---|---|
| Tiotropium | 3.488 |
| Salmeterol | 3.474 |
| Placebo | 3.353 |
Pulse rate collected in conjunction with spirometry at 6 weeks (NCT00350207)
Timeframe: After 6 weeks of treatment
| Intervention | bpm (Mean) |
|---|---|
| Tiotropium | 74.7 |
| Salmeterol | 74.9 |
| Placebo | 74.2 |
Pulse rate collected in conjunction with spirometry at 12 weeks (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | bpm (Mean) |
|---|---|
| Tiotropium | 74.8 |
| Salmeterol | 74.6 |
| Placebo | 74.2 |
Pulse rate collected in conjunction with spirometry at 16 weeks (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | bpm (Mean) |
|---|---|
| Tiotropium | 74.4 |
| Salmeterol | 75.3 |
| Placebo | 74.7 |
Systolic blood pressure collected in conjunction with spirometry at 6 weeks (NCT00350207)
Timeframe: After 6 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Tiotropium | 124.68 |
| Salmeterol | 123.11 |
| Placebo | 126.41 |
Systolic blood pressure collected in conjunction with spirometry at 12 weeks (NCT00350207)
Timeframe: After 12 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Tiotropium | 124.81 |
| Salmeterol | 123.92 |
| Placebo | 125.18 |
Systolic blood pressure collected in conjunction with spirometry at 16 weeks (NCT00350207)
Timeframe: After 16 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Tiotropium | 124.23 |
| Salmeterol | 123.83 |
| Placebo | 124.47 |
(NCT01231230)
Timeframe: maximum change in Qaw within 240 minutes post drug inhalation
| Intervention | change from baseline ( µl/min/ml) (Mean) |
|---|---|
| Fluticasone | -11.0 |
| Placebo | 14.1 |
| Salmeterol | 23.9 |
| Fluticasone/Salmeterol | 25.5 |
Bronchial responsiveness to serial concentrations of inhaled methacholine solution (mg/ml) as measured by serial ratios of follow-up to baseline FEV1 (forced volume of air expired from the lungs in one second). A dose-response curve is calculated from the serial ratios in relation to the serial concentrations to determine PC20, the concentration associated with a 20% drop from baseline in FEV1; this PC20 is the outcome measure with units mg/ml of methacholine. (NCT00000575)
Timeframe: 4-6 years from baseline
| Intervention | mg/ml of methacholine (Geometric Mean) |
|---|---|
| 1 Budesonide | 3.0 |
| 2 Nedocromil | 1.8 |
| 3 Placebo | 1.9 |
Change from baseline proportion of days without asthma symptoms or other asthma related events to proportion of days during the 4-6 years of follow-up. Asthma free days were determined from daily asthma diaries kept from baseline to the end of treatment, 4-6 years later. (NCT00000575)
Timeframe: 4-6 years from baseline
| Intervention | days per month (Mean) |
|---|---|
| 1 Budesonide | 11.3 |
| 2 Nedocromil | 9.3 |
| 3 Placebo | 9.3 |
Change in standing height from baseline to end of treatment. Standing height is measured three times without shoes using a calibrated Harpenden stadiometer; the average of the three repeated heights to the nearest 0.1 cm is the height measure at either baseline or end of treatment. (NCT00000575)
Timeframe: 4-6 years from baseline
| Intervention | cm (Mean) |
|---|---|
| 1 Budesonide | 22.7 |
| 2 Nedocromil | 23.7 |
| 3 Placebo | 23.8 |
Counts of deaths from asthma. (NCT00000575)
Timeframe: 4-6 years from baseline
| Intervention | participants (Number) |
|---|---|
| 1 Budesonide | 0 |
| 2 Nedocromil | 1 |
| 3 Placebo | 0 |
Counts during the period of treatment (4-6 years) of visits to emergency rooms or equivalent urgent care settings for asthma treatment. (NCT00000575)
Timeframe: 4-6 years from baseline
| Intervention | rate per 100 person years (Number) |
|---|---|
| 1 Budesonide | 12 |
| 2 Nedocromil | 16 |
| 3 Placebo | 22 |
Change in FEV1 % of predicted, post-bronchodilator use, from baseline to the end of treatment (4-6 years after randomization). Percent predicted determined from three separate published sets of reference equations for white, black, and Hispanic children - see NEJM 343: 1054-1062, 2000 for more details and references. (NCT00000575)
Timeframe: At the end of treatment, 4-6 years from baseline assessment
| Intervention | percentage of predicted value (Mean) |
|---|---|
| 1 Budesonide | 0.6 |
| 2 Nedocromil | -0.5 |
| 3 Placebo | -0.1 |
Change in total score on the Children's Depression Inventory from baseline to the end of treatment, 4-6 years later. The total score ranges from 0-54 with higher scores indicating greater levels of depression. (NCT00000575)
Timeframe: 4-6 years from baseline
| Intervention | units on a scale (Mean) |
|---|---|
| 1 Budesonide | -3.2 |
| 2 Nedocromil | -1.8 |
| 3 Placebo | -2.2 |
The forced expiratory volume in the first second, expressed as a percent predicted. (NCT00643578)
Timeframe: 1 hour after dose
| Intervention | percent predicted (Mean) |
|---|---|
| 12 Mcg of Formoterol | 88 |
| 24 Mcg of Formoterol | 91 |
The PC20 is the provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second. (NCT00643578)
Timeframe: 3-7 days after visits 1 and 2
| Intervention | mg/mL (Geometric Mean) |
|---|---|
| 12 Mcg Formoterol | 7 |
| 24 Mcg Formoterol | 16 |
duration of hospitalization, calculated by discharge date minus admission date (NCT03438383)
Timeframe: From day of admission to day of discharge from the hospital
| Intervention | days (Mean) | |
|---|---|---|
| Type of OBS: gastroplasty | Type of OBS: open gastric bypass | |
| Bi-PAP | 6 | 10 |
| Sham Bi-PAP | 6 | 10 |
difference in FEV1 value measured by spirometry pre- and post-operatively (NCT03438383)
Timeframe: 24 h before surgery and at 24, 48 and 72 h post-operatively
| Intervention | Litres (Mean) | |||
|---|---|---|---|---|
| 24h before surgery | 24h post-op | 48h post-op | 72h post-op | |
| Bi-PAP | 3.1 | 1.4 | 1.7 | 1.9 |
| Sham Bi-PAP | 3.1 | 1.3 | 1.3 | 1.4 |
difference in FVC value measured by spirometry pre- and post-operatively (NCT03438383)
Timeframe: 24 h before surgery and at 24, 48 and 72 hours post-operatively
| Intervention | Litres (Mean) | |||
|---|---|---|---|---|
| 24h before surgery | 24h post-op | 48h post-op | 72h post-op | |
| Bi-PAP | 3.5 | 1.6 | 2.0 | 2.3 |
| Sham Bi-PAP | 3.4 | 1.3 | 1.5 | 1.9 |
occurrence of atelectasis as defined by chest X-ray (CXR) post-operatively with CXR before surgery as baseline (NCT03438383)
Timeframe: At 24, 48 and 72 hours post-operatively
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 24h post-op | 48h list-op | 72h post-op | |
| Bi-PAP | 0 | 0 | 0 |
| Sham Bi-PAP | 3 | 3 | 3 |
occurrence of hypoxemia, considered as SpO2<90%, post-operatively (NCT03438383)
Timeframe: At 24, 48 and 72 hours post-operatively
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 24h post-op | 48h post-op | 72h post-op | |
| Bi-PAP | 0 | 0 | 0 |
| Sham Bi-PAP | 5 | 0 | 0 |
difference in PEFR value measured by spirometry pre- and post-operatively (NCT03438383)
Timeframe: 24 h before surgery and at 24, 48 and 72 hours post-operatively
| Intervention | Litres/minute (Mean) | |||
|---|---|---|---|---|
| 24h before surgery | 24h post-op | 48h post-op | 72h post-op | |
| Bi-PAP | 325.3 | 137.4 | 195.7 | 247.5 |
| Sham Bi-PAP | 376.9 | 146.9 | 166.0 | 190.1 |
Intensity of pain was assessed post-operatively by Numerical Rating Scale (NRS) (0-10, 0=no pain, 10=worst pain imaginable) (NCT03438383)
Timeframe: right before spirometry, at 24, 48 and 72 h post-operatively
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| 24h post-op | 48h post-op | 72h post-op | |
| Bi-PAP | 6.5 | 5.3 | 3.5 |
| Sham Bi-PAP | 6.5 | 4.5 | 3.3 |
difference in SpO2 value measured by spirometry pre- and post-operatively (NCT03438383)
Timeframe: 24 h before surgery and at 24, 48 and 72 hours post-operatively
| Intervention | percentage of SpO2 (Mean) | |||
|---|---|---|---|---|
| 24h before surgery | 24h post-op | 48h post-op | 72h post-op | |
| Bi-PAP | 96.9 | 92.6 | 95.2 | 96.8 |
| Sham Bi-PAP | 96.9 | 91.6 | 92.4 | 92.5 |
Adherence to ICS medication was measured during the last 3 months of the intervention (i.e., for the time period of 9-12 months post-randomization). Adherence was measured using pharmacy claims data, and represents the percent of prescribed medication taken. The normal range for this value is 0-100%. (NCT00459368)
Timeframe: 1 year
| Intervention | Percent of ICS medication taken (Mean) |
|---|---|
| Patient Medication Adherence Feedback | 21.3 |
| Usual Care | 23.3 |
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
The main outcome measure is the concentration of Fluticasone Propionate in blood following inhalation of the dose. This will be found by calculating the area under the curve of concentration versus time 0 and 12 hours. (NCT00692978)
Timeframe: 12 hours
| Intervention | pg.h/ml (Median) |
|---|---|
| FP From Active 250 ug MDI Inhaler Asthma | 188.2 |
| FP 50ug 1.5um Asthma | 756 |
| FP 50ug 3um Asthma | 978 |
| FP 50ug 6um Asthma | 380.5 |
| FP From Active 250 ug MDI Inhaler HV | 172.3 |
| FP 50ug 1.5um HV | 740 |
| FP 50ug 3um HV | 934.6 |
| FP 50ug 6um HV | 250.4 |
The concentration of Adenosine Monophosphate (AMP), measured in mg/ml, required to see a 20% fall in the patient's forced expiratory volume in 1 second (FEV1) is measured after taking FP aerosol. AMP is a bronchoconstrictor agent (ie it narrows the airways. We would expect that more would be necessary to produce the same 20% fall in FEV1 after receiving the FP than before due to the reduction in airways inflammation. This change is the primary outcome measure. (NCT01662778)
Timeframe: 2 hours
| Intervention | mg/ml (Mean) |
|---|---|
| Monodisperse FP 1.5um | 79.21 |
| Monodisperse FP 6.0um | 79.74 |
| Placebo STAG | 62.69 |
| MDI FP | 92.1 |
The concentration of Fluticasone Propionate in blood following inhalation of the dose will be measured. Cmax will be measured. (NCT01662778)
Timeframe: 4 hours
| Intervention | pg/ml (Mean) |
|---|---|
| Monodisperse Fluticasone Propionate 6.0 Microns | 283.4 |
| Monodisperse Fluticasone Propionate 1.5microns | 636 |
| Placebo STAG | 0 |
| Metered Dose Inhaler of Fluticasone Propionate | 86.94 |
"Spirometry used to measure FEV1, was performed according to internationally accepted standards. Results show the change from baseline in FEV1 AUC(0-12h), normalized by time on Day 14; it was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Definitions:~AUC=Area under the curve; AUC(0-12h)=AUC between 0 and 12 h; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period; FEV1=Forced expiratory volume in the 1st second;" (NCT03086460)
Timeframe: Baseline, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) |
|---|---|
| Treatment A | 0.174 |
| Treatment B | 0.221 |
| Treatment C | 0.197 |
| Treatment D | 0.231 |
| Treatment E | 0.064 |
| Treatment F | 0.208 |
"Spirometry used to measure FEV1, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1 post-dose
| Intervention | Litres (Least Squares Mean) |
|---|---|
| Treatment A | 0.181 |
| Treatment B | 0.221 |
| Treatment C | 0.260 |
| Treatment D | 0.282 |
| Treatment E | 0.067 |
| Treatment F | 0.239 |
"Patients achieving onset of action, defined as a change from baseline in post-dose FEV1 ≥12% and ≥200 mL, on Day 1. These are the subjects who contributed to the results, reported as median and 95% CI for 'Time to onset of action' presented in the Outcome Measure 13, above.~For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.~Definitions:~Onset of action=Change from baseline in post-dose FEV1 ≥12% and ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose);" (NCT03086460)
Timeframe: Baseline, Day 1 post-dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment A | 23 |
| Treatment B | 22 |
| Treatment C | 30 |
| Treatment D | 29 |
| Treatment E | 11 |
| Treatment F | 31 |
"Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) |
|---|---|
| Treatment A | 0.071 |
| Treatment B | 0.102 |
| Treatment C | 0.073 |
| Treatment D | 0.149 |
| Treatment E | 0.037 |
| Treatment F | 0.126 |
"Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) |
|---|---|
| Treatment A | 0.048 |
| Treatment B | 0.044 |
| Treatment C | 0.048 |
| Treatment D | 0.114 |
| Treatment E | 0.053 |
| Treatment F | 0.114 |
"The primary analysis was repeated, considering patients as randomized and including only the first instance of each treatment.~Patients receiving the same treatment in more than one period were included in the analysis with only data from the first instance of each treatment." (NCT03086460)
Timeframe: Baseline, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) |
|---|---|
| Treatment A | 0.169 |
| Treatment B | 0.224 |
| Treatment C | 0.196 |
| Treatment D | 0.232 |
| Treatment E | 0.058 |
| Treatment F | 0.206 |
"The primary analysis was repeated, considering only patients and treatment periods for which treatment was assigned on or after the randomization error occurred.~The number of patients shown represents those with at least one post-baseline assessment available." (NCT03086460)
Timeframe: Baseline, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) |
|---|---|
| Treatment A | 0.129 |
| Treatment B | 0.180 |
| Treatment C | 0.159 |
| Treatment D | 0.179 |
| Treatment E | -0.006 |
| Treatment F | 0.170 |
"Patients receiving the same treatment during two treatment periods are considered twice in the ANCOVA model (once for each period attended).~Patients considered in this analysis are those with at least one available post-baseline assessment." (NCT03086460)
Timeframe: Baseline, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) |
|---|---|
| Treatment A | 0.144 |
| Treatment B | 0.194 |
| Treatment C | 0.170 |
| Treatment D | 0.198 |
| Treatment E | 0.037 |
| Treatment F | 0.184 |
"Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~For patients receiving the same treatment twice, the analysis includes only data from the first instance of each treatment.~Definitions:~Time to onset of action=The time (in minutes) from receiving the study drug on Day 1, until the FEV1 change from baseline is ≥200 mL; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1 post-dose
| Intervention | minutes (Median) |
|---|---|
| Treatment A | 358.8 |
| Treatment B | 60.3 |
| Treatment C | 33.6 |
| Treatment D | 44.3 |
| Treatment E | NA |
| Treatment F | 45.5 |
"Results are shown by treatment group, as change from baseline (in bpm).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | bpm (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, 30 min post-dose | Day 1, 1h post-dose | Day 1, 4h post-dose | Day 1, 8h post-dose | Day 1, 12h post-dose | Day 14, pre-dose | Day 14, 30 min post-dose | Day 14, 1h post-dose | Day 14, 4h post-dose | Day 14, 8h post-dose | Day 14, 12h post-dose | |
| Treatment A | 0.3 | -1.3 | 2.1 | 5.0 | 5.1 | 2.5 | 2.9 | 1.9 | 2.8 | 5.5 | 7.4 |
| Treatment B | 1.2 | 0.3 | 1.5 | 2.4 | 5.5 | 0.1 | -0.8 | -1.2 | 2.3 | 3.5 | 7.5 |
| Treatment C | 1.7 | 2.7 | 3.3 | 5.0 | 5.5 | 3.1 | 1.6 | 1.6 | 6.7 | 4.9 | 6.7 |
| Treatment D | 2.5 | 1.5 | 5.3 | 3.9 | 7.6 | 2.0 | 4.3 | 3.2 | 3.4 | 3.8 | 5.4 |
| Treatment E | -2.4 | -1.8 | 0.2 | 0.5 | 2.4 | 0.7 | -1.5 | -1.2 | 1.8 | 1.6 | 0.5 |
| Treatment F | -0.3 | -1.2 | 3.2 | 2.1 | 5.2 | 0.4 | 1.3 | 0.4 | 2.3 | 2.6 | 5.1 |
"12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | msec (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, 30 min post-dose | Day 1, 1h post-dose | Day 1, 4h post-dose | Day 1, 8h post-dose | Day 1, 12h post-dose | Day 14, pre-dose | Day 14, 30 min post-dose | Day 14, 1h post-dose | Day 14, 4h post-dose | Day 14, 8h post-dose | Day 14, 12h post-dose | |
| Treatment A | -0.1 | 1.1 | -1.2 | -1.9 | -3.4 | 1.3 | -0.2 | 1.0 | -1.5 | -2.6 | -5.0 |
| Treatment B | 1.6 | 2.2 | 1.6 | -0.5 | -2.3 | 3.7 | 4.5 | 5.7 | 2.5 | 1.5 | 1.7 |
| Treatment C | -1.3 | -1.1 | -1.5 | -3.0 | -3.8 | -1.7 | -1.5 | 0.1 | -2.5 | -3.2 | -4.8 |
| Treatment D | -3.6 | -0.7 | -4.0 | -2.6 | -3.0 | -2.9 | -3.1 | -1.6 | -3.2 | -5.4 | -1.4 |
| Treatment E | 1.0 | 0.4 | -1.6 | -2.4 | -2.6 | 0.1 | 3.4 | 5.2 | 0.8 | -1.1 | 0.1 |
| Treatment F | 3.2 | 2.0 | 1.9 | -0.0 | -1.7 | 2.2 | 5.1 | 6.1 | 1.3 | 0.8 | -0.3 |
"12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | msec (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, 30 min post-dose | Day 1, 1h post-dose | Day 1, 4h post-dose | Day 1, 8h post-dose | Day 1, 12h post-dose | Day 14, pre-dose | Day 14, 30 min post-dose | Day 14, 1h post-dose | Day 14, 4h post-dose | Day 14, 8h post-dose | Day 14, 12h post-dose | |
| Treatment A | 1.2 | 1.3 | 1.2 | 0.6 | 0.5 | 0.5 | 1.4 | 1.3 | 2.0 | 0.7 | 0.8 |
| Treatment B | 1.2 | 1.0 | 2.1 | 0.9 | 1.0 | 1.0 | 1.6 | 0.9 | 1.8 | 1.2 | 0.4 |
| Treatment C | 1.7 | 1.2 | 2.2 | 1.3 | 1.0 | -0.5 | 0.5 | 0.4 | 0.6 | 0.1 | 0.3 |
| Treatment D | 1.1 | 1.6 | 2.1 | 0.5 | 0.9 | 1.7 | 2.4 | 2.3 | 2.8 | 1.4 | 1.4 |
| Treatment E | 0.8 | 1.0 | 1.0 | -0.2 | 0.4 | -0.9 | -0.3 | 0.0 | -0.2 | -0.8 | -1.0 |
| Treatment F | 1.3 | 1.4 | 1.1 | 0.5 | 0.8 | 0.8 | 1.7 | 1.0 | 1.1 | 0.9 | 0.5 |
"12-lead electrocardiogram (ECG) parameters were monitored during the study. Results are shown by treatment group, as change from baseline (in msec).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | msec (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, 30 min post-dose | Day 1, 1h post-dose | Day 1, 4h post-dose | Day 1, 8h post-dose | Day 1, 12h post-dose | Day 14, pre-dose | Day 14, 30 min post-dose | Day 14, 1h post-dose | Day 14, 4h post-dose | Day 14, 8h post-dose | Day 14, 12h post-dose | |
| Treatment A | 3.9 | 2.1 | 2.5 | 2.4 | 2.0 | 1.5 | 4.4 | 4.0 | 3.8 | 3.4 | 3.7 |
| Treatment B | 3.8 | 1.4 | 1.5 | 1.1 | 0.9 | -0.4 | 1.0 | 1.0 | 0.9 | 1.7 | 1.7 |
| Treatment C | 2.7 | 3.9 | 0.8 | 0.6 | -0.3 | 1.6 | 3.5 | 1.9 | 1.1 | 1.7 | -0.9 |
| Treatment D | 4.9 | 4.2 | 2.4 | 0.8 | 1.1 | 5.8 | 10.4 | 7.7 | 5.0 | 2.2 | 3.7 |
| Treatment E | -0.2 | 0.4 | -2.4 | -0.2 | -1.5 | -2.3 | 1.9 | 0.9 | -1.1 | 1.5 | -0.6 |
| Treatment F | 1.4 | -0.9 | -1.3 | -2.4 | -2.2 | 1.2 | 1.7 | 0.6 | -1.1 | 0.4 | -1.6 |
"Spirometry used to measure FEV1, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) | |
|---|---|---|
| Day 1 | Day 14 | |
| Treatment A | 0.220 | 0.214 |
| Treatment B | 0.250 | 0.251 |
| Treatment C | 0.270 | 0.231 |
| Treatment D | 0.317 | 0.278 |
| Treatment E | 0.047 | 0.061 |
| Treatment F | 0.288 | 0.259 |
"Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) | |
|---|---|---|
| Day 1 | Day 14 | |
| Treatment A | 0.359 | 0.346 |
| Treatment B | 0.370 | 0.373 |
| Treatment C | 0.393 | 0.349 |
| Treatment D | 0.430 | 0.389 |
| Treatment E | 0.178 | 0.183 |
| Treatment F | 0.416 | 0.367 |
"Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) | |
|---|---|---|
| Day 1 | Day 14 | |
| Treatment A | 0.111 | 0.103 |
| Treatment B | 0.156 | 0.134 |
| Treatment C | 0.160 | 0.120 |
| Treatment D | 0.182 | 0.142 |
| Treatment E | 0.059 | 0.060 |
| Treatment F | 0.172 | 0.134 |
"Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) | |
|---|---|---|
| Day 1 | Day 14 | |
| Treatment A | 0.158 | 0.135 |
| Treatment B | 0.186 | 0.146 |
| Treatment C | 0.159 | 0.136 |
| Treatment D | 0.215 | 0.194 |
| Treatment E | 0.036 | 0.050 |
| Treatment F | 0.213 | 0.177 |
"Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Patients receiving the same treatment during two periods are considered twice in the ANCOVA model (once for each period attended).~Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose) on Day 1 of the treatment period;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | Litres (Least Squares Mean) | |
|---|---|---|
| Day 1 | Day 14 | |
| Treatment A | 0.331 | 0.310 |
| Treatment B | 0.347 | 0.331 |
| Treatment C | 0.354 | 0.304 |
| Treatment D | 0.367 | 0.350 |
| Treatment E | 0.216 | 0.198 |
| Treatment F | 0.385 | 0.340 |
"Heart rate (HR) AUC(0-4h) and HR peak(0-4h), normalized by time (in bpm).~Results are shown as change from pre-dose on Day 14 (in bpm).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~Definitions:~HR=Heart rate; HR AUC(0-4h)=Area under the curve between 0 and 4 h for heart rate; HR peak(0-4h)=The maximum observed value over 4 h after dosing;" (NCT03086460)
Timeframe: Baseline, Day 14 post-dose
| Intervention | bpm (Mean) | |
|---|---|---|
| HR AUC(0-4h) | HR peak(0-4h) | |
| Treatment A | -0.4 | 3.5 |
| Treatment B | 0.5 | 5.1 |
| Treatment C | 0.4 | 5.1 |
| Treatment D | 1.3 | 5.3 |
| Treatment E | -0.2 | 4.3 |
| Treatment F | 0.9 | 4.8 |
"Heart rate HR AUC(0-4h) normalized by time. Results are shown by treatment group, as change from baseline (in bpm).~The HR AUC(0-4h) normalized by time is calculated based on the actual times, using the linear trapezoidal rule.~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | bpm (Mean) | |
|---|---|---|
| Day 1 | Day 14 | |
| Treatment A | 0.2 | 2.3 |
| Treatment B | 0.8 | 0.2 |
| Treatment C | 2.7 | 3.5 |
| Treatment D | 3.0 | 3.3 |
| Treatment E | -1.0 | -0.1 |
| Treatment F | 0.3 | 1.2 |
"Heart rate (HR) peak(0-4h) normalized by time.~Results are shown by treatment group, as change from baseline (in bpm).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period.~Definitions:~HR=Heart rate; HR peak(0-4h)=The maximum observed value over 4 hours following dosing;" (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | bpm (Mean) | |
|---|---|---|
| Day 1 | Day 14 | |
| Treatment A | 4.7 | 6.1 |
| Treatment B | 4.4 | 4.8 |
| Treatment C | 6.5 | 8.3 |
| Treatment D | 7.5 | 7.3 |
| Treatment E | 2.9 | 4.4 |
| Treatment F | 5.1 | 5.2 |
"Serum glucose level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | mmol/L (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1; 1.5h post-dose | Day 1; 3h post-dose | Day 1; 5h post-dose | Day 1; 7h post-dose | Day 1; 11h post-dose | Day 14; pre-dose | Day 14; 1.5h post-dose | Day 14; 3h post-dose | Day 14; 5h post-dose | Day 14; 7h post-dose | Day 14; 11h post-dose | |
| Treatment A | 0.49 | 0.45 | 0.83 | 0.81 | 0.98 | -0.34 | 0.09 | 0.09 | 0.04 | -0.04 | 0.39 |
| Treatment B | 0.34 | 0.54 | 1.12 | 0.42 | 1.08 | 0.00 | 0.26 | 0.77 | 0.90 | 0.60 | 1.30 |
| Treatment C | 0.57 | 1.10 | 1.11 | 1.24 | 1.89 | 0.49 | 0.97 | 1.31 | 1.12 | 0.73 | 1.50 |
| Treatment D | 1.19 | 1.79 | 1.58 | 1.37 | 1.42 | 0.49 | 1.21 | 1.51 | 1.16 | 1.09 | 1.47 |
| Treatment E | 0.47 | 0.26 | 0.51 | 0.84 | 1.40 | 0.37 | 0.35 | 0.25 | 0.32 | 0.25 | 1.03 |
| Treatment F | -0.06 | 0.39 | 0.44 | 0.61 | 0.90 | -0.03 | -0.03 | 0.16 | 0.53 | 0.18 | 0.68 |
"Serum potassium level was monitored during the study. Results are shown by treatment group, as change from baseline (in mmol/L).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~For safety variables, the baseline for each period was defined as pre-dose measurements on Day 1 of each treatment period." (NCT03086460)
Timeframe: Baseline, Day 1, Day 14 post-dose
| Intervention | mmol/L (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1; 1.5h post-dose | Day 1; 3h post-dose | Day 1; 5h post-dose | Day 1; 7h post-dose | Day 1; 11h post-dose | Day 14; pre-dose | Day 14; 1.5h post-dose | Day 14; 3h post-dose | Day 14; 5h post-dose | Day 14; 7h post-dose | Day 14; 11h post-dose | |
| Treatment A | -0.01 | -0.06 | -0.14 | -0.02 | 0.07 | 0.06 | -0.02 | -0.04 | -0.02 | 0.05 | 0.11 |
| Treatment B | -0.05 | -0.08 | -0.03 | -0.00 | 0.02 | -0.02 | -0.03 | -0.09 | -0.05 | 0.06 | 0.05 |
| Treatment C | -0.08 | -0.23 | -0.12 | -0.05 | -0.08 | 0.08 | -0.10 | -0.13 | -0.01 | 0.09 | 0.03 |
| Treatment D | -0.17 | -0.28 | -0.19 | -0.16 | -0.10 | -0.14 | -0.23 | -0.24 | -0.26 | -0.19 | -0.06 |
| Treatment E | -0.06 | 0.03 | -0.04 | 0.04 | 0.01 | 0.05 | -0.03 | -0.00 | 0.00 | 0.02 | 0.01 |
| Treatment F | -0.18 | -0.21 | -0.20 | -0.14 | -0.13 | -0.13 | -0.15 | -0.15 | -0.15 | -0.09 | -0.02 |
"Vital signs -- Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) were measured at pre-specified times (at baseline - pre dose and on Day 14 of each treatment period or on the day of early study termination).~Results are shown by treatment group, as change from baseline (in mmHg).~For patients receiving the same treatment in 2 periods, the average of the 2 available data points was considered in the calculation.~Definitions:~For safety variables, the baseline for each treatment period was defined as pre-dose measurements on Day 1 of each treatment period; Day 14=The day of the last dosing of a treatment period. Day 14 of the second, third, and fourth treatment periods (day of last dosing); treatments were separated by a 2-week wash-out interval;" (NCT03086460)
Timeframe: Baseline, Day 1 and Day 14 post-dose
| Intervention | mmHg (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP, Day 1, 30 min post-dose | SBP, Day 1, 1 h post-dose | SBP, Day 1, 4 h post-dose | SBP, Day 1, 8 h post-dose | SBP, Day 1, 12 h post-dose | SBP, Day 14, pre-dose | SBP, Day 14, 30 min post-dose | SBP, Day 14, 1 h post-dose | SBP, Day 14, 4 h post-dose | SBP, Day 14, 8 h post-dose | SBP, Day 14, 12 h post-dose | DBP, Day 1, 30 min post-dose | DBP, Day 1, 1 h post-dose | DBP, Day 1, 4 h post-dose | DBP, Day 1, 8 h post-dose | DBP, Day 1, 12 h post-dose | DBP, Day 14, pre-dose | DBP, Day 14, 30 min post-dose | DBP, Day 14, 1 h post-dose | DBP, Day 14, 4 h post-dose | DBP, Day 14, 8 h post-dose | DBP, Day 14, 12 h post-dose | |
| Treatment A | -1.2 | -0.1 | 1.7 | 0.8 | 1.8 | 1.0 | 0.3 | 0.1 | 0.9 | 0.7 | 1.2 | -2.1 | 0.0 | -0.6 | -1.5 | -0.5 | -1.2 | -0.2 | -0.3 | -1.0 | -1.1 | 0.0 |
| Treatment B | 0.2 | 0.5 | 0.4 | 0.2 | 2.1 | -1.8 | -3.1 | -1.8 | 0.1 | 1.3 | 1.0 | -1.5 | -1.9 | -1.4 | -0.9 | -0.1 | 0.1 | -2.1 | -2.4 | -1.5 | -1.0 | -0.7 |
| Treatment C | -0.8 | -0.6 | -0.9 | 1.1 | 3.0 | 0.0 | -0.7 | -1.8 | -1.4 | 1.1 | 1.5 | -1.2 | -0.4 | -0.4 | -0.4 | 0.4 | 1.1 | -0.8 | -0.5 | -1.7 | 0.3 | 0.7 |
| Treatment D | -1.2 | -0.6 | 0.9 | 0.7 | 1.4 | -0.4 | -0.7 | -1.9 | 1.0 | 0.6 | 4.4 | -2.0 | -1.6 | -1.0 | -1.9 | -1.0 | -0.1 | -2.9 | -2.4 | -2.5 | -2.6 | -0.6 |
| Treatment E | -0.5 | -0.8 | 0.2 | 0.5 | -0.1 | -2.5 | -3.6 | -1.7 | -0.5 | -3.3 | -0.3 | -0.3 | -2.5 | -1.6 | -1.7 | -0.3 | -0.6 | -1.5 | -1.8 | 0.4 | -1.7 | 1.4 |
| Treatment F | -0.8 | -0.8 | 0.5 | 2.5 | 3.4 | -0.3 | -2.5 | -1.1 | -0.8 | 0.6 | 2.5 | -1.2 | -1.7 | -1.0 | 0.4 | 0.0 | -0.7 | -2.0 | -1.6 | -2.3 | -1.3 | -0.1 |
"To observe bronchodilator response(BDR) distribution curve for Chinese non-asthmatic children from 4-12 years, BDR calculated as: (FEV 1 L post-bronchodilator - FEV 1 L pre-bronchodilator)/FEV 1 L pre-bronchodilator × 100%.~To observe BDR distribution curve for Chinese controller-naïve asthmatic children from 4-12 years~To compare BDR values between non-asthmatic group and controller-naïve asthmatic group, and analyze appropriate cut-off point value" (NCT01500525)
Timeframe: 3 years
| Intervention | percentage of BDR (Mean) |
|---|---|
| Asthmatic Children | 9.45 |
| Non-asthmatic Children | 3.30 |
We powered our study to detect a difference of 0.5 mmol/L between pre and post-treatment lactate levels, but hypothesize that the difference will be greater than 1.0 mmol/L. (NCT02073747)
Timeframe: Change in serum lactate from baseline to 1 hour
| Intervention | mmol/L (Mean) |
|---|---|
| Normal Saline Control Group | -0.15 |
| Albuterol Trial Group | 0.77 |
Time to discharge eligibility (hours) (NCT00410150)
Timeframe: Hospital discharge
| Intervention | hours (Mean) |
|---|---|
| Heliox Group | 66.2 |
| Control Group | 63.4 |
Images of the lungs will be taken for radiolabelled salbutamol treatment. The images will be processed using computer software and the lungs divided into central airways (C - region) and peripheral airways (P -region). We will analyse the amount of radiolabelled salbutamol in each region and calculate how deep into the lungs the inhaled salbutamol has reached by using the ratio C/P which is known as the Penetration Index. (NCT01721291)
Timeframe: 5 MINUTES AFTER INHALATION OF SALBUTAMOL
| Intervention | ratio (Mean) |
|---|---|
| Healthy_1.5um Slow | 0.8 |
| Healthy_1.5um Fast | 0.72 |
| COPD 1_1.5um Slow | 0.69 |
| COPD1_1.5um Fast | 0.58 |
| Healthy_3um Slow | 0.75 |
| Healthy_3um Fast | 0.63 |
| COPD_3um Slow | 0.65 |
| COPD_3um Fast | 0.48 |
| Healthy_6um Slow | 0.51 |
| Healthy_6um Fast | 0.46 |
| COPD_6um Slow | 0.37 |
| COPD_6um Fast | 0.32 |
(NCT00595361)
Timeframe: 2 weeks after 1st dose of Salmeterol
| Intervention | % fall FEV1 (Mean) |
|---|---|
| Arg/Arg | -12.6 |
| Gly/Gly | -16.5 |
(NCT00595361)
Timeframe: 2 weeks after exercise challenge
| Intervention | % fall FEV1 (Mean) |
|---|---|
| Arg/Arg | 12.6 |
| Gly/Gly | 16.5 |
(NCT00595361)
Timeframe: 2 weeks from pre-salmeterol baseline
| Intervention | % fall FEV1 (Mean) |
|---|---|
| Arg/Arg | 5.9 |
| Gly/Gly | 4.3 |
Determine differences in healthcare visits which include all-cause and respiratory related, acute care outpatient visits, emergency department visits, and hospitalizations between groups (NCT03137303)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergency room visit72551318 | Emergency room visit72551317 | Hospitalization72551317 | Hospitalization72551318 | Acute outpatient visit72551318 | Acute outpatient visit72551317 | Routine primary care visits72551317 | Routine primary care visits72551318 | New diagnostic tests72551318 | New diagnostic tests72551317 | |||||||||||||||||||||
| No | Missing | Yes | ||||||||||||||||||||||||||||
| Patient Subject Usual Care | 111 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 76 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 119 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 93 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 1 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 48 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 17 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 182 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 152 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 61 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 35 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 169 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 134 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 198 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 138 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 32 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 31 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 2 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 126 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 72 | |||||||||||||||||||||||||||||
| Patient Subject Usual Care | 104 | |||||||||||||||||||||||||||||
| Patient-Subject Intervention | 97 | |||||||||||||||||||||||||||||
Duration (in days) of continuous nebulized albuterol. (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week
| Intervention | days (Median) |
|---|---|
| Methylprednisolone Arm - Standard Care | 1 |
| Dexamethasone Arm - Interventional Arm | 0.8 |
Hospital length of stay measured in days. (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week
| Intervention | days (Mean) |
|---|---|
| Methylprednisolone Arm - Standard Care | 2.9 |
| Dexamethasone Arm - Interventional Arm | 2.9 |
"Number of participants receiving an adjunctive therapy:~use of non-invasive ventilation (NIV)~terbutaline~inhaled helium~inhaled anesthetic gas~mechanical ventilation~extracorporeal life support" (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm - Standard Care | 41 |
| Dexamethasone Arm - Interventional Arm | 16 |
Rates of known corticosteroid-related adverse events including clinically-relevant gastrointestinal bleeding, gastritis, ventilator associated pneumonia, necrotizing enterocolitis, hypertension, hyperglycemia, altered mentation (including hallucinations and delirium), and adrenal insufficiency observed prior to hospital discharge. (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Hyperglycemia | Hypertension | Adrenal insufficiency | Altered mentation | Clinically-relevant gastrointestinal bleeding | Gastritis | Necrotizing enterocolitis | Ventilator associated pneumonia | |
| Dexamethasone Arm | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Methylprednisolone Arm | 7 | 1 | 2 | 2 | 0 | 0 | 0 | 0 |
Healthcare consists of one or other of hospital admission, emergency department attendance, unscheduled consultation with a GP (NCT00129987)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Nurse Group | 61 |
| Lay Educator Group | 65 |
Number of participants with courses of steriod tablets (NCT00129987)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Nurse Group | 60 |
| Lay Educator Group | 62 |
The investigators will determine if each patient had any unscheduled visits to the emergency room, urgent care or primary care physician. (NCT02192827)
Timeframe: 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Single Dose Dexamethasone | 14 |
| Two Dose Dexamethasone | 12 |
Will determine number of days to symptom resolution, including missed school days. (NCT02192827)
Timeframe: 5 days
| Intervention | Days (Mean) |
|---|---|
| Single Dose Dexamethasone | 2.4 |
| Two Dose Dexamethasone | 2.5 |
The investigators will determine during phone follow up if patient experienced any side effects related to the Dexamethasone, including vomiting, mood swings, behavior changes, appetite changes, sweating or headache. (NCT02192827)
Timeframe: 5 days
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| No side effects | Decreased Appetite | Difficulty Sleeping | Mood swings/Agitation | Headache | Other | Multiple | |
| Single Dose Dexamethasone | 71 | 4 | 9 | 7 | 3 | 5 | 17 |
| Two Dose Dexamethasone | 83 | 7 | 0 | 3 | 1 | 4 | 18 |
Mean of heart rate in beats per minute before treatment minus mean of heart rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol (NCT00393367)
Timeframe: From the initial heart rate to heart rate 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator
| Intervention | Beats per minute (Mean) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | 12 |
| Placebo (Normal Saline) | 13 |
The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator. (NCT00393367)
Timeframe: Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator
| Intervention | Units on a scale (Mean) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | -2.9 |
| Placebo (Normal Saline) | -3.0 |
Mean respiratory rate in breaths per minute before treatment minus respiratory rate 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator. (NCT00393367)
Timeframe: Initial rate, minus rate taken 2 hours after budesonide/albuterol intervention or saline/albuterol comparator
| Intervention | Breaths per minute (Mean) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | -6 |
| Placebo (Normal Saline) | -6 |
The scale used is the Asthma Score published by Qureshi et al. The Asthma Score ranges from a low of 5 to maximum of 15 points. One to 3 points are given for each of 5 categories: age-based respiratory rate, oxygen saturation, wheeze, retractions, and dyspnea. For category detalails, please see the Qureshi reference. Scores of 5-7 are considered mild, 8-11 moderate, and 12-15 severe. Asthma Scores are recorded prior to any intervention and at 2 hours after budesonide inhalation suspension/albuterol intervention or saline placebo/albuterol comparator. (NCT00393367)
Timeframe: Initial asthma score minus score 2 hours after budesonide/albuterol intervention or saline placebo/albuterol comparator
| Intervention | Units on a scale (Median) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | -3 |
| Placebo (Normal Saline) | -3 |
The number of patients requiring hospital admission 4 hours after budesonide/albuterol intervention or saline/albuterol comparator. All hospitalization decisions are made at the discretion of the attending physician. (NCT00393367)
Timeframe: within 4 hours after the budesonide/albuterol intervention or saline/albuterol placebo
| Intervention | Participants (Number) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | 56 |
| Placebo (Saline) | 55 |
Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the mild category (Asthma Severity score 5-7) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator. (NCT00393367)
Timeframe: From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator
| Intervention | Participants (Number) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | 8 |
| Placebo (Normal Saline) | 10 |
Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who moved to the moderate category (Asthma Severity score 8-11) 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator. (NCT00393367)
Timeframe: From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator
| Intervention | Participants (Number) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | 22 |
| Placebo (Normal Saline) | 11 |
Of the patients who presented in the severe asthma category (Asthma Severity score of 12-15), those who remained in this category 2 hours after the budesonide/albuterol intervention or saline/albuterol comparator. (NCT00393367)
Timeframe: From the initial score to 2 hours after intervention with budesonide/albuterol or saline/albuterol comparator
| Intervention | Participants (Number) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | 4 |
| Placebo (Normal Saline) | 4 |
Mean oxygen saturation (non-invasive pulse-oximetry, % hemoglobin saturation) 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator minus mean oxygen saturation before treatment. (NCT00393367)
Timeframe: 2 hours after treatment with either budesonide/albuterol or saline/albuterol comparator
| Intervention | Percent Hemoglobin Saturation (Mean) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | 1.0 |
| Placebo (Normal Saline) | 1.0 |
Participants admitted to the hospital within 5 days of the ED visit (NCT00393367)
Timeframe: within 5 days of ED visit
| Intervention | Participants (Number) |
|---|---|
| Budesonide Inhalation Suspension (BIS) | 2 |
| Placebo (Normal Saline) | 2 |
(NCT00393367)
Timeframe: within 30 days of the ED visit
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Rhinorrhea | Headache | Diarrhea | Sore throat | Cough | Hyperglycemia | |
| Budesonide Inhalation Suspension (BIS) | 6 | 5 | 3 | 4 | 2 | 2 |
| Placebo (Normal Saline) | 11 | 9 | 7 | 3 | 3 | 0 |
Serious Adverse Events (NCT00393367)
Timeframe: 0-5 days
| Intervention | participants (Number) | |
|---|---|---|
| Return within 5 days with hosptial admission | Increased level of care | |
| Budesonide Inhalation Suspension (BIS) | 2 | 1 |
| Placebo (Saline) | 2 | 0 |
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Area under the curve from time zero to 6 hours post-dose (AUC[0-6]) was calculated using the trapezoidal rule. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose
| Intervention | pg*min/mL (Mean) |
|---|---|
| Treatment T | 8498 |
| Treatment C | 6191 |
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at Baseline (prior to dosing) in each treatment period following a specified washout period (3-14 days), and were analyzed using an established analysis method. Baseline concentration (C0) is the concentration of epinephrine measured in the plasma at this time point. (NCT01188577)
Timeframe: 0 to 30 minutes prior to dosing
| Intervention | pg/mL (Mean) |
|---|---|
| Treatment T | 2.6 |
| Treatment C | 4.3 |
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Half-life (t1/2) is the amount of time it takes for epinephrine to decrease to half the peak concentration in plasma during the treatment period. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose
| Intervention | min (Mean) |
|---|---|
| Treatment T | 145.9 |
| Treatment C | 289.8 |
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Peak (maximum) concentration (Cmax) is the highest concentration of epinephrine measured in plasma during the treatment period. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose
| Intervention | pg/mL (Mean) |
|---|---|
| Treatment T | 862 |
| Treatment C | 190 |
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Tmax is the amount of time it takes for epinephrine to reach peak concentration in plasma during the treatment period. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose
| Intervention | min (Mean) |
|---|---|
| Treatment T | 2.3 |
| Treatment C | 3.4 |
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. (NCT01188577)
Timeframe: Pre-dose to 6 hours post-dose
| Intervention | pg/mL (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 min (Baseline) | 2 min post-dose | 5 min post-dose | 7.5 min post-dose | 10 min post-dose | 12.5 min post-dose | 15 min post-dose | 20 min post-dose | 25 min post-dose | 30 min post-dose | 45 min post-dose | 60 min post-dose | 90 min post-dose | 120 min post-dose | 240 min post-dose | 360 min post-dose | |
| Treatment C | 4.3 | 189.0 | 99.1 | 48.8 | 39.7 | 33.9 | 32.0 | 30.1 | 20.3 | 17.7 | 19.8 | 13.2 | 11.2 | 6.9 | 17.7 | 17.2 |
| Treatment T | 2.6 | 861.5 | 379.4 | 186.6 | 118.3 | 75.6 | 46.8 | 22.9 | 10.9 | 10.5 | 10.5 | 8.7 | 3.5 | 6.5 | 16.1 | 17.1 |
Qaw will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days. (NCT01219738)
Timeframe: participants will be followed for 6 hours after budesonide dose
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Budesonide 360ug | 22.3 |
| Budesonide 720ug | 29.4 |
| Budesonide 1440ug | 34.1 |
| Budesonide 720ug 4 Times | 28.2 |
| Placebo | 5.1 |
FEV1 will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days. (NCT01219738)
Timeframe: participant will be followed up to 6 hours after budesonide dose
| Intervention | percentage of change from baseline (Mean) |
|---|---|
| Budesonide 360 ug | 0.1 |
| Budesonide 720 ug | 3.2 |
| Budesonide 1440 ug | 1.6 |
| 720ug of Budesonide 4 Times | 3.2 |
| Placebo | 0.8 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 6. Minimum FEV1 over 4-10 hours post-allergen challenge is the minimum value of all of the post-saline time points between 4 and 10 hrs post-allergen challenge, inclusive of the 4 hr and 10 hr timepoints (i.e., minimum over 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs). Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)
| Intervention | Liters (Least Squares Mean) |
|---|---|
| Placebo | -1.034 |
| FP 100 µg | -0.396 |
| FP 500 µg | -0.373 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hour after dosing on Day 6. The WM FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. LAR WM FEV1 was measured at 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs post-allergen challenge on Day 6. Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)
| Intervention | Liters (Least Squares Mean) |
|---|---|
| Placebo | -0.688 |
| FP 100 µg | -0.212 |
| FP 500 µg | -0.158 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hour after dosing on Day 6. The WM FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. LAR WM FEV1 was measured at 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs post-allergen challenge on Day 6. Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)
| Intervention | Liters (Least Squares Mean) |
|---|---|
| Placebo | -0.364 |
| FP 100 µg | -0.188 |
| FP 500 µg | -0.198 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 6. Minimum FEV1 over 4-10 hours post-allergen challenge is the minimum value of all of the post-saline time points between 4 and 10 hrs post-allergen challenge, inclusive of the 4 hr and 10 hr timepoints (i.e., minimum over 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs). Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)
| Intervention | Liters (Least Squares Mean) |
|---|---|
| Placebo | -0.592 |
| FP 100 µg | -0.420 |
| FP 500 µg | -0.431 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline FEV1 was measured on Day 1 pre-dose administration. FEV1 was measured on Day 1 post-dose, on Day 6 (prior to allergen challenge), and on Day 7 pre dose administration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Baseline, Day 1, Day 6, and Day 7
| Intervention | Liters (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Day 1, Smokers, n=17, 17, 17 | Day 6, Smokers, n=16, 17, 17 | Day 7, Smokers, n=17, 17, 17 | Day 1, Non-smokers, n=16, 18, 17 | Day 6, Non-smokers, n=18, 18, 18 | Day 7, Non-smokers, n=18, 18, 18 | |
| FP 100 µg | 0.216 | 0.016 | -0.083 | 0.237 | 0.114 | -0.079 |
| FP 500 µg | 0.177 | 0.032 | -0.053 | 0.217 | 0.058 | 0.012 |
| Placebo | 0.156 | -0.081 | -0.123 | 0.201 | -0.028 | -0.341 |
The concentration of eNO was measured on Day 6 pre-dose and on Day 7 post-study medication administration. eNO was measured 3 times at each time point, and all 3 measurements were recorded. The mean of the 3 measurements was calculated and was used in the derivation of summary statistics. (NCT01400906)
Timeframe: Day 6 and Day 7 of each treatment period (up to 11 weeks)
| Intervention | Parts per billion (Mean) | |||
|---|---|---|---|---|
| Day 6, Pre-dose, Smokers, n=16, 17, 17 | Day 7, Post-dose, Smokers, n=17, 17, 17 | Day 6, Pre-dose, Non-smokers, n=17, 18, 18 | Day 7, Post-dose, Non-smokers, n=18, 18, 18 | |
| FP 100 µg | 12.718 | 16.602 | 37.252 | 42.869 |
| FP 500 µg | 14.049 | 16.298 | 32.572 | 34.989 |
| Placebo | 21.117 | 45.167 | 62.980 | 98.837 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 6. Minimum FEV1 over 0-2 hrs post-allergen challenge (Minimum EAR) is the minimum value of all of the post-allergen challenge timepoints up to and including 2 hours post-allergen challenge (i.e., minimum over 5 minutes [min], 10 min, 15 min, 20 min, 30 min, 45 min and 1 hr, 1.5 hrs, and 2 hrs). The WM FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Absolute change from saline at each time point was calculated as the highest allergen challenge FEV1 value minus the highest saline FEV1 value. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 6 of each treatment period (up to 11 weeks)
| Intervention | Liters (Least Squares Mean) | |||
|---|---|---|---|---|
| Minimum FEV1, Smokers, n=16, 17, 17 | Minimum FEV1, Non-smokers, n=18, 18, 18 | WM FEV1, Smokers, n=16, 17, 17 | WM FEV1, Non-smokers, n=18, 18, 18 | |
| FP 100 µg | -0.769 | -0.743 | -0.303 | -0.349 |
| FP 500 µg | -0.817 | -0.676 | -0.362 | -0.311 |
| Placebo | -0.799 | -0.984 | -0.423 | -0.531 |
Sputum induction was performed using hypertonic saline solution to collect an adequate sample of secretions from lungs. The collected sputum was analyzed for neutrophil and eosinophil counts. Sputum induction was performed after methacholine challenge and post-dose administration on Day 7. Zero values are imputed to 0.001 for this analysis. Data were adjusted for the following covariates: period, smoking status, treatment, participant-level Baseline, period-level Baseline, and treatment by smoking status interaction. (NCT01400906)
Timeframe: Day 7 of each treatment period (up to 11 weeks)
| Intervention | 10^4 cells per gram of sputum (Geometric Mean) | |||
|---|---|---|---|---|
| Eosinophil count, Smokers, n=7, 7, 5 | Eosinophil count, Non-smokers, n=11, 11, 10 | Neutrophil count, Smokers, n=7, 7, 5 | Neutrophil count, Non-smokers, n=11, 11, 10 | |
| FP 100 µg | 0.489 | 0.878 | 50.313 | 49.532 |
| FP 500 µg | 0.459 | 0.144 | 87.699 | 36.561 |
| Placebo | 0.400 | 6.911 | 96.231 | 78.768 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants inhaled doubling increments of methacholine until a >=20% decrease in FEV1 from the post-saline value was achieved. (NCT01400906)
Timeframe: Day 7 of each treatment period (up to 11 weeks)
| Intervention | milligrams per milliliter (Geometric Mean) | |
|---|---|---|
| Smokers, n=16, 17, 17 | Non smokers, n=18, 17, 18 | |
| FP 100 µg | 1.233 | 1.488 |
| FP 500 µg | 1.439 | 2.080 |
| Placebo | 0.579 | 0.514 |
291 reviews available for albuterol and Asthma
| Article | Year |
|---|---|
Recent Advances in β
Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Clinical Trials as Topic; Heart Failure; Humans; Muscle | 2020 |
The environmental impact of inhalers for asthma: A green challenge and a golden opportunity.
Topics: Administration, Inhalation; Albuterol; Asthma; Dry Powder Inhalers; Environment; Greenhouse Gases; H | 2022 |
Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis.
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic | 2021 |
Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.
Topics: Administration, Inhalation; Albuterol; Asthma; Doping in Sports; Humans; Substance Abuse Detection | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Pharmacists' perspectives on school stock inhaler access for children.
Topics: Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers; Pharmacists; Surveys and Questionnaires | 2023 |
Asthma Care Protocol Implementation in the Pediatric Intensive Care Unit.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Hospitalization; Humans; Intensive Care Units, Pedi | 2023 |
Breathe easy: inhalational therapy for feline inflammatory airway disease.
Topics: Albuterol; Animals; Asthma; Bronchitis, Chronic; Cat Diseases; Cats; Emotions; Humans; Veterinarians | 2023 |
BET 1: Efficacy of different techniques using a metered-dose inhaler with Spacer to relieve symptoms in children with acute asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Equipment Design; Female; Hu | 2019 |
Metered-dose inhalers versus nebulization for the delivery of albuterol for acute exacerbations of wheezing or asthma in children: A systematic review with meta-analysis.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Disease | 2020 |
A meta-analysis of the influence of ADRB2 genetic polymorphisms on albuterol (salbutamol) therapy in patients with asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Polymorphism, Single Nucleotide; Receptors, Adrene | 2021 |
Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis.
Topics: Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2021 |
A compendium and review of pediatric pulmonary function testing assessment opportunities for asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Forced Expiratory Volume; Humans; Respi | 2022 |
Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreacti | 2018 |
Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volu | 2018 |
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Age Factors; Albute | 2018 |
[Asthmatic attack].
Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Middle Aged; Respiratory Sounds | 2018 |
Anti-doping Policy, Therapeutic Use Exemption and Medication Use in Athletes with Asthma: A Narrative Review and Critical Appraisal of Current Regulations.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagonists; Albuterol; Asthma; Athletes; Bronch | 2019 |
Tolerance & resistance to β₂-agonist bronchodilators.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; | 2013 |
Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Anti-Ast | 2013 |
Clinical Practice. Mild asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Algorithms; Anti-Asthmatic Agents; | 2013 |
Development of the siriraj clinical asthma score.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans; In | 2013 |
Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, | 2014 |
[Pregnancy and bronchial asthma].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A | 2014 |
[Influence of inhaler and fine particle on efficacy of inhalation therapy in COPD].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosol Propellants; Aerosols; Albuterol; Asth | 2014 |
Intravenous salbutamol for childhood asthma: evidence-based medicine?
Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Child, Preschool; Evid | 2014 |
COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma | 2014 |
What is the role of tiotropium in asthma?: a systematic review with meta-analysis.
Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Cholinergic Antagonists; Disease Progression; Drug Thera | 2015 |
[A new fixed dose combination of fluticasone and formoterol in a pressurised metered-dose inhaler for the treatment of asthma].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinati | 2014 |
Advances in acute asthma.
Topics: Acute Disease; Adrenergic beta-1 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; | 2015 |
Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma.
Topics: Albuterol; Androstadienes; Asthma; Beclomethasone; Drug Combinations; Dry Powder Inhalers; Ethanolam | 2015 |
Anticholinergics for treatment of asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agen | 2015 |
Salmeterol Xinafoate.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Biotran | 2015 |
Question 2: Blast from the past: is oral salbutamol useful in resource-poor settings?
Topics: Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; | 2015 |
In brief: a new albuterol inhaler (ProAir RespiClick) for asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Forced Expiratory Volume; Humans; M | 2015 |
Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Ast | 2015 |
Pharmacokinetics, pharmacodynamics, and clinical efficacy of albuterol RespiClick(™) dry-powder inhaler in the treatment of asthma.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Ap | 2016 |
Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Atropine; Cholinergic | 2017 |
Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Br | 2008 |
[Causes of prolonged and chronic cough].
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Chronic Disease; Clenbuterol; Cough; Dr | 2008 |
Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Child; Drug Combination | 2008 |
Regular treatment with salmeterol for chronic asthma: serious adverse events.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Ca | 2008 |
Regular treatment with formoterol for chronic asthma: serious adverse events.
Topics: Adrenergic beta-Agonists; Adult; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child; Chron | 2008 |
The risk of asthma mortality with inhaled long acting beta-agonists.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic A | 2008 |
Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod | 2009 |
Safety of long-acting beta2-agonists in the treatment of asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2007 |
Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Budesonide; Disease Progressi | 2008 |
Use of dry powder inhalers in acute exacerbations of asthma and COPD.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Disease Progression; Ethanolamin | 2009 |
Seretide: a pharmacoeconomic analysis.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone-Salmeterol | 2008 |
[Asthma therapy: combination of topical glucocorticosteroids and theophylline].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; B | 1997 |
[Long-acting beta(2)-adrenoceptor agonists for asthma and COPD].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Ant | 1997 |
Safety of long-acting beta-agonists: are new data really required?
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; De | 2009 |
Should salmeterol be used for long-term asthma control?
Topics: Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Evidence-Based Medicine; Female; Humans; | 2009 |
Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agen | 2009 |
Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Ast | 2009 |
Current options in the treatment of acute bronchospasm.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; A | 2005 |
Review article: management of acute severe and near-fatal asthma.
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aged; Albuterol; Amino | 2009 |
Salmeterol/fluticasone propionate: a review of its use in asthma.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Clinical Trials as Topic; Drug Combination | 2009 |
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; | 2009 |
Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Albuterol; Androst | 2009 |
[Do fixed combinations increase effectiveness in asthma bronchiale?].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmati | 2009 |
[Are there any advantages of a fixed combination in the treatment of asthma with respect to safety and tolerability?].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm | 2009 |
Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Bronchodila | 2010 |
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Ast | 2010 |
Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast.
Topics: Acetates; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Body Mass Index; Cyclopro | 2010 |
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al | 2009 |
Stopping long-acting beta-2 agonists.
Topics: Adrenal Cortex Hormones; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; | 2010 |
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al | 2010 |
Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic | 2010 |
Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000-2009 period.
Topics: Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bude | 2010 |
Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma.
Topics: Adult; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Cromolyn Sodium; Et | 2010 |
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Ethanolamines; Formoterol Fumarate; Glu | 2010 |
[Bronchial asthma in children].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2011 |
(R)-salbutamol in the treatment of asthma and chronic obstructive airways disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Pulmonary Dis | 2011 |
Safe use of long-acting β-agonists: what have we learnt?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; Ethanolamines; Formoterol Fum | 2011 |
Controversies regarding long-acting β2-agonists.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; Asth | 2011 |
Safety of formoterol in adults and children with asthma: a meta-analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Child, | 2011 |
[What helps for persistent symptoms of asthma during inhalative steroid therapy?].
Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; | 2011 |
Single maintenance and reliever therapy (SMART) for asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Albuterol; | 2011 |
Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Child; Drug | 2011 |
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Anti-Asthmatic Agent | 2012 |
Anticholinergic therapy for acute asthma in children.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Albutero | 2012 |
Regular treatment with formoterol for chronic asthma: serious adverse events.
Topics: Adrenergic beta-Agonists; Adult; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child; Chron | 2012 |
[Salbutamol in asthma treatment: with nebulizer or inhaler?].
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Delivery Systems | 2012 |
Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenal Insufficiency; Albuterol; Androstadiene | 2012 |
Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Child; Drug Therapy, Combination; Ethanolamines; Formotero | 2012 |
Management of asthma during pregnancy.
Topics: Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Antibodies, Anti-Idiotypic; Antibodies, M | 2013 |
Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans; Stereoiso | 2013 |
Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma.
Topics: Acetamides; Acute Disease; Administration, Inhalation; Administration, Intravenous; Adrenal Cortex H | 2012 |
Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Anti-Ast | 2012 |
Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Confidence Intervals; D | 2002 |
[symbol: see text] Seretide and [symbol: see text] Symbicort in asthma management.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Ast | 2002 |
Antagonism of long-acting beta2-adrenoceptor agonism.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Infla | 2002 |
Safety of sputum induction.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage; | 2002 |
Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control.
Topics: Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Clinical Trials | 2002 |
beta2-Agonists in acute asthma: the evolving state of the art.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Infusions | 2002 |
The long and short of beta2-agonists.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2002 |
From adrenaline to formoterol: advances in beta-agonist therapy in the treatment of asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Etha | 2002 |
Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Ethanolamines; For | 2002 |
Single-isomer levalbuterol: a review of the acute data.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Humans | 2003 |
Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD.
Topics: Administration, Inhalation; Albuterol; Area Under Curve; Asthma; Biological Availability; Bronchodil | 2002 |
[Milestones in inhalation therapy of airway diseases].
Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Aerosols; Albuterol; | 2002 |
[State of the art of the inhalation therapy of asthma].
Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Adult; Albuterol; All | 2002 |
Mechanisms of asthma.
Topics: Adenine; Adult; Albuterol; Asthma; Bronchodilator Agents; Chemokines; Child; Cytokines; Disease Prog | 2003 |
Long-term management of asthma.
Topics: Administration, Inhalation; Albuterol; Allergens; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bro | 2003 |
Salmeterol (Serevent) asthma trial halted early.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Black People; Humans; Multicente | 2003 |
Airway-stabilizing effect of long-acting beta2-agonists as add-on therapy to inhaled corticosteroids.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanol | 2003 |
Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-Response Rela | 2003 |
Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Drug Synergism; Drug Therapy, Combina | 2003 |
Long acting beta-agonists versus theophylline for maintenance treatment of asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Delayed-Action Preparatio | 2003 |
[Pharmacological action and clinical aspects of salmeterol].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2003 |
Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cost-Benefit Analysis; Drug Combinations; | 2003 |
Inhaled long acting beta agonists for stable chronic asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumara | 2003 |
Novolizer: a multidose dry powder inhaler.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agent | 2003 |
State of the art in beta2-agonist therapy: a safety review of long-acting agents.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Drug | 2003 |
The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.
Topics: Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Ethanolamines; Forced Expiratory Volu | 2004 |
Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Do | 2002 |
Best evidence topic reports. Is intravenous aminophylline better than intravenous salbutamol in the treatment of moderate to severe asthma?
Topics: Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Humans; Infusions, Intravenous | 2004 |
[Fixed combination of inhalant steroids and long-acting beta(2) agonists].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2004 |
[Recent study on pathogenesis of bronchial asthma and the therapeutic strategy].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Anti-Inflamm | 2004 |
Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Br | 2004 |
Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Molecular Structure; Pulmonary Disease, Chronic Ob | 2004 |
The cost effectiveness of levalbuterol versus racemic albuterol.
Topics: Albuterol; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Humans; Stereoisomerism; United Sta | 2004 |
Combination therapy in asthma--fixed or variable dosing in different patients?
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Budesonide; Bu | 2004 |
The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Child; Drug Administration Schedule; | 2004 |
[Treatment of exacerbation of asthma: what are today's issues?].
Topics: Acute Disease; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aeroso | 2005 |
What is new with the beta2-agonists: issues in the management of asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Clin | 2005 |
Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2005 |
Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.
Topics: Acetates; Administration, Inhalation; Albuterol; Androstadienes; Asthma; Asthma, Exercise-Induced; B | 2005 |
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Anti-Asthmatic Agent | 2005 |
Advances in pediatric asthma and atopic dermatitis.
Topics: Albuterol; Asthma; Bronchodilator Agents; Calcineurin Inhibitors; Child; Dermatitis, Atopic; Dermato | 2005 |
Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And | 2005 |
Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; A | 2006 |
Beta-adrenoceptor responses of the airways: for better or worse?
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory | 2006 |
Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.
Topics: Acetylcysteine; Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Anti-Bacterial Agents; | 2006 |
Asthma pathophysiology and evidence-based treatment of severe exacerbations.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Disease Progression; Evidence-Based Medicine; Humans; S | 2006 |
Managing acute attacks of asthma.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2006 |
Best evidence topic reports. Beta-agonists with or without anti-cholinergics in the treatment of acute childhood asthma?
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilat | 2006 |
Long-acting beta-agonists role in asthma management.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; C | 2006 |
Heliox-driven albuterol nebulization for asthma exacerbations: an overview.
Topics: Adult; Aerosol Propellants; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Delivery Systems; | 2006 |
Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Ch | 2006 |
[Comparison of different vehicles for nebulized salbutamol in treatment of bronchial asthma exacerbations: a Meta-analysis].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Female; Humans; Magnesium Sulfate; Male; Nebulizers and | 2006 |
Long-acting beta2-agonists in asthma: not so SMART?
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2006 |
[Right and wrong of salmeterol/fluticasone propionate combination].
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone; Humans; Sa | 2006 |
Review of guidelines and the literature in the treatment of acute bronchospasm in asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Albuterol; Asthma; Bronchial Spasm; Bronchodil | 2006 |
Managing bronchospasm with short-acting beta(2)-agonists.
Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Albuterol; Asth | 2006 |
Long-acting beta-agonists in adult asthma: Evidence that these drugs are safe.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; As | 2006 |
Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Controlled Cli | 2007 |
Formoterol as a rescue medication for asthma.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Doub | 2006 |
The controversy over long-acting beta agonists: examining the evidence.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Black or African American; | 2006 |
Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Chronic Disease; E | 2007 |
Evidence based review on levosalbutamol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Child; | 2007 |
Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.
Topics: Adrenergic beta-Agonists; Aerosol Propellants; Albuterol; Asthma; Atmosphere; Bronchodilator Agents; | 2007 |
Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Ast | 2007 |
Levalbuterol for asthma: a better treatment?
Topics: Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; Clinical Trials as Top | 2007 |
Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Delayed-Action Preparatio | 2007 |
Predictors of a more favourable response to combined therapy with salmeterol and fluticasone as initial maintenance therapy in asthma.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; A | 2008 |
beta-Adrenergic receptor polymorphisms: relationship to the beta-agonist controversy and clinical implications.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Genotype | 2007 |
Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists | 2008 |
Safety of long-acting beta-agonists in asthma: a review.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
The role of magnesium sulfate in the acute and chronic management of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Routes; Humans; Magnesiu | 2008 |
Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Budesonide; Ethanolamines; Female; Formoterol Fu | 2007 |
Vascular remodelling in asthma.
Topics: Adolescent; Albuterol; Animals; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Matr | 2008 |
Inhalatory therapy training: a priority challenge for the physician.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aerosols; Aged; Albuterol; Androstadiene | 2007 |
Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review.
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; | 2008 |
Pharmacogenetic response to albuterol among asthmatics.
Topics: Albuterol; Asthma; Genetic Variation; Humans; Pharmacogenetics; Receptors, Adrenergic, beta-2 | 2008 |
[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alb | 2008 |
Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And | 2008 |
Adrenergic drugs.
Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Catecholamines; Chemical Phenomena; Chemistry | 1983 |
[Preventive treatment of asthma due to exertion in children: comparative study of 4 drugs].
Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Atropine Derivatives; Beclomethasone; Child; Cromolyn S | 1981 |
Adrenergic agents in acute asthma: valuable new alternatives.
Topics: Acute Disease; Aerosols; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Epinephrine; Humans; Iso | 1983 |
Bronchial asthma in adults: presentation to the emergency department. Part II: Sympathomimetics, respiratory failure, recommendations for initial treatment, indications for admission, and summary.
Topics: Adrenal Cortex Hormones; Albuterol; Aminophylline; Asthma; Emergencies; Epinephrine; Humans; Hydroge | 1983 |
Response: asthma in childhood.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aerosols; Albuterol; Asthma; Bronchodilator Agents; C | 1983 |
[Inhalation provocation tests in the diagnosis of bronchial asthma].
Topics: Albuterol; Allergens; Asthma; Bronchi; Bronchial Provocation Tests; Carbachol; Evaluation Studies as | 1982 |
Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance.
Topics: Aerosols; Albuterol; Allergens; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Cold Temperatu | 1981 |
Salmeterol for the treatment of asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Chro | 1995 |
Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol F | 1995 |
Administration of albuterol by continuous nebulization.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers | 1995 |
Salmeterol: its place in asthma management.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Sche | 1994 |
Salmeterol in the management of paediatric asthma.
Topics: Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Asthma, Exercise-Induced; Bronchodilator | 1994 |
Salmeterol: a novel, long-acting beta 2-agonist.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Clinic | 1993 |
Beta-agonist inhaler causing hallucinations.
Topics: Albuterol; Animals; Asthma; Child; Chlorofluorocarbons, Methane; Hallucinations; Humans; Male; Nebul | 1994 |
Beta 2-agonists as anti-inflammatory therapies in the lung.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchitis; Ca | 1993 |
Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; | 1993 |
Evolution of asthma treatments.
Topics: Albuterol; Asthma; Beclomethasone; Humans | 1993 |
Efficacy and safety of salmeterol in childhood asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; A | 1995 |
[Anti-allergic effects of beta-adrenoceptor agonists in the clinical pharmacological studies].
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Allergic Agents; Asthma; Bronchi; Bronchial Hyperreactivit | 1996 |
[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics].
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Fenote | 1996 |
Bronchodilators: new drugs and controversies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Asthma, Exercise-Induced; Bron | 1997 |
A paradoxical effect of bronchodilators.
Topics: Acidosis, Lactic; Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; | 1997 |
Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Bro | 1997 |
Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.
Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; | 1997 |
Salmeterol in the treatment of chronic asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Humans; Salmeterol Xinafoate | 1997 |
Long-acting beta 2-agonists. Role in primary care asthma treatment.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Ethanolamines; Formoterol | 1997 |
New developments in bronchodilator therapy.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-Agonists; | 1996 |
Is the tolerance to the bronchoprotective effect of salmeterol clinically relevant?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodilator Age | 1998 |
Long-acting beta(2)-agonists: how are they used in an optimal way?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Schedule; Dr | 1997 |
Sympathomimetic enantiomers and asthma.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Spasm; Clinical Trials as Topic; Humans; Isoprot | 1998 |
Long-acting inhaled beta2-agonists in asthma therapy.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchial Spasm; Ethanolamines; Formoterol Fum | 1998 |
Salmeterol: a long-acting beta 2-agonist.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist | 1998 |
Bronchodilator therapy in asthma.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; Treat | 1998 |
Recent findings in asthma likely to impact patient care.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Gastroesophageal Reflux; Humans; | 1998 |
The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Fe | 1998 |
An overview of nine clinical trials of salmeterol in an asthmatic population.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Drug Administration Sch | 1998 |
[Inhaler therapy for adults with obstructive lung diseases: powder or aerosol?].
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Human | 1998 |
Inhaled beta2-agonists and airway responses to allergen.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Allergens; | 1998 |
A steroid-induced acute psychosis in a child with asthma.
Topics: Acute Disease; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child; Dose-Respo | 1998 |
Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate | 1998 |
Newer therapeutic agents for asthma.
Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Albuterol; Androstadi | 1999 |
Salmeterol. An appraisal of its quality-of-life benefits and potential pharmacoeconomic positioning in asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Drug Costs; Humans; Quality | 1995 |
Newer therapeutic agents for asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator A | 1999 |
Salmeterol/fluticasone propionate combination.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Ast | 1999 |
[Established combinations of inhaled corticoids and long-acting beta 2-symphathomimetics for long-term therapy of bronchial asthma. Position of an expert panel study].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 1999 |
Contrasting properties of albuterol stereoisomers.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoconstriction; Bronchodilator Agents; Dr | 1999 |
Prospects for improved therapy in chronic obstructive pulmonary disease by the use of levalbuterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Inflammation; Lung Disea | 1999 |
The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchi; Bronchoconstriction; Bronchodilator A | 1999 |
Clinical experience with levalbuterol.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Clinical Trials as | 1999 |
Long-acting beta 2-agonists: the new symptom controllers for asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Alg | 1999 |
A meta-analysis of the effects of ipratropium bromide in adults with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronc | 1999 |
[A rational combination for the treatment of asthma. Salmeterol and fluticasone in one preparation].
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; | 1999 |
Atopic diseases and upper respiratory infections.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child | 1999 |
Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Chlorofluorocarbons; Clinical Trials as Topic; Drug Del | 1999 |
New millennium bronchodilators for asthma: single-isomer beta agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchoconstrictor Agents; Bronchodilator Agen | 2000 |
Management of respiratory failure in patients with asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Calcium Channel Blockers; Gluc | 2000 |
Long-acting inhaled beta 2-agonists in the management of asthma: recent advances and current recommendations.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Forced Expiratory | 1998 |
Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Huma | 2000 |
Association of sputum parameters with clinical and functional measurements in asthma.
Topics: Albuterol; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Eosinophils; Forced Expirato | 2000 |
Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature.
Topics: Administration, Topical; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Asth | 2000 |
Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; | 1999 |
Long acting beta-agonists versus theophylline for maintenance treatment of asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Delayed-Action Preparatio | 2000 |
Bronchodilator resuscitation in the emergency department. Part 2 of 2: dosing strategies.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosols; Airway Obstruction; Albuterol; Asthm | 2000 |
Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; Drug Administration Schedule; Drug Ther | 2000 |
The pathobiologic implications for treatment. Old and new strategies in the treatment of chronic asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chronic D | 2000 |
The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Cholinergic Agents; | 2000 |
The expanding role of long-acting beta-agonists.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2000 |
The effect of long-acting beta2-agonists on airway inflammation in asthmatic patients.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchitis; Bronchoalveolar Lavage Fluid; Chronic Disea | 2000 |
The anti-inflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Infla | 2000 |
Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent | 2000 |
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
Topics: Administration, Inhalation; Adrenergic Agents; Albuterol; Androstadienes; Asthma; Bronchodilator Age | 2001 |
Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; | 2000 |
The pharmacokinetics of levosalbutamol: what are the clinical implications?
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Animals; Area | 2001 |
Single-isomer beta-agonists.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodilator Age | 2001 |
Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Child | 2001 |
[Use of glucocorticosteroids in asthmatic conditions (review)].
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Algorithms; Asthma; Bronchodilator Agents | 2001 |
Pharmacological similarities and differences between beta2-agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Blood Glucose; Blood Pressure; Bronchodilator | 2001 |
Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Anti-A | 2001 |
Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2001 |
What's new: newly approved drugs for children.
Topics: Adolescent; Age Factors; Albuterol; Androstadienes; Anticonvulsants; Asthma; Atovaquone; Attention D | 2001 |
Long-acting inhaled beta(2)-agonist therapy in asthma.
Topics: Administration, Topical; Adrenergic beta-Agonists; Adult; Age Factors; Albuterol; Androstadienes; An | 2001 |
Clinical efficacy with formoterol in the absence of a response to salmeterol: a review.
Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Forced Expiratory Volume; Formoterol Fumara | 2001 |
[Long-acting beta 2-stimulants].
Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenerg | 2001 |
[Combination treatment with inhaled corticosteroid/long-acting beta 2-adrenergic bronchodilator in the treatment of asthma].
Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-2 Receptor Agonists; Adrenergic | 2001 |
Chronic asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; Chronic Dis | 2001 |
Levalbuterol hydrochloride.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Eos | 2002 |
Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2002 |
[Inhalation therapy].
Topics: Adrenergic beta-Antagonists; Aerosols; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; A | 2001 |
Does adding ipratropium to salbutamol (albuterol) help children with asthma?
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Drug Therapy, Combination; Female; Humans; Ipratrop | 2001 |
Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilation.
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-Response Relationship, Drug; | 2002 |
Rimiterol: a review of its pharmacological properties and therapeutic efficacy in asthma.
Topics: Absorption; Administration, Oral; Aerosols; Albuterol; Animals; Asthma; Bronchodilator Agents; Catec | 1977 |
Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration.
Topics: Administration, Oral; Adrenergic beta-Agonists; Aerosols; Albuterol; Arrhythmias, Cardiac; Asthma; E | 1977 |
[Pulmonary function tests with the bronchodilator Terbutaline].
Topics: Administration, Oral; Adult; Aged; Albuterol; Asthma; Atropine; Clenbuterol; Epinephrine; Female; Fe | 1979 |
On the action of combination bronchodilators.
Topics: Albuterol; Animals; Asthma; Bronchodilator Agents; Dogs; Drug Combinations; Drug Synergism; Ephedrin | 1979 |
Inhibition of exercise-induced asthma by different pharmacological pathways.
Topics: Adolescent; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Bronchodilator Agents; Chil | 1976 |
Beta-adrenergic bronchodilators.
Topics: Administration, Oral; Aerosols; Albuterol; Animals; Anisoles; Asthma; Bronchi; Bronchial Spasm; Bron | 1975 |
Beta 2 agonist therapy: oral versus inhaled delivery.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Human | 1992 |
[Bronchodilator effect of salmeterol and inhibition of bronchial hyperreactivity].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; | 1992 |
Metabolic effects of beta 2-agonists.
Topics: Acidosis, Lactic; Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Female; Glucose; Human | 1992 |
[Variety of pharmacological action of beta agonists].
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchial Provocati | 1992 |
Long-acting beta 2-agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Drug Tolerance; Ethanol | 1992 |
Pediatric pulmonary function testing in asthma.
Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Child; Humans; Infant; Re | 1992 |
The beta-agonist controversy: fact or fiction?
Topics: Albuterol; Animals; Asthma; Blood Pressure; Bronchoconstriction; Double-Blind Method; Fenoterol; Hum | 1992 |
[Comparison of treatment of acute asthma attacks in children with salbutamol dispensed by the Volumatic dispenser or by a nebulizer].
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Child; Dose-Response Relationship, Dru | 1992 |
The challenge of long-acting beta-adrenoceptor agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol Fumarate; Humans; Salmeterol | 1991 |
Long-acting beta 2-adrenoceptor agonists: a new perspective in the treatment of asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Ethanolamines; Formoterol Fum | 1991 |
Salmeterol: a novel drug for the treatment of asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchodilator | 1991 |
Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoconstrictio | 1991 |
[Isolated cough and bronchial asthma].
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Chronic Dis | 1991 |
The current place of beta 2-agonists in the management of asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Bronchia | 1990 |
Basic pharmacology of new long-acting sympathomimetics.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Animals; Asthma; | 1990 |
Long-term studies on long-acting sympathomimetics.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; D | 1990 |
[Current concepts in the treatment of asthma (in the United States)].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Albuterol; Asthma; Bronchial Spasm; Costs and | 1990 |
Controlled--release salbutamol tablets.
Topics: Administration, Oral; Albuterol; Asthma; Delayed-Action Preparations; Humans | 1990 |
[Treatment of the severe asthma attack and status asthmaticus].
Topics: Airway Resistance; Albuterol; Asthma; Drug Therapy, Combination; Fenoterol; Humans; Prednisolone; St | 1989 |
The effect of theophylline and beta 2 agonists on airway reactivity.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Test | 1987 |
Theophylline as a bronchodilator in COPD and its combination with inhaled beta-adrenergic drugs.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchi; Bronchitis; Clinical Trials as Topic; | 1987 |
Aminophylline treatment in severe, acute asthma. A meta-analysis.
Topics: Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Epinephrine; Glucocorticoids; Humans; M | 1988 |
In-vivo and in-vitro responsiveness of bronchial smooth muscle.
Topics: Airway Resistance; Albuterol; Animals; Asthma; Atropine; Atropine Derivatives; Bronchi; Carbachol; D | 1986 |
Treatment of severe asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Aminophylline; Asthma | 1974 |
Antiasthmatic drugs I: pathophysiological and clinical pharmacological aspects.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Albuterol; Amines; Asthma; Autacoids; Bradykin | 1974 |
[Treatment of bronchial asthma].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Bronchitis; C | 1974 |
Asthma: current concepts.
Topics: Adolescent; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Carboxylic Acids; Child; Child | 1974 |
1634 trials available for albuterol and Asthma
| Article | Year |
|---|---|
Bronchodilator response to albuterol nebulized with hypertonic saline in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blin | 2021 |
Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Budesonide; Child; Drug Combinatio | 2021 |
Effects of nebulized budesonide plus salbutamol and nebulized salbutamol monotherapy on mild to moderate acute exacerbation of asthma in children: A comparative study.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Child, Pres | 2021 |
As-Needed Use of Short-Acting β
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Child | 2022 |
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Budesonide; Child; Child, Preschoo | 2022 |
Efficacy of a loading dose of IV salbutamol in children with severe acute asthma admitted to a PICU: a randomized controlled trial.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Intensive Care | 2022 |
Nebulized Salbutamol with or without Magnesium Sulphate in the Management of Acute Asthma in Children in India: A Randomized Controlled Trial.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Double-B | 2022 |
Effectiveness of a Digital Inhaler System for Patients With Asthma: A 12-Week, Open-Label, Randomized Study (CONNECT1).
Topics: Administration, Inhalation; Albuterol; Asthma; Bayes Theorem; Bronchodilator Agents; Humans; Nebuliz | 2022 |
Optimising intravenous salbutamol in children: a phase 2 study.
Topics: Administration, Intravenous; Albuterol; Asthma; Child; Emergency Service, Hospital; Humans; Prospect | 2023 |
Comparative Efficacy of Levosalbutamol and Racemic Salbutamol in the Treatment of Acute Exacerbation of Asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bangladesh; Bronchodilator Agen | 2023 |
Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial.
Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Child; Dexamethasone; Humans; Methylprednisolone; Prospe | 2023 |
Comparison efficacy of randomized nebulized magnesium sulfate and ipratropium bromide/fenoterol in children with moderate to severe asthma exacerbation.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2022 |
Impact of sleep opportunity on asthma outcomes in adolescents.
Topics: Adolescent; Albuterol; Asthma; Child; Cross-Over Studies; Female; Humans; Male; Quality of Life; Sle | 2020 |
A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Fema | 2020 |
Clinical Efficacy of Vibrating Mesh and Jet Nebulizers With Different Interfaces in Pediatric Subjects With Asthma.
Topics: Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; C | 2020 |
The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bisoprolol; Bronchod | 2021 |
Randomized pilot trial of ipratropium versus placebo in children with critical asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2020 |
Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; B | 2020 |
A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; | 2021 |
Bronchodilatory effects of B-type natriuretic peptide in acute asthma attacks: a randomized controlled clinical trial.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Fe | 2020 |
Evaluation of efficacy of nebulized low molecular weight heparin as an adjunctive extra treatment for acute mild-moderate asthma attack; a randomized clinical trial study.
Topics: Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Heparin, Lo | 2021 |
Association Between Intravenous Magnesium Therapy in the Emergency Department and Subsequent Hospitalization Among Pediatric Patients With Refractory Acute Asthma: Secondary Analysis of a Randomized Clinical Trial.
Topics: Acute Disease; Administration, Inhalation; Administration, Intravenous; Adolescent; Albuterol; Anti- | 2021 |
Nurse-Driven Clinical Pathway for Inpatient Asthma: A Randomized Controlled Trial.
Topics: Albuterol; Asthma; Attitude of Health Personnel; Bronchodilator Agents; Canada; Child; Child, Presch | 2017 |
Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide, Formoterol | 2017 |
Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge | 2018 |
Effect of extending the time after bronchodilator administration on identifying bronchodilator responsiveness in a pediatric pulmonary clinic.
Topics: Adolescent; Albuterol; Ambulatory Care Facilities; Asthma; Bronchodilator Agents; Child; Female; For | 2017 |
The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzen | 2017 |
Effect of Nebulized 3% Hypertonic Saline with Salbutamol on Management of Acute Asthma in Outpatient Adults: A Double-blind, Randomized Clinical Trial in Emergency Department.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Ambulatory Care; Asthma; Disease Manage | 2017 |
Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma?
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Age Distribution; Aged; Albuterol; Anti-Asthmatic Agents | 2017 |
Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial.
Topics: Acute Disease; Administration, Intravenous; Albuterol; Asthma; Bronchodilator Agents; Child, Prescho | 2018 |
Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma.
Topics: Adult; Albuterol; Asthma; Cholinergic Antagonists; Female; Humans; Inflammation; Interleukin-13; Mal | 2018 |
Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool; Dose- | 2018 |
A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Equipment Design; Fem | 2018 |
Comparison of the Clinical Efficacy of Salbutamol with Jet and Mesh Nebulizers in Asthmatic Children.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; | 2018 |
MDI with DIY Spacer versus Nebulizer for Bronchodilator Therapy in Children Admitted with Asthmatic Attack.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2016 |
Chinese herbal medicine formula for acute asthma: A multi-center, randomized, double-blind, proof-of-concept trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Biomarkers; Bronch | 2018 |
Comparison of two methods of determining lung de-recruitment, using the forced oscillation technique.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Middle Aged; Pulmonary | 2018 |
Usefulness of Nonvalved Spacers for Administration of Inhaled Steroids in Young Children with Recurrent Wheezing and Risk Factors for Asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Fluticasone; Humans; Infant; Inhalation Spacers; M | 2018 |
Analysis of the advantages and disadvantages in application of oxygen-driven aerosol and aerosol inhalation by air compressor for the pediatric asthma.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Budesonide; Child; Compressed Air; Female; | 2018 |
Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Cannula; Child; Child, Preschool; Emergency Se | 2019 |
Bronchodilator responsiveness in children with asthma is not influenced by spacer device selection.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Over | 2019 |
Characteristics of inner-city children with life-threatening asthma.
Topics: Adult; Albuterol; Allergens; Anti-Asthmatic Agents; Asthma; Caregivers; Child; Child, Preschool; Cot | 2019 |
Low-dose l-isoproterenol versus salbutamol in hospitalized pediatric patients with severe acute exacerbation of asthma: A double-blind, randomized controlled trial.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Doubl | 2019 |
Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Asthma; Bro | 2019 |
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studie | 2019 |
Mesh nebulizer is as effective as jet nebulizer in clinical practice of acute asthma in children
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Female; For | 2019 |
Effect of inhaled inactivated Mycobacterium phlei in children with moderate asthma.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bacterial Vaccines; Child; Child, Pre | 2013 |
Comparison of salbutamol with normal saline and salbutamol with magnesium sulphate in the treatment of severe acute asthma.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; | 2013 |
Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclome | 2013 |
Non-inferiority trial between two dry-powder inhalers containing fluticasone/salmeterol in asthmatic patients.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Dry Powder Inhal | 2013 |
Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadie | 2014 |
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me | 2013 |
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me | 2013 |
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me | 2013 |
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me | 2013 |
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me | 2013 |
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me | 2013 |
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me | 2013 |
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me | 2013 |
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Contrast Me | 2013 |
Perception of bronchoconstriction: a complementary disease marker in children with asthma.
Topics: Adolescent; Albuterol; Androstadienes; Anti-Allergic Agents; Asthma; Bronchial Hyperreactivity; Bron | 2013 |
Comparison of salbutamol and ipratropium bromide versus salbutamol alone in the treatment of acute severe asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Albuterol, Ipratropium Drug Combination; Asthma; Bronc | 2013 |
Real life clinical study design supporting the effectiveness of extra-fine inhaled beclomethasone/formoterol at the level of small airways of asthmatics.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammato | 2013 |
[Efficacy and safety of tulobuterol patch versus oral salbutamol sulfate in children with mild or moderate acute attack of bronchial asthma: a comparative study].
Topics: Acute Disease; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Female; | 2013 |
Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; | 2014 |
Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Benzyl Alcohols; Chil | 2013 |
Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Cost-Benefit Analysis; Dos | 2013 |
Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Ther | 2014 |
Low-dose salbutamol suppresses airway responsiveness to histamine but not methacholine in subjects with asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; | 2013 |
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
Topics: 5-Lipoxygenase-Activating Protein Inhibitors; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 | 2013 |
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
Topics: 5-Lipoxygenase-Activating Protein Inhibitors; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 | 2013 |
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
Topics: 5-Lipoxygenase-Activating Protein Inhibitors; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 | 2013 |
Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
Topics: 5-Lipoxygenase-Activating Protein Inhibitors; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 | 2013 |
Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi | 2013 |
Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aerosols; Aged; Albuterol; A | 2014 |
Metrics of salbutamol use as predictors of future adverse outcomes in asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Drug Overdose; Female; Humans; Male; | 2013 |
Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; | 2013 |
[Observation on the effects of the treatment of sillicosis merger asthma].
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Drug Combinations; Female; Flu | 2013 |
Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma.
Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; As | 2014 |
Predictors of response to tiotropium versus salmeterol in asthmatic adults.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator | 2013 |
Inhaled salbutamol does not affect athletic performance in asthmatic and non-asthmatic cyclists.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Athletic Performance; Bicycling; Bronchodilato | 2015 |
Safety of bronchial thermoplasty in patients with severe refractory asthma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchi; Bronch | 2013 |
Safety of bronchial thermoplasty in patients with severe refractory asthma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchi; Bronch | 2013 |
Safety of bronchial thermoplasty in patients with severe refractory asthma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchi; Bronch | 2013 |
Safety of bronchial thermoplasty in patients with severe refractory asthma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchi; Bronch | 2013 |
Childhood asthma clusters and response to therapy in clinical trials.
Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Anti-Asthmatic | 2014 |
Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Anti-Asthmatic Ag | 2013 |
Effect of inhaled MgSO4 on FEV1 and PEF in children with asthma induced by acetylcholine: a randomized controlled clinical trail of 330 cases.
Topics: Acetylcholine; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, P | 2014 |
Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmati | 2014 |
Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anticonvulsants; Asthma; Bronchodi | 2013 |
Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses.
Topics: Adolescent; Adult; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; | 2014 |
Effect of heliox- and air-driven nebulized bronchodilator therapy on lung function in patients with asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aerosol Propellants; Aged; A | 2014 |
Real-world effects of two inhaled corticosteroid/long-acting β₂-agonist combinations in the treatment of asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadie | 2014 |
The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma.
Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Cyclopropan | 2014 |
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Antipsychotic Agents; Asth | 2014 |
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Antipsychotic Agents; Asth | 2014 |
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Antipsychotic Agents; Asth | 2014 |
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Antipsychotic Agents; Asth | 2014 |
[A multi-center, randomized, double-blind, positive controlled clinical trial of salbutamol sulfate MDI without CFC in the treatment of asthma].
Topics: Albuterol; Asthma; Double-Blind Method; Forced Expiratory Volume; Humans; Metered Dose Inhalers | 2014 |
Comparison between the effects of generic and original salmeterol/fluticasone combination (SFC) treatment on airway inflammation in stable asthmatic patients.
Topics: Adult; Aged; Airway Obstruction; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Cross- | 2014 |
Eczema and race as combined determinants for differential response to step-up asthma therapy.
Topics: Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Black or African Ame | 2014 |
Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Budes | 2014 |
Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Alb | 2014 |
Treatment of asthma exacerbations with the human-powered nebuliser: a randomised parallel-group clinical trial.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Child | 2014 |
Metered-dose inhaler ipratropium bromide in moderate acute asthma in children: A single-blinded randomised controlled trial.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bro | 2015 |
Dependence of bronchoconstrictor and bronchodilator responses on thoracic gas compression volume.
Topics: Adult; Aged; Albuterol; Asthma; Body Height; Bronchial Provocation Tests; Bronchoconstrictor Agents; | 2014 |
Lung deposition of 99mTc-radiolabeled albuterol delivered through a pressurized metered dose inhaler and spacer with facemask or mouthpiece in children with asthma.
Topics: Administration, Inhalation; Aerosols; Age Factors; Albuterol; Asthma; Child, Preschool; Cross-Over S | 2014 |
Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; | 2014 |
Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; | 2014 |
Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; | 2014 |
Inhaler reminders improve adherence with controller treatment in primary care patients with asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; | 2014 |
Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation.
Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; | 2014 |
Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Asthma; Cross-Over Studies; | 2014 |
Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronc | 2015 |
Acute effect of an inhaled glucocorticosteroid on albuterol-induced bronchodilation in patients with moderately severe asthma.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Dose-Res | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Nebulized magnesium for moderate and severe pediatric asthma: A randomized trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2015 |
Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Airway Obstruction; Albuterol; Anti-As | 2015 |
High-Dose Inhaled Salbutamol Does Not Improve 10-km Cycling Time Trial Performance.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Athletic Performance; Bicycling; Body Weight; | 2015 |
Effect of ADRB2 (adrenergic receptor β2) gene polymorphisms on the occurrence of asthma and on the response to nebulized salbutamol in South Indian patients with bronchial asthma.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asian People; Asthma; Bronchodila | 2015 |
Clinical outcomes and treatment cost comparison of levalbuterol versus albuterol in hospitalized adults with chronic obstructive pulmonary disease or asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Hospitalization; Humans; | 2015 |
A Randomized Controlled Trial of 2 Inhalation Methods When Using a Pressurized Metered Dose Inhaler With Valved Holding Chamber.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Breath Holding; Bronchodilator Agents; Ch | 2015 |
Reversibility of pulmonary function after inhaling salbutamol in different doses and body postures in asthmatic children.
Topics: Administration, Inhalation; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Cross-Over St | 2015 |
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2016 |
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2016 |
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2016 |
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2016 |
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2016 |
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2016 |
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2016 |
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2016 |
Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2016 |
Efficacy of acupuncture for chronic asthma: study protocol for a randomized controlled trial.
Topics: Acupuncture Therapy; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-2 | 2015 |
Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Black or African | 2015 |
Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Albuterol (Salbuterol) Multi-dose Dry-Powder Inhaler and ProAir(®) Hydrofluoroalkane for the Treatment of Persistent Asthma: Results of Two Randomized Double-Blind Studies.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dou | 2016 |
Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bicycling | 2015 |
Formoterol as reliever medication in asthma: a post-hoc analysis of the subgroup of the RELIEF study in East Asia.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; | 2016 |
Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter.
Topics: Adolescent; Adult; Albuterol; Asthma; Child; Child, Preschool; Drug Tolerance; Dry Powder Inhalers; | 2016 |
Effect of smoking status on the efficacy of the SMART regimen in high risk asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; | 2016 |
Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2016 |
Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Topics: Administration, Inhalation; Administration, Sublingual; Adolescent; Adrenal Cortex Hormones; Adrener | 2016 |
Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A | 2016 |
Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dry Powder Inhalers; Female; | 2016 |
Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dry Powder Inhalers; Female; | 2016 |
Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dry Powder Inhalers; Female; | 2016 |
Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in children with asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dry Powder Inhalers; Female; | 2016 |
Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations.
Topics: Adolescent; Adult; Albuterol; Asthma; Biomarkers; Body Mass Index; Breath Tests; Bronchodilator Agen | 2017 |
Albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane versus placebo in children with persistent asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Prescho | 2016 |
Individualized therapy for persistent asthma in young children.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Child, Preschool; Female; Fo | 2016 |
Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy.
Topics: Administration, Oral; Adult; Albuterol; Asthma; Biological Availability; Cross-Over Studies; Glucans | 2017 |
Parental decision making associated with pediatric emergency department use for asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Caregivers; Child; Child, Preschool; Cluster Analys | 2016 |
Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Aerosols; Aged; Albuterol; Anti | 2016 |
Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Child, Pr | 2017 |
Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations: A Randomized Controlled Trial.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Combined Modality Therapy; Emergency Service, Hospi | 2017 |
Use of long-acting beta2 agonists in arginine-16 homozygous patients with asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bu | 2008 |
Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchodilator Agents | 2008 |
Temporal strength changes from resistance exercise and albuterol on unloaded muscle.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Double-Blind Method; Ergometry; Female; Humans; Male; M | 2008 |
Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchodilator Agents | 2008 |
Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Ast | 2008 |
Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
Topics: Acute Disease; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Hospital Costs; Hospitalizati | 2008 |
Ventilation heterogeneity in children with well controlled asthma with normal spirometry indicates residual airways disease.
Topics: Adolescent; Albuterol; Asthma; Bronchial Diseases; Bronchodilator Agents; Case-Control Studies; Chil | 2009 |
A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod | 2008 |
Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Androstadienes; A | 2008 |
Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down".
Topics: Acetates; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Dose-Response Rel | 2008 |
Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study.
Topics: Acetates; Adolescent; Albuterol; Anti-Bacterial Agents; Asthma; Azithromycin; Bronchodilator Agents; | 2008 |
Lung function and asthma control with beclomethasone and formoterol in a single inhaler.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Broncho | 2009 |
Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children.
Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child | 2008 |
Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Child, Preschool; Cohort Studies; Femal | 2008 |
Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asian People; Asthma; Bronchodilator Agents; Fem | 2008 |
Asthma control over 3 years in a real-life study.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Double-Blind Meth | 2009 |
Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Therap | 2009 |
Impulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthma.
Topics: Acetates; Adolescent; Albuterol; Androstadienes; Asthma; Biomarkers; Child; Cyclopropanes; Double-Bl | 2009 |
Efficacy and cost comparisons of bronchodilatator administration between metered dose inhalers with disposable spacers and nebulizers for acute asthma treatment.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cost- | 2011 |
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma.
Topics: Adenosine; Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Androstadienes; Anti-Allergic A | 2009 |
Determining the time to maximal bronchodilator response in asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Forced Expiratory Volume; Human | 2009 |
Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study.
Topics: Acetates; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Belgium; Budesonide; Cycl | 2009 |
Adverse effects of salmeterol in asthma: a neuronal perspective.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Albuterol; Androst | 2009 |
Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodila | 2009 |
Patient-reported outcomes among omalizumab and salmeterol/fluticasone combination therapy patients.
Topics: Activities of Daily Living; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Antibodies, Ant | 2009 |
Influence of ambulatory inhaled treatment with different devices on the duration of acute asthma findings in children.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Metered Dose | 2009 |
A comparative study of efficacy of salbutamol via metered dose inhaler with volumatic spacer and via dry powder inhaler, easyhaler, to nebulization in mild to moderate severity acute asthma exacerbation in childhood.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child | 2008 |
Pharmacological stress myocardial perfusion scintigraphy: use of a modified adenosine protocol in patients with asthma.
Topics: Adenosine; Aged; Albuterol; Asthma; Bronchial Spasm; Case-Control Studies; Female; Humans; Male; Myo | 2009 |
In vivo performance testing of the novel Medspray wet aerosol inhaler.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Cross-Over St | 2009 |
Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.
Topics: Administration, Inhalation; Adult; Aerosol Propellants; Albuterol; Androstadienes; Asthma; Bronchodi | 2009 |
Effects of salmeterol and fluticasone propionate combination versus fluticasone propionate on airway function and eosinophilic inflammation in mild asthma.
Topics: Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Drug Combinations; Eosinophils; | 2009 |
High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial.
Topics: Adolescent; Albuterol; Asthma; Blood Glucose; Bronchodilator Agents; Child; Dose-Response Relationsh | 2009 |
Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 2009 |
Bronchodilator effects of exercise hyperpnea and albuterol in mild-to-moderate asthma.
Topics: Adaptation, Physiological; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchoconstriction | 2009 |
Home use of albuterol for asthma exacerbations.
Topics: Albuterol; Asthma; Bronchodilator Agents; Caregivers; Child; Child, Preschool; Cross-Sectional Studi | 2009 |
Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence.
Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Albuterol; Allergens; Androstadienes; Anti-Asthmatic | 2009 |
Evidence for adverse phonatory change following an inhaled combination treatment.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Drug Combinations; | 2010 |
Childhood evaluation of salmeterol tolerance--a double-blind randomized controlled trial.
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; | 2010 |
Regular vs prn nebulized treatment in wheeze preschool children.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator | 2009 |
Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED).
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol | 2009 |
Does parental involvement in pediatric emergency department asthma treatment affect home management?
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Emergency Se | 2009 |
Interaction of ambient air pollution with asthma medication on exhaled nitric oxide among asthmatics.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Air Pollutants; Air Polluti | 2009 |
Transient expiratory flow interruptions (TEFI) increase expiratory flow in acute asthma exacerbation.
Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Female; Forced Expirator | 2009 |
Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadiene | 2010 |
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros | 2009 |
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros | 2009 |
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros | 2009 |
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros | 2009 |
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros | 2009 |
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros | 2009 |
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros | 2009 |
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros | 2009 |
Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Cros | 2009 |
Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator | 2010 |
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anxiety; Ast | 2010 |
Levosalbutamol vs racemic salbutamol in the treatment of acute exacerbation of asthma.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Metho | 2009 |
Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclome | 2010 |
Comparative effects of caffeine and albuterol on the bronchoconstrictor response to exercise in asthmatic athletes.
Topics: Albuterol; Analysis of Variance; Asthma; Bronchoconstriction; Bronchodilator Agents; Caffeine; Centr | 2010 |
Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Allergic Agents; Area Under Curve | 2010 |
Providing feedback on adherence increases use of preventive medication by asthmatic children.
Topics: Adolescent; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Drug Combinations; Feed | 2010 |
Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Drug | 2010 |
Plasma concentrations of salbutamol in the treatment of acute asthma in a pediatric emergency. Could age be a parameter of influence?
Topics: Acute Disease; Administration, Inhalation; Adolescent; Age Factors; Albuterol; Asthma; Body Weight; | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Al | 2010 |
Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bioma | 2008 |
Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: a randomised controlled trial.
Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Denmark; Drug Therapy, Combination; | 2009 |
Respiratory impedance and response to salbutamol in asthmatic Vietnamese children.
Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Respiratory Function Tes | 2010 |
Down-titration from high-dose combination therapy in asthma: Removal of long-acting beta(2)-agonist.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Dose-Response Relations | 2010 |
Effect of salmeterol/fluticasone propionate combination on airway hyper-responsiveness in patients with well-controlled asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Double-Blind Meth | 2010 |
Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Ast | 2010 |
Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group st
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A | 2010 |
A pediatric asthma management program in a low-income setting resulting in reduced use of health service for acute asthma.
Topics: Acute Disease; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Brazil; Child; | 2010 |
Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children.
Topics: Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchoconstriction; | 2010 |
Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al | 2010 |
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross | 2010 |
Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Ch | 2010 |
Written action plan in pediatric emergency room improves asthma prescribing, adherence, and control.
Topics: Adolescent; Adrenal Cortex Hormones; Advance Care Planning; Albuterol; Androstadienes; Asthma; Bronc | 2011 |
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil | 2011 |
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil | 2011 |
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil | 2011 |
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil | 2011 |
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil | 2011 |
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil | 2011 |
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil | 2011 |
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil | 2011 |
Regulatory haplotypes in ARG1 are associated with altered bronchodilator response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Arginase; Asthma; Bronchodilator Agents; Chil | 2011 |
Levalbuterol versuss levalbuterol plus ipratropium in the treatment of severe acute asthma.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Dru | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Choline | 2010 |
Multidetector row computed tomography to assess changes in airways linked to asthma control.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchi; Bronchography; Drug C | 2011 |
Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Allergic Agents; Anti-Asthmatic Agents; Ast | 2011 |
Comparison of heat-sensitive moxibustion versus fluticasone/salmeterol (seretide) combination in the treatment of chronic persistent asthma: design of a multicenter randomized controlled trial.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Chronic Disease; Clinical Protocols; Dru | 2010 |
[Comparative observation on therapeutic effect of chronic persistent bronchial asthma treated with heat-sensitive moxibustion and medication].
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Chronic Disease; Drug Combinations; Fema | 2010 |
Efficacy of racemic albuterol versus levalbuterol used as a continuous nebulization for the treatment of acute asthma exacerbations: a randomized, double-blind, clinical trial.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Double-Blind Method; Emer | 2011 |
Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; | 2011 |
Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combinati | 2011 |
Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2011 |
Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2011 |
Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2011 |
Randomized controlled trial of a breath-actuated nebulizer in pediatric asthma patients in the emergency department.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2011 |
Effect of short-term oral and inhaled corticosteroids on airway inflammation and responsiveness in a feline acute asthma model.
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Allergens; Androstadienes; Animals; Ant | 2012 |
Comparison of high-dose salmeterol/fluticasone and moderate-dose salmeterol/fluticasone plus low-dose mometasone in patients with severe persistent asthma.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma | 2011 |
Randomized controlled trial to improve care for urban children with asthma: results of the School-Based Asthma Therapy trial.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cotinine; Counsel | 2011 |
Lung function response to bronchodilator nebulization via hood in wheezy infants: a pilot study.
Topics: Administration, Inhalation; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents; Female; Func | 2011 |
Comparison of salbutamol efficacy in children--via the metered-dose inhaler (MDI) with Volumatic spacer and via the dry powder inhaler, Easyhaler, with the nebulizer--in mild to moderate asthma exacerbation: a multicenter, randomized study.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dry Po | 2011 |
Urine concentrations of repetitive doses of inhaled salbutamol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Case-Cont | 2011 |
A cumulative dose, safety and tolerability study of arformoterol in pediatric subjects with stable asthma.
Topics: Albuterol; Asthma; Blood Glucose; Blood Pressure; Bronchodilator Agents; Child; Child, Preschool; Cr | 2011 |
Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Analysis of Varia | 2011 |
Impact of obesity on the severity and therapeutic responsiveness of acute episodes of asthma.
Topics: Adult; Albuterol; Asthma; Body Mass Index; Body Weight; Emergency Service, Hospital; Hospitalization | 2011 |
Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilat | 2011 |
Effect of bronchoconstriction on airway remodeling in asthma.
Topics: Adult; Albuterol; Animals; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoconstriction; Bronch | 2011 |
Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma.
Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Drug Combinations; Etha | 2011 |
Fluticasone/Salmeterol combination confers benefits in people with asthma who smoke.
Topics: Adult; Albuterol; Androstadienes; Asthma; Cross-Over Studies; Double-Blind Method; Drug Combinations | 2012 |
Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cross-Over Studies; Fem | 2011 |
Components of asthma control and treatment response of individual control criteria in children: analysis of the PEACE study.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; A | 2011 |
Active albuterol or placebo, sham acupuncture, or no intervention in asthma.
Topics: Acupuncture Therapy; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Diagnostic | 2011 |
Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; | 2011 |
Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.
Topics: Administration, Inhalation; Albuterol; Arginine; Asthma; Bronchodilator Agents; Double-Blind Method; | 2011 |
The effect of airway remodelling on airway hyper-responsiveness in asthma.
Topics: Adult; Airway Remodeling; Airway Resistance; Albuterol; Androstadienes; Asthma; Bronchial Hyperreact | 2011 |
Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Comorbid | 2011 |
Most nocturnal asthma symptoms occur outside of exacerbations and associate with morbidity.
Topics: Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; | 2011 |
Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Beclo | 2011 |
Impact of race on asthma treatment failures in the asthma clinical research network.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Biomedical Research; Bl | 2011 |
Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent | 2012 |
[Dynamics of functional parameters in different schemes for bronchial asthma therapy: results of the STRELA-ACT multicentre study].
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Androstadienes; Anti-Inflammatory | 2011 |
The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: a randomized, double-blind, parallel group study.
Topics: Acute Disease; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Carbon Dio | 2011 |
Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma.
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Androstadienes; Anti-Asthmatic Agen | 2012 |
Bronchodilator responsiveness in wheezy infants and toddlers is not associated with asthma risk factors.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Female; Humans; Infant; Male; Prevalence | 2012 |
Effects of hydrocortisone on acute β-adrenoceptor blocker and histamine induced bronchoconstriction.
Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Adult; Albuterol; Anti-Inflammatory Agents; | 2012 |
Salmeterol or doxycycline do not inhibit acute bronchospasm and airway inflammation in cats with experimentally-induced asthma.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Albuterol; An | 2012 |
Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Albuterol; Asthma; Bronchodilator Age | 1976 |
Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes.
Topics: Acceleration; Administration, Oral; Adult; Albuterol; Asthma; Athletes; Bronchodilator Agents; Cross | 2012 |
Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents.
Topics: Adolescent; Adult; Albuterol; Algorithms; Asthma; Disease Progression; Drug Utilization; Female; Fol | 2012 |
Efficacy of salbutamol by nebulizer versus metered dose inhaler with home-made non-valved spacer in acute exacerbation of childhood asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Disease Progression; Equipment De | 2012 |
Predicting asthma treatment outcome at diagnosis: the role of symptom perception during a histamine challenge test.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Diagnostic Self Evaluation; Female; Forced Ex | 2012 |
The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-2 Receptor Agonists; A | 2012 |
Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Bud | 2012 |
Effect of switching from salmeterol/fluticasone to formoterol/ budesonide combinations in patients with uncontrolled asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Budesonide; Drug Subs | 2012 |
Salbutamol but not ipratropium abolishes leukotriene D4-induced gas exchange abnormalities in asthma.
Topics: Administration, Inhalation; Adult; Airway Obstruction; Albuterol; Arteries; Asthma; Bronchoconstrict | 2012 |
Oral versus intravenous steroids in acute exacerbation of asthma--randomized controlled study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Bronc | 2011 |
Airways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics.
Topics: Adolescent; Albuterol; Androstadienes; Asthma; Asthma, Exercise-Induced; Bronchial Hyperreactivity; | 2012 |
Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients.
Topics: Acetates; Administration, Inhalation; Age Factors; Aged; Aged, 80 and over; Albuterol; Anti-Asthmati | 2012 |
Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists | 2012 |
Salmeterol and fluticasone in young children with multiple-trigger wheeze.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Asthma; | 2012 |
Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Beclomethasone; Bronchodilator Agents; D | 2012 |
The reliability and patient acceptability of the SmartTrack device: a new electronic monitor and reminder device for metered dose inhalers.
Topics: Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Drug Monit | 2012 |
Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma.
Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchial Spasm; Cross-Over Studies; Double-Blind Method; | 2012 |
Original salbutamol versus similar salbutamol in children with asthma exacerbation: a randomized, controlled, double-blind study.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Disease Progression; Double-Blind Metho | 2012 |
Transient sputum eosinophilia may occur over time in non-eosinophilic asthma and this is not prevented by salmeterol.
Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Eosinophilia; Female; Fluticasone; | 2012 |
Association of airway pentosidine levels with bronchodilator response mediated by salbutamol administration in asthmatic patients.
Topics: Adult; Airway Obstruction; Albuterol; Arginine; Asthma; Biomarkers; Bronchial Provocation Tests; Bro | 2012 |
[Comparative study on effect of acupoint heat-sensitive moxibustion and Seretide on the symptoms of bronchial asthma at chronic persistent stage].
Topics: Acupuncture Points; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Chronic Disease; Drug Comb | 2012 |
Comparison of the bronchodilating effects of albuterol delivered by valved vs. non-valved spacers in pediatric asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Hum | 2012 |
Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Confide | 2012 |
Effects of low-dose fluticasone propionate/salmeterol combination therapy on exhaled nitric oxide and nitrite/nitrate in breath condensates from patients with mild persistent asthma.
Topics: Adult; Albuterol; Androstadienes; Asthma; Breath Tests; Bronchial Provocation Tests; Bronchodilator | 2013 |
Tailored second-line therapy in asthmatic children with the Arg(16) genotype.
Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Amino Acid Motifs; Anti-Asthma | 2013 |
Tailored second-line therapy in asthmatic children with the Arg(16) genotype.
Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Amino Acid Motifs; Anti-Asthma | 2013 |
Tailored second-line therapy in asthmatic children with the Arg(16) genotype.
Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Amino Acid Motifs; Anti-Asthma | 2013 |
Tailored second-line therapy in asthmatic children with the Arg(16) genotype.
Topics: Acetates; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Amino Acid Motifs; Anti-Asthma | 2013 |
Sensitivity of impulse oscillometry and spirometry in beta-blocker induced bronchoconstriction and beta-agonist bronchodilatation in asthma.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Airway Resistance; Albuterol; Asthma; | 2012 |
Salbutamol tolerance to bronchoprotection: course of onset.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction | 2012 |
Efficacy of theophylline plus salmeterol/fluticasone propionate combination therapy in patients with asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Circadian Rhythm; | 2013 |
Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety.
Topics: Absenteeism; Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Broncho | 2013 |
Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Dru | 2002 |
The combination of nebulized sodium cromoglycate and salbutamol in the treatment of moderate-to-severe asthma in children.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cromolyn S | 2002 |
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Beclomethasone; Blood | 2002 |
One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2002 |
Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the childhood asthma management program.
Topics: Albuterol; Allergens; Asthma; Bronchodilator Agents; Child; Disease Progression; Female; Forced Expi | 2002 |
Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodila | 2002 |
Comparison of acute bronchodilator effects of inhaled ipratropium bromide and salbutamol in bronchial asthma.
Topics: Administration, Inhalation; Adult; Aging; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studi | 2002 |
Effect of salmeterol on seasonal changes in airway responsiveness and exhaled nitric oxide in pollen-sensitive asthmatic subjects.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adult; Airway Resistance; Albuterol | 2002 |
Metal versus plastic spacers: an in vitro and in vivo comparison.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dos | 2002 |
Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Analysis of Variance; Androstadienes; Anti-Asthmatic A | 2002 |
The effects of inhaled albuterol and salmeterol in 2- to 5-year-old asthmatic children as measured by impulse oscillometry.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child Welfare; Child, P | 2002 |
Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Confidenc | 2002 |
Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Chronic | 2002 |
Importance of drug delivery system in steroid aerosol therapy via nebulizer.
Topics: Adult; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchoconstrictor Agents; | 2002 |
Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method | 2002 |
Efficacy and safety of a home-made non-valved spacer for bronchodilator therapy in acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Child, Preschool; C | 2002 |
A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bayes Th | 2002 |
Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients wit
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Doubl | 2002 |
Clinical equivalence between salbutamol hydrofluoroalkane pMDI and salbutamol Turbuhaler at the same cumulative microgram doses in paediatric patients.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Over Studies; Double-Blind Method | 2002 |
Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cross | 2002 |
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma.
Topics: Acetates; Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Age | 2002 |
Randomised pragmatic comparison of UK and US treatment of acute asthma presenting to hospital.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Drug Therapy, Combin | 2002 |
A randomized controlled trial of intravenous montelukast in acute asthma.
Topics: Acetates; Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Varianc | 2003 |
Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.
Topics: Acetates; Adenosine Monophosphate; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmati | 2003 |
Both local anesthetics and salbutamol pretreatment affect reflex bronchoconstriction in volunteers with asthma undergoing awake fiberoptic intubation.
Topics: Adult; Airway Resistance; Albuterol; Anesthetics, Local; Asthma; Bronchial Provocation Tests; Bronch | 2002 |
Comparison of single 7.5-mg dose treatment vs sequential multidose 2.5-mg treatments with nebulized albuterol in the treatment of acute asthma.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Emergencies; Female; Forced Expiratory Volume; | 2002 |
[Comparative efficiency of nebulized adrenaline and salbutamol in severe acute asthma. A randomized, controlled prospective study].
Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma | 2002 |
Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Asthma; Biopsy; Bronchi; Bronchoalveolar | 2002 |
Children with mild asthma: do they benefit from inhaled corticosteroids?
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchial P | 2002 |
[A comparison between the effects of albuterol and isoproterenol in bronchodilation test].
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Humans; Male; Max | 2001 |
Preserved bronchial dilatation after salbutamol does not guarantee protection against bronchial hyperresponsiveness.
Topics: Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchial Hyperreact | 2003 |
The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma.
Topics: Acetates; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Cyclopro | 2003 |
Addition of ipratropium to nebulized albuterol in children with acute asthma presenting to a pediatric office.
Topics: Acute Disease; Administration, Inhalation; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Ch | 2003 |
Salbutamol and/or beclomethasone diproprionate in asthma.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child; Child, | 2003 |
Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial.
Topics: Abdominal Pain; Acute Disease; Adolescent; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthm | 2003 |
Efficacy of a consensus protocol therapy in adults with acute, severe asthma.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Forced Expiratory Volume; Hospi | 2003 |
Creatininuria in asthmatic children treated with a combination of glucocorticoid and beta-agonist.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Becl | 2003 |
Metabolism of salbutamol differs between asthmatic patients and healthy volunteers.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Area Under Curve; Asthma; Bron | 2003 |
Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Drug Overdose; Drug The | 2003 |
Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agen | 2003 |
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.
Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthm | 2003 |
Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients.
Topics: Adenosine Monophosphate; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; | 2003 |
A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchoconstrictor Agents; Bronchodilator | 2003 |
Bronchodilator tolerance: the impact of increasing bronchoconstriction.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchial Provo | 2003 |
Triple inhaled drug protocol for the treatment of acute severe asthma.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronc | 2003 |
Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchoalveolar | 2003 |
Reversibility to a beta2-agonist in COPD: relationship to atopy and neutrophil activation.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Eosinoph | 2003 |
Effect of salmeterol xinafoate on lung mucociliary clearance in patients with asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind | 2003 |
Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Female; Humans; Male; | 2003 |
Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Calci | 2003 |
Comparison of innovator and generic salbutamol inhalers: a double-blind randomized study of efficacy and tolerance.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Humans; Male; Me | 2002 |
Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate.
Topics: Adult; Airway Obstruction; Albuterol; Androstadienes; Asthma; Biopsy; Bronchi; Cromolyn Sodium; Doub | 2003 |
Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Biopsy; Bronchi; Double-Blind | 2003 |
Effects of salmeterol on smooth muscle versus inflammatory outcomes.
Topics: Albuterol; Androstadienes; Asthma; Cross-Over Studies; Drug Therapy, Combination; Fluticasone; Human | 2003 |
Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma.
Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchi; Bronchoconstrictor Agents; Bronchodilator Agents; | 2003 |
Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; As | 2003 |
[The comparative effects of aminophylline and salbutamol on the treatment of infant allergic cough].
Topics: Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Cough; Humans; Treatment Outcome | 2003 |
Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears!
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Delivery System | 2003 |
Electrostatic charge on spacer devices and salbutamol response in young children.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agent | 2003 |
Regular salbutamol use increases CXCL8 responses in asthma: relationship to the eosinophil response.
Topics: Adult; Albuterol; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; | 2003 |
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind | 2003 |
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind | 2003 |
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind | 2003 |
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind | 2003 |
Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients?
Topics: Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Delivery Systems; F | 2003 |
Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Ethanolamines; Female; Formoter | 2003 |
[Fixed-dose fluticasone-salmeterol combination: at least effective and better tolerated than open-dose combinations].
Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Female; Fl | 2003 |
Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Anti-Asthmatic | 2003 |
Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Albuterol; Anti-Asthmatic Agents; Asthma | 2003 |
Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Albuterol; Asthma; Bronchodilato | 2003 |
Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2003 |
Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilat | 2003 |
Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide.
Topics: Acetates; Administration, Inhalation; Adolescent; Albuterol; Asthma; Breath Tests; Bronchodilator Ag | 2003 |
Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.
Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Broncho | 2003 |
Tolerance to the protective effect of salmeterol in mild untreated asthmatics.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Asthma; B | 2003 |
Effects of ambient air pollution on symptom severity and medication use in children with asthma.
Topics: Adolescent; Air Pollutants; Air Pollution; Albuterol; Asthma; Bronchodilator Agents; Carbon Monoxide | 2003 |
Effect of inhalation of salbutamol, beclomethasone dipropionate & ipratropium bromide on mucociliary clearance in some patients with chronic stable bronchial asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Broncho | 2003 |
Effects of respiratory timing and cheek support on resistance measurements, before and after bronchodilation in asthmatic children using the interrupter technique.
Topics: Adolescent; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents | 2003 |
Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al | 2003 |
Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; | 2003 |
Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2003 |
Comparison of racemic albuterol and levalbuterol for treatment of acute asthma.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double | 2003 |
Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous beta2-adrenoceptor haplotypes at positions 16 and 27.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Female; Forced Expir | 2004 |
[A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination].
Topics: Acetates; Administration, Inhalation; Adult; Aerosols; Albuterol; Androstadienes; Anti-Asthmatic Age | 2003 |
Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilat | 2002 |
Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bone and Bones; Bronchodilator Agents | 2004 |
Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Double-Blind Meth | 2004 |
Nebulised salbutamol administered during sputum induction improves bronchoprotection in patients with asthma.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents | 2004 |
Metered dose inhaler with spacer versus dry powder inhaler for delivery of salbutamol in acute exacerbations of asthma: a randomized controlled trial.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator A | 2004 |
Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Over | 2004 |
Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol | 2004 |
Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Analysis of Variance; Androstadienes; Asthma; | 2004 |
Salmeterol decreases eosinophilic cationic protein and rescue medication in patients inhaling beclomethasone dipropionate: preliminary study in mild and moderate asthma in Trinidad, West Indies.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Inflammatory Agen | 2003 |
Nebulized salbutamol vs salbutamol and ipratropium combination in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administration Schedule; Drug Ther | 2004 |
One week treatment with salmeterol does not prevent early and late asthmatic responses and sputum eosinophilia induced by allergen challenge in asthmatics.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Cross-O | 2004 |
Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronchoconstriction; | 2004 |
Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study.
Topics: Albuterol; Antiviral Agents; Asthma; Bronchodilator Agents; Female; Follow-Up Studies; Hepatitis C, | 2004 |
Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents; Female; | 2004 |
Response to inhaled albuterol during nocturnal asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over | 2004 |
Inhaled corticosteroids and growth of airway function in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Analysis of Variance; As | 2004 |
Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Delayed-Acti | 2004 |
Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Cal | 2004 |
Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study.
Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cyclopr | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodil | 2004 |
Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; | 2004 |
Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator | 2004 |
Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study.
Topics: Acetates; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; | 2004 |
Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Blood Proteins; Bre | 2004 |
Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; D | 2004 |
Montelukast and airway remodeling in children with chronic persistent asthma: an open study.
Topics: Acetates; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Ch | 2004 |
Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadi | 2004 |
Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction.
Topics: Administration, Inhalation; Adult; Albuterol; Area Under Curve; Asthma; Bronchoconstriction; Broncho | 2004 |
[Efficacy and acceptability of the fixed fluticasone + salmeterol combination in the treatment of acute asthma attacks. Results of a one-year comparative study].
Topics: Adult; Albuterol; Androstadienes; Asthma; Drug Combinations; Female; Fluticasone-Salmeterol Drug Com | 2004 |
Comparison of terbutaline and salbutamol inhalation in children with mild or moderate acute exacerbation of asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Confidence Intervals; Dose-Respons | 2004 |
Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, p
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi | 2004 |
Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; | 2005 |
BAL eotaxin and IL-5 in asthma, and the effects of inhaled corticosteroid and beta2 agonist.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2004 |
Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agent | 2005 |
Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma.
Topics: Adolescent; Adult; Aerosol Propellants; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Inf | 2004 |
Pycnogenol as an adjunct in the management of childhood asthma.
Topics: Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Antioxidants; Asthma; Bronch | 2004 |
Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma.
Topics: Administration, Oral; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Delayed-A | 2005 |
Evaluation of the magnitude of the bronchodilator response in children and adolescents with asthma.
Topics: Adolescent; Adult; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; | 2005 |
Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi | 2005 |
Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
Topics: Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Cross-Over Studies; Doubl | 2005 |
[Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Therapy, | 2005 |
The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Chemistry, Pharmaceutical; Chromatography, High Pre | 2005 |
Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma.
Topics: Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Chemical Phe | 2005 |
Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects.
Topics: Adolescent; Adult; Aerosol Propellants; Albuterol; Anti-Asthmatic Agents; Asthma; Chemical Phenomena | 2005 |
Increase in daytime symptoms is a sensitive and specific criterion for predicting corticosteroid-treated exacerbations in a clinical asthma trial.
Topics: Acute Disease; Administration, Oral; Albuterol; Asthma; Drug Administration Schedule; Follow-Up Stud | 2005 |
Haemodynamic responses to salbutamol and isometric exercise are altered in young adults with mild asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Cros | 2005 |
Monitoring nebulizer use in children: comparison of electronic and asthma diary data.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool; Femal | 2005 |
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi | 2005 |
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi | 2005 |
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi | 2005 |
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi | 2005 |
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi | 2005 |
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi | 2005 |
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi | 2005 |
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi | 2005 |
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Biomarkers; Bronchodi | 2005 |
The 24 h duration of bronchodilator action of the salmeterol/fluticasone combination inhaler.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Age | 2005 |
[Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma].
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Drug | 2005 |
Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi | 2005 |
Benefit from anti-inflammatory treatment during clinical remission of atopic asthma.
Topics: Adolescent; Adult; Albuterol; Analysis of Variance; Androstadienes; Anti-Asthmatic Agents; Anti-Infl | 2005 |
Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Androstadienes; Anti-Inflammatory Agents; As | 2005 |
Reversal of the late asthmatic response increases exhaled nitric oxide.
Topics: Adult; Albuterol; Allergens; Asthma; Breath Tests; Bronchial Provocation Tests; Bronchodilator Agent | 2005 |
Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways.
Topics: Adenylyl Cyclases; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta- | 2005 |
The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast
Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Double-Blind Method; Dr | 2005 |
A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attacks.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Bronchodilator Agents; Calcium Channe | 2005 |
Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi | 2005 |
Correct use of three powder inhalers: comparison between Diskus, Turbuhaler, and Easyhaler.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Equipment Design; Female; Humans; Male; Middle Aged | 2005 |
Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aerosol Propellants; Aged; A | 2005 |
Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2005 |
Effects of long-acting bronchodilators and placebo on histamine-induced asthma symptoms and mild bronchusobstruction.
Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Delayed-Action Preparations; D | 2006 |
Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agon | 2006 |
Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children.
Topics: Adolescent; Adult; Albuterol; Asthma; Blood Gas Analysis; Bronchodilator Agents; Child; Child, Presc | 2005 |
Effects of two nebulization regimens on heart rate variability during acute asthma exacerbations in children.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; | 2005 |
Comparative analysis of the bronchodilator response measured by impulse oscillometry (IOS), spirometry and body plethysmography in asthmatic children.
Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Oscill | 2005 |
The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Blood Pressure; Child; Child, Preschool | 2005 |
Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agen | 2005 |
Beneficial effects of albuterol therapy driven by heliox versus by oxygen in severe asthma exacerbation.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Dy | 2005 |
The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: a randomized, placebo-controlled, double-blind, crossover study.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchoconstrictor Agent | 2005 |
Regular vs ad-lib albuterol for patients hospitalized with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Doubl | 2005 |
Comparison of the short-term effects of salmeterol and formoterol on heart rate variability in adult asthmatic patients.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Ethanolamines; Femal | 2005 |
Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio | 2005 |
Formoterol induces tolerance to the bronchodilating effect of Salbutamol following methacholine-provocation test in asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Blood Cell Count; Bronchial Provocation Tests; Bronchodilator Agents; | 2006 |
Does an asthma education program improve quality of life? A two-year randomized trial.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lung Volume Measurements; Mal | 2005 |
Deposition pattern of heliox-driven bronchodilator aerosol in the airways of stable asthmatics.
Topics: Administration, Inhalation; Adult; Aerosol Propellants; Albuterol; Asthma; Biological Availability; | 2005 |
Evaluation of severity of bronchial asthma through an exercise bronchial challenge.
Topics: Adolescent; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Child; Child, Pre | 2005 |
Alterations in T-lymphocyte subsets in the airways of asthmatic patients with active hepatitis C virus infection.
Topics: Albuterol; Antiviral Agents; Asthma; Bronchodilator Agents; CD4-CD8 Ratio; Drug Therapy, Combination | 2006 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; H | 2005 |
Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Dose-Response Relationship, Drug; Double | 2005 |
Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Alb | 2005 |
[Is guideline-defined asthma control achievable?--secondary publication. The Gaining Optimal Asthma ControL (GOAL) Study].
Topics: Adrenal Cortex Hormones; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Ag | 2005 |
Co-administration of salbutamol and fluticasone for emergency treatment of children with moderate acute asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory A | 2005 |
Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilat | 2006 |
Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial.
Topics: Acute Disease; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; | 2005 |
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma | 2005 |
Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Br | 2005 |
Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils.
Topics: Administration, Inhalation; Albuterol; Allergens; Androstadienes; Asthma; Bronchodilator Agents; Cro | 2005 |
Beclomethasone dipropionate attenuates airways hyperresponsiveness to neurokinin A and histamine in asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Ana | 2006 |
Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstricto | 2005 |
Plant-based formulation for bronchial asthma: a controlled clinical trial to compare its efficacy with oral salbutamol and theophylline.
Topics: Administration, Oral; Adult; Albendazole; Albuterol; Asthma; Double-Blind Method; Drug Therapy, Comb | 2006 |
Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma.
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Airway Resistance; Albuterol; Androstadienes; Asth | 2005 |
Risk of severe asthma episodes predicted from fluctuation analysis of airway function.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Placebos; Probability; Random | 2005 |
Risk of severe asthma episodes predicted from fluctuation analysis of airway function.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Placebos; Probability; Random | 2005 |
Risk of severe asthma episodes predicted from fluctuation analysis of airway function.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Placebos; Probability; Random | 2005 |
Risk of severe asthma episodes predicted from fluctuation analysis of airway function.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Placebos; Probability; Random | 2005 |
beta-Adrenergic receptor polymorphisms and response to salmeterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Drug Therapy, Combin | 2006 |
The correlation of urinary levels of albuterol and its metabolites isomers following inhalation from a dry powder inhaler and in vitro particle size characterisation.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Biological Availability; Bronchodilator Agents | 2007 |
Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge.
Topics: Administration, Inhalation; Adult; Albuterol; Allergens; Androstadienes; Asthma; Bronchodilator Agen | 2006 |
Aminophilline suppress the release of chemical mediators in treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Aged; Albuterol; Aminophylline; Anti-Inflammatory | 2006 |
Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2006 |
Comparison of morning and afternoon exercise training for asthmatic children.
Topics: Abdominal Muscles; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Budesonide; Case- | 2006 |
[Metered-dose inhaler with spacer vs nebulization for severe and potentially severe acute asthma treatment in the pediatric emergency department].
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronch | 2006 |
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al | 2006 |
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al | 2006 |
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al | 2006 |
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al | 2006 |
Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Doubl | 2006 |
Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Analysis of Variance; Androstadienes; Anti-Asthmatic A | 2006 |
Formoterol Turbuhaler as reliever medication in patients with acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Australia; Bronchodilator Agents; Dose-Re | 2006 |
The structural basis of airways hyperresponsiveness in asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchoconstriction; | 2006 |
Bronchodilator effect of salbutamol from two different spacer devices.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Cross-Over Studies; Equipment Design; Female; Fo | 2006 |
Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and beta2-agonist use.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cell Adhesion Molecules; Humans; | 2006 |
Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Topics: Adolescent; Adult; Aerosol Propellants; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; | 2006 |
Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Clinical Protocols; Connecticut; Female; Hospita | 2006 |
Improved lung function and symptom control with formoterol on demand in asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Ethanolami | 2006 |
Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmat | 2006 |
[Bronchodilators via metered-dose inhaler with spacer in the pediatric emergency department: what is the dosage?].
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 2006 |
Responses to inhaled bronchodilators in infancy are not linked with asthma in later childhood.
Topics: Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; Child, Preschool; Cross-Over S | 2006 |
Determinants of the bronchodilation response to salbutamol on histamine-induced bronchoconstriction.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchocons | 2006 |
Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadienes; Anti-As | 2006 |
Bronchial asthma as neurogenic paroxysmal inflammatory disease: a randomized trial with carbamazepine.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Anticonvulsa | 2006 |
Once-daily ciclesonide in children: efficacy and safety in asthma.
Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dose-Res | 2006 |
Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Dru | 2006 |
Cost-effectiveness of asthma control: an economic appraisal of the GOAL study.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Double-Blind Method | 2006 |
A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of V | 2006 |
EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alb | 2006 |
Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Clinical Pharmacy Information System | 2006 |
Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2006 |
Oral montelukast treatment of preschool-aged children with acute asthma.
Topics: Acetates; Acute Disease; Administration, Oral; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodila | 2006 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Brazil; Bronchodilator Agents; Child; Dietary | 2007 |
Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Body Height; Bronchodilator Agents; Child, | 2006 |
Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asth | 2006 |
Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Asthma; Bronchoalveolar Lavage Fluid; Fe | 2006 |
Bronchodilator effect of infused B-type natriuretic peptide in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expirato | 2006 |
Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-Response Relations | 2006 |
The effect of nebulized NaHCO3 treatment on "RADS" due to chlorine gas inhalation.
Topics: Adolescent; Adult; Air Pollutants; Albuterol; Asthma; Chlorine; Double-Blind Method; Drug Therapy, C | 2006 |
Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Area Under Curve; Asthma; Bronchodi | 2007 |
Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Cross-O | 2006 |
Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic | 2006 |
Does the combination of inhaled steroids with long acting beta2 agonists decrease the risk for osteoporosis? A 1-year prospective follow-up study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And | 2006 |
Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inadequately controlled asthma patients on inhaled corticosteroids.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Anti-Inflammatory Agents | 2006 |
Randomised trial comparing as-needed versus regular treatment with formoterol in patients with persistent asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Sch | 2007 |
Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Asthma; Bronchodilator | 2007 |
Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma.
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; | 2007 |
Fluticasone propionate/salmeterol hydrofluoroalkane via metered-dose inhaler with integrated dose counter: Performance and patient satisfaction.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent | 2006 |
Speed of onset of bronchodilator response to salbutamol inhaled via different devices in asthmatics: a bioassay based on functional antagonism.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilato | 2006 |
Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 an | 2006 |
Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma.
Topics: Administration, Cutaneous; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Femal | 2006 |
A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma.
Topics: Adult; Aerosols; Albuterol; Asthma; Double-Blind Method; Drug Therapy, Combination; Female; Humans; | 2006 |
The correlation between asthma control and health status: the GOAL study.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Age | 2007 |
The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Bronc | 2007 |
The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Adu | 2006 |
Ventolin to Salamol--a crossover study in New Zealand.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cross-Over Studies; Equipment | 2006 |
Asthmatics: too drunk to drive? The time curve of exhaled ethanol levels after use of Salamol in normal subjects.
Topics: Administration, Inhalation; Adult; Albuterol; Alcoholic Intoxication; Asthma; Breath Tests; Bronchod | 2006 |
Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Androstadienes; Asthma; Bronchodilator A | 2006 |
Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Drug Therapy, Comb | 2006 |
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial.
Topics: Acetates; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Body Height; Child; | 2007 |
Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchoconst | 2006 |
Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma.
Topics: Acetates; Administration, Intranasal; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchod | 2006 |
A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma.
Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Breath Tests; Bronchodilator Agents; Cross-Over Stud | 2007 |
Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
Topics: Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Dose-Response Relationship, D | 2007 |
Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-O | 2007 |
Management of acute asthma in children using metered dose inhaler and small volume nebulizer.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronc | 2006 |
Age dependent systemic exposure to inhaled salbutamol.
Topics: Administration, Inhalation; Adolescent; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child | 2007 |
Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cholinergic Antagoni | 2007 |
Formoterol turbuhaler is as effective as salbutamol diskus in relieving adenosine-induced bronchoconstriction in children.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol | 2007 |
Placebo response in asthma: a robust and objective phenomenon.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Cross-Over Studies; Double-Blind Me | 2007 |
A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Me | 2007 |
Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler.
Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albute | 2007 |
Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity.
Topics: Adult; Albuterol; Asthma; Breath Tests; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; | 2007 |
Randomized comparison of strategies for reducing treatment in mild persistent asthma.
Topics: Acetates; Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic A | 2007 |
Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm | 2007 |
Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization.
Topics: Administration, Inhalation; Albuterol; Asthma; Biological Availability; Chemistry, Pharmaceutical; C | 2007 |
[Effects of combined therapy with domestic inhalational anti-asthmatic drugs on oxidant status of patients with bronchial asthma].
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Antioxidants; Asthma; Budesonid | 2007 |
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Br | 2007 |
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Br | 2007 |
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Br | 2007 |
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Br | 2007 |
Lipid peroxides in stable asthmatics receiving inhaled steroids and long-acting beta2 -agonists.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Asthma; Budeson | 2007 |
Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchodilator Agents | 2007 |
Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; B | 2007 |
Is there any point in a corticosteroid treatment of intermittent asthma?
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Drug Combi | 2007 |
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.
Topics: Adult; Albuterol; Androstadienes; Asthma; Double-Blind Method; Drug Combinations; Female; Fluticason | 2007 |
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.
Topics: Adult; Albuterol; Androstadienes; Asthma; Double-Blind Method; Drug Combinations; Female; Fluticason | 2007 |
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.
Topics: Adult; Albuterol; Androstadienes; Asthma; Double-Blind Method; Drug Combinations; Female; Fluticason | 2007 |
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.
Topics: Adult; Albuterol; Androstadienes; Asthma; Double-Blind Method; Drug Combinations; Female; Fluticason | 2007 |
Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 microg bd versus fluticasone propionate 100 microg bd alone in patients with persistent asthma: integrated analysis of four randomised trials.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Double-Bli | 2007 |
Randomized trial of spacers in asthma.
Topics: Adolescent; Adrenergic alpha-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presc | 2007 |
Swimming and persons with mild persistant asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomethasone; Bronchial Hyperreactivity; Femal | 2007 |
Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction.
Topics: Adolescent; Adult; Albuterol; Area Under Curve; Asthma; Breath Tests; Bronchial Provocation Tests; B | 2007 |
Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Alkanes; Androstadienes; Asthma; Bronc | 2007 |
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agen | 2007 |
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agen | 2007 |
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agen | 2007 |
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agen | 2007 |
[The effect of desloratadine on use of rescue beta2-agonists and symptoms in patients suffering from seasonal allergic rhinitis and asthma].
Topics: Administration, Oral; Adult; Albuterol; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Broncho | 2005 |
Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma.
Topics: Acetates; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; | 2007 |
Adding long-acting beta-agonists to inhaled corticosteroids after discharge from the emergency department for acute asthma: a randomized controlled trial.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adrenergic be | 2007 |
Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Albuterol; Analysis of Varianc | 2007 |
Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al | 2007 |
Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study.
Topics: Adrenergic beta-Agonists; Adult; Age Factors; Aged; Albuterol; Androstadienes; Anti-Allergic Agents; | 2007 |
Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the goal study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma | 2007 |
[A clinical study on the significance of airway hyperresponsiveness monitoring in the adjustment of combined therapy for asthmatic patients].
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivi | 2007 |
Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation.
Topics: Adrenal Cortex Hormones; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; B | 2008 |
Agreement between two methods for assessing bioequivalence of inhaled salbutamol.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronc | 2008 |
Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Blood Pressure; Bronchodilator Agents; El | 2007 |
Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Cross-Ov | 2008 |
Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks.
Topics: Administration, Inhalation; Adult; Albuterol; Algorithms; Asthma; Biological Availability; Bronchodi | 2008 |
The effects of combination treatment with a long-acting beta2-agonist and a corticosteroid on salivary flow rate, secretory immunoglobulin A, and oral health in children and adolescents with moderate asthma: a 1-month, single-blind clinical study.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol | 2007 |
Rapid corticosteroid effect on beta(2)-adrenergic airway and airway vascular reactivity in patients with mild asthma.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Thera | 2008 |
Is Salamol less effective than Ventolin? A randomised, blinded, crossover study in New Zealand.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cross-Over Studies; | 2007 |
AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Blood Glucose; Cross-Ov | 2008 |
Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A | 2008 |
Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma : a placebo-controlled comparison.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator | 2008 |
Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; F | 2007 |
Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadie | 2008 |
The effects of nebulized albuterol on esophageal function in asthmatic patients.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Dru | 2008 |
Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilato | 2008 |
Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A | 2008 |
[Efficacy of pulmicort suspension plus salbutamol and ipratropium bromide for management of acute asthma exacerbation in children: a comparative study].
Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Ch | 2008 |
Salmeterol vs. formoterol: a comparison of rapid bronchodilator effect in a randomized controlled trial.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Etha | 2008 |
Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; D | 2008 |
Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma.
Topics: Adult; Aged; Aged, 80 and over; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents; Cross-Ov | 2008 |
Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Bli | 2008 |
Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast.
Topics: Acetates; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Biomarkers; Breath Tests; Bronchodil | 2008 |
Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budeson | 2008 |
Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Child | 2008 |
Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Black or African American; Bronchodilator Agen | 2008 |
Ketotifen in adult asthma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Doubl | 1980 |
Double-blind crossover study of carbuterol and salbutamol in bronchial asthma.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Clinical Trial | 1981 |
Inhaled prazosin in asthma.
Topics: Adrenergic alpha-Antagonists; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Metho | 1981 |
Comparison of cardiorespiratory effects of procaterol and salbutamol in asthmatic patients.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cardiovascular System; Clinical Tria | 1982 |
Two new beta 2-adrenoceptor agonists, D-2343 and QH 25, studied in asthmatic patients.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Animals; Asthma; Bronchodilator Agents; Depression | 1982 |
Pirbuterol.
Topics: Albuterol; Animals; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Double-Blind Method; Et | 1984 |
Selectivity of beta-adrenergic stimulating and blocking agents.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Airway Resistance; Albuterol; Asthma; Bronchi | 1984 |
Aminophylline for morning dips in chronic asthma.
Topics: Albuterol; Aminophylline; Asthma; Beclomethasone; Circadian Rhythm; Clinical Trials as Topic; Double | 1984 |
A therapeutic comparison of ipratropium bromide and salbutamol in asthmatic patients.
Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Drug Tolerance; Fema | 1982 |
Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma.
Topics: Acute Disease; Adult; Aerosols; Aged; Albuterol; Asthma; Atropine Derivatives; Female; Humans; Iprat | 1983 |
Nebulised ipratropium bromide in wheezy infants and young children.
Topics: Administration, Intranasal; Age Factors; Airway Resistance; Albuterol; Asthma; Atropine Derivatives; | 1983 |
Salbutamol versus Duovent (a combination of fenoterol and ipratropium bromide) in asthma.
Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Drug Combinations; E | 1983 |
A comparison between a combination of ipratropium bromide plus fenoterol in a single metered dose inhaler (Duovent) and salbutamol in asthma.
Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Chronic Disease; Drug Combinations; Ethanolami | 1983 |
[Comparison by double-blind study of the combination of an aerosol of salbutamol and ipratropium bromide and its individual effect in chronic bronchitis and bronchial asthma].
Topics: Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Chronic Disease; Double-Blind Method; | 1983 |
Comparison of Duovent and salbutamol inhalers in chronic stable asthma.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Atropine Derivatives; Chronic Disease; Clinical Trials as | 1984 |
Ipratropium bromide in patients with nocturnal asthma.
Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Female; Humans; Ipra | 1984 |
[Effectiveness of disodium cromoglycate, salbutamol, and ipratropium bromide in the inhibition of exercise-induced bronchospasm].
Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Atropine Derivatives; Bronchial Spasm; Child; Clinical | 1984 |
Combination of salbutamol inhalational powder and tablets in asthma.
Topics: Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Double-B | 1983 |
Bronchodilator effects of salbutamol powder administered via Rotahaler and of terbutaline aerosol administered via Misthaler. A comparison study in children with asthma.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchi; Child; Child, Preschool; Clinical Trials as Topic; | 1983 |
Comparison of bronchodilator effects of oral salbutamol and theophylline and their combination with hydroxyzine.
Topics: Administration, Oral; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug | 1983 |
A 21-day double-blind study of the effect of adding sustained-release theophylline (Nuelin SA) to inhaled salbutamol in patients with asthma.
Topics: Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind | 1983 |
Effect of a timed interval between inhalation of beta-agonist and corticosteroid aerosols on the control of chronic asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Chronic Disease; Clinical Tria | 1983 |
[Inhalation therapy with fenoterol powder in children with bronchial asthma].
Topics: Adolescent; Albuterol; Asthma; Child; Clinical Trials as Topic; Ethanolamines; Female; Fenoterol; Hu | 1983 |
Chamber assisted inhalant treatment (CAIR).
Topics: Albuterol; Asthma; Beclomethasone; Child; Child, Preschool; Clinical Trials as Topic; Humans; Infant | 1983 |
Nebulized salbutamol in life-threatening asthma: is IPPB necessary?
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; | 1983 |
The duration of protection from exercise-induced asthma by inhaled salbutamol, and a comparison with inhaled reproterol.
Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Clinical Trials as Topic; Drug Combi | 1983 |
Bronchodilator effect of two inhaled H1-receptor antagonists, clemastine and chlorpheniramine, in wheezy school-children.
Topics: Albuterol; Asthma; Bronchi; Child; Child, Preschool; Chlorpheniramine; Clemastine; Clinical Trials a | 1983 |
Drug effect on bronchial response to PGF2 alpha and water inhalation.
Topics: Albuterol; Asthma; Benzothiazoles; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; Clin | 1983 |
Comparison of inhaled fenoterol and salbutamol in the prevention of exercise-induced asthma.
Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced | 1983 |
A cumulative dose response study of oxitropium bromide (Ba 253) in asthmatics.
Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fe | 1983 |
Fenoterol versus salbutamol nebuliser solution in asthma.
Topics: Administration, Intranasal; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Doub | 1983 |
The bronchodilator response to inhalation of increasing doses of aerosolized albuterol.
Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchodilator Age | 1983 |
Cardiac response to oral and aerosol administration of beta agonists.
Topics: Administration, Oral; Adolescent; Aerosols; Albuterol; Asthma; Child; Clinical Trials as Topic; Hear | 1983 |
Fenoterol versus salbutamol nebulization in asthma.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Ethanolamin | 1983 |
[Effect, tolerance and dose dependence of salbutamol powder inhalations].
Topics: Administration, Intranasal; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Dose-Response | 1983 |
Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Clinical Trials as Topic; Double-Blin | 1984 |
[Effect of treatment with ventolin and becotide on ventilation and hemodynamics in patients with bronchial asthma].
Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Clinical Trials as Topic; Drug Therapy, Combination; He | 1983 |
Assessment of a new combination inhaler containing salbutamol and beclomethasone dipropionate in the management of asthmatic patients.
Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Child; Clinical Trials as Topic; Double-Blind | 1984 |
Methacholine dose-response curves in normal and asthmatic man: effect of starting conductance and pharmacological antagonism.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Atropine; Bronchi; Chlorpheniramine; Dose-Response Rela | 1984 |
Comparative study of the bronchospasmolytic effect of fenoterol (0.2 mg) salbutamol (0.4 mg) as powder inhalations in 20 patients with reversible bronchial obstruction.
Topics: Administration, Intranasal; Adult; Airway Resistance; Albuterol; Asthma; Clinical Trials as Topic; D | 1984 |
A comparison of sustained-release terbutaline with ordinary salbutamol in bronchial asthma.
Topics: Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind | 1984 |
Isosorbide dinitrate and isoxsuprine in exercise induced asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Cromolyn Sodium; Forced Expiratory V | 1983 |
Simple drug delivery system for use by young asthmatics.
Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Respiratory Therapy | 1983 |
Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma.
Topics: Adult; Albuterol; Arrhythmias, Cardiac; Asthma; Delayed-Action Preparations; Female; Humans; Male; M | 1984 |
Comparison of atropine with ipratropium bromide in patients with reversible airways obstruction unresponsive to salbutamol.
Topics: Adult; Albuterol; Asthma; Atropine; Atropine Derivatives; Clinical Trials as Topic; Dose-Response Re | 1980 |
Effect of freon inhalation on maximal expiratoryflows and heart rhythm after treatment with salbutamol and ipratropium bromide.
Topics: Adult; Aerosol Propellants; Aerosols; Albuterol; Arrhythmias, Cardiac; Asthma; Atropine Derivatives; | 1980 |
[Clinical pharmacological trials of a new metered dose inhaler, IK-6, a combination of the bronchodilators fenoterol and ipratropium bromide (author's transl)].
Topics: Aerosols; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Drug Combinations; Ethanolami | 1980 |
Ipratropium bromide in acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical | 1981 |
[Bronchial asthma induced by exercise (author's transl)].
Topics: Airway Resistance; Albuterol; Asthma; Cromolyn Sodium; Humans; Ipratropium; Physical Exertion | 1981 |
Pretreatment of exercise-induced asthma in adults with aerosols and pulverized tablets.
Topics: Administration, Oral; Adolescent; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Clin | 1980 |
Bronchodilator effects of clemastine, ipratropium, bromide, and salbutamol in preschool children with asthma.
Topics: Airway Resistance; Albuterol; Asthma; Atropine Derivatives; Bronchodilator Agents; Child, Preschool; | 1981 |
Adrenaline and nebulized salbutamol in acute asthma.
Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child; Epinephrine; Female; Humans; Injections; Male | 1984 |
[Pirbuterol and salbutamol aerosol for exercise-induced bronchoconstriction].
Topics: Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Ethanolamines; | 1984 |
Deep-inspiration induced bronchoconstriction: a mechanism for beclomethasone aerosol intolerance.
Topics: Aerosols; Airway Resistance; Albuterol; Asthma; Beclomethasone; Bronchial Spasm; Cough; Humans; Prem | 1983 |
Bronchodilatory effect of inhaled versus oral salbutamol in bronchial asthma.
Topics: Administration, Oral; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expi | 1983 |
Comparison of salbutamol powder with terbutaline aerosol administered with a tube spacer in asthmatic children.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchi; Child; Forced Expiratory Volume; Humans; Maximal M | 1983 |
Effects of oral theophylline and oral salbutamol in the treatment of asthma.
Topics: Adolescent; Albuterol; Asthma; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Drug | 1982 |
Comparison of salbutamol given by intermittent positive-pressure breathing and pressure-packed aerosol in chronic asthma.
Topics: Aerosols; Albuterol; Asthma; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Humans; | 1982 |
A comparison of the effects of different methods of administration of beta-2-sympathomimetics in patients with asthma.
Topics: Administration, Oral; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Humans; Resp | 1982 |
Salbutamol: tablets, inhalational powder, or nebuliser?
Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; | 1981 |
Combined treatment with sustained-release theophylline and beta2-adrenoceptor-stimulating agents in chronic childhood asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Chronic Disease; Clinical Trials as Topic; Delayed-Action Prep | 1981 |
Bronchodilator effect of sodium cromoglycate and its clinical implications.
Topics: Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Cromolyn Sodium; Female; Humans; | 1981 |
Comparison of ketotifen, disodium cromoglycate and placebo in the treatment of adult patients with mild extrinsic asthma.
Topics: Adult; Albuterol; Asthma; Circadian Rhythm; Cromolyn Sodium; Female; Humans; Ketotifen; Male; Middle | 1981 |
Actions of salbutamol, disodium cromoglycate, and placebo administered as aerosols in acute asthma.
Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Cromolyn Sodium; Dr | 1981 |
The immediate effect of sodium cromoglycate on the airway.
Topics: Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Child; Cromolyn Sodium; Female; Humans | 1982 |
A double blind crossover trial of lithium carbonate in asthma.
Topics: Adult; Albuterol; Asthma; Double-Blind Method; Female; Humans; Lithium; Lithium Carbonate; Male; Mid | 1982 |
Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study.
Topics: Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic | 1982 |
Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Blood Gas Analysis; Child; Double-Blind Method; Epinep | 1983 |
Comparison between an alpha-adrenergic antagonist and a beta 2-adrenergic agonist in bronchial asthma.
Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Drug Evaluation; Drug Therapy, Combination; Female; Human | 1983 |
Double-blind comparison of acute effects of inhaled albuterol, isoproterenol and placebo on cardiopulmonary function and gas exchange in asthmatic children.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Blood Pressure; Child; Double-Blind Method; Female; Heart; | 1983 |
Prostaglandins and the control of airways responses to histamine in normal and asthmatic subjects.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Dose-Response Relationship | 1983 |
The effect of powder aerosol compared to pressurized aerosol.
Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Humans; Powders; Pressure; Random Allocation; Respirato | 1982 |
Protective effect of inhaled salbutamol powder in children assessed by histamine challenge.
Topics: Adolescent; Albuterol; Asthma; Bronchial Provocation Tests; Child; Clinical Trials as Topic; Double- | 1980 |
Efficacy of orally administered salbutamol and theophylline in pre-schoolchildren with asthma.
Topics: Administration, Oral; Airway Resistance; Albuterol; Asthma; Child, Preschool; Clinical Trials as Top | 1980 |
Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels.
Topics: Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Chronic Disease; Circadian Rhythm; Clinic | 1980 |
Salbutamol by powder or spray inhalation in childhood asthma.
Topics: Administration, Intranasal; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials | 1980 |
Aminophylline vs. salbutamol in exercise-induced asthma.
Topics: Adult; Albuterol; Aminophylline; Asthma; Asthma, Exercise-Induced; Clinical Trials as Topic; Forced | 1980 |
Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Drug A | 1980 |
A comparison of the duration of action of fenoterol and salbutamol in asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; | 1981 |
Regular versus symptomatic aerosol bronchodilator treatment of asthma.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Admini | 1981 |
How important is the sequence of administration of inhaled beclomethasone dipropionate and salbutamol in asthma.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Clinical Trials as Topic; Double-Blind Met | 1981 |
Clinical effects of albuterol aerosol in the treatment of asthma.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Humans; Isoproterenol; Middle Ag | 1981 |
Tolerance to beta-adrenergics and results of rising dose studies of albuterol, isoproterenol and placebo.
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchial Spasm; Clinical Trials as Topic; Dose-Response Relatio | 1981 |
Interaction between proxyphylline and salbutamol.
Topics: Adolescent; Adult; Albuterol; Aminophylline; Animals; Asthma; Bronchodilator Agents; Clinical Trials | 1981 |
Optimal dose of salbutamol respiratory solution: comparison of three doses with plasma levels.
Topics: Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; | 1981 |
[Broncholytic effect of salbutamol, ventolin and berotec aerosols in bronchial asthma].
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Clinical Trials as T | 1981 |
Severe acute asthma: a comparison of three methods of inhaling salbutamol.
Topics: Acute Disease; Albuterol; Asthma; Heart Rate; Humans; Intermittent Positive-Pressure Breathing; Maxi | 1982 |
A comparison of isoetharine and albuterol: report of changes in pulmonary functions over 1 hour.
Topics: Albuterol; Amino Alcohols; Asthma; Bronchial Spasm; Bronchodilator Agents; Clinical Trials as Topic; | 1982 |
Oral albuterol in the treatment of childhood asthma.
Topics: Administration, Oral; Adolescent; Albuterol; Asthma; Child; Double-Blind Method; Female; Forced Expi | 1982 |
Salbutamol in the treatment of asthmatic children. A comparison of oral and inhalation therapy alone and in combination.
Topics: Administration, Oral; Adolescent; Aerosols; Albuterol; Asthma; Child; Double-Blind Method; Female; F | 1982 |
Albuterol by aerosol and orally administered theophylline in asthmatic children.
Topics: Administration, Oral; Adolescent; Aerosols; Albuterol; Asthma; Child; Humans; Pulmonary Ventilation; | 1982 |
Salbutamol: comparison of bronchodilating effect of inhaled powder and aerosol in asthmatic subjects.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Female; Forced Expirator | 1982 |
Albuterol syrup in the treatment of the young asthmatic child.
Topics: Albuterol; Asthma; Blood Pressure; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Fe | 1981 |
Pulmonary function and airways resistance studies on chronic stabilized asthma: comparison of acute and long-term effects of albuterol and isoproterenol aerosols.
Topics: Acute Disease; Airway Resistance; Albuterol; Asthma; Female; Heart Rate; Humans; Isoproterenol; Male | 1981 |
Cardiovascular response during severe acute asthma and its treatment in children.
Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Blood Pressure; Cardiac Output; Cardiov | 1981 |
Intravenous salbutamol and aminophylline in asthma: a search for synergy.
Topics: Albuterol; Aminophylline; Asthma; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Co | 1981 |
Corticosteroids in status asthmaticus.
Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Aminophylline; Asthma; Child; Evaluation Studies as | 1980 |
Salbutamol aerosol causes a tachycardia due to the inhaled rather than the swallowed fraction.
Topics: Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Humans; Tachycardia; Time Factors | 1980 |
Oral and inhaled salbutamol in the prevention of exercise-induced bronchospasm.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Aerosols; Albuterol; Asthma; Asthma, E | 1980 |
A comparative trial of slow-release aminophylline, salbutamol and a half dose combination in the prevention of childhood asthma.
Topics: Adolescent; Albuterol; Aminophylline; Asthma; Child; Delayed-Action Preparations; Dose-Response Rela | 1980 |
Inhalation of racemic epinephrine in children with asthma. Dose-response relation and comparison with salbutamol.
Topics: Acute Disease; Administration, Intranasal; Adolescent; Albuterol; Asthma; Child; Dose-Response Relat | 1980 |
Plasma atrial natriuretic peptide during spontaneous bronchoconstriction in asthmatics.
Topics: Acute Disease; Adult; Albuterol; Analysis of Variance; Asthma; Atrial Natriuretic Factor; Bronchi; F | 1995 |
Effect of zatebradine, a novel 'sinus node inhibitor', on pulmonary function compared to placebo.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Benzazepines; Bronchial Hyperreactivity; Cardiovascular | 1994 |
Safety of salmeterol in the maintenance treatment of asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Chronic Disease; Double | 1995 |
A controlled trial of nebulized salbutamol and adrenaline in acute severe asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Blood Gas Analysis; Bronchodila | 1995 |
Salbutamol in the treatment of asthma.
Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Double-Blind Method; Forced E | 1995 |
Validation of an asthma quality of life diary in a clinical trial.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Cross-Sectional S | 1995 |
The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blin | 1995 |
Influence of budesonide on the response to inhaled terbutaline in children with mild asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; | 1995 |
Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Analysis of Varia | 1995 |
The assessment of dyspnea in bronchial asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dyspnea; Female; Forced | 1995 |
Salmeterol xinafoate in children on high dose inhaled steroids.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol | 1995 |
Rapid onset of tolerance to the bronchoprotective effect of salmeterol.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agen | 1995 |
Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Doubl | 1995 |
Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Eq | 1995 |
An open multi-centre study to assess the efficacy of inhaled salmeterol in bronchial asthma in Nigeria.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Femal | 1994 |
Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Cr | 1995 |
Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients.
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Cros | 1995 |
Efficacy of a simple DIY spacer with a metered dose inhaler in asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Cross-Over Studies; Equipment Design; Female; Humans; | 1995 |
Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomized controlled study.
Topics: Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Chronic Disease; Female; Follow-Up Studies; Hu | 1995 |
Comparison of the effect of inhaled selective and non-selective adrenergic agonists on cardiorespiratory parameters in chronic stable asthma.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Chronic Disease; Cross-Over Studies; Dou | 1994 |
Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study.
Topics: Acute Disease; Adult; Aerosols; Albuterol; Asthma; Female; Humans; Injections, Intravenous; Male; Pe | 1995 |
Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-O | 1995 |
Regular use of inhaled albuterol and the allergen-induced late asthmatic response.
Topics: Administration, Inhalation; Adult; Albuterol; Allergens; Asthma; Cross-Over Studies; Double-Blind Me | 1995 |
Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Chlorofluorocarbons; Cross-Over St | 1995 |
Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Cetirizine; Cross-Over Studies; Double-Blind Method; Drug | 1995 |
Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Chronic Disease; Double-Blind Method | 1995 |
[Bronchial reactivity after regular inhalation of salbutamol].
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Dose-Response Rel | 1995 |
Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind | 1995 |
Long-term intervention in childhood asthma: the Dutch study results. Dutch Chronic Nonspecific Lung Disease Study Group.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronc | 1995 |
Some technical factors influencing the induction of sputum for cell analysis.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Cell Count; Cross | 1995 |
High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group.
Topics: Aerosols; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Budesonide; Double-Blind Meth | 1995 |
Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma.
Topics: Acute Disease; Adolescent; Albuterol; Analysis of Variance; Asthma; Child; Child, Preschool; Double- | 1995 |
Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; Cross-Over Studies; Dose-Re | 1994 |
Incidence of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients.
Topics: Aerosol Propellants; Age Factors; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Dou | 1994 |
Comparison of Bricanyl Turbuhaler and Ventolin Rotahaler in children with asthma.
Topics: Albuterol; Asthma; Child; Child, Preschool; Cross-Over Studies; Drug Tolerance; Female; Humans; Lung | 1995 |
Randomised trial spacer v nebuliser for acute asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Child, Preschool; Drug Delivery Systems; Drug Therapy | 1995 |
The influence of an inhaled steroid on quality of life in patients with asthma or COPD.
Topics: Administration, Inhalation; Albuterol; Asthma; Beclomethasone; Female; Forced Expiratory Volume; Hea | 1995 |
The reversibility of airway obstruction to an inhaled beta 2-adrenergic agent is less satisfactory after methacholine testing in asthmatic subjects.
Topics: Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchial Provocation Tests; Double-Blind Method | 1995 |
Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Asthma; Cetirizine; Double-Blind Method; Ephedrine; Humans; Male; Plac | 1995 |
Comparison of metered dose inhaler and oral administration of albuterol in the outpatient treatment of infants and children.
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Female | 1995 |
Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Proteins; Bronchi; Bronchial Provocation | 1995 |
[Duration of the effect of inhaled corticosteroids on lung function and sensitivity of the respiratory tract in patients with bronchial asthma].
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Beclomethasone; Bronchial P | 1995 |
[Asthma is asthma, is asthma...].
Topics: Administration, Inhalation; Airway Resistance; Albuterol; Asthma; Beclomethasone; Bronchial Provocat | 1995 |
A randomized comparison of 100-mg vs 500-mg dose of methylprednisolone in the treatment of acute asthma.
Topics: Acute Disease; Adult; Albuterol; Asthma; Double-Blind Method; Female; Forced Expiratory Volume; Huma | 1995 |
Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Combined Modality Therapy; Double-Blind M | 1995 |
GR106642X: a new, non-ozone depleting propellant for inhalers.
Topics: Aerosol Propellants; Albuterol; Asthma; Bronchial Hyperreactivity; Cross-Over Studies; Double-Blind | 1995 |
The effect of transfusion on pulmonary function in patients with thalassemia major.
Topics: Adolescent; Adult; Albuterol; Asthma; beta-Thalassemia; Child; Erythrocyte Transfusion; Female; Huma | 1994 |
Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronchod | 1995 |
Effect of inhaled norepinephrine on the nitroglycerin-induced bronchodilatation in asthmatics.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Cross-Over Studies; Double-Blin | 1995 |
[Effect of an inhaled beta-2-adrenergic agent administered at the time of delayed bronchial reactions to occupational agents].
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Double-Blind Meth | 1994 |
[Contribution of the bronchodilator test in the study of bronchial reversibility].
Topics: Adult; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchitis; Diagnosis, Differential; | 1994 |
Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo.
Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Cross-Over Studies; Culture Techniques; Dose-Response | 1994 |
High-dose MDI salbutamol treatment of asthma in the ED.
Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Emergencies; Female; | 1995 |
[Salmeterol improves control in asthmatic patients treated in general practice. A comparative study of salmeterol (Serevent) and salbutamol (Ventoline) in patients with mild to moderate asthma].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Doubl | 1995 |
Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids.
Topics: Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Budesonide | 1995 |
A double-blind, cross-over study using salbutamol, beclomethasone, and a combination of both in bronchial asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Child; Cross-Over | 1995 |
Early administration of hydrocortisone in the emergency room treatment of acute asthma: a controlled clinical trial.
Topics: Acute Disease; Adult; Albuterol; Asthma; Double-Blind Method; Drug Administration Schedule; Drug The | 1994 |
Metered-dose inhalers with spacers vs nebulizers for pediatric asthma.
Topics: Acute Disease; Administration, Inhalation; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Dru | 1995 |
Theophylline does not shorten hospital stay for children admitted for asthma.
Topics: Adolescent; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Double-Blind Method; Drug The | 1995 |
Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronch | 1995 |
Nebulized salbutamol (Asmasal) in Thai children with asthma: comparison of three doses.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Cross-Over Studies; Dose-Response Relationship | 1994 |
Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction.
Topics: Adenosine Monophosphate; Adult; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchocons | 1994 |
Does single dose salmeterol affect exercise capacity in asthmatic men?
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Exercise T | 1994 |
Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma.
Topics: Albuterol; Asthma; Chlorofluorocarbons; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 1994 |
Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Pressure; Cross-Over Studies; Dose-Respo | 1995 |
Clinical equivalence of a novel multiple dose powder inhaler versus a conventional metered dose inhaler on bronchodilating effects of salbutamol.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Cross-O | 1995 |
[The effect of a single dose of formoterol using an aerosol inhaler in asthmatic children. A randomized, controlled, double-blind study].
Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Me | 1994 |
Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch CNSLD Study Group.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronc | 1994 |
A 1-week dose-ranging study of inhaled salmeterol in patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod | 1994 |
Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod | 1994 |
Regular vs as-needed inhaled salbutamol in asthma control.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Double-Blind Method; Drug Ad | 1994 |
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; Double-Blin | 1994 |
Sensitivity of quality of life domains and constructs to longitudinal change in a clinical trial comparing salmeterol with placebo in asthmatics.
Topics: Activities of Daily Living; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Double-Blind M | 1994 |
Salmeterol compared with slow-release terbutaline in nocturnal asthma. A multicenter, randomized, double-blind, double-dummy, sequential clinical trial. French Multicenter Study Group.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Delayed-Action Preparations; D | 1994 |
Osmotic release oral drug delivery system of metoprolol in hypertensive asthmatic patients. Pharmacodynamic effects on beta 2-adrenergic receptors.
Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Atenolol; Double- | 1994 |
Comparison of salmeterol with placebo in mild asthma: effect on peripheral blood phagocyte function and cytokine levels.
Topics: Adult; Albuterol; Asthma; Cross-Over Studies; Double-Blind Method; Female; Humans; Interleukins; Lum | 1994 |
Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lav | 1994 |
Nebulized beta 2-adrenoceptor agonists do not affect plasma selenium or glutathione peroxidase activity in patients with asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aerosols; Albuterol; Asthma; Double-Blind Method; Female | 1994 |
Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Aminophylline; Asthma; Double-Blind Met | 1994 |
Efficacy and safety of inhaled Salmeterol (Serevent) as maintenance therapy for asthma in Nairobi.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Femal | 1994 |
A clinical study of colchicine in childhood asthma.
Topics: Albuterol; Asthma; Child; Colchicine; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; | 1994 |
[Bronchial hyperreactivity in patients with bronchial asthma treated with salbutamol and salbutamol combined with beclocort or nedocromil].
Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchial Hyperreactivity; Drug Therapy, Combination; Fema | 1994 |
[Inhalation corticosteroid therapy and nonspecific bronchial responsiveness enhanced with salbutamol].
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Hista | 1994 |
Partial inhibition of the early and late asthmatic response by a single dose of salmeterol.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Animals; Antigens, Dermatophagoides; Asthma; Blood Prote | 1994 |
Comparison of a single dose of aerosol salbutamol and fenoterol/ipratropium on bronchial asthmatic patients.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Drug Combinations; Female; Fenoter | 1994 |
Reversal of bronchial obstruction in children with mild stable asthma by aerosolized furosemide.
Topics: Administration, Inhalation; Adolescent; Albuterol; Analysis of Variance; Asthma; Child; Chronic Dise | 1994 |
Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double- | 1994 |
Effect of out-of-hospital albuterol inhalation treatments on patient comfort and morbidity.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Cohort Studies; Confidence Inte | 1994 |
Salbutamol in treatment of bronchial asthma--comparison of controlled release tablet with standard tablet.
Topics: Adult; Aged; Albuterol; Asthma; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Mal | 1993 |
The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cros | 1994 |
High dose inhaled atrial natriuretic peptide is a bronchodilator in asthmatic subjects.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Bronchoconstriction | 1994 |
Effect of intravenous magnesium infusion on salbutamol-induced bronchodilatation in patients with asthma.
Topics: Adult; Aged; Albuterol; Analysis of Variance; Asthma; Blood Pressure; Cross-Over Studies; Double-Bli | 1994 |
Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Analysis of Variance; | 1994 |
Delivery of salbutamol by metered dose inhaler and valved spacer to wheezy infants: effect on bronchial responsiveness.
Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Double-Blind Method; Equi | 1993 |
Protective effect of albuterol delivered via a spacer device (Babyhaler) against methacholine induced bronchoconstriction in young wheezy children.
Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Child, Preschool; Double-Blind | 1994 |
Bronchodilator treatment in asthma and bronchitis.
Topics: Albuterol; Asthma; Bronchitis; Chronic Disease; Humans; Ipratropium; Lung; Random Allocation; Respir | 1994 |
Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream").
Topics: Adult; Aged; Albuterol; Asthma; Drug Delivery Systems; Humans; Middle Aged; Nebulizers and Vaporizer | 1994 |
Systemic effects of salbutamol and salmeterol in patients with asthma.
Topics: Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Dose-Response Relationship, Drug; D | 1994 |
Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Airway Obstruction; Albuterol; Ast | 1993 |
Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Double-Blind Method; Drug Administra | 1993 |
Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Br | 1993 |
Effect on airway responsiveness of six weeks treatment with salmeterol.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Drug | 1993 |
The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Blood Proteins; Bronchial Provocation | 1993 |
Asthma control during and after cessation of regular beta 2-agonist treatment.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma | 1993 |
Regular inhaled salbutamol and airway responsiveness to allergen.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Asthma; Bronchial Provocation T | 1993 |
A novel multiple dose powder inhaler. Salbutamol powder and aerosol give equal bronchodilatation with equal doses.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Female; Humans; Male; Middle Aged; Nebulizers and | 1994 |
Nedocromil sodium versus albuterol in the management of allergic asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocati | 1994 |
Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations.
Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Double-Blind M | 1994 |
Prednisolone and salbutamol in the hospital treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Pr | 1994 |
Prednisolone and salbutamol in the hospital treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Pr | 1994 |
Prednisolone and salbutamol in the hospital treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Pr | 1994 |
Prednisolone and salbutamol in the hospital treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Pr | 1994 |
The effect of controlled-release salbutamol on sleep and nocturnal oxygenation in patients with asthma and chronic obstructive pulmonary disease.
Topics: Albuterol; Asthma; Delayed-Action Preparations; Double-Blind Method; Female; Forced Expiratory Volum | 1994 |
Therapeutic regimes for acute bronchial asthma.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Aminophylline; Asthma; Clinical Protocols; Epinephrine; | 1993 |
Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchi; Bronchial | 1993 |
A multicentre comparison of the efficacy of terbutaline Turbuhaler and salbutamol pressurized metered dose inhaler in hot, humid regions.
Topics: Aerosols; Albuterol; Asthma; Child; Female; Hot Temperature; Humans; Humidity; Male; Middle Aged; Ne | 1994 |
The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Azepin | 1994 |
Easyhaler, a novel multiple dose powder inhaler: clinically equivalent to salbutamol metered dose inhaler and easier to use.
Topics: Adult; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Double-Blind Method; Female; Force | 1994 |
Effect of nebulized ipratropium bromide on intraocular pressures in children.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Double-Blind Method; Drug Therapy, Combination; Fema | 1994 |
[Reference controlled, randomized double-blind study of the effectiveness of salbutamol/DNCG DA combination in bronchial hyperreactivity in comparison with salbutamol DA alone (parallel group comparison)].
Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cromolyn Sodium; Double-B | 1994 |
Effect of adding aminophylline infusion to nebulised salbutamol in severe acute asthma.
Topics: Adolescent; Adult; Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Humans; Middle Aged; | 1994 |
Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchoconstriction; Dose-Response Relation | 1994 |
Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Emergency Service, Hospital; Fe | 1993 |
Continuous versus intermittent albuterol nebulization in the treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Emergency Service, Hospital; Fe | 1993 |
Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. The Dutch CNSLD Study Group.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Prov | 1993 |
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
Topics: Adult; Albuterol; Asthma; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory | 1993 |
Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma?
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Aminophylline; Asthma; Double-Blind Met | 1993 |
Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Aminophylline; Asthma; Bronchodilator A | 1993 |
Objective and subjective bronchodilation over 12 hours after inhaled formoterol: individual responses.
Topics: Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Double-Blind Method; Ethanolamines; Female; | 1993 |
Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients.
Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Double-Blind Method; Female; F | 1993 |
Anti-inflammatory action of steroid inhalers.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Chronic Disease; Female; Human | 1993 |
Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Double-Blind Method; | 1994 |
A comparison of a bodyweight dose versus a fixed dose of nebulised salbutamol in acute asthma in children.
Topics: Administration, Inhalation; Albuterol; Asthma; Body Weight; Child; Child, Preschool; Double-Blind Me | 1993 |
Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method | 1993 |
Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method | 1993 |
Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method | 1993 |
Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method | 1993 |
Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma.
Topics: Administration, Inhalation; Adult; Aged; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents | 1993 |
Duration and magnitude of action of 50 and 100 micrograms of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma.
Topics: Administration, Inhalation; Adult; Air; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agent | 1993 |
A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma.
Topics: Acute Disease; Adult; Albuterol; Asthma; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 1993 |
[Reference controlled, randomized double-blind study of the effectiveness of a salbutamol/DNCG DA combination in bronchial hyperreactivity in comparison with salbutamol DA alone (parallel group comparison)].
Topics: Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cromolyn Sodium; D | 1993 |
Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma.
Topics: Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Blood Pressure; Bronchi; Cyclic GMP; Double-Bli | 1993 |
Albuterol and nedocromil sodium affect airway and leukocyte responses to allergen.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Analysis of Variance; Anti-Infl | 1993 |
Effects of therapeutic doses of salbutamol alone and combined with beclomethasone dipropionate on airway responsiveness and cyclic AMP plasma levels in asthmatic patients.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Cyclic AMP; Double-Blind Metho | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Double-Bl | 1993 |
Is combined therapy of sympathomimetics and theophylline indicated?
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Drug Therapy, Combination; Female; Forced Expirat | 1993 |
Efficacy and side effects of salbutamol in acute asthma in children: comparison of oral route and two different nebulizer systems.
Topics: Acute Disease; Administration, Oral; Adolescent; Albuterol; Asthma; Blood Pressure; Child; Female; F | 1993 |
The effect of salbutamol controlled release on airways responsiveness to inhaled methacholine in mild asthmatic subjects.
Topics: Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Delayed-Action Pre | 1993 |
Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Met | 1993 |
Efficacy of intravenously administered theophylline in children hospitalized with severe asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method; Drug Administ | 1993 |
Evaluation of a new spacer device for drug inhalation.
Topics: Adult; Albuterol; Asthma; Double-Blind Method; Evaluation Studies as Topic; Female; Humans; Male; Mi | 1993 |
Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Bronchodilato | 1993 |
Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchoconstriction; Double-Blind | 1993 |
Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.
Topics: Adolescent; Adult; Aged; Airway Obstruction; Albuterol; Asthma; Chemistry, Pharmaceutical; Double-Bl | 1993 |
Duration of preventive effect of inhaled salbutamol on early airway response to allergen in asthmatic subjects.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Asthma; Bronchial Hyperreactivi | 1993 |
Effect of oral bronchodilators on lung mucociliary clearance during sleep in patients with asthma.
Topics: Aged; Albuterol; Asthma; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Lung; Male; | 1993 |
Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma.
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests | 1993 |
Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tes | 1995 |
MDI with spacer vs nebulizer in pediatric asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Infant; Nebulizers and V | 1996 |
Drug delivery in asthma: a comparison of spacers with a jet nebuliser.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Deliv | 1995 |
The effect of regular inhaled albuterol on exercise-induced bronchoconstriction.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Air; Albuterol; Analysis of Variance; A | 1996 |
Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics.
Topics: Adult; Albuterol; Asthma; Blood Proteins; Cell Count; Cross-Over Studies; Eosinophil Granule Protein | 1995 |
Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects.
Topics: Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Bronchodilator Agents; Double-Blind Method; Fem | 1995 |
Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Alprostadil; Aspirin; Asthma; Br | 1996 |
Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Bronchial Provocation Tes | 1996 |
Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; | 1995 |
Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics.
Topics: Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Blood Pressure; Bronchodilator Agents; Dose-Res | 1995 |
A 4-week comparison of salmeterol and terbutaline in adult asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; | 1995 |
Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Cromoly | 1996 |
Relative efficacy of hydrocortisone and methylprednisolone in acute severe asthma.
Topics: Acute Disease; Adult; Albuterol; Aminophylline; Anti-Inflammatory Agents; Asthma; Bronchodilator Age | 1995 |
Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; | 1995 |
Treatment of nocturnal asthma by addition of oral slow-release albuterol to standard treatment in stable asthma patients.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cross-Over Studies; | 1996 |
Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Chlorofl | 1996 |
Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Analysis of Variance; | 1995 |
Isoetharine versus albuterol for acute asthma: greater immediate effect, but more side effects.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-B | 1996 |
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthm | 1996 |
Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Child; Delayed-Action Preparations; Double-Blind Method; Female; Huma | 1996 |
Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; | 1996 |
Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; | 1996 |
An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group.
Topics: Adolescent; Adult; Aged; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Chronic | 1996 |
Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma.
Topics: Adolescent; Airway Resistance; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; | 1996 |
Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP).
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Bronchodilator Agen | 1996 |
Comprehensive long-term management program for asthma: effect on outcomes in adult African-Americans.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Black or A | 1996 |
Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults.
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Drug Administration Sch | 1996 |
Comparison of non-chlorofluorocarbon-containing salbutamol and conventional inhaler.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Chlorofluorocarbons; Do | 1996 |
Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationshi | 1996 |
Asthma treatment in pregnancy: a randomized controlled study.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agon | 1996 |
[Salmeterol improves the control of disease in patients with moderate asthma. A comparative study of inhaled salmeterol 50 mg and salbutamol depot tablets 8 mg, both administered twice daily].
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studie | 1996 |
A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadi | 1996 |
Nebulized flunisolide in infants and young children with asthma: a pilot study.
Topics: Airway Resistance; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child, Presch | 1996 |
Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Anti-Asthmatic Ag | 1996 |
A comparison of the clinical efficacy and patient acceptability of terbutaline Turbuhaler and salbutamol Rotahaler, in adult patients with asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Female; Follow-Up S | 1996 |
A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma.
Topics: Administration, Inhalation; Administration, Topical; Adult; Albuterol; Anti-Inflammatory Agents; Ast | 1996 |
The effect of inhaled albuterol in moderate to severe asthma.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studie | 1996 |
Fluticasone propionate compared with theophylline for mild-to-moderate asthma.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Androstadienes | 1996 |
[A comparison of two delivery methods on the bronchodilator effects of beta 2-stimulant].
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blin | 1996 |
Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma.
Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchoconstriction; Bronchodilator Agents; Cromolyn Sodiu | 1996 |
Effect of two beta 2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Aged; Albuterol; A | 1995 |
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; D | 1996 |
Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammator | 1996 |
Effect of acute hyperoxia on the bronchodilator response to salbutamol in stable asthmatic patients.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Fe | 1996 |
Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; A | 1996 |
A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma.
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Bli | 1996 |
Efficacy and safety of salmeterol in childhood asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; A | 1995 |
Relative efficacy of three different inhalers containing salbutamol in patients with asthma.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Female; Forced Expiratory | 1996 |
Delivery of albuterol in a pediatric emergency department.
Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Colorado; Emergency | 1996 |
Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cross-Over Studies; Double-Bli | 1996 |
Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Ag | 1996 |
Serum eosinophil cationic protein (ECP) as a marker of disease activity and treatment efficacy in seasonal asthma.
Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Biomarkers; Blood Proteins; Bronchi | 1996 |
Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Anti-Asthmatic Ag | 1996 |
A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Child; Female; Humans; | 1996 |
Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma | 1996 |
Salmeterol in exercise-induced bronchoconstriction in asthmatic children: comparison of two doses.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchoconstric | 1996 |
Acute cardiovascular effects of salmeterol in subjects with stable bronchial asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 1996 |
Effects of bronchomotor tone and gas density on time dependence of forced expiratory vital capacity maneuver.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Helium; Humans; Lung Diseases, Obstru | 1996 |
Effect of inhaled salmeterol on sulfur dioxide-induced bronchoconstriction in asthmatic subjects.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Air; Air Pollutants; Albuterol; Asthma; | 1996 |
Continuous vs intermittent nebulized albuterol for emergency management of asthma.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female | 1996 |
Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Glucose; Bronchodilator Agents; Double-Bli | 1996 |
[Sympathomimetics and theophylline: combined use?].
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug | 1995 |
Effect of regular nedocromil sodium or albuterol on bronchial inflammation in chronic asthma.
Topics: Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchitis; Chronic Disease; Double-Blind Metho | 1996 |
Efficacy of salmeterol in the treatment of childhood asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C | 1996 |
[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics].
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Fenote | 1996 |
Salmeterol tachyphylaxis in steroid treated asthmatic subjects.
Topics: Administration, Topical; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; | 1996 |
Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator | 1996 |
An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist.
Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Adult; Albuterol; Ant | 1996 |
Salmeterol does not cause tolerance during long-term asthma therapy.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Double-Blind Method; Drug Tolerance; Humans; Salmeterol | 1996 |
Tolerance to the protective effect of salmeterol on allergen challenge.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Bronchial Provocation Tes | 1996 |
The effect of nebulized albuterol on the activity of the renin-angiotensin system in asthma.
Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Angiotensin II; Asthma; Cross-Over Studies; Double-Bl | 1997 |
Inhaled salmeterol or oral theophylline in nocturnal asthma?
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol; | 1997 |
A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 1997 |
Hypokalaemia following nebulized salbutamol in children with acute attack of bronchial asthma.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child | 1996 |
Albuterol via Turbuhaler versus albuterol via pressurized metered-dose inhaler in asthma.
Topics: Adult; Albuterol; Asthma; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Fem | 1997 |
Efficacy of nebulized ipratropium in severely asthmatic children.
Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind M | 1997 |
Intravenous versus oral corticosteroids in the management of acute asthma in children.
Topics: Administration, Oral; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents | 1997 |
Oral fenoterol versus sustained release theophylline in adult asthmatics.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Asthma; Bronchodilator Agents; C | 1997 |
Randomised trial of intravenous salbutamol in early management of acute severe asthma in children.
Topics: Acute Disease; Aerosols; Albuterol; Anti-Inflammatory Agents; Asthma; Australia; Bronchodilator Agen | 1997 |
A one-week dose-ranging study of inhaled salmeterol in children with asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dose- | 1997 |
Comparison of bronchodilating effects of two salbutamol dry powder inhalers in asthmatic patients.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Area Under Curve; Asthma; Bronc | 1997 |
Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids.
Topics: Acetates; Adolescent; Adult; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Cross-O | 1997 |
The duration of action of inhaled formoterol dry powder.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 1996 |
The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Drug Combin | 1997 |
Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction | 1997 |
Efficacy of atropine sulfate in combination with albuterol in the treatment for acute asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Atropine; Blood Pressure; Bronchodilator Agents; | 1997 |
The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchia | 1997 |
Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Combined Modality Therapy; Dose-Response Rela | 1997 |
Hospitalization patterns in severe acute asthma in children.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 1997 |
Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Humans; Infant; Nebu | 1997 |
Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma.
Topics: Adenosine Monophosphate; Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonis | 1997 |
Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Ast | 1997 |
Generic inhaled salbutamol versus branded salbutamol. A randomised double-blind study.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Double-Blind Method; Drug Delivery | 1997 |
The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Proteins; Bronchoalveolar Lavage Fluid; Br | 1997 |
Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-O | 1996 |
Salmeterol versus theophylline in the treatment of asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al | 1997 |
Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 1997 |
[Therapy of nocturnal asthma: salmeterol versus nocturnal administration of retard theophylline--comparison of effectiveness and tolerance].
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Delayed-Action Preparations; Do | 1997 |
The Spacehaler for delivery of salbutamol: a comparison with the standard metered-dose inhaler plus Volumatic spacer device.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug | 1997 |
Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children.
Topics: Acute Disease; Administration, Oral; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi-Squar | 1997 |
Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Cost Control; Costs and | 1997 |
Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Breath Tes | 1997 |
Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Cros | 1997 |
Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Bronchodil | 1997 |
Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronc | 1997 |
Nebulized glutathione induces bronchoconstriction in patients with mild asthma.
Topics: Adult; Aerosols; Albuterol; Analysis of Variance; Asthma; Bronchoconstriction; Bronchodilator Agents | 1997 |
The current dilemma with spirometric inclusion criteria for asthma drug trials.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Female; Humans; Male; Middle | 1997 |
Sleep disturbances in clinically stable young asthmatic adults.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Female; Humans; India; Male; Peak | 1997 |
One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; Body Height; Bronchial Prov | 1997 |
Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma.
Topics: Adenosine Monophosphate; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivi | 1997 |
Clinical and physiological improvement after inhalation of low-dose beclomethasone dipropionate and salbutamol in wheezy infants.
Topics: Administration, Inhalation; Albuterol; Analysis of Variance; Asthma; Beclomethasone; Bronchodilator | 1997 |
Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Anti-I | 1997 |
Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Androstadienes; Anti-Asthm | 1997 |
Symptomatic improvement following emergency department management of asthma: a pilot study of intramuscular dexamethasone versus oral prednisone.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Age Factors; Albuterol; Anti-Inflammat | 1997 |
Treatment of nocturnal airway obstruction improves daytime cognitive performance in asthmatics.
Topics: Administration, Inhalation; Adult; Airway Obstruction; Albuterol; Androstadienes; Anti-Asthmatic Age | 1997 |
Comparative efficacy of jet nebulizer and metered dose inhaler with spacer device in the treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, P | 1997 |
Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler.
Topics: Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; C | 1997 |
Varied effects of regular salbutamol on airway responsiveness to inhaled spasmogens.
Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Humans | 1997 |
Early parenteral corticosteroid administration in acute asthma.
Topics: Acute Disease; Adult; Aerosols; Airway Obstruction; Albuterol; Anti-Asthmatic Agents; Anti-Inflammat | 1997 |
[Better control of asthma symptoms with salmeterol].
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Forced Expiratory Volume; Humans | 1997 |
A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; | 1997 |
Sustained protection against distilled water provocation by a single dose of salmeterol in patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Airway Resistance; Albuterol; Analysis of Variance; A | 1997 |
Altered cardiovascular autonomic regulation after 2-week inhaled salbutamol treatment in asthmatic children.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Autonomic Nervous System; B | 1997 |
Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine.
Topics: Adult; Akathisia, Drug-Induced; Albuterol; Asthma; Bronchoconstriction; Bronchoconstrictor Agents; B | 1997 |
Nebulized wet aerosol treatment in emergency department--is it essential? Comparison with large spacer device for metered-dose inhaler.
Topics: Aerosols; Aged; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distribution; Double-Blind Meth | 1997 |
[Evaluation of the effectiveness and safety of salmeterol in children with nocturnal dyspnea].
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol | 1997 |
[Inhaled salmeterol or oral theophylline in nocturnal asthma?].
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Cross-Ov | 1997 |
[Influence of the inhaler device on bronchodilatation in the asthmatic child].
Topics: Administration, Inhalation; Adolescent; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child | 1997 |
Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma.
Topics: Adenosine Monophosphate; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation T | 1997 |
Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Blood Pro | 1997 |
Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Respo | 1997 |
Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator | 1997 |
Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchodi | 1996 |
Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Drug Therapy, Combination; E | 1997 |
Single-breath counting for the assessment of bronchospastic patients in the ED.
Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Humans; Peak Expira | 1998 |
[Evaluation of combined therapy efficacy with disodium cromoglycate and salmeterol in children with atopic bronchial asthma].
Topics: Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Cromolyn Sodium; | 1997 |
[The effect of salmeterol on the number of hypodense eosinophils, eosinophilic cationic protein levels ECP in serum, bronchial hyperresponsiveness and lung function test in patients with bronchial asthma].
Topics: Adult; Albuterol; Asthma; Blood Proteins; Bronchi; Bronchial Provocation Tests; Bronchodilator Agent | 1997 |
Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attack.
Topics: Acute Disease; Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Fe | 1997 |
Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial.
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Drug Combinations; E | 1998 |
Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment.
Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Bronchi; Bronchia | 1998 |
Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio | 1997 |
Proventil HFA and ventolin have similar safety profiles during regular use.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosol Propellants; Aged; | 1998 |
Proventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosol Propellants; Age Fa | 1998 |
Effect of salmeterol is independent of previously inhaled salbutamol: a clinical controlled study.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cross-Over Studies; | 1998 |
Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Ag | 1998 |
Effect of inhaled furosemide in acute asthma.
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Furosemide; | 1998 |
Inhaled flunisolide for acute severe asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; A | 1998 |
Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group.
Topics: Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadiene | 1998 |
Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm | 1998 |
Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm | 1998 |
Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm | 1998 |
Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm | 1998 |
Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al | 1998 |
Elevation of peak expiratory flow by a "spitting" maneuver: measured with five peak flowmeters.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle Aged; Peak Expiratory Flow Rate; Rhe | 1998 |
A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma.
Topics: Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Double-Blind Method; Drug Administration Schedul | 1998 |
[The effect of salben on the rheological properties of the bronchial secretion].
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Benzoates; Benzoic Acid; Bronchi; Bronch | 1998 |
Treatment of acute asthma: salbutamol via jet nebuliser vs spacer and metered dose inhaler.
Topics: Acute Disease; Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child | 1998 |
Short-term cardiovascular effects of salmeterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Bron | 1998 |
Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Double-Blind Method; | 1998 |
A comparison of regular salmeterol vs 'as required' salbutamol therapy in asthmatic children.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; Asthma; Bronchoconstrictor Ag | 1998 |
Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma.
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Cross-Over Studies; Drug Administration Schedule; | 1998 |
Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma.
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Cross-Over Studies; Drug Administration Schedule; | 1998 |
Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma.
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Cross-Over Studies; Drug Administration Schedule; | 1998 |
Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma.
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Cross-Over Studies; Drug Administration Schedule; | 1998 |
[Dose-effect of adrenaline nebulization in asthma: comparative study with salbutamol].
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relations | 1997 |
Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Child; | 1998 |
Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilat | 1998 |
Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double- | 1998 |
Bronchodilator response to salbutamol after spontaneous recovery from nonspecific bronchial provocation tests in asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Female; Fo | 1998 |
Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al | 1998 |
Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agents; Child; Double-Blind | 1998 |
Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Blood P | 1998 |
Long-term treatment of asthmatic patients with salmeterol vs slow-release theophylline.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Dela | 1998 |
Albuterol delivered by metered-dose inhaler (MDI), MDI with spacer, and Rotahaler device--a comparison of efficacy and safety.
Topics: Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Cross-Over Studies; Double-Blind Me | 1998 |
Possible interaction between exposure to environmental tobacco smoke and therapy in children with asthma.
Topics: Adolescent; Albuterol; Asthma; Biomarkers; Bronchial Hyperreactivity; Bronchial Provocation Tests; B | 1998 |
Comparison of two dosage regimens of albuterol in acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Res | 1998 |
Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Chronic Disease; Double-Blind Met | 1998 |
Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices.
Topics: Absorption; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Equipment D | 1998 |
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi | 1997 |
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi | 1997 |
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi | 1997 |
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi | 1997 |
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi | 1997 |
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi | 1997 |
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi | 1997 |
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi | 1997 |
Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Topics: Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodilator Agents; Cross-Over Studi | 1997 |
Short-term effects of budesonide, nedocromil sodium and salmeterol on bronchial hyperresponsiveness in childhood asthma.
Topics: Adolescent; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma | 1998 |
How long should Atrovent be given in acute asthma?
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Bli | 1998 |
Altered cardiovascular autonomic regulation after salmeterol treatment in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Autonomic Nervous System; Blood Pressure; | 1998 |
Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration.
Topics: Administration, Intranasal; Adrenergic beta-Agonists; Albuterol; Asthma; Capillary Permeability; Cel | 1998 |
The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Al | 1998 |
Influence of beclomethasone and salmeterol on the perception of methacholine-induced bronchoconstriction.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchoconstrictio | 1998 |
Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma: a clinical trial.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind | 1998 |
Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchial P | 1998 |
Potential masking effects of salmeterol on airway inflammation in asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm | 1998 |
Comparison of the Maxair Autohaler to wet nebulizer in patients with acute asthma.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents | 1998 |
Bronchodilator responses to salbutamol using diskhaler versus metered-dose inhaler.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose- | 1998 |
[Evaluation of the efficacy of nebulized salbutamol in exacerbation of chronic asthma].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Ambulatory Care; Asthma; Chronic Disease; Female; Humans | 1997 |
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 1998 |
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 1998 |
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 1998 |
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 1998 |
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 1998 |
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 1998 |
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 1998 |
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 1998 |
Effect of nebulized ipratropium on the hospitalization rates of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double-Blind Method; | 1998 |
Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Aspirin; Asthma; Bronchial P | 1998 |
Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid.
Topics: Acute Disease; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Child; Cross-Over Studies; | 1998 |
[Clinical study on treating asthma of cold type with wenyang tongluo mixture].
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethason | 1996 |
Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dose-R | 1998 |
Salmeterol compared with current therapies in chronic asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Double- | 1998 |
Comparison of the bronchodilating efficacies of a novel salbutamol metered dose powder inhaler and a pressurised metered dose aerosol with a spacer.
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; | 1998 |
A low cost spacer device used for asthma treatment in a Calcutta street clinic to improve efficacy of metered dose inhalers.
Topics: Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Doub | 1998 |
Paper spacers coupled to metered dose inhalers in family practice.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Child; Developing Countries; Doubl | 1998 |
Effect of systemic beta-agonist therapy on IgE production in allergic subjects in vivo.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Double-Blind Method; Female; Humans; Hypersensit | 1998 |
Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer.
Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Emergency Servi | 1998 |
Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Child; Female; | 1998 |
A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Et | 1998 |
[Treatment with salmeterol and quality of life in patients with asthma].
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Humans; Male; Middle A | 1998 |
Airway and lung tissue mechanics in asthma. Effects of albuterol.
Topics: Administration, Inhalation; Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator | 1999 |
Serum levels of soluble interleukin-2 receptor at acute asthma exacerbation: relationship with severity of exacerbation and bronchodilator response.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Forced Expiratory Volume; Hu | 1998 |
Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma.
Topics: Adult; Aerosol Propellants; Aged; Albuterol; Asthma; Chlorofluorocarbons; Cross-Over Studies; Dose-R | 1998 |
A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio | 1999 |
Use of heliox-driven nebulizer therapy in the treatment of acute asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Female; Forced Expiratory Volu | 1999 |
Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asth | 1999 |
Single centre open study to compare patient recording of PRN salbutamol use on a daily diary card with actual use as recorded by the MDI compliance monitor.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Drug Delivery Systems; Female; Humans; Mal | 1998 |
An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; | 1999 |
Hypokalemia and salbutamol therapy in asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Age Factors; Albuterol; Asthma; Bl | 1999 |
Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Eq | 1999 |
The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Budesonide; Child; Child, Preschool | 1999 |
Efficacy of inhaled steroids (beclomethasone dipropionate) for treatment of mild to moderately severe asthma in the emergency department: a randomized clinical trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Anti-A | 1999 |
Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; | 1999 |
Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Br | 1999 |
As-required versus regular nebulized salbutamol for the treatment of acute severe asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; A | 1999 |
Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic | 1999 |
Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic | 1999 |
Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic | 1999 |
Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP)
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic | 1999 |
Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Pro | 1999 |
Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol.
Topics: Administration, Inhalation; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Spasm; Bro | 1999 |
Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Infla | 1999 |
Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.
Topics: Adult; Aerosol Propellants; Albuterol; Asthma; Chlorofluorocarbons; Chlorofluorocarbons, Methane; Fe | 1999 |
Effective application of bronchodilator aerosols from metered-dose inhalers (MDI) via resuscitator-bag and adapter.
Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; E | 1998 |
Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Beclomet | 1999 |
Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cardiovascular System; Child; | 1999 |
Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Fe | 1999 |
[Changes in specific airway resistance after powder inhalation of formoterol or salmeterol in moderate bronchial asthma].
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Etha | 1999 |
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Albuterol; Androst | 1999 |
Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; | 1999 |
Ipratropium bromide added to asthma treatment in the pediatric emergency department.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflammatory Agents; A | 1999 |
Clinical comparison of Gentle-Haler Actuator and Aerochamber Spacer for Metered Dose Inhaler (MDI) use by asthmatics.
Topics: Adolescent; Adult; Albuterol; Analysis of Variance; Asthma; California; Child; Double-Blind Method; | 1992 |
The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy.
Topics: Albuterol; Asthma; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Ethanolamines; Femal | 1993 |
Clinical evaluation of CFC-free metered dose inhalers.
Topics: Adult; Aerosol Propellants; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodila | 1995 |
Randomised controlled trial of aminophylline for severe acute asthma.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Aminophylline; Asthma; Bronch | 1998 |
A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provoca | 1998 |
Effect of single doses of inhaled lignocaine on FEV1 and bronchial reactivity in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Anesthetics, Local; Asthma; Bronchial Hyperreactivity; | 1998 |
The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cross | 1999 |
Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Cardiac Output; Chil | 1999 |
Safety of long-term treatment with HFA albuterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aerosol Propellants; Aerosols; Albutero | 1999 |
Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator | 1999 |
A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child | 1999 |
Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: A randomized controlled study.
Topics: Adult; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Double-Blind Method; Drug Adm | 1999 |
Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Cross-Over Studies; Female; | 1999 |
The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Ag | 1999 |
A double-blind study on the effect of inhaled corticosteroids on plasma protein exudation in asthma.
Topics: Administration, Inhalation; Administration, Topical; Adult; Albuterol; Androstadienes; Anti-Inflamma | 1999 |
Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Cross-Ove | 1999 |
Salbutamol pretreatment does not change eosinophil percentage and eosinophilic cationic protein concentration in hypertonic saline-induced sputum in asthmatic subjects.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Proteins; Bronchial Provocation Tests; Bro | 1999 |
Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severity.
Topics: Adolescent; Albuterol; Asthma; Biomarkers; Blood Proteins; Bronchial Provocation Tests; Cell Count; | 1999 |
Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Bronc | 1998 |
Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Dose-Response Relat | 1999 |
Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group.
Topics: Administration, Inhalation; Administration, Topical; Adolescent; Airway Obstruction; Albuterol; Anti | 1999 |
A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Beclomethasone; Dose-Response Relationsh | 1999 |
Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Humans; Pla | 1998 |
Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Thera | 1999 |
Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Et | 1998 |
Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma.
Topics: Adenosine Diphosphate; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchial Provoc | 1999 |
[The effect of salmeterol on specific and non-specific bronchial response in allergic asthma patients].
Topics: Adult; Albuterol; Animals; Asthma; Blood Proteins; Bronchi; Bronchial Provocation Tests; Bronchodila | 1998 |
[Clinical evaluation of 12 week salmeterol therapy in allergic asthma patients].
Topics: Adult; Albuterol; Animals; Asthma; Bronchodilator Agents; Female; Humans; Male; Mites; Respiratory F | 1998 |
Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; | 1999 |
A comparison of the bronchodilatory effect of 50 and 100 microg salbutamol via Turbuhaler and 100 microg salbutamol via pressurized metered dose inhaler in children with stable asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Chronic Disease; Cross-Over Studies; Dose-Response | 1999 |
Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma; Blood Proteins | 1999 |
Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod | 1999 |
Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
Topics: Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Anti-Asthmatic Agents; Asthma; Bronch | 1999 |
Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio | 1999 |
[The influence of salmeterol and salbutamol on bronchial constriction in patients with bronchial asthma].
Topics: Adult; Aged; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Double-Blind Method; Dru | 1998 |
Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma.
Topics: Adolescent; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool; | 1999 |
Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma.
Topics: Adolescent; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool; | 1999 |
Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma.
Topics: Adolescent; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool; | 1999 |
Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma.
Topics: Adolescent; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool; | 1999 |
Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children.
Topics: Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Inf | 1999 |
A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Child; Double-Bli | 1999 |
Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Cr | 1999 |
Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma.
Topics: Adenosine Monophosphate; Adult; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Cross-Over Studie | 1999 |
A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Cell Count; Collagen; | 1999 |
Regular albuterol or nedocromil sodium--effects on airway subepithelial tenascin in asthma.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Biopsy; Female; | 1999 |
A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. The French Bambuterol Study Group.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol; | 1999 |
A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 1999 |
Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronchodilator Age | 1999 |
Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Amenorrhea; Asthma; Cross-Over Studi | 1999 |
Outcome evaluation of early discharge of asthmatic children from hospital: a randomized control trial.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Drug Administration Schedule; Fem | 1999 |
Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Bronchial | 1999 |
Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.
Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Ag | 1999 |
Dose-response characteristics of nebulized albuterol in the treatment of acutely ill, hospitalized asthmatics.
Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents | 1999 |
Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Anti-Inflamma | 1999 |
Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Broncho | 1999 |
Long acting inhaled beta2-agonists: anti-inflammatory effects not evident during treatment of day to day asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchodilator | 1999 |
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Bronch | 1999 |
Tolerance to beta-agonists during acute bronchoconstriction.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Airway Obstruction; Albuterol; Asthma; B | 1999 |
Bronchodilation using combined urodilatin - albuterol administration in asthma: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Albuterol; Asthma; Atrial Natriuretic Factor; Bronchodilator Agents; Cyclic AMP; Double-Blind | 1999 |
A comparison of the bronchodilator effect of salbutamol inhaled via Turbuhaler as two consecutive doses or as two divided doses at different time intervals.
Topics: Administration, Inhalation; Adult; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; C | 1999 |
Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchial Provocation Tests; C | 1999 |
Comparison of different methods to evaluate population dose-response and relative potency: importance of interoccasion variability.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Computer Simulation; Cross-Ove | 1999 |
Comparison of the efficacy of inhaled fluticasone propionate, 880 microg/day, with flunisolide, 1500 microg/day, in moderate-to-severe persistent asthma.
Topics: Absenteeism; Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Asthma; Child; Cross | 1999 |
Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aerosols; Aged; Albuterol; Anti- | 1999 |
Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Aged; Albuterol; | 1999 |
An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents | 1999 |
A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Asthma; Broncho | 1999 |
Asthma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Beclomethasone; Blood Proteins; Bronc | 1999 |
Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Area Under Curve; Asthma; Blood Glucose; B | 1999 |
A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchial Provocation Tests; B | 1999 |
Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Beclo | 1999 |
Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; As | 2000 |
[The effect of sputum induction on spirometry parameters in patients with bronchial asthma].
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstricti | 1999 |
Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; | 1999 |
Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.
Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Ag | 1999 |
Use of fluticasone in asthma.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bias; Dose-Res | 2000 |
Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Ag | 2000 |
Low- and high-dose fluticasone propionate in asthma; effects during and after treatment.
Topics: Administration, Inhalation; Administration, Topical; Adult; Albuterol; Androstadienes; Anti-Asthmati | 2000 |
Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Biological Availability; Bronchial Provocation Tests; Cr | 2000 |
Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-B | 2000 |
Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; | 1999 |
Comparison of different long-term asthma treatments in subjects with mild-to-moderate asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchial Provoca | 1999 |
Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Met | 2000 |
Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma.
Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Child, Preschool; Cost-Benefit Analysis; Do | 2000 |
[Control of inhaled triggering factors decreases prolonged drug therapy requirements in patients with asthma].
Topics: Adolescent; Albuterol; Allergens; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Beclometh | 2000 |
Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids.
Topics: Acetates; Adenosine Monophosphate; Administration, Inhalation; Administration, Oral; Adrenergic beta | 2000 |
Immunohistochemically stained activated eosinophils in sputum in patients with asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Antibodies, Monoclonal; Antibody Specificity; Asthma; | 2000 |
A low dose of albuterol by metered-dose inhaler with a spacer was as effective as higher doses by metered-dose inhaler or low doses by nebulizer in children with mild acute asthma.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans | 2000 |
Undiluted albuterol aerosols in the pediatric emergency department.
Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Administr | 2000 |
Wet nebulization in acute asthma: the last refrain?
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Dose- | 2000 |
Is nebulized aerosol treatment necessary in the pediatric emergency department?
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Chil | 2000 |
The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction.
Topics: Adolescent; Adult; Aged; Airway Resistance; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial | 2000 |
Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma.
Topics: Adenosine Monophosphate; Administration, Inhalation; Albuterol; Anti-Inflammatory Agents; Asthma; Br | 2000 |
First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department.
Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Do | 2000 |
Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent | 2000 |
Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadie | 2000 |
Induced sputum and bronchoalveolar lavage as tools for evaluating the effects of inhaled corticosteroids in patients with asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Blood P | 2000 |
Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relat | 2000 |
Effects of on-demand beta2-agonist inhalation in moderate-to-severe asthma. A randomized controlled trial.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-As | 2000 |
Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol.
Topics: Adult; Albuterol; Allergens; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Chymases; C | 2000 |
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype; | 2000 |
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype; | 2000 |
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype; | 2000 |
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype; | 2000 |
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype; | 2000 |
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype; | 2000 |
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype; | 2000 |
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype; | 2000 |
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Female; Genotype; | 2000 |
Short-acting inhaled beta-agonists: to be taken regularly or as needed?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Administration Schedule; Humans; Peak Expiratory F | 2000 |
Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Disease Progre | 2000 |
Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Aged, 80 and over; Albuter | 2000 |
Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Asthma; Broncho | 2000 |
Equivalent therapeutic ratio of salbutamol given by Turbuhaler and Diskus.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studie | 2000 |
Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind | 2000 |
Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; A | 2000 |
Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator | 2000 |
Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Inflammatory Agents; Ast | 2000 |
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group.
Topics: Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Budesonid | 2000 |
A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadi | 2000 |
Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadi | 2000 |
A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Al | 2000 |
Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist | 2000 |
Is there a clinical difference in outcomes when beta-agonist therapy is delivered through metered-dose inhaler (MDI) with a spacing device compared with standard nebulizer treatments in acutely wheezing children?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child, Preschool; Double-Blind Method; Humans; Infant; | 2000 |
Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chronic airflow obstruction: metered dose inhaler versus jet nebulizer.
Topics: Administration, Inhalation; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; C | 2000 |
Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cross-Over Studies; Double-Blind Met | 2000 |
Salmeterol in paediatric asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Preschool; Cross-Over Studies | 2000 |
Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Bronc | 2000 |
Reducing electrostatic charge on spacer devices and bronchodilator response.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind | 2000 |
Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Bronc | 2000 |
Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Drug Delivery Syste | 2000 |
Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Circadian Rhythm; Drug Adminis | 2000 |
Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Glucose; Blood Pressure; Bronchodilator | 2000 |
The efficacy of nebulized racemic epinephrine in children with acute asthma: a randomized, double-blind trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2000 |
Intravenous magnesium sulfate in acute severe asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Anti-Inflammatory Agents; Asthma; Bronchod | 2000 |
Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Anesthesia, Inhalation; Anesthetics, Inhalation; Anest | 2000 |
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Androst | 2000 |
Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma.
Topics: Aerosols; Albuterol; Alkanes; Asthma; Bronchodilator Agents; Chemistry, Pharmaceutical; Child; Child | 2000 |
Salbutamol via Easyhaler is at least as effective as salbutamol via Turbuhaler in the treatment of histamine-induced bronchoconstriction.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocati | 2000 |
Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler.
Topics: Adolescent; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Budeson | 2000 |
Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge.
Topics: Administration, Inhalation; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; C | 2001 |
Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; B | 2001 |
Regular inhaled salbutamol : effect on airway responsiveness to methacholine and adenosine 5'-monophosphate and tolerance to bronchoprotection.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Ast | 2001 |
Cumulative and single-dose design to assess the bronchodilator effects of beta2-agonists in individuals with asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 2001 |
Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma.
Topics: Aerosol Propellants; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Chlorofluoro | 2000 |
The influence of polymorphism at position 16 of the beta2-adrenoceptor on the development of tolerance to beta-agonist.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Amino Acid Sequence; Asthma; Bronchodilator Agents | 2000 |
Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Over Studies; Double | 2000 |
Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers.
Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Asthma; Bronchodilator Agents; Child; Ch | 2001 |
A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Br | 2001 |
Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Drug Adm | 2001 |
Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Analysis of Variance; Androstadienes; | 2001 |
Efficacy of a home-made spacer with acute exacerbation of bronchial asthma: a randomized controlled trial.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cost Control; Humans; | 2001 |
Effectiveness and safety of salmeterol in nonspecialist practice settings.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Double-Blind | 2001 |
Effects of therapeutic doses of albuterol on beta2-adrenergic receptor density and metabolic changes.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cross-Over Studies; Double-Blind Method; Female; | 2001 |
Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma.
Topics: Adolescent; Adult; Albuterol; Allergens; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-B | 2001 |
Acceptance of the Accuhaler, a multi-dose powder inhaler, among asthmatic patients: a comparison with the pressurized metered-dose inhaler.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Anti-Asthmatic Agents; Ast | 2000 |
The effect of acute alteration in oxygen tension on the bronchodilator response to salbutamol in vitro and in vivo in man.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Fe | 2001 |
The effect of salmeterol on markers of airway inflammation following segmental allergen challenge.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Analysis of Varia | 2001 |
Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aerosol Propellants; Albuterol; Asthma; Bronchodilator | 2001 |
Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids.
Topics: Acetates; Adenosine Monophosphate; Administration, Inhalation; Administration, Topical; Adrenergic b | 2001 |
Comparative efficiency of commercial and improvised spacer device in acute bronchial asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Dose-Response Relationship, | 2001 |
Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; | 2001 |
A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Animals; Asthma; Bronchial Hyperreactivity; D | 2001 |
Therapeutic equivalence of the Sofotec Novolizer to established standard devices in COPD and asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Humans; Lung Diseases, Obstructive; Nebulizers | 2001 |
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agent | 2001 |
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchia | 2001 |
Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma | 2001 |
Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoscopy; Collagen; Double-Blind Method; Fem | 2001 |
[The evaluation of efficacy and tolerability of salbutamol administered by nebulization in patients with stable severe bronchial asthma].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Female; Heart | 2001 |
Comparison of the acute effects of salbutamol and terbutaline on heart rate variability in adult asthmatic patients.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Autonomic Nervous System; Cross-Over Studies; | 2001 |
Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; | 2001 |
Unaltered perception of dyspnoea during treatment with long-acting beta2-agonists.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction | 2001 |
Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.
Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmat | 2001 |
Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammator | 2001 |
Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Anti-A | 2001 |
Salbutamol prevents the increase of respiratory resistance caused by tracheal intubation during sevoflurane anesthesia in asthmatic children.
Topics: Adolescent; Airway Resistance; Albuterol; Algorithms; Anesthesia, Inhalation; Anesthetics, Inhalatio | 2001 |
Long-acting bronchodilators in premenstrual exacerbation of asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Age | 2001 |
In patients with asthma that is not well controlled with inhaled steroids, does salmeterol (Serevent) or montelukast (Singulair) offer better symptom relief?
Topics: Acetates; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; | 2001 |
The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationshi | 2001 |
Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Cross-Over | 2001 |
Implementing randomization procedures in the asthma clinical research network.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Female; Humans; Male; Quality Contro | 2001 |
Effect of salmeterol and salmeterol plus beclomethasone on saliva flow and IgA in patients with moderate-persistent chronic asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Beclomethasone; | 2001 |
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma; | 2001 |
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma; | 2001 |
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma; | 2001 |
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Anti-Inflammatory Agents; Asthma; | 2001 |
Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Arrhythmias, Cardiac; Asthma; Bron | 2001 |
Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Double- | 2001 |
Therapeutic equivalence of three metered-dose inhalers containing salbutamol (Albuterol) in protecting against methacholine-induced bronchoconstriction in children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchoconstrictor | 2001 |
Lower arrythmogenic risk of low dose albuterol plus ipratropium.
Topics: Albuterol; Arrhythmias, Cardiac; Asthma; Bronchodilator Agents; Female; Humans; Infant; Ipratropium; | 2001 |
The efficacy of a new salbutamol metered-dose powder inhaler in comparison with two other inhaler devices.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Analysis of Variance; | 2001 |
The incremental shuttle walking test in elderly people with chronic airflow limitation.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Drug | 2002 |
Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Drug | 2002 |
Salbutamol dry powder inhaler: efficacy, tolerability, and acceptability study.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Cross-Ov | 2002 |
Subcutaneous epinephrine vs nebulized salbutamol in asthma.
Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Developing Cou | 2001 |
[Cardiovascular and metabolic effects in nebulizer therapy of bronchial asthma].
Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Heart Rate; Hemodynamics; Humans; Male; Middle Age | 2002 |
Bronchodilator therapy and hyperactivity in preschool children.
Topics: Administration, Inhalation; Akathisia, Drug-Induced; Albuterol; Asthma; Bronchodilator Agents; Child | 2002 |
Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agen | 2002 |
Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial | 2002 |
Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department.
Topics: Adolescent; Aerosols; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Child; Child, | 2002 |
Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Double-Blind Method; | 2002 |
Comparative evaluation of market spacer and home made spacer in the management of bronchial asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Equipment Design; Female; Humans | 2002 |
Development of an economic model to assess the cost effectiveness of asthma management strategies.
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents; | 2002 |
Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Dose-Response Relationship, Drug | 2002 |
[Pharmacodynamics of inhalation broncholytic agents introduced in a single dose by nebulizer in patients with severe exacerbation of bronchial asthma].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug | 2002 |
[Clinical and biochemical aspects of flixotide administration in patients with moderate bronchial asthma].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; alpha-Tocopherol; Androstadienes; Anti-Inflammatory Agen | 2002 |
The utility of albuterol nebulized with heliox during acute asthma exacerbations.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Drug Combinations; Emergencies; Female; Forced | 2002 |
Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Cost-Benefit Analysis; Drug Costs; E | 2002 |
Comparison of the effects of salmeterol and formoterol in patients with severe asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind | 2002 |
Measurement of inflammatory mediators of eosinophils and lymphocytes in blood in acute asthma: serum levels of ECP influence the bronchodilator response.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Proteins; Bronchodilator Agent | 2002 |
A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults.
Topics: Administration, Inhalation; Adult; Albuterol; Analgesics; Asthma; Bronchodilator Agents; Double-Blin | 2002 |
A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Albuterol; Asthma; Bronchodilato | 2002 |
Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Androstadienes; | 2002 |
Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction.
Topics: Adult; Aged; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Cross-Over Studies; Dou | 2002 |
Mouthpiece versus facemask for delivery of nebulized salbutamol in exacerbated childhood asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Equipment D | 2002 |
Effect of patient education on self-management skills and health status in patients with asthma: a randomized trial.
Topics: Adult; Albuterol; Asthma; Attitude to Health; Bronchodilator Agents; Female; Hospitalization; Humans | 2002 |
Salmefamol and Salbutamol in exercise-induced asthma in children.
Topics: Adolescent; Adrenergic Agonists; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topi | 1976 |
Double-blind cross-over comparison of clenbuterol and salbutamol tablets in asthmatic out-patients.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Ethanolamines; F | 1975 |
Rimiterol: a review of its pharmacological properties and therapeutic efficacy in asthma.
Topics: Absorption; Administration, Oral; Aerosols; Albuterol; Animals; Asthma; Bronchodilator Agents; Catec | 1977 |
Further studies of rimiterol and salbutamol administered by intermittent positive-pressure ventilation, and an important observation on the technique of using the Bennett ventilator.
Topics: Adult; Aged; Albuterol; Asthma; Catechols; Female; Forced Expiratory Volume; Heart Rate; Humans; Int | 1977 |
Diminished leukocyte cyclic AMP responses to adrenergic stimulation after therapeutic administration of beta-adrenergic agonists.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Clinical Trials as Topic; Cyclic AMP; Double-Bli | 1978 |
[Competitive effects of pindolol and salbutamol on airway resistance in asthmatics].
Topics: Adrenergic beta-Antagonists; Adult; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchi; Drug Th | 1978 |
A comparison of slow-release salbutamol with slow-release aminophylline in nocturnal asthma.
Topics: Adult; Aged; Albuterol; Aminophylline; Asthma; Delayed-Action Preparations; Female; Humans; Male; Mi | 1979 |
[Parasympathicolytic drugs in treatment of obstructive lung diseases (author's transl)].
Topics: Adrenergic beta-Agonists; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Cromolyn Sodi | 1979 |
Letter: Alpha-receptor-blocking drugs in bronchial asthma.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Airway Obstruction; Airway Resistance; Albut | 1975 |
Combined therapy with salbutamol and beclomethasone inhalers in chronic asthma.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Bronchi; Chronic Disease; Circadian Rhythm | 1978 |
A comparison of the bronchodilator activity of Sch 1000 and salbutamol.
Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Clinical Trials as Topic; Drug Eva | 1977 |
Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Chronic Disease; Drug | 1978 |
Comparison of ipratropium bromide and salbutamol in a long-term trial in asthmatic and bronchitic patients in a cold climate.
Topics: Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Clinical Trials as Topic; Cold Climate; D | 1979 |
A double blind cross-over study of maximal expiratory flows and arterial blood gas tensions in normals, asthmatics and bronchitics after salbutamol and ipratropin.
Topics: Albuterol; Asthma; Atropine Derivatives; Bronchitis; Carbon Dioxide; Clinical Trials as Topic; Doubl | 1979 |
SCH 1000 in psychogenic asthma.
Topics: Aerosols; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Double-Blind Method; Dr | 1979 |
The relative potencies and beta2-selectivities of intravenous rimiterol, salbutamol and isoprenaline in asthmatic patients.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Bronchi; Bronchodilator Agents; | 1975 |
Effect in bronchial asthma of a new beta-adrenergic blocking drug atenolol (ICI 66, 082).
Topics: Adult; Aged; Albuterol; Asthma; Atenolol; Clinical Trials as Topic; Drug Interactions; Female; Human | 1977 |
Metabolic effects of salbutamol: comparison of aerosol and intravenous administration.
Topics: Adult; Aerosols; Albuterol; Asthma; Blood Glucose; Bronchi; Chronic Disease; Clinical Trials as Topi | 1977 |
Comparison of intravenous aminophylline and salbutamol in severe asthma.
Topics: Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Humans; Injections, Intravenous | 1977 |
Terbutaline: an effective bronchodilator by inhalation.
Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Female; Humans; Male; | 1977 |
The bronchodilator effect of NAB 365.
Topics: Adult; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Ethan | 1977 |
Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: response to albuterol, isoproterenol, and placebo aerosols.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Cardiomyopathy, Hypertrophic; Clinica | 1977 |
[Clinical experimentation with salbutamol in bronchial obstructive diseases of early infancy].
Topics: Albuterol; Asthma; Bronchial Spasm; Child, Preschool; Clinical Trials as Topic; Drug Evaluation; Fem | 1977 |
Comparison of terbutaline and salbutamol aerosols.
Topics: Adult; Aged; Albuterol; Asthma; Bronchitis; Chronic Disease; Clinical Trials as Topic; Female; Force | 1977 |
Intramuscular salbutamol in treatment of acute exacerbations of childhood asthma.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Hum | 1977 |
Comparative study of acute effects of albuterol and isoproterenol sulphate aerosols in bronchial asthma.
Topics: Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Is | 1977 |
Subsensitivity to the bronchodilator action of albuterol produced by chronic administration.
Topics: Adolescent; Albuterol; Asthma; Bronchi; Child; Clinical Trials as Topic; Dose-Response Relationship, | 1977 |
Comparison of albuterol and isoproterenol aerosols in bronchial asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Dose-Response Relati | 1977 |
Comparison of intravenous and nebulised salbutamol in initial treatment of severe asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; | 1978 |
A trial of clenbuterol in bronchial asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Clenbuterol; Clinical Trials as Topic; Double-Blind Meth | 1977 |
Effect of salbutamol with IPPB and physiotherapy for three days.
Topics: Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Force | 1977 |
A controlled comparison of salbutamol and terbutaline inhaled by IPPV in asthmatic patients: a dose-response study.
Topics: Adult; Albuterol; Asthma; Bronchitis; Clinical Trials as Topic; Dose-Response Relationship, Drug; Do | 1977 |
A comparison of two modes of administering beta2-adrenoceptor stimulants in asthmatics: tablets and metered aerosol.
Topics: Administration, Oral; Aerosols; Albuterol; Asthma; Blood Pressure; Clinical Trials as Topic; Dose-Re | 1977 |
Clinical comparison of fenoterol and albuterol administered by inhalation. A double-blind study.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Eval | 1978 |
Comparison of NAB 365 and salbutamol tablets in chronic bronchitis and asthma.
Topics: Adult; Aged; Albuterol; Asthma; Bronchitis; Chronic Disease; Clenbuterol; Clinical Trials as Topic; | 1978 |
Comparative study of carbuterol and salbutamol from metered aerosols in bronchial asthma.
Topics: Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Ethanol | 1978 |
Bronchodilator effect of hexoprenaline aerosol in bronchial asthma and chronic bronchitis.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Bronchitis; Chronic Disease; Clinical Trials as T | 1977 |
Comparison of terbutaline and salebutamol aerosols in patients with bronchial asthma.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Female; Forced Expiratory | 1978 |
Comparison of salbutamol and ephedrine in oral bronchodilator combinations with theophylline and hydroxyzine: their effects on asthmatics.
Topics: Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; Clinical Trials as | 1977 |
[Effect of joint administration of antagonists of serotonin, histamine and acetylcholine on ventilatory disorders in asthma].
Topics: Acetylcholine; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Female; Histamine Antagonis | 1978 |
Two methods of administering nebulized salbutamol: a controlled study.
Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Humans; Infant, Newb | 1978 |
Aerosol salbutamol administration by IPPB: lowest effective dose.
Topics: Adult; Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Administrati | 1978 |
Problems of inhalation therapy.
Topics: Albuterol; Asthma; Bronchi; Clinical Trials as Topic; Forced Expiratory Volume; Humans; Placebos; Pr | 1979 |
Comparison of salbutamol given intravenously and by intermittent positive-pressure breathing in life-threatening asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Heart Rate; Hum | 1979 |
An evaluation of a controlled-release aminophylline tablet (Phyllocontin Continus) as a concomitant therapy in patients receiving salbutamol.
Topics: Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Delayed-Action Preparations; Humans | 1979 |
Additive interaction of aminophylline and salbutamol in asthma: an in vivo study using dose-response curves.
Topics: Adolescent; Adult; Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Dose-Response Relatio | 1979 |
A comparative study of atropine methonitrate, salbutamol, and their combination in airways obstruction.
Topics: Aerosols; Aged; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topi | 1979 |
Albuterol and isoproterenol in bronchial asthma. Efficacy and toxicity of drugs administered via intermittent positive pressure breathing.
Topics: Adult; Aged; Albuterol; Asthma; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Force | 1979 |
NAB 365 (clenbuterol) and salbutamol in asthmatics: a double-blind clinical trial.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Clenbuterol; Clinical Trials as Topic; Double-Blind Meth | 1979 |
Nebulised salbutamol in life-threatening asthma.
Topics: Acute Disease; Albuterol; Asthma; Clinical Trials as Topic; Humans; Injections, Intravenous; Intermi | 1979 |
Nebulised salbutamol in life-threatening asthma.
Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Humans; Injections, Intra | 1979 |
Double-blind, crossover comparison of carbuterol and salbutamol.
Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Clinical Trials as Topi | 1979 |
Comparative investigations on pirbuterol, salbutamol and placebo aerosols in bronchial asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topi | 1979 |
Comparison of IV salbutamol with IV aminophylline in the treatment of severe, acute asthma in childhood.
Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Clinical Trials as Topic; | 1979 |
Controlled clinical trial of oral hexoprenaline in bronchial asthma.
Topics: Albuterol; Asthma; Clinical Trials as Topic; Forced Expiratory Volume; Hexoprenaline; Humans; Phenet | 1979 |
Comparison of IV salbutamol with IV aminophylline in severe acute asthma.
Topics: Albuterol; Aminophylline; Asthma; Child; Clinical Trials as Topic; Double-Blind Method; Humans; Inje | 1979 |
Salbutamol in the treatment of asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Female; Forced Expir | 1979 |
Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Female; Hum | 1979 |
Continuous and intermittent salbutamol tablet administration in asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Child; Clinical Trials as Topic; Double-Blind Method; Drug Administra | 1979 |
A comparison of controlled-release aminophylline (Phyllocontin Continus tablets) and sympathomimetic bronchodilators.
Topics: Albuterol; Aminophylline; Asthma; Delayed-Action Preparations; Forced Expiratory Volume; Humans; Met | 1979 |
Aerosolized clenbuterol (NAB 365) and salbutamol in exercise-induced asthma.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Child; Clenbuterol; Ethanolamines; Female; Hemodynam | 1979 |
[Comparative studies on pirbuterol, salbutamol and a placebo administered as an aerosol in asthmatic patients].
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Evaluation Studies a | 1978 |
Comparison of salbutamol Rotahaler with conventional pressurized aerosol.
Topics: Administration, Intranasal; Adult; Aerosols; Aged; Albuterol; Asthma; Forced Expiratory Volume; Huma | 1977 |
Intravenous infusion of salbutamol in severe acute asthma.
Topics: Acute Disease; Adult; Albuterol; Aminophylline; Asthma; Female; Forced Expiratory Volume; Humans; In | 1978 |
[The bronchospasmolytics salbutamol, fenoterol, terbutaline and reproterol. Their effects and side effects in asthmatics after inhalation with an electric nebulizer].
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Fenoterol; Humans; Hypoxia; Male; Met | 1978 |
Bronchodilatation after inhalation of the antihistamine clemastine.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Clemastine; Forced Expiratory Volume; Humans; Mid | 1978 |
[Comparison of Tyloxapol (Tacholiquin, Alevaire) with physiological saline as inhalation carrier solutions].
Topics: Albuterol; Asthma; Clinical Trials as Topic; Drug Synergism; Expectorants; Humans; Respiratory Thera | 1975 |
Beta-adrenergic function in airways of healthy and asthmatic subjects.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Cardiovascular System; Clinical Trials as Topi | 1975 |
Comparison of salmefamol with salbutamol aerosols in asthamatics.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Blood Pressure; Clinical Trials as Topic; Female; Forced E | 1976 |
Determination of the optimum dose of subcutaneous salbutamol in asthmatic patients.
Topics: Adult; Albuterol; Asthma; Clinical Trials as Topic; Drug Evaluation; Electrocardiography; Female; Fo | 1976 |
Inhalation of fenoterol (Berotec) by asthmatic children: A clinical comparison with salbutamol, orciprenaline and isoprenaline.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Clinical Trials as Topic; Ethanolamines; Female; Fen | 1976 |
The efficacy, as modified by the circadian rhythm of salbutamol administered by different routes.
Topics: Administration, Oral; Adult; Aerosols; Albuterol; Asthma; Circadian Rhythm; Clinical Trials as Topic | 1976 |
A controlled trial of intravenous salbutamol and aminophylline in acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; | 1976 |
Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients.
Topics: Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Dronabinol; Female; Humans; Male | 1976 |
Double-blind trial with standard doses of fenoterol and salbutamol in asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Et | 1976 |
Suppression of exercise-induced asthma by salbutamol, theophylline, atropine, cromolyn, and placebo in a group of asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Atropine; Child; Child, Preschool; Cromolyn Sodium; Female; Humans; M | 1975 |
Carbuterol: a double-blind clinical trial comparing carbuterol and salbutamol.
Topics: Adult; Airway Obstruction; Albuterol; Asthma; Blood Pressure; Bronchitis; Bronchodilator Agents; Cli | 1976 |
Inhibition of exercise-induced asthma by different pharmacological pathways.
Topics: Adolescent; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; Bronchodilator Agents; Chil | 1976 |
Studies of new sympathomimetic beta-receptor stimulating drugs in asthmatic patients. IV Acomparative trial of subcutaneous terbutaline (Bricanyl) and salbutamol (Ventolin).
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Female; Heart Rate; Humans; Male; Middle Aged; Te | 1976 |
Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma.
Topics: Aerosols; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Atropine; Atropine Derivatives; | 1975 |
Comparison of two methods of administering bronchodilator aerosol to asthmatic patients.
Topics: Adult; Aerosols; Aged; Airway Resistance; Albuterol; Asthma; Chronic Disease; Clinical Trials as Top | 1975 |
[Level of lactates and examinations of tremor under Clenbuterol (NAB 365)].
Topics: Albuterol; Analysis of Variance; Aniline Compounds; Asthma; Clinical Trials as Topic; Drug Evaluatio | 1975 |
[Testing of the bronchodilator NAB 365 in a double blind trial author's transl].
Topics: Airway Resistance; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Carbon Dioxide; Clinical Tr | 1975 |
[Letter: Study of the delay of action of an injected corticoid on bronchial obstruction in asthmatics. Comparison with an inhaled beta-stimulating agent].
Topics: Adrenal Cortex Hormones; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials | 1975 |
The measurement of response to beclomethasone dipropionate treatment for asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Clinical Trials as Topic; Huma | 1975 |
Comparison of intravenous aminophylline and salbutamol in severe asthma.
Topics: Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Drug Evaluation; Humans | 1975 |
Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol.
Topics: Adult; Aerosols; Airway Obstruction; Albuterol; Asthma; Blood Pressure; Bronchi; Bronchitis; Broncho | 1975 |
Intravenous treatment with rimiterol and salbutamol in asthma.
Topics: Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Catechols; Dose-Response Relationship, Dru | 1975 |
Evaluation of tolerance after continuous and prolonged oral administration of salbutamol to asthmatic patients.
Topics: Albuterol; Asthma; Delayed-Action Preparations; Drug Evaluation; Drug Tolerance; Female; Humans; Mal | 1975 |
Effect of intravenous injection of salbutamol in asthma.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Blood Pressure; Female; Forced Expiratory Volume; Heart Ra | 1975 |
The effect of intramuscular salbutamol in asthmatics.
Topics: Adult; Albuterol; Asthma; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Injections, Int | 1975 |
Evaluation of a breath actuated pressurized aerosol.
Topics: Aerosols; Albuterol; Asthma; Evaluation Studies as Topic; Humans; Respiratory Therapy | 1976 |
Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Dose-Response Relationship, Drug; Female; For | 1992 |
Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Cold Temperatur | 1992 |
A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion.
Topics: Adrenergic beta-Agonists; Albuterol; Allergens; Asthma; Bronchial Hyperreactivity; Bronchial Provoca | 1992 |
Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Bronchodilator Ag | 1992 |
Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Etha | 1992 |
[Salmeterol and prolonged treatment of asthma: international clinical data].
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Double-Blind Method; Drug Tole | 1992 |
[Duration of bronchial protective effect of salmeterol in asthma induced by hyperventilation with dry cold air].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction | 1992 |
[Usefulness of salmeterol in nocturnal asthma: a comparative study with theophylline-ketotifen association. A French multicenter group].
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Double-Blind Method; Drug Ther | 1992 |
The effect of repeat action albuterol sulfate (Proventil Repetabs) in nocturnal symptoms of asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Circadian Rhy | 1992 |
Which patients benefit from adding theophylline to beta 2-agonist treatment in severe acute asthma?
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Female; Humans; Male; Middl | 1992 |
Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol | 1992 |
Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction | 1992 |
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Do | 1992 |
Breath-actuated inhalers in chronic asthma: comparison of Diskhaler and Turbohaler for delivery of beta-agonists.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Chronic Diseas | 1992 |
Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; Fema | 1992 |
Sustained improvement in asthma with long-term use of formoterol fumarate.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Double-Blind Method; Ethanolam | 1992 |
Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator | 1992 |
[Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 1992 |
Effects of ipratropium bromide nebulizer solution with and without preservatives in the treatment of acute and stable asthma.
Topics: Aerosols; Albuterol; Asthma; Bronchoconstriction; Double-Blind Method; Female; Forced Expiratory Vol | 1992 |
Single-dose and steady-state effects of controlled-release salbutamol on drug level and airflow obstruction in patients with asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Delayed-Action Preparations; Dose-Response Relationship, Drug; | 1992 |
Effects of salbutamol and bitolterol mesilate on pO2 levels in asthmatic patients and healthy volunteers.
Topics: Adult; Albuterol; Asthma; Blood Gas Monitoring, Transcutaneous; Bronchodilator Agents; Ethanolamines | 1992 |
A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Doubl | 1992 |
Mechanisms of abnormal glucose metabolism during the treatment of acute severe asthma.
Topics: Acute Disease; Adult; Albuterol; Aminophylline; Asthma; Blood Glucose; Glucagon; Glucocorticoids; Hu | 1992 |
Comparative assessment of a new breath-actuated inhaler in patients with reversible airways obstruction.
Topics: Adult; Aged; Airway Obstruction; Albuterol; Asthma; Double-Blind Method; Forced Expiratory Volume; H | 1992 |
Increased inhaled bronchodilator vs increased inhaled corticosteroid in the control of moderate asthma.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Beclomethasone; Bronchodilator Agent | 1992 |
A long-term prospective assessment of home nebulizer treatment.
Topics: Adult; Aged; Albuterol; Ambulatory Care; Asthma; Bronchodilator Agents; Drug Combinations; Humans; I | 1992 |
Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics.
Topics: Adult; Albuterol; Asthma; Cardiovascular System; Double-Blind Method; Female; Fenoterol; Forced Expi | 1992 |
Intravenous theophylline after beta 2-agonist treatment in severe acute asthma. Effect on patients who are not pre-treated with theophylline.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Drug Therapy, | 1992 |
Facemasks versus mouthpieces for aerosol treatment of asthmatic children.
Topics: Acute Disease; Adolescent; Adult; Aerosols; Albuterol; Asthma; Humans; Masks; Respiratory Function T | 1992 |
Hypomagnesemia due to beta 2-agonist use in bronchial asthma.
Topics: Administration, Oral; Albuterol; Asthma; Humans; Injections, Subcutaneous; Magnesium; Potassium; Ter | 1992 |
Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. French Multicentre Study Group.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Bronch | 1992 |
Preventive effects of inhaled formoterol and salbutamol on histamine-induced bronchoconstriction--a placebo-controlled study.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchoconstriction; Bronchodilator | 1992 |
Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma.
Topics: Adult; Airway Obstruction; Albuterol; Analysis of Variance; Asthma; Double-Blind Method; Drug Therap | 1992 |
Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchodilator Agents; D | 1992 |
[Changes in the heart rhythm and slow-release beta-2 agonist therapy (peroral) in asthmatic patients. A Holter study].
Topics: Administration, Oral; Adult; Albuterol; Arrhythmias, Cardiac; Asthma; Delayed-Action Preparations; E | 1992 |
Effect of astemizole on allergic asthma.
Topics: Adolescent; Adult; Albuterol; Astemizole; Asthma; Bronchial Provocation Tests; Double-Blind Method; | 1992 |
Kinetics of action of salbutamol inhaled from a metered dose inhaler (MDI) and a "Diskhaler".
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Double-Blind Method; Female; Forced Expiratory | 1992 |
Separate and combined effects of corticosteroids and bronchodilators on airflow obstruction and airway hyperresponsiveness in asthma.
Topics: Adrenal Cortex Hormones; Adult; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bronchial | 1992 |
Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma.
Topics: Adolescent; Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-R | 1992 |
Effect of age on bronchodilator response.
Topics: Adolescent; Adult; Aging; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Dose-Response Re | 1992 |
Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; California; C | 1992 |
The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronc | 1992 |
Bronchodilator intake and plasma levels on admission for severe acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Blood Pressure; Dose-Resp | 1992 |
Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast--MK-0679) in asthmatic patients.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relations | 1992 |
A clinically relevant modification to existing inhaler therapy.
Topics: Adult; Albuterol; Asthma; Double-Blind Method; Drug Carriers; Female; Forced Expiratory Volume; Huma | 1992 |
Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Asthma; Beclomethasone; Chi | 1992 |
Treatment of nocturnal asthma with pulsed-release albuterol.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Circadian Rhythm; Delayed-Action Preparations; Double-Bl | 1992 |
Dose of inhaled beta 2-agonists in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Double-Blind Method; Drug Evaluation; Female; | 1991 |
Exacerbations of asthma in patients on salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate | 1991 |
Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist.
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Bronchoconstriction; Double | 1991 |
Asthma exacerbations in patients taking regular salmeterol, or salbutamol for symptoms.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Evaluation; Follow-Up Studies; Humans; Salmeterol | 1991 |
Asthma specific quality of life scale in a study of salmeterol hydroxynaphthoate.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Double-Blind Method; Humans; Quality of Life; Salmetero | 1991 |
A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pr | 1991 |
Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Ethanolamines; Femal | 1991 |
Inhaled formoterol during one year in asthma: a comparison with salbutamol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Beclomethasone | 1991 |
A study with cumulative doses of formoterol and salbutamol in children with asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-Response | 1991 |
Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Do | 1991 |
Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoconstrictio | 1991 |
Controlled trial of nebulized albuterol in children younger than 2 years of age with acute asthma.
Topics: Acute Disease; Administration, Intranasal; Albuterol; Asthma; Double-Blind Method; Female; Heart Rat | 1992 |
[Treatment of asthma in the adult using a combination of salbutamol 100 micrograms--beclomethasone 50 micrograms. Results of a study on 1917 patients seen in general medicine].
Topics: Adolescent; Adult; Aerosols; Aged; Aged, 80 and over; Albuterol; Asthma; Beclomethasone; Drug Combin | 1991 |
Asthmatic responses to passive cigarette smoke: persistence of reactivity and effect of medications.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Cromolyn Sodium; Female; Humans; Hypersensiti | 1991 |
Inhaled and oral salbutamol: how effective in the prophylaxis of asthma?
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Albuterol; Animals; Antigens; A | 1991 |
The effect of a beta 2-adrenergic agonist and a histamine H1-receptor antagonist on the late asthmatic response to inhaled antigen.
Topics: Administration, Inhalation; Adult; Albuterol; Animals; Antigens; Asthma; Bronchial Provocation Tests | 1991 |
Salbutamol plus beclomethasone dipropionate, but not salbutamol alone, completely prevent early and late asthmatic responses to allergen.
Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Double-Blind Meth | 1991 |
Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma.
Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asian People; Asthma; Delayed-Action Preparation | 1991 |
[Delayed-release salbutamol, a new beta-mimetic with prolonged action. Results of a comparative study against theophylline L.A].
Topics: Adolescent; Aged; Albuterol; Asthma; Delayed-Action Preparations; Female; Humans; Male; Maximal Expi | 1991 |
Inhaled procaterol versus salbutamol in bronchial asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Ethan | 1991 |
Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis.
Topics: Age Factors; Albuterol; Asthma; Bronchitis; Chronic Disease; Female; Humans; Hypersensitivity; Iprat | 1991 |
Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis.
Topics: Adult; Aged; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchitis; Bronchoc | 1991 |
Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study.
Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Bronchitis; Chronic Disease; Drug Administration Schedule; | 1991 |
In vitro inhalation behaviour and therapeutical response of salbutamol particles administered from two metered dose aerosols.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Particle Size; Peak Exp | 1991 |
Comparison of albuterol and metaproterenol syrup in the treatment of childhood asthma.
Topics: Administration, Oral; Albuterol; Asthma; Child; Drug Administration Schedule; Female; Forced Expirat | 1991 |
The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease.
Topics: Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchoconstriction; Dose-Response Relationship, | 1991 |
A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Doubl | 1991 |
A randomized, controlled comparison of isoetharine and albuterol in the treatment of acute asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Isoetharine; Male; M | 1991 |
The inhibitory effect of nebulized albuterol on the early and late asthmatic reactions and increase in airway responsiveness provoked by inhaled allergen in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Allergens; Asthma; Bronchial Hyperreactivity; Bronchia | 1991 |
Bronchodilator effect of salbutamol via the Volumatic in children.
Topics: Adolescent; Albuterol; Asthma; Bronchi; Child; Forced Expiratory Volume; Humans; Nebulizers and Vapo | 1991 |
Effect of controlled release salbutamol on nocturnal cough in asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Cough; Delayed-Action Preparations; Double-Blind Method; Femal | 1991 |
[Slow-release salbutamol in the treatment of nocturnal asthma. Result of a comparative study vs. long-acting theophylline].
Topics: Adult; Albuterol; Asthma; Circadian Rhythm; Delayed-Action Preparations; Double-Blind Method; Drug E | 1991 |
Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as | 1990 |
Nebulized or intravenous beta 2 adrenoceptor agonist therapy in acute asthma?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Clinical Trials a | 1990 |
Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma.
Topics: Administration, Oral; Adult; Albuterol; Allergens; Asthma; Asthma, Exercise-Induced; Bronchi; Bronch | 1990 |
Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Aerosols; Aged; A | 1990 |
Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double-blind cross-over study versus salbutamol.
Topics: Adolescent; Adrenergic beta-Agonists; Aerosols; Albuterol; Analysis of Variance; Asthma; Bronchodila | 1990 |
Can a new beta 2-agonist reduce the mortality of asthma?
Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Albutero | 1990 |
Acute and long-term effectiveness of tulobuterol inhaler, a new beta 2-agonist, in the treatment of asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Double- | 1990 |
Long-term studies on long-acting sympathomimetics.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; D | 1990 |
Long-term efficacy of formoterol compared to salbutamol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Al | 1990 |
Formoterol, a new long-acting selective beta 2-agonist, decreases airway responsiveness in children with asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Te | 1990 |
Efficacy of formoterol metered aerosol in children.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asth | 1990 |
Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Dose-Response | 1990 |
The pulmonary and extrapulmonary effects of inhaled beta-agonists in patients with asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Bronchodil | 1990 |
Formoterol in the treatment of nocturnal asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; Double- | 1990 |
Protection against allergen-induced asthma by salmeterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma | 1990 |
Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchoconstri | 1990 |
Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; D | 1990 |
Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod | 1990 |
Metered dose inhalers for bronchodilator delivery in intubated, mechanically ventilated patients.
Topics: Aerosols; Aged; Albuterol; Asthma; Costs and Cost Analysis; Female; Humans; Intubation, Intratrachea | 1991 |
Effect of salbutamol on gastroesophageal reflux in healthy volunteers and patients with asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Female; Gastroesophageal Reflux; Humans; Male | 1991 |
Occupational asthma and rhinoconjunctivitis from inhalation of crystalline bovine serum albumin powder.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Conjunctivitis; Crystallization; Double-Blind | 1991 |
Improved stability in oral delivery of albuterol provides less variability in bronchodilation in adults with asthma.
Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Dose-Res | 1991 |
Management of childhood asthma--addition of oral controlled release salbutamol to an inhaled treatment regimen.
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Delaye | 1991 |
Effect of injected long-acting epinephrine in addition to aerosolized albuterol in the treatment of acute asthma in children.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Drug Therapy, Combination; E | 1991 |
The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations.
Topics: Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Electrocardiography; Ethanolamines; F | 1991 |
Inhaled beta-stimulants--a study of high-dose v. conventional-dose treatment in asthmatic outpatients.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchial Provocation Tests; | 1991 |
The efficacy and safety of a controlled release formulation of salbutamol in the management of patients with asthma in Nairobi, Kenya.
Topics: Adult; Albuterol; Asthma; Consumer Behavior; Delayed-Action Preparations; Female; Humans; Male; Midd | 1990 |
Antigen-induced T-cell changes: modulation by pharmacologic agents.
Topics: Administration, Inhalation; Albuterol; Antigens; Asthma; Bronchi; Bronchial Provocation Tests; Const | 1990 |
Nebulized ipratropium in the treatment of acute asthma.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchodilator | 1990 |
A clinical and immunologic study of colchicine in asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Chronic Disease; Colchicine; Conc | 1990 |
[Effects of ipratropium bromide and salbutamol on isolated lung hyperinflation in symptom-free intervals in asthmatic children].
Topics: Administration, Inhalation; Adolescent; Airway Obstruction; Albuterol; Asthma; Atropine Derivatives; | 1990 |
Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy.
Topics: Administration, Inhalation; Albuterol; Aminophylline; Anti-Bacterial Agents; Asthma; Atropine Deriva | 1990 |
Evaluation of peak flow and symptoms only self management plans for control of asthma in general practice.
Topics: Administration, Oral; Adult; Aerosols; Albuterol; Asthma; Child; Family Practice; Humans; Office Vis | 1990 |
Home nebulizers: can optimal therapy be predicted by laboratory studies?
Topics: Adult; Aged; Albuterol; Asthma; Double-Blind Method; Female; Humans; Ipratropium; Lung Diseases, Obs | 1990 |
Comparison of Berodual and salbutamol in asthma: a multicenter evaluation.
Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Combinations; Evaluation Studies as Topic; | 1990 |
High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma. Swedish Society of Chest Medicine.
Topics: Administration, Inhalation; Albuterol; Asthma; Drug Therapy, Combination; Female; Humans; Infusions, | 1990 |
Ambulatory long-term subcutaneous salbutamol infusion in chronic severe asthma.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Ambulatory Care; Asthma; Chronic Disease; Double-Blind Me | 1990 |
Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Capsules; Delayed-Action Preparations; Double-Blind Method; Hu | 1990 |
Comparative protective effect of the inhaled beta 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma.
Topics: Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adult; Aerosols; Albuterol; Asthma; | 1990 |
Single breath versus panting technique in salbutamol delivery through a 750 mL spacing device.
Topics: Adolescent; Albuterol; Asthma; Bronchi; Child; Forced Expiratory Volume; Humans; Male; Maximal Midex | 1990 |
Methylprednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial.
Topics: Acute Disease; Albuterol; Asthma; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; D | 1990 |
Efficacy of atropine methylnitrate alone and in combination with albuterol in children with asthma.
Topics: Adolescent; Albuterol; Asthma; Atropine Derivatives; Bronchi; Child; Double-Blind Method; Drug Thera | 1990 |
Nebulized albuterol in acute childhood asthma: comparison of two doses.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Method; Drug Administration Sch | 1990 |
A random double-blind trial of the combination of nebulized atropine methylnitrate and albuterol in nocturnal asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchodilat | 1990 |
Inhaled albuterol and oral prednisone therapy in hospitalized adult asthmatics. Does aminophylline add any benefit?
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Albuterol; Amino | 1990 |
[Clinico-functional evaluation of flunisolide + salbutamol combination (VAL 679/A) vs salbutamol in pediatric patients].
Topics: Administration, Topical; Albuterol; Anti-Inflammatory Agents; Asthma; Child; Double-Blind Method; Dr | 1990 |
Comparison of the efficacy and systemic effects of 4 mg and 8 mg formulations of salbutamol controlled release in patients with asthma.
Topics: Adult; Albuterol; Asthma; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blin | 1990 |
Comparison of the effects of inhaled corticosteroids on the airway response to histamine, methacholine, hyperventilation, and sulfur dioxide in subjects with asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Airway Resistance; Albuterol; Asthma; Beclometh | 1990 |
Placebo controlled trial of systemic corticosteroids in acute childhood asthma.
Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Female; Heart Rate; Humans | 1990 |
Aerosolized budesonide in asthmatic infants: a double blind study.
Topics: Administration, Intranasal; Albuterol; Asthma; Budesonide; Double-Blind Method; Drug Evaluation; Glu | 1990 |
Continuous nebulization of albuterol (salbutamol) in acute asthma.
Topics: Acute Disease; Adult; Albuterol; Asthma; Drug Administration Schedule; Female; Forced Expiratory Vol | 1990 |
[Effect of nebulized salbutamol in 26 patients hospitalized for asthma attack].
Topics: Adult; Albuterol; Asthma; Drug Tolerance; Female; Hospitalization; Humans; Injections, Intravenous; | 1990 |
Can the morbidity of asthma be reduced by high dose inhaled therapy? A prospective study.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Drug Therapy, Combination; Fem | 1990 |
A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Ethanolamines; Female | 1990 |
The effect of albuterol aerosol on fine-motor performance in children with chronic asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Met | 1990 |
Asthma, cardiac arrhythmias, and albuterol aerosol.
Topics: Adult; Aerosols; Aged; Albuterol; Arrhythmias, Cardiac; Asthma; Cardiac Complexes, Premature; Clinic | 1986 |
The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics.
Topics: Adrenergic beta-Antagonists; Aged; Albuterol; Asthma; Bisoprolol; Blood Pressure; Bronchial Provocat | 1986 |
Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges.
Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Atropine Derivatives; Cromolyn Sodium; Female; F | 1989 |
Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition.
Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Dose-Response Relationship, Drug; Female; | 1989 |
[Comparative study of procaterol and salbutamol in single inhaled doses].
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Female; Humans; Lung Volum | 1989 |
Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F2 alpha-induced bronchospasm.
Topics: Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchial Provocation Tests; Bronchial S | 1989 |
Comparison of a combination of fenoterol with ipratropium bromide (Duovent) and salbutamol in young adults with nocturnal asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic | 1989 |
Relative bronchodilatory responsiveness attributable to sympathetic and parasympathetic activity in bronchial asthma.
Topics: Administration, Intranasal; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchi; Drug Therapy, C | 1989 |
[Effects of ipratropium bromide (IPB) and its combination with salbutamol sulfate (SAS) in acute asthmatic attack].
Topics: Adult; Albuterol; Asthma; Atropine Derivatives; Double-Blind Method; Drug Therapy, Combination; Fema | 1989 |
Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration.
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Dose-Res | 1989 |
Randomized controlled trial of small group education on the outcome of chronic asthma in general practice.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child; Child, Preschool; Chronic Disease; Education, Med | 1989 |
Fenoterol and serum potassium.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Female; Fenoterol; Humans; Male; Middle Aged; | 1989 |
Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Atropine Derivatives; | 1989 |
Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Doubl | 1989 |
Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Clinical Trials as Topic; Dose-Response Relation | 1989 |
Dose-effect relationship of terbutaline using a multi-dose powder inhalation system ('Turbuhaler') and salbutamol administered by powder inhalation ('Rotahaler') in asthmatics.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Dose-Response Relationship, Drug; Forced Expir | 1989 |
Effect of nebulised salbutamol on maximal exercise performance in men with mild asthma.
Topics: Adult; Albuterol; Asthma; Exercise Test; Forced Expiratory Volume; Heart Rate; Humans; Male; Nebuliz | 1989 |
Comparison of subcutaneous injections of terbutaline, salbutamol and adrenaline in acute asthmatic attacks in children.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Blood Pressure; Child; Child, Preschool; Epinephrine; | 1989 |
Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Dose-Response Rela | 1989 |
Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma.
Topics: Adult; Albuterol; Asthma; Delayed-Action Preparations; Double-Blind Method; Female; Forced Expirator | 1989 |
Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma.
Topics: Administration, Inhalation; Administration, Oral; Administration, Sublingual; Adult; Aged; Albuterol | 1989 |
Wet nebulizer versus spacer and metered dose inhaler via tidal breathing.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Double-Blind Method; Female; Human | 1989 |
Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol.
Topics: Adolescent; Albuterol; Asthma; Beclomethasone; Bronchi; Child; Drug Combinations; Female; Forced Exp | 1989 |
A comparative bronchodilator study of salbutamol and salbutamol sulphate that were administered by metered-dose inhalers.
Topics: Adult; Aged; Albuterol; Asthma; Double-Blind Method; Female; Humans; Male; Middle Aged; Nebulizers a | 1989 |
Effect of theophylline and salbutamol on hepatic drug metabolism.
Topics: Adult; Albuterol; Antipyrine; Asthma; Coffee; Female; Humans; Liver; Male; Middle Aged; Respiratory | 1989 |
Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Glucose; Dose-Response Relationship, Dru | 1989 |
Duration of action of inhaled terbutaline at two different doses and of albuterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in asthmatic subjects.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Child; Cold Temperature; Female | 1989 |
Formoterol and salbutamol metered aerosols: comparison of a new and an established beta-2-agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthma.
Topics: Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; C | 1989 |
Effects of inhaled beclomethasone dipropionate on beta 2-receptor function in the airways and adrenal responsiveness in bronchial asthma.
Topics: Adrenal Glands; Adult; Albuterol; Asthma; Beclomethasone; Blood Glucose; Bronchi; Dose-Response Rela | 1988 |
The effects of ketotifen on beta-adrenergic activity in asthmatics.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Double-Blind Method; Female; Humans; Ipra | 1988 |
Evaluation of reproterol's effectiveness in preventing exercise-induced bronchospasm in children.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Child; | 1985 |
Treatment of asthma syndromes in pediatric patients using a combination of a beta 2-stimulant drug and a histamine antagonist.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Auscultation; Child; Child, Preschool; Clinical Trials | 1985 |
Broxaterol: a double-blind clinical trial comparing broxaterol and salbutamol.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Blood Pressure; Bronchitis; Clinical Trial | 1985 |
Treatment of asthma with an extempore combination of a bronchodilator, salbutamol, and a new antihistamine drug, oxatomide.
Topics: Adrenal Cortex Hormones; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Drug Combinations | 1986 |
Terbutaline slow-release tablets in children with asthma. A comparison with t.i.d. beta 2-agonist therapy.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Prescho | 1986 |
Duration of oral procaterol protection from methacholine-induced bronchial obstruction.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Child; Ethanolamines; Female; Humans | 1986 |
Theophylline in maintenance treatment of chronic asthma: concentration-dependent additional effect to beta 2-agonist therapy.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Chronic Disease; Clinical Trials as Topic; | 1987 |
Effect of a single oral dose of prednisolone in acute childhood asthma.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child, Preschool | 1987 |
The effect of theophylline and beta 2 agonists on airway reactivity.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Test | 1987 |
Theophylline as a bronchodilator in COPD and its combination with inhaled beta-adrenergic drugs.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchi; Bronchitis; Clinical Trials as Topic; | 1987 |
Comparative trials including a beta 2 adrenergic agonist, a methylxanthine, and a mast cell stabilizer.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Attention; Child; Cromolyn Sodium; Dose-Response Relati | 1988 |
A comparison of the bronchodilator effects of broxaterol and salbutamol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Blood Pressure | 1988 |
Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Blood Pressure; Clini | 1988 |
A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Double-Blind Method; Female; Histamine H1 Ant | 1988 |
Ergogenic effect of inhaled beta 2-agonists in asthmatics.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Double-Blind Method; E | 1988 |
The superiority of combination beclomethasone and salbutamol over standard dosing of salbutamol in the treatment of chronic asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Drug Therapy, Combination; Eva | 1989 |
High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Nebuliz | 1989 |
Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Atropine Derivatives; Child; Clinical Trials as Topic; | 1985 |
[Pharmacological prevention of exercise-induced bronchospasm in patients with asthma].
Topics: Adult; Aerosols; Albuterol; Aminophylline; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; | 1985 |
A place for ipratropium bromide in the treatment of severe acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as | 1985 |
Effect of bronchodilators on the cough response to inhaled citric acid in normal and asthmatic subjects.
Topics: Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Citrates; Citric Acid; Cough; | 1985 |
Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma.
Topics: Adult; Albuterol; Asthma; Atropine Derivatives; Bronchial Provocation Tests; Chemotactic Factors; Cr | 1985 |
Nebulized salbutamol and ipratropium bromide in asthmatic children.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Atropine Derivatives; Child; Child, Preschool; Dose-Respons | 1986 |
Nebulised ipratropium and salbutamol in asthma.
Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Atropine Derivatives; Child; Child, Preschoo | 1986 |
Single dose comparison of salbutamol and a fenoterol/ipratropium combination from metered aerosols in patients with asthma.
Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Double-Blind Met | 1986 |
Platelet activation during exercise induced asthma: effect of prophylaxis with cromoglycate and salbutamol.
Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; beta-Thromboglobulin; Blood Platelets; Cromolyn | 1986 |
A new bronchodilating agent, procaterol, in preventing exercise-induced asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Child; Ethano | 1986 |
Influence of pindolol on asthmatics and effect of bronchodilators.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Child; Female; Forced | 1986 |
Salbutamol and ipratropium bromide solution in the treatment of bronchospasm in asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Atropine Derivatives; Bronchial Spasm; Child; Drug Therapy, Combinati | 1987 |
Cold-air isocapnic hyperventilation test in the study of the effects and duration of action of Duovent. Comparison with fenoterol, salbutamol, disodium cromoglycate and placebo.
Topics: Adolescent; Adult; Air; Albuterol; Asthma; Atropine Derivatives; Bronchial Provocation Tests; Bronch | 1986 |
Histamine-induced bronchial response after administration of placebo, salbutamol and a combination of a beta-2-adrenergic drug (fenoterol) with an anticholinergic agent (ipratropium bromide) in asymptomatic asthma patients.
Topics: Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchial Provocation Tests; Bronchial S | 1986 |
Single-dose comparison of salbutamol and Duovent-Berodual in asthma.
Topics: Adult; Albuterol; Asthma; Atropine Derivatives; Drug Combinations; Female; Fenoterol; Forced Expirat | 1986 |
Blind randomized cross-over comparative study of salbutamol and the combination fenoterol-ipratropium IK6 in patients with bronchial asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Double-Blind Method; Drug Combinat | 1986 |
75 deaths in asthmatics prescribed home nebulizers.
Topics: Albuterol; Asthma; Humans; Ipratropium; Nebulizers and Vaporizers | 1987 |
Salbutamol and ipratropium in acute asthma.
Topics: Adolescent; Albuterol; Asthma; Atropine Derivatives; Child; Child, Preschool; Clinical Trials as Top | 1987 |
[Ultrasonic spray protection against bronchospasm. Comparison of fenoterol and a combination of salbutamol and ipratropium bromide].
Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Double-Blind Method; Drug Therapy, Combina | 1987 |
Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchi; Dose-Response Relationship, Drug; Forced Expira | 1987 |
Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children.
Topics: Administration, Inhalation; Albuterol; Asthma; Atropine Derivatives; Child; Drug Synergism; Forced E | 1988 |
A dose response study comparing Duovent vs salbutamol.
Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Bronchodilator Agents; Chronic | 1987 |
Prevention of exercise-induced asthma by drugs inhaled from metered aerosols.
Topics: Administration, Inhalation; Adolescent; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Child | 1988 |
Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma.
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Atropine Derivatives; Dose- | 1988 |
Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma?
Topics: Acute Disease; Adult; Albuterol; Asthma; Atropine Derivatives; Clinical Trials as Topic; Double-Blin | 1988 |
Posture-induced airflow limitation in asthma: relationship to plasma catecholamines and an inhaled anticholinergic agent.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Aged; Airway Resistance; Albuterol; Asthma; A | 1988 |
Cumulative dose-response curves for assessing combined effects of salbutamol and ipratropium bromide in chronic asthma.
Topics: Adult; Albuterol; Asthma; Atropine Derivatives; Dose-Response Relationship, Drug; Drug Interactions; | 1988 |
A comparison of oral procaterol and albuterol in reversible airflow obstruction.
Topics: Administration, Oral; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials | 1988 |
Comparison between oral procaterol and salbutamol in patients with bronchial asthma.
Topics: Administration, Oral; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug | 1988 |
Air or oxygen as driving gas for nebulised salbutamol.
Topics: Acute Disease; Air; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Female; Hu | 1988 |
An inexpensive spacer for use with metered-dose bronchodilators in young asthmatic children.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Do | 1988 |
[Intravenous infusion of reproterol (a beta-2-mimetic agent) in the therapy of severe asthma attacks in childhood].
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Carbon Dioxide; Child; Child, Preschool; Combi | 1986 |
Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Asthma; Beclomethasone; Bronchi | 1987 |
A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Child; C | 1987 |
Treatment of bronchial asthma with terfenadine; a randomized controlled trial.
Topics: Adolescent; Adult; Albuterol; Asthma; Benzhydryl Compounds; Child; Clinical Trials as Topic; Double- | 1987 |
Intravenous beta agonist in severe acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Female; Humans; Infusions, Intravenous; M | 1988 |
[The role of anticholinergic drugs in the treatment of bronchospastic conditions].
Topics: Albuterol; Asthma; Atropine Derivatives; Bronchial Spasm; Bronchitis; Clinical Trials as Topic; Huma | 1985 |
Open cross-over comparison of tulobuterol and fenoterol in asthmatic adult patients.
Topics: Adult; Albuterol; Asthma; Drug Evaluation; Fenoterol; Humans; Middle Aged; Random Allocation; Respir | 1988 |
Effects of albuterol (salbutamol) on esophageal motility and gastroesophageal reflux in healthy volunteers.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Double-Blind Method; Esophagus; Female; Gastro | 1988 |
Evaluation of the combination inhaler of salbutamol and beclomethasone dipropionate in the management of asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Beclomethasone; Drug Combina | 1988 |
Effect of ketotifen on the bronchodilation induced by salbutamol.
Topics: Adult; Albuterol; Asthma; Bronchi; Dilatation, Pathologic; Female; Forced Expiratory Volume; Humans; | 1988 |
Use of bronchial provocation with histamine to compare the pharmacodynamics of inhaled albuterol and metaproterenol in patients with asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Clinical Trials as Topic; Dose-Re | 1987 |
Nifedipine treatment of patients with bronchial asthma.
Topics: Adult; Aged; Albuterol; Asthma; Blood Pressure; Circadian Rhythm; Clinical Trials as Topic; Double-B | 1987 |
Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Betamethasone; Bronchi; Clinical Trials as Topic; Doubl | 1987 |
Oral salbutamol vs fenoterol in childhood asthma.
Topics: Administration, Oral; Adolescent; Albuterol; Asthma; Child; Clinical Trials as Topic; Double-Blind M | 1987 |
Hypokalaemic and electrocardiographic effects of aminophylline and salbutamol in obstructive airways disease.
Topics: Administration, Inhalation; Adult; Albuterol; Aminophylline; Arrhythmias, Cardiac; Asthma; Clinical | 1987 |
Delivery of albuterol aerosol by aerochamber to young children.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Heart Rate | 1988 |
Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise-induced asthma in children.
Topics: Administration, Oral; Albuterol; Altitude; Asthma; Asthma, Exercise-Induced; Child; Clenbuterol; Dou | 1988 |
A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients.
Topics: Albuterol; Asthma; Dose-Response Relationship, Drug; Fenoterol; Forced Expiratory Volume; Heart Rate | 1987 |
Differing bioavailability of salbutamol metered-dose inhalers.
Topics: Aerosols; Albuterol; Asthma; Biological Availability; Double-Blind Method; Drug Administration Sched | 1987 |
Duration of action of oral albuterol in an asthmatic population.
Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Bronchial Spasm; Child; Clinical Trials | 1986 |
How to use a rotahaler.
Topics: Acute Disease; Adolescent; Aerosols; Age Factors; Albuterol; Asthma; Child; Clinical Trials as Topic | 1986 |
Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma.
Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Pressure; Bronchodilator Agents; Clinical | 1986 |
Comparison of oral salbutamol with reproterol in reversible airway obstruction.
Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Clini | 1986 |
[Comparative study of the effects of regular or on-demand salbutamol inhalation in the treatment of asthma].
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Clinical Trials as Topic; Do | 1986 |
The response of asthmatic children to the heated nebulization of salbutamol.
Topics: Administration, Inhalation; Albuterol; Asthma; Child; Clinical Trials as Topic; Female; Forced Expir | 1986 |
Response to bronchodilators assessed by lung mechanics.
Topics: Acute Disease; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Female; Functio | 1986 |
Extrapulmonary effects of maintenance therapy with theophylline and inhaled albuterol in patients with chronic asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bicarbonates; Calcium; Chron | 1986 |
Inhalation powder and oral salbutamol combination.
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Chroni | 1986 |
[Comparative study of anticholinergic and betamimetic agents in the treatment of asthma attacks].
Topics: Administration, Inhalation; Albuterol; Asthma; Atropine; Clinical Trials as Topic; Female; Humans; I | 1986 |
Nifedipine in asthma. Dose-related effect on resting bronchial tone.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Clinical Trials as Topic; Dose-Response Relationship, | 1987 |
Comparison of inhaled albuterol powder and aerosol in asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Child; Clinical Tr | 1987 |
Is twice daily prophylaxis with salbutamol and beclomethasone dipropionate effective in the management of asthma?
Topics: Adult; Aged; Albuterol; Asthma; Beclomethasone; Drug Administration Schedule; Drug Therapy, Combinat | 1986 |
Is the combination inhaler of salbutamol and beclomethasone dipropionate as effective as the same agents from separate inhalers in the management of childhood asthma?
Topics: Adolescent; Albuterol; Asthma; Beclomethasone; Child; Double-Blind Method; Drug Combinations; Female | 1987 |
Nebulised adrenaline in acute severe asthma: comparison with salbutamol.
Topics: Acute Disease; Adult; Albuterol; Asthma; Epinephrine; Female; Humans; Male; Middle Aged; Nebulizers | 1987 |
Lack of cardiac effect from repeated doses of albuterol aerosol. A margin of safety.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Double-Blind Method; Forced Expiratory Volume; Heart | 1986 |
A comparative study of the bronchodilating effect of oral fenoterol and salbutamol in children with asthma.
Topics: Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Double-Blind Method; Fenoterol; Hu | 1986 |
Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols.
Topics: Adult; Aerosols; Albuterol; Asthma; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Sc | 1986 |
[Nocturnal asthma: inhalation treatment with high doses of salbutamol and beclomethasone].
Topics: Adult; Albuterol; Asthma; Beclomethasone; Circadian Rhythm; Drug Therapy, Combination; Female; Human | 1986 |
Orally administered nifedipine in chronic stable asthma. Comparison with an orally administered sympathomimetic.
Topics: Administration, Oral; Adult; Albuterol; Asthma; Double-Blind Method; Female; Forced Expiratory Volum | 1986 |
Comparison of the effects of sequential or simultaneous administration of salbutamol and beclomethasone dipropionate.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Double-Blind Method; Drug Administration S | 1986 |
The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment.
Topics: Adult; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Male; Theophylline | 1986 |
Long-term regularly inhaled salbutamol.
Topics: Administration, Inhalation; Albuterol; Asthma; Double-Blind Method; Drug Administration Schedule; Dr | 1986 |
Cough and wheezing from beclomethasone aerosol.
Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Cough; Double-Blind Method; Forced Expiratory Volume; H | 1987 |
Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Chronic Disease; Drug Administration Schedule; Drug Ther | 1987 |
Evaluation of inhalation aids of metered dose inhalers in asthmatic children.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers | 1987 |
Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease.
Topics: Adult; Albuterol; Asthma; Biological Availability; Delayed-Action Preparations; Double-Blind Method; | 1986 |
"Cup-Mask' salbutamol in acute asthma in children.
Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Doubl | 1985 |
Fenoterol administered as an inhaled powder. A comparison with salbutamol powder.
Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; | 1985 |
Inhaled albuterol powder for the treatment of asthma--a dose-response study.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Child; Clinical Trials as Topic; Dose-Response Relat | 1985 |
A trial of tiaramide in asthma.
Topics: Administration, Oral; Adult; Aerosols; Aged; Albuterol; Asthma; Benzothiazoles; Bronchodilator Agent | 1985 |
Treatment of acute bronchoconstriction in children with use of a tube spacer aerosol and a dry powder inhaler.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Dou | 1985 |
Albuterol syrup in the treatment of asthma.
Topics: Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Ele | 1985 |
Inhalation therapy during acute asthma. The role of a combined steroid and beta-stimulant preparation.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Clinical Trials as Topic; Doubl | 1985 |
Comparison of intravenous salbutamol (albuterol) and aminophylline in the treatment of acute asthmatic attacks.
Topics: Albuterol; Aminophylline; Asthma; Clinical Trials as Topic; Headache; Heart Rate; Humans; Injections | 1985 |
A comparison of inhaled powders of fenoterol and salbutamol in asthma.
Topics: Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Ethanolam | 1985 |
Oxitropium, salbutamol and their combination in asthma.
Topics: Adult; Albuterol; Asthma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Forced Expira | 1985 |
Albuterol nebulizer solution for the treatment of asthma.
Topics: Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Humans; Isoetharine; Ran | 1985 |
Nifedipine in chronic bronchial asthma: a randomized double-blind crossover trial against placebo.
Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Dou | 1985 |
Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate.
Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Female; Forced Expiratory Volume; Hu | 1986 |
Is driving gas flow rate clinically important for nebulizer therapy?
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Random Allocation; Resp | 1986 |
A comparative study of two doses of salbutamol nebulized at 4 and 8 litres per minute in patients with chronic asthma.
Topics: Aerosols; Albuterol; Asthma; Chronic Disease; Female; Forced Expiratory Volume; Humans; Lung; Male; | 1986 |
Efficacy of parenteral albuterol in the treatment of asthma. Comparison of its metabolic side effects with subcutaneous epinephrine.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Double-Blind Method; Epinephrine; Female; | 1986 |
Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Dose-Response | 1985 |
Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics.
Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Double-Blind Method; Fe | 1985 |
Response to frequent low doses of nebulized salbutamol in acute asthma.
Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Asthma; Child; Dose-Response Relationship, Drug; Dru | 1985 |
Nebulised salbutamol without oxygen in severe acute asthma: how effective and how safe?
Topics: Acute Disease; Adolescent; Adult; Aerosols; Albuterol; Asthma; Drug Administration Schedule; Female; | 1985 |
Comparison of inhaled salbutamol powder and aerosol in asthmatic patients with low peak expiratory flow level.
Topics: Aerosols; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Powders; | 1985 |
A comparison of inhaled fenoterol and albuterol in asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Fenoterol; Forced Expiratory Volume; | 1985 |
A comparative study of the inhaled dry powders of salbutamol and fenoterol and their delivery systems.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Female | 1985 |
[Spirometric monitoring of the effects of puncturing thoracic pain points in asthmatic disease].
Topics: Acupuncture Therapy; Adult; Airway Resistance; Albuterol; Asthma; Female; Humans; Male; Maximal Expi | 1985 |
[Pulmonary function tests on the bronchospasmolytic effects of the beta-2-adrenergics: salbutamol, terbutaline and NAB 365 (double placebo experiment)].
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Alcohols; Amines; Asthma; Bronchitis; Chlori | 1974 |
Letter: Alpha-adrenoceptor-blocking drugs in asthma.
Topics: Adrenergic beta-Antagonists; Albuterol; Asthma; Drug Synergism; Humans; Receptors, Adrenergic | 1974 |
Demonstration by placebo response in asthma by means of exercise testing.
Topics: Adolescent; Albuterol; Asthma; Atropine; Child; Child, Preschool; Cromolyn Sodium; Female; Humans; L | 1973 |
Substitution of beclomethasone aerosol for oral prednisolone in the treatment of chronic asthma.
Topics: Administration, Oral; Administration, Topical; Adrenocorticotropic Hormone; Aerosols; Albuterol; Ant | 1973 |
A clinical trial of long-term oral salbutamol in reversible diffuse airway obstruction.
Topics: Adolescent; Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchitis; Chronic Disease; Clinica | 1973 |
The role of oral bronchodilator therapy as shown by a comparison between salbutamol and terbutaline.
Topics: Administration, Oral; Adult; Airway Obstruction; Albuterol; Asthma; Blood Pressure; Clinical Trials | 1973 |
Response to rimiterol and salbutamol aerosols administered by intermittent positive-pressure ventilation.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Electrocardiography | 1974 |
A controlled trial of beclomethasone dipropionate in asthma.
Topics: 17-Hydroxycorticosteroids; Administration, Topical; Adolescent; Adult; Aerosols; Aged; Albuterol; An | 1974 |
A controlled trial of beclomethasone dipropionate by aerosol in chronic asthmatics.
Topics: Administration, Topical; Aerosols; Albuterol; Anti-Inflammatory Agents; Asthma; Beclomethasone; Clin | 1974 |
Salbutamol.
Topics: Albuterol; Asthma; Clinical Trials as Topic; Ephedrine; Humans | 1973 |
[Double blind test with hexoprenaline (Ipradol)-dosage-aerosol apparatus in bronchial asthma].
Topics: Adolescent; Adult; Aerosols; Albuterol; Amino Alcohols; Asthma; Blood Pressure; Bronchodilator Agent | 1974 |
[Bronchodilator effect of aerosol salbutamol in infantile bronchial asthma].
Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Clinical Trials as Topic; Drug Evaluation; Fem | 1974 |
Comparative study of modern beta adrenoreceptor stimulation aerosols in asthma.
Topics: Aerosols; Albuterol; Asthma; Clinical Trials as Topic; Humans; Isoproterenol; Metaproterenol; Placeb | 1973 |
Oral salbutamol in obstructive airway disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchitis; Clinical Trials as Top | 1974 |
[Beclomethasone aerosol in asthma therapy].
Topics: Administration, Topical; Adult; Aerosols; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Beclome | 1974 |
Evaluation of orally administered salbutamol in the relief of bronchospasm in bronchial asthma.
Topics: Administration, Oral; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Spasm; Clinical Trials | 1974 |
Bronchodilator effect of oral salbutamol and an ephedrine+theophylline+hydroxyzine combination in asthmatic out-patients.
Topics: Adolescent; Adult; Albuterol; Asthma; Clinical Trials as Topic; Drug Combinations; Ephedrine; Female | 1974 |
Oral salbutamol in asthma-a preliminary report.
Topics: Adolescent; Adult; Albuterol; Asthma; Blood Pressure; Clinical Trials as Topic; Female; Humans; Male | 1974 |
The effect of betamethasone valerate aerosol on exercise-induced asthma in children.
Topics: Aerosols; Albuterol; Asthma; Betamethasone; Betamethasone Valerate; Child; Clinical Trials as Topic; | 1974 |
[Oral therapy of asthma. Studies on the effects of bronchodilators in tabelts].
Topics: Administration, Oral; Adolescent; Adult; Albuterol; Amino Alcohols; Asthma; Bronchodilator Agents; F | 1972 |
A comparison of salbutamol and terbutaline aerosols in bronchial asthma.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Blood Pressure; Heart Rate; Humans; Middle Aged; Spirometr | 1973 |
A comparison of the effects of subcutaneous orciprenaline, salbutamol and terbutaline in asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Blood Pressure; Child; Child, Preschool; Dose-Response Relationship, | 1974 |
A comparative trial of salbutamol and isoprenaline in asthma.
Topics: Adult; Aerosols; Airway Obstruction; Albuterol; Asthma; Carbon Dioxide; Female; Heart Rate; Humans; | 1974 |
1951 other studies available for albuterol and Asthma
| Article | Year |
|---|---|
New bronchodilators. Synthesis and bronchodilating activity of some 3-(alkoxymethyl)-alpha-(N-substituted aminomethyl)-4-hydroxybenzyl alcohols.
Topics: Airway Resistance; Animals; Asthma; Benzyl Alcohols; Benzyl Compounds; Bronchodilator Agents; Chemic | 1979 |
A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Anti-Asthmatic Agents; Asthma; Cell Line; Drug Discove | 2012 |
Prospective Observational Study of Clinical Outcomes After Intravenous Magnesium for Moderate and Severe Acute Asthma Exacerbations in Children.
Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Drug Therapy, Combination; Female; H | 2022 |
Inpatient albuterol spacing as an indicator of discharge readiness.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hospital; Female; Hospitalizatio | 2023 |
Bronchodilator Responsiveness: An Underappreciated Biomarker for Asthma Exacerbations.
Topics: Albuterol; Asthma; Biomarkers; Bronchodilator Agents; Humans | 2022 |
Is the use of a combined FABA/ICS single inhaler for mild asthma effective and safe?
Topics: Administration, Inhalation; Albuterol; Asthma; Drug Combinations; Drug Therapy, Combination; Humans; | 2022 |
Medication adherence in Medicare-enrolled older adults with asthma before and during the coronavirus disease 2019 pandemic.
Topics: Aged; Albuterol; Anti-Asthmatic Agents; Asthma; COVID-19; COVID-19 Drug Treatment; Humans; Medicare; | 2022 |
Cost analysis of hospitals performing continuous albuterol in non-intensive care settings.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Hospital Costs; Hospitals; Humans; Length of | 2023 |
Role of ethnicity/language in documented rates of pediatric asthma prescription refills.
Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Ethnicity; Humans; Language; Prescriptions | 2023 |
Variation in Prehospital Protocols for Pediatric Respiratory Distress Management in the United States.
Topics: Albuterol; Anaphylaxis; Asthma; Child; Croup; Dyspnea; Emergency Medical Services; Epiglottitis; Epi | 2022 |
[Salbutamol as an indicator of poor asthma control].
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans | 2021 |
Association between beta-2 adrenergic receptor variants and clinical outcomes in children and adolescents with acute asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Humans; Metered Dose Inhalers; Nebulizers an | 2022 |
Sustained delivery of salbutamol from cubosomal gel for management of paediatric asthma:
Topics: Administration, Cutaneous; Albuterol; Animals; Asthma; Drug Delivery Systems; Drug Liberation; Gels; | 2022 |
Severe lactic acidosis and persistent diastolic hypotension following standard dose of intermittent nebulized salbutamol in a child: a case report.
Topics: Acidosis, Lactic; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Famil | 2022 |
Dexmedetomidine with continuous salbutamol inhalation in the treatment of paediatric near-fatal asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Dexmedetomidine; Humans | 2022 |
Quality of acute asthma care: an audit of clinical practice in a Victorian health service.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Emergency Service, Hospita | 2023 |
School-based Stock Inhaler Programs and Neighborhood Disadvantage.
Topics: Albuterol; Asthma; Humans; Nebulizers and Vaporizers; Neighborhood Characteristics; Residence Charac | 2022 |
Mind the gap: Mapping variation between national and local clinical practice guidelines for acute paediatric asthma from the United Kingdom and the Netherlands.
Topics: Adolescent; Albuterol; Asthma; Child; Humans; Netherlands; Quality of Health Care; United Kingdom | 2022 |
Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease exacerbation: attitudes of patients and healthcare providers in the COVID-19 era.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Attitude of Health Personnel; Bronchodilator A | 2023 |
Potentiality of impulse oscillometry to evaluate bronchodilator reversibility in untreated adult patients with newly diagnosed asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Middle Aged; Oscillometry; Re | 2022 |
Pharmacology Focus: Is it Time to Ditch the Albuterol Inhaler? S.M.A.R.T. Treatment for Asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Nebulizers and Vaporiz | 2022 |
The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice.
Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Fluticasone; Fluticasone-Salmeterol | 2023 |
Is Seizure an Adverse Effect of Salbutamol in the Pediatric Population?
Topics: Albuterol; Asthma; Child; Epilepsy; Humans; Retrospective Studies; Seizures | 2022 |
Safe and Effective Use of Score-Based Continuous Albuterol Therapy in a Pathway for Treatment of Pediatric Asthma Exacerbation.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Female; Humans; Length of Stay; Male; Status Asthma | 2022 |
In moderate-to-severe asthma, as-needed albuterol-budesonide reduced severe exacerbations vs. albuterol alone.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Drug Combinations; | 2022 |
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
Topics: Albuterol; Asthma; Budesonide; Humans; Nebulizers and Vaporizers | 2022 |
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. Reply.
Topics: Albuterol; Asthma; Budesonide; Humans; Nebulizers and Vaporizers | 2022 |
Albuterol: Still first-line in rescue therapy?
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Biological Products; Bronchi | 2022 |
Effects of Different Intervention Factors on Vascular Endothelial Growth Factor-Induced Human Airway Smooth Muscle Cell Migration.
Topics: Airway Remodeling; Albuterol; Asthma; Budesonide; Humans; Ipratropium; Myocytes, Smooth Muscle; p38 | 2022 |
[Pharmacoeconomics analysis of using a fixed combination of budesonide/formoterol in patients with asthma in the health care system of the Russian Federation].
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Budesonide, Formot | 2022 |
Evaluating the Clinical Impact of a Novel Pediatric Emergency Medicine Curriculum on Asthma Outcomes in Belize.
Topics: Albuterol; Asthma; Belize; Child; Curriculum; Emergencies; Emergency Service, Hospital; Humans; Pedi | 2022 |
As-needed steroid/albuterol is superior to albuterol alone in preventing asthma exacerbation.
Topics: Albuterol; Asthma; Humans; Steroids | 2022 |
As-needed steroid/albuterol is superior to albuterol alone in preventing asthma exacerbation.
Topics: Albuterol; Asthma; Humans; Steroids | 2022 |
As-needed steroid/albuterol is superior to albuterol alone in preventing asthma exacerbation.
Topics: Albuterol; Asthma; Humans; Steroids | 2022 |
As-needed steroid/albuterol is superior to albuterol alone in preventing asthma exacerbation.
Topics: Albuterol; Asthma; Humans; Steroids | 2022 |
Bronchodilator Responsiveness Does Not Help Determine Anti-IL-5 Targeted Biologic Success in Patients With Severe Asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans | 2022 |
Bronchodilator Responsiveness Does Not Help Determine Anti-IL-5 Targeted Biologic Success in Patients With Severe Asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans | 2022 |
Bronchodilator Responsiveness Does Not Help Determine Anti-IL-5 Targeted Biologic Success in Patients With Severe Asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans | 2022 |
Bronchodilator Responsiveness Does Not Help Determine Anti-IL-5 Targeted Biologic Success in Patients With Severe Asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans | 2022 |
Medication use in uncontrolled pediatric asthma: Results from the SysPharmPediA study.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Child; H | 2023 |
Medication use in uncontrolled pediatric asthma: Results from the SysPharmPediA study.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Child; H | 2023 |
Medication use in uncontrolled pediatric asthma: Results from the SysPharmPediA study.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Child; H | 2023 |
Medication use in uncontrolled pediatric asthma: Results from the SysPharmPediA study.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Child; H | 2023 |
Use of Drugs Considering Route of Administration on Drug Prescription Pattern for Bronchial Asthma in a Tertiary Level Hospital.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Cross-Sectional Studies; Drug | 2023 |
Assessment and management of asthma exacerbations in an emergency department unit.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hosp | 2023 |
Efficacy of Nebulised Salbutamol with Ipratropium Bromide in Magnesium Sulphate Base in Acute Flare-up of Wheeze among Children Aged 1-12 y.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Humans; Ipratropium; Magnesium | 2023 |
Safety and Effectiveness of As-Needed Formoterol in Asthma Patients Taking Inhaled Corticosteroid (ICS)-Formoterol or ICS-Salmeterol Maintenance Therapy.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Budes | 2023 |
THE INFLUENCE OF SPELEOTHERAPY ON BRONCHI PASSAGE IN CHILDREN WITH BRONCHIAL ASTHMA USING A PHARMACO-FUNCTIONAL TEST WITH SALBUTAMOL.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchi; Child; Humans; Speleotherapy | 2023 |
Regular formoterol plus inhaled corticosteroid vs. salmeterol plus inhaled corticosteroid for asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Drug | 2023 |
[Availability and affordability of diagnosis and treatment for asthma and COPD in Ouagadougou, Burkina Faso].
Topics: Albuterol; Asthma; Burkina Faso; Costs and Cost Analysis; Cross-Sectional Studies; Health Services A | 2023 |
New Combination Asthma Drug.
Topics: Albuterol; Asthma; Budesonide; Drug Combinations; Humans | 2023 |
Calcium-Sensing Receptor Negative Allosteric Modulators Oppose Contraction of Mouse Airways.
Topics: Albuterol; Animals; Asthma; Bronchodilator Agents; Guinea Pigs; HEK293 Cells; Humans; Methacholine C | 2023 |
Comparison of associations of household-level and neighbourhood-level poverty markers with paediatric asthma care utilisation by race/ethnicity in an open cohort of community health centre patients.
Topics: Albuterol; Asthma; Child; Ethnicity; Humans; Income; Poverty | 2023 |
Bronchodilator response does not associate with asthma control or symptom burden among patients with poorly controlled asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Humans; Male; Obesity; P | 2023 |
Clinical standards for the diagnosis and management of asthma in low- and middle-income countries.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Developing Countries; Humans; Pr | 2023 |
Utilization and Spending With Preventive Drug Lists for Asthma Medications in High-Deductible Health Plans.
Topics: Adult; Albuterol; Asthma; Case-Control Studies; Deductibles and Coinsurance; Female; Humans; Male | 2023 |
Gamma irradiation effect on some asthma drugs: EPR detection of radiosterilization.
Topics: Albuterol; Asthma; Electron Spin Resonance Spectroscopy; Gamma Rays; Government Agencies; Humans | 2023 |
Amitriptyline inhibits bronchoconstriction and directly promotes dilatation of the airways.
Topics: 1-Methyl-3-isobutylxanthine; Acetylcholine; Albuterol; Amitriptyline; Animals; Asthma; Bronchoconstr | 2023 |
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Double-Blind Metho | 2023 |
Clinical significance of the bronchodilator response in children with severe asthma.
Topics: Adolescent; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Child; Cohort Studies; Cross-Sec | 2019 |
Evaluation of Disposable and Traditional Accessory Devices for Use With a Pressurized Metered-Dose Inhaler.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Delivery System | 2020 |
Bronchodilation Test with Inhaled Salbutamol Versus Bronchial Methacholine Challenge to Make an Asthma Diagnosis: Do They Provide the Same Information?
Topics: Albuterol; Asthma; Bronchial Provocation Tests; Forced Expiratory Volume; Humans; Methacholine Chlor | 2020 |
Case report: Paradoxical responses to short acting beta-agonists in a pediatric patient.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Humans | 2021 |
Anti-inflammatory reliever therapy for asthma.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bron | 2020 |
Bronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Forced Expiratory Volume; Humans; Quali | 2020 |
Prehospital management of pediatric asthma patients in a large emergency medical services system.
Topics: Adolescent; Albuterol; Anaphylaxis; Asthma; Child; Emergency Medical Services; Female; Humans; Infus | 2020 |
]Risk of dental caries in pediatric asthmatic patients undergoing treatment with salbutamol and budesonide inhalation therapy, Peru.]
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Case-Control Studi | 2019 |
Incidence of supraventricular tachycardia after inhaled short-acting beta agonist treatment in children.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Body Mass Index; Child; Child, Preschool; Fe | 2021 |
Telehealth delivery of adherence and medication management system improves outcomes in inner-city children with asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Humans; Male; Medication Adhere | 2020 |
Functional characterization of 3D contractile smooth muscle tissues generated using a unique microfluidic 3D bioprinting technology.
Topics: Albuterol; Asthma; Bioprinting; Cells, Cultured; Humans; Microfluidics; Muscle Contraction; Muscle, | 2020 |
An Efficient, Lung-Targeted, Drug-Delivery System To Treat Asthma Via Microparticles.
Topics: A549 Cells; Albuterol; Animals; Asthma; Drug Delivery Systems; Drug Stability; Humans; Injections, I | 2019 |
Lessons of the month 1: Salbutamol induced lactic acidosis: clinically recognised but often forgotten.
Topics: Acidosis, Lactic; Administration, Inhalation; Aged, 80 and over; Albuterol; Asthma; Female; Humans | 2020 |
Metered-dose inhalers vs nebulization for the delivery of albuterol in pediatric asthma exacerbations: A cost-effectiveness analysis in a middle-income country.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Colombia; Cost-Benefit | 2020 |
Asthmatic children and MDI verbal inhalation technique counseling.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Beclomethasone; Child; Counseling; Female | 2020 |
Air Trapping Correlates With Increased Frequency of Albuterol Use and Severity of Wheeze in Persistent Asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Humans; Male; Metered Do | 2020 |
Prevalence of asthma at a school-based health clinic in Nicaragua.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Hospitalizati | 2020 |
Finger-Prick Blood Sampling for Therapeutic Drug Monitoring: Be Aware of Skin Contamination by Nebulized Drugs.
Topics: Albuterol; Asthma; Blood Specimen Collection; Bronchodilator Agents; Child; Drug Monitoring; Humans; | 2020 |
Investigation of the Interaction Mechanism between Salbutamol and Human Serum Albumin by Multispectroscopic and Molecular Docking.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Humans; Molecular Docking Simulation; Recept | 2020 |
Clinical Progress Note: Care of Children Hospitalized for Acute Asthma Exacerbation.
Topics: Acute Disease; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child; Child, Hos | 2020 |
Novel measure of lung function for assessing disease activity in asthma.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Female; Forced Expirato | 2020 |
Comparative pharmacokinetics of salbutamol inhaled from a pressurized metered dose inhaler either alone or connected to a newly enhanced spacer design.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Biological Availability; Bronchodila | 2020 |
Benzalkonium Chloride in Albuterol Solutions: Time for a Change?
Topics: Albuterol; Asthma; Benzalkonium Compounds; Bronchodilator Agents; Child; Humans; Longitudinal Studie | 2020 |
Continuous Albuterol With Benzalkonium in Children Hospitalized With Severe Asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Benzalkonium Compounds; Bronchodilator Ag | 2020 |
Preventing Asthma Emergencies in Schools.
Topics: Advisory Committees; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Drug Storage; Emergencies; Gov | 2020 |
Acute salbutamol bronchoprotection against methacholine: Asthma compared with chronic obstructive pulmonary disease.
Topics: Albuterol; Asthma; Bronchoconstrictor Agents; Disease Management; Female; Humans; Male; Methacholine | 2020 |
Prevalence and risk factors for wheeze, decreased forced expiratory volume in 1 s and bronchoconstriction in young children living in Havana, Cuba: a population-based cohort study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchoconstriction; Broncho | 2020 |
What constitutes a "clinically significant" bronchodilator response in children?
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans | 2020 |
Effect of long-acting β-agonist on bronchodilator response in children with asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Chil | 2020 |
Clinical course of asthma in 4 cases of coronavirus disease 2019 infection.
Topics: Acetates; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Betacoronavirus; Black or African America | 2020 |
COVID-19: Time to embrace MDI+ valved-holding chambers!
Topics: Administration, Inhalation; Albuterol; Asthma; Betacoronavirus; Bronchodilator Agents; Coronavirus I | 2020 |
Thunderstorm asthma medication management during an external emergency (Code Brown): An observational study of the impact of electronic prescribing and clinical documentation.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Documentation; Electronic | 2020 |
Global Initiative for Asthma 2019 Guidelines: New Changes to the Treatment of Mild Asthmatics 12 Years and Older.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists | 2020 |
Relationship between age and bronchodilator response at diagnosis in adult-onset asthma.
Topics: Administration, Inhalation; Adult; Age of Onset; Aged; Albuterol; Asthma; Bronchial Provocation Test | 2020 |
Study finds poorer asthma outcomes with preservative-containing nebulization solution.
Topics: Administration, Inhalation; Albuterol; Asthma; Benzalkonium Compounds; Humans; Nebulizers and Vapori | 2020 |
Levodopa inhalation powder in a patient with persistent asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Dopamine Agents; Dry Powder In | 2020 |
A comparative analysis of the bronchodilatador response measured by impulse oscillometry and spirometry in asthmatic children living at high altitude.
Topics: Adolescent; Albuterol; Altitude; Asthma; Bronchodilator Agents; Child; Female; Humans; Male; Oscillo | 2021 |
Adult Patients with Respiratory Distress: Current Evidence-based Recommendations for Prehospital Care.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; California; Dyspnea; Emergency Medical Services; Ho | 2020 |
Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Inflammation; Oscillometry; Spirometry | 2021 |
Parental attitude and knowledge towards asthma care measures for their children in Saudi Arabia.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Child; Child, Preschool; Female; Health Education | 2020 |
Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils.
Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Case-Control Studies; Cell Count; Chemokine CC | 2021 |
Association of obesity with severity outcomes in hospitalized pediatric asthma exacerbations.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Hospitalization; Humans; Intensive Care Unit | 2022 |
Comparison of Two Assessment Tools for Hospitalized Subjects With Asthma.
Topics: Albuterol; Asthma; Child; Hospitalization; Humans; Prospective Studies; Status Asthmaticus | 2021 |
Prevalence and risk factors of lactic acidosis in children with acute moderate and severe asthma, a prospective observational study.
Topics: Acidosis, Lactic; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Humans; Prevalence; Risk F | 2021 |
CAN BURST VENTOLIN THERAPY BE SAFELY GIVEN AT HOME TO REDUCE EMERGENCY AND HOSPITAL PRESENTATIONS WITH ASTHMA IN CHILDREN?
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hospital; Hospitals; Humans | 2020 |
Clinical Outcomes in People with Difficult-to-Control Asthma Using Electronic Monitoring to Support Medication Adherence.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Asthma; Drug Combina | 2021 |
Health provider perspectives of electronic medication monitoring in outpatient asthma care: a qualitative investigation using the consolidated framework for implementation research.
Topics: Albuterol; Asthma; Child; Electronics; Humans; Outpatients; Primary Health Care; Qualitative Researc | 2022 |
Managing Asthma in Adolescents and Adults: 2020 Asthma Guideline Update From the National Asthma Education and Prevention Program.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adrenergic be | 2020 |
Variability in care for children with severe acute asthma in Latin America.
Topics: Adolescent; Albuterol; Aminophylline; Anti-Bacterial Agents; Asthma; Bronchodilator Agents; Cannula; | 2021 |
Large-volume, preservative-free albuterol concentrate.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Humans; Preservatives, Pharmaceutic | 2020 |
Implementation of a Critical Asthma Protocol in a Pediatric ICU.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Intensive Car | 2021 |
Managing respiratory emergencies at school: A county-wide stock inhaler program.
Topics: Administration, Inhalation; Adolescent; Albuterol; Arizona; Asthma; Child; Emergencies; Female; Huma | 2021 |
It is high time for the scholarly societies to standardize the bronchodilator responsiveness in children.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Methacholine Chloride; Nitric Oxide; Spirom | 2021 |
[Induced asthma and sport].
Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Doping in Sports; Humans; Sports | 2020 |
Evaluating the impact of coronavirus disease 2019 on asthma morbidity: A comprehensive analysis of potential influencing factors.
Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; California; Child; Child, Preschool; COVID-1 | 2021 |
High-Flow Nasal Cannula in Pediatric Critical Asthma.
Topics: Adolescent; Albuterol; Asthma; Cannula; Child; Child, Preschool; Humans; Nebulizers and Vaporizers; | 2021 |
Heterogeneity of emergency treatment practices in wheezing preschool children.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Cross-Sectional Studies; Emergency Treat | 2021 |
Budesonide/formoterol as maintenance and reliever therapy compared to fixed-budesonide/formoterol plus albuterol reliever for pediatric asthma: A cost-utility analysis in Colombia.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Child; Colombia; C | 2021 |
Implementing the Asthma Scripts to School Programs to Facilitate Student Access to Albuterol.
Topics: Albuterol; Asthma; Child; Humans; Pharmaceutical Services; Schools; Students | 2021 |
Role of social deprivation on asthma care quality among a cohort of children in US community health centres.
Topics: Albuterol; Asthma; Child; Cohort Studies; Community Health Centers; Humans; Residence Characteristic | 2021 |
Is Delivery of Aerosolized Medication via HFNC for Critical Asthma Effective Concurrent Therapy?
Topics: Albuterol; Asthma; Humans; Nebulizers and Vaporizers | 2021 |
[Guideline on diagnosis and treatment: bronchial asthma in children ≥ 6 years old. Update 2021].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child | 2021 |
Pharmacology Update: Emergency and Controller Medications for Treatment of Asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Nebulizers and | 2022 |
Asthma in Singapore: Past, Present and Future.
Topics: Adrenal Cortex Hormones; Albuterol; Arsenic Poisoning; Asthma; Bronchodilator Agents; Developed Coun | 2017 |
Modeling Seasonal and Spatiotemporal Variation: The Example of Respiratory Prescribing.
Topics: Age Distribution; Air Pollution; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Drug Uti | 2017 |
Regional Ventilation Changes in the Lung: Treatment Response Mapping by Using Hyperpolarized Gas MR Imaging as a Quantitative Biomarker.
Topics: Adult; Aged; Albuterol; Algorithms; Asthma; Biomarkers; Bronchodilator Agents; Female; Helium; Human | 2017 |
Small airway function before and after cold dry air challenge in pediatric asthma patients during remission.
Topics: Adolescent; Air; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Child; Cold Temperature; Ex | 2017 |
Enhanced expression of Organic Cation Transporters in bronchial epithelial cell layers following insults associated with asthma - Impact on salbutamol transport.
Topics: Albuterol; Allergens; Asthma; Biological Transport; Bronchi; Bronchodilator Agents; Cell Culture Tec | 2017 |
Free-breathing Functional Pulmonary MRI: Response to Bronchodilator and Bronchoprovocation in Severe Asthma.
Topics: Adult; Albuterol; Asthma; Bronchoconstrictor Agents; Bronchodilator Agents; Female; Humans; Image Pr | 2017 |
Value-Based Insurance Design Pharmacy Benefits for Children and Youth With Special Health Care Needs: Principles and Opportunities.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Disabled Children; Drug Costs; Humans; Insurance Co | 2017 |
Self-reported racial/ethnic discrimination and bronchodilator response in African American youth with asthma.
Topics: Adolescent; Albuterol; Asthma; Black or African American; Bronchodilator Agents; Case-Control Studie | 2017 |
The Weekday Wheezer.
Topics: Albuterol; Animals; Asthma; Bronchodilator Agents; Child; Diagnosis, Differential; Fluticasone; Guin | 2017 |
Study of pH Stability of R-Salbutamol Sulfate Aerosol Solution and Its Antiasthmatic Effects in Guinea Pigs.
Topics: Aerosols; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chemistry, Pharm | 2017 |
Mycoplasma pneumoniae-Associated Bronchiolitis Obliterans Following Acute Bronchiolitis.
Topics: Albuterol; Asthma; Bronchiolitis; Bronchiolitis Obliterans; Child; Child, Preschool; Female; Humans; | 2017 |
Small airway oscillometry indices: Repeatability and bronchodilator responsiveness in young children.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans; Lung; Male; Oscil | 2017 |
Racial/Ethnic Variation in Emergency Department Care for Children With Asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cross-Sectional Studi | 2019 |
Stevens-Johnson syndrome secondary to isolated albuterol use.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Diagnosis, Differential; Human | 2017 |
Efficacy and usability of a novel nebulizer targeting both upper and lower airways.
Topics: Administration, Inhalation; Adolescent; Albuterol; Ambulatory Care Facilities; Asthma; Bronchodilato | 2017 |
Agreement Between Maternal Report and Medical Records During Pregnancy: Medications for Rheumatoid Arthritis and Asthma.
Topics: Adult; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Asthma; Et | 2018 |
Many patients labelled as having mild asthma do not have well-controlled asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans | 2018 |
Breathing pattern recordings using respiratory inductive plethysmography, before and after a physiotherapy breathing retraining program for asthma: A case report.
Topics: Albuterol; Anxiety; Asthma; Breathing Exercises; Bronchodilator Agents; Depression; Female; Forced E | 2018 |
Long-term prognosis of chronic cough: a prospective, observational cohort study.
Topics: Aged; Albuterol; Asthma; Bronchial Provocation Tests; Chronic Disease; Comorbidity; Cough; Female; F | 2017 |
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent | 2018 |
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent | 2018 |
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent | 2018 |
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent | 2018 |
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent | 2018 |
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent | 2018 |
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent | 2018 |
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent | 2018 |
Further Studies of Unsuspected Emphysema in Nonsmoking Patients With Asthma With Persistent Expiratory Airflow Obstruction.
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Albuterol; Asthma; Autopsy; Bronchodilator Agent | 2018 |
Quantitation of salbutamol using micro-volume blood sampling - applications to exacerbations of pediatric asthma.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Blood Specimen Collection; Child; Dose | 2018 |
Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm | 2017 |
Translating Research into Health Policy: Stock Albuterol Legislation.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Health Policy; Humans; Nebulizers and V | 2018 |
Repeated doses of salbutamol and aeroallergen sensitisation both increased salbutamol-induced hypoxia in children and adolescents with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi | 2018 |
Food and Drug Administration-mandated Trials of Long-Acting β-Agonist Safety in Asthma. Bang for the Buck?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Drug | 2018 |
Everyone with asthma should have a metered dose inhaler and a spacer.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Metered Dose Inhalers; | 2018 |
Whole-Genome Sequencing of Pharmacogenetic Drug Response in Racially Diverse Children with Asthma.
Topics: Adolescent; Albuterol; Asthma; Black or African American; Bronchodilator Agents; Child; Female; Geno | 2018 |
The acute effects of bronchial thermoplasty on FEV
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Albu | 2018 |
Children with severe acute asthma admitted to Dutch PICUs: A changing landscape.
Topics: Acute Disease; Administration, Intravenous; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Ca | 2018 |
Access to asthma medicines at the household level in eight counties of Kenya.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Family Characteristics; Female; Health | 2018 |
Sample Size Determination for a 3-Treatment 3-Period Crossover Trial in Frequency Data.
Topics: Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Cross-Over Studies; Humans; Mont | 2018 |
Should reversibility be assessed in all asthmatic children with normal spirometry?
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Databases, | 2018 |
Exertional dyspnea and operating lung volumes in asthma.
Topics: Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Anti-Asthmatic Agents; Asthma; Dyspne | 2018 |
Beware of beta! A case of salbutamol-induced lactic acidosis in severe asthma.
Topics: Acidosis, Lactic; Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Al | 2018 |
1064 nm Dispersive Raman Microspectroscopy and Optical Trapping of Pharmaceutical Aerosols.
Topics: Aerosols; Albuterol; Anti-Allergic Agents; Asthma; Bronchodilator Agents; Equipment Design; Fluoresc | 2018 |
Prevalence of paradoxical bronchoconstriction after inhaled albuterol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchoconstrict | 2018 |
Increased β2-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors.
Topics: Albuterol; Asthma; Bronchodilator Agents; Cells, Cultured; Cyclic AMP; Disease Progression; Fibrobla | 2018 |
Asthma Severity Pathway in the PICU.
Topics: Albuterol; Asthma; Humans; Intensive Care Units, Pediatric; Length of Stay; Retrospective Studies; S | 2018 |
Clinical differences between children with asthma and rhinitis in rural and urban areas.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Colombia; Emergency Service, Hospital; | 2018 |
The Usefulness of the Forced Oscillation Technique in the Diagnosis of Bronchial Asthma in Children.
Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Child, Pre | 2018 |
Quantifying beta-agonist utilization: Occasions or puffs?
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Administr | 2019 |
Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Delayed-Action Preparations; Drug Compoundi | 2019 |
Paradoxical Bronchoconstriction with Short-Acting Beta Agonist.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Airway Remodeling; Albuterol; Asthma; Bronchoconstrictio | 2018 |
Free to breathe hard in the Tour de France.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bicycling; Bronchodilator Agents; Confoundin | 2018 |
Measuring the effects of bronchial thermoplasty using oscillometry.
Topics: Adrenal Cortex Hormones; Aged; Airway Resistance; Albuterol; Asthma; Bronchial Thermoplasty; Broncho | 2019 |
Asthma admission rates and patterns of salbutamol and inhaled corticosteroid prescribing in England from 2013 to 2017.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Prescriptions; Drug Thera | 2019 |
Errors in Aerosol Inhaler Use and Their Effects on Maternal and Fetal Outcomes among Pregnant Asthmatic Women (Subanalysis from QAKCOP Study).
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Budesonide, | 2018 |
Anti-asthmatic activity of alkaloid compounds from Pericarpium Citri Reticulatae (Citrus reticulata 'Chachi').
Topics: Albuterol; Alkaloids; Animals; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Citrus; Female; | 2019 |
The effect of single pretreatment with salbutamol on recovery of bronchoalveolar lavage fluid in horses with suspected or confirmed severe equine asthma.
Topics: Albuterol; Animals; Asthma; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Bronchodilator Age | 2019 |
A Statewide Study of the Epidemiology of Emergency Medical Services' Management of Pediatric Asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Emergency Medical Services; Humans; Ipratrop | 2021 |
How to diagnose and treat acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Emergenc | 2019 |
Jailhouse self-induced lesions by misuse of salbutamol inhaler.
Topics: Aerosols; Albuterol; Asthma; Black or African American; Cold Temperature; Humans; Hypopigmentation; | 2019 |
Clinical impact of omalizumab treatment in children with severe asthma: Report of a local experience.
Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Female; Humans | 2019 |
Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists | 2019 |
A Respiratory Therapist-Driven Asthma Pathway Reduced Hospital Length of Stay in the Pediatric Intensive Care Unit.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Clinical Protocols; C | 2019 |
Neutrophilic inflammation in asthma and defective epithelial translational control.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Hyperreactiv | 2019 |
Regional airflow obstruction after bronchoconstriction and subsequent bronchodilation in subjects without pulmonary disease.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstricti | 2019 |
Impact of SULT1A3/SULT1A4 genetic polymorphisms on the sulfation of phenylephrine and salbutamol by human SULT1A3 allozymes.
Topics: Albuterol; Arylsulfotransferase; Asthma; Genotype; Humans; Hypotension; Isoenzymes; Kinetics; Mutage | 2019 |
Let Them Breathe: A Plea to Pediatricians to Advocate for Stock Inhaler Policies at School.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergencies; Health Policy; Humans; Nebulizers and | 2019 |
Bronchodilator reversibility in asthma and COPD: findings from three large population studies.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi | 2019 |
I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance Measurements.
Topics: Aged; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Equipment Design; Female; Forced | 2019 |
Acute effects of salbutamol on systemic vascular function in people with asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Blood Pre | 2019 |
Ultra-LAMA, ultra-LABA, ultra-inhaled steroids? The future has landed.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Ethanolamines; F | 2013 |
[Clinical significance of bronchial reversibility test in the treatment of childhood asthma].
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Asthma; Bronchi; Child; Drug Comb | 2013 |
Volatile anesthetic rescue therapy in children with acute asthma: innovative but costly or just costly?.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Anesthesia, Inhalation; Anesthetics, Inh | 2013 |
Evaluating a clinical practice intervention to promote delivery of salbutamol by metered-dose inhalers with holding chambers in a pediatric emergency department.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Equipment Design; Follo | 2013 |
[Cushing's syndrome during HIV treatment: pharmacological interaction during use of ritonavir].
Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cushing Syndrome; Cytochrome P-450 | 2013 |
Influence of β(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Argentina; Asthma; Child; Disease Progre | 2013 |
Effect of liposomes on the absorption of water-soluble active pharmaceutical ingredients via oral administration.
Topics: Absorption; Administration, Oral; Albuterol; Animals; Asthma; Biological Availability; Bronchodilato | 2013 |
Corticosteroid therapy in critically ill pediatric asthmatic patients.
Topics: Administration, Intravenous; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Canada; | 2013 |
Teaching corner: Adult asthma in Malawi.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Clinical Compe | 2011 |
An evaluation of asthma medication utilization for risk evaluation and mitigation strategies (REMS) in the United States: 2005-2011.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Andro | 2013 |
Use of magnesium in moderating tachycardia in acute severe asthma in pregnancy.
Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Female; Humans; Magnes | 2013 |
Role of interactions in pharmacogenetic studies: leukotrienes in asthma.
Topics: Albuterol; Alleles; Asthma; Biomarkers, Pharmacological; Bronchodilator Agents; Gene-Environment Int | 2013 |
Correlation between nitrites in induced sputum and asthma symptoms in asthmatic schoolchildren.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Disease Progression; Emergency Service, | 2014 |
Asthma, steroids, and surveys…science or merely my opinion?
Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Critical Illness; Humans; Methylprednisolone; Practice P | 2013 |
Long acting β2 agonists in adult asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Drug Monitor | 2013 |
Rapid and severe adverse reaction to adenosine during a pharmacological stress test for a myocardial perfusion scan.
Topics: Adenosine; Albuterol; Asthma; Electrocardiography; Exercise Test; Humans; Male; Middle Aged; Myocard | 2013 |
[Inadequate use of inhalers among asma patients who use Salbutamol].
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Medication Errors; Nebulizers and Vaporizers | 2013 |
A genome-wide association study of bronchodilator response in Latinos implicates rare variants.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Forced Expiratory Volume; Genome | 2014 |
Management of acute asthma in the emergency department.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Emergency Service, Hospital; Humans; Ipratr | 2013 |
Asthma patients' inability to use a pressurised metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the global initiative for asthma (GINA) strategy: a retrospective analysis.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; A | 2013 |
The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Budesonide; Cross-Sectional Studies; Data | 2013 |
Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A | 2013 |
Prostaglandin E2 elicits greater bronchodilation than salbutamol in mouse intrapulmonary airways in lung slices.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Bronchodilator Agents; Calcium; Din | 2014 |
Association between respiratory prescribing, air pollution and deprivation, in primary health care.
Topics: Adult; Air Pollution; Albuterol; Asthma; Bronchodilator Agents; Drug Prescriptions; Female; Humans; | 2013 |
LABA monotherapy in asthma: an avoidable problem.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A | 2013 |
A young girl with apparent treatment-resistant asthma treated at Bambino Gesù children's hospital.
Topics: Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child; Diagnosis, Differential; Drug Resistanc | 2014 |
[Lactic acidosis after inhaled beta-2 agonists: about 2 cases].
Topics: Acidosis, Lactic; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma | 2014 |
The interpretation of exhaled nitric oxide values in children with asthma depends on the degree of bronchoconstriction and the levels of asthma severity.
Topics: Adolescent; Albuterol; Asthma; Biomarkers; Breath Tests; Bronchoconstriction; Bronchodilator Agents; | 2014 |
Serum lactate increase during acute asthma treatment: a new piece of the puzzle.
Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lactic Acid; Male | 2014 |
Salmeterol and lactic acidosis: clinical and educational aspects.
Topics: Acidosis, Lactic; Albuterol; Androstadienes; Asthma; Drug Overdose; Female; Humans; Intention; Lacti | 2014 |
Notes on testing equality and interval estimation in Poisson frequency data under a three-treatment three-period crossover trial.
Topics: Albuterol; Asthma; Cross-Over Studies; Double-Blind Method; Female; Humans; Least-Squares Analysis; | 2016 |
A comparison of long-term anti-inflammatory effect of two ICS/LABA combination inhalers; fix-dosed maintenance therapy with budesonide/formoterol and salmeterol/fluticasone.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Androstadienes | 2014 |
Transient occult cardiotoxicity in children receiving continuous beta-agonist therapy.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; | 2014 |
Bronchial obstruction and reversibility in children: inspiratory or expiratory resistance?
Topics: Airway Obstruction; Albuterol; Asthma; Bronchial Diseases; Bronchodilator Agents; Case-Control Studi | 2014 |
Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic Ag | 2014 |
Impact of adherence to treatment with fluticasone propionate/salmeterol in asthma patients.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Albuterol; Andr | 2014 |
Mechanical factors affecting nebulized albuterol aerosol particle sizes for asthma drug delivery.
Topics: Administration, Inhalation; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Nebulizers a | 2014 |
SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels?
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Arylsulfotransferase; Asthma; | 2015 |
Adrenal suppression with mometasone furoate/formoterol.
Topics: Albuterol; Androstadienes; Asthma; Ethanolamines; Female; Humans; Hypothalamo-Hypophyseal System; Ma | 2014 |
Thyrotoxic periodic paralysis triggered by β2-adrenergic bronchodilators.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodi | 2014 |
An unusual mechanism of foreign body aspiration: a vignette from the emergency department.
Topics: Albuterol; Asthma; Bronchodilator Agents; Bronchoscopy; Emergency Service, Hospital; Foreign Bodies; | 2014 |
Too much testing?
Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lactic Acid; Male | 2014 |
Response.
Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lactic Acid; Male | 2014 |
Nocturnal asthma and the importance of race/ethnicity and genetic ancestry.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Black or African American; Body Mass Index; Br | 2014 |
Addressing ethnic disparity in asthma trials.
Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Ethanolamines; Female; Formoterol Fumarate; Hu | 2014 |
Understanding nocturnal asthma. The plot thickens.
Topics: Albuterol; Asthma; Black or African American; Female; Forced Expiratory Volume; Humans; Male; Pharma | 2014 |
Clinical application of inert gas Multiple Breath Washout in children and adolescents with asthma.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Breath Tests; Bronchodilator Age | 2014 |
An innovative childhood asthma score predicts the need for bronchodilator nebulization in children with acute asthma independent of auscultative findings.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Auscultation; Bronchodilat | 2014 |
The orl rat is more responsive to methacholine challenge than wild type.
Topics: Administration, Inhalation; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchoconstrictor Ag | 2014 |
Which intravenous bronchodilators are being administered to children presenting with acute severe wheeze in the UK and Ireland?
Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Child; Child, Pr | 2015 |
Airway obstruction, upper airway artifact and response to bronchodilator in asthmatic and healthy children.
Topics: Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Huma | 2015 |
Peripheral airways dysfunction in obesity reflects increased bronchomotor tone.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Obesity; R | 2015 |
Molecular insights into the dynamics of pharmacogenetically important N-terminal variants of the human β2-adrenergic receptor.
Topics: Albuterol; Asthma; Binding Sites; Humans; Molecular Dynamics Simulation; Pharmacogenetics; Polymorph | 2014 |
[Reaction of population of pulmonary mast cells in rat bronchial asthma under the effect of β-adrenoreceptor antagonists].
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Alcian Blue; Animals; Anti-Asthmat | 2013 |
Clinical outcomes after bilevel positive airway pressure treatment for acute asthma exacerbations.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Continuous Positive A | 2015 |
Identification of high affinity bioactive Salbutamol conformer directed against mutated (Thr164Ile) beta 2 adrenergic receptor.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Amino Acid Substi | 2015 |
Salbutamol or aminophylline for acute severe asthma: how to choose which one, when and why?
Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Child; Humans | 2015 |
How to improve prescription of inhaled salbutamol by providing standardised feedback on administration: a controlled intervention pilot study with follow-up.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Chil | 2015 |
Safety of β2-Agonists in Asthma: Linking Mechanisms, Meta-Analyses and Regulatory Practice.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Forced Expiratory Vol | 2015 |
Reversibility after inhaling salbutamol in different body postures in asthmatic children: a pilot study.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Monito | 2015 |
Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol.
Topics: Age Factors; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Child; Child, Preschool; Dose | 2015 |
Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; Black People; Br | 2015 |
Treasure in the chest.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Diagnosis, Differential; Female; Foreign Bodie | 2015 |
Not Breathing Easier With the US FDA's Ban on Chlorofluorocarbons in Inhalers.
Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Female; Humans; Male; Nebulizers and | 2015 |
On Chlorofluorocarbon Bans and Inhaled Albuterol Prices.
Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Female; Humans; Male; Nebulizers and | 2015 |
The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Chlorofluorocarbons; Fe | 2015 |
A case of pediatric Steven-Johnson Syndrome associated with albuterol consumption.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Immunoglobulins, Intravenous; Male; Pharmac | 2015 |
Insulin therapy in hyperglycemic children with severe acute asthma.
Topics: Acute Disease; Administration, Intravenous; Adolescent; Albuterol; Asthma; Blood Glucose; Bronchodil | 2015 |
Hypokalaemia in children with asthma treated with nebulised salbutamol.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans; Hypokalemia; Infa | 2015 |
Analysis of ADRB2 (Arg16Gly) Gene Variant with Susceptibility, Pharmacogenetic Response and Disease Severity in South Indian Asthmatics.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodi | 2015 |
Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Alb | 2017 |
HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A | 2015 |
Can 'extrafine' dry powder aerosols improve lung deposition?
Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C | 2015 |
Can 'extrafine' dry powder aerosols improve lung deposition?
Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C | 2015 |
Can 'extrafine' dry powder aerosols improve lung deposition?
Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C | 2015 |
Can 'extrafine' dry powder aerosols improve lung deposition?
Topics: Administration, Inhalation; Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; C | 2015 |
A Genome-Wide Association Study of Post-bronchodilator Lung Function in Children with Asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Carrier Proteins; Child; Cystic Fibrosi | 2015 |
[Emergency checklist: Asthmatic attack].
Topics: Adult; Albuterol; Asthma; Checklist; Dyspnea; Emergencies; Female; Humans; Medical History Taking; M | 2015 |
Implementation of a Policy Change: Replacement of Nebulizers by Spacers for the Treatment of Asthma in Children.
Topics: Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2015 |
Spirometry in children with asthma and/or allergic rhinitis: comparison of FEF25-75% with the standard measures.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Female; Forced Ex | 2019 |
Impulse oscillometry in acute and stable asthmatic children: a comparison with spirometry.
Topics: Adolescent; Albuterol; Asthma; Child; Female; Forced Expiratory Volume; Humans; Male; Oscillometry; | 2016 |
An explosive side effect of albuterol nebulizers.
Topics: Abdominal Injuries; Aged; Albuterol; Asthma; Bronchodilator Agents; Explosions; Foreign Bodies; Huma | 2015 |
Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea.
Topics: Adult; Aged; Albuterol; Asthma; Disease Progression; Dyspnea; Female; Forced Expiratory Volume; Huma | 2016 |
The True Environmental Cost of Chlorofluorocarbon-Based Inhalers.
Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Female; Humans; Male; Nebulizers and | 2015 |
Second-order Texture Measurements of (3)He Ventilation MRI: Proof-of-concept Evaluation of Asthma Bronchodilator Response.
Topics: Administration, Inhalation; Adult; Albuterol; Area Under Curve; Asthma; Bronchial Provocation Tests; | 2016 |
Long-Acting Beta Agonists Enhance Allergic Airway Disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Anti-Asthmatic Agents; Arrestins; Aspergill | 2015 |
Bidirectional Counterregulation of Human Lung Mast Cell and Airway Smooth Muscle β2 Adrenoceptors.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Benzoxazines; Cell Adhesion Molecule-1; Cell | 2016 |
Bronchodilator response as a marker of poor asthma control.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Animals; A | 2016 |
Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
Topics: Administration, Inhalation; Aged; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Cros | 2016 |
Implementation and Evaluation of a Stock Albuterol Program for Students with Asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Nebulizers and Vaporizers; Prog | 2016 |
Is Gly16Arg β2 Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting?
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Air | 2016 |
[Asthma-COPD overlap syndrome].
Topics: Adult; Aged; Albuterol; Asthma; Comorbidity; Disease Progression; Female; Humans; Male; Prevalence; | 2015 |
[Effects and significance of methacholine bronchial provocation tests and salbutamol bronchial dilation test on measurements of fractional exhaled nitric oxide in patients with asthma].
Topics: Albuterol; Asthma; Breath Tests; Bronchial Provocation Tests; Exhalation; Humans; Methacholine Chlor | 2016 |
Perception of Bronchodilation Assessed by Visual Analog Scale in Asthmatics: A Real-life Study.
Topics: Adult; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents; Cross-Sectional Studies; Female; | 2016 |
Utility of impulse oscillometry in patients with moderate to severe persistent asthma.
Topics: Adrenal Cortex Hormones; Adult; Airway Resistance; Albuterol; Anti-Asthmatic Agents; Asthma; Female; | 2016 |
ADRB2 Polymorphism and Salbutamol Responsiveness in Northern Indian Children with Mild to Moderate Exacerbation of Asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cross-Sectional Studi | 2016 |
It is time to stop prescribing oral salbutamol.
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Humans; | 2016 |
Salbutamol in paediatrics: pharmacology, prescribing and controversies.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Prescriptions; Female; Humans; Infant; | 2016 |
Measurement of intraindividual airway tone heterogeneity and its importance in asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Functional Residual Capacity; Humans; Lung; | 2016 |
Manual external chest compression in severe pediatric asthma.
Topics: Adrenal Cortex Hormones; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child; | 2016 |
Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Agammaglobulinaemia Tyrosine Kinase | 2016 |
Smoke and viruses-a hindrance to relaxing the airways?
Topics: Albuterol; Animals; Asthma; Humans; Pulmonary Disease, Chronic Obstructive; Smoke; Viruses | 2016 |
Diastolic Hypotension, Troponin Elevation, and Electrocardiographic Changes Associated With the Management of Moderate to Severe Asthma in Children.
Topics: Albuterol; Arterial Pressure; Asthma; Bronchodilator Agents; Child; Child, Preschool; Disease Manage | 2016 |
Beta2-Agonist Doping Control and Optical Isomer Challenges.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Asthmatic Agents; A | 2016 |
Conundrum in an asthma exacerbation.
Topics: Acidosis, Lactic; Adrenal Cortex Hormones; Aged; Albuterol; Asthma; Humans; Male; Prednisolone; Trea | 2016 |
Albuterol via metered-dose inhaler in children: Lower doses are effective, and higher doses are safe.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2016 |
Tidal changes in respiratory resistance are sensitive indicators of airway obstruction in children.
Topics: Airway Resistance; Albuterol; Anthropometry; Asthma; Bronchodilator Agents; Child; Child, Preschool; | 2016 |
Asthma control and bronchodilator response.
Topics: Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans | 2016 |
Bronchodilator response not a significant marker of poor asthma control.
Topics: Albuterol; Asthma; Biomarkers; Bronchodilator Agents; Forced Expiratory Volume; Humans | 2016 |
Pressurised metered dose inhaler-spacer technique in young children improves with video instruction.
Topics: Administration, Inhalation; Age Factors; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pre | 2016 |
Wastewater-based epidemiological evaluation of the effect of air pollution on short-acting beta-agonist consumption for acute asthma treatment.
Topics: Adrenergic beta-2 Receptor Agonists; Air Pollutants; Albuterol; Asthma; Bronchodilator Agents; Envir | 2016 |
The efficacy of nebulized magnesium sulfate alone and in combination with salbutamol in acute asthma.
Topics: Acute Disease; Administration, Inhalation; Airway Obstruction; Albuterol; Asthma; Double-Blind Metho | 2016 |
Effect of Traditional Chinese Medicine on Inflammatory Mediators in Pediatric Asthma.
Topics: Acetates; Albuterol; Asthma; Child, Preschool; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Fem | 2016 |
Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Hum | 2017 |
Assessment of Airway Bronchodilation by Spirometry Compared to Airway Obstruction in Young Children with Asthma.
Topics: Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Human | 2016 |
Association of Beta 2 adrenergic receptor (Thr164Ile) polymorphism with Salbutamol refractoriness in severe asthmatics from Indian population.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Case-Control S | 2016 |
A Cost Analysis of Salbutamol Administration by Metered-Dose Inhalers with Spacers versus Nebulization for Patients with Wheeze in the Pediatric Emergency Department: Evidence from Observational Data in Nova Scotia.
Topics: Albuterol; Asthma; Child; Child, Preschool; Cohort Studies; Cost Savings; Cost-Benefit Analysis; Eme | 2017 |
Safety of Long-Acting Beta-Agonists in Children with Asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm | 2016 |
Using Hyperpolarized
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Healthy Volunteers; Humans; Lung; Magnetic | 2016 |
Safety Study of Salmeterol in Asthma in Adults.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm | 2016 |
Safety Study of Salmeterol in Asthma in Adults.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm | 2016 |
Safety Study of Salmeterol in Asthma in Adults.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm | 2016 |
Safety Study of Salmeterol in Asthma in Adults.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm | 2016 |
Clinical outcomes of levalbuterol versus racemic albuterol in pediatric patients with asthma: Propensity score matching approach in a medicaid population.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cohort Studies; Emerg | 2017 |
Association of emergency department albuterol dispensing with pediatric asthma revisits and readmissions.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emergency Service, Hospital; Fema | 2017 |
Within-microenvironment exposure to particulate matter and health effects in children with asthma: a pilot study utilizing real-time personal monitoring with GPS interface.
Topics: Adolescent; Air Pollutants; Albuterol; Asthma; Biomarkers; Child; Cities; Colorado; Computer Systems | 2016 |
Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator A | 2017 |
Takotsubo cardiomyopathy following recurrent doses of albuterol due to asthma attack: a very rare case report.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents; Coronary Angiog | 2016 |
Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; | 2016 |
Impact of Copayment Changes on Children's Albuterol Inhaler Use and Costs after the Clean Air Act Chlorofluorocarbon Ban.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Chlorofluorocarbons; Cost Sharing; Female; H | 2018 |
Free asthma medications reduces hospital admissions in Brazil (Free asthma drugs reduces hospitalizations in Brazil).
Topics: Adolescent; Adult; Age Distribution; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Brazi | 2016 |
Salmeterol and Fluticasone Propionate in Children with Asthma.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator | 2016 |
Salmeterol and Fluticasone Propionate in Children with Asthma.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator | 2016 |
[Lactic acidosis in a 24-year-old woman with status asthmaticus].
Topics: Acidosis, Lactic; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Female; Humans; Lactates; | 2016 |
Long-acting beta agonists do not increase serious asthma-related event risk.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Br | 2017 |
Improved Muscular Weakness During Asthma Exacerbation.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Diagnosis, Differential; Electromyography; Humans; Lordosi | 2017 |
Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Aged, 80 and over; Albuterol; Asthma; | 2017 |
Bilateral acute angle closure developing due to use of ipratropium bromide and salbutamol.
Topics: Albuterol; Antihypertensive Agents; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; | 2018 |
Effect of an Asthma Guideline in 2 Pediatric Emergency Departments and an Urgent Care Center.
Topics: Adolescent; Albuterol; Ambulatory Care Facilities; Asthma; Bronchodilator Agents; Child; Child, Pres | 2018 |
Systematic Review on Efficacy of Magnesium (Intravenous or Nebulized) for Acute Asthma Episodes in Children: Evidence-based Medicine Viewpoint.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Evidence-Based | 2017 |
Systematic Review on Efficacy of Magnesium (Intravenous or Nebulized) for Acute Asthma Episodes in Children: Pediatric Pulmonologist's Viewpoint.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Humans; Magnesi | 2017 |
WHY ASTHMA STILL KILLS.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Drug Utilization Review; Humans; Nebulizers | 2017 |
Drug safety and salmeterol: the controversy continues.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Br | 2008 |
Albuterol vs. levalbuterol for asthma treatment in children.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Humans | 2008 |
A survey of pediatricians' knowledge on asthma management in children.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Child; Clinical Competence; Epinephrine; Female; | 2008 |
Quercetin inhalation inhibits the asthmatic responses by exposure to aerosolized-ovalbumin in conscious guinea-pigs.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Airway Resistance; Albuterol; Animals; A | 2008 |
Biochemical markers as a response guide for steroid therapy in asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Biomarkers; Breath | 2008 |
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2008 |
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2008 |
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2008 |
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2008 |
Inhaled corticosteroids and augmented bronchodilator responsiveness in Latino and African American asthmatic patients.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Albuterol; Asth | 2008 |
Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Asthma; Bronchodilat | 2008 |
When should a reversibility test be performed on patients with early stages of asthma and normal spirometry?
Topics: Adrenergic beta-Agonists; Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Female | 2008 |
Increased use of beta-agonists leading to non-ST-segment elevation myocardial infarction in a patient with hemodynamically significant myocardial bridging.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Coronary Angiography; Coronary Vessel Anomalies; Electr | 2008 |
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma.
Topics: Adrenal Cortex Hormones; Aged; Albuterol; Androstadienes; Asthma; Cohort Studies; Drug Therapy, Comb | 2008 |
Inhalational diesel exhaust exposure in submariners: observational study.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Anti-Inflammatory A | 2008 |
Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; | 2008 |
[The effects of dose of salbutamol and observation time on bronchodilation test].
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Dose-Response Relations | 2008 |
Validation of Ramathibodi's acute asthma predictive score.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; M | 2008 |
A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Al | 2008 |
An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes .
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Allergic Agents; Asthma; Cohort Studies; Disease | 2008 |
Effect of educational and policy interventions on institutional utilization of wet nebulization respiratory drugs and portable inhalers.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Health Services; Hospital Bed | 2008 |
Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Ambulatory Care; Androstadienes; Ast | 2009 |
Asthma/Allergy. FDA advises asthma patients to switch to new Albuterol inhalers.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Nebulizers and Vaporizers; United States; United S | 2008 |
Associations between air pollution and peak expiratory flow among patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Air; Air Pollutants; Albute | 2009 |
A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured population.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Drug Combination | 2008 |
Final count down to hfa albuterol inhalers: are we ready as yet?
Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Humans; Hydrocarbons, Fluorinated; Me | 2009 |
Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Preschool; Disease Progressio | 2009 |
Misconceptions regarding levalbuterol in the treatment of acute asthma exacerbations in children.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Humans | 2009 |
[Influence of changing inhalation device from separate diskus of salmeterol and fluticasone propionate to combination diskus in asthma patients].
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Al | 2008 |
Effectiveness of combination therapies in asthma: an observational study.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchodi | 2009 |
Complex dream-enacting behavior in sleepwalking.
Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Consciousness Disorders; Diagnosis, Differential; D | 2009 |
Can beta agonists cause dilated cardiomyopathy?
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cardiomyopathy, | 2009 |
Reduction in asthma morbidity following a community-based asthma self-management programme in Tonga.
Topics: Adolescent; Adult; Albuterol; Asthma; Child; Disease Management; Emergency Service, Hospital; Female | 2009 |
Safety of long-acting beta-agonists: urgent need to clear the air remains.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol Fumarate; Glucocorticoids; Hu | 2009 |
Levalbuterol kinetics.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchod | 2009 |
Metabolic acidosis, respiratory distress, and children with severe acute asthma.
Topics: Acidosis; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Pre | 2009 |
[Long-acting bronchodilators (formoterol and salmeterol) for treatment of asthma].
Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Salmeterol Xin | 2009 |
[Rhabdomyolysis in severe acute asthma].
Topics: Acidosis; Acute Disease; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Biomarkers; Combined Modal | 2009 |
[Study of personal best value of peak expiratory flow in patients with asthma--comparison of the highest value of daily PEF under good control and the highest value of daily PEF obtained after using repeated inhaled beta2-agonist during high-dose inhaled
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Female; Humans | 2008 |
Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control.
Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Biomarkers; Bronchitis; Bronchodilator Agents; Common Co | 2009 |
Single-inhaler combination therapy for maintenance and relief of asthma: a new strategy in disease management.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Anti-Asthmatic Agent | 2009 |
Are we adequately managing children with wheeze using the standard case management guidelines?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Bacterial Agents; Asthma; Ausc | 2008 |
Socioeconomic, family, and pediatric practice factors that affect level of asthma control.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Child | 2009 |
Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Amino Acid Substitution; Androstadienes; Arginine; Asthm | 2009 |
Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Diagnosis, Differential; Femal | 2008 |
Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propiona
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Area Under Curve; Asthma; Bronchodilator Agents; | 2009 |
Increased levels of outdoor air pollutants are associated with reduced bronchodilation in children with asthma.
Topics: Adrenergic beta-Agonists; Air Pollutants; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Age | 2009 |
Images in cardiology. Acute myocardial infarction due to coronary vasospasm and salbutamol abuse.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Coronary Vasospasm; Female; Humans; Myocardial Infa | 2009 |
Enantiomer-specific effects of albuterol on airway inflammation in healthy and asthmatic cats.
Topics: Albuterol; Animals; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Cats; Cytokines; Ma | 2009 |
[Long-acting bronchodilators (formoterol and salmeterol) for treatment of asthma].
Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Salmeterol Xin | 2009 |
Adolescents and asthma: why bother with our meds?
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; At | 2009 |
Adolescents and asthma: why bother with our meds?
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; At | 2009 |
Adolescents and asthma: why bother with our meds?
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; At | 2009 |
Adolescents and asthma: why bother with our meds?
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; At | 2009 |
[Long-acting bronchodilators (formoterol and salmeterol) for treatment of asthma. Comment of the German Airway League and the German Respiratory Society].
Topics: Albuterol; Asthma; Bronchodilator Agents; Dosage Forms; Ethanolamines; Formoterol Fumarate; Germany; | 2009 |
Fluticasone/salmeterol: labeling change.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Approval; Drug Labeling; Drug Therapy | 2008 |
[Lactic acidosis secondary to inhaled salbutamol in children with acute severe asthma].
Topics: Acidosis, Lactic; Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchod | 2009 |
An analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Asthmatic Agents; As | 2009 |
Genetic variants of GSNOR and ADRB2 influence response to albuterol in African-American children with severe asthma.
Topics: Adolescent; Albuterol; Aldehyde Oxidoreductases; Asthma; Black or African American; Bronchodilator A | 2009 |
Transdermal delivery of salbutamol sulphate: formulation and evaluation.
Topics: Administration, Cutaneous; Adult; Albuterol; Animals; Asthma; Bronchodilator Agents; Drug Delivery S | 2009 |
Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Child, Preschool; Drug Combinations | 2009 |
Augmentation of bronchodilator responsiveness by leukotriene modifiers in Puerto Rican and Mexican children.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Cross-Sectional Studies; Drug Interacti | 2009 |
Love it or lev it: levalbuterol for severe acute asthma--for now, leave it.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hospital; Forced Expiratory Volu | 2009 |
Simultaneous determination of beta2-agonists in human urine by fast-gas chromatography/mass spectrometry: method validation and clinical application.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Gas Chromatography | 2010 |
Treatment of acute bronchospasm in elderly patients.
Topics: Acute Disease; Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Aging; Albuterol; Asth | 2005 |
Acute bronchospasm from the patient's perspective.
Topics: Acute Disease; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Spasm | 2005 |
Effects of airway obstruction on albuterol-mediated variations in the resistive and elastic properties of the respiratory system of patients with asthma.
Topics: Adolescent; Adult; Aged; Airway Obstruction; Airway Resistance; Albuterol; Analysis of Variance; Ast | 2009 |
Levalbuterol versus albuterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Clinical Trials as | 2009 |
Measuring the assessment and counseling provided with the supply of nonprescription asthma reliever medication: a simulated patient study.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; | 2009 |
Comparison of the bronchodilative effects of salbutamol delivered via three mesh nebulizers in children with bronchial asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Drug Delivery Systems; Feasibility Studies; Female; | 2009 |
Adherence to pediatric asthma treatment in economically disadvantaged African-American children and adolescents: an application of growth curve analysis.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol | 2010 |
The beta2 receptor and airway hyper-responsiveness: are sensory nerves involved?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Humans; Neurons, Afferent; R | 2009 |
[Long acting beta-2 agonists. Discussion of their use in asthma].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Delayed | 2009 |
Salmeterol and formoterol: asthma aggravation. Use should be restricted.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Contraindications; | 2009 |
[Long-acting beta2-agonist bronchodilators safety for asthma treatment].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Delayed-Action Preparatio | 2009 |
Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Alleles; Ast | 2009 |
[Diagnostic value of peak flow variability in patients with suspected diagnosis of bronchial asthma in general practice].
Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agents; Bronchodilator Agents; Di | 2009 |
Mometasone furoate vs fluticasone propionate with salmeterol: multivariate analysis of resource use and asthma-related charges.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent | 2009 |
Go and see.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Clinical Competence; Fatal Outcome; Huma | 2009 |
Counterregulation of beta(2)-adrenoceptor function in human mast cells by stem cell factor.
Topics: Albuterol; Asthma; Cell Line; Histamine Release; Humans; Lung; Mast Cells; Potassium Channels, Calci | 2010 |
Implementation of spacer therapy for acute asthma in children.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2009 |
Adherence to combined montelukast and fluticasone treatment in economically disadvantaged african american youth with asthma.
Topics: Acetates; Adolescent; Albuterol; Ambulatory Care; Androstadienes; Anti-Allergic Agents; Anti-Asthmat | 2009 |
Pharmacogenetics of beta(2)-agonists in children.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Ethanolamin | 2009 |
Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; | 2009 |
Acute severe asthma: new approaches to assessment and treatment.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2009 |
Acute severe asthma: new approaches to assessment and treatment.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2009 |
Acute severe asthma: new approaches to assessment and treatment.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2009 |
Acute severe asthma: new approaches to assessment and treatment.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Age | 2009 |
Blood and urinary concentrations of salbutamol in asthmatic subjects.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Bronchodilat | 2010 |
Achieving control of asthma in preschoolers.
Topics: Albuterol; Amoxicillin; Anti-Infective Agents; Anti-Inflammatory Agents; Asthma; Beclomethasone; Bro | 2010 |
Evaluation of asthma control using patient based measures and peak expiratory flow rate.
Topics: Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agents; | 2009 |
Regression of giant bullous emphysema.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Hum | 2010 |
An elevated bronchodilator response predicts large airway inflammation in mild asthma.
Topics: Adolescent; Albuterol; Asthma; Biomarkers; Breath Tests; Bronchodilator Agents; California; Child; E | 2010 |
Omalizumab: when the non-responder is a late-responder.
Topics: Adult; Albuterol; Allergens; Androstadienes; Animals; Anti-Asthmatic Agents; Antibodies, Anti-Idioty | 2009 |
A comparative study of two different metered-dose inhaler-valved holding chambers in the administration of salbutamol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Dose-Response Relati | 2010 |
A 19-month-old boy with recurrent respiratory distress.
Topics: Acid-Base Equilibrium; Albuterol; Alkalosis, Respiratory; Aspirin; Asthma; Bicarbonates; Bites, Huma | 2010 |
Acute exacerbation of asthma complicated by hyperventilation in emergency department.
Topics: Adult; Albuterol; Asthma; Emergency Service, Hospital; Female; Forced Expiratory Volume; Heart Rate; | 2010 |
Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Animals; Asthma; Disease Models, Animal; Drug | 2010 |
In vitro and in vivo evaluation of buccal bioadhesive films containing salbutamol sulphate.
Topics: Acrylic Resins; Adhesiveness; Administration, Buccal; Albuterol; Animals; Anti-Asthmatic Agents; Ast | 2010 |
Choosing asthma step-up care.
Topics: Acetates; Adolescent; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child; Cyclopropanes | 2010 |
Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Sy | 2010 |
The synergistic anti-asthmatic effects of glycyrrhizin and salbutamol.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; Anti-Asthmatic Ag | 2010 |
Meeting the obligation to balance bioethics and clinical trial design in asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bioethical Issues; Bronchodila | 2010 |
GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol.
Topics: Albuterol; Aldehyde Oxidoreductases; Asthma; Bronchodilator Agents; Drug Interactions; Genes; Genoty | 2010 |
[Cost-effectiveness of salmeterol/fluticasone combination therapy vs. fluticasone propionate in Japanese asthmatic patients].
Topics: Albuterol; Androstadienes; Asian People; Asthma; Cost-Benefit Analysis; Drug Combinations; Evidence- | 2010 |
Use of ozone-depleting substances; removal of essential-use designation (flunisolide, etc.). Final rule.
Topics: Air Pollutants; Air Pollution; Albuterol; Anti-Asthmatic Agents; Asthma; Atmosphere; Bronchodilator | 2010 |
Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Cells, Cultured; Dexamethasone; Dual Specifici | 2010 |
Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker asthmatics.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cholinergic Antagonists; | 2010 |
Letter: Perioral dermatitis in a child associated with an inhalation steroid.
Topics: Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cl | 2010 |
Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodi | 2010 |
Hyperlactic acidosis as metabolic side-effect of albuterol and theophylline in acute severe asthma.
Topics: Acidosis, Lactic; Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inf | 2010 |
beta2-agonists promote host defense against bacterial infection in primary human bronchial epithelial cells.
Topics: Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Asthma; Bacterial | 2010 |
Salbutamol modulates the balance of Th1 and Th2 cytokines by mononuclear cells from allergic asthmatics.
Topics: Adult; Albuterol; Antigens, Dermatophagoides; Asthma; Chemokine CCL5; Female; Humans; Interferon-gam | 2010 |
[Comments of the German Airway League and the German Respiratory Society to the US Food and Drug Administration (FDA)'s announcement from February 18th 2010 on the use of long acting beta-2 agonists in treatment of asthma].
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Adverse Drug Reaction Reportin | 2010 |
Salmeterol use and risk of hospitalization among emergency department patients with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agon | 2010 |
Assessment and validation of bronchodilation using the interrupter technique in preschool children.
Topics: Airway Resistance; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Child; Child, Preschool; Cough | 2010 |
Step-up therapy for children with uncontrolled asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Genotype; Glucocorti | 2010 |
Central and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma.
Topics: Acute Disease; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Breath Tests; Broncho | 2010 |
TPI 1020, a novel anti-inflammatory, nitric oxide donating compound, potentiates the bronchodilator effects of salbutamol in conscious guinea-pigs.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory Agents; | 2010 |
Thymic stromal lymphopoietin gene promoter polymorphisms are associated with susceptibility to bronchial asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Binding Sites; Bronchodilator Agents; Case-Control Studi | 2011 |
High exposure to passive tobacco smoking and the development of asthma in an adult patient who had never smoked.
Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Cetirizine; Confined Spaces; Female; Histamine | 2010 |
The article by Daley-Yates et al.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone-Salmeterol | 2010 |
Use of the inhaled corticosteroid to bronchodilator ratio in an audit of the treatment of asthma in an academic family medicine residency programme.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Inflammatory Agents; Asthma; Br | 2010 |
The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Dosage Calculations; Drug | 2010 |
Antiasthmatic action of dibenzylbutyrolactone lignans from fruits of Forsythia viridissima on asthmatic responses to ovalbumin challenge in conscious guinea-pigs.
Topics: 4-Butyrolactone; Airway Resistance; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveol | 2011 |
Anti-asthmatic effects of phenylpropanoid glycosides from Clerodendron trichotomum leaves and Rumex gmelini herbes in conscious guinea-pigs challenged with aerosolized ovalbumin.
Topics: Airway Resistance; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; | 2011 |
ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos.
Topics: 5-Lipoxygenase-Activating Proteins; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Carrier Pr | 2010 |
Call for withdrawal of LABA single-therapy inhaler in asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2010 |
Impact of an emergency nurse-initiated asthma management protocol on door-to-first-salbutamol-nebulization-time in a pediatric emergency department.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distribution; Child; Child, Pres | 2010 |
Rosiglitazone reverses salbutamol-induced β(2) -adrenoceptor tolerance in airway smooth muscle.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Carbachol; Cells, Cultured; Dexamet | 2011 |
Lung function in preschool children with a history of wheezing measured by forced oscillation and plethysmographic specific airway resistance.
Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans | 2010 |
Asthma inhalers and colour coding: universal dots.
Topics: Albuterol; Asthma; Bronchodilator Agents; Color; Equipment Design; Humans; Nebulizers and Vaporizers | 2010 |
Response to salbutamol in patients with mild asthma treated with nadolol.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Adult; Albuterol; Asth | 2010 |
No association of catastrophic events with Advair.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agen | 2010 |
Dr Nathan Tucker's Asthma Specific--a treatment for asthma preceding inhaled steroids and beta-agonists.
Topics: Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Cocaine; Female; Glucocorticoids; Human | 2010 |
Predicting the clinical effect of a short acting bronchodilator in individual patients using artificial neural networks.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Force | 2010 |
Airway peroxidases catalyze nitration of the {beta}2-agonist salbutamol and decrease its pharmacological activity.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Ascorbic Acid; Asthma; Breath Tests; Bronchi; Cataly | 2011 |
Products at risk.
Topics: Administration, Inhalation; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Cholinergic An | 2010 |
Anticholinergics for patients with asthma?
Topics: Administration, Inhalation; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Cholinergic An | 2010 |
The improvement of cognitive functions in patients with bronchial asthma after therapy.
Topics: Aged; Aged, 80 and over; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Cognition Disorders; | 2010 |
A 20-year-old woman with severe asthma refractory to Primatene Mist.
Topics: Acidosis, Lactic; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Cholinergic | 2010 |
Aerosol inhalation from spacers and valved holding chambers requires few tidal breaths for children.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presch | 2010 |
Intravenous magnesium sulphate prevents intravenous salbutamol tachycardia in asthma.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Arrhythmia Agents; Asthma; Bronchod | 2010 |
[My private opinion on Asthma Prevention and Management Guideline 2009--chemotherapy plans for long term care of adult asthma patients--with special reference to handling of LABA].
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Practi | 2010 |
Salbutamol misuse or abuse with fatal outcome: a case-report.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Arrhythmogenic Right Ventricular Dysplasia; A | 2011 |
2007 San Diego wildfires and asthmatics.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; California; Eosinophils; Fires; Forced Expiratory V | 2011 |
Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity.
Topics: Aged; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lung Volume Meas | 2010 |
Influence of gene-gene interactions on response to albuterol therapy.
Topics: Albuterol; Asthma; Epistasis, Genetic; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Re | 2011 |
Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool | 2010 |
Eosinophilic cationic protein: is it useful in assessing control of childhood asthma?
Topics: Albuterol; Androstadienes; Asthma; Biomarkers; Bronchodilator Agents; Case-Control Studies; Child; C | 2010 |
The dilemma of albuterol dosing for acute asthma exacerbations in pediatric patients.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Humans; | 2011 |
Control maintenance can be predicted by exhaled NO monitoring in asthmatic patients.
Topics: Adult; Albuterol; Anti-Inflammatory Agents; Asthma; Biomarkers; Dyspnea; Exhalation; Female; Forced | 2011 |
Tiotropium step-up therapy in asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Chol | 2011 |
A case of accidental ingestion of a salbutamol sulfate inhalant, Venetlin®.
Topics: Accidents, Home; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Humans; Nebulizers and | 2009 |
Inhibitory effects of albuterol and fenoterol on RANTES and IP-10 expression in bronchial epithelial cells.
Topics: Albuterol; Asthma; Azides; Bronchi; Cell Line; Chemokine CCL5; Chemokine CXCL10; Cyclic AMP; Epithel | 2011 |
New insights into the treatment of persistent asthma.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator | 2011 |
Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma: a retrospective cohort study.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Anti- | 2011 |
Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Benzoxa | 2011 |
Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Analysis of Variance; An | 2011 |
Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Female; Forced Expiratory Volume; Ga | 2011 |
Cost-effectiveness of metered-dose inhalers for asthma exacerbations in the pediatric emergency department.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; British Columbia; Child; Child, Preschool | 2011 |
Effects of salbutamol given by metered-dose inhaler on dispersion of ventricular repolarization.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Ch | 2011 |
Induced sputum in children: success determinants, safety, and cell profiles.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchial Hyperreactivity; Cell Count; Ch | 2011 |
Prescription patterns in asthma patients initiating salmeterol in UK general practice: a retrospective cohort study using the General Practice Research Database (GPRD).
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists | 2011 |
Treatment of acute asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Female; Humans; Male; Nebulizers and Vaporiz | 2011 |
Treatment of mild persistent asthma in children.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Inflammatory Agents | 2011 |
Device type and real-world effectiveness of asthma combination therapy: an observational study.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; A | 2011 |
Asthma treatment through the beta receptor: lessons from animal models.
Topics: Adrenergic beta-Antagonists; Albuterol; Animals; Asthma; Disease Models, Animal; Stereoisomerism | 2011 |
Relationship between bronchial hyperreactivity and bronchodilation in patients with allergic rhinitis.
Topics: Adult; Albuterol; Asthma; Bronchi; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchodi | 2011 |
A case of haemorrhagic cystitis by inhaled salbutamol and salmeterol.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; As | 2011 |
Effective bronchodilator resuscitation of children in the emergency room: device or interface?
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerg | 2011 |
Beta agonist use during asthma exacerbations: how much is too much?
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And | 2011 |
Meaningful placebos--controlling the uncontrollable.
Topics: Acupuncture Therapy; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Placebo Eff | 2011 |
Airway resistance at maximum inhalation as a marker of asthma and airway hyperresponsiveness.
Topics: Adolescent; Airway Resistance; Albuterol; Asthma; Boston; Bronchial Hyperreactivity; Bronchial Provo | 2011 |
Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodilator Agent | 2011 |
Relationship between polymorphisms in the 5' leader cistron, positions 16 and 27 of the adrenergic β2 receptor gene and asthma in a Han population from southwest China.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Arginine; Asian People; Asthma; Bronchodilator Agent | 2011 |
Spirometric maneuvers and inhaled salbutamol do not affect exhaled nitric oxide measurements among patients with allergic asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Breath Tests; Bronchodilator | 2012 |
Asthma challenges: The place of inhaled long-acting beta-agonists.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Ethanolamines; Glucocorticoids; Humans | 2010 |
Cushing's syndrome with low levels of serum cortisol: the role of inhaled steroids.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Cushing Syndrome; Drug Combinations; | 2011 |
Will recording of lung function fluctuation open the door to internet-guided treatment of asthma?
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Female; Humans; Male; Peak Expiratory Flow Rate; Salmetero | 2011 |
The response of children with asthma to ambient particulate is modified by tobacco smoke exposure.
Topics: Adolescent; Albuterol; Asthma; Child; Colorado; Drug Utilization; Environmental Exposure; Female; Hu | 2011 |
Compliance with guidelines in the treatment of asthma exacerbations in primary care.
Topics: Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Cross-Sectional Studies; Female; Follow-Up St | 2011 |
Influence of obesity on control in asthmatic Japanese patients defined by the Japanese definition of obesity.
Topics: Adrenal Cortex Hormones; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Humans; Inci | 2011 |
Comparison of bronchodilator response in patients with asthma and healthy subjects using spirometry and oscillometry.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Humans; Linear Models; Middle Age | 2011 |
Placebo and other interventions in asthma.
Topics: Acupuncture Therapy; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Placebo Effect; | 2011 |
Placebo and other interventions in asthma.
Topics: Acupuncture Therapy; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Placebo Effect; | 2011 |
Placebo and other interventions in asthma.
Topics: Acupuncture Therapy; Albuterol; Asthma; Bronchodilator Agents; Placebo Effect | 2011 |
Long-acting β-agonists in asthma management: what is the current status?
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm | 2011 |
Exhaled carbon monoxide levels in preschool-age children with episodic asthma.
Topics: Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Carbon Monoxide; Cromolyn Sodium; Drug Thera | 2012 |
ProAir(®) HFA delivers warmer, lower-impact, longer-duration plumes containing higher fine particle dose than Ventolin(®) HFA.
Topics: Albuterol; Asthma; Bronchodilator Agents; Equipment Design; Humans; Hydrocarbons, Fluorinated; Meter | 2012 |
Effects of oral salbutamol and pirbuterol on FEV1, heart rate and blood pressure in asthmatics.
Topics: Administration, Oral; Aged; Albuterol; Asthma; Blood Pressure; Bronchodilator Agents; Dose-Response | 1976 |
Salmeterol attenuates the inflammatory response in asthma and decreases the pro-inflammatory cytokine secretion of dendritic cells.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Cells, Cultured; Cytokines; Dendrit | 2012 |
Maternal asthma medication use and the risk of selected birth defects.
Topics: Abnormalities, Drug-Induced; Adult; Albuterol; Anal Canal; Androstadienes; Anti-Asthmatic Agents; An | 2012 |
Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition.
Topics: 1-Phosphatidylinositol 4-Kinase; Adenine; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonis | 2012 |
Late-night wheezer: providers respond to pediatric asthma patient.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Medical Services; Female; Humans; Nebuliz | 2012 |
Asthma guidelines and smokers: it's time to be inclusive.
Topics: Albuterol; Androstadienes; Asthma; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combinatio | 2012 |
Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Beclomethasone; Computer Simulation; Cost- | 2012 |
Pharmacogenetics of asthma controller treatment.
Topics: Acetates; Administration, Inhalation; Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; | 2013 |
Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients.
Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Androstadienes; Anti-Asthmatic Agents; A | 2012 |
Adrenal insufficiency and growth failure secondary to inhaled corticosteroids: a paradoxical complication.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenal Insufficiency; Albuterol; Androstadiene | 2012 |
Evaluating the length of stay and value of time in a pediatric emergency department with two models by comparing two different albuterol delivery systems.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Child, Preschool; Emergen | 2012 |
Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Biomarkers; | 2012 |
Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery.
Topics: Administration, Inhalation; Albuterol; Analysis of Variance; Animals; Anti-Asthmatic Agents; Anura; | 2012 |
Mycoplasma pneumoniae bronchiolitis mimicking asthma in an adult.
Topics: Adult; Albuterol; Anti-Infective Agents; Asthma; Aza Compounds; Bronchiolitis; Bronchodilator Agents | 2012 |
[Cardiogenic pulmonary edema following β2 agonist infusion for acute, severe asthma].
Topics: Acute Disease; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Combined Modality Ther | 2015 |
Magnesium use in asthma pharmacotherapy: a Pediatric Emergency Research Canada study.
Topics: Adolescent; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Child, Prescho | 2012 |
Investigating asthma symptoms in primary care.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Child; Diagnosis, Diff | 2012 |
Long-acting beta-agonists and the risk of intensive care unit admission in children.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists | 2012 |
Lung blood flow must be considered when prescribing a long-acting β2-agonist/inhaled corticosteroid combination.
Topics: Airway Resistance; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchodilator | 2012 |
Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor.
Topics: Albuterol; Animals; Asthma; beta-Alanine; Bronchial Hyperreactivity; Bronchoconstriction; Fingolimod | 2012 |
Treating acute asthma--salbutamol may not always be the right answer.
Topics: Acidosis, Lactic; Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Al | 2012 |
Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Bronchi; Bronchoconstriction; Bronc | 2012 |
Allergic rhinitis and non-allergic rhinitis in children in the tropics: prevalence and risk associations.
Topics: Adrenal Cortex Hormones; Albuterol; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Child; Chil | 2012 |
Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action.
Topics: Adenosine Monophosphate; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Benzothiaz | 2012 |
Quantitative analysis of dynamic airway changes after methacholine and salbutamol inhalation on xenon-enhanced chest CT.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchoconstrictor Agents; Female; Force | 2012 |
A case of recurrent acute haemorrhagic cystitis associated with salbutamol and beclomethasone use in a paediatric patient.
Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child; Cystitis; Hematuria; | 2012 |
Pitfalls associated with the therapeutic reference pricing practice of asthma medication.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alb | 2012 |
Can a rare form of myasthenia gravis shed additional light on disease mechanisms?
Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Autoantibodies; Calcium Signaling; Carbon Dioxide; | 2013 |
The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; Delayed-Action Preparations; | 2013 |
Response to treatment in individuals with late-onset asthma.
Topics: Adult; Age of Onset; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Female; Flutica | 2012 |
Regional pulmonary response to a methacholine challenge using hyperpolarized (3)He magnetic resonance imaging.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronc | 2012 |
Salbutamol with metered dose inhalers with spacers - an established emergency treatment for preschool wheeze.
Topics: Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child, Preschool; Drug Administration Schedule | 2012 |
Are we overlooking persistent small airways dysfunction in community-managed asthma?
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Airway Resistance; Albuterol; Androstadi | 2012 |
The correlation of average monthly ambient sulfur dioxide concentration and the use of inhalation bronchodilators in children.
Topics: Air Pollutants; Albuterol; Asthma; Bosnia and Herzegovina; Bronchodilator Agents; Child; Child, Pres | 2012 |
Effectiveness of a breath-actuated nebulizer device on asthma care in the pediatric emergency department.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2012 |
Long-acting β-agonist prescribing in people with asthma in primary care.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Therapy, Combination; | 2013 |
Practice patterns in asthma discharge pharmacotherapy in pediatric emergency departments: a pediatric emergency research Canada study.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Age Factors; | 2012 |
Severe intraoperative bronchospasm treated with a vibrating-mesh nebulizer.
Topics: Aerosols; Albuterol; Albuterol, Ipratropium Drug Combination; Anesthesia, Inhalation; Anesthetics, I | 2012 |
Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Database | 2012 |
Efficacy of budesonide in combination with formoterol in patients with inadequately controlled asthma on fluticasone in combination with salmeterol.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Drug Therapy, Combination; Eth | 2012 |
Xenon-enhanced dual-energy CT of patients with asthma: dynamic ventilation changes after methacholine and salbutamol inhalation.
Topics: Administration, Inhalation; Adult; Albuterol; Analysis of Variance; Asthma; Bronchoconstrictor Agent | 2012 |
Lactic acidosis following intentional overdose by inhalation of salmeterol and fluticasone.
Topics: Acidosis, Lactic; Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Albut | 2012 |
An assessment of community pharmacists' responses to hypothetical medical emergency situations.
Topics: Adult; Albuterol; Anaphylaxis; Anti-Asthmatic Agents; Asthma; Attitude of Health Personnel; Communit | 2012 |
P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Black or African American; Case-Control Studies; | 2013 |
Management of COPD in general practice.
Topics: Aged; Albuterol; Asthma; Australia; Bronchodilator Agents; Comorbidity; Female; General Practice; Hu | 2012 |
High exhaled nitric oxide levels may predict bronchial reversibility in allergic children with asthma or rhinitis.
Topics: Adolescent; Albuterol; Asthma; Breath Tests; Child; Cohort Studies; Cross-Sectional Studies; Female; | 2013 |
Research on the molecular mechanism of Seretide treatment to asthma disease.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Databases, Genetic; | 2012 |
Inappropriate home albuterol use during an acute asthma exacerbation.
Topics: Adolescent; Albuterol; Asthma; Caregivers; Child; Child, Preschool; Cross-Sectional Studies; Emergen | 2012 |
RGS5 gene and therapeutic response to short acting bronchodilators in paediatric asthma patients.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Forced Expira | 2013 |
Bronchodilator responsiveness using spirometry in healthy and asthmatic preschool children.
Topics: Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Child, Preschool; Forced Expi | 2013 |
Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powd
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Asthma; Cohort Studi | 2013 |
[Nebulized salbutamol as a possible cause of lactate acidosis in a patient with acute asthma].
Topics: Acidosis, Lactic; Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Al | 2013 |
[Lactic acidosis in a patient with exercabation of asthma receiving inhalation therapy].
Topics: Acidosis, Lactic; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; | 2013 |
Evaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distrib | 2013 |
The dark side of airway management. Forensic cases in EMS advanced airway management.
Topics: Aged; Airway Management; Albuterol; Asthma; Bronchodilator Agents; Clinical Protocols; Emergency Med | 2013 |
Supramaximal flow in asthmatic patients.
Topics: Adult; Albuterol; Asthma; Bronchoconstrictor Agents; Bronchodilator Agents; Forced Expiratory Volume | 2002 |
Respiratory impedance response to a deep inhalation in asthmatic children with spontaneous airway obstruction.
Topics: Adolescent; Airway Obstruction; Airway Resistance; Albuterol; Analysis of Variance; Asthma; Bronchod | 2002 |
Transient lactic acidosis as a side effect of inhaled salbutamol.
Topics: Acidosis, Lactic; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans | 2002 |
Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Clinical Trials as Topic; | 2002 |
Levalbuterol has not been established to have therapeutic advantage over racemic albuterol.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Consumer Product Safety; | 2002 |
Expression of bronchodilator response: comparison of four indices.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Bronchospirometry; Female; Forced Expiratory Volume | 2002 |
Effect of beta2-agonist treatment and spirometry on exhaled nitric oxide in healthy children and children with asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Breath Tests; Child; Humans; Luminescent Me | 2002 |
Achieving guideline-based asthma control: does the patient benefit?
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Fluticasone; Gu | 2002 |
Airway obstruction induced by inhaled acetaldehyde in asthma: repeatability relationship to adenosine 5'-monophosphate responsiveness.
Topics: Acetaldehyde; Adenosine Monophosphate; Administration, Inhalation; Adolescent; Adult; Airway Obstruc | 2002 |
The current landscape of asthma: a new geometry.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchial Hyperreactivity; Drug Combinatio | 2002 |
Lung dose of inhaled drugs in children with acute asthma.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; | 2002 |
Should combination therapy with inhaled corticosteroids and long-acting beta2-agonists be prescribed as initial maintenance treatment for asthma?
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Drug Combinations; Drug Therapy, Combin | 2002 |
Dyspnoea worsened by salmeterol.
Topics: Adenocarcinoma; Albuterol; Asthma; Breast Neoplasms; Bronchodilator Agents; Diagnosis, Differential; | 2002 |
Question from the clinician: levalbuterol in managing pediatric asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug | 2002 |
Selecting the best method to evaluate bronchodilation when analysing bronchodilator studies.
Topics: Age Factors; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Human | 2002 |
In vitro evaluation of aerosol bronchodilator delivery during noninvasive positive pressure ventilation: effect of ventilator settings and nebulizer position.
Topics: Aerosols; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Drug Delivery Systems; Hum | 2002 |
[Contribution of salmeterol in ambulatory practice to the improvement of asthma and quality of life in childhood].
Topics: Adolescent; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Albuterol; Anti-Ast | 2002 |
Nitrogen oxides reduce albuterol-induced bronchodilation in patients with bronchial asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agen | 2002 |
[Optimization of asthma control with fluticasone/salmeterol (seretide) combination: new clinical data].
Topics: Albuterol; Androstadienes; Asthma; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Force | 2002 |
Occupational rhinoconjunctivitis and asthma in a wool worker caused by Dermestidae spp.
Topics: Adult; Albuterol; Allergens; Animals; Antibody Specificity; Asthma; Bronchial Provocation Tests; Bro | 2002 |
Nonreversible conductive airway ventilation heterogeneity in mild asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Fem | 2003 |
[Combination of beta-1 agonist and corticosteroid is advantageous not only in asthma. COPD patients spared exacerbations].
Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Albuterol; Androstadi | 2002 |
Diabetic ketoacidosis associated with oral salbutamol overdose.
Topics: Administration, Oral; Adult; Albuterol; Asthma; Diabetic Ketoacidosis; Drug Overdose; Female; Follow | 2002 |
Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Female; Hospitalization; Humans; Male; Middle Aged; Pul | 2003 |
Pharmacists helping physicians.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone-Salmeterol | 2003 |
Clinical and biological heterogeneity in children with moderate asthma.
Topics: Adolescent; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Biomarkers; Bronchodilator | 2003 |
Interferon therapy induces the improvement of lung function by inhaled corticosteroid therapy in asthmatic patients with chronic hepatitis C virus infection: a preliminary study.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Th | 2003 |
How to design a negative study.
Topics: Albuterol; Asthma; Bias; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Formoterol Fu | 2003 |
Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler.
Topics: Aerosols; Albuterol; Analysis of Variance; Androstadienes; Asthma; Bronchodilator Agents; Chromatogr | 2002 |
[The MMW Drug Prize 2002: Prize for a new classic with innovation potential].
Topics: Administration, Topical; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agen | 2002 |
Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England.
Topics: Albuterol; Asthma; Chemistry, Pharmaceutical; Child; England; Female; Humans; Hydrocarbons, Fluorina | 2003 |
Clarification of salmeterol studies.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Powders; Salmeterol Xi | 2003 |
Effect of pharmacist counseling in patients hospitalized with acute exacerbation of asthma.
Topics: Acetates; Acute Disease; Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Anti | 2003 |
Intravenous salbutamol.
Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Emergency Service, Hospital; Humans; | 2003 |
Second line treatment for severe acute childhood asthma.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Child; Drug Combinations; | 2003 |
Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma.
Topics: Albuterol; Animals; Antigens, CD34; Apoptosis; Asthma; Cell Division; Female; Humans; Male; Methacho | 2003 |
Correlations between exhaled nitric oxide levels, blood eosinophilia, and airway obstruction reversibility in childhood asthma are detectable only in atopic individuals.
Topics: Adrenergic beta-Agonists; Airway Obstruction; Albuterol; Asthma; Breath Tests; Bronchodilator Agents | 2003 |
Early detection of cardiac disease masquerading as acute bronchospasm: The role of bedside limited echocardiography by the emergency physician.
Topics: Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Calcinosis; Cardiomyopathy, Dilated; Chil | 2003 |
Herbal therapy use in a pediatric emergency department population: expect the unexpected.
Topics: Adolescent; Adult; Albuterol; Asthma; Caregivers; Child; Child, Preschool; Complementary Therapies; | 2003 |
Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects.
Topics: Adrenergic beta-Agonists; Aerosol Propellants; Albuterol; Area Under Curve; Asthma; Biological Avail | 2003 |
Rapidly repeated intravenous boluses of salbutamol for acute severe asthma.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child | 2003 |
(R,S)-salbutamol plasma concentrations in severe asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relations | 2003 |
[The effect of time on the perception of dyspnea following inhaled long-acting bronchodilator].
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Dyspnea; Forced Expiratory Vol | 2003 |
Asthma, age, and early reversibility testing.
Topics: Adult; Age Factors; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Case-Control | 2003 |
Prescriber and pharmacist responses to intervention letters for Connecticut Medicaid beneficiaries with asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distribution; | 2003 |
Funhaler spacer: improving adherence without compromising delivery.
Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Drug Administration Sch | 2003 |
Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agent | 2003 |
Nebulised magnesium in asthma: the right solution for an old remedy?
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Calcium Channel Blockers; Chem | 2003 |
Prescribing for asthmatic children in primary care. Are we following guidelines?
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presch | 2003 |
Outcome evaluation of early discharge from hospital with asthma.
Topics: Adolescent; Albuterol; Asthma; Australia; Bronchodilator Agents; Child; Child, Preschool; Dose-Respo | 2003 |
Use of intravenous salbutamol in acute severe asthma.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Algorithms; Asthma; Bronchodilator Agents; Human | 2003 |
Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma.
Topics: Airway Resistance; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; Child, Presc | 2003 |
Excess mortality with salmeterol as single-agent therapy.
Topics: Albuterol; Asthma; Clinical Trials as Topic; Drug Evaluation; Humans; United States; United States F | 2003 |
Occupational asthma due to IgE mediated allergy to the flower Molucella laevis (Bells of Ireland).
Topics: Air Pollutants, Occupational; Albuterol; Allergens; Asthma; Bronchodilator Agents; Humans; Immunoglo | 2003 |
Exhaled nitric oxide corresponds with office evaluation of asthma control.
Topics: Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Child; Female; Forced Expiratory Volume; Hum | 2003 |
Cardiovascular collapse in a 77-year-old-woman with an asthma exacerbation following bronchodilator treatment.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents | 2003 |
Levalbuterol vs racemic albuterol: science or drug company propaganda?
Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Industry; Humans; Propaganda; Racemases and Epimerase | 2003 |
Levalbuterol is not more cost-effective than albuterol for COPD.
Topics: Albuterol; Asthma; Bias; Bronchodilator Agents; Cost-Benefit Analysis; Hospitalization; Humans; Pulm | 2003 |
The administration of beta2-agonists for paediatric asthma and its adverse reaction in Australian and New Zealand emergency departments: a cross-sectional survey.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Austra | 2003 |
[Theomyl, a new synthetic asthma preparation].
Topics: Albuterol; Asthma; Caffeine; Epinephrine; Ipratropium; Theophylline | 1962 |
Nebulised salbutamol and magnesium sulphate in acute asthma.
Topics: Acute Disease; Adjuvants, Pharmaceutic; Administration, Inhalation; Albuterol; Asthma; Bronchodilato | 2003 |
Nebulised salbutamol and magnesium sulphate in acute asthma.
Topics: Acute Disease; Adjuvants, Pharmaceutic; Administration, Inhalation; Albuterol; Asthma; Bronchodilato | 2003 |
Nebulised salbutamol and magnesium sulphate in acute asthma.
Topics: Acute Disease; Adjuvants, Pharmaceutic; Albuterol; Asthma; Humans; Isotonic Solutions; Magnesium Sul | 2003 |
FDA alerts asthmatics to drug safety risk.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Consumer Product Safety; Humans; Product Surveillance, | 2003 |
A response to 'Rapidly repeated intravenous boluses of salbutamol for acute severe asthma' Sellers WFS, Messahel B, Anaesthesia 2003; 58: 680-3.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Infusions | 2003 |
Asthma-like syndrome in a teenager.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Albuterol; Amoxicillin; Androstadienes; Anti-Ba | 2003 |
Prescribing for asthmatic children in primary care. Are we following the guidelines?
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Practice Guidelines as Topic; Practice Patt | 2003 |
Mirror images: is levalbuterol the fairest of them all?
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Humans; Isomerism; Resear | 2003 |
Asthma variability in patients previously treated with beta2-agonists alone.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Androstadienes; Asthma; Child; Disease | 2003 |
Outcome of occupational asthma in patients with continuous exposure: a 3-year longitudinal study during pharmacologic treatment.
Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Female; Humans; Longitudinal Studie | 2003 |
Concomitant occasional use of salbutamol influences bronchoprotective responsiveness afforded by formoterol in patients with the glycine-16 genotype.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; Cholinergic Antagonists; Et | 2004 |
Effect of inhaled racemic and (R)-albuterol on airway vascular smooth muscle tone in healthy and asthmatic subjects.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Case-Contro | 2003 |
[Bronchial asthma -- to set the measuring rod higher. Combination therapy defines asthma control anew].
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodilato | 2003 |
Levalbuterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans | 2003 |
[Adding a prolonged action beta-2-agonist].
Topics: Acetates; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Cyclo | 2003 |
[Adding an anti-leukotriene: results of the IMPACT study].
Topics: Acetates; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Chroni | 2003 |
Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Clinical Trial | 2004 |
Plasma cortisol levels in acute asthma.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Humans; Hydrocortisone; Male | 2003 |
Beta2-agonist eutomers: a rational option for the treatment of asthma?
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; Anti-Asthmatic Ag | 2002 |
Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study.
Topics: Acute Disease; Adult; Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Female; Forced | 2004 |
A rare side-effect of intravenous salbutamol.
Topics: Acidosis, Lactic; Albuterol; Asthma; Bronchodilator Agents; Humans; Infusions, Intravenous; Male; Mi | 2004 |
Intravenous magnesium sulphate and salbutamol for asthma.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Humans; Magnesiu | 2004 |
Characterization of the generation of radiolabeled monodisperse albuterol particles using the spinning-top aerosol generator.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Drug Delivery Systems; Female; Human | 2004 |
Salmeterol multicentre asthma research trial (SMART): interim analysis shows increased risk of asthma related deaths.
Topics: Albuterol; Asthma; Cause of Death; Clinical Trials as Topic; Female; Humans; Incidence; Male; Multic | 2003 |
Airway responsiveness to beta-adrenergic agonist (salbutamol) in asthma.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Hyperreactivity; Bronch | 2003 |
The use of inhaled and related respiratory medications in Christchurch rest homes.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Aged; Aged, 80 and ov | 2003 |
Pro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts.
Topics: Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchi; Cells, Cultured; Cytokines; Dr | 2004 |
Increasing compliance with inhaled corticosteroids through the use of combination therapy.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Androstadienes; Anti-Asthmatic Agent | 2004 |
Near-fatal asthma related to menstruation.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Menstru | 2004 |
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adult; Albuterol; Androstadienes; Anti-A | 2004 |
Long-acting beta agonists in asthma therapy.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanol | 2004 |
Relationship between quality of life and clinical status in asthma: a factor analysis.
Topics: Activities of Daily Living; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Airway Resistance; Al | 2004 |
Point-counterpoint: A comparison of levalbuterol and racemic albuterol in the treatment of pediatric asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; History, Medieval; Humans; Stereoisomerism | 2004 |
Contamination of dry powder inhalers for asthma with milk proteins containing lactose.
Topics: Administration, Inhalation; Albuterol; Anaphylaxis; Androstadienes; Asthma; Bronchodilator Agents; C | 2004 |
Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2004 |
HFA inhalers.
Topics: Aerosol Propellants; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Glucocorticoids; Huma | 2004 |
Three 20-minute interspaced salbutamol inhalations as a test for the diagnosis of reversible airflow limitation in adult asthmatics.
Topics: Administration, Inhalation; Administration, Oral; Aged; Airway Obstruction; Albuterol; Anti-Inflamma | 2004 |
Exhaled nitric oxide.
Topics: Acetates; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Budesonide; Cyclopropanes; Exhalat | 2004 |
Asthma exacerbations and formoterol.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Br | 2004 |
Contamination of nebulizer equipment with cockroach allergen: there's a bug in the system!
Topics: Adolescent; Albuterol; Allergens; Androstadienes; Animals; Asthma; Bronchodilator Agents; Child; Coc | 2004 |
Evaluation of a physician-focused educational intervention on medicaid children with asthma.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Asthma; Child; Child, Preschool; Drug Ut | 2004 |
[Effect of high doses of broncholytics on the state of cardiovascular system during treatment of sever exacerbation of bronchial asthma].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug | 2004 |
[Lactic acidosis occurring after inhaled beta2 agonists during an asthma attack].
Topics: Acidosis, Lactic; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Female; H | 2004 |
Pupil blown by a puffer.
Topics: Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Child; Drug Combinations; Humans; Ipratropium; M | 2004 |
A response to 'A rare side-effect of intravenous salbutamol', Girgis M and Milner Q, Anaesthesia 2004; 59: 196-7.
Topics: Acidosis, Lactic; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans | 2004 |
Hypercapnia: what is the limit in paediatric patients? A case of near-fatal asthma successfully treated by multipharmacological approach.
Topics: Acidosis, Respiratory; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Therapy, Combination; G | 2004 |
Asthmalike symptoms following intratracheal exposure of Guinea pigs to sulfur mustard aerosol: therapeutic efficacy of exogenous lung surfactant curosurf and salbutamol.
Topics: Aerosols; Albuterol; Animals; Asthma; Biological Products; Bronchoalveolar Lavage Fluid; Bronchodila | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Alveolar and airway sites of nitric oxide inflammation in treated asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Asthmatic Agents; Anti-Infl | 2004 |
Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Cell C | 2004 |
[Comparison of the bronchodilator effect of salbutamol between pressure metered dosed inhaler and dry powder inhaler in patients with stable bronchial asthma].
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Metered Dose Inhalers; | 2004 |
Induced sputum methodology: Validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Biomarkers; Dithiothreitol; | 2004 |
Steroids and antibiotics for treatment of acute asthma exacerbations in African-American children.
Topics: Adolescent; Albuterol; Amoxicillin; Asthma; Black or African American; Bronchodilator Agents; Child; | 2004 |
A comparison of lung function methods for assessing dose-response effects of salbutamol.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Female; For | 2004 |
Asthma in emergency departments: combined adult and paediatric versus paediatric only centres.
Topics: Adolescent; Albuterol; Asthma; Australia; Bronchodilator Agents; Child; Child, Preschool; Emergency | 2004 |
Reduced eosinophil pro-fibrogenic effect in severe childhood asthma compared to mild disease: an effect of corticosteroids?
Topics: Acetates; Adolescent; Albuterol; Androstadienes; Asthma; Child; Cyclopropanes; Dexamethasone; Eosino | 2004 |
Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adult; Albuterol; Androstadienes; Anti-A | 2004 |
Differentiating asthma and COPD patients.
Topics: Albuterol; Androstadienes; Asthma; Drug Therapy, Combination; Fluticasone; Forced Expiratory Volume; | 2004 |
Tremor side effects of salbutamol, quantified by a laser pointer technique.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Child; Child, | 2004 |
Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2004 |
Cost of using levalbuterol in the emergency room.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hospital; Hospitalization; Human | 2004 |
Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Doping in Sports; Humans; Male; Sports Medicine; | 2004 |
Hypokalemic paralysis mimicking Guillain-Barré syndrome and causing acute respiratory failure.
Topics: Acidosis, Respiratory; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Gas Analysis; Diagn | 2004 |
Salbutamol via metered-dose inhaler with spacer versus nebulization for acute treatment of pediatric asthma in the emergency department.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Antagonists; Albuterol; Asthm | 2004 |
Asthma update: clinical aspects and management.
Topics: Adrenergic beta-Agonists; Albuterol; Algorithms; Anti-Asthmatic Agents; Anti-Bacterial Agents; Asthm | 2004 |
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Case-Control Studies; Fluticasone; Humans; | 2004 |
Laryngeal findings in users of combination corticosteroid and bronchodilator therapy.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Andros | 2004 |
Development, implementation, and evaluation of a community pharmacy-based asthma care model.
Topics: Adult; Albuterol; Asthma; Australia; Bronchodilator Agents; Case-Control Studies; Community Pharmacy | 2004 |
Pulmonary outcome in adolescents of extreme preterm birth: a regional cohort study.
Topics: Adolescent; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchopulmon | 2004 |
Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma.
Topics: Active Transport, Cell Nucleus; Adolescent; Albuterol; Androstadienes; Apoptosis; Asthma; Caspases; | 2004 |
Ten puffs too many.
Topics: Albuterol; Asthma; Bronchodilator Agents; Burns, Chemical; Child; Humans; Male; Nebulizers and Vapor | 2004 |
Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma.
Topics: Adolescent; Albuterol; Alleles; Asthma; Bronchodilator Agents; Child; Female; Gene Frequency; Genoty | 2005 |
The allergic march in pollinosis: natural history and therapeutic implications.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; Coho | 2004 |
Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients.
Topics: Adult; Age Factors; Aged; Albuterol; Allergens; Ambrosia; Asthma; Betula; Bronchodilator Agents; Fem | 2004 |
Airway reactivity is a determinant of bronchodilator responsiveness after methacholine-induced bronchoconstriction.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchi | 2004 |
Effect of mouthpiece washing on aerosol performance of CFC-free Ventolin.
Topics: Administration, Inhalation; Aerosols; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; Asthma | 2004 |
Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and | 2004 |
Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate: comment.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Infla | 2004 |
Diagnostic accuracy of bronchodilator responsiveness in wheezy children.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Femal | 2005 |
Rubbing ointments and asthma morbidity in adolescents.
Topics: Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Camphor; Cross-Sectional Studies; Drug Combina | 2004 |
Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics.
Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchodilator Agents; Cells, Cultu | 2005 |
Metered dose inhalers: a need for dose counters.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Packaging; Equipme | 2005 |
Correspondence regarding levalbuterol and racemic albuterol, July 2004 Supplement.
Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Cost-Benefit Analysis; Emergency Service, Hospital; | 2005 |
Evaluation of particle size distribution of albuterol sulfate hydrofluoroalkane administered via metered-dose inhaler with and without valved holding chambers.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Humans; Hydrocarbons, Fluorinated; Meter | 2005 |
Respiratory failure precipitated by salbutamol.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Ne | 2005 |
Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison.
Topics: Administration, Inhalation; Aged; Albuterol; Asthma; Computer Simulation; Equipment Design; Female; | 2005 |
Combination therapy with a long-acting beta2-agonist and an inhaled corticosteroid as initial maintenance treatment in asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthm | 2005 |
A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator.
Topics: Albuterol; Asthma; Bronchodilator Agents; Clinical Protocols; Delayed-Action Preparations; Drug Ther | 2005 |
Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
Topics: Acetates; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic Age | 2005 |
Use of ozone-depleting substances; removal of essential-use designations. Final rule.
Topics: Adrenergic beta-Agonists; Air Pollutants; Air Pollution; Albuterol; Asthma; Chlorofluorocarbons; Cos | 2005 |
Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Broncho | 2005 |
Rapid onset of tolerance to beta-agonist bronchodilation.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Area Under Curve; Asthma; Bronchia | 2005 |
Images in clinical medicine. Airway dilatation after inhalation of a beta-agonist.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Airway Obstruction; Albuterol; Asthma; | 2005 |
The GOAL study: designed to favor a long-acting beta2-agonist?
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchial Hyperr | 2005 |
An own GOAL or a real breakthrough?
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Therapy, Co | 2005 |
Salivary-type hyperamylasemia in theophylline poisoning.
Topics: Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Humans; Hyperamyl | 2005 |
Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Andros | 2005 |
Delayed-type asthmatic response induced by repeated intratracheal exposure to toluene-2,4-diisocyanate in guinea pigs.
Topics: Airway Resistance; Albumins; Albuterol; Allergens; Animals; Asthma; Chromones; Dexamethasone; Diseas | 2005 |
Out-of-hospital administration of albuterol for asthma by basic life support providers.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child | 2005 |
Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Asthmatic | 2005 |
Effects of salbutamol and enantiomers on allergen-induced asthmatic reactions and airway hyperreactivity.
Topics: Albuterol; Allergens; Animals; Asthma; Bronchial Hyperreactivity; Disease Models, Animal; Guinea Pig | 2005 |
Salamol asthma inhaler fails roadside alcohol breath testing.
Topics: Albuterol; Alcohol Drinking; Asthma; Automobile Driving; Breath Tests; Bronchodilator Agents; Ethano | 2005 |
Elevated plasma lactate level associated with high dose inhaled albuterol therapy in acute severe asthma.
Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Asthma; Carbon Dioxide; Female; Forced | 2005 |
Effect of salbutamol on pulmonary responsiveness in chronic pulmonary allergic inflammation in guinea pigs.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Chronic Disease; Disease Models, Animal; Dose- | 2005 |
Altered protein tyrosine phosphorylation in asthmatic bronchial epithelium.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; As | 2005 |
Acute electrophysiologic effects of inhaled salbutamol in humans.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Atrioventricular Node; Dose | 2005 |
Role of combination inhaled corticosteroids and long acting beta agonists in the treatment of adult asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And | 2005 |
Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected].
Topics: Acetates; Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Allergic Agents; Anti-A | 2005 |
Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expi | 2005 |
Beta(2)-adrenergic receptor polymorphisms and response to salbutamol among Indian asthmatics*.
Topics: 5' Untranslated Regions; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchodilator Ag | 2005 |
Effects of various anti-asthmatic agents on mite allergen-pulsed murine bone marrow-derived dendritic cells.
Topics: Albuterol; Androstadienes; Animals; Anti-Asthmatic Agents; Antigens, Dermatophagoides; Asthma; Bone | 2005 |
Treatment patterns for pediatric asthma prior to and after emergency department events.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Albuterol; As | 2005 |
Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Area Under Curve; Asthma; Bronchodilator Agents; | 2005 |
Treatment of mild asthma.
Topics: Acetates; Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Chil | 2005 |
Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Apoptosis; Asthma; Bronchial Hyperreactivity; Disease | 2005 |
[A three-year-old boy with hypoglycaemia].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Child, Prescho | 2005 |
PHARMAC and Ventolin in New Zealand.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Industry; Equipment Design; Equipment F | 2005 |
Time to death, airway wall inflammation and remodelling in fatal asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Death; Female; Humans; Lung; Male; Mucu | 2005 |
PHARMAC responds on salbutamol.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Drug Industry; Equipment Failure Analysis; H | 2005 |
Adherence to asthma controller medication regimens.
Topics: Acetates; Administration, Inhalation; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthm | 2005 |
Pressure oscillation amplitude after interruption of tidal breathing as an index of change in airway mechanics in preschool children.
Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Diagnosis, Computer-A | 2005 |
Association between bronchodilating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of beta-adrenoceptor gene.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi-Square Distribution; Child; Female; Haplot | 2005 |
Recognition of asthma in adolescents and young adults: which objective measure is best?
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Antigens; Asthma; Bro | 2005 |
Lupine inhalation induced asthma in a child.
Topics: Administration, Inhalation; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Chil | 2005 |
Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB.
Topics: Actins; Active Transport, Cell Nucleus; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-In | 2005 |
Misleading data analyses in salmeterol (SMART) study.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Data Interpreta | 2005 |
Long-acting beta2-agonists in asthma: safety concerns.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol Fumarate; Humans; Randomized | 2005 |
Where are the guidelines for the treatment of asthma with panic spectrum symptoms?
Topics: Albuterol; Antidepressive Agents; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans; P | 2005 |
Long-acting inhaled bronchodilators for COPD--lack of logic continues.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Approval; Ethanolamines; | 2005 |
Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 2005 |
Clinically masked increases in bronchial inflammation in guideline-treated persistent asthma.
Topics: Adolescent; Adult; Albuterol; Allergens; Androstadienes; Asthma; Bronchitis; Bronchodilator Agents; | 2006 |
[The management of bronchial asthma during pregnancy--Hungarian experiences].
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Birth Weight; Budesonid | 2005 |
Hearing half the message? A re-audit of the care of patients with acute asthma by emergency ambulance crews in London.
Topics: Acute Disease; Adult; Albuterol; Ambulances; Asthma; Bronchodilator Agents; Child; Clinical Protocol | 2005 |
Nitrogen washout slope in poorly controlled asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Case-Control Studies; Fem | 2006 |
Salmeterol and paroxetine: more evidence for paradoxical medicine.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Clinical Trials | 2006 |
Safety of long-acting beta-agonists--an urgent need to clear the air.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; Drug | 2005 |
Utility and efficacy of fluticasone propionate and salmeterol inhaled from a single inhaler for persistent asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma | 2005 |
Cost-effectiveness of including salmeterol in asthma therapy in a primary care setting in Japan.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi | 2006 |
Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Age | 2005 |
No role for inhaled magnesium sulfate in the treatment of acute asthma?
Topics: Acute Disease; Administration, Inhalation; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; A | 2007 |
A survey of consultant practice: intravenous salbutamol or aminophylline for acute severe childhood asthma and awareness of potential hypokalaemia.
Topics: Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Clinical Competence; Humans; Hypokalemia; I | 2006 |
Beta2 déjà vu.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2006 |
Levalbuterol inhibits human airway smooth muscle cell proliferation: therapeutic implications in the management of asthma.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Asthma; Bronchodilator Agents; Cel | 2006 |
Planning ahead. Albuterol & the potential for hypokalemia-induced ventricular tachycardia in prehospital care.
Topics: Aged; Albuterol; Ambulatory Care; Asthma; Bronchodilator Agents; Emergency Treatment; Female; Humans | 2006 |
Contact dermatitis around a tracheostoma due to salbutamol sulfate and Aldecin.
Topics: Albuterol; Allergens; Anti-Asthmatic Agents; Asthma; Beclomethasone; Dermatitis, Allergic Contact; D | 2006 |
[Fatal asthma in childhod preventable by recognizing risk factors and presenting features].
Topics: Adolescent; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; | 2006 |
Invalid and irrelevant comparisons: apples or oranges?
Topics: Acetates; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cost-Benefit Analysis; Cycloprop | 2006 |
Safety of long-acting beta-agonists.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Dr | 2006 |
A levalbuterol metered-dose inhaler (Xopenex HFA) for asthma.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Metered Dose Inhalers; | 2006 |
Exhaled carbon monoxide levels in school-age children with episodic asthma.
Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Asthma; Breath Tests; Bronchodilator Agents; Carbon | 2006 |
Safety of long-acting beta-agonists.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Therapy, Combination; Hum | 2006 |
Comparing outcomes in patients with persistent asthma: a registry of two therapeutic alternatives.
Topics: Acetates; Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Broncho | 2006 |
Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Br | 2006 |
Children's asthma and the third world: an approach.
Topics: Adolescent; Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Child; Child Health Services; Chil | 2006 |
[The clinicofunctional characterization of the phenotypes of severe uncontrollable bronchial asthma].
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agen | 2006 |
Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone.
Topics: Administration, Inhalation; Adolescent; Adrenal Insufficiency; Albuterol; Androstadienes; Asthma; Br | 2006 |
Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting beta2-agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Preschool; Female; Forced Expiratory Volu | 2006 |
[CD28 and CTLA-4 costimulatory molecules expression on T lymphocytes and NK cells in nonallergic bronchial asthma].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differ | 2006 |
Spontaneous pneumopericardium, pneumomediastinum and subcutaneous emphysema: unusual complications of asthma in a 2-year-old boy.
Topics: Albuterol; Anti-Asthmatic Agents; Anti-Bacterial Agents; Asthma; Child, Preschool; Drug Therapy, Com | 2006 |
Buteyko breathing technique and asthma in children: a case series.
Topics: Adolescent; Albuterol; Androstadienes; Asthma; Breathing Exercises; Bronchodilator Agents; Child; Co | 2006 |
Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice.
Topics: Albuterol; Allergens; Androstadienes; Animals; Anti-Allergic Agents; Asthma; Bronchoalveolar Lavage; | 2006 |
[FEV1 after three years of observation in patients with bronchial asthma and patients with chronic obstructive pulmonary disease].
Topics: Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Female; Follow-Up Studies | 2005 |
Impact of race on the severity of acute episodes of asthma and adrenergic responsiveness.
Topics: Acute Disease; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Black or African American; Emerge | 2006 |
Profiles in patient safety: Antibiotic timing in pneumonia and pay-for-performance.
Topics: Aged, 80 and over; Albuterol; Anti-Bacterial Agents; Asthma; Chest Pain; Female; Humans; Male; Middl | 2006 |
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F | 2006 |
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F | 2006 |
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F | 2006 |
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F | 2006 |
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F | 2006 |
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F | 2006 |
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F | 2006 |
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F | 2006 |
Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Arginine; Asthma; Child; Cross-Sectional Studies; F | 2006 |
Lessons from structure-function studies in asthma: myths and truths about what we teach.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Forced Expi | 2006 |
Summaries for patients. What are the risks of using inhaled long-acting beta-agonist medications for the relief of asthma?
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Ch | 2006 |
Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy.
Topics: Acetates; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; C | 2006 |
PP-ICONS--another tool to help interpret asthma utilization studies.
Topics: Abstracting and Indexing; Acetates; Albuterol; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Drug Th | 2006 |
Telithromycin in acute exacerbations of asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Bacterial Agents; Asthma; Cytoc | 2006 |
Pneumomediastinum and subcutaneous emphysema associated with asthma exacerbation.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Male; Mediastinal Emphysema; Nebulizers and | 2006 |
Long-acting beta agonists--prescribe with care.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2006 |
Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Budeso | 2006 |
Levosalbutamol in the treatment of asthma.
Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Asthma; Bronchial Provocation T | 2006 |
Cysteinyl-leukotrienes in the regulation of beta2-adrenoceptor function: an in vitro model of asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Allergens; Asthma; Bronchi; Bronchodilator Agents; Cells, Cultu | 2006 |
SMART therapy.
Topics: Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Humans; | 2006 |
Variations in management of common inpatient pediatric illnesses: hospitalists and community pediatricians.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Albuterol; An | 2006 |
Effects of long-term low-dose corticosteroid therapy on humoral immunity.
Topics: Acetates; Agammaglobulinemia; Albuterol; Anti-Asthmatic Agents; Antibodies, Bacterial; Antibody Form | 2006 |
Long-acting bronchodilators: time for a re-think.
Topics: Adolescent; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Delayed-Ac | 2006 |
Evidence based answers--is salmeterol safe in asthma?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 2006 |
Treatment outcome of asthma after one year follow-up in health centres of several developing countries.
Topics: Adolescent; Adult; Albuterol; Algeria; Ambulatory Care; Asthma; Bronchodilator Agents; Child; Child, | 2006 |
Magnitude of bronchoprotection of albuterol vs methacholine: relationship to baseline airway caliber.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchoconstrictor Agents; Forced | 2006 |
[Effects of salbutamo and ipraopium bromide inhalation on pulmonary function in young children with asthmatoid bronchitis].
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child, Preschool; | 2006 |
Exhaled breath condensate pH measurement in children with asthma, allergic rhinitis and atopic dermatitis.
Topics: Adolescent; Albuterol; Asthma; Breath Tests; Bronchodilator Agents; Budesonide; Case-Control Studies | 2006 |
Life-threatening asthma during treatment with salmeterol.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; | 2006 |
The structural basis of airways hyperresponsiveness in asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchoconstriction; | 2006 |
Systemic reaction to omalizumab.
Topics: Acetates; Adrenal Cortex Hormones; Aged; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; | 2006 |
The impact of spirometry on pediatric asthma diagnosis and treatment.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Albuterol; Anti-Inflamm | 2006 |
Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction.
Topics: Acetates; Adolescent; Airway Obstruction; Albuterol; Asthma; Child; Chronic Disease; Cyclopropanes; | 2006 |
Dyspnea perception and reversibility of methacholine-induced unlimited airway narrowing in asthmatics.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchoconstriction; Dyspnea; Female; Forced Expirato | 2006 |
The Salmeterol Multicenter Asthma Research Trial.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Black or African American; Bronchodilator Agents; Humans | 2006 |
Cause of death in the SMART Trial.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Black or African American; Cause of Death; Dose-Respons | 2006 |
Why SMART about second-line treatment when first-line treatment is being ignored?
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Therapy, Combination; Gui | 2006 |
Comments on the Salmeterol Multicenter Asthma Research Trial.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug-Related Side Effects and Adverse Reactions; Endpoi | 2006 |
[A move meat beginning...and evolutive].
Topics: Adolescent; Adrenergic Agonists; Albuterol; Angioedema; Asthma; Bronchial Spasm; Bronchodilator Agen | 2006 |
Adherence and persistence with fluticasone propionate/salmeterol combination therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchod | 2006 |
Peak inspiratory flow rate after methacholine challenge in asthmatic patients and its impact on the effect of formoterol via different inhalers.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchial | 2006 |
Room air entrainment during beta-agonist delivery with heliox.
Topics: Adrenergic beta-Agonists; Air; Airway Resistance; Albuterol; Asthma; Dose-Response Relationship, Dru | 2006 |
Symptom perception and adherence to asthma controller medications.
Topics: Adaptation, Psychological; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Aw | 2006 |
Deep inspiration-induced changes in lung volume decrease with severity of asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoconstrictor | 2007 |
(R)-albuterol for asthma: pro [a.k.a. (S)-albuterol for asthma: con].
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Cost of Illness; Disease Models, Animal; Disea | 2006 |
Treatment with (R)-albuterol has no advantage over racemic albuterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Cost of Illness; Dose-Resp | 2006 |
Salamol and inequalities in New Zealand.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Equipment Design; Equipment Failure | 2006 |
Excess mortality in patients with asthma on long-acting beta2-agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Schedule; Hu | 2006 |
The use of rhinitis medications in children receiving initial controller therapy for asthma.
Topics: Acetates; Administration, Intranasal; Adolescent; Adrenal Cortex Hormones; Albuterol; Androstadienes | 2006 |
More on life-threatening asthma and salmeterol.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Logistic Models; Occup | 2006 |
The confounding effects of thoracic gas compression on measurement of acute bronchodilator response.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Middle Aged; Nebulizers and V | 2007 |
Comparative effects of a high-intensity interval warm-up and salbutamol on the bronchoconstrictor response to exercise in asthmatic athletes.
Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchoconstrictor Agents; Exercise; | 2007 |
[How to make easier the treatment of asthma].
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Aerosols; Albuterol; Androstadienes | 2006 |
Salamol and asthma in New Zealand.
Topics: Albuterol; Asthma; Bronchodilator Agents; Ethics, Research; Humans; New Zealand; Research Design; Tr | 2006 |
Inhaled Glucocorticosteroid and Long-Acting beta(2)-Adrenoceptor Agonist Single-Inhaler Combination for Both Maintenance and Rescue Therapy : A Paradigm Shift in Asthma Management.
Topics: Albuterol; Asthma; Budesonide; Drug Combinations; Ethanolamines; Humans; Nebulizers and Vaporizers | 2006 |
Post hoc analysis and claims of superiority in the EXCEL trial.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Budesonide; Drug Combinations; Drug Therap | 2007 |
Lactic acidosis in children with acute exacerbation of severe asthma.
Topics: Acidosis, Lactic; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Humans; Male; Retr | 2007 |
Is salmeterol safe in asthma?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Receptors, Adrenergic, beta-2; Salmeterol Xinaf | 2006 |
Control of airway inflammation.
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Fluticasone; | 2007 |
Beta2-agonists and paresthesias in multiple sclerosis.
Topics: Adrenergic beta-Agonists; Albuterol; Amantadine; Analgesics, Non-Narcotic; Androstadienes; Aromatase | 2007 |
[Bronchodilators in acute asthma: metered dose inhalers or wet nebulizations?].
Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents | 2006 |
Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Albuterol; Androstadie | 2007 |
Onset of action of formoterol versus salmeterol.
Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Salmeterol Xin | 2007 |
[Expiratory flow limitation detected by negative expiratory pressure in patients with bronchial asthma].
Topics: Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Dyspnea; Female; Forced Ex | 2006 |
[Metabolic acidosis in a context of acute severe asthma].
Topics: Acidosis, Lactic; Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Middle Ag | 2007 |
[Acute myocardial infarction triggered by salbutamol in asthma bronchiale].
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents; Electrocardiography; Femal | 2006 |
A matched crossover design for clinical trials.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Case-Control Studies; Clinical Trials as Topic; Cross-O | 2007 |
Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Inflammatory Agen | 2007 |
beta-adrenergic receptor genotype and response to salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Therapy, Co | 2007 |
Salmeterol response and beta(2)-adrenergic receptor genotype.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Genotype; Humans; Receptors, Adr | 2007 |
Correlations between pulse oximetry and peak expiratory flow in acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Chi | 2007 |
Optimization of dosing schedule of daily inhalant dexamethasone to minimize phase shifting of clock gene expression rhythm in the lungs of the asthma mouse model.
Topics: Acetylcholine; Administration, Inhalation; Albuterol; Animals; Anti-Inflammatory Agents; Asthma; Cel | 2007 |
Asthma: fatal exacerbations with long-acting beta2 agonist therapy without concomitant steroid therapy.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; Clinical Tria | 2007 |
Adenosine for salbutamol-induced supraventricular tachycardia.
Topics: Adenosine; Albuterol; Anti-Arrhythmia Agents; Asthma; Bronchodilator Agents; Humans; Male; Tachycard | 2007 |
Case records of the Massachusetts General Hospital. Case 15-2007. A 20-year-old woman with asthma and cardiorespiratory arrest.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Cause of Death; Fatal Outcome; F | 2007 |
Clinical Decisions. Treatment of mild persistent asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm | 2007 |
The role of the large airways on smooth muscle contraction in asthma.
Topics: Albuterol; Asthma; Bronchi; Bronchodilator Agents; Humans; Muscle Contraction; Muscle, Smooth | 2007 |
Hyperlactaemia due to nebulised salbutamol.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lactic Acid; Nebulizers and Vaporiz | 2007 |
Clinical Decisions. Mild persistent asthma--polling results.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Becl | 2007 |
Benefits of long-acting beta2-agonists.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; De | 2007 |
Anti-inflammatory activity of beta2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Blotting, Western; Bronchi; Bronchodilator Agents; Bude | 2007 |
Albuterol inhalers.
Topics: Aerosol Propellants; Albuterol; Asthma; Chlorofluorocarbons; Drugs, Generic; Fees, Pharmaceutical; H | 2007 |
Aseptic femoral head necrosis in a patient receiving long term courses of inhaled and intranasal corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Anti-Asthmatic Agents; Arthro | 2007 |
Identification of bronchodilator responsiveness by forced oscillation admittance in children.
Topics: Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Child; Chi | 2007 |
Efficacy of the combination of fluticasone propionate and salmeterol in patients with moderate persistent asthma within a "real-life" setting.
Topics: Administration, Inhalation; Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Th | 2007 |
Reducing asthma treatment.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Administration Schedule; Drug Therapy | 2007 |
Beclomethasone and albuterol in mild asthma.
Topics: Administration, Inhalation; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Drug Combinati | 2007 |
Reducing asthma treatment.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 2007 |
Beclomethasone and albuterol in mild asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Child; | 2007 |
Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Ant | 2007 |
A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
Topics: Adult; Aerosol Propellants; Aged; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Com | 2007 |
Interrupter resistance short-term repeatability and bronchodilator response in preschool children.
Topics: Albuterol; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Child; | 2007 |
Salbutamol, terbutaline and pirbuterol allergy in an asthmatic patient.
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Drug Hypersensitivit | 2007 |
Hyperlactaemia in asthmatics.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Lactic Acid | 2007 |
Body mass index and response to emergency department treatment in adults with severe asthma exacerbations: a prospective cohort study.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; Asthma; Bo | 2007 |
The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Biological Availability; Caco-2 Cells; CHO Cel | 2007 |
Commentary on "The role of the large airways on smooth muscle contraction in asthma".
Topics: Albuterol; Artifacts; Asthma; Bronchi; Bronchoconstriction; Bronchoconstrictor Agents; Bronchodilato | 2007 |
Commentary on "The role of the large airways on smooth muscle contraction in asthma".
Topics: Albuterol; Artifacts; Asthma; Bronchi; Bronchoconstriction; Bronchodilator Agents; Humans; Lung Volu | 2007 |
Commentary on "The role of the large airways on smooth muscle contraction in asthma".
Topics: Albuterol; Animals; Asthma; Bronchi; Bronchodilator Agents; Disease Models, Animal; Humans; Lung Vol | 2007 |
Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation.
Topics: Acute Disease; Adult; Aged; Albuterol; Asthma; Female; Humans; Inhalation Spacers; Lung; Male; Meter | 2008 |
The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations.
Topics: Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Drug Costs; Drug Therapy, Combination; Dru | 2007 |
A 39-year-old woman with intractable asthma.
Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Female; Forced Expiratory Volume; | 2007 |
[Salmeterol for the treatment of childhood asthma: the experience of 96 cases].
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Child, Preschool; Female; Forced Exp | 2007 |
Adrenergic responsiveness: FEV1 and symptom differences in Whites and African Americans with mild asthma.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Black or African American; Bronchial Provocation | 2007 |
Validating a guidelines based asthma decision support system: step one.
Topics: Albuterol; Asthma; Bronchodilator Agents; Decision Making, Computer-Assisted; Female; Humans; Male; | 2007 |
Ethnic-specific differences in bronchodilator responsiveness among African Americans, Puerto Ricans, and Mexicans with asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Black or African American; Bronchodilator Agents; Child; Femal | 2007 |
Heterogeneity of bronchoconstriction does not distinguish mild asthmatic subjects from healthy controls when supine.
Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provoc | 2008 |
Bronchodilator response: another piece in the asthma mosaic.
Topics: Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans; Nebulizers and Vaporizer | 2007 |
Value of the bronchodilator response in assessing controller naïve asthmatic children.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Forced Expiratory Volume; | 2007 |
Metabolic acidosis in severe asthma: Is it the disease or is it the doctor?
Topics: Acidosis; Acute Disease; Albuterol; Asthma; Blood Gas Analysis; Bronchodilator Agents; Child, Presch | 2007 |
Paradoxical asthma hazard of short-acting beta2-agonists.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstrictio | 2008 |
A predictive score for unfavorable outcome of acute asthma in the emergency room.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Emergency Service, Hospital; Female; Health | 2007 |
Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Budesonide; Cells, Cultured; E | 2008 |
Salamol--was it worth it?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Costs; Drugs, Generic; | 2007 |
The effects of Heliox on the output and particle-size distribution of salbutamol using jet and vibrating mesh nebulizers.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Carriers; Equipment Desig | 2007 |
[Voiding difficulties in a child attributed to the use of ipratropium and salbutamol].
Topics: Administration, Inhalation; Albuterol; Asthma; Child, Preschool; Female; Humans; Ipratropium; Urinat | 2007 |
[More asthma death cases with beta-2-antagonists: with inhaled corticosteroids on the safe side?].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Clinica | 2007 |
Benefits of combination therapy on exacerbations in nonsmoking patients with asthma.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Fluticasone; Fluticason | 2008 |
Inhibition by salmeterol and cilomilast of fluticasone-enhanced IP-10 release in airway epithelial cells.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Carboxylic Acids; Cells, Cultured; Chemokine CXCL10; Cy | 2008 |
Treatment of mild persistent asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthm | 2008 |
Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Asthma | 2008 |
Adenosine 5'-monophosphate in asthma: gas exchange and sputum cellular responses.
Topics: Adenosine Monophosphate; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation T | 2008 |
The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Costs and Cost Analysis | 2008 |
Increased RhoGDI2 and peroxiredoxin 5 levels in asthmatic murine model of beta2-adrenoceptor desensitization: a proteomics approach.
Topics: Albuterol; Animals; Asthma; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Female; G | 2008 |
Benzalkonium chloride induced bronchoconstriction in patients with stable bronchial asthma.
Topics: Adult; Albuterol; Asthma; Benzalkonium Compounds; Bronchial Provocation Tests; Bronchoconstriction; | 2007 |
The economic effect of the hydrofluoroalkane albuterol transition on children with asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Humans; Hydrocarbons, Fluorinated; Metered Dose Inh | 2008 |
Utility of impulse oscillometry in young children with asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Eosinophils; Female; Humans; Immu | 2008 |
The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female | 2008 |
The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female | 2008 |
The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female | 2008 |
The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female | 2008 |
Proliferation is not increased in airway myofibroblasts isolated from asthmatics.
Topics: Adult; Albuterol; Androstadienes; Asthma; Bronchodilator Agents; Cell Proliferation; Cyclin D1; Fema | 2008 |
Paediatric acute asthma management in Australia and New Zealand: practice patterns in the context of clinical practice guidelines.
Topics: Acute Disease; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Australia; Child; | 2008 |
Mechanisms by which S-albuterol induces human bronchial smooth muscle cell proliferation.
Topics: Albuterol; Asthma; Blotting, Western; Bronchodilator Agents; Cell Proliferation; Cyclin-Dependent Ki | 2008 |
Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children.
Topics: Adolescent; Albuterol; Argentina; Asthma; Bronchodilator Agents; Child; Drug Tolerance; Female; Forc | 2008 |
FEF75 in asthma management.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Ast | 2007 |
Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronc | 2008 |
An under-recognized complication of treatment of acute severe asthma.
Topics: Acidosis, Lactic; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Male; Respiration, Artifi | 2008 |
Paradoxical response to levalbuterol.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Diseases; Constriction, Pathologic; Hu | 2008 |
Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchodilator Agents; C | 2008 |
[Influence of education level on self-evaluation and control of patients with bronchial asthma].
Topics: Adolescent; Adult; Aged; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Educational Statu | 2008 |
Age-dependency of alpha- and beta-adrenoceptors on thrombocytes and lymphocytes of asthmatic and nonasthmatic children.
Topics: Adolescent; Adult; Aging; Albuterol; Asthma; Blood Platelets; Child; Child, Preschool; Humans; Infan | 1984 |
Nebulised salbutamol in general practice.
Topics: Acute Disease; Albuterol; Asthma; Child; Child, Preschool; Family Practice; Humans; Infant; Methods | 1980 |
Bronchodilating drugs and airway reactivity.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Female; Forced Expirato | 1980 |
Combined vs. sequential vs. single-entity therapy.
Topics: Albuterol; Aminophylline; Asthma; Beclomethasone; Drug Therapy, Combination; Ephedrine; Epinephrine; | 1981 |
[Treatment of bronchial asthma].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Cromolyn Sodium | 1981 |
Maximal oxygen consumption rate in patients with bronchial asthma-the effect of beta 2-adrenoreceptor stimulation.
Topics: Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Pressu | 1980 |
beta 2-Adrenoceptor stimulants and theophylline in asthma therapy.
Topics: Administration, Oral; Adrenergic beta-Agonists; Aerosols; Albuterol; Aminophylline; Asthma; Bronchod | 1981 |
[Protective effect of adrenergic alpha blockaders on posthistamine bronchial spasm].
Topics: Adrenergic alpha-Antagonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchial Spasm | 1981 |
Effect of beta 2-adrenergic stimulation on serum lipids.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; | 1982 |
Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Dose-Response Relationship, Drug; Forced Expirat | 1983 |
Safe drugs for childhood asthma?
Topics: Aerosols; Albuterol; Asthma; Child, Preschool; Humans | 1983 |
Beta-adrenergic drugs in the management of asthma in athletes.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Asthma, Exercise-Induced; Dose-Response Relationship, D | 1984 |
Inhaled therapy reduces morning dips in asthma.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Beclomethasone; Child; Circadian Rhythm; Drug Therap | 1984 |
Analysis of beta-sympathicomimetics in man with high performance liquid chromatography using mode sequencing and electrochemical detection.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Chromatography, High Pressure Liquid; Food; Humans; Kin | 1984 |
Beta-adrenoceptor agonist responses in the skin and lungs of asthmatic subjects.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Endothelium; Forced Expiratory Volume; Histamine | 1984 |
Adrenergic receptors of normal and asthmatic airways.
Topics: Adrenergic alpha-Agonists; Albuterol; Asthma; Bronchial Spasm; Catecholamines; Dose-Response Relatio | 1984 |
Persisting airflow limitation in asthmatics receiving routine self-adjusted medication.
Topics: Adult; Aerosols; Age Factors; Albuterol; Asthma; Beclomethasone; Female; Forced Expiratory Volume; H | 1984 |
Asthma caused by occupational exposure to a furan-based binder system.
Topics: Albuterol; Asthma; Binding Sites; Butanols; Forced Expiratory Volume; Furans; Histamine Release; Hum | 1980 |
Anti-allergic activities of the beta-adrenoceptor stimulant formoterol (BD 40A).
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Ethanolamines; Female; Formoterol Fumarate; Gu | 1981 |
Histamine content of sputum from patients with asthma and chronic bronchitis.
Topics: Albuterol; Animals; Asthma; Bronchitis; Carcinoma, Bronchogenic; Chronic Disease; Guinea Pigs; Hista | 1982 |
Do human mast cells possess functional beta adrenoceptors in vivo?
Topics: Adult; Albuterol; Asthma; Female; Histamine; Histamine Release; Humans; Male; Mast Cells; Propranolo | 1983 |
Effects of fenoterol hydrobromide on histamine release from human leukocytes.
Topics: Albuterol; Allergens; Asthma; Child; Ethanolamines; Fenoterol; Histamine Release; Humans; Leukocytes | 1983 |
A comparison of late reactions to antigen and exercise.
Topics: Albuterol; Antigens; Asthma; Asthma, Exercise-Induced; Bronchial Provocation Tests; Chemotactic Fact | 1984 |
Organizing a general-practitioner therapeutical trial.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchitis; Clinical Trials as Topic; Double-Blind M | 1982 |
Maximal expiratory flows and forced vital capacity in normal, asthmatic and bronchitic subjects after salbutamol and ipratropium bromide.
Topics: Adult; Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchi; Bronchitis; Dose-Response Relatio | 1982 |
Impaired atropine responsiveness in asthma: role of atopy.
Topics: Adult; Aged; Albuterol; Asthma; Atropine; Atropine Derivatives; Female; Humans; Hypersensitivity, Im | 1983 |
[Asthmatic crises in children. Value of salbutamol nebulization].
Topics: Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Infant; Respiratory Therapy | 1983 |
Factors determining residual volume in normal and asthmatic subjects.
Topics: Adult; Aerosols; Albuterol; Asthma; Female; Humans; Ipratropium; Lung Volume Measurements; Male; Mid | 1984 |
Reversible airflow obstruction: clinical spectrum and responsiveness to anticholinergic drugs.
Topics: Adult; Aged; Airway Resistance; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Female; Forced | 1984 |
Asthma vs. non-specific reversible airflow obstruction: clinical features and responsiveness to anticholinergic drugs.
Topics: Adolescent; Adult; Aged; Airway Resistance; Albuterol; Asthma; Atropine Derivatives; Bronchial Provo | 1984 |
[Influence of sympathomimetic drugs on immediate intradermal reactions induced by allergens].
Topics: Adult; Albuterol; Asthma; Clenbuterol; Ethanolamines; Humans; Hypersensitivity, Immediate; Intraderm | 1984 |
Cyclic nucleotides, beta receptors, and bronchial asthma.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Albuterol; Asthma; Bronchi; Cyclic AMP; Cyclic GMP; Epinephrine | 1980 |
[The treatment of asthmatic patients using an alpha-adrenoreceptor blocking agents--changes of various pulmonary function tests and plasma cyclic AMP levels (author's transl)].
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Cyclic AMP; Female; Humans; Lung Volume Measurements; Ma | 1981 |
Plasma cyclic nucleotide levels in exercise-induced asthma.
Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Cyclic AMP; Cyclic GMP; Humans; Male; Middle Age | 1981 |
Anti-asthmatic activity of BB-1502 by inhalation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Albuterol; Animals; Ascaris; Asthma; Bronchodilator Ag | 1982 |
Selective subsensitization of beta-adrenergic receptors in central airways of asthmatics and normal subjects during long-term therapy with inhaled salbutamol.
Topics: Administration, Intranasal; Adult; Albuterol; Asthma; Bronchial Spasm; Bronchodilator Agents; Dose-R | 1982 |
Relationships between responsiveness of the bronchi to acetylcholine and cyclic AMP response of lymphocytes to beta 1- and beta 2-adrenergic receptor stimulation in patients with asthma.
Topics: Acetylcholine; Albuterol; Asthma; Bronchi; Cyclic AMP; Humans; Lymphocytes; Norepinephrine; Receptor | 1983 |
Interactions between beta-adrenergic activity and prostaglandin synthesis in control of airways bronchoconstrictor responsiveness.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Female; Histamine; Humans; Indomethacin; Male; | 1983 |
Is asthma due to partial beta-blockade of airways?
Topics: Airway Resistance; Albuterol; Asthma; Bronchi; Dose-Response Relationship, Drug; Humans; Receptors, | 1983 |
Circadian variation in number and affinity of beta 2-adrenoceptors in lymphocytes of asthmatic patients.
Topics: Albuterol; Asthma; Circadian Rhythm; Forced Expiratory Volume; Humans; Hydrocortisone; Kinetics; Lym | 1984 |
Airway hyperreactivity. Cholinergic and adrenergic receptors.
Topics: Albuterol; Asthma; Bronchi; Humans; Parasympathetic Nervous System; Practolol; Prenalterol; Receptor | 1983 |
Comparison of beta 2-adrenoceptor stimulation in bronchial and skeletal muscle in experimental and clinical studies.
Topics: Albuterol; Animals; Asthma; Bronchi; Cats; Guinea Pigs; Histamine; Humans; Muscle, Smooth; Muscles; | 1984 |
Influence of beta-receptor-agonists and glucocorticoids on alpha- and beta-adrenoceptors of isolated blood cells from asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Blood Platelets; Child; Humans; Infant; Lymphocytes; Prednisolone; Ra | 1983 |
Bronchodilator effects of fenoterol and salbutamol administered by intermittent positive pressure breathing to patients with asthma or chronic obstructive bronchitis.
Topics: Albuterol; Asthma; Bronchitis; Ethanolamines; Female; Fenoterol; Humans; Intermittent Positive-Press | 1984 |
Improvement after training of children with exercise-induced asthma.
Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Cromolyn Sodium; Exercise Therapy; F | 1983 |
Addiction to aerosol treatment: the asthmatic alternative to glue sniffing.
Topics: Adolescent; Aerosol Propellants; Aerosols; Albuterol; Asthma; Beclomethasone; Female; Humans; Substa | 1983 |
A new treatment for asthma: promotional expediency versus pharmaceutical responsibility.
Topics: Albuterol; Asthma; Beclomethasone; Drug Combinations; Humans | 1984 |
Oxygen as a driving gas for nebulisers: safe or dangerous?
Topics: Adult; Aerosols; Aged; Air; Albuterol; Asthma; Bronchitis; Carbon Dioxide; Female; Humans; Male; Mid | 1984 |
Illogical warnings on Ventolin inhalers.
Topics: Albuterol; Asthma; Drug Labeling; Humans | 1984 |
Domiciliary nebulized beta-agonists. Long-term treatment in asthmatics, and drug intake and plasma levels in acute asthma.
Topics: Adult; Aerosols; Aged; Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Human | 1984 |
Decrease of exercise-induced asthma after physical training.
Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Carbon Dioxide; Child; Combined Modality Therapy; Cromo | 1984 |
[Exercise-induced pathophysiological changes in asthmatic children. VII. Late asthmatic response in exercise-induced asthma: changes in chemical mediators and effects of the use of a mask and drugs].
Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Chemotactic Factors; Child; Cromolyn Sodium | 1984 |
Intravenous salbutamol in the treatment of status asthmaticus in children.
Topics: Adolescent; Adult; Albuterol; Asthma; Carbon Dioxide; Child; Child, Preschool; Drug Evaluation; Hear | 1984 |
Evaluation of complement (C3) inhibition in vitro by drugs used in the management of bronchial asthma.
Topics: Adolescent; Adult; Albuterol; Aminophylline; Animals; Asthma; Complement Activation; Complement C3; | 1984 |
Non-specific broncho-reactivity obtained with an ultrasonic aerosol of distilled water.
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Cromolyn Sodium; Female; H | 1980 |
The effect of vagolytic drugs on airway obstruction in patients with bronchial asthma.
Topics: Airway Obstruction; Albuterol; Asthma; Atropine; Forced Expiratory Volume; Humans; Ipratropium; Maxi | 1981 |
Influence of age on response to ipratropium and salbutamol in asthma.
Topics: Adult; Aging; Albuterol; Asthma; Atropine Derivatives; Forced Expiratory Volume; Humans; Ipratropium | 1981 |
[Measurement of the effect of a bronchodilator using FEV1: how to express it?].
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Male; Middle Age | 1984 |
Cardiac output and blood pressure in asthmatic children before and during induced asthma.
Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Pressure; Bronchi; Cardiac Output; Ch | 1984 |
Drug intake and plasma concentrations in acute asthma.
Topics: Acute Disease; Administration, Oral; Aerosols; Albuterol; Asthma; Ethanolamines; Female; Fenoterol; | 1984 |
Nifedipine enhances the bronchodilator effect of salbutamol.
Topics: Adult; Albuterol; Asthma; Double-Blind Method; Drug Synergism; Forced Expiratory Volume; Humans; Mal | 1984 |
Atropine resistance in asthma: definition and provisional hypothesis.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Atropine; Drug Resistance; Female; Forced Expiratory Vol | 1984 |
Safety and efficacy of salbutamol aerosol on Dermatophagoides farinae induced bronchospasm in asthmatic patients.
Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Airway Obstruction; Albuterol; Antigens; As | 1984 |
Arterial oxygen desaturation following salbutamol inhalation in acute asthma.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child, Preschool; Female; Humans; Male; Oxygen | 1984 |
Multiparametrical approach to fog-challenge-induced bronchial hyperreactivity in asthmatics--protective effects of salbutamol plus beclomethasone dipropionate.
Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Drug Therapy, Combination; Humans; Male; Middle Aged; R | 1984 |
Metabolic effects of salbutamol in bronchial asthma.
Topics: Albuterol; Asthma; Blood Glucose; Fatty Acids, Nonesterified; Humans; Potassium | 1984 |
Treatment of hypertension in mild asthmatic patients with atenolol.
Topics: Adult; Albuterol; Asthma; Atenolol; Blood Pressure; Electrocardiography; Exercise Test; Female; Hear | 1984 |
Lung distensibility and airway function in asthmatic children.
Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Child; Huma | 1984 |
[Comparative study of the effect of a single oral dose of theophylline and etamiphyllin in children with asthma].
Topics: Administration, Oral; Adolescent; Albuterol; Asthma; Child; Double-Blind Method; Drug Evaluation; Fo | 1984 |
The antidiuretic hormone response to therapy for acute asthma.
Topics: Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Female; Fluid Therapy; Humans; Male; Oxyg | 1984 |
[Effective combined therapy of selective beta 1-adrenergic antagonist and selective beta 2-adrenergic agonist in a patient with bronchial asthma and hypertrophic cardiomyopathy].
Topics: Albuterol; Asthma; Cardiomyopathy, Hypertrophic; Drug Therapy, Combination; Female; Humans; Metoprol | 1984 |
Anti-asthmatic effects and drug tolerance of selective beta 2-adrenergic stimulants in guinea-pigs.
Topics: Albuterol; Animals; Asthma; Disease Models, Animal; Drug Tolerance; Ethanolamines; Fenoterol; Guinea | 1983 |
The use of fenoterol powder for the treatment of children with asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Ethanolamines; Female; Fenoterol; Humans; Male; Powders | 1983 |
Effect of domiciliary treatment with nebulized beta 2-stimulants--a retrospective follow-up of 102 patients.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchitis; Chronic Disease; Follow-Up Studies; Humans; Mi | 1984 |
Predicting rapid and slow response to treatment in acute severe asthma.
Topics: Acute Disease; Adult; Age Factors; Albuterol; Asthma; Female; Humans; Hydrocortisone; Male; Peak Exp | 1983 |
Ascaris-induced bronchoconstriction in primates experimentally infected with Ascaris suum ova.
Topics: Airway Resistance; Albuterol; Allergens; Animals; Ascariasis; Ascaris; Asthma; Atropine; Benzopyrans | 1983 |
An inexpensive nebuliser for asthmatic patients.
Topics: Aerosols; Aged; Albuterol; Asthma; Child; Female; Humans; Male; Respiratory Therapy | 1983 |
Aerosol bag for administration of bronchodilators to young asthmatic children.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; Res | 1984 |
Asthma and irreversible airflow obstruction.
Topics: Adult; Age Factors; Albuterol; Asthma; Chronic Disease; Female; Forced Expiratory Volume; Humans; Lu | 1984 |
[Severe status asthmaticus in children: evaluation and treatment].
Topics: Albuterol; Aminophylline; Asthma; Child; Humans; Isoproterenol; Metaproterenol; Respiration, Artific | 1984 |
Corticosteroid resistance in chronic asthma.
Topics: Adrenal Cortex Hormones; Adult; Airway Obstruction; Albuterol; Asthma; Bronchi; Chronic Disease; Cir | 1981 |
Bronchodilator effect of sodium cromoglycate and its clinical implications.
Topics: Albuterol; Asthma; Child; Cromolyn Sodium; Humans | 1981 |
Deaths from asthma on holiday.
Topics: Aerosols; Albuterol; Asthma; Equipment and Supplies; Humans | 1981 |
Misplaced confidence in nebulised bronchodilators in severe asthmatic attacks.
Topics: Adult; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male | 1982 |
Effects of oral theophylline and oral salbutamol in the treatment of asthma.
Topics: Albuterol; Asthma; Child; Humans; Theophylline | 1983 |
[Inhalation of beta-stimulators: comparison of the effects of 6 different inhalation devices].
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchi; Female; Humans; Male; Middle Aged; Respiratory Fu | 1983 |
MMEF or FEV1 in estimating bronchial obstruction in asthmatic children.
Topics: Administration, Intranasal; Adolescent; Airway Obstruction; Albuterol; Asthma; Bronchospirometry; Ch | 1983 |
[Therapeutic and preventive procedures in bronchial asthma in children].
Topics: Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Child; Drug Evaluation; Humans; Metaprotere | 1983 |
Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator, and airway calibre.
Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Circadian Rhythm; Female; Forced Expiratory Volume; Histami | 1982 |
A comparison between different methods for detecting bronchial hyperreactivity. Bronchial hyperreactivity: methods of study.
Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchi; Bronchial Provocation Tests | 1980 |
The response of asthmatic patients and normal subjects to maximum respiratory manoeuvres. Spirometry--induced bronchoconstriction.
Topics: Adult; Albuterol; Asthma; Bronchi; Forced Expiratory Volume; Humans; Maximal Voluntary Ventilation; | 1980 |
[Protection from exercise-induced asthma after salbutamol (Ventolin) in powder form, inhaled with the Rotahaler].
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Female; Humans; Male; Midd | 1981 |
Inhaled bronchodilators: a comparison of different methods of inhaling.
Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male | 1981 |
Clinical use of dry powder systems.
Topics: Albuterol; Asthma; Beclomethasone; Fenoterol; Humans; Powders; Respiratory Therapy | 1982 |
Status asthmaticus--a case history.
Topics: Adolescent; Albuterol; Asthma; Humans; Intermittent Positive-Pressure Breathing; Male; Physical Ther | 1980 |
Drug-induced changes in airways obstruction reflected by forced expiratory flows and airway resistance measured with an oscillometric method using quiet breathing.
Topics: Adult; Aged; Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Male; M | 1981 |
Airway responsiveness to histamine and methacholine: relationship to minimum treatment to control symptoms of asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Female; Forced Exp | 1981 |
Persistent cough a forme-fruste of asthma.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchial Spasm; Child; Child, Preschool; Cough; Eosinophil | 1982 |
Abuse of salbutamol inhalers in young people.
Topics: Administration, Intranasal; Adolescent; Albuterol; Asthma; Chlorofluorocarbons, Methane; Dose-Respon | 1982 |
Status asthmaticus and the syndrome of inappropriate secretion of antidiuretic hormone.
Topics: Acute Disease; Albuterol; Asthma; Female; Humans; Inappropriate ADH Syndrome; Middle Aged; Vasopress | 1982 |
Failure of body plethysmography in bronchial asthma.
Topics: Acetylcholine; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Spasm; Dilatation; Fal | 1982 |
Bronchodilator tolerance and dosage.
Topics: Albuterol; Asthma; Drug Tolerance; Humans | 1982 |
Analysis of antigen-induced changes in pulmonary mechanics in sensitized inbred rats.
Topics: Albuterol; Aminophylline; Animals; Antigens; Asthma; Female; Forced Expiratory Volume; Lung; Male; M | 1982 |
Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects.
Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Dose- | 1982 |
Long-term stability of bronchial responsiveness to histamine.
Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchi; Bronchial Provocation Tests; Female; Forced Expir | 1982 |
Childhood bronchial asthma in northern Nigeria.
Topics: Adolescent; Albuterol; Asthma; Breast Feeding; Child; Child, Preschool; Feces; Female; Humans; Hydro | 1982 |
Domiciliary monitoring of lung function.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Circadian Rhythm; Humans; Middle Aged; Monitoring, Physi | 1982 |
Intramuscular and intravenous albuterol in the treatment of asthma.
Topics: Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Hemodynamics; Humans; Infusions, Pare | 1982 |
Interactions between response to inhaled prostaglandin E2 and chronic beta-adrenergic agonist treatment.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Dose-Response Relationship, Drug; Humans; Male | 1982 |
Respiratory heat and water loss during exercise in patients with asthma. Effect of repeated exercise challenge.
Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Body Temperature; Body Water; Exerci | 1982 |
[Pharmacological testing in assessing bronchial function].
Topics: Acetylcholine; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; Child | 1982 |
[Clinical forms and lung physiology changes in children with bronchial asthma].
Topics: Airway Resistance; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Female; Humans; Lung Volume M | 1982 |
Histamine dose-response relationships in normal and asthmatic subjects. The importance of starting airway caliber.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Atropine; Bronchial Provocation Tests; Chlorpheniramine | 1982 |
[A case from practice (12)].
Topics: Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Female; Humans; Middle Aged | 1982 |
Cardio-selective beta-adrenergic therapy in a patient with asthma and hypertrophic obstructive cardiomyopathy.
Topics: Adult; Albuterol; Asthma; Cardiomyopathy, Hypertrophic; Female; Heart; Humans; Male; Pindolol | 1981 |
The effect of bronchodilators on diurnal rhythms in airway obstruction.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Circadian Rhythm; Fem | 1981 |
Tonic inspiratory muscle activity as a cause of hyperinflation in asthma.
Topics: Adult; Albuterol; Asthma; Diaphragm; Electromyography; Female; Humans; Intercostal Muscles; Lung Vol | 1981 |
Adrenergic compounds and corticosteroids.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aerosols; Albuterol; Asthma; Beclomethasone; Bronchod | 1981 |
Salbutamol inhalation in chronic asthma bronchiale: dose aerosol vs jet nebulizer.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Dosage Forms; Female; Forced Expiratory Volume; Humans; Ma | 1981 |
Exercise-induced asthma in Nepalese children.
Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Child, Preschool; Exercise Test; Fem | 1981 |
Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Dose-Response Relationship, Drug; Humans; Injections, I | 1981 |
Maximum or mean FEV1 for bronchodilator aerosol evaluation in acute asthmatics.
Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Evaluation; Forced Expiratory Volume; Human | 1981 |
Albuterol.
Topics: Aerosols; Albuterol; Asthma; Humans | 1981 |
[Electrocardiographic changes in asthma as affected by various drugs combined with phentolamine (Regitine)].
Topics: Adult; Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Electrocardiography; Female; Hea | 1981 |
[Comparison of bronchodilator effects of salbutamol and theophylline (author's transl)].
Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Injections, Intravenous; Male; M | 1981 |
The lack of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol.
Topics: Adult; Aerosols; Albuterol; Asthma; Dose-Response Relationship, Drug; Female; Humans; Isoproterenol; | 1981 |
The use of albuterol for the prevention of exercise-induced bronchospasm.
Topics: Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Atropine; Child; Humans; Isoproterenol; Theop | 1981 |
Worldwide experience with albuterol (salbutamol).
Topics: Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Blood Glucose; Child; Heart Rate; Humans; Inj | 1981 |
Salbutamol powder inhalation for bronchial asthma.
Topics: Administration, Intranasal; Adolescent; Adult; Albuterol; Asthma; Child; Humans; Powders | 1981 |
[Evaluation of the bronchodilating effect of TH 1165 A and of salbutamol in patients with spastic obstructive ventilatory syndrome].
Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Spasm; Ethanolamines; Fenoterol; Humans; Lung Dis | 1981 |
[Fenoterol in the diagnosis and treatment of reversible bronchospasm].
Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Ethanolamines; Female; Fenoterol; Humans; Lung Diseases, | 1981 |
Cardiopulmonary effects of fenoterol and salbutamol aerosols.
Topics: Aerosols; Albuterol; Arrhythmias, Cardiac; Asthma; Blood Pressure; Dose-Response Relationship, Drug; | 1980 |
[Salbutamol in asthmatic children, lung function and plasma levels of free salbutamol after treatment with salbutamol rectally and by pressurized aerosol (author's transl)].
Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Respiratory Function Tests | 1980 |
Bronchomotor effect of bronchoconstriction-induced deep inspirations in asthmatics.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Carbachol; Constr | 1980 |
[Problems of indication and execution of long-term steroid therapy in advanced disabling bronchial asthma].
Topics: Adrenal Cortex Hormones; Albuterol; Altitude; Asthma; Beclomethasone; Humans; Prednisone; Respirator | 1980 |
[Significance of reversibility of obstructive respiratory disorders in bronchial asthma for prognosis of the effectiveness of treatment].
Topics: Aerosols; Airway Obstruction; Albuterol; Asthma; Humans; Prognosis | 1980 |
Acute myocardial infarction following intravenous salbutamol.
Topics: Albuterol; Asthma; Humans; Male; Middle Aged; Myocardial Infarction | 1980 |
Effects of long-term inhaled salbutamol therapy on the provocation of asthma by histamine.
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Drug Tolerance; Female; Forced Expiratory Vol | 1980 |
Teaching patients correct use of asthma aerosols.
Topics: Aerosols; Albuterol; Asthma; Humans; Patient Compliance; Physician-Patient Relations; Teaching | 1980 |
The effectiveness of nebulised salbutamol in the management of acute asthma in children.
Topics: Administration, Intranasal; Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Prescho | 1980 |
Comparative efficacy of salbutamol by pressurized aerosol and wet nebulizer in acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Dose-Response Relationship, Dru | 1980 |
An unusual asthma death.
Topics: Albuterol; Asthma; Child; Humans; Male | 1981 |
Reversible airway obstruction in cystic fibrosis.
Topics: Adolescent; Age Factors; Airway Obstruction; Albuterol; Asthma; Child; Child, Preschool; Cystic Fibr | 1980 |
Long-acting beta 2-agonists and their role in asthma management.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Humans; Salmeterol Xinafoate | 1995 |
Asthma mortality and beta-agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate | 1995 |
Constitutive expression of endothelin in bronchial epithelial cells of patients with symptomatic and asymptomatic asthma and modulation by histamine and interleukin-1.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Bronchoscopy; Cells, Cultured; | 1995 |
Pediatric asthma--a correlation of clinical treatment and oxygen saturation.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Nebulizers and Vaporiz | 1995 |
Paradoxical bronchoconstriction with salbutamol.
Topics: Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; Child, Preschool; Humans; Male | 1995 |
Bronchodilation subsensitivity to salbutamol after salmeterol.
Topics: Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Forced Expiratory Volume | 1995 |
Bronchodilation subsensitivity to salbutamol after salmeterol.
Topics: Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans; Lung; Peak Expiratory Fl | 1995 |
Bronchodilation subsensitivity to salbutamol after salmeterol.
Topics: Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Forced Expiratory Volume | 1995 |
Emergency treatment of asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Emergencies; Humans; Terbutaline | 1995 |
Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan.
Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Ae | 1995 |
Eosinophil cationic protein and tidal flow volume loops in children 0-2 years of age.
Topics: Albuterol; Asthma; Blood Proteins; Bronchial Provocation Tests; Bronchodilator Agents; Case-Control | 1995 |
Long-acting inhaled beta agonists in the treatment of bronchial asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Delayed-Action Preparations | 1995 |
Supraventricular tachycardia: a complication of nebulized albuterol.
Topics: Adult; Albuterol; Asthma; Electrocardiography; Female; Humans; Infant; Male; Nebulizers and Vaporize | 1995 |
Generic salbutamol metered dose inhalers.
Topics: Aerosols; Albuterol; Asthma; Drug Delivery Systems; Humans; Lung; Nebulizers and Vaporizers; Time Fa | 1995 |
Generic salbutamol metered dose inhalers.
Topics: Aerosols; Albuterol; Asthma; Drug Delivery Systems; Humans; Lung; Nebulizers and Vaporizers; Time Fa | 1995 |
A new approach to the evaluation of bronchodilatator response.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Evaluation Studies as Topic; Forced Expiratory Volu | 1994 |
Forced oscillation technique vs spirometry to assess bronchodilatation in patients with asthma and COPD.
Topics: Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Lung Diseases, Obstr | 1995 |
Sympathomimetics in severe acute asthma.
Topics: Acute Disease; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Humans; Injections, | 1995 |
[Pharmacy clinics. Drug of the month. Salmeterol (Serevent)].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate | 1995 |
[Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience].
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Child; Drug Therapy, Combination; Emer | 1995 |
Treating acute asthma.
Topics: Acute Disease; Aerosols; Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Humans; Infusi | 1995 |
Pharmacology of long-acting beta-agonists.
Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Receptors, Adr | 1995 |
Effective argon-FRC with a rebreathing technique in children with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Argon; Asthma; Bronchodilator Agen | 1995 |
Differential effects of anti-asthmatic drugs on arachidonic acid and platelet-activating factor.
Topics: Albuterol; Aminophylline; Arachidonic Acid; Asthma; Blood Platelets; Bronchodilator Agents; Humans; | 1994 |
[Statistics: Salmeterol and asthma].
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; Treatment Outcome | 1995 |
Knowledge of asthma and its management in newly qualified doctors in Accra, Ghana.
Topics: Acute Disease; Adult; Albuterol; Aminophylline; Asthma; Chronic Disease; Clinical Competence; Develo | 1995 |
Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction.
Topics: Acute Disease; Adult; Aged; Albuterol; Asthma; Combined Modality Therapy; Dose-Response Relationship | 1995 |
Tidal breathing analysis and response to salbutamol in awake young children with and without asthma.
Topics: Albuterol; Asthma; Child, Preschool; Consciousness; Female; Humans; Male; Pulmonary Ventilation; Sig | 1994 |
[Response to bronchodilators among patients with bronchial asthma].
Topics: Albuterol; Asthma; Bronchospirometry; Humans; Retrospective Studies | 1994 |
[Behavior of some parameters of the autonomic nervous system in patients with bronchial asthma].
Topics: Adult; Albuterol; Asthma; Autonomic Nervous System; Cyclic AMP; Female; Humans; Male; Middle Aged; R | 1994 |
Salmeterol xinafoate in children.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Child | 1995 |
Synergistic protective effects with azelastine and salbutamol in a guinea pig asthma model.
Topics: Administration, Oral; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; | 1995 |
[The therapeutic potentials of Ditec in bronchial asthma patients].
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cromolyn | 1995 |
Association between reported use of inhaled triamcinolone and differential short-term responses to aerosolized albuterol in asthmatics in an emergency department setting.
Topics: Acute Disease; Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Emergency Service, Ho | 1994 |
Acute asthma, salbutamol and hyperglycaemia.
Topics: Acute Disease; Age Factors; Albuterol; Asthma; Blood Glucose; Child; Child, Preschool; Chromatograph | 1995 |
Beta 2 adrenergic receptor gene restriction fragment length polymorphism and bronchial asthma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Alleles; Asthma; Bronchi; Bronchial Provocati | 1995 |
Scintigraphic appearance of albuterol-induced inhibition of hypoxic pulmonary vasoconstriction.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Female; Humans; Hypoxia; Lung; Pregnancy; Preg | 1994 |
[Bronchial hyperresponsiveness and relaxability in patients with mitral stenosis].
Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Female; Humans; Male; Met | 1994 |
Salmeterol in the treatment of asthma.
Topics: Albuterol; Asthma; Drug Approval; Humans; Salmeterol Xinafoate | 1994 |
[Effect of salbutamol on left ventricular function and selected biochemical parameters in patients with bronchial asthma].
Topics: Adult; Albuterol; Asthma; Creatine Kinase; Echocardiography; Fatty Acids, Nonesterified; Female; Hum | 1994 |
Inhaled salmeterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Huma | 1994 |
Short- and long-term effect of oral salbutamol on growth hormone secretion in prepubertal asthmatic children.
Topics: Administration, Oral; Albuterol; Asthma; Child; Growth Hormone; Humans; Time Factors | 1995 |
TAME-esterase activity during a prolonged attack of asthma.
Topics: Adult; Albuterol; Asthma; Humans; Peptide Hydrolases | 1994 |
Platelet-derived growth factor-beta mRNA in human alveolar macrophages in vivo in asthma.
Topics: Adult; Aerosols; Albuterol; Asthma; Beclomethasone; Blotting, Northern; Bronchodilator Agents; Budes | 1994 |
Salmeterol-induced vertigo.
Topics: Administration, Inhalation; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Salmeter | 1994 |
Effectiveness of nebulised salbutamol administered in ambulances to patients with severe acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Airway Obstru | 1995 |
The AB/BA crossover: past, present and future?
Topics: Albuterol; Analysis of Variance; Asthma; Bayes Theorem; Bias; Cross-Over Studies; Data Interpretatio | 1994 |
Hypokalemia after normal doses of neubulized albuterol (salbutamol).
Topics: Adult; Albuterol; Asthma; Electrocardiography; Humans; Hypokalemia; Male | 1995 |
Beta-agonists and asthma.
Topics: Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Humans; Methacholine Chloride; Salmet | 1993 |
Salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Drug A | 1994 |
A word of caution regarding a new long-acting bronchodilator.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate | 1994 |
Asthma control.
Topics: Albuterol; Asthma; Bronchodilator Agents; Follow-Up Studies; Forced Expiratory Volume; Humans | 1994 |
Asthma control.
Topics: Albuterol; Asthma; Bronchial Hyperreactivity; Humans; Sympathomimetics | 1994 |
Respiratory arrests in young asthmatics on salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Male; Respiratory Insufficiency; Salmeterol Xin | 1994 |
Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol | 1994 |
Asthma control.
Topics: Albuterol; Asthma; Humans | 1994 |
Regular versus as-needed inhaled salbutamol in asthma control.
Topics: Administration, Inhalation; Albuterol; Asthma; Drug Administration Schedule; Humans | 1994 |
Compliance with pharmacologic prophylaxis and therapy in bronchial asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Ch | 1994 |
Asthma control.
Topics: Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Administration Schedule; Humans; Salm | 1994 |
Asthma control.
Topics: Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Tolerance; Humans; Nebulizers and Vap | 1994 |
Common measures of asthma severity lack association for describing its clinical course.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Humans; Medical Records; Patie | 1994 |
Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis.
Topics: Albuterol; Anaphylaxis; Animals; Antigens; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator Agen | 1994 |
Risks of salmeterol?
Topics: Aged; Albuterol; Asthma; Bronchodilator Agents; Fatal Outcome; Humans; Patient Education as Topic; R | 1994 |
Salmeterol: a long-acting beta 2-agonist for asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate | 1994 |
[Long-acting beta-2-agonists in the treatment of asthma].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumara | 1994 |
Demonstration of bioequivalence between ventasol syrup and ventolin syrup in humans and in dogs.
Topics: Adult; Albuterol; Animals; Asthma; Dogs; Humans; Therapeutic Equivalency | 1994 |
Results of prescription event monitoring study of salmeterol.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Cause of | 1994 |
[Change of nonspecific bronchial responsiveness and other indices of asthma severity in groups of patients treated with beta2-adrenomimetics "on demand". Test of correlation].
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Drug Administration Schedule; Eosinophils; Fe | 1994 |
The influence of age, diagnosis, and gender on proper use of metered-dose inhalers.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Albuterol; Asthma; Female; Humans; Inspiratory Capacity | 1994 |
Confounding by severity does not explain the association between fenoterol and asthma death.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Case-Control Studies; Child; Child | 1994 |
[Efficacy of salmeterol in patients with allergic bronchial asthma].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 1994 |
Comparison between peak expiratory flow rates (PEFR) and FEV1 in the monitoring of asthmatic subjects at an outpatient clinic.
Topics: Adolescent; Adult; Aged; Albuterol; Ambulatory Care Facilities; Asthma; Female; Forced Expiratory Vo | 1994 |
Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance?
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Budesonide; Drug Therapy, Comb | 1994 |
[Relations between nonspecific bronchial hyperreactivity, diurnal variation of peak expiratory flow and medication requirements in patients with mild asthma].
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchodilator Agents; Circadian Rh | 1994 |
[Corrective effect of the Russian bronchodilator preparations saventol and troventol on the lymphocyte regulatory function of atopic bronchial asthma patients in vitro].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Bronchodilator A | 1994 |
Reversibility of the allergen-provoked late asthmatic response by an inhaled beta 2-adrenoceptor agonist.
Topics: Adult; Albuterol; Allergens; Asthma; Bronchi; Bronchial Provocation Tests; Female; Forced Expiratory | 1994 |
Asthma: audit of peak flow rate guidelines for admission and discharge.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Medical Audit; Patient | 1994 |
Occupational asthma in salbutamol process workers.
Topics: Adult; Albuterol; Asthma; Drug Industry; Forced Expiratory Volume; Humans; Lung; Male; Middle Aged; | 1994 |
Anaesthetic management of an asthmatic child for appendicectomy.
Topics: Adolescent; Albuterol; Anesthesia, Epidural; Appendectomy; Asthma; Beclomethasone; Bupivacaine; Fent | 1994 |
[Effect of vaporizing high doses of ipratropium bromide on lung ventilation in patients with chronic obstructive pulmonary disease and bronchial asthma].
Topics: Albuterol; Asthma; Drug Administration Schedule; Forced Expiratory Flow Rates; Forced Expiratory Vol | 1994 |
[Comparison of the influence of ipratropium bromide and salbutamol on activity of phosphocreatine kinase (CK) and isoenzyme CK-MB].
Topics: Adult; Albuterol; Asthma; Creatine Kinase; Female; Humans; Ipratropium; Isoenzymes; Male; Middle Age | 1994 |
Wet nebulizers vs metered dose inhalers.
Topics: Acute Disease; Albuterol; Asthma; Evaluation Studies as Topic; Humans; Nebulizers and Vaporizers | 1994 |
Effects of salbutamol inhalations on transcutaneous blood gases in children during the acute asthmatic attack: from acute deterioration to recovery.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Blood Gas Monitoring, Transcutaneous; Carbon Dioxide; | 1994 |
Effective pulmonary blood flow in children with acute asthma attack requiring hospitalization.
Topics: Acute Disease; Adolescent; Aerosols; Albuterol; Argon; Asthma; Bronchodilator Agents; Case-Control S | 1994 |
Short-term effects of inhaled albuterol on maternal and fetal circulations.
Topics: Adolescent; Adult; Albuterol; Aorta; Asthma; Blood Circulation; Blood Flow Velocity; Blood Pressure; | 1994 |
Dose equivalence of drugs for asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Humans | 1993 |
Bronchodilator treatment in asthma. Increase in deaths during salmeterol treatment unexplained.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Product Surveillance, Po | 1993 |
Bronchodilator treatment in asthma. Manufacturers underestimate mortality from asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate | 1993 |
Bronchodilator treatment in asthma. Regular treatment with beta agonists remains unevaluated.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Research Design; Salmete | 1993 |
Bronchodilator treatment in asthma. Study too small to detect increase in deaths.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; St | 1993 |
[A new long-acting asthma spray. Preliminary wait-and-see attitude?].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Dela | 1993 |
[Comparison of the bronchodilating effects of five beta-adrenergic stimulants administered by inhalation to patients with bronchial asthma].
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoc | 1993 |
Systemic absorption of salbutamol following nebulizer delivery in acute asthma.
Topics: Absorption; Acute Disease; Adolescent; Age Factors; Albuterol; Asthma; Child; Child, Preschool; Dose | 1993 |
Allergic bronchial eosinophilia: a therapeutic approach for the selection of potential bronchial anti-inflammatory drugs.
Topics: Albuterol; Allergens; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Bronchoa | 1993 |
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Albute | 1994 |
Effect of salbutamol on gas compression in cystic fibrosis and asthma.
Topics: Adolescent; Albuterol; Asthma; Bias; Child; Cystic Fibrosis; Female; Forced Expiratory Volume; Human | 1994 |
Acute angle-closure glaucoma as a complication of combined beta-agonist and ipratropium bromide therapy in the emergency department.
Topics: Acute Disease; Aged; Albuterol; Asthma; Drug Therapy, Combination; Female; Glaucoma, Angle-Closure; | 1994 |
Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD?
Topics: Administration, Inhalation; Aged; Albuterol; Asthma; Diagnosis, Differential; Forced Expiratory Volu | 1994 |
Patient handling of a multidose dry powder inhalation device for albuterol.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Child; Female; Humans; Male; | 1994 |
In vivo bronchodilator action of a novel K+ channel opener, KC 399, in the guinea pig.
Topics: Administration, Inhalation; Albuterol; Anesthesia; Animals; Antigens; Asthma; Benzopyrans; Bronchoco | 1994 |
Home nebulizer therapy in asthmatics in Qatar.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Emergency Service, Hospital; Female; Hom | 1994 |
A comparison of "closed" and "open" mouth techniques of inhalation of a salbutamol metered-dose inhaler.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Female; Forced Expiratory Volume; | 1994 |
Effect of albuterol nebulization on peripheral WBC counts.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Emergencies; Female; Humans; Leukocyte Count; | 1994 |
Nonspecific refractoriness to adenylyl cyclase stimulation in alveolar macrophages from infants with recurrent bronchiolitis.
Topics: Adenylyl Cyclases; Albuterol; Asthma; Bronchiolitis; Bronchoalveolar Lavage Fluid; Bronchoscopy; Col | 1994 |
Intravenous theophylline-induced excretion of calcium, magnesium and sodium in patients with recurrent asthmatic attacks.
Topics: Administration, Oral; Adult; Aged; Albuterol; Asthma; Calcium; Female; Humans; Infusions, Intravenou | 1994 |
Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.
Topics: Albuterol; Asthma; Child; Forced Expiratory Volume; Humans | 1993 |
[Serevent. Salmeterolxinafoate].
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Austria; Bronchodilator Agen | 1993 |
A study of self poisoning with oral salbutamol--laboratory and clinical features.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Child, Preschool; Female; Humans; Male; Middle Aged; Pot | 1993 |
Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation.
Topics: Adult; Albuterol; Asthma; Blood Proteins; Cell Degranulation; Chemotaxis, Leukocyte; Dose-Response R | 1993 |
[The bronchodilator agent, Ventodisk, in the powdered inhalation form without freon is better].
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Female; Forced Expiratory Volume; Hu | 1993 |
Changes in frequency spectra of breath sounds during histamine challenge test in adult asthmatics and healthy control subjects.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Female; Forc | 1994 |
Albuterol protocol.
Topics: Adult; Albuterol; Asthma; Humans | 1994 |
Albuterol.
Topics: Adult; Albuterol; Asthma; Humans | 1994 |
Extrapulmonary effects of fenoterol compared to salbutamol in asthmatics.
Topics: Albuterol; Asthma; Cardiovascular Diseases; Drug Administration Schedule; Fenoterol; Humans | 1993 |
Respiratory arrests in young asthmatics on salmeterol.
Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Humans; Respiratory Insufficien | 1993 |
Bronchodilator treatment in asthma.
Topics: Adolescent; Adult; Age Distribution; Aged; Albuterol; Asthma; Bronchodilator Agents; Humans; Middle | 1993 |
Rates of change in peak expiratory flow and in diurnal variation in peak flow in patients recovering from acute severe asthma.
Topics: Acute Disease; Adult; Albuterol; Asthma; Circadian Rhythm; Follow-Up Studies; Humans; Lung; Peak Exp | 1994 |
Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction.
Topics: Adult; Aged; Albuterol; Asthma; Drug Delivery Systems; Female; Humans; Lung; Male; Middle Aged; Nebu | 1993 |
Prolonged hypoxaemia after nebulised salbutamol.
Topics: Acute Disease; Albuterol; Asthma; Child; Child, Preschool; Humans; Hypoxia; Infant; Nebulizers and V | 1993 |
Influence of airway inflammatory changes on airway hyperresponsiveness in asthmatics.
Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchial Hyperreactivity; Bronchial Provocation Tests; Br | 1993 |
Use of pulse oximetry in the hospital management of acute asthma in childhood.
Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Female; Hospit | 1993 |
Paradoxical bronchoconstriction with nebulized albuterol but not with terbutaline.
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoc | 1993 |
Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Chlorofluorocarbons, Methane; Dyspnea; Female; Humans; Neb | 1993 |
Management of chronic obstructive pulmonary disease.
Topics: Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Humans | 1993 |
Propranolol treatment of albuterol poisoning in two asthmatic patients.
Topics: Adolescent; Albuterol; Asthma; Charcoal; Drug Overdose; Female; Gastric Lavage; Humans; Hypokalemia; | 1993 |
[Improvement of intractable nocturnal asthma treated by therapeutic awakening].
Topics: Adult; Albuterol; Asthma; Circadian Rhythm; Female; Humans; Wakefulness | 1993 |
[Bronchial hyperreactivity after chronic use of salbutamol].
Topics: Adult; Albuterol; Asthma; Bronchial Hyperreactivity; Female; Humans; Male; Spirometry | 1993 |
Controlled-release oral salbutamol and cardiac arrhythmias in asthmatic patients.
Topics: Administration, Oral; Adult; Albuterol; Arrhythmias, Cardiac; Asthma; Delayed-Action Preparations; F | 1993 |
Bronchodilator treatment in asthma.
Topics: Adolescent; Adult; Age Factors; Aged; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presch | 1993 |
Nedocromil sodium blocks the early and late phases of allergen challenge in a guinea pig model of asthma.
Topics: Aerosols; Albuterol; Allergens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchoalv | 1993 |
[Bronchodilating action of salbutamol depending on route of administration].
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchoconstriction; Female; | 1993 |
[Effect of corticosteroids on tachyphylaxis induced by beta-2- receptor agonists in patients with bronchial asthma].
Topics: Adult; Albuterol; Asthma; Down-Regulation; Female; Humans; Male; Prednisone; Receptors, Adrenergic, | 1993 |
Chronopharmacology of albuterol in hospitalized asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Child; Circadian Rhythm; Female; Hospitalization; Humans; Male; Pulmo | 1993 |
Repeated inhalation of nebulized albuterol did not induce arrhythmias in a patient with Wolff-Parkinson-White syndrome and asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Arrhythmias, Cardiac; Asthma; Contraindications; Elect | 1993 |
Safety of continuous nebulized albuterol for bronchospasm in infants and children.
Topics: Acute Disease; Albuterol; Asthma; Bronchial Spasm; Bronchiolitis; Bronchopulmonary Dysplasia; Child, | 1993 |
High serum albuterol levels and tachycardia in adult asthmatics treated with high-dose continuously aerosolized albuterol.
Topics: Adult; Aerosols; Albuterol; Aminophylline; Asthma; Female; Forced Expiratory Volume; Heart Rate; Hum | 1993 |
Assessment of exercise capacity in asthmatic children with various degrees of activity.
Topics: Adolescent; Albuterol; Anthropometry; Asthma; Child; Exercise Test; Exercise Tolerance; Female; Huma | 1993 |
Functional characteristics of bronchial epithelium obtained by brushing from asthmatic and normal subjects.
Topics: Adult; Albuterol; Asthma; Bronchi; Bronchoalveolar Lavage Fluid; Bronchoscopy; Calcimycin; Cell Surv | 1993 |
Nebulized salbutamol (albuterol): systemic absorption could be important in achieving bronchodilatation.
Topics: Absorption; Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchi; Dose-Response Rel | 1993 |
The effect of age on bronchodilator responsiveness.
Topics: Aging; Albuterol; Asthma; Bronchi; Child; Child, Preschool; Dose-Response Relationship, Drug; Female | 1993 |
The efficacy and safety of a continuous albuterol protocol for the treatment of acute adult asthma attacks.
Topics: Acute Disease; Administration, Intranasal; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Emerge | 1993 |
Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Drug Delivery Systems; Female; Humans; Male; Middle Aged; | 1993 |
Dose equivalence of drugs for asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; | 1993 |
Dose equivalence of drugs for asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; | 1993 |
Asthma. Assessment and management in a pediatric hospital.
Topics: Acute Disease; Albuterol; Asthma; Canada; Child; Child, Preschool; Emergency Medicine; Emergency Ser | 1993 |
Asthma management guidelines.
Topics: Adult; Albuterol; Asthma; Child; Humans; Practice Guidelines as Topic; Prednisolone | 1993 |
Respiratory arrests in young asthmatics on salmeterol.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Female; Huma | 1993 |
Treating nocturnal asthma poses challenges.
Topics: Albuterol; Asthma; Circadian Rhythm; Delayed-Action Preparations; Humans; Peak Expiratory Flow Rate; | 1993 |
Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children.
Topics: Administration, Oral; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Growth Hormone; | 1993 |
Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Cross-Sectional Studies; Drug Pres | 1993 |
Assessment of bronchodilator response in children with asthma. Dutch CNSLD Study Group.
Topics: Adolescent; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Child; Forced | 1993 |
Prehospital management of pediatric asthma requiring hospitalization.
Topics: Adolescent; Albuterol; Asthma; Boston; Bronchodilator Agents; Child; Child, Preschool; Emergency Med | 1995 |
Clinical value of monitoring eosinophil activity in asthma.
Topics: Albuterol; Asthma; Blood Proteins; Bronchodilator Agents; Budesonide; Child; Child, Preschool; Cysti | 1995 |
[Right diaphragmatic kinetics measured by TM-mode ultrasonography with concomitant spirometry in normal subjects and asthmatic patients. Preliminary results].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Diaphragm; Female; Humans; Lung Volume Measureme | 1995 |
Educate the patient.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy; Drug Therapy, Combination; Humans; Ma | 1996 |
Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Albuterol; Asth | 1996 |
Volume history response of airway resistance.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Functional Residual Capacity; Humans | 1995 |
Muscle weakness in mechanically ventilated patients with severe asthma.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Atracurium; Bronchodilator Agents; Cohort | 1996 |
Long-acting beta-agonists, tachyphylaxis, and corticosteroids.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Broncho | 1996 |
Asthma caused by topical application of ketorolac.
Topics: Administration, Topical; Adult; Albuterol; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-S | 1996 |
Loss of bronchoprotection with salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Dru | 1996 |
Determination of post-salbutamol methacholine dose shift.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Humans; Methacholine Chlor | 1996 |
Albuterol delivery by metered-dose inhaler in a mechanically ventilated pediatric lung model.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Disease Models, Animal; Drug Delivery Systems; Drug | 1996 |
Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro.
Topics: Adenosine Triphosphate; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents; Asthma | 1996 |
Characterization of a primate model of asthma using anti-allergy/anti-asthma agents.
Topics: Albuterol; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Antigens; Asthma; Bronchoconstri | 1996 |
[Cardiac monitoring in bronchial asthma patients taking salben].
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Arrhythmias, Cardiac; Asthma; Bronchodilator Age | 1996 |
Paradoxical bronchospasm and cutaneous rash after metered-dose inhaled bronchodilators.
Topics: Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Bronchial Spasm; Bronchodilator | 1996 |
Probability of particle and salbutamol deposition in the respiratory tract: comparison between MDI and Autohaler.
Topics: Administration, Inhalation; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Humans; Lung Disease | 1996 |
Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists.
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Biopsy, Needle; Blood Chemical An | 1996 |
Inhaled beta 2-agonists in the treatment of asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Drug Administration Schedul | 1996 |
Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma.
Topics: Acetates; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchodilator | 1996 |
Effects of immunotherapy on symptoms, PEFR, spirometry, and airway responsiveness in patients with allergic asthma to house-dust mites (D. pteronyssinus) on inhaled steroid therapy.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Allergens; Animals; Antigens, Dermatophago | 1996 |
High-resolution computed tomography of airway changes after induced bronchoconstriction and bronchodilation in asthmatic volunteers.
Topics: Adult; Albuterol; Asthma; Bronchi; Bronchial Diseases; Bronchoconstrictor Agents; Bronchodilator Age | 1996 |
Exhaled nitric oxide during acute changes of airways calibre in asthma.
Topics: Adult; Airway Resistance; Albuterol; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bron | 1996 |
Doping taboos.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Contraindications; Doping in Spo | 1995 |
Inhaled albuterol does not inhibit cellular influx or lung injury produced by segmental antigen challenge in humans.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Antigens; Asthma; Bronchial | 1995 |
Health beliefs of adults with asthma: toward an understanding of the difference between symptomatic and preventive use of inhaler treatment.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Attitude to Health; Beclomethasone; Bronchodilator Agents; | 1996 |
Safety and appropriate use of salmeterol in the treatment of asthma. AAAAI Committee on Drugs, American Academy of Allergy, Asthma and Immunology.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate; So | 1996 |
The influence of breathhold on peak expiratory flow in normal and asthmatic children.
Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Female; Fo | 1996 |
A portable device based on the interrupter technique to measure bronchodilator response in schoolchildren.
Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Humans | 1996 |
Evaluation of a new interrupter device for measuring bronchial responsiveness and the response to bronchodilator in 3 year old children.
Topics: Airway Resistance; Albuterol; Asthma; Blood Gas Monitoring, Transcutaneous; Bronchial Provocation Te | 1996 |
Ex vivo pharmacologic modulation of basophil histamine release in asthmatic patients.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Anti-Infla | 1996 |
[Difference of lung deposition rate of disodium cromoglycate (DSCG) among three kinds of electric nebulizer].
Topics: Adolescent; Adult; Albuterol; Asthma; Child; Cromolyn Sodium; Humans; Lung; Middle Aged; Nebulizers | 1996 |
Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Guinea Pigs; Humans | 1996 |
The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Chemo | 1996 |
Treating acute asthma in adults.
Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Hu | 1996 |
Safety of fibreoptic bronchoscopy in asthmatic and control subjects and effect on asthma control over two weeks.
Topics: Adolescent; Adult; Albuterol; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bronchodila | 1996 |
Bronchodilator response in pulmonary disease at two different states of respiratory mechanics.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Cross-Sectional Studies; Female; | 1996 |
The role of pharmacology and forensics in the death of an asthmatic.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Fatal Outcome; Heroin; Humans; Lung; Male; Mor | 1995 |
Gas chromatographic-mass spectrometric determination of beta 2-agonists in postmortem blood: application in forensic medicine.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Autopsy; Calibration; Fenoterol; Forensic Medicine; Gas | 1996 |
Confounding by indication and channeling over time: the risks of beta 2-agonists.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Child; C | 1996 |
Ventilatory function in British adults after asthma or wheezing illness at ages 0-35.
Topics: Adolescent; Adult; Age of Onset; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child; Child, | 1996 |
Asthma group issues guidelines for safe use of salmeterol.
Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Humans; Practice Guidelines as | 1996 |
Sequential designs for equivalence studies.
Topics: Albuterol; Asthma; Bronchodilator Agents; Confidence Intervals; Humans; Models, Statistical; Randomi | 1996 |
An unconscious man with asthma and a fixed, dilated pupil.
Topics: Albuterol; Asthma; Brain Edema; Bronchodilator Agents; Carbon Dioxide; Humans; Hypoxia; Intracranial | 1997 |
CFC-free inhalers.
Topics: Albuterol; Asthma; Bronchodilator Agents; Equipment Failure; Humans; Nebulizers and Vaporizers | 1997 |
Observations on the effects of aerosolized albuterol in acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Dose-Response | 1997 |
Oscillatory pressure transients after flow interruption during bronchial challenge test in children.
Topics: Acoustics; Adolescent; Air; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bronchial Prov | 1997 |
Respiratory resistive impedance in obstructive patients: linear regression analysis vs viscoelastic modelling.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Airway Resistance; Albuterol; Asthma; Br | 1997 |
Albuterol in mild asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Patient Selection; Randomiz | 1997 |
Lung hyperinflation and flow limitation in chronic airway obstruction.
Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Case-Control Studies; Female; | 1997 |
Early management of acute severe asthma.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Emergenc | 1997 |
Allergen challenge of passively sensitized human bronchi alters M2 and beta2 receptor function.
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Allergens; Animals; Asthma; Bronchi; Bronchial Hyp | 1997 |
Are beta-adrenergic bronchodilators safe?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug Therapy, Combination; Drug | 1997 |
Oral vs i.v. steroids for asthma.
Topics: Administration, Oral; Adolescent; Adult; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; | 1997 |
The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma.
Topics: Administration, Inhalation; Administration, Topical; Adrenergic beta-Agonists; Adult; Aged; Albutero | 1997 |
Perception of airway obstruction in asthma: sequential daily analyses of symptoms, peak expiratory flow rate, and mood.
Topics: Adolescent; Adult; Affect; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Female; Hum | 1997 |
A minimal response to albuterol challenge does not exclude a diagnosis of asthma.
Topics: Adult; Albuterol; Asthma; Bronchitis; Child; Forced Expiratory Volume; Humans; Middle Aged; Nebulize | 1997 |
The influence of parasympatholytics on the resolution of acute attacks of asthma.
Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Female; Hospitalization; Humans; Ipr | 1997 |
Isoetherine or albuterol for acute asthma.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Humans; Isoetharine; Therapeutic Equivalenc | 1997 |
Successful treatment of salbutamol-induced panic disorder with citalopram.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Citalopram; Humans; Male; Middle Aged; Panic Disorder; Psy | 1997 |
Effect of age on bronchodilator response in acute severe asthma treatment.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Age Factors; Albuterol; | 1997 |
Safety of one method of sputum induction in asthmatic subjects.
Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Female; Forced Expiratory Volu | 1997 |
Several studies have shown salmeterol to be more potent than salbutamol for systemic effects.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Delivery Systems; Humans; Salmeterol Xinafoate; Th | 1997 |
[Latent long QT syndrome: discription of a clinical case].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Electrocardiography; | 1997 |
Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Case-Control | 1997 |
Loss of normal cyclical beta 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients.
Topics: Adenosine Monophosphate; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Varianc | 1997 |
Asthma guidelines.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; B | 1997 |
PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro.
Topics: Adult; Albuterol; Asthma; Cell Separation; Centrifugation, Density Gradient; Chemotaxis, Leukocyte; | 1997 |
Beta 2-agonist-elevated stress response in human bronchial epithelial cells in vivo and in vitro.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Asthma; Biopsy; Bronchi; Bronchial Provocatio | 1997 |
Expiratory flow limitation in stable asthmatic patients during resting breathing.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bias; Bronchodilator Agents; Female; Forced Expiratory F | 1997 |
Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Asthma; Becl | 1997 |
Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodi | 1997 |
Re: "Confounding by indication and channeling over time: the risks of beta2-agonists".
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Case-Control Studies; Cohort Studies; Confounding Facto | 1997 |
A guinea-pig model of ultrasonically nebulized distilled water-induced bronchoconstriction.
Topics: Administration, Inhalation; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchial Provoca | 1997 |
Effects of beta-agonists on dose-response curves.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agents; | 1997 |
[The effect of salmeterol on the activity of neutrophil chemotactic factor in patients with asthma].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Female; Humans; Interleukin-8; Male; Middle Aged | 1996 |
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.
Topics: Adrenergic beta-Agonists; Albuterol; Alleles; Arginine; Asthma; Bronchodilator Agents; Child; Glutam | 1997 |
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.
Topics: Adrenergic beta-Agonists; Albuterol; Alleles; Arginine; Asthma; Bronchodilator Agents; Child; Glutam | 1997 |
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.
Topics: Adrenergic beta-Agonists; Albuterol; Alleles; Arginine; Asthma; Bronchodilator Agents; Child; Glutam | 1997 |
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.
Topics: Adrenergic beta-Agonists; Albuterol; Alleles; Arginine; Asthma; Bronchodilator Agents; Child; Glutam | 1997 |
Salbutamol enantiomers: early clinical evidence in humans.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Stereoisomerism; Structure-Activity Relationship | 1997 |
Dosing interval with albuterol MDI for asthma.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Method; Dru | 1997 |
Defining the asthma phenotype for the purpose of genetic analysis.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstrictor Agents; Bronch | 1997 |
Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Arrhythmia | 1997 |
MDI for acute asthma in children.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; | 1998 |
Proventil HFA: a new inhaler for asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Nebulizers and Vaporizers | 1997 |
[Salmeterol, a new long-acting beta 2-agonist in asthma treatment].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate | 1997 |
The change to non-CFC metered dose inhalers.
Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Asthma; Australia; Bronchodilator Agents | 1997 |
Effect of pneumonia and whooping cough in childhood on adult lung function.
Topics: Adult; Albuterol; Asthma; Child; Child, Preschool; Cohort Studies; Female; Forced Expiratory Volume; | 1998 |
Relative efficacy of three different inhalers containing salbutamol in patients with asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Humans; Nebulizers and V | 1997 |
Reducing asthma morbidity in the community: the effect of a targeted nurse-run asthma clinic in an English general practice.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Child; Chil | 1997 |
Counseling about chlorofluorocarbon-free inhalers.
Topics: Aerosol Propellants; Albuterol; Anti-Asthmatic Agents; Asthma; Chlorofluorocarbons, Methane; Drug Ca | 1998 |
Beta2-adrenoceptor regulation and function in female asthmatic patients receiving the oral combined contraceptive pill.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Area Under Curve; Asthma; Beclome | 1998 |
Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; A | 1998 |
Effects of airway calibre on lung delivery of nebulised salbutamol.
Topics: Absorption; Administration, Inhalation; Adult; Albuterol; Asthma; Biological Availability; Bronchi; | 1997 |
Inhaled glucocorticoids and acute asthma: therapeutic breakthrough or nonspecific effect?
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Ag | 1998 |
Albuterol does not antagonize the inhibitory effect of dexamethasone on monocyte cytokine release.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Cells, | 1998 |
The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Allergens; Anti-Asthmatic Agents; A | 1998 |
Off-label prescribing for infants.
Topics: Age Factors; Albuterol; Asthma; Bronchodilator Agents; Drug Prescriptions; Humans; Infant; Nurse Pra | 1998 |
Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report.
Topics: Albuterol; Antiviral Agents; Asthma; Bronchial Hyperreactivity; Bronchiolitis; Bronchodilator Agents | 1998 |
Histamine affects interleukin-4, interleukin-5, and interferon-gamma production by human T cell clones from the airways and blood.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Clone | 1998 |
Long acting beta 2 agonists and the risk of life threatening asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Fenoterol; Humans; Odds Ratio; Salmeterol Xinafoate | 1998 |
Case-control study of salmeterol and near-fatal attacks of asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Case-Control Studies; Child; Child, | 1998 |
Adrenal function and physiologic stress during acute asthma exacerbation.
Topics: Acute Disease; Adrenal Glands; Adult; Albuterol; Asthma; Bronchodilator Agents; Cosyntropin; Emergen | 1998 |
Acute bronchodilatory effect of salmeterol on methacholine-induced bronchoconstriction in childhood asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Child; Female; Forced Exp | 1998 |
Changes in treatment and outcomes of children receiving care in the intensive care unit for severe acute asthma.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Asthma; Bronchodilator Agents; Canada; Child; Cri | 1998 |
Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Electrocardiography; Humans; Hypokalemia; Male; | 1998 |
Inhalation devices in childhood asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Anti-Asthmatic Agents; Asthma; Bron | 1998 |
How often should beta-agonists be administered?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Drug | 1998 |
Severe childhood asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Humans; | 1998 |
Inhaler medicament effects on saliva and plaque pH in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Analysis of Variance; A | 1998 |
Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Aged; Albuterol; Arrhythmias, Cardiac; Asthma; Blood Pressure; Bronchodi | 1998 |
Airway mucosal blood flow in bronchial asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents | 1998 |
When should your asthmatic patients refill their MDI propelled with chlorofluorocarbons?
Topics: Albuterol; Asthma; Bronchodilator Agents; Chlorofluorocarbons; Drug Labeling; Drug Packaging; Humans | 1998 |
Final measurements vs ANOVA for data analysis.
Topics: Albuterol; Analysis of Variance; Asthma; Bronchodilator Agents; Data Interpretation, Statistical; Eq | 1998 |
Bronchodilator response in 3-6.5 years old healthy and stable asthmatic children.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Body Height; Bronchodilator Agents; | 1998 |
Comparison of beclomethasone, salmeterol, and placebo in children with asthma.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Body Height; Child; Humans; Salmeterol Xin | 1998 |
Language of dyspnea in assessment of patients with acute asthma treated with nebulized albuterol.
Topics: Acute Disease; Administration, Inhalation; Adult; Airway Obstruction; Albuterol; Asthma; Bronchodila | 1998 |
Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Age Factors; Albuterol; Anti-Asthmatic Agents; Asthma; | 1998 |
Glucocorticoid receptors in bronchial epithelial cells in asthma.
Topics: Administration, Oral; Adult; Aged; Albuterol; Anti-Inflammatory Agents; Asthma; Biopsy; Bronchi; Bro | 1998 |
Young inner-city children visiting the emergency room (ER) for asthma: risk factors and chronic care behaviors.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Child Welfare; Child, Preschool; Drug Utilization; | 1998 |
Can oral beta2 agonists cause heart failure?
Topics: Administration, Oral; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents; Coho | 1998 |
About long-acting bronchodilators.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; Delayed-Acti | 1998 |
Prehospital treatment of acute asthma in a rural state.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Emergency Medical Technicians; Emergency | 1998 |
Prevalence of asthma and respiratory symptoms in dairy farmers in the French province of the Doubs.
Topics: Adult; Age Factors; Albuterol; Allergens; Asthma; Bronchitis; Bronchodilator Agents; Chronic Disease | 1998 |
[Asthmatic crisis and spontaneous rupture of the esophagus].
Topics: Aged; Albuterol; Asthma; Bronchodilator Agents; Dexamethasone; Diagnosis, Differential; Esophageal D | 1998 |
Awareness of environmental issues and the acceptance of CFC-free inhalers.
Topics: Adult; Air Pollution; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Chlorofluor | 1998 |
Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Case-Control Studies; C | 1998 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adr | 1999 |
The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Cost Savings; Costs and Cost Ana | 1999 |
Inhaled corticosteroid therapy in asthma: a balancing act.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Androstadi | 1999 |
An in vivo model of beta-adrenoceptor desensitization.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoconstrictor | 1998 |
Selective airway responsiveness in asthma.
Topics: Albuterol; Animals; Asthma; Bradykinin; Bronchial Hyperreactivity; Bronchoconstrictor Agents; Bronch | 1999 |
The cost per treatment success.
Topics: Albuterol; Asthma; Cost-Benefit Analysis; Ethanolamines; Humans; Treatment Outcome | 1994 |
Antiasthma drugs: quality-of-life rating scales and sensitivity to longitudinal change.
Topics: Albuterol; Asthma; Humans; Longitudinal Studies; Quality of Life; Surveys and Questionnaires | 1994 |
Clinical efficacy and safety of Turbuhaler as compared to pressurized MDIs-beta 2-agonists.
Topics: Aged; Albuterol; Asthma; Chlorofluorocarbons; Equipment Design; Humans; Middle Aged; Nebulizers and | 1994 |
Point-of-service outcomes data and its effect on asthma treatment: a salmeterol pilot investigation.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Outcome Assessment, Health Care; Physician-Patient | 1997 |
Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Cost-Benefit Analysis; Decision Making, Organizational; Fo | 1997 |
Experience of an emergency mobile asthma treatment programme.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Albuterol; Ambulances; Asthma; Broncho | 1997 |
Evidence of acinar airway involvement in asthma.
Topics: Adult; Aging; Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Functional | 1999 |
Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Arginine; Asthma; Bronchodilator Agents; Female; Forced | 1999 |
Caregiver knowledge and delivery of a commonly prescribed medication (albuterol) for children.
Topics: Administration, Oral; Adult; Albuterol; Asthma; Bronchodilator Agents; Caregivers; Child; Educationa | 1999 |
Levalbuterol for asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Digoxin; Drug Interactions; Humans; Isomerism | 1999 |
Perception of bronchodilation in subjects with asthma and smokers with airflow limitation.
Topics: Aged; Airway Resistance; Albuterol; Asthma; Attitude to Health; Bronchodilator Agents; Female; Force | 1999 |
Salmeterol for nocturnal asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child; Double-Blind Method; Hu | 1999 |
Optimization of testing times and critical values in sequential equivalence testing.
Topics: Albuterol; Asthma; Bronchodilator Agents; Computer Simulation; Humans; Models, Biological; Normal Di | 1999 |
Postmortem stability and interpretation of beta 2-agonist concentrations.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Stability; Fenoterol; Humans; Postmortem Changes; | 1999 |
Application and efficacy of the multi-dose powder inhaler, Easyhaler, in children with asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Pres | 1999 |
An in vitro analysis of the output of salbutamol from different nebulizers.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Humans | 1999 |
A low-cost spacer device.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Ethics, Medical; Humans; India | 1999 |
[Comparative effects of acute tests using ventolin, ventodisk and intal plus in the ambulatory pulmonological practice].
Topics: Albuterol; Ambulatory Care; Asthma; Bronchial Spasm; Bronchitis; Cromolyn Sodium; Humans; Lung Disea | 1999 |
Beta2-agonist enantiomers: is there a glitch with the chiral switch?
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Human | 1999 |
Asthma from the perspective of the patient.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma | 1999 |
Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents | 1999 |
Prior use of long-acting beta-agonists: friend or foe in the emergency department?
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Emergency Treatme | 1999 |
Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bronchial Provocation Tests; B | 1999 |
Sequentially induced sputum in patients with asthma or chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol; | 1999 |
Salmeterol, inhaled corticosteroids, and tolerance to allergen bronchoprotection.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Allergens; Asthma; Beclomethasone; | 1999 |
Characteristics of users of inhaled long-acting beta 2-agonists in a southern European population.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Age Factors; Aged; Albuterol; Asthma; Child; Chronic Di | 1999 |
Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; CD4-Po | 1999 |
Intranasal salbutamol instillation in asthma attack.
Topics: Acute Disease; Administration, Intranasal; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronc | 1999 |
Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma.
Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adult; Aged; Albuterol; Androstadie | 2000 |
Salmeterol and tolerance.
Topics: Albuterol; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Drug Tolerance; Humans; Long- | 2000 |
Excessive use of inhaled salbutamol: the potential benefits of dose-reduction. A case report.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Female; Humans; Subs | 1999 |
Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma.
Topics: Administration, Inhalation; Administration, Oral; Adult; Albuterol; Anti-Inflammatory Agents; Asthma | 2000 |
Long-acting beta(2)-agonists in childhood asthma: Don't change a winning team (yet)
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; | 2000 |
Lymphocytes apoptosis in patients with acute exacerbation of asthma.
Topics: Adult; Aged; Aged, 80 and over; Albuterol; Apoptosis; Asthma; Cells, Cultured; fas Receptor; Humans; | 1999 |
Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Ethanolamines; F | 2000 |
Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis.
Topics: Albuterol; Asthma; Bucladesine; Chemotaxis, Leukocyte; Colforsin; Cyclic AMP; Humans; Interleukin-8; | 2000 |
Laryngospasm and paradoxical bronchoconstriction after repeated doses of beta 2-agonists containing edetate disodium.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoconstriction; | 2000 |
Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosol Propellants; Aged; Albuterol; Asthma; Broncho | 2000 |
Dispensing home nebulizers for acute wheezing from the hospital is cost-effective.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilat | 2000 |
Hollow porous particles in metered dose inhalers.
Topics: Administration, Inhalation; Aerosols; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agent | 2000 |
Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Beclomethasone; Developing Countries; Glucocorticoids; Hum | 2000 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta | 2000 |
Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Dose-Response Relations | 1999 |
Therapeutic equivalence of inhaled salbutamol.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans; Nebulizers and Vaporiz | 2000 |
Beta-adrenoceptor agonists in bronchial asthma: role of k+-channel opening in mediating their bronchodilator effects.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 1993 |
[Two out-of-the-ordinary (?) case reports an asthmatic disease].
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Family Practice; Female; Fluocinolone Acet | 2000 |
[The role of beta 2-adrenoceptor gene polymorphisms in asthma].
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asian People; Asthma; Down-Regulation; Force | 2000 |
Clinically meaningful changes in quantitative measures of asthma severity.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Dyspnea; Female; Humans; Logistic Models; Male; Pea | 2000 |
Myoclonus secondary to albuterol (salbutamol) instillation.
Topics: Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; | 2000 |
The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI).
Topics: Abnormalities, Drug-Induced; Acetates; Administration, Inhalation; Administration, Intranasal; Admin | 2000 |
Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma | 2000 |
Airway resistance and atopy in preschool children with wheeze and cough.
Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Cough; Female; Humans | 2000 |
Increased risk for dental caries in asthmatic children.
Topics: Adolescent; Albuterol; Amoxicillin; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; | 1999 |
[Reproducibility in induced sputum in children with asthma].
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Feasibility Studies; Forced Expiratory | 2000 |
Treatment of acute asthma in a field environment using albuterol and a large volume spacer.
Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchodilator Agents; Hawaii; Humans; Male; Military Perso | 2000 |
Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagoni | 2000 |
Importance of beta(2)adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Black People; Bronchodilator Agents; | 2000 |
Management of acute childhood asthma: a prospective multicentre study.
Topics: Acute Disease; Adolescent; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Child; Child, Pr | 2000 |
Delayed eosinophil apoptosis in asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Apoptosis; Asthma; Cells, Cultu | 2000 |
To go by the books.
Topics: Accidents, Traffic; Albuterol; Asthma; Bronchodilator Agents; Cervical Vertebrae; Child; Child, Pres | 2000 |
Limitations in the use of median frequency for lung sound analysis.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Chil | 2000 |
[C. Kroegel on "Asthma therapy in a double-pack". Compliance next to the toothbrush. Interview by Dr. med. Julia Rautenstrauch].
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinations; Fluticasone; Humans; Ne | 1999 |
The pressurized metered dose inhaler (pMDI) remains the most commonly prescribed device for the delivery of inhaled asthma medications.
Topics: Administration, Inhalation; Aerosol Propellants; Albuterol; Androstadienes; Anti-Asthmatic Agents; A | 2000 |
Palmar erythema nodosum.
Topics: Aged; Albuterol; Asthma; Drug Therapy, Combination; Erythema Nodosum; Erythromycin; Female; Hand Der | 2000 |
Easier breathing?
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agent | 2000 |
Suppression of neural activity of bronchial irritant receptors by surface-active phospholipid in comparison with topical drugs commonly prescribed for asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory Agents; Asthma; Bronchi; Bronchial P | 2000 |
Seattle's breath of fresh air.
Topics: Administration, Inhalation; Albuterol; Asthma; Emergency Medical Services; Humans; Lung Diseases, Ob | 2000 |
Persistent asthma: patient characteristics, courses of asthma, and utility of salmeterol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Allergens; Animals; Asthma; Bronchodilator Ag | 2000 |
Functional significance of air trapping detected in moderate asthma.
Topics: Administration, Inhalation; Adult; Aged; Air; Albuterol; Asthma; Bronchodilator Agents; Bronchograph | 2000 |
Acute angle-closure glaucoma after albuterol nebulizer treatment.
Topics: Acute Disease; Adrenergic beta-Agonists; Aged; Albuterol; Asthma; Bronchodilator Agents; Female; Gla | 2000 |
Regular use of salbutamol in asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Humans | 2000 |
Changes in malondialdehyde levels in bronchoalveolar fluid and serum by the treatment of asthma with inhaled steroid and beta2-agonist.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronch | 2000 |
Short-acting beta2-agonists.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Airway Obstruction; Albuterol; Asthma; Bro | 2000 |
[Increased dosage of inhaled corticosteroids or addition of salmeterol in symptomatic asthma].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchodila | 2000 |
Familial aggregation of bronchodilator response: a community-based study.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; | 2000 |
Cost comparison of bronchodilator delivery methods in Emergency Department treatment of asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Emergency Service, Hospital; E | 2000 |
Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists | 2000 |
A spoonful of medicine. Or is it more?
Topics: Administration, Oral; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Emergency Treatmen | 2000 |
Recurrent supraventricular tachycardia as a complication of nebulized albuterol treatment.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child; Electrocardiography; He | 2000 |
Rapid-onset asthma attack: a prospective cohort study about characteristics and response to emergency department treatment.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agen | 2000 |
Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Anti-Inflammatory Agents; Asthma; Bronchoconstrictor A | 2001 |
Practical pharmacotherapy for pediatric asthma.
Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Budesonide; Child; Glucocorticoi | 2000 |
Fatal and near-fatal asthma in children exposed to fireworks.
Topics: Administration, Inhalation; Albuterol; Asthma; Blast Injuries; Child; Child, Preschool; Explosions; | 2000 |
Adrenergic airway vascular smooth muscle responsiveness in healthy and asthmatic subjects.
Topics: Administration, Inhalation; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adult; Albuterol; A | 2001 |
Clinical characteristics of asthmatic patients prescribed various beta-agonist metered-dose inhalers at Yamagata University Hospital.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Ch | 2001 |
Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.
Topics: Acetates; Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Ant | 2001 |
Are asthma medications and management related to deaths from asthma?
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Case-Control Studies; Fem | 2001 |
New therapeutic approach to persistent asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Glucocorticoids; Humans; Salmete | 2000 |
Salmeterol and conventional asthma therapy.
Topics: Albuterol; Asthma; Bronchodilator Agents; Drug Interactions; Humans; Salmeterol Xinafoate | 2001 |
[Salmeterol plus fluticasone--a powerful team. New combined preparation improves compliance].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinati | 2001 |
Beta2-agonist exerts differential effects on the development of cord blood T cells but not on peripheral blood T cells.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cell Division; Female; Fetal Blood; Humans; Immu | 2001 |
[Bronchial asthma. A combination preparation improves patient compliance].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Combinati | 2001 |
Clinical predictors of health-related quality of life depend on asthma severity.
Topics: Adult; Albuterol; Analysis of Variance; Asthma; Female; Follow-Up Studies; Humans; Hydroxyurea; Male | 2001 |
The diagnosis and treatment of cough.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchitis; Common Cold; Cough; Diagnost | 2001 |
Fluticasone propionate/salmeterol combination.
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator A | 2001 |
The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in asthma clinical research.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Area Under Curve; Asthma; False Positive Rea | 2001 |
Rise and fall of asthma-related mortality in Italy and sales of beta2-agonists, 1980-1994.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Age Factors; Aged; Albutero | 2000 |
A combination of fluticasone and salmeterol for asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; | 2001 |
Lidocaine inhalation for cough suppression.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Anesthetics, Local; Antitussive Agents; Asthma; | 2001 |
Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Asthma | 2001 |
Effects of glucocorticoids on endogenous and transcellular metabolism of eicosanoids in asthma.
Topics: 5-Lipoxygenase-Activating Proteins; Administration, Inhalation; Administration, Oral; Adrenergic bet | 2001 |
Ambulatory use of inhaled beta(2)-agonists for the treatment of asthma in Quebec : a population-based utilization review.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Ag | 2001 |
Formoterol (Foradil Aerolizer) for asthma.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma | 2001 |
[Powder inhaler with integrated motor. The anti-asthmatic drug stays fresh].
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Budesonide; Drug Combinations; Humans; Nebulizers and Vapo | 2001 |
Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies.
Topics: Adrenergic beta-Agonists; Adult; Age Distribution; Aged; Aged, 80 and over; Albuterol; Asthma; Bronc | 2001 |
Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; | 2001 |
What is "more effective asthma control"?
Topics: Acetates; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chronic Disease; Cyclopro | 2001 |
Tolerance to the protective effect of salmeterol on allergen challenge can be partially restored by the withdrawal of salmeterol regular treatment.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Broncho | 2001 |
[Precise direction or flexible self-control. How strictly must the asthma patient adhere to medical advice?].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Budesonide; Dr | 2001 |
Is overall asthma control being achieved? A hypothesis-generating study.
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; | 2001 |
Time to consign cromoglycate to history?
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Child; Child, Preschool; Cromolyn Sodium; Humans | 2001 |
Acute changes in bronchoconstriction influences exhaled nitric oxide level.
Topics: Adult; Albuterol; Asthma; Breath Tests; Bronchoconstriction; Bronchoconstrictor Agents; Bronchodilat | 2001 |
Selected contribution: airway caliber in healthy and asthmatic subjects: effects of bronchial challenge and deep inspirations.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoconstricti | 2001 |
Revisiting interactions between hypoxaemia and beta2 agonists in asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Cardiovascular Diseases; Dose-Response Relationship, Dr | 2001 |
EG-1 positive eosinophils in asthma.
Topics: Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator Agents; Eosinophils; Humans; Salmete | 2001 |
Is there a need for another inhalative beta(2)-agonist besides formoterol in patients with asthma?
Topics: Administration, Topical; Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Drug | 2001 |
[Controlling inflammation plus bronchodilation. Advantages of fixed combinations].
Topics: Adult; Albuterol; Androstadienes; Asthma; Child; Drug Combinations; Fluticasone; Humans; Salmeterol | 2001 |
Predictors of hospitalization in children with acute asthma.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Female; Forced Expiratory | 2001 |
[Bronchial asthma. Patient management still has deficits].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Asthma; Drug Synergism; Drug Therapy, Combina | 2001 |
Beta2-agonists--from pharmacological properties to everyday clinical practice.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Ethanolamines; Formoterol Fumarate; Humans; Nebulizers | 2001 |
To the editor: Exacerbation of asthma by ibuprofen in a very young child.
Topics: Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchodilator Agents; Child, Preschool; | 2001 |
Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Cost of Illness; Drug Therapy, Comb | 2001 |
Magnesium concentration in plasma, leukocytes and urine of children with intermittent asthma.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Case-Control Studies; Child; Child, Preschool; | 2001 |
The tolerability, safety, and success of sputum induction and combined hypertonic saline challenge in children.
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Child; Female; Humans; Male; Saline Solutio | 2001 |
Regulation of NO-producing function of the lungs with salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchoalveolar Lavage Fluid; Bronchodilator A | 2001 |
Levalbuterol and racemic albuterol: are there therapeutic differences?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Spasm; Bronchodila | 2001 |
Childhood asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child, Preschool; Cholinergic Antagonists; Drug Therapy | 2001 |
Safety of sputum induction with isotonic saline in adults with acute severe asthma.
Topics: Acute Disease; Adolescent; Adrenergic beta-Agonists; Adult; Age Factors; Aged; Aged, 80 and over; Al | 2001 |
[How compliance is improved. Combined treatment of asthma].
Topics: Albuterol; Androstadienes; Asthma; Delayed-Action Preparations; Drug Therapy, Combination; Ethanolam | 2001 |
Using humanistic health outcomes data in asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Clinical Trials as Topic; Health Status; Hum | 2001 |
Impact of an asthma carepath on the management of acute asthma exacerbations.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Critical Pathways; Female; Hospitals, Teaching; Hum | 2001 |
The clinical trials in the initial five-year award period of the Asthma Clinical Research Network.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Area Under | 2001 |
Genetic analysis in the Asthma Clinical Research Network.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Clinical Trials as Topic; Confidentiality; Ethics Commi | 2001 |
Recruitment strategies in the Asthma Clinical Research Network.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Child | 2001 |
Angiogenesis and remodeling of airway vasculature in chronic inflammation.
Topics: Adrenergic beta-Antagonists; Adult; Albuterol; Angiopoietin-1; Animals; Asthma; Bronchitis; Bronchod | 2001 |
Early prediction of poor outcome in patients with acute asthma in the emergency room.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service | 2002 |
Salmeterol and inhaled corticosteroids in patients with persistent asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child; | 2001 |
Salmeterol and inhaled corticosteroids in patients with persistent asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Glucoc | 2001 |
Salmeterol and inhaled corticosteroids in patients with persistent asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Child; | 2001 |
Salmeterol and inhaled corticosteroids in patients with persistent asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Glucoc | 2001 |
Improving pediatric asthma patient outcomes by incorporation of effective interventions.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator | 2001 |
When the whole is more than the sum of its parts.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Dr | 2001 |
Salmeterol 100 microg: an analysis of its tolerability in single- and chronic-dose studies.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Child; Child, | 2001 |
Evaluation of particle size distribution of salmeterol administered via metered-dose inhaler with and without valved holding chambers.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Chromatograp | 2001 |
Number needed to treat (NNT): estimation of a measure of clinical benefit.
Topics: Albuterol; Asthma; Bronchodilator Agents; Cross-Over Studies; Humans; Quality of Life; Randomized Co | 2001 |
Response of asthma-related voice dysfunction to allergen immunotherapy: a case report of confirmation by methacholine challenge.
Topics: Adult; Albuterol; Asthma; Bronchoconstrictor Agents; Bronchodilator Agents; Desensitization, Immunol | 2001 |
Reversible selective beta(2)-adrenoceptor agonist-induced myopathy.
Topics: Administration, Intranasal; Administration, Oral; Adrenergic beta-Antagonists; Aged; Albuterol; Asth | 2002 |
Validation of the pulmonary score: an asthma severity score for children.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge | 2002 |
Validation of the pulmonary score: an asthma severity score for children.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge | 2002 |
Validation of the pulmonary score: an asthma severity score for children.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge | 2002 |
Validation of the pulmonary score: an asthma severity score for children.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Emerge | 2002 |
Bronchodilator responsiveness and atopy in 5-10-yr-old coughers.
Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cough; Cross-S | 2001 |
[Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Asthma; Bronchodilator Agents | 2002 |
MIASMA: asthma exacerbation reduction with salmeterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Glucocorticoids; Humans; Sa | 2002 |
Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs.
Topics: Acetates; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; | 2002 |
Effects of theophylline on CD4+ T lymphocyte, interleukin-5, and interferon gamma in induced sputum of asthmatic subjects.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; CD4-Positive T-Lymphocytes; Delayed-Action Preparat | 2002 |
[Fixed combination of salmeterol and fluticasone. A mile stone in asthma therapy].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Clinical Trial | 2002 |
[Good asthma control is possible. Synergy of 2 soloists].
Topics: Administration, Inhalation; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Clinical Trial | 2002 |
Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma.
Topics: Administration, Inhalation; Administration, Topical; Adult; Albuterol; Androstadienes; Anti-Inflamma | 2002 |
A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Child; Dose-Response R | 2002 |
Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation.
Topics: Aged; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Lung Volume Measu | 2002 |
A comparison of the validity of different diagnostic tests in adults with asthma.
Topics: Adolescent; Adult; Aged; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Bronchod | 2002 |
Bronchodilator reversibility to albuterol predicts bronchodilator response to salmeterol.
Topics: Acetates; Administration, Inhalation; Airway Resistance; Albuterol; Anti-Asthmatic Agents; Asthma; B | 2002 |
Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma.
Topics: Administration, Topical; Adult; Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Broncho | 2002 |
In children hospitalized for asthma exacerbations, does adding ipratropium bromide to albuterol and corticosteroids improve outcome?
Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Presch | 2002 |
[Bronchial asthma. Dual problem--dual therapy].
Topics: Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Drug Therapy, Combination; Fluticasone; Hu | 2002 |
Xopenex. New asthma relief for kids.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child; Drug Approval; Humans | 2002 |
Preventing unnecessary emergency department visits for "albuterol nebs".
Topics: Albuterol; Asthma; Bronchodilator Agents; Emergency Service, Hospital; Humans; Nebulizers and Vapori | 2002 |
[Inducible nitric oxide synthase in rat lungs in experimental bronchial asthma and its status in administering drugs with adrenergic action].
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Albuterol; Animals; Asthma; Fenote | 2002 |
Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy.
Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Albuterol; Anti-Asthmatic Agents; Ast | 2002 |
[Use of beta-adrenergic drugs in pediatric therapy].
Topics: Adrenergic beta-Agonists; Age Factors; Albuterol; Asthma; Child; Dyspnea; Humans; Isoproterenol; Met | 1976 |
[Comparative effectiveness of some beta-adrenergic drugs used in the treatment of asthma-like syndromes].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Evaluation; Dyspnea; Humans; Metaproterenol; Respi | 1976 |
[Physiopathological and clinical studies on the use of beta-stimulating drugs].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Evaluation; Humans; Lung Diseases, Obstructive; Pu | 1976 |
[Effect of beta-adrenergic drugs on bronchial secretion].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchi; Bronchitis; Drug Evaluation; Female; Hu | 1976 |
[Comparative study of the effectiveness of beta-adrenergic stimulatin drugs].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Drug Evaluation; For | 1976 |
[Comparative clinical data on the bronchodilating effect of some selective beta-2 stimulating drugs].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchodilator Agents; Child; Female; Forced Expiratory | 1977 |
A comparison of rimiterol and salbutamol by inhalation at high and low dose in asthmatic patients.
Topics: Aerosols; Albuterol; Asthma; Blood Pressure; Bronchial Spasm; Catechols; Heart Rate; Humans; Peak Ex | 1978 |
Blood eosinophil leucocyte and eosinophil cationic protein. In vivo study of the influence of beta-2-adrenergic drugs and steroid medication.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Asthma; B | 1978 |
Aspects on bronchial beta2-receptor tolerance.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Drug Resistance; Humans; Time Factors | 1979 |
Which bronchodilator-and when?
Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Aminophylline; Asthma; Bronchodilator Agents; Humans; | 1979 |
[Bronchospasmolytic agents].
Topics: Adrenergic beta-Agonists; Albuterol; Aminophylline; Asthma; Bronchi; Drug Therapy, Combination; Huma | 1979 |
Granulocyte response in vitro to isoproterenol, histamine, and prostaglandin E1, during treatment with beta-adrenergic aerosols in asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Cyclic AMP; Glucuronidase; | 1979 |
Letter: Intravenous prednisolone in asthma.
Topics: Albuterol; Asthma; Drug Interactions; Humans; Hydrocortisone; Injections, Intravenous; Isoproterenol | 1976 |
Myocardial infarction in status asthmaticus.
Topics: Albuterol; Aminophylline; Asthma; Female; Humans; Middle Aged; Myocardial Infarction | 1977 |
Intravenous versus inhaled salbutamol.
Topics: Acute Disease; Aerosols; Albuterol; Asthma; Humans; Injections, Intravenous | 1978 |
Intravenous versus inhaled salbutamol.
Topics: Albuterol; Asthma; Evaluation Studies as Topic; Humans; Injections, Intravenous; Intermittent Positi | 1978 |
Nebulised salbutamol in treatment of acute asthma in children.
Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child, Preschool; Cromolyn Sodium; Home Care Services; H | 1978 |
Nebulised salbutamol in adult asthma.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Female; Humans; Male; Middle Aged | 1978 |
Salbutamol and beclomethasone in chronic asthma.
Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Chronic Disease; Drug Therapy, Combination; Humans | 1978 |
Salbutamol and beclomethasone in chronic asthma.
Topics: Albuterol; Asthma; Beclomethasone; Chronic Disease; Drug Therapy, Combination; Humans | 1978 |
Nebulised salbutamol in treatment of acute asthma in children.
Topics: Acute Disease; Aerosols; Age Factors; Albuterol; Asthma; Child; Child, Preschool; Humans; Infant; Ma | 1978 |
A simple standardized approach to childhood asthma.
Topics: Albuterol; Asthma; Beclomethasone; Child; Child Health Services; Child, Preschool; Cromolyn Sodium; | 1979 |
[Value and limitations of salbutamol in the treatment of the obstructive syndrome. Comparative study with a synthetic atropine-like agent].
Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Female; Humans; Ipratropium; Lung | 1976 |
Protective effect of drugs on histamine-induced asthma.
Topics: Albuterol; Ascorbic Acid; Asthma; Atropine; Choline; Cromolyn Sodium; Female; Histamine; Humans; Ipr | 1977 |
[Effect of an adrenergic-parasympatholytic aerosol combination on the respiratory function].
Topics: Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchial Spasm; Bronchitis; Drug Combinations; D | 1979 |
[Concerning the therapy of exercise-induced asthma (author's transl)].
Topics: Albuterol; Asthma; Asthma, Exercise-Induced; Atropine Derivatives; Cromolyn Sodium; Humans; Ipratrop | 1979 |
Clinical pharmacology of a combination of bronchodilators.
Topics: Aerosols; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Bronchodilator Agents; Drug Combinati | 1979 |
Mechanisms of the bronchoconstrictor effects of deep inspiration in asthmatic patients.
Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Constriction, Pathologic; Cromolyn | 1979 |
[Combined inhalation of salbutamol and ipratropin in chronic bronchial obstruction].
Topics: Adult; Aged; Albuterol; Asthma; Atropine Derivatives; Bronchitis; Drug Therapy, Combination; Female; | 1979 |
Editorial: Treatment of asthmatic children with steroids.
Topics: Adrenocorticotropic Hormone; Aerosols; Albuterol; Asthma; Beclomethasone; Child; Child, Preschool; C | 1975 |
Treatment of a case of allergic asthma with a synthetic human ACTH preparation.
Topics: Adrenocorticotropic Hormone; Albuterol; Asthma; Child; Cromolyn Sodium; Female; Hormones; Humans | 1976 |
[Use of bronchodilators].
Topics: Administration, Intranasal; Administration, Oral; Albuterol; Asthma; Bronchial Spasm; Bronchodilator | 1976 |
The lymphocyte beta-adrenoceptor in normal subjects and patients with bronchial asthma: the effect of different forms of treatment on receptor function.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Cyclic AMP; Female; Humans; Isoproterenol; Lymphocytes; | 1976 |
Effect of salbutamol inhalations of plasma and urinary cyclic adenosine monophosphate levels in asthmatics and non-atopic controls.
Topics: Administration, Oral; Adolescent; Adult; Aerosols; Albuterol; Asthma; Cyclic AMP; Female; Humans; Ma | 1976 |
Comparison of cyclic adenosine monophosphate response of lymphocytes in normal and asthmatic subjects to norepinephrine and salbutamol.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Cyclic AMP; Female; Humans; In Vitro | 1977 |
[Plasma cortisol, cyclic adenosine monophosphate and lung function in asthmatic patients].
Topics: Adult; Aged; Albuterol; Asthma; Cosyntropin; Cyclic AMP; Female; Humans; Hydrocortisone; Middle Aged | 1978 |
[Broncholytic effect of stimulation of beta-2 adrenergic receptors in asthma, bronchiectasis and pulmonary tuberculosis].
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Bronchiectasis; Female; Humans; Male; Receptors, Adre | 1978 |
Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Female; Humans; Lymphocyte | 1978 |
Circadian rhythmicity in medicine with special regard to asthmatic patients.
Topics: Adrenocorticotropic Hormone; Albuterol; Asthma; Circadian Rhythm; Corticosterone; Humans; Hydrocorti | 1979 |
Metabolic and cardiovascular effects of salbutamol in atopic subjects with and without asthma.
Topics: Adult; Albuterol; Asthma; Blood Glucose; Fatty Acids, Nonesterified; Female; Forced Expiratory Volum | 1979 |
Exercise-induced asthma.
Topics: Acidosis, Respiratory; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Air | 1975 |
[Induced beta-adrenergic stimulation and blockade in asthma bronchomotor effects (author's transl)].
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Airway Obstruction; Airway Resistance; Albute | 1975 |
Annals of allergy.
Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Epinephrine; Fenoterol; Hexoprenaline; Isopro | 1975 |
Effect of beta-adrenoreceptor stimulants on exercise-induced asthma.
Topics: Adrenergic beta-Agonists; Airway Obstruction; Albuterol; Asthma; Child; Epinephrine; Humans; Isoetha | 1975 |
A comparison of oral theophylline and oral salbutamol in exercise-induced asthma.
Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Child; Female; Humans; Male; Peak Expira | 1977 |
Case report: an asthmatic child with a very high consumption of Ventoline respirator solution.
Topics: Adolescent; Albuterol; Asthma; Drug Tolerance; Female; Humans; Respiratory Therapy; Substance-Relate | 1977 |
Volume of trapped gas (VTG) during provoked asthma and after inhalation of salbutamol.
Topics: Albuterol; Asthma; Female; Forced Expiratory Volume; Functional Residual Capacity; Humans; Lung Volu | 1977 |
[Broncholytic aerosols; with special attention to juvenile patients].
Topics: Adolescent; Aerosols; Age Factors; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Body He | 1978 |
Bronchodilator effects of oral salbutamol and theophylline-salbutamol combinations in chronic steroid-dependent asthmatics.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Chronic Disease; Double-Bli | 1979 |
Intermittent positive-pressure breathing.
Topics: Adult; Albuterol; Asthma; Female; Humans; Intermittent Positive-Pressure Breathing; Male; Methods; P | 1978 |
A comparison of salbutamol given by pressure-packed aerosol or nebulization via IPPB in acute asthma.
Topics: Acute Disease; Adult; Aerosols; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Intermi | 1978 |
Aerosolised bronchodilator therapy with & without IPPR in bronchial asthma--a comparative evaluation.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Intermittent | 1978 |
Nebulised salbutamol in life-threatening asthma.
Topics: Aerosols; Albuterol; Asthma; Humans; Intermittent Positive-Pressure Ventilation | 1979 |
Status asthmaticus in children: a one-year study.
Topics: Adolescent; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Female; Follow-Up Studies; Ho | 1979 |
Effects of exercise on asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Child; Cromolyn Sodium; Humans; Middle Aged; Physical Exertion | 1977 |
A case of intrinsic asthma.
Topics: Albuterol; Asthma; Cromolyn Sodium; Humans | 1977 |
Treatment of asthma in children.
Topics: Albuterol; Asthma; Child; Cromolyn Sodium; Humans; Sympathomimetics; Theophylline | 1978 |
Saving asthmatics.
Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Humans | 1979 |
[Use of ventolin for detection of latent bronchial spasm in the inter-attack period of bronchial asthma in children].
Topics: Albuterol; Asthma; Bronchi; Bronchial Spasm; Child; Child, Preschool; Humans | 1979 |
Saving asthmatics.
Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Humans; Kinetics; Random Allocation | 1979 |
Transit-time analysis of the forced expiratory spirogram during clinical remission in juvenile asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Female; Forced Expiratory Flow Rates; Humans; Male; Remission, | 1979 |
Bronchodilator effects of antiasthmatic cigarette smoke (Datura stramonium).
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Datura stramonium; Dilatation; Female; Heart R | 1979 |
Plasma and white blood cell ascorbic acid concentrations in patients with bronchial asthma.
Topics: Adult; Age Factors; Albuterol; Ascorbic Acid; Asthma; Body Weight; Cholesterol; Humans; Leukocyte Co | 1979 |
[Prolonged use of salbutamol syrup in 25 aged patients].
Topics: Administration, Oral; Aged; Albuterol; Asthma; Bronchial Spasm; Female; Follow-Up Studies; Humans; M | 1979 |
Bronchodilator drugs and young children.
Topics: Age Factors; Albuterol; Asthma; Humans; Infant | 1979 |
Respiratory and circulatory interactions of salbutamol and theophyllamine in asthmatic patients.
Topics: Adolescent; Adult; Albuterol; Asthma; Double-Blind Method; Drug Interactions; Female; Hemodynamics; | 1979 |
A comparison of the bronchodilator efficacy of oral salbutamol and terbutaline.
Topics: Adult; Albuterol; Asthma; Female; Humans; Male; Pulmonary Ventilation; Terbutaline | 1979 |
Dose-titration comparison of inhaled salbutamol and oral theophylline in asthma.
Topics: Administration, Oral; Adult; Aerosols; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Fo | 1979 |
Physiological patterns in early morning asthma.
Topics: Adult; Aged; Albuterol; Asthma; Circadian Rhythm; Helium; Humans; Lung; Middle Aged; Respiratory Fun | 1977 |
Salbutamol-induced ketoacidosis.
Topics: Acidosis; Albuterol; Asthma; Female; Humans; Hyperglycemia; Ketosis; Middle Aged | 1977 |
[The controlled administration of salbutamol in asthmatics by means of "Airflometer" (author's transl)].
Topics: Albuterol; Asthma; Humans; Respiratory Function Tests | 1977 |
[Clinical evaluation of salbutamol in bronchial asthma in childhood].
Topics: Age Factors; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Female; Humans; Infant; In | 1977 |
[Management of severe asthma in childhood (author's transl)].
Topics: Acetylcysteine; Age Factors; Airway Obstruction; Albuterol; Aminophylline; Asthma; Bromhexine; Child | 1977 |
Intravenous or inhaled salbutamol in severe acute asthma?
Topics: Acute Disease; Adult; Aerosols; Albuterol; Asthma; Female; Humans; Injections, Intravenous; Male; Mi | 1977 |
Metabolic effects of intravenous salbutamol in the course of acute severe asthma.
Topics: Acute Disease; Albuterol; Asthma; Fatty Acids, Nonesterified; Humans; Injections, Intravenous; Potas | 1977 |
Oral salbutamol therapy of asthma in young children.
Topics: Administration, Oral; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male | 1977 |
Treatment of severe attacks of asthma in children with nebulized B2 adrenergic agents.
Topics: Administration, Intranasal; Albuterol; Asthma; Auscultation; Child; Child, Preschool; Dyspnea; Human | 1978 |
Management of severe acute asthma.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Asthma; Hospitalization; Humans | 1978 |
[Effect of stimulation of beta-2 adrenergic receptors on the exercise capacity and subjective exercise tolerance in patients with asthma].
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchi; Humans; Male; Physical Exertion | 1978 |
Management of severe acute asthma.
Topics: Acute Disease; Albuterol; Asthma; Humans | 1978 |
[Comparison between intravenous administration of salbutamol and theophylline in asthma].
Topics: Albuterol; Asthma; Humans; Theophylline | 1978 |
Intravenous infusion of salbutamol in severe acute asthma.
Topics: Acute Disease; Albuterol; Aminophylline; Asthma; Humans; Infusions, Parenteral; Research Design | 1978 |
Changes in volume of trapped gas in the lungs during provoked asthma followed by beta-2 receptor stimulation.
Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Bronchospirometry; Closing Volume; Female; Humans; Lung; | 1978 |
Bronchofiberscopy in asthmatics: a method for minimizing risk of complications.
Topics: Adult; Aged; Albuterol; Asthma; Bronchial Spasm; Bronchitis; Bronchoscopy; Female; Forced Expiratory | 1978 |
[Long-term effect and tolerance of broncholytics].
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Drug Resistance; Drug Tolerance; Fenoterol; Hexoprenaline; | 1978 |
Comparison of the metabolic effects of salbutamol administered in a one-minute bolus and a continuous infusion in patients with bronchial asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Blood Glucose; Female; Heart Rate; Humans; Male; Peak Expirato | 1978 |
[Use of sympathomimetics in the treatment of asthma].
Topics: Albuterol; Asthma; Bronchodilator Agents; Ephedrine; Epinephrine; Humans; Isoproterenol; Metaprotere | 1978 |
Acute changes of lung volumes and lung mechanics in asthma and in normal subjects.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Functional Residual C | 1978 |
At what age do bronchodilator drugs work?
Topics: Age Factors; Airway Resistance; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Child, Prescho | 1978 |
The volume of trapped gas: a new and sensitive test for the detection of exercise-induced bronchospasm in children.
Topics: Adolescent; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Female; Humans; Lung Volume Measurem | 1978 |
[Pathogenesis and prevention of exercise-induced asthma].
Topics: Airway Obstruction; Albuterol; Asthma; Humans; Physical Exertion | 1978 |
Use of salbutamol powder in childhood asthma.
Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Powders; Res | 1978 |
Inhalation of beta-stimulants: dose-response relationship.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Dose-Response Relationship, Drug; Female; Huma | 1978 |
[The neurovegetative system in the pathogenesis of bronchial spasm].
Topics: Albuterol; Aminophylline; Animals; Asthma; Atropine; Autonomic Nervous System; Bronchial Spasm; Dogs | 1977 |
[Use of a new Bronchodilator agent in the prevention and control of bronchial spasm induced by surface anesthesin].
Topics: Adult; Aged; Albuterol; Anesthesia; Anesthetics; Asthma; Bronchial Spasm; Bronchodilator Agents; Fem | 1977 |
Metabolic and cardiotoxic effects of salbutamol.
Topics: Albuterol; Asthma; Heart; Humans | 1977 |
Reversibility of small airway obstruction after therapy with salbutamol. Studies in asymptomatic asthmatic patients after inhalation of pressurized aerosol.
Topics: Adolescent; Adult; Aerosols; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Female; Force | 1977 |
Correct use of aerosol inhalers.
Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Humans; Lung Diseases; Methods | 1977 |
[Clinical evaluation of beta-sympathomimetics in the treatment of infantile allergic asthma].
Topics: Albuterol; Asthma; Child; Drug Evaluation; Humans; Infant | 1977 |
Metabolic response to intravenous salbutamol therapy in acute asthma.
Topics: Acute Disease; Adult; Albuterol; Asthma; Blood Glucose; Fatty Acids, Nonesterified; Female; Humans; | 1977 |
[Salbutamol in the treatment of severe broncho-asthmatic attacks].
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Drug Evaluation; Female; Humans; Lung Diseases, Obstruct | 1977 |
Studies in chronic allergic bronchopulmonary aspergillosis. 1. Clinical and physiological findings.
Topics: Adult; Aged; Albuterol; Aspergillosis; Asthma; Chronic Disease; Female; Humans; Lung Diseases, Funga | 1977 |
A case of intrinsic asthma.
Topics: Aged; Albuterol; Asthma; Beclomethasone; Humans; Male; Prednisone | 1977 |
[Respiratory function data in juvenile bronchial asthma].
Topics: Albuterol; Asthma; Bronchi; Child; Child, Preschool; Humans; Plethysmography, Whole Body; Prognosis; | 1977 |
Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics.
Topics: Adult; Aerosols; Albuterol; Asthma; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart | 1977 |
[Treatment of bronchospastic attack and the asthmatic state].
Topics: Albuterol; Asthma; Bronchial Spasm; Drug Combinations; Drug Evaluation; Ephedrine; Humans; Prednisol | 1977 |
[Bronchopulmonary ememgencies in childhood (author's transl)].
Topics: Albuterol; Asthma; Child; Emergencies; Humans; Intubation; Laryngitis; Pneumonia; Prednisolone; Trac | 1976 |
Asthma due to 'glycyl compound' powder--an intermediate in production of salbutamol.
Topics: Acetophenones; Albuterol; Asthma; Chemical Phenomena; Chemistry; Drug Industry; Humans; Male; Middle | 1976 |
Effect of intravenous injection of salbutamol in asthma.
Topics: Acute Disease; Aerosols; Albuterol; Asthma; Humans; Injections, Intravenous | 1976 |
Intramuscular salbutamol in acute asthma.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Humans; Injections, Intramuscular; Middle Aged | 1976 |
Comparison of intravenous and aerosol salbutamol.
Topics: Aerosols; Albuterol; Asthma; Humans; Injections, Intravenous | 1976 |
[Salbutamol therapy of chronic bronchopathic patients with cardiac arrhythmias].
Topics: Aged; Albuterol; Arrhythmias, Cardiac; Asthma; Chronic Disease; Female; Heart Rate; Humans; Lung Dis | 1976 |
Important new drugs in asthma.
Topics: Albuterol; Asthma; Beclomethasone; Humans | 1976 |
Nocturnal asthma and sudden death.
Topics: Adolescent; Adult; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Circadian Rhythm; D | 1976 |
[Evaluations of the effects of salbutamol retard on the functional indices of asthmatic children].
Topics: Albuterol; Asthma; Child; Delayed-Action Preparations; Humans; Respiration | 1976 |
Salbutamol by various routes.
Topics: Albuterol; Asthma; Humans; Injections, Intramuscular | 1976 |
[Orciprenaline: an "old" bronchodilator still valid. Comparative study of the bronchodilator effect of orciprenaline and salbutamol in patients with obstructive type respiratory dysfunctional syndrome].
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Drug Evaluation; Female; Humans; Male; Metaproterenol; M | 1976 |
[Salbutamol in the early diagnosis of infantile asthma].
Topics: Age Factors; Albuterol; Asthma; Child, Preschool; Humans; Infant; Infant, Newborn; Time Factors | 1976 |
[Salbutamol. Clinical and functional evaluation in the pediatric field].
Topics: Age Factors; Albuterol; Asthma; Cardiovascular System; Child; Humans | 1976 |
Intravenous salbutamol in management of status asthmaticus.
Topics: Acute Disease; Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Carbon Dioxide; Female; Humans; | 1975 |
[Use in anesthesiology of a new beta-2-stimulator, Salbutamol. Original technic and considerations].
Topics: Adjuvants, Anesthesia; Administration, Oral; Administration, Topical; Adult; Aerosols; Aged; Albuter | 1975 |
Ventilatory response to carbon dioxide in Nigerian asthmatics before and after aerosol salbutamol inhalation.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Carbon Dioxide; Female; Forced Expiratory Volu | 1975 |
New bronchodilator aerosol, salmefamol, in asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Anisoles; Asthma; Bronchodilator Agents; Cresols; Epin | 1975 |
[Data on the use in pediatrics of oral administration of salbutamol in soluble tablets in the therapy of asthmatic attacks].
Topics: Administration, Oral; Age Factors; Albuterol; Asthma; Child; Female; Heart; Humans; Male; Respiratio | 1975 |
Editorial: Management of acute asthma.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Aminophylline; Asthma; Humans; Oxygen Inhalation | 1975 |
[Comparison of the bronchodilator action of fenoterol and salbutamol by aerosol administration in patients with bronchial asthma].
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Chronic Disease; Drug Evaluation; | 1975 |
Patterns of response to isoprenaline in asthmatic patients.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Isoproterenol | 1975 |
Letter: Deaths in asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Death, Sudden; Heart; Humans | 1975 |
[Prospects of inhalation therapy in infantile bronchial asthma].
Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Child; Drug Evaluation; Humans; Metaproterenol; Methylp | 1975 |
Intravenous infusion of salbutamol in the treatment of asthma.
Topics: Adult; Albuterol; Asthma; Blood Pressure; Female; Forced Expiratory Volume; Heart Rate; Humans; Infu | 1975 |
Proceedings: Treatment of severe acute attacks of bronchial asthma and wheezy bronchitis with salbutamol administered by nebulizer.
Topics: Aerosols; Albuterol; Asthma; Bronchitis; Humans | 1976 |
Wheezing children.
Topics: Acute Disease; Adrenal Cortex Hormones; Albuterol; Aminophylline; Asthma; Child; Child, Preschool; D | 1976 |
[Salbutamol in the treatment of bronchial asthma].
Topics: Aged; Albuterol; Asthma; Drug Evaluation; Female; Humans; Male; Middle Aged | 1976 |
[The broncholytic effect of salbutamol in relation to method of administration and dosage].
Topics: Albuterol; Asthma; Bronchitis; Humans; Metaproterenol; Respiratory Function Tests | 1976 |
[Some effects of salbutamol in severe obstructive chronic emphysema].
Topics: Albuterol; Asthma; Blood Glucose; Child; Child, Preschool; Drug Evaluation; Fatty Acids, Nonesterifi | 1976 |
[Study of the ventilatory and cardiocirculatory effects of a beta-2-stimulating drug (salbutamol) in patients with the respiratory dysfunctional syndrome of the obstructive type].
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Cardiovascular System; Drug Evaluation; Hemodynamics; Hu | 1976 |
[Clinical study of the use of salbutamol in patients with bronchial asthma].
Topics: Adult; Albuterol; Asthma; Drug Evaluation; Female; Humans; Male; Middle Aged | 1976 |
[Data on the use of the aerosol salbutamol in infantile bronchial asthma].
Topics: Aerosols; Age Factors; Albuterol; Asthma; Child; Drug Evaluation; Female; Humans; Male | 1976 |
[Comparative study of the effect of some bronchodilator substances].
Topics: Aged; Albuterol; Aminophylline; Asthma; Bronchial Diseases; Bronchodilator Agents; Doxylamine; Drug | 1976 |
[Clinical experience with delayed-action salbutamol].
Topics: Albuterol; Asthma; Chronic Disease; Delayed-Action Preparations; Drug Evaluation; Hemodynamics; Huma | 1976 |
[Our experience with salbutamol in the treatment of bronchial asthma and chronic asthmatiform bronchitis].
Topics: Albuterol; Asthma; Bronchitis; Chronic Disease; Delayed-Action Preparations; Humans; Respiratory Fun | 1976 |
[Study of the effects of salbutamol in chronic obstructive bronchopneumopathies].
Topics: Albuterol; Asthma; Drug Evaluation; Hemodynamics; Humans; Lung Diseases, Obstructive; Respiration; S | 1976 |
[Possibilities of the use of salbutamol in anesthesia and resuscitation].
Topics: Adjuvants, Anesthesia; Albuterol; Anesthesia; Asthma; Bronchitis; Humans; Preanesthetic Medication; | 1976 |
[Action of salbutamol by aerosol administration on ventilatory mechanics in asthmatic subjects].
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchial Spasm; Drug Evaluation; Female; Humans; Ma | 1976 |
[Clinical and functional considerations on the use of salbutamol].
Topics: Adult; Albuterol; Asthma; Bronchitis; Drug Evaluation; Female; Hemodynamics; Humans; Lung Volume Mea | 1976 |
[Comparison of the bronchodilator action of salbutamol and orciprenaline by aerosol administration in patients with chronic bronchopneumopathy].
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Bronchial Spasm; Bronchitis; Drug Evaluation; Female; Huma | 1976 |
[Our experience in the treatment of bronchial asthma and asthmatic bronchitis with salbutamol].
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchitis; Child; Drug Evaluation; Female; Humans; Isop | 1976 |
[The salbutamol test in the early diagnosis of infantile asthma].
Topics: Age Factors; Albuterol; Asthma; Child; Humans | 1976 |
[Effects of salbutamol in bronchial asthma and in chronic obstructive bronchopathy].
Topics: Adult; Albuterol; Asthma; Bronchitis; Cardiovascular System; Chronic Disease; Drug Evaluation; Femal | 1976 |
[Beta 2 specificity of salbutamol: clinical and functional evaluation in children].
Topics: Albuterol; Asthma; Cardiovascular System; Child; Child, Preschool; Drug Evaluation; Humans; Infant; | 1976 |
[Ventilatory and cardiocirculatory effects of salbutamol].
Topics: Adult; Aged; Albuterol; Asthma; Bronchial Spasm; Cardiovascular System; Drug Evaluation; Female; Hum | 1976 |
[Changes in static and dynamic volumes in bronchial asthmatics treated with salbutamol by oral administration].
Topics: Administration, Oral; Adolescent; Adult; Albuterol; Asthma; Drug Evaluation; Female; Humans; Lung Vo | 1976 |
[Bronchodilator action and side effects of salbutamol in patients with bronchospasm of the respiratory tract].
Topics: Adult; Aged; Albuterol; Asthma; Bronchitis; Bronchodilator Agents; Drug Evaluation; Dyspnea; Female; | 1976 |
[Clinical study of the use of salbutamol (ventolin Glaxo)].
Topics: Adult; Albuterol; Asthma; Bronchitis; Drug Evaluation; Humans; Isoproterenol; Middle Aged; Respirati | 1976 |
Effects of salbutamol and propranolol on closing volume in extrinsic bronchial asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Female; Humans; Male; Propranolol; Respiratory Function Tests; | 1976 |
[Effect of compounds selectively stimulating beta adrenergic receptors on pulmonary circulation, ventilation and gas exchange in patients with asthma].
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Ethanolamines; Female; Fenoterol; Humans; Male; Middle A | 1976 |
RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Albuterol; Anesthesia; A | 1992 |
[Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma].
Topics: Adolescent; Adult; Albuterol; Asthma; Child; Female; Humans; Male; Middle Aged; Procaterol | 1992 |
Relationship between spontaneous dyspnoea and lability of airway obstruction in asthma.
Topics: Adolescent; Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchi; Carbachol; Dyspnea; Female; | 1992 |
Recovery of leukotriene E4 from the urine of patients with airway obstruction.
Topics: Acute Disease; Adult; Aged; Albuterol; Asthma; Female; Humans; Leukotriene E4; Male; Middle Aged; Pe | 1992 |
Evolution of therapy for childhood asthma.
Topics: Aerosols; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchodilator Agents; Budeson | 1992 |
Leukotriene B4 level in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapy.
Topics: Adult; Albuterol; Asthma; Calcimycin; Female; Humans; In Vitro Techniques; Leukotriene B4; Macrophag | 1992 |
Mood and peak flow in asthma.
Topics: Affect; Albuterol; Asthma; Humans; Peak Expiratory Flow Rate; Time Factors | 1992 |
The use of beta-agonists and the risk of death and near death from asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Case-Control Studies | 1992 |
Bronchodilator treatment in asthma: continuous or on demand?
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug Administration Schedule; Forced Expiratory Volume; | 1992 |
Continuous subcutaneous infusion of beta 2-agonists in infantile asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Feasibility Studies; Humans; Infant; Infusion Pumps; In | 1992 |
[Can the management of patients with asthma be improved at present?].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Health Education; Humans; Physical Therapy Modalities; | 1992 |
[Salmeterol: towards new perspectives in the treatment of asthma].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Anti-Inflammatory Agents, Non-S | 1992 |
Beta-agonists and death from asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Case-Control Studies; Dose-Response Relationship, Drug; | 1992 |
Media mishandle medical news.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Mass Media; Public Opinion; Substance Withdrawa | 1992 |
Stimulation of cyclic AMP production in human alveolar macrophages induced by inflammatory mediators and beta-sympathicomimetics.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Cyclic AMP; Dinoproston | 1992 |
Asthma mortality and inhaled beta agonist therapy.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Guinea Pigs; Humans | 1992 |
Muscling in on salbutamol.
Topics: Albuterol; Animals; Asthma; Clenbuterol; Delayed-Action Preparations; Doping in Sports; Humans; Musc | 1992 |
Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Blood Platelet | 1992 |
Myopathy in severe asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Aminophylline; Asthma; Blood | 1992 |
Asthma drug therapy debate.
Topics: Acute Disease; Albuterol; Asthma; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Ther | 1992 |
Pulse oximetry and peak flow as indicators of wheezing severity in children and improvement following bronchodilator treatments.
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Child; Emergency Service, Hos | 1992 |
Salmeterol, a long acting bronchodilator, in the treatment of asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Humans; Salmeterol Xinafoate | 1992 |
High-dose systemic glucocorticoid therapy in the treatment of severe asthma: a case of resistance and patterns of response.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Dose-Response Relationship, Drug; | 1992 |
[Study of circadian rhythm of bronchial patency for timely correction and evaluation of the effectiveness of inhalation powder forms of salbutamol in children with bronchial asthma].
Topics: Administration, Inhalation; Adolescent; Airway Obstruction; Albuterol; Asthma; Bronchi; Child; Circa | 1992 |
Development of an animal model of late asthmatic response in guinea pigs and effects of anti-asthmatic drugs.
Topics: Albuterol; Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cromolyn Sodium; Cytodiagnosis; | 1992 |
Frequently nebulized beta-agonists for asthma: effects on serum electrolytes.
Topics: Adolescent; Adult; Aged; Albuterol; Analysis of Variance; Asthma; Electrolytes; Female; Humans; Magn | 1992 |
Chest radiography and high resolution computed tomography of the lungs in asthma.
Topics: Adult; Albuterol; Asthma; Female; Humans; Lung; Male; Methylprednisolone; Time Factors; Tomography, | 1992 |
Albuterol dosage and acute asthma.
Topics: Acute Disease; Albuterol; Asthma; Humans | 1992 |
An evaluation of severity-modulated compliance with q.i.d. dosing of inhaled beclomethasone.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Drug Administration Schedule; | 1992 |
A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1.
Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Cross-Sectional Studies; Female; For | 1992 |
A protocol for aerosol therapy in acute hospitalized asthmatics.
Topics: Acute Disease; Aerosols; Albuterol; Algorithms; Asthma; Child; Clinical Protocols; Hospitalization; | 1992 |
Transcutaneous blood gas monitoring during salbutamol inhalations in young children with acute asthmatic symptoms.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Asthma; Blood Gas Monitoring, Transcutaneous; | 1992 |
Transcutaneous and arterial blood gas monitoring during acute asthmatic symptoms in older children.
Topics: Acute Disease; Adolescent; Albuterol; Arteries; Asthma; Blood Gas Monitoring, Transcutaneous; Carbon | 1992 |
Creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) activity in serum before and after intravenous salbutamol administration of patients with bronchial asthma.
Topics: Adult; Albuterol; Asthma; Creatine Kinase; Female; Heart; Humans; Injections, Intravenous; Isoenzyme | 1992 |
The prehospital use of nebulized albuterol on patients with wheezing whose chief complaint is shortness of breath.
Topics: Adult; Aged; Albuterol; Asthma; Child; Child, Preschool; Emergency Medical Services; Female; Humans; | 1992 |
[The experience of using Ditec in bronchial asthma].
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Cromolyn Sodium; Drug Combinations; Drug Evaluation; Femal | 1992 |
Acute childhood asthma and plasma salbutamol levels.
Topics: Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers | 1992 |
Early diagnosis of proximal femoral deficiency.
Topics: Adult; Albuterol; Asthma; Female; Femur; Fetal Diseases; Gestational Age; Humans; Maternal Age; Olig | 1992 |
Lung volumes measured by the forced rebreathing technique in children with airways obstruction.
Topics: Adolescent; Albuterol; Asthma; Child; Cystic Fibrosis; Female; Humans; Lung Volume Measurements; Mal | 1992 |
Maximum voluntary cough ratios reflect antitussive activity of inhaled albuterol.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Cough; Female; Humans; Male; Maximal Exp | 1992 |
Perception of bronchoconstriction in chronic asthma.
Topics: Aerosols; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Child; Female; | 1992 |
[Lung function of adult patients with bronchial asthma or chronic obstructive lung disease prior to and following a 3-month-stay in the Dutch Asthma Center in Davos].
Topics: Albuterol; Asthma; Female; Hospitals, Special; Humans; Lung Diseases, Obstructive; Lung Volume Measu | 1992 |
Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Biopsy; Bronchi; Bronchitis; Bronchoscopy; Dru | 1992 |
Reversible volume changes of trapped gas in nonspecific bronchoprovocation tests.
Topics: Acetylcholine; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Forced Exp | 1992 |
Methotrexate treatment of severe asthma in children.
Topics: Adolescent; Albuterol; Asthma; Beclomethasone; Body Height; Body Weight; Child; Child, Preschool; Cr | 1992 |
[Sudden unexpected death and near death among children with asthma].
Topics: Adolescent; Albuterol; Asthma; Child; Death, Sudden; Female; Humans; Infant; Male; Norway | 1992 |
Profound, reversible, myocardial depression in acute asthma treated with high-dose catecholamines.
Topics: Administration, Inhalation; Adult; Albuterol; Aminophylline; Asthma; Barotrauma; Cardiomyopathies; C | 1992 |
Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study.
Topics: Adolescent; Adult; Albuterol; Asthma; Case-Control Studies; Child; Child, Preschool; Fenoterol; Huma | 1992 |
Effects of NZ-107 on bronchoconstriction in guinea pigs.
Topics: Albuterol; Animals; Asthma; Bronchoconstriction; Cromolyn Sodium; Disease Models, Animal; Guinea Pig | 1992 |
Assessment of bronchodilatation after spontaneous recovery from a histamine challenge in asthmatic children.
Topics: Adolescent; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Child; Female; Forc | 1992 |
Management of asthma.
Topics: Albuterol; Asthma; Child; Child, Preschool; Emergencies; Female; Hospitalization; Humans; Male; Oxyg | 1992 |
Asthma knowledge and management in primary schools in south Auckland.
Topics: Albuterol; Asthma; Beclomethasone; Child; Cromolyn Sodium; Evaluation Studies as Topic; Faculty; Hea | 1992 |
Influence of short- and long-term inhalation of salbutamol on lung function and beta 2-adrenoceptors of mononuclear blood cells in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Airway Resistance; Albuterol; Asthma; Child; Forced Expirato | 1991 |
Beta 2-agonists in asthma.
Topics: Albuterol; Asthma; Drug Information Services; Fenoterol; Humans; Product Surveillance, Postmarketing | 1991 |
The severity of asthma in relation to beta agonist prescribing.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Chronic Dise | 1991 |
Salmeterol in nocturnal asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate; Sleep | 1991 |
Salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate; Time Factors | 1991 |
Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Provocatio | 1991 |
Beta 2 agonists and asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Provocation Tests; E | 1991 |
[Pharmacological action of SN-408, a novel long-acting selective beta 2-adrenoceptor agonist].
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchodilator Agents; Capillary Permeability; | 1991 |
[Treatment of asthma with salmeterol--a new prolonged-action inhalatory beta 2 agonist].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Delayed-Action Preparations | 1991 |
Salmeterol in children.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Humans; Salmeterol Xinafoate | 1991 |
Salmeterol therapy in mild asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Salmeterol Xinafoate | 1991 |
Salmeterol therapy in mild asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Quality of Life; Salmeterol Xinafoate | 1991 |
A European respiratory review on salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchi; Humans; Inflammation; Salmeterol Xinafoate | 1991 |
Appropriate prescribing of beta-2 agonists.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Nebulizers and Vaporizers; Salmeterol Xinafoate | 1991 |
Saliva composition in asthmatic patients after treatment with two dose levels of a beta 2-adrenoceptor agonist.
Topics: Adolescent; Adult; Albuterol; Amylases; Asthma; Buffers; Female; Hexosamines; Humans; Hydrogen-Ion C | 1990 |
In vitro and in vivo effect of salbutamol on histamine release from human basophils.
Topics: Adult; Albuterol; Asthma; Basophils; Female; Histamine Release; Humans; Hypersensitivity; Injections | 1991 |
Reduced responsiveness of adenylate cyclase in alveolar macrophages from patients with asthma.
Topics: 1-Methyl-3-isobutylxanthine; Adenylyl Cyclases; Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Cel | 1991 |
Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Female; Forced Exp | 1991 |
Acute asthma in children.
Topics: Acute Disease; Albuterol; Asthma; Emergencies; Humans; Patient Education as Topic; Theophylline | 1991 |
Management of acute asthma attacks in general practice.
Topics: Acute Disease; Adolescent; Adult; Aged; Albuterol; Asthma; Attitude of Health Personnel; Attitude to | 1991 |
The effect of salbutamol on breath alcohol testing in asthmatics.
Topics: Adult; Aged; Albuterol; Asthma; Breath Tests; Ethanol; Female; Humans; Male; Middle Aged | 1991 |
Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs.
Topics: Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Chemotaxis, Leukocyte; Guinea Pigs; Male; Pla | 1991 |
T cell receptor gamma delta bearing cells are decreased in the peripheral blood of patients with atopic diseases.
Topics: Adolescent; Adult; Albuterol; Antibodies, Monoclonal; Asthma; Beclomethasone; CD8 Antigens; Child; C | 1991 |
Outcome of assessments for occupational asthma.
Topics: Adult; Albuterol; Allergens; Asthma; Bronchial Provocation Tests; Diagnosis, Differential; Female; F | 1991 |
Assessment of bronchodilator response to a beta-adrenergic delivered from an ultrasonic nebulizer.
Topics: Adult; Aerosols; Albuterol; Analysis of Variance; Asthma; Blood Pressure; Bronchi; Equipment Design; | 1991 |
Saliva composition and caries development in asthmatic patients treated with beta 2-adrenoceptor agonists: a 4-year follow-up study.
Topics: Adolescent; Adult; Albuterol; Asthma; Dental Caries; DMF Index; Female; Follow-Up Studies; Humans; H | 1991 |
[New aspects of using adrenomimetics in the diagnosis and treatment of bronchial asthma].
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronc | 1991 |
[Effects of inhaled prostaglandin E1, salbutamol and verapamil on the bronchial reactivity in asthmatics].
Topics: Administration, Inhalation; Adult; Albuterol; Alprostadil; Asthma; Bronchi; Female; Forced Expirator | 1991 |
Hypokalaemic effect of salbutamol and terbutaline in bronchial asthma.
Topics: Adult; Aged; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Hypokalemia; Male; Middle | 1991 |
The use of inhaled formoterol in asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Drug Administration Schedule; | 1991 |
Relationship between response to inhaled salbutamol and methacholine bronchial provocation in children with suspected asthma.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Chi | 1991 |
Cyclosporin for steroid-dependent asthma.
Topics: Adult; Albuterol; Aminophylline; Asthma; Beclomethasone; Cyclosporins; Female; Humans; Male; Middle | 1991 |
Occupational rhinitis and asthma caused by inhalation of Balfourodendron riedelianum (Pau Marfim) wood dust.
Topics: Adult; Air Pollutants, Occupational; Albuterol; Asthma; Dust; Electrophoresis, Polyacrylamide Gel; H | 1991 |
The ventilatory and oxygen costs in the anesthetized rhesus monkey of inhaling drugs used in the therapy and diagnosis of asthma.
Topics: Administration, Inhalation; Albuterol; Anesthesia; Animals; Asthma; Cromolyn Sodium; Epinephrine; Fu | 1991 |
Pharmacological modulation of a model of bronchial inflammation after aerosol-induced active anaphylactic shock in conscious guinea pigs.
Topics: Albuterol; Anaphylaxis; Animals; Asthma; Bronchitis; Bronchoalveolar Lavage Fluid; Cromolyn Sodium; | 1991 |
Audit of the effect of a nurse run asthma clinic on workload and patient morbidity in a general practice.
Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; Child; Emergenci | 1991 |
Recently introduced products.
Topics: Albuterol; Asthma; Bacterial Infections; Breast Diseases; Carboprost; Cefixime; Cefotaxime; Fatty Ac | 1991 |
Plasma levels and effects of salbutamol after inhaled or i.v. administration in stable asthma.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Female; Heart Rate; Humans; Infusions, I | 1991 |
Sensitivity of FEV1 response following one and two inhalations of albuterol: a pilot study.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Dose-Response Relationship, | 1991 |
Asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Australia; Humans; Patient Education as Topic | 1991 |
Special comment.
Topics: Albuterol; Asthma; Drug Hypersensitivity; Female; Humans; Nebulizers and Vaporizers; Oleic Acids | 1991 |
Are you taking the medicine?
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Bronchodilator Agents; Humans; Mal | 1990 |
[Effects of flutropium bromide, a new anti-asthma drug, alone or in combination with salbutamol, aminophylline and disodium cromoglycate on the acetylcholine induced bronchoconstriction].
Topics: Acetylcholine; Administration, Inhalation; Albuterol; Aminophylline; Animals; Asthma; Atropine Deriv | 1990 |
Effect of salbutamol on potassium influx in erythrocytes of allergic subjects and investigation of beta 2 receptor autoantibodies.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Albuterol; Antibodies, Monoclonal; Ast | 1990 |
Response of acute asthma to a beta 2 agonist in children less than two years of age.
Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Child, Preschool; Female; Humans; Infant | 1990 |
Approaches to a long-acting, selective beta 2-adrenoceptor stimulant.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Animals; Asthma; Delayed-Action Preparations | 1990 |
Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol.
Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Albuterol; Asthma; Bronchi; Bronchial Provo | 1990 |
[The influence of serum theophylline concentration on the bronchodilating effect of salbutamol inhalation for bronchial asthma].
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Br | 1990 |
Salbutamol nebuliser and precipitation of critical cardiac ischaemia.
Topics: Acute Disease; Albuterol; Asthma; Coronary Disease; Humans; Male; Middle Aged; Myocardial Infarction | 1990 |
Use of antiasthmatic drugs in Australia.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adrenergic be | 1990 |
Salmeterol.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Bronchoconstriction; Bronchodilator Agents; Chemical Ph | 1990 |
The safety aspects of fiberoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma.
Topics: Adult; Aged; Albuterol; Asthma; Biopsy, Needle; Bronchial Provocation Tests; Bronchoalveolar Lavage | 1991 |
The allergic patient who is noncompliant and abusive: dealing with the adverse experience.
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Female; Humans; Middle Aged; Pa | 1991 |
Peak flow rates in young children.
Topics: Albuterol; Asthma; Child, Preschool; Humans; Peak Expiratory Flow Rate | 1991 |
Home nebulisers in childhood asthma: survey of hospital supervised use.
Topics: Adolescent; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Female; Home Nursing; | 1991 |
Salbutamol injections.
Topics: Albuterol; Asthma; Humans; Injections, Intramuscular | 1991 |
Pulse oximetry in acute asthma.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Hospitalization; Humans; Infa | 1991 |
Ventilation-perfusion mismatch after methacholine challenge in patients with mild bronchial asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Female; Forced Expiratory Volume; | 1991 |
Occupational asthma due to styrene.
Topics: Adult; Albuterol; Asthma; Beclomethasone; Forced Expiratory Volume; Humans; Male; Military Personnel | 1991 |
Effect of inhaled disodium cromoglycate and albuterol on energy cost of running in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Cromolyn Sodium; Energy Metabolism | 1990 |
Gas exchange abnormalities in asthma.
Topics: Airway Resistance; Albuterol; Asthma; Follow-Up Studies; Forced Expiratory Volume; Humans; Infusions | 1990 |
A request for an inhaler.
Topics: Administration, Inhalation; Albuterol; Asthma; Child, Preschool; Cromolyn Sodium; Diagnosis, Differe | 1990 |
Bronchoconstriction induced by spirometric maneuvers in patients with bronchial asthma.
Topics: Adult; Albuterol; Asthma; Bronchoconstriction; Female; Humans; Ipratropium; Male; Middle Aged; Spiro | 1990 |
Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction.
Topics: Administration, Inhalation; Adult; Age Factors; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchod | 1990 |
Osmolality and pH of anti-asthmatic drug solutions.
Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Cromolyn Sodium; Fenoterol; Humans; Hydrogen-Ion | 1990 |
Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Blood Glucose; Dose-Response Relationship, Dru | 1990 |
Metabolic and hormonal responses to salbutamol in asthma. Evidence of beta-adrenergic overactivity?
Topics: Albuterol; Asthma; Blood Glucose; Fatty Acids, Nonesterified; Female; Hemodynamics; Humans; Insulin; | 1990 |
Evaluation of beta-adrenergic function in normal and asthmatic children.
Topics: Albuterol; Asthma; Blood Glucose; Child; Epinephrine; Female; Humans; Male; Receptors, Adrenergic, b | 1990 |
The effect of benzalkonium chloride on the bronchodilator response to salbutamol nebuliser solution.
Topics: Albuterol; Asthma; Benzalkonium Compounds; Bronchi; Forced Expiratory Volume; Humans; Nebulizers and | 1990 |
Treatment of the asthmatic child.
Topics: Adrenal Cortex Hormones; Albuterol; Algorithms; Asthma; Child; Costa Rica; Drug Therapy, Combination | 1990 |
[Sulfur dioxide-induced bronchial constriction in asthmatics and its prophylaxis by salbutamol].
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchial Spasm; | 1990 |
Asthma and its management at a student health service.
Topics: Activities of Daily Living; Adaptation, Psychological; Adult; Albuterol; Asthma; Attitude to Health; | 1990 |
The asthmatic child.
Topics: Albuterol; Asthma; Child, Preschool; Humans; Nebulizers and Vaporizers | 1990 |
Treatment for acute asthma in the ambulance.
Topics: Adult; Aerosols; Albuterol; Ambulances; Asthma; Humans | 1990 |
Aerosol addiction.
Topics: Adult; Aerosols; Albuterol; Asthma; Humans; Intellectual Disability; Male; Nebulizers and Vaporizers | 1990 |
Bronchodilating effect of intravenous magnesium sulfate in acute severe bronchial asthma.
Topics: Administration, Inhalation; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Infusions, Int | 1990 |
Description of a delivery method for continuously aerosolized albuterol in status asthmaticus.
Topics: Adult; Aerosols; Albuterol; Asthma; Critical Care; Equipment Design; Humans; Male; Status Asthmaticu | 1990 |
Spacer-induced atrial fibrillation.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Atrial Fibrillation; Humans; Male; Time Factor | 1990 |
Pulmonary gas exchange in severe chronic asthma. Response to 100% oxygen and salbutamol.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Blood Gas Analysis; Chronic Disease; Hem | 1990 |
Effects of increasing doses of beta-agonists on airway and parenchymal hysteresis.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchi; Female; Humans; Lung Volume Measureme | 1990 |
Late asthmatic reactions to occupational sensitizing agents: frequency of changes in nonspecific bronchial responsiveness and of response to inhaled beta 2-adrenergic agent.
Topics: Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Forced Expiratory Volume; Humans; Hypersens | 1990 |
Late-onset asthma in a demented elderly patient. The value of methacholine challenge in diagnosis.
Topics: Aged; Albuterol; Alzheimer Disease; Asthma; Bronchial Provocation Tests; Diagnosis, Differential; Fe | 1990 |
Respiratory impedance and multibreath N2 washout in healthy, asthmatic, and cystic fibrosis subjects.
Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Bronchi; Child; Cystic Fibrosis; Female; Fo | 1990 |
[High-dose inhaled beta-2 sympathomimetics in severe bronchial asthma].
Topics: Administration, Inhalation; Administration, Oral; Albuterol; Asthma; Dose-Response Relationship, Dru | 1990 |
Compliance with inhaled therapy and morbidity from asthma.
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Beclomethasone; Female; Forced Expiratory Volu | 1990 |
Plasma concentrations of salbutamol in acute severe asthmatics.
Topics: Acute Disease; Adult; Aged; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Peak Expiratory Fl | 1990 |
Role of purinergic system in tracheobronchial reactivity of healthy and bronchopathic subjects.
Topics: Adenosine; Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Bronchi; Bronchitis; Bronchodi | 1990 |
Time course of change in oxygen saturation and peak expiratory flow in children admitted to hospital with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Albuterol; Asthma; Child; Child, Preschool; F | 1990 |
Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Bronchi; Female; Humans; Lung; Male; Mid | 1990 |
Albuterol and spacer-induced atrial fibrillation.
Topics: Adult; Albuterol; Asthma; Atrial Fibrillation; Electrocardiography; Humans; Male; Nebulizers and Vap | 1990 |
Lack of adverse cardiac effects of combined treatment with theophylline and albuterol in asthmatic children.
Topics: Albuterol; Asthma; Child; Child, Preschool; Electrocardiography, Ambulatory; Exercise Test; Heart; H | 1990 |
[Comparative study of the bronchodilator effect of inhaled fenoterol and aerosol salbutamol in patients with chronic bronchial asthma].
Topics: Administration, Inhalation; Adult; Aerosols; Aged; Albuterol; Asthma; Chronic Disease; Female; Fenot | 1989 |
Late asthmatic response to allergen challenge (LAR), its clinical feature and pharmacological modulation.
Topics: Albuterol; Allergens; Asthma; Beclomethasone; Bronchial Provocation Tests; Cromolyn Sodium; Humans; | 1989 |
Therapeutic use of bronchoalveolar lavage in a very difficult asthmatic: a case report.
Topics: Acute Disease; Adult; Albuterol; Asthma; Bronchoalveolar Lavage Fluid; Drug Therapy, Combination; Hu | 1989 |
[Treatment of asthma in the emergency clinic of a pediatric hospital].
Topics: Adolescent; Albuterol; Asthma; Child; Costa Rica; Emergencies; Humans | 1989 |
Maximum achievable bronchodilatation in asthma.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Aminophylline; Asthma; Female; Forced Expiratory | 1989 |
Prostaglandin E2 and salbutamol are less effective in raising cAMP levels of alveolar macrophages from ovalbumin-sensitized guinea-pigs as compared to controls.
Topics: Albuterol; Animals; Asthma; Cyclic AMP; Dinoprostone; Guinea Pigs; Immunization; Macrophages; Ovalbu | 1989 |
Responses of neutrophilic granulocytes in vitro of asthmatic and healthy subjects and the degree of inhibition by several drugs.
Topics: Adolescent; Albuterol; Asthma; Calcimycin; Child; Child, Preschool; Cromolyn Sodium; Enzyme Inhibito | 1989 |
Preferences for salbutamol delivery systems among young asthmatics.
Topics: Albuterol; Asthma; Child; Humans; Nebulizers and Vaporizers | 1989 |
Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study.
Topics: Acute Disease; Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; | 1989 |
Preservatives in bronchodilator nebuliser solutions.
Topics: Acute Disease; Albuterol; Asthma; Atropine Derivatives; Drug Therapy, Combination; Humans; Ipratropi | 1989 |
[Respiratory arrest in an asthmatic girl treated with beta-2-mimetics and theophylline. Possible role of hypokalemia in sudden death in asthmatic patients].
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Child; Death, Sudden; Drug Interactions; Female; Humans | 1989 |
Does urinary salbutamol reflect compliance with the aerosol regimen in patients with asthma?
Topics: Aerosols; Albuterol; Asthma; Chromatography, Thin Layer; Female; Humans; Male; Middle Aged; Patient | 1989 |
Exercise-induced allergic syndromes on the increase.
Topics: Adolescent; Adult; Albuterol; Anaphylaxis; Asthma; Asthma, Exercise-Induced; Beclomethasone; Exercis | 1989 |
Cardiac arrhythmias during acute exacerbations of chronic airflow limitation: effect of fall in plasma potassium concentration induced by nebulised beta 2-agonist therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Albuterol; Arrhythmias, Cardiac; Asthma; Humans; Male | 1989 |
Plasma potassium in acute severe asthma before and after treatment.
Topics: Adolescent; Adult; Aged; Albuterol; Aminophylline; Asthma; Drug Therapy, Combination; Female; Humans | 1989 |
Assessing the cost of albuterol inhalers in the Michigan and California Medicaid Programs: a total cost-of-care approach.
Topics: Adult; Albuterol; Asthma; California; Costs and Cost Analysis; Female; Humans; Male; Medicaid; Michi | 1989 |
Response localization of the pharmacological agents histamine and salbutamol along the respiratory system by forced oscillations in asthmatic subjects.
Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchial Provocation Tests; Female; Forced Expiratory | 1989 |
Serum potassium responses to nebulized salbutamol administered during an acute asthmatic attack.
Topics: Adult; Aerosols; Albuterol; Asthma; Female; Humans; Hypokalemia; Male; Potassium; Prospective Studie | 1989 |
The use of non-prescription salbutamol inhalers by asthmatic patients in the Hunter Valley, New South Wales. Newcastle Retail Pharmacy Research Group.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Drug Pres | 1989 |
Experience with a metered-dose inhaler with a spacer in the pediatric emergency department.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Emergency Service, Hospital; | 1989 |
2 year old asthmatics can learn to operate a tube spacer by copying their mothers.
Topics: Administration, Inhalation; Albuterol; Asthma; Child, Preschool; Female; Humans; Infant; Learning; M | 1989 |
The biochemical effects of high-dose inhaled salbutamol in patients with asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Blood Glucose; Dose-Response | 1989 |
Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach.
Topics: Albuterol; Asthma; Bronchi; Bronchitis; Chronic Disease; Diagnosis, Differential; Female; Forced Exp | 1989 |
Acute asthma attack due to ophthalmic indomethacin.
Topics: Aged; Albuterol; Asthma; Combined Modality Therapy; Female; Glucocorticoids; Humans; Indomethacin; O | 1989 |
Benzalkonium chloride and bronchoconstriction.
Topics: Albuterol; Asthma; Benzalkonium Compounds; Bronchi; Constriction, Pathologic; Drug Therapy, Combinat | 1989 |
Ventilation-perfusion mismatching in acute severe asthma: effects of salbutamol and 100% oxygen.
Topics: Acute Disease; Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Female; Humans; Infusions | 1989 |
The effects of deep inhalation on maximal expiratory flow during intensive treatment of spontaneous asthmatic episodes.
Topics: Adult; Albuterol; Asthma; Constriction, Pathologic; Dilatation, Pathologic; Female; Glucocorticoids; | 1989 |
Breath-actuated inhalers: comparison of terbutaline Turbohaler with salbutamol Rotahaler.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Chronic Disease; Evaluation | 1989 |
Nebulisers in acute childhood asthma.
Topics: Acute Disease; Albuterol; Asthma; Child; Child, Preschool; Humans; Nebulizers and Vaporizers | 1989 |
Asthma in the very young baby.
Topics: Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Humans; Infant; Nebulizers and Vaporizer | 1989 |
Beta-adrenoceptor density and resolution of high and low affinity state on B- and T-cells in asthmatic and non-asthmatic children.
Topics: Adolescent; Albuterol; Asthma; B-Lymphocytes; Child; Child, Preschool; Humans; Infant; Iodocyanopind | 1988 |
Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma.
Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Blood Pressure; Cyclic AMP; Dose-Respons | 1988 |
Home nebulisers.
Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Infant; Oxygen | 1985 |
Beta 2 agonists for acute asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Humans; Isoetharine; Metaproterenol; Terbutaline | 1985 |
Clinical use of beta-adrenergic agonists.
Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Asthma; Catecholamines; Drug Resistance; Heart Rate; | 1985 |
A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Ethanolamines; Force | 1985 |
[Evaluation of procaterol aerosol as an aerosolized beta 2-adrenergic bronchodilator in conscious guinea pigs].
Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Animals; Asthma; Bronchodilator Agents; Drug Resistan | 1985 |
Treatment of asthma.
Topics: Acute Disease; Aerosols; Albuterol; Asthma; Humans; Terbutaline | 1986 |
Asthma death due to ibuprofen.
Topics: Acute Disease; Aged; Albuterol; Asthma; Beclomethasone; Drug Interactions; Female; Humans; Ibuprofen | 1987 |
[A new aerosol adrenergic bronchodilator, procaterol. Comparative study of salbutamol and procaterol].
Topics: Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Me | 1987 |
Bronchodilator action of the anti-histaminic terfenadine.
Topics: Adult; Albuterol; Asthma; Benzhydryl Compounds; Bronchodilator Agents; Female; Forced Expiratory Vol | 1987 |
Development of drug tachyphylaxis in asthmatic patients treated with beta-adrenergic drugs.
Topics: Adrenergic beta-Agonists; Adult; Aerosols; Airway Resistance; Albuterol; Asthma; Female; Forced Expi | 1987 |
Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators.
Topics: Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Bronchodilator Agents; Cyclic AMP; Female; Hu | 1988 |
Effects of theophylline, beta-adrenergic stimulants and prednisolone on platelet and urine cyclic guanosine monophosphate (cGMP).
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Aminophylline; Asthma; Blood Platelets; Cyclic GMP | 1988 |
[Severe asthma in children. Value of home nebulization of salbutamol].
Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Female; Home Care Services; Humans | 1986 |
[An uncommon adverse effect of salbutamol].
Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Humans; Male | 1987 |
Emergency use of nebulised bronchodilator drugs in British hospitals.
Topics: Aerosols; Albuterol; Asthma; Bronchodilator Agents; Drug Utilization; Emergencies; Hospitals, Distri | 1987 |
Fixed dose combination therapy in the treatment of asthma--the case against it.
Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Combinations; Fenoterol; Hu | 1988 |
Home nebulizers in childhood asthma. Parental perceptions and practices.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Cromolyn Sodium; Female; Hospitalization; Hu | 1988 |
The duration of action of the combination of fenoterol hydrobromide and ipratropium bromide in protecting against asthma provoked by hyperpnea.
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Atropine Derivatives; Drug Therapy | 1988 |
Emergency endotracheal drug administration using aerosol.
Topics: Adult; Aerosols; Albuterol; Asthma; Emergencies; Female; Humans; Intermittent Positive-Pressure Vent | 1987 |
Influence of airway calibre on the intrapulmonary dose and distribution of inhaled aerosol in normal and asthmatic subjects.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Female; Humans; Lung; Male; Methacho | 1988 |
The assessment of a computer administered questionnaire in the differential diagnosis of asthma and chronic airflow limitation.
Topics: Adult; Aged; Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Diagnosis, Computer-Assisted; | 1988 |
Effects of ketotifen upon responses to platelet activating factor: a basis for asthma prophylaxis.
Topics: Albuterol; Asthma; Cromolyn Sodium; Humans; Hypersensitivity; Injections, Intravenous; Ketotifen; Lu | 1986 |
The U.S. Olympic Committee experience with exercise-induced bronchospasm, 1984.
Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Cromolyn Sodium; Female; Humans; Male; Sex Facto | 1986 |
Exercise-induced asthma.
Topics: Aerosols; Albuterol; Asthma; Asthma, Exercise-Induced; Child; Cromolyn Sodium; Humans; Peak Expirato | 1986 |
Effect of drugs used in the treatment of asthma on the production of eosinophil-activating factor by monocytes.
Topics: Albuterol; Asthma; Beclomethasone; Cromolyn Sodium; Eosinophils; Humans; Lymphokines; Methylpredniso | 1988 |
Intravenous beta agonist in severe acute asthma.
Topics: Acute Disease; Albuterol; Asthma; Humans | 1988 |
The effect of cromolyn sodium and albuterol on early and late phase bronchoconstriction and airway leukocyte infiltration after allergen challenge of nonanesthetized guinea pigs.
Topics: Airway Obstruction; Airway Resistance; Albuterol; Allergens; Animals; Asthma; Bronchi; Bronchoalveol | 1988 |
[Effect of the diagnosis and prevention of exercise-induced bronchial obstruction on sports participation by asthmatic school children].
Topics: Airway Resistance; Albuterol; Asthma; Asthma, Exercise-Induced; Beclomethasone; Child; Cromolyn Sodi | 1988 |
A study of acute asthma in the accident and emergency department.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Aerosols; Aged; Albuterol; Asthma; Bronch | 1988 |
Ability of asthmatics with and without respiratory arrest to detect added resistive loads.
Topics: Adult; Albuterol; Asthma; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Regression An | 1988 |
[The effect of hyperosmolar mixed solution of sodium chloride and beta 2 sympathomimetics on lung function in asthmatic children and adolescents].
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Child; Humans; Lung; Osmolar Concentration; Respirat | 1988 |
Comparison of beta-adrenergic agents delivered by nebulizer vs metered dose inhaler with InspirEase in hospitalized asthmatic patients.
Topics: Adult; Albuterol; Asthma; Female; Hospitalization; Humans; Male; Metaproterenol; Nebulizers and Vapo | 1988 |
[Effects of salbutamol spray administered with metered dose inhaler on oral cavities in asthma patients].
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Asthma; Blood | 1988 |
Pharmacodynamics of salbutamol in humans.
Topics: Aged; Albuterol; Asthma; Blood Pressure; Electrocardiography; Fatty Acids, Nonesterified; Female; He | 1988 |
[Asymptomatic electrical myocardial necrosis during the infusion of betamimetics in status asthmaticus].
Topics: Albuterol; Asthma; Cardiomyopathy, Dilated; Electrocardiography; Female; Humans; Middle Aged; Myocar | 1988 |
Trachea-noise biofeedback in asthma: a comparison of the effect of trachea-noise biofeedback, a bronchodilator, and no treatment on the rate of recovery from exercise- and eucapnic hyperventilation-induced asthma.
Topics: Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Biofeedback, Psychology; Bronchial Spasm; Double | 1988 |
Influence of breathing pattern on lung deposition and bronchodilator response to nebulised salbutamol in patients with stable asthma.
Topics: Airway Resistance; Albuterol; Asthma; Female; Humans; Lung; Male; Middle Aged; Nebulizers and Vapori | 1988 |
Intermittent and continuous salbutamol rotacaps inhalation in asthmatic patients.
Topics: Administration, Inhalation; Adult; Airway Resistance; Albuterol; Asthma; Female; Humans; Male; Middl | 1988 |
[Effect of salbutamol on post-exertion bronchial spasm and post-exertion refraction time].
Topics: Adult; Albuterol; Asthma; Bronchial Spasm; Depression, Chemical; Exercise Test; Female; Forced Expir | 1988 |
[Nonspecific bronchial hyperreactivity after long-term use of a beta 2 agonist].
Topics: Administration, Inhalation; Adult; Albuterol; Asthma; Bronchi; Bronchial Spasm; Female; Forced Expir | 1988 |
An assessment of methacholine inhalation tests in elderly asthmatics.
Topics: Aged; Aged, 80 and over; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Dizziness; | 1988 |
Aerosol treatment abuse.
Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Child, Preschool; Chlorofluorocarbons, Methane; Humans; | 1988 |
Effects of a fish oil enriched diet on aspirin intolerant asthmatic patients: a pilot study.
Topics: Adult; Aged; Albuterol; Aspirin; Asthma; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Drug Comb | 1988 |
Treatment of asthma-related respiratory arrest with endotracheal albuterol (salbutamol).
Topics: Acute Disease; Aged; Albuterol; Asthma; Female; Humans; Intubation, Intratracheal; Respiratory Insuf | 1988 |
Childhood asthma: prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection.
Topics: Albuterol; Asthma; Child, Preschool; Drug Therapy, Combination; Female; Humans; Male; Metaproterenol | 1988 |
Effect of therapy on bronchial hyperresponsiveness in the long-term management of asthma.
Topics: Adult; Albuterol; Asthma; Beclomethasone; Bronchi; Female; Forced Expiratory Volume; Humans; Male; M | 1988 |
Effects of salbutamol.
Topics: Albuterol; Asthma; Child Behavior Disorders; Child, Preschool; Female; Humans | 1988 |
[The possibilities and prospects in using the calcium antagonist korinfar in patients with bronchial asthma].
Topics: Administration, Inhalation; Aged; Albuterol; Asthma; Bronchial Provocation Tests; Calcium Channel Bl | 1988 |
[Treatment of asthma crises in children with nebulized salbutamol].
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Female; Humans; Male; Nebul | 1988 |
Enhancement of theophylline clearance by intravenous albuterol.
Topics: Albuterol; Asthma; Drug Interactions; Humans; Infant; Infusions, Intravenous; Male; Metabolic Cleara | 1988 |
Plasma catecholamine concentrations during a 72-hour aminophylline infusion in children with acute asthma.
Topics: Acute Disease; Administration, Inhalation; Albuterol; Aminophylline; Asthma; Child; Drug Therapy, Co | 1988 |
Predictive value of oxygen saturation in emergency evaluation of asthmatic children.
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Emergencies; Female; Humans; | 1988 |
Rising asthma admissions and self referral.
Topics: Adolescent; Age Factors; Albuterol; Asthma; Child; Child, Preschool; England; Hospitals, Pediatric; | 1988 |
Muscle atrophy in severe exacerbation of asthma requiring mechanical ventilation.
Topics: Albuterol; Asthma; Beclomethasone; Humans; Male; Methylprednisolone; Middle Aged; Muscular Atrophy; | 1988 |
A dosage schedule for salbutamol nebulisation in childhood asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Administration Schedule; Female; Humans | 1987 |
[Effects of a spacer on beta-stimulant inhalation].
Topics: Administration, Inhalation; Adolescent; Adult; Albuterol; Asthma; Evaluation Studies as Topic; Femal | 1987 |
Tomography of regional ventilation and perfusion using krypton 81m in normal subjects and asthmatic patients.
Topics: Adult; Albuterol; Asthma; Female; Humans; Krypton; Lung; Male; Middle Aged; Posture; Radioisotopes; | 1986 |
Bronchoalveolar lavage does not alter airway responsiveness in asthmatic subjects.
Topics: Albuterol; Asthma; Bronchi; Bronchial Provocation Tests; Humans; Methacholine Chloride; Methacholine | 1987 |
Salbutamol versus atropine. Site of bronchodilatation in asthmatic patients.
Topics: Adolescent; Adult; Airway Resistance; Albuterol; Asthma; Atropine; Humans; Respiratory Function Test | 1987 |
"Aerosol-in-bag" administration of inhaled bronchodilators.
Topics: Administration, Inhalation; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Humans; Nebul | 1987 |
Nebulized salbutamol in acute childhood asthma.
Topics: Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Infant; Male; Nebulizers and Vaporizers | 1986 |
Failure of long-acting, recently introduced beta-agonist in asthma.
Topics: Albuterol; Asthma; Delayed-Action Preparations; Humans; Tablets, Enteric-Coated; Terbutaline | 1987 |
[Acute effect of intravenous salbutamol in status asthmaticus].
Topics: Adult; Albuterol; Asthma; Female; Hemodynamics; Humans; Infusions, Intravenous; Injections, Intraven | 1987 |
[Ventolin--measured aerosol].
Topics: Aerosols; Albuterol; Asthma; Humans | 1986 |
Post-mortem concentrations of salbutamol, terbutaline and theophylline in asthma patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Albuterol; Animals; Asthma; Female; Human | 1987 |
Postcoital severe exacerbation of asthma requiring mechanical ventilation.
Topics: Acute Disease; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Coitus; Emotions; Female; Humans; | 1987 |
Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma.
Topics: Albuterol; Asthma; Dose-Response Relationship, Drug; Female; Humans; Lung; Male; Middle Aged; Nebuli | 1987 |
[Subcutaneous adrenaline versus inhaled salbutamol in the treatment of childhood asthmatic crisis].
Topics: Adolescent; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Epinephrine; Huma | 1987 |
Underdiagnosis of asthma in the elderly.
Topics: Aged; Aged, 80 and over; Albuterol; Asthma; Cough; Humans; Respiratory Function Tests | 1987 |
Asthma management.
Topics: Albuterol; Asthma; Child; Humans | 1987 |
Aerosol deposition in automatic dosimeter nebulization.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Evaluation Studies as Topic; Female; Humans; Lung; Male; M | 1987 |
Effect of bronchodilation on the deposition and clearance of radioaerosol in bronchial asthma in remission.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Albuterol; Asthma; Bronchodilator Agents | 1987 |
Use of anti-asthma drugs in New Zealand.
Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Bronchitis; Child; Drug Therapy, Combination; Drug Utili | 1987 |
Paradoxical response to nebulised salbutamol in wheezy infants.
Topics: Airway Resistance; Albuterol; Asthma; Humans; Infant | 1987 |
A near fatal asthma attack in a patient unaware of deteriorating lung function.
Topics: Albuterol; Aminophylline; Asthma; Emergencies; Forced Expiratory Volume; Humans; Male; Middle Aged; | 1987 |
Dynamic lung volumes in children with bronchial asthma.
Topics: Albuterol; Asthma; Child; Humans; Lung; Lung Volume Measurements | 1987 |
The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment.
Topics: Albuterol; Asthma; Drug Administration Schedule; Humans; Theophylline | 1987 |
[Hyperkalemia precipitated by beta 2 receptor agonists].
Topics: Aged; Albuterol; Asthma; Female; Humans; Hyperkalemia; Terbutaline | 1986 |
The perception of asthma.
Topics: Adolescent; Airway Obstruction; Albuterol; Asthma; Child; Female; Forced Expiratory Volume; Humans; | 1986 |
[The effects of inhalation combined with high-frequency vibration on asthmatic children].
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Child; Evaluation Studies as Topic; Female; Humans; | 1986 |
Cardiac effects of salbutamol given by air driven nebuliser at home.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Electrocardiography; Female; Heart; Heart Rate; Home Care | 1986 |
Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis.
Topics: Albuterol; Arthritis, Rheumatoid; Asthma; Bronchial Spasm; Choline; Drug Combinations; Drug Hypersen | 1986 |
Albuterol nebulizer solution for the treatment of asthma.
Topics: Albuterol; Asthma; Humans | 1986 |
Ventide--a useful combination?
Topics: Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Drug Combinations; Humans | 1986 |
[Treatment of acute crises of bronchial asthma in children using subcutaneous salbutamol as an alternative to adrenaline: comparative study].
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Drug Evaluation; Epinephrine; Female; Heart | 1986 |
Systemic cardiovascular and metabolic effects associated with the inhalation of an increased dose of albuterol. Influence of mouth rinsing and gargling.
Topics: Adult; Aerosols; Albuterol; Asthma; Blood Glucose; Female; Heart Rate; Humans; Lung Volume Measureme | 1987 |
[The nurse in front of an asthma crisis].
Topics: Aerosols; Albuterol; Asthma; Blood Gas Analysis; Emergencies; Humans; Theophylline | 1985 |
Children with asthma: will nebulised salbutamol reduce hospital admissions?
Topics: Acute Disease; Adolescent; Aerosols; Age Factors; Albuterol; Asthma; Child; Child, Preschool; Drug A | 1985 |
Histamine-induced asthma in children: effects on the ventilation-perfusion relationship.
Topics: Adolescent; Albuterol; Arteries; Asthma; Bronchial Provocation Tests; Carbon Dioxide; Cardiac Output | 1985 |
Children with asthma: will nebulised salbutamol reduce hospital admissions?
Topics: Aerosols; Albuterol; Asthma; Child; Hospitalization; Humans | 1985 |
Asthma in a country hospital.
Topics: Adolescent; Adult; Albuterol; Asthma; Beclomethasone; Bronchodilator Agents; Cromolyn Sodium; Female | 1985 |
Domiciliary nebulisers in asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Female; Humans; Male; Middle Aged; Self Admini | 1985 |
[Bronchial hyperreactivity to pneumo-allergens].
Topics: Adolescent; Albuterol; Allergens; Asthma; Beclomethasone; Bronchi; Bronchial Provocation Tests; Bron | 1985 |
Effects of treatment on mortality from asthma.
Topics: Administration, Oral; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Inject | 1986 |
[Relation between blood theophylline levels and bronchodilator effect in asthmatics: comparison with salbutamol].
Topics: Adult; Albuterol; Asthma; Humans; Middle Aged; Theophylline | 1985 |
Relapse after single dose nebulised salbutamol in children with acute asthma.
Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Female; Humans; Male; Peak Expiratory Flow R | 1985 |
The effect of intravenously administered salbutamol on serum potassium in asthmatic and nonasthmatic atopic subjects.
Topics: Adolescent; Adult; Albuterol; Asthma; Blood Glucose; Blood Pressure; Female; Heart Rate; Humans; Hyp | 1985 |
Intravenous vs. nebulized salbutamol for treatment of severe status asthmaticus.
Topics: Aerosols; Albuterol; Asthma; Humans; Infusions, Parenteral; Status Asthmaticus | 1985 |
Intravenous salbutamol for status asthmaticus.
Topics: Albuterol; Asthma; Child; Humans; Infusions, Parenteral; Status Asthmaticus | 1985 |
Effects of histamine on lung permeability in normal and asthmatic subjects.
Topics: Adult; Albuterol; Asthma; Histamine; Humans; Lung; Middle Aged; Mucous Membrane; Peak Expiratory Flo | 1985 |
[Relation between number of attacks per year and respiratory function tests in the asthmatic child: importance of spirometry in the child with episodic asthma].
Topics: Albuterol; Asthma; Child; Female; Forced Expiratory Flow Rates; Forced Expiratory Volume; Humans; Ma | 1985 |
Acute asthma in childhood and the role of nebulisers.
Topics: Acute Disease; Aerosols; Albuterol; Asthma; Child; Child, Preschool; Humans; Infant | 1985 |
Comparison of bronchodilator effect of tulobuterol and salbutamol aerosols in patients with asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Forced Expiratory Volume; Hemodynamics; Humans; Mid | 1985 |
Salbutamol by intermittent positive pressure ventilation in status asthmaticus.
Topics: Adolescent; Adult; Aerosols; Aged; Albuterol; Asthma; Carbon Dioxide; Cardiac Complexes, Premature; | 1974 |
[Bronchoconstrictor effects of beta-adrenergic blockade in asthma: influence of baseline value (author's transl)].
Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Albuterol; Asthma; Bronchi | 1974 |
Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma.
Topics: Administration, Oral; Adrenergic beta-Agonists; Aerosols; Airway Resistance; Albuterol; Asthma; Bloo | 1973 |
Problems of interpreting exercise-induced asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Child; Cromolyn Sodium; Heart Rate; Humans; Isoproterenol; Phy | 1973 |
Maximal expiratory flow and lung volume changes associated with exercise-induced asthma in children and the effect of breathing a low-density gas mixture.
Topics: Adolescent; Albuterol; Asthma; Atmospheric Pressure; Child; Helium; Humans; Lung; Oxygen; Physical E | 1974 |
Bronchial asthma.
Topics: Adrenocorticotropic Hormone; Aerosols; Airway Obstruction; Albuterol; Aminophylline; Antigens; Asthm | 1974 |
Oral salbutamol in bronchial asthma.
Topics: Administration, Oral; Albuterol; Asthma; Drug Combinations; Ephedrine; Humans; Phenobarbital; Theoph | 1974 |
Changes in specific airways conductance and forced expiratory volume in one second after a bronchodilator in normal subjects and patients with airways obstruction.
Topics: Administration, Oral; Adult; Aerosols; Airway Obstruction; Airway Resistance; Albuterol; Asthma; Bro | 1974 |
The effects of pressurized isoproterenol and salbutamol in asthmatic children.
Topics: Administration, Intranasal; Adolescent; Aerosols; Albuterol; Asthma; Child; Dose-Response Relationsh | 1974 |
[Inhalation of salbutamol 0,5% water solution in the treatment of acute asthma in children].
Topics: Acute Disease; Adolescent; Albuterol; Asthma; Child; Child, Preschool; Humans; Respiratory Therapy | 1974 |
[Treatment of bronchiolar obstruction].
Topics: Aerosols; Airway Obstruction; Albuterol; Asthma; Bronchial Diseases; Bronchial Spasm; Diagnosis, Dif | 1974 |
[Beta 2 specificity of salbutamol: metabolic evaluations].
Topics: Albuterol; Asthma; Blood Glucose; Carbohydrate Metabolism; Child, Preschool; Fatty Acids, Nonesterif | 1974 |
Effect of beta receptor-stimulating drugs on the cardiovascular and respiratory function of critically ill patients with serious heart disorders.
Topics: Albuterol; Arrhythmias, Cardiac; Asthma; Blood Pressure; Cardiovascular System; Female; Heart; Heart | 1974 |
Closing volume, spirometry and nitrogen wash-out in provoked asthma treated with salbutamol.
Topics: Adolescent; Adult; Airway Obstruction; Airway Resistance; Albuterol; Allergens; Asthma; Female; Huma | 1974 |
[Effect of B2 adrenergic drugs in asthma].
Topics: Albuterol; Asthma; Humans; Pulmonary Ventilation; Respiration; Respiratory Function Tests | 1973 |
The fate of nebulized salbutamol (albuterol) administered by intermittent positive pressure respiration to asthmatic patients.
Topics: Aerosols; Airway Resistance; Albuterol; Asthma; Feces; Female; Humans; Male; Positive-Pressure Respi | 1973 |
A comparison of three different techniques for giving nebulized albuterol to asthmatic patients.
Topics: Aerosols; Albuterol; Asthma; Humans; Methods; Positive-Pressure Respiration; Spirometry | 1974 |
Salbutamol therapy in status asthmaticus.
Topics: Acetylcysteine; Albuterol; Asthma; Epinephrine; Humans; Positive-Pressure Respiration | 1974 |
[Basic broncholytic therapy with Salbutamol. Literature review and our experience].
Topics: Adolescent; Adult; Aerosols; Albuterol; Asthma; Bronchitis; Child; Female; Humans; Male; Middle Aged | 1972 |
[Effects of salbutamol on pulmonary circulation, ventilation, and gas exchanges in bronchial asthma patients].
Topics: Adolescent; Adult; Aged; Airway Resistance; Albuterol; Asthma; Blood Pressure; Carbon Dioxide; Cardi | 1973 |
Arterial blood levels of fluorocarbons in asthmatic patients following use of pressurized aerosols.
Topics: Adult; Aerosols; Aged; Albuterol; Asthma; Chlorofluorocarbons, Methane; Chromatography, Gas; Compute | 1974 |
Management of severe viral bronchiolitis and severe acute asthma.
Topics: Acute Disease; Airway Obstruction; Albuterol; Aminophylline; Anti-Bacterial Agents; Asthma; Bronchio | 1974 |
[Over-8-hour salbutamol effect in obstructive respiratory tract diseases].
Topics: Adult; Albuterol; Asthma; Bronchitis; Child; Chronic Disease; Humans; Lung Diseases, Obstructive; Ti | 1974 |